<?xml version="1.0" encoding="UTF-8"?>
<projectSnippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC6711314\results\search\drug\results.xml">
   <result pre="functions of the respiratory secretions that generate aerosols, droplets, or" exact="dried" post="particles, materials in faeces and the environment that influence"/>
   <result pre="the influenza A virus polymerase PB2 C-terminal region with importin" exact="alpha" post="isoforms provides insights into host adaptation and polymerase assembly."/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC6749704\results\search\drug\results.xml">
   <result pre="in injecting drug users: pooling of UK evidenceAddiction2011106111978198810.1111/j.1360-0443.2011.03515.x21615585 18.LawitzEPoordadFFPangPSHylandRHDingXMoHSymondsWTMcHutchisonJGMembrenoFESofosbuvir and" exact="ledipasvir" post="fixed-dose combination with and without ribavirin in treatment-naive and"/>
   <result pre="UK evidenceAddiction2011106111978198810.1111/j.1360-0443.2011.03515.x21615585 18.LawitzEPoordadFFPangPSHylandRHDingXMoHSymondsWTMcHutchisonJGMembrenoFESofosbuvir and ledipasvir fixed-dose combination with and without" exact="ribavirin" post="in treatment-naive and previously treated patients with genotype 1"/>
   <result pre="infection (LONESTAR): an open-label, randomised, phase 2 trialLancet2014383991651552310.1016/S0140-6736(13)62121-224209977 19.GaneEJStedmanCAHylandRHSorensenRDSymondsWTHindesRBerreyMMOnce daily" exact="PSI-7977" post="plus RBV: pegylated interferon-alfa not required for complete rapid"/>
   <result pre="CNew England Journal of Medicine20133681455310.1056/NEJMoa120880923281975 21.GaneEJStedmanCAHylandRHDingXSvarovskaiaESubramanianGMSymondsWTMcHutchisonJGPangPSEfficacy of nucleotide polymerase inhibitor" exact="sofosbuvir" post="plus the NS5A inhibitor ledipasvir or the NS5B non-nucleoside"/>
   <result pre="21.GaneEJStedmanCAHylandRHDingXSvarovskaiaESubramanianGMSymondsWTMcHutchisonJGPangPSEfficacy of nucleotide polymerase inhibitor sofosbuvir plus the NS5A inhibitor" exact="ledipasvir" post="or the NS5B non-nucleoside inhibitor GS-9669 against HCV genotype"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC6832525\results\search\drug\results.xml">
   <result pre="sofosbuvirâ€™s inhibitory effects on YFV replication: in a mouse model," exact="sofosbuvir" post="was able to decrease mortality and weight loss associated"/>
   <result pre="domain (TIM) and TAM (Tyro3, Axl and Mer) families of" exact="phosphatidylserine" post="receptors have been shown to mediate DENV infection, with"/>
   <result pre="feverAntivir. Res.20087811612410.1016/j.antiviral.2007.10.00918061688 34.SacramentoC.Q.de MeloG.R.de FreitasC.S.RochaN.HoelzL.V.B.MirandaM.Fintelman-RodriguesN.MarttorelliA.FerreiraA.C.Barbosa-LimaG.et al.The clinically approved antiviral drug" exact="sofosbuvir" post="inhibits Zika virus replicationSci. Rep.201774092010.1038/srep4092028098253 35.XuH.-T.Colby-GerminarioS.P.HassounahS.A.FogartyC.OsmanN.PalanisamyN.HanY.OliveiraM.QuanY.WainbergM.A.Evaluation of Sofosbuvir (Î²-D-2â€™-deoxy-2â€™-Î±-fluoro-2â€™-Î²-C-methyluridine)"/>
   <result pre="antiviral drug sofosbuvir inhibits Zika virus replicationSci. Rep.201774092010.1038/srep4092028098253 35.XuH.-T.Colby-GerminarioS.P.HassounahS.A.FogartyC.OsmanN.PalanisamyN.HanY.OliveiraM.QuanY.WainbergM.A.Evaluation of" exact="Sofosbuvir" post="(Î²-D-2â€™-deoxy-2â€™-Î±-fluoro-2â€™-Î²-C-methyluridine) as an inhibitor of Dengue virus replicationSci. Rep.20177634510.1038/s41598-017-06612-228740124"/>
   <result pre="Rep.20177634510.1038/s41598-017-06612-228740124 36.De FreitasC.S.HigaL.M.SacramentoC.Q.FerreiraA.C.ReisP.A.DelvecchioR.MonteiroF.L.Barbosa-LimaG.James WestgarthH.VieiraY.R.et al.Yellow fever virus is susceptible to" exact="sofosbuvir" post="both in vitro and in vivoPLoS Negl. Trop. Dis.201913e000707210.1371/journal.pntd.000707230699122"/>
   <result pre="in vitro and in vivoPLoS Negl. Trop. Dis.201913e000707210.1371/journal.pntd.000707230699122 37.YinZ.ChenY.-L.SchulW.WangQ.-Y.GuF.DuraiswamyJ.KondreddiR.R.NiyomrattanakitP.LakshminarayanaS.B.GohA.et al.An" exact="adenosine" post="nucleoside inhibitor of dengue virusProc. Natl. Acad. Sci. USA2009106204352043910.1073/pnas.090701010619918064"/>
   <result pre="replicationPLoS Negl. Trop. Dis.20126e182010.1371/journal.pntd.000182023029581 67.MeertensL.CarnecX.LecoinM.P.RamdasiR.Guivel-BenhassineF.LewE.LemkeG.SchwartzO.AmaraA.The TIM and TAM families of" exact="phosphatidylserine" post="receptors mediate dengue virus entryCell Host Microbe20121254455710.1016/j.chom.2012.08.00923084921 68.GermiR.CranceJ.-M.GarinD.GuimetJ.Lortat-JacobH.RuigrokR.W.H.ZarskiJ.-P.DrouetE.Heparan sulfate-mediated"/>
   <result pre="NS3 proteinase domain and NS2B are required for cleavages at" exact="dibasic" post="sitesJ. Virol.199165604260501833562 84.ChambersT.J.DrollD.A.TangY.LiangY.GaneshV.K.MurthyK.H.M.NickellsM.Yellow fever virus NS2B-NS3 protease: Characterization of"/>
   <result pre="reticulum adaptor that facilitates innate immune signallingNature200845567467810.1038/nature0731718724357 132.Schuberth-WagnerC.LudwigJ.BruderA.K.HerznerA.-M.ZillingerT.GoldeckM.SchmidtT.Schmid-BurgkJ.L.KerberR.WolterS.et al.A Conserved" exact="Histidine" post="in the RNA Sensor RIG-I Controls Immune Tolerance to"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC6893414\results\search\drug\results.xml">
   <result pre="courier ; font-style : italic;} VirusesVirusesvirusesViruses1999-4915MDPI doi: 10.3390/v11111064viruses-11-01064 : Article" exact="Erythromycin" post="Estolate Inhibits Zika Virus Infection by Blocking Viral Entry"/>
   <result pre="screened a library of clinical drugs with good safety profiles." exact="Erythromycin" post="estolate (Ery-Est), one of the macrolide antibiotics, was found"/>
   <result pre="promising drug for patients with ZIKV infection, particularly pregnant women." exact="erythromycin" post="estolate ZIKV viral entry inhibitor inactivator 1. Introduction Zika"/>
   <result pre="library consisting of FDA-approved medical drugs with good safety, and" exact="erythromycin" post="estolate (Ery-Est), which could be safely used by pregnant"/>
   <result pre="the macrolide antibiotics, is the lauryl sulfate ester of propionyl" exact="erythromycin" post="(Ery) (Figure 1A), and it has commonly been used"/>
   <result pre="studied to treat a wide spectrum of viruses. For example," exact="clarithromycin" post="and the macrolide therapy have been utilized to treat"/>
   <result pre="and Middle East respiratory syndrome coronavirus (MERS-CoV) infection respectively, and" exact="ivermectin" post="and azithromycin (Azi) were identified to effectively inhibit ZIKV"/>
   <result pre="East respiratory syndrome coronavirus (MERS-CoV) infection respectively, and ivermectin and" exact="azithromycin" post="(Azi) were identified to effectively inhibit ZIKV infection [17,18,19,20,21,22,23]."/>
   <result pre="in this study were propagated in C6/36 cells. 2.2. Compounds" exact="Erythromycin" post="estolate (Ery-Est), Erythromycin (Ery), and azithromycin (Azi) powders were"/>
   <result pre="were propagated in C6/36 cells. 2.2. Compounds Erythromycin estolate (Ery-Est)," exact="Erythromycin" post="(Ery), and azithromycin (Azi) powders were bought from Santa"/>
   <result pre="C6/36 cells. 2.2. Compounds Erythromycin estolate (Ery-Est), Erythromycin (Ery), and" exact="azithromycin" post="(Azi) powders were bought from Santa Cruz Biotechnology, Inc."/>
   <result pre="MedChemExpress (Shanghai, China), and the lyophilized powder was dissolved in" exact="dimethyl sulphoxide" post="(DMSO) and then stored at âˆ’20 Â°C. 2.3. Plaque"/>
   <result pre="days, then fixed by 4% formaldehyde and stained with 1%" exact="crystal violet" post="for plaque visualization. The titer of virus stock was"/>
   <result pre="cells were fixed by 4% formaldehyde and stained with 1%" exact="crystal violet" post="for plaque visualization. For the entry experiment, BHK21 cells"/>
   <result pre="cells were fixed by 4% formaldehyde and stained with 1%" exact="crystal violet" post="for plaque visualization. Azi, Ery, and DMSO were also"/>
   <result pre="infection [38], and the ZIKV-forming plaques were presented visually by" exact="crystal violet" post="dyeing. As shown in Figure 1B, numbers of ZIKV"/>
   <result pre="time of our study. Besides, some macrolide antibiotics, such as" exact="azithromycin" post="and ivermectin, have been previously found to effectively inhibit"/>
   <result pre="have been previously found to effectively inhibit ZIKV infection. Moreover," exact="azithromycin" post="was reported to not only inhibit ZIKV in vitro,"/>
   <result pre="Origins, Pathological Action, and Treatment StrategiesFront. Microbiol.20189325210.3389/fmicb.2018.0325230666246 44.CroteauD.BergeronM.G.LeBelM.Pharmacokinetic advantages of" exact="erythromycin" post="estolate over ethylsuccinate as determined by high-pressure liquid chromatographyAntimicrob."/>
   <result pre="Rev.2007Cd00440410.1002/14651858.CD004404.pub317636756 46.LangleyJ.M.HalperinS.A.BoucherF.D.SmithB.Azithromycin is as effective as and better tolerated than" exact="erythromycin" post="estolate for the treatment of pertussisPediatrics.2004114e96e10110.1542/peds.114.1.e9615231980 47.Raynes-GreenowC.H.RobertsC.L.BellJ.C.PeatB.GilbertG.L.Antibiotics for ureaplasma"/>
   <result pre="fetal disease in miceNature201654044344710.1038/nature2056427819683 Figure 1 The molecular formula of" exact="erythromycin" post="estolate (Ery-Est) and Ery and their inhibitory activity against"/>
   <result pre="for about 5 days, infected cells were stained with 1%" exact="crystal violet" post="for plaque visualization and (C) the inhibitions of infection"/>
   <result pre="for about 5 days, infected cells were stained with 1%" exact="crystal violet" post="for plaque visualization and the inhibitions of infection were"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC6904818\results\search\drug\results.xml">
   <result pre="1 Rilpivirine Inhibits ZIKV by Blocking Viral RdRp (A) Proposed" exact="rilpivirine" post="binding site on ZIKV RdRp. ZIKV NS5 (PDB: 5TMH)15"/>
   <result pre="PyMOL. (B) InÂ vivo efficacy. Treatment of ZIKV-infected mice with" exact="rilpivirine" post="suppressed viral replication and prevented animal death. First, Sariyer"/>
   <result pre="ZIKV infection of astrocytes as a screening assay, they identified" exact="rilpivirine" post="as a ZIKV inhibitor from eight FDA-approved HIV nucleoside"/>
   <result pre="killing of non-tumor cells. It remains to be tested if" exact="rilpivirine" post="also inhibits closely related flaviviruses, such as dengue, yellow"/>
   <result pre="viruses. Nevertheless, the authors have established the antiviral activity of" exact="rilpivirine" post="against ZIKV in cell culture. Second, Sariyer etÂ al.2"/>
   <result pre="etÂ al.2 provided five lines of evidence to support that" exact="rilpivirine" post="targets ZIKV RdRp (FigureÂ 1A). (1) Computational docking suggests"/>
   <result pre="targets ZIKV RdRp (FigureÂ 1A). (1) Computational docking suggests that" exact="rilpivirine" post="may bind to the palm site of RdRp protein."/>
   <result pre="site of RdRp protein. (2) Differential scanning fluorimetry showed that" exact="rilpivirine" post="binds to recombinant RdRp with a KD of 100Â"/>
   <result pre="cells, but not the 14-amino acid mutant protein, competed for" exact="rilpivirine" post="binding and thus alleviated compound-mediated antiviral activity. Although these"/>
   <result pre="improved potency. (2) The selection of ZIKV variants resistant to" exact="rilpivirine" post="will identify mutations that are likely mapped to the"/>
   <result pre="Third, Sariyer etÂ al.2 demonstrated the inÂ vivo efficacy of" exact="rilpivirine" post="in a ZIKV interferon Î±/Î² receptor (IFNAR)âˆ’/âˆ’ mouse (type"/>
   <result pre="knockout) model (FigureÂ 1B). Treatment of ZIKV-infected IFNARâˆ’/âˆ’ mice with" exact="rilpivirine" post="reduced organ viral burden and weight loss, improved clinical"/>
   <result pre="caused significant inflammation and abundant apoptotic/necrotic cell damage. Treatment with" exact="rilpivirine" post="reduced the levels of viral RNA in the brain"/>
   <result pre="but it did not eliminate inflammation. These results indicate that" exact="rilpivirine" post="suppressed viral replication and disease development. However, it was"/>
   <result pre="better inÂ vivo efficacy. Nevertheless, the inÂ vivo potency of" exact="rilpivirine" post="seems better than sofosbuvir, a hepatitis C virus (HCV)"/>
   <result pre="(HCV) nucleoside drug that was reported with anti-ZIKV activity.9 Specifically," exact="rilpivirine" post="completely protected ZIKV-infected mice from death, whereas sofosbuvir and"/>
   <result pre="activity.9 Specifically, rilpivirine completely protected ZIKV-infected mice from death, whereas" exact="sofosbuvir" post="and other nucleoside inhibitors only conferred partial protection.10 The"/>
   <result pre="readily advanced to clinical trials for the new indication.11 As" exact="rilpivirine" post="inhibits HIV-1 and ZIKV with EC50 in the single-digit"/>
   <result pre="to ensure clinical efficacy in patients. To achieve this goal," exact="rilpivirine" post="analogs previously synthesized during lead optimization could be tested"/>
   <result pre="with better potency for ZIKV may be identified from the" exact="rilpivirine" post="analogs. Meanwhile, efforts could be made to solve the"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC6913311\results\search\drug\results.xml">
   <result pre="10% fetal calf serum (FCS; Biosera, Kansas City, MO, U.S.A.)," exact="penicillin G" post="(100 units/ml, Meiji Seika Pharma, Tokyo, Japan), and streptomycin"/>
   <result pre="penicillin G (100 units/ml, Meiji Seika Pharma, Tokyo, Japan), and" exact="streptomycin" post="(100â€‰Âµg/ml, Meiji Seika Pharma). Human influenza virus strain A/Udorn/72"/>
   <result pre="at concentrations of 2.5 or 3â€‰mg/ml in DMEM supplemented with" exact="penicillin G" post="and streptomycin at 50Â°C for 1â€‰h, clarified by low-speed"/>
   <result pre="2.5 or 3â€‰mg/ml in DMEM supplemented with penicillin G and" exact="streptomycin" post="at 50Â°C for 1â€‰h, clarified by low-speed centrifugation following"/>
   <result pre="drugs, a reagent at a concentration of 12.5â€‰mg/ml was used." exact="Ethanol" post="(70%) was used for an inactivating control. 2.5. Investigation"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC6943894\results\search\drug\results.xml">
   <result pre="cells were fixed with 10% formaldehyde and stained with 1%" exact="crystal violet." post="Quantitative RT-PCR assays for vRNA and mRNA To evaluate"/>
   <result pre="residues 31, 377 and 450 of NP on polymerase activity," exact="alanine" post="substitutions were analyzed. Both 31A and 450A, but not"/>
   <result pre="33â€‰Â°C and 37â€‰Â°C (Fig. 3c and d). Thus, we suggest" exact="alanine" post="substitution at 31 and 450 of NP dramatically decreased"/>
   <result pre="NP at (a) 33â€‰Â°C and (b) 37â€‰Â°C. Polymerase activity with" exact="alanine" post="point substitutions was also analyzed both at (c) 33â€‰Â°C"/>
   <result pre="via regulation of the polymerase activity. Reverse genetics viruses with" exact="alanine" post="mutation at residues 31, 377 and 450 were also"/>
   <result pre="exist at sites that have yet to be identified. Via" exact="alanine" post="mutation and reverse genetics system, 74 conserved residues among"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC6954140\results\search\drug\results.xml">
   <result pre="seroconverted were homeless and injected heroin, often in combination with" exact="cocaine" post="(speedball). TableÂ 1 Characteristics of individuals within the HIV"/>
   <result pre="Unknown 0 5 (50.0) 25 (78.1) Reported drug use Â" exact="Heroin" post="7 (100) 5 (50.0) 6 (18.8) Â Cocaine 5"/>
   <result pre="use Â Heroin 7 (100) 5 (50.0) 6 (18.8) Â" exact="Cocaine" post="5 (71.4) 4 (40.0) 6 (18.8) Â Methamphetamine 1"/>
   <result pre="(18.8) Â Cocaine 5 (71.4) 4 (40.0) 6 (18.8) Â" exact="Methamphetamine" post="1 (14.3) 2 (20.0) 3 (9.4) Â Crack 1"/>
   <result pre="city with versus a city without needle and syringe programsDrug" exact="Alcohol" post="Depend20121231â€&quot;325525910.1016/j.drugalcdep.2011.12.00122209091 15.OsterAMFranceAMPanneerNBanez OcfemiaMCCampbellEDasguptaSet al.Identifying clusters of recent and rapid"/>
   <result pre="CityPLoS Pathog2017131e100600010.1371/journal.ppat.100600028068413 18.PetersPJPontonesPHooverKWPatelMRGalangRRShieldsJet al.HIV infection linked to injection use of" exact="oxymorphone" post="in Indiana, 2014â€&quot;2015N Engl J Med201637522923910.1056/NEJMoa151519527468059 19.ParaskevisDParaschivSSypsaVNikolopoulosGTsiaraCMagiorkinisGet al.Enhanced HIV-1"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC6958409\results\search\drug\results.xml">
   <result pre="the clinic are Matrix 2 (M2) ion channel inhibitors, (e.g.," exact="amantadine" post="and rimantadine) and neuraminidase (NA) inhibitors (e.g., oseltamivir and"/>
   <result pre="M2 and compared the efficacy of the novel compounds to" exact="amantadine" post="which led to new lead compounds against M2 [134,135]."/>
   <result pre="found to have a more severe phenotype than females. Importantly," exact="amantadine" post="was shown to rescue the M2 phenotype, suggesting Drosophila"/>
   <result pre="reactive oxygen species (ROS) and had increased expression of nicotinamide" exact="adenine" post="dinucleotide phosphate oxidases (Nox) [256]. One particular Nox that"/>
   <result pre="on NECs derived from male and female donors, showing that" exact="estrogen" post="exhibited protective effects upon infection in female, but not"/>
   <result pre="and ProtocolsJimenezG.SpringerNew York, NY, USA2017658810.1007/978-1-4939-6424-6_5 117.DeverT.E.ChenJ.J.BarberG.N.CiganA.M.FengL.DonahueT.F.LondonI.M.KatzeM.G.HinnebuschA.G.Mammalian eukaryotic initiation factor 2" exact="alpha" post="kinases functionally substitute for GCN2 protein kinase in the"/>
   <result pre="virus NS1 and Postsynaptic density protein-95 (PSD-95), and inhibition of" exact="nitric oxide" post="productionVirol. J.2011829810.1186/1743-422X-8-29821668967 152.WolffT.Oâ€™NeillR.E.PaleseP.Interaction cloning of NS1-I, a human protein"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC6958466\results\search\drug\results.xml">
   <result pre="NS5 methyltransferase inhibitors: The structure of ZIKV MTase with the" exact="S-adenosyl-L-methionine" post="(SAM) analog, sinefungin was recently elucidated. In the structural"/>
   <result pre="ZIKV (EC50 = 142.9 mg/mL) [126]. However, poor inhibition of" exact="ribavirin" post="as shown in the above virus-induced CPE study indicates"/>
   <result pre="further development particularly as antivirals against ZIKV [127]. BCX4430 an" exact="adenosine" post="nucleoside analog has shown EC50 values in the low"/>
   <result pre="safety and better efficacy evaluations. Another RdRp inhibitor, NITD008, an" exact="adenosine" post="nucleoside analog, has also exhibited antiviral activity against ZIKV"/>
   <result pre="the hypothesis by demonstrating anti-ZIKV activities of compounds such as" exact="warfarin" post="and a few similar structural analogues identified using in"/>
   <result pre="strain and 0.49 mM for the PRVABC59 strain. Another compound," exact="Niclosamide" post="blocks the acidification of endosomes but probably with a"/>
   <result pre="based on the measurement of intracellular viral RNA [95]. Incidentally," exact="niclosamide" post="is an FDA-approved drug, mainly used in the treatment"/>
   <result pre="in the published literature [85], we identified three antimalarial aminoquinolines," exact="Quinacrine" post="(QC), Mefloquine (MQ), and GSK369796 active against ZIKV in"/>
   <result pre="characterization of protein sequences and application to voltage-gated sodium channel" exact="alpha" post="subunit phylogenySilico Biol.20099778710.3233/ISB-2009-0389 60.GhoshA.ChattopadhyayS.Chawla-SarkarM.NandyP.NandyA.In Silico Study of Rotavirus VP7"/>
   <result pre="to Carrier ProteinsJ. Am. Chem. Soc.19881105959596710.1021/ja00226a00522148765 71.WangZ.LiY.AiC.WangY.In Silico Prediction of" exact="Estrogen" post="Receptor Subtype Binding Affinity and Selectivity Using Statistical Methods"/>
   <result pre="congenital microcephaly in miceEBioMedicine20172418919410.1016/j.ebiom.2017.09.03429033372 156.ShiryaevS.A.MesciP.PintoA.FernandesI.SheetsN.ShrestaS.FarhyC.HuangC.-T.StronginA.Y.MuotriA.R.et al.Repurposing of the anti-malaria drug" exact="chloroquine" post="for Zika virus treatment and prophylaxisSci. Rep.201771577110.1038/s41598-017-15467-629150641 157.HanY.MespledeT.XuH.QuanY.WainbergM.A.The antimalarial"/>
   <result pre="compounds having the potential to be drugs. Compounds Derivatives Reference" exact="Chloroquine" post="Derivatives particularly at the C-4 position of N-(2-arylmethylimino)ethyl-7-chloroquinolin-4-amine derivatives"/>
   <result pre="Derivatives particularly at the C-4 position of N-(2-arylmethylimino)ethyl-7-chloroquinolin-4-amine derivatives [98]" exact="Quinacrine" post="(QC), Mefloquine (MQ), and GSK369796 Antimalarial aminoquinoline derivatives [41,87]"/>
   <result pre="anti-ZIKV activity of which five were found promising. These are" exact="Lovastatin" post="(Pubchem CID: 53232), 5-Fluorouracil (Pubchem CID: 3385); 6-Azauridine (Pubchem"/>
   <result pre="five were found promising. These are Lovastatin (Pubchem CID: 53232)," exact="5-Fluorouracil" post="(Pubchem CID: 3385); 6-Azauridine (Pubchem CID: 5901); Palonosetron (Pubchem"/>
   <result pre="in vitro plaque assay [104] NITD008 A type of nucleoside" exact="adenosine" post="analog [105] Warfarin and a few similar structural analogues"/>
   <result pre="assay [104] NITD008 A type of nucleoside adenosine analog [105]" exact="Warfarin" post="and a few similar structural analogues Inhibitors of dimerization"/>
   <result pre="methyltransferase inhibitor [111] 6-azauridine and 5-fluorouracil Pyrimidine biosynthesis inhibitors [93,95]" exact="Lovastatin" post="and Mevastatin HMG-CoA reductase inhibitor [112] BCX4430 An adenosine"/>
   <result pre="[93,95] Lovastatin and Mevastatin HMG-CoA reductase inhibitor [112] BCX4430 An" exact="adenosine" post="nucleoside analog, functions as a selective inhibitor of viral"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC6968813\results\search\drug\results.xml">
   <result pre="of TB showing resistance to single first-line anti-TB drugs only." exact="Isoniazid" post="(H) resistance is a type of mono-DR-TB and has"/>
   <result pre="to more than one first-line anti-TB drug other than both" exact="rifampicin" post="(R) and H. RR-TB is defined as a case"/>
   <result pre="drugs â€&quot; at least one of three FQs (ofloxacin [Ofx]," exact="levofloxacin" post="[Lfx], moxifloxacin [Mfx]) or one of three SLIDs (capreomycin"/>
   <result pre="[Lfx], moxifloxacin [Mfx]) or one of three SLIDs (capreomycin [Cm]," exact="kanamycin" post="[Km], amikacin (Am)] but not to both â€&quot; also"/>
   <result pre="[Mfx]) or one of three SLIDs (capreomycin [Cm], kanamycin [Km]," exact="amikacin" post="(Am)] but not to both â€&quot; also known as"/>
   <result pre="state; drug malabsorption of anti-TB drugs, such as R and" exact="ethambutol" post="(E), leading to drug resistance and treatment failure; early"/>
   <result pre="1â€&quot;2 days. Resistance can be detected by WGS for even" exact="bedaquiline" post="(Bdq) and delamanid (Dlm) lacking validated DST. However, there"/>
   <result pre="can be detected by WGS for even bedaquiline (Bdq) and" exact="delamanid" post="(Dlm) lacking validated DST. However, there are various concerns"/>
   <result pre="smear) with Km, gatifloxacin (Gfx) or Mfx, prothionamide (Pto)/ethionamide (Eto)," exact="clofazimine" post="(Cfz), high-dose H, Z, and E followed by a"/>
   <result pre="evidence regarding treatment outcome and profile of ADRs, especially with" exact="linezolid" post="(Lzd), Cfz, Bdq, and Dlm.1 The conventional regimen contains"/>
   <result pre="a regimen to achieve better outcomes. High-dose H, Gfx, and" exact="clarithromycin" post="(Clr) have been omitted from a recent classification, because"/>
   <result pre="for treatment of HIV Group Antiretroviral drugs Nucleoside reverse-transcriptase inhibitors" exact="Zidovudine" post="(Azt/Zdv); stavudine (d4T); lamivudine (3TC); abacavir (Abc); didanosine (ddl);"/>
   <result pre="of HIV Group Antiretroviral drugs Nucleoside reverse-transcriptase inhibitors Zidovudine (Azt/Zdv);" exact="stavudine" post="(d4T); lamivudine (3TC); abacavir (Abc); didanosine (ddl); zalcitabine (ddC);"/>
   <result pre="Group Antiretroviral drugs Nucleoside reverse-transcriptase inhibitors Zidovudine (Azt/Zdv); stavudine (d4T);" exact="lamivudine" post="(3TC); abacavir (Abc); didanosine (ddl); zalcitabine (ddC); emtricitabine (FTC)"/>
   <result pre="drugs Nucleoside reverse-transcriptase inhibitors Zidovudine (Azt/Zdv); stavudine (d4T); lamivudine (3TC);" exact="abacavir" post="(Abc); didanosine (ddl); zalcitabine (ddC); emtricitabine (FTC) Nucleotide reverse-transcriptase"/>
   <result pre="reverse-transcriptase inhibitors Zidovudine (Azt/Zdv); stavudine (d4T); lamivudine (3TC); abacavir (Abc);" exact="didanosine" post="(ddl); zalcitabine (ddC); emtricitabine (FTC) Nucleotide reverse-transcriptase inhibitors Tenofovir"/>
   <result pre="Zidovudine (Azt/Zdv); stavudine (d4T); lamivudine (3TC); abacavir (Abc); didanosine (ddl);" exact="zalcitabine" post="(ddC); emtricitabine (FTC) Nucleotide reverse-transcriptase inhibitors Tenofovir (TDF) Nonâ€&quot;nucleoside"/>
   <result pre="stavudine (d4T); lamivudine (3TC); abacavir (Abc); didanosine (ddl); zalcitabine (ddC);" exact="emtricitabine" post="(FTC) Nucleotide reverse-transcriptase inhibitors Tenofovir (TDF) Nonâ€&quot;nucleoside reverse-transcriptase inhibitors"/>
   <result pre="emtricitabine (FTC) Nucleotide reverse-transcriptase inhibitors Tenofovir (TDF) Nonâ€&quot;nucleoside reverse-transcriptase inhibitors" exact="Nevirapine" post="(Nvp); efavirenz (Efv); delavirdine (Dlv); rilpivirine (Rpv); eltravirine (Etv)"/>
   <result pre="Nucleotide reverse-transcriptase inhibitors Tenofovir (TDF) Nonâ€&quot;nucleoside reverse-transcriptase inhibitors Nevirapine (Nvp);" exact="efavirenz" post="(Efv); delavirdine (Dlv); rilpivirine (Rpv); eltravirine (Etv) Protease inhibitors"/>
   <result pre="(TDF) Nonâ€&quot;nucleoside reverse-transcriptase inhibitors Nevirapine (Nvp); efavirenz (Efv); delavirdine (Dlv);" exact="rilpivirine" post="(Rpv); eltravirine (Etv) Protease inhibitors Saquinavir (Sqv); ritonavir (Rtv);"/>
   <result pre="efavirenz (Efv); delavirdine (Dlv); rilpivirine (Rpv); eltravirine (Etv) Protease inhibitors" exact="Saquinavir" post="(Sqv); ritonavir (Rtv); nelfinavir (Nfv); amprenavir (Apv); indinavir (Inv);"/>
   <result pre="delavirdine (Dlv); rilpivirine (Rpv); eltravirine (Etv) Protease inhibitors Saquinavir (Sqv);" exact="ritonavir" post="(Rtv); nelfinavir (Nfv); amprenavir (Apv); indinavir (Inv); lopinavir (Lpv);"/>
   <result pre="rilpivirine (Rpv); eltravirine (Etv) Protease inhibitors Saquinavir (Sqv); ritonavir (Rtv);" exact="nelfinavir" post="(Nfv); amprenavir (Apv); indinavir (Inv); lopinavir (Lpv); fosamprenavir (Fpv);"/>
   <result pre="eltravirine (Etv) Protease inhibitors Saquinavir (Sqv); ritonavir (Rtv); nelfinavir (Nfv);" exact="amprenavir" post="(Apv); indinavir (Inv); lopinavir (Lpv); fosamprenavir (Fpv); atazanavir (Atv);"/>
   <result pre="Saquinavir (Sqv); ritonavir (Rtv); nelfinavir (Nfv); amprenavir (Apv); indinavir (Inv);" exact="lopinavir" post="(Lpv); fosamprenavir (Fpv); atazanavir (Atv); tipranavir (Tpv); darunavir (Drv)"/>
   <result pre="ritonavir (Rtv); nelfinavir (Nfv); amprenavir (Apv); indinavir (Inv); lopinavir (Lpv);" exact="fosamprenavir" post="(Fpv); atazanavir (Atv); tipranavir (Tpv); darunavir (Drv) Integrase strandâ€&quot;transferase"/>
   <result pre="nelfinavir (Nfv); amprenavir (Apv); indinavir (Inv); lopinavir (Lpv); fosamprenavir (Fpv);" exact="atazanavir" post="(Atv); tipranavir (Tpv); darunavir (Drv) Integrase strandâ€&quot;transferase inhibitors Raltegravir"/>
   <result pre="amprenavir (Apv); indinavir (Inv); lopinavir (Lpv); fosamprenavir (Fpv); atazanavir (Atv);" exact="tipranavir" post="(Tpv); darunavir (Drv) Integrase strandâ€&quot;transferase inhibitors Raltegravir (Rgv); elvitegravir"/>
   <result pre="established coinfection Regimens for DR-TB component Regimens for HIV component" exact="Isoniazid" post="(H) mono/polydrug resistanceWHO 2016 IP (3â€&quot;6 months): Lfx +"/>
   <result pre="cases of H-monoresistant or poly-DR-TB: R to be substituted with" exact="rifabutin" post="or rifapentine if patient is on PI or integrase"/>
   <result pre="or integrase inhibitors. The currently approved regimen includes tenofovir (TDF)," exact="lamivudine" post="(3TC), and efavirenz (Efv)/nevirapine (Nvp) or dolutegravir (Dtg), if"/>
   <result pre="The currently approved regimen includes tenofovir (TDF), lamivudine (3TC), and" exact="efavirenz" post="(Efv)/nevirapine (Nvp) or dolutegravir (Dtg), if available. Second-line regimens"/>
   <result pre="recommended second-line regimens for adults include two NRTIs, such as" exact="zidovudine" post="(Azt) with 3TC, and a boosted protease inhibitor (PI),"/>
   <result pre="drugs. NRTIs, PIs, integrase strandâ€&quot;transferase inhibitors, and the CCR5 antagonist" exact="maraviroc" post="are more prone to interactions with R than NRTIs,"/>
   <result pre="by CYP3A4 and have weak inhibitory activity. Of all PIs," exact="ritonavir" post="has a potent inhibitory effect on CYP3A4 and Pgp."/>
   <result pre="mono-DR-TB. Relevant drugâ€&quot;drug interactions are described in Table 4. Buffered" exact="didanosine" post="(ddl), which contains an aluminum magnesiumâ€&quot;based antacid, may result"/>
   <result pre="(inhibitor) Pgp/BCRP/MRP1 R (inducer); Cfz (inhibitor) All PIs; Efv; Nvp;" exact="maraviroc" post="Uridine 5Ê¹-diphospho-glucuronosyltransferase (UGT) R (inducer); Cfz (inducer); Clr (inducer);"/>
   <result pre="neuropathy associated primarily with either HIV infection or combination with" exact="stavudine" post="(d4T) and also bone-marrow depression when coadministered with Azt."/>
   <result pre="(D4T, ddI, or ddC) in future.â—� Also consider gallstones or" exact="alcohol" post="as a potential cause of pancreatitis Diarrhea All protease"/>
   <result pre="Hepatotoxicity Nvp, Efv, all PIs, all NsRTIs, all integrase inhibitors," exact="maraviroc" post="H, R, E, Z, PAS, Eto/Pto, Ofx, Lfx, Mfx,"/>
   <result pre="B, C, and CMV) Skin rash Abc, Nvp, Efv, D4T," exact="maraviroc" post="H, R, Z, PAS, Am, Km, Ofx, Lfx, Mfx,"/>
   <result pre="â—� Clinical correlation to rule out offending drugâ—� Monitoring with" exact="creatine" post="phosphokinaseâ—� Thorough clinical evaluation to rule out HIV-associated myopathyâ—�"/>
   <result pre="on three components known as the â€œthree Isâ€�: intensified case-finding," exact="isoniazid" post="preventive therapy, and infection control. The Joint United Nations"/>
   <result pre="both first- and second-line anti-TB drugs, and DST-tailored individualized treatment." exact="Prompt" post="initiation of appropriate anti-TB regimens tailored to DST results"/>
   <result pre="for diagnosis of drug-resistant tuberculosis in people living with HIV." exact="Prompt" post="Introduction of ART in M/XDR-TB/HIV Patients as Soon as"/>
   <result pre="often infected with the same strain as the index case." exact="Prompt" post="treatment of the index case with DR-TB should be"/>
   <result pre="suspected and investigated further with the CBNAAT or appropriate investigation." exact="Prompt" post="initiation of treatment with a regimen designed to treat"/>
   <result pre="14.LawnSD, BrooksSV, KranzerK, et al. Screening for HIV-associated tuberculosis and" exact="rifampicin" post="resistance before antiretroviral therapy using the xpert MTB/RIF assay:"/>
   <result pre="amplification technology for rapid and simultaneous detection of tuberculosis and" exact="rifampicin" post="resistance: xpert MTB/RIF assay for the diagnosis of pulmonary"/>
   <result pre="al. Xpert MTB/RIF Ultra for detection of Mycobacterium tuberculosis and" exact="rifampicin" post="resistance: a prospective multi-centre diagnostic accuracy study. Lancet Infect"/>
   <result pre="2008;198(7):948â€&quot;961. doi:10.1086/59145918713054 63.SemvuaHH, KibikiGS, KisangaER, et al. Pharmacological interactions between" exact="rifampicin" post="and antiretroviral drugs: challenges and research priorities for resource-limited"/>
   <result pre="2015;37:22â€&quot;32. doi:10.1097/FTD.000000000000010824943062 64.Oâ€™DonnellMR, PadayatchiN, DaftaryA, et al. Antiretroviral switching and" exact="bedaquiline" post="treatment of drug-resistant tuberculosis HIV co-infection. Lancet HIV. 2019;6(3):e201â€&quot;e204."/>
   <result pre="co-infection. Lancet HIV. 2019;6(3):e201â€&quot;e204. doi:10.1016/S2352-3018(19)30035-930846058 65.MallikaarjunS, WellsC, PetersenC, et al." exact="Delamanid" post="co-administered with antiretroviral drugs or anti-tuberculosis drugs shows no"/>
   <result pre="SaraceniV, MoultonLH, et al. Effect of improved tuberculosis screening and" exact="isoniazid" post="preventive therapy on incidence of tuberculosis and death in"/>
   <result pre="trial. Lancet Infect Dis. 2013;13(10):852â€&quot;858. doi:10.1016/S1473-3099(13)70187-723954450 100.AyeleHT, MourikMS, DebrayTP, BontenMJ." exact="Isoniazid" post="prophylactic therapy for the prevention of tuberculosis in HIV"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC6977312\results\search\drug\results.xml">
   <result pre="[84], sheathing of the vessels, which are best explored using" exact="fluorescein" post="angiography. In series, vitreous reaction with vitreal haze or"/>
   <result pre="with aqueous flare and fine non-granulomatous keratic precipitates [84, 85]." exact="Fluorescein" post="angiography performed during the active phase of the disease"/>
   <result pre="vessels sheathing and staining, and vascular occlusions when present. Follow-up" exact="fluorescein" post="angiography performed several months after RVF diagnosis have revealed"/>
   <result pre="or non-granulomatous anterior uveitis Stromal keratitis Several weeks after inoculation" exact="Ceftriaxone" post="Doxycycline Topical or systemic corticosteroids Rickettsia spp. White retinal"/>
   <result pre="non-granulomatous anterior uveitis Stromal keratitis Several weeks after inoculation Ceftriaxone" exact="Doxycycline" post="Topical or systemic corticosteroids Rickettsia spp. White retinal lesions"/>
   <result pre="retinal vessels Mild to moderate vitreous reaction No No â€&quot;" exact="Doxycycline" post="Systemic corticosteroids Dengue virus Maculopathy with macular edema, focal"/>
   <result pre="central (10%) Mild vitreous reaction Mild anterior uveitis No â€&quot;" exact="Ganciclovir" post="Foscarnet HSV Retinal edema, ARN syndrome, macular yellowish exudative"/>
   <result pre="uveitis bilateral in 50% Stromal keratitis Several weeks after inoculation" exact="Penicillin G" post="Topical or systemic corticosteroids RPE retinal pigment epithelium, ONH"/>
   <result pre="to a reference center. If necessary, whole-blood specimens can be" exact="dried" post="on blotting paper, stored 30â€&quot;60Â days and transported without"/>
   <result pre="available. Iatrogenic use of medications such as hepatotoxic analgesics (acetaminophen)," exact="aspirin" post="or non-steroid anti-inflammatory drugs, which enhance the risk of"/>
   <result pre="evaluated the feasibility of a randomized, placebo-controlled trial using intravenous" exact="ribavirin" post="in patients with suspected severe RVF, but no official"/>
   <result pre="Pathogens Laboratory Network in 2016, it was briefly mentioned that" exact="ribavirin" post="was used without efficacy in Saudi Arabia [101]. Evidence"/>
   <result pre="was used without efficacy in Saudi Arabia [101]. Evidence suggests" exact="ribavirin" post="efficacy in animal models [102, 103], but it failed"/>
   <result pre="neuropathology in mice infected by RVFV by aerosol exposure [75]." exact="Ribavirin" post="is recommended for the treatment and the prophylaxis of"/>
   <result pre="case reports of encephalitis, the use of amantadine, rifampicin, and" exact="dexamethasone" post="[72], doubled prednisone doses with a stop in immunosuppressive"/>
   <result pre="encephalitis, the use of amantadine, rifampicin, and dexamethasone [72], doubled" exact="prednisone" post="doses with a stop in immunosuppressive drugs [74], and"/>
   <result pre="prednisone doses with a stop in immunosuppressive drugs [74], and" exact="phenytoin" post="[70] were reported but not evaluated precisely. Early renal"/>
   <result pre="funduscopy by indirect ophthalmoscopy. In case of RVF signs, a" exact="fluorescein" post="angiography should be performed as well as fundus photography"/>
   <result pre="a delayed peripapillary choroidal filling in the arteriovenous phase of" exact="fluorescein" post="angiography has been described [38, 85]. Optic Coherence Tomography"/>
   <result pre="lâ€™homme. https://studylibfr.com/doc/1012718/fiÃ¨vre-de-la-vallÃ©e-du-rift-en-afriqueâ€&quot;aspects-cliniques. Accessed 30 June 2019. 102.KendeMAlvingCRRillWLSwartzGMCanonicoPGEnhanced efficacy of liposome-encapsulated" exact="ribavirin" post="against Rift Valley fever virus infection in miceAntimicrob Agents"/>
   <result pre="the literature and proposed guidelines for the use of oral" exact="ribavirin" post="as postexposure prophylaxis for Lassa feverClin Infect Dis2010511435144110.1086/65731521058912 106.IslamMKStrandMSaleebMSvenssonRBaranczewskiPArturssonPet"/>
   <result pre="fever virus infection and reduces delayed-onset neurologic disease observed with" exact="ribavirin" post="treatmentAntiviral Res2014104849210.1016/j.antiviral.2014.01.01624486952 108.SmeeDFJungK-HWestoverJGowenBB2â€²-Fluoro-2â€²-deoxycytidine is a broad-spectrum inhibitor of bunyaviruses"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC6993835\results\search\drug\results.xml">
   <result pre="2. Convulsions are best managed with intravenous anticonvulsants such as" exact="phenytoin" post="or valproate which do not depress the sensorium. Tube"/>
   <result pre="to 1.0 mg/kg every 4 to 6 hours) or intravenous" exact="furosemide" post="may be needed. Hypertonic saline (3%) in a dose"/>
   <result pre="of viral infection with steroids. A study that evaluated high-dose" exact="dexamethasone" post="in JE found no benefit of steroid therapy 55."/>
   <result pre="centers in the West, in the absence of an epidemic," exact="acyclovir" post="is started as soon as VE is suspected clinically,"/>
   <result pre="country is not really known. It seems reasonable to start" exact="acyclovir" post="in non-seasonal cases, especially if focal features are present"/>
   <result pre="reveal temporal lobe involvement. The toxicity and side effects of" exact="acyclovir" post="include bone marrow suppression, vomiting and hypotension after intravenous"/>
   <result pre="in as high as 5% of cases 54. Resistance to" exact="acyclovir" post="is rare (about 0.5% in immunocompetent patients) 58. Foscarnet"/>
   <result pre="59. Acyclovir is also recommended for varicella zoster encephalitis, and" exact="ganciclovir" post="is an alternative drug. A combination of ganciclovir and"/>
   <result pre="encephalitis, and ganciclovir is an alternative drug. A combination of" exact="ganciclovir" post="and foscarnet is recommended for cytomegaloviral encephalitis 59. Pleconaril"/>
   <result pre="be considered for influenza (H1N1) encephalitis/encephalopathy 59. Trials with interferon" exact="alpha" post="and nasogastric ribavirin in JE in children have revealed"/>
   <result pre="influenza (H1N1) encephalitis/encephalopathy 59. Trials with interferon alpha and nasogastric" exact="ribavirin" post="in JE in children have revealed no benefit 61,"/>
   <result pre="JE in children have revealed no benefit 61, 62. The" exact="tetracycline" post="drug minocycline is a known neuroprotective agent with antiviral"/>
   <result pre="at 3 months from onset and neurologic sequelae 63. Intravenous" exact="azithromycin" post="or oral minocycline/doxycycline is currently recommended for rickettsial meningoencephalitis"/>
   <result pre="for rickettsial meningoencephalitis 64.Treatment of AIE is immunosuppression through high-dose" exact="methylprednisolone" post="pulse therapy, intravenous immunoglobulin, plasmapheresis, rituximab, and azathioprine 31."/>
   <result pre="through high-dose methylprednisolone pulse therapy, intravenous immunoglobulin, plasmapheresis, rituximab, and" exact="azathioprine" post="31. References 1ProberCGSrinivasNS: Viral meningoencephalitis.In: Nelson Textbook of Pediatrics,"/>
   <result pre="Intracranial Pressure.J Neurocrit Care.2016;9(2):105â€&quot;12. 10.18700/jnc.160101 55HokeCHJrVaughnDWNisalakAet al.: Effect of high-dose" exact="dexamethasone" post="on the outcome of acute encephalitis due to Japanese"/>
   <result pre="First South Asia Edn,2016;1572â€&quot;8. Reference Source 57de MirandaPBlumMR: Pharmacokinetics of" exact="acyclovir" post="after intravenous and oral administration.J Antimicrob Chemother.1983;12(Suppl B):29â€&quot;37. 10.1093/jac/12.suppl_b.296355048"/>
   <result pre="placebo-controlled trial.Lancet.2003;361(9360):821â€&quot;6. 10.1016/s0140-6736(03)12709-212642049 62KumarRTripathiPBaranwalMet al.: Randomized, controlled trial of oral" exact="ribavirin" post="for Japanese encephalitis in children in Uttar Pradesh, India.Clin"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7001263\results\search\drug\results.xml">
   <result pre="[14]. Recognizing the scale of PWID, primarily the use of" exact="heroin" post="[14] and high prevalence of HIV infection among them"/>
   <result pre="problems, and prior treatment experience in a sample of young" exact="heroin" post="injectors in Dar es Salaam, TanzaniaAfr J Drug Alcohol"/>
   <result pre="young heroin injectors in Dar es Salaam, TanzaniaAfr J Drug" exact="Alcohol" post="Stud20111011923024611"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7004624\results\search\drug\results.xml">
   <result pre="doi: 10.1111/j.1537-2995.2011.03078.x.21382047 24.PetersPJPontonesPHooverKWPatelMRGalangRRShieldsJet al.HIV infection linked to injection use of" exact="oxymorphone" post="in Indiana, 2014â€&quot;2015. N Engl J Med2016; 375:229â€&quot;239. doi:"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7019949\results\search\drug\results.xml">
   <result pre="blood-borne infections among injection drug users: Understanding the epidemiologic bridgeDrug" exact="Alcohol" post="Depend.20079010711910.1016/j.drugalcdep.2007.03.01417485179 22.PannetierJ.RavalihasyA.LydieN.LertF.Desgrees du LouA.Parcours studyG.Prevalence and circumstances of forced"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7020194\results\search\drug\results.xml">
   <result pre="in A431 skin epidermoid carcinoma cells. They further showed that" exact="gefitinib" post="upregulated CD151 protein levels in MDA-MB-231 breast and A549"/>
   <result pre="(2002). Expression of the palmitoylation-deficient CD151 weakens the association of" exact="alpha" post="3 beta 1 integrin with the tetraspanin-enriched microdomains and"/>
   <result pre="lung cancer.Cancers11:597. 10.3390/cancers1105059731035440 NguyenN. M.MinerJ. H.PierceR. A.SeniorR. M. (2002). Laminin" exact="alpha" post="5 is required for lobar septation and visceral pleural"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7064018\results\search\drug\results.xml">
   <result pre="Yet unconfirmed reports indicated that inhibitors of SARS-CoV-2 replication including" exact="chloroquine" post="are clinical efficient against declared SARS-CoV-2 infection [62â€&quot;64]. If"/>
   <result pre="against declared SARS-CoV-2 infection [62â€&quot;64]. If these findings are confirmed," exact="chloroquine" post="might be used to prophylactically treat vulnerable individuals (in"/>
   <result pre="medical problems) that have a high risk of viral exposure." exact="Chloroquine" post="has been used for decades for the prevention and"/>
   <result pre="with SARS-CoV-2 in Wuhan, China.Allergy.202010.1111/all.14238 62WangMCaoRZhangLYangXLiuJXuMShiZHuZZhong W and XiaoGRemdesivir and" exact="chloroquine" post="effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in"/>
   <result pre="novel coronavirus SARS-CoV-2.Int J Antimicrob Agents2020202010592310.1016/j.ijantimicag.2020.105923 64GaoJTian Z and YangXBreakthrough:" exact="Chloroquine" post="phosphate has shown apparent efficacy in treatment of COVID-19"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7073332\results\search\drug\results.xml">
   <result pre="cell lines. We further identify three potential drug combinations (e.g.," exact="sirolimus" post="plus dactinomycin, mercaptopurine plus melatonin, and toremifene plus emodin)"/>
   <result pre="further identify three potential drug combinations (e.g., sirolimus plus dactinomycin," exact="mercaptopurine" post="plus melatonin, and toremifene plus emodin) captured by the"/>
   <result pre="drug combinations (e.g., sirolimus plus dactinomycin, mercaptopurine plus melatonin, and" exact="toremifene" post="plus emodin) captured by the â€œComplementary Exposureâ€� pattern: the"/>
   <result pre="drugs. bâ€&quot;e Inferred mechanism-of-action networks for four selected drugs: b" exact="toremifene" post="(first-generation nonsteroidal-selective estrogen receptor modulator), c irbesartan (an angiotensin"/>
   <result pre="mechanism-of-action networks for four selected drugs: b toremifene (first-generation nonsteroidal-selective" exact="estrogen" post="receptor modulator), c irbesartan (an angiotensin receptor blocker), d"/>
   <result pre="selected drugs: b toremifene (first-generation nonsteroidal-selective estrogen receptor modulator), c" exact="irbesartan" post="(an angiotensin receptor blocker), d mercaptopurine (an antimetabolite antineoplastic"/>
   <result pre="estrogen receptor modulator), c irbesartan (an angiotensin receptor blocker), d" exact="mercaptopurine" post="(an antimetabolite antineoplastic agent with immunosuppressant properties), and e"/>
   <result pre="mercaptopurine (an antimetabolite antineoplastic agent with immunosuppressant properties), and e" exact="melatonin" post="(a biogenic amine for treating circadian rhythm sleep disorders)."/>
   <result pre="HSV-1 and -2 herpes simplex viruses, CVB4 Coxsackievirus B4. Selective" exact="estrogen" post="receptor modulators An overexpression of estrogen receptor has been"/>
   <result pre="CVB4 Coxsackievirus B4. Selective estrogen receptor modulators An overexpression of" exact="estrogen" post="receptor has been shown to play a crucial role"/>
   <result pre="to play a crucial role in inhibiting viral replication37. Selective" exact="estrogen" post="receptor modulators (SERMs) have been reported to play a"/>
   <result pre="in inhibiting viral replication through the non-classical pathways associated with" exact="estrogen" post="receptor37. SERMs interfere at the post viral entry step"/>
   <result pre="activity still can be observed in the absence of detectable" exact="estrogen" post="receptor expression18. Toremifene (Zâ€‰=â€‰â€&quot;3.23, Fig. 5a), the first generation"/>
   <result pre="be observed in the absence of detectable estrogen receptor expression18." exact="Toremifene" post="(Zâ€‰=â€‰â€&quot;3.23, Fig. 5a), the first generation of nonsteroidal SERM,"/>
   <result pre="established cell lines17,38. Compared to the classical ESR1-related antiviral pathway," exact="toremifene" post="prevents fusion between the viral and endosomal membrane by"/>
   <result pre="and eventually inhibiting viral replication39. As shown in Fig. 5b," exact="toremifene" post="potentially affects several key host proteins associated with HCoV,"/>
   <result pre="HCoV, such as RPL19, HNRNPA1, NPM1, EIF3I, EIF3F, and EIF3E40,41." exact="Equilin" post="(Zâ€‰=â€‰â€&quot;2.52 and GSEA scoreâ€‰=â€‰3), an estrogenic steroid produced by"/>
   <result pre="and human immunodeficiency virus (ZEBOV-GP/HIV)18. Altogether, network-predicted SERMs (such as" exact="toremifene" post="and equilin) offer candidate repurposable drugs for 2019-nCoV/SARS-CoV-2. Angiotensin"/>
   <result pre="have been reported to associate with viral infection, including HCoVs42â€&quot;44." exact="Irbesartan" post="(Zâ€‰=â€‰â€&quot;5.98), a typical ARB, was approved by the FDA"/>
   <result pre="proteins in the human interactome. As shown in Fig. 5c," exact="irbesartan" post="targets SLC10A1, encoding the sodium/bile acid cotransporter (NTCP) protein"/>
   <result pre="hepatitis B virus (HBV) and the hepatitis delta virus (HDV)." exact="Irbesartan" post="can inhibit NTCP, thus inhibiting viral entry45,46. SLC10A1 interacts"/>
   <result pre="antineoplastic agents Previous studies have confirmed the mammalian target of" exact="rapamycin" post="complex 1 (mTORC1) as the key factor in regulating"/>
   <result pre="(Zâ€‰=â€‰â€&quot;2.35 and GSEA scoreâ€‰=â€‰3), an inhibitor of mammalian target of" exact="rapamycin" post="(mTOR), was reported to effectively block viral protein expression"/>
   <result pre="release effectively50. Indeed, the latest study revealed the clinical application:" exact="sirolimus" post="reduced MERS-CoV infection by over 60%51. Moreover, sirolimus usage"/>
   <result pre="clinical application: sirolimus reduced MERS-CoV infection by over 60%51. Moreover," exact="sirolimus" post="usage in managing patients with severe H1N1 pneumonia and"/>
   <result pre="and acute respiratory failure can improve those patientsâ€™ prognosis significantly50." exact="Mercaptopurine" post="(Zâ€‰=â€‰â€&quot;2.44 and GSEA scoreâ€‰=â€‰1), an antineoplastic agent with immunosuppressant"/>
   <result pre="diseases, including rheumatoid arthritis, systemic lupus erythematosus, and Crohnâ€™s disease52." exact="Mercaptopurine" post="has been reported as a selective inhibitor of both"/>
   <result pre="roles in viral maturation and antagonism to interferon stimulation53,54. Mechanistically," exact="mercaptopurine" post="potentially target several host proteins in HCoVs, such as"/>
   <result pre="play essential roles in viral infections56,57. As a biogenic amine," exact="melatonin" post="(N-acetyl-5-methoxytryptamine) (Zâ€‰=â€‰â€&quot;1.72 and GSEA scoreâ€‰=â€‰2) plays a key role"/>
   <result pre="on the function of multiple organs60. The antioxidant effect of" exact="melatonin" post="makes it a putative candidate drug to relieve patientsâ€™"/>
   <result pre="to relieve patientsâ€™ clinical symptoms in antiviral treatment, even though" exact="melatonin" post="cannot eradicate or even curb the viral replication or"/>
   <result pre="the viral replication or transcription61,62. In addition, the application of" exact="melatonin" post="may prolong patientsâ€™ survival time, which may provide a"/>
   <result pre="and eventually eradicate the virus. As shown in Fig. 5e," exact="melatonin" post="indirectly targets several HCoV cellular targets, including ACE2, BCL2L1,"/>
   <result pre="several HCoV cellular targets, including ACE2, BCL2L1, JUN, and IKBKB." exact="Eplerenone" post="(Zâ€‰=â€‰â€&quot;1.59), an aldosterone receptor antagonist, is reported to have"/>
   <result pre="Inferred mechanism-of-action networks for three selected pairwise drug combinations: b" exact="sirolimus" post="(a potent immunosuppressant with both antifungal and antineoplastic properties)"/>
   <result pre="(a potent immunosuppressant with both antifungal and antineoplastic properties) plus" exact="dactinomycin" post="(an RNA synthesis inhibitor for treatment of various tumors),"/>
   <result pre="(an RNA synthesis inhibitor for treatment of various tumors), c" exact="toremifene" post="(first-generation nonsteroidal-selective estrogen receptor modulator) plus emodin (an experimental"/>
   <result pre="inhibitor for treatment of various tumors), c toremifene (first-generation nonsteroidal-selective" exact="estrogen" post="receptor modulator) plus emodin (an experimental drug for the"/>
   <result pre="experimental drug for the treatment of polycystic kidney), and d" exact="melatonin" post="(a biogenic amine for treating circadian rhythm sleep disorders)"/>
   <result pre="(a biogenic amine for treating circadian rhythm sleep disorders) plus" exact="mercaptopurine" post="(an antimetabolite antineoplastic agent with immunosuppressant properties). Sirolimus plus"/>
   <result pre="mercaptopurine (an antimetabolite antineoplastic agent with immunosuppressant properties). Sirolimus plus" exact="Dactinomycin" post="Sirolimus, an inhibitor of mTOR with both antifungal and"/>
   <result pre="treatment of various cancer types. An early study showed that" exact="dactinomycin" post="(1â€‰Î¼g/ml) inhibited the growth of feline enteric CoV67. As"/>
   <result pre="As shown in Fig. 6b, our network analysis shows that" exact="sirolimus" post="and dactinomycin synergistically target HCoV-associated host protein subnetwork by"/>
   <result pre="in Fig. 6b, our network analysis shows that sirolimus and" exact="dactinomycin" post="synergistically target HCoV-associated host protein subnetwork by â€œComplementary Exposureâ€�"/>
   <result pre="pattern, offering potential combination regimens for treatment of HCoV. Specifically," exact="sirolimus" post="and dactinomycin may inhibit both mTOR signaling and RNA"/>
   <result pre="potential combination regimens for treatment of HCoV. Specifically, sirolimus and" exact="dactinomycin" post="may inhibit both mTOR signaling and RNA synthesis pathway"/>
   <result pre="both mTOR signaling and RNA synthesis pathway (including DNA topoisomerase" exact="2-alpha" post="(TOP2A) and DNA topoisomerase 2-beta (TOP2B)) in HCoV-infected cells"/>
   <result pre="synthesis pathway (including DNA topoisomerase 2-alpha (TOP2A) and DNA topoisomerase" exact="2-beta" post="(TOP2B)) in HCoV-infected cells (Fig. 6b). Toremifene plus Emodin"/>
   <result pre="and DNA topoisomerase 2-beta (TOP2B)) in HCoV-infected cells (Fig. 6b)." exact="Toremifene" post="plus Emodin Toremifene is among the approved first-generation nonsteroidal"/>
   <result pre="2-beta (TOP2B)) in HCoV-infected cells (Fig. 6b). Toremifene plus Emodin" exact="Toremifene" post="is among the approved first-generation nonsteroidal SERMs for the"/>
   <result pre="the Ebola virus glycoprotein39. In vitro assays have demonstrated that" exact="toremifene" post="inhibited growth of MERS-CoV17,69 and SARA-CoV38 (Table 1). Emodin,"/>
   <result pre="Altogether, network analyses and published experimental data suggested that combining" exact="toremifene" post="and emdoin offered a potential therapeutic approach for 2019-nCoV/SARS-CoV-2"/>
   <result pre="emdoin offered a potential therapeutic approach for 2019-nCoV/SARS-CoV-2 (Fig. 6c)." exact="Mercaptopurine" post="plus Melatonin As shown in Fig. 5a, targets of"/>
   <result pre="plus Melatonin As shown in Fig. 5a, targets of both" exact="mercaptopurine" post="and melatonin showed strong network proximity with HCoV-associated host"/>
   <result pre="As shown in Fig. 5a, targets of both mercaptopurine and" exact="melatonin" post="showed strong network proximity with HCoV-associated host proteins in"/>
   <result pre="interactome network. Recent in vitro and in vivo studies identified" exact="mercaptopurine" post="as a selective inhibitor of both SARS-CoV and MERS-CoV"/>
   <result pre="in viral infection of HCoVs, including 2019-nCoV/SARS-CoV-2 (ref. 33). Specifically," exact="melatonin" post="was reported to inhibit calmodulin and calmodulin interacts with"/>
   <result pre="in HCoV infectious bronchitis virus74. As shown in Fig. 6d," exact="mercaptopurine" post="and melatonin may synergistically block c-Jun signaling by targeting"/>
   <result pre="infectious bronchitis virus74. As shown in Fig. 6d, mercaptopurine and" exact="melatonin" post="may synergistically block c-Jun signaling by targeting multiple cellular"/>
   <result pre="signaling by targeting multiple cellular targets. In summary, combination of" exact="mercaptopurine" post="and melatonin may offer a potential combination therapy for"/>
   <result pre="targeting multiple cellular targets. In summary, combination of mercaptopurine and" exact="melatonin" post="may offer a potential combination therapy for 2019-nCoV/SARS-CoV-2 by"/>
   <result pre="(Fig. 6d). However, further experimental observations on ACE2 pathways by" exact="melatonin" post="in 2019-nCoV/SARS-CoV-2 are highly warranted. Discussion In this study,"/>
   <result pre="East respiratory syndrome coronavirus infectionAntimicrob. Agents Chemother.2014584885489310.1128/AAC.03036-1424841273 18.JohansenLMet al.FDA-approved selective" exact="estrogen" post="receptor modulators inhibit Ebola virus infectionSci. Transl. Med.20135190ra17910.1126/scitranslmed.3005471 19.HeSet"/>
   <result pre="Ebola virus infectionSci. Transl. Med.20135190ra17910.1126/scitranslmed.3005471 19.HeSet al.Repurposing of the antihistamine" exact="chlorcyclizine" post="and related compounds for treatment of hepatitis C virus"/>
   <result pre="Top. Med. Chem.200441433145410.2174/156802604338781815379656 43.SekoYEffect of the angiotensin II receptor blocker" exact="olmesartan" post="on the development of murine acute myocarditis caused by"/>
   <result pre="Na(+)-dependent taurocholate cotransporting polypeptide activityAntivir. Res.201512014014610.1016/j.antiviral.2015.06.00726086883 46.KoCet al.The FDA-approved drug" exact="irbesartan" post="inhibits HBV-infection in HepG2 cells stably expressing sodium taurocholate"/>
   <result pre="RNA replicationGut2016652017202810.1136/gutjnl-2014-30897126276683 50.WangCHet al.Adjuvant treatment with a mammalian target of" exact="rapamycin" post="inhibitor, sirolimus, and steroids improves outcomes in patients with"/>
   <result pre="deubiquitinating and deISGylating enzymeAntivir. Chem. Chemother.20091915115610.1177/09563202090190040219374142 54.ChengKWet al.Thiopurine analogs and" exact="mycophenolic acid" post="synergistically inhibit the papain-like protease of Middle East respiratory"/>
   <result pre="Metab. Immune Drug Discov.20126303910.2174/18722141279901531722264213 60.TanDXKorkmazAReiterRJManchesterLCEbola virus disease: potential use of" exact="melatonin" post="as a treatmentJ. Pineal Res.20145738138410.1111/jpi.1218625262626 61.TanDXManchesterLCTerronMPFloresLJReiterRJOne molecule, many derivatives:"/>
   <result pre="Pineal Res.20145738138410.1111/jpi.1218625262626 61.TanDXManchesterLCTerronMPFloresLJReiterRJOne molecule, many derivatives: a never-ending interaction of" exact="melatonin" post="with reactive oxygen and nitrogen species?J. Pineal Res.200742284210.1111/j.1600-079X.2006.00407.x17198536 62.GalanoATanDXReiterRJOn"/>
   <result pre="of eplerenone on viral myocarditisEur. J. Heart Fail.20091134935310.1093/eurjhf/hfp02319213804 64.WangManliCaoRuiyuanZhangLeikeYangXinglouLiuJiaXuMingyueShiZhengliHuZhihongZhongWuXiaoGengfuRemdesivir and" exact="chloroquine" post="effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in"/>
   <result pre="Gen. Virol.1992733285328810.1099/0022-1317-73-12-32851335030 68.ZhouWBDingQChenLLiuXAWangSToremifene is an effective and safe alternative to" exact="tamoxifen" post="in adjuvant endocrine therapy for breast cancer: results of"/>
   <result pre="its ectodomainFEBS Lett.200858238539010.1016/j.febslet.2007.11.08518070603 73.DaiJInschoEWYuanLHillSMModulation of intracellular calcium and calmodulin by" exact="melatonin" post="in MCF-7 human breast cancer cellsJ. Pineal Res.20023211211910.1034/j.1600-079x.2002.1844.x12071468 74.FungTSLiuDXActivation"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7089181\results\search\drug\results.xml">
   <result pre="resistance mutations in the antiviral target areas, as shown with" exact="tecovirimat" post="(ST-246) for orthopoxviruses. This concludes the classical in vitro"/>
   <result pre="activity in the central nervous system (CNS) cells compared to" exact="sofosbuvir" post="(Bugert-MBDC-2018-GO3), novel protease inhibitors for Zika virus as surrogate"/>
   <result pre="56, 115, 116, 118, 139]. The F13L virus egress inhibitor" exact="tecovirimat" post="(ST-246, TPOXXÂ®) has been independently developed to treat smallpox"/>
   <result pre="detail elsewhere [133]. Further candidate anti-poxvirus drugs include kinase inhibitors" exact="imatinib" post="(Gleevec/STI-571; [122, 123]) and olomoucine [61], terameprocol [119], mitoxandrone"/>
   <result pre="these two Mabs for all further treatments [150]. Remdesivir (GS-5734;1-cyano-substituted" exact="adenosine" post="nucleotide analogue), a nucleoside-analogue prodrug and lead compound of"/>
   <result pre="shown the efficacy of favipiravir [13, 14]). While extensively tested," exact="ribavirin" post="is not FDA approved for EBOV [65]. Other promising"/>
   <result pre="alleviating peripheral symptoms but not providing cure [1, 3]. Intranasal" exact="ribavirin" post="may be more effective. Ribavirin resolves joint swelling in"/>
   <result pre="providing cure [1, 3]. Intranasal ribavirin may be more effective." exact="Ribavirin" post="resolves joint swelling in CHIKV [121], but has no"/>
   <result pre="FDA approval is pending [49]. An in vitro comparison between" exact="ribavirin" post="and favipiravir revealed that efficacy is cell-type dependent [45]."/>
   <result pre="[141]. Compounds with known cellular targets include the cancer drugs" exact="mefenamic acid" post="and sorafenib, inhibiting replication of CHIKV and other alphaviruses"/>
   <result pre="and their main cellular targets are antigen-presenting cells. Anti-arenavirus drugs." exact="Ribavirin" post="is used under compassionate use protocols for the treatment"/>
   <result pre="with volume replacement, and prevention of edema and inflammation [68]." exact="Ribavirin" post="has been used to treat CCHF patients under compassionate"/>
   <result pre="clinical trials were unable to show significant beneficial effects of" exact="ribavirin" post="versus CCHFV [70, 78]. Further interesting candidates for virus-specific"/>
   <result pre="coupled receptors for entry into host cells [42]. Anti-flavivirus drugs." exact="Ribavirin" post="is an effective early treatment for yellow fever under"/>
   <result pre="by the FDA (TableÂ 1), the most promising candidate is" exact="sofosbuvir" post="[18]. Sofosbuvir was initially developed and approved by FDA"/>
   <result pre="FDA (TableÂ 1), the most promising candidate is sofosbuvir [18]." exact="Sofosbuvir" post="was initially developed and approved by FDA for treatment"/>
   <result pre="B viruses [42]. Anti-orthomyxovirus drugs. FDA-approved neuraminidase inhibitors oseltamivir (TamifluÂ®)," exact="zanamivir" post="(RelenzaÂ®), laninamivir (InavirÂ®), and peramivir have marginal clinical benefits"/>
   <result pre="FDA-approved neuraminidase inhibitors oseltamivir (TamifluÂ®), zanamivir (RelenzaÂ®), laninamivir (InavirÂ®), and" exact="peramivir" post="have marginal clinical benefits only when given early but"/>
   <result pre="the polymerase PA-PB1 subunits of influenza virus [106]. Alicyclic amines/aminoadamantanes" exact="amantadine" post="and rimantadine, first described in 1985 as M2 protein"/>
   <result pre="Cochrane review found no evidence for efficacy or safety of" exact="amantadine" post="for the treatment of influenza A [6]. However, their"/>
   <result pre="ss-RNA genome (mononegavirales) replicating in the cytoplasm [42]. Anti-paramyxovirus drugs." exact="Ribavirin" post="administered with cyclodextrin has been shown to be effective"/>
   <result pre="combinations of antiviral compounds with similar or different MoA are" exact="ribavirin" post="with vitamin A in measles infections [12], ribavirin with"/>
   <result pre="MoA are ribavirin with vitamin A in measles infections [12]," exact="ribavirin" post="with favipiravir in Zika virus infections [75], and ribavirin"/>
   <result pre="[12], ribavirin with favipiravir in Zika virus infections [75], and" exact="ribavirin" post="with mefenamic acid in infections with Chikungunya virus [126]."/>
   <result pre="with favipiravir in Zika virus infections [75], and ribavirin with" exact="mefenamic acid" post="in infections with Chikungunya virus [126]. Antiviral drug combinations"/>
   <result pre="viruses in mice [134]. Previously thought as a one-family-broad-spectrum compound," exact="sofosbuvir" post="(Sovaldiâ&quot;¢, Soforalâ&quot;¢) has in vitro and in vivo activity"/>
   <result pre="in extracts [27]. Treatment of viral hemorrhagic fevers (VHF) with" exact="ribavirin" post="Viral hemorrhagic fevers (VHFs) cause the highest mortality in"/>
   <result pre="VHF and is used under compassionate use protocols only. Intravenous" exact="ribavirin" post="reduces mortality of HFRS if combined with hemodialysis and"/>
   <result pre="morbidity and mortality in the case of Lassa fever (LassaF)." exact="Ribavirin" post="(Copegusâ&quot;¢, Rebetolâ&quot;¢, VirazoleÂ® ICN/Valeant (IND)) is used for the"/>
   <result pre="bunyaviruses (HFRS, Crimean-Congo fever, and Rift Valley fever). However, intravenous" exact="ribavirin" post="does not show any benefits for the treatment of"/>
   <result pre="by mitoxantroneAntivir Res20129330530810.1016/j.antiviral.2011.12.00122182595 6.Alves GalvÃ£oMGRocha Crispino SantosMAAlves da CunhaAJAmantadine and" exact="rimantadine" post="for influenza A in children and the elderlyCochrane Database"/>
   <result pre="BeinekeABaumgÃ¤rtnerWWohlseinPCross-species transmission of canine distemper virusâ€&quot;an updateOne Health20151495910.1016/j.onehlt.2015.09.00228616465 12.BichonAAubryCBenarousLDrouetHZandottiCParolaPLagierJ-CCase report:" exact="ribavirin" post="and vitamin A in a severe case of measlesMedicine"/>
   <result pre="hazards in the Kosovo warNephrol Dial Transpl1999141843184410.1093/ndt/14.8.1843 18.Bullard-FeibelmanKMGoveroJZhuZSalazarVVeselinovicMDiamondMSGeissBJThe FDA-approved drug" exact="sofosbuvir" post="inhibits Zika virus infectionAntivir Res201713713414010.1016/j.antiviral.2016.11.02327902933 19.CallawayEâ€˜Make Ebola a thing"/>
   <result pre="bromocriptine as a Zika virus NS2B-NS3 protease inhibitorAntivir Res.2017141293710.1016/j.antiviral.2017.02.00228185815 24.ChanJF-WZhuZChuHYuanSChikKK-HChanCC-SPoonVK-MYipCC-YZhangXTsangJO-LZouZTeeK-MShuaiHLuGYuenK-YThe" exact="celecoxib" post="derivative kinase inhibitor AR-12 (OSU-03012) inhibits Zika virus via"/>
   <result pre="yearsClin Microbiol Rev20162969574710.1128/CMR.00102-1527281742 33.de FreitasCSHigaLMSacramentoCQFerreiraACReisPADelvecchioRMonteiroFLBarbosa-LimaGJames-WestgarthHVieiraYRMattosMRochaNHoelzLVBLemeRPPBastosMMRodriguesGOLLopesCEMQueiroz-JuniorCMLimaCXCostaVVTeixeiraMMBozzaFABozzaPTBoechatNTanuriASouzaTMLYellow fever virus is susceptible to" exact="sofosbuvir" post="both in vitro and in vivoPLoS Negl Trop Dis.201913707210.1371/journal.pntd.0007072"/>
   <result pre="for 2016. https://www.ecdc.europa.eu/en/publications-data/hantavirus-infection-annual-epidemiological-report-2016 39.EyerLZouharovÃ¡DÅ irmarovÃ¡JFojtÃ­kovÃ¡MÅ tefÃ¡nikMHaviernikJNenckaRde ClercqERÅ¯Å¾ekDAntiviral activity of the" exact="adenosine" post="analogue BCX4430 against West Nile virus and tick-borne flavivirusesAntivir"/>
   <result pre="LoiolaETrindadePRangel VieiraYBarbosa-LimaGde Castro Faria NetoHCBoechatNRehenSKBrÃ¼ningKBozzaFABozzaPTSouzaTMLBeyond members of the Flaviviridae family," exact="Sofosbuvir" post="also inhibits chikungunya virus replicationAntimicrob Agents Chemother201910.1128/AAC.01389-1831844010 41.Ferreira-RamosASLiCEydouxCContrerasJMMoriceCQuÃ©ratGGiganteAPÃ©rez PÃ©rezM-JJungM-LCanardBGuillemotJ-CDecrolyECoutardBApproved"/>
   <result pre="and T-1106 pyrazine derivatives in phlebovirus disease modelsAntivir Res20108612112710.1016/j.antiviral.2009.10.01519874853 55.GrosenbachDWHoneychurchKRoseEAChinsangaramJFrimmAMaitiBLovejoyCMearaILongPHrubyDEOral" exact="tecovirimat" post="for the treatment of smallpoxN Engl J Med2018379445310.1056/NEJMoa170568829972742 56.GrossiIMFosterSAGaineyMRKrileRTDunnJABrundageTKhouriJMEfficacy"/>
   <result pre="weapons-a primer for microbiologistsAnnu Rev Microbiol20015523525310.1146/annurev.micro.55.1.23511544355 59.HawmanDWHaddockEMeade-WhiteKWilliamsonBHanleyPWRosenkeKKomenoTFurutaYGowenBBFeldmannHFavipiravir (T-705) but not" exact="ribavirin" post="is effective against two distinct strains of Crimean-Congo hemorrhagic"/>
   <result pre="and control strategy in admitted patientsCasp J Intern Med20123443444 69.JeulinHVenardVCarapitoDFinanceCKedzierewiczFEffective" exact="ribavirin" post="concentration in mice brain using cyclodextrin as a drug"/>
   <result pre="protein against a small-molecule membrane fusion inhibitorVirus Res2019259283710.1016/j.virusres.2018.10.00330296457 75.KimJ-ASeongR-KKumarMShinOSFavipiravir and" exact="ribavirin" post="inhibit replication of Asian and African strains of Zika"/>
   <result pre="drug screening in primary human cellsAntivir Res2018150202910.1016/j.antiviral.2017.12.00529224735 78.KoksalIYilmazGAksoyFAydinHYavuzIIskenderSAkcayKErensoySCaylanRAydinKThe efficacy of" exact="ribavirin" post="in the treatment of Crimean-Congo hemorrhagic fever in Eastern"/>
   <result pre="89.LubySPThe pandemic potential of Nipah virusAntivir Res2013100384310.1016/j.antiviral.2013.07.01123911335 90.LundbergLBrahmsAHooperICareyBLinS-CDahalBNarayananAKehn-HallKRepurposed FDA-Approved drug" exact="sorafenib" post="reduces replication of Venezuelan equine encephalitis virus and other"/>
   <result pre="Lassa virus antiviral targets an arenavirus virulence determinantPLoS Pathog201814e100743910.1371/journal.ppat.100743930576397 92.MalinoskiFJHastySEUsseryMADalrympleJMProphylactic" exact="ribavirin" post="treatment of dengue type 1 infection in rhesus monkeysAntivir"/>
   <result pre="virus serotypes in AG129 mouse models: proof-of-concept studies with the" exact="adenosine" post="nucleoside inhibitor NITD-008Antivir Res201815410410910.1016/j.antiviral.2018.04.01229665374 102.MohrELMcMullanLKLoMKSpenglerJRBergeronÃ‰AlbariÃ±oCGShrivastava-RanjanPChiangC-FNicholSTSpiropoulouCFFlintMInhibitors of cellular kinases with"/>
   <result pre="virus (smallpox)Antimicrob Agents Chemother201357126246625310.1128/aac.00977-1324100494 105.MumtazNJimmersonLCBushmanLRKiserJJAronGReuskenCBEMKoopmansMPGvan KampenJJACell-line dependent antiviral activity of" exact="sofosbuvir" post="against Zika virusAntivir Res.201714616116310.1016/j.antiviral.2017.09.00428912011 106.NannettiGMassariSMercorelliBBertagninCDesantisJPalÃ¹GTabarriniOLoregianAPotent and broad-spectrum cycloheptathiophene-3-carboxamide compounds"/>
   <result pre="of GTP pool is not the predominant mechanism by which" exact="ribavirin" post="exerts its antiviral effect on Lassa virusAntivir Res201191899310.1016/j.antiviral.2011.05.00621616094 113.OoARausaluKMeritsAHiggsSVanlandinghamDBakarSAZandiKDeciphering"/>
   <result pre="116.ParkerSTouchetteEOberleCAlmondMRobertsonATrostLCLampertBPainterGBullerRMEfficacy of therapeutic intervention with an oral ether-lipid analogue of" exact="cidofovir" post="(CMX001) in a lethal mousepox modelAntivir Res.200877394910.1016/j.antiviral.2007.08.00317904231 117.PetersenEKanteleAKoopmansMAsogunDYinka-OgunleyeAIhekweazuCZumlaAHuman monkeypox:"/>
   <result pre="prevention2019InfectDis Clin N Am 118.PiresMARodriguesNFSde OliveiraDBde AssisFLCostaGBKroonEGMotaBEFIn vitro susceptibility to" exact="ST-246" post="and Cidofovir corroborates the phylogenetic separation of Brazilian Vaccinia"/>
   <result pre="N Am 118.PiresMARodriguesNFSde OliveiraDBde AssisFLCostaGBKroonEGMotaBEFIn vitro susceptibility to ST-246 and" exact="Cidofovir" post="corroborates the phylogenetic separation of Brazilian Vaccinia virus into"/>
   <result pre="infection in macaquesEmerg Infect Dis2018241696169910.3201/eid2409.18023329882740 126.RothanHABahraniHAbdulrahmanAYMohamedZTeohTCOthmanSRashidNNRahmanNAYusofRMefenamic acid in combination with" exact="ribavirin" post="shows significant effects in reducing chikungunya virus infection In"/>
   <result pre="members of the family BunyaviridaeVirus Adapt Treat2010292010.2147/VAAT.S6903 136.TaylorRKotianPWarrenTPanchalRBavariSJulanderJDoboSRoseAEl-KattanYTaubenheimBBabuYSheridanWPBCX4430â€&quot;a broad-spectrum antiviral" exact="adenosine" post="nucleoside analog under development for the treatment of Ebola"/>
   <result pre="J Suid-Afr Tydskr Vir Geneeskd198568718721 141.VargheseFSKaukinenPGlÃ¤skerSBespalovMHanskiLWennerbergKKÃ¼mmererBMAholaTDiscovery of berberine, abamectin and" exact="ivermectin" post="as antivirals against chikungunya and other alphavirusesAntivir Res201612611712410.1016/j.antiviral.2015.12.01226752081 142.WaltonTEJohnsonKMMonathTPVenezuelan"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7090748\results\search\drug\results.xml">
   <result pre="efficiency of the FDA-approved drugs including ribavirin, penciclovir, nitazoxanide, nafamostat," exact="chloroquine" post="(CQ) and two well-known broad-spectrum antiviral drugs remdesivir (RDV,"/>
   <result pre="clinical drugs for treatment of 2019-nCoV infections. RDV is an" exact="adenosine" post="analogue prodrug and can be incorporated into nascent chains"/>
   <result pre="Republic of China (2020) http://www.nhc.gov.cn/xcs/yqfkdt/202001/e71bd2e7a0824ca69f87bbf1bef2a3c9.shtml RainsfordKDParkeALClifford-RashotteMKeanWFTherapy and pharmacological properties of" exact="hydroxychloroquine" post="and chloroquine in treatment of systemic lupus erythematosus, rheumatoid"/>
   <result pre="China (2020) http://www.nhc.gov.cn/xcs/yqfkdt/202001/e71bd2e7a0824ca69f87bbf1bef2a3c9.shtml RainsfordKDParkeALClifford-RashotteMKeanWFTherapy and pharmacological properties of hydroxychloroquine and" exact="chloroquine" post="in treatment of systemic lupus erythematosus, rheumatoid arthritis and"/>
   <result pre="systemic lupus erythematosus, rheumatoid arthritis and related diseasesInflammopharmacology20152323126910.1007/s10787-015-0239-y26246395 SavarinoABoelaertJRCassoneAMajoriGCaudaRobertoEffects of" exact="chloroquine" post="on viral infections: an old drug against today's diseasesLancet"/>
   <result pre="inhibits both epidemic and zoonotic coronavirusesSci Trans Med201710.1126/scitranslmed.aal3653 WangMCaoRZhangLYangXLiuJXuMShiZLHuZZhongWXiaoGRemdesivir and" exact="chloroquine" post="effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7090771\results\search\drug\results.xml">
   <result pre="or antipyretic drug treatment should be performed. Common drugs include:" exact="ibuprofen" post="orally, 5â€&quot;10Â mg/kg every time; acetaminophen orally, 10â€&quot;15Â mg/kg"/>
   <result pre="performed. Common drugs include: ibuprofen orally, 5â€&quot;10Â mg/kg every time;" exact="acetaminophen" post="orally, 10â€&quot;15Â mg/kg every time. Keep children quiet and"/>
   <result pre="in a short period (3â€&quot;5Â days). The recommended dose of" exact="methylprednisolone" post="should not exceed 1â€&quot;2Â mg/kg/day. Immunoglobulin Immunoglobulin can be"/>
   <result pre="toys by heating at 56Â Â°C for 30Â min, 75%" exact="alcohol" post="or chlorine-containing disinfectants, and ultraviolet rays. Reduce exposure to"/>
   <result pre="coronavirus: an observational studyInt J Infect Dis201420424610.1016/j.ijid.2013.12.00324406736 18.WangHQMaLLJiangJDPangRChenYJLiYHRecombinant human interferon" exact="alpha" post="2b broad-spectrum anti-respiratory viruses pharmacodynamics study in vitroActa Pharmaceu"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7091034\results\search\drug\results.xml">
   <result pre="that Avian influenza viruses preferentially bind to sialic acids via" exact="alpha" post="2,3 linkages present on alveolar type II cells and"/>
   <result pre="to NAAT tests. Treatment The neuroaminase inhibitors like Oseltamivir and" exact="Zanamivir" post="are the mainstay for treatment and help to inhibit"/>
   <result pre="patients with Oseltamivir resistance who develop infection. The alternative antiviral," exact="Zanamivir" post="given by inhalation is approved for age more than"/>
   <result pre="given in those with underlying airway disease. The older antivirals," exact="Amantidine" post="and Rimatidine are no longer recommended since 2006 due"/>
   <result pre="have the potential to cause pandemic [22]. Two intravenous NIs," exact="Peramivir" post="and Zanamivir, are currently undergoing clinical trials [19]. Laninamivir"/>
   <result pre="oral Oseltamivir (for above 3 mo of age) or inhaled" exact="Zanamivir" post="(for above 7 y of age) is recommended for"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7091691\results\search\drug\results.xml">
   <result pre="COVID-19. On 17 February, the Chinese State Council announced that" exact="chloroquine" post="phosphate â€&quot; a structural analogue of quinine, originally extracted"/>
   <result pre="and regulatory effects on the immune system. Clinical evaluation of" exact="chloroquine" post="phosphate in more than ten hospitals across several provinces"/>
   <result pre="on the management of the COVID-19 outbreak, has said that" exact="chloroquine" post="phosphate is not a highly effective cure but its"/>
   <result pre="deserve attention, even though its pharmaceutical mechanism remains unclear. However," exact="quinine" post="and quinine derivatives have been used for two hundred"/>
   <result pre="even though its pharmaceutical mechanism remains unclear. However, quinine and" exact="quinine" post="derivatives have been used for two hundred years, and"/>
   <result pre="Wuhan University has proposed a combination of diammonium glycyrrhizinate and" exact="vitamin C" post="as a COVID-19 therapy. This approach became popular through"/>
   <result pre="and thus their safety and effects have been repeatedly tested;" exact="chloroquine" post="phosphate has been used to treat malaria for over"/>
   <result pre="they inhibit virus entry and key viral enzyme activities7,8. Like" exact="chloroquine" post="phosphate, these herbal medicines are generally not highly potent"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7093024\results\search\drug\results.xml">
   <result pre="United States), 1000 units/mL of penicillin, and 100 Î¼g/mL of" exact="streptomycin" post="(Invitrogen, Carlsbad, CA, United States). Infections were performed in"/>
   <result pre="States). Infections were performed in Opti-MEM containing 2 Î¼g/mL N-tosyl-" exact="L-phenylalanine" post="chloromethyl ketone (TPCK)â€&quot;trypsin (Sigmaâ€&quot;Aldrich, St. Louis, MO, United States)."/>
   <result pre="three times, and fresh Opti-MEM containing 2 Î¼g/mL of N-tosyl-" exact="L-phenylalanine" post="chloromethyl ketone (TPCK)â€&quot;trypsin was added for another 2-h incubation,"/>
   <result pre="of influenza virus infections, including oseltamivir (Shobugawa et al., 2012)," exact="zanamivir" post="(von Itzstein et al., 1993), peramivir (Alame et al.,"/>
   <result pre="(Shobugawa et al., 2012), zanamivir (von Itzstein et al., 1993)," exact="peramivir" post="(Alame et al., 2016), and laninamivir (Kashiwagi et al.,"/>
   <result pre="Alves GalvaoM. G.Rocha Crispino SantosM. A.Alves da CunhaA. J. (2014)." exact="Amantadine" post="and rimantadine for influenza A in children and the"/>
   <result pre="G.Rocha Crispino SantosM. A.Alves da CunhaA. J. (2014). Amantadine and" exact="rimantadine" post="for influenza A in children and the elderly.Cochrane Database"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7098069\results\search\drug\results.xml">
   <result pre="Chemical Society doi: 10.1021/acsinfecdis.0c00052 : Review Broad Spectrum Antiviral Agent" exact="Niclosamide" post="and Its Therapeutic Potential XuJiminâ€ ShiPei-Yongâ€¡Â§LiHongminâˆ¥ZhouJia*â€ Â§[], â€ â€¡Â§University"/>
   <result pre="this brief review, we summarize the broad antiviral activity of" exact="niclosamide" post="and highlight its potential clinical use in the treatment"/>
   <result pre="highlight its potential clinical use in the treatment of COVID-19." exact="niclosamide" post="broad antiviral agents coronavirus SARS-CoV MERS-CoV SARS-CoV-2 (COVID-19) flavivirus"/>
   <result pre="into four genera (alpha, beta, gamma, and delta), of which" exact="alpha" post="and beta coronaviruses are known to infect humans.2 Human"/>
   <result pre="safer and more effective drugs to be accessed by patients.8,9" exact="Niclosamide" post="is an FDA-approved anthelminthic drug that has been widely"/>
   <result pre="listed on the World Health Organizationâ€™s list of essential medicines.10,11" exact="Niclosamide" post="exerts its anticestodal effect by inhibiting oxidative phosphorylation and"/>
   <result pre="exerts its anticestodal effect by inhibiting oxidative phosphorylation and stimulating" exact="adenosine" post="triphosphatase activity in the mitochondria.12 Over the past several"/>
   <result pre="triphosphatase activity in the mitochondria.12 Over the past several years," exact="niclosamide" post="has been identified as a multifunctional drug via drug"/>
   <result pre="viral infections,19âˆ’22 and metabolic diseases.23 These broad biological activities of" exact="niclosamide" post="including relevant cell signaling pathways were briefly reviewed by"/>
   <result pre="review, we focus on summarizing the broad antiviral activities of" exact="niclosamide" post="(Figure 1) and highlighting its therapeutic potential in combating"/>
   <result pre="and highlighting its therapeutic potential in combating COVID-19. Figure 1" exact="Niclosamide" post="has great potential in being repurposed to treat a"/>
   <result pre="vivo toxicity profile as an FDA-approved drug in clinical use." exact="Niclosamide" post="and Viral Infections Niclosamide and Coronavirus Coronaviruses are a"/>
   <result pre="an FDA-approved drug in clinical use. Niclosamide and Viral Infections" exact="Niclosamide" post="and Coronavirus Coronaviruses are a group of enveloped and"/>
   <result pre="need for new drug discovery. Wu et al. found that" exact="niclosamide" post="was able to inhibit SARS-CoV replication and totally abolished"/>
   <result pre="of 1.56 Î¼M after screening a small marketed drug library.27" exact="Niclosamide" post="suppressed the cytopathic effect (CPE) of SARS-CoV at a"/>
   <result pre="was discovered as potent inhibitors against SARS-CoV 3CL protease. Interestingly," exact="niclosamide" post="showed no obvious inhibitory activity against SARS-CoV 3CL protease"/>
   <result pre="the BENC1 level, enhances autophagy, and efficiently reduces MERS-CoV replication.33" exact="Niclosamide" post="was reported to inhibit MERS-CoV replication by up to"/>
   <result pre="and affected the autophagic flux in the MERS-CoV-infected cells.33 Since" exact="niclosamide" post="is a multifunctional drug, we cannot exclude the possibility"/>
   <result pre="its anti-MERS activity by regulating other targets besides SKP2 inhibition." exact="Niclosamide" post="and Flavivirus Flavivirus, a genus of viruses in the"/>
   <result pre="used caspase-3 activity as the primary screening assay and discovered" exact="niclosamide" post="as a potent inhibitor of ZIKV infection, displaying an"/>
   <result pre="the intracellular ZIKV RNA level.22 The time-of-addition studies indicated that" exact="niclosamide" post="inhibits ZIKV infection at a postentry stage, probably in"/>
   <result pre="a viral RNA replication step. Our research team also identified" exact="niclosamide" post="as a potent anti-ZIKV inhibitor through an independent quantitative"/>
   <result pre="an independent quantitative high-throughput screening (qHTS) campaign and found that" exact="niclosamide" post="directly inhibits flavivirus NS2B-NS3 interactions.14 Protease complex NS2B-NS3 is"/>
   <result pre="essential for flaviviral polyprotein processing.39âˆ’41 Our team also found that" exact="niclosamide" post="is a broad-spectrum inhibitor against other flaviviruses including DENV-2,"/>
   <result pre="HTS assay to screen 1280 pharmacologically active compounds and identified" exact="niclosamide" post="as a potent JEV inhibitor with micromolar potency.42 The"/>
   <result pre="JEV inhibitor with micromolar potency.42 The time-of-addition studies showed that" exact="niclosamide" post="inhibits JEV at the stage of replication. Niclosamide and"/>
   <result pre="showed that niclosamide inhibits JEV at the stage of replication." exact="Niclosamide" post="and Hepatitis C Virus Hepatitis C virus (HCV) is"/>
   <result pre="vaccine against hepatitis C, although clinically approved therapeutics are available." exact="Niclosamide" post="was reported to show very promising activity against HCV"/>
   <result pre="antiviral treatment, which may make a host-targeted approach less attractive." exact="Niclosamide" post="and Ebola Virus Ebola virus (EBOV) is an enveloped"/>
   <result pre="in past outbreaks. Through a systematic screen of FDA-approved drugs," exact="niclosamide" post="was identified as one of the most potent EBOV"/>
   <result pre="vivo efficacy has not yet been evaluated in animal models.48" exact="Niclosamide" post="and Human Rhinovirus Human rhinoviruses (HRVs) are nonenveloped, positive-sense"/>
   <result pre="chronic pulmonary disease, and severe bronchiolitis in infants and children.49" exact="Niclosamide" post="is a weak lipophilic acid and was reported to"/>
   <result pre="acidification of the endolysosomal compartments, acting as a proton carrier.50" exact="Niclosamide" post="and Chikungunya Virus Chikungunya virus (CHIKV) is a positive-sense"/>
   <result pre="Currently, there is no effective antiviral therapy approved for Chikungunya." exact="Niclosamide" post="was discovered as a potent anti-CHIKV inhibitor with a"/>
   <result pre="fusion but also inhibits the cell-to-cell transmission of CHIKV infection.51" exact="Niclosamide" post="and Human Adenovirus Human adenoviruses (HAdVs) are nonenveloped double-stranded"/>
   <result pre="available to treat these infections. Three salicylanilide anthelmintic drugs including" exact="niclosamide" post="were screened out as potent anti-HAdV inhibitors. Niclosamide showed"/>
   <result pre="drugs including niclosamide were screened out as potent anti-HAdV inhibitors." exact="Niclosamide" post="showed very promising anti-HAdV activity with an EC50 value"/>
   <result pre="Î¼M in the plaque assay. Subsequent mechanistic studies indicated that" exact="niclosamide" post="inhibits the transport of the HAdV particle from the"/>
   <result pre="the HAdV particle from the endosome to the nuclear envelop.52" exact="Niclosamide" post="and Epsteinâ€&quot;Barr Virus Epsteinâ€&quot;Barr virus (EBV), also known as"/>
   <result pre="Hodgkinâ€™s lymphoma, and nasopharyngeal carcinoma.53 Huang et al. demonstrated that" exact="niclosamide" post="inhibits EBV lytic replication in lymphoma cells and epithelial"/>
   <result pre="to treat acute EBV-associated infectious diseases.54 Conclusions and Future Directions" exact="Niclosamide" post="has traditionally been used to treat tapeworm infections for"/>
   <result pre="single oral doses of 0.5, 1, and 2 g of" exact="niclosamide" post="are recommended for children under 2 years, children between"/>
   <result pre="were eliminated by 5â€&quot;7 daily doses of 2 g of" exact="niclosamide" post="each, while the treatment of Hymenolepis nana infection requires"/>
   <result pre="nana infection requires one or several 5â€&quot;7 day courses of" exact="niclosamide" post="treatment. One 7 day course regimen for adults is"/>
   <result pre="7 day course regimen for adults is 2 g of" exact="niclosamide" post="on day 1 followed by 1 g daily for"/>
   <result pre="of 2000 mg of niclosamide, the maximum serum concentration of" exact="niclosamide" post="was equivalent to 0.25â€&quot;6.0 Î¼g/mL (0.76â€&quot;18.3 Î¼M). The wide"/>
   <result pre="wide concentration range was caused by the intraindividual absorption differences." exact="Niclosamide" post="is only partially absorbed from the intestinal tract, and"/>
   <result pre="in human.10 Through a series of drug repurposing screening campaigns," exact="niclosamide" post="was found to be effective against a variety of"/>
   <result pre="infections. Currently, there are four ongoing human clinical trials of" exact="niclosamide" post="in ulcerative colitis, prostate carcinoma, and colorectal cancer in"/>
   <result pre="colorectal cancer in the ClinicalTrails.gov clinical trials registry.56 Of note," exact="niclosamide" post="has several weaknesses such as unneglectable cytotoxicity and limited"/>
   <result pre="group has made substantial efforts in medicinal chemistry based on" exact="niclosamide" post="as a lead compound and discovered a series of"/>
   <result pre="orally bioavailable anticancer agents with improved aqueous solubility16 and diversified" exact="salicylamide" post="derivatives as potent anti-HAdV inhibitors with increased potency (submicromolar"/>
   <result pre="in the HAdV life cycle.58 The ester derivative prodrug of" exact="niclosamide" post="was also reported to increase its systemic drug exposure"/>
   <result pre="useful strategy for improving the pharmacological and pharmacokinetic properties of" exact="niclosamide" post="and maximizing its therapeutic potential for clinical applications.60âˆ’62 The"/>
   <result pre="a prodrug of tizoxanide, which shares considerable structural similarity with" exact="niclosamide" post="as a salicylamide derivative.47 Notably, niclosamide displays promising inhibitory"/>
   <result pre="tizoxanide, which shares considerable structural similarity with niclosamide as a" exact="salicylamide" post="derivative.47 Notably, niclosamide displays promising inhibitory activity against SARS-CoV"/>
   <result pre="considerable structural similarity with niclosamide as a salicylamide derivative.47 Notably," exact="niclosamide" post="displays promising inhibitory activity against SARS-CoV replication with an"/>
   <result pre="activity is validated in animal models or human clinical trials," exact="niclosamide" post="and its optimized analogues may be developed as effective"/>
   <result pre="ChuL.; ZhangY.; TerryK.; LiuH.; ShenQ.; ZhouJ. (2013) Discovery of O-alkylamino-tethered" exact="niclosamide" post="derivatives as potent and orally bioavailable anticancer agents. ACS"/>
   <result pre="ZhangY.; ChelluriR.; BoufraqechM.; NilubolN.; PatelD.; ShenM.; KebebewE. (2016) Identification of" exact="niclosamide" post="as a novel anticancer agent for adrenocortical carcinoma. Clin."/>
   <result pre="ClayT. M.; ChenW.; MorseM. A.; LyerlyH. K. (2011) Antihelminth compound" exact="niclosamide" post="downregulates Wnt signaling and elicits antitumor responses in tumors"/>
   <result pre="XuJ.; PachÃ³n-IbÃ¡Ã±ezM. E.; Cebrero-CangueiroT.; ChenH.; SÃ¡nchez-CÃ©spedesJ.; ZhouJ. (2019) Discovery of" exact="niclosamide" post="and its O-alkylamino-tethered derivatives as potent antibacterial agents against"/>
   <result pre="D.; EndsleyJ. J.; ZhouJ.; EndsleyM. A. (2019) Dual activity of" exact="niclosamide" post="to suppress replication of integrated HIV-1 and Mycobacterium tuberculosis"/>
   <result pre="Med.22, 1101â€&quot;1107. 10.1038/nm.4184.27571349 TaoH.; ZhangY.; ZengX.; ShulmanG. I.; JinS. (2014)" exact="Niclosamide" post="ethanolamineâ€&quot;induced mild mitochondrial uncoupling improves diabetic symptoms in mice."/>
   <result pre="NS3 proteinase domain and NS2B are required for cleavages at" exact="dibasic" post="sites. J. Virol.65, 6042â€&quot;6050. 10.1128/JVI.65.11.6042-6050.1991.1833562 FalgoutB.; PethelM.; ZhangY. M.;"/>
   <result pre="135â€&quot;162. 10.1128/CMR.00077-12.23297263 JurgeitA.; McDowellR.; MoeseS.; MeldrumE.; SchwendenerR.; GreberU. F. (2012)" exact="Niclosamide" post="is a proton carrier and targets acidic endosomes with"/>
   <result pre="ChinY.-F.; WuT.-Y.; LinL.-I.; LaiZ.-Z.; KuoS.-C.; HoY.-J. (2016) Antiviral activities of" exact="niclosamide" post="and nitazoxanide against chikungunya virus entry and transmission. Antiviral"/>
   <result pre="Mech. Dis.1, 375â€&quot;404. 10.1146/annurev.pathol.1.110304.100209. HuangL.; YangM.; YuanY.; LiX.; KuangE. (2017)" exact="Niclosamide" post="inhibits lytic replication of Epstein-Barr virus by disrupting mTOR"/>
   <result pre="disrupting mTOR activation. Antiviral Res.138, 68â€&quot;78. 10.1016/j.antiviral.2016.12.002.27939840 JonesW. E. (1979)" exact="Niclosamide" post="as a treatment for Hymenolepis diminuta and Dipylidium caninum"/>
   <result pre="ChangY.-W.; YehT.-K.; LinK.-T.; ChenW.-C.; YaoH.-T. (2006) Pharmacokinetics of anti-SARS-CoV agent" exact="niclosamide" post="and its analogs in rats. J. Food Drug Anal.14,"/>
   <result pre="ChenH.; PachÃ³nJ.; ZhouJ.; Sanchez-CespedesJ. (2020) Structure-activity relationship studies on diversified" exact="salicylamide" post="derivatives as potent inhibitors of human adenovirus infection. J."/>
   <result pre="K.; ChenW. (2015) Structureâ€&quot;activity studies of Wnt/Î²-catenin inhibition in the" exact="Niclosamide" post="chemotype: Identification of derivatives with improved drug exposure. Bioorg."/>
   <result pre="BarbosaE. J.; LÃ¶benbergR.; de AraujoG. L. B.; Bou-ChacraN. A. (2019)" exact="Niclosamide" post="repositioning for treating cancer: Challenges and nano-based drug delivery"/>
   <result pre="BiancaR.; SorrentinoR.; MiroA.; QuagliaF.; ImperiF.; LeoniL.; UngaroF. (2015) Toward repositioning" exact="niclosamide" post="for antivirulence therapy of Pseudomonas aeruginosa lung infections: Development"/>
   <result pre="YangX.; LiuJ.; XuM.; ShiZ.; HuZ.; ZhongW.; XiaoG. (2020) Remdesivir and" exact="chloroquine" post="effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7102556\results\search\drug\results.xml">
   <result pre="studies, the clinical effect was not consistent [75], in that" exact="ribavirin" post="does not prolong the survival of SARS-CoV patients [74,76],"/>
   <result pre="prolong the survival of SARS-CoV patients [74,76], while lopinavir/ritonavir plus" exact="ribavirin" post="seemed to improve clinical outcomes for SARS patients [77],"/>
   <result pre="GS-5734 inhibits both epidemic and zoonotic coronavirusesSci Transl Med92017eaal3653 76GrossA.E.BrysonM.L.Oral" exact="ribavirin" post="for the treatment of noninfluenza respiratory viral infections: a"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7102570\results\search\drug\results.xml">
   <result pre="Guanosine, inosine, and AICAR are biosynthesized in the body, and" exact="ribavirin" post="and ribosyl favipiravir are synthesized nucleoside analogues. They have"/>
   <result pre="with efficacy, but they did not exceed the efficacy of" exact="acyclovir" post="in animals. Approximately 30,000 compounds synthesized in the company"/>
   <result pre="of interferon (IFN) and cytokines that induce cyclooxygenase expression and" exact="prostaglandin E2" post="production and cause fever. The effects of interferon and"/>
   <result pre="1998; Kurokawa, Brown, Kagawa, &amp;amp; Shiraki, 2003). Cinnamyl compounds and" exact="clarithromycin" post="increase the levels of IL-12 on day 2 and"/>
   <result pre="influenza-infected mice by decreasing the serum IL-1 level. In contrast," exact="aspirin" post="suppresses fever by inhibiting hypothalamic cyclooxygenase activity and prostaglandin"/>
   <result pre="contrast, aspirin suppresses fever by inhibiting hypothalamic cyclooxygenase activity and" exact="prostaglandin E2" post="production without affecting the high level of IL-1 (Kurokawa,"/>
   <result pre="we have experience in conducting a pharmacological study for a" exact="famciclovir" post="approval application in Japan, the efficacy and validation studies"/>
   <result pre="infected cell and proceeds to the next round of infection." exact="Amantadine" post="blocks uncoating by inhibiting acidification mediated by the M2"/>
   <result pre="site, and no new RNA is generated in the cell." exact="Baloxavir marboxil" post="prevents Cap-snatching, and the viral mRNA is not produced,"/>
   <result pre="genomic RNA serves as a rich source of resistant viruses." exact="Amantadine" post="inhibits the uncoating of influenza A in late endosomes,"/>
   <result pre="and viral RNA does not replicate in the infected cells." exact="Amantadine" post="inhibits only influenza A and not B. However, influenza"/>
   <result pre="infection. NAIs are currently the main choice of anti-influenza drugs." exact="Baloxavir marboxil" post="(baloxavir, XofluzaÂ®) is a selective inhibitor of influenza Cap-dependent"/>
   <result pre="different from the range of 0.014â€&quot;0.55Â Î¼g/mL in medium without" exact="adenosine" post="and guanosine and 10Â Î¼g/mL, respectively (Furuta et al.,"/>
   <result pre="strand cannot be completed. In contrast, the anti-RNA virus drug" exact="ribavirin" post="is incorporated into the replicating strand, which further elongates"/>
   <result pre="accumulates mismatched nucleotides at the incorporated sites. Base pairing with" exact="ribavirin" post="in the complementary strand during replication, transcription, and translation"/>
   <result pre="and infectious viruses with mutations in viral RdRp that affect" exact="ribavirin" post="incorporation are produced, drug-resistant viruses can be selected in"/>
   <result pre="et al., 2012; Vanderlinden et al., 2016). B. Lethal mutagenesis" exact="Ribavirin" post="is incorporated into the elongating RNA strand, and viral"/>
   <result pre="to elongate until completion. Next, the RNA strand with multiple" exact="ribavirin" post="incorporation sites further incorporates ribavirin or serves as mRNA"/>
   <result pre="the RNA strand with multiple ribavirin incorporation sites further incorporates" exact="ribavirin" post="or serves as mRNA for viral protein synthesis. The"/>
   <result pre="serves as mRNA for viral protein synthesis. The incorporation of" exact="ribavirin" post="in the viral RNA causes the mismatch of base"/>
   <result pre="(Daikoku et al., 2017; Daikoku, Yoshida, Okuda, &amp;amp; Shiraki, 2014)." exact="Ribavirin" post="is known to cause lethal mutagenesis, as shown in"/>
   <result pre="known to cause lethal mutagenesis, as shown in Fig. 5." exact="Ribavirin" post="is incorporated into the elongating RNA strand, resulting in"/>
   <result pre="(Jin et al., 2013; Sangawa et al., 2013). Favipiravir-RTP and" exact="ribavirin" post="TP inhibit the RdRp activity in a dose-dependent manner,"/>
   <result pre="and a low IC50 (0.14Â Î¼M). On the other hand," exact="ribavirin" post="induces competitive inhibition with GTP, and incorporation results in"/>
   <result pre="incorporate labeled GTP without stopping at the incorporation site. Thus," exact="ribavirin" post="has a high IC50 value (2.4Â Î¼M) because its"/>
   <result pre="6.3 Mutation due to chain termination and proofreading activity by" exact="acyclovir" post="Proofreading activity mediated by enzymes such as the 3â€²-5â€²"/>
   <result pre="virus DNA and prevents viral DNA synthesis. However, the incorporated" exact="acyclovir" post="is removed by the proofreading activity of viral DNA"/>
   <result pre="1999; Shimada et al., 2007; Talarico, Phelps, &amp;amp; Biron, 1993)." exact="Penciclovir" post="(famciclovir) and ganciclovir (valganciclovir), which are guanosine analogues, function"/>
   <result pre="al., 2007; Talarico, Phelps, &amp;amp; Biron, 1993). Penciclovir (famciclovir) and" exact="ganciclovir" post="(valganciclovir), which are guanosine analogues, function as an anti-herpes"/>
   <result pre="activity causes a lower mutation frequency in subjects treated with" exact="penciclovir" post="and ganciclovir than in subjects treated with acyclovir. If"/>
   <result pre="a lower mutation frequency in subjects treated with penciclovir and" exact="ganciclovir" post="than in subjects treated with acyclovir. If favipiravir induces"/>
   <result pre="of favipiravir into viral RNA followed by elongation, similar to" exact="ribavirin" post="or acyclovir (Fig. 5). Favipiravir is unlikely to induce"/>
   <result pre="into viral RNA followed by elongation, similar to ribavirin or" exact="acyclovir" post="(Fig. 5). Favipiravir is unlikely to induce mismatches upon"/>
   <result pre="mismatched transition mutations without treatment with mutagens such as ribavirin." exact="Ribavirin" post="reduces GTP levels by inhibiting inosine monophosphate dehydrogenase, but"/>
   <result pre="has a similar mechanism of action to the antiherpesvirus drug" exact="acyclovir" post="and has the property of not producing a resistant"/>
   <result pre="of deoxyribonucleotidesAmerican Journal of Physiology. Cell Physiology2812001C1776C178411698235 BeisI.NewsholmeE.A.The contents of" exact="adenine" post="nucleotides, phosphagens and some glycolytic intermediates in resting muscles"/>
   <result pre="herpes simplex virus with mutation of homopolymeric guanosine strings during" exact="acyclovir" post="therapyJournal of Dermatological Science82201616016526917345 DaikokuT.YoshidaY.OkudaT.ShirakiK.Characterization of susceptibility variants of"/>
   <result pre="respiratory tract of miceActa Virologica53200923324019941386 HawmanD.W.HaddockE.Meade-WhiteK.WilliamsonB.HanleyP.W.RosenkeK. â€¦FeldmannH.Favipiravir (T-705) but not" exact="ribavirin" post="is effective against two distinct strains of Crimean-Congo hemorrhagic"/>
   <result pre="South East Asia and South AfricaAntiviral Research832009909319501261 IdaM.KageyamaS.SatoH.KamiyamaT.ToyomotoT.OzakiT. â€¦ShirakiK.Characterization of" exact="acyclovir" post="susceptibility and genetic stability of varicella-zoster viruses isolated during"/>
   <result pre="acyclovir susceptibility and genetic stability of varicella-zoster viruses isolated during" exact="acyclovir" post="therapyJournal of Dermatological Science232000637210699766 IdaM.KageyamaS.SatoH.KamiyamaT.YamamuraJ.KurokawaM. â€¦ShirakiK.Emergence of resistance to"/>
   <result pre="acyclovir therapyJournal of Dermatological Science232000637210699766 IdaM.KageyamaS.SatoH.KamiyamaT.YamamuraJ.KurokawaM. â€¦ShirakiK.Emergence of resistance to" exact="acyclovir" post="and penciclovir in varicella-zoster virus and genetic analysis of"/>
   <result pre="of Dermatological Science232000637210699766 IdaM.KageyamaS.SatoH.KamiyamaT.YamamuraJ.KurokawaM. â€¦ShirakiK.Emergence of resistance to acyclovir and" exact="penciclovir" post="in varicella-zoster virus and genetic analysis of acyclovir-resistant variantsAntiviral"/>
   <result pre="in influenza virus-infected miceChem Pharm Bull (Tokyo)461998144414479775439 KurosakiK.MiwaN.YoshidaY.KurokawaM.KurimotoM.EndoS.ShirakiK.Therapeutic basis of" exact="vidarabine" post="on adenovirus-induced haemorrhagic cystitisAntiviral Chemistry &amp;amp; Chemotherapy15200428128515535050 LaiS.QinY.CowlingB.J.RenX.WardropN.A.GilbertM. â€¦YuH.Global"/>
   <result pre="of arenavirus hemorrhagic feverPLoS Neglected Tropical Diseases52011e1342 MiwaN.KurosakiK.YoshidaY.KurokawaM.SaitoS.ShirakiK.Comparative efficacy of" exact="acyclovir" post="and vidarabine on the replication of varicella-zoster virusAntiviral Research652005495515652971"/>
   <result pre="hemorrhagic feverPLoS Neglected Tropical Diseases52011e1342 MiwaN.KurosakiK.YoshidaY.KurokawaM.SaitoS.ShirakiK.Comparative efficacy of acyclovir and" exact="vidarabine" post="on the replication of varicella-zoster virusAntiviral Research652005495515652971 MoriH.ShirakiK.KatoT.HayakawaY.YamanishiK.TakahashiM.Molecular analysis"/>
   <result pre="Research1052014172124583123 OestereichL.RiegerT.LudtkeA.RuibalP.WurrS.PallaschE. â€¦GuntherS.Efficacy of Favipiravir alone and in combination with" exact="ribavirin" post="in a lethal, Immunocompetent mouse model of Lassa feverThe"/>
   <result pre="(H1N1) infectionFrontiers in Immunology102019216131572376 RaabeV.N.KannG.RibnerB.S.MoralesA.VarkeyJ.B.MehtaA.K. â€¦Emory Serious Communicable DiseasesU.Favipiravir and" exact="ribavirin" post="treatment of epidemiologically linked cases of Lassa feverClinical Infectious"/>
   <result pre="fever virus infection and reduces delayed-onset neurologic disease observed with" exact="ribavirin" post="treatmentAntiviral Research1042014849224486952 ShimadaY.SuzukiM.ShirasakiF.SaitoE.SogoK.HasegawaM. â€¦ShirakiK.Genital herpes due to acyclovir-sensitive herpes"/>
   <result pre="for herpesvirus infection: Towards practical application for treating herpes zosterDrugs" exact="Today" post="(Barc)53201757358429451274 ShirakiK.Antiviral drugs against AlphaherpesvirusAdvances in Experimental Medicine and"/>
   <result pre="of drug-resistant mutants of varicella-zoster virus - cross resistance of" exact="acyclovir" post="resistant mutants with phosphonoacetic acid and bromodeoxyuridineBiken Journal26198317236312958 ShirakiK.OginoT.YamanishiK.TakahashiM.Immunochemical"/>
   <result pre="with AIDSJournal of Virology671993102410338380452 TanakaT.KamiyamaT.DaikokuT.TakahashiK.NomuraN.KurokawaM.ShirakiK.T-705 (Favipiravir) suppresses tumor necrosis factor" exact="alpha" post="production in response to influenza virus infection: A beneficial"/>
   <result pre="(IL)-12 level in the airway of mice administered orally with" exact="clarithromycin" post="or intranasally with IL-12 results in alleviation of influenza"/>
   <result pre="Jan 1434635531309975 VanderlindenE.VranckenB.Van HoudtJ.RajwanshiV.K.GillemotS.AndreiG. â€¦NaesensL.Distinct effects of T-705 (Favipiravir) and" exact="ribavirin" post="on influenza virus replication and viral RNA synthesisAntimicrobial Agents"/>
   <result pre="patients with influenza virus infectionJ Infect Dis2019jiz65610.1093/infdis/jiz65631822885 WestoverJ.B.SefingE.J.BaileyK.W.Van WettereA.J.JungK.H.DagleyA. â€¦GowenB.B.Low-dose" exact="ribavirin" post="potentiates the antiviral activity of favipiravir against hemorrhagic fever"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7102582\results\search\drug\results.xml">
   <result pre="severe disease need frequent blood glucose monitoring. Oral agents especially" exact="metformin" post="and sodium glucose cotransporter-2 inhibitors need to be stopped."/>
   <result pre="drugs like lopinavir, ritonavir, interferon-1Î², RNA polymerase inhibitor remdesivir, and" exact="chloroquine" post="has been reported. 2019-nCoV receptor binding site has a"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7102591\results\search\drug\results.xml">
   <result pre="even for the management of more complex cases of COVID-19." exact="Chloroquine" post="and hydroxychloroquine have now been permanently included, alongside antiviral"/>
   <result pre="the management of more complex cases of COVID-19. Chloroquine and" exact="hydroxychloroquine" post="have now been permanently included, alongside antiviral drugs, in"/>
   <result pre="NSAIDs in the course of viral infections is still controversial." exact="Ibuprofen" post="has been demonstrated to induce an overexpression of ACE2"/>
   <result pre="patients [15]. In addition, the use of both NSAIDs and" exact="acetaminophen" post="could be associated with a masking of the fever"/>
   <result pre="database demonstrated a slightly reduced risk of hospitalized infection for" exact="methotrexate" post="(adjusted RR 0.81, 95% CI 0.70â€&quot;0.93) and hydroxychloroquine (adjusted"/>
   <result pre="infection for methotrexate (adjusted RR 0.81, 95% CI 0.70â€&quot;0.93) and" exact="hydroxychloroquine" post="(adjusted RR 0.74, 95% CI 0.62â€&quot;0.89) [52]. A recent"/>
   <result pre="roughly comparable with bDMARDs [64,65], although these early years of" exact="tofacitinib" post="and baricitinib use have raised the issue of an"/>
   <result pre="risk of Herpes Zoster virus (HZV) infections [66]. Data from" exact="tofacitinib" post="pooled population enrolled in RCTs showed an HZV incidence"/>
   <result pre="that the risk of HZV was higher in patients receiving" exact="tofacitinib" post="compared to those treated with abatacept (aHR 2.01 (95%"/>
   <result pre="2-fold higher versus all bDMARDs [70]. Older age, female sex," exact="prednisone" post="&amp;gt;7.5Â mg/day, prior infection, and greater number of hospitalizations"/>
   <result pre="load and improve disease outcome [77]. In addition, remdesivir, an" exact="adenosine" post="analogue currently under development for the management of Ebola"/>
   <result pre="of anti-rheumatic drugs in COVID-19 infection. Table 1 PROS CONS" exact="Chloroquine" post="Anti-viral effect (increase of endosomal pH required for virus/cell"/>
   <result pre="with terminal glycosylation of the cellular receptor ACE 2) â€&quot;" exact="Hydroxychloroquine" post="IL-6 inhibitors Treatment of cytokine storm manifestations during ARDS"/>
   <result pre="IFNÂ =Â interferon, NSAIDsÂ =Â nonsteroidal anti-inflammatory drugs. 5.1 Chloroquine/hydroxychloroquine" exact="Chloroquine" post="and hydroxychloroquine are widely used anti-malarial drugs with well-known"/>
   <result pre="interferon, NSAIDsÂ =Â nonsteroidal anti-inflammatory drugs. 5.1 Chloroquine/hydroxychloroquine Chloroquine and" exact="hydroxychloroquine" post="are widely used anti-malarial drugs with well-known immunomodulatory properties"/>
   <result pre="to several immuno-rheumatological diseases including RA [83]. The ability of" exact="chloroquine" post="to produce an anti-viral effect has been known since"/>
   <result pre="in vivo experience was controversial [86,87]. At clinically admissible concentrations" exact="chloroquine" post="is able to increase the endosomal pH required for"/>
   <result pre="post-entry stages of the SARS CoV infection. As a consequence," exact="chloroquine" post="has recently been included in at least 10 randomized"/>
   <result pre="Interim results from more than 100 patients have demonstrated that" exact="chloroquine" post="is superior to the control treatment in improving lung"/>
   <result pre="disease course at different levels of severity [92]. More recently," exact="hydroxychloroquine" post="was demonstrated to be more 3-times more potent than"/>
   <result pre="hydroxychloroquine was demonstrated to be more 3-times more potent than" exact="chloroquine" post="in an in vitro study based on pharmacokinetic models"/>
   <result pre="with antiviral drugs such as lopinavir/ritonavir and remdesivir [109]. Interestingly," exact="tofacitinib" post="shows no detectable inhibition of AAK1 [104], whereas currently"/>
   <result pre="blockade in the management of COVID-19 is currently ongoing with" exact="ruxolitinib" post="(ChiCTR2000029580). On the other side, IFN is one of"/>
   <result pre="as being inappropriate for the management of SARS-CoV2 interstitial pneumonia." exact="Chloroquine" post="and hydroxychloroquine are currently included in the treatment protocol"/>
   <result pre="inappropriate for the management of SARS-CoV2 interstitial pneumonia. Chloroquine and" exact="hydroxychloroquine" post="are currently included in the treatment protocol for the"/>
   <result pre="Rheumatol21200788590610.1016/j.berh.2007.06.00217870034 39BoersM.VerhoevenA.C.MarkusseH.M.van de LaarM.A.WesthovensR.van DenderenJ.C.Randomised comparison of combined step-down prednisolone," exact="methotrexate" post="and sulphasalazine with sulphasalazine alone in early rheumatoid arthritisLancet350199730931810.1016/s0140-6736(97)01300-79251634"/>
   <result pre="with sulphasalazine alone in early rheumatoid arthritisLancet350199730931810.1016/s0140-6736(97)01300-79251634 40van EverdingenA.A.JacobsJ.W.G.van ReesemaD.R.S.BijlsmaJ.W.J.Low-dose" exact="prednisone" post="therapy for patients with early active rheumatoid arthritis: clinical"/>
   <result pre="effects: a randomized, double-blindPlacebo-Controlled Clinical Trial Ann Intern Med1362002110.7326/0003-4819-136-1-200201010-00006 41BakkerM.F.JacobsJ.W.G.WelsingP.M.J.VerstappenS.M.M.TekstraJ.TonE.Low-dose" exact="prednisone" post="inclusion in a methotrexate-based, tight control strategy for early"/>
   <result pre="in patients with rheumatoid arthritisJ Rheumatol35200838739318260176 53IbrahimA.AhmedM.ConwayR.CareyJ.J.Risk of infection with" exact="methotrexate" post="therapy in inflammatory diseases: a systematic review and meta-analysisJ"/>
   <result pre="treatmentJ Rheumatol46201871810.3899/jrheum.17136130219772 69CurtisJ.R.XieF.YunH.BernatskyS.WinthropK.L.Real-world comparative risks of herpes virus infections in" exact="tofacitinib" post="and biologic-treated patients with rheumatoid arthritisAnn Rheum Dis7520161843184710.1136/annrheumdis-2016-20913127113415 70PawarA.DesaiR.J.GautamN.KimS.C.Risk"/>
   <result pre="70PawarA.DesaiR.J.GautamN.KimS.C.Risk of admission to hospital for serious infection after initiating" exact="tofacitinib" post="versus biologic DMARDs in patients with rheumatoid arthritis: a"/>
   <result pre="rheumatoid arthritis: a multidatabase cohort studyLancet Rheumatol22020e84e9810.1016/s2665-9913(19)30137-7 71CaporaliR.ZavagliaD.Real-world experience with" exact="tofacitinib" post="for treatment of rheumatoid arthritisClin Exp Rheumatol373201948549530183607 72BiggioggeroM.BeccioliniA.CrottiC.AgapeE.FavalliE.G.Upadacitinib and"/>
   <result pre="inhibits both epidemic and zoonotic coronavirusesSci Transl Med92017eaal365310.1126/scitranslmed.aal3653 80WangM.CaoR.ZhangL.YangX.LiuJ.XuM.Remdesivir and" exact="chloroquine" post="effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in"/>
   <result pre="monoclonal 1 antibody blocking SARS-CoV-2 infectionBiorxiv202010.1101/2020.03.11.987958 83SchrezenmeierE.DÃ¶rnerT.Mechanisms of action of" exact="hydroxychloroquine" post="and chloroquine: implications for rheumatologyNat Rev Rheumatol16202015516610.1038/s41584-020-0372-x32034323 84InglotA.D.Comparison of"/>
   <result pre="randomised, double-blind, placebo controlled trialLancet Infect Dis11201167768310.1016/s1473-3099(11)70065-221550310 87RoquesP.ThibervilleS.-D.Dupuis-MaguiragaL.LumF.-M.LabadieK.MartinonF.Paradoxical effect of" exact="chloroquine" post="treatment in enhancing chikungunya virus infectionViruses10201826810.3390/v10050268 88VincentM.J.BergeronE.BenjannetS.EricksonB.R.RollinP.E.KsiazekT.G.Chloroquine is a"/>
   <result pre="and spreadVirol J220056910.1186/1743-422x-2-6916115318 89DevauxC.A.RolainJ.-M.ColsonP.RaoultD.New insights on the antiviral effects of" exact="chloroquine" post="against coronavirus: what to expect for COVID-19?Int J Antimicrob"/>
   <result pre="of chloroquineLancet Infect Dis62006676910.1016/s1473-3099(06)70361-916439323 91Chinese Clinical Trial Registry. 2020. 92GaoJ.TianZ.YangX.Breakthrough:" exact="chloroquine" post="phosphate has shown apparent efficacy in treatment of COVID-19"/>
   <result pre="vitro antiviral activity and projection of optimized dosing design of" exact="hydroxychloroquine" post="for the treatment of severe acute respiratory syndrome coronavirus"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7105126\results\search\drug\results.xml">
   <result pre="were women aged â‰¥18 years-old who self-reported active use of" exact="cocaine" post="or heroin, and who were followed by a comprehensive"/>
   <result pre="blood borne viral infections (HIV, HCV, HBV and syphilis) using" exact="dried" post="blood spot and syphilis through of a mobile van"/>
   <result pre="drugs, 32 (29.4%) used drugs daily and 96 (88.1%) reported" exact="cocaine" post="as the drug they had â€œmost often usedâ€�, 24"/>
   <result pre="Project WINGS (Women Initiating New Goals of Safety). Drug and" exact="alcohol" post="review. 2017;36(1):125â€&quot;33. 10.1111/dar.1243727770541 26El-BasselN, GilbertL, WitteS, WuE, ChangM. Intimate"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7106608\results\search\drug\results.xml">
   <result pre="essential for achieving UNAIDS 90â€&quot;90-90 goals in people who use" exact="heroin" post="in Vietnam. Social determinants of health associated with ART"/>
   <result pre="and setting This study reports cross-sectional baseline characteristics of the" exact="Buprenorphine" post="to Improve HIV Care Engagement and Outcomes (BRAVO) Randomized"/>
   <result pre="Participants were ineligible if they had a known hypersensitivity to" exact="buprenorphine" post="or naloxone, an aspartate aminotransferase or alanine aminotransferase greater"/>
   <result pre="known hypersensitivity to buprenorphine or naloxone, an aspartate aminotransferase or" exact="alanine" post="aminotransferase greater than five times the upper limit of"/>
   <result pre="methadone, or buprenorphine), and self-reported daily tobacco use and risky" exact="alcohol" post="use (defined as an AUDIT-C score greater than 3"/>
   <result pre="153 (81.0%) â€ƒNo 51 (18.0%) 37 (19.4%) 36 (19.0%) Risky" exact="alcohol" post="use (nâ€‰=â€‰266) pâ€‰=â€‰0.14 â€&quot; pâ€‰=â€‰0.41 â€&quot; â€ƒYes 90 (31.8%)"/>
   <result pre="â€&quot; â€ƒYes 4 (1.4%) â€ƒNo 279 (98.6%) Positive UDS for" exact="buprenorphine" post="â€&quot; â€&quot; â€&quot; â€&quot; â€ƒYes 1 (0.4%) â€ƒNo 282"/>
   <result pre="Virus/Acquired Immune Deficiency Syndrome DASS Depression Anxiety Stress Score BRAVO" exact="Buprenorphine" post="to Improve HIV Care Engagement and Outcomes UDS Urine"/>
   <result pre="16]; Available from: https://www.molecular.abbott/us/en/products/infectious-disease/realtime-hiv-1-viral-load. 20.BradleyKAet al.Predictive validity of clinical AUDIT-C" exact="alcohol" post="screening scores and changes in scores for three objective"/>
   <result pre="alcohol-related outcomes in a veterans affairs populationAddiction2016111111975198410.1111/add.1350527349855 21.BradleyKAet al.The AUDIT" exact="alcohol" post="consumption questions: reliability, validity, and responsiveness to change in"/>
   <result pre="male primary care patientsAlcohol Clin Exp Res1998228184218499835306 22.BushKet al.The AUDIT" exact="alcohol" post="consumption questions (AUDIT-C): an effective brief screening test for"/>
   <result pre="test for problem drinking. Ambulatory care quality improvement project (ACQUIP)." exact="Alcohol" post="use disorders identification testArch Intern Med1998158161789179510.1001/archinte.158.16.17899738608 23.BradleyKAet al.AUDIT-C as"/>
   <result pre="testArch Intern Med1998158161789179510.1001/archinte.158.16.17899738608 23.BradleyKAet al.AUDIT-C as a brief screen for" exact="alcohol" post="misuse in primary careAlcohol Clin Exp Res20073171208121710.1111/j.1530-0277.2007.00403.x17451397 24.KorthuisPTEdelmanEJSubstance use"/>
   <result pre="have sex with men accessing support services in New YorkDrug" exact="Alcohol" post="Depend201514726627110.1016/j.drugalcdep.2014.09.78025482501 42.Goodman-MezaDet al.Methamphetamine use drives decreases in viral suppression"/>
   <result pre="large municipal jail: results of the LINK LA clinical trialDrug" exact="Alcohol" post="Depend201920217818410.1016/j.drugalcdep.2019.05.00731352308 43.HoodJEet al.The changing burden of HIV attributable to"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7108526\results\search\drug\results.xml">
   <result pre="lopinavir/ritonavir is under evaluation as anti 2019-nCoV therapy. Lopinavir and" exact="Ritonavir" post="are known anti-retroviral drug targeting protease of the human"/>
   <result pre="of Ebola and Marburg virus infection, and the anti-malarial drug" exact="chloroquine" post="are effective to inhibit 2019-nCoV replication in vitro (Wang"/>
   <result pre="2020; pii: JVI.00127-20. doi: 10.1128/JVI.00127-20 WangM, CaoR, ZhangLet al..Remdesivir and" exact="chloroquine" post="effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7111068\results\search\drug\results.xml">
   <result pre="approach. However, patient enrolment for a MERS treatment trial with" exact="lopinavir" post="(an antiretroviral proteinase inhibitor)/ritonavir (cytochrome P450 inhibitor to prolong"/>
   <result pre="on viral RNA transcription at the postviral entry level, while" exact="chloroquine" post="needs to be applied at the beginning of the"/>
   <result pre="a better activity against MERS coronavirus than the protease inhibitor" exact="lopinavir" post="combined with ritonavir, and this both in cell culture"/>
   <result pre="Liu, J., and Xu, M., et al (2020a) Remdesivir and" exact="chloroquine" post="effectively inhibit the recently emerged novel coronavirus (2019â€�nCoV) in"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7113379\results\search\drug\results.xml">
   <result pre="no established drugs to treat COVID-19, some are showing promise." exact="Chloroquine" post="phosphate, an anti-malarial, has been shown to be useful"/>
   <result pre="if taking ibuprofen, so it is recommended that patients take" exact="acetaminophen" post="or paracetamol for fever and pain. In conclusion, COVID-19"/>
   <result pre="An unaddressed health problemJ Nutr Health Aging20202424324510.1007/s12603-020-1323-632115602 10.ColsonPRolainJMLagierJCet al.Chloroquine and" exact="hydroxychloroquine" post="as available weapons to fight COVID-19Int J Antimicrob Agents2020"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7117553\results\search\drug\results.xml">
   <result pre="Antimalarials, JAK inhibitors, IL-1 inhibitors, IL-6 inhibitors, intravenous immunoglobulin and" exact="leflunomide" post="have all been put forward as potential treatments for"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7117787\results\search\drug\results.xml">
   <result pre="other viral respiratory diseases and influenza, yet (50,51). Steroids and" exact="methylprednisolone" post="seem to be widely used in the recent pandemic."/>
   <result pre="3; 2020Available online: https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports (accessed on 25 January 2020) 48GaoJTianZYangXBreakthrough:" exact="Chloroquine" post="phosphate has shown apparent efficacy in treatment of COVID-19"/>
   <result pre="pneumonia in clinical studies Bioscience trends2020 14172332074550 49WangMCaoRZhangLYangXLiuJXuMet al.Remdesivir and" exact="chloroquine" post="effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7118644\results\search\drug\results.xml">
   <result pre="virus infection [8], remdesivir is a prodrug of the parent" exact="adenosine" post="analog, GS-441524 (Fig. 1b), both of which are metabolized"/>
   <result pre="host metabolizes remdesivir into active NTP, the metabolite competes with" exact="adenosine" post="triphosphate (ATP; the natural nucleotide normally used in this"/>
   <result pre="inhibiting SARS-CoV-2. EC50 values ranged widely from 109.5Â Î¼M for" exact="ribavirin" post="to 1.13Â Î¼M for choloquine and 0.77Â Î¼M for"/>
   <result pre="a different amino acid at a specific site (phenylalanine to" exact="leucine" post="at residue 483), a dissimilarity that has been previously"/>
   <result pre="that is being evaluated in multiple trials against COVID-19 is" exact="chloroquine" post="(or hydroxychloroquine), which is already approved as an antimalarial"/>
   <result pre="naturally occurring feline infectious peritonitisJ. Feline Med. Surg.214201927128130755068 17WangM.CaoR.ZhangL.YangX.LiuJ.XuM.Remdesivir and" exact="chloroquine" post="effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7126217\results\search\drug\results.xml">
   <result pre="chicken red blood cells DMEM Dulbecco's Modified Eagle Medium DMSO" exact="dimethyl sulfoxide" post="EID50 50% egg infective dose FBS fetal bovine serum"/>
   <result pre="progoitrin, epigoitrin and goitrin were dissolved in 1Â mL of" exact="dimethyl sulfoxide" post="(DMSO) and diluted with sodium chloride injection to get"/>
   <result pre="day to eliminate infertile eggs and dead embryos. 2.3 Reagents" exact="Peramivir" post="(Guangzhou Nanxin Pharmaceutical Co., Ltd.) was used as the"/>
   <result pre="injection (Shijiazhuang Siyao Co., Ltd.), phosphate buffered saline (PBS, Hyclone)," exact="dimethyl sulfoxide" post="(DMSO, Sigma), Alsever's solution (pH 6.1) an isotonic solution"/>
   <result pre="experiments with virus concentration of 50 EID50. 3Â mg/mL of" exact="peramivir" post="was used as the positive control and sodium chloride"/>
   <result pre="solution at different concentrations (0.625, 1.25, 2.5 and 5Â mg/mL)." exact="Peramivir" post="at different concentrations (0.375, 0.75, 1.5 and 3Â mg/mL)"/>
   <result pre="activity of the drugs. As shown in Table 2 ," exact="peramivir" post="presented dose-dependent NA inhibitory activity with IC50 value of"/>
   <result pre="PressBeijing CorreiaV.SantosL.A.GiriaM.Almeida-SantosM.M.Rebelo-de-AndradeH.Influenza A(H1N1)pdm09 resistance and cross-decreased susceptibility to oseltamivir and" exact="zanamivir" post="antiviral drugsJ. Med. Virol.872015455625042157 CourtinN.FotsoA.F.FautradP.MasF.AlessiM.C.RiteauB.Antiviral activity of formyl peptide"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7127009\results\search\drug\results.xml">
   <result pre="that hydroxychloroquine, which shares the same mechanism of action as" exact="chloroquine" post="but has a better safety profile and is frequently"/>
   <result pre="connective tissue disease, has a more potent anti-viral effect than" exact="chloroquine" post="in vitro. From the results of physiologically-based pharmacokinetic models,"/>
   <result pre="daily for four days reaches three times the potency of" exact="chloroquine" post="and is therefore a promising drug for both the"/>
   <result pre="clinical trials that are ongoing to study the efficacy of" exact="chloroquine" post="or hydroxychloroquine in CoViD-19 patients. Hydroxychloroquine is thus being"/>
   <result pre="that are ongoing to study the efficacy of chloroquine or" exact="hydroxychloroquine" post="in CoViD-19 patients. Hydroxychloroquine is thus being used in"/>
   <result pre="study the efficacy of chloroquine or hydroxychloroquine in CoViD-19 patients." exact="Hydroxychloroquine" post="is thus being used in Italy for the treatment"/>
   <result pre="such as baricitinib, since they block the downstream signaling of" exact="alpha" post="and beta IFN receptors. The situation is complicated by"/>
   <result pre="avoid contact with crowded places. Smart working is encouraged. 3-" exact="Chloroquine" post="and hydroxychloroquine seem to have some efficacy on SARS-CoV2"/>
   <result pre="with crowded places. Smart working is encouraged. 3- Chloroquine and" exact="hydroxychloroquine" post="seem to have some efficacy on SARS-CoV2 infection. 4-"/>
   <result pre="vitro antiviral activity and projection of optimized dosing design of" exact="hydroxychloroquine" post="for the treatment of severe acute respiratory syndrome coronavirus"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7129715\results\search\drug\results.xml">
   <result pre="ACE-2 receptors. There have been some anecdotal reports of successful" exact="chloroquine" post="treatment from China, and the guidelines of the Italian"/>
   <result pre="of COVID-19, but there is a question as to whether" exact="chloroquine" post="and hydroxychloroquine can play a prophylactic role as a"/>
   <result pre="but there is a question as to whether chloroquine and" exact="hydroxychloroquine" post="can play a prophylactic role as a randomised, double-blind,"/>
   <result pre="prophylactic role as a randomised, double-blind, placebo-controlled clinical trial of" exact="chloroquine" post="found that it did not prevent influenza infection [5]."/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7134984\results\search\drug\results.xml">
   <result pre="lung rescue therapies included neuromuscular blockade (28% of patients), inhaled" exact="nitric oxide" post="(13.7%), high-frequency oscillatory ventilation (11.9%), ECMO (4.2%), and prone"/>
   <result pre="available quantities of available required agents, such as oseltamivir and" exact="peramivir" post="for influenza, plus appropriate antimicrobial drugs for secondary bacterial"/>
   <result pre="in adult critical care (2001-2016)JÂ Crit Care41201728328828622641 30VailE.GershengornH.B.HuaM.Association between US" exact="norepinephrine" post="shortage and mortality among patients with septic shockJAMA31720171433144228322415 31ReddS.C.FriedenT.R.CDC's"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7138017\results\search\drug\results.xml">
   <result pre="National Health Commission suggests taking an anti-HIV drug combination of" exact="lopinavir" post="and ritonavir and inhaling a dose of nebulised interferon"/>
   <result pre="Commission suggests taking an anti-HIV drug combination of lopinavir and" exact="ritonavir" post="and inhaling a dose of nebulised interferon Î± for"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7138156\results\search\drug\results.xml">
   <result pre="de-escalating therapy by switching to immunomodulatory DMTs, such as interferon-beta," exact="glatiramer acetate" post="or teriflunomide, or interrupting dosing of DMTs to wait"/>
   <result pre="beneficial in the case of COVID-19 Very low Glatiramer acetate" exact="Copaxone" post="Immunomodulatoy (not immunosuppressive), pleitropic immune effects Moderate Maintenance immunomodulatoy"/>
   <result pre="that may be beneficial in the case of COVID-19 Low" exact="Dimethyl fumarate" post="Tecfidera Pleotropic, NRF2 activation, downregulation of NFÎšÎ² Moderate (2nd-3rd-line)"/>
   <result pre="shedding. Paradoxically S1P modulators may reduce the severity of COVID-19;" exact="fingolimod" post="is currently being trialed. Intermediate Anti-CD20 Ocrelizumab (Ocrevus), Ofatumumab."/>
   <result pre="other anti-CD20 therapies may result in prolonged viral shedding. Intermediate" exact="Cladribine" post="Mavenclad Deoxyadenosine (purine) analogue, adenosine deaminase inhibitor, selective T"/>
   <result pre="therapies may result in prolonged viral shedding. Intermediate Cladribine Mavenclad" exact="Deoxyadenosine" post="(purine) analogue, adenosine deaminase inhibitor, selective T and B"/>
   <result pre="in prolonged viral shedding. Intermediate Cladribine Mavenclad Deoxyadenosine (purine) analogue," exact="adenosine" post="deaminase inhibitor, selective T and B cell depletion High"/>
   <result pre="Yes, intermittent Theoretical risk that in the immune depletion phase" exact="cladribine" post="may result in prolonged viral shedding. High* Mitoxantrone Novatrone"/>
   <result pre="depletion phase cladribine may result in prolonged viral shedding. High*" exact="Mitoxantrone" post="Novatrone Immune depleter (topoisomerase inhibitor) Very high IRT (non-selective)"/>
   <result pre="Yes, intermittent Theoretical risk that in the immune depletion phase" exact="mitoxantrone" post="may result in prolonged viral shedding. High* Alemtuzumab Lemtrada"/>
   <result pre="the treatment, i.e. haematopoietic stem cell transplantation (HSCT), alemtuzumab (Lemtrada)," exact="mitoxantrone" post="(Novantrone) and cladribine (Mavenclad). After immune reconstitution, once the"/>
   <result pre="haematopoietic stem cell transplantation (HSCT), alemtuzumab (Lemtrada), mitoxantrone (Novantrone) and" exact="cladribine" post="(Mavenclad). After immune reconstitution, once the total lymphocyte counts"/>
   <result pre="comorbidities and are relatively young. Of the immune reconstitution therapies," exact="cladribine" post="(Mavenclad) is classed as intermediate risk, because it is"/>
   <result pre="urinary tract infections and cellulitis). We therefore feel that both" exact="cladribine" post="and anti-CD20 therapies are relatively safe to use during"/>
   <result pre="a problem dealing with community acquired viral infections. Patients on" exact="fingolimod" post="who are exposed to and acquire exotic viral infections"/>
   <result pre="virus cleared the virus without complications similar to those on" exact="fingolimod" post="(FragosoÂ etÂ al., 2016b). Clearly, any decision to start"/>
   <result pre="recommend continuing the current DMT specifically with: -First-line DMTs (beta-interferons," exact="glatiramer acetate," post="teriflunomide or dimethyl fumarate). These DMTs can be prescribed"/>
   <result pre="and hand sanitizing (particularly for patients on fingolimod, alemtuzumab, ocrelizumab," exact="cladribine" post="or rituximab). -If possible, work from home. -Good personal"/>
   <result pre="coronavirus OC43J. Virol.7319993338335010074188 CookS.VermerschP.ComiG.GiovannoniG.RammohanK.RieckmannP.SÃ¸rensenP.S.HamlettA.MiretM.WeinerJ.VigliettaV.MuschB.GreenbergS.J.collab: CLARITY Study GroupSafety and tolerability of" exact="cladribine" post="tablets in multiple sclerosis: the CLARITY (CLAdRIbine Tablets treating"/>
   <result pre="Dis.57201384985223728144 FragosoY.D.GamaP.D.daGomesS.KhouriJ.M.N.MattaA.P.daC.Fernanda MendesM.StellaC.R.A.V.Dengue fever in patients with multiple sclerosis taking" exact="fingolimod" post="or natalizumabMult. Scler. Relat. Disord.62016646527063625 FragosoY.D.GamaP.D.daGomesS.KhouriJ.M.N.MattaA.P.daC.Fernanda MendesM.StellaC.R.A.V.Dengue fever in"/>
   <result pre="Disord.62016646527063625 FragosoY.D.GamaP.D.daGomesS.KhouriJ.M.N.MattaA.P.daC.Fernanda MendesM.StellaC.R.A.V.Dengue fever in patients with multiple sclerosis taking" exact="fingolimod" post="or natalizumabMult. Scler. Relat. Disord.62016646527063625 FrancisG.KapposL.O'ConnorP.CollinsW.TangD.MercierF.CohenJ.A.Temporal profile of lymphocyte"/>
   <result pre="FrancisG.KapposL.O'ConnorP.CollinsW.TangD.MercierF.CohenJ.A.Temporal profile of lymphocyte counts and relationship with infections with" exact="fingolimod" post="therapyMult. Scler.20201447148023950550 GhoshS.GoldinE.GordonF.H.MalchowH.A.Rask-MadsenJ.RutgeertsP.VyhnÃ¡lekP.ZÃ¡dorovÃ¡Z.PalmerT.DonoghueS.collab: Natalizumab Pan-European Study GroupNatalizumab for active"/>
   <result pre="treatment of autoimmune and inflammatory diseasesPharmacol. Res.2019104170 StuveO.Soelberg SoerensenP.LeistT.GiovannoniG.HyvertY.DamianD.DangondF.BoschertU.Effects of" exact="cladribine" post="tablets on lymphocyte subsets in patients with multiple sclerosis:"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7138334\results\search\drug\results.xml">
   <result pre="syndrome (2). Persons whose lungs may be compromised from vaping" exact="nicotine" post="or tetrahydrocannabinol (or even just flavorings) may also be"/>
   <result pre="Persons whose lungs may be compromised from vaping nicotine or" exact="tetrahydrocannabinol" post="(or even just flavorings) may also be at risk."/>
   <result pre="at increased risk for the most adverse consequences of COVID-19." exact="Methamphetamine" post="is a highly toxic drug that causes pulmonary damage,"/>
   <result pre="overdoses happening when there are no observers who can administer" exact="naloxone" post="to reverse them and thus when they are more"/>
   <result pre="physicians with increased caseloads may be less likely to initiate" exact="buprenorphine" post="therapy for patients with OUD, which is an important"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7138382\results\search\drug\results.xml">
   <result pre="with lopinavir/ritonavir (Chan et al., 2015; Sheahan et al., 2020)," exact="ribavirin" post="(Chen et al., 2004; Morgenstern et al., 2005; Omrani"/>
   <result pre="(Sheahan et al., 2020), while a combination of IFNÎ±2a with" exact="ribavirin" post="delayed mortality without decreasing it on the long run"/>
   <result pre="(Omrani et al., 2014). Similarly, the combination of IFNÎ±2b with" exact="ribavirin" post="gave excellent results in the rhesus macaque (Falzarano et"/>
   <result pre="in pulmonary endothelial cells, resulting in the secretion of anti-inflammatory" exact="adenosine" post="and the maintenance of endothelial barrier function. This process"/>
   <result pre="inhalation twice a day to the patients, in combination with" exact="ribavirin" post="(Dong et al., 2020; Lu, 2020). Clinical trials have"/>
   <result pre="lopinavir/ritonavir and IFNÎ±2b (ChiCTR2000029387) or a combination of lopinavir/ritonavir with" exact="ribavirin" post="and IFNÎ²1b administered subcutanously (NCT04276688) for the treatment of"/>
   <result pre="(Mager and Jusko, 2002). The combination of IFN-I with lopinavir/ritonavir," exact="ribavirin" post="or remdesivir could improve its efficacy, because of the"/>
   <result pre="syndrome coronavirus: an observational studyInt. J. Infect. Dis.202014424610.1016/j.ijid.2013.12.00324406736 ArabiY.M.ShalhoubS.Al-OmariA.MandourahY.Al-HameedF.SindiA.AlraddadiB.Al-MotairiA.Al-KhatibK.Abdul-MomminA.QushmaqI.A.MadyA.SolaimanO.Al-AithanA.BalkhyH.H.Al-RaddadiR.RajabA.Al-MekhlafiG.A.Al-HarthyA.KharabaA.Al-JabbaryA.PintoR.SadatM.Al-MutairiH.Al-QasimE.JoseJ.DeebA.M.MersonL.HaydenF.G.FowlerR.AldawoodA.S.Effect of" exact="ribavirin" post="and interferon on the outcome of critically ill patients"/>
   <result pre="prevent acute viral respiratory infections in military recruitsVaccine2820104445445110.1016/j.vaccine.2010.03.06220394720 HartB.J.DyallJ.PostnikovaE.ZhouH.KindrachukJ.JohnsonR.F.OlingerG.G.FriemanM.B.HolbrookM.R.JahrlingP.B.HensleyL.Interferon-Î² and" exact="mycophenolic acid" post="are potent inhibitors of middle east respiratory syndrome coronavirus"/>
   <result pre="host defensesAnnu. Rev. Immunol.32201451354510.1146/annurev-immunol-032713-12023124555472 ShalhoubS.FarahatF.Al-JiffriA.SimhairiR.ShammaO.SiddiqiN.MushtaqA.IFN-Î±2a or IFN-Î²1a in combination with" exact="ribavirin" post="to treat Middle East respiratory syndrome coronavirus pneumonia: a"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7144238\results\search\drug\results.xml">
   <result pre="at Institut Pasteur of Shanghai. Mice were anesthetized with 80â€…mg/Kg" exact="pentobarbital" post="sodium dissolved in phosphate-buffered saline (PBS) by intraperitoneal injection."/>
   <result pre="antibody was from Merck/Millipore (Merck KGaA, Darmstadt, Germany). Human/Mouse HIF-1" exact="alpha" post="(APC) antibody was from R&amp;amp;D (R&amp;amp;D Systems, Minneapolis, USA)."/>
   <result pre="TX, USA). IFITM3 Antibody (11714-1-AP) was from Proteintech (Rosemont, USA)." exact="Chloroquine" post="diphosphate salt solid (C6628-25G) was from Sigma/flu/Ald (Merck KGaA,"/>
   <result pre="incubated for 10â€…min with 100â€…Âµl/well of Quencher (0.5% Tritonâ€‰Ã—â€‰100, 20â€…mM" exact="glycine" post="in PBS). After 10â€…min the cells were washed with"/>
   <result pre="quality control. The amplified PCR products from previous step were" exact="denatured" post="and circularized by the splint oligo sequence to get"/>
   <result pre="GCCCTTTGCGTTATATTGTAT. Histology After mice were anesthetized and sacrificed with 80â€…mg/Kg" exact="pentobarbital" post="sodium, the chest and abdomen were rapidly opened. The"/>
   <result pre="applying autophagy inhibitors, LY294002 (Figure 6(A)), 3-MA (Figure 6(B)) and" exact="chloroquine" post="(CQ) (Figure 6(C)). As previously reported, our results also"/>
   <result pre="after the disruption of autophagy. We further took advantage of" exact="rapamycin" post="to induce autophagy and observe the change in viral"/>
   <result pre="observe the change in viral replication. Our results showed that" exact="rapamycin" post="treatment increased the expression of LC3-II and IAV replication"/>
   <result pre="an increasing dose of LY294002 (A) or 3-MA (B) or" exact="chloroquine" post="(C) or Rapamycin (D) for 30â€…min and then mock-infected"/>
   <result pre="by the US Food and Drug Administration (FDA); oseltamivir, zanamivir," exact="amantadine" post="and rimantadine, these drugs mainly target two of the"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7147535\results\search\drug\results.xml">
   <result pre="are being studied in clinical trials, including antiviral agents and" exact="hydroxychloroquine" post="[12â€&quot;14]; widespread uptake of the latter has resulted in"/>
   <result pre="vitro antiviral activity and projection of optimized dosing design of" exact="hydroxychloroquine" post="for the treatment of severe acute respiratory syndrome coronavirus"/>
   <result pre="Infect Dis.202010.1093/cid/ciaa23732161968 14.ZhouDDaiS-MTongQCOVID-19: a recommendation to examine the effect of" exact="hydroxychloroquine" post="in preventing infection and progressionJ Antimicrob Chemother.202010.1093/jac/dkaa11432196083 15.KimAHJSparksJALiewJWet al.A"/>
   <result pre="dissemination of results and its consequences regarding the use of" exact="hydroxychloroquine" post="for COVID-19Ann Intern Med202010.7326/M20-122332271869 16.ZhangWZhaoYZhangFet al.The use of anti-inflammatory"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7151436\results\search\drug\results.xml">
   <result pre="dyspnea and tachypnea; more leukocytosis, neutrophilia, and lymphopenia; and higher" exact="alanine" post="and aspartate aminotransferase, bilirubin, creatinine, procalcitonin, troponin, D-dimer, and"/>
   <result pre="(IP10), monocyte chemoattractant protein 1 (MCP1), macrophage inflammatory protein 1" exact="alpha" post="(MIP1Î±), and tumor necrosis factor alpha (TNF-Î±).15 Cytokine storms"/>
   <result pre="macrophage inflammatory protein 1 alpha (MIP1Î±), and tumor necrosis factor" exact="alpha" post="(TNF-Î±).15 Cytokine storms are known to be associated with"/>
   <result pre="antiviral therapy for COVID-19 in pregnancy are limited.51 In SARS," exact="ribavirin" post="and corticosteroid showed possible harm with inconclusive clinical data,"/>
   <result pre="inconclusive clinical data, whereas studies on convalescent plasma, interferon, and" exact="lopinavir" post="were inconclusive.51 In the first randomized controlled trial on"/>
   <result pre="chloroquine, 61.88 for favipiravir, and 109.50 for ribavirin.54 EC50 for" exact="hydroxychloroquine" post="was significantly higher than chloroquine.55 In a French nonrandomized"/>
   <result pre="chloroquine.55 In a French nonrandomized study,56 26 patients received 200-mg" exact="hydroxychloroquine" post="thrice daily for 10 days, 6 of whom also"/>
   <result pre="thrice daily for 10 days, 6 of whom also received" exact="azithromycin" post="500 mg on day 1 and 250 mg daily"/>
   <result pre="the 2019 novel coronavirus (2019-nCoV)Nat Rev Drug Discov19202014915032127666 55WangM.CaoR.ZhangL.Remdesivir and" exact="chloroquine" post="effectively inhibit the recently emerged novel coronavirus (2019-nCoV) inÂ"/>
   <result pre="effective in inhibiting SARS-CoV-2 infection inÂ vitroCell Discov620201632194981 57GautretP.LagierJ.C.ParolaP.Hydroxychloroquine and" exact="azithromycin" post="as a treatment of COVID-19: results of an open-label"/>
   <result pre="COVID-19 patient SVR: systemic vascular resistance TNF-Î±: tumor necrosis factor" exact="alpha" post="TTE: transthoracic echocardiography WHO: World Health Organization Antenatal management"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7155909\results\search\drug\results.xml">
   <result pre="chloroquine, which prevents endosomal acidification that triggers viral membrane fusion." exact="Chloroquine" post="may also modify ACE2 terminal glycosylation and inhibit coronavirus"/>
   <result pre="to be a target of human immunodeficiency virus protease inhibitors" exact="lopinavir" post="or ritonavir, although in silico studies have questioned this"/>
   <result pre="SARS-2-CoVâ€&quot;infected patients should be carefully disinfected with 70% or greater" exact="ethanol" post="for small surfaces or 0.1% or greater sodium hypochlorite"/>
   <result pre="with the current best supported regimen. Interestingly, the antimalaria drug" exact="chloroquine" post="has also been shown to inhibit SARS-CoV-2 at micromolar"/>
   <result pre="Middle East respiratory syndrome coronavirus.J Biol Chem2020DOI: 10.1074/jbc.AC120.013056 87.WangMCaoRZhangLYangXLiuJXuMShiZHuZZhongWXiaoGRemdesivir and" exact="chloroquine" post="effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in"/>
   <result pre="pneumonia.Am J Ther2007; 14:422â€&quot;617890928 98.RadzikowskaEWiatrELangfortRBestryISkoczylasASzczepulska-WÃ³jcikEGawrylukDRudziÅ&quot;skiPChorostowska-WynimkoJRoszkowski-ÅšliÅ¼KCryptogenic organizing pneumonia-Results of treatment with" exact="clarithromycin" post="versus corticosteroids-Observational study.PLoS One2017; 12:e018473928945804 99.WuCChenXCaiYXiaJZhouXXuSHuangHZhangLZhouXDuCZhangYSongJWangSChaoYYangZXuJZhouXChenDXiongWXuLZhouFJiangJBaiCZhengJSongYRisk factors associated with"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7156260\results\search\drug\results.xml">
   <result pre="treatment protocol for management of COVID-19 patients, which included moxifloxacin," exact="levofloxacin" post="(consider tolerance) and arbidol administration (8). However, the underlying"/>
   <result pre="potentially effective in treating COVID-19, including oseltamivir, ganciclovir, arbidol and" exact="lopinavir" post="/ ritonavir. Many clinical trials are currently underway to"/>
   <result pre="treated with antiviral agents. The most commonly used antivirals were" exact="lopinavir" post="/ ritonavir, oseltamivir, ribavirin and arbidol, respectively. Route and"/>
   <result pre="The most commonly used antivirals were lopinavir / ritonavir, oseltamivir," exact="ribavirin" post="and arbidol, respectively. Route and duration of administration were"/>
   <result pre="China (12) 9 14 to 56 5 Symptomatic COVID-19 Lopinavir/" exact="Ritonavir" post="9 800 mg/200 mg daily Oral 4 to 11"/>
   <result pre="80 46.10 Â± 15.42 39 All severity ranges of COVID-19" exact="Ribavirin" post="80 NR NR 2-12 days Yes 21 patients were"/>
   <result pre="COVID-19 Lopinavir/ritonavirArbidolLopinavir/ritonavir + Arbidol 25121 Lopinavir 400 mg twice daily" exact="ritonavir" post="100 mg twice dailyArbidol 200 mg three time daily"/>
   <result pre="the MIRACLE trial, was designed to evaluate the efficacy of" exact="lopinavir" post="/ ritonavir and interferon-Î²1b combination therapy in the treatment"/>
   <result pre="trial, was designed to evaluate the efficacy of lopinavir /" exact="ritonavir" post="and interferon-Î²1b combination therapy in the treatment of MERS-CoV"/>
   <result pre="A systematic review and meta-analysis Reviews in medical virology2018283e197729664167 36GrossAEBrysonMLOral" exact="Ribavirin" post="for the Treatment of Noninfluenza Respiratory Viral Infections: A"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7162773\results\search\drug\results.xml">
   <result pre="experts is that neuraminidase inhibitors (oseltamivir, peramivir, zanamivir, etc) and" exact="ganciclovir" post="are not generally recommended. Routine prophylactic antibiotics, especially combined"/>
   <result pre="in the guidelines of the NHC Medication instruction Alpha-interferon Lopinavir/ritonavir" exact="Ribavirin" post="Chloroquine Arbidol Recommended dosage and course 5 million units"/>
   <result pre="the guidelines of the NHC Medication instruction Alpha-interferon Lopinavir/ritonavir Ribavirin" exact="Chloroquine" post="Arbidol Recommended dosage and course 5 million units or"/>
   <result pre="than in the lopinavir/ritonavir group.43 In early inÂ vitro studies," exact="chloroquine" post="and hydroxychloroquine were found to inhibit SARS-CoV-2 infection efficiently,40,44"/>
   <result pre="the lopinavir/ritonavir group.43 In early inÂ vitro studies, chloroquine and" exact="hydroxychloroquine" post="were found to inhibit SARS-CoV-2 infection efficiently,40,44 and several"/>
   <result pre="conducted in China to evaluate the efficacy and safety of" exact="chloroquine" post="and hydroxychloroquine. Gao etÂ al. summarized that compared with"/>
   <result pre="Gao etÂ al. summarized that compared with the control treatment," exact="chloroquine" post="phosphate was effective in inhibiting the exacerbation of pneumonia,"/>
   <result pre="conversion, and shortening the disease course.45 The expert consensus on" exact="chloroquine" post="phosphate recommends 500 mg twice daily for 10 days"/>
   <result pre="10 days for patients diagnosed with COVID-19. Adverse effects of" exact="chloroquine" post="and hydroxychloroquine must be carefully monitored.46 Zhou etÂ al."/>
   <result pre="for patients diagnosed with COVID-19. Adverse effects of chloroquine and" exact="hydroxychloroquine" post="must be carefully monitored.46 Zhou etÂ al. proposed that"/>
   <result pre="hydroxychloroquine must be carefully monitored.46 Zhou etÂ al. proposed that" exact="hydroxychloroquine" post="could serve as a better therapeutic agent than chloroquine,"/>
   <result pre="etÂ al. used physiologically based pharmacokinetics models and found that" exact="hydroxychloroquine" post="was more potent than chloroquine at inhibiting SARS-CoV-2 inÂ"/>
   <result pre="pharmacokinetics models and found that hydroxychloroquine was more potent than" exact="chloroquine" post="at inhibiting SARS-CoV-2 inÂ vitro. They recommended 400 mg"/>
   <result pre="chloroquine at inhibiting SARS-CoV-2 inÂ vitro. They recommended 400 mg" exact="hydroxychloroquine" post="sulfate twice daily for 1 day, followed by 200"/>
   <result pre="to treat SARS-CoV-2 infection.48 The efficacy and safety data of" exact="chloroquine" post="or hydroxychloroquine from high-quality clinical trials are urgently needed."/>
   <result pre="SARS-CoV-2 infection.48 The efficacy and safety data of chloroquine or" exact="hydroxychloroquine" post="from high-quality clinical trials are urgently needed. Glucocorticoid therapy"/>
   <result pre="of corticosteroids at low to moderate dose (â‰¤ 0.5-1 mg/kg/d" exact="methylprednisolone" post="or equivalent) for critically ill patients with COVID-19.50 According"/>
   <result pre="vital signs (blood pressure and heart rate), laboratory tests including" exact="creatine" post="kinase, lactate dehydrogenase, high-sensitivity cardiac Troponin I, creatine kinase"/>
   <result pre="tests including creatine kinase, lactate dehydrogenase, high-sensitivity cardiac Troponin I," exact="creatine" post="kinase MB, B-type natriuretic peptide (BNP) and N-terminal proBNP,"/>
   <result pre="(BNP) and N-terminal proBNP, and electrocardiography. Antiviral drugs, such as" exact="ribavirin" post="and lopinavir/ritonavir, have been widely used in cardiac patients,"/>
   <result pre="adults hospitalized with severe Covid-19N Engl J Med38220201787179932187464 40WangM.CaoR.ZhangL.Remdesivir and" exact="chloroquine" post="effectively inhibit the recently emerged novel coronavirus (2019-nCoV) inÂ"/>
   <result pre="is effective in inhibiting SARS-CoV-2 infection inÂ vitroCell Discov620201632194981 45GaoJ.TianZ.YangX.Breakthrough:" exact="chloroquine" post="phosphate has shown apparent efficacy in treatment of COVID-19"/>
   <result pre="of Guangdong Province and Health Commission of Guangdong Province for" exact="Chloroquine" post="in the Treatment of Novel Coronavirus Pneumonia. [Expert consensus"/>
   <result pre="in the Treatment of Novel Coronavirus Pneumonia. [Expert consensus on" exact="chloroquine" post="phosphate for the treatment of novel coronavirus pneumonia]Zhonghua Jie"/>
   <result pre="Tong Q. COVID-19: a recommendation to examine the effect of" exact="hydroxychloroquine" post="in preventing infection and progression [e-pub before print]. J"/>
   <result pre="vitro antiviral activity and projection of optimized dosing design of" exact="hydroxychloroquine" post="for the treatment of severe acute respiratory syndrome coronavirus"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7166105\results\search\drug\results.xml">
   <result pre="Knee Surgeons recommends continued nonsurgical treatment for arthritis, which includes" exact="acetaminophen" post="use, bracing, joint injections, stretching, and a low-impact exercise"/>
   <result pre="Evaluation, and Treatment Coronavirus (COVID-19)2020StatPearls PublishingTreasure Island, FL 12WangM.CaoR.ZhangL.YangX.LiuJ.XuM.Remdesivir and" exact="chloroquine" post="effectively inhibit the recently emerged noval coronavirus (2019 n-CoV)"/>
   <result pre="of Guangdong Province and Health Commission of Guangdong Province for" exact="Chloroquine" post="in the Treatment of Novel Coronavirus Pneumonia[Expert consensus on"/>
   <result pre="Chloroquine in the Treatment of Novel Coronavirus Pneumonia[Expert consensus on" exact="chloroquine" post="phosphate for the treatment of novel coronavirus pneumonia]Zhonghua Jie"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7167217\results\search\drug\results.xml">
   <result pre="the combination of lopinavir/ritonavir (LPV/RTV) (anti-HIV drugs), pegylated interferon and" exact="ribavirin" post="provided successful viral clearance (Arabi et al. 2018). Another"/>
   <result pre="X, Liu J, Xu M et al (2020) Remdesivir and" exact="chloroquine" post="effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7169409\results\search\drug\results.xml">
   <result pre="results [29,46,47]. The efficacy, route of administration, and dosing of" exact="ribavirin" post="for treatments of respiratory infections have been topics of"/>
   <result pre="[29,30]. These include recombinant vaccines such as vaccines based on" exact="alpha" post="virus or bovine PIV3 [59,60,61]. Killed virus has been"/>
   <result pre="treatment of human metapneumovirus pneumonia using combination therapy with intravenous" exact="ribavirin" post="and immune globulinBr. J. Haematol.200914566766910.1111/j.1365-2141.2009.07654.x19344395 47.ParkS.Y.BaekS.LeeS.O.ChoiS.H.KimY.S.WooJ.H.SungH.KimM.N.KimD.Y.LeeJ.H.et al.Efficacy of oral"/>
   <result pre="ribavirin and immune globulinBr. J. Haematol.200914566766910.1111/j.1365-2141.2009.07654.x19344395 47.ParkS.Y.BaekS.LeeS.O.ChoiS.H.KimY.S.WooJ.H.SungH.KimM.N.KimD.Y.LeeJ.H.et al.Efficacy of oral" exact="ribavirin" post="in hematologic disease patients with paramyxovirus infection: Analytic strategy"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7169770\results\search\drug\results.xml">
   <result pre="in vitro and a clinical study indicate that remdesivir, an" exact="adenosine" post="analogue that acts as a viral protein inhibitor, has"/>
   <result pre="replication of HCoVâ€�229E 16. A combination of the antiretroviral drugs" exact="lopinavir" post="and ritonavir significantly improved the clinical condition of SARSâ€�CoV"/>
   <result pre="HCoVâ€�229E 16. A combination of the antiretroviral drugs lopinavir and" exact="ritonavir" post="significantly improved the clinical condition of SARSâ€�CoV patients 17"/>
   <result pre="of remdesivir, immunoglobulins, arbidol hydrochloride combined with interferon atomisation, ASC09F+Oseltamivir," exact="ritonavir" post="plus oseltamivir, lopinavir plus ritonavir, mesenchymal stem cell treatment,"/>
   <result pre="arbidol hydrochloride combined with interferon atomisation, ASC09F+Oseltamivir, ritonavir plus oseltamivir," exact="lopinavir" post="plus ritonavir, mesenchymal stem cell treatment, darunavir plus cobicistat,"/>
   <result pre="plus ritonavir, mesenchymal stem cell treatment, darunavir plus cobicistat, hydroxychloroquine," exact="methylprednisolone" post="and washed microbiota transplantation 19. Given the fragile health"/>
   <result pre="Engl J Med2019. 15WangM, CaoR, ZhangL et al. Remdesivir and" exact="chloroquine" post="effectively inhibit the recently emerged novel coronavirus (2019â€�nCoV) in"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7171518\results\search\drug\results.xml">
   <result pre="promising viral impact [42]. Remdesivir alone and in combination with" exact="chloroquine" post="or Î²-interferon significantly blocked the SARS-CoV-2 replication and patients"/>
   <result pre="Moderate results were exhibited by Favipiravir, Nitazoxanide, Ribavirin, Baricitinib, Penciclovir," exact="Ritonavir" post="and Arbidol when tested against infection inÂ vitro clinical"/>
   <result pre="wash with soap or disinfection with hand sanitizer having 60%" exact="alcohol" post="in it, maintaining an appropriate distance as much as"/>
   <result pre="by the viral polymerase and the proofreading exoribonucleaseMBio922018e00221-18 43WangM.CaoR.ZhangL.YangX.LiuJ.XuM.Remdesivir and" exact="chloroquine" post="effectively inhibit the recently emerged novel coronavirus (2019-nCoV) inÂ"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7171523\results\search\drug\results.xml">
   <result pre="Review on the global epidemiological situation and the efficacy of" exact="chloroquine" post="and hydroxychloroquine for the treatment of COVID-19 SaqraneS.s.saqrane@usms.ma1âˆ—El MhammediM.A.2[1)],"/>
   <result pre="the global epidemiological situation and the efficacy of chloroquine and" exact="hydroxychloroquine" post="for the treatment of COVID-19 SaqraneS.s.saqrane@usms.ma1âˆ—El MhammediM.A.2[1)], [2)], âˆ—Corresponding"/>
   <result pre="tests are also being conducted to assess the efficacy of" exact="chloroquine" post="and hydroxychloroquine for the treatment of this epidemic, which"/>
   <result pre="also being conducted to assess the efficacy of chloroquine and" exact="hydroxychloroquine" post="for the treatment of this epidemic, which is considered"/>
   <result pre="subject to change and modification as the epidemic progresses. Keywords" exact="Chloroquine" post="coronavirus Covid-19 epidemic hydroxychloroquine treatment Introduction In mid-December 2019,"/>
   <result pre="modification as the epidemic progresses. Keywords Chloroquine coronavirus Covid-19 epidemic" exact="hydroxychloroquine" post="treatment Introduction In mid-December 2019, in the city of"/>
   <result pre="itself, the world epidemiological situation and the effectiveness of using" exact="chloroquine" post="and hydroxychloroquine in the treatment. Answers to these questions"/>
   <result pre="world epidemiological situation and the effectiveness of using chloroquine and" exact="hydroxychloroquine" post="in the treatment. Answers to these questions will be"/>
   <result pre="According to the US Centers for Disease Control and Prevention," exact="hydroxychloroquine" post="and chloroquine are oral prescription drugs that have been"/>
   <result pre="the US Centers for Disease Control and Prevention, hydroxychloroquine and" exact="chloroquine" post="are oral prescription drugs that have been used for"/>
   <result pre="been used for treatment of malaria and certain inflammatory conditions." exact="Chloroquine" post="has been used for malaria treatment and chemoprophylaxis, and"/>
   <result pre="Chloroquine has been used for malaria treatment and chemoprophylaxis, and" exact="hydroxychloroquine" post="is used for treatment of rheumatoid arthritis, systemic lupus"/>
   <result pre="have in-vitro activity against SARS-CoV, SARS-CoV-2, and other coronaviruses, with" exact="hydroxychloroquine" post="having relatively higher potency against SARS-CoV-2 [[7], [8], [9]]."/>
   <result pre="[6,10]. According to Colson etÂ al., 2020 the activity of" exact="hydroxychloroquine" post="on viruses is probably the same as that of"/>
   <result pre="hydroxychloroquine on viruses is probably the same as that of" exact="chloroquine" post="since the mechanism of action of these two molecules"/>
   <result pre="mechanism of action of these two molecules is identical, and" exact="hydroxychloroquine" post="was prescribed for long periods, which would be therefore"/>
   <result pre="carried out by a Chinese group on the effect of" exact="chloroquine" post="inÂ vitro, using Vero E6 cells infected with SARS-CoV-2"/>
   <result pre="multiplicity of infection (MOI) of 0.05. The study demonstrated that" exact="chloroquine" post="was very effective in reducing viral replication, with an"/>
   <result pre="tissues, including in the lungs [7]. The authors described that" exact="chloroquine" post="is known to block viral infection by increasing endosomal"/>
   <result pre="Beijing and Shanghai in particular) to measure the effectiveness of" exact="chloroquine" post="on treatment of pneumonia associated with Covid-19 [13]. In"/>
   <result pre="it was confirmed that the anti-viral and anti-inflammatory activities of" exact="chloroquine" post="may account for its potent efficacy in treating patients"/>
   <result pre="According to Chinese researchers, a treatment of 500 mg of" exact="chloroquine" post="per day for ten days would be sufficient. According"/>
   <result pre="According to Chinese researchers, a treatment of 500 mg of" exact="chloroquine" post="per day for ten days would be sufficient. Chinese"/>
   <result pre="so far on more than 100 patients have shown that" exact="chloroquine" post="phosphate was more effective than the treatment received by"/>
   <result pre="efficacy against the coronavirus. He considers that the use of" exact="chloroquine" post="is a preferred route according to him rather than"/>
   <result pre="diverge and critics on the effectiveness of its treatment with" exact="chloroquine" post="to treat patients with coronavirus, a second study was"/>
   <result pre="coronavirus [14]. The objective of this study is to defend" exact="chloroquine" post="and to prove the effectiveness of the protocol adopted"/>
   <result pre="the protocol adopted and the relevance of the combination of" exact="hydroxychloroquine" post="and azithromycin. According to this study [14], only one"/>
   <result pre="March, 2020 a new article demonstrated that the combination of" exact="hydroxychloroquine" post="and azithromycin has a synergistic effect inÂ vitro on"/>
   <result pre="a new article demonstrated that the combination of hydroxychloroquine and" exact="azithromycin" post="has a synergistic effect inÂ vitro on SARS-CoV-2 at"/>
   <result pre="scientific committee of the Ministry of Health decided to prescribe" exact="chloroquine" post="for all patients, and not only severe cases, with"/>
   <result pre="References 1https://www.pasteur.fr/fr/centre-medical/fiches-maladies/coronavirus-wuhan 2https://www.who.int/fr/emergencies/diseases/novel-coronavirus2019/advice-for-public/q-a-coronaviruses 3https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200402-sitrep-73-covid-19.pdf?sfvrsn=5ae25bc7_4 4http://www.euro.who.int/fr/health-topics/health-emergencies/coronavirus-covid 19/news/news/2020/3/who-announces-covid-19-outbreak-a-pandemic 5https://www.lemonde.fr/afrique/article/2020/03/16/covid-19-le-tour-d-afrique-des mesures_6033295_3212.html 6SavarinoA.BoelaertJ.R.CassoneA.MajoriG.CaudaR.Effects of" exact="chloroquine" post="on viral infections: an old drug against today's diseases?Lancet"/>
   <result pre="an old drug against today's diseases?Lancet Infect Dis3200372272714592603 7WangM.CaoR.ZhangL.YangX.LiuJ.XuM.ShiZ.HuZ.ZhongW.XiaoG.Remdesivir and" exact="chloroquine" post="effectively inhibit the recently emerged novel coronavirus (2019-nCoV) inÂ"/>
   <result pre="emerged novel coronavirus (2019-nCoV) inÂ vitroCell Res3032020 Mar26927132020029 8ColsonP.RolainJ.M.LagierJ.C.BrouquiP.RaoultD.Chloroquine and" exact="hydroxychloroquine" post="as available weapons to fight COVID-19Int J Antimicrob Agents2020"/>
   <result pre="Vitro antiviral activity and projection of optimized dosing design of" exact="hydroxychloroquine" post="for the treatment of severe acute respiratory syndrome coronavirus"/>
   <result pre="coronavirus 2 (SARS-CoV-2)Clin Infect Dis2020 Mar 910.1093/cid/ciaa237pii: ciaa237 10YanY.ZouZ.SunY.LiX.XuK.F.WeiY.JinN.JiangC.Anti-malaria drug" exact="chloroquine" post="is highly effective in treating avian influenza A H5N1"/>
   <result pre="Res23201330030223208422 11CortegianiA.IngogliaG.IppolitoM.AÂ systematic review on the efficacy and safety of" exact="chloroquine" post="for the treatment of COVID-19JÂ Crit Care2020 March10.1016/j.jcrc.2020.03.005 13GaoJ.TianZ.YangX.Breakthrough:"/>
   <result pre="chloroquine for the treatment of COVID-19JÂ Crit Care2020 March10.1016/j.jcrc.2020.03.005 13GaoJ.TianZ.YangX.Breakthrough:" exact="chloroquine" post="phosphate has shown apparent efficacy in treatment of COVID-19"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7174188\results\search\drug\results.xml">
   <result pre="a minimum, patient limits should be removed to allow existing" exact="buprenorphine" post="prescribers to take on more new patients. CONCLUSIONS These"/>
   <result pre="Mental Health Services Administration (SAMHSA). FAQs: provision of methadone and" exact="buprenorphine" post="for the treatment of opioid use disorder in the"/>
   <result pre="use disorders and its consequences for healthcare delivery: systematic reviewDrug" exact="Alcohol" post="Depend1311â€&quot;22013233510.1016/j.drugalcdep.2013.02.01823490450 15VolkowNDStigma and the toll of addictionN Engl J"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7174922\results\search\drug\results.xml">
   <result pre="to target SARS-CoV-2: Favipiravir [17], Galidesivir [18], Remdesivir [19] and" exact="Ribavirin" post="[20]. Interestingly, the docking site is not located in"/>
   <result pre="[21]. In addition, other possible drugs such as Filibuvir, Cepharanthine," exact="Simeprevir" post="and Tegobuvir, are predicted to be potential inhibitors of"/>
   <result pre="SARS-CoV-2 RdRp, including Favipiravir [17, 19], Galidesivir [18], Remdesivir [19]," exact="Ribavirin" post="[20], Penciclovir [31], Galidesivir [32] and Ponatinib [33]. Additionally,"/>
   <result pre="including Favipiravir [17, 19], Galidesivir [18], Remdesivir [19], Ribavirin [20]," exact="Penciclovir" post="[31], Galidesivir [32] and Ponatinib [33]. Additionally, other drugs"/>
   <result pre="[18], Remdesivir [19], Ribavirin [20], Penciclovir [31], Galidesivir [32] and" exact="Ponatinib" post="[33]. Additionally, other drugs such as Simeprevir (FDA approved"/>
   <result pre="Galidesivir [32] and Ponatinib [33]. Additionally, other drugs such as" exact="Simeprevir" post="(FDA approved HCV protease inhibitor), as well as Filibuvir"/>
   <result pre="interaction map reveals drug targets and potential drug-repurposingBioRxiv202010.1101/2020.03.22.002386 31.ManliWRuiyuanCLeikeZYangXLiuJXuMShiZHuZZhongWXiaoGRemdesivir and" exact="chloroquine" post="effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in"/>
   <result pre="of a ribavirin-resistant NS5B mutation of hepatitis C virus during" exact="ribavirin" post="monotherapyHepatology200310.1053/jhep.2003.5044514512874 35.GoldhillDHte VelthuisAJWFletcherRALangatPZambonMLackenbyABarclayWSThe mechanism of resistance to favipiravir in"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7174982\results\search\drug\results.xml">
   <result pre="investigation to control this disease with a potentially fatal outcome." exact="Chloroquine" post="is one of the widely used drugs, with in"/>
   <result pre="reduces viral replication (Deponti et al., 2017). A combination of" exact="hydroxychloroquine" post="and azithromycin has also been found to have a"/>
   <result pre="replication (Deponti et al., 2017). A combination of hydroxychloroquine and" exact="azithromycin" post="has also been found to have a significant synergistic"/>
   <result pre="on the information that they contain volatile oils rich in" exact="alcohol" post="(J. Kim et al., 2016), terpenoids (Ludwiczuk et al.,"/>
   <result pre="against Solenopsis invicta workers (Hymenoptera:Formicidae)J. Insect Sci.15201512910.1093/jisesa/iev11226392574 GautretP.LagierJ.-C.ParolaP.HoangV.T.MeddebL.MailheM.DoudierB.CourjonJ.GiordanengoV.VieiraV.E.DupontH.T.HonorÃ©S.ColsonP.ChabriÃ¨reE.La ScolaB.RolainJ.-M.BrouquiP.RaoultD.Hydroxychloroquine and" exact="azithromycin" post="as a treatment of COVID-19: results of an open-label"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7179500\results\search\drug\results.xml">
   <result pre="temperature monitoring during labour and appropriate management if fever develops." exact="Nitrous oxide" post="and remifentanil analgesia Use of an EntonoxÂ® breathing system"/>
   <result pre="women with suspected or confirmed COVID-19 who wish to use" exact="nitrous oxide" post="analgesia during labour. There is, however, a risk of"/>
   <result pre="A variety of agents (dexmedetomidine, remifentanil, fentanyl, intra-cuff or intravenous" exact="lidocaine" post="and lidocaine via tracheal or topical application) were evaluated"/>
   <result pre="of agents (dexmedetomidine, remifentanil, fentanyl, intra-cuff or intravenous lidocaine and" exact="lidocaine" post="via tracheal or topical application) were evaluated and found"/>
   <result pre="or no medication in reducing moderate to severe emergence cough;" exact="dexmedetomidine" post="was ranked the most effective. However, whether these findings"/>
   <result pre="is unknown. The use of agents such as remifentanil and" exact="dexmedetomidine" post="has to be carefully balanced against their sedative, respiratory"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7180007\results\search\drug\results.xml">
   <result pre="of mental disorders specifically depression and anxiety (S28-S30). Agomelatine (a" exact="melatonin" post="receptor agonist) and Vilazodone (a serotonin reuptake inhibitor and"/>
   <result pre="depression and anxiety (S28-S30). Agomelatine (a melatonin receptor agonist) and" exact="Vilazodone" post="(a serotonin reuptake inhibitor and partial agonist of serotonin"/>
   <result pre="such cases the alternative drugs (that modulate GABA signaling), including," exact="gabapentin" post="and pregabalin can be used. In case of severe"/>
   <result pre="the alternative drugs (that modulate GABA signaling), including, gabapentin and" exact="pregabalin" post="can be used. In case of severe anxiety, risperidone"/>
   <result pre="and pregabalin can be used. In case of severe anxiety," exact="risperidone" post="or quetiapine (atypical antipsychotics) should be given as an"/>
   <result pre="can be used. In case of severe anxiety, risperidone or" exact="quetiapine" post="(atypical antipsychotics) should be given as an adjunct to"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7180238\results\search\drug\results.xml">
   <result pre="been tested widely for the newly emerged SARS-CoV-2. Remdesivir and" exact="chloroquine" post="were found highly effective in vitro for the control"/>
   <result pre="infection (44). Treatment with remdesivir alone or in combination with" exact="chloroquine" post="or interferon beta was found effective against COVID-19 infection."/>
   <result pre="hence could be a suitable therapeutic strategy for SARS-CoV-2. (35)" exact="Ribavirin" post="Targets RdRp (RNAâ€‘dependent RNA polymerase) enzyme to inhibit synthesis"/>
   <result pre="pathogenic viruses, thus might be used against SARS-CoV-2. (62) Hexamethylene" exact="amiloride" post="Targets viral envelope to inhibit ion channel activity Has"/>
   <result pre="inducers or recombinant interferons (1). Recombinant interferons such as interferon" exact="alpha" post="and interferon beta that have been tested against SARS-CoV"/>
   <result pre="combination with other potential antiviral drugs, including remdesivir. Both interferon" exact="alpha" post="and beta inhibit viral replication (1). The use of"/>
   <result pre="synergistic effects against SARS-CoV-2. In addition, calcineurin inhibitors such as" exact="cyclosporine" post="(53), in combination with antibiotics and traditional Chinese medicines,"/>
   <result pre="scenario of pneumonia in Wuhan, China. Broad-range combinational therapies, including" exact="lopinavir" post="and interferon antiviral peptides, can also be evaluated and"/>
   <result pre="CaoR, ZhangL, YangX, LiuJ, XuM, ShiZ, HuZ, ZhongW, XiaoG2020Remdesivir and" exact="chloroquine" post="effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in"/>
   <result pre="doi:10.2174/1570163814666170727130003.28748751 65.Ma-LauerY, ZhengY, MaleÅ¡eviÄ‡M, von BrunnB, FischerG, von BrunnA2020Influences of" exact="cyclosporin A" post="and non-immunosuppressive derivatives on cellular cyclophilins and viral nucleocapsid"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7182166\results\search\drug\results.xml">
   <result pre="Anti-viral treatment with interferon-alpha inhalation (50 Î¼g two times daily)," exact="lopinavir" post="and ritonavir (anti-retroviral drugs) (400 mg twice each day"/>
   <result pre="with interferon-alpha inhalation (50 Î¼g two times daily), lopinavir and" exact="ritonavir" post="(anti-retroviral drugs) (400 mg twice each day and 100"/>
   <result pre="with 24-hour interval using an RT-PCRÂ [13]. Other drugs like" exact="chloroquine" post="(anti-malaria drug), hydroxychloroquine (used to treat rheumatoid arthritis, Lupus),"/>
   <result pre="using an RT-PCRÂ [13]. Other drugs like chloroquine (anti-malaria drug)," exact="hydroxychloroquine" post="(used to treat rheumatoid arthritis, Lupus), azithromycin (anti-bacterial drug),"/>
   <result pre="chloroquine (anti-malaria drug), hydroxychloroquine (used to treat rheumatoid arthritis, Lupus)," exact="azithromycin" post="(anti-bacterial drug), and favipiravir are all either drugs recommended"/>
   <result pre="infections caused by SARS-CoV-2. Protease inhibitors (lopinavir/ritonavir) in combination with" exact="ribavirin" post="may be used for anti-viral therapy in the early"/>
   <result pre="be used for anti-viral therapy in the early phase, and" exact="nelfinavir" post="was found to be a promising alternative. The role"/>
   <result pre="the chances of transmissionÂ [30]. The use of high-dose pulse" exact="methylprednisolone" post="during the clinical course of a SARS outbreak was"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7184357\results\search\drug\results.xml">
   <result pre="1b study of pegylated interferon lambda 1 with or without" exact="ribavirin" post="in patients with chronic genotype 1 hepatitis C virus"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7186945\results\search\drug\results.xml">
   <result pre="providing high PEEP, and when prone positioning is implemented. GABA-agonist" exact="propofol" post="is likely the best choice during proning, but this"/>
   <result pre="unit patientsAnesthesiology20061041212616394685 79.Girard TD, Exline MC, Carson SS, et al." exact="Haloperidol" post="and Ziprasidone for Treatment of Delirium in Critical Illness."/>
   <result pre="79.Girard TD, Exline MC, Carson SS, et al. Haloperidol and" exact="Ziprasidone" post="for Treatment of Delirium in Critical Illness. N Engl"/>
   <result pre="J Med. 2018;379(26):2506â€&quot;16. 10.1056/NEJMoa1808217. 80.van den BoogaardMSlooterAJCBruggemannRJMSchoonhovenLBeishuizenAVermeijdenJWPretoriusDde KoningJSimonsKSDennesenPJWet al.Effect of" exact="haloperidol" post="on survival among critically ill adults with a high"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7189021\results\search\drug\results.xml">
   <result pre="bring the situation under control. Keywords Wuhan China COVID-19 Outbreak" exact="Chloroquine" post="Hydroxychloroquine Introduction Several cases of unknown etiology pneumonia have"/>
   <result pre="the situation under control. Keywords Wuhan China COVID-19 Outbreak Chloroquine" exact="Hydroxychloroquine" post="Introduction Several cases of unknown etiology pneumonia have been"/>
   <result pre="antiviral mechanism as an analogue nucleotide (Wang et al. 2020)." exact="Chloroquine" post="Chloroquine, a widely used drug for antimalarial and autoimmune"/>
   <result pre="has been recently described as a possible broad-spectrum antiviral medicine." exact="Chloroquine" post="is known to prevent viral infection by growing the"/>
   <result pre="(Vincent et al. 2005). In addition to its antiviral function," exact="chloroquine" post="has an immune-modulating role that can improve synergistically its"/>
   <result pre="improve synergistically its antiviral effect in vivo. Upon oral administration," exact="chloroquine" post="is spread extensively throughout the entire body, including the"/>
   <result pre="the entire body, including the lung. The EC90 value of" exact="chloroquine" post="in Vero E6 cells against COVID-19 was 6.90Â Î¼M,"/>
   <result pre="The time-of-addition assay demonstrated, in an in vitro analysis, that" exact="chloroquine" post="performed at both entry and post-entry stages of COVID-19"/>
   <result pre="COVID-19 infections in Vero E6 cells (Wang et al. 2020)." exact="Hydroxychloroquine" post="Hydroxychloroquine and chloroquine are cellular autophagy modulators that interact"/>
   <result pre="infections in Vero E6 cells (Wang et al. 2020). Hydroxychloroquine" exact="Hydroxychloroquine" post="and chloroquine are cellular autophagy modulators that interact with"/>
   <result pre="Vero E6 cells (Wang et al. 2020). Hydroxychloroquine Hydroxychloroquine and" exact="chloroquine" post="are cellular autophagy modulators that interact with enveloped viruses,"/>
   <result pre="of replication (Savarino et al. 2003; Byrd and Horwitz 1991)." exact="Hydroxychloroquine" post="or chloroquine anti-HIV-1 activity was demonstrated in conjunction with"/>
   <result pre="(Savarino et al. 2003; Byrd and Horwitz 1991). Hydroxychloroquine or" exact="chloroquine" post="anti-HIV-1 activity was demonstrated in conjunction with antiretroviral drugs"/>
   <result pre="in conjunction with antiretroviral drugs such as zidovudine, hydroxyurea, and" exact="didanosine" post="in vitro, or patients (Paton and Aboulhab 2005). Hydroxychloroquine"/>
   <result pre="and didanosine in vitro, or patients (Paton and Aboulhab 2005)." exact="Hydroxychloroquine" post="raises the pH in intracellular vacuoles and improves processes"/>
   <result pre="viruses and pathogens of zoonotic origin are likely to occur." exact="Hydroxychloroquine" post="has been used for 70Â years as a cheap"/>
   <result pre="against COVID-19. There is hope in this high-need scenario that" exact="chloroquine" post="could change the whole history of this pandemic assault."/>
   <result pre="iron. A potential new mechanism for the therapeutic effect of" exact="chloroquine" post="against intracellular pathogensJ Clin Invest19918835135710.1172/JCI1153012056129 Cascella M, Rajnik M,"/>
   <result pre="trial of Ebola virus disease therapeuticsN Engl J Med20193812293230310.1056/NEJMoa191099331774950 PatonNIAboulhabJHydroxychloroquine," exact="hydroxyurea" post="and didanosine as initial therapy for HIV-infected patients with"/>
   <result pre="Ebola virus disease therapeuticsN Engl J Med20193812293230310.1056/NEJMoa191099331774950 PatonNIAboulhabJHydroxychloroquine, hydroxyurea and" exact="didanosine" post="as initial therapy for HIV-infected patients with low viral"/>
   <result pre="efficacy and resistance profile after 144 weeksHIV Med200561132010.1111/j.1468-1293.2005.00259.x15670247 SavarinoABoelaertJRCassoneAMajoriGCaudaREffects of" exact="chloroquine" post="on viral infections: an old drug against todayâ€™s diseasesLancet"/>
   <result pre="of SARS coronavirus infection and spreadVirol J200526910.1186/1743-422X-2-6916115318 WangMCaoRZhangLet al.Remdesivir and" exact="chloroquine" post="effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7189412\results\search\drug\results.xml">
   <result pre="= âˆ’7.8â€‰kcal/mol) for 3CLpro and Dolutegravir (Î&quot;G = âˆ’9.4â€‰kcal/mol) and" exact="Bictegravir" post="(Î&quot;G = âˆ’8.4â€‰kcal/mol) for 2â€²-OMTase]. After the extensive computational"/>
   <result pre="After the extensive computational analysis, we proposed that Raltegravir, Paritaprevir," exact="Bictegravir" post="and Dolutegravir are excellent lead candidates for these crucial"/>
   <result pre="four genera: alpha, beta, delta and gamma, out of which" exact="alpha" post="and beta coronaviruses (CoVs) are known to infect humans"/>
   <result pre="protein-drug complexes at the long-interval. Table 3. Interaction details of" exact="Paritaprevir" post="and Raltegravir with 3CLpro. S/No DrugBank ID HB D"/>
   <result pre="DrugBank ID HB D (Ã…) Pi-SR D (Ã…) vdWISR 1." exact="Paritaprevir" post="(DB09297) Ser46 2.33 Met49 Leu50 Cys145 Pro168 5.27 3.85,"/>
   <result pre="ID EBE (kcal/mol) EIC (M) Molecular formula Chemical scheme 1" exact="Paritaprevir" post="(DB09297) âˆ’9.8 65.52â€‰nM C40H43N7O7S 2 Raltegravir (DB06817) âˆ’7.8 1.916"/>
   <result pre="formula Chemical scheme 1 Dolutegravir (DB08930) âˆ’9.4 128.7â€‰nM C20H19F2N3O5 2" exact="Bictegravir" post="(DB11799) âˆ’8.4 0.696 ÂµM C21H18F3N3O5 EBE: Estimated Binding Free"/>
   <result pre="of 3CLpro (see Table 1), we chose two molecules, namely" exact="Paritaprevir" post="(DB09297) and Raltegravir (DB06817). Similarly, for 2â€²-OMTase (see Table"/>
   <result pre="best two drugs were found to be Dolutegravir (DB08930) and" exact="Bictegravir" post="(DB11799). 3.3. Binding pattern of drug molecules against 3CLpro"/>
   <result pre="Three dimensional representation of 3CLpro active site residues interacting with" exact="Paritaprevir" post="(DB09297) (Green). (b) Two dimensional representation of 3CLpro active"/>
   <result pre="Two dimensional representation of 3CLpro active site residues interacting with" exact="Paritaprevir" post="(Green) via Van der Waals interactions (slightly green colour),"/>
   <result pre="interacting with Raltegravir(Orange). The estimated binding free energy (Î&quot;G) of" exact="Paritaprevir" post="against 3CLpro was observed to be âˆ’9.8â€‰kcal/mol, and the"/>
   <result pre="to be âˆ’7.8â€‰kcal/mol, and the inhibitory constant was 1.916â€‰ÂµM. Both" exact="Paritaprevir" post="and Raltegravir were found to be interacting with the"/>
   <result pre="the bottom of the central groove might bind the first" exact="adenine" post="nucleotide conserved as the acceptor of methyl group during"/>
   <result pre="Three dimensional representation of 2â€²-OMTase active site residues interacting with" exact="Bictegravir" post="(DB11799) (Yellow). (d) Two dimensional representation of 2â€²-OMTase active"/>
   <result pre="(Î&quot;G) of âˆ’9.4â€‰kcal/mol, and the inhibition constant was 128.7â€‰nM. Besides," exact="Bictegravir" post="conferred an estimated binding free energy (Î&quot;G) of âˆ’8.4â€‰kcal/mol"/>
   <result pre="the estimated inhibition constant was 0.696â€‰ÂµM. Moreover, both Dolutegravir and" exact="Bictegravir" post="were found to be actively interacting with the catalytic"/>
   <result pre="Asn43, Lys46, Gly71, Gly73, Ser74, Asp75, Asp99, Asn101, Glu203 2" exact="Bictegravir" post="(DB11799) Asp130 Lys170 Asn198 2.43 2.28 2.15 Met42 Leu100"/>
   <result pre="the proteins. Figure 3. The electrostatic surface potential interaction of" exact="Paritaprevir" post="(DB09297) (Green) and Raltegravir (DB06817) (Orange) bound to 3CLpro."/>
   <result pre="The electrostatic surface potential interaction of Dolutegravir (DB08930) (Sand) and" exact="Bictegravir" post="(DB11799) (Yellow) bound to 2â€²-OMTase. The zoomed view is"/>
   <result pre="RMSF, Rg and SASA additionally supported that Raltegravir and also" exact="Paritaprevir" post="could be the most promising candidates which might be"/>
   <result pre="of the MD simulation analysis, PCA supported that Dolutegravir and" exact="Bictegravir" post="could be the most promising drugs capable of inhibiting"/>
   <result pre="the findings of this study. Raltegravir (Markowitz etÂ al., 2007)," exact="Bictegravir" post="(Sax etÂ al., 2017) and Dolutegravir (Cahn etÂ al.,"/>
   <result pre="in HCV genotype 1b patients with cirrhosis receiving ombitasvir/paritaprevir/r and" exact="dasabuvir" post="for 12weeks. Journal of Hepatology, 64(2), 301â€&quot;307. doi:10.1016/j.jhep.2015.10.00526476290 GimenoA.,"/>
   <result pre="WhiteK., SenGuptaD., ChengA., &amp;amp; QuirkE. (2017). Coformulated bictegravir, emtricitabine, and" exact="tenofovir alafenamide" post="versus dolutegravir with emtricitabine and tenofovir alafenamide, for initial"/>
   <result pre="(2017). Coformulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with" exact="emtricitabine" post="and tenofovir alafenamide, for initial treatment of HIV-1 infection"/>
   <result pre="bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and" exact="tenofovir alafenamide," post="for initial treatment of HIV-1 infection (GS-US-380â€&quot;1490): A randomised,"/>
   <result pre="â€¦ PodsadeckiT. (2015). Ombitasvir, paritaprevir co-dosed with ritonavir, dasabuvir, and" exact="ribavirin" post="for hepatitis C in patients co-infected with HIV-1: A"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7190301\results\search\drug\results.xml">
   <result pre="a range of therapies, including immunosuppressants and the anti-malarial drugs" exact="chloroquine" post="and hydroxychloroquine. One therapy being tested is convalescent plasma,"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7190393\results\search\drug\results.xml">
   <result pre="have to choose: quickly but painfully, or gently but slowly." exact="Today" post="we find ourselves in a zugzwang situation: a greater"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7190742\results\search\drug\results.xml">
   <result pre="HCV core antigen detection and quantification using serum samples and" exact="dried" post="blood spots in people who inject drugs in Dar-es-Salaam,"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7191286\results\search\drug\results.xml">
   <result pre="effectiveness: the anti-HIV medicines lopinavir/ritonavir, the investigational anti-viral medicine remdesivir," exact="chloroquine" post="and hydroxychloroquine (authorised as anti-malarials and as anti-inflammatory treatments"/>
   <result pre="anti-HIV medicines lopinavir/ritonavir, the investigational anti-viral medicine remdesivir, chloroquine and" exact="hydroxychloroquine" post="(authorised as anti-malarials and as anti-inflammatory treatments for autoimmune"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7194560\results\search\drug\results.xml">
   <result pre="nicotinamide) and other miscellaneous systemically acting drugs. Of special interest," exact="ribavirin" post="had been used in treating cases of SARS CoV."/>
   <result pre="1 anticancer and other miscellaneous systemically acting drugs. Among antivirals," exact="ribavirin" post="and telbivudine were ranked at the second and third"/>
   <result pre="and other miscellaneous systemically acting drugs. Among antivirals, ribavirin and" exact="telbivudine" post="were ranked at the second and third positions. They"/>
   <result pre="2 folds increase in the docking scores, compared with curcumin." exact="Vitamin B12" post="and nicotinamide were ranked at the 4th and 6th"/>
   <result pre="Clinical uses Chromocarb C10H6O4 190 2.08 4.03 0.92 4.80 Vasoprotective" exact="Ribavirin" post="C8H12N4O5 244 2.01 3.21 0.37 4.36 Antiviral Telbivudine C10H14N2O5"/>
   <result pre="4.80 Vasoprotective Ribavirin C8H12N4O5 244 2.01 3.21 0.37 4.36 Antiviral" exact="Telbivudine" post="C10H14N2O5 242 2.00 3.19 0.44 6.12 Hepatitis B virus"/>
   <result pre="Telbivudine C10H14N2O5 242 2.00 3.19 0.44 6.12 Hepatitis B virus" exact="Vitamin B12" post="C63H88CoN14O14P 1355 1.99 0.60 0.49 9.70 Vitamin Aminophylline C16H24N10O4"/>
   <result pre="virus Vitamin B12 C63H88CoN14O14P 1355 1.99 0.60 0.49 9.70 Vitamin" exact="Aminophylline" post="C16H24N10O4 420 1.92 4.00 0.46 3.20 Bronchodilator Nicotinamide C6H6N2O"/>
   <result pre="3.20 Bronchodilator Nicotinamide C6H6N2O 122 1.91 5.76 0.71 5.76 Vitamin" exact="Triflusal" post="C10H7F3O4 248 1.87 2.99 1.05 2.53 Cardiovascular Bemegride C8H13NO2"/>
   <result pre="Aminosalicylate Sodium C7H6NNaO3 175 1.80 4.44 0.76 1.60 Antituberculosis agents" exact="Pyrazinamide" post="C5H5N3O 123 1.80 5.42 0.52 4.29 Antituberculosis agents Temozolomide"/>
   <result pre="agents Pyrazinamide C5H5N3O 123 1.80 5.42 0.52 4.29 Antituberculosis agents" exact="Temozolomide" post="C6H6N6O2 194 1.79 3.47 0.12 3.20 Anticancer Methazolamide C5H8N4O3S2"/>
   <result pre="5.76 Glaucoma Tioxolone C7H4O3S 168 1.78 4.38 0.92 3.20 Anti-acne" exact="Propylthiouracil" post="C7H10N2OS 170 1.77 4.38 0.56 3.20 Antithyroid agent Cysteamine"/>
   <result pre="Anti-acne Propylthiouracil C7H10N2OS 170 1.77 4.38 0.56 3.20 Antithyroid agent" exact="Cysteamine" post="HCl C2H8ClNS 114 1.77 12.01 0.00 2.00 Nephropathic cystinosis"/>
   <result pre="Cysteamine HCl C2H8ClNS 114 1.77 12.01 0.00 2.00 Nephropathic cystinosis" exact="methoxamine" post="hydrochloride C11H18ClNO3 248 1.77 3.20 0.10 5.09 Alpha-adrenergic agonist"/>
   <result pre="(+,-)-Octopamine HCl C8H12ClNO2 190 1.76 4.33 0.09 5.09 Adrenergic agonist" exact="Amiloride" post="hydrochloride C6H9Cl2N7O 266 1.76 3.18 0.30 6.69 Diuretic Ribavirin"/>
   <result pre="agonist Amiloride hydrochloride C6H9Cl2N7O 266 1.76 3.18 0.30 6.69 Diuretic" exact="Ribavirin" post="is abroad spectrum antiviral agent acting by induction of"/>
   <result pre="mutations in the viral genome, especially in RNA viruses [24]." exact="Ribavirin" post="is officially approved for treating respiratory syncytial virus (RSV)"/>
   <result pre="[25]. Given the high similarity of SARS and COVID-19 Mpros," exact="ribavirin" post="might be of a value in treating COVID-19. Telbivudine"/>
   <result pre="Mpros, ribavirin might be of a value in treating COVID-19." exact="Telbivudine" post="is approved for treating hepatitis B virus [26]. The"/>
   <result pre="and best fits the viral polymerase. The high rank of" exact="telbivudine" post="in this study suggests its repurposing for COVID-19 treatment"/>
   <result pre="interactions were the driving force for binding (Fig. 2 )." exact="Ribavirin" post="formed two hydrogen bonds with the backbone of THR25"/>
   <result pre="THR25 and side chain of GLN189 (Fig. 2B and C)." exact="Telbivudine" post="formed two hydrogen bonds with SER49 and GLV189 (Fig."/>
   <result pre="into the Mpro binding site. B) The docking site of" exact="ribavirin" post="C) The ligand interactions of ribavirin with Mpro D)"/>
   <result pre="The docking site of ribavirin C) The ligand interactions of" exact="ribavirin" post="with Mpro D) The site of docking of telbivudine"/>
   <result pre="of ribavirin with Mpro D) The site of docking of" exact="telbivudine" post="E) The ligand interactions of telbivudine with Mpro. Hydrogen"/>
   <result pre="site of docking of telbivudine E) The ligand interactions of" exact="telbivudine" post="with Mpro. Hydrogen bonds are shown in purple arrows,"/>
   <result pre="17MurgueitioM.S.BermudezM.MortierJ.WolberG.In silico virtual screening approaches for anti-viral drug discoveryDrug Discov." exact="Today" post="Technol.92012(e219-e25) 18SheikhA.Al-TaherA.Al-NazawiM.Al-MubarakA.I.KandeelM.Analysis of preferred codon usage in the coronavirus"/>
   <result pre="docking studiesInterdiscip. Sci. Comput. Life Sci.82016132141 24CrottyS.MaagD.ArnoldJ.J.ZhongW.LauJ.Y.HongZ.The broad-spectrum antiviral ribonucleoside" exact="ribavirin" post="is an RNA virus mutagenNat. Med.620001375137911100123 25KorenG.KingS.KnowlesS.PhillipsE.Ribavirin in the"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7194707\results\search\drug\results.xml">
   <result pre="latest coronavirus updates on treatment were questioned, for example, if" exact="hydroxychloroquine" post="alone or in combination with azithromycin have been used"/>
   <result pre="questioned, for example, if hydroxychloroquine alone or in combination with" exact="azithromycin" post="have been used as a preventive therapy against coronavirus"/>
   <result pre="awareness concerning the use of non-steroidal anti-inflammatory drugs such as" exact="ibuprofen" post="when there is an infection.24,25 Other questions in the"/>
   <result pre="increases the opportunistic infection33,34; and the role of garlic, mushrooms," exact="vitamin C" post="and D was also questioned. Not smoking and the"/>
   <result pre="245 (95.7) 453 (96.4) 0.649 Non-steroidal anti-inflammatory drugs such as" exact="Ibuprofen" post="can decrease the risk of complications when used during"/>
   <result pre="contract coronavirus infection. 461 (63.5) 151 (59.0) 310 (66.0) 0.062" exact="Hydroxychloroquine" post="has not been used as a preventative therapy against"/>
   <result pre="coronavirus infection. 427 (58.8) 125 (48.8) 302 (64.3) &amp;lt;Â 0.001*" exact="Azithromycin" post="has been used along with hydroxychloroquine in the treatment"/>
   <result pre="302 (64.3) &amp;lt;Â 0.001* Azithromycin has been used along with" exact="hydroxychloroquine" post="in the treatment of the coronavirus infection cases. 521"/>
   <result pre="student participants (69.9%) knew that non-steroidal anti-inflammatory drugs such as" exact="ibuprofen" post="may theoretically increase the risk of complications when used"/>
   <result pre="pandemic when needed. Only 22% reported that they would provide" exact="hydroxychloroquine" post="to patients who need it even if they don't"/>
   <result pre="situation.19 Some participants indicated that they were willing to dispense" exact="hydroxychloroquine" post="directly to patients. This is quite surprising as hydroxychloroquine"/>
   <result pre="dispense hydroxychloroquine directly to patients. This is quite surprising as" exact="hydroxychloroquine" post="has been regulated by the Jordan Food and Drug"/>
   <result pre="community pharmacy without a valid prescription. Furthermore, the efficacy of" exact="hydroxychloroquine" post="has not been thoroughly established for COVID-19 and the"/>
   <result pre="may be influenced by the media which has been proposing" exact="hydroxychloroquine" post="as the treatment of COVID-19. About 95% of participants"/>
   <result pre="information.11 Many pharmacists were not sure about the role of" exact="hydroxychloroquine" post="(12%) and 29% of them thought it has been"/>
   <result pre="course have trialed and may be using treatments such as" exact="chloroquine" post="or hydroxychloroquine, as well as of course ventilatory support"/>
   <result pre="with severe respiratory distress symptoms.46 Most participants (72%) knew that" exact="azithromycin" post="has been trialed along with hydroxychloroquine in the treatment"/>
   <result pre="participants (72%) knew that azithromycin has been trialed along with" exact="hydroxychloroquine" post="in the treatment of the coronavirus infection, while only"/>
   <result pre="critical cases of the infection and 46% were not sure.46" exact="Ibuprofen" post="the non-steroidal anti-inflammatory medicine, or NSAID, is sold under"/>
   <result pre="designing this study, it was said that NSAIDs such as" exact="ibuprofen" post="can increase the risk of complications when used during"/>
   <result pre="conflicting reportsâ€™ that â€˜there's no evidence to suggest that using" exact="ibuprofen" post="to manage symptoms of COVID-19 will worsen the conditionâ€™."/>
   <result pre="conditionâ€™. Earlier reports said a spokesperson had cautioned against using" exact="ibuprofen" post="to manage symptoms of the illness caused by the"/>
   <result pre="pharmacy workforce The Netherlands: international pharmaceutical federationAvailable at:https://www.fip.org/files/content/priority-areas/coronavirus/Coronavirus-guidance-update-ENGLISH.pdf2020 20GautretP.LagierJ.-C.ParolaP.Hydroxychloroquine and" exact="azithromycin" post="as a treatment of COVID-19: results of an open-label"/>
   <result pre="the 2019 novel coronavirus SARS-CoV-2Int J Antimicrob Agents553202010592310.1016/j.ijantimicag.2020.10593232070753 23ColsonP.RolainJ.M.LagierJ.C.Chloroquine and" exact="hydroxychloroquine" post="as available weapons to fight COVID-19Int J Antimicrob Agents554202010.1016/j.ijantimicag.2020"/>
   <result pre="as available weapons to fight COVID-19Int J Antimicrob Agents554202010.1016/j.ijantimicag.2020 24DayM.Covid-19:" exact="ibuprofen" post="should not be used for managing symptoms, say doctors"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7194797\results\search\drug\results.xml">
   <result pre="and rodents are considered to be the genetic sources of" exact="alpha" post="and beta-coronavirus, avian species represents the genetic sources of"/>
   <result pre="including chloroform, ether (75%), ethanol, peroxyacetic acid and chlorine-containing disinfectant." exact="Chlorhexidine" post="does not inactivate this virus [4], [5]. 3 Transmission"/>
   <result pre="non coronary false positive; refer TableÂ 3 ), D-dimer, ferritin," exact="Creatine" post="kinase and ESR [24]. CRP may be used to"/>
   <result pre="in humans, few small-scale studies have claimed some benefit with" exact="chloroquine" post="and hydroxychloroquine in less severely ill patients. Other drugs"/>
   <result pre="few small-scale studies have claimed some benefit with chloroquine and" exact="hydroxychloroquine" post="in less severely ill patients. Other drugs which are"/>
   <result pre="in Wuhan, China: a descriptive studyLancet Infect Dis3099202020110 32SinghA.K.SinghA.SaikhA.SinghR.MisraA.Chloroquine and" exact="hydroxychloroquine" post="in the treatment of COVID-19 with or without diabetes:"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7194918\results\search\drug\results.xml">
   <result pre="Hypotheses0306-98771532-2777Published by Elsevier Ltd. pmcid: 7194918S0306-9877(20)30578-8 doi: 10.1016/j.mehy.2020.109754109754 : Article" exact="5-Fluorouracil" post="in combination with deoxyribonucleosides and deoxyribose as possible therapeutic"/>
   <result pre="new drugs are continuing. Here the author is proposing that" exact="5-Fluorouracil" post="(5-FU) which when used on its own is failing"/>
   <result pre="of these drugs to patients suffering from Covid-19. These are" exact="Chloroquine" post="phosphate and hydroxychloroquine sulphate (also known as anti-malarial drugs),"/>
   <result pre="to patients suffering from Covid-19. These are Chloroquine phosphate and" exact="hydroxychloroquine" post="sulphate (also known as anti-malarial drugs), arbidol, Remdesivir (GS-5734),"/>
   <result pre="(also known as anti-malarial drugs), arbidol, Remdesivir (GS-5734), Favipitavir and" exact="ribavirin" post="(a complex structure but best viewed as ribosyl purine"/>
   <result pre="decreased, and no or little Coronavirus titres were observed [8]." exact="Chloroquine" post="phosphate has been used in a multicenter clinical trial"/>
   <result pre="identified 10 publications. The most recent in 2019 showed that" exact="5-Fluorouracil" post="(5-FU) has remained ineffective to treat any coronavirus infection."/>
   <result pre="the same principle, except that instead of deoxyadenosine we used" exact="adenosine" post="in the selective medium [21]. DeoxyadenosineÂ +Â PiÂ â†’Â"/>
   <result pre="the selective medium [21]. DeoxyadenosineÂ +Â PiÂ â†’Â dRib-1-PÂ +Â" exact="adenine" post="DeoxyguanosineÂ +Â PiÂ â†’Â dRib-1-PÂ +Â Guanine Purine nucleoside"/>
   <result pre="4DongL.HuS.GaoJ.Discovering drugs to treat coronavirus disease 2019 (COVID-19)Drug Discov14120204860 5GaoJ.TianZ.YangX.Breakthrough:" exact="chloroquine" post="phosphate has shown apparent efficacy in treatment of COVID-19"/>
   <result pre="pneumonia monitored by quantitative RT-PCRJ Korean Med Sci3562020e7910.3346/jkms.2020.35.e7932056407 9TouretF.de LamballerieOf" exact="chloroquine" post="and COVID-19Antiviral Res177202010476210.101016/j.antiviral.2020.104762[Epub ahead of print]32147496 10SmithE.C.CaseJ.B.BlancH.Mutation in Coronavirus"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7194968\results\search\drug\results.xml">
   <result pre="acted rapidly by imposing a lockdown, banning the sale of" exact="alcohol" post="and taking homeless people into facilities where they could"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7195149\results\search\drug\results.xml">
   <result pre="shelf. More than 90 have been approved since 1963, when" exact="idoxuridine" post="was authorised for the treatment of herpes simplex, but"/>
   <result pre="groups are now evaluating the use of long-standing malaria drug" exact="chloroquine" post="and its close cousin hydroxychloroquine. Although the drugs are"/>
   <result pre="a trial in which 26 people with covid-19 were given" exact="hydroxychloroquine" post="three times a day, in some cases alongside the"/>
   <result pre="to self-medicate with the drug. Now several clinical trials of" exact="hydroxychloroquine" post="are in the works, including one that began on"/>
   <result pre="efficacy be proven, the low cost and ready availability of" exact="hydroxychloroquine" post="should make it easy to mass produce for widespread"/>
   <result pre="â€&quot; Trump's enthusiasm notwithstanding. At this point, the hype around" exact="hydroxychloroquine" post="says more about our desperation than its genuine promise,"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7196187\results\search\drug\results.xml">
   <result pre="and therapeutic approaches to develop vaccines and drugs for COVID-19." exact="Chloroquine" post="Convalescent plasma (CP) COVID-19 Current diagnostics SARS-CoV-2 INTRODUCTION The"/>
   <result pre="diagnostics methods for accurate results to guide treatment options. Currently," exact="chloroquine" post="and hydroxychloroquine are the most-used drugs, which have been"/>
   <result pre="for accurate results to guide treatment options. Currently, chloroquine and" exact="hydroxychloroquine" post="are the most-used drugs, which have been discussed along"/>
   <result pre="(Table 3). CHLOROQUINE AS A THERAPEUTIC DRUG FOR HUMAN DISEASES" exact="Chloroquine" post="was first developed in the 1940s, as an aminoquinolone"/>
   <result pre="for the treatment of malaria (17). The chemical formula of" exact="chloroquine" post="is C18H6CIN3. Chloroquine was granted FDA approval on October"/>
   <result pre="of malaria (17). The chemical formula of chloroquine is C18H6CIN3." exact="Chloroquine" post="was granted FDA approval on October 31, 1949 (FDA,"/>
   <result pre="approval on October 31, 1949 (FDA, Approved Drug Products: Aralen" exact="Chloroquine" post="Oral Tablets). Chloroquine and its derivative, hydroxychloroquine, are very"/>
   <result pre="31, 1949 (FDA, Approved Drug Products: Aralen Chloroquine Oral Tablets)." exact="Chloroquine" post="and its derivative, hydroxychloroquine, are very closely related and"/>
   <result pre="related and used to treat malaria and rheumatologic conditions, respectively." exact="Hydroxychloroquine" post="is a disease-modifying anti-rheumatic drug, and it regulates the"/>
   <result pre="arthritis, discoid and systemic lupus erythematosus, and juvenile idiopathic arthritis." exact="Chloroquine" post="and hydroxychloroquine have been repurposed for the treatment of"/>
   <result pre="and systemic lupus erythematosus, and juvenile idiopathic arthritis. Chloroquine and" exact="hydroxychloroquine" post="have been repurposed for the treatment of several disease"/>
   <result pre="conditions, including HIV, Systemic lupus erythematosus, and rheumatoid arthritis (18)." exact="Chloroquine" post="is classified as an anti-malarial drug and has shown"/>
   <result pre="shown potential in the treatment of avian influenza A (19)." exact="Chloroquine" post="has been indicated to treat infections caused by P."/>
   <result pre="be used to treat extraintestinal amebiosis (FDA; Approved Drug Products:" exact="Chloroquine" post="Phosphate Oral tablets) and prophylaxis caused by Zika virus"/>
   <result pre="prophylaxis caused by Zika virus (20, 21). The anti-malarial drugs" exact="hydroxychloroquine" post="and chloroquine have demonstrated antiviral activity SARS-CoV-2 in vitro"/>
   <result pre="by Zika virus (20, 21). The anti-malarial drugs hydroxychloroquine and" exact="chloroquine" post="have demonstrated antiviral activity SARS-CoV-2 in vitro (22). A"/>
   <result pre="activity SARS-CoV-2 in vitro (22). A Chinese study found that" exact="chloroquine" post="will reduce the symptom duration, exacerbation of pneumonia, including"/>
   <result pre="the FDA has approved an emergency authorization for use of" exact="chloroquine" post="and hydroxychloroquine (FDA: Emergency Use Authorization Information). Chloroquine is"/>
   <result pre="has approved an emergency authorization for use of chloroquine and" exact="hydroxychloroquine" post="(FDA: Emergency Use Authorization Information). Chloroquine is currently undergoing"/>
   <result pre="use of chloroquine and hydroxychloroquine (FDA: Emergency Use Authorization Information)." exact="Chloroquine" post="is currently undergoing clinical trials for the treatment of"/>
   <result pre="principally used as an anti-malarial and autoimmune-treating drug (19, 24)." exact="Chloroquine" post="and its combination of drugs used in the treatment"/>
   <result pre="the treatment of COVID-19 has been listed in Table 4." exact="Hydroxychloroquine" post="and chloroquine are currently undergoing clinical trials to ensure"/>
   <result pre="of COVID-19 has been listed in Table 4. Hydroxychloroquine and" exact="chloroquine" post="are currently undergoing clinical trials to ensure their preventive"/>
   <result pre="to ensure their preventive action for SARS-CoV-2 infected patients (8)." exact="Chloroquine" post="diffuses to the cell passively through the cell membranes"/>
   <result pre="lysosomes, and Golgi vesicles, where it becomes protonated, trapping the" exact="chloroquine" post="in the organelle and raising the surrounding pH (25,"/>
   <result pre="using their activity for fusion and entry into the cell." exact="Chloroquine" post="does not affect the expression of ACE2 on cell"/>
   <result pre="for cell entry targeted by SARS-CoV and SARS-CoV-2 (26-28). The" exact="chloroquine" post="and hydroxychloroquine have various way to inhibit SARS-CoV-2 action."/>
   <result pre="entry targeted by SARS-CoV and SARS-CoV-2 (26-28). The chloroquine and" exact="hydroxychloroquine" post="have various way to inhibit SARS-CoV-2 action. Also, because"/>
   <result pre="the viral attachment to the human host receptors. Additionally, the" exact="chloroquine" post="can constrain the quinone reductase-2, which is an essential"/>
   <result pre="used as the receptor moieties by the SARS-CoV-2. Moreover, the" exact="chloroquine" post="obstructs the MAP-kinase, which results in SARS-CoV-2 virus molecular"/>
   <result pre="of the virus (26). Savarino et al. (29) hypothesized that" exact="chloroquine" post="might block the production of pro-inflammatory cytokines like interleukin-6"/>
   <result pre="blocking the pathway leading to ARDS. Additional assays demonstrated that" exact="chloroquine" post="functioned at both entries and post-entry stages of the"/>
   <result pre="cells. The in vitro study findings revealed that remdesivir and" exact="chloroquine" post="are highly effective in the control of COVID-19. Because"/>
   <result pre="with COVID-19 infection and who have no complications with the" exact="chloroquine" post="drug are advised to take 500 mg of chloroquine"/>
   <result pre="the chloroquine drug are advised to take 500 mg of" exact="chloroquine" post="two times a day for 10 days (31). The"/>
   <result pre="for 10 days (31). The ICMR recommends the use of" exact="hydroxychloroquine" post="for high-risk COVID-19 cases (32). In China and France,"/>
   <result pre="France, small studies provide some indications of possible benefits of" exact="chloroquine" post="phosphate against pneumonia caused by COVID-19, but need confirmation"/>
   <result pre="caused by COVID-19, but need confirmation through randomized trials (9)." exact="Chloroquine" post="also has been shown to have anti-viral as well"/>
   <result pre="the endosomal pH required for viral fusion (Fig. 2) (30)." exact="Azithromycin" post="has been suggested to act in combination with Chloroquine/hydroxychloroquine"/>
   <result pre="(31). Several in vitro studies reported the anti-viral activity of" exact="Chloroquine" post="and hydroxychloroquine against SARS-CoV-2. At present, there is insufficient"/>
   <result pre="in vitro studies reported the anti-viral activity of Chloroquine and" exact="hydroxychloroquine" post="against SARS-CoV-2. At present, there is insufficient in vivo"/>
   <result pre="in a particular individual. Based on the efficiency of the" exact="hydroxychloroquine" post="and chloroquine drugs, it should be approved soon as"/>
   <result pre="particular individual. Based on the efficiency of the hydroxychloroquine and" exact="chloroquine" post="drugs, it should be approved soon as the one-stop"/>
   <result pre="government professionals and should reduce their intake of smoking and" exact="alcohol" post="consumption in order to improve will improve their immunity."/>
   <result pre="Kidney DiseasesBethesda (MD)2017 Feb 2 18PlantoneDKoudriavtsevaT2018Current and future use of" exact="chloroquine" post="and hydroxychloroquine in infectious, immune, neoplastic and neurological diseases:"/>
   <result pre="(MD)2017 Feb 2 18PlantoneDKoudriavtsevaT2018Current and future use of chloroquine and" exact="hydroxychloroquine" post="in infectious, immune, neoplastic and neurological diseases: A Mini-ReviewClin"/>
   <result pre="and neurological diseases: A Mini-ReviewClin Drug Investig3865367110.1007/s40261-018-0656-y29737455 19YanYZouZSunYet al.2013Anti-malaria drug" exact="chloroquine" post="is highly effective in treating avian influenza A H5N1"/>
   <result pre="congenital microcephaly in miceEBioMedicine2418919410.1016/j.ebiom.2017.09.03429033372 21ShiryaevSAMesciPPintoAet al.2017Repurposing of the anti-malaria drug" exact="chloroquine" post="for Zika virus treatment and prophylaxisSci Rep71577110.1038/s41598-017-15467-629150641 22YaoXYeFZhangMet al.2020In"/>
   <result pre="vitro antiviral activity and projection of optimized dosing design of" exact="hydroxychloroquine" post="for the treatment of severe acute respiratory syndrome coronavirus"/>
   <result pre="syndrome coronavirus 2 (SARS-CoV-2)Clin Infect Dis[Online ahead of print]10.1093/cid/ciaa23732150618 23GaoJTianZYangX2020Breakthrough:" exact="chloroquine" post="phosphate has shown apparent efficacy in treatment of COVID-19"/>
   <result pre="of chloroquine. Focus on recent advancementsClin Pharmacokinet3125727410.2165/00003088-199631040-000038896943 26WangMCaoRZhangLet al.2020Remdesivir and" exact="chloroquine" post="effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in"/>
   <result pre="and spreadVirol J26910.1186/1743-422X-2-6916115318 28DevauxCARolainJMColsonPRaoultD2020New insights on the antiviral effects of" exact="chloroquine" post="against coronavirus: what to expect for COVID-19?Int J Antimicrob"/>
   <result pre="for COVID-19?Int J Antimicrob Agents[Online ahead of print]10.1016/j.ijantimicag.2020.10593832171740 29SavarinoABoelaertJRCassoneAMajoriGCaudaR2003Effectd of" exact="chloroquine" post="on viral infections: an old drug against today's diseasesLancet"/>
   <result pre="evidenceInt J Antimicrob Agents[Online ahead of print]10.1016/j.ijantimicag.2020.10594832201353 31GautretPLagierJCParolaPet al.2020Hydroxychloroquine and" exact="azithromycin" post="as a treatment of COVID-19: results of an open-label"/>
   <result pre="a laboratory for further processing. Fig. 2 Probable mechanism of" exact="hydroxychloroquine" post="(HC) against SARS-CoV-2: The figure depicts the mechanism of"/>
   <result pre="against SARS-CoV-2: The figure depicts the mechanism of action of" exact="hydroxychloroquine" post="targeting the SARS-CoV-2 through many ways. (1) The hydroxychloroquine"/>
   <result pre="of hydroxychloroquine targeting the SARS-CoV-2 through many ways. (1) The" exact="hydroxychloroquine" post="has the ability to constrain the quinone reductase-2 which"/>
   <result pre="used as the receptor moieties by the SARS-CoV-2. (2) The" exact="hydroxychloroquine" post="could change the pH of lysosomes that leads to"/>
   <result pre="ACE2 receptors and inhibits the viral infection. (4) Moreover, the" exact="hydroxychloroquine" post="obstructs the MAP-kinase pathway which results to SARS-CoV-2 virus"/>
   <result pre="Not yet recruiting - 2. Lopinavir/ritonavir tablets or Arbidol or" exact="Chloroquine" post="phosphate Efficacy and Safety of Corticosteroids in COVID-19 Methylprednisolone"/>
   <result pre="or Chloroquine phosphate Efficacy and Safety of Corticosteroids in COVID-19" exact="Methylprednisolone" post="Recruiting 1. Hubei province hospital of integrated Chinese &amp;amp;"/>
   <result pre="2019-nCoV Remdesivir RCT Remdesivir Recruiting Bin Cao; Beijing, Beijing, China" exact="Nitric Oxide" post="Gas Inhalation for Severe Acute Respiratory Syndrome in COVID-19"/>
   <result pre="Oxide Gas Inhalation for Severe Acute Respiratory Syndrome in COVID-19" exact="Nitric Oxide" post="Gas Not yet recruiting - Efficacy and Safety of"/>
   <result pre="Regional Medical left Everett, Everett, Washington, United States Lopinavir/ Ritonavir," exact="Ribavirin" post="and IFN-beta Combination for nCoV Treatment 1. Lopinavir/ritonavir Recruiting"/>
   <result pre="Lopinavir/ritonavir Recruiting University of Hong Kong, Queen Mary Hospital 2." exact="Ribavirin" post="Hong Kong, Hong Kong 3. Interferon Beta-1B Efficacy of"/>
   <result pre="Ribavirin Hong Kong, Hong Kong 3. Interferon Beta-1B Efficacy of" exact="Chloroquine" post="and Lopinavir/ Ritonavir in mild/general novel coronavirus (CoVID-19) infections:"/>
   <result pre="Hong Kong 3. Interferon Beta-1B Efficacy of Chloroquine and Lopinavir/" exact="Ritonavir" post="in mild/general novel coronavirus (CoVID-19) infections: a prospective, open-label,"/>
   <result pre="infections: a prospective, open-label, multileft randomized controlled clinical study 1." exact="Chloroquine" post="- The Fifth Affiliated Hospital Sun Yat-Sen University 2."/>
   <result pre="- The Fifth Affiliated Hospital Sun Yat-Sen University 2. Lopinavir/" exact="Ritonavir" post="A prospective, randomized, open-label, parallel controlled trial for the"/>
   <result pre="randomized, open-label, parallel controlled trial for the preventive effect of" exact="hydroxychloroquine" post="on medical personnel after exposure to COVID-19 Hydroxychloroquine -"/>
   <result pre="effect of hydroxychloroquine on medical personnel after exposure to COVID-19" exact="Hydroxychloroquine" post="- Renmin Hospital of Wuhan University Glucocorticoid Therapy for"/>
   <result pre="Novel Coronavirus Critically Ill Patients with Severe Acute Respiratory Failure" exact="Methylprednisolone" post="Recruiting Medical ICU,Peking Union Medical College HospitalBeijing, Beijing, China"/>
   <result pre="Medical University A prospective clinical study for recombinant human interferon" exact="alpha" post="1b spray in the prevention of novel coronavirus (COVID-19)"/>
   <result pre="(COVID-19) infection in highly exposed medical staffs recombinant human interferon" exact="alpha" post="1b - Chinese PLA General Hospital A Pilot Study"/>
   <result pre="Disease, Wuhan, Hubei, China A study for the efficacy of" exact="hydroxychloroquine" post="for mild and moderate COVID-19 infectious diseases Hydroxychloroquine -"/>
   <result pre="efficacy of hydroxychloroquine for mild and moderate COVID-19 infectious diseases" exact="Hydroxychloroquine" post="- The Second Affiliated Hospital of Chongqing Medical University"/>
   <result pre="Hospital of Chongqing Medical University The Efficacy and Safety of" exact="Thalidomide" post="Combined with Low-dose Hormones in the Treatment of Severe"/>
   <result pre="Combined with Low-dose Hormones in the Treatment of Severe COVID-19" exact="Thalidomide" post="Not yet recruiting - Various Combination of Protease Inhibitors,"/>
   <result pre="recruiting - Various Combination of Protease Inhibitors, Oseltamivir, Favipiravir, and" exact="Chloroquine" post="for Treatment of COVID19: A Randomized Control Trial Oral"/>
   <result pre="Minnesota, United States University of Minnesota, Minneapolis, Minnesota, United States" exact="Chloroquine" post="Prevention of Coronavirus Disease (COVID-19) in the Healthcare Setting"/>
   <result pre="Chloroquine Prevention of Coronavirus Disease (COVID-19) in the Healthcare Setting" exact="Chloroquine" post="Not yet recruiting - Favipiravir Combined with Tocilizumab in"/>
   <result pre="of Minnesota, Minneapolis, Minnesota, United States Comparison of Lopinavir/Ritonavir or" exact="Hydroxychloroquine" post="in Patients with Mild Coronavirus Disease (COVID-19) 1. Lopinavir/ritonavir"/>
   <result pre="Hydroxychloroquine in Patients with Mild Coronavirus Disease (COVID-19) 1. Lopinavir/ritonavir" exact="Hydroxychloroquine" post="sulfate Recruiting Asan Medical left, University of Ulsan College"/>
   <result pre="Korea, Republic of Korea Evaluation of Ganovo (Danoprevir) Combined with" exact="Ritonavir" post="in the Treatment of Novel Coronavirus Infection Ganovo with"/>
   <result pre="Ritonavir in the Treatment of Novel Coronavirus Infection Ganovo with" exact="ritonavir" post="+/-Interferon Recruiting The Ninth Hospital of Nanchang Nanchang, Jiangxi,"/>
   <result pre="Infected Patients Eculizumab Initiated - Norwegian Coronavirus Disease 2019 Study" exact="Hydroxychloroquine" post="Sulfate Not yet recruiting - Post-exposure Prophylaxis for SARS-Coronavirus-2"/>
   <result pre="Hydroxychloroquine Sulfate Not yet recruiting - Post-exposure Prophylaxis for SARS-Coronavirus-2" exact="Hydroxychloroquine" post="Recruiting University of Minnesota, Minneapolis, Minnesota, United States The"/>
   <result pre="Minnesota, Minneapolis, Minnesota, United States The efficacy and safety of" exact="pirfenidone" post="capsules in the treatment of severe new coronavirus pneumonia"/>
   <result pre="in the treatment of COVID-19 Name of Drug Illnesses treated" exact="Ribavirin" post="RSV and RSV pneumonia Reverse transcriptase inhibitors: zidovudine, didanosine,"/>
   <result pre="RSV pneumonia Reverse transcriptase inhibitors: zidovudine, didanosine, zalcitabine, stavudine, lamivudine," exact="abacavir" post="and emtricitabine SARS Cathespin L SARS Methylprednisolone SARS, MERS"/>
   <result pre="Reverse transcriptase inhibitors: zidovudine, didanosine, zalcitabine, stavudine, lamivudine, abacavir and" exact="emtricitabine" post="SARS Cathespin L SARS Methylprednisolone SARS, MERS Protease Inhibitors"/>
   <result pre="zalcitabine, stavudine, lamivudine, abacavir and emtricitabine SARS Cathespin L SARS" exact="Methylprednisolone" post="SARS, MERS Protease Inhibitors (PIs): saquinavir, ritonavir, indinavir, nelfinavir,"/>
   <result pre="MERS Protease Inhibitors (PIs): saquinavir, ritonavir, indinavir, nelfinavir, amprenavir, lopinavir," exact="atazanavir" post="and fosamprenavir SARS Fusion inhibitor: enfuvirtide. Lamivudine and adefovir"/>
   <result pre="Inhibitors (PIs): saquinavir, ritonavir, indinavir, nelfinavir, amprenavir, lopinavir, atazanavir and" exact="fosamprenavir" post="SARS Fusion inhibitor: enfuvirtide. Lamivudine and adefovir dipivoxil SARS"/>
   <result pre="nelfinavir, amprenavir, lopinavir, atazanavir and fosamprenavir SARS Fusion inhibitor: enfuvirtide." exact="Lamivudine" post="and adefovir dipivoxil SARS Baricitinib COVID-19 Umifenovir ARVI, influenza,"/>
   <result pre="glycoprotein (hCoV-EMC) SARS, Human Coronavirus Guanosine-analog RNA synthesis inhibitors Coronavirus" exact="Ritonavir" post="and lopinavir SARS, MERS Interferon Subtypes of Î²-1b, Î±-n1,"/>
   <result pre="SARS, Human Coronavirus Guanosine-analog RNA synthesis inhibitors Coronavirus Ritonavir and" exact="lopinavir" post="SARS, MERS Interferon Subtypes of Î²-1b, Î±-n1, Î±-n3, and"/>
   <result pre="SARS, MERS Favipiravir COVID-19 Darunavir COVID-19 Lopinavir COVID-19, SARS, MERS" exact="Alcohol" post="Vaporization/Nebulization Inhalation Therapy COVID-19 Chloroquine SARS, Human Coronavirus OC43"/>
   <result pre="COVID-19 Lopinavir COVID-19, SARS, MERS Alcohol Vaporization/Nebulization Inhalation Therapy COVID-19" exact="Chloroquine" post="SARS, Human Coronavirus OC43 Chloroquine phosphate; Arbidol COVID-19 ASC09"/>
   <result pre="Alcohol Vaporization/Nebulization Inhalation Therapy COVID-19 Chloroquine SARS, Human Coronavirus OC43" exact="Chloroquine" post="phosphate; Arbidol COVID-19 ASC09 ARDS, Respiratory distress syndrome, SARS,"/>
   <result pre="and COVID-19 Non-nucleoside reverse transcriptase inhibitors (NNRTIs): nevirapine, delavirdine and" exact="efavirenz" post="SARS Ruxolitinib COVID-19 Saquinavir SARS and Feline Coronavirus Relenza,"/>
   <result pre="Non-nucleoside reverse transcriptase inhibitors (NNRTIs): nevirapine, delavirdine and efavirenz SARS" exact="Ruxolitinib" post="COVID-19 Saquinavir SARS and Feline Coronavirus Relenza, Tamiflu, Amantadine"/>
   <result pre="transcriptase inhibitors (NNRTIs): nevirapine, delavirdine and efavirenz SARS Ruxolitinib COVID-19" exact="Saquinavir" post="SARS and Feline Coronavirus Relenza, Tamiflu, Amantadine Influenza virus"/>
   <result pre="SARS Ruxolitinib COVID-19 Saquinavir SARS and Feline Coronavirus Relenza, Tamiflu," exact="Amantadine" post="Influenza virus Indinavir SARS and COVID-19 Carfilzomib COVID-19 Oseltamivir"/>
   <result pre="Coronavirus Relenza, Tamiflu, Amantadine Influenza virus Indinavir SARS and COVID-19" exact="Carfilzomib" post="COVID-19 Oseltamivir COVID-19 Azvudine COVID-19 Baloxavir marboxil COVID-19 Thymosin"/>
   <result pre="Indinavir SARS and COVID-19 Carfilzomib COVID-19 Oseltamivir COVID-19 Azvudine COVID-19" exact="Baloxavir marboxil" post="COVID-19 Thymosin Î±1 MERS Nucleotide reverse transcriptase inhibitor: tenofovir"/>
   <result pre="Syncytial Virus, ARVI - Acute respiratory viral infections. Table 4" exact="Chloroquine" post="and its combination of drugs used in the treatment"/>
   <result pre="in the treatment of COVID-19 Study Particulars Drugs Dosage Reference" exact="Chloroquine" post="(C) phosphate against pneumonia caused by COVID-19 but need"/>
   <result pre="pneumonia caused by COVID-19 but need confirmation through randomized trials" exact="Chloroquine" post="phosphate Not specified 15 SARS-CoV-2 and blocked viral infection"/>
   <result pre="infection by increasing the endosomal pH required for viral fusion" exact="Chloroquine" post="1.13 Î¼M at half maximal concentration 27 (Nichol et"/>
   <result pre="Î¼M at half maximal concentration 27 (Nichol et al., 2020)" exact="Chloroquine" post="(C) and Hydroxychloroquine (HC) are under investigation in clinical"/>
   <result pre="maximal concentration 27 (Nichol et al., 2020) Chloroquine (C) and" exact="Hydroxychloroquine" post="(HC) are under investigation in clinical trials for pre-exposure"/>
   <result pre="and treatment of patients with mild, moderate, and severe COVID-19" exact="Chloroquine" post="and Hydroxychloroquine Not specified 8 C and HC inhibit"/>
   <result pre="of patients with mild, moderate, and severe COVID-19 Chloroquine and" exact="Hydroxychloroquine" post="Not specified 8 C and HC inhibit in vitro"/>
   <result pre="vitro antiviral activity of C and HC against SARS-CoV-2 reported" exact="Chloroquine" post="and Hydroxychloroquine Not specified 27 (Nichol et al., 2020);"/>
   <result pre="activity of C and HC against SARS-CoV-2 reported Chloroquine and" exact="Hydroxychloroquine" post="Not specified 27 (Nichol et al., 2020); 43 (Liu"/>
   <result pre="(Nichol et al., 2020); 43 (Liu et al., 2020) Prescribing" exact="Hydroxychloroquine" post="treatment on a large scale, and decided to perform"/>
   <result pre="at demonstrating that HC is effective in vivo against SARS-CoV-2" exact="Hydroxychloroquine" post="Not specified 31 (Parola et al., 2020) Azithromycinâ€&quot;suggested to"/>
   <result pre="2020) Azithromycinâ€&quot;suggested to act in combination with C/HC against SARs-CoV-2" exact="Azithromycin" post="+ Chloroquine + Hydroxychloroquine Not specified 31 (Parola et"/>
   <result pre="to act in combination with C/HC against SARs-CoV-2 Azithromycin +" exact="Chloroquine" post="+ Hydroxychloroquine Not specified 31 (Parola et al., 2020)"/>
   <result pre="in combination with C/HC against SARs-CoV-2 Azithromycin + Chloroquine +" exact="Hydroxychloroquine" post="Not specified 31 (Parola et al., 2020) Two drugs,"/>
   <result pre="specified 31 (Parola et al., 2020) Two drugs, remdesivir and" exact="chloroquine" post="phosphate, efficiently inhibited SARS-CoV-2 infection in vitro Remdesivir +"/>
   <result pre="chloroquine phosphate, efficiently inhibited SARS-CoV-2 infection in vitro Remdesivir +" exact="chloroquine" post="phosphate Not specified 27 (Nichol et al., 2020) COVID-19"/>
   <result pre="and without contraindications to chloroquine, be treated with 500 mg" exact="chloroquine" post="twice a day for ten days Chloroquine 500 mg"/>
   <result pre="with 500 mg chloroquine twice a day for ten days" exact="Chloroquine" post="500 mg twice a day 31 (Parola et al.,"/>
   <result pre="500 mg twice a day 31 (Parola et al., 2020)" exact="Hydroxychloroquine" post="is recommended for high-risk COVID-19 cases Hydroxychloroquine Not specified"/>
   <result pre="et al., 2020) Hydroxychloroquine is recommended for high-risk COVID-19 cases" exact="Hydroxychloroquine" post="Not specified 32 (Hoffman et al., 2006) HC and"/>
   <result pre="vitro and in small, poorly controlled or uncontrolled clinical studies" exact="Chloroquine" post="and Hydroxychloroquine Not specified 22 (Zhang et al., 2020)"/>
   <result pre="in small, poorly controlled or uncontrolled clinical studies Chloroquine and" exact="Hydroxychloroquine" post="Not specified 22 (Zhang et al., 2020) Reducing symptom"/>
   <result pre="promoting virus-negative seroconversion without any severe side effects in COVID-19" exact="Chloroquine" post="Not specified 23 (Yang et al., 2020)"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7196535\results\search\drug\results.xml">
   <result pre="6 4.96E-06 Endocrine system Thyroid hormone signaling pathway 11 1.17E-11" exact="Estrogen" post="signaling pathway 8 9.55E-08 Progesterone-mediated oocyte maturation 7 1.04E-06"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7196844\results\search\drug\results.xml">
   <result pre="treatment of chronic pancreatitis (4), but no clinical trials of" exact="camostat" post="in coronavirus infection have yet been conducted. Among the"/>
   <result pre="patientâ€™s cells (5). According to preliminary reports, the antimalarial drug" exact="chloroquine" post="prevents the terminal glycosylation of ACE2. Moreover, chloroquineâ€&quot;or its"/>
   <result pre="cell cultures, the replication of SARS-CoV-2 was inhibited at a" exact="chloroquine" post="concentration (EC50 = concentration with half-maximal effect) of 1.13"/>
   <result pre="Several clinical trials are investigating the efficacy and tolerability of" exact="chloroquine" post="in the prevention and treatment of COVID-19 (table 1)."/>
   <result pre="also not recommended for COVID-19 (9â€&quot; 11). The nucleoside analog" exact="ribavirin" post="was used at the beginning of the SARS epidemic"/>
   <result pre="is similar for the administration of some antiretrovirals, such as" exact="lopinavir" post="and nelfinavir, that were developed for the treatment of"/>
   <result pre="developed for the treatment of HIV infection. The protease inhibitor" exact="lopinavir" post="has been usedâ€&quot;together with a small booster dose of"/>
   <result pre="but yielded no clear evidence for the potential efficacy of" exact="lopinavir" post="(12). In Wuhan, 41 (21%) of 181 patients were"/>
   <result pre="hospital. The initial treatment was unspecific, with antipyretics such as" exact="ibuprofen" post="and paracetamol. Chest radiography then indicated pneumonia, upon which"/>
   <result pre="paracetamol. Chest radiography then indicated pneumonia, upon which the antibiotics" exact="vancomycin" post="and cefepime were given. They were discontinued a day"/>
   <result pre="radiography then indicated pneumonia, upon which the antibiotics vancomycin and" exact="cefepime" post="were given. They were discontinued a day later, however,"/>
   <result pre="Drugs are also available for acute viral infections. Treatment with" exact="aciclovir" post="can save the life of a patient with herpes"/>
   <result pre="the â€œnucleoside era,â€� in the 1970s, it was recognized that" exact="cytarabine" post="could not be used as a virustatic in disseminated"/>
   <result pre="&amp;gt;100 ÂµM. As shown in table 2, the nucleoside analog" exact="penciclovir" post="had a relatively weak effect (EC50: 96 ÂµM). Favipiravir,"/>
   <result pre="mechanisms and potential therapeutic targetIntensive Care Med2020 6WangMCaoRZhangLet al.Remdesivir and" exact="chloroquine" post="effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in"/>
   <result pre="in the United StatesN Engl J Med202038292993632004427 15StevensDAJordanGWWaddellTFMeriganTCAdverse effect of" exact="cytosine arabinoside" post="on disseminated zoster in a controlled trialN Engl J"/>
   <result pre="description of trial Number of participants Institution/sponsor Country Planned completion" exact="Chloroquine" post="Prevention, placebo-controlled trial (1:1 randomization)Participants: Employees in a health"/>
   <result pre="e.g., relatives of patients with COVID-19Treatment: Placebo or 10 mg" exact="chloroquine" post="base/kg, thereafter 250 mg chloroquine phosphate daily for 3"/>
   <result pre="COVID-19Treatment: Placebo or 10 mg chloroquine base/kg, thereafter 250 mg" exact="chloroquine" post="phosphate daily for 3 months 10 000 University of"/>
   <result pre="positive COVID-19 test resultTreatment: 800 mg darunavir (plus 150 mg" exact="cobicistat" post="as booster) for 7 days together with chloroquine; contacts"/>
   <result pre="for 7 days together with chloroquine; contacts receive 1 g" exact="chloroquine" post="phosphate on days 1 and 2, 0.5 g on"/>
   <result pre="Center Spain (Catalonia)Department of Health, Generalitat de Catalunya July 2020" exact="Hydroxychloroquine" post="Open trial, pilot studyParticipants: Patients with pneumonia from SARS-CoV-2Treatment:"/>
   <result pre="trial, pilot studyParticipants: Patients with pneumonia from SARS-CoV-2Treatment: 400 mg" exact="hydroxychloroquine" post="daily for 5 days 30 Shanghai Public Health Clinical"/>
   <result pre="mg/day for 2 weeks 400 Tongji Hospital China July 2020" exact="Thalidomide" post="Placebo-controlled double-blind trialParticipants: Patients with PCR-confirmed COVID-19 (max. 8"/>
   <result pre="since diagnosis); pulmonary findings on imagingTreatment: 1 Ã— 100 mg" exact="thalidomide" post="or placebo daily for 14 days 100 Second Affiliated"/>
   <result pre="substance to combat ebolaviruses, several clinical trials in COVID-19 0.77" exact="Chloroquine" post="4-Aminoquinoline derivative; prevention and treatment of malaria, also in"/>
   <result pre="action, clinical trials in influenza and other virus infections 2.1" exact="Nafamostat" post="Serine protease inhibitor, anticoagulant, inhibits membrane fusion, showed action"/>
   <result pre="clinical trials in influenza and other virus infections 2.1 Nafamostat" exact="Serine" post="protease inhibitor, anticoagulant, inhibits membrane fusion, showed action against"/>
   <result pre="membrane fusion, showed action against MERS-CoV in vitro 22 Favipiravir" exact="Pyrazine carboxamide," post="inhibits viral RNA-dependent RNA polymerase, licensed for treatment of"/>
   <result pre="RNA polymerase, licensed for treatment of influenza in Japan 62" exact="Penciclovir" post="Nucleoside analog, guanosine derivative, inhibits viral DNA polymerase; its"/>
   <result pre="Nucleoside analog, guanosine derivative, inhibits viral DNA polymerase; its prodrug" exact="famciclovir" post="is licensed for treatment of herpes zoster 96 Ribavirin"/>
   <result pre="prodrug famciclovir is licensed for treatment of herpes zoster 96" exact="Ribavirin" post="Nucleoside analog, guanosine derivative, inhibits inosine monophosphate dehydrogenase and"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7196923\results\search\drug\results.xml">
   <result pre="medical and health care (CPAM) recommend using anti-SARS properties of" exact="lopinavir" post="and ritonavir capsule for older age COVID-19 patients with"/>
   <result pre="health care (CPAM) recommend using anti-SARS properties of lopinavir and" exact="ritonavir" post="capsule for older age COVID-19 patients with the underlying"/>
   <result pre="et al. (2020) reported that two important class of compounds," exact="theophylline" post="and pyrimidone drugs as possible inhibitors of RNA binding"/>
   <result pre="regions have an antiparallel Î²-sheet structure, third region has five" exact="alpha" post="helices arranged into a cluster. The third region is"/>
   <result pre="inhibitors, tipranavir, saquinavir, ritonavir, nelfinavir, lopinavir, indinavir, darunavir, atazanavir, and" exact="amprenavir" post="are widely reported to be able to deactivate Mpro"/>
   <result pre="production. In this respect, Wilson et al., showed that hexamethylene" exact="amiloride" post="inhibitor has shown to block the E-protein ion channel"/>
   <result pre="efforts to develop a novel therapy and treatment. For example," exact="Chloroquine" post="and Hydroxychloroquine, old drugs, have been used to treat"/>
   <result pre="sun allergies for more than sixty years. The activity of" exact="hydroxychloroquine" post="on viruses is probably same as that of chloroquine"/>
   <result pre="of hydroxychloroquine on viruses is probably same as that of" exact="chloroquine" post="since the mechanism of the action of these two"/>
   <result pre="mechanism of the action of these two molecules is identical." exact="Chloroquine" post="as an antimalarial and autoimmune disease drugs has shown"/>
   <result pre="cell culture has been prevented (Vincent et al., 2005). The" exact="hydroxychloroquine" post="has shown a potent efficacy in treating patients with"/>
   <result pre="COVID-19 pneumonia. More than hundred patients showed the superiority of" exact="chloroquine" post="compared with treatment of standard care in terms of"/>
   <result pre="n.d.; Gao et al., 2020). Colson group have suggested that" exact="chloroquine" post="and hydroxychloroquine as available weapons to fight COVID-19 (Colson"/>
   <result pre="et al., 2020). Colson group have suggested that chloroquine and" exact="hydroxychloroquine" post="as available weapons to fight COVID-19 (Colson et al.,"/>
   <result pre="weapons to fight COVID-19 (Colson et al., 2020). In 2014-2017," exact="ivermectin" post="antiviral drug used for phase 3 treatment of dengue"/>
   <result pre="M. Wang et al. (2020) study reported that remdesivir and" exact="chloroquine" post="are highly effective in the control of COVID-19 infection"/>
   <result pre="not to be effective for COVID-19 (Baden &amp;amp; Rubin, 2020)." exact="Azithromycin" post="has been displayed an antiviral property against Zika and"/>
   <result pre="Gautret group have treated successfully chronic disease patients with long-term" exact="hydroxychloroquine" post="medicines with 600â€‰mg per day for 12 to 18â€‰months."/>
   <result pre="and 16 control patients. Among hydroxychloroquine-treated patients, six patients received" exact="azithromycin" post="with 500â€‰mg on day 1 followed by 250â€‰mg per"/>
   <result pre="next four days. At day 6, 100% patients treated with" exact="hydroxychloroquine" post="and azithromycin combination have cured comparing with 57.1% in"/>
   <result pre="days. At day 6, 100% patients treated with hydroxychloroquine and" exact="azithromycin" post="combination have cured comparing with 57.1% in patients treated"/>
   <result pre="combination have cured comparing with 57.1% in patients treated with" exact="hydroxychloroquine" post="only, and 12.5% in the control group. Finally, they"/>
   <result pre="and 12.5% in the control group. Finally, they found that" exact="hydroxychloroquine" post="and azithromycin combination have cured the COVID-19 patients but"/>
   <result pre="in the control group. Finally, they found that hydroxychloroquine and" exact="azithromycin" post="combination have cured the COVID-19 patients but the drawback"/>
   <result pre="doses of the flu drug oseltamivir combined with HIV drugs" exact="lopinavir" post="and ritonavir could improve the conditions of several COVID-19"/>
   <result pre="the flu drug oseltamivir combined with HIV drugs lopinavir and" exact="ritonavir" post="could improve the conditions of several COVID-19 patients at"/>
   <result pre="promotive association for medical and health care) recommends to take" exact="lopinavir" post="400â€‰mg, ritonavir 100â€‰mg (two tablets by mouth twice in"/>
   <result pre="for medical and health care) recommends to take lopinavir 400â€‰mg," exact="ritonavir" post="100â€‰mg (two tablets by mouth twice in daily) or"/>
   <result pre="ritonavir 100â€‰mg (two tablets by mouth twice in daily) or" exact="chloroquine" post="(500â€‰mg tablet by mouth twice in daily) for older"/>
   <result pre="patients with under underlying conditions and serious symptoms. In case" exact="chloroquine" post="is unavailable, consider to use of hydroxychloroquine (400â€‰mg by"/>
   <result pre="symptoms. In case chloroquine is unavailable, consider to use of" exact="hydroxychloroquine" post="(400â€‰mg by mouth once daily). It cannot be recommended"/>
   <result pre="by mouth once daily). It cannot be recommended to take" exact="ribavirin" post="and interferon drug because of the high risk for"/>
   <result pre="these drugs may be considered if treatment with lopinavir, ritonavir," exact="chloroquine" post="or hydroxychloroquine are ineffective (Chu et al., 2004; Gao"/>
   <result pre="may be considered if treatment with lopinavir, ritonavir, chloroquine or" exact="hydroxychloroquine" post="are ineffective (Chu et al., 2004; Gao et al.,"/>
   <result pre="drugs have become promises, other are being ruled out including" exact="lopinavir" post="and ritonavir, mix of two drugs used to treat"/>
   <result pre="Mpro with each inhibitor of ritonavir, lopinavir, Azithromycin, hydroxychloroquine, N3," exact="ribavirin" post="and new inhibitors based on free energy calculations. 4."/>
   <result pre="Heart, Lung, and Blood Instituteâ€™s AsthmaNet (2015). Early Administration of" exact="azithromycin" post="and prevention of severe lower respiratory tract illnesses in"/>
   <result pre="NhanT., de PinaJ. J., RolainJ. M., RaoultD., &amp;amp; MussoD. (2018)." exact="Azithromycin" post="inhibits the replication of Zika virus. Journal of Antivirals"/>
   <result pre="59(3), 252â€&quot;256. 10.1136/thorax.2003.01265814985565 ColsonP., RolainJ.-M., LagierJ.-C., BrouquiP., &amp;amp; RaoultD. (2020)." exact="Chloroquine" post="and hydroxychloroquine as available weapons to fight COVID-19. International"/>
   <result pre="10.1136/thorax.2003.01265814985565 ColsonP., RolainJ.-M., LagierJ.-C., BrouquiP., &amp;amp; RaoultD. (2020). Chloroquine and" exact="hydroxychloroquine" post="as available weapons to fight COVID-19. International Journal of"/>
   <result pre="https://pdbj.org/featured/covid-19. Retrieved from https://pdbj.org/featured/covid-19 GaoJ., TianZ., &amp;amp; YangX. (2020). Breakthrough:" exact="Chloroquine" post="phosphate has shown apparent efficacy in treatment of COVID-19"/>
   <result pre="HonorÃ©S., ColsonP., ChabriÃ¨reE., La ScolaB., RolainJ.-M., BrouquiP., &amp;amp; RaoultD. (2020)." exact="Hydroxychloroquine" post="and azithromycin as a treatment of COVID-19: Results of"/>
   <result pre="ChabriÃ¨reE., La ScolaB., RolainJ.-M., BrouquiP., &amp;amp; RaoultD. (2020). Hydroxychloroquine and" exact="azithromycin" post="as a treatment of COVID-19: Results of an open-label"/>
   <result pre="studies of drug repurposing and synergism of lopinavir, oseltamivir and" exact="ritonavir" post="binding with SARS-CoV-2 Protease against COVID-19. Journal of Biomolecular"/>
   <result pre="MaheswariU., ParthasarathyK., NgL., LiuD. X., &amp;amp; GongX. (2007). Conductance and" exact="amantadine" post="binding of a pore formed by a lysine-flanked transmembrane"/>
   <result pre="RollinP. E., KsiazekT. G., SeidahN. G., &amp;amp; NicholS. T. (2005)." exact="Chloroquine" post="is a potent inhibitor of SARS coronavirus infection and"/>
   <result pre="LiuJ., XuM., ShiZ., HuZ., ZhongW., &amp;amp; XiaoG. (2020). Remdesivir and" exact="chloroquine" post="effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in"/>
   <result pre="(n.d). Retrieved from https://www.who.int/dg/speeches/detail/who-director-general-s-remarks-at-the-media-briefing-on-2019-ncov-on-11-february-2020 WilsonL., GageP., &amp;amp; EwartG. (2006). Hexamethylene" exact="amiloride" post="blocks E protein ion channels and inhibits coronavirus replication."/>
   <result pre="SunY., LiX., XuK.-F., WeiY., JinN., &amp;amp; JiangC. (2013). Anti-malaria drug" exact="chloroquine" post="is highly effective in treating avian influenza A H5N1"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7197622\results\search\drug\results.xml">
   <result pre="by reducing reactive oxygen species and increasing antioxidants, and ameliorate" exact="nitric oxide" post="bioavailability, endothelial function, and integrity. Most of these effects"/>
   <result pre="of symptoms in statin-naÃ¯ve patients hospitalized for seasonal influenza receiving" exact="atorvastatin" post="40 mg compared with placebo. An association between outpatient"/>
   <result pre="a proinflammatory trigger such as hypoxia.8 Moreover, in murine cells," exact="atorvastatin" post="0.1 Î¼M (corresponding to the plasma concentration obtained with"/>
   <result pre="administration of CYP3A4 inhibitors currently used in COVID-19, such as" exact="ritonavir" post="and cobicistat, could increase the risk of muscle and"/>
   <result pre="therefore, starting with a lower dose of statin and monitoring" exact="creatine" post="kinase and transaminases would be advisable in these cases."/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7198433\results\search\drug\results.xml">
   <result pre="therapy. This list includes antimicrobials with potential activity against COVID-19:" exact="Chloroquine" post="and Hydroxychloroquine both used â€&quot; In vitro and limited"/>
   <result pre="list includes antimicrobials with potential activity against COVID-19: Chloroquine and" exact="Hydroxychloroquine" post="both used â€&quot; In vitro and limited clinical data"/>
   <result pre="[31] and Favipiravir â€&quot; their potential use is being studied." exact="Azithromycin" post="and Immunomodulating agents are used in some protocols based"/>
   <result pre="drugs reported the antibiotic azithromicyn added to the anti-malaria drug" exact="hydroxychloroquine" post="is used in clinical trials in Marseille, France and"/>
   <result pre="Allergy and Infectious Disease (NIAID) did question the use of" exact="hydroxychloroquine" post="as drug therapy. Also recently Ivermectin, an FDA-approved anti-parasitic"/>
   <result pre="Hosp. Epidemiol.202010.1017/ice.2020.97as part of Cambridge Coronavirus Collection 29GautretPhilippeLagierJean-ChristopheParolaPhilippeHoangVanThuanMeddebLineMailheMorganeDoudierBarbaraCourjonJohanGiordanengoValÃ©rieVieiraVeraEstevesDupontHervÃ©TissotHonorÃ©StÃ©phaneColsonPhilippeChabriÃ¨reEricScolaBernard LaRolainJean-MarcBrouquiPhilippeRaoultDidierHydroxychloroquine and" exact="azithromycin" post="as a treatment of COVID-19: results of an open-label"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7199731\results\search\drug\results.xml">
   <result pre="virus IVIg, intravenous gammaglobulin PLP, papain-like protease LPV, Lopinavir RTV," exact="ritonavir" post="RDV, Remdesivir NO, Nitric oxide Mpro, Main protease HLA,"/>
   <result pre="PLP, papain-like protease LPV, Lopinavir RTV, ritonavir RDV, Remdesivir NO," exact="Nitric oxide" post="Mpro, Main protease HLA, human leukocyte antigen 1 Introduction"/>
   <result pre="COVID-19, some clinical trials are in progress [10]. Lopinavir and" exact="Ritonavir" post="were used in preliminary clinical studies [3]. Nevertheless, in"/>
   <result pre="et al. [78]. Keil et al. [79] had reported that" exact="vitamin B2" post="and UV light effectively reduced the titer of MERS-CoV"/>
   <result pre="human plasma products. Atherton et al. [80] had reported that" exact="vitamin C" post="increased the resistance of chick embryo tracheal organ cultures"/>
   <result pre="viral mutations [86]. 6.2 Immunoenhancers A combination of interferon-Î±-2a with" exact="ribavirin" post="was administered to patients with severe MERS-CoV infection and"/>
   <result pre="been shown to restore antibody production in old mice [92]." exact="levamisole" post="can act as either an immunostimulant agent or an"/>
   <result pre="SARS-CoV receptor ACE2 were found by Sui et al. [103]." exact="Chloroquine" post="has many interesting biochemical properties including antiviral effects. In"/>
   <result pre="treatment of HIV infection. Lopinavir (LPV) is usually combined with" exact="ritonavir" post="(RTV) to increase and Polygonum and it is also"/>
   <result pre="hepatitis C [110]. Morgenstern et al. [111] had reported that" exact="ribavirin" post="and interferon-Î² synergistically inhibited the replication of SARS-associated coronavirus"/>
   <result pre="and the lack of in vitro efficacy, the use of" exact="ribavirin" post="should be seriously considered for the treatment of COVID-19,"/>
   <result pre="even in combination with other antiviral drugs. The combination of" exact="lopinavir" post="(LPV) with ritonavir (RTV) is widely used as a"/>
   <result pre="with other antiviral drugs. The combination of lopinavir (LPV) with" exact="ritonavir" post="(RTV) is widely used as a boosted protease inhibitor"/>
   <result pre="efficacy of remdesivir. Yamamoto et al. [116] had found that" exact="nelfinavir" post="could strongly inhibit the replication of SARS-CoV. Arbidol and"/>
   <result pre="the reproduction of SARS virus in the cultured cells [117]." exact="Nitric oxide" post="(NO) is a gas with diverse biological activities and"/>
   <result pre="hepatitis B Restore antibody production (Duchateau, Servais et al., 1985)" exact="Levamisole" post="SARSâ€�CoV Immunostimulant agent or immunosuppressive agent (Joffe, Sukha et"/>
   <result pre="Treatment of manyÂ solid tumors (Sui, Li et al., 2004)" exact="Chloroquine" post="SARSâ€�CoV Prevention of malaria in adults (Savarino, Boelaert et"/>
   <result pre="reduce the infection (Cauwenberghs, Feijge et al., 2006) Antiviral treatments" exact="Ribavirin" post="SARSâ€�CoV Treatment of hepatitis C (Ksiazek, Erdman et al.,"/>
   <result pre="virus disease and Marburg virus (Yamamoto, Yang et al., 2004)" exact="Nelfinavir" post="SARSâ€�CoV Treatment of HIV (Mohanasundaram and Sekhar 2018) Arbidol"/>
   <result pre="SARSâ€�CoV Treatment for influenza infection (Khamitov, Loginova et al., 2008)" exact="Nitric oxide" post="SARSâ€�CoV Treatment of inflammatory airway disease (Robbins and Grisham"/>
   <result pre="such treatment is better than a placebo [125]. Lopinavir and" exact="Ritonavir" post="were identified in earlier studies to target the Main"/>
   <result pre="ill patients with severe acute respiratory syndromeJAMA290200337438012865379 89BaumannC.A.BadamchianM.GoldsteinA.L.Thymosin Î±1 antagonizes" exact="dexamethasone" post="and CD3-induced apoptosis of CD4+ CD8+ thymocytes through the"/>
   <result pre="measles. Depressed helper/inducer subpopulation reversed by in vitro treatment with" exact="levamisole" post="and ascorbic acidJ. Clin. Invest.7219839719806604071 94LuoC.LuoH.ZhengS.GuiC.YueL.YuC.Nucleocapsid protein of SARS"/>
   <result pre="receptor associationProc. Natl. Acad. Sci. Unit. States Am.101200425362541 104SavarinoA.BoelaertJ.R.CassoneA.MajoriG.CaudaR.Effects of" exact="chloroquine" post="on viral infections: an old drug against today's diseasesLancet"/>
   <result pre="Res. Commun.326200590590815607755 112TsangK.ZhongN.S.SARS: pharmacotherapyRespirology82003S25S3015018130 113KimU.J.WonE.-J.KeeS.-J.JungS.-I.JangH.-C.Case report Combination therapy with lopinavir/ritonavir," exact="ribavirin" post="and interferon-Î± for Middle East respiratory syndromeAntivir. Ther.21201645545926492219 114AgostiniM.L.AndresE.L.SimsA.C.GrahamR.L.SheahanT.P.LuX.Coronavirus"/>
   <result pre="ritonavir, and interferon beta against MERS-CoVNat. Commun.11202011431911652 116YamamotoN.YangR.YoshinakaY.AmariS.NakanoT.CinatlJ.HIV protease inhibitor" exact="nelfinavir" post="inhibits replication of SARS-associated coronavirusBiochem. Biophys. Res. Commun.318200471972515144898 117KhamitovR.LoginovaS.ShchukinaV.BorisevichS.MaksimovV.ShusterA.Antiviral"/>
   <result pre="122MohanasundaramN.SekharT.Computational studies of molecular targets regarding the adverse effects of" exact="isoniazid" post="drug for tuberculosisCurr. Pharmacogenom. Pers. Med. (Former. Curr. Pharmacogenom.)162018210218"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7200052\results\search\drug\results.xml">
   <result pre="reaction [12, 13]. However, while positive-sense RNA viruses show a" exact="glycine" post="preceding the two aspartates, negative-sense RNA viruses show a"/>
   <result pre="the only ones to show a serine instead of a" exact="glycine" post="preceding the two aspartate residues. Fig.Â 1 Alignment of"/>
   <result pre="Favipiravir (Influenza virus) [19], NHC EIDD-1931 (broad spectrum) [20] and" exact="Sofosbuvir" post="(Hepatitis C virus) [21]. Remdesivir and Favipiravir are currently"/>
   <result pre="compared to the positive-sense SARS-CoV-2 RNA virus. In this respect," exact="Sofosbuvir" post="could represent the optimal nucleoside analog to be repositioned"/>
   <result pre="which shares high sequence and structural homology with SARS-CoV-2. Moreover," exact="Sofosbuvir" post="has been already shown to be effective for other"/>
   <result pre="RNA virus with a genome of the same polarity (i.e." exact="Sofosbuvir" post="for HCV) could have a higher inhibitory efficacy against"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7202545\results\search\drug\results.xml">
   <result pre="have limitations. Previous studies showed that postulated geroprotectors, such as" exact="sirolimus" post="(rapamycin) and its close derivative rapalog everolimus (RAD001), decreased"/>
   <result pre="geroprotectors, such as sirolimus (rapamycin) and its close derivative rapalog" exact="everolimus" post="(RAD001), decreased infection rates in a small sample of"/>
   <result pre="undergone clinical evaluation for this purpose. Keywords: COVID-19 SARS-CoV-2 coronavirus" exact="sirolimus" post="rapalog INTRODUCTION Aging is a complex, multifactorial process [1]"/>
   <result pre="viral disease [31]. For influenza, the neuraminidase inhibitors oseltamivir and" exact="zanamivir" post="are occasionally given prophylactically to high-risk individuals in long-term"/>
   <result pre="cost and may be associated with side effects; for example," exact="zanamivir" post="can induce bronchospasms in patients with chronic respiratory disease"/>
   <result pre="efficacy, neurological side effects, and widespread resistance, adamantanes (M2 inhibitors," exact="amantadine" post="and rimantadine), are only active against influenza A [31]."/>
   <result pre="still limited by a lack of large clinical trials, are" exact="sirolimus" post="(rapamycin) and everolimus. These may be used as single"/>
   <result pre="also delays age-related diseases in humans [65â€&quot;68], and Blagosklonny proposed" exact="rapamycin" post="for the prevention of multiple age-related diseases in humans"/>
   <result pre="derivatives and mimetics of rapamycin, target critical factors in the" exact="rapamycin" post="(TOR) pathway. Everolimus (RAD001), another close structural derivative of"/>
   <result pre="rapamycin (TOR) pathway. Everolimus (RAD001), another close structural derivative of" exact="sirolimus" post="developed by Novartis, acts as an immunosuppressant; but like"/>
   <result pre="the cyclical secretion that occurs physiologically, which normally indirectly increases" exact="testosterone" post="levels, actually reduces hormone levels. Therefore, it might be"/>
   <result pre="Torin2, AZD8055, PP242, KU-006379 and GSK1059615, may act similarly to" exact="rapamycin" post="in low-doses and may have a geroprotective effect [77â€&quot;79]."/>
   <result pre="that patients with cytomegalovirus (CMV) disease who were treated with" exact="rapamycin" post="demonstrated better outcomes and were better able to control"/>
   <result pre="following transplantation [74, 80]. In 2009, two seminal studies of" exact="sirolimus" post="demonstrated the immunostimulatory effects of rapamycin on the CD8+"/>
   <result pre="two seminal studies of sirolimus demonstrated the immunostimulatory effects of" exact="rapamycin" post="on the CD8+ memory T cell response following pathogen"/>
   <result pre="[74, 80]. Later studies also showed that monkeys treated with" exact="sirolimus" post="exhibited increased recall responses and enhanced differentiation of memory"/>
   <result pre="role of rapalogs in the elderly using the Novartis rapalog" exact="everolimus" post="(RAD001), a close structural analog of sirolimus (rapamycin). Administration"/>
   <result pre="the Novartis rapalog everolimus (RAD001), a close structural analog of" exact="sirolimus" post="(rapamycin). Administration of everolimus ameliorated immunosenescence in healthy elderly"/>
   <result pre="(RAD001), a close structural analog of sirolimus (rapamycin). Administration of" exact="everolimus" post="ameliorated immunosenescence in healthy elderly volunteers and enhanced the"/>
   <result pre="which demonstrated that a low-dose combination of dactolisib (BEZ235) and" exact="everolimus" post="in an elderly population was safe and associated with"/>
   <result pre="(BEZ235), a PI3K inhibitor [84] and catalytic mTOR inhibitor, and" exact="everolimus" post="in an elderly population was safe and associated with"/>
   <result pre="endpoint and further trials were withdrawn [85]. In prior studies," exact="everolimus" post="(RAD001) was used as a standalone agent or in"/>
   <result pre="protection against SARS-CoV-2 (COVID-19) and other gerophilic and gerolavic infections." exact="Metformin" post="Metformin is a drug approved to treat type 2"/>
   <result pre="against SARS-CoV-2 (COVID-19) and other gerophilic and gerolavic infections. Metformin" exact="Metformin" post="is a drug approved to treat type 2 diabetes"/>
   <result pre="decreasing IGF-1 levels, inhibiting mTOR, and inhibiting mitochondrial complex 1." exact="Metformin" post="is currently in the first large-scale human clinical trial"/>
   <result pre="large-scale human clinical trial of aging, the Targeting Aging with" exact="Metformin" post="(TAME) study, which is investigating its effect on time"/>
   <result pre="outcome that includes cardiovascular events, cancer, dementia, and mortality [87]." exact="Metformin" post="would likely still be contraindicated in elderly patients with"/>
   <result pre="TAME study, and other clinical trials involving metformin. NAD boosters" exact="Nicotine" post="adenine dinucleotide (NAD) is a cofactor of multiple fundamental"/>
   <result pre="study, and other clinical trials involving metformin. NAD boosters Nicotine" exact="adenine" post="dinucleotide (NAD) is a cofactor of multiple fundamental enzymes."/>
   <result pre="human data have been reported with the tyrosine kinase inhibitor" exact="dasatinib" post="in combination with the plant flavonol quercetin in a"/>
   <result pre="nephrotoxicity although milder side effect profile reported in preliminary studies." exact="Metformin" post="mTOR inhibition.Mitochondrial complex 1 inhibition.Reduction of hepatic gluconeogenesis. Long-term"/>
   <result pre="it may be entirely plausible that the immunomodulatory properties of" exact="rapamycin" post="may go beyond prevention and may provide an effective"/>
   <result pre="that several geroprotective and senoremediative interventions, such as treatment with" exact="sirolimus" post="and rapalogs, can induce immunopotentiation, increase resistance to infection,"/>
   <result pre="of this article, another group utilizing computational approaches proposed using" exact="melatonin" post="and sirolimus (rapamycin) in combination to treat the COVID-19"/>
   <result pre="article, another group utilizing computational approaches proposed using melatonin and" exact="sirolimus" post="(rapamycin) in combination to treat the COVID-19 infection outside"/>
   <result pre="speculative aging reversal treatments, such as experimental geroprotective strategies using" exact="everolimus" post="(RAD001) and sirolimus (rapamycin). We summarize the current possible"/>
   <result pre="treatments, such as experimental geroprotective strategies using everolimus (RAD001) and" exact="sirolimus" post="(rapamycin). We summarize the current possible interventions and identify"/>
   <result pre="comments.BMJ. 2014; 348:g2545. 10.1136/bmj.g254524811411 40HeneghanCJ, OnakpoyaI, ThompsonM, SpencerEA, JonesM, JeffersonT." exact="Zanamivir" post="for influenza in adults and children: systematic review of"/>
   <result pre="CorteseF, ArtemovA, Karpinsky-SemperD, MoskalevA, SwickAG, ZhavoronkovA. Towards natural mimetics of" exact="metformin" post="and rapamycin.Aging (Albany NY). 2017; 9:2245â€&quot;68. 10.18632/aging.10131929165314 52AspinallR, LangPO."/>
   <result pre="10.1016/j.cub.2004.03.05915186745 58ScialÃ²F, SriramA, NaudÃ­A, AyalaV, JovÃ©M, PamplonaR, SanzA. Target of" exact="rapamycin" post="activation predicts lifespan in fruit flies.Cell Cycle. 2015; 14:2949â€&quot;58."/>
   <result pre="Glover-CutterK, LammingDW, MizunumaM, NarasimhanSD, Neumann-HaefelinE, SabatiniDM, BlackwellTK. TOR signaling and" exact="rapamycin" post="influence longevity by regulating SKN-1/Nrf and DAF-16/FoxO.Cell Metab. 2012;"/>
   <result pre="ToshkovI, KuropatwinskiKK, ChernovaOB, PolinskyA, BlagosklonnyMV, GudkovAV, AntochMP. New nanoformulation of" exact="rapamycin" post="Rapatar extends lifespan in homozygous p53-/- mice by delaying"/>
   <result pre="RostaingL, KreisH, BurkeJT, BraultY, et al.. Sirolimus therapy after early" exact="cyclosporine" post="withdrawal reduces the risk for cancer in adult renal"/>
   <result pre="Immunol. 2018; 9:2953. 10.3389/fimmu.2018.0295330619313 74FerrerIR, ArakiK, FordML. Paradoxical aspects of" exact="rapamycin" post="immunobiology in transplantation.Am J Transplant. 2011; 11:654â€&quot;59. 10.1111/j.1600-6143.2011.03473.x21446969 75GarcÃ­a-SastreA,"/>
   <result pre="Garcia-EchevrriaC, YungWK. NVP-BEZ235, a novel dual phosphatidylinositol 3-kinase/mammalian target of" exact="rapamycin" post="inhibitor, elicits multifaceted antitumor activities in human gliomas.Mol Cancer"/>
   <result pre="Search of: Rad001, Certican, Rapamycin, Rapamune.https://clinicaltrials.gov/ct2/results?cond=&amp;amp;term=rad001&amp;amp;cntry=&amp;amp;state=&amp;amp;city=&amp;amp;dist=&amp;amp;rslt=With&amp;amp;phase=2 87BarzilaiN, CrandallJP, KritchevskySB, EspelandMA." exact="Metformin" post="as a Tool to Target Aging.Cell Metab. 2016; 23:1060â€&quot;65."/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7202804\results\search\drug\results.xml">
   <result pre="and metabolic diseases. 4Exposure to environmental immuno-interfering factors (tobacco smoke," exact="alcohol" post="consumption, substances of abuse and drugs, environmental pollutants, and"/>
   <result pre="Vitamins such as A, B6, B12, C, D, E and" exact="folic acid" post="and minerals like zinc, iron, selenium, magnesium and copper"/>
   <result pre="fatty acids in subjects who do not usually consume fish;" exact="vitamin C" post="to ensure intakes of 200â€‰mg/d (maximum bioavailability); and appropriate"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7202810\results\search\drug\results.xml">
   <result pre="exposures to bleach products and alcohol-based sanitizers [7]. Even though" exact="chloroquine" post="derivates are not approved treatments for COVID-19, there has"/>
   <result pre="media attention surrounding chloroquine, an Arizona man died after ingesting" exact="chloroquine" post="phosphate (an additive to household products meant to treat"/>
   <result pre="8McLaughlinE.C.Fearing coronavirus, Arizona man dies after taking a form of" exact="chloroquine" post="used in aquariums [Internet][cited 2020Apr24]. Available fromhttps://www.cnn.com/2020/03/23/health/arizona-coronavirus-chloroquine-death/index.html2020[CNN. Cable News"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7202902\results\search\drug\results.xml">
   <result pre="transient ischemic attack (mean age, 64â€‰years), it was reported that" exact="perindopril" post="decreased pneumonia risk in Asian but not in non-Asian"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7203261\results\search\drug\results.xml">
   <result pre="treatment of HIV in combination with a low dose of" exact="ritonavir" post="to increase its plasma half-life, has been used to"/>
   <result pre="11]. However, despite the use of lopinavir/ritonavir in combination with" exact="ribavirin" post="was initially considered a promising therapy for treating COVID-19"/>
   <result pre="Pneumonia [14] included as useful therapy, together with the antimalarial" exact="chloroquine" post="and the antiviral treatment for influenza arbidol, the broad-spectrum"/>
   <result pre="for its undesiderable side effect like anemia, the use of" exact="ribavirin" post="may not be convenient in patients who are already"/>
   <result pre="performed on 20 COVID-19 patients shows that the use of" exact="hydroxychloroquine" post="also by adding the antibacterial drug azithromycin is efficient"/>
   <result pre="the use of hydroxychloroquine also by adding the antibacterial drug" exact="azithromycin" post="is efficient in viral load reduction/disappearance [16]. Hydroxychloroquine and"/>
   <result pre="antibacterial drug azithromycin is efficient in viral load reduction/disappearance [16]." exact="Hydroxychloroquine" post="and chloroquine's antiviral activity appears to be due to"/>
   <result pre="report on the use of a combination of hydroxicloroquine and" exact="azithromycin" post="to treat COVID-19 patients showed no evidence of a"/>
   <result pre="development of type II transmembrane serine protease (TMPRSS2) inhibitors like" exact="camostat" post="mesilate, approved in Japan for the treatment of pancreatic"/>
   <result pre="safer therapies is humanity's ultimateÂ challenge in the twenty-first century." exact="Today" post="we really had proof of this. Publisher's Note Springer"/>
   <result pre="2019-nCoV therapy registered in ChinaJ Med Virol20209254054510.1002/jmv.25733 16.GautretPLagierJCParolaPet al.Hydroxychloroquine and" exact="azithromycin" post="as a treatment of COVID-19: results of an open-label"/>
   <result pre="chloroquineLancet Infect Dis200662676910.1016/S1473-3099(06)70361-916439323 18.DevauxCARolainJMColsonPRaoultDNew insights on the antiviral effects of" exact="chloroquine" post="against coronavirus: what to expect for COVID-19?Int J Antimicrob"/>
   <result pre="rapid antiviral clearance or clinical benefit with the combination of" exact="hydroxychloroquine" post="and azithromycin in patients with severe COVID-19 infectionMed Mal"/>
   <result pre="clearance or clinical benefit with the combination of hydroxychloroquine and" exact="azithromycin" post="in patients with severe COVID-19 infectionMed Mal Infect202010.1016/j.medmal.2020.03.00632240719 22.CalyLDruceJDCattonMGJansDAWagstaffKMThe"/>
   <result pre="patients with severe COVID-19 infectionMed Mal Infect202010.1016/j.medmal.2020.03.00632240719 22.CalyLDruceJDCattonMGJansDAWagstaffKMThe FDA-approved drug" exact="ivermectin" post="inhibits the replication of SARS-CoV-2 in vitroAntivir Res202010.1016/j.antiviral.2020.10478732251768 23.https://clinicaltrials.gov/ct2/show/NCT04304053?term=cobicistat&amp;amp;cond=covid-19&amp;amp;phase=2&amp;amp;draw=2&amp;amp;rank=1."/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7207128\results\search\drug\results.xml">
   <result pre="to severe forms of COVID-19. Keywords COVID-19 Haemophagocytic lymphohistiocytosis HLH" exact="Etoposide" post="Introduction The COVID-19 was declared first by the World"/>
   <result pre="or Ebola frizzled drug) as well as promising malaria drugs" exact="chloroquine" post="and hydroxychloroquine. COVID-19 and haemophagocytic lymphohistiocytosis (HLH) The development"/>
   <result pre="aims at dampening the cytokine storm and is based on" exact="etoposide" post="and dexamethasone with intrathecal methotrexate in case of central"/>
   <result pre="dampening the cytokine storm and is based on etoposide and" exact="dexamethasone" post="with intrathecal methotrexate in case of central nervous system"/>
   <result pre="storm and is based on etoposide and dexamethasone with intrathecal" exact="methotrexate" post="in case of central nervous system involvement [14], [15]."/>
   <result pre="may be due to their rarity or to their under-diagnosis." exact="Etoposide" post="is an ancient cytotoxic agent with predictable side effects"/>
   <result pre="in this fragile sub-group. Additionally, it should be noticed that" exact="Etoposide" post="is a widely used and a relatively cheap medication."/>
   <result pre="progressing with a non-neglectable mortality. The expected therapeutic mechanism of" exact="etoposide" post="Etoposide is a topoisomerase II inhibitor. It has been"/>
   <result pre="with a non-neglectable mortality. The expected therapeutic mechanism of etoposide" exact="Etoposide" post="is a topoisomerase II inhibitor. It has been shown,"/>
   <result pre="hamper antiviral response in human since the combined therapy with" exact="dexamethasone" post="increased the survival of patients with EBV associated HLH"/>
   <result pre="and severe sHLH is the use of the combination of" exact="etoposide" post="and dexamethasone for eight weeks. Age-adjusted doses of Etoposide"/>
   <result pre="sHLH is the use of the combination of etoposide and" exact="dexamethasone" post="for eight weeks. Age-adjusted doses of Etoposide are administered"/>
   <result pre="of etoposide and dexamethasone for eight weeks. Age-adjusted doses of" exact="Etoposide" post="are administered once a week with weekly decisions on"/>
   <result pre="once a week with weekly decisions on whether to continue" exact="etoposide" post="treatment or not, following the clinical and laboratory response"/>
   <result pre="with 2009 influenza A (H1N1) infectionCrit Care152011R8021366922 14BergstenE.HorneA.AricoM.Confirmed efficacy of" exact="etoposide" post="and dexamethasone in HLH treatment: long-term results of the"/>
   <result pre="influenza A (H1N1) infectionCrit Care152011R8021366922 14BergstenE.HorneA.AricoM.Confirmed efficacy of etoposide and" exact="dexamethasone" post="in HLH treatment: long-term results of the cooperative HLH-2004"/>
   <result pre="report from the HLH study centerMed Pediatr Oncol41200310310912825212 18ImashukuS.KuriyamaK.TeramuraT.Requirement for" exact="etoposide" post="in the treatment of Epstein-Barr virus-associated hemophagocytic lymphohistiocytosisJ Clin"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7211516\results\search\drug\results.xml">
   <result pre="justify the empirical use of HIV protease inhibitors, such as" exact="lopinavir" post="and ritonavir, that proved effective in some COVID-19 patients.21"/>
   <result pre="(25 g/day for 5 days) combined with antivirals (lopinavir/ritonavir) and" exact="methylprednisolone" post="in severe COVID-19 in Wuhan, China demonstrated elevation of"/>
   <result pre="gp120 and GagUpdated 2020Accessed May 1, 2020https://www.biorxiv.org/content/10.1101/2020.01.30.927871v110.1101/2020.01.30.927871 21NuthoBMahalapbutrPHengphasatpornKPattaranggoonNCSimanonNShigetaYet al.Why are" exact="lopinavir" post="and ritonavir effective against the newly emerged coronavirus 2019?:"/>
   <result pre="GagUpdated 2020Accessed May 1, 2020https://www.biorxiv.org/content/10.1101/2020.01.30.927871v110.1101/2020.01.30.927871 21NuthoBMahalapbutrPHengphasatpornKPattaranggoonNCSimanonNShigetaYet al.Why are lopinavir and" exact="ritonavir" post="effective against the newly emerged coronavirus 2019?: atomistic insights"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7211730\results\search\drug\results.xml">
   <result pre="complexes with other proteins (cross-talk), such as AhR-interacting protein (AIP)," exact="estrogen" post="receptor (ER), inducible nitric oxide synthase (iNOS), matrix metalloproteinase"/>
   <result pre="(cross-talk), such as AhR-interacting protein (AIP), estrogen receptor (ER), inducible" exact="nitric oxide" post="synthase (iNOS), matrix metalloproteinase (MMP), nuclear factor-ÎºB (NF-ÎºB), prostaglandin"/>
   <result pre="ESC, 2020). It has been posited that the antimalaric drugs" exact="chloroquine" post="and hydroxychloroquine reduce glycosylation of ACE2, thus preventing SARS-CoV-2"/>
   <result pre="It has been posited that the antimalaric drugs chloroquine and" exact="hydroxychloroquine" post="reduce glycosylation of ACE2, thus preventing SARS-CoV-2 from binding"/>
   <result pre="SARS-CoV-2 from binding to host cells (Devaux et al., 2020)." exact="Chloroquine" post="has also been shown to inhibit quinone reductase 2,"/>
   <result pre="the host cells is mainly mediated by the endocytic pathway," exact="chloroquine" post="seems effective in blocking endocytosis and/or inducing viral entrapment"/>
   <result pre="viral entry into the host cell (Yang et al., 2004)." exact="Chloroquine" post="may also thwart viral protein maturation, block the recognition"/>
   <result pre="SARS-CoV-2 and other viruses replication (Briant et al., 1998). Moreover," exact="chloroquine" post="affects immune system activity by mediating an anti-inflammatory response,"/>
   <result pre="response, which might reduce damage due to the cytokine storm." exact="Chloroquine" post="inhibits IL-1Î² mRNA expression in THP-1Â cells, reduces IL-1Î²"/>
   <result pre="in animal models (Holshue et al., 2020). Remdesivir is an" exact="adenosine" post="analogue, antagonizing adenosine for RNA-dependent RNA polymerase, causing their"/>
   <result pre="(Holshue et al., 2020). Remdesivir is an adenosine analogue, antagonizing" exact="adenosine" post="for RNA-dependent RNA polymerase, causing their premature viral RNA"/>
   <result pre="as vitamins A, C, D, E, B2, B6, and B12," exact="folic acid," post="iron, selenium, and zinc to optimal (Maggini et al.,"/>
   <result pre="effective immune system. For example, arginine is necessary for the" exact="nitric oxide" post="generation by macrophages, and vitamin A and zinc are"/>
   <result pre="Western-type diet (described as a diet rich in processed sugars," exact="trans-" post="and saturated-fats, but low in complex carbohydrates, fibers, micronutrients,"/>
   <result pre="CACancer J. Clin.69201943845110.3322/caac.21583 DevauxC.A.RolainJ.-M.ColsonP.RaoultD.New insights on the antiviral effects of" exact="chloroquine" post="against coronavirus: what to expect for COVID-19?Int. J. Antimicrob."/>
   <result pre="the expression of cell cycle- and metastasis-related genes via an" exact="estrogen" post="receptor-dependent pathway in cellular and xenografted ovarian cancer modelsToxicol."/>
   <result pre="of their immunogenicityMethods (San Diego, Calif)4012006202910.1016/j.ymeth.2006.05.018 KarziV.TzatzarakisM.N.VakonakiE.AlegakisT.KatsikantamiI.SifakisS.RizosA.TsatsakisA.M.Biomonitoring of bisphenol A," exact="triclosan" post="and perfluorooctanoic acid in hair samples of children and"/>
   <result pre="azinphos-methyl agricultural pesticide exposureAppl. Environ. Microbiol.832201610.1128/AEM.02149-16e02149-16 SteizM.ValbrachtJ.QuachJ.LotzM.Gold sodium thiomalate and" exact="chloroquine" post="inhibit cytokine production in monocytic THP-1 cells through distinct"/>
   <result pre="altered immune function in mice treated with TCDDToxicology1882003152810.1016/s0300-483x(02)00749-712748038 WangM.CaoR.ZhangL.YangX.LiuJ.XuM.ShiZ.HuZ.ZhongW.XiaoG.Remdesivir and" exact="chloroquine" post="effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in"/>
   <result pre="Human Wellness532016116123 ZhouD.DaiS.M.TongQ.COVID-19: a recommendation to examine the effect of" exact="hydroxychloroquine" post="in preventing infection and progressionJ Antimicrob Chemother. pii: dkaa114.202010.1093/jac/dkaa114"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7212074\results\search\drug\results.xml">
   <result pre="COVID-19 pandemic era. Systemic corticosteroids Historically, systemic corticosteroids, usually oral" exact="prednisone" post="alone or in combination with immunosuppressive drugs, have been"/>
   <result pre="clinical response, lower incidence of serious adverse events and rapid" exact="prednisone" post="tapering compared to old immunosuppressive therapies making its approval"/>
   <result pre="follow up visits (19). Other immunosuppressive agents Most guidelines suggest" exact="azathioprine" post="(AZA) or mycophenolate mofetil (MMF) as first-line steroid-sparing agents"/>
   <result pre="(19). Other immunosuppressive agents Most guidelines suggest azathioprine (AZA) or" exact="mycophenolate mofetil" post="(MMF) as first-line steroid-sparing agents for treatment of pemphigus"/>
   <result pre="be treated less aggressively with local steroids (topical or intralesional)," exact="dapsone" post="and doxycycline (7). If indicated, it is better to"/>
   <result pre="less aggressively with local steroids (topical or intralesional), dapsone and" exact="doxycycline" post="(7). If indicated, it is better to administer RTX"/>
   <result pre="Am Acad Dermatol202082357585 e129438767 19JolyPMaho-VaillantMProst-SquarcioniCHebertVHouivetECalboSet al.First-line rituximab combined with short-term" exact="prednisone" post="versus prednisone alone for the treatment of pemphigus (Ritux"/>
   <result pre="Dermatol202082357585 e129438767 19JolyPMaho-VaillantMProst-SquarcioniCHebertVHouivetECalboSet al.First-line rituximab combined with short-term prednisone versus" exact="prednisone" post="alone for the treatment of pemphigus (Ritux 3): a"/>
   <result pre="simplex virus infection in pemphigus vulgaris treated with rituximab and" exact="prednisolone" post="Acta Derm Venereol2013932200122948546 23WeiKWangYWangWChenWFatal infection of Pneumocystis jiroveci pneumonia"/>
   <result pre="Acad Dermatol2020 8251272127332224276 32DevauxCARolainJ-MColsonPRaoultDNew insights on the antiviral effects of" exact="chloroquine" post="against coronavirus: what to expect for COVID-19? Int J"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7212248\results\search\drug\results.xml">
   <result pre="death, unaltered by the administration of antiviral drugs such as" exact="Ritonavir" post="and Lopinavir [4]. The median time of requirement of"/>
   <result pre="2019-novel coronavirus (2019-nCoV) Real-time RT-PCR diagnostic panel. https://www.who.int/emergencies/diseases/novel-coronavirus-2019/technical-guidance/laboratory-guidance 7.WangMCaoRZhangLYangXLiuJXuMShiZHuZZhongWXiaoGRemdesivir and" exact="chloroquine" post="effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7213034\results\search\drug\results.xml">
   <result pre="of various drugs that are used in COVID -19. (A)" exact="Hydroxychloroquine" post="and chloroquine inhibits virus entry into the cell by"/>
   <result pre="drugs that are used in COVID -19. (A) Hydroxychloroquine and" exact="chloroquine" post="inhibits virus entry into the cell by changing the"/>
   <result pre="receptor (B) Remdesivir and Favipiravir inhibit the RNA polymerase (C)" exact="Azithromycin" post="inhibits mRNA expression and protein production, it is also"/>
   <result pre="shown as a part of viral replication cycle). (E) Lopinavir," exact="Ritonavir" post="inhibit the protease enzyme SARS- CoV- 2 replicates both"/>
   <result pre="function) with elevated liver enzymes and bilirubin (liver injury), elevated" exact="creatine" post="(kidney injury), elevated lactate dehydrogenase (severe lung injury/multisystem involvement),"/>
   <result pre="receptor monoclonal antibody and preventing the effects of cytokine storm)," exact="ivermectin" post="(inhibits the interaction between the viral integrase protein (IN)"/>
   <result pre="importin (IMP) a/b1 heterodimer responsible for IN nuclear import) and" exact="azithromycin" post="(probable mechanism- inhibits mRNA expression and protein production, it"/>
   <result pre="Immunomodulators that do not increase the risk of infection include" exact="glatiramer acetate," post="interferons and natalizumab. Immunomodulators that increase the risk of"/>
   <result pre="and natalizumab. Immunomodulators that increase the risk of infection include" exact="dimethyl fumarate," post="fingolimod, siponimod and teriflunomide. Immunosuppressants increasing the risk of"/>
   <result pre="Immunosuppressants increasing the risk of infection include alemtuzumab, ocrelizumab, rituximab," exact="mitoxantrone" post="and cladribine.[29] With the help, many novel methods like"/>
   <result pre="26SmithTBushekJProsserTCOVID-19 drug therapyClinical Drug Information, Clinical Solutions2020Elsevier 27GautretPLagierJCParolaPMeddebLMailheMDoudierBet al.Hydroxychloroquine and" exact="azithromycin" post="as a treatment of COVID-19:results of an open-label non-randomized"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7213617\results\search\drug\results.xml">
   <result pre="CMJ-2020-249 doi: 10.1097/CM9.000000000000079000024 : Correspondence Comparative effectiveness and safety of" exact="ribavirin" post="plus interferon-alpha, lopinavir/ritonavir plus interferon-alpha, and ribavirin plus lopinavir/ritonavir"/>
   <result pre="and safety of ribavirin plus interferon-alpha, lopinavir/ritonavir plus interferon-alpha, and" exact="ribavirin" post="plus lopinavir/ritonavir plus interferon-alpha in patients with mild to"/>
   <result pre="which advocated the use of interferon-alpha (IFN-Î±), lopinavir/ritonavir (LPV/r) and" exact="ribavirin" post="for the treatment of COVID-19. Based on the previous"/>
   <result pre="the most widely used antiviral regimen was the combination of" exact="ribavirin" post="and IFN, and this use was based on studies"/>
   <result pre="of therapeutic drugs used to manage SARS and MERS patients:" exact="ribavirin" post="(intravenous loading dose of 2 g, followed by oral"/>
   <result pre="days). We refer to the three different therapeutic regimens as" exact="ribavirin" post="plus IFN-Î±1b (arm A); LPV/r plus IFN-Î±1b (arm B);"/>
   <result pre="plus IFN-Î±1b (arm A); LPV/r plus IFN-Î±1b (arm B); and" exact="ribavirin" post="plus LPV/r plus IFN-Î±1b (arm C), and we aim"/>
   <result pre="or are pregnant or breastfeeding women, having aspartate aminotransferase or" exact="alanine" post="aminotransferase &amp;gt;5â€ŠÃ— upper normal limit or creatinine clearance &amp;lt;50"/>
   <result pre="YQ, Harypursat V, Chen YK. Comparative effectiveness and safety of" exact="ribavirin" post="plus interferon-alpha, lopinavir/ritonavir plus interferon-alpha, and ribavirin plus lopinavir/ritonavir"/>
   <result pre="and safety of ribavirin plus interferon-alpha, lopinavir/ritonavir plus interferon-alpha, and" exact="ribavirin" post="plus lopinavir/ritonavir plus interferon-alpha in patients with mild to"/>
   <result pre="from: http://www.gov.cn/zhengce/zhengceku/2020-02/05/5474791/files/de44557832ad4be1929091dcbcfca891.pdf. [Accessed February 6, 2020] 2.KimUJWonEJKeeSJJungSIJangHCCombination therapy with lopinavir/ritonavir," exact="ribavirin" post="and interferon-Î± for Middle East respiratory syndrome. Antivir Ther2016;"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7214343\results\search\drug\results.xml">
   <result pre="for emergency LTX. Common causes of acute liver failure include" exact="acetaminophen" post="overdose, acute viral hepatitis, drug-induced liver injury, mushroom poisoning,"/>
   <result pre="unlikely to be required. White: No clinically significant interaction expected." exact="Chloroquine" post="and hydroxychloroquine Chloroquine and hydroxychloroquine act either as viral"/>
   <result pre="be required. White: No clinically significant interaction expected. Chloroquine and" exact="hydroxychloroquine" post="Chloroquine and hydroxychloroquine act either as viral entry blockers"/>
   <result pre="required. White: No clinically significant interaction expected. Chloroquine and hydroxychloroquine" exact="Chloroquine" post="and hydroxychloroquine act either as viral entry blockers or"/>
   <result pre="No clinically significant interaction expected. Chloroquine and hydroxychloroquine Chloroquine and" exact="hydroxychloroquine" post="act either as viral entry blockers or as immunomodulators."/>
   <result pre="effects, and interactions with other medications are well known [55]." exact="Chloroquine" post="has potential interactions with commonly used drugs like ampicillin,"/>
   <result pre="used drugs like ampicillin, amlodipine, azithromycin, propranolol, and antacids [56]." exact="Chloroquine" post="has significant drug interaction with ciclosporin as it increases"/>
   <result pre="propranolol, and antacids [56]. Chloroquine has significant drug interaction with" exact="ciclosporin" post="as it increases levels of cyclosporin by decreasing its"/>
   <result pre="it increases levels of cyclosporin by decreasing its metabolism. Also," exact="Chloroquine" post="increases levels of tacrolimus by the same mechanism but"/>
   <result pre="cyclosporin by decreasing its metabolism. Also, Chloroquine increases levels of" exact="tacrolimus" post="by the same mechanism but to a lesser extent"/>
   <result pre="be affected by enzyme inducers like Clarithromycin, Rifampin, Phenytoin, and" exact="Phenobarbital" post="[57]. Favipiravir It is also an investigational drug with"/>
   <result pre="treatment of HIV infection. The cytochrome P450 inhibitory effects of" exact="ritonavir" post="prolong the half-life of Lopinavir and extend its protease"/>
   <result pre="by Lopinavir/ritonavir in liver transplant recipients [58]. Lopinavir/ritonavir can increase" exact="chloroquine" post="and hydroxychloroquine concentrations. Also, Lopinavir/ritonavir induces QT interval prolongation"/>
   <result pre="in liver transplant recipients [58]. Lopinavir/ritonavir can increase chloroquine and" exact="hydroxychloroquine" post="concentrations. Also, Lopinavir/ritonavir induces QT interval prolongation that may"/>
   <result pre="concentrations. Also, Lopinavir/ritonavir induces QT interval prolongation that may potentiate" exact="chloroquine" post="and hydroxychloroquine toxicity [57]. Tocilizumab Tocilizumab is a monoclonal"/>
   <result pre="Lopinavir/ritonavir induces QT interval prolongation that may potentiate chloroquine and" exact="hydroxychloroquine" post="toxicity [57]. Tocilizumab Tocilizumab is a monoclonal antibody that"/>
   <result pre="calcineurin inhibitors with necessary drug level monitoring. Its use with" exact="chloroquine" post="and hydroxychloroquine may have additive toxicity. Also, It may"/>
   <result pre="with necessary drug level monitoring. Its use with chloroquine and" exact="hydroxychloroquine" post="may have additive toxicity. Also, It may potentiate hematological"/>
   <result pre="have additive toxicity. Also, It may potentiate hematological toxicity of" exact="ribavirin" post="and interferon-beta if used together as Tocilizumab has a"/>
   <result pre="if used together as Tocilizumab has a myelosuppressive effect [57]." exact="Ribavirin" post="Ribavirin is an old antiviral drug used in the"/>
   <result pre="used together as Tocilizumab has a myelosuppressive effect [57]. Ribavirin" exact="Ribavirin" post="is an old antiviral drug used in the treatment"/>
   <result pre="the treatment of SARS. As it causes dose-dependent hemolytic anemia," exact="Ribavirin" post="may potentiate the hematological toxicity of Interferon-beta and Tocilizumab."/>
   <result pre="Ribavirin may potentiate the hematological toxicity of Interferon-beta and Tocilizumab." exact="Ribavirin" post="had no significant interaction with immunosuppressive drugs [57]. Interferon"/>
   <result pre="should not be combined with Tocilizumab. Also, potential interaction with" exact="chloroquine" post="and hydroxychloroquine may increase its toxicity [57]. Management of"/>
   <result pre="be combined with Tocilizumab. Also, potential interaction with chloroquine and" exact="hydroxychloroquine" post="may increase its toxicity [57]. Management of liver transplant"/>
   <result pre="dosage; consider decreasing tacrolimus/cyclosporine by 50%, stop mycophenolate (CellCept/Myfortic) and" exact="Azathioprine" post="especially in the setting of lymphopenia, fever, or worsening"/>
   <result pre="the case of ground-glass opacities, pneumonia switching mammalian target of" exact="rapamycin" post="(mTOR) to calcineurin inhibitors (CNI, e.g., tacrolimus) should be"/>
   <result pre="stop all immunosuppression [59]. For outpatients on belatacept, switching to" exact="tacrolimus" post="or cyclosporine should be considered after 28Â days from"/>
   <result pre="immunosuppression [59]. For outpatients on belatacept, switching to tacrolimus or" exact="cyclosporine" post="should be considered after 28Â days from the last"/>
   <result pre="CNI should be considered. For CNI intolerant patients, increasing daily" exact="prednisone" post="dose from 5Â mg to 7.5â€&quot;10Â mg daily might"/>
   <result pre="mg to 7.5â€&quot;10Â mg daily might be considered. Low dose" exact="prednisone" post="(5Â mg) in all patients who were receiving it"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7214347\results\search\drug\results.xml">
   <result pre="recently hypothesized that Sodium-Glucose-Transporter-2 inhibitors (SGLT-2i), Glucagon-Like-Peptide-1 Receptor Agonists (GLP-1RAs)," exact="Pioglitazone" post="and even Insulin might induce an over-expression of the"/>
   <result pre="Med3766201758459410.1056/NEJMsr140879528177862 44JaberEmamiPasuttoFranco M.MercerJohn R.Jamali Fakhreddin. Inhibition of insulin metabolism by" exact="hydroxychloroquine" post="and its enantiomers in cytosolic fraction of liver homogenates"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7215132\results\search\drug\results.xml">
   <result pre="natural environments are spilling over into livestock and human communities." exact="Today" post="three crop species, wheat, rice, and corn provide more"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7215134\results\search\drug\results.xml">
   <result pre="Short Report Knowledge-based repositioning of the anti-HCV direct antiviral agent" exact="Sofosbuvir" post="as SARS-CoV-2 treatment http://orcid.org/0000-0002-6380-7114BuonaguroLuigil.buonaguro@istitutotumori.na.it1BuonaguroFranco M.2[1], grid.417893.00000 0001 0807 2568Laboratory"/>
   <result pre="a possible repositioning of the anti-HCV direct antiviral agent (DAA)" exact="Sofosbuvir" post="as treatment for SARS-CoV-2. Indeed, the RNA-dependent RNA-polymerases (RdRp)"/>
   <result pre="sequence and structural homology, supporting the likelihood of binding the" exact="Sofosbuvir" post="molecule with similar efficiency. Such a repositioning would allow"/>
   <result pre="treatment of the two previous coronavirus epidemics [6]. Similarly, anti-malaria" exact="chloroquine" post="or hydroxychloroquine are tested [7]. The inhibitor of Influenzaâ€™s"/>
   <result pre="the two previous coronavirus epidemics [6]. Similarly, anti-malaria chloroquine or" exact="hydroxychloroquine" post="are tested [7]. The inhibitor of Influenzaâ€™s polymerase Favipiravir"/>
   <result pre="clinical use, is hepatitis C virus (HCV). In the specific," exact="Sofosbuvir" post="(SovaldiÂ®; EpclusaÂ® by Gilead) is a direct antiviral agent"/>
   <result pre="from negative-sense Influenza and Ebola RNA viruses. Therefore, repositioning of" exact="Sofosbuvir" post="(SovaldiÂ®; EpclusaÂ® by Gilead), the inhibitor of the HCV"/>
   <result pre="by the great diversity between the molecular structure of the" exact="Sofosbuvir" post="and the inhibitors of Influenza and Ebola viruses currently"/>
   <result pre="Remdesivir (developed for the Ebola virus) are shown together with" exact="Sofosbuvir" post="(developed for the HCV) Moreover, Sofosbuvir is a prodrug"/>
   <result pre="are shown together with Sofosbuvir (developed for the HCV) Moreover," exact="Sofosbuvir" post="is a prodrug of the protide type and is"/>
   <result pre="comparable to liver cells, ensuring the appropriate activation of the" exact="Sofosbuvir" post="to become an effective substrate of the SARS-CoV-2 RdRp"/>
   <result pre="respiratory tract. In conclusion, the data here reported indicate the" exact="Sofosbuvir" post="as the lead compound with the highest potential of"/>
   <result pre="humans will hold the premises of the in silico analyses," exact="Sofosbuvir" post="will become an extraordinary therapeutic tool to inhibit the"/>
   <result pre="S. A systematic review on the efficacy and safety of" exact="chloroquine" post="for the treatment of COVID-19. J Crit Care. 2020;S0883-9441(20)30390â€&quot;7."/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7216567\results\search\drug\results.xml">
   <result pre="and using communal waiting areas. WHO encourages hand washing with" exact="alcohol" post="gels and solutions, although there is limited evidence that"/>
   <result pre="neutral soap and sodium hypochlorite 0.1% to clean equipment or" exact="ethanol" post="(70% concentration) if specific formulations are lacking [19]. In"/>
   <result pre="equipment should be cleaned where possible with chlorine-based disinfectant, 70%" exact="alcohol" post="or an alternative disinfectant used within the organisation that"/>
   <result pre="treating patients with doses as high as 1â€‰g daily of" exact="hydroxychloroquine" post="(HCQ) for 10 days. However as retinal toxicity due"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7216760\results\search\drug\results.xml">
   <result pre="C-reactive protein [CRP], ferritin), d-dimer, prothrombin time (PT), troponin and" exact="creatine" post="phosphokinase (CPK), and acute kidney injury.15 Chest CT scans"/>
   <result pre="Interestingly, several Janus Kinase (JAK) inhibitors such as baricitinib and" exact="ruxolitinib" post="are currently being evaluated given their involvement in interleukin"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7217781\results\search\drug\results.xml">
   <result pre="NIH Director's Pioneer Award and previously described in Drug Discovery" exact="Today" post="in 2014 [1], for precisely this type of pandemic"/>
   <result pre="CANDO based on drug-drug similarity to known SARS-CoV actives identified" exact="chloroquine" post="and other antimalarials at rank 36-41, which may be"/>
   <result pre="the drugs at rank 1 and 14 (omacetaxine mepesuccinate and" exact="mycophenolate mofetil," post="not shown) were previously identified in experimental assays to"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7217786\results\search\drug\results.xml">
   <result pre="HCoV-NL63, and HCoV-HKU1) [12]. HCoV-229E and HCoV-NL63 belong to the" exact="alpha" post="genus, while the other 5 CoVs belong to the"/>
   <result pre="Most often used for treatment of SARS and MERS are" exact="ribavirin" post="and lopinavir/ritonavir. Ribavirin is similar to guanosine and inosine"/>
   <result pre="for treatment of SARS and MERS are ribavirin and lopinavir/ritonavir." exact="Ribavirin" post="is similar to guanosine and inosine and interfere viral"/>
   <result pre="interferons to treat chronic hepatitis C infection [108]. Lopinavir and" exact="ritonavir" post="are two protease inhibitors previously approved for HIV treatment,"/>
   <result pre="previously approved for HIV treatment, which usually used together and" exact="ritonavir" post="as CYP3A4 inhibitor to enhance the activity of lopinavir"/>
   <result pre="and ritonavir as CYP3A4 inhibitor to enhance the activity of" exact="lopinavir" post="[109]. The suitable medications for COVID-19 are still under"/>
   <result pre="(GS-5734), produced by Gilead Science, a nucleoside analog that mimics" exact="adenosine" post="for previously treatment of the Ebola virus infection [110]."/>
   <result pre="other treatment on COVID-19 patients [112]. Another promising drug is" exact="chloroquine" post="or its analog, hydroxychloroquine. It was reported that these"/>
   <result pre="well as rheumatoid arthritis, or systemic lupus erythematosus etc. Moreover," exact="hydroxychloroquine" post="showed fewer side effects than chloroquine [114]. Several clinical"/>
   <result pre="lupus erythematosus etc. Moreover, hydroxychloroquine showed fewer side effects than" exact="chloroquine" post="[114]. Several clinical studies on hydroxychloroquine and chloroquine provided"/>
   <result pre="fewer side effects than chloroquine [114]. Several clinical studies on" exact="hydroxychloroquine" post="and chloroquine provided fairly satisfying results, better trial designing"/>
   <result pre="effects than chloroquine [114]. Several clinical studies on hydroxychloroquine and" exact="chloroquine" post="provided fairly satisfying results, better trial designing would be"/>
   <result pre="ion channel inhibitors (amantadine and rimantadine), neuraminidase inhibitors (oseltamivir, zanamivir," exact="peramivir" post="and laninamivir), and the most recently RNA polymerase inhibitors"/>
   <result pre="laninamivir), and the most recently RNA polymerase inhibitors (balxavirmarboxil) [117]." exact="Amantadine" post="and rimantadine can prevent the virus from shelling in"/>
   <result pre="the most recently RNA polymerase inhibitors (balxavirmarboxil) [117]. Amantadine and" exact="rimantadine" post="can prevent the virus from shelling in the cytoplasm,"/>
   <result pre="of print] 114PereiraB.B.Challenges and cares to promote rational use of" exact="chloroquine" post="and hydroxychloroquine in the management of coronavirus disease 2019"/>
   <result pre="114PereiraB.B.Challenges and cares to promote rational use of chloroquine and" exact="hydroxychloroquine" post="in the management of coronavirus disease 2019 (COVID-19) pandemic:"/>
   <result pre="Crit Rev23202017718132281481 115ChowdhuryM.S.RathodJ.GernsheimerJ.AÂ rapid systematic review of clinical trials utilizing" exact="chloroquine" post="and hydroxychloroquine as a treatment for COVID-19Acad Emerg Med202010.1111/acem.14005[online"/>
   <result pre="115ChowdhuryM.S.RathodJ.GernsheimerJ.AÂ rapid systematic review of clinical trials utilizing chloroquine and" exact="hydroxychloroquine" post="as a treatment for COVID-19Acad Emerg Med202010.1111/acem.14005[online ahead of"/>
   <result pre="to fight against a long-lived enemyFront Immunol10201953130941148 118JiaQ.LiD.WangX.YangS.QianY.QiuJ.Simultaneous determination of" exact="amantadine" post="and rimantadine in feed by liquid chromatography-Qtrap mass spectrometry"/>
   <result pre="against a long-lived enemyFront Immunol10201953130941148 118JiaQ.LiD.WangX.YangS.QianY.QiuJ.Simultaneous determination of amantadine and" exact="rimantadine" post="in feed by liquid chromatography-Qtrap mass spectrometry with information-dependent"/>
   <result pre="information-dependent acquisitionAnal Bioanal Chem41020185555556529651527 119TsuruokaY.NakajimaT.KandaM.HayashiH.MatsushimaY.YoshikawaS.Simultaneous determination of amantadine, rimantadine, and" exact="memantine" post="in processed products, chicken tissues, and eggs by liquid"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7219411\results\search\drug\results.xml">
   <result pre="before randomized clinical trials showed his inefficacy in mortality reduction6;" exact="chloroquine" post="and hydroxychloroquine, which are largely used in systemic lupus"/>
   <result pre="as those affected by SLE and AR, who could face" exact="hydroxychloroquine" post="stock exhaustion.8 Conversely, preliminary data about a potential role"/>
   <result pre="J Med002020 Mar 18null 7LenzerJ.Covid-19: US gives emergency approval to" exact="hydroxychloroquine" post="despite lack of evidenceBMJ2020 Apr 1 8YazdanyJ.KimA.H.J.Use of hydroxychloroquine"/>
   <result pre="to hydroxychloroquine despite lack of evidenceBMJ2020 Apr 1 8YazdanyJ.KimA.H.J.Use of" exact="hydroxychloroquine" post="and chloroquine during the COVID-19 pandemic: what every clinician"/>
   <result pre="despite lack of evidenceBMJ2020 Apr 1 8YazdanyJ.KimA.H.J.Use of hydroxychloroquine and" exact="chloroquine" post="during the COVID-19 pandemic: what every clinician should knowAnn"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7219724\results\search\drug\results.xml">
   <result pre="very small group of patients that the concomitant administration of" exact="hydroxychloroquine" post="and azithromycin (Sumamed) had an even better effect in"/>
   <result pre="group of patients that the concomitant administration of hydroxychloroquine and" exact="azithromycin" post="(Sumamed) had an even better effect in COVID-19 patients."/>
   <result pre="experimental design), they indicate that, despite the adverse effects of" exact="Azithromycin" post="(severe diarrhea due to Clostridium difficile and prolonged QT"/>
   <result pre="whether patients should stop taking ACE inhibitors (ACEI: Enalapril, Lisinopril," exact="Ramipril" post="and others) and angiotensin receptor blocking drugs (ARB: Losartan,"/>
   <result pre="are widely available over the counter and on prescription. Oral" exact="Ibuprofen" post="(over the counter or with a prescription) is used,"/>
   <result pre="such as headaches, flu, dental pain and dysmenorrhoea (period pain)." exact="Ibuprofen" post="is also prescribed for the treatment of arthritis and"/>
   <result pre="also prescribed for the treatment of arthritis and rheumatic conditions." exact="Ketoprofen" post="is a similar medicine, mostly prescribed for use in"/>
   <result pre="in some Member States it is available over the counter." exact="Ibuprofen" post="has also been authorised centrally as Pedea to treat"/>
   <result pre="â€œThere is currently no scientific evidence establishing a link between" exact="ibuprofen" post="and worsening of COVID-19â€�. There is currently no scientific"/>
   <result pre="There is currently no scientific evidence establishing a link between" exact="ibuprofen" post="and worsening of COVID-19. EMA is monitoring the situation"/>
   <result pre="committee (PRAC) started a review of the non-steroidal anti-inflammatory medicines" exact="ibuprofen" post="and ketoprofen following a survey by the French National"/>
   <result pre="started a review of the non-steroidal anti-inflammatory medicines ibuprofen and" exact="ketoprofen" post="following a survey by the French National Agency for"/>
   <result pre="possible period. Further to the ongoing PRAC safety review on" exact="Ibuprofen" post="and Ketoprofen, EMA highlights the need for epidemiological studies"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7219859\results\search\drug\results.xml">
   <result pre="and the ORCHID trial (Outcomes Related to COVID-19 Treated With" exact="Hydroxychloroquine" post="Among In-patients With Symptomatic Disease), sponsored by the National"/>
   <result pre="high doses of antiinflammatory and antioxidant dietary supplements such as" exact="eicosapentaenoic acid" post="and gamma-linolenic acid has excluded pregnant women. A singular"/>
   <result pre="of inclusion is the CROWN CORONATION study, aimed to repurpose" exact="chloroquine" post="to health workers for coronavirus mitigation. Although this is"/>
   <result pre="studies. For example, several trials are investigating the benefit of" exact="hydroxychloroquine" post="with or without azithromycin in patients with COVID-19 infection."/>
   <result pre="trials are investigating the benefit of hydroxychloroquine with or without" exact="azithromycin" post="in patients with COVID-19 infection. However, pregnant women are"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7220586\results\search\drug\results.xml">
   <result pre="COVID-19 is not known, though there are some theoretical considerations." exact="Metformin" post="has shown modest benefits in lower respiratory tract infections"/>
   <result pre="discontinuation due to the risk of dehydration and euglycaemic ketoacidosis." exact="Metformin" post="may also need to be stopped if there is"/>
   <result pre="in treatment of COVID-19 which could have effect on glycaemia:" exact="Chloroquine" post="has also been licensed for use in India for"/>
   <result pre="for patients with type 2 diabetes. Although the efficacy of" exact="chloroquine" post="is not proven; it has been used in patients"/>
   <result pre="proven; it has been used in patients with COVID-19 [38]." exact="Chloroquine" post="has a weak anti-hyperglycaemic effect and there is a"/>
   <result pre="and exercise if motivated. Some people have stopped or reduced" exact="alcohol" post="and smoking because of non-availability. There has been significant"/>
   <result pre="Liu B, Wu R, Yang YY, Xiao XQ, et al." exact="Pioglitazone" post="upregulates angiotensin converting enzyme 2 expression in insulin-sensitive tissues"/>
   <result pre="epicardial fat from coronary artery disease patients is reduced by" exact="dapagliflozin" post="treatmentAtherosclerosis2020292606910.1016/j.atherosclerosis.2019.11.01631783199 23.SalemESBGrobeNElasedKMInsulin treatment attenuates renal ADAM17 and ACE2 shedding"/>
   <result pre="glucocorticoids: A study of a familial clusterClin Immunol2020214108413.10.1016/j.clim.2020.10841332276139 38.SinghAKSinghAShaikhASinghRMisraAChloroquine and" exact="hydroxychloroquine" post="in the treatment of COVID-19 with or without diabetes:"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7222554\results\search\drug\results.xml">
   <result pre="drugs available on the market to act against SARS-CoV-2 [65â€&quot;67]." exact="Chloroquine" post="and hydroxychloroquine stand as excellent examples and are being"/>
   <result pre="on the market to act against SARS-CoV-2 [65â€&quot;67]. Chloroquine and" exact="hydroxychloroquine" post="stand as excellent examples and are being adopted at"/>
   <result pre="can be considered to relieve pain. The reports for avoiding" exact="ibuprofen" post="are not validated yet [69,70]. These reports suggest that"/>
   <result pre="of SARS-CoV-2 in Washington, USA. The dosage of 650Â mg" exact="acetaminophen" post="everyÂ 4Â h and 600Â mg ibuprofen every 6"/>
   <result pre="of 650Â mg acetaminophen everyÂ 4Â h and 600Â mg" exact="ibuprofen" post="every 6 h was administered as prescribed to the"/>
   <result pre="6Â days of hospitalization, he was also given 600Â mg" exact="guaifenesin" post="for persistent coughing and around 6 L of regular"/>
   <result pre="a combination of antibiotics. Used antibiotics included cephalosporins, quinolones, carbapenems," exact="tigecycline" post="and/or linezolid [75]. Another study on 139 patients has"/>
   <result pre="of antibiotics. Used antibiotics included cephalosporins, quinolones, carbapenems, tigecycline and/or" exact="linezolid" post="[75]. Another study on 139 patients has shown that"/>
   <result pre="The investigations include antiviral drugs such as lopinavir, ritonavir, favipiravir," exact="ribavirin" post="and remdesivir [78]. Investigated drugs also include antimalarials, immunomodulators,"/>
   <result pre="(LPV) is a HIV type 1 aspartate protease inhibitor while" exact="ritonavir" post="(RTV) is usually combined to it to increase the"/>
   <result pre="twice daily; days 2â€&quot;14: 600Â mg twice daily) plus interferon" exact="alpha" post="(IFN-Î±) by aerosol inhalation (5Â million U twice daily)."/>
   <result pre="antiviral regimens. Examples of combinations are LPV/RTV plus FPV, darunavir/ritonavir," exact="chloroquine" post="and FPV combined with tocilizumab [83]. Clinical trials are"/>
   <result pre="to death will be compared with the placebo group [88]." exact="Ribavirin" post="(RBV) is another broad-spectrum antiviral agent and acts as"/>
   <result pre="clinical trial for its potentials against SAR-CoV-2 [95]. Antimalarial agents" exact="Chloroquine" post="(CQ) is currently being investigated extensively for its promising"/>
   <result pre="poisoning risk (rhythm disturbance, QT interval prolongation) [98]. The derivative" exact="hydroxychloroquine" post="(HCQ) was developed later and showed better clinical safety"/>
   <result pre="duration 10 days) [77]. A novel combination of CQ and" exact="azithromycin" post="was used recently in a small French clinical trial"/>
   <result pre="10 days. Out of the HCQ-treated patients, six patients received" exact="azithromycin" post="500Â mg on day 1 and 250Â mg for"/>
   <result pre="in HCQ compared with the control group (70 vs 12.5%)." exact="Azithromycin" post="+ HCQ group showed 100% virological clearance on day"/>
   <result pre="with the sigma receptor. The sigma receptors interact with CQ." exact="Azithromycin" post="has also been shown to be an off-target activity"/>
   <result pre="disease-modifying antirheumatic drug (BoDMARD) and recommended as an alternative to" exact="methotrexate" post="or TNF-Î± antagonists in RA patients [111]. Tocilizumab is"/>
   <result pre="corticosteroids in the recent SARS-CoV-2 outbreak [122]. Corticosteroids such as" exact="methylprednisolone" post="are expected to inhibit inflammatory response that is the"/>
   <result pre="that was diagnosed with SARS-CoV-2, showed that the administration of" exact="methylprednisolone" post="(80Â mg twice daily) to the standard care did"/>
   <result pre="antibiotic (moxifloxacin) and RBV antiviral therapy. Only 12 patients received" exact="methylprednisolone" post="to improve patients' shortness of breath. The study did"/>
   <result pre="study did not indicate any advantages for the use of" exact="methylprednisolone" post="in those patients [28]. Another study was conducted on"/>
   <result pre="IFN-Î±) and nutritional support. Of those, 26 patients additionally received" exact="methylprednisolone" post="at a dose of 12Â mg/kg/d for 5â€&quot;7Â days"/>
   <result pre="supplemental oxygen and better absorption of lung focus [122]. Accordingly," exact="methylprednisolone" post="did not improve mortality outcomes but may result in"/>
   <result pre="trial currently being conducted in China on 48 patients and" exact="methylprednisolone" post="to be administrated to half of them like a"/>
   <result pre="improve the immune response (I4R) approach. Low-level radiation, statins and" exact="aspirin" post="are suggested for the treatment of SARS-CoV-2 pneumonia. This"/>
   <result pre="(ivermectin) Recent in vitro reports demonstrated the potential efficacy of" exact="ivermectin" post="against SAR-COV-2. 5000-fold reduced the viral load (in 2-h"/>
   <result pre="post-infection with SARS-CoV-2 Vero-hSLAM cells) after 48Â h of single" exact="ivermectin" post="treatment (5Â Î¼M) [126]. An observational study showed the"/>
   <result pre="An observational study showed the survival benefits of using single" exact="ivermectin" post="dose (150Â mg/kg) after initiating mechanical ventilation in critically"/>
   <result pre="mechanical ventilation in critically ill SAR-COV-2 patients. Patients who received" exact="ivermectin" post="showed better survival, shorter hospital stay and intensive care"/>
   <result pre="study from Italy is suggesting a synergistic effect of combining" exact="hydroxychloroquine" post="with ivermectin against SAR-COV-2. The study is hypothesizing that"/>
   <result pre="Italy is suggesting a synergistic effect of combining hydroxychloroquine with" exact="ivermectin" post="against SAR-COV-2. The study is hypothesizing that the two"/>
   <result pre="to reduce the symptoms of SARS-CoV-2 infection with baricitinib, and" exact="melatonin" post="being the most related [131]. Baricitinib, a drug approved"/>
   <result pre="Ebola viral infection [134]. As suggested by ChengÂ et al.," exact="melatonin" post="could reduce the clinical symptoms of SARS-CoV-2 infection and"/>
   <result pre="gls-5300 in healthy volunteers. (2020). https://clinicaltrials.gov/ct2/show/study/NCT03721718?term=vaccine&amp;amp;cond=Mers+CoV&amp;amp;draw=2&amp;amp;rank=7 55.Efficacy and safety of" exact="hydroxychloroquine" post="for treatment of pneumonia caused by 2019-ncov (hc-ncov)2020). https://clinicaltrials.gov/ct2/show/NCT04261517"/>
   <result pre="TaoG , ZhangYW , YangGN , HuangPDrug interaction monitoring of" exact="lopinavir" post="/ ritonavir in COVID-19 patients with cancer. Zhonghua Nei"/>
   <result pre="ZhangYW , YangGN , HuangPDrug interaction monitoring of lopinavir /" exact="ritonavir" post="in COVID-19 patients with cancer. Zhonghua Nei Ke Za"/>
   <result pre="infection. (2020). https://clinicaltrials.gov/ct2/results?cond=covid+19&amp;amp;term=Favipiravir+&amp;amp;cntry=&amp;amp;state=&amp;amp;city=&amp;amp;dist= 84.WangM , CaoR , ZhangLet al.Remdesivir and" exact="chloroquine" post="effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in"/>
   <result pre="91.collab: Clinicaltrials.Gov. An Open-label Randomized Controlled Trial on Lopinavir/ Ritonavir," exact="Ribavirin" post="and Interferon Beta 1b Combination Versus Lopinavir/ Ritonavir Alone,"/>
   <result pre="Lopinavir/ Ritonavir, Ribavirin and Interferon Beta 1b Combination Versus Lopinavir/" exact="Ritonavir" post="Alone, as Treatment for 2019 Novel Coronavirus Infection. (2020)."/>
   <result pre="a review. 2020030275 (2020). . 97.GaoJ , TianZ , YangXBreakthrough:" exact="chloroquine" post="phosphate has shown apparent efficacy in treatment of COVID-19"/>
   <result pre="ShabaniM , ShokouhiS , SaffaeiAAminoquinolines Against Coronavirus Disease 2019 (COVID-19):" exact="Chloroquine" post="or Hydroxychloroquine. Int J Antimicrob Agents.105945 (2020).32194152 99.PhilippeGautreta J-CL"/>
   <result pre="(2020).32194152 99.PhilippeGautreta J-CL , PhilippeParolaa , VanThuan Hoanget al.Hydroxychloroquine and" exact="azithromycin" post="as a treatment of COVID-19: results of an open-label"/>
   <result pre="Vitro Antiviral activity and projection of optimized dosing design of" exact="hydroxychloroquine" post="for the treatment of severe acute respiratory syndrome coronavirus"/>
   <result pre="SARS-CoV-2/COVID-19 with nitazoxanide and hydroxychloroquine. 103.collab: Chctr.Org. Clinical Trials on" exact="Chloroquine" post="for SARS-COV-2 infection. (2020). http://www.chictr.org.cn/searchprojen.aspx 104.collab: Clinicaltrials.Gov. Clinical trials"/>
   <result pre="for SARS-COV-2 infection. (2020). http://www.chictr.org.cn/searchprojen.aspx 104.collab: Clinicaltrials.Gov. Clinical trials on" exact="chloroquine" post="(2020). https://clinicaltrials.gov/ct2/results?cond=Covid+19&amp;amp;term=chloroquine&amp;amp;cntry=&amp;amp;state=&amp;amp;city=&amp;amp;dist= 105.collab: Clinicaltrials.Gov. Various Combination of Protease Inhibitors,"/>
   <result pre=", ColsonP , RaoultDNew insights on the antiviral effects of" exact="chloroquine" post="against coronavirus: what to expect for COVID-19?Int. J. Antimicrob."/>
   <result pre="Randomized, Controlled Trial (2020). www.chictr.org.cn/showprojen.aspx?proj=51126 118.GaoJ , TianZ , YangXBreakthrough:" exact="chloroquine" post="phosphate has shown apparent efficacy in treatment of COVID-19"/>
   <result pre=", DruceJD , CattonMG , JansDA , WagstaffKMThe FDA-approved drug" exact="ivermectin" post="inhibits the replication of SARS-CoV-2 in vitro. Antivir. Res.178,"/>
   <result pre="KorkmazA , ReiterRJ , ManchesterLCEbola virus disease: potential use of" exact="melatonin" post="as a treatment. J. PIneal Res.57(4), 381â€&quot;384 (2014).25262626 134.TanDX"/>
   <result pre="KorkmazA , ReiterRJ , ManchesterLCEbola virus disease: potential use of" exact="melatonin" post="as a treatment. J. Pineal Res.57(4), 381â€&quot;384 (2014).25262626 135.GlowackaI"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7223264\results\search\drug\results.xml">
   <result pre="into emerging coronaviruses. Nat Rev Microbiol2016;14:523â€&quot;34. 10.1038/nrmicro.2016.8127344959 6YazdanyJ, KimAHJUse of" exact="hydroxychloroquine" post="and chloroquine during the COVID-19 pandemic: what every clinician"/>
   <result pre="coronaviruses. Nat Rev Microbiol2016;14:523â€&quot;34. 10.1038/nrmicro.2016.8127344959 6YazdanyJ, KimAHJUse of hydroxychloroquine and" exact="chloroquine" post="during the COVID-19 pandemic: what every clinician should know."/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7224629\results\search\drug\results.xml">
   <result pre="corona virus disease 2019 epidemicWorld J Clin Cases20208652732149049 15collab: India" exact="Today" post="TechWhatsApp and MyGov launch official coronavirus and COVID-19 alert"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7227507\results\search\drug\results.xml">
   <result pre="During the Covid-19 epidemic, one of the best examples was" exact="hydroxychloroquine" post="and chloroquine. Rumors of effectiveness caused shortages for their"/>
   <result pre="are higher than expected from clinically confirmed casesmedRxivM20-133420202020.2004.2005.20051540https://www.medrxiv.org/content/medrxiv/early/2020/04/07/2020.04.05.20051540.full.pdf 33YazdanyJ.KimA.H.J.Use of" exact="Hydroxychloroquine" post="and Chloroquine during the COVID-19 pandemic: what every clinician"/>
   <result pre="than expected from clinically confirmed casesmedRxivM20-133420202020.2004.2005.20051540https://www.medrxiv.org/content/medrxiv/early/2020/04/07/2020.04.05.20051540.full.pdf 33YazdanyJ.KimA.H.J.Use of Hydroxychloroquine and" exact="Chloroquine" post="during the COVID-19 pandemic: what every clinician should knowAnn."/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7228272\results\search\drug\results.xml">
   <result pre="might have infections with some bacteria, so he took oral" exact="amoxicillin" post="and Chinese traditional medicines for 2Â days on his"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7228359\results\search\drug\results.xml">
   <result pre="al., 2019, Li &amp;amp; De Clercq, 2020), the antiâ€�malaria drug" exact="chloroquine" post="(Gao, Tian, &amp;amp; Yang, 2020), and a traditional Chinese"/>
   <result pre="were observed in hypertensive patients treated with the AT1R antagonist" exact="olmesartan" post="(Furuhashi et al., 2015). Taken together, these observations suggest"/>
   <result pre="ACE2 virus binding site, will not seem paradoxical. Losartan, telmisartan," exact="olmesartan" post="(and additional AT1R antagonists) are widely applied in the"/>
   <result pre="tentative suggestion to apply AT1R antagonists such as losartan and" exact="telmisartan" post="as SARSâ€�CoVâ€�2 therapeutics for treating patients prior to the"/>
   <result pre="652â€&quot;653.14675530 Gao, J., Tian, Z., &amp;amp; Yang, X. (2020). Breakthrough:" exact="Chloroquine" post="phosphate has shown apparent efficacy in treatment of COVIDâ€�19"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7229974\results\search\drug\results.xml">
   <result pre="fresh frozen plasma and 7 versus various pharmacologic agents including" exact="hydroxychloroquine" post="and antiviral drugs). Also our group, in collaboration with"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7230338\results\search\drug\results.xml">
   <result pre="treatment used for malaria, which widely involves the use of" exact="chloroquine" post="and its derivatives (in particular, hydroxychloroquine). These drugs are"/>
   <result pre="[13,14]. More recently, some authors have reported the usefulness of" exact="hydroxychloroquine" post="at a dosage of 400 mg per day for"/>
   <result pre="contributes to increasing their efficacy in vivo [16]. Of note," exact="chloroquine" post="is commonly used in several countries in the treatment"/>
   <result pre="MERS-CoV [18]. Surprisingly, even some medications used in cases of" exact="chloroquine" post="resistance (e.g., doxycycline, azithromycin) have demonstrated antiviral action against"/>
   <result pre="non-African countries. For instance, the effect of the administration of" exact="chloroquine" post="derivatives in areas where malaria is endemic seems to"/>
   <result pre="clinical trials are currently underway to verify the efficacy of" exact="chloroquine" post="and its derivates for COVID-19 (e.g., NCT04261517, 2/14/20; ChiCTR2000029826,"/>
   <result pre="derivates for COVID-19 (e.g., NCT04261517, 2/14/20; ChiCTR2000029826, 2/2/20) [20]. Interestingly," exact="hydroxychloroquine" post="is a less toxic derivate of chloroquine that has"/>
   <result pre="2/2/20) [20]. Interestingly, hydroxychloroquine is a less toxic derivate of" exact="chloroquine" post="that has demonstrated potential against Beta-CoVs [21]. In particular,"/>
   <result pre="economic and social outcomes. Even the mere prophylactic administration of" exact="chloroquine" post="or its derivatives to â€˜exposedâ€™ health workers would help"/>
   <result pre="role of the renin-angiotensin systemFront. Cell. Infect. Microbiol.2016510310.3389/fcimb.2015.0010326779452 13.SavarinoA.BoelaertJ.R.CassoneA.MajoriG.CaudaR.Effects of" exact="chloroquine" post="on viral infections: An old drug against todayâ€™s diseasesLancet"/>
   <result pre="therapiesDrugs2017771935196610.1007/s40265-017-0830-129143192 16.CortegianiA.IngogliaG.IppolitoM.GiarratanoA.EinavS.A systematic review on the efficacy and safety of" exact="chloroquine" post="for the treatment of COVID-19J. Crit. Care202010.1016/j.jcrc.2020.03.00532173110 17.OcanM.AkenaD.NsobyaS.KamyaM.R.SenonoR.KinengyereA.A.ObukuE.A.Persistence of"/>
   <result pre="chloroquine for the treatment of COVID-19J. Crit. Care202010.1016/j.jcrc.2020.03.00532173110 17.OcanM.AkenaD.NsobyaS.KamyaM.R.SenonoR.KinengyereA.A.ObukuE.A.Persistence of" exact="chloroquine" post="resistance alleles in malaria endemic countries: A systematic review"/>
   <result pre="of burden and risk factorsMalar. J.20191810.1186/s12936-019-2716-z30871535 18.Al-BariM.A.A.Targeting endosomal acidification by" exact="chloroquine" post="analogs as a promising strategy for the treatment of"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7230702\results\search\drug\results.xml">
   <result pre="pathway inhibitor (TFPI), and protein S, which inhibit blood coagulation;" exact="nitric oxide" post="(NO), prostacyclin (PGI2), and ecto-ATP/ADPase, which inhibit platelet activation;"/>
   <result pre="molecular patterns; AT, antithrombin; TFPI, tissue factor pathway inhibitor; NO," exact="nitric oxide;" post="PGI2, prostacyclin; t-PA, tissue plasminogen activator; IL-4, interleukin-4; IL-10,"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7231470\results\search\drug\results.xml">
   <result pre="China to be sold in live animal markets or as" exact="dried" post="scales to be sold in Chinese Medicine store. Furthermore,"/>
   <result pre="PeÃ±aranda S, Bankamp B, Maher K, Chen MH, Tong S," exact="Tamin" post="A, Lowe L, Frace M, DeRisi JL, Chen Q,"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7232076\results\search\drug\results.xml">
   <result pre="developed [3]. Therefore, repurpose of existing antiviral agents including interferon," exact="chloroquine" post="(an anti-malarial agent) and niclosamide (a broad spectrum anthelminthic)"/>
   <result pre="existing antiviral agents including interferon, chloroquine (an anti-malarial agent) and" exact="niclosamide" post="(a broad spectrum anthelminthic) have attracted considerable attention and"/>
   <result pre="coronavirus disease 2019 (COVID-19)Drug Discov Ther1412020586010.5582/ddt.2020.0101232147628 5XuJ.ShiP.Y.LiH.ZhouJ.Broad spectrum antiviral agent" exact="niclosamide" post="and its therapeutic potentialACS Infect Dis202010.1021/acsinfecdis.0c00052 6GuoYan-RongCaoQing-DongHongZhong-SiThe origin, transmission"/>
   <result pre="respiratory burst in BALB/c miceImmunopharmacol Immunotoxicol34201247748322564175 16SakaguchiY.ShirahaseH.KunishiroK.IchikawaA.KandaM.UeharaY.Effect of combination of" exact="nitric oxide" post="synthase and cyclooxygenase inhibitors on carrageenan-induced pleurisy in ratsLife"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7232149\results\search\drug\results.xml">
   <result pre="7.4 at 4 Â°C for 2 h; then dehydrated in" exact="ethanol" post="(50Â°, 70Â°, 96Â°, 100Â°) followed by acetone and Araldite-Epon"/>
   <result pre="In this study, a new neuraminidase inhibitor (ethyl (3S,4R,5S)-4-acetamido-5-amino-3-(1-ethylpropoxy)cyclohex-1-en-1-carboxylate ethoxy" exact="succinate" post="(oseltamivir ethoxysuccinate) [26] (Figure 1) which features antiviral activity"/>
   <result pre="novel compound is prepared by treatment of ethyl(3S,4R,5S)-4-acetamido-5-amino-3-(1-ethylpropoxy)cyclohex-1-en-1-carboxylate with ethoxy" exact="succinic acid" post="in ethyl acetate. 2.7. Determination of Anti-Influenza Drugs Efficacy"/>
   <result pre="[39,40]. Between the NA inhibitors of oseltamivir phosphate (TamifluÂ®) and" exact="zanamivir" post="(RelenzaÂ®), the former is considered the most effective because"/>
   <result pre="a sodium (4-methylumbelliferyl-alpha-D-N-acetylneuraminate) substrateAnal Biochem.19799428729610.1016/0003-2697(79)90362-2464297 26.DygayA.M.Ethyl (3s,4r,5s)-4-Acetamido-5-Amino-3-(1-ethyl propoxy) Cyclohex-1-en-1-Carboxylate Etoxy" exact="Succinate" post="as Anti-Viral Drug and Method for its ProductionAvailable online:"/>
   <result pre="City, JapanTohoku J. Exp. Med.200821411312010.1620/tjem.214.11318285668 Figure 1 Ethyl (3S,4R,5S)-4-acetamido-5-amino-3-(1-ethylpropoxy)cyclohex-1-en-1-carboxylate ethoxy" exact="succinate" post="formula. âœ­ -hydrogen bonding. Figure 2 Comparative analysis of"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7232622\results\search\drug\results.xml">
   <result pre="and Kidney Diseases U01AI096299, U01AI069911, U01AI069924, U01AI069919 http://dx.doi.org/10.13039/100000027National Institute on" exact="Alcohol" post="Abuse and Alcoholism U01AI096299, U01AI069911, U01AI069924, U01AI069919 Strengths and"/>
   <result pre="non-nucleoside reverse transcriptase inhibitor (2NRTIs+1NNRTI). The combination of tenofovir (TDF)," exact="lamivudine" post="(3TC) (or emtricitabine (FTC)) and efavirenz (EFV) is the"/>
   <result pre="inhibitor (2NRTIs+1NNRTI). The combination of tenofovir (TDF), lamivudine (3TC) (or" exact="emtricitabine" post="(FTC)) and efavirenz (EFV) is the current treatment of"/>
   <result pre="combination of tenofovir (TDF), lamivudine (3TC) (or emtricitabine (FTC)) and" exact="efavirenz" post="(EFV) is the current treatment of choice. The phasing"/>
   <result pre="is the current treatment of choice. The phasing out of" exact="stavudine" post="(D4T) and nevirapine (NVP) was almost complete in 2014"/>
   <result pre="treatment of choice. The phasing out of stavudine (D4T) and" exact="nevirapine" post="(NVP) was almost complete in 2014 (table 2). East"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7233228\results\search\drug\results.xml">
   <result pre="Over the last few weeks, two investigational drugs: Remdesivir and" exact="Hydroxychloroquine" post="were granted an emergency use authorization (EUA) from the"/>
   <result pre="has recommended Remdesivir as a preferred antiviral agent followed by" exact="Hydroxychloroquine" post="for children with positive virologic COVID-19 testing [34]. This"/>
   <result pre="recommendation was subsequently endorsed by The Pediatric Infectious Diseases Society." exact="Hydroxychloroquine" post="may be considered (with careful consideration of its potential"/>
   <result pre="randomised, double-blind, placebo-controlled, multicentre trialLancet2020 Apr 29 32GelerisJ.SunY.PlattJ.ZuckerJ.BaldwinM.HripcsakG.Observational study of" exact="hydroxychloroquine" post="in hospitalized patients with covid-19N Engl J Med2020 May"/>
   <result pre="patients with covid-19N Engl J Med2020 May 7 33ChenZ.HuJ.ZhangZ.JiangS.HanS.YanD.Efficacy of" exact="hydroxychloroquine" post="in patients with COVID-19: results of a randomized clinical"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7233243\results\search\drug\results.xml">
   <result pre="(HIV, Zika, Hepatitis B, and SV40) Suggests Topological Control of" exact="Adenosine" post="N 6-MethylationACS Cent. Sci.52201921822810.1021/acscentsci.8b0096330834310 89Hansel-HertschR.BeraldiD.LensingS.V.MarsicoG.ZynerK.ParryA.Di AntonioM.PikeJ.KimuraH.NaritaM.G-Quadruplex Structures Mark Human"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7235275\results\search\drug\results.xml">
   <result pre="Chinese HIV-infected patient with a 2-year treatment history with tenofovir," exact="lamivudine" post="and efavirenz (CD4 cell count and HIV-RNA levels unreported),"/>
   <result pre="patient with a 2-year treatment history with tenofovir, lamivudine and" exact="efavirenz" post="(CD4 cell count and HIV-RNA levels unreported), had a"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7235449\results\search\drug\results.xml">
   <result pre="(ethoxycarbonyl)- N,N,N- trimethylbenzenaminium trifluoromethanesulfonate (precursor for SFB synthesis) with azeotropically" exact="dried" post="[18F]fluoride. The HPLC purified [18F]SFB was trapped into an"/>
   <result pre="Siemens Inveon PET-CT. Briefly, animals were sedated using 1.5% inhaled" exact="isoflurane" post="and injected with [18F]FB-IL-2 (~10 MBq per animal) via"/>
   <result pre="ONNV-infected mice were subjected to a post-infection treatment regimen of" exact="fingolimod" post="(FTY720, 20 Î¼g daily from 2 to 6 dpi)."/>
   <result pre="with no effect on viremia (Figures 5A,B). Figure 5 Therapeutic" exact="fingolimod" post="(FTY720) treatments alleviate ONNV-induced joint pathology by inhibiting CD4+"/>
   <result pre="= 6 per group). Treated mice were intraperitoneally administered with" exact="FTY720" post="(20 Î¼g) daily from 2 to 6 dpi, as"/>
   <result pre="per gram tissue were quantified in ONNV-infected mice treated with" exact="FTY720" post="or DMSO at 3 hpi, 4 and 6 dpi."/>
   <result pre="Whitney U test (***P &amp;lt; 0.001). The immunomodulatory effects of" exact="FTY720" post="treatment on pathogenic CD4+ T cell infiltration into ONNV-infected"/>
   <result pre="the infected joints and the draining popliteal lymph node (pLN)." exact="FTY720" post="treatment efficiently suppressed the ingress of CD4+ T cells"/>
   <result pre="CD4+ T cells in the pLN (Figure 5F), suggesting that" exact="FTY720" post="could also inhibit CD4+ T cell ingress or proliferation"/>
   <result pre="be used to reduce ONNV induced joint swelling. Administration of" exact="FTY720" post="into ONNV-infected joints reduced the joint swelling during the"/>
   <result pre="inflammation at 6 dpi (Figure 5). We previously showed that" exact="FTY720" post="could effectively reduce CHIKV-induced arthralgia (28), suggesting that this"/>
   <result pre="Rheumatol. (2012) 8:420â€&quot;9. 10.1038/nrrheum.2012.6422565316 33.MalakarSSreelathaLDechtawewatTNoisakranSYenchitsomanusPThai ChuJJHet al.. Drug repurposing of" exact="quinine" post="as antiviral against dengue virus infection. Virus Res. (2018)"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7235487\results\search\drug\results.xml">
   <result pre="by VSV (efficacy) while maintaining A549 (efficacy). These therapies included" exact="amantadine" post="HCl, dexamethasone, azithromycin, chloroquine diphosphate, naproxen sodium, fluoxetine HCl,"/>
   <result pre="maintaining A549 (efficacy). These therapies included amantadine HCl, dexamethasone, azithromycin," exact="chloroquine" post="diphosphate, naproxen sodium, fluoxetine HCl, loratadine, omeprazole sodium, ritonavir,"/>
   <result pre="(efficacy). These therapies included amantadine HCl, dexamethasone, azithromycin, chloroquine diphosphate," exact="naproxen" post="sodium, fluoxetine HCl, loratadine, omeprazole sodium, ritonavir, lopinavir, doxycycline"/>
   <result pre="therapies included amantadine HCl, dexamethasone, azithromycin, chloroquine diphosphate, naproxen sodium," exact="fluoxetine" post="HCl, loratadine, omeprazole sodium, ritonavir, lopinavir, doxycycline and ribavirin."/>
   <result pre="HCl, dexamethasone, azithromycin, chloroquine diphosphate, naproxen sodium, fluoxetine HCl, loratadine," exact="omeprazole" post="sodium, ritonavir, lopinavir, doxycycline and ribavirin. The 12 candidate"/>
   <result pre="diphosphate, naproxen sodium, fluoxetine HCl, loratadine, omeprazole sodium, ritonavir, lopinavir," exact="doxycycline" post="and ribavirin. The 12 candidate therapies were selected based"/>
   <result pre="as tolerability by broad classes of patients, among others. Specifically," exact="Amantadine" post="HCl is an organic compound that was developed to"/>
   <result pre="It has been successfully used to treat dengueâ€�related hemophagocytic syndrome.[13]" exact="Azithromycin" post="is an antibiotic given to patients with bacterial infections"/>
   <result pre="pneumonia.[15] It has been explored as a novel antimalarial agent.[16]" exact="Chloroquine" post="disphosphate is the most widely used drug against malaria."/>
   <result pre="to target other infectious diseases, including HIV and fungal infections.[17]" exact="Naproxen" post="sodium is an established nonselective, nonsteroidal antiâ€�inflammatory drug (NSAID)"/>
   <result pre="disorders.[20] Its antiviral properties have been explored for treating coxsackievirus.[21]" exact="Loratadine" post="is a secondâ€�generation nonsedating antihistamine used for allergies.[22] Recent"/>
   <result pre="evaluated its use as abortive therapy in pegfilgrastimâ€�associated bone pain.[23]" exact="Omeprazole" post="sodium is a proton pump inhibitor (PPI) used to"/>
   <result pre="in Helicobacter pylori eradication therapy for gastritis and peptic ulcers.[24]" exact="Omeprazole" post="and other PPIs have recently been investigated for and"/>
   <result pre="been investigated for and demonstrated antitumor activity and antiâ€�inflammatory effects.[25]" exact="Ritonavir" post="and lopinavir are antiretroviral medications commonly used in combination"/>
   <result pre="for and demonstrated antitumor activity and antiâ€�inflammatory effects.[25] Ritonavir and" exact="lopinavir" post="are antiretroviral medications commonly used in combination treatment for"/>
   <result pre="used in combination treatment for patients infected with (HIV), with" exact="ritonavir" post="used as a booster with other protease inhibitors like"/>
   <result pre="a booster with other protease inhibitors like lopinavir.[26] Lopinavir and" exact="ritonavir" post="combination has demonstrated in vitro antiviral activity against SARS"/>
   <result pre="against SARS and favorable clinical response in patients with SARS.[27]" exact="Ritonavir" post="has also been explored and shown to be highly"/>
   <result pre="a booster in fixedâ€�dose combinations for patients with Hepatitis C.[27]" exact="Doxycycline" post="is a tetracycline antibiotic with a broad antimicrobial spectrum"/>
   <result pre="fixedâ€�dose combinations for patients with Hepatitis C.[27] Doxycycline is a" exact="tetracycline" post="antibiotic with a broad antimicrobial spectrum of activity.[28] In"/>
   <result pre="a broad antimicrobial spectrum of activity.[28] In recent clinical trials," exact="doxycycline" post="has been shown to treat nasal polyps and rosacea,"/>
   <result pre="shown to treat nasal polyps and rosacea, as an antiâ€�inflammatory.[29]" exact="Ribavirin" post="is an antiviral medication often administered in combination with"/>
   <result pre="with interferonâ€�based therapies for patients with chronic Hepatitis C.[30] Additionally," exact="Ribavirin" post="has been shown to be an effective treatment for"/>
   <result pre="to the host cells for coâ€�incubation. Dose response curves for" exact="Amantadine" post="HCl (AMT); Dexamethasone (DEX); Azithromycin (AZT); Chloroquine Diphosphate (CLR);"/>
   <result pre="coâ€�incubation. Dose response curves for Amantadine HCl (AMT); Dexamethasone (DEX);" exact="Azithromycin" post="(AZT); Chloroquine Diphosphate (CLR); NPX, Naproxen Sodium (NPX); Fluoxetine"/>
   <result pre="response curves for Amantadine HCl (AMT); Dexamethasone (DEX); Azithromycin (AZT);" exact="Chloroquine" post="Diphosphate (CLR); NPX, Naproxen Sodium (NPX); Fluoxetine HCl (FLX);"/>
   <result pre="HCl (AMT); Dexamethasone (DEX); Azithromycin (AZT); Chloroquine Diphosphate (CLR); NPX," exact="Naproxen" post="Sodium (NPX); Fluoxetine HCl (FLX); LRT, Loratadine (LRT); Omeprazole"/>
   <result pre="Diphosphate (CLR); NPX, Naproxen Sodium (NPX); Fluoxetine HCl (FLX); LRT," exact="Loratadine" post="(LRT); Omeprazole Sodium (OMP); Ritonavir (RTN); Lopinavir (LPN); Doxycycline"/>
   <result pre="NPX, Naproxen Sodium (NPX); Fluoxetine HCl (FLX); LRT, Loratadine (LRT);" exact="Omeprazole" post="Sodium (OMP); Ritonavir (RTN); Lopinavir (LPN); Doxycycline (DOX); Ribavirin"/>
   <result pre="(NPX); Fluoxetine HCl (FLX); LRT, Loratadine (LRT); Omeprazole Sodium (OMP);" exact="Ritonavir" post="(RTN); Lopinavir (LPN); Doxycycline (DOX); Ribavirin (RBV) (Figure2). NPX"/>
   <result pre="LRT, Loratadine (LRT); Omeprazole Sodium (OMP); Ritonavir (RTN); Lopinavir (LPN);" exact="Doxycycline" post="(DOX); Ribavirin (RBV) (Figure2). NPX and RBV were tested"/>
   <result pre="(LRT); Omeprazole Sodium (OMP); Ritonavir (RTN); Lopinavir (LPN); Doxycycline (DOX);" exact="Ribavirin" post="(RBV) (Figure2). NPX and RBV were tested at concentrations"/>
   <result pre="cells for coâ€�incubation. Dose response curves for drugs. Abbreviations: AMT," exact="Amantadine" post="HCl; DEX, Dexamethasone; AZT, Azithromycin; CLR, Chloroquine Diphosphate; NPX,"/>
   <result pre="drugs. Abbreviations: AMT, Amantadine HCl; DEX, Dexamethasone; AZT, Azithromycin; CLR," exact="Chloroquine" post="Diphosphate; NPX, Naproxen Sodium; FLX, Fluoxetine HCl; LRT, Loratadine;"/>
   <result pre="Amantadine HCl; DEX, Dexamethasone; AZT, Azithromycin; CLR, Chloroquine Diphosphate; NPX," exact="Naproxen" post="Sodium; FLX, Fluoxetine HCl; LRT, Loratadine; OMP, Omeprazole Sodium;"/>
   <result pre="Diphosphate; NPX, Naproxen Sodium; FLX, Fluoxetine HCl; LRT, Loratadine; OMP," exact="Omeprazole" post="Sodium; RTN, Ritonavir; LPN, Lopinavir; DOX, Doxycycline; RBV, Ribavirin."/>
   <result pre="in combination with other candidates, and merit further optimization included" exact="amantadine" post="HCl, azithromycin, chloroquine diphosphate, omeprazole sodium, and ribavirin. Figure"/>
   <result pre="other candidates, and merit further optimization included amantadine HCl, azithromycin," exact="chloroquine" post="diphosphate, omeprazole sodium, and ribavirin. Figure 3 Systematic optimization"/>
   <result pre="and merit further optimization included amantadine HCl, azithromycin, chloroquine diphosphate," exact="omeprazole" post="sodium, and ribavirin. Figure 3 Systematic optimization of 12"/>
   <result pre="and their interactions are tagged with red boxes. Abbreviations: AMT," exact="Amantadine" post="HCl; NPX, Naproxen Sodium; RTN, Ritonavir; DEX, Dexamethasone; FLX,"/>
   <result pre="are tagged with red boxes. Abbreviations: AMT, Amantadine HCl; NPX," exact="Naproxen" post="Sodium; RTN, Ritonavir; DEX, Dexamethasone; FLX, Fluoxetine HCl; LPN,"/>
   <result pre="HCl; LPN, Lopinavir; AZT, Azithromycin; LRT, Loratadine; DOX, Doxycycline; CLR," exact="Chloroquine" post="Diphosphate; OMP, Omeprazole Sodium; RBV, Ribavirin. Of note, some"/>
   <result pre="AZT, Azithromycin; LRT, Loratadine; DOX, Doxycycline; CLR, Chloroquine Diphosphate; OMP," exact="Omeprazole" post="Sodium; RBV, Ribavirin. Of note, some of the candidate"/>
   <result pre="rate compared to no drug treatment and was comprised of" exact="Amantadine" post="HCl (5 Ã— 10âˆ’6 m), Azithromycin (5 Ã— 10âˆ’6"/>
   <result pre="and was comprised of Amantadine HCl (5 Ã— 10âˆ’6 m)," exact="Azithromycin" post="(5 Ã— 10âˆ’6 m), Chloroquine Diphosphate (0.5 Ã— 10âˆ’6"/>
   <result pre="HCl (5 Ã— 10âˆ’6 m), Azithromycin (5 Ã— 10âˆ’6 m)," exact="Chloroquine" post="Diphosphate (0.5 Ã— 10âˆ’6 m), and Ribavirin (2.5 Ã—"/>
   <result pre="Ã— 10âˆ’6 m), Chloroquine Diphosphate (0.5 Ã— 10âˆ’6 m), and" exact="Ribavirin" post="(2.5 Ã— 10âˆ’6 m). Optimal Combo 2 mediated an"/>
   <result pre="1.6% compared to no drug treatment and was comprised of" exact="Amantadine" post="HCl (5 Ã— 10âˆ’6 m), Azithromycin (5 Ã— 10âˆ’6"/>
   <result pre="and was comprised of Amantadine HCl (5 Ã— 10âˆ’6 m)," exact="Azithromycin" post="(5 Ã— 10âˆ’6 m), Chloroquine Diphosphate (0.5 Ã— 10âˆ’6"/>
   <result pre="HCl (5 Ã— 10âˆ’6 m), Azithromycin (5 Ã— 10âˆ’6 m)," exact="Chloroquine" post="Diphosphate (0.5 Ã— 10âˆ’6 m), and Omeprazole Sodium (0.5"/>
   <result pre="Ã— 10âˆ’6 m), Chloroquine Diphosphate (0.5 Ã— 10âˆ’6 m), and" exact="Omeprazole" post="Sodium (0.5 Ã— 10âˆ’6 m) (Table1). Of note, both"/>
   <result pre="in mediating optimal efficacy when coâ€�administered. As an example, for" exact="Amantadine" post="HCl, Chloroquine Diphosphate, and Omeprazole Sodium, monotherapy was shown"/>
   <result pre="optimal efficacy when coâ€�administered. As an example, for Amantadine HCl," exact="Chloroquine" post="Diphosphate, and Omeprazole Sodium, monotherapy was shown to be"/>
   <result pre="coâ€�administered. As an example, for Amantadine HCl, Chloroquine Diphosphate, and" exact="Omeprazole" post="Sodium, monotherapy was shown to be relatively ineffective at"/>
   <result pre="relatively ineffective at high doses. Compared to no drug treatment," exact="Amantadine" post="(HCl) treatment exhibited infection rates of â‰ˆ75%. Chloroquine Diphosphate"/>
   <result pre="drug treatment, Amantadine (HCl) treatment exhibited infection rates of â‰ˆ75%." exact="Chloroquine" post="Diphosphate treatment exhibited infection rates of â‰ˆ25%, and Omeprazole"/>
   <result pre="â‰ˆ75%. Chloroquine Diphosphate treatment exhibited infection rates of â‰ˆ25%, and" exact="Omeprazole" post="Sodium treatment exhibited infection rates of â‰ˆ50%. To further"/>
   <result pre="optimization. This is further confirmed by the scenario where replacing" exact="Amantadine" post="HCl with Omeprazole Sodium and administering this combination at"/>
   <result pre="further confirmed by the scenario where replacing Amantadine HCl with" exact="Omeprazole" post="Sodium and administering this combination at a subâ€�optimal dose"/>
   <result pre="effects, 2â€�drug interaction synergy and 3â€�drug interaction synergy. Abbreviations: AMT," exact="Amantadine" post="HCl; AZT, Azithromycin; CLR, Chloroquine Diphosphate; OMP, Omeprazole Sodium;"/>
   <result pre="3â€�drug interaction synergy. Abbreviations: AMT, Amantadine HCl; AZT, Azithromycin; CLR," exact="Chloroquine" post="Diphosphate; OMP, Omeprazole Sodium; RBV, Ribavirin. Table 1 AIâ€�optimized"/>
   <result pre="Abbreviations: AMT, Amantadine HCl; AZT, Azithromycin; CLR, Chloroquine Diphosphate; OMP," exact="Omeprazole" post="Sodium; RBV, Ribavirin. Table 1 AIâ€�optimized regimens. Two optimal,"/>
   <result pre="during the AI optimization process are shown (units = micromolar)" exact="Amantadine" post="HCI Azithromycin Chloroquine Diphosphate Omeprazole Sodium Ribavirin Viral Infection"/>
   <result pre="AI optimization process are shown (units = micromolar) Amantadine HCI" exact="Azithromycin" post="Chloroquine Diphosphate Omeprazole Sodium Ribavirin Viral Infection Rate Optimal"/>
   <result pre="optimization process are shown (units = micromolar) Amantadine HCI Azithromycin" exact="Chloroquine" post="Diphosphate Omeprazole Sodium Ribavirin Viral Infection Rate Optimal 1"/>
   <result pre="are shown (units = micromolar) Amantadine HCI Azithromycin Chloroquine Diphosphate" exact="Omeprazole" post="Sodium Ribavirin Viral Infection Rate Optimal 1 5 5"/>
   <result pre="(units = micromolar) Amantadine HCI Azithromycin Chloroquine Diphosphate Omeprazole Sodium" exact="Ribavirin" post="Viral Infection Rate Optimal 1 5 5 0.5 0"/>
   <result pre="1 (0.5Â Ã— 10âˆ’6 m Azithromycin, 5Â Ã— 10âˆ’6 m" exact="Chloroquine" post="Diphosphate, 0.5Â Ã— 10âˆ’6 m Omeprazole Sodium and 25Â"/>
   <result pre="5Â Ã— 10âˆ’6 m Chloroquine Diphosphate, 0.5Â Ã— 10âˆ’6 m" exact="Omeprazole" post="Sodium and 25Â Ã— 10âˆ’6 m Ribavirin). â€œNonâ€�opt. Combo"/>
   <result pre="2 (0.5Â Ã— 10âˆ’6 m Azithromycin, 0.5Â Ã— 10âˆ’6 m" exact="Chloroquine" post="Diphosphate, 5Â Ã— 10âˆ’6 m Omeprazole Sodium and 25Â"/>
   <result pre="0.5Â Ã— 10âˆ’6 m Chloroquine Diphosphate, 5Â Ã— 10âˆ’6 m" exact="Omeprazole" post="Sodium and 25Â Ã— 10âˆ’6 m Ribavirin). â€œOptimal Combo"/>
   <result pre="concurrent treatment with Optimal Combo 1 (5Â Ã— 10âˆ’6 m" exact="Amantadine" post="HCl, 5Â Ã— 10âˆ’6 m Azithromycin, 0.5Â Ã— 10âˆ’6"/>
   <result pre="HCl, 5Â Ã— 10âˆ’6 m Azithromycin, 0.5Â Ã— 10âˆ’6 m" exact="Chloroquine" post="Diphosphate and 25Â Ã— 10âˆ’6 m Ribavirin). â€œOptimal Combo"/>
   <result pre="concurrent treatment with Optimal Combo 2 (5Â Ã— 10âˆ’6 m" exact="Amantadine" post="HCl, 5Â Ã— 10âˆ’6 m Azithromycin, 0.5Â Ã— 10âˆ’6"/>
   <result pre="HCl, 5Â Ã— 10âˆ’6 m Azithromycin, 0.5Â Ã— 10âˆ’6 m" exact="Chloroquine" post="Diphosphate and 0.5Â Ã— 10âˆ’6 m Omeprazole Sodium) The"/>
   <result pre="Ã— 10âˆ’6 m Chloroquine Diphosphate and 0.5Â Ã— 10âˆ’6 m" exact="Omeprazole" post="Sodium) The host cell density = 12k, VSV MOI"/>
   <result pre="on drug repurposing were used in the clinic. These included" exact="Kaletra" post="(ritonavir/lopinavir) in combination with oseltamivir. (TamifluÂ®), and other regimens."/>
   <result pre="parasites in parts of Thailand and Vietnam were resistant to" exact="artemisinin" post="and piperaquine, and that the failure rates of the"/>
   <result pre="Selleckchem (TX, USA) were included in this study. These included" exact="amantadine" post="HCl, dexamethasone, azithromycin, chloroquine diphosphate, naproxen sodium, fluoxetine HCl,"/>
   <result pre="included in this study. These included amantadine HCl, dexamethasone, azithromycin," exact="chloroquine" post="diphosphate, naproxen sodium, fluoxetine HCl, loratadine, omeprazole sodium, ritonavir,"/>
   <result pre="this study. These included amantadine HCl, dexamethasone, azithromycin, chloroquine diphosphate," exact="naproxen" post="sodium, fluoxetine HCl, loratadine, omeprazole sodium, ritonavir, lopinavir, doxycycline"/>
   <result pre="These included amantadine HCl, dexamethasone, azithromycin, chloroquine diphosphate, naproxen sodium," exact="fluoxetine" post="HCl, loratadine, omeprazole sodium, ritonavir, lopinavir, doxycycline and ribavirin."/>
   <result pre="HCl, dexamethasone, azithromycin, chloroquine diphosphate, naproxen sodium, fluoxetine HCl, loratadine," exact="omeprazole" post="sodium, ritonavir, lopinavir, doxycycline and ribavirin. Amantadine HCl, chloroquine"/>
   <result pre="diphosphate, naproxen sodium, fluoxetine HCl, loratadine, omeprazole sodium, ritonavir, lopinavir," exact="doxycycline" post="and ribavirin. Amantadine HCl, chloroquine diphosphate, naproxen sodium, fluoxetine"/>
   <result pre="fluoxetine HCl, loratadine, omeprazole sodium, ritonavir, lopinavir, doxycycline and ribavirin." exact="Amantadine" post="HCl, chloroquine diphosphate, naproxen sodium, fluoxetine HCl, omeprazole sodium,"/>
   <result pre="loratadine, omeprazole sodium, ritonavir, lopinavir, doxycycline and ribavirin. Amantadine HCl," exact="chloroquine" post="diphosphate, naproxen sodium, fluoxetine HCl, omeprazole sodium, doxycycline and"/>
   <result pre="sodium, ritonavir, lopinavir, doxycycline and ribavirin. Amantadine HCl, chloroquine diphosphate," exact="naproxen" post="sodium, fluoxetine HCl, omeprazole sodium, doxycycline and ribavirin were"/>
   <result pre="lopinavir, doxycycline and ribavirin. Amantadine HCl, chloroquine diphosphate, naproxen sodium," exact="fluoxetine" post="HCl, omeprazole sodium, doxycycline and ribavirin were diluted using"/>
   <result pre="and ribavirin. Amantadine HCl, chloroquine diphosphate, naproxen sodium, fluoxetine HCl," exact="omeprazole" post="sodium, doxycycline and ribavirin were diluted using complete cell"/>
   <result pre="Amantadine HCl, chloroquine diphosphate, naproxen sodium, fluoxetine HCl, omeprazole sodium," exact="doxycycline" post="and ribavirin were diluted using complete cell culture medium,"/>
   <result pre="chloroquine diphosphate, naproxen sodium, fluoxetine HCl, omeprazole sodium, doxycycline and" exact="ribavirin" post="were diluted using complete cell culture medium, while dexamethasone,"/>
   <result pre="complete cell culture medium, while dexamethasone, azithromycin, loratadine, ritonavir, and" exact="lopinavir" post="were diluted in DMSO. The final stock concentration of"/>
   <result pre="drugs was 100Â Ã— 10âˆ’3 m. With the exception of" exact="naproxen" post="sodium and ribavirin, the other 10 drugs were further"/>
   <result pre="10âˆ’6 m during the drug optimization process. The concentrations of" exact="naproxen" post="sodium and ribavirin during the drug optimization process were"/>
   <result pre="the drug optimization process. The concentrations of naproxen sodium and" exact="ribavirin" post="during the drug optimization process were 0.5, 5, 50,"/>
   <result pre="1 equivalent dose refers to 5Â Ã— 10âˆ’6 m for" exact="naproxen" post="sodium and ribavirin, and 1Â Ã— 10âˆ’6 m for"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7235633\results\search\drug\results.xml">
   <result pre="the most frequently evaluated antiviral therapies were lopinavir/ritonavir (LPV/r) (nâ€‰=â€‰15)," exact="chloroquine" post="(nâ€‰=â€‰11), arbidol (nâ€‰=â€‰9), hydroxychloroquine (nâ€‰=â€‰7), favipiravir (nâ€‰=â€‰7) and remdesivir"/>
   <result pre="antiviral therapies were lopinavir/ritonavir (LPV/r) (nâ€‰=â€‰15), chloroquine (nâ€‰=â€‰11), arbidol (nâ€‰=â€‰9)," exact="hydroxychloroquine" post="(nâ€‰=â€‰7), favipiravir (nâ€‰=â€‰7) and remdesivir (nâ€‰=â€‰5).3 Most of these"/>
   <result pre="four most promising therapies at this time: the malaria drugs" exact="chloroquine" post="and hydroxychloroquine; remdesivir, an experimental antiviral drug; LPV/r, an"/>
   <result pre="an HIV drug combination; and LPV/r plus interferon-beta, an immunomodulator.4" exact="Chloroquine" post="and hydroxychloroquine Chloroquine and hydroxychloroquine are anti-malaria drugs that"/>
   <result pre="drug combination; and LPV/r plus interferon-beta, an immunomodulator.4 Chloroquine and" exact="hydroxychloroquine" post="Chloroquine and hydroxychloroquine are anti-malaria drugs that have been"/>
   <result pre="combination; and LPV/r plus interferon-beta, an immunomodulator.4 Chloroquine and hydroxychloroquine" exact="Chloroquine" post="and hydroxychloroquine are anti-malaria drugs that have been widely"/>
   <result pre="LPV/r plus interferon-beta, an immunomodulator.4 Chloroquine and hydroxychloroquine Chloroquine and" exact="hydroxychloroquine" post="are anti-malaria drugs that have been widely used to"/>
   <result pre="to the emergence of chloroquine-resistant Plasmodium parasites, the use of" exact="chloroquine" post="to treat malaria has been more restricted. Hydroxychloroquine is"/>
   <result pre="use of chloroquine to treat malaria has been more restricted." exact="Hydroxychloroquine" post="is also administered to patients with auto-immune disorders such"/>
   <result pre="with auto-immune disorders such as lupus and rheumatoid arthritis. Both" exact="chloroquine" post="and hydroxychloroquine are considered as safe drugs and the"/>
   <result pre="disorders such as lupus and rheumatoid arthritis. Both chloroquine and" exact="hydroxychloroquine" post="are considered as safe drugs and the side effects"/>
   <result pre="that the window between therapeutic and toxic doses is narrow." exact="Chloroquine" post="poisoning has been associated with cardiovascular symptoms and can"/>
   <result pre="associated with cardiovascular symptoms and can be life-threatening. Self-treatment with" exact="chloroquine" post="and hydroxychloroquine is therefore not recommended. The antiviral activity"/>
   <result pre="cardiovascular symptoms and can be life-threatening. Self-treatment with chloroquine and" exact="hydroxychloroquine" post="is therefore not recommended. The antiviral activity of chloroquine"/>
   <result pre="and hydroxychloroquine is therefore not recommended. The antiviral activity of" exact="chloroquine" post="was already identified in the late 1960s.5 Both chloroquine"/>
   <result pre="of chloroquine was already identified in the late 1960s.5 Both" exact="chloroquine" post="and hydroxychloroquine are able to inhibit a broad range"/>
   <result pre="was already identified in the late 1960s.5 Both chloroquine and" exact="hydroxychloroquine" post="are able to inhibit a broad range of viruses"/>
   <result pre="influenza A virus H5N1.10 However, in a SARS-CoV-1 mouse model," exact="chloroquine" post="was not able to reduce viral titres in the"/>
   <result pre="than 10 hospitals in China to assess the efficacy of" exact="chloroquine" post="to treat COVID-19 patients. In a recent publication,12 it"/>
   <result pre="briefingâ€™, â€˜results from more than 100 patients have demonstrated that" exact="chloroquine" post="phosphate is superior to the control treatment in inhibiting"/>
   <result pre="France, 26 COVID-19 patients were treated for 6 days with" exact="hydroxychloroquine" post="(200 mg, three times per day).13 Six of these"/>
   <result pre="post-inclusion in the study. In addition, a synergistic effect of" exact="azithromycin" post="and hydroxychloroquine was suggested, because all patients treated with"/>
   <result pre="the study. In addition, a synergistic effect of azithromycin and" exact="hydroxychloroquine" post="was suggested, because all patients treated with this combination"/>
   <result pre="the immune system of the patient. Furthermore, the combination of" exact="chloroquine" post="and azithromycin is associated with severe QT prolongation and"/>
   <result pre="system of the patient. Furthermore, the combination of chloroquine and" exact="azithromycin" post="is associated with severe QT prolongation and should thus"/>
   <result pre="QT prolongation and should thus be considered with care. Before" exact="chloroquine" post="can be considered safe and effective as a treatment"/>
   <result pre="is an HIV protease inhibitor that is usually combined with" exact="ritonavir" post="to increase its half-life via cytochrome P450 inhibition. Whether"/>
   <result pre="case reports describing MERS patients receiving LPV/r in combination with" exact="ribavirin" post="and interferon-alpha reported conflicting results.24,25 The preclinical and clinical"/>
   <result pre="Available at: https://www.sciencemag.org/news/2020/03/who-launches-global-megatrial-four-most-promising-coronavirus-treatments (accessed 21 April 2020). 5TouretFde LamballerieX. Of" exact="chloroquine" post="and COVID-19. Antiviral Res2020; 177: 104762. 6KeyaertsEVijgenLMaesP, et al.In"/>
   <result pre="culture. Antimicrob Agents Chemother2014; 58: 4875â€&quot;4884.24841269 8WangMCaoRZhangL, et al.Remdesivir and" exact="chloroquine" post="effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in"/>
   <result pre="vitro. Cell Res2020; 30: 269â€&quot;271.32020029 9KeyaertsELiSVijgenL, et al.Antiviral activity of" exact="chloroquine" post="against human coronavirus OC43 infection in newborn mice. Antimicrob"/>
   <result pre="Antimicrob Agents Chemother2009; 53: 3416â€&quot;3421.19506054 10YanYZouZSunY, et al. Anti-malaria drug" exact="chloroquine" post="is highly effective in treating avian influenza A H5N1"/>
   <result pre="replication in BALB/c mice. Antivir Chem Chemother2006; 17: 275â€&quot;284.17176632 12GaoJTianZYangX.Breakthrough:" exact="chloroquine" post="phosphate has shown apparent efficacy in treatment of COVID-19"/>
   <result pre="in clinical studies. Biosci Trends2020; 14: 72â€&quot;73.32074550 13GautretPLagierJ-CParolaP, et al." exact="Hydroxychloroquine" post="and azithromycin as a treatment of COVID-19: results of"/>
   <result pre="studies. Biosci Trends2020; 14: 72â€&quot;73.32074550 13GautretPLagierJ-CParolaP, et al. Hydroxychloroquine and" exact="azithromycin" post="as a treatment of COVID-19: results of an open-label"/>
   <result pre="Antimicrob Agents2014; 44: 528â€&quot;532.25288266 25KimUJWonEJKeeSJ, et al.Combination therapy with lopinavir/ritonavir," exact="ribavirin" post="and interferon-a for Middle East respiratory syndrome. Antivir Ther2016;"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7236586\results\search\drug\results.xml">
   <result pre="dyspnea (1/9). Laboratory tests showed elevated CRP (6/9), lymphopenia (5/9)," exact="alanine" post="aminotransferase (ALT), and aspartate aminotransferase (AST) (3/9). CT scans"/>
   <result pre="Antiviral treatment including oseltamivir (75 mg every 12 hours, orally)," exact="ganciclovir" post="(0.25 g every 12 hours, intravenously) and interferon (40"/>
   <result pre="All patients received treatment with antibiotics (cephalosporin, quinolones and macrolides)." exact="Methylprednisolone" post="was also used after cesarean section in 71%. All"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7236853\results\search\drug\results.xml">
   <result pre="RASi were equally prevalent among outcome groups, while beta-blockers and" exact="spironolactone" post="seem unevenly distributed with higher prevalence among patients, who"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7236857\results\search\drug\results.xml">
   <result pre="who use drugs. While the initial changes in regulation allowing" exact="buprenorphine" post="prescribing by telehealth are welcomed by providers and patients,"/>
   <result pre="to fill the gaps. Whether through efforts at opioid stewardship,1" exact="naloxone" post="distribution and education, initiation of treatment with buprenorphine,2 or"/>
   <result pre="Enforcement Administration (DEA) now allows patients to be initiated on" exact="buprenorphine" post="through a telemedicine visit, including telephone only.4 While this"/>
   <result pre="management and social work services are wholly feasible by phone." exact="Buprenorphine" post="prescribers in any setting (and especially the ED and"/>
   <result pre="ED and correctional facilities) should provide a longer duration of" exact="buprenorphine" post="prescriptions to create flexibility in coordinating follow up care."/>
   <result pre="of X-waivered providers, pharmacies have already served as locations for" exact="buprenorphine" post="initiation. During this pandemic, they should be recruited as"/>
   <result pre="should be recruited as accessible sites for the dispensation of" exact="naloxone" post="and possibly as hubs for telemedicine kiosks to access"/>
   <result pre="due to the COVID pandemic and the reduced barriers on" exact="buprenorphine" post="prescribing. While the initial changes in regulation to address"/>
   <result pre="incarceration. Health Justice2014; 2:5Published 2014 Mar 25. 8.JakubowskiAndreaFoxAaron. Defining Low-threshold" exact="Buprenorphine" post="Treatment. J Addict Med2020; 14(2):95â€&quot;98.31567596"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7237358\results\search\drug\results.xml">
   <result pre="of Plant-Derived Medicines Currently under Investigation for COVID-19 Treatment. (A)" exact="Quinine" post="was discovered as the principal bioactive compound from Cinchona"/>
   <result pre="compound from Cinchona officinalis, a South American antimalarial medicinal plant." exact="Chloroquine" post="and hydroxychloroquine are synthetic analogs of quinine and have"/>
   <result pre="Cinchona officinalis, a South American antimalarial medicinal plant. Chloroquine and" exact="hydroxychloroquine" post="are synthetic analogs of quinine and have been approved"/>
   <result pre="antimalarial medicinal plant. Chloroquine and hydroxychloroquine are synthetic analogs of" exact="quinine" post="and have been approved for treating malaria, HIV, systemic"/>
   <result pre="in the last two centuries when modern science took off." exact="Quinine" post="was isolated from Cinchona tree bark by the French"/>
   <result pre="structure fully resolved a century later (Hoffmann, 2018) (FigureÂ 1A)." exact="Quinine" post="and its synthetic analogs became some of the earliest"/>
   <result pre="medicines for treating various diseases. Vitamin C, chemically named as" exact="L-ascorbic acid" post="in honor of its activity against scurvy, was discovered"/>
   <result pre="by Ge Hong (AD 284â€&quot;346), Chinese phytochemist Tu Youyou identified" exact="artemisinin" post="from sweet wormwood in the 1970s, which led to"/>
   <result pre="Using a modern chemical biology approach, the action mechanism of" exact="artemisinin" post="was recently elucidated, which entails activation of the signature"/>
   <result pre="elucidated, which entails activation of the signature endoperoxide bridge of" exact="artemisinin" post="by heme iron enriched in the Plasmodium falciparum parasite"/>
   <result pre="preliminary clinical study in France recently showed promising results of" exact="chloroquine" post="and hydroxychloroquine in reducing the SARS-CoV-2 viral load in"/>
   <result pre="study in France recently showed promising results of chloroquine and" exact="hydroxychloroquine" post="in reducing the SARS-CoV-2 viral load in COVID-19 patients"/>
   <result pre="viral load in COVID-19 patients (Gautret etÂ al., 2020). Interestingly," exact="chloroquine" post="and hydroxychloroquine are synthetic analogs of quinine (FigureÂ 1A),"/>
   <result pre="in COVID-19 patients (Gautret etÂ al., 2020). Interestingly, chloroquine and" exact="hydroxychloroquine" post="are synthetic analogs of quinine (FigureÂ 1A), and have"/>
   <result pre="al., 2020). Interestingly, chloroquine and hydroxychloroquine are synthetic analogs of" exact="quinine" post="(FigureÂ 1A), and have previously been repurposed for treating"/>
   <result pre="arthritis, in addition to their antimalarial use. Studies of the" exact="quinine" post="scaffold showed that this class of molecules has the"/>
   <result pre="underpins their antimalarial and antiviral activities. Multiple clinical trials using" exact="chloroquine" post="and hydroxychloroquine to treat COVID-19 are currently ongoing (www.ClinicalTrials.gov)."/>
   <result pre="antimalarial and antiviral activities. Multiple clinical trials using chloroquine and" exact="hydroxychloroquine" post="to treat COVID-19 are currently ongoing (www.ClinicalTrials.gov). In China,"/>
   <result pre="virus (IAV)-induced pulmonary injury in mice (Cheng etÂ al., 2016)." exact="Ephedrine" post="and pseudoephedrine, the principal bioactive compounds of Ephedra sinica,"/>
   <result pre="activities of atractylon from Atractylodis rhizomaMol. Med. Rep.1420163704371027600871 GautretP.LagierJ.-C.ParolaP.HoangV.T.MeddebL.MailheM.DoudierB.CourjonJ.GiordanengoV.VieiraV.E.Hydroxychloroquine and" exact="azithromycin" post="as a treatment of COVID-19: results of an open-label"/>
   <result pre="Heligmosomoides bakeri (Nematoda: Heligmosomatidae)Vet. Med. Int.2011201114029321772960 WangJ.ZhangC.-J.ChiaW.N.LohC.C.Y.LiZ.LeeY.M.HeY.YuanL.-X.LimT.K.LiuM.Haem-activated promiscuous targeting of" exact="artemisinin" post="in Plasmodium falciparumNat. Commun.620151011126694030 ZhangD.ZhangB.LvJ.-T.SaR.-N.ZhangX.-M.LinZ.-J.The clinical benefits of Chinese"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7237904\results\search\drug\results.xml">
   <result pre="[4]. A follow-up clinical trial to test efficacy demonstrated that" exact="sofosbuvir" post="was unable to cure any patients with chronic HEV"/>
   <result pre="infection [5]. Recent in silico molecular docking has indicated that" exact="sofosbuvir" post="may inhibit RdRp of SARS-CoV-2 [6]. Without further extensive"/>
   <result pre="inhibit RdRp of SARS-CoV-2 [6]. Without further extensive preclinical studies," exact="sofosbuvir" post="has already entered clinical trials for treating COVID-19 [1]."/>
   <result pre="remdesivir, lopinavir/ritonavir, favipiravir, or interferon alpha, and the antimalarial drugs" exact="chloroquine" post="and hydroxychloroquine [1]. Given that many studies have small"/>
   <result pre="favipiravir, or interferon alpha, and the antimalarial drugs chloroquine and" exact="hydroxychloroquine" post="[1]. Given that many studies have small patient sizes"/>
   <result pre="this approach can also be applicable to the trials comparing" exact="hydroxychloroquine" post="with standard treatment (Clinical Trial Number: NCT04315948, NCT04261517, and"/>
   <result pre="the management of the COVID-19 pandemicTrends Pharmacol. Sci.41202036338232291112 2.WangM.Remdesivir and" exact="chloroquine" post="effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in"/>
   <result pre="for hepatitis E virus?Lancet Gastroenterol. Hepatol.22017154155 5.CornbergM.Efficacy and safety of" exact="sofosbuvir" post="monotherapy in patients with chronic hepatitis E-The HepNet SofE"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7237932\results\search\drug\results.xml">
   <result pre="inhibitor combination of lopinavir-ritonavir, chloroquine, hydroxychloroquine, and remdesivir. Lopinavir-ritonavir and" exact="hydroxychloroquine" post="have not shown clear clinical benefits to date, although"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7238722\results\search\drug\results.xml">
   <result pre="heating to 56â€‰Â°C for 30Â min may inactivate the virus." exact="Chlorhexidine" post="is not recommended as aÂ disinfectant [11]. The clinical"/>
   <result pre="ARDS, and death rates were lower than those treated with" exact="ribavirin" post="and aÂ corticosteroid [1]. Most studies published have not"/>
   <result pre="are used in coronavirus infections. In fact, the use of" exact="methylprednisolone" post="as an intervention for SARS patients was associated with"/>
   <result pre="cell line sensitive to SARS-CoVâ€‘2 [6]. The same authors tested" exact="chloroquine" post="and concluded â€œremdesivir and chloroquine are highly effective in"/>
   <result pre="[6]. The same authors tested chloroquine and concluded â€œremdesivir and" exact="chloroquine" post="are highly effective in the control of COVID-19 infection"/>
   <result pre="COVID-19 [6]. Finally, neuraminidase inhibitors, such as oral oseltamivir, inhaled" exact="zanamivir" post="and intravenous peramivir are approved antiviral treatments for influenza"/>
   <result pre="neuraminidase inhibitors, such as oral oseltamivir, inhaled zanamivir and intravenous" exact="peramivir" post="are approved antiviral treatments for influenza and MERS infections;"/>
   <result pre="in South Korea: an epidemiological outbreak studyLancet2016388994100110.1016/S0140-6736(16)30623-727402381 6.WangMCoaRZhangLet al.Remdesivir and" exact="chloroquine" post="effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7238951\results\search\drug\results.xml">
   <result pre="2013 that derives primarily from commonly injected illicit opioids (e.g.," exact="heroin" post="and fentanyl) (2). This injection drug use behavior has"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7239338\results\search\drug\results.xml">
   <result pre="100 antiviral drugs have been approved since the approval of" exact="idoxuridine" post="in 1963 (an antiâ€�herpes virus drug), these molecules are"/>
   <result pre="of multiple proâ€�inflammatory mediators, including TNFÎ±, interleukin (IL)â€�1, ILâ€�6, and" exact="nitric oxide" post="by activated monocytes/macrophages.22 Consistent with EVD pathogenesis, high levels"/>
   <result pre="antiviral efficacy in vitro or in vivo. Combining favipiravir and" exact="ribavirin" post="in Lassa fever Favipiravir was also reported to have"/>
   <result pre="Indeed. several in vitro studies and mice studies showed that" exact="ribavirin" post="may potentiate the efficacy of favipiravir against various RNA"/>
   <result pre="Lassa fever virus infection.78 In order to better understand how" exact="ribavirin" post="may potentiate the efficacy of favipiravir in mice, we"/>
   <result pre="In order to gain information on the potential role of" exact="ribavirin" post="on loss cell death, we assumed that the level"/>
   <result pre="in HCV to quantify the levels of hepatocytes injury using" exact="alanine" post="aminotransferase dynamics79: d A d t = s x"/>
   <result pre="infected cells. We assumed four potential mechanisms of action for" exact="ribavirin" post="that could (i) act as a mutagen limiting the"/>
   <result pre="Our analyses did not find a statistically significant effect of" exact="ribavirin" post="in reducing viral production, however, the best description to"/>
   <result pre="to the data was obtained by assuming an effect of" exact="ribavirin" post="in preventing infected cells from dying. This possibly explains"/>
   <result pre="also explain the viral plateau observed at peak viremia in" exact="ribavirin" post="monotherapy group.80 Thus, our model suggested that ribavirin did"/>
   <result pre="viremia in ribavirin monotherapy group.80 Thus, our model suggested that" exact="ribavirin" post="did not act much as a direct antiviral against"/>
   <result pre="virus, it is unlikely that the combination of favipiravir and" exact="ribavirin" post="is relevant against EBOV, as no gain in terms"/>
   <result pre="new epidemic clusters arising. Likewise, the combination of favipiravir and" exact="ribavirin" post="in Lassa virus hemorrhagic fever could be of relevance"/>
   <result pre="9Oestereich, L.et alEfficacy of favipiravir alone and in combination with" exact="ribavirin" post="in a lethal, immunocompetent mouse model for Lassa fever."/>
   <result pre="66Dixit, N.M., Laydenâ€�Almer, J.E., Layden, T.J. &amp;amp; Perelson, A.S.Modelling how" exact="ribavirin" post="improves interferon response rates in hepatitis C virus infection."/>
   <result pre="kinetic and modeling analyses indicate similar time to cure among" exact="sofosbuvir" post="combination regimens with daclatasvir, simeprevir or ledipasvir. J. Hepatol.64,"/>
   <result pre="similar time to cure among sofosbuvir combination regimens with daclatasvir," exact="simeprevir" post="or ledipasvir. J. Hepatol.64, 1232â€&quot;1239 (2016).26907973 68Madelain, V.et alEbola"/>
   <result pre="in macaques. Emerg. Infect. Dis.24, 1696â€&quot;1699 (2018).29882740 77Westover, J.B.et alLowâ€�dose" exact="ribavirin" post="potentiates the antiviral activity of favipiravir against hemorrhagic fever"/>
   <result pre="fever viruses. Antiviral Res.126, 62â€&quot;68 (2016).26711718 78Raabe, V.N.et alFavipiravir and" exact="ribavirin" post="treatment of epidemiologically linked cases of Lassa fever. Clin."/>
   <result pre="Laydenâ€�Almer, J., Powers, K.A., Layden, T.J. &amp;amp; Perelson, A.S.Dynamics of" exact="alanine" post="aminotransferase during hepatitis C virus treatment. Hepatology38, 509â€&quot;517 (2003).12883496"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7239775\results\search\drug\results.xml">
   <result pre="15Soo YOYCheng Y.WongR.Retrospective comparison of convalescent plasma with continuing high-dose" exact="methylprednisolone" post="treatment in SARS patientsClin Microbiol Infect10200467667815214887 16ArabiY.BalkhyH.HajeerA.H.Feasibility, safety, clinical,"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7241406\results\search\drug\results.xml">
   <result pre="appear efficacious via systemic administration. A combination such as hydroxychloroquine," exact="azithromycin" post="and zinc, all of which have previously been used"/>
   <result pre="with into the nasopharynx accesses lungs and gut. â€¢Local hydroxychloroquine," exact="azithromycin" post="and zinc could block viral binding. â€¢This may offer"/>
   <result pre="anti-viral role. Crystallography studies demonstrate that while the ACE inhibitor" exact="lisinopril" post="binds in a region near the centre of the"/>
   <result pre="receptor near the N terminal [39], so direct blocking by" exact="lisinopril" post="of the virus attachment site seems unlikely. However, the"/>
   <result pre="of FDA-approved drug libraries identified a number of drugs including" exact="chloroquine" post="as potentially having anti-coronavirus actions [71] and therefore potentially"/>
   <result pre="(for SARS-CoV-2-unrelated disease) In Vivo In Vitro Clinical Human Animal" exact="Chloroquine" post="Phosphate +72 -a73 Â±74 +75,76(0.03%) 0 OHChloroquine +72 0"/>
   <result pre="-a73 Â±74 +75,76(0.03%) 0 OHChloroquine +72 0 Â±74 0 0" exact="Azithromycin" post="+77 0 Â±77 +78,79(1â€&quot;1.5% +80,81 (0.2â€&quot;1.5%) Zinc +aa82s 0"/>
   <result pre="denotes equivocal results, 0 denotes lack of studies. aFor SARS-CoV." exact="Chloroquine" post="has long been used in the treatment of malaria"/>
   <result pre="well as in oncology and for pediatric inflammatory disease. However," exact="chloroquine" post="has direct antiviral effects, inhibiting pH-dependent steps of the"/>
   <result pre="to interfere with terminal glycosylation of ACE2 [[87], [88], [89]]." exact="Chloroquine" post="also has immuno-modulatory effects [86,90], suppressing the production/release of"/>
   <result pre="severe inflammatory cascade associated with severe COVID-19 disease [86]. Recently," exact="hydroxychloroquine" post="was found to be more potent than chloroquine at"/>
   <result pre="[86]. Recently, hydroxychloroquine was found to be more potent than" exact="chloroquine" post="at inhibiting SARS-CoV-2 in vitro [91], fortuitous, since it"/>
   <result pre="derivative [92]. A recent systematic review of clinical trials utilising" exact="chloroquine" post="or hydroxychloroquine [74] concluded that 5/7 trials had shown"/>
   <result pre="A recent systematic review of clinical trials utilising chloroquine or" exact="hydroxychloroquine" post="[74] concluded that 5/7 trials had shown favorable outcomes"/>
   <result pre="study, a pilot observational study [93] showed that use of" exact="hydroxychloroquine" post="and azithromycin demonstrated apparent improved clinical outcomes in 65/80"/>
   <result pre="pilot observational study [93] showed that use of hydroxychloroquine and" exact="azithromycin" post="demonstrated apparent improved clinical outcomes in 65/80 patients, expanding"/>
   <result pre="are needed and have been called for [74]. While systemic" exact="chloroquine" post="and its derivatives appear to be associated with relatively"/>
   <result pre="[94] and this may be exacerbated by combination treatment with" exact="azithromycin" post="[74]. The well-known association with irreversible visual loss due"/>
   <result pre="concert with zinc have been explained by the fact that" exact="chloroquine" post="acts as a zinc ionophore [100], significantly, inhibiting cellular"/>
   <result pre="viral replication. For this reason, combination treatment for Covid-19 with" exact="chloroquine" post="and zinc has been suggested [102], although this intervention"/>
   <result pre="have all been used topically in the eye (Table 2)." exact="Chloroquine" post="as 0.03% chloroquine phosphate eye drops have apparently been"/>
   <result pre="used topically in the eye (Table 2). Chloroquine as 0.03%" exact="chloroquine" post="phosphate eye drops have apparently been efficacious in the"/>
   <result pre="effects were not reported, however there is a report of" exact="chloroquine" post="keratopathy in workers chronically exposed to chloroquine dust [103]."/>
   <result pre="a report of chloroquine keratopathy in workers chronically exposed to" exact="chloroquine" post="dust [103]. Chronic usage is unlikely in the setting"/>
   <result pre="glaucoma [104]. In this class of drugs, agents such as" exact="telmisartan" post="are long acting, with a mean half-life of 24Â"/>
   <result pre="drops or as an excipient, zinc sulphate (0.25%) [83]. Since" exact="chloroquine" post="and ACE2 inhibitors seem to act at different parts"/>
   <result pre="a risk factor for infection but these are unconfirmed [107]." exact="Azithromycin" post="has also previously been safely used topically in the"/>
   <result pre="initial local delivery of a combination of chloroquine, zinc and" exact="azithromycin" post="to the eyelids and ocular surface with eye drops"/>
   <result pre="syndrome coronavirus replication in cell cultureAntimicrob Agents Chemother5820144875488424841269 72WangM.CaoR.ZhangL.Remdesivir and" exact="chloroquine" post="effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in"/>
   <result pre="Chem Chemother17200627528417176632 74ChowdhuryM.S.RathodJ.GernsheimerJ.A rapid systematic review of clinical trials utilizing" exact="chloroquine" post="and hydroxychloroquine as a treatment for COVID-19Acad Emerg Med2020"/>
   <result pre="74ChowdhuryM.S.RathodJ.GernsheimerJ.A rapid systematic review of clinical trials utilizing chloroquine and" exact="hydroxychloroquine" post="as a treatment for COVID-19Acad Emerg Med2020 May 210.1111/acem.14005.Mar9:ciaa237"/>
   <result pre="May 210.1111/acem.14005.Mar9:ciaa237 75BhavsarAnkita SamirBhavsarSamir G.JainSunita M.Evaluation of the effects of" exact="chloroquine" post="phosphate eye drops in patients with dry eye syndromeInt"/>
   <result pre="syndromeInt J Biomed Adv Res22011198214 76TitiyalJ.S.KaurM.FaleraR.BharghavaA.SahR.SenS.Efficacy and safety of topical" exact="chloroquine" post="in mild to moderate dry eye diseaseCurr Eye Res4420191306131231283891"/>
   <result pre="Eye Res4420191306131231283891 77DamleB.VourvahisM.WangE.Clinical pharmacology perspectives on the antiviral activity of" exact="azithromycin" post="and use in COVID-19Clin Pharmacol Ther2020 Apr 1710.1002/cpt.1857 78OpitzD.L.HarthanJ.S.Review"/>
   <result pre="and use in COVID-19Clin Pharmacol Ther2020 Apr 1710.1002/cpt.1857 78OpitzD.L.HarthanJ.S.Review of" exact="azithromycin" post="ophthalmic 1% solution (AzaSite(Â®)) for the treatment of ocular"/>
   <result pre="79AmzaA.GoldschmidtP.EinterzE.Elimination of active trachoma after two topical mass treatments with" exact="azithromycin" post="1.5% eye dropsPLoS Neglected Trop Dis4112010e895 80KuehneJ.J.YuA.L.HollandG.N.Corneal pharmacokinetics of"/>
   <result pre="eye dropsPLoS Neglected Trop Dis4112010e895 80KuehneJ.J.YuA.L.HollandG.N.Corneal pharmacokinetics of topically applied" exact="azithromycin" post="and clarithromycinAm J Ophthalmol138200454755315488779 81TabbaraK.F.KotbA.A.HammoudaE.F.Effects of dehydration on corneal"/>
   <result pre="Ophthalmol138200454755315488779 81TabbaraK.F.KotbA.A.HammoudaE.F.Effects of dehydration on corneal tissue absorption of topical" exact="azithromycin" post="in rabbitsCurr Eye Res30200591591816251129 82te VelthuisA.J.van den WormS.H.SimsA.C.BaricR.S.SnijderE.J.van HemertM.J.Zn(2+)"/>
   <result pre="cause more damage than help fight COVID-19Microb Infect202020S1286S457930071-X 86SavarinoA.BoelaertJ.R.CassoneA.MajoriG.CaudaR.Effects of" exact="chloroquine" post="on viral infections: an old drug against today's diseases?Lancet"/>
   <result pre="vitro antiviral activity and projection of optimized dosing design of" exact="hydroxychloroquine" post="for the treatment of severe acute respiratory syndrome coronavirus"/>
   <result pre="vitroCell Discovery62020161932194981 93GautretP.LagierJ.C.ParolaP.Clinical and microbiological effect of a combination of" exact="hydroxychloroquine" post="and azithromycin in 80 COVID-19 patients with at least"/>
   <result pre="93GautretP.LagierJ.C.ParolaP.Clinical and microbiological effect of a combination of hydroxychloroquine and" exact="azithromycin" post="in 80 COVID-19 patients with at least a six-day"/>
   <result pre="studyTrav Med Infect Dis2020 Apr 11101663 94SalehM.GabrielsJ.ChangD.The effect of chloroquine," exact="hydroxychloroquine" post="and azithromycin on the corrected QT interval in patients"/>
   <result pre="Infect Dis2020 Apr 11101663 94SalehM.GabrielsJ.ChangD.The effect of chloroquine, hydroxychloroquine and" exact="azithromycin" post="on the corrected QT interval in patients with SARS-CoV-2"/>
   <result pre="Apr 29Circ Arrhythm Electrophysiol 95YusufI.H.SharmaS.LuqmaniR.DownesS.M.Hydroxychloroquine retinopathyEye31201782884528282061 96PasaogluI.OnmezF.E.Macular toxicity after short-term" exact="hydroxychloroquine" post="therapyIndian J Ophthalmol67201928929230672499 97ShroyerN.F.LewisR.A.LupskiJ.R.Analysis of the ABCR (ABCA4) gene"/>
   <result pre="ABCR (ABCA4) gene in 4-aminoquinoline retinopathy: is retinal toxicity by" exact="chloroquine" post="and hydroxychloroquine related to Stargardt disease?Am J Ophthalmol131200176176611384574 98HednerT.SamulessonO.WÃ¤hrborgP.WadenvikH.UngK.A.EkbomA.Nabumetone:"/>
   <result pre="gene in 4-aminoquinoline retinopathy: is retinal toxicity by chloroquine and" exact="hydroxychloroquine" post="related to Stargardt disease?Am J Ophthalmol131200176176611384574 98HednerT.SamulessonO.WÃ¤hrborgP.WadenvikH.UngK.A.EkbomA.Nabumetone: therapeutic use"/>
   <result pre="souffrant de toxicitÃ© maculaire aux antipaludÃ©ens de synthÃ¨se [Variability of" exact="chloroquine" post="and hydroxychloroquine retinopathy among various ethnicities]J Fr Ophtalmol41201836336729678344 100XueJ.MoyerA.PengB.WuJ.HannafonB.N.DingW.Q.Chloroquine"/>
   <result pre="toxicitÃ© maculaire aux antipaludÃ©ens de synthÃ¨se [Variability of chloroquine and" exact="hydroxychloroquine" post="retinopathy among various ethnicities]J Fr Ophtalmol41201836336729678344 100XueJ.MoyerA.PengB.WuJ.HannafonB.N.DingW.Q.Chloroquine is a"/>
   <result pre="of viral RNA-dependent RNA polymeraseJ Virol912017e00754-17 102ShittuM.O.AfolamiO.I.Improving the efficacy of" exact="Chloroquine" post="and Hydroxychloroquine against SARS-CoV-2 may require Zinc additives -"/>
   <result pre="RNA-dependent RNA polymeraseJ Virol912017e00754-17 102ShittuM.O.AfolamiO.I.Improving the efficacy of Chloroquine and" exact="Hydroxychloroquine" post="against SARS-CoV-2 may require Zinc additives - a better"/>
   <result pre="future COVID-19 clinical trialsInf Med282020192197Ahead of print 103EriksenL.S.Chloroquine keratopathy in" exact="chloroquine" post="workers after topical dust exponation. A case reportActa Ophthalmol571979823825525306"/>
   <result pre="Virol2020 Mar 16e210310.1002/rmv.2103Epub ahead of print. PMID: 32175637 108TettS.E.CutlerD.J.DayR.O.BrownK.F.Bioavailability of" exact="hydroxychloroquine" post="tablets in healthy volunteersBr J Clin Pharmacol2719897717792757893 109XuH.ZhongL.DengJ.PengJ.DanH.ZengX.LiT.ChenQ.High expression"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7242729\results\search\drug\results.xml">
   <result pre="used to slow or treat COVID-19 disease. Here, we suggest" exact="melatonin" post="be given consideration for prophylactic use or treatment alone"/>
   <result pre="increased age. Under the current critical conditions, large doses of" exact="melatonin" post="alone or in combination with currently-recommended drugs, e.g., hydroxychloroquine/chloroquine,"/>
   <result pre="drugs, e.g., hydroxychloroquine/chloroquine, to resist COVID-19 infection would seem judicious." exact="melatonin" post="COVID-19 SARS-CoV-2 treatment-drug prevention &amp;amp; control Funding FundaciÃƒÂ³n Canaria"/>
   <result pre="a clinical trial called SOLIDARITY to investigate 4 potential treatments:" exact="lopinavir" post="and ritonavir plus interferon-beta, lopinavir and ritonavir, chloroquine/hydroxychloroquine, and"/>
   <result pre="trial called SOLIDARITY to investigate 4 potential treatments: lopinavir and" exact="ritonavir" post="plus interferon-beta, lopinavir and ritonavir, chloroquine/hydroxychloroquine, and remdesivir (7)."/>
   <result pre="to investigate 4 potential treatments: lopinavir and ritonavir plus interferon-beta," exact="lopinavir" post="and ritonavir, chloroquine/hydroxychloroquine, and remdesivir (7). The medical profession"/>
   <result pre="for a cheap, viable, and readily available treatment such as" exact="melatonin" post="(8). Melatonin is synthesized from tryptophan in the pineal"/>
   <result pre="associated with mitochondria. It is noteworthy that high levels of" exact="melatonin" post="play positive roles in health and aging. Melatonin, a"/>
   <result pre="Herein, we review the current evidence for a role of" exact="melatonin" post="as a COVID-19 treatment. Since the clinical data is"/>
   <result pre="clinical data is very limited, we propose the use of" exact="melatonin" post="in patients with COVID-19 to reduce morbidity and mortality."/>
   <result pre="even of non-infected cells (13). COVID-19 infection may attack the" exact="melatonin" post="synthetic pathway resulting in reduced melatonin levels at a"/>
   <result pre="infection may attack the melatonin synthetic pathway resulting in reduced" exact="melatonin" post="levels at a time when melatonin is most needed"/>
   <result pre="pathway resulting in reduced melatonin levels at a time when" exact="melatonin" post="is most needed (14). The uncontrolled innate immune response"/>
   <result pre="16). The pineal gland produces and maintains the concentration of" exact="melatonin" post="in the blood. The melatonin synthesized in the pineal"/>
   <result pre="and maintains the concentration of melatonin in the blood. The" exact="melatonin" post="synthesized in the pineal gland is &amp;lt;5% of the"/>
   <result pre="synthesized in the pineal gland is &amp;lt;5% of the total" exact="melatonin" post="produced. The melatonin produced in the mitochondria is not"/>
   <result pre="pineal gland is &amp;lt;5% of the total melatonin produced. The" exact="melatonin" post="produced in the mitochondria is not discharged into the"/>
   <result pre="it (15). If patients do not generate sufficient amounts of" exact="melatonin" post="their health status is likely compromised (16). Autophagy plays"/>
   <result pre="different stages of the viral life cycle. The fact that" exact="melatonin" post="is a regulator of autophagy due to its properties"/>
   <result pre="human papilloma, and inter alia, have demonstrated the success of" exact="melatonin" post="in protecting against viral infections. There is no evidence"/>
   <result pre="in protecting against viral infections. There is no evidence that" exact="melatonin" post="is viricidal but rather it reduces the severity of"/>
   <result pre="this disease. Melatonin, the Elderly &amp;amp; COVID-19 A relationship between" exact="melatonin" post="and aging has been suggested, due to a decrease"/>
   <result pre="suggested, due to a decrease in the concentration of nocturnal" exact="melatonin" post="levels in the elderly (23). It has been hypothesized"/>
   <result pre="levels in the elderly (23). It has been hypothesized that" exact="melatonin" post="can prolong life (24). The relationship of melatonin with"/>
   <result pre="hypothesized that melatonin can prolong life (24). The relationship of" exact="melatonin" post="with aging involves three potential mechanisms: first, melatonin is"/>
   <result pre="relationship of melatonin with aging involves three potential mechanisms: first," exact="melatonin" post="is a key molecule in regular circadian rhythms (25);"/>
   <result pre="is a key molecule in regular circadian rhythms (25); second," exact="melatonin" post="prevents cardiolipin peroxidation and regulates the synthesis of mitochondrial"/>
   <result pre="peroxidation and regulates the synthesis of mitochondrial proteins (26); finally," exact="melatonin" post="secreted by leukocytes exerts a powerful immunomodulatory function (24)."/>
   <result pre="COVID-19 (25). Recent studies have shown that high levels of" exact="melatonin" post="in the blood play a positive role in health"/>
   <result pre="health and aging (27). These findings support a rationale for" exact="melatonin" post="use in elderly suffering with COVID-19. Melatonin, Medical Comorbidities"/>
   <result pre="HEIJO-KYO cohort (cohort of elderly Japanese patients), urinary excretion of" exact="melatonin" post="was associated with reduced nocturnal systolic blood pressure, independent"/>
   <result pre="other cardiovascular risk factors. More precisely, an increase in urinary" exact="melatonin" post="excretion from 4.2 to 10.5 Î¼g caused a 2"/>
   <result pre="mmHg decrease in nocturnal systolic blood pressure. Patients who took" exact="melatonin" post="at a dose of 2â€&quot;5 mg/day for 7â€&quot;90 days"/>
   <result pre="is a risk factor for cardiovascular disease. In different studies," exact="melatonin" post="has been shown to have anti-obesity effects (30, 31)."/>
   <result pre="has been shown to have anti-obesity effects (30, 31). Taking" exact="melatonin" post="reduces intra-abdominal visceral fat deposition and body weight. Its"/>
   <result pre="melatonin, showing that diabetic subjects have a lower concentration of" exact="melatonin" post="(33). Furthermore, decreased blood melatonin levels have been documented"/>
   <result pre="have a lower concentration of melatonin (33). Furthermore, decreased blood" exact="melatonin" post="levels have been documented in patients with insulin resistance"/>
   <result pre="intolerance (34). The results of several studies suggest that low" exact="melatonin" post="production is associated with an increased risk of cardiovascular"/>
   <result pre="prognosis for patients with COVID-19. Published reports routinely show that" exact="melatonin" post="reduces the consequences of the comorbidities in patients with"/>
   <result pre="Prevention in the Population (Elderly &amp;amp; Medical Comorbidities) While physiological" exact="melatonin" post="concentrations in biological fluids oscillate between 10âˆ’10 and 10âˆ’11"/>
   <result pre="justifying the need of a more generous supplementation of exogenous" exact="melatonin" post="in life-threatening pathologies. Oral melatonin use by humans is"/>
   <result pre="more generous supplementation of exogenous melatonin in life-threatening pathologies. Oral" exact="melatonin" post="use by humans is generally considered safe, with minor"/>
   <result pre="headache, drowsiness, etc. (43). To date, the best dose of" exact="melatonin" post="in older adults has not been determined, as its"/>
   <result pre="some of which were not blinded, the efficacy of oral" exact="melatonin" post="administration (1â€&quot;20 mg) was evaluated caused only a few"/>
   <result pre="drowsiness (45). In elderly patients with medical comorbidities, treatment with" exact="melatonin" post="is beneficial, as it strengthens the immune response. We"/>
   <result pre="bedtime to better simulate the normal physiological circadian rhythm of" exact="melatonin" post="(Figure 1). Furthermore, it may be beneficial in people"/>
   <result pre="contracting COVID-19 infection, local health workers, where preventive treatment with" exact="melatonin" post="would favor maximizing the immune response, along with anti-inflammatory"/>
   <result pre="the clinical features parallel those of COVID-19 viral infection; moreover," exact="melatonin" post="has been demonstrated to relieve many of the symptoms"/>
   <result pre="situation and in consideration of evidence-based medicine, the efficacy of" exact="melatonin" post="and its high pharmacological safety profile supports its use"/>
   <result pre="Our research group has extensive experience in the use of" exact="melatonin" post="in the context of cardiovascular physiology. Melatonin can be"/>
   <result pre="years ago in which he gave humans one gram of" exact="melatonin" post="daily for a month with no untoward effect. Melatonin"/>
   <result pre="no time or clinical trials to test the efficacy of" exact="melatonin" post="at different concentrations, we suggest the use of melatonin"/>
   <result pre="of melatonin at different concentrations, we suggest the use of" exact="melatonin" post="(100 or 400 mg per day) as an adjunct,"/>
   <result pre="available (Figure 2). Figure 2 Therapeutic algorithm for use of" exact="melatonin" post="in patients with COVID-19. Melatonin will likely reduce the"/>
   <result pre="patients with COVID-19. Melatonin will likely reduce the toxicity of" exact="chloroquine" post="and increase its efficacy. BID, twice daily; PO, per"/>
   <result pre="(51) and Zhang et al. (8), support the use of" exact="melatonin" post="in patients with COVID-19. We agree with the suggestion"/>
   <result pre="COVID-19. We agree with the suggestion by those authors that" exact="melatonin" post="should be given consideration for prophylactic use or treatment"/>
   <result pre="16.SedovaKABernikovaOGCuprovaJIIvanovaADKutaevaGAPlissMGet al.. Association between antiarrhythmic, electrophysiological, and antioxidative effects of" exact="melatonin" post="in ischemia/reperfusion. Int J Mol Sci. (2019) 20:E6331. 10.3390/ijms2024633131847485"/>
   <result pre="Mol Sci. (2019) 20:E6331. 10.3390/ijms2024633131847485 17.BogaJACaballeroBPotesYPerez-MartinezZReiterRJVega-NaredoIet al.. Therapeutic potential of" exact="melatonin" post="related to its role as an autophagy regulator: a"/>
   <result pre="review. J Pineal Res. (2019) 66:e12534. 10.1111/jpi.1253430329173 18.AndersonGMaesMMarkusRPRodriguezM. Ebola virus:" exact="melatonin" post="as a readily available treatment option. J Med Virol."/>
   <result pre="Med Virol. (2015) 87:537â€&quot;43. 10.1002/jmv.2413025611054 19.PaemaneeAHitakarunARoytrakulSSmithDR. Screening of melatonin, Î±-tocopherol," exact="folic acid," post="acetyl-L-carnitine and resveratrol for anti-dengue 2 virus activity. BMC"/>
   <result pre="ahead of print]. 32220033 26.MajidiniaMReiterRJShakouriSKMohebbiIRastegarMKavianiMet al.. The multiple functions of" exact="melatonin" post="in regenerative medicine. Ageing Res Rev. (2018) 45:33â€&quot;52. 10.1016/j.arr.2018.04.00329630951"/>
   <result pre="mechanisms. J Pineal Res. (2013) 55:325â€&quot;56. 10.1111/jpi.1209024112071 28.ObayashiKSaekiKToneNKurumataniN. Relationship between" exact="melatonin" post="secretion and nighttime blood pressure in elderly individuals with"/>
   <result pre="meta-analyses. Br J Clin Pharmacol. (2017) 83:163â€&quot;71. 10.1111/bcp.1290226852373 30.GubinDGGubinGDGaponLIWeinertD. Daily" exact="melatonin" post="administration attenuates age-dependent disturbances of cardiovascular rhythms. Curr Aging"/>
   <result pre="cardiovascular rhythms. Curr Aging Sci. (2016) 9:5â€&quot;13. 10.2174/187460980966615113022001126632428 31.ImenshahidiMKarimiGHosseinzadehHEffects of" exact="melatonin" post="on cardiovascular risk factors and metabolic syndrome: a comprehensive"/>
   <result pre="Naunyn SchmiedebergsArch Pharmacol. (2020) 393:521â€&quot;36. 10.1007/s00210-020-01822-4 32.PradoNJFerderLManuchaWDiezER. Anti-inflammatory effects of" exact="melatonin" post="in obesity and hypertension. Curr Hypertens Rep. (2018) 20:45."/>
   <result pre="10.1016/j.ijcard.2016.07.05627404706 36.Dominguez-RodriguezAAbreu-GonzalezPde la Torre-HernandezJMConsuegra-SanchezLPiccoloRGonzalez-GonzalezJet al.. Usefulness of early treatment with" exact="melatonin" post="to reduce infarct size in patients with ST-segment elevation"/>
   <result pre="ST-segment elevation myocardial infarction receiving percutaneous coronary intervention (from the" exact="melatonin" post="adjunct in the acute myocardial infarction treated with angioplasty"/>
   <result pre="10.1016/S0735-1097(17)34668-528645475 37.Dominguez-RodriguezAAbreu-GonzalezPde la Torre-HernandezJMGonzalez-GonzalezJGarcia-CamareroTConsuegra-SanchezLet al.. Effect of intravenous and intracoronary" exact="melatonin" post="as an adjunct to primary percutaneous coronary intervention for"/>
   <result pre="coronary intervention for acute ST-elevation myocardial infarction: results of the" exact="melatonin" post="adjunct in the acute myocardial infarction treated with angioplasty"/>
   <result pre="ahead of print]. 22546772 42.NogueiraLMSampsonJNChuLWYuKAndrioleGChurchTet al.. Individual variations in serum" exact="melatonin" post="levels through time: implications for epidemiologic studies. PLoS ONE."/>
   <result pre="12 (Suppl 1):S54â€&quot;S65. 10.21037/jtd.2019.12.8532148926 44.VuralEMvan MunsterBCde RooijSE. Optimal dosages for" exact="melatonin" post="supplementation therapy in older adults: a systematic review of"/>
   <result pre="Cell Discov. (2020) 6:14. 10.1038/s41421-020-0153-332194980 49.NordlundJJLernerAB. The effects of oral" exact="melatonin" post="on skin color and on the release of pituitary"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7242884\results\search\drug\results.xml">
   <result pre="affordable antiretroviral supplies. Specifically, both sought to procure and provide" exact="efavirenz" post="(marketed as Sustiva by Merck) and lopinavir/ritonavir (marketed as"/>
   <result pre="efavirenz (marketed as Sustiva by Merck) and lopinavir/ritonavir (marketed as" exact="Kaletra" post="by AbbVie, then Abbott Laboratories) to their patients. In"/>
   <result pre="their patients. In initial price negotiations with Thailand, Merck offered" exact="efavirenz" post="at the price of US$500 per patient per year"/>
   <result pre="drugs from India at a significantly lowered cost â€&quot; generic" exact="efavirenz" post="at US$224 PPPY and generic lopinavir/ritonavir at US$676 PPPY"/>
   <result pre="PPPY [8]. Like Thailand, Brazil issued a compulsory license for" exact="efavirenz" post="in 2007. Merck initially offered efavirenz to Brazil at"/>
   <result pre="a compulsory license for efavirenz in 2007. Merck initially offered" exact="efavirenz" post="to Brazil at the price of US$760 PPPY. By"/>
   <result pre="compulsory license for efavirenz, Brazil was able to generically import" exact="efavirenz" post="at US$170 per patient/y. However, unlike Thailand, Brazil did"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7242950\results\search\drug\results.xml">
   <result pre="2003 when Savarino et al. hypothesized the possible usefulness of" exact="chloroquine" post="and hydroxychloroquine in the treatment of SARS-CoV,1 prompting several"/>
   <result pre="Savarino et al. hypothesized the possible usefulness of chloroquine and" exact="hydroxychloroquine" post="in the treatment of SARS-CoV,1 prompting several studies in"/>
   <result pre="immune system,5, 7 the combined antiviral and immunomodulatory action of" exact="hydroxychloroquine" post="makes its use pathophysiologically attractive. The first study of"/>
   <result pre="use pathophysiologically attractive. The first study of the use of" exact="chloroquine" post="in coronavirus-19 infection was conducted in China and was"/>
   <result pre="assess the effect, they measured EC50, the minimum concentration of" exact="chloroquine" post="needed to inhibit 50% of the virus, and CC50,"/>
   <result pre="harming the organism, as was seen in the case of" exact="chloroquine" post="and remdesivir.8 Since chloroquine works by preventing the entry"/>
   <result pre="was seen in the case of chloroquine and remdesivir.8 Since" exact="chloroquine" post="works by preventing the entry of the virus into"/>
   <result pre="treatment regimens were tested that verified the inhibitory potential of" exact="chloroquine" post="before and after the Vero cells infection, while remdesivir"/>
   <result pre="infection already established.8 The fact that the concentration with which" exact="chloroquine" post="managed to inhibit 90% of the pathogen, of 6.90Â"/>
   <result pre="Given this evidence, the article itself recommended the use of" exact="chloroquine" post="phosphate in patients with COVID-19,9 a recommendation which was"/>
   <result pre="On 9th March, the second in vitro clinical trial of" exact="chloroquine" post="was published, this time comparing this drug with another"/>
   <result pre="by the virus. This study revealed that the EC50 of" exact="hydroxychloroquine" post="was lower than that of chloroquine, both in therapeutic"/>
   <result pre="therapeutic and prophylactic use, which translated into greater efficacy of" exact="hydroxychloroquine" post="compared to its precursor. Likewise, the efficacy was greater"/>
   <result pre="57.1% of the patients who received 200Â daily mg of" exact="hydroxychloroquine" post="sulphate for 10 days, and 100% of those who"/>
   <result pre="days, and 100% of those who received the combination of" exact="hydroxychloroquine" post="and azithromycin, the latter at doses of 500Â mg"/>
   <result pre="of pneumonia among the group treated with 400Â mg/day of" exact="hydroxychloroquine" post="for 5 days (80.6%) compared to the control group"/>
   <result pre="and optimize the treatment offered. In addition, the use of" exact="hydroxychloroquine" post="has the incentive of its low price in relation"/>
   <result pre="efficacy and safety of the administration of 400Â mg of" exact="hydroxychloroquine" post="together with the different treatments recommended by the Chinese"/>
   <result pre="at the doses it is intended to be used because" exact="chloroquine" post="and/or hydroxychloroquine are used at high doses in the"/>
   <result pre="doses it is intended to be used because chloroquine and/or" exact="hydroxychloroquine" post="are used at high doses in the acute attack"/>
   <result pre="studies confirm that the cardiac complications reported in case of" exact="hydroxychloroquine" post="overdose, a risk that we can face with short"/>
   <result pre="Medicines.8, 12, 14 The evidence for the concomitant use of" exact="azithromycin" post="and chloroquine is more limited. Although in a 2011"/>
   <result pre="14 The evidence for the concomitant use of azithromycin and" exact="chloroquine" post="is more limited. Although in a 2011 article evaluating"/>
   <result pre="adverse events such as the presence of nausea associated with" exact="azithromycin" post="were reported,20 a recent study of 84 patients with"/>
   <result pre="a recent study of 84 patients with COVID-19 treated with" exact="hydroxychloroquine" post="and azithromycin demonstrates QTc interval prolongation, from 435Â Â±Â"/>
   <result pre="study of 84 patients with COVID-19 treated with hydroxychloroquine and" exact="azithromycin" post="demonstrates QTc interval prolongation, from 435Â Â±Â 24Â ms"/>
   <result pre="any case, a multinational study on the safety profile of" exact="hydroxychloroquine" post="alone and in combination with azithromycin is currently underway"/>
   <result pre="the safety profile of hydroxychloroquine alone and in combination with" exact="azithromycin" post="is currently underway in more than 130,000 patients with"/>
   <result pre="context in which we find ourselves, the general use of" exact="hydroxychloroquine" post="is imminent, to the extent that the availability of"/>
   <result pre="administration. Conflict of interests None declared. References References 1SavarinoA.BoelaertJ.R.CassoneA.MajoriG.CaudaR.Effects of" exact="chloroquine" post="on viral infections: an old drug against today's diseases?Lancet"/>
   <result pre="an old drug against today's diseases?Lancet Infect. Dis.3200372272710.1016/S1473-3099(03)00806-514592603 2ColsonP.RolainJ.-M.LagierJ.-C.BrouquiP.RaoultD.Chloroquine and" exact="hydroxychloroquine" post="as available weapons to fight COVID-19Int. J. Antimicrob. Agents202010593210.1016/j.ijantimicag.2020.10593232145363"/>
   <result pre="J. Antimicrob. Agents202010593210.1016/j.ijantimicag.2020.10593232145363 3DevauxC.A.RolainJ.M.ColsonP.RaoultD.New insights on the antiviral effects of" exact="chloroquine" post="against coronavirus: what to expect for COVID-19?Int. J. Antimicrob."/>
   <result pre="COVID-19?Int. J. Antimicrob. Agents202010593810.1016/j.ijantimicag.2020.10593832171740 4SahraeiZ.ShabaniM.ShokouhiS.SaffaeiA.Aminoquinolines against coronavirus disease 2019 (COVID-19):" exact="chloroquine" post="or hydroxychloroquineInt. J. Antimicrob. Agents202010594510.1016/j.ijantimicag.2020.10594532194152 5YaoX.YeF.ZhangM.CuiC.HuangB.NiuP.In vitro antiviral activity"/>
   <result pre="vitro antiviral activity and projection of optimized dosing design of" exact="hydroxychloroquine" post="for the treatment of severe acute respiratory syndrome coronavirus"/>
   <result pre="7ShangL.ZhaoJ.HuY.DuR.CaoB.On the use of corticosteroids for 2019-nCoV pneumoniaLancet395202068368410.1016/S0140-6736(20)30361-532122468 8WangM.CaoR.ZhangL.YangX.LiuJ.XuM.Remdesivir and" exact="chloroquine" post="effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in"/>
   <result pre="the recently emerged novel coronavirus (2019-nCoV) in vitroCell Res.30202026927110.1038/s41422-020-0282-032020029 9GaoJ.TianZ.YangX.Breakthrough:" exact="chloroquine" post="phosphate has shown apparent efficacy in treatment of COVID-19"/>
   <result pre="pneumonia (trial version 6)2020117Available from: http://www.gov.cn/zhengce/zhengceku/2020-02/19/content_5480948.htm 11MarmorM.F.KellnerU.LaiT.Y.Y.MellesR.B.MielerW.F.LumF.Recommendations on screening for" exact="chloroquine" post="and hydroxychloroquine retinopathy (2016 revision)Ophthalmology12320161386139410.1016/j.ophtha.2016.01.05826992838 12Agencia EspaÃ±ola de Medicamentos"/>
   <result pre="version 6)2020117Available from: http://www.gov.cn/zhengce/zhengceku/2020-02/19/content_5480948.htm 11MarmorM.F.KellnerU.LaiT.Y.Y.MellesR.B.MielerW.F.LumF.Recommendations on screening for chloroquine and" exact="hydroxychloroquine" post="retinopathy (2016 revision)Ophthalmology12320161386139410.1016/j.ophtha.2016.01.05826992838 12Agencia EspaÃ±ola de Medicamentos y Productos"/>
   <result pre="(2016 revision)Ophthalmology12320161386139410.1016/j.ophtha.2016.01.05826992838 12Agencia EspaÃ±ola de Medicamentos y Productos SanitariosFicha tÃ©cnica" exact="Hidroxicloroquina" post="Ratiopharm 200Â mgOctubre 201111110.1017/CBO9781107415324.004 13GautretP.LagierJ.-C.ParolaP.HoangV.T.MeddebL.MailheM.Hydroxychloroquine and azithromycin as a"/>
   <result pre="Productos SanitariosFicha tÃ©cnica Hidroxicloroquina Ratiopharm 200Â mgOctubre 201111110.1017/CBO9781107415324.004 13GautretP.LagierJ.-C.ParolaP.HoangV.T.MeddebL.MailheM.Hydroxychloroquine and" exact="azithromycin" post="as a treatment of COVID-19: results of an open-label"/>
   <result pre="Antimicrob. Agents202010594910.1016/j.ijantimicag.2020.10594932205204 14GautretP.LagierJ.-C.ParolaP.HoangV.T.MeddebL.SevestreJ.Clinical and microbiological effect of a combination of" exact="hydroxychloroquine" post="and azithromycin in 80 COVID-19 patients with at least"/>
   <result pre="14GautretP.LagierJ.-C.ParolaP.HoangV.T.MeddebL.SevestreJ.Clinical and microbiological effect of a combination of hydroxychloroquine and" exact="azithromycin" post="in 80 COVID-19 patients with at least a six-day"/>
   <result pre="an observational studyTravel Med Infect Dis2020Available from: https://www.groupedeveillecovid.fr/blog/2020/03/28/clinical-and-microbiological-effect-of-a-combination-of-hydroxychloroquine-and-azithromycin-in-80-covid-19-patients-with-at-least-a-six-day-follow-up-an-observational-study/ 15ChenZ.HuJ.ZhangZ.Z.JiangS.HanS.YanD.Efficacy of" exact="hydroxychloroquine" post="in patients with COVID-19: results of a randomized clinical"/>
   <result pre="Wuhan, China: a retrospective cohort studyLancet39520201054106210.1016/s0140-6736(20)30566-332171076 17ChenJ.LiuD.LiuL.A pilot study of" exact="hydroxychloroquine" post="in treatment of patients with common coronavirus disease-19 (COVID-19)J"/>
   <result pre="(COVID-19)J Zhehiang Univ492020Available from: http://www.zjujournals.com/med 18MahaseE.Covid-19: six million doses of" exact="hydroxychloroquine" post="donated to US despite lack of evidenceBMJ3682020m116610.1136/bmj.m116632205321 19Centers for"/>
   <result pre="EvidÃ¨ncia Actual de lâ€™ EficÃ cia i Seguretat de La" exact="Hidroxicloroquina" post="i lâ€™ Azitromicina Com a Tractament o PrevenciÃ³ de"/>
   <result pre="lâ€™ EficÃ cia i Seguretat de La Hidroxicloroquina i lâ€™" exact="Azitromicina" post="Com a Tractament o PrevenciÃ³ de La COVID-192020 23Observational"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7243793\results\search\drug\results.xml">
   <result pre="as SARS-CoV 3CLpro inhibitors.11 Nitroanilides (6), derived from the drug" exact="niclosamide" post="were also found to inhibit 3CLpro.12 Î±-aminoacylamides were identified"/>
   <result pre="of SARS-CoV-2 3CLpro, which might have higher mutation tolerance than" exact="lopinavir" post="or ritonavir. Flavonoids (10â€&quot;14) are plant-derived natural products with"/>
   <result pre="shuanghuanglian, a Chinese herbal medicine that contains extracts from the" exact="dried" post="fruit lianqiao (Forsythiae fructus), which is purported to have"/>
   <result pre="aldehydes, trifluoromethyl ketones, Î±,Î²-unsaturated ketone, activated esters, or vinyl sulfones." exact="Disulfiram" post="(19), an approved drug for the treatment of chronic"/>
   <result pre="Disulfiram (19), an approved drug for the treatment of chronic" exact="alcohol" post="dependence, has a great potential for drug repurposing because"/>
   <result pre="shown to inhibit PLpro of MERS-CoV and SARS-CoV.26 The antimetabolites" exact="6-mercaptopurine" post="(20) and 6-thioguanine (21) are additional drugs inhibiting PLpro"/>
   <result pre="PLpro of MERS-CoV and SARS-CoV.26 The antimetabolites 6-mercaptopurine (20) and" exact="6-thioguanine" post="(21) are additional drugs inhibiting PLpro (Scheme 3 )."/>
   <result pre="to treat Covid-19 The broad-spectrum antiviral drug remdesivir together with" exact="chloroquine" post="effectively inhibit the recently emerged novel CoV (SARS-CoV-2) inÂ"/>
   <result pre="Ebola and SARS. The presumed mode of action of the" exact="adenosine" post="analog prodrug remdesivir is pre-mature RNA synthesis termination by"/>
   <result pre="with potential in COVID-19 treatment (FigureÂ 7). It is an" exact="adenosine" post="analog and is currently developed for Ebola virus disease"/>
   <result pre="literature, for example, broad-spectrum antiviral 6â€²-bis fluorinated aristeromycin analog (27).44" exact="Chloroquine" post="(28) is an existing anti-malaria medicine also used to"/>
   <result pre="of 1.13Â Î¼M.40,41 Its mode of action is unclear. However," exact="chloroquine" post="inhibits endosomal acidification and thus could stop the release"/>
   <result pre="Med.32006e34316968120 22LinS.ShenR.HeJ.LiX.GuoX.Molecular modeling evaluation of the binding effect of ritonavir," exact="lopinavir" post="and Darunavir to severe acute respiratory syndrome coronavirus 2"/>
   <result pre="approved for marketing. China Daily, February 17, 2020https://www.chinadaily.com.cn/2020 40WangM.CaoR.ZhangL.YangX.LiuJ.XuM.ShiZ.HuZ.ZhongW.XiaoG.Remdesivir and" exact="chloroquine" post="effectively inhibit the recently emerged novel coronavirus (2019-nCoV) inÂ"/>
   <result pre="novel coronavirus (2019-nCoV) inÂ vitroCell Res.30202026927110.1038/s41422-020-0282-032020029 41HuT.Y.FriemanM.WolframJ.Insights from nanomedicine into" exact="chloroquine" post="efficacy against COVID-19Nat. Nanotechnol.15202024724932203437 42WarrenT.K.JordanR.LoM.K.RayA.S.MackmanR.L.SolovevaV.SiegelD.PerronM.BannisterR.HuiH.C.Therapeutic efficacy of the small"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7246053\results\search\drug\results.xml">
   <result pre="Hard nonporous Human coronavirus Healthcare, institutional, residential 777-136; Reckitt Benckiser" exact="Ethanol" post="0.5 Hard nonporous Human coronavirus Healthcare, institutional, residential 8383-14;"/>
   <result pre="an undetectable level.42 They reported that the efficacy of 70%" exact="ethanol" post="was equivalent to that of the PVP-I products.42 In"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7246824\results\search\drug\results.xml">
   <result pre="effects, with a remarkable occurrence of side effects. Data concerning" exact="Peramivir" post="are even more limited, with few randomized clinical trials"/>
   <result pre="patients with COVID-19. The usage of Ribavirin, a pro-drug of" exact="ribavirin" post="triphosphate and a competitive inhibitor of the enzyme inosine"/>
   <result pre="count [2]. Few patients are being treated with gancivlovir, an" exact="acyclovir" post="analogue and inhibitor of the Herpesvirus family including cytomegalovirus"/>
   <result pre="analogue and inhibitor of the Herpesvirus family including cytomegalovirus (CMV)." exact="Ganciclovir" post="is approved for the treatment of complications arising from"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7247743\results\search\drug\results.xml">
   <result pre="(2). Ritonavir/lopinavir, remdesivir (repurposed from Ebola and FDA emergency approved)," exact="chloroquine" post="and hydroxychloroquine (both now FDA emergency approved, see Supplementary"/>
   <result pre="remdesivir (repurposed from Ebola and FDA emergency approved), chloroquine and" exact="hydroxychloroquine" post="(both now FDA emergency approved, see Supplementary Material) are"/>
   <result pre="have been tested for other indications (11). This analysis highlighted" exact="chloroquine" post="as one of the most repurposed approved drugs which"/>
   <result pre="has been tested against hundreds of diseases (11). Not surprisingly," exact="chloroquine" post="has also been identified by several groups (in China,"/>
   <result pre="activity against SARS-CoV-2 in vitro and along with the derivative" exact="hydroxychloroquine" post="has even entered multiple clinical trials (Supplementary Material). The"/>
   <result pre="raising the endocytic and lysosomal pH, which it shares with" exact="chloroquine" post="(15). Review of the text-mined literature also indicated a"/>
   <result pre="effective in inhibiting SARS-CoV-2 infection in vitroCell Discov202061610.1038/s41421-020-0156-032194981 7.WangMCaoRZhangLYangXLiuJXuMShiZHuZZhongWXiaoGRemdesivir and" exact="chloroquine" post="effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in"/>
   <result pre="ClÃ¡udioDaniel-RibeiroClÃ¡udio-TadeuMonteiroWuelton MarceloLacerdaMarcus VinÃ­cius GuimarÃ£esEffect of High vs Low Doses of" exact="Chloroquine" post="Diphosphate as Adjunctive Therapy for Patients Hospitalized With Severe"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7249458\results\search\drug\results.xml">
   <result pre="lacking interferon production is uncertain. For example, while the antidepressant" exact="sertraline" post="was found to have potent in vitro activity against"/>
   <result pre="example, based on a small clinical study,43 the combination of" exact="hydroxychloroquine" post="(a small molecule traditionally used to treat malaria and"/>
   <result pre="small molecule traditionally used to treat malaria and lupus) and" exact="azithromycin" post="(a macrolide antibiotic with anti-inflammatory properties) has been suggested"/>
   <result pre="results are controversial.44 Poly(lactide) and poly(lactide-co-glycolide) (PLGA) microparticles can deliver" exact="azithromycin" post="for up to 60 days with zero-order release kinetics.45"/>
   <result pre="There are also formulations using fumaryl diketopiperazine microparticles to deliver" exact="azithromycin" post="via intratracheal insufflation directly to the lungs, resulting in"/>
   <result pre="and intravenous routes of delivery.46 Given that the half-life of" exact="hydroxychloroquine" post="is &amp;gt;40 days, extended drug delivery options may not"/>
   <result pre="PLGA nanoparticles for specific cell targeting.48 While the efficacy of" exact="hydroxychloroquine" post="and azithromycin in the prevention and treatment of SARS-CoV-2"/>
   <result pre="for specific cell targeting.48 While the efficacy of hydroxychloroquine and" exact="azithromycin" post="in the prevention and treatment of SARS-CoV-2 remains an"/>
   <result pre="of print]; DOI: 10.2139/ssrn.3555145 29.HonkoA.N., JohnsonJ.C., MarchandJ.S., et al.High dose" exact="sertraline" post="monotherapy fails to protect rhesus macaques from lethal challenge"/>
   <result pre="in Wuhan, China. F1000Res9,72, 202032117569 43.GautretP., LagierJ.-C., ParolaP., et al." exact="Hydroxychloroquine" post="and azithromycin as a treatment of COVID-19: results of"/>
   <result pre="China. F1000Res9,72, 202032117569 43.GautretP., LagierJ.-C., ParolaP., et al. Hydroxychloroquine and" exact="azithromycin" post="as a treatment of COVID-19: results of an open-label"/>
   <result pre="dissemination of results and its consequences regarding the use of" exact="hydroxychloroquine" post="for COVID-19. Ann Intern Med 2020 [Epub ahead of"/>
   <result pre="of print]; DOI: 10.7326/M20-1223 45.LiX., ChangS., DuG., et al.Encapsulation of" exact="azithromycin" post="into polymeric microspheres by reduced pressure-solvent evaporation method. Int"/>
   <result pre="of pneumonia. Biomaterials160,107, 201829407340 47.TettS., CutlerD., DayR., and BrownK.Bioavailability of" exact="hydroxychloroquine" post="tablets in healthy volunteers. Br J Clin Pharmacol27,771, 19892757893"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7249615\results\search\drug\results.xml">
   <result pre="new treatment strategies for COVID-19: is there a role for" exact="bromhexine" post="as add-on therapy? DepfenhartMarkusdr@drdepfenhart.de12de VilliersDanielle3LemperleGottfried4MeyerMarkus5Di SommaSalvatore67[1], [2], [3], [4],"/>
   <result pre="on SARS-CoV-2 have brought attention to the possible benefit of" exact="chloroquine" post="in the treatment of patients infected by SARS-CoV-2. Whether"/>
   <result pre="chloroquine in the treatment of patients infected by SARS-CoV-2. Whether" exact="chloroquine" post="can treat SARS-CoV-2 alone and also work as a"/>
   <result pre="a protease inhibitor or a competitive virus ACE2-binding inhibitor. Using" exact="bromhexine" post="at a dosage that selectively inhibits TMPRSS2 and, in"/>
   <result pre="to be effective against SARS-CoV-2. We propose the use of" exact="bromhexine" post="as a prophylactic and treatment. We encourage the scientific"/>
   <result pre="prophylactic and treatment. We encourage the scientific community to assess" exact="bromhexine" post="clinically as a prophylactic and curative treatment. If proven"/>
   <result pre="accessible, and cost-effective application worldwide. Keywords SARS-CoV-2 COVID-19 Prophylactic Treatment" exact="Bromhexine" post="Protease inhibitor Background â€œPandemic is not a word to"/>
   <result pre="since entry of the virus into cells was reduced by" exact="camostat" post="mesilate, a TMPRSS2 inhibitor. It is currently only approved"/>
   <result pre="could be a potential treatment option of CoV infections [29]." exact="Nafamostat" post="mesilate is also a serine protease inhibitor widely used"/>
   <result pre="pancreatic and kidney disease. It is structurally closely related to" exact="camostat" post="mesilate. Researchers previously identified nafamostat mesilateâ€™s potential to inhibit"/>
   <result pre="is structurally closely related to camostat mesilate. Researchers previously identified" exact="nafamostat" post="mesilateâ€™s potential to inhibit MERS-CoV [30]. Risks of complications"/>
   <result pre="cough suppressants, as a potential TMPRSS2 inhibitor for their application." exact="Bromhexine" post="is orally readily bioavailable. Endonasal application is also a"/>
   <result pre="readily bioavailable. Endonasal application is also a good alternative option." exact="Bromhexine" post="is an over-the-counter (OTC) drug [32] that is affordable"/>
   <result pre="are highly dependent on the endosomal pathway and particularly pH." exact="Chloroquine" post="(N4-(7-chloro-4-quinolinyl)-N1,N1-diethyl-1,4-pentanediamine), an FDA-approved drug, [36] has been used to"/>
   <result pre="malaria for many years, [37] as well as autoimmune diseases." exact="Chloroquine" post="is known to block virus infection by increasing endosomal"/>
   <result pre="release of viral DNA or RNA into the cytosol. Moreover," exact="chloroquine" post="has immunomodulatory effects, suppressing the production/release of TNF-Î±, IL-1Î²,"/>
   <result pre="with viral infection and replication. A combination of remdesivir and" exact="chloroquine" post="was proven to effectively inhibit the recently emerged SARS-CoV-2"/>
   <result pre="to effectively inhibit the recently emerged SARS-CoV-2 in vitro [41]." exact="Chloroquine" post="and hydroxychloroquine (HCQ) have been found to be efficient"/>
   <result pre="inhibit the recently emerged SARS-CoV-2 in vitro [41]. Chloroquine and" exact="hydroxychloroquine" post="(HCQ) have been found to be efficient against SARS-CoV-2,"/>
   <result pre="and reported to be efficient in Chinese COVID-19 patients [42]." exact="Chloroquine" post="is easily available and relatively low in cost. Therefore,"/>
   <result pre="is potentially clinically applicable against COVID-19. However, an overdose of" exact="chloroquine" post="can cause acute poisoning and death [43]. HCQ sulfate,"/>
   <result pre="derivative of chloroquine, demonstrated much less (~ 40%) toxicity than" exact="chloroquine" post="in animals [44] and is a good alternative. As"/>
   <result pre="will go hand-in-hand with partial loss of this lung protection." exact="Chloroquine" post="and the less toxic HCQ are of particular importance"/>
   <result pre="activity is inhibited by an elevated endosomal pH and, thus," exact="chloroquine" post="treatment will also work [52]. Interference with viral replication"/>
   <result pre="Interference with RNA-dependent RNA polymerase Remdesivir (GS-5734) is a 1â€²-cyano-substituted" exact="adenosine" post="nucleotide analog prodrug (RNA-dependent RNA polymerase inhibitor) and shows"/>
   <result pre="drug moleculesâ€™ docking study of the 3CLpro pocket indicates that" exact="chloroquine" post="and bromhexine have high binding affinity to 3CLpro [61]."/>
   <result pre="docking study of the 3CLpro pocket indicates that chloroquine and" exact="bromhexine" post="have high binding affinity to 3CLpro [61]. Interestingly, quercetin"/>
   <result pre="has a strong binding affinity for 3CLpro, greater than both" exact="bromhexine" post="and chloroquine, and thus, all three drugs are inhibitors"/>
   <result pre="of becoming infected or transmitting the virus from being reached." exact="Bromhexine" post="or bromhexine hydrochloride (N-cyclo-N-methyl-(2-amino-3,5-dibromo-benzyl) amine hydrochloride) is derived from"/>
   <result pre="infected or transmitting the virus from being reached. Bromhexine or" exact="bromhexine" post="hydrochloride (N-cyclo-N-methyl-(2-amino-3,5-dibromo-benzyl) amine hydrochloride) is derived from Vasicin, a"/>
   <result pre="vasica, and is a brominated aniline and benzylamine derivative [62]." exact="Bromhexine" post="hydrochloride acts as a mucolytic (breaks down mucus and"/>
   <result pre="characterized by low side effects and a low purchase price." exact="Bromhexine" post="is structurally related to ambroxol, an active demethylated metabolite"/>
   <result pre="medicine in the market. The available data suggest further that" exact="ambroxol" post="is a potent inducer of surfactant synthesis in AT2"/>
   <result pre="the potential as an adjuvant in anti-infective therapy [64]. Thus," exact="bromhexine" post="also provides indirect protective effects. Bromhexine hydrochloride is sold"/>
   <result pre="anti-infective therapy [64]. Thus, bromhexine also provides indirect protective effects." exact="Bromhexine" post="hydrochloride is sold under a few brand names, such"/>
   <result pre="the package inserts (information for use), the medicinal products containing" exact="bromhexine" post="hydrochloride are usually administered three times a day (8â€&quot;16Â"/>
   <result pre="times higher in pulmonary parenchyma compared to plasma concentrations. Unchanged" exact="bromhexine" post="is bound to plasma proteins by 95% [66, 67]."/>
   <result pre="cancer using TMPRSS2 inhibitors. The extent of metastasis reduction with" exact="bromhexine" post="was slightly lower in the wild-type mice than in"/>
   <result pre="in the study (72Â h) [31]. The terminal half-life of" exact="bromhexine" post="in an oral application of 8Â mg per single"/>
   <result pre="per single dose is an average of 6.6Â h [67]." exact="Bromhexine" post="is orally readily bioavailable, and thus, a more frequent"/>
   <result pre="the first pass effect. Laporte and Naesens [68] reported that" exact="bromhexine" post="did not show any significant cell entry or replication"/>
   <result pre="these results are not representative for SARS-CoV-2 [68]. In theory," exact="bromhexine" post="is an attractive drug against COVID-19, because it is"/>
   <result pre="off-label use. The IC90 (inhibitory concentration) for TMPRSS2 inhibition using" exact="bromhexine" post="is favorable at 1Â Î¼mol compared to 10Â Î¼mol"/>
   <result pre="is favorable at 1Â Î¼mol compared to 10Â Î¼mol for" exact="camostat" post="mesilate. However, the first pass effect for bromhexine is"/>
   <result pre="Î¼mol for camostat mesilate. However, the first pass effect for" exact="bromhexine" post="is much higher than for camostat mesilate (75â€&quot;80% versus"/>
   <result pre="first pass effect for bromhexine is much higher than for" exact="camostat" post="mesilate (75â€&quot;80% versus 33â€&quot;40%). The currently recommended oral dose"/>
   <result pre="mesilate (75â€&quot;80% versus 33â€&quot;40%). The currently recommended oral dose for" exact="camostat" post="mesilate is 300â€&quot;600Â mg per day which would translate"/>
   <result pre="body-based preliminary exploratory randomized-controlled clinical study on treating COVID-19 with" exact="bromhexine" post="hydrochloride tablets (BHT). The clinical study evaluated the efficacy"/>
   <result pre="for the experimental group and 66.67% for the control group)." exact="Bromhexine" post="and ambroxol appear to have a liver protective effect."/>
   <result pre="experimental group and 66.67% for the control group). Bromhexine and" exact="ambroxol" post="appear to have a liver protective effect. Comparatively, liver"/>
   <result pre="The exploratory results of the study support our proposal that" exact="bromhexine" post="hydrochloride may have a good effect on the treatment"/>
   <result pre="on COVID-19 have brought attention to the possible benefit of" exact="chloroquine" post="in the treatment of patients infected by SARS-CoV-2. Whether"/>
   <result pre="chloroquine in the treatment of patients infected by SARS-CoV-2. Whether" exact="chloroquine" post="can treat COVID-19 alone and also work as a"/>
   <result pre="poisoned and one death has occurred due to overdose using" exact="chloroquine" post="[69]. The FDA does say that studies are under"/>
   <result pre="does say that studies are under way to see if" exact="chloroquine" post="can be effective in the treatment of COVID-19. Chloroquine"/>
   <result pre="if chloroquine can be effective in the treatment of COVID-19." exact="Chloroquine" post="had been approved for â€œcompassionate useâ€� where patients are"/>
   <result pre="where patients are in a life-threatening condition. Past research on" exact="chloroquine" post="has shown in vitro activity against many different viruses,"/>
   <result pre="many different viruses, but no benefit in animal models [70]." exact="Chloroquine" post="in almost all animal models of different viral infections"/>
   <result pre="only partially worked or did not work [71â€&quot;73]. Treatment with" exact="chloroquine" post="did not prevent influenza infection in a randomized, double-blind,"/>
   <result pre="virus replication. This may explain the recent success reported with" exact="chloroquine" post="to assist in the curing of the virus. In"/>
   <result pre="has to contain, at least, either a TMPRSS2 inhibitor, e.g.," exact="bromhexine" post="or a competitive virus ACE2-binding inhibitor, e.g., a peptide"/>
   <result pre="the hostâ€™s body. Furthermore, a combination with the lesser toxic" exact="chloroquine" post="derivate, HCQ sulfate, that is (amongst other functions) an"/>
   <result pre="the following 4Â days [78]. The toxic dosage range of" exact="chloroquine" post="and HCQ is close to the therapeutic range [79]."/>
   <result pre="HCQ is close to the therapeutic range [79]. Especially, since" exact="chloroquine" post="derivatives are quite toxic, a combination with bromhexine and"/>
   <result pre="Especially, since chloroquine derivatives are quite toxic, a combination with" exact="bromhexine" post="and a lower dose of HCQ could be applicable."/>
   <result pre="same could be applicable for the herein proposed drug application." exact="Bromhexine" post="would be a valuable addition in combination with antivirals"/>
   <result pre="how we can exploit these mechanisms to treat SARS-CoV-2 using" exact="bromhexine" post="and/or hydroxychloroquine (HCQ) and/or quercetin. SARS-CoV-2 employs two routes"/>
   <result pre="can exploit these mechanisms to treat SARS-CoV-2 using bromhexine and/or" exact="hydroxychloroquine" post="(HCQ) and/or quercetin. SARS-CoV-2 employs two routes for host"/>
   <result pre="was put forward for the repurposing of existing drugs namely" exact="bromhexine" post="in combination with HCQ and/or quercetin as an immediately"/>
   <result pre="already existing approved drug to be used for off-label usage." exact="Bromhexine" post="or preferably in combination with HCQ could be such"/>
   <result pre="of the disease. We encourage the scientific community to test" exact="bromhexine" post="and the suggested combinations and to follow our recommended"/>
   <result pre="clinical study project, entitled â€œEvaluating the Efficacy and Safety of" exact="Bromhexine" post="Hydrochloride Tablets Combined with Standard Treatment/ Standard Treatment in"/>
   <result pre="protocol for a randomized controlled trial on the assessment of" exact="camostat" post="treatment in chronic pancreatitis (TACTIC)Trials201920150110.1186/s13063-019-3606-y31412955 29.ZhouYVedanthamPLuKAgudeloJCarrionRNunneleyJWet al.Protease inhibitors targeting"/>
   <result pre="inhibitors targeting coronavirus and filovirus entryAntiviral Res2015116768410.1016/j.antiviral.2015.01.01125666761 30.YamamotoMMatsuyamaSLiXTakedaMKawaguchiYInoueJ-Iet al.Identification of" exact="nafamostat" post="as a potent inhibitor of middle east respiratory syndrome"/>
   <result pre="(2020) Antiandrogens. https://www.drugs.com/drug-class/antiandrogens.html. Accessed 14 Apr 2020 36.Sanofi-Synthelabo Inc. (2001)" exact="Chloroquine" post="FDA label. https://s3-us-west-2.amazonaws.com/drugbank/fda_labels/DB00608.pdf?1265922797. Accessed 22 Mar 2020 37.AguiarACCMurceECortopassiWAPimentelASAlmeidaMBarrosDCSet al.Chloroquine"/>
   <result pre="a novel class of autophagy inhibitorsNeurosurg Focus201538E1210.3171/2014.12.FOCUS1474825727221 41.WangMCaoRZhangLYangXLiuJXuMet al.Remdesivir and" exact="chloroquine" post="effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in"/>
   <result pre="emerged novel coronavirus (2019-nCoV) in vitroCell Res202030326927110.1038/s41422-020-0282-032020029 42.GautretPLagierJCParolaPHoangVTMeddedLMailheMet al.Hydroxychloroquine and" exact="Azithromycin" post="as a treatment of COVID-19: preliminary results of an"/>
   <result pre="toxicity of chloroquine1979GenevaWorld Health Organization 44.McChesneyEWAnimal toxicity and pharmacokinetics of" exact="hydroxychloroquine" post="sulfateAm J Med1983751a111810.1016/0002-9343(83)91265-26408923 45.ZhangHPenningerJMLiYZhongNSlutskyASAngiotensin-converting enzyme 2 (ACE2) as a"/>
   <result pre="51.FrlanRGobecSInhibitors of cathepsin BCurr Med Chem2006132309232710.2174/09298670677793512216918357 52.SchrezenmeierEDornerTMechanisms of action of" exact="hydroxychloroquine" post="and chloroquine: implications for rheumatologyNat Rev Rheumatol202016315516610.1038/s41584-020-0372-x32034323 53.AgostiniMLAndresELSimsACGrahamRLSheahanTPLuXet al.Coronavirus"/>
   <result pre="Thorac Soc201512576577410.1513/AnnalsATS.201411-507FR25742123 64.PlomerMde ZeeuwJMore than expectorant: new scientific data on" exact="ambroxol" post="in the context of the treatment of bronchopulmonary diseasesMMW"/>
   <result pre="bronchopulmonary diseasesMMW Fortschritte der Medizin2017159Suppl 5223310.1007/s15006-017-9805-028643291 65.GaoXHuangYHanYBaiC-XWangGThe protective effects of" exact="Ambroxol" post="in Pseudomonas aeruginosa-induced pneumonia in ratsArch Med Sci20117340541310.5114/aoms.2011.2340322312374 66.Boehringer"/>
   <result pre="Fearing coronavirus, Arizona man dies after taking a form of" exact="chloroquine" post="used to treat aquariums. CNN Health. https://edition.cnn.com/2020/03/23/health/arizona-coronavirus-chloroquine-death/index.html. Accessed 30"/>
   <result pre="aquariums. CNN Health. https://edition.cnn.com/2020/03/23/health/arizona-coronavirus-chloroquine-death/index.html. Accessed 30 Mar 2020. 70.TouretFde LamballerieXOf" exact="chloroquine" post="and COVID-19Antiviral Res202017710476210.1016/j.antiviral.2020.10476232147496 71.KeyaertsELiSVijgenLRysmanEVerbeeckJVan RanstMet al.Antiviral activity of chloroquine"/>
   <result pre="LamballerieXOf chloroquine and COVID-19Antiviral Res202017710476210.1016/j.antiviral.2020.10476232147496 71.KeyaertsELiSVijgenLRysmanEVerbeeckJVan RanstMet al.Antiviral activity of" exact="chloroquine" post="against human coronavirus OC43 infection in newborn miceAntimicrob Agents"/>
   <result pre="OC43 infection in newborn miceAntimicrob Agents Chemother20095383416342110.1128/aac.01509-0819506054 72.TanYWYamWKSunJChuJJHAn evaluation of" exact="chloroquine" post="as a broad-acting antiviral against hand, foot and mouth"/>
   <result pre="against hand, foot and mouth diseaseAntiviral Res201814914314910.1016/j.antiviral.2017.11.01729175128 73.YanYZouZSunYLiXXuK-FWeiYet al.Anti-malaria drug" exact="chloroquine" post="is highly effective in treating avian influenza A H5N1"/>
   <result pre="a randomised, double-blind, placebo controlled trialLancet Infect Dis201111967768310.1016/S1473-3099(11)70065-221550310 75.ShimizuYYamamotoSHommaMIshidaNEffect of" exact="chloroquine" post="on the growth of animal virusesArchiv fÃ¼r die gesamte"/>
   <result pre="vitro antiviral activity and projection of optimized dosing design of" exact="hydroxychloroquine" post="for the treatment of severe acute respiratory syndrome coronavirus"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7250111\results\search\drug\results.xml">
   <result pre="7250111S1198-743X(20)30293-7 doi: 10.1016/j.cmi.2020.05.016 : Systematic Review Clinical evidence for repurposing" exact="chloroquine" post="and hydroxychloroquine as antiviral agents: a systematic review RodrigoC.1FernandoS.D.2RajapakseS.3âˆ—[1)],"/>
   <result pre="10.1016/j.cmi.2020.05.016 : Systematic Review Clinical evidence for repurposing chloroquine and" exact="hydroxychloroquine" post="as antiviral agents: a systematic review RodrigoC.1FernandoS.D.2RajapakseS.3âˆ—[1)], [2)], [3)],"/>
   <result pre="as the COVID-19 resource centre remains active. Abstract Background Repurposing" exact="hydroxychloroquine" post="(HCQ) and chloroquine (CQ) as antiviral agents is a"/>
   <result pre="resource centre remains active. Abstract Background Repurposing hydroxychloroquine (HCQ) and" exact="chloroquine" post="(CQ) as antiviral agents is a re-emerging topic with"/>
   <result pre="or CQ is beneficial in COVID-19 infection. Keywords Antivirals Chikungunya" exact="Chloroquine" post="COVID-19 Dengue Hydroxychloroquine Pneumonia Editor: M. Paul Introduction With"/>
   <result pre="beneficial in COVID-19 infection. Keywords Antivirals Chikungunya Chloroquine COVID-19 Dengue" exact="Hydroxychloroquine" post="Pneumonia Editor: M. Paul Introduction With the advent of"/>
   <result pre="properties inÂ vitro or in animal studies is gaining popularity." exact="Chloroquine" post="(CQ), a well-established antimalarial agent, and hydroxychloroquine (HCQ), a"/>
   <result pre="is gaining popularity. Chloroquine (CQ), a well-established antimalarial agent, and" exact="hydroxychloroquine" post="(HCQ), a similarly established disease-modifying anti-rheumatic drug (DMARD), have"/>
   <result pre="800 mg/d for 16Â weeks (nÂ =Â 35) or 2)" exact="Zidovudine" post="500 mg/d for same duration (nÂ =Â 37) Significant"/>
   <result pre="decrease in viral load in both HCQ (p 0.02) and" exact="zidovudine" post="groups (p 0.001)No change in absolute CD4+ cell count"/>
   <result pre="copies/Î¼L and CD4+ cell countÂ &amp;gt;Â 150/Î¼L HCQ 200 mg/bid," exact="hydroxyurea" post="500 mg/bid and didanoside 125â€&quot;200 mg/bid according to bodyweight"/>
   <result pre="A,B or C; CDC immunological category 2 or 3 1)" exact="Zidovudine" post="(ZDV)+ didanosine (ddI) (nÂ =Â 25)2) ZDVÂ +Â ddIÂ"/>
   <result pre="C; CDC immunological category 2 or 3 1) Zidovudine (ZDV)+" exact="didanosine" post="(ddI) (nÂ =Â 25)2) ZDVÂ +Â ddIÂ +Â CQ"/>
   <result pre="1: pegylated interferon (IFN) 160 Î¼g subcutaneously weeklyÂ +Â oral" exact="ribavirin" post="1000â€&quot;1200 md/d for 12Â weeks (nÂ =Â 60)Group 2:"/>
   <result pre="with HCV (genotype 1) not responding to standard IFN and" exact="ribavirin" post="therapy CQ 150 mg (base)/d for 8Â weeks or"/>
   <result pre="effects due to recruiting control patients from a different institution," exact="azithromycin" post="administration in some patients only, and baseline age difference"/>
   <result pre="ROBINS-I tool. TableÂ 3 Clinical trials/studies in progression on using" exact="chloroquine" post="(CQ) or hydroxychloroquine (HCQ) as antiviral agents TableÂ 3"/>
   <result pre="3 Clinical trials/studies in progression on using chloroquine (CQ) or" exact="hydroxychloroquine" post="(HCQ) as antiviral agents TableÂ 3 Namea Reference ID"/>
   <result pre="Post-exposure prophylaxis for SARS-Coronavirus-2 NCT04308668 ClinicalTrials.gov Comparison of lopinavir/ritonavir or" exact="hydroxychloroquine" post="in patients with mild coronavirus disease (COVID-19) NCT04307693 ClinicalTrials.gov"/>
   <result pre="hydroxychloroquine in patients with mild coronavirus disease (COVID-19) NCT04307693 ClinicalTrials.gov" exact="Chloroquine" post="prevention of coronavirus disease (COVID-19) in the healthcare setting"/>
   <result pre="NCT04304053 ClinicalTrials.gov Various combination of protease inhibitors, oseltamivir, favipiravir, and" exact="chloroquine" post="for treatment of COVID19: a randomized control trial NCT04303299"/>
   <result pre="WHO ICTRP A prospective, open label, randomized, control trial for" exact="chloroquine" post="or hydroxychloroquine in patients with mild and common novel"/>
   <result pre="A prospective, open label, randomized, control trial for chloroquine or" exact="hydroxychloroquine" post="in patients with mild and common novel coronavirus pulmonary"/>
   <result pre="Clinical Trials Registry A prospective, randomized, open-label, controlled trial for" exact="chloroquine" post="and hydroxychloroquine in patients with severe novel coronavirus pneumonia"/>
   <result pre="Registry A prospective, randomized, open-label, controlled trial for chloroquine and" exact="hydroxychloroquine" post="in patients with severe novel coronavirus pneumonia (COVID-19) ChiCTR2000029992"/>
   <result pre="Chinese Clinical Trials Registry Evaluation the efficacy and safety of" exact="hydroxychloroquine" post="sulfate in comparison with phosphate chloroquine in mild and"/>
   <result pre="efficacy and safety of hydroxychloroquine sulfate in comparison with phosphate" exact="chloroquine" post="in mild and common patients with novel coronavirus pneumonia"/>
   <result pre="Chinese Clinical Trials Registry Evaluation the efficacy and safety of" exact="hydroxychloroquine" post="sulfate in comparison with phosphate chloroquine in severe patients"/>
   <result pre="efficacy and safety of hydroxychloroquine sulfate in comparison with phosphate" exact="chloroquine" post="in severe patients with novel coronavirus pneumonia (COVID-19): a"/>
   <result pre="open-label, controlled clinical study to evaluate the preventive effect of" exact="hydroxychloroquine" post="on close contacts after exposure to the novel coronavirus"/>
   <result pre="Trials Registry A multicenter, single-blind, randomized controlled clinical trial for" exact="chloroquine" post="phosphate in the treatment of novel coronavirus pneumonia (COVID-19)"/>
   <result pre="Registry A randomized controlled trial for favipiravir tablets combine with" exact="chloroquine" post="phosphate in the treatment of novel coronavirus pneumonia (COVID-19)"/>
   <result pre="(COVID-19) ChiCTR2000030987 Chinese Clinical Trials Registry Randomized controlled trial for" exact="chloroquine" post="phosphate in the treatment of novel coronavirus pneumonia (COVID-19)"/>
   <result pre="pneumonia (COVID-19) ChiCTR2000030718 Chinese Clinical Trials Registry Clinical study of" exact="chloroquine" post="phosphate in the treatment of severe novel coronavirus pneumonia"/>
   <result pre="Chinese Clinical Trials Registry Single arm study for exploration of" exact="chloroquine" post="phosphate aerosol inhalation in the treatment of novel coronavirus"/>
   <result pre="Clinical Trials Registry A single-blind, randomized, controlled clinical trial for" exact="chloroquine" post="phosphate in the treatment of novel coronavirus pneumonia 2019"/>
   <result pre="ChiCTR2000029939 Chinese Clinical Trials Registry A single-arm clinical trial for" exact="chloroquine" post="phosphate in the treatment of novel coronavirus pneumonia 2019"/>
   <result pre="pneumonia 2019 (COVID-19) ChiCTR2000029935 Chinese Clinical Trials Registry Efficacy of" exact="chloroquine" post="and lopinavir/ritonavir in mild/general novel coronavirus (CoVID-19) infections: a"/>
   <result pre="Registry A prospective, open-label, multiple-center study for the efficacy of" exact="chloroquine" post="phosphate in patients with novel coronavirus pneumonia (COVID-19) ChiCTR2000029609"/>
   <result pre="ChiCTR2000029609 Chinese Clinical Trials Registry Study for the efficacy of" exact="chloroquine" post="in patients with novel coronavirus pneumonia (COVID-19) ChiCTR2000029542 Chinese"/>
   <result pre="mg/d to 800 mg/d and comparators included placebo [17,20] or" exact="zidovudine" post="[18]. Two RCTs reported a significant decrease in viral"/>
   <result pre="used HCQ 400 mg/d alone [23] or in combination with" exact="hydroxyurea" post="plus didanosine [24]. There was a modest reduction in"/>
   <result pre="400 mg/d alone [23] or in combination with hydroxyurea plus" exact="didanosine" post="[24]. There was a modest reduction in viral load"/>
   <result pre="70 patients [21]. The comparators were either placebo [21,22] or" exact="zidovudine" post="plus didanosine (paediatric trial) [19]. Both adult trials enrolled"/>
   <result pre="[21]. The comparators were either placebo [21,22] or zidovudine plus" exact="didanosine" post="(paediatric trial) [19]. Both adult trials enrolled patients with"/>
   <result pre="400 mg/d for 12Â weeks added to interferon (IFN) and" exact="ribavirin" post="therapy, while the control group received IFN and ribavirin"/>
   <result pre="and ribavirin therapy, while the control group received IFN and" exact="ribavirin" post="only. HCQ was well tolerated and a significantly higher"/>
   <result pre="versus placebo in patients who had already failed IFN and" exact="ribavirin" post="therapy, and noted a significant drop in viral RNA"/>
   <result pre="therapy (p 0.04), but this effect was transient. IFN and" exact="ribavirin" post="therapy for HCV is largely outdated nowadays as highly"/>
   <result pre="approximately 14Â years) between test and control groups. Administration of" exact="azithromycin" post="to six subjects who also received HCQ does not"/>
   <result pre="achieving negative viraemia by day 14 compared to treatment with" exact="lopinavir" post="and ritonavir [40]. The authors report faster radiological improvement"/>
   <result pre="viraemia by day 14 compared to treatment with lopinavir and" exact="ritonavir" post="[40]. The authors report faster radiological improvement and reduced"/>
   <result pre="strategies against SARS coronavirus infectionsExpert Rev Anti-Infect Ther4200629130216597209 5RolainJ.M.ColsonP.RaoultD.Recycling of" exact="chloroquine" post="and its hydroxyl analogue to face bacterial, fungal and"/>
   <result pre="infections in the 21st centuryInt J Antimicrob Ag302007297308 6SavarinoA.BoelaertJ.R.CassoneA.MajoriG.CaudaR.Effects of" exact="chloroquine" post="on viral infections: an old drug against today's diseases?Lancet"/>
   <result pre="Zika virus NS2B-NS3 proteaseACS Omega32018181321814130613818 10ShiryaevS.A.MesciP.PintoA.FernandesI.SheetsN.ShrestaS.Repurposing of the anti-malaria drug" exact="chloroquine" post="for Zika virus treatment and prophylaxisSci Rep72017 11AkpovwaH.Chloroquine could"/>
   <result pre="patients with human immunodeficiency virus type 1Clin Ther1719956226368565026 18SperberK.ChiangG.ChenH.RossW.ChusidE.GoncharM.Comparison of" exact="hydroxychloroquine" post="with zidovudine in asymptomatic patients infected with human immunodeficiency"/>
   <result pre="human immunodeficiency virus type 1Clin Ther1719956226368565026 18SperberK.ChiangG.ChenH.RossW.ChusidE.GoncharM.Comparison of hydroxychloroquine with" exact="zidovudine" post="in asymptomatic patients infected with human immunodeficiency virus type"/>
   <result pre="with human immunodeficiency virus type 1Clin Ther1919979139239385480 19EngchanilC.KosalaraksaP.LumbiganonP.LulitanondV.PongjunyakulP.ThuennadeeR.Therapeutic potential of" exact="chloroquine" post="added to zidovudine plus didanosine for HIV-1 infected childrenJÂ"/>
   <result pre="virus type 1Clin Ther1919979139239385480 19EngchanilC.KosalaraksaP.LumbiganonP.LulitanondV.PongjunyakulP.ThuennadeeR.Therapeutic potential of chloroquine added to" exact="zidovudine" post="plus didanosine for HIV-1 infected childrenJÂ Med Assoc Thai8920061229123617048434"/>
   <result pre="1Clin Ther1919979139239385480 19EngchanilC.KosalaraksaP.LumbiganonP.LulitanondV.PongjunyakulP.ThuennadeeR.Therapeutic potential of chloroquine added to zidovudine plus" exact="didanosine" post="for HIV-1 infected childrenJÂ Med Assoc Thai8920061229123617048434 20PatonN.I.GoodallR.L.DunnD.T.FranzenS.Collaco-MoraesY.GazzardB.G.Effects of"/>
   <result pre="didanosine for HIV-1 infected childrenJÂ Med Assoc Thai8920061229123617048434 20PatonN.I.GoodallR.L.DunnD.T.FranzenS.Collaco-MoraesY.GazzardB.G.Effects of" exact="hydroxychloroquine" post="on immune activation and disease progression among HIV-infected patients"/>
   <result pre="receiving antiretroviral therapy: a randomized controlled trialJAMA308201235336122820788 21JacobsonJ.M.BosingerS.E.KangM.Belaunzaran-ZamudioP.MatiningR.M.WilsonC.C.The effect of" exact="chloroquine" post="on immune activation and interferon signatures associated with HIV-1AIDS"/>
   <result pre="with HIV-1AIDS Res Hum Retroviruses32201663664726935044 22MurrayS.M.DownC.M.BoulwareD.R.StaufferW.M.CavertW.P.SchackerT.W.Reduction of immune activation with" exact="chloroquine" post="therapy during chronic HIV infectionJÂ Virol842010120821208620844049 23PiconiS.ParisottoS.RizzardiniG.PasseriniS.TerziR.ArgenteriB.Hydroxychloroquine drastically reduces"/>
   <result pre="activation in HIV-infected, antiretroviral therapy-treated immunologic nonrespondersBlood11820113263327221576701 24PatonN.I.AboulhabJ.KarimF.Hydroxychloroquine, hydroxycarbamide, and" exact="didanosine" post="as economic treatment for HIV-1Lancet35920021667166812020529 25PeymaniP.GhavamiS.YeganehB.TabriziR.SabourS.GeramizadehB.Effect of chloroquine on"/>
   <result pre="hydroxycarbamide, and didanosine as economic treatment for HIV-1Lancet35920021667166812020529 25PeymaniP.GhavamiS.YeganehB.TabriziR.SabourS.GeramizadehB.Effect of" exact="chloroquine" post="on some clinical and biochemical parameters in non-response chronic"/>
   <result pre="pilot clinical trialActa Biomed8720164653 26PeymaniP.YeganehB.SabourS.GeramizadehB.FattahiM.R.KeyvaniH.New use of an old drug:" exact="chloroquine" post="reduces viral and ALT levels in HCV non-responders (a"/>
   <result pre="Pharmacol94201661361926998724 27HelalG.K.GadM.A.Abd-EllahM.F.EidM.S.Hydroxychloroquine augments early virological response to pegylated interferon plus" exact="ribavirin" post="in genotype-4 chronic hepatitis C patientsJÂ Med Virol8820162170217827183377 28TricouV.MinhN.N.VanT.P.LeeS.J.FarrarJ.WillsB.AÂ"/>
   <result pre="hepatitis C patientsJÂ Med Virol8820162170217827183377 28TricouV.MinhN.N.VanT.P.LeeS.J.FarrarJ.WillsB.AÂ randomized controlled trial of" exact="chloroquine" post="for the treatment of dengue in Vietnamese adultsPLoS Negl"/>
   <result pre="symptomsMem Inst Oswaldo Cruz108201359659923903975 30De LamballerieX.BoissonV.ReynierJ.C.EnaultS.CharrelR.N.FlahaultA.On chikungunya acute infection and" exact="chloroquine" post="treatmentVector Borne Zoonotic Dis8200883783918620511 31de LamballerieX.NinoveL.CharrelR.N.Antiviral treatment of chikungunya"/>
   <result pre="of chikungunya virus infectionInfect Disord Drug Targets9200910110419275698 32RoquesP.ThibervilleS.D.Dupuis-MaguiragaL.LumF.M.LabadieK.MartinonF.Paradoxical effect of" exact="chloroquine" post="treatment in enhancing chikungunya virus infectionViruses102018 33RavindranV.AliasG.Efficacy of combination"/>
   <result pre="enhancing chikungunya virus infectionViruses102018 33RavindranV.AliasG.Efficacy of combination DMARD therapy vs." exact="hydroxychloroquine" post="monotherapy in chronic persistent chikungunya arthritis: a 24-week randomized"/>
   <result pre="technology of Guangdong Province health commission of Guangdong Province for" exact="chloroquine" post="in the treatment of novel coronavirus pneumoniaExpert Consensus Chloroquine"/>
   <result pre="for chloroquine in the treatment of novel coronavirus pneumoniaExpert Consensus" exact="Chloroquine" post="Phosphate Treat Novel Coronavirus Pneumonia432020185188 35GautretP.LagierJ.-C.ParolaP.HoangV.T.MeddebL.MailheM.Hydroxychloroquine and azithromycin as"/>
   <result pre="pneumoniaExpert Consensus Chloroquine Phosphate Treat Novel Coronavirus Pneumonia432020185188 35GautretP.LagierJ.-C.ParolaP.HoangV.T.MeddebL.MailheM.Hydroxychloroquine and" exact="azithromycin" post="as a treatment of COVID-19: results of an open-label"/>
   <result pre="clinical trialInt J Antimicrob Agents202010594932205204 36Chen JunL.D.LiL.PingL.QingnianX.LuX.YunL.AÂ pilot study of" exact="hydroxychloroquine" post="in treatment of patients with common coronavirus disease-19 (COVID-19)JÂ"/>
   <result pre="patients with COVID-19: an open-label, randomized, controlled trialmedRxiv2020202004.10.20060558 38ChenZ.HuJ.ZhangZ.JiangS.HanS.YanD.Efficacy of" exact="hydroxychloroquine" post="in patients with COVID-19: results of a randomized clinical"/>
   <result pre="with COVID-19: results of a randomized clinical trialmedRxiv2020202003.22.20040758 39MagagnoliJ.NarendranS.PereiraF.CummingsT.HardinJ.W.SuttonS.S.Outcomes of" exact="hydroxychloroquine" post="usage in United States veterans hospitalized with Covid-19medRxiv2020202004.16.20065920 40HuangM.TangT.PangP.LiM.MaR.LuJ.Treating"/>
   <result pre="Mol Cell Biol2020 41BorbaM.G.S.ValF.F.A.SampaioV.S.AlexandreM.A.A.MeloG.C.BritoM.Effect of high vs low doses of" exact="chloroquine" post="diphosphate as adjunctive therapy for patients hospitalized with severe"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7251044\results\search\drug\results.xml">
   <result pre="and therefore with the virus [3, 4]. The antimalarial (AM)" exact="hydroxychloroquine" post="(HCQ) and chloroquine (CQ) have demonstrated antiviral activity against"/>
   <result pre="the virus [3, 4]. The antimalarial (AM) hydroxychloroquine (HCQ) and" exact="chloroquine" post="(CQ) have demonstrated antiviral activity against severe SARS-CoV-2 in"/>
   <result pre="vitro antiviral activity and projection of optimized dosing design of" exact="hydroxychloroquine" post="for the treatment of severe acute respiratory syndrome coronavirus"/>
   <result pre="Infect Dis. 10.1093/cid/ciaa237 6.Yazdany J, Kim AHJ (2020) Use of" exact="hydroxychloroquine" post="and chloroquine during the COVID-19 pandemic: what every clinician"/>
   <result pre="10.1093/cid/ciaa237 6.Yazdany J, Kim AHJ (2020) Use of hydroxychloroquine and" exact="chloroquine" post="during the COVID-19 pandemic: what every clinician should know."/>
   <result pre="Cummings T, Hardin JW, Sutton SS, Ambati J. Outcomes of" exact="hydroxychloroquine" post="usage in United States veterans hospitalized with Covid-19. medRxiv"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7251277\results\search\drug\results.xml">
   <result pre="considering the thorax CT result and the patientâ€™s comorbid diseases." exact="Azithromycin" post="and hydroxychloroquine treatment combinations were started. On the first"/>
   <result pre="thorax CT result and the patientâ€™s comorbid diseases. Azithromycin and" exact="hydroxychloroquine" post="treatment combinations were started. On the first day of"/>
   <result pre="phase reactants (Figure 2). Close follow-up was continued by adding" exact="ceftriaxone" post="to the treatment. On the 6th day, the subfebrile"/>
   <result pre="and serum acute phase reactants were in the normal range." exact="Azithromycin" post="and hydroxychloroquine treatment combinations were started, and the patient"/>
   <result pre="acute phase reactants were in the normal range. Azithromycin and" exact="hydroxychloroquine" post="treatment combinations were started, and the patient was isolated"/>
   <result pre="in the normal range. She was hospitalized and started on" exact="azithromycin" post="and hydroxychloroquine treatments. During the hospital stay, the patient"/>
   <result pre="normal range. She was hospitalized and started on azithromycin and" exact="hydroxychloroquine" post="treatments. During the hospital stay, the patient did not"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7252029\results\search\drug\results.xml">
   <result pre="None Not requiring vasopressors Requiring a vasopressor with or without" exact="vasopressin" post="Requiring multiple vasopressors (excluding vasopressin) And/orb Hypoxia None Requiring"/>
   <result pre="triggers the increase of body temperature through the release of" exact="prostaglandin E2" post="(PGE2). Tocilizumab is indicated for adult patients with autoimmune"/>
   <result pre="to treat CRS is being reported [26]. Baricitinib, fedratinib and" exact="ruxolitinib" post="are potent and selective JAK inhibitors approved for indications"/>
   <result pre="potential benefit for Bruton's tyrosine kinase (BTK) inhibitors such as" exact="ibrutinib" post="(ImbruvicaTM) to protect against lung pathology in patients with"/>
   <result pre="SARS-CoV-2 pneumonia [44]. Therefore, further antiviral agents have been proposed." exact="Hydroxychloroquine" post="and chloroquine are drugs that interfere with digestive vacuole"/>
   <result pre="[44]. Therefore, further antiviral agents have been proposed. Hydroxychloroquine and" exact="chloroquine" post="are drugs that interfere with digestive vacuole function within"/>
   <result pre="neutrophils and chemotaxis of eosinophils and; impair complement-dependent antigen-antibody reactions." exact="Chloroquine" post="has been used for malaria treatment and chemoprophylaxis and"/>
   <result pre="Chloroquine has been used for malaria treatment and chemoprophylaxis and" exact="hydroxychloroquine" post="is used for treatment of several autoimmune conditions including"/>
   <result pre="arthritis. Both drugs have in vitro activity against coronaviruses, with" exact="hydroxychloroquine" post="having relatively higher potency against SARS-CoV-2 [45]. On the"/>
   <result pre="On the basis of limited in vitro and anecdotal data," exact="chloroquine" post="or hydroxychloroquine administered either with or without azithromycin (a"/>
   <result pre="basis of limited in vitro and anecdotal data, chloroquine or" exact="hydroxychloroquine" post="administered either with or without azithromycin (a macrolide with"/>
   <result pre="anecdotal data, chloroquine or hydroxychloroquine administered either with or without" exact="azithromycin" post="(a macrolide with anti-inflammatory properties) have been recommended for"/>
   <result pre="of emapalumab (anti-interferon-Î³ monoclonal antibody Sobi-IMMUNO-101 study) and the antiparasitic" exact="ivermectin" post="[48]. To date, more than 600 worldwide studies and"/>
   <result pre="haemophagocytic lymphohistiocytosis: an open-label, single-centre, pilot trialLancet Haematol62019e630e63731537486 27TreonS.P.CastilloJ.SkarbnikA.P.SoumeraiL.D.GhobrialI.M.GuerreraM.L.The BTK-inhibitor" exact="ibrutinib" post="may protect against pulmonary injury in COVID-19 infected patientsBlood13520201912191532302379"/>
   <result pre="adults hospitalized with severe COVID-19N Engl J Med38220201787179932187464 45WangM.CaoR.ZhangL.YangX.LiuJ.XuM.Remdesivir and" exact="chloroquine" post="effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in"/>
   <result pre="patients with severe Covid-19N Engl J Med38220202327233610.1056/NEJMoa200701632275812 48CalyL.DruceJ.D.CattonM.G.JansD.A.WagstaffK.M.The FDA-approved drug" exact="ivermectin" post="inhibits the replication of SARS-CoV-2 in vitroAntiviral Res1782020104787 49Rome"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7252082\results\search\drug\results.xml">
   <result pre="and efficacy are being conducted. Camostat mesilate/nafamostat mesilateTreatment for pancreatitis" exact="Serine" post="protease/TMPRSS2 inhibitor â€¢In mice, camostat mesilate dosed at concentrations"/>
   <result pre="Camostat mesilate/nafamostat mesilateTreatment for pancreatitis Serine protease/TMPRSS2 inhibitor â€¢In mice," exact="camostat" post="mesilate dosed at concentrations akin to the clinically achievable"/>
   <result pre="infection from 100% to 30â€&quot;35%. â€¢In vitro studies demonstrated that" exact="camostat" post="mesilate can block SARS-COV-2 entry into human lung cells"/>
   <result pre="clinical practice. A randomized, placebo-controlled trial exploring the impact of" exact="camostat" post="mesilate on COVID-19 Infection has begun recruiting patients (nÂ"/>
   <result pre="=Â 180) to provide key insights into the safety of" exact="camostat" post="mesilate in COVID-19 patients. Favipiravir (favilavir)Approved drug for novel"/>
   <result pre="case series of hospitalised COVID-19 patients (nÂ =Â 138) used" exact="azithromycin" post="for antibacterial coverage,31 although the available evidence is insufficient"/>
   <result pre="evidence is insufficient to establish safety and benefit of adjunct" exact="azithromycin" post="use in patients with COVID-19. Risk of cardiac arrhythmias"/>
   <result pre="of cardiac arrhythmias (such as QT prolongation) and psychiatric disturbances" exact="Azithromycin" post="causes additive toxicity with amiodarone hydrochloride ChloroquineAntimalarial agent May"/>
   <result pre="QT prolongation) and psychiatric disturbances Azithromycin causes additive toxicity with" exact="amiodarone" post="hydrochloride ChloroquineAntimalarial agent May interfere with ACE2 receptor glycosylation"/>
   <result pre="is available to substantiate the efficacy and possible benefits of" exact="chloroquine" post="in patients with COVID-19.36 â€¢Although the pharmacokinetics and toxicity"/>
   <result pre="patients with COVID-19.36 â€¢Although the pharmacokinetics and toxicity profile of" exact="chloroquine" post="is well-established in malaria treatment (the use of high"/>
   <result pre="use); caution in patients with glucose-6-phosphate-dehdrogenase deficiency and diabetic patients." exact="Chloroquine" post="may increase ciclosporin's concentration and risk of toxicity (creatinine"/>
   <result pre="(creatinine concentration may increase even with low doses of ciclosporin);" exact="cimetidine" post="reduces metabolism of chloroquine Hydroxychloroquine Hydroxychloroquine (hydroxyl analog of"/>
   <result pre="even with low doses of ciclosporin); cimetidine reduces metabolism of" exact="chloroquine" post="Hydroxychloroquine Hydroxychloroquine (hydroxyl analog of chloroquine) has similar antiviral"/>
   <result pre="with low doses of ciclosporin); cimetidine reduces metabolism of chloroquine" exact="Hydroxychloroquine" post="Hydroxychloroquine (hydroxyl analog of chloroquine) has similar antiviral mechanism"/>
   <result pre="low doses of ciclosporin); cimetidine reduces metabolism of chloroquine Hydroxychloroquine" exact="Hydroxychloroquine" post="(hydroxyl analog of chloroquine) has similar antiviral mechanism as"/>
   <result pre="findings from China reported good prognosis for patients who received" exact="hydroxychloroquine" post="sulfate 400 mg daily for 5 days.39 â€¢A randomized,"/>
   <result pre="immunoglobulin, with or without corticosteroids) vs standard treatment plus oral" exact="hydroxychloroquine" post="in patients in COVID-19 patients (nÂ =Â 68) from"/>
   <result pre="care alone (nÂ =Â 84) vs standard care plus oral" exact="hydroxychloroquine" post="(nÂ =Â 97) but found no significant difference in"/>
   <result pre="but it may interact with drugs affecting blood glucose concentration" exact="Hydroxychloroquine" post="with azithromycin See above for information about each agent."/>
   <result pre="may interact with drugs affecting blood glucose concentration Hydroxychloroquine with" exact="azithromycin" post="See above for information about each agent. â€¢Preliminary findings"/>
   <result pre="nonrandomized study showed that patients (nÂ =Â 36) who received" exact="hydroxychloroquine" post="with azithromycin had a higher percentage of negative PCR"/>
   <result pre="showed that patients (nÂ =Â 36) who received hydroxychloroquine with" exact="azithromycin" post="had a higher percentage of negative PCR results in"/>
   <result pre="in nasopharyngeal samples at day 6 than those who received" exact="hydroxychloroquine" post="alone.36 â€¢A pilot uncontrolled non-comparative observational study in Marseille,"/>
   <result pre="non-comparative observational study in Marseille, France investigated the efficacy of" exact="hydroxychloroquine" post="with azithromycin in mild COVID-19 patients (nÂ =Â 80),"/>
   <result pre="study in Marseille, France investigated the efficacy of hydroxychloroquine with" exact="azithromycin" post="in mild COVID-19 patients (nÂ =Â 80), and revealed"/>
   <result pre="other drugs causing QT prolongation.43 â€¢Another study recently reported that" exact="azithromycin" post="used alone has caused QT prolongation,44 demonstrating the need"/>
   <result pre="Hydroxychloroquine/chloroquine use was not associated with a safety signal while" exact="azithromycin" post="used alone was associated with TdP/QT prolongation. See above"/>
   <result pre="combination. See above for information about each agent. Other agentsb" exact="Ibuprofen" post="and other NSAIDS â€¢A letter published in The Lancet"/>
   <result pre="Respir Med46 reported a link between use of thiazolidinediones and" exact="ibuprofen" post="and an increased ACE2 expression, resulting in worsened outcomes"/>
   <result pre="is no compelling published evidence to support an association between" exact="ibuprofen" post="and poor outcomes in patients diagnosed with COVID-19. â€¢On"/>
   <result pre="with NSAIDs, increasing the risk of hyperkalaemia and renal impairment" exact="Nitric oxide" post="(inhaled) A selective pulmonary vasodilator with demonstrated benefit in"/>
   <result pre="â€¢There is in vitro evidence of direct antiviral activity of" exact="nitric oxide" post="against SARS-CoV.53 â€¢Clinical trials evaluating the use of inhaled"/>
   <result pre="oxide against SARS-CoV.53 â€¢Clinical trials evaluating the use of inhaled" exact="nitric oxide" post="in the management of mild-to-moderate COVID-19 are underway.54 â€¢At"/>
   <result pre="against SARS-CoV-2 â€¢An in vitro study showed a potential for" exact="ivermectin" post="against SARS-CoV-2.55 Safe at a dose for anti-parasitic use,"/>
   <result pre="pandemic of fake â€œessentialâ€� medicines (including the COVID-19 candidate drug" exact="chloroquine" post="and hydroxychloroquine) and other medical supplies. Since COVID-19 was"/>
   <result pre="producers of medical supplies, China and India, following lockdown. After" exact="hydroxychloroquine" post="was claimed effective for COVID-19 treatment, there was a"/>
   <result pre="panic. A classic example is the recent media announcements that" exact="hydroxychloroquine" post="and chloroquine are the â€œgame changersâ€� and potential cure"/>
   <result pre="classic example is the recent media announcements that hydroxychloroquine and" exact="chloroquine" post="are the â€œgame changersâ€� and potential cure for COVID-19,"/>
   <result pre="inappropriate stockpiling and use by the public. Inappropriate stockpiling of" exact="hydroxychloroquine" post="has also resulted in substantial shortages affecting arthritis or"/>
   <result pre="Â°C, and widely circulated myths on social media around taking" exact="Ibuprofen" post="(Advil, Motrin), naproxen (Aleve) and other non-steroidal anti-inflammatory drugs"/>
   <result pre="circulated myths on social media around taking Ibuprofen (Advil, Motrin)," exact="naproxen" post="(Aleve) and other non-steroidal anti-inflammatory drugs (NSAIDs), vitamins: C,"/>
   <result pre="suggestions on the potential efficacy of certain drugs, such as" exact="chloroquine" post="and hydroxychloroquine, have resulted in hoarding of the drugs"/>
   <result pre="(TGA) implemented restrictions on the medical specialists that can initiate" exact="hydroxychloroquine" post="prescribing. Further to this, TGA has released a statement"/>
   <result pre="acute respiratory infections caused by 2019â€�nCoVChembiochem2020 9YaoT.T.QianJ.D.ZhuW.Y.WangY.WangG.Q.A systematic review of" exact="lopinavir" post="therapy for SARS coronavirus and MERS coronavirusâ€&quot;A possible reference"/>
   <result pre="Assoc2020 Feb 7e201585 32DevauxC.A.RolainJ.-M.ColsonP.RaoultD.New insights on the antiviral effects of" exact="chloroquine" post="against coronavirus: what to expect for COVID-19?Int J Antimicrob"/>
   <result pre="expect for COVID-19?Int J Antimicrob Agents2020 Mar 1210593832171740 33ColsonP.RolainJ.-M.LagierJ.-C.BrouquiP.RaoultD.Chloroquine and" exact="hydroxychloroquine" post="as available weapons to fight COVID-19Int J Antimicrob Agents5542020"/>
   <result pre="vitro antiviral activity and projection of optimized dosing design of" exact="hydroxychloroquine" post="for the treatment of severe acute respiratory syndrome coronavirus"/>
   <result pre="syndrome coronavirus 2 (SARS-CoV-2)Clin Infect Dis2020 Mar 9ciaa237 35WangM.CaoR.ZhangL.Remdesivir and" exact="chloroquine" post="effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in"/>
   <result pre="emerged novel coronavirus (2019-nCoV) in vitroCell Res3032020 Mar26927132020029 36GautretP.LagierJ.-C.ParolaP.Hydroxychloroquine and" exact="azithromycin" post="as a treatment of COVID-19: results of an open-label"/>
   <result pre="non-randomized clinical trialInt J Antimicrob Agents2020 Mar 2010594932205204 37RolainJ.-M.ColsonP.RaoultD.Recycling of" exact="chloroquine" post="and its hydroxyl analogue to face bacterial, fungal and"/>
   <result pre="Oct29730817629679 38CortegianiA.IngogliaG.IppolitoM.GiarratanoA.EinavS.A systematic review on the efficacy and safety of" exact="chloroquine" post="for the treatment of COVID-19J Crit CareS0883â€&quot;9441202020 Mar 103039030397"/>
   <result pre="COVID-19J Crit CareS0883â€&quot;9441202020 Mar 103039030397 39Chen JunL.D.LiuLiLiuPingXuA pilot study of" exact="hydroxychloroquine" post="in treatment of patients with common coronavirus disease-19 (COVID-19)J"/>
   <result pre="common coronavirus disease-19 (COVID-19)J Zhejiang Univ (Med Sci)49120200-0 40ChenZ.HuJ.ZhangZ.Efficacy of" exact="hydroxychloroquine" post="in patients with COVID-19: results of a randomized clinical"/>
   <result pre="a randomized clinical trialMedrxiv202010.1101/2020.03.22.20040758 41MahevasM.TranV.-T.RoumierM.No evidence of clinical efficacy of" exact="hydroxychloroquine" post="in patients hospitalized for COVID-19 infection with oxygen requirement:"/>
   <result pre="target trialmedRxiv202010.1101/2020.04.10.200606992020.2004.2010.20060699 42GautretP.LagierJ.-C.ParolaP.Clinical and microbiological effect of a combination of" exact="hydroxychloroquine" post="and azithromycin in 80 COVID-19 patients with at least"/>
   <result pre="42GautretP.LagierJ.-C.ParolaP.Clinical and microbiological effect of a combination of hydroxychloroquine and" exact="azithromycin" post="in 80 COVID-19 patients with at least a six-day"/>
   <result pre="1110166332289548 43ChorinE.DaiM.ShulmanE.The QT interval in patients with COVID-19 treated with" exact="hydroxychloroquine" post="and azithromycinNat Med202010.1038/s41591-020-0888-2 44SarayaniA.CicaliB.HenriksenC.H.BrownJ.D.Safety signals for QT prolongation or"/>
   <result pre="signals for QT prolongation or Torsades de Pointes associated with" exact="azithromycin" post="with or without chloroquine or hydroxychloroquineRes Soc Adm Pharm2020"/>
   <result pre="or Torsades de Pointes associated with azithromycin with or without" exact="chloroquine" post="or hydroxychloroquineRes Soc Adm Pharm2020 Apr 19S1551-7411(20)30391-0 45collab: US"/>
   <result pre="council on hypertension on ACE-inhibitors and angiotensin receptor blockershttps://www.escardio.org/Councils/Council-on-Hypertension-(CHT)/News/position-statement-of-the-esc-council-on-hypertension-on-ace-inhibitors-and-ang2020 52GebistorfF.KaramO.WetterslevJ.AfshariA.Inhaled" exact="nitric oxide" post="for acute respiratory distress syndrome (ARDS) in children and"/>
   <result pre="Virol7932005 Feb1966196915650225 54BiospaceBiospace mallinckrodt evaluates the potential role for inhaled" exact="nitric oxide" post="to treat COVID-19 associated lung complications, engages with scientific,"/>
   <result pre="controlled clinical study to evaluate the efficacy of ASC09F and" exact="Ritonavir" post="for 2019-nCoV Pneumonia. ClinicalTrials.gov Identifier: NCT04261270https://clinicaltrials.gov/ct2/show/NCT04261270?term=NCT04261270&amp;amp;draw=2&amp;amp;rank=12020 58LythgoeM.P.MiddletonP.Ongoing clinical trials"/>
   <result pre="of AustraliaCOVID-19 New Information/Update2020https://www.guild.org.au/resources/business-operations/covid-19 66Therapeutic Goods AdministrationNew Restrictions on Prescribing" exact="Hydroxychloroquine" post="for COVID-192020https://www.tga.gov.au/alert/new-restrictions-prescribing-hydroxychloroquine-covid-19 67Health DoEnsuring Continued Access to Medicines during"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7252421\results\search\drug\results.xml">
   <result pre="poor outcome of that risk group [35]. Furthermore, drugs like" exact="chloroquine" post="and indometazine [35] as well as ACE inhibitors and"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7253763\results\search\drug\results.xml">
   <result pre="of COVID-19, as it is happening with the combination of" exact="azithromycin" post="and hydroxychloroquine.2 In addition, antimicrobials are being used as"/>
   <result pre="of antimicrobials must be addressed. First, current clinical data on" exact="azithromycin" post="or other antimicrobials as part of a combination for"/>
   <result pre="ParolaP, et al.Clinical and microbiological effect of a combination of" exact="hydroxychloroquine" post="and azithromycin in 80 COVID-19 patients with at least"/>
   <result pre="al.Clinical and microbiological effect of a combination of hydroxychloroquine and" exact="azithromycin" post="in 80 COVID-19 patients with at least a six-day"/>
   <result pre="rapid antiviral clearance or clinical benefit with the combination of" exact="hydroxychloroquine" post="and azithromycin in patients with severe COVID-19 infection. MÃ©decine"/>
   <result pre="clearance or clinical benefit with the combination of hydroxychloroquine and" exact="azithromycin" post="in patients with severe COVID-19 infection. MÃ©decine et Maladies"/>
   <result pre="et al.Risk of QT interval prolongation associated with use of" exact="hydroxychloroquine" post="with or without concomitant azithromycin among hospitalized patients testing"/>
   <result pre="prolongation associated with use of hydroxychloroquine with or without concomitant" exact="azithromycin" post="among hospitalized patients testing positive for coronavirus disease 2019"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7254006\results\search\drug\results.xml">
   <result pre="Article Discovery of the FDA-approved drugs bexarotene, cetilistat, diiodohydroxyquinoline, and" exact="abiraterone" post="as potential COVID-19 treatments with a robust two-tier screening"/>
   <result pre="library consisting 1528 FDA-approved drugs. Cetilistat (anti-pancreatic lipase), diiodohydroxyquinoline (anti-parasitic)," exact="abiraterone" post="acetate (synthetic androstane steroid), and bexarotene (antineoplastic retinoid) exhibited"/>
   <result pre="(anti-pancreatic lipase), diiodohydroxyquinoline (anti-parasitic), abiraterone acetate (synthetic androstane steroid), and" exact="bexarotene" post="(antineoplastic retinoid) exhibited potent in vitro anti-SARS-CoV-2 activity (EC50"/>
   <result pre="retinoid) exhibited potent in vitro anti-SARS-CoV-2 activity (EC50 1.13â€&quot;2.01 Î¼M)." exact="Bexarotene" post="demonstrated the highest Cmax:EC50 ratio (1.69) which was higher"/>
   <result pre="compounds studied in this article Abiraterone acetate (PubChem CID: 9821849)" exact="Bexarotene" post="(PubChem CID: 82146) Cetilistat (PubChem CID: 9952916) Diiodohydroxyquinoline (PubChem"/>
   <result pre="Keywords Antiviral Coronavirus COVID-19 Library SARS-CoV-2 Treatment Cetilistat Diiodohydroxyquinoline Abiraterone" exact="Bexarotene" post="1 Introduction Coronaviruses are positive sense, single stranded, enveloped"/>
   <result pre="nucleotide analogue with broad-spectrum antiviral activities including against SARS-CoV-2 [12]." exact="Chloroquine" post="and hydroxychloroquine are mildly immunosuppressive drugs used in the"/>
   <result pre="with broad-spectrum antiviral activities including against SARS-CoV-2 [12]. Chloroquine and" exact="hydroxychloroquine" post="are mildly immunosuppressive drugs used in the treatment of"/>
   <result pre="human [12,16]. A recent non-randomized small-scale clinical study showed that" exact="hydroxychloroquine" post="with or without azithromycin significantly reduced the viral load"/>
   <result pre="non-randomized small-scale clinical study showed that hydroxychloroquine with or without" exact="azithromycin" post="significantly reduced the viral load and duration of virus"/>
   <result pre="and duration of virus shedding in 20 COVID-19 patients [13]." exact="Nafamostat" post="and camostat are a serine protease inhibitor used in"/>
   <result pre="of virus shedding in 20 COVID-19 patients [13]. Nafamostat and" exact="camostat" post="are a serine protease inhibitor used in the treatment"/>
   <result pre="identified a number of drug compounds with anti-SARS-CoV-2 activity, including" exact="bexarotene" post="which has broad-spectrum anti-coronaviral activity and a higher Cmax"/>
   <result pre="bovine serum (FBS, Gibco), 50 U/mL penicillin, and 50 Î¼g/ml" exact="streptomycin" post="as previously described [17]. All experiments involving live SARS-CoV-2"/>
   <result pre="the agarose plugs, the monolayers were stained with 0.7 %" exact="crystal violet" post="(BDH, Merck) and the plaques counted. The percentage of"/>
   <result pre="(-1 to 0 hpi) or post-infection (0 to +1 hpi)." exact="Dimethyl sulfoxide" post="(0.5 %) was included as a negative control. Other"/>
   <result pre="generates a luminescent signal directly proportional to the amount of" exact="adenosine" post="triphosphate (ATP) present and is proportional to the number"/>
   <result pre="at 72 hpi (Table 1 ). Notably, hydroxychloroquine, nafamostat, and" exact="ivermectin" post="which were previously shown to exhibit anti-SARS-CoV-2 activity were"/>
   <result pre="Synthetic androstane steroid Prostate cancer Asenapine (hydrochloride) Atypical antipsychotic Schizophrenia" exact="Azacytidine" post="Nucleoside analogue Myelodysplastic syndrome and acute myeloid leukemia Bexarotene"/>
   <result pre="Schizophrenia Azacytidine Nucleoside analogue Myelodysplastic syndrome and acute myeloid leukemia" exact="Bexarotene" post="Retinoid (retinoid X receptor activator) Cutaneous T cell lymphoma"/>
   <result pre="Hypertension and congestive heart failure Cetilistat Pancreatic lipase inhibitor Obesity" exact="Chloroquine" post="(diphosphate) 4-Aminoquinoline Malaria and amoebic liver abscess Ciclesonide Glucocorticoid"/>
   <result pre="inhibitor Obesity Chloroquine (diphosphate) 4-Aminoquinoline Malaria and amoebic liver abscess" exact="Ciclesonide" post="Glucocorticoid Asthma and allergic rhinitis Diethylstilbestrol Nonsteroidal estrogen Prostate"/>
   <result pre="and amoebic liver abscess Ciclesonide Glucocorticoid Asthma and allergic rhinitis" exact="Diethylstilbestrol" post="Nonsteroidal estrogen Prostate cancer Diiodohydroxyquinoline Quinoline derivative Amoebiasis Fluoxetine"/>
   <result pre="liver abscess Ciclesonide Glucocorticoid Asthma and allergic rhinitis Diethylstilbestrol Nonsteroidal" exact="estrogen" post="Prostate cancer Diiodohydroxyquinoline Quinoline derivative Amoebiasis Fluoxetine (hydrochloride) Selective"/>
   <result pre="Quinoline derivative Amoebiasis Fluoxetine (hydrochloride) Selective serotonin reuptake inhibitor Depression" exact="Micafungin" post="(sodium) Echinocandin Fungal infection Permethrin Insecticide Scabies and lice"/>
   <result pre="Selective serotonin reuptake inhibitor Depression Micafungin (sodium) Echinocandin Fungal infection" exact="Permethrin" post="Insecticide Scabies and lice Pimavanserin Atypical antipsychotic Parkinsonâ€™s disease"/>
   <result pre="Insecticide Scabies and lice Pimavanserin Atypical antipsychotic Parkinsonâ€™s disease psychosis" exact="Raloxifene" post="(hydrochloride) Selective estrogen receptor modulator Osteoporosis Sofalcone Synthetic sophoradin"/>
   <result pre="lice Pimavanserin Atypical antipsychotic Parkinsonâ€™s disease psychosis Raloxifene (hydrochloride) Selective" exact="estrogen" post="receptor modulator Osteoporosis Sofalcone Synthetic sophoradin analogue Gastrointestinal tract"/>
   <result pre="modulator Osteoporosis Sofalcone Synthetic sophoradin analogue Gastrointestinal tract mucosal protection" exact="Tamoxifen" post="(Citrate) Selective estrogen receptor modulator Breast cancer, infertility, and"/>
   <result pre="Synthetic sophoradin analogue Gastrointestinal tract mucosal protection Tamoxifen (Citrate) Selective" exact="estrogen" post="receptor modulator Breast cancer, infertility, and gynecomastia Tilorone (dihydrochloride)"/>
   <result pre="their dose-dependent anti-SARS-CoV-2 effects. Four drug compounds, namely, cetilistat, diiodohydroxyquinoline," exact="abiraterone" post="acetate, and bexarotene were identified as the most potent"/>
   <result pre="effects. Four drug compounds, namely, cetilistat, diiodohydroxyquinoline, abiraterone acetate, and" exact="bexarotene" post="were identified as the most potent anti-SARS-CoV-2 drug compounds"/>
   <result pre="hpi, the 50 % cytotoxic concentrations (CC50) of cetilistat, diiodohydroxyquinoline," exact="abiraterone" post="acetate, and bexarotene were &amp;gt;100 Î¼M, &amp;gt;100 Î¼M, 92.35"/>
   <result pre="% cytotoxic concentrations (CC50) of cetilistat, diiodohydroxyquinoline, abiraterone acetate, and" exact="bexarotene" post="were &amp;gt;100 Î¼M, &amp;gt;100 Î¼M, 92.35 Î¼M, and 38.21"/>
   <result pre="plaque reduction assay are shown: (A) cetilistat, (B) diiodohydroxyquinoline, (C)" exact="abiraterone" post="acetate, and (D) bexarotene. Table 2 Antiviral activity and"/>
   <result pre="&amp;gt;100.00 4.50 1.38 &amp;gt;72.46 Abiraterone (acetate) 92.35 8.40 1.94 47.60" exact="Bexarotene" post="38.21 9.40 2.01 19.01 Abbreviations: CC50, 50 % cytotoxic"/>
   <result pre="CPE development in VeroE6 cells at 72 hpi, while diiodohydroxyquinoline," exact="abiraterone" post="acetate, and bexarotene achieved up to âˆ¼70 % CPE"/>
   <result pre="VeroE6 cells at 72 hpi, while diiodohydroxyquinoline, abiraterone acetate, and" exact="bexarotene" post="achieved up to âˆ¼70 % CPE inhibition (Fig. 5C)."/>
   <result pre="inhibition (Fig. 5C). Overall, these results demonstrated that cetilistat, diiodohydroxyquinoline," exact="abiraterone" post="acetate, and bexarotene inhibited the viral load, viral antigen"/>
   <result pre="Overall, these results demonstrated that cetilistat, diiodohydroxyquinoline, abiraterone acetate, and" exact="bexarotene" post="inhibited the viral load, viral antigen expression, and infectious"/>
   <result pre="(MOI = 0.100) VeroE6 cells after treatment with cetilistat, diiodohydroxyquinoline," exact="abiraterone" post="acetate, or bexarotene (10Î¼M each) and incubated at 37"/>
   <result pre="VeroE6 cells after treatment with cetilistat, diiodohydroxyquinoline, abiraterone acetate, or" exact="bexarotene" post="(10Î¼M each) and incubated at 37 Â°C with 5%"/>
   <result pre="Â± standard deviations. 3.4 Modes of action of cetilistat, diiodohydroxyquinoline," exact="abiraterone" post="acetate, and bexarotene against SARS-CoV-2 To investigate which steps"/>
   <result pre="3.4 Modes of action of cetilistat, diiodohydroxyquinoline, abiraterone acetate, and" exact="bexarotene" post="against SARS-CoV-2 To investigate which steps of the SARS-CoV-2"/>
   <result pre="carried out (Fig. 6 A). Addition of cetilistat, diiodohydroxyquinoline, or" exact="abiraterone" post="acetate at 0 hpi and 3 hpi, but not"/>
   <result pre="events of the SARS-CoV-2 replication cycle (Fig. 6B). In contrast," exact="bexarotene" post="was only effective when co-infected with cells, suggesting that"/>
   <result pre="enabled virus internalization (Fig. 6C). As shown in Fig. 6D," exact="bexarotene" post="did not block virus-host receptor binding, but significantly reduced"/>
   <result pre="reduced viral load during virus internationalization. These results suggested that" exact="bexarotene" post="interfered with SARS-CoV-2 internalization without blocking its binding to"/>
   <result pre="without blocking its binding to the host cell surface. Interestingly," exact="bexarotene" post="also demonstrated antiviral activity against the highly virulent MERS-CoV"/>
   <result pre="DMSO as control. (C) Virus entry assay with or without" exact="bexarotene" post="addition. Viral attachment was performed at 4â&quot;ƒ and then"/>
   <result pre="Viral load reduction assay showing the dose-dependent anti-MERS-CoV activity of" exact="bexarotene" post="(10Î¼M). VeroE6 cells were infected with MERS-CoV (MOI ="/>
   <result pre="antivirals to reduce viral shedding in the gastrointestinal tract. Both" exact="abiraterone" post="acetate and bexarotene are non-chemotherapeutic antineoplastic drugs with limited"/>
   <result pre="viral shedding in the gastrointestinal tract. Both abiraterone acetate and" exact="bexarotene" post="are non-chemotherapeutic antineoplastic drugs with limited immunosuppressive effects. Abiraterone"/>
   <result pre="deprivation by inhibition of the androgen synthesizing enzyme CYP17A1 [33,34]." exact="Bexarotene" post="is a third-generation retinoid used in the treatment of"/>
   <result pre="and breast cancer [[35], [36], [37], [38]]. We showed that" exact="abiraterone" post="acetate and bexarotene potently inhibited SARS-CoV-2 replication in vitro"/>
   <result pre="[[35], [36], [37], [38]]. We showed that abiraterone acetate and" exact="bexarotene" post="potently inhibited SARS-CoV-2 replication in vitro with EC50 of"/>
   <result pre="1.94 Î¼M and 2.01 Î¼M, respectively. Of particular interest is" exact="bexarotene" post="which has a peak serum concentration (Cmax) of 3.39"/>
   <result pre="of 300 mg/m2 [39]. The Cmax to EC50 ratio of" exact="bexarotene" post="for SARS-CoV-2 (1.69) is higher than those achieved with"/>
   <result pre="than those achieved with standard dosing of chloroquine, hydroxychloroquine, and" exact="ivermectin" post="(0.02â€&quot;1.04). Moreover, the time required to achieve Cmax (Tmax)"/>
   <result pre="required to achieve Cmax (Tmax) with standard oral dosing of" exact="bexarotene" post="is short (2.5 h), which is important especially in"/>
   <result pre="adenovirus [21]. We therefore additionally tested the antiviral activity of" exact="bexarotene" post="against the highly virulent MERS-CoV, and showed that it"/>
   <result pre="MERS-CoV with an EC50 of 2.12 Î¼M. The potential of" exact="bexarotene" post="and its related analogue compounds as â€œpan-coronavirusâ€� agents should"/>
   <result pre="for COVID-19. The topical and/or systemic effects of cetilistat, diiodohydroxylquinoline," exact="abiraterone" post="acetate, and bexarotene should be further evaluated in suitable"/>
   <result pre="topical and/or systemic effects of cetilistat, diiodohydroxylquinoline, abiraterone acetate, and" exact="bexarotene" post="should be further evaluated in suitable ex vivo human"/>
   <result pre="drug discovery and therapeutic optionsNat. Rev. Drug Discov.15201632734726868298 12WangM.CaoR.ZhangL.YangX.LiuJ.XuM.ShiZ.HuZ.ZhongW.XiaoG.Remdesivir and" exact="chloroquine" post="effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in"/>
   <result pre="recently emerged novel coronavirus (2019-nCoV) in vitroCell Res.30202026927132020029 13GautretP.LagierJ.C.ParolaP.HoangV.T.MeddebL.MailheM.DoudierB.CourjonJ.GiordanengoV.VieiraV.E.Hydroxychloroquine and" exact="azithromycin" post="as a treatment of COVID-19: results of an open-label"/>
   <result pre="vitro antiviral activity and projection of optimized dosing design of" exact="hydroxychloroquine" post="for the treatment of severe acute respiratory syndrome coronavirus"/>
   <result pre="Biochem. Mol. Biol.84200353754212767278 34ArasaratnamM.CrumbakerM.BhatnagarA.McKayMjMolloyMpGurneyH.Inter- and intra-patient variability in pharmacokinetics of" exact="abiraterone" post="acetate in metastatic prostate cancerCancer Chemother. Pharmacol.84201913914631081533 35BoehmM.F.ZhangL.ZhiL.McClurgM.R.BergerE.WagonerM.MaisD.E.SutoC.M.Design and"/>
   <result pre="apoptosis in leukemia cellsJ. Med. Chem.381995314631557636877 36GniadeckiR.AssafC.BagotM.DummerR.DuvicM.KnoblerR.RankiA.SchwandtP.WhittakerS.The optimal use of" exact="bexarotene" post="in cutaneous T-cell lymphomaBr. J. Dermatol.157200743344017553039 37DragnevK.H.PettyW.J.ShahS.J.LewisL.D.BlackC.C.MemoliV.NugentW.C.HermannT.Negro-VilarA.RigasJ.R.A proof-of-principle clinical"/>
   <result pre="cutaneous T-cell lymphomaBr. J. Dermatol.157200743344017553039 37DragnevK.H.PettyW.J.ShahS.J.LewisL.D.BlackC.C.MemoliV.NugentW.C.HermannT.Negro-VilarA.RigasJ.R.A proof-of-principle clinical trial of" exact="bexarotene" post="in patients with non-small cell lung cancerClin. Cancer Res.1320071794180017363535"/>
   <result pre="lung cancerClin. Cancer Res.1320071794180017363535 38EstevaF.J.GlaspyJ.BaidasS.LaufmanL.HutchinsL.DicklerM.TripathyD.CohenR.Multicenter phase II study of oral" exact="bexarotene" post="for patients with metastatic breast cancerJ. Clin. Oncol.212003999100612637463 39ListonD.R.DavisM.Clinically"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7255394\results\search\drug\results.xml">
   <result pre="did not receive empirical pharmacologic treatment. The drugs administered were" exact="azithromycin" post="(6/7), lopinavir/ritonavir (6/7), corticosteroids (5/7), and hydroxychloroquine (6/7). Remdesivir,"/>
   <result pre="drugs administered were azithromycin (6/7), lopinavir/ritonavir (6/7), corticosteroids (5/7), and" exact="hydroxychloroquine" post="(6/7). Remdesivir, immunoglobulins, and tocilizumab were given to the"/>
   <result pre="days based on clinical progression (Table 1). In one case," exact="methylprednisolone" post="was used despite no suspicion of MAS. In that"/>
   <result pre="massive thrombosis (brain, lungs, and lower extremities), we empirically started" exact="methylprednisolone" post="to treat the suspected inflammation related to SARS-CoV-2 binding"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7256352\results\search\drug\results.xml">
   <result pre="(Boopathi etÂ al., 2020; Elmezayen etÂ al., 2020). For example," exact="chloroquine" post="and remdesivir (RDV, GS-5734) are two drugs that inÂ"/>
   <result pre="1â€&quot;12. 10.1080/07391102.2020.1758790 AggarwalM., LeserG. P., &amp;amp; LambR. A. (2020). Repurposing" exact="papaverine" post="as an antiviral agent against influenza viruses and paramyxoviruses."/>
   <result pre="studies of drug repurposing and synergism of lopinavir, oseltamivir and" exact="ritonavir" post="binding with SARS-CoV-2 Protease against COVID-19. Journal of Biomolecular"/>
   <result pre="synthesis of a phosphoramidate prodrug of a pyrrolo [2, 1-f][triazin-4-amino]" exact="adenine" post="C-nucleoside (GS-5734) for the treatment of Ebola and emerging"/>
   <result pre="LiuJ., XuM., ShiZ., HuZ., ZhongW., &amp;amp; XiaoG. (2020). Remdesivir and" exact="chloroquine" post="effectively inhibit the recently emerged novel coronavirus (2019-nCoV) inÂ"/>
   <result pre="XuJ., ShiP.-Y., LiH., &amp;amp; ZhouJ. (2020). Broad spectrum antiviral agent" exact="niclosamide" post="and its therapeutic potential. ACS Infectious Diseases, 6(5), 909â€&quot;915."/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7256451\results\search\drug\results.xml">
   <result pre="the other hand lowers blood pressure, possibly through production of" exact="nitric oxide." post="Furthermore, the ACE2-Angâ€&quot;(1-7)-MasR pathway is anti-inflammatory. Thus, ACE2 not"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7256510\results\search\drug\results.xml">
   <result pre="have shown increases in lactate dehydrogenase (LDH), aspartate aminotransferase (AST)," exact="alanine" post="transaminase (ALT), C-reactive protein (CRP), creatine kinase (CK), erythrocyte"/>
   <result pre="(LDH), aspartate aminotransferase (AST), alanine transaminase (ALT), C-reactive protein (CRP)," exact="creatine" post="kinase (CK), erythrocyte sedimentation rate (ESR), white blood cell"/>
   <result pre="recommended for use in the clinic, like the combination of" exact="Hydroxychloroquine" post="and Azithromycin because of the potential for toxicity. Other"/>
   <result pre="use in the clinic, like the combination of Hydroxychloroquine and" exact="Azithromycin" post="because of the potential for toxicity. Other conceivable treatments"/>
   <result pre="Peramivir, and Zanamivir), Ganciclovir, Acyclovir, and Ribavirin, as well as" exact="Methylprednisolone" post="which reduced the risk of death in ARDS patients"/>
   <result pre="recommended [66]. 8.1.1 Nucleoside analogs Nucleoside analogs are derivatives of" exact="adenine" post="or guanine that block the RNA-dependent RNA polymerase enzyme"/>
   <result pre="the efficacy of Favipiravir plus Interferon-Î± (ChiCTR2000029600), and Favipiravir plus" exact="Baloxavir marboxil" post="(an approved Influenza inhibitor targeting the cap-dependent endonuclease) (ChiCTR2000029544)."/>
   <result pre="approved as an experimental coronavirus drug against SARS-CoV-2 [70]. 8.1.1.3" exact="Ribavirin" post="Ribavirin is a guanine derivative approved for treating respiratory"/>
   <result pre="as an experimental coronavirus drug against SARS-CoV-2 [70]. 8.1.1.3 Ribavirin" exact="Ribavirin" post="is a guanine derivative approved for treating respiratory syncytial"/>
   <result pre="8.1.1.4 Remdesivir (GS-5734) Remdesivir is a phosphoramidite pro-drug of an" exact="adenine" post="derivative with a chemical structure similar to Tenofovir alafenamide,"/>
   <result pre="of an adenine derivative with a chemical structure similar to" exact="Tenofovir alafenamide," post="an approved inhibitor of HIV reverse transcriptase. Remdesivir had"/>
   <result pre="effective COVID-19 treatment [78]. 8.1.1.5 Galidesivir (BCX4430) Galidesivir is an" exact="adenosine" post="analog that was initially developed to treat HCV, and"/>
   <result pre="it has been shown that the combination of Lopinavir and" exact="Ritonavir" post="is not effective in treating patients with severe COVID-19"/>
   <result pre="not effective in treating patients with severe COVID-19 [82]. 8.1.1.6.3" exact="Disulfiram" post="Disulfiram is a drug used for treating chronic alcoholism"/>
   <result pre="effective in treating patients with severe COVID-19 [82]. 8.1.1.6.3 Disulfiram" exact="Disulfiram" post="is a drug used for treating chronic alcoholism by"/>
   <result pre="for treating chronic alcoholism by inducing an acute intolerance to" exact="ethanol" post="(drinking alcohol). Disulfiram was reported to inhibit the papain-like"/>
   <result pre="alcoholism by inducing an acute intolerance to ethanol (drinking alcohol)." exact="Disulfiram" post="was reported to inhibit the papain-like protease of MERS"/>
   <result pre="inhibitors Other 3CLpro inhibitors, such as Cinanserin [84], Flavonoids [85]," exact="Cobicistat" post="[86], Atazanavir, Efavirenz, Ritonavir, Dolutegravir [87], Thymopentin, Carfilzomib, Saquinavir"/>
   <result pre="[85], Cobicistat [86], Atazanavir, Efavirenz, Ritonavir, Dolutegravir [87], Thymopentin, Carfilzomib," exact="Saquinavir" post="[88], Ledipasvir, and Velpatasvir [89] and PLP inhibitors, like"/>
   <result pre="Efavirenz, Ritonavir, Dolutegravir [87], Thymopentin, Carfilzomib, Saquinavir [88], Ledipasvir, and" exact="Velpatasvir" post="[89] and PLP inhibitors, like Diarylheptanoids [90], Grazoprevir, Telaprevir,"/>
   <result pre="like Diarylheptanoids [90], Grazoprevir, Telaprevir, Boceprevir [91], Darunavir [92], and" exact="Formoterol" post="chloroquine [93] are other potential approaches to combat SARS-CoV-2,"/>
   <result pre="Diarylheptanoids [90], Grazoprevir, Telaprevir, Boceprevir [91], Darunavir [92], and Formoterol" exact="chloroquine" post="[93] are other potential approaches to combat SARS-CoV-2, but"/>
   <result pre="for investigating its effectiveness against COVID-19 are in progress. 8.2" exact="Chloroquine" post="(CQ) and Hydroxychloroquine (HCQ) CQ is an anti-malarial drug"/>
   <result pre="effectiveness against COVID-19 are in progress. 8.2 Chloroquine (CQ) and" exact="Hydroxychloroquine" post="(HCQ) CQ is an anti-malarial drug [100] with practical"/>
   <result pre="must be mentioned that although the combination of HCQ plus" exact="Azithromycin" post="c was an effective treatment of COVID-19 [109], the"/>
   <result pre="useful in controlling CRS, for instance in cancer immunotherapy. Initially," exact="dexamethasone" post="was proposed as an effective agent for managing CRS."/>
   <result pre="respiratory status, and may be an effective treatment [165]. 8.9" exact="Ibuprofen" post="Ibuprofen has shown problems with safety [166]. Discussions over"/>
   <result pre="status, and may be an effective treatment [165]. 8.9 Ibuprofen" exact="Ibuprofen" post="has shown problems with safety [166]. Discussions over the"/>
   <result pre="some cases, but most patients with COVID-19 symptoms should use" exact="Paracetamol" post="rather than Ibuprofen, because the latter could worsen the"/>
   <result pre="the condition of four young people with COVID-19 after taking" exact="Ibuprofen" post="[167]. So, it is wise to use Paracetamol instead"/>
   <result pre="after taking Ibuprofen [167]. So, it is wise to use" exact="Paracetamol" post="instead of Ibuprofen for COVID-19 patients. 8.10 Angiotensin-converting enzyme"/>
   <result pre="[167]. So, it is wise to use Paracetamol instead of" exact="Ibuprofen" post="for COVID-19 patients. 8.10 Angiotensin-converting enzyme inhibitors (ACE-I) and"/>
   <result pre="an effective COVID-19 therapy. However, further investigations are essential. 8.13" exact="Nitric oxide" post="Newborns with severe ARDS, are treated with highâ€�dose pulmonary"/>
   <result pre="with severe ARDS, are treated with highâ€�dose pulmonary surfactant, inhaled" exact="nitric oxide," post="highâ€�frequency oscillatory ventilation, and extracorporeal membrane oxygenation. This approach"/>
   <result pre="prevent the entry of SARS-CoV-2 into the cytoplasm [177]. Moreover," exact="Azithromycin" post="has shown some success against COVID-19. 8.17 Ivermectin Ivermectin"/>
   <result pre="more investigation is needed. Besides, the combination of Nitazoxanide and" exact="Azithromycin" post="could be more effective than using them as single"/>
   <result pre="8.21 Vitamins It has been demonstrated in several studies that" exact="vitamin B3" post="(niacin or nicotinamide) was effective in reducing injury in"/>
   <result pre="involving vaccines, antiviral drugs, immunotherapies, monoclonal antibodies, stem cells, and" exact="nitric oxide" post="are summarized in Table 1 . Table 1 Clinical"/>
   <result pre="Infections, Are They Harmful or Protective? NCT04322786 Not yet recruiting" exact="Nitric Oxide" post="Gas Inhalation for Severe Acute Respiratory Syndrome in COVID-19."/>
   <result pre="Acute Respiratory Syndrome in COVID-19. NCT04290871 Withdrawn Proactive Prophylaxis With" exact="Azithromycin" post="and Chloroquine in Hospitalized Patients With COVID-19 NCT04322396 Not"/>
   <result pre="Syndrome in COVID-19. NCT04290871 Withdrawn Proactive Prophylaxis With Azithromycin and" exact="Chloroquine" post="in Hospitalized Patients With COVID-19 NCT04322396 Not yet recruiting"/>
   <result pre="Trial - CORIMUNO-19 - SARI NCT04324073 Not yet recruiting France" exact="Hydroxychloroquine" post="Versus Placebo in Patients Presenting COVID-19 Infection and at"/>
   <result pre="Treatment of New Coronavirus Infected Pneumonia NCT04275388 Not yet recruiting" exact="Chloroquine" post="Diphosphate for the Treatment of Severe Acute Respiratory Syndrome"/>
   <result pre="Not yet recruiting Italy Efficacy and Safety of Darunavir and" exact="Cobicistat" post="for Treatment of Pneumonia Caused by 2019-nCoV NCT04252274 Recruiting"/>
   <result pre="Treating Severe or Critical COVID-19 Infection NCT04326426 Not yet recruiting" exact="Nitric Oxide" post="Gas Inhalation in Severe Acute Respiratory Syndrome in COVID-19"/>
   <result pre="Respiratory Syndrome in COVID-19 NCT04306393 Recruiting United States Inhaled Gaseous" exact="Nitric Oxide" post="(gNO) Antimicrobial Treatment of Difficult Bacterial and Viral Lung"/>
   <result pre="sc NCT04322773 Not yet recruiting Denmark Safety and Efficacy of" exact="Hydroxychloroquine" post="Associated With Azythromycin in SARS-Cov-2 Virus NCT04322123 Not yet"/>
   <result pre="Virus NCT04322123 Not yet recruiting Brazil Comparison of Lopinavir/Ritonavir or" exact="Hydroxychloroquine" post="in Patients With Mild Coronavirus Disease (COVID-19) NCT04307693 Recruiting"/>
   <result pre="Pneumonia-RCT (BEST-RCT) NCT04305106 Recruiting China The Efficacy and Safety of" exact="Thalidomide" post="in the Adjuvant Treatment of Moderate New Coronavirus (COVID-19)"/>
   <result pre="Pneumonia NCT04273529 Not yet recruiting The Efficacy and Safety of" exact="Thalidomide" post="Combined With Low-dose Hormones in the Treatment of Severe"/>
   <result pre="COVID-19 Patients Using Wharton's Jelly-Mesenchymal Stem Cells NCT04313322 Recruiting Jordan" exact="Hydroxychloroquine" post="Treatment for Severe COVID-19 Pulmonary Infection (HYDRA Trial) (HYDRA)"/>
   <result pre="Efficacy and Safety of Corticosteroids in COVID-19(Methylprednisolone) NCT04273321 Recruiting China" exact="Hydroxychloroquine" post="Post Exposure Prophylaxis for Coronavirus Disease (COVID-19) NCT04318444 Not"/>
   <result pre="for Coronavirus Disease (COVID-19) NCT04318444 Not yet recruiting United States" exact="Hydroxychloroquine" post="Chemoprophylaxis in Healthcare Personnel in Contact With COVID-19 Patients"/>
   <result pre="Coronavirus Infection Pneumonia (General and Severe) NCT04295551 Not yet recruiting" exact="Chloroquine" post="Prevention of Coronavirus Disease (COVID-19) in the Healthcare Setting"/>
   <result pre="NCT04303507 Not yet recruiting Evaluating the Efficacy and Safety of" exact="Bromhexine" post="Hydrochloride Tablets Combined With Standard Treatment/ Standard Treatment in"/>
   <result pre="recruiting China Various Combination of Protease Inhibitors, Oseltamivir, Favipiravir, and" exact="Chloroquine" post="for Treatment of COVID19: A Randomized Control Trial (THDMS-COVID19)"/>
   <result pre="Controlled Clinical Study to Evaluate the Efficacy of ASC09F and" exact="Ritonavir" post="for 2019-nCoV Pneumonia NCT04261270 recruiting China Intravenous Aviptadil for"/>
   <result pre="The Efficacy of Different Hormone Doses in 2019-nCoV Severe PneumoniaDrug:" exact="Methylprednisolone" post="NCT04263402 recruiting China Nitric Oxide Gas Inhalation Therapy for"/>
   <result pre="Hormone Doses in 2019-nCoV Severe PneumoniaDrug: Methylprednisolone NCT04263402 recruiting China" exact="Nitric Oxide" post="Gas Inhalation Therapy for Mild/Moderate COVID-19 (NoCovid) NCT04305457 Recruiting"/>
   <result pre="Recruiting China NO Prevention of COVID-19 for Healthcare ProvidersDrug: Inhaled" exact="nitric oxide" post="gas NCT04312243 Not yet recruiting Treatment of Acute Severe"/>
   <result pre="Prevent 2019-nCOV in Medical StaffDrug: recombinant human Interferon Alpha-1b, thymosin" exact="alpha" post="1 NCT04320238 Recruiting China Anti-SARS-CoV-2 Inactivated Convalescent Plasma in"/>
   <result pre="NCT04260594 Not yet recruiting Evaluation of Ganovo (Danoprevir) Combined With" exact="Ritonavir" post="in the Treatment of Novel Coronavirus InfectionDrug: GanovoÂ +Â"/>
   <result pre="Not yet recruiting Italy Efficacy and Safety of Darunavir and" exact="Cobicistat" post="for Treatment of Pneumonia Caused by 2019-nCoV NCT04252274 recruiting"/>
   <result pre="Caused by 2019-nCoV NCT04252274 recruiting China Efficacy and Safety of" exact="Hydroxychloroquine" post="for Treatment of Pneumonia Caused by 2019-nCoV (HC-nCoV) NCT04261517"/>
   <result pre="for Novel CoronavirusCritically Ill Patients With Severe Acute Respiratory FailureDrug:" exact="methylprednisolone" post="therapy NCT04244591 Recruiting China Norwegian Coronavirus Disease 2019 StudyDrug:"/>
   <result pre="methylprednisolone therapy NCT04244591 Recruiting China Norwegian Coronavirus Disease 2019 StudyDrug:" exact="Hydroxychloroquine" post="Sulfate NCT04316377 Not yet recruiting Lopinavir/ Ritonavir, Ribavirin and"/>
   <result pre="2019 StudyDrug: Hydroxychloroquine Sulfate NCT04316377 Not yet recruiting Lopinavir/ Ritonavir," exact="Ribavirin" post="and IFN-beta Combination for nCoV Treatment NCT04276688 Recruiting China"/>
   <result pre="nCoV Treatment NCT04276688 Recruiting China Post-exposure Prophylaxis for SARS-Coronavirus-2 Drug:" exact="Hydroxychloroquine" post="NCT04308668 Recruiting United States A Pilot Clinical Study on"/>
   <result pre="Exosomes Treating Severe Novel Coronavirus Pneumonia NCT04276987 Not yet recruiting" exact="Nitric Oxide" post="Gas Inhalation Therapy for Mild/Moderate COVID19 Infection NCT04290858 Withdrawn"/>
   <result pre="Oxide Gas Inhalation Therapy for Mild/Moderate COVID19 Infection NCT04290858 Withdrawn" exact="Nitric Oxide" post="Gas Inhalation for Severe Acute Respiratory Syndrome in COVID-19."/>
   <result pre="T-705 (favipiravir) in a small animal modelAntiviral Res.1052014172124583123 69WangM.CaoR.ZhangL.YangX.LiuJ.XuM.Remdesivir and" exact="chloroquine" post="effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in"/>
   <result pre="therapeutic optionsNat. Rev. Drug Discovery155201632726868298 72FalzaranoD.De WitE.RasmussenA.L.FeldmannF.OkumuraA.ScottD.P.Treatment with interferon-Î±2b and" exact="ribavirin" post="improves outcome in MERS-CoVâ€&quot;infected rhesus macaquesNat. Med.191020131313131724013700 73ArabiY.M.ShalhoubS.MandourahY.Al-HameedF.Al-OmariA.Al QasimE.Ribavirin"/>
   <result pre="inhibits autophagic flux by decreasing autophagosome-lysosome fusionAutophagy.14820181435145529940786 105ARENA CT. Coronavirus:" exact="Chloroquine" post="yields positive data in Covid-19 trial 2020 FEBRUARY 18"/>
   <result pre="FEBRUARY 18 [Available from: https://www.clinicaltrialsarena.com/news/coronavirus-covid-19-choroquine-data/. 106McChesneyE.W.Animal toxicity and pharmacokinetics of" exact="hydroxychloroquine" post="sulfateThe American journal of medicine.751198311186408923 107WenigerH.OrganizationW.H.Review of side effects"/>
   <result pre="erythematosus: a clinical study with determination of serum concentrations of" exact="chloroquine" post="and hydroxychloroquineScand. J. Rheumatol.3219741031084608161 109GautretP.LagierJ.-C.ParolaP.MeddebL.MailheM.DoudierB.Hydroxychloroquine and azithromycin as a"/>
   <result pre="serum concentrations of chloroquine and hydroxychloroquineScand. J. Rheumatol.3219741031084608161 109GautretP.LagierJ.-C.ParolaP.MeddebL.MailheM.DoudierB.Hydroxychloroquine and" exact="azithromycin" post="as a treatment of COVID-19: results of an open-label"/>
   <result pre="LancetRheumatology2020 166Hub AE. Coronavirus (COVID-19) Update: Early Safety Signals Around" exact="Ibuprofen" post="and Renin-Angiotensin Inhibitors 2020 March 23 [Available from: https://edhub.ama-assn.org/jn-learning/audio-player/18329925."/>
   <result pre="Inhibitors 2020 March 23 [Available from: https://edhub.ama-assn.org/jn-learning/audio-player/18329925. 167Day M. Covid-19:" exact="ibuprofen" post="should not be used for managing symptoms, say doctors"/>
   <result pre="et al. Protocol for a randomized controlled trial testing inhaled" exact="nitric oxide" post="therapy in spontaneously breathing patients with COVID-19. medRxiv. 2020."/>
   <result pre="2020 April 21 [Available from: https://www.who.int/emergencies/diseases/novel-coronavirus-2019/global-research-on-novel-coronavirus-2019-ncov/solidarity-clinical-trial-for-covid-19-treatments. 182NagaiA.MatsumiyaH.HayashiM.YasuiS.OkamotoH.KonnoK.Effects of nicotinamide and" exact="niacin" post="on bleomycin-induced acute injury and subsequent fibrosis in hamster"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7256539\results\search\drug\results.xml">
   <result pre="steroid hormones. Moreover, age-associated decreases in sex steroid hormones, namely," exact="estrogen" post="and testosterone, may mediate proinflammatory increases in older adults"/>
   <result pre="In this article, we explore the possible anti-inflammatory effects of" exact="estrogen" post="and testosterone and the anabolic effect of testosterone, with"/>
   <result pre="article, we explore the possible anti-inflammatory effects of estrogen and" exact="testosterone" post="and the anabolic effect of testosterone, with particular attention"/>
   <result pre="developing therapeutic strategies against COVID-19. Moreover, the anabolic effects of" exact="testosterone" post="may have clinical relevance for older male patients with"/>
   <result pre="with COVID-19. In this article, we explore the effects of" exact="estrogen" post="and testosterone and their possible therapeutic role of hormone"/>
   <result pre="In this article, we explore the effects of estrogen and" exact="testosterone" post="and their possible therapeutic role of hormone replacement therapy"/>
   <result pre="is postulated to be largely driven by sex hormones.14 Although" exact="estrogen" post="has a complex role in modulating the immune system,"/>
   <result pre="immunity in HIV-infected patients.16 Female mice receiving high levels of" exact="estrogen" post="are reported to have increased survival and lower cytokine"/>
   <result pre="production in the lung after influenza infection.4 Likewise, the activated" exact="estrogen" post="receptor, specifically estrogen receptor-alpha, has been found to inhibit"/>
   <result pre="lung after influenza infection.4 Likewise, the activated estrogen receptor, specifically" exact="estrogen" post="receptor-alpha, has been found to inhibit NF-ÎºBâ€&quot;mediated inflammation response"/>
   <result pre="NF-ÎºB pathway to increase cytokine synthesis after SARS infection while" exact="estrogen" post="can shut down the NF-ÎºB pathway holds possible relevance"/>
   <result pre="did age-matched female mice.18 Second, SARS-CoVâ€&quot;infected female mice that were" exact="estrogen" post="depleted by oophorectomy or estrogen receptor blocker had a"/>
   <result pre="SARS-CoVâ€&quot;infected female mice that were estrogen depleted by oophorectomy or" exact="estrogen" post="receptor blocker had a worse SARS-CoV prognosis.18 Although patients"/>
   <result pre="COVID-19 suffer from lymphopenia, which might cast doubt on the" exact="estrogen" post="anti-inflammatory effect, these findings were independent of T- or"/>
   <result pre="genomic similarity of SARS-CoV-2 and SARS-CoV,19 it is possible that" exact="estrogen" post="plays a similarly protective role against SARS-CoV-2. Although women"/>
   <result pre="is strongly protective against adverse outcomes. It is possible that" exact="testosterone" post="has a protective anti-inflammatory effect in younger men, analogous"/>
   <result pre="anti-inflammatory effect in younger men, analogous to the effect of" exact="estrogen" post="in younger women. Testosterone is reported to have anti-inflammatory"/>
   <result pre="men, analogous to the effect of estrogen in younger women." exact="Testosterone" post="is reported to have anti-inflammatory functions via suppression of"/>
   <result pre="of both the cellular and humoral immune systems. In fact," exact="testosterone" post="was found to lower IL-6 and TNF-Î± levels via"/>
   <result pre="inhibition of the NF-ÎºB proinflammatory pathway, analogous to estrogen.21 Moreover," exact="testosterone" post="deficiency has been linked with autoimmune disease and increases"/>
   <result pre="underlie their increased risk of lung damage after pneumonia.24,25 Importantly," exact="testosterone" post="can be peripherally converted to estrogen via aromatase enzyme,"/>
   <result pre="damage after pneumonia.24,25 Importantly, testosterone can be peripherally converted to" exact="estrogen" post="via aromatase enzyme, which might add an anti-inflammatory effect.26"/>
   <result pre="might add an anti-inflammatory effect.26 It is also plausible that" exact="testosterone" post="might reduce the need for assisted ventilation through its"/>
   <result pre="intensive care unit stays.28 Several small-scale clinical studies indicate that" exact="testosterone" post="therapy may improve outcomes in hospitalized patients with chronic"/>
   <result pre="patients at a higher risk of COVID-19 death for which" exact="estrogen" post="and testosterone hold potential therapeutic modalities. In evaluating sex"/>
   <result pre="a higher risk of COVID-19 death for which estrogen and" exact="testosterone" post="hold potential therapeutic modalities. In evaluating sex and age"/>
   <result pre="(30.6%) than for those not taking these medications (26.7%).2 Exogenous" exact="estrogen" post="and testosterone therapies have a therapeutic potential to mitigate"/>
   <result pre="for those not taking these medications (26.7%).2 Exogenous estrogen and" exact="testosterone" post="therapies have a therapeutic potential to mitigate the damaging"/>
   <result pre="sex hormones in immune response, specifically the anti-inflammatory effects of" exact="estrogen" post="and testosterone and the anabolic effect of testosterone, it"/>
   <result pre="in immune response, specifically the anti-inflammatory effects of estrogen and" exact="testosterone" post="and the anabolic effect of testosterone, it is important"/>
   <result pre="the immunobiology of human immunodeficiency virus-1 infectionEndocr Rev3112010799719903932 17BiswasD.K.SinghS.ShiQ.PardeeA.B.IglehartJ.D.Crossroads of" exact="estrogen" post="receptor and NF-ÎºB signalingSci STKE20052882005pe2715956359 18ChannappanavarR.FettC.MackM.Ten EyckP.P.MeyerholzD.K.PerlmanS.Sex-based differences in"/>
   <result pre="27DillonE.L.DurhamW.J.UrbanR.J.Sheffield-MooreM.Hormone treatment and muscle anabolism during aging: androgensClin Nutr296201069770020452103 28AlmoosaK.F.GuptaA.PedrozaC.WattsN.B.Low" exact="testosterone" post="levels are frequent in patients with acute respiratory failure"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7258628\results\search\drug\results.xml">
   <result pre="Spanish flu pandemic, physicians in desperation turned to the antimalarial" exact="quinine" post="(2). It is disappointing that 100 years later, despite"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7261908\results\search\drug\results.xml">
   <result pre="1994; Lalezari et al., 2003), and a small-molecule CCR5 antagonist," exact="maraviroc" post="(Fatkenheuer et al., 2005), must act on the cell"/>
   <result pre="in clinics, including (1) M2 ion channel inhibitors, such as" exact="amantadine" post="(Bright et al., 2006) and rimantadine, which block viral"/>
   <result pre="FDA-approved drugs with anti-ZIKV activities have been identified, such as" exact="Sofosbuvir" post="(Xu et al., 2016), but no drug has been"/>
   <result pre="of HSV infection, including (1) the nucleoside analogs such as" exact="acyclovir" post="(ACV), (2) the acyclic nucleotide analog cidofovir and (3)"/>
   <result pre="analogs such as acyclovir (ACV), (2) the acyclic nucleotide analog" exact="cidofovir" post="and (3) the pyrophosphate analog foscarnet (Kimberlin and Whitley,"/>
   <result pre="immunological response, and vaccine development.J. Immunol. Res.2019:649173810.1155/2019/6491738 NgK. E. (2019)." exact="Xofluza" post="(Baloxavir Marboxil) for the treatment of acute uncomplicated influenza.P"/>
   <result pre="fusion inhibitor.Clin. Immunol.11526â€&quot;32. 10.1016/j.clim.2005.02.01915870017 PhillipsD. M.TaylorC. L.ZacharopoulosV. R.MaguireR. A. (2000)." exact="Nonoxynol-9" post="causes rapid exfoliation of sheets of rectal epithelium.Contraception62149â€&quot;154. 10.1016/s0010-7824(00)00156-611124363"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7262150\results\search\drug\results.xml">
   <result pre="output COVIDâ€�19 coronavirus diseaseâ€�2019 CRTâ€�D cardiac resynchronization therapy defibrillator HCQ" exact="hydroxychloroquine" post="HF heart failure HR hazard ratio hsâ€�cTnI highâ€�sensitivity cardiac"/>
   <result pre="admission than in those not treated in the ICU (median" exact="creatine" post="kinaseâ€�MB level 18 U/l vsÂ 14 U/l; Pâ€‰ Pâ€‰=â€‰.004),"/>
   <result pre="would make anticoagulation therapy for atrial fibrillation very complex.30 1.3" exact="Chloroquine" post="and hydroxychloroquine side effects on cardiovascular system Another essential"/>
   <result pre="anticoagulation therapy for atrial fibrillation very complex.30 1.3 Chloroquine and" exact="hydroxychloroquine" post="side effects on cardiovascular system Another essential aspect to"/>
   <result pre="cardiovascular system Another essential aspect to be discussed is about" exact="chloroquine" post="cardiovascular side effects since this is one of the"/>
   <result pre="tested in patients with COVIDâ€�19. It is wellâ€�reported that longâ€�term" exact="chloroquine" post="use may increase depolarization length duration and Purkinje fiber"/>
   <result pre="nodal and/or His system malfunction.31 As an antimalarial drug, both" exact="chloroquine" post="and hydroxychloroquine (HCQ) are accumulated in lysosomes, directly inhibiting"/>
   <result pre="His system malfunction.31 As an antimalarial drug, both chloroquine and" exact="hydroxychloroquine" post="(HCQ) are accumulated in lysosomes, directly inhibiting phospholipase activity,"/>
   <result pre="VarkeyK, KoshyTS. Ventricular tachycardia in a patient on dehydroemetine and" exact="chloroquine" post="for amoebic liver abscess. Med J Aust. 1979;1:406â€�407.38383 33FauchierJP,"/>
   <result pre="Mal Coeur Vaiss. 1993;86:757â€�767.8267504 34Siqueiraâ€�BatistaR, Ramos JÃºniorAN, PessanhaBS, Sforzaâ€�deâ€�AlmeidaMP, PotschDF." exact="Chloroquine" post="and cardiac arrhythmia: case report. East Afr Med J."/>
   <result pre="new cases. Presse Med. 1992;2:800â€�804. 37CapelRA, HerringN, KallaM, et al." exact="Hydroxychloroquine" post="reduces heart rate by modulating the hyperpolarizationâ€�activated current if:"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7262202\results\search\drug\results.xml">
   <result pre="Oncol2017; 3: 610â€&quot;9.28056112 6ZhongWZ, WangQ, MaoWMet alGefitinib versus vinorelbine plus" exact="cisplatin" post="as adjuvant treatment for stage IIâ€�IIIA (N1â€�N2) EGFRâ€�mutant NSCLC"/>
   <result pre="Pulmonary toxicity among cancer patients treated with a combination of" exact="docetaxel" post="and gemcitabine: A metaâ€�analysis of clinical trials. Cancer Chemother"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7262305\results\search\drug\results.xml">
   <result pre="currently under consideration include inhibition of the mechanistic target of" exact="rapamycin" post="(mTOR) pathway of nutrient sensing.3 Inhibition of this pathway"/>
   <result pre="nutrient sensing.3 Inhibition of this pathway with a combination of" exact="everolimus" post="(a derivative of rapamycin) and RTB101 (a catalytic site"/>
   <result pre="incidence or severity of viral respiratory tract infections. Importantly, both" exact="everolimus" post="and RTB101 have been shown to be well tolerated"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7263255\results\search\drug\results.xml">
   <result pre="amount and lower levels of albumin while the levels of" exact="creatine" post="kinase, aminotransferases, lactic dehydrogenases, and C-protein increased [21]. Patients"/>
   <result pre="of internalization including that of SARS-CoV. Therefore, drugs such as" exact="chlorpromazine" post="inhibiting clathrin-mediated endocytosis are tested for their potential in"/>
   <result pre="Potential candidates for repurposing for SARS-CoV-2 5.1.1 Antimalarial agents 5.1.1.1" exact="Chloroquine" post="The SARS-CoV-2 (COVID-19) host interactions can be modulated by"/>
   <result pre="be modulated by small-molecule agents authorized for other human diseases." exact="Chloroquine" post="(CQ), a commonly used anti-malarial drug and authorized immune"/>
   <result pre="in China for the safety and efficacy of CQ and" exact="hydroxychloroquine" post="for treating COVID-19 linked pneumonia [66]. Reports have so"/>
   <result pre="COVID-19 linked pneumonia [66]. Reports have so far shown that" exact="chloroquine" post="phosphate is preferred in managing the treatment by constraining"/>
   <result pre="years, making it potential and clinically beneficial towards COVID-19. 5.1.1.2" exact="Hydroxychloroquine" post="Hydroxychloroquine (HCQ), which demonstrates a highly related structure (as"/>
   <result pre="making it potential and clinically beneficial towards COVID-19. 5.1.1.2 Hydroxychloroquine" exact="Hydroxychloroquine" post="(HCQ), which demonstrates a highly related structure (as shown"/>
   <result pre="from their chart defined protocol, and 6 patients obtained simultaneous" exact="azithromycin" post="(AZM) treatment to avoid bacterial superinfection. Patients who received"/>
   <result pre="a larger sample size. Fig. 4 The chemical composition of" exact="chloroquine" post="and hydroxychloroquine. Fig. 5 Schematic representation of chloroquine and"/>
   <result pre="composition of chloroquine and hydroxychloroquine. Fig. 5 Schematic representation of" exact="chloroquine" post="and hydroxychloroquine antiviral mechanisms. 5.1.2 Antiviral agents 5.1.2.1 Lopinavir"/>
   <result pre="chloroquine and hydroxychloroquine. Fig. 5 Schematic representation of chloroquine and" exact="hydroxychloroquine" post="antiviral mechanisms. 5.1.2 Antiviral agents 5.1.2.1 Lopinavir and ritonavir"/>
   <result pre="and hydroxychloroquine antiviral mechanisms. 5.1.2 Antiviral agents 5.1.2.1 Lopinavir and" exact="ritonavir" post="Several kinds of research have concentrated on repurposing existing"/>
   <result pre="confirmed to be effective towards SARS-CoV and MERS-CoV such as" exact="lopinavir" post="(LPV) and ritonavir (RTV). Clinical trials (e.g., ChiCTR2000029539) are"/>
   <result pre="effective towards SARS-CoV and MERS-CoV such as lopinavir (LPV) and" exact="ritonavir" post="(RTV). Clinical trials (e.g., ChiCTR2000029539) are conducted to test"/>
   <result pre="5.1.2.2 Remdesivir Remdesivir (RDV) is a broad-spectrum anti-viral and an" exact="adenosine" post="triphosphate nucleoside analog. It is an investigational small molecule"/>
   <result pre="of RDV in hospitalized adults diagnosed with COVID-19 [85]. 5.1.2.3" exact="Ribavirin" post="Ribavirin (RBV) is an antiviral purine nucleoside analog approved"/>
   <result pre="RDV in hospitalized adults diagnosed with COVID-19 [85]. 5.1.2.3 Ribavirin" exact="Ribavirin" post="(RBV) is an antiviral purine nucleoside analog approved for"/>
   <result pre="respiratory syncytial virus (MERS-CoV, SARS-CoV-2) [86]. RBV is metabolized by" exact="adenosine" post="kinase to its prodrug mono, di and triphosphate metabolites."/>
   <result pre="it's given in combination with other antiviral drugs like lopinavir," exact="chloroquine" post="analogs and with interferon-Î± [90]. A Study on Vero"/>
   <result pre="bioavailability of 64%. It is metabolized in the liver by" exact="adenosine" post="kinase to its mono, di and tri phosphate metabolites."/>
   <result pre="the mortality in patients with COVID-19 infection compared with lopinavir/" exact="ritonavir" post="[94]. 5.1.2.4 Arbidol Arbidol (ARB) or Umifenovir is an"/>
   <result pre="randomized, open study to assess the safety and efficacy of" exact="Bromhexine" post="Hydrochloride tablets given in combination with ARB and recombinant"/>
   <result pre="DRV is used in trial number NCT04252274 in combination with" exact="cobicistat" post="[112]. Such a combination is currently approved by the"/>
   <result pre="in treating AIDS. DRV is a HIV protease inhibitor, and" exact="cobicistat" post="is a supplement to enhance DRV's pharmacodynamics and pharmacokinetics"/>
   <result pre="China [116]. Oseltamivir is also used in clinical trials with" exact="chloroquine" post="and FPV in multiple combinations [117]. 5.1.2.8 Interferons Interferons"/>
   <result pre="the in vitro studies of INF given in combination with" exact="ribavirin" post="showed a potent synergistic effect in treating SARS [122]."/>
   <result pre="effect in treating SARS [122]. The combination of INF and" exact="ribavirin" post="at a lower dose showed an inhibitory action on"/>
   <result pre="cells of lungs and results in the secretion of anti-inflammatory" exact="adenosine" post="[125]. These studies showed that INF can be used"/>
   <result pre="open-label controlled trial on the combination therapy of lopinavir/ ritonavir," exact="ribavirin" post="and INFÎ²1b in comparison with monotherapy of lopinavir/ ritonavir"/>
   <result pre="ritonavir, ribavirin and INFÎ²1b in comparison with monotherapy of lopinavir/" exact="ritonavir" post="as a treatment for novel coronavirus infection has been"/>
   <result pre="with COVID-19 infection have been initiated [127,128]. 5.1.3 Antibiotic 5.1.3.1" exact="Azithromycin" post="Azithromycin (AZ) is a semi synthetic broad spectrum macrolide"/>
   <result pre="COVID-19 infection have been initiated [127,128]. 5.1.3 Antibiotic 5.1.3.1 Azithromycin" exact="Azithromycin" post="(AZ) is a semi synthetic broad spectrum macrolide antibiotic"/>
   <result pre="[129]. There are several reports suggesting that a combination of" exact="chloroquine" post="and AZ is effective in reducing the viral load"/>
   <result pre="treatment of COVID-19. Usually a dose of 1â€&quot;2Â g of" exact="azithromycin" post="in combination with hydroxychloroquine or chloroquine is used in"/>
   <result pre="a dose of 1â€&quot;2Â g of azithromycin in combination with" exact="hydroxychloroquine" post="or chloroquine is used in the treatment of COVID-19."/>
   <result pre="of 1â€&quot;2Â g of azithromycin in combination with hydroxychloroquine or" exact="chloroquine" post="is used in the treatment of COVID-19. There are"/>
   <result pre="been initiated to compare the efficiency of the two drugs" exact="hydroxychloroquine" post="and AZ to see which one is better in"/>
   <result pre="the safety and efficacy of tocilizumab given in combination with" exact="azithromycin" post="and hydroxychloroquine in the treatment of SARS-CoV-2 [135]. A"/>
   <result pre="and efficacy of tocilizumab given in combination with azithromycin and" exact="hydroxychloroquine" post="in the treatment of SARS-CoV-2 [135]. A phase II"/>
   <result pre="has been initiated to evaluate the safety and effectiveness of" exact="hydroxychloroquine" post="and AZ to prevent the hospitalization or death in"/>
   <result pre="yrs age to deduce the efficacy of combination therapy of" exact="hydroxychloroquine" post="and AZ [137]. They concluded that hydroxychloroquine (500Â mg/day)"/>
   <result pre="combination therapy of hydroxychloroquine and AZ [137]. They concluded that" exact="hydroxychloroquine" post="(500Â mg/day) and AZ (250Â mg/ day for 5Â"/>
   <result pre="5Â days) successfully reduced the viral load. The activity of" exact="hydroxychloroquine" post="in reducing the viral load was further reinforced by"/>
   <result pre="reducing the viral load was further reinforced by AZ. 5.1.3.2" exact="Tetracycline" post="Tetracyclines (doxycycline, tetracyclines, minocycline) are a class of polyketide"/>
   <result pre="bacteriostatic activity against various bacterial infections. The bactericidal activity of" exact="tetracycline" post="is mainly due to its ability to reversibly bind"/>
   <result pre="potential antiviral activity against a host of virus including SARS-CoV-2." exact="Tetracycline" post="act by three possible mechanism against SARS-Cov-2 virus. Coronavirus"/>
   <result pre="the respiratory submucosa mast cells. The third possible mechanism of" exact="tetracycline" post="in treating COVID-19 is by inhibiting the replication of"/>
   <result pre="penetrating ability and lipophilic nature of tetracycline. The bioavailability of" exact="tetracycline" post="upon intramuscular injection is 40% and the oral bioavailability"/>
   <result pre="aim of this study is to assess the efficacy of" exact="doxycycline" post="in reducing/ abolishing the cytokine storm which is induced"/>
   <result pre="agent to prevent organ transplant rejection. The immunosuppressive activity of" exact="sirolimus" post="is mainly due to its ability to inhibit T-lymphocyte"/>
   <result pre="form a immunosuppressive complex and inhibits the mammalian target of" exact="rapamycin" post="(mTOR) kinase which in turn halts the formation of"/>
   <result pre="play an important role in viral replication. Studies showed that" exact="sirolimus" post="successfully inhibited mTOR signalling pathway and there by inhibited"/>
   <result pre="signalling pathway and there by inhibited MERS-CoV [150], thus making" exact="sirolimus" post="a suitable candidate to further test and use in"/>
   <result pre="blind, randomized, placebo controlled clinical trial on the use of" exact="sirolimus" post="in treating COVD-19. The aim of the study is"/>
   <result pre="aim of the study is to determine the efficacy of" exact="sirolimus" post="in improving the clinical outcomes among the patients hospitalized"/>
   <result pre="evaluate the pharmacokinetics, pharmacodynamics, virological efficacy, tolerability and safety of" exact="sirolimus" post="as an adjuvant therapy in treating patients with COVID-19"/>
   <result pre="investigate the safety and efficacy of combination therapy of lopinavir/ritonavir," exact="hydroxychloroquine" post="sulphate and baricitinib in the treatment of moderate to"/>
   <result pre="and investigate their efficacy in treating COVID-19. A combination of" exact="hydroxychloroquine" post="(200Â mg), ritonavir (50Â mg), baricitinib (4Â mg) and"/>
   <result pre="efficacy in treating COVID-19. A combination of hydroxychloroquine (200Â mg)," exact="ritonavir" post="(50Â mg), baricitinib (4Â mg) and imatinib (400Â mg)"/>
   <result pre="hydroxychloroquine (200Â mg), ritonavir (50Â mg), baricitinib (4Â mg) and" exact="imatinib" post="(400Â mg) will be administered to the patients with"/>
   <result pre="reducing the inflammatory responses [158]. In the case of COVID-19," exact="cyclosporine" post="blocks RNA-dependent-RNA polymerase and peptidyl-prolyl isomerase activity of SARS-CoV-2"/>
   <result pre="the angiotensin converting enzyme-2 (ACE-2) at a low cytosolic Ph," exact="cyclosporine" post="s known to maintain the cytosolic pH at normal"/>
   <result pre="in SARS-CoV-2 infection is mainly caused due to SHL and" exact="cyclosporine" post="is the choice of drug to treat SHL as"/>
   <result pre="cyclosporine is the choice of drug to treat SHL as" exact="cyclosporine" post="blocks the production of IL-2 and inhibits the proliferation"/>
   <result pre="a volume of distribution 0f 4â€&quot;8Â L/kg. The half-life of" exact="cyclosporine" post="is 19Â h and its metabolized in intestine and"/>
   <result pre="pre-clinical and clinical data proving the safety and efficacy of" exact="cyclosporine" post="in the treatment of COVID-19 available. 5.1.5 Monoclonal antibodies"/>
   <result pre="evaluate the use of TCZ when given in combination with" exact="azithromycin" post="and hydroxychloroquine in treating the patients hospitalized with COVID-19"/>
   <result pre="use of TCZ when given in combination with azithromycin and" exact="hydroxychloroquine" post="in treating the patients hospitalized with COVID-19 [135]. A"/>
   <result pre="paralysis and death of the parasite. The anti-viral activity of" exact="ivermectin" post="was first discovered with its ability to block the"/>
   <result pre="flavivirus and dengue virus [169]. The in vitro study of" exact="ivermectin" post="anti-viral activity against SARS-CoV-2 virus showed an inhibition of"/>
   <result pre="the safety and efficacy profile of the combination therapy of" exact="hydroxychloroquine" post="and ivermectin I the treatment of hospitalized COVD-19 patients"/>
   <result pre="and efficacy profile of the combination therapy of hydroxychloroquine and" exact="ivermectin" post="I the treatment of hospitalized COVD-19 patients [171]. 5.1.7"/>
   <result pre="(41.8%) patients acquired ARDS and 44 (52.4%) of those died." exact="Methylprednisolone" post="therapy reduced the risk of mortality in ARDS patients"/>
   <result pre="is planned to examine clinical progress in patients administered with" exact="methylprednisolone" post="IV [66,179]. In another study, Zhou et al. indicated"/>
   <result pre="emphasizes on the four most assuring therapies: the antimalarial medications" exact="chloroquine" post="and hydroxychloroquine, an antiviral compound remdesivir, a combination of"/>
   <result pre="messenger, interferon-beta that can aid in paralyzing the virus [191]." exact="Chloroquine" post="and hydroxychloroquine prevent the entry and transport of the"/>
   <result pre="that can aid in paralyzing the virus [191]. Chloroquine and" exact="hydroxychloroquine" post="prevent the entry and transport of the virus by"/>
   <result pre="the RNA synthesis leading to the induction of mutagenesis. Both" exact="ritonavir" post="and lopinavir being protease inhibitors block the viral cellular"/>
   <result pre="synthesis leading to the induction of mutagenesis. Both ritonavir and" exact="lopinavir" post="being protease inhibitors block the viral cellular entry where"/>
   <result pre="lopinavir being protease inhibitors block the viral cellular entry where" exact="ritonavir" post="inhibits Cyt-P450 and prolongs the half-life of lopinavir. Interferon-beta"/>
   <result pre="administration Category and purpose in COVID-19 Sponsor ClinicalTrials.gov identifier 1" exact="Chloroquine" post="2 &amp;amp; 3, 4, 2 Oral route Antimalarial, to"/>
   <result pre="Oxford University Clinical Research Unit, Vietnam NCT04333628, NCT04331600, NCT04328493 2" exact="Hydroxychloroquine" post="3, 3, 2, 2, 2 Oral route Antimalarial, to"/>
   <result pre="Antiviral in treatment of COVID-19 Gilead Sciences, NCT04292899, NCT04292730 4" exact="Azithromycin" post="3 Oral route Antibiotic, to prevent COVD-19 disease progression"/>
   <result pre="patients Sunnybrook Health Sciences Centre, Canada NCT04330690 7 Lopinavir/ritonavir vs" exact="Hydroxychloroquine" post="sulfate 2 Oral route To treat Mild COVID-19 Asan"/>
   <result pre="Lisa Barrett, Canada NCT04321993 9 Remdesivir, Lopinavir/ritonavir, interferon Î²-1A, and" exact="hydroxychloroquine" post="3 I.V infusion, oral route, S.C injection, and oral"/>
   <result pre="of Health and Medical Research, France NCT04315948 10 Hydroxychloroquine, Oseltamivir," exact="Azithromycin" post="3 Oral route To treat COVID-19 patients Shehnoor Azhar,"/>
   <result pre="route To treat COVID-19 patients Shehnoor Azhar, Pakistan NCT04338698 11" exact="Hydroxychloroquine" post="and Nitazoxanide 2, 3 Oral route To evaluate safety"/>
   <result pre="safety and efficacy in COVID-19 patients Tanta University NCT04361318 12" exact="Hydroxychloroquine" post="vs. Azithromycin 2, 3 Oral route To treat COVID-19"/>
   <result pre="efficacy in COVID-19 patients Tanta University NCT04361318 12 Hydroxychloroquine vs." exact="Azithromycin" post="2, 3 Oral route To treat COVID-19 patients Intermountain"/>
   <result pre="Intermountain Medical Center, United States NCT04329832, NCT04334382 13 1. Lopinavir/ritonavir,2." exact="Ribavirin" post="and3. Interferon beta-1b 2 1 &amp;amp; 2 oral route,"/>
   <result pre="Second Affiliated Hospital of Wenzhou Medical University, China NCT04273763 20" exact="Deferoxamine" post="1 &amp;amp; 2 Intravenous infusion Iron chelator, to reduce"/>
   <result pre="University Hospital, Spain NCT04325061 22 Piclidenoson 2 Oral route A3" exact="adenosine" post="receptor agonist, to treat COVID-19 patients Can-Fite BioPharma, Israel"/>
   <result pre="route Adjuvant treatment of COVID-19 Tongji Hospital, China NCT04291053 25" exact="Tranexamic acid" post="2 Oral route Antifibrinolytics, to study its effect on"/>
   <result pre="COVID-19 University of Kansas Medical Center, United States NCT04335123 29" exact="Telmisartan" post="2 Oral route Angiotensin receptor blocker, to evaluate the"/>
   <result pre="the deteroration of COVID-19 patients Mount Auburn Hospital NCT04380402 31" exact="Prazosin" post="2 Oral route Alpha-blockers, to evaluate the safety and"/>
   <result pre="for COVID-19 treatment Centre Hospitalier St Anne, France NCT04366739 33" exact="Lenalidomide" post="4 Oral route Antiangiogenic agent, to treat mild to"/>
   <result pre="C5a antibody, to treat pneumonia. InflaRx GmbH, Netherlands NCT04333420 42" exact="Acalabrutinib" post="with Best supportive care 2 Oral route Bruton's tyrosine"/>
   <result pre="with cytokine release syndrome Novartis Pharmaceuticals, United States NCT04362813 46" exact="Ruxolitinib" post="2 â€&quot; Kinase inhibitor, to treat hyper inflammation in"/>
   <result pre="with stage II/III COVID-19 Dr. Andreas Hochhaus, Germany NCT04338958 47" exact="Ruxolitinib" post="3 Oral route To evaluate safety and efficacy in"/>
   <result pre="vitro for an antiviral and antimalarial drug namely remdesivir and" exact="chloroquine" post="have shown promising results in suppressing the virus. In"/>
   <result pre="into the antiviral effects of chloroquineLancet Infect. Dis.62006676910.1016/S1473-3099(06)70361-916439323 63YanY.ZouZ.SunY.LiX.XuK.-F.WeiY.JinN.JiangC.Anti-malaria drug" exact="chloroquine" post="is highly effective in treating avian influenza A H5N1"/>
   <result pre="inhibitor of SARS coronavirus infection and spreadVirol. J.220056910.1186/1743-422X-2-6916115318 65WangM.CaoR.ZhangL.YangX.LiuJ.XuM.ShiZ.HuZ.ZhongW.XiaoG.Remdesivir and" exact="chloroquine" post="effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in"/>
   <result pre="organization registered platform, (n.d.). http://www.chictr.org.cn/showprojen.aspx?proj=49145 (accessed April 8, 2020). 67GaoJ.TianZ.YangX.Breakthrough:" exact="Chloroquine" post="phosphate has shown apparent efficacy in treatment of COVID-19"/>
   <result pre="Med. Chem.4920062845284910.1021/jm060185616640347 69MarmorM.F.KellnerU.LaiT.Y.Y.MellesR.B.MielerW.F.American academy of ophthalmology, recommendations on screening for" exact="chloroquine" post="and hydroxychloroquine retinopathy (2016 revision)Ophthalmology.12320161386139410.1016/j.ophtha.2016.01.05826992838 70D. Zhou, S.-M. Dai,"/>
   <result pre="69MarmorM.F.KellnerU.LaiT.Y.Y.MellesR.B.MielerW.F.American academy of ophthalmology, recommendations on screening for chloroquine and" exact="hydroxychloroquine" post="retinopathy (2016 revision)Ophthalmology.12320161386139410.1016/j.ophtha.2016.01.05826992838 70D. Zhou, S.-M. Dai, Q. Tong,"/>
   <result pre="Q. Tong, COVID-19: a recommendation to examine the effect of" exact="hydroxychloroquine" post="in preventing infection and progression, J. Antimicrob. Chemother.. (n.d.)."/>
   <result pre="infection and progression, J. Antimicrob. Chemother.. (n.d.). doi:10.1093/jac/dkaa114. 71GautretP.LagierJ.C.ParolaP.HoangV.T.MeddedL.MailheM.DoudierB.CourjonJ.GiordanengoV.VieiraV.E.DupontH.T.HonoreS.ColsonP.ChabriereE.ScolaB.L.RolainJ.M.BrouquiP.RaoultD.Hydroxychloroquine and" exact="Azithromycin" post="as a Treatment of COVID-19: Preliminary Results of an"/>
   <result pre="clinically approved antiviral drugsEmerg. Infect. Dis.10200458158610.3201/eid1004.03045815200845 87TeH.S.RandallG.JensenD.M.Mechanism of action of" exact="ribavirin" post="in the treatment of chronic hepatitis CGastroenterol Hepatol (N"/>
   <result pre="chronic hepatitis CGastroenterol Hepatol (N Y)3200721822521960835 88GraciJ.D.CameronC.E.Mechanisms of action of" exact="ribavirin" post="against distinct virusesRev. Med. Virol.162006374810.1002/rmv.48316287208 89Ã–lschlÃ¤gerS.NeytsJ.GÃ¼ntherS.Depletion of GTP pool"/>
   <result pre="of GTP pool is not the predominant mechanism by which" exact="ribavirin" post="exerts its antiviral effect on Lassa virusAntivir. Res.912011899310.1016/j.antiviral.2011.05.00621616094 90FalzaranoD.de"/>
   <result pre="&amp;amp; Therapeutics142020586010.5582/ddt.2020.0101232147628 92KnowlesS.R.PhillipsE.J.DresserL.MatukasL.Common adverse events associated with the use of" exact="ribavirin" post="for severe acute respiratory syndrome in CanadaClin. Infect. Dis.3720031139114210.1086/37830414523782"/>
   <result pre="the treatment of SARS: initial virological and clinical findingsThorax59200425225610.1136/thorax.2003.01265814985565 94Lopinavir/Ritonavir," exact="Ribavirin" post="and IFN-beta combination for nCoV treatment - full text"/>
   <result pre="(accessed April 9, 2020). 106Evaluating the efficacy and safety of" exact="bromhexine" post="hydrochloride tablets combined with standard treatment/standard treatment in patients"/>
   <result pre="(accessed May 17, 2020). 112LuH.Efficacy and safety of darunavir and" exact="cobicistat" post="for treatment of COVID-19, clinicaltrials.govhttps://clinicaltrials.gov/ct2/show/NCT042522742020 113SantosJ.R.CurranA.Navarro-MercadeJ.AmpueroM.F.PelaezP.PÃ©rez-AlvarezN.ClotetB.ParedesR.MoltÃ³J.Simplification of antiretroviral treatment"/>
   <result pre="prospective, open label, randomized, in Multicenter Study of, Oseltamivir Plus" exact="Hydroxychloroquine" post="Versus Lopipinavir/Ritonavir Plus Oseltamivir Versus Darunavir/Ritonavir Plus Oseltamivir Plus"/>
   <result pre="Hydroxychloroquine Versus Lopipinavir/Ritonavir Plus Oseltamivir Versus Darunavir/Ritonavir Plus Oseltamivir Plus" exact="Hydroxychloroquine" post="in Mild COVID-19 AND Lopipinavir/Ritonavir Plus Oseltamivir Versus Favipiravir"/>
   <result pre="Oseltamivir Versus Favipiravir Plus Lopipinavir/Ritonavir Versus Darunavir/Ritonavir Plus Oseltamivir Plus" exact="Hydroxychloroquine" post="Versus Favipiravir Plus Darunavir and Ritonavir Plus Hydroxychloroquine in"/>
   <result pre="Darunavir/Ritonavir Plus Oseltamivir Plus Hydroxychloroquine Versus Favipiravir Plus Darunavir and" exact="Ritonavir" post="Plus Hydroxychloroquine in Moderate to Critically Ill COVID-19, clinicaltrials.govhttps://clinicaltrials.gov/ct2/show/NCT043032992020"/>
   <result pre="Oseltamivir Plus Hydroxychloroquine Versus Favipiravir Plus Darunavir and Ritonavir Plus" exact="Hydroxychloroquine" post="in Moderate to Critically Ill COVID-19, clinicaltrials.govhttps://clinicaltrials.gov/ct2/show/NCT043032992020 118LiuY.-J.IPC: professional"/>
   <result pre="Chemother.63201910.1128/AAC.00394-19e00394-19, /aac/63/12/AAC.00394-19.atom 133DamleB.VourvahisM.WangE.LeaneyJ.CorriganB.Clinical pharmacology perspectives on the antiviral activity of" exact="azithromycin" post="and use in COVID-19Clin. Pharmacol. Ther.202010.1002/cpt.1857(cpt.1857) 134Hydroxychloroquine vs. azithromycin"/>
   <result pre="of azithromycin and use in COVID-19Clin. Pharmacol. Ther.202010.1002/cpt.1857(cpt.1857) 134Hydroxychloroquine vs." exact="azithromycin" post="for hospitalized patients with suspected or confirmed COVID-19 -"/>
   <result pre="(n.d.). https://clinicaltrials.gov/ct2/show/NCT04332094 (accessed May 18, 2020). 136Evaluating the efficacy of" exact="hydroxychloroquine" post="and azithromycin to prevent hospitalization or death in persons"/>
   <result pre="(accessed May 18, 2020). 136Evaluating the efficacy of hydroxychloroquine and" exact="azithromycin" post="to prevent hospitalization or death in persons with COVID-19"/>
   <result pre="ClinicalTrials.gov, (n.d.). https://clinicaltrials.gov/ct2/show/NCT04358068 (accessed May 18, 2020). 137GautretP.LagierJ.-C.ParolaP.HoangV.T.MeddebL.MailheM.DoudierB.CourjonJ.GiordanengoV.VieiraV.E.DupontH.T.HonorÃ©S.ColsonP.ChabriÃ¨reE.La ScolaB.RolainJ.-M.BrouquiP.RaoultD.Hydroxychloroquine and" exact="azithromycin" post="as a treatment of COVID-19: results of an open-label"/>
   <result pre="evaluating the virological efficacy, safety, tolerability, pharmacokinetics, and pharmacodynamics of" exact="sirolimus" post="adjuvant therapy in patients with coronavirus disease (COVID-19), clinicaltrials.govhttps://clinicaltrials.gov/ct2/show/NCT043716402020"/>
   <result pre="ClinicalTrials.gov, (n.d.). https://clinicaltrials.gov/ct2/show/NCT04346147 (accessed May 19, 2020). 157ChighizolaC.B.OngV.H.MeroniP.L.The use of" exact="cyclosporine" post="a in rheumatology: a 2016 comprehensive reviewClinic Rev Allerg"/>
   <result pre="inhibits the replication of diverse coronavirusesJ. Gen. Virol.9220112542254810.1099/vir.0.034983-021752960 160CureE.Cumhur CureM.Can" exact="dapagliflozin" post="have a protective effect against COVID-19 infection? A hypothesisDiabetes"/>
   <result pre="of HIV-1 and dengue virusBiochem. J.443201285185610.1042/BJ2012015022417684 169YangS.N.Y.AtkinsonS.C.WangC.LeeA.BogoyevitchM.A.BorgN.A.JansD.A.The broad spectrum antiviral" exact="ivermectin" post="targets the host nuclear transport importin Î±/Î²1 heterodimerAntivir. Res.177202010476010.1016/j.antiviral.2020.104760"/>
   <result pre="host nuclear transport importin Î±/Î²1 heterodimerAntivir. Res.177202010476010.1016/j.antiviral.2020.104760 170CalyL.DruceJ.D.CattonM.G.JansD.A.WagstaffK.M.The FDA-approved drug" exact="ivermectin" post="inhibits the replication of SARS-CoV-2 in vitroAntivir. Res.178202010478710.1016/j.antiviral.2020.104787 171Centenario"/>
   <result pre="in vitroAntivir. Res.178202010478710.1016/j.antiviral.2020.104787 171Centenario Hospital Miguel HidalgoEfficacy and safety of" exact="hydroxychloroquine" post="and ivermectin in hospitalized no critical patients secondary to"/>
   <result pre="Res.178202010478710.1016/j.antiviral.2020.104787 171Centenario Hospital Miguel HidalgoEfficacy and safety of hydroxychloroquine and" exact="ivermectin" post="in hospitalized no critical patients secondary to COVID-19 infection:"/>
   <result pre="megatrial of the four most promising coronavirus treatmentsScience222020 192SinghA.K.SinghA.ShaikhA.SinghR.MisraA.Chloroquine and" exact="hydroxychloroquine" post="in the treatment of COVID-19 with or without diabetes:"/>
   <result pre="197covexit, Professor Didier Raoult releases the results of a New" exact="Hydroxychloroquine" post="Treatment Study on 1061 patients â€&quot; COVEXIT.com, (n.d.). http://covexit.com/professor-didier-raoult-releases-the-results-of-a-new-hydroxychloroquine-treatment-study-on-1061-patients/"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7264504\results\search\drug\results.xml">
   <result pre="Letters to the Editor Why we should not stop giving" exact="aspirin" post="to pregnant women during the COVIDâ€�19 pandemic Aspirin, pregnancy"/>
   <result pre="been made in a small group of young people taking" exact="ibuprofen" post="for COVIDâ€�19 symptoms3, 4. As a result, French health"/>
   <result pre="of Health has stated that there is no evidence that" exact="ibuprofen" post="(or other NSAIDs) could worsen SARSâ€�CoVâ€�2 infection. However, it"/>
   <result pre="other NSAIDs) could worsen SARSâ€�CoVâ€�2 infection. However, it stated that" exact="ibuprofen" post="might mask the symptoms of infection, therefore delaying diagnosis6."/>
   <result pre="cause for concern regarding the wellbeing of pregnant women taking" exact="aspirin" post="for prophylaxis of preâ€�eclampsia and fetal growth restriction. The"/>
   <result pre="professionals and pregnant women, leading to withdrawal of prophylactic lowâ€�dose" exact="aspirin" post="therapy. Currently, there are no available data regarding the"/>
   <result pre="pregnant women in the series of Schwartz was severe11. Lowâ€�dose" exact="aspirin" post="has been proven to be an effective regimen for"/>
   <result pre="pregnancy, including preâ€�eclampsia and fetal growth restriction. Intake of lowâ€�dose" exact="aspirin" post="during pregnancy is not associated with an increased risk"/>
   <result pre="of the ductus arteriosus8. The recommended dosage of 150â€‰mg of" exact="aspirin" post="daily for the prevention of preâ€�eclampsia is based on"/>
   <result pre="preterm preâ€�eclampsia occurred in 1.6% of women in the lowâ€�dose" exact="aspirin" post="group, as compared with 4.3% in the placebo group"/>
   <result pre="an official statement recommending not to avoid the use of" exact="ibuprofen" post="based on the current available data12. To our knowledge,"/>
   <result pre="that there is an association between prophylactic use of lowâ€�dose" exact="aspirin" post="and increased risk of progression of SARSâ€�CoVâ€�2 infection. In"/>
   <result pre="provide firstâ€�trimester screening for placental complications and to prescribe lowâ€�dose" exact="aspirin" post="in women who are identified as high risk for"/>
   <result pre="risks of adverse outcome related to the usage of lowâ€�dose" exact="aspirin" post="in patients with SARSâ€�CoVâ€�2 infection. References References 1SchwartzDA, GrahamAL."/>
   <result pre="and delivery: rapid review. Ultrasound Obstet Gynecol2020; 55: 586â€&quot;592.32180292 3DayM.Covidâ€�19:" exact="ibuprofen" post="should not be used for managing symptoms, say doctors"/>
   <result pre="Lab Med2020 DOI: 10.5858/arpa.2020-0901-SA. 12Updated: WHO Now Doesn't Recommend Avoiding" exact="Ibuprofen" post="For COVIDâ€�19 Symptoms. https://www.sciencealert.com/who-recommends-to-avoid-taking-ibuprofen-for-covid-19-symptoms [Accessed 23 March 2020]"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7264535\results\search\drug\results.xml">
   <result pre="the human CNS. Nataf42 thinks that an alteration in the" exact="dopamine" post="synthetic pathway is possibly involved in the COVIDâ€�19 pathophysiology."/>
   <result pre="syndrome. Acta Neurol Taiwan. 2005;14:113â€�119.16252612 42NatafS. An alteration of the" exact="dopamine" post="synthetic pathway is possibly involved in the pathophysiology of"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7264541\results\search\drug\results.xml">
   <result pre="and against malaria. Recent studies have shown antiviral effects of" exact="chloroquine" post="and in vitro studies concluded that it was highly"/>
   <result pre="19 Lopinavir, a viral protease inhibitor, with its pharmacological booster" exact="ritonavir" post="(LPV/R) is commonly used in HIVâ€�positive patients. It has"/>
   <result pre="are expected from new undergoing phase 3 clinical trials.21, 22" exact="Ribavirin" post="is a guanosine analogue that interferes with the replication"/>
   <result pre="for the treatment of SARSâ€�CoVâ€�2 disease.23 SARSâ€�CoVâ€�2â€�infected patients treated with" exact="Ribavirin" post="have been reported in studies from China5, 24 but"/>
   <result pre="undertaken during the Zika virus epidemic, have also suggested that" exact="chloroquine" post="may also reduce the risk of viral transplacental transmission"/>
   <result pre="but it appears that there is no pharmacokinetic difference between" exact="chloroquine" post="and its major metabolite between pregnant and nonâ€�pregnant women,30"/>
   <result pre="effects have been demonstrated in all animal species exposed to" exact="ribavirin" post="and it is therefore currently contraindicated in pregnant women"/>
   <result pre="pregnant women and in their male sexual partners, although the" exact="ribavirin" post="pregnancy registry did not provide evidence of teratogenicity in"/>
   <result pre="7WangM, CaoR, ZhangL, YangX, LiuJ, XuM, et al. Remdesivir and" exact="chloroquine" post="effectively inhibit the recently emerged novel coronavirus (2019â€�nCoV) in"/>
   <result pre="vitro antiviral activity and projection of optimized dosing design of" exact="hydroxychloroquine" post="for the treatment of severe acute respiratory syndrome coronavirus"/>
   <result pre="syndrome coronavirus 2 (SARSâ€�CoVâ€�2). Clin Infect Dis202010.1093/cid/ciaa237 14ColsonP, RolainJâ€�M, RaoultD." exact="Chloroquine" post="for the 2019 novel coronavirus SARSâ€�CoVâ€�2. Int J Antimicrob"/>
   <result pre="LiL, PingL, QingnianX, LuX, et al. A pilot study of" exact="hydroxychloroquine" post="in treatment of patients with common coronavirus diseaseâ€�19 (COVIDâ€�19)."/>
   <result pre="coronavirus diseaseâ€�19 (COVIDâ€�19). J Zhejiang Univ Med Sci2020;49. 16Hydroxychloroquine, hydroxychloroquine," exact="azithromycin" post="in the treatment of SARS CoVâ€�2 infection â€&quot; Full"/>
   <result pre="ClinicalTrials.gov [https://clinicaltrials.gov/ct2/show/NCT04341727]. Accessed 18 April 2020. 17Safety and efficacy of" exact="hydroxychloroquine" post="as COVIDâ€�19 prophylaxis for atâ€�risk population (SHARP): a cluster"/>
   <result pre="Text View â€&quot; ClinicalTrials.gov [https://clinicaltrials.gov/ct2/show/NCT04342156]. Accessed 18 April 2020. 18Will" exact="hydroxychloroquine" post="impede or prevent COVIDâ€�19 â€&quot; Full Text View â€&quot;"/>
   <result pre="patients with novel coronavirus disease (COVIDâ€�19). J Intern Med202010.1111/joim.13063 25Lopinavir/Ritonavir," exact="ribavirin" post="and IFNâ€�beta combination for nCoV treatment â€&quot; Full Text"/>
   <result pre="J Med2019;381:2293â€&quot;303.31774950 28LevyRA, VilelaVS, CataldoMJ, RamosRC, DuarteJL, TuraBR, et al." exact="Hydroxychloroquine" post="(HCQ) in lupus pregnancy: doubleâ€�blind and placeboâ€�controlled study. Lupus2001;10:401â€&quot;4.11434574"/>
   <result pre="study. Lupus2001;10:401â€&quot;4.11434574 29ZhangS, YiC, LiC, ZhangF, PengJ, WangQ, et al." exact="Chloroquine" post="inhibits endosomal viral RNA release and autophagyâ€�dependent viral replication"/>
   <result pre="Antiviral Res2019;169:104547.31251958 30LeeSJ, McGreadyR, FernandezC, StepniewskaK, PawMK, Viladpaiâ€�nguenSJ, et al." exact="Chloroquine" post="pharmacokinetics in pregnant and nonpregnant women with vivax malaria."/>
   <result pre="BMC Infect Dis2015;16:1â€&quot;11. 32SinclairSM, JonesJK, MillerRK, GreeneMF, KwoPY, MaddreyWC. The" exact="ribavirin" post="pregnancy registry: an interim analysis of potential teratogenicity at"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7264596\results\search\drug\results.xml">
   <result pre="confusion and misconception. The President has touted the benefits of" exact="hydroxychloroquine" post="(HQ) and advocated its offâ€�label use, and the FDA"/>
   <result pre="International Society of Antimicrobial Chemotherapy 5. The President's endorsement of" exact="hydroxychloroquine" post="has raised concern among scientists and clinicians at many"/>
   <result pre="with introducing any new medication, particularly in severely ill people." exact="Hydroxychloroquine" post="is not an innocuous agent. It causes retinal degeneration,"/>
   <result pre="acute respiratory distress syndrome associated with COVIDâ€�19, the clearance of" exact="hydroxychloroquine" post="is delayed, increasing the risk of cardiac arrhythmias. Its"/>
   <result pre="https://www.who.int/blueprint/priorityâ€�diseases/keyâ€�action/novelâ€�coronavirusâ€�landscapeâ€�ncov.pdf. Accessed March 20, 2020. 4GautretP, LagierJC, ParolaP et al." exact="Hydroxychloroquine" post="and azithromycin as a treatment of COVIDâ€�19: Results of"/>
   <result pre="March 20, 2020. 4GautretP, LagierJC, ParolaP et al. Hydroxychloroquine and" exact="azithromycin" post="as a treatment of COVIDâ€�19: Results of an openâ€�label"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7264656\results\search\drug\results.xml">
   <result pre="to identify COVIDâ€�19. For hospitalized patients, drug treatment such as" exact="alpha" post="interferon, lopinavir/ritonavir, ribavirin, chloroquine phosphate and arbidol, and convalescent"/>
   <result pre="hospitalized patients, drug treatment such as alpha interferon, lopinavir/ritonavir, ribavirin," exact="chloroquine" post="phosphate and arbidol, and convalescent plasma therapy may be"/>
   <result pre="and S (28144C) based on the different amino acid of" exact="leucine" post="and serine in nt28144. S type was indicated to"/>
   <result pre="benefit was observed in hospitalized adult patients with severe Covidâ€�19" exact="Disulfiram" post="Li and De Clercq 2020 In vitro Has inhibitory"/>
   <result pre="2020 Clinical trial Remdesivir is effective in treating severe COVIDâ€�19." exact="Ribavirin" post="and Galidesivir Li and De Clercq 2020 No evidence"/>
   <result pre="with SARS and MERS but lacking the evidence for SARSâ€�COVâ€�2" exact="Chloroquine" post="Virusâ€�host fusion inhibitors Wang et al 2020 In vitro"/>
   <result pre="against COVIDâ€�19â€�associated pneumonia in multicentre clinical trials conducted in China." exact="Hydroxychloroquine" post="Wang et al 2020 In vitro Have the same"/>
   <result pre="al 2020 In vitro Have the same antiviral mechanism with" exact="chloroquine" post="Gautret et al 2020 Clinical trial HydroxychloroquineÂ treatmentÂ is"/>
   <result pre="IDXâ€�184 Elfiky 2020 In vitro Have effective against SARSâ€�CoVâ€�2 strain." exact="Sofosbuvir" post="Elfiky 2020 In vitro Tightly combine with SARSâ€�CoVâ€�2 RdRp"/>
   <result pre="Wiley &amp;amp; Sons, Ltd, 8.2 Viral protease inhibitors Lopinavir/ritonavir and" exact="disulfiram" post="are the wellâ€�known viral protease inhibitors and have been"/>
   <result pre="reported to reduce mortality, intubation rate and the use of" exact="methylprednisolone" post="when introduced as a treatment of SARS patients in"/>
   <result pre="lopinavir/ritonavir treatment beyond standard care in hospitalized severe COVIDâ€�19 patients.79" exact="Disulfiram" post="is a drug for the treatment of alcohol dependence,"/>
   <result pre="COVIDâ€�19 patients.79 Disulfiram is a drug for the treatment of" exact="alcohol" post="dependence, and studies have confirmed its inhibitory activity against"/>
   <result pre="fusion inhibitors In a study involving more than 100 patients," exact="chloroquine" post="was superior to the control group in suppression of"/>
   <result pre="specific primary or secondary endâ€�points. For clinicians accustomed to it," exact="hydroxychloroquine" post="may be preferable for clinical SARSâ€�CoVâ€�2 treatment. To obtain"/>
   <result pre="recent smallâ€�scale study of COVIDâ€�19 found that most patients taking" exact="chloroquine" post="cleared the novel coronavirus much faster than the control"/>
   <result pre="novel coronavirus much faster than the control group and adding" exact="azithromycin" post="to the medicine could significantly improve the efficiency of"/>
   <result pre="efficiency of eliminating viruses.88 However, a recent study indicated that" exact="chloroquine" post="and hydroxychloroquine could not only be useless in treating"/>
   <result pre="eliminating viruses.88 However, a recent study indicated that chloroquine and" exact="hydroxychloroquine" post="could not only be useless in treating COVIDâ€�19 patients"/>
   <result pre="inflammatory response in combination with direct antiviral drugs (lopinavir or" exact="ritonavir" post="and remdesivir). This approach could facilitate the subsequent development"/>
   <result pre="infections. Chemistry. 2019;14(22):3962â€�3968. 81WangM, CaoR, ZhangL, et al. Remdesivir and" exact="chloroquine" post="effectively inhibit the recently emerged novel coronavirus (2019â€�nCoV) in"/>
   <result pre="Covidâ€�19. N Engl J Med. 2020. 85GaoJ, TianZ, YangX. Breakthrough:" exact="Chloroquine" post="phosphate has shown apparent efficacy in treatment of COVIDâ€�19"/>
   <result pre="clinical studies. Bioscience Trends. 2020;14(1):72â€�73.32074550 86ColsonP, RolainJM, LagierJC, BrouquiP, RaoultD." exact="Chloroquine" post="and hydroxychloroquine as available weapons to fight COVIDâ€�19. Int"/>
   <result pre="Bioscience Trends. 2020;14(1):72â€�73.32074550 86ColsonP, RolainJM, LagierJC, BrouquiP, RaoultD. Chloroquine and" exact="hydroxychloroquine" post="as available weapons to fight COVIDâ€�19. Int J Antimicrob"/>
   <result pre="fight COVIDâ€�19. Int J Antimicrob Agents. 2020;55(4):105932.32145363 87ColsonP, RolainJM, RaoultD." exact="Chloroquine" post="for the 2019 novel coronavirus SARSâ€�CoVâ€�2. Int J Antimicrob"/>
   <result pre="Int J Antimicrob Agents. 2020;55(3):105923.32070753 88GautretP, LagierJC, ParolaP, et al." exact="Hydroxychloroquine" post="and azithromycin as a treatment of COVIDâ€�19: results of"/>
   <result pre="Antimicrob Agents. 2020;55(3):105923.32070753 88GautretP, LagierJC, ParolaP, et al. Hydroxychloroquine and" exact="azithromycin" post="as a treatment of COVIDâ€�19: results of an openâ€�label"/>
   <result pre="disease 2019 (COVIDâ€�19) treatment?Clin Infect Dis. 2020. 90GbinigieK, FrieK. Should" exact="chloroquine" post="and hydroxychloroquine be used to treat COVIDâ€�19? A rapid"/>
   <result pre="(COVIDâ€�19) treatment?Clin Infect Dis. 2020. 90GbinigieK, FrieK. Should chloroquine and" exact="hydroxychloroquine" post="be used to treat COVIDâ€�19? A rapid review. BJGP"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7264879\results\search\drug\results.xml">
   <result pre="cardboards (van Doremalen et al., 2020). For coronavirus, disinfection with" exact="ethanol" post="or propanol (85â€&quot;95%) is effective after 30Â s; followed"/>
   <result pre="effective after 30Â s; followed by sodium hypochlorite (0.2%), while" exact="chlorhexidine" post="is inefficient (Kampf et al., 2020). Masks Quantitative microbial"/>
   <result pre="patients per arm. No major improvement was seen in the" exact="lopinavir" post="group. The negative outcome might be due to the"/>
   <result pre="effect on viral shedding was seen, it was concluded that" exact="lopinavir" post="does not inhibit SARSâ€�CoVâ€�2 replication in vivo (Baden and"/>
   <result pre="controls and concomitant treatment with antivirals (Shen et al., 2020a)." exact="Chloroquine" post="A small and poorly controlled French trial reported viral"/>
   <result pre="at day 6 in 100% of COVIDâ€�19 patients treated with" exact="hydroxychloroquine" post="and azithromycin, compared to 57% treated with hydroxychloroquine alone,"/>
   <result pre="treated with hydroxychloroquine and azithromycin, compared to 57% treated with" exact="hydroxychloroquine" post="alone, and 13% in controls (Gautret et al., 2020)."/>
   <result pre="that no acute viral infection has been successfully treated with" exact="chloroquine" post="in humans in the past (Touret and de Lamballerie,"/>
   <result pre="Hoang, V.T., Meddeb, L., Mailhe, M., and Doudier, B. (2020)" exact="Hydroxychloroquine" post="and azithromycin as a treatment of COVIDâ€�19: results of"/>
   <result pre="Meddeb, L., Mailhe, M., and Doudier, B. (2020) Hydroxychloroquine and" exact="azithromycin" post="as a treatment of COVIDâ€�19: results of an openâ€�label"/>
   <result pre="Med Virol92: 518â€&quot;521.32022275 Guastalegname, M., and Vallone, A. (2020) Could" exact="Chloroquine" post="/hydroxychloroquine be harmful in Coronavirus disease 2019 (COVIDâ€�19) treatment?Clin"/>
   <result pre="print]. 10.1016/S1473-3099(20)30196-1 Touret, F., and de Lamballerie, X. (2020) Of" exact="chloroquine" post="and COVIDâ€�19. Antiviral Res177: 104762.32147496 Verity, R., Okell, L.C.,"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7264920\results\search\drug\results.xml">
   <result pre="protein and ACE2 [95]. A combination of broad-spectrum antiviral drugs," exact="lopinavir" post="and ritonavir has been recommended for clinical trial in"/>
   <result pre="ACE2 [95]. A combination of broad-spectrum antiviral drugs, lopinavir and" exact="ritonavir" post="has been recommended for clinical trial in the latest"/>
   <result pre="related to the severity of the disease. An anticoagulant drug" exact="dipyridamole" post="(DIP) can inhibit the replication of novel coronavirus, significantly"/>
   <result pre="studies have shown that the combined application of ridsivir and" exact="chloroquine" post="can effectively inhibit the in vitro activity of SARS-CoV-2"/>
   <result pre="inhibit the in vitro activity of SARS-CoV-2 [99]. In addition," exact="chloroquine" post="also has immunomodulatory effects, can inhibit the emergence and"/>
   <result pre="P, Raoult D. New insights on the antiviral effects of" exact="chloroquine" post="against coronavirus: what to expect for COVID-19? Int J"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7266578\results\search\drug\results.xml">
   <result pre="viral respiratory tract infections in healthy adultsPLoS One52010e11088 36HeaneyR.P.DaviesK.M.ChenT.C.Human serum" exact="25-hydroxycholecalciferol" post="response to extended oral dosing with cholecalciferolAm J Clin"/>
   <result pre="J Clin Nutr77200320421012499343 37CharoenngamN.ShirvaniA.KalajianT.A.SongA.HolickM.F.The Effect of Various Doses of Oral" exact="Vitamin D3" post="Supplementation on Gut Microbiota in Healthy Adults: A Randomized,"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7266583\results\search\drug\results.xml">
   <result pre="effects of other immunosuppressive drugs, such as glucocorticoids, IL-1 inhibitors," exact="mycophenolate mofetil," post="anti-TNF-Î±agents, methotrexate, and NSAIDs in COVIS-19, and further in"/>
   <result pre="M.CD147 as a Target for COVID-19 Treatment: Suggested Effects of" exact="Azithromycin" post="and Stem Cell EngagementStem Cell Rev. Rep.163202043444010.1007/s12015-020-09976-732307653 40WangK.ChenW.ZhouY.S.LianJ.Q.ZhangZ.DuP.SARS-CoV-2 invades"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7266750\results\search\drug\results.xml">
   <result pre="or bars of soap is not practical. Instead, distribution of" exact="alcohol" post="pads and disinfectants is more useful and helpful. For"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7266814\results\search\drug\results.xml">
   <result pre="exhaustion was recently made by another research group, who provided" exact="vitamin C" post="during the ex vivo expansion of VÎ³9VÎ´2-T cells.44 Here,"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7267113\results\search\drug\results.xml">
   <result pre="200â€‰mL within 4â€‰h, antibody titer &amp;gt;1:640 arbidol or/and remdesivir/ribavirin/peramivir (nâ€‰=â€‰9)" exact="ribavirin" post="(nâ€‰=â€‰1) Antibacterial/antifungal for coninfecion (nâ€‰=â€‰8) Onset to CPT (xÌƒ"/>
   <result pre="2020 69â€‰y/F, HTN 900â€‰mL in 3 doses arbidol, lopinavirâ€�ritonavir, interferon" exact="alpha" post="After admission 19th d Critically ill invasive mechanical ventilation"/>
   <result pre="(35 wk &amp;amp; 2 d) 300â€‰mL lopinavirâ€�ritonavir and ribavirin, Imipenem," exact="vancomycin" post="for coinfection After admission 19th d Critically ill ARDS,"/>
   <result pre="toÂ 18 March 2020 69/M 600â€‰mL in 3 doses arbidol," exact="levofloxacin" post="After symptom 33th d Myalgia, Chest CTâ€�patchy areas of"/>
   <result pre="et al. Retrospective comparison of convalescent plasma with continuing highâ€�dose" exact="methylprednisolone" post="treatment in SARS patients. Clin Microbiol Infect. 2004;10(7):676â€�678.15214887 13HungIF,"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7267115\results\search\drug\results.xml">
   <result pre="disease. 17 Less commonly, there may also be elevations in" exact="alanine" post="aminotransferase (ALT), aspartate aminotransferase (AST), creatine kinase (CK) and"/>
   <result pre="also be elevations in alanine aminotransferase (ALT), aspartate aminotransferase (AST)," exact="creatine" post="kinase (CK) and Dâ€�dimer.17 Recommendations on whom to test"/>
   <result pre="Risk of respiratory tract infections Risk of serious infections Steroids" exact="Prednisolone" post="URTI for influenza compared to placebo OR 1.22 (95%"/>
   <result pre="compared to placebo69 OR 3.32 (95% CI 0.13â€�84.9) compared to" exact="prednisolone" post="69 Immunomodulators Thiopurines 2.1 per patientâ€�years70 OR 0.143 (95%"/>
   <result pre="per patientâ€�years70 OR 0.143 (95% CI 0.43â€�4.76) compared to placebo70" exact="Methotrexate" post="OR 1.02 (95% 0.88â€�1.19)73 compared with placebo OR 0.52"/>
   <result pre="and increase the risk of COVIDâ€�19 exposure and infection. 4.1" exact="Sulfasalazine" post="and 5â€�aminosalicylates (5â€�ASAs) Sulfasalazine and the 5â€�ASA medications are"/>
   <result pre="of COVIDâ€�19 exposure and infection. 4.1 Sulfasalazine and 5â€�aminosalicylates (5â€�ASAs)" exact="Sulfasalazine" post="and the 5â€�ASA medications are used as firstâ€�line induction"/>
   <result pre="not demonstrate an increased risk of serious or opportunistic infections.53" exact="Sulfasalazine" post="and 5â€�ASA Treatment with 5â€�ASA therapy should continue without"/>
   <result pre="hospitalisation and mortality in IBD patients, particularly at doses of" exact="prednisolone" post="or its equivalent â‰¥20Â mg.61, 62, 63, 64 Therefore,"/>
   <result pre="placebo.65, 66, 67, 68, 69 Corticosteroids Corticosteroids (particularly â‰¥20Â mg" exact="prednisolone" post="or its equivalent) are associated with an increased risk"/>
   <result pre="upper respiratory tract infections or pulmonary infections.70, 71 In addition," exact="mercaptopurine" post="has been shown to inhibit one of the proteases"/>
   <result pre="although no further animalâ€�based models exist to suggest clinical efficacy.72" exact="Methotrexate" post="has variably been demonstrated to increase the risk of"/>
   <result pre="population, there was not an increased risk of infection with" exact="methotrexate" post="(1.03, 95% CI0.82â€�1.3).73 This applied similarly to respiratory infections"/>
   <result pre="of antiâ€�TNFs.90 Serious infection was found to be increased with" exact="tofacitinib" post="in the induction trials for UC, but similar across"/>
   <result pre="placebo in the maintenance trial.91 Of 4789 patients treated with" exact="tofacitinib" post="in phase II, III and LTE studies, 259 patients"/>
   <result pre="associated with increased serious infection risk.92, 93 Therefore, patients on" exact="tofacitinib" post="should be maintained on the lower 5Â mg twice"/>
   <result pre="daily as opposed to 10Â mg twice daily. Avoid commencing" exact="tofacitinib" post="during pandemic unless there are no other alternatives. This"/>
   <result pre="is in contact with someone with COVIDâ€�19, consider temporarily withholding" exact="tofacitinib" post="for 2Â weeks. If a patient tests positive for"/>
   <result pre="patient tests positive for SARSâ€�CoVâ€�2 and/or develops COVIDâ€�19, consider withholding" exact="tofacitinib" post="until patient clears the infection. 4.6 Recommencement of medications"/>
   <result pre="hours. Pharmacodynamic effects generally reversible in 14Â days after discontinuation" exact="Methotrexate" post="Methotrexate in serum has a halfâ€�life of 6Â hours"/>
   <result pre="Pharmacodynamic effects generally reversible in 14Â days after discontinuation Methotrexate" exact="Methotrexate" post="in serum has a halfâ€�life of 6Â hours but"/>
   <result pre="a halfâ€�life of 6Â hours but is converted quickly to" exact="methotrexate" post="polyglutamate which is stored for much longer in liver"/>
   <result pre="and erythrocytes.132 3â€�10Â hours (for methotrexate, not activity) 75% of" exact="methotrexate" post="eliminated by within 24Â hours but effect continues through"/>
   <result pre="with soap and water for 20Â seconds or use an" exact="alcohol" post="rub, practice social distancing by working from home, standing"/>
   <result pre="to limit nonâ€�urgent pathology requests and avoid commencing thiopurines or" exact="tofacitinib" post="that require frequent blood monitoring early on. Finally, elective"/>
   <result pre="and CYP2B6 â€�unlikely clinically significant All in vitro data Lopinavir/" exact="Ritonavir" post="(Kaltera) (400Â mg/100Â mg) 400mg/100mg twice daily for 14"/>
   <result pre="Crushing tablet â†&quot; absorption â‰… 45%133. Use oral liquid (42.4%" exact="alcohol" post="and 15.3% propylene glycol) Use compatible feeding tubes (PVC"/>
   <result pre="propylene glycol) Use compatible feeding tubes (PVC or silicone) Avoid" exact="metronidazole" post="and disulfiram Absorbed in jejunum: NG ok; NJ may"/>
   <result pre="Use compatible feeding tubes (PVC or silicone) Avoid metronidazole and" exact="disulfiram" post="Absorbed in jejunum: NG ok; NJ may â†&quot; effect"/>
   <result pre="â€�care with narrow therapeutic index drugs dependent on CYP450 clearance" exact="Ribavirin" post="Do not crush â€&quot;known teratogen. Contact hospital pharmacy for"/>
   <result pre="to CYP interactions. Inhibits inosine monophosphate dehydrogenase: Can interfere with" exact="azathioprine" post="metabolism possibly leading to accumulation of 6â€�methylthioinosine monophosphate (6â€�MTIMP),"/>
   <result pre="plus interferonâ€�Î± ChiCTR2000029544 favipiravir plus baloxavir marboxil Metabolised by: Nicotinamide" exact="adenine" post="dinucleotide phosphate (NADPH) independent and dependent enzymes. Inhibits: CYP2C8"/>
   <result pre="CYP1A2(weak), CYP2C9(weak), CYP2C19(weak), CYP2CD6(weak), CYP2E1(weak), CYP3A4(weak) Low risk QT prolongation" exact="Atazanavir" post="Requires pH &amp;lt;4. Avoid antacids 2Â h before and"/>
   <result pre="Absorption depends on low pH; drugs increasing pH will decrease" exact="atazanavir" post="concentration Dose related prolongation in PR interval. Care with"/>
   <result pre="clinically relevant Thiopurines (azathioprine/ mercaptopurine) Metabolised by: TMPT, HGPRT, XO" exact="Methotrexate" post="Transported into the cell by: Reduced folate carrier 1"/>
   <result pre="TMPT, HGPRT, XO Methotrexate Transported into the cell by: Reduced" exact="folate" post="carrier 1 Tacrolimus Inhibits: CYP3A4 (weak) Metabolised by CYP3A4"/>
   <result pre="Methotrexate Transported into the cell by: Reduced folate carrier 1" exact="Tacrolimus" post="Inhibits: CYP3A4 (weak) Metabolised by CYP3A4 Ciclosporin Metabolised by"/>
   <result pre="Crushing tablet â†&quot; absorption â‰… 45%133. Use oral liquid (42.4%" exact="alcohol" post="and 15.3% propylene glycol) Use compatible feeding tubes (PVC"/>
   <result pre="propylene glycol) Use compatible feeding tubes (PVC or silicone) Avoid" exact="metronidazole" post="and disulfiram Absorbed in jejunum: NG ok; NJ may"/>
   <result pre="Use compatible feeding tubes (PVC or silicone) Avoid metronidazole and" exact="disulfiram" post="Absorbed in jejunum: NG ok; NJ may â†&quot; effect"/>
   <result pre="Methylprednisolone: Consider 50% dose reduction 124. â†‘ Prednisolone: â†&quot; plasma" exact="cortisol" post="(level if appropriate) â†‘ Budesonide: 10â€�20% absorbed134. AUC may"/>
   <result pre="low bioavailability, increased absorption may occur, monitor for effect69 â†‘" exact="Tacrolimus" post="levels: perform levels, consider clinical need and cease â†‘"/>
   <result pre="consider clinical need and cease. If necessary, use lowest dose" exact="tofacitinib" post="possible Chloroquine / Hydroxychloroquine 200Â mg three times a"/>
   <result pre="need and cease. If necessary, use lowest dose tofacitinib possible" exact="Chloroquine" post="/ Hydroxychloroquine 200Â mg three times a day for"/>
   <result pre="cease. If necessary, use lowest dose tofacitinib possible Chloroquine /" exact="Hydroxychloroquine" post="200Â mg three times a day for 10 days"/>
   <result pre="thiopurine in acute severe infection â†‘ myelosuppression risk. Recommend ceasing" exact="methotrexate" post="in acute severe infection â†‘ risk of QTâ€�interval prolongation."/>
   <result pre="of QTâ€�interval prolongation. consider baseline and follow up ECG â†‘" exact="ciclosporin" post="levels, perform levels if appropriate May â†‘ tofacitinib, clinical"/>
   <result pre="May â†‘ corticosteroid levels, clinical significance unknown, monitor. May â†‘" exact="ciclosporin" post="levels, clinical significance unknown, monitor levels May â†‘ tofacitinib,"/>
   <result pre="tofacitinib, clinical significance unknown, monitor. Consider lower dose where appropriate" exact="Ribavirin" post="Do not crush â€&quot;known teratogen. Contact hospital pharmacy for"/>
   <result pre="of thiopurine induced myelosuppression Cease thiopurine â†‘ risk myelosuppression Cease" exact="methotrexate" post="Favipiravir Atazanavir Requires pH &amp;lt;4. Avoid antacids 2 hours"/>
   <result pre="induced myelosuppression Cease thiopurine â†‘ risk myelosuppression Cease methotrexate Favipiravir" exact="Atazanavir" post="Requires pH &amp;lt;4. Avoid antacids 2 hours before and"/>
   <result pre="Methylprednisolone: Consider 50% dose reduction 124. â†‘ Prednisolone: â†&quot; plasma" exact="cortisol" post="(level if appropriate) â†‘ Budesonide: 10â€�20% absorbed134. AUC may"/>
   <result pre="low bioavailability, increased absorption may occur, monitor for effect69 â†‘" exact="ciclosporin" post="and â†‘ atazanavir. Do not coâ€�administer. â†‘ tofacitinib, recommend"/>
   <result pre="and â†‘ atazanavir. Do not coâ€�administer. â†‘ tofacitinib, recommend ceasing" exact="tofacitinib" post="Nitazoxanide (prodrug) (active metabolite: tizoxanide) May be dispersible or"/>
   <result pre="emergency. 6.1 Remdesivir (GSâ€�5734) Remdesivir is a prodrug of the" exact="adenosine" post="nucleotide analogue GSâ€�441524 that incorporates into nascent viral RNA"/>
   <result pre="combines two protease inhibitors, the latter used to pharmacokinetically â€˜boostâ€™" exact="lopinavir" post="concentrations and prolong the effect through CYP3A4 inhibition.104 Licensed"/>
   <result pre="medication regime. Importantly lopinavir/ritonavir inhibits the metabolism of corticosteroids, tacrolimus," exact="ciclosporin" post="and tofacitinib which may lead to toxicity (TableÂ 4)."/>
   <result pre="Importantly lopinavir/ritonavir inhibits the metabolism of corticosteroids, tacrolimus, ciclosporin and" exact="tofacitinib" post="which may lead to toxicity (TableÂ 4). 6.3 Chloroquine"/>
   <result pre="and tofacitinib which may lead to toxicity (TableÂ 4). 6.3" exact="Chloroquine" post="or hydroxychloroquine Chloroquine is a widely used antiâ€�malarial and"/>
   <result pre="which may lead to toxicity (TableÂ 4). 6.3 Chloroquine or" exact="hydroxychloroquine" post="Chloroquine is a widely used antiâ€�malarial and autoimmune disease"/>
   <result pre="may lead to toxicity (TableÂ 4). 6.3 Chloroquine or hydroxychloroquine" exact="Chloroquine" post="is a widely used antiâ€�malarial and autoimmune disease drug."/>
   <result pre="antiâ€�viral effect and reduce COVIDâ€�19 complications synergistically.108 Compared to controls," exact="chloroquine" post="had a superior effect in 100 patients in China"/>
   <result pre="of pneumonia, duration of symptoms and delay in viral clearance.109" exact="Chloroquine" post="is not accessible in Australia and it has been"/>
   <result pre="not accessible in Australia and it has been suggested that" exact="hydroxychloroquine" post="could be an effective alternative given that it is"/>
   <result pre="effective alternative given that it is an identical molecule to" exact="chloroquine" post="apart from the addition of a hydroxyl group. 108,"/>
   <result pre="study, 20 COVIDâ€�19 positive patients (&amp;gt;12Â years of age) received" exact="hydroxychloroquine" post="200Â mg three times a day for 10Â days"/>
   <result pre="At day 6, virological clearance was 57% in those receiving" exact="hydroxychloroquine" post="compared with 12.5% in the control group (PÂ =Â"/>
   <result pre="patients who were transferred to ICU. Furthermore, the combination of" exact="azithromycin" post="and hydroxychloroquine should be considered with caution given additive"/>
   <result pre="were transferred to ICU. Furthermore, the combination of azithromycin and" exact="hydroxychloroquine" post="should be considered with caution given additive potential of"/>
   <result pre="fees from Abbvie, personal fees from Abgenomics, personal fees from" exact="Allergan" post="Inc, personal fees from Boehringer Ingelheim Ltd, personal fees"/>
   <result pre="et al. Quantitative proteomic analysis reveals the deregulation of nicotinamide" exact="adenine" post="dinucleotide metabolism and CD38 in inflammatory bowel disease. Biomed"/>
   <result pre="respiratory syndrome: the impact of high dosage and duration of" exact="methylprednisolone" post="therapy. Zhonghua Nei Ke Za Zhi. 2004;43:179â€&quot;182.15059370 60LiY. Relationship"/>
   <result pre="MangusoF, ZibelliniM, et al. Oral prolonged release beclomethasone dipropionate and" exact="prednisone" post="in the treatment of active ulcerative colitis: results from"/>
   <result pre="Ther. 2009;29:1106â€&quot;1113.19222411 72ChengKâ€�W, ChengSâ€�C, ChenWâ€�Y, et al. Thiopurine analogs and" exact="mycophenolic acid" post="synergistically inhibit the papainâ€�like protease of Middle East respiratory"/>
   <result pre="Res. 2015;115:9â€&quot;16.25542975 73IbrahimA, AhmedM, ConwayR, CareyJJ. Risk of infection with" exact="methotrexate" post="therapy in inflammatory diseases: a systematic review and metaâ€�analysis."/>
   <result pre="metaâ€�analysis. J Clin Med. 2019;8:15. 74ConwayR, LowC, CoughlanRJ, et al." exact="Methotrexate" post="use and risk of lung disease in psoriasis, psoriatic"/>
   <result pre="2018;24:2258â€&quot;2265.29850873 90WollenhauptJ, LeeEB, CurtisJR, et al. Safety and efficacy of" exact="tofacitinib" post="for up to 9.5 years in the treatment of"/>
   <result pre="1):i34â€&quot;i42.30806708 93WeisshofR, Aharoni GolanM, SossenheimerPH, et al. Realâ€�world experience with" exact="tofacitinib" post="in IBD at a Tertiary Center. Dig Dis Sci."/>
   <result pre="exoribonuclease. mBio. 2018;9. 103WangM, CaoR, ZhangL, et al. Remdesivir and" exact="chloroquine" post="effectively inhibit the recently emerged novel coronavirus (2019â€�nCoV) in"/>
   <result pre="RolainJâ€�M, ColsonP, RaoultD. New insights on the antiviral effects of" exact="chloroquine" post="against coronavirus: what to expect for COVIDâ€�19?Int J Antimicrob"/>
   <result pre="COVIDâ€�19?Int J Antimicrob Agents. 2020. 109ColsonP, RolainJâ€�M, LagierJâ€�C, et al." exact="Chloroquine" post="and hydroxychloroquine as available weapons to fight COVIDâ€�19. Int"/>
   <result pre="Antimicrob Agents. 2020. 109ColsonP, RolainJâ€�M, LagierJâ€�C, et al. Chloroquine and" exact="hydroxychloroquine" post="as available weapons to fight COVIDâ€�19. Int J Antimicrob"/>
   <result pre="fight COVIDâ€�19. Int J Antimicrob Agents. 2020;105932. 110ColsonP, RolainJM, RaoultD." exact="Chloroquine" post="for the 2019 novel coronavirus SARSâ€�CoVâ€�2. Int J Antimicrob"/>
   <result pre="Int J Antimicrob Agents. 2020;55:105923.32070753 111GautretP, LagierJâ€�C, ParolaP, et al." exact="Hydroxychloroquine" post="and azithromycin as a treatment of COVIDâ€�19: results of"/>
   <result pre="Antimicrob Agents. 2020;55:105923.32070753 111GautretP, LagierJâ€�C, ParolaP, et al. Hydroxychloroquine and" exact="azithromycin" post="as a treatment of COVIDâ€�19: results of an openâ€�label"/>
   <result pre="to view. 123CohenSB, TanakaY, MarietteX, et al. Longâ€�term safety of" exact="tofacitinib" post="for the treatment of rheumatoid arthritis up to 8.5"/>
   <result pre="Clin Pharmacokinet. 2018;57:1075â€&quot;1106.29512050 125GisbertJP, NinoP, CaraC, RodrigoL. Comparative effectiveness of" exact="azathioprine" post="in Crohn's disease and ulcerative colitis: prospective, longâ€�term, followâ€�up"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7267122\results\search\drug\results.xml">
   <result pre="SARSâ€�CoVâ€�2019 2019 Novel Coronavirus TEN Toxic Epidermal Necrolysis TMSP Transmembrane" exact="Serine" post="Protease 1 INTRODUCTION The initial outbreak of the novel"/>
   <result pre="hygiene: Washing hands with sanitizers containing a high concentration of" exact="ethanol" post="can inactivate the virus.28 Consistent cleaning of environmental surfaces"/>
   <result pre="(TEN), Colitis haemorrhage etc. Atleast three trials (eg, NCT04303299 3/12/2020)" exact="Chloroquine" post="Interferes with the cellular receptor ACE2 and also impairs"/>
   <result pre="etc. At least ten trials (eg, NCT04303507, 3/11/20; NCT04261517, 2/14/20)" exact="Ribavirin" post="Nucleoside analog of ribofuranose that inhibits viral RNA synthesis"/>
   <result pre="transaminase Two trials (NCT04260594,2/7/20; NCT04286503, 2/27/20) 4.1 Lopinavir/ritonavir Lopinavir and" exact="ritonavir" post="are protease inhibitors that work in conjunction to block"/>
   <result pre="lopinavir, thus boosting its levels. A 4 ug/mL concentration of" exact="lopinavir" post="was required for in vitro antiviral activity against SARS"/>
   <result pre="for in vitro antiviral activity against SARS while 1ug/mg of" exact="lopinavir" post="was enough when used in combination with ribavirin.30 Both"/>
   <result pre="might be required for efficacy.20 Nevertheless, lopinavir/ritonavir is advantageous over" exact="ribavirin" post="because of its wide availability and an established toxicity"/>
   <result pre="vitro at a concentration of 10 to 30â€‰Î¼M.34, 36 4.6" exact="Chloroquine" post="Chloroquine, generally used for amebiasis and malaria, is currently"/>
   <result pre="acidification of endosomes, thereby impeding virus trafficking inside cells. Although" exact="chloroquine" post="has been unsuccessful in treatment of SARSâ€�infected mice,37 recent"/>
   <result pre="SARSâ€�infected mice,37 recent reports from in vitro data show that" exact="chloroquine" post="inhibits SARSâ€�CoVâ€�2 at a 50% inhibitory concentration of 1"/>
   <result pre="worth mentioning that for SARS, the 50% inhibitory concentration of" exact="chloroquine" post="is near to 9 uM,39 implying chloroquine is more"/>
   <result pre="inhibitory concentration of chloroquine is near to 9 uM,39 implying" exact="chloroquine" post="is more potent against SARSâ€�CoVâ€�2 than SARS. Studies of"/>
   <result pre="chloroquine is more potent against SARSâ€�CoVâ€�2 than SARS. Studies of" exact="chloroquine" post="and hydroxychloroquine are underway.40, 41, 42, 43 At the"/>
   <result pre="more potent against SARSâ€�CoVâ€�2 than SARS. Studies of chloroquine and" exact="hydroxychloroquine" post="are underway.40, 41, 42, 43 At the same time,"/>
   <result pre="potential drugs Several other potential drugs include BCRâ€�ABL kinase inhibitor" exact="imatinib" post="and Typeâ€�II transmembrane serine protease (TMSPSS2) inhibitors.44 Imatinib inhibits"/>
   <result pre="disulfiram, chalcone, ebselen, tideglusib, carmofur, PX12, shikonin, TDZDâ€�8, cinanserin, and" exact="cyclosporin A." post="Also, some Chinese herbal medicines such as Radix Sophorae"/>
   <result pre="SARSâ€�CoVâ€�1. N Engl J Med. 2020;382:1564â€�1567. 10.1056/NEJMc2004973.32182409 28KampfG. Efficacy of" exact="ethanol" post="against viruses in hand disinfection. J Hosp Infect. 2018;98(4):331â€�338.28882643"/>
   <result pre="Chem Chemother. 2006;17(5):275â€�284.17176632 38WangM, CaoR, ZhangL, et al. Remdesivir and" exact="chloroquine" post="effectively inhibit the recently emerged novel coronavirus (2019â€�nCoV) in"/>
   <result pre="in vitro. Cell Res. 2020;30(3):269â€�271.32020029 39Alâ€�BariMA. Targeting endosomal acidification by" exact="chloroquine" post="analogs as a promising strategy for the treatment of"/>
   <result pre="emerging viral diseases. Pharmacol Res Perspect. 2017;5(1). 40ColsonP, RolainJM, RaoultD." exact="Chloroquine" post="for the 2019 novel coronavirus. Int J Antimicrob Agents."/>
   <result pre="Int J Antimicrob Agents. 2020;15:105923. 41ColsonP, RolainJM, LagierJC, BrouquiP, RaoultD." exact="Chloroquine" post="and hydroxychloroquine as available weapons to fight COVIDâ€�19. Int"/>
   <result pre="Antimicrob Agents. 2020;15:105923. 41ColsonP, RolainJM, LagierJC, BrouquiP, RaoultD. Chloroquine and" exact="hydroxychloroquine" post="as available weapons to fight COVIDâ€�19. Int J Antimicrob"/>
   <result pre="Int J Antimicrob Agents. 2020;55(4):105932.32145363 42GautretP, LagierJC, ParolaP, et al." exact="Hydroxychloroquine" post="and azithromycin as a treatment of COVIDâ€�19: results of"/>
   <result pre="Antimicrob Agents. 2020;55(4):105932.32145363 42GautretP, LagierJC, ParolaP, et al. Hydroxychloroquine and" exact="azithromycin" post="as a treatment of COVIDâ€�19: results of an openâ€�label"/>
   <result pre="43SahraeiZ, ShabaniM, ShokouhiS, SaffaeiA. Aminoquinolines Against Coronavirus Disease 2019 (COVIDâ€�19):" exact="Chloroquine" post="or Hydroxychloroquine. Int J Antimicrob Agents. 2020;16:105945. 44HoffmannM, Kleineâ€�WeberH,"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7267399\results\search\drug\results.xml">
   <result pre="protease RBD receptor binding domain RBM receptor binding motif RBV" exact="ribavirin" post="RdRP RNAâ€�dependent RNA polymerase SARSâ€�CoV severe acute respiratory syndrome"/>
   <result pre="A recent hypothesis proposed that ACE inhibitors (ACEIs), such as" exact="captopril" post="and enalapril, or angiotensin AT1 receptor antagonists, including losartan"/>
   <result pre="an in vitro study found that the serine protease inhibitor" exact="camostat" post="mesylate could significantly block the activity of TMPRSS2, which"/>
   <result pre="therapeutic target for the treatment of SARSâ€�CoVâ€�2â€�infected patients. More remarkably," exact="camostat" post="mesylate has already been approved for safety for the"/>
   <result pre="of pancreatic inflammatory disease in Japan, which reminds us that" exact="camostat" post="mesylate should be given sufficient consideration as a promising"/>
   <result pre="finding from the University of Tokyo, a comparable drug named" exact="nafamostat" post="mesylate can prevent TMPRSS2â€�triggered SARSâ€�CoVâ€�2 membrane fusion at a"/>
   <result pre="membrane fusion at a concentration less than oneâ€�tenth that of" exact="camostat" post="mesylate, suggesting that nafamostat mesylate may also be a"/>
   <result pre="concentration less than oneâ€�tenth that of camostat mesylate, suggesting that" exact="nafamostat" post="mesylate may also be a promising inhibitor of SARSâ€�CoVâ€�2"/>
   <result pre="He, 2005), which indicates its potential for antiâ€�SARSâ€�CoVâ€�2 drug development." exact="Ribavirin" post="(RBV), a broadâ€�spectrum antiviral drug, has been studied in"/>
   <result pre="St, &amp;amp; Mesecar, 2015). The identified 6â€�mercaptopurine, 6â€�thioguanine, Nâ€�ethylmaleimide, and" exact="mycophenolic acid" post="could act as MERSâ€�CoV PLpro inhibitors to suppress its"/>
   <result pre="SARSâ€�CoV patients (Wu et al., 2004). Based on these results," exact="lopinavir" post="and ritonavir may also be promising drugs for SARSâ€�CoVâ€�2"/>
   <result pre="(Wu et al., 2004). Based on these results, lopinavir and" exact="ritonavir" post="may also be promising drugs for SARSâ€�CoVâ€�2 treatment. Interestingly,"/>
   <result pre="drugs for SARSâ€�CoVâ€�2 treatment. Interestingly, treatment with a formulation of" exact="lopinavir" post="and ritonavir in tablet form (800/200 mgÂ·dayâˆ’1) called Kaletra"/>
   <result pre="SARSâ€�CoVâ€�2 treatment. Interestingly, treatment with a formulation of lopinavir and" exact="ritonavir" post="in tablet form (800/200 mgÂ·dayâˆ’1) called Kaletra can quickly"/>
   <result pre="of lopinavir and ritonavir in tablet form (800/200 mgÂ·dayâˆ’1) called" exact="Kaletra" post="can quickly improve clinical symptoms by inhibiting SARSâ€�CoVâ€�2 replication"/>
   <result pre="silico and enzyme activity test) on January 25, 2020, including" exact="lopinavir" post="and ritonavir. Even though this combination has produced a"/>
   <result pre="to test the effectiveness of HIV protease inhibitors such as" exact="lopinavir" post="and ritonavir in patients infected with SARSâ€�CoVâ€�2. However, an"/>
   <result pre="the effectiveness of HIV protease inhibitors such as lopinavir and" exact="ritonavir" post="in patients infected with SARSâ€�CoVâ€�2. However, an increasing number"/>
   <result pre="et al., 2020). Although hopes are fading for treatment with" exact="lopinavir" post="and ritonavir, targeting 3CLpro is still a potential therapeutic"/>
   <result pre="I. H., â€¦ Chou, C. Y. (2015). Thiopurine analogs and" exact="mycophenolic acid" post="synergistically inhibit the papainâ€�like protease of Middle East respiratory"/>
   <result pre="protease. PLoS Pathogens, 10(5), 1â€&quot;15. e100411310.1371/journal.ppat.1004113 RIddell, S. R. (2018)." exact="Adrenaline" post="fuels a cytokine storm during immunotherapy. Nature, 564(7735), 194â€&quot;196."/>
   <result pre="in rheumatoid arthritis clinical trials of tocilizumab or adalimumab or" exact="methotrexate" post="monotherapy. Annals of the Rheumatic Diseases, 79(4), 460â€&quot;463. 10.1136/annrheumdis-2019-21653732033935"/>
   <result pre="(2019). Initiating tocilizumab, with or without methotrexate, compared with starting" exact="methotrexate" post="with prednisone within stepâ€�up treatment strategies in early rheumatoid"/>
   <result pre="tocilizumab, with or without methotrexate, compared with starting methotrexate with" exact="prednisone" post="within stepâ€�up treatment strategies in early rheumatoid arthritis: An"/>
   <result pre="Liu, J., Xu, M., â€¦ Xiao, G. (2020). Remdesivir and" exact="chloroquine" post="effectively inhibit the recently emerged novel coronavirus (2019â€�nCoV) in"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7267548\results\search\drug\results.xml">
   <result pre="after convalescent plasma therapy in SARS patients who deteriorated despite" exact="ribavirin" post="and highâ€�dose steroid therapy (74% vs. 19%; p ="/>
   <result pre="Compared with five people who died in the continuing highâ€�dose" exact="methylprednisolone" post="group, there were no deaths in the plasma group"/>
   <result pre="who developed severe progression and failed to respond to the" exact="ribavirin" post="or methylprednisone. The study shows that viral load dropped"/>
   <result pre="of infections. SARS patients whose clinical condition deteriorated after receiving" exact="ribavirin" post="and methylprednisolone had a higher discharge rate by Day"/>
   <result pre="SARS patients whose clinical condition deteriorated after receiving ribavirin and" exact="methylprednisolone" post="had a higher discharge rate by Day 22, a"/>
   <result pre="et al. Retrospective comparison of convalescent plasma with continuing highâ€�dose" exact="methylprednisolone" post="treatment in SARS patients. Clin Microbiol Infect2004;10(7):676â€�8.15214887 7BeigelJH, LukeTC."/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7267562\results\search\drug\results.xml">
   <result pre="306 http://6LU7A 100.0 100.0 homoâ€�dimer(A, C) A, C: 1â€&quot;306 AZP," exact="Carfilzomib" post="0 0 4.54 YP_009725302.1 nsp6 290 n.a. YP_009725303.1 nsp7"/>
   <result pre="human betacoronavirus 2C EMC/2012 http://5C8T, http://3R24, http://5YNI, http://5YNM, http://5YN6 1.000" exact="Ademetionine" post="D07128 0.946 Sinefungin C00052045, D05846 0.862 Tecadenoson D06019 0.814"/>
   <result pre="EMC/2012 http://2XYR, http://5YNN, http://5YNP, http://5YNB 1.000 Sinefungin C00052045, D05846 0.946" exact="Ademetionine" post="D07128 0.862 Tecadenoson D06019 0.832 Adenosine monophosphate D02769 0.832"/>
   <result pre="Sinefungin C00052045, D05846 0.946 Ademetionine D07128 0.862 Tecadenoson D06019 0.832" exact="Adenosine" post="monophosphate D02769 0.832 Selodenoson D05818 7â€�Methylâ€�Guanosineâ€�5'â€�Triphosphateâ€�5'â€�Guanosine GTG 2'â€�Oâ€�Ribose methyltransferase"/>
   <result pre="C00032442 (5s,8s,14r)â€�Ethyl 11â€�(3â€�Aminoâ€�3â€� Oxopropyl)â€�8â€�Benzylâ€�14â€�Hydroxyâ€�5â€�Isobutylâ€�3,6,9,12â€�Tetraoxoâ€�1â€�Phenylâ€�2â€�Oxaâ€�4,7,10,11â€�Tetraazapentadecanâ€�15â€�Oate AZP 3Câ€�like proteinase SARSâ€�CoV http://2GTB 0.754" exact="Carfilzomib" post="D08880 1â€�((2S)â€�2â€�{[(1S)â€�1â€�Carboxyâ€�3â€�Phenylpropyl]Amino}Propanpyl)â€�Lâ€�Proline EAL ACE Human http://1UZE 1.000 Enalaprilat D03769"/>
   <result pre="D08880 1â€�((2S)â€�2â€�{[(1S)â€�1â€�Carboxyâ€�3â€�Phenylpropyl]Amino}Propanpyl)â€�Lâ€�Proline EAL ACE Human http://1UZE 1.000 Enalaprilat D03769 0.932" exact="Lisinopril" post="D00362 0.926 Enalaprilat D00621 0.925 Spiraprilat D03775 0.918 Lisinopril"/>
   <result pre="0.932 Lisinopril D00362 0.926 Enalaprilat D00621 0.925 Spiraprilat D03775 0.918" exact="Lisinopril" post="D00362 [N2â€�[(S)â€�1â€�Carboxyâ€�3â€�phenylpropyl]â€�Lâ€�lysylâ€�Lâ€�proline LPR ACE somatic isoform Human http://1O86 1.000"/>
   <result pre="Lisinopril D00362 [N2â€�[(S)â€�1â€�Carboxyâ€�3â€�phenylpropyl]â€�Lâ€�lysylâ€�Lâ€�proline LPR ACE somatic isoform Human http://1O86 1.000" exact="Lisinopril" post="D00362 0.932 Enalaprilat D03769 0.896 Enalaprilat D07892 0.867 Ceronapril"/>
   <result pre="D03440 0.857 Spiraprilat D03775 Lâ€�Captopril X8Z ACE Human http://4C2P 1.000" exact="Captopril" post="D00251 0.853 Telmesteine D08565 0.851 Oxaceprol D07215 0.795 Undecanoic"/>
   <result pre="known drug molecules (TableÂ 2). As a peptide mimetic drug," exact="carfilzomib" post="showed highest score to the template ligand (ligand code"/>
   <result pre="score between the ligand and the drug was only 0.754." exact="Carfilzomib" post="is the irreversible proteasome inhibitor targeted to the subunits"/>
   <result pre="model of carfilzomibâ€&quot;SARSâ€�CoVâ€�2 3Câ€�like proteinase was constructed. In the model," exact="carfilzomib" post="formed a parallel Î²â€�sheet with His164â€&quot;Glu166, and side chains"/>
   <result pre="conserved between the template (SARSâ€�CoV) and the model (SARSâ€�CoVâ€�2) proteins." exact="Carfilzomib" post="covalently binds to active site threonine through epoxy moiety,"/>
   <result pre="thiol group of cysteine. Although a possible covalent linkage between" exact="carfilzomib" post="and the catalytic Cys145 of SARSâ€�CoVâ€�2 3Câ€�like proteinase was"/>
   <result pre="Overall structure of the model. (C) Close view of the" exact="carfilzomib" post="binding site. Hydrogen bonds are shown in yellow lines."/>
   <result pre="hostâ€&quot;pathogen interaction. Fig. 2 Surface glycoproteinâ€&quot;ACE2â€&quot;lisinopril/enalaprilat/captopril model. (A) Formula of" exact="lisinopril" post="(ligand code LPR), enalaprilat (EAL), and captopril (X8Z). (B)"/>
   <result pre="(A) Formula of lisinopril (ligand code LPR), enalaprilat (EAL), and" exact="captopril" post="(X8Z). (B) Overall structure of the model. (C) Close"/>
   <result pre="Hydrogen bonds are shown in yellow lines. Lisinopril, enalaprilat, and" exact="captopril" post="were superposed, and the carbon atoms were colored light"/>
   <result pre="and magenta, respectively. The DSX scores for lisinopril, enalaprilat, and" exact="captopril" post="in the models were âˆ’32.7, âˆ’43.6, and âˆ’25.0, respectively."/>
   <result pre="SARSâ€�CoVâ€�2. As the drugs similar to these ligands, several investigational" exact="adenosine" post="A1 receptor agonists, namely tecadenoson, selodenoson, and trabodenoson, were"/>
   <result pre="selodenoson, and trabodenoson, were found (Fig.Â 3A). These molecules share" exact="adenosine" post="moiety, and this moiety interacts with the aforementioned 5"/>
   <result pre="50], as a marginally resembling drug. The model showed, however," exact="carfilzomib" post="fits well (even better than the specific inhibitor N3,"/>
   <result pre="LiuJ, XuM, ShiZ, HuZ, ZhongW and XiaoG (2020) Remdesivir and" exact="chloroquine" post="effectively inhibit the recently emerged novel coronavirus (2019â€�nCoV) in"/>
   <result pre="vitro. Cell Res30, 269â€&quot;271.32020029 5GaoJ, TianZ and YangX (2020) Breakthrough:" exact="Chloroquine" post="phosphate has shown apparent efficacy in treatment of COVIDâ€�19"/>
   <result pre="[PREPRINT]. 17XuZ, PengC, ShiY, ZhuZ, MuK, WangX and ZhuW. (2020)" exact="Nelfinavir" post="was predicted to be a potential inhibitor of 2019â€�nCov"/>
   <result pre="AcharyaKR (2004) Structural details on the binding of antihypertensive drugs" exact="captopril" post="and enalaprilat to human testicular angiotensin Iâ€�converting enzyme. Biochemistry43,"/>
   <result pre="TurinG, McKinstryD and GavrasH (1978) Innappropriate renin secretion unmasked by" exact="captopril" post="(SQ 14 225) in hypertension of chronic renal failure."/>
   <result pre="WengerHC, VassilTC and StoneCA (1981) Effect of Nâ€�[(S)â€�1â€�carboxyâ€�3â€�phenylpropyl]â€�Lâ€�Alaâ€�Lâ€�Pro and its" exact="ethyl ester" post="(MKâ€�421) on angiotensin converting enzyme in vitro and angiotensin"/>
   <result pre="463â€&quot;465.4792069 75PetermanC and SanoskiCA (2005) Tecadenoson: a novel, selective A1" exact="adenosine" post="receptor agonist. Cardiol Rev13, 315â€&quot;321.16230891 76LiG, TorrejonKY, UnserAM, AhmedF,"/>
   <result pre="UnserAM, AhmedF, NavarroID, BaumgartnerRA, AlbersDS and StamerWD (2018) Trabodenoson, an" exact="adenosine" post="mimetic with A1 receptor selectivity lowers intraocular pressure by"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7269097\results\search\drug\results.xml">
   <result pre="without Interferon Î²-1a (to help stimulate the immune system); and" exact="hydroxychloroquine" post="(this last treatment has currently been paused). The FDA-approved"/>
   <result pre="RdRP.5 The FDA has issued an emergency use authorization of" exact="hydroxychloroquine" post="and chloroquine, both of which are approved to treat"/>
   <result pre="have emerged as popular targets for COVID-19. HIV protease inhibitors" exact="lopinavir" post="and ritonavir, included in the SOLIDARITY trial despite mixed"/>
   <result pre="SARS-CoV-2 by remdesivir. Science2020, eabc156010.1126/science.abc1560. SchrezenmeierE.; DÃ¶rnerT.Mechanisms of action of" exact="hydroxychloroquine" post="and chloroquine: implications for rheumatology. Nat. Rev. Rheumatol.2020, 16"/>
   <result pre="NuthoB.; MahalapbutrP.; HengphasatpornK.; PattaranggoonN. C.; SimanonN.; ShigetaY.; HannongbuaS.; RungrotmongkolT.Why are" exact="lopinavir" post="and ritonavir effective against the newly emerged coronavirus 2019?"/>
   <result pre="HengphasatpornK.; PattaranggoonN. C.; SimanonN.; ShigetaY.; HannongbuaS.; RungrotmongkolT.Why are lopinavir and" exact="ritonavir" post="effective against the newly emerged coronavirus 2019? Atomistic insights"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7270404\results\search\drug\results.xml">
   <result pre="it has also been demonstrated that the serine protease inhibitor" exact="camostat" post="(see also below section on Therapeutic targets and Conclusion)"/>
   <result pre="the membrane proteases of the TTSP family (see above) using" exact="camostat" post="mesilate (5 hits). Repurposing of non-antiviral drugs may offer"/>
   <result pre="vitro. Antiviral Res. (2020) 178:10478710.1016/j.antiviral.2020.10478732251768 89.SchrezenmeierEDornerT. Mechanisms of action of" exact="hydroxychloroquine" post="and chloroquine: implications for rheumatology. Nat Rev Rheumatol. (2020)"/>
   <result pre="al.. Risk of QT interval prolongation associated with use of" exact="hydroxychloroquine" post="with or without concomitant azithromycin among hospitalized patients testing"/>
   <result pre="prolongation associated with use of hydroxychloroquine with or without concomitant" exact="azithromycin" post="among hospitalized patients testing positive for Coronavirus Disease 2019"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7270517\results\search\drug\results.xml">
   <result pre="Immunosupp. (nâ€‰=â€‰7) ACEI/ARBa(nâ€‰=â€‰6) OACa (nâ€‰=â€‰5) Rituximab (maintenance tx; 500Â mg/dose)" exact="Prednisone" post="(15Â mg/day) IVIGa (2Â g/kg) High dose ASA Lef"/>
   <result pre="mg/day) IVIGa (2Â g/kg) High dose ASA Lef HQ MPSa" exact="Meloxicam" post="Famotidine Folic acid TOC (5 weekly) ETAa (nâ€‰=â€‰2) ABAa"/>
   <result pre="(2Â g/kg) High dose ASA Lef HQ MPSa Meloxicam Famotidine" exact="Folic acid" post="TOC (5 weekly) ETAa (nâ€‰=â€‰2) ABAa (nâ€‰=â€‰1) TOFa (nâ€‰=â€‰1)"/>
   <result pre="anakinra, anti-dsDNA anti-double stranded DNA, ARB antigotensin receptor blocker, ASA" exact="acetylsalicylic acid," post="Ass associated, CAD coronary artery disease, Can canakinumab, CAPS"/>
   <result pre="immunosuppressive, IVIG intravenous immunoglobulin, JAK janus kinase, Lef leflunamide, MMF" exact="mycophenolate mofetil," post="MPS methylprednisolone, MTX methotrexate, mos months, NA not applicable,"/>
   <result pre="patients, Gendelman et al. reported that three were on chronic" exact="hydroxychloroquine" post="(HCQ) and seven were on chronic colchicine treatment [45]."/>
   <result pre="is also observed in severe vasculopathies such as deficiency of" exact="adenosine" post="deaminase 2 [85, 86]. These vascular lesions could be"/>
   <result pre="primary therapeutic options, especially in the treatment of oligoarticular JIA." exact="Ibuprofen" post="has been reported to increase ACE2 expression [111]. And"/>
   <result pre="influenza-associated ARDS [122]. Regarding COVID-19, Wu et al. demonstrated that" exact="methylprednisolone" post="treatment appeared to decrease the risk of death among"/>
   <result pre="et al. observed that early, low-dose, and short-term application of" exact="methylprednisolone" post="was associated with better clinical outcomes while they did"/>
   <result pre="evidence and may enlighten the role of glucocorticoids in COVID-19." exact="Hydroxychloroquine" post="Hydroxychloroquine (HCQ), an antimalarial agent, is the mainstay of"/>
   <result pre="and may enlighten the role of glucocorticoids in COVID-19. Hydroxychloroquine" exact="Hydroxychloroquine" post="(HCQ), an antimalarial agent, is the mainstay of treatment,"/>
   <result pre="associated with viral load reduction with more efficient results when" exact="azithromycin" post="was added [128]. Studies are underway to obtain a"/>
   <result pre="trials planned to test the efficacy of leflunomid, ecluzimab, and" exact="ruxolitinib" post="[148]. The readers are referred to the review by"/>
   <result pre="for disease control during COVID-19 pandemic. And for pain control," exact="acetaminophen" post="could be selected over NSAIDs. Since HCQ is an"/>
   <result pre="RED-ZONE declarationDermatol Ther202010.1111/dth.1347532415727 37.DousaKMMalavadeSSFurinJGripshoverBHatszegiMHojatLSaadeESalataRASARS-CoV-2 infection in a patient on chronic" exact="hydroxychloroquine" post="therapy: implications for prophylaxisIDCases202010.1016/j.idcr.2020.e0077832341910 38.DuretPMSebbagEMallickAGravierSSpielmannLMesserLRecovery from COVID-19 in a"/>
   <result pre="in patients with rheumatic diseases?Ann Rheum Dis202010.1136/annrheumdis-2020-21761532451344 41.KonigMFKimAHScheetzMHGraefERLiewJWSimardJMachadoPMGianfrancescoMYazdanyJLangguthDRobinsonPCAllianceC-GRBaseline use of" exact="hydroxychloroquine" post="in systemic lupus erythematosus does not preclude SARS-CoV-2 infection"/>
   <result pre="14 States, March 1â€&quot;30, 2020MMWR Morb Mortal Wkly Rep20206945846410.15585/mmwr.mm6915e332298251 45.GendelmanOAmitalHBragazziNLWatadAChodickGContinuous" exact="hydroxychloroquine" post="or colchicine therapy does not prevent infection with SARS-CoV-2:"/>
   <result pre="acro-ischemiaZhonghua Xue Ye Xue Za Zhi202041E00610.3760/cma.j.issn.0253-2727.2020.000632220276 85.BatuEDKaradagOTaskiranEZKalyoncuUAksentijevichIAlikasifogluMOzenSA case series of" exact="adenosine" post="deaminase 2-deficient patients emphasizing treatment and genotype-phenotype correlationsJ Rheumatol2015421532153410.3899/jrheum.15002426233953"/>
   <result pre="86.OzenSBatuEDTaskiranEZOzkaraHAUnalSGulerayNErdenAKaradagOGumrukFCetinMSonmezHEBilginerYAyvazDCTezcanIA Monogenic disease with a variety of phenotypes: deficiency of" exact="adenosine" post="deaminase 2J Rheumatol20204711712510.3899/jrheum.18138431043544 87.ZhangYXiaoMZhangSXiaPCaoWJiangWChenHDingXZhaoHZhangHWangCZhaoJSunXTianRWuWWuDMaJChenYZhangDXieJYanXZhouXLiuZWangJDuBQinYGaoPQinXXuYZhangWLiTZhangFZhaoYLiYZhangSCoagulopathy and antiphospholipid antibodies in patients"/>
   <result pre="a randomised, double-blind, placebo-controlled, multicentre trialLancet202010.1016/S0140-6736(20)31022-932479790 108.YaoTTQianJDZhuWYWangYWangGQA systematic review of" exact="lopinavir" post="therapy for SARS coronavirus and MERS coronavirus-A possible reference"/>
   <result pre="mellitus at increased risk for COVID-19 infection?Lancet Respir Med20208e2110.1016/S2213-2600(20)30116-832171062 112.DayMCovid-19:" exact="ibuprofen" post="should not be used for managing symptoms, say doctors"/>
   <result pre="in Wuhan, ChinaJAMA Intern Med202010.1001/jamainternmed.2020.099432338717 124.WangYJiangWHeQWangCWangBZhouPDongNTongQA retrospective cohort study of" exact="methylprednisolone" post="therapy in severe patients with COVID-19 pneumoniaSignal Transduct Target"/>
   <result pre="pandemicJ Rheumatol202010.3899/jrheum.20036932241801 127.ShahSDasSJainAMisraDPNegiVSA systematic review of the prophylactic role of" exact="chloroquine" post="and hydroxychloroquine in coronavirus disease-19 (COVID-19)Int J Rheum Dis202010.1111/1756-185X.1384232281213"/>
   <result pre="127.ShahSDasSJainAMisraDPNegiVSA systematic review of the prophylactic role of chloroquine and" exact="hydroxychloroquine" post="in coronavirus disease-19 (COVID-19)Int J Rheum Dis202010.1111/1756-185X.1384232281213 128.GautretPLagierJCParolaPHoangVTMeddebLMailheMDoudierBCourjonJGiordanengoVVieiraVEDupontHTHonoreSColsonPChabriereELa ScolaBRolainJMBrouquiPRaoultDHydroxychloroquine"/>
   <result pre="in coronavirus disease-19 (COVID-19)Int J Rheum Dis202010.1111/1756-185X.1384232281213 128.GautretPLagierJCParolaPHoangVTMeddebLMailheMDoudierBCourjonJGiordanengoVVieiraVEDupontHTHonoreSColsonPChabriereELa ScolaBRolainJMBrouquiPRaoultDHydroxychloroquine and" exact="azithromycin" post="as a treatment of COVID-19: results of an open-label"/>
   <result pre="Antimicrob Agents202010.1016/j.ijantimicag.2020.10594932205204 129.MarmorMFKellnerULaiTYMellesRBMielerWFcollab: American Academy of ORecommendations on screening for" exact="chloroquine" post="and hydroxychloroquine retinopathy (2016 revision)Ophthalmology20161231386139410.1016/j.ophtha.2016.01.05826992838 130.O'LaughlinJPMehtaPHWongBCLife threatening severe QTc"/>
   <result pre="129.MarmorMFKellnerULaiTYMellesRBMielerWFcollab: American Academy of ORecommendations on screening for chloroquine and" exact="hydroxychloroquine" post="retinopathy (2016 revision)Ophthalmology20161231386139410.1016/j.ophtha.2016.01.05826992838 130.O'LaughlinJPMehtaPHWongBCLife threatening severe QTc prolongation in"/>
   <result pre="131.MasonJWAntimicrobials and QT prolongationJ Antimicrob Chemother2017721272127410.1093/jac/dkw59128160473 132.SalehMGabrielsJChangDKimBSMansoorAMahmoodEMakkerPIsmailHGoldnerBWillnerJBeldnerSMitraRJohnRChinitzJSkipitarisNMountantonakisSEpsteinLMThe effect of chloroquine," exact="hydroxychloroquine" post="and azithromycin on the corrected QT interval in patients"/>
   <result pre="QT prolongationJ Antimicrob Chemother2017721272127410.1093/jac/dkw59128160473 132.SalehMGabrielsJChangDKimBSMansoorAMahmoodEMakkerPIsmailHGoldnerBWillnerJBeldnerSMitraRJohnRChinitzJSkipitarisNMountantonakisSEpsteinLMThe effect of chloroquine, hydroxychloroquine and" exact="azithromycin" post="on the corrected QT interval in patients with SARS-CoV-2"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7271460\results\search\drug\results.xml">
   <result pre="for the adult population, anti-retroviral therapy (ART) based-on tenofovir (TDF)," exact="lamivudine" post="(3TC) and efavirenz (EFV) has dual treatment benefits for"/>
   <result pre="population, anti-retroviral therapy (ART) based-on tenofovir (TDF), lamivudine (3TC) and" exact="efavirenz" post="(EFV) has dual treatment benefits for both HBV and"/>
   <result pre="and hepatitis C seroprevalence among injection drug users in GeorgiaDrug" exact="Alcohol" post="Depend200682Suppl 1S35S3816769443 36.Cook C, Phelan M, Sander G, Stone"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7273044\results\search\drug\results.xml">
   <result pre="coronavirus by restricting binding and entry. In patients with COVIDâ€�19," exact="hydroxychloroquine" post="decreases the inflammatory response and cytokine storm, but overdose"/>
   <result pre="toxicity and mortality. Neuraminidase inhibitors such as oseltamivir, peramivir, and" exact="zanamivir" post="are invalid for 2019â€�nCoV and are not recommended for"/>
   <result pre="has a direct antiviral effect on early replication of SARSâ€�CoV." exact="Ribavirin" post="reduces hemoglobin concentrations in respiratory patients, and remdesivir improves"/>
   <result pre="in respiratory patients, and remdesivir improves respiratory symptoms. Use of" exact="ribavirin" post="in combination with LPV/r in patients with SARSâ€�CoV reduces"/>
   <result pre="clinical problem reducing agent such as favipiravir in addition to" exact="hydroxychloroquine" post="and corticosteroids. In late December 2019 in Wuhan, China,"/>
   <result pre="syndrome coronavirus (MERSâ€�CoV), and Influenza virus. In patients with COVIDâ€�19," exact="hydroxychloroquine" post="decreases the inflammatory response and cytokine storm, but overdose"/>
   <result pre="toxicity and mortality. Neuraminidase inhibitors such as oseltamivir, peramivir, and" exact="zanamivir" post="are invalid for 2019â€�nCoV and are not recommended for"/>
   <result pre="clinical problem reducing agent such as favipiravir in addition to" exact="hydroxychloroquine" post="and corticosteroids. antiviral coronavirus COVIDâ€�19 drug treatment fig-count: table-count:"/>
   <result pre="Drug Activity Effectiveness The drug's mechanism of action in COVIDâ€�19" exact="Kaletra" post="(lopinavir/ritonavir) Used to treat HIV infection 400â€‰mg/100â€‰mg twice daily"/>
   <result pre="Used to treat HIV infection 400â€‰mg/100â€‰mg twice daily Protease inhibitor" exact="Chloroquine" post="Inhibit quinone reductase 2 that used to treat malaria"/>
   <result pre="the glycosylation of cellular receptors of SARSâ€�CoV Remdesivir (GSâ€�5734) An" exact="adenosine" post="nucleotide analog inhibitor of RdRp 10â€‰mg/kg for 12 days"/>
   <result pre="nucleotide analogs against singleâ€�stranded RNA viruses such as coronaviruses IFNâ€�" exact="alpha" post="Used to treat HBV infection 5 million U bid"/>
   <result pre="to treat influenza virus infection 75â€‰mg every 12â€‰hr Neuraminidase inhibitors" exact="Ribavirin" post="Used to treat RSV infection, hepatitis C, and some"/>
   <result pre="and RNAâ€�containing viruses, including coronaviruses. There is some evidence that" exact="chloroquine" post="is effective in animal models of mice on viruses"/>
   <result pre="Tan, Yam, Sun, &amp;amp; Chu,Â 2018; Yan et al.,Â 2013)." exact="Chloroquine" post="has recently been shown to be an inhibitor of"/>
   <result pre="M. Wang et al. (2020) reported that the EC50 of" exact="Chloroquine" post="against COVIDâ€�19 tested on VERO E6 was 1.13â€‰Î¼M and"/>
   <result pre="on VERO E6 was 1.13â€‰Î¼M and the EC90 was 6.90â€‰Î¼M." exact="Chloroquine" post="inhibits SARSâ€�CoV entry, which exerts its inhibitory effect by"/>
   <result pre="the ACE2 receptor and spike protein. In patients with COVIDâ€�19," exact="hydroxychloroquine" post="has been shown to decrease inflammatory responses and decrease"/>
   <result pre="to decrease inflammatory responses and decrease cytokine storm in vitro." exact="Chloroquine" post="also interferes with proteolytic processing of M protein and"/>
   <result pre="of M protein and modifies virion assembly and budding. Also," exact="chloroquine" post="indirectly act against COVIDâ€�19 by reducing the production of"/>
   <result pre="et al.,Â 2020). 2.3 Antiviral drugs 2.3.1 Remdesivir (GSâ€�5734) An" exact="adenosine" post="nucleotide analog introduced by Gilead Sciences in 2017 to"/>
   <result pre="production of viral RNA. It has a similar structure to" exact="tenofovir alafenamide," post="a nucleotide analog of adenosine 5â€�monophosphate with antiviral activity"/>
   <result pre="a similar structure to tenofovir alafenamide, a nucleotide analog of" exact="adenosine" post="5â€�monophosphate with antiviral activity against hepatitis B virus and"/>
   <result pre="Lopinavir is an antiretroviral protease inhibitor used in combination with" exact="ritonavir" post="to treat patients with AIDS and HIV infection. Lopinavir"/>
   <result pre="is a potent and highly specific inhibitor of HIVâ€�1 protease." exact="Ritonavir" post="inhibits the metabolism of lopinavir, therefore coadministration of lopinavir"/>
   <result pre="protease. Ritonavir inhibits the metabolism of lopinavir, therefore coadministration of" exact="lopinavir" post="and ritonavir in healthy volunteers increases the area under"/>
   <result pre="inhibits the metabolism of lopinavir, therefore coadministration of lopinavir and" exact="ritonavir" post="in healthy volunteers increases the area under the lopinavir"/>
   <result pre="and ritonavir in healthy volunteers increases the area under the" exact="lopinavir" post="plasma concentrationâ€�time curve&amp;gt;â€‰100â€�fold (Hurst &amp;amp; Faulds,Â 2000). In a"/>
   <result pre="a study by Cao et al. (2020), the effect of" exact="lopinavir" post="plus ritonavir on adult patients with COVIDâ€�19 in China"/>
   <result pre="by Cao et al. (2020), the effect of lopinavir plus" exact="ritonavir" post="on adult patients with COVIDâ€�19 in China showed that"/>
   <result pre="in Hangzhou, China. A 2020 study showed that 400â€‰mg daily" exact="lopinavir" post="with IFNâ€�Î±2b atomization inhalation, 5 million U twice daily,"/>
   <result pre="million U twice daily, as well as the use of" exact="lopinavir" post="alone could be useful for patients with COVIDâ€�19 and"/>
   <result pre="those admitted to the intensive care unit (ICU). Oseltamivir and" exact="zanamivir" post="are firstâ€�line medications for the treatment and prophylaxis of"/>
   <result pre="and cytotoxicity for up to 4 days. It is an" exact="ethyl ester" post="prodrug that is hydrolyzed by hepatic esterases to its"/>
   <result pre="the ICU (Behillil et al.,Â 2019; Ison et al.,Â 2018)." exact="Zanamivir" post="solution is also a class of neuraminidase inhibitors that"/>
   <result pre="patients who are ventilated and show drug resistance to oseltamivir." exact="Peramivir" post="is also used intravenously as an antiviral drug. It"/>
   <result pre="the latest research, neuraminidase inhibitors such as oseltamivir, peramivir, and" exact="zanamivir" post="are invalid for nCoVâ€�2019 and are not recommended for"/>
   <result pre="the treatment of patients (Li &amp;amp; De Clercq,Â 2020). 2.3.4" exact="Ribavirin" post="Ribavirin is a guanosine nucleoside analog and antiviral compound"/>
   <result pre="treatment of patients (Li &amp;amp; De Clercq,Â 2020). 2.3.4 Ribavirin" exact="Ribavirin" post="is a guanosine nucleoside analog and antiviral compound used"/>
   <result pre="virus, bunyavirus, herpesvirus, adenovirus, poxvirus, and some viral hemorrhagic fevers." exact="Ribavirin" post="was first used in 1980 to treat the RSV"/>
   <result pre="to treat the RSV in children. The antiviral activity of" exact="ribavirin" post="is by intracellular guanosine depletion through inhibition of the"/>
   <result pre="replication by increasing IFN gene expression and modulating immune responses." exact="Ribavirin" post="is an inhibitor of RNA synthesis by viral RdRp"/>
   <result pre="as an immunomodulator (Ning et al.,Â 1998). In most cases," exact="ribavirin" post="is combined with IFN, and although the results of"/>
   <result pre="ribavirin is combined with IFN, and although the results of" exact="ribavirin" post="and IFNÎ±â€�2b in a MERSâ€�CoV rhesus macaque model were"/>
   <result pre="with the results of the trial and the effect of" exact="ribavirin" post="and IFN (either Î±2a or Î²1) on MERSâ€�CoV infected"/>
   <result pre="or Î²1) on MERSâ€�CoV infected patients it was different, however," exact="ribavirin" post="lowers hemoglobin concentrations in respiratory patients and therefore reduces"/>
   <result pre="replication, modulating host response, and improving clinical outcomes. Studies using" exact="ribavirin" post="plus lopinavir/ritonavir on patients with SARS have reduced ARDS"/>
   <result pre="B viruses. Favipiravir has also been used in combination with" exact="zanamivir" post="to successfully clear the type B influenza virus in"/>
   <result pre="and hepatitis C virus replication in combination with IFNâ€�Î± and" exact="cyclosporine" post="A. Mycophenolic acid (MPA) in use with cyclosporine, it"/>
   <result pre="Lin et al. (2018) also showed that MPA along with" exact="disulfiram" post="and 6â€�thioguanine was synergistically inhibitors of the MERSâ€�CoV papainâ€�like"/>
   <result pre="in certain groups of people. For example, excessive use of" exact="chloroquine" post="is toxic and can even be fatal, or the"/>
   <result pre="recommended for the treatment of patients. However, the use of" exact="hydroxychloroquine" post="as prophylaxis is appropriate because it blocks the entry"/>
   <result pre="decreased viral replication, modulated host response, and improved clinical outcomes." exact="Ribavirin" post="plus lopinavir/ritonavir in patients with SARSâ€�CoV reduces ARDS and"/>
   <result pre="&amp;amp; Eugui, E. M. (1993). Immunosuppressive and other effects of" exact="mycophenolic acid" post="and an ester prodrug, mycophenolate mofetil. Immunological Reviews, 136(1),"/>
   <result pre="and other effects of mycophenolic acid and an ester prodrug," exact="mycophenolate mofetil." post="Immunological Reviews, 136(1), 5â€&quot;28.7907572 Andrews, N. (2006). The fluâ€¦and"/>
   <result pre="F., Sindi, A., â€¦ Aldawood, A. S. (2017). Effect of" exact="ribavirin" post="and interferon on the outcome of critically Ill patients"/>
   <result pre="Raoult, D. (2020). New insights on the antiviral effects of" exact="chloroquine" post="against coronavirus: What to expect for COVIDâ€�19?International Journal of"/>
   <result pre="D. P., â€¦ Feldmann, H. (2013). Treatment with interferonâ€�Î±2b and" exact="ribavirin" post="improves outcome in MERSâ€�CoVâ€&quot;infected rhesus macaques. Nature Medicine, 19(10),"/>
   <result pre="D., &amp;amp; Cameron, C. E. (2006). Mechanisms of action of" exact="ribavirin" post="against distinct viruses. Reviews in Medical Virology, 16(1), 37â€&quot;48.16287208"/>
   <result pre="inhibits hepatitis C virus replication and acts in synergy with" exact="cyclosporin A" post="and interferonâ€�Î±. Gastroenterology, 131(5), 1452â€&quot;1462.17101321 Holmes, E. C. (2013)."/>
   <result pre="Cheng, S.â€�C., Chen, Y.â€�H., Sun, C.â€�Y., &amp;amp; Chou, C.â€�Y. (2018)." exact="Disulfiram" post="can inhibit mers and sars coronavirus papainâ€�like proteases via"/>
   <result pre="Tutill, H., Shah, D., â€¦ Breuer, J. (2020). Favipiravir and" exact="zanamivir" post="cleared infection with influenza B in a severely immunocompromised"/>
   <result pre="activity of the IMP dehydrogenase inhibitor VXâ€�497: A comparison with" exact="ribavirin" post="and demonstration of antiviral additivity with alpha interferon. Antimicrobial"/>
   <result pre="A comparison with ribavirin and demonstration of antiviral additivity with" exact="alpha" post="interferon. Antimicrobial Agents and Chemotherapy, 44(4), 859â€&quot;866.10722482 Martinez, M."/>
   <result pre="Cattral, M., Gorczynski, R., Cole, E., â€¦ Levy, G. (1998)." exact="Ribavirin" post="inhibits viralâ€�induced macrophage production of TNF, ILâ€�1, the procoagulant"/>
   <result pre="Aerts, J. L., De Clercq, E., &amp;amp; Neyts, J. (2003)." exact="Mycophenolate mofetil" post="inhibits the development of Coxsackie B3â€�virusâ€�induced myocarditis in mice."/>
   <result pre="J., &amp;amp; Chu, J. J. H. (2018). An evaluation of" exact="chloroquine" post="as a broadâ€�acting antiviral against hand, foot and mouth"/>
   <result pre="Liang, W.â€�M., Chen, C.â€�Y., Chang, Y.â€�J., â€¦ Sung, F.â€�C. (2015)." exact="Prompt" post="oseltamivir therapy reduces medical care and mortality for patients"/>
   <result pre="Liu, J., Xu, M., â€¦ Xiao, G. (2020). Remdesivir and" exact="chloroquine" post="effectively inhibit the recently emerged novel coronavirus (2019â€�nCoV) in"/>
   <result pre="Xu, K.â€�F., Wei, Y., â€¦ Jiang, C. (2013). Antiâ€�malaria drug" exact="chloroquine" post="is highly effective in treating avian influenza A H5N1"/>
   <result pre="&amp;amp; Wang, Q. (2016). Bioinformatics analysis on molecular mechanism of" exact="ribavirin" post="and interferonâ€�Î± in treating MERSâ€�CoV. Zhonghua Liuxingbingxue Zazhi, 37(2),"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7277397\results\search\drug\results.xml">
   <result pre="3.1. Therapeutic Agents Among therapeutics, the use of protease inhibitors" exact="lopinavir" post="and ritonavir as a combination therapy with other antiretroviral"/>
   <result pre="Agents Among therapeutics, the use of protease inhibitors lopinavir and" exact="ritonavir" post="as a combination therapy with other antiretroviral agents for"/>
   <result pre="in marmosets with a MERS-like disease [85]. In comparison to" exact="mycophenolate mofetil" post="(MFF), the treatment showed improved clinical, radiological and pathological"/>
   <result pre="recent COVID-19 pandemic, a clinical trial on 99 patients receiving" exact="lopinavir" post="and ritonavir were compared to 100 patients subjected to"/>
   <result pre="pandemic, a clinical trial on 99 patients receiving lopinavir and" exact="ritonavir" post="were compared to 100 patients subjected to standard care."/>
   <result pre="analogues were designed based on the acrylic sugar scaffold of" exact="acyclovir" post="[90]. One compound displayed selective antiviral activity against HCoV-NL63"/>
   <result pre="symptoms in two weeks. In another approach, the guanosine analogue" exact="ribavirin" post="was administered together with interferon-Î±2a in adult patients with"/>
   <result pre="ventilation support [92]. The study demonstrated that patients treated with" exact="ribavirin" post="and interferon-Î±2a showed a significantly improved survival rate at"/>
   <result pre="of treatment compared to the control group of patients. The" exact="adenosine" post="nucleoside analogue remdesivir has proven efficient for inhibition of"/>
   <result pre="load [97]. Neuraminidase inhibitors such as zanamivir, laninamivir, oseltamivir and" exact="peramivir" post="have demonstrated potency against most influenza strains [98]. In"/>
   <result pre="[98]. In this context, the neuraminidase inhibitors oseltamivir (Tamiflu) and" exact="zanamivir" post="(Relenza) were tested for inhibition of cytopathic effects of"/>
   <result pre="not against SARS-CoV [90] FIP Successful treatment of FIP [91]" exact="Ribavirin" post="MERS-CoV Improved survival at 14 days [92] Remdesivir HCoV-OC43,"/>
   <result pre="effect of the widely used antimalarial and auto-immune disease drug" exact="chloroquine" post="on coronaviruses [96]. Chloroquine blocks virus infection and interferes"/>
   <result pre="used antimalarial and auto-immune disease drug chloroquine on coronaviruses [96]." exact="Chloroquine" post="blocks virus infection and interferes with the glycosylation of"/>
   <result pre="glycosylation of cellular receptors of SARS-CoV [110]. The application of" exact="chloroquine" post="for COVID-19 patients has been justified by its common"/>
   <result pre="locals [111]. However, as indications of severe side effects of" exact="chloroquine" post="use have been reported, hydroxychloroquine, possessing a similar antiviral"/>
   <result pre="have been reported, hydroxychloroquine, possessing a similar antiviral potency to" exact="chloroquine" post="but a safer clinical profile, should be considered [112]."/>
   <result pre="viral load in comparison to control patients [103]. Addition of" exact="azithromycin" post="further significantly improved the efficiency of virus elimination. Despite"/>
   <result pre="elimination. Despite the small sample size, the study indicated that" exact="hydroxychloroquine" post="treatment was associated with a significant viral load reduction"/>
   <result pre="mechanical ventilation and had been treated with antiviral agents and" exact="methylprednisolone" post="showed a normalized body temperature within 3â€&quot;4 days and"/>
   <result pre="earlier [106]. Although the study indicated some therapeutic effect of" exact="hydroxychloroquine" post="and at least 80 trials on chloroquine, hydroxychloroquine, or"/>
   <result pre="Chinese trial in more than 100 patients demonstrated superiority of" exact="chloroquine" post="phosphate compared to control treatment in inhibition of pneumonia"/>
   <result pre="in a placebo-controlled randomized trial of two different doses of" exact="hydroxychloroquine" post="in 62 patients with radiological conformation of pneumonia, but"/>
   <result pre="reported and the trial was terminated prematurely [175]. Supporters of" exact="hydroxychloroquine" post="have referred to the history of wide and safe"/>
   <result pre="history of wide and safe use of the drug. However," exact="hydroxychloroquine" post="will potentially expose patients to serious cutaneous adverse reactions"/>
   <result pre="[176], hepatic failure [177] and ventricular arrhythmias when co-administered with" exact="azithromycin" post="[178]. In the context of lopinavir/ritonavir, a randomized, controlled,"/>
   <result pre="frequent in the standard-care group. The Efficacy of Lopinavir Plus" exact="Ritonavir" post="and Arbidol against Coronavirus Infection (ELACOI) single-blind randomized controlled"/>
   <result pre="from Middle East respiratory syndrome coronavirusJ. Biol. Chem.202010.1074/jbc.AC120.01305632094225 96.WangM.CaoR.ZhangL.YangX.LiuJ.XuM.ShiZ.HuZ.ZhongW.XiaoG.Remdesivir and" exact="chloroquine" post="effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in"/>
   <result pre="2020) 171.Available online: www.theguardian.com/world/2020/apr/23/high-hopes-drug-for-covid-19-treatment-failed-in-full-trial(accessed on 30 April 2020) 172.FernerR.E.AronsonJ.K.Chloroquine and" exact="hydroxychloroquine" post="in COVID-19BMJ2020369m143210.1136/bmj.m143232269046 173.GaoJ.TianZ.YangX.Breakthrough: Chloroquine phosphate has shown apparent efficacy"/>
   <result pre="on 30 April 2020) 172.FernerR.E.AronsonJ.K.Chloroquine and hydroxychloroquine in COVID-19BMJ2020369m143210.1136/bmj.m143232269046 173.GaoJ.TianZ.YangX.Breakthrough:" exact="Chloroquine" post="phosphate has shown apparent efficacy in treatment of COVID-19"/>
   <result pre="of COVID-19 associated pneumonia in clinical studiesBiosci. Trends202014727310.5582/bst.2020.0104732074550 174.ChenZ.HuJ.ZhangZ.JiangS.HanS.YanD.ZhuangR.HuB.ZhangZ.Efficacy of" exact="hydroxychloroquine" post="in patients with COVID-19: Results of a randomized clinical"/>
   <result pre="of a randomized clinical trial. Version 2medRxiv202010.1101/2020.03.22.20040758 175.YanD.ZhangZ.Therapeutic Effect of" exact="Hydroxychloroquine" post="on Novel Coronavirus Pneumonia (COVID-19)Chinese Clinical Trials RegistryAvailable online:"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7278221\results\search\drug\results.xml">
   <result pre="trial to validate four drugs especially in combinations, including ritonavir/lopinavir," exact="lopinavir" post="and ritonavir with interferon-beta, chloroquine and/or remdesivir. Several clinical"/>
   <result pre="validate four drugs especially in combinations, including ritonavir/lopinavir, lopinavir and" exact="ritonavir" post="with interferon-beta, chloroquine and/or remdesivir. Several clinical trials, over"/>
   <result pre="especially in combinations, including ritonavir/lopinavir, lopinavir and ritonavir with interferon-beta," exact="chloroquine" post="and/or remdesivir. Several clinical trials, over 1673, have been"/>
   <result pre="significant clinical trials. Conditions Numbers of enrollment (estimated) Results Reference/trials" exact="Hydroxychloroquine" post="Mild 30 Negative 39 Hydroxychloroquine Mild/severe 62 Positive 41"/>
   <result pre="of enrollment (estimated) Results Reference/trials Hydroxychloroquine Mild 30 Negative 39" exact="Hydroxychloroquine" post="Mild/severe 62 Positive 41 Hydroxychloroquine Symptomatic disease 510 Ongoing"/>
   <result pre="Hydroxychloroquine Mild 30 Negative 39 Hydroxychloroquine Mild/severe 62 Positive 41" exact="Hydroxychloroquine" post="Symptomatic disease 510 Ongoing https://clinicaltrials.gov/ct2/show/NCT04332991 Hydroxychloroquine Prevention 40,000 Ongoing"/>
   <result pre="Mild/severe 62 Positive 41 Hydroxychloroquine Symptomatic disease 510 Ongoing https://clinicaltrials.gov/ct2/show/NCT04332991" exact="Hydroxychloroquine" post="Prevention 40,000 Ongoing https://clinicaltrials.gov/ct2/show/NCT04303507 Lopinavir/ritonavir Severe 199 Negative 51"/>
   <result pre="Mild 80 Ongoing https://clinicaltrials.gov/ct2/show/NCT04340232 Convalescent plasma Severe 10 Positive 63" exact="Chloroquine" post="and hydroxychloroquine Chloroquine (CQ) and its related drug hydroxychloroquine"/>
   <result pre="Ongoing https://clinicaltrials.gov/ct2/show/NCT04340232 Convalescent plasma Severe 10 Positive 63 Chloroquine and" exact="hydroxychloroquine" post="Chloroquine (CQ) and its related drug hydroxychloroquine (HCQ), both"/>
   <result pre="https://clinicaltrials.gov/ct2/show/NCT04340232 Convalescent plasma Severe 10 Positive 63 Chloroquine and hydroxychloroquine" exact="Chloroquine" post="(CQ) and its related drug hydroxychloroquine (HCQ), both of"/>
   <result pre="63 Chloroquine and hydroxychloroquine Chloroquine (CQ) and its related drug" exact="hydroxychloroquine" post="(HCQ), both of which are well-known for their effectiveness"/>
   <result pre="for now. Moreover, the combination of HCQ with antibiotic drug" exact="azithromycin" post="has been reported to have added benefit. Since azithromycin"/>
   <result pre="drug azithromycin has been reported to have added benefit. Since" exact="azithromycin" post="is known to reversibly binds to the 50S ribosomal"/>
   <result pre="effect is not known. It is also not known whether" exact="azithromycin" post="synergize with HCQ to provide better antiviral activity. A"/>
   <result pre="active anti-retroviral therapy (HAART). The combination of LPV/r with additional" exact="ribavirin" post="was reported to be able to reduce the risk"/>
   <result pre="we recently find that administration of LPV/r along with interferon" exact="alpha" post="inhaling was not associated with faster virological clearance or"/>
   <result pre="effective in treating COVID-19. Remdesivir Another promising drug is the" exact="adenosine" post="analog remdesivir (GS-5734) that is incorporated into nascent viral"/>
   <result pre="viral entry4â€&quot;6 showed the specificity of the serine protease inhibitor" exact="camostat" post="mesylate as an active compond against TMPRSS2 which is"/>
   <result pre="the priming of the viral S protein. Clinical trial of" exact="camostat" post="mesylate or its derivatives are therefore required4â€&quot;6. Ivermectin The"/>
   <result pre="required4â€&quot;6. Ivermectin The recent work on the FDA-approved anti-parasitic compound" exact="ivermectin" post="seems extremely powerful even though so far it is"/>
   <result pre="report of 1014 cases. Radiology, 10.1148/radiol.2020200642 (2020). 37.WangMet al.Remdesivir and" exact="chloroquine" post="effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in"/>
   <result pre="vitro antiviral activity and projection of optimized dosing design of" exact="hydroxychloroquine" post="for the treatment of severe acute respiratory syndrome coronavirus"/>
   <result pre="10.1093/cid/ciaa237 (2020). 39.Chen, J. et al. A pilot study of" exact="hydroxychloroquine" post="in treatment of patients with common coronavirus disease-19 (COVID-19)."/>
   <result pre="S. &amp;amp; Saffaei, A. Aminoquinolines against coronavirus disease 2019 (COVID-19):" exact="chloroquine" post="or hydroxychloroquine. Int. J. Antimicrob. Agents55,105945 (2020). 41.Chen, Z."/>
   <result pre="J. Antimicrob. Agents55,105945 (2020). 41.Chen, Z. et al. Efficacy of" exact="hydroxychloroquine" post="in patients with COVID-19: results of a randomized clinical"/>
   <result pre="at https://www.medrxiv.org/content/10.1101/2020.03.22.20040758v3 (2020) 42.Juurlink, D. N. Safety considerations with chloroquine," exact="hydroxychloroquine" post="and azithromycin in the management of SARS-CoV-2 infection. CMAJ10.1503/cmaj.200528"/>
   <result pre="(2020) 42.Juurlink, D. N. Safety considerations with chloroquine, hydroxychloroquine and" exact="azithromycin" post="in the management of SARS-CoV-2 infection. CMAJ10.1503/cmaj.200528 (2020). 43.Molina,"/>
   <result pre="rapid antiviral clearance or clinical benefit with the combination of" exact="hydroxychloroquine" post="and azithromycin in patients with severe COVID-19 infection. Med."/>
   <result pre="clearance or clinical benefit with the combination of hydroxychloroquine and" exact="azithromycin" post="in patients with severe COVID-19 infection. Med. Mal. Infect."/>
   <result pre="Med. Mal. Infect. 10.1016/j.medmal.2020.03.006 (2020). 44.Principi, N. &amp;amp; Esposito, S." exact="Chloroquine" post="or hydroxychloroquine for prophylaxis of COVID-19. Lancet Infect. Dis."/>
   <result pre="Infect. 10.1016/j.medmal.2020.03.006 (2020). 44.Principi, N. &amp;amp; Esposito, S. Chloroquine or" exact="hydroxychloroquine" post="for prophylaxis of COVID-19. Lancet Infect. Dis. 10.1016/s1473-3099(20)30296-6 (2020)."/>
   <result pre="matched cohort studyHong Kong Med. J.2003939940614660806 46.KimUJWonEJKeeSJJungSIJangHCCombination therapy with lopinavir/ritonavir," exact="ribavirin" post="and interferon-a for Middle East respiratory syndromeAntivir. Ther.20162145545926492219 47.MinCKet"/>
   <result pre="Wang, Y. &amp;amp; Wang, G. Q. A systematic review of" exact="lopinavir" post="therapy for SARS coronavirus and MERS coronavirusâ€&quot;a possible reference"/>
   <result pre="Remdesivir accelerates recovery from advanced COVID-19. https://www.nih.gov/news-events/news-releases/nih-clinical-trial-shows-remdesivir-accelerates-recovery-advanced-covid-19. 61.CalyLDruceJDCattonMGJansDAWagstaffKMThe FDA-approved drug" exact="ivermectin" post="inhibits the replication of SARS-CoV-2 in vitroAntiviral Res.202017810478732251768 62.Shen,"/>
   <result pre="Dis.200524444615616839 65.SooYOYet al.Retrospective comparison of convalescent plasma with continuing high-dose" exact="methylprednisolone" post="treatment in SARS patientsClin. Microbiol. Infect.20041067667815214887 66.HungIFNet al.Convalescent plasma"/>
   <result pre="severe 2019-nCoV pneumoniaSignal Transduct. Target. Ther.202051832296012 80.SchrezenmeierEDÃ¶rnerTMechanisms of action of" exact="hydroxychloroquine" post="and chloroquine: implications for rheumatologyNat. Rev. Rheumatol.20201615516632034323 81.PatonNIet al.Effects"/>
   <result pre="and chloroquine: implications for rheumatologyNat. Rev. Rheumatol.20201615516632034323 81.PatonNIet al.Effects of" exact="hydroxychloroquine" post="on immune activation and disease progression among HIV-infected patients"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7278986\results\search\drug\results.xml">
   <result pre="be caused by the high dose of steroid treatment using" exact="methylprednisolone" post="[43]. In another study, Nguyen et al. explored changes"/>
   <result pre="47 lipid species/classes such as arachidonic acid, docosahexaenoic acid, and" exact="eicosapentaenoic acid" post="were consistently upregulated after infection [45]. These data highlight"/>
   <result pre="clinical trial, Makris et al. studied the impact of using" exact="pravastatin" post="on reducing the frequency of ventilator-associated pneumonia. Moreover, they"/>
   <result pre="studies looked at the effect of a combination therapy using" exact="atorvastatin" post="(40 mg/day) and irbesartan (150 mg/day). Statinâ€™s beneficial impact"/>
   <result pre="effect of a combination therapy using atorvastatin (40 mg/day) and" exact="irbesartan" post="(150 mg/day). Statinâ€™s beneficial impact on viral infection could"/>
   <result pre="drug library and showed that AM580, a retinoid acid receptor" exact="alpha" post="(RAR-a) agonist could interrupt the life cycle of MERS-CoV"/>
   <result pre="of COVID-19 infection [76]. On this basis, the FDA-approved immunomodulator" exact="FTY720" post="(Fingolimod), one of the best characterized â€œsphingomimeticâ€� drugs [75],"/>
   <result pre="associated with slow multiple sclerosis progression and good response to" exact="fingolimod" post="treatment [81]. Recently, more specific functionally related compounds have"/>
   <result pre="short term mortality after pneumonia episode: Cohort studyBMJ2011342d164210.1136/bmj.d164221471172 58.MakrisD.ManoulakasE.KomnosA.PapakrivouE.TzovarasN.HovasA.ZintzarasE.ZakynthinosE.Effect of" exact="pravastatin" post="on the frequency of ventilator-associated pneumonia and on intensive"/>
   <result pre="diseaseNat. Rev. Mol. Cell Biol.20181917519110.1038/nrm.2017.10729165427 75.HuwilerA.Zangemeister-WittkeU.The sphingosine 1-phosphate receptor modulator" exact="fingolimod" post="as a therapeutic agent: Recent findings and new perspectivesPharmacol."/>
   <result pre="with multiple sclerosisNeurology20158487287910.1212/WNL.000000000000130225636714 81.Al-TemaimiR.CherianP.Abu-FarhaM.AlroughaniR.Angiopoietin-like proteins in multiple sclerosisJ. Neuroimmunol.2019330313410.1016/j.jneuroim.2019.02.00630784773 82.ChewW.S.WangW.HerrD.R.To" exact="fingolimod" post="and beyond: The rich pipeline of drug candidates that"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7278987\results\search\drug\results.xml">
   <result pre="with similar activities, either as monotherapy or in association with" exact="mycophenolic acid," post="been shown against the MERS-CoV PLP [77]. Due to"/>
   <result pre="would like to highlight that a recent report demonstrated that" exact="disulfiram" post="(a clinically approved alcohol abuse antagonist, now repurposed as"/>
   <result pre="that a recent report demonstrated that disulfiram (a clinically approved" exact="alcohol" post="abuse antagonist, now repurposed as an anticancer drug) can"/>
   <result pre="and MERS PLPs, respectively, and this activity is synergic with" exact="6-thioguanine" post="(a thiopurine) and mycophenolic acid against MERS, but not"/>
   <result pre="and this activity is synergic with 6-thioguanine (a thiopurine) and" exact="mycophenolic acid" post="against MERS, but not SARS, PLP [78]. These recent"/>
   <result pre="vitro, together with a relatively good risk/benefit ratio, may make" exact="disulfiram" post="a clinically evaluable drug against COVID-19. However, as a"/>
   <result pre="may need to be retrospective and their administration reasoned cautiously." exact="Disulfiram" post="may be tested more safely, paying attention to its"/>
   <result pre="more safely, paying attention to its pharmacological interactions and any" exact="alcohol" post="consumption. Author Contributions V.C., P.D. and M.B. wrote the"/>
   <result pre="Trends202014697110.5582/bst.2020.0102031996494 10.CortegianiA.IngogliaG.IppolitoM.GiarratanoA.EinavS.A systematic review on the efficacy and safety of" exact="chloroquine" post="for the treatment of COVID-19J. Crit. Care202010.1016/j.jcrc.2020.03.005 11.ChenC.ZhangX.R.JuZ.Y.HeW.F.[Advances in"/>
   <result pre="Sci. USA2016113E5192E520110.1073/pnas.160343511327519799 52.LiS.-W.LaiC.-C.PingJ.-F.TsaiF.-J.WanL.LinY.-J.KungS.-H.LinC.-W.Severe acute respiratory syndrome coronavirus papain-like protease suppressed" exact="alpha" post="interferon-induced responses through downregulation of extracellular signal-regulated kinase 1-mediated"/>
   <result pre="of severe acute respiratory syndrome coronavirusBiochem. Pharmacol.2008751601160910.1016/j.bcp.2008.01.00518313035 77.ChengK.-W.ChengS.-C.ChenW.-Y.LinM.-H.ChuangS.-J.ChengI.-H.SunC.-Y.ChouC.-Y.Thiopurine analogs and" exact="mycophenolic acid" post="synergistically inhibit the papain-like protease of Middle East respiratory"/>
   <result pre="The facts during the third epidemicLiver Transpl.202010.1002/lt.2575632196933 94.LiH.S.KuokD.I.T.CheungM.C.NgM.M.T.NgK.C.HuiK.P.Y.PeirisJ.S.M.ChanM.C.W.NichollsJ.M.Effect of interferon" exact="alpha" post="and cyclosporine treatment separately and in combination on Middle"/>
   <result pre="during the third epidemicLiver Transpl.202010.1002/lt.2575632196933 94.LiH.S.KuokD.I.T.CheungM.C.NgM.M.T.NgK.C.HuiK.P.Y.PeirisJ.S.M.ChanM.C.W.NichollsJ.M.Effect of interferon alpha and" exact="cyclosporine" post="treatment separately and in combination on Middle East Respiratory"/>
   <result pre="95.MehtaP.McAuleyD.F.BrownM.SanchezE.TattersallR.S.MansonJ.J.COVID-19: Consider cytokine storm syndromes and immunosuppressionLancet20203951033103410.1016/S0140-6736(20)30628-032192578 96.YannakiE.PapadopoulouA.AthanasiouE.KaloyannidisP.ParaskevaA.BougiouklisD.PalladasP.YiangouM.AnagnostopoulosA.The proteasome inhibitor" exact="bortezomib" post="drastically affects inflammation and bone disease in adjuvant-induced arthritis"/>
   <result pre="PLP protease and MERS-CoV PLP protease and DUB Clinically used" exact="6-Mercaptopurine" post="Acethaldeyde dehydrogenase inhibitor [78] Disulfiram SARS and MERS-CoV PLPs"/>
   <result pre="protease and DUB Clinically used 6-Mercaptopurine Acethaldeyde dehydrogenase inhibitor [78]" exact="Disulfiram" post="SARS and MERS-CoV PLPs Clinically used Endogenous peptide [79]"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7278991\results\search\drug\results.xml">
   <result pre="not affect disease outcome in male mice, whilst ovariectomy or" exact="estrogen" post="receptor antagonists caused increased mortality in females after SARS-CoV"/>
   <result pre="any other possible sex advantage [27,28,29,30]. As concerns sex hormones," exact="testosterone" post="suppresses innate immune responses, whilst estrogens have immune-suppressive effect"/>
   <result pre="with previous GWAS on A(H1N1) and A(H7N9) influenza [46]. Conversely," exact="estrogen" post="fall in postmenopausal females in turn affects TMPRSS2 expression,"/>
   <result pre="activation promotes antithrombotic activity, and the known antithrombotic properties of" exact="captopril" post="(ACE inhibitor) and losartan (AT1-receptor blocker) are attenuated by"/>
   <result pre="PD domain could affect ACE2-SARS-CoV-2 interaction [105,108], as demonstrated by" exact="chloroquine" post="treatment of SARS-CoV patients, in which chloroquine inhibited virus"/>
   <result pre="as demonstrated by chloroquine treatment of SARS-CoV patients, in which" exact="chloroquine" post="inhibited virus infection by interfering with the terminal glycosylation"/>
   <result pre="Interestingly, the X-linked ACE2 gene, in transgender males treated with" exact="estrogen" post="therapy and androgen antagonists shows significantly higher expression and"/>
   <result pre="complex role of estrogens in inflammationEndocr. Rev.20072852157410.1210/er.2007-000117640948 33.MalkinC.J.PughP.J.JonesR.D.KapoorD.ChannerK.S.JonesT.H.The effect of" exact="testosterone" post="replacement on endogenous inflammatory cytokines and lipid profiles in"/>
   <result pre="expression in HUVECs by regulating ADAM10 and ADAM17 via the" exact="estrogen" post="receptorBiochem. Biophys. Res. Commun.202052375375810.1016/j.bbrc.2020.01.00831952790 42.YanR.ZhangY.LiY.XiaL.GuoY.ZhouQ.Structural basis for the recognition"/>
   <result pre="Wuhan, Hubei Province in 2020Pharm. Res.202010.1016/j.phrs.2020.10482132360481 169.RussoP.BonassiS.GiacconiR.MalavoltaM.TominoC.MaggiF.COVID-19 and Smoking. Is" exact="Nicotine" post="the Hidden Link?Eur. Respir. J.202010.1183/13993003.01116-202032341101 170.ZhengZ.PengF.XuB.ZhaoJ.LiuH.PengJ.LiQ.JiangC.ZhouY.LiuS.et al.Risk factors of"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7279248\results\search\drug\results.xml">
   <result pre="cases, plasma from recently cured patients [10,11,12,13]. Antimalarial agents like" exact="chloroquine" post="are used to block the virus entry, while new"/>
   <result pre="the virus entry, while new drugs like tocilizumab, anakinra or" exact="ruxolitinib" post="[14], directed against a specific key element of the"/>
   <result pre="inhibitor, it has been shown, alone or in combination with" exact="chloroquine" post="or interferon-Î², to effectively block the replication of SARS-CoV-2"/>
   <result pre="Peramivir, Zanamivir, etc.), Ganciclovir, Aciclovir and Rribavirin, as well as" exact="methylprednisolone" post="[42,43] for the influenza virus, are not valid for"/>
   <result pre="for COVID-19 and are not recommended. Another effective drug is" exact="chloroquine" post="(500 mg every 12 h) and hydroxychloroquine (200 mg"/>
   <result pre="effective drug is chloroquine (500 mg every 12 h) and" exact="hydroxychloroquine" post="(200 mg every 12 h), drugs used for many"/>
   <result pre="treatment of rheumatoid arthritis. Several possible mechanisms have been studied." exact="Chloroquine" post="can inhibit the pH-dependent phases of the replication of"/>
   <result pre="effect on the infection and spread of SARS-CoV [45]. Furthermore," exact="chloroquine" post="has immuno-modulatory effects, suppressing the production/release of TNF-Î± and"/>
   <result pre="production/release of TNF-Î± and IL-6. Several studies have found that" exact="chloroquine" post="interferes with the glycosylation of SARS-CoV cell receptors [45],"/>
   <result pre="inhibition of viral replication [50,51]. The best-known proteasome inhibitor is" exact="Bortezomib" post="(Valcade) [50], which was approved in 2008 as a"/>
   <result pre="(Figure 2) [49,52]. Interestingly, Computational Drug Repurposing Studies showed that" exact="Carfilzomib" post="is a good candidate for the treatment of COVID-19"/>
   <result pre="A and tripeptidyl peptidase II) [67], Eepoxomomine, Llactacystine and Velcade" exact="Bortezomib" post="affect the proteasome more specifically [68,69,70]. Finally, a 2012"/>
   <result pre="the activation of the UPS. In the few papers published," exact="bortezomib" post="did not show great efficacy, but we have new"/>
   <result pre="dynamics simulation followed by binding free energy calculations, demonstrating that" exact="Carfilzomib" post="presented the best binding free energy, and therefore supporting"/>
   <result pre="molecules appear to be promising candidates; in particular, MG132, epoxomycin," exact="bortezomib" post="and carfilzomib have the potential to affect both viral"/>
   <result pre="to be promising candidates; in particular, MG132, epoxomycin, bortezomib and" exact="carfilzomib" post="have the potential to affect both viral replication as"/>
   <result pre="coronavirus in the United StatesN. Engl. J. Med.202010.1056/NEJMoa2001191 41.WangM.CaoR.ZhangL.YangX.LiuJ.XuM.ShiZ.HuZ.ZhongW.XiaoG.Remdesivir and" exact="chloroquine" post="effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in"/>
   <result pre="CoronavirusZhonghua Jie He He Hu Xi Za Zhi202010.3760/cma.j.issn.1001-0939.2020.03.004 44.SavarinoA.BoelaertJ.R.CassoneA.MajoriG.CaudaR.Effects of" exact="chloroquine" post="on viral infections: An old drug against todayâ€™s diseases?Lancet"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7279901\results\search\drug\results.xml">
   <result pre="acute kidney failure KDIGO stage 1. Treatment with lopinavir/ritonavir and" exact="hydroxychloroquine" post="for 7 days was initiated. In addition, we prescribed"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7280142\results\search\drug\results.xml">
   <result pre="There have also been proposals for other combinations, such as" exact="pembrolizumab" post="plus axitinib and avelumab plus axitinib [53]. The efficacy"/>
   <result pre="virus [79]. Thus, lysosomotropic agents, such as the antimalaria drugs" exact="chloroquine" post="and hydroxychloroquine, can accumulate intracellularly and neutralize the endosome-lysosomal"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7280701\results\search\drug\results.xml">
   <result pre="protected by copyright. All rights reserved. COVIDâ€�19 dermatology immunosuppressive steroids" exact="methotrexate" post="azathioprine cyclophosphamide mycophenolate ciclosporine pathogenesis immunology fig-count: table-count: page-count:"/>
   <result pre="by copyright. All rights reserved. COVIDâ€�19 dermatology immunosuppressive steroids methotrexate" exact="azathioprine" post="cyclophosphamide mycophenolate ciclosporine pathogenesis immunology fig-count: table-count: page-count: word-count:"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7280997\results\search\drug\results.xml">
   <result pre="drugs have shown promising results. For example, the combination of" exact="chloroquine" post="and azithromycin [14]. Furthermore, the antiviral drug remdesivir and"/>
   <result pre="shown promising results. For example, the combination of chloroquine and" exact="azithromycin" post="[14]. Furthermore, the antiviral drug remdesivir and the malaria"/>
   <result pre="[14]. Furthermore, the antiviral drug remdesivir and the malaria drug" exact="chloroquine" post="have gained much attention globally as potential medications for"/>
   <result pre="antiviral drugs for the treatment of COVID-19. Oseltamivir, peramivir, and" exact="zanamivir" post="are neuraminidase inhibitors that have been used for influenza"/>
   <result pre="out of the infected cell. Another recent study suggests that" exact="ribavirin" post="if combined with interferon-Î², might be a promising drug"/>
   <result pre="no significant activity against SAS-CoV, and on the other hand," exact="ribavirin" post="is toxic with hemolysis activity [37,38]. Even though, there"/>
   <result pre="against SARS-CoV-2, or constituted a treatment option of COVID-19. 3.1." exact="Chloroquine" post="and Hydroxychloroquine Although many drugs have been reported to"/>
   <result pre="or constituted a treatment option of COVID-19. 3.1. Chloroquine and" exact="Hydroxychloroquine" post="Although many drugs have been reported to show promising"/>
   <result pre="these drugs have gained much attention like the antimalarial drugs" exact="Chloroquine" post="(CQ) and Hydroxychloroquine (HCQ) [14,49,50]. HCQ is a CQ"/>
   <result pre="gained much attention like the antimalarial drugs Chloroquine (CQ) and" exact="Hydroxychloroquine" post="(HCQ) [14,49,50]. HCQ is a CQ analog that has"/>
   <result pre="acute respiratory distress syndrome (ARDS) [52]. Currently, the use of" exact="hydroxychloroquine" post="is approved by many of COVID-19 treatment protocols, especially"/>
   <result pre="others seriously considering it [1,4,40,50]. 3.2. Remdesivir Remdesivir is an" exact="adenosine" post="nucleoside analog drug showing antiviral activity against Ebola and"/>
   <result pre="A recent report found that a combination of remdesivir and" exact="chloroquine" post="inhibited SARS-CoV-2 in vitro [56]. Very recently, the drug"/>
   <result pre="in stopping the replication mechanism of SARS-CoV-2. 3.3. Losartan and" exact="Telmisartan" post="Losartan and telmisartan are drugs that belong to the"/>
   <result pre="replication mechanism of SARS-CoV-2. 3.3. Losartan and Telmisartan Losartan and" exact="telmisartan" post="are drugs that belong to the angiotensin II receptor"/>
   <result pre="process [42]. 3.5. Lopinavir/Ritonavir It is a combination of both" exact="lopinavir" post="and ritonavir drugs that have been used for HIV"/>
   <result pre="3.5. Lopinavir/Ritonavir It is a combination of both lopinavir and" exact="ritonavir" post="drugs that have been used for HIV treatment and"/>
   <result pre="pneumonia in Saudi ArabiaNew Engl. J. Med.20123671814182010.1056/NEJMoa121172123075143 14.GautretP.LagierJ.-C.ParolaP.HoangV.T.MeddebL.MailheM.DoudierB.CourjonJ.GiordanengoV.VieiraV.E.et al.Hydroxychloroquine and" exact="azithromycin" post="as a treatment of COVID-19: Results of an open-label"/>
   <result pre="in vitro with clinically approved antiviral drugsEmerg. Infect. Dis.20041058158610.3201/eid1004.03045815200845 39.GaoJ.TianZ.YangX.Breakthrough:" exact="Chloroquine" post="phosphate has shown apparent efficacy in treatment of COVID-19"/>
   <result pre="vitro antiviral activity and projection of optimized dosing design of" exact="hydroxychloroquine" post="for the treatment of severe acute respiratory syndrome coronavirus"/>
   <result pre="effective in inhibiting SARS-CoV-2 infection in vitroCell Discov.202061410.1038/s41421-019-0132-831934347 50.ColsonP.RolainJ.-M.LagierJ.-C.BrouquiP.RaoultD.Chloroquine and" exact="hydroxychloroquine" post="as available weapons to fight COVID-19Int. J. Antimicrob. Agents20205510593210.1016/j.ijantimicag.2020.10593232145363"/>
   <result pre="J. Antimicrob. Agents20205510593210.1016/j.ijantimicag.2020.10593232145363 51.DevauxC.A.RolainJ.-M.ColsonP.RaoultD.New insights on the antiviral effects of" exact="chloroquine" post="against coronavirus: What to expect for COVID-19?Int. J. Antimicrob."/>
   <result pre="expect for COVID-19?Int. J. Antimicrob. Agents202010593810.1016/j.ijantimicag.2020.10593832171740 52.SchrezenmeierE.DornerT.Mechanisms of action of" exact="hydroxychloroquine" post="and chloroquine: Implications for rheumatologyNat. Rev. Rheumatol.20201615516610.1038/s41584-020-0372-x32034323 53.WarrenT.K.JordanR.LoM.K.RayA.S.MackmanR.L.SolovevaV.SiegelD.PerronM.BannisterR.HuiH.C.et al.Therapeutic"/>
   <result pre="of Ebola Virus RNA-Dependent RNA polymerase by remdesivirViruses20191132610.3390/v1104032630987343 56.WangM.CaoR.ZhangL.YangX.LiuJ.XuM.ShiZ.HuZ.ZhongW.XiaoG.Remdesivir and" exact="chloroquine" post="effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in"/>
   <result pre="Author Drugs Therapy Strategy Categories Mechanisms of Therapy Status [14,39,40]" exact="Chloroquine" post="phosphate/ hydroxychloroquine Anti-malariaanti-viralanti-inflammatory Increasing endosomal pH, interfering with the"/>
   <result pre="Therapy Strategy Categories Mechanisms of Therapy Status [14,39,40] Chloroquine phosphate/" exact="hydroxychloroquine" post="Anti-malariaanti-viralanti-inflammatory Increasing endosomal pH, interfering with the glycosylation of"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7281209\results\search\drug\results.xml">
   <result pre="for controlling viral diseases. Neuraminidase inhibitors such as oseltamivir and" exact="zanamivir" post="are often used for the treatment of influenza virus"/>
   <result pre="localization of RS in the gastrointestinal tract was determined using" exact="fluorescein" post="isothiocyanate (FITC)-labeled RS and used for subsequent analysis. FITC-RS"/>
   <result pre="RS RS (1 g) was dissolved in 50 mL of" exact="dimethyl sulfoxide" post="with a few drops of pyridine (Kanto Chemical, Tokyo,"/>
   <result pre="with a few drops of pyridine (Kanto Chemical, Tokyo, Japan)." exact="Fluorescein" post="isothiocyanate (20 mg; TCI, Tokyo, Japan) was added, followed"/>
   <result pre="potential inhibitors of HIV-1Mar. Drugs2013113000301410.3390/md1108300023966033 28.IsonM.G.GnannJ.W.Jr.Nagy-AgrenS.TreannorJ.PayaC.SteigbigelR.ElliottM.WeissH.L.HaydenF.G.Safety and efficacy of nebulized" exact="zanamivir" post="in hospitalized patients with serious influenzaAntivir. Ther.2003818319012924534 29.LeekhaS.ZitterkopfN.L.EspyM.J.SmithT.F.ThompsonR.L.SampathkumarP.Duration of"/>
   <result pre="microfold cells (M cells) on the intestinal epithelium of mice." exact="Fluorescein" post="isothiocyanate (FITC)-labeled RS was orally administered to mice, and"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7281404\results\search\drug\results.xml">
   <result pre="trials to be justified for clinical use. COVID-19 SARS-CoV-2 remdesivir" exact="chloroquine" post="lopinavir favipiravir baricitinib interferons ACE2 TMPRSS2 1. Introduction The"/>
   <result pre="to be justified for clinical use. COVID-19 SARS-CoV-2 remdesivir chloroquine" exact="lopinavir" post="favipiravir baricitinib interferons ACE2 TMPRSS2 1. Introduction The pandemic"/>
   <result pre="is under review [14]. 3.1.1. Remdesivir (GS-5734) Remdesivir is an" exact="adenosine" post="analog that leads to the premature or delayed termination"/>
   <result pre="currently investigating the drug; see Table 1. 3.1.2. Lopinavir and" exact="Ritonavir" post="The combination of lopinavir and ritonavir was developed as"/>
   <result pre="see Table 1. 3.1.2. Lopinavir and Ritonavir The combination of" exact="lopinavir" post="and ritonavir was developed as protease inhibitors for the"/>
   <result pre="1. 3.1.2. Lopinavir and Ritonavir The combination of lopinavir and" exact="ritonavir" post="was developed as protease inhibitors for the treatment of"/>
   <result pre="the liver by microsomal enzymes â€œcytochrome 3A4 (CYP3A4)â€� and â€œCYP3A5.â€�" exact="Ritonavir" post="inhibits the CYP3A4 enzyme and results in increased concentrations"/>
   <result pre="inhibits the CYP3A4 enzyme and results in increased concentrations of" exact="lopinavir" post="when the two drugs are co-administered [24]. Lopinavir/ritonavir combination"/>
   <result pre="improvement, viral load, or mortality [26]. However, the combination of" exact="lopinavir" post="and ritonavir was included in two arms of the"/>
   <result pre="load, or mortality [26]. However, the combination of lopinavir and" exact="ritonavir" post="was included in two arms of the SOLIDARITY trial"/>
   <result pre="another smaller study (150 participants were recruited) in comparison to" exact="hydroxychloroquine" post="and a control (no intervention group) for 7â€&quot;10 days"/>
   <result pre="days (NCT04307693); see Table 1. Interestingly, a computational study suggested" exact="lopinavir" post="(as well as oseltamivir) as a potential therapy for"/>
   <result pre="as a potential therapy for COVID-19 [27]. 3.1.3. Darunavir and" exact="Cobicistat" post="Another combination of protease inhibitors was previously reported to"/>
   <result pre="volunteers, with the advantage of avoiding the adverse effects of" exact="ritonavir" post="[28]. Cobicistat is an analog of ritonavir and a"/>
   <result pre="the advantage of avoiding the adverse effects of ritonavir [28]." exact="Cobicistat" post="is an analog of ritonavir and a potent CYP3A"/>
   <result pre="adverse effects of ritonavir [28]. Cobicistat is an analog of" exact="ritonavir" post="and a potent CYP3A inhibitor. It has no antiviral"/>
   <result pre="no antiviral activity. Like ritonavir, it inhibits CYP2D6 and p-glycoprotein." exact="Cobicistat" post="also inhibits drug transporters, e.g., organic anion transport protein"/>
   <result pre="trials were registered to compare the combination of darunavir and" exact="cobicistat" post="for conventional treatment in patients with COVID-19 (NCT04252274 and"/>
   <result pre="with other antiviral drugs (including lopinavir/ritonavir); see Table 1. 3.1.5." exact="Ribavirin" post="The drug is an inosine monophosphate dehydrogenase inhibitor. The"/>
   <result pre="acute respiratory distress syndrome (ARDS) in patients with SARS-CoV [33]." exact="Ribavirin" post="was also used in combination with lopinavir/ritonavir and an"/>
   <result pre="after starting the combination therapy in severe cases [36]. Interestingly," exact="ribavirin" post="inhibited SARS-COV-2 replication at low concentrations in Caco-2 cells"/>
   <result pre="results of this study are concordant with previous reports of" exact="ribavirin" post="effectiveness against other coronaviruses including HCoV-43, CoV-NL63, and MERS-CoV-16,"/>
   <result pre="other coronaviruses including HCoV-43, CoV-NL63, and MERS-CoV-16, but not SARS-CoV-126." exact="Ribavirin" post="is under investigation in COVID-19 in combination with interferon-Î±"/>
   <result pre="and inflammasome, thus inducing cell pyroptosis in SARS-CoV-2 infection [46]." exact="Tranilast" post="is an antagonist of NLRP3 that inhibits the inflammasome"/>
   <result pre="is an antagonist of NLRP3 that inhibits the inflammasome pathway." exact="Tranilast" post="is a tryptophan analog used to treat allergic conditions,"/>
   <result pre="MERS-CoV. IFNÎ²1 up-regulates CD73 in the pulmonary endothelium, leading to" exact="adenosine" post="secretion. Adenosine is an anti-inflammatory molecule that supports the"/>
   <result pre="up-regulates CD73 in the pulmonary endothelium, leading to adenosine secretion." exact="Adenosine" post="is an anti-inflammatory molecule that supports the endothelial barrier."/>
   <result pre="(five million U twice a day), combined with the antiviral" exact="ribavirin" post="[62]. Clinical trials have been recently registered to assess"/>
   <result pre="lopinavir/ritonavir and IFNÎ±2b (ChiCTR2000029387) or a combination of lopinavir/ritonavir with" exact="ribavirin" post="and subcutaneously-administered IFNÃŸ1b (NCT04276688) for the treatment of COVID-19;"/>
   <result pre="more than placebo in patients treated with baricitinib [74]. 4.2." exact="Ruxolitinib" post="Ruxolitinib is an orally available and potent JAK1 and"/>
   <result pre="than placebo in patients treated with baricitinib [74]. 4.2. Ruxolitinib" exact="Ruxolitinib" post="is an orally available and potent JAK1 and JAK2"/>
   <result pre="the FDA in November 2011 [75]. The pharmacokinetic analysis of" exact="ruxolitinib" post="predicted that the unbound plasma concentration required to inhibit"/>
   <result pre="reduce the inflammatory response of the host by inhibiting JAK." exact="Ruxolitinib" post="is currently being studied to combine it with COVID-19"/>
   <result pre="who acquired these infections were taking concomitant immunosuppressants, such as" exact="methotrexate" post="or corticosteroids, and, as such, the drug should be"/>
   <result pre="severe COVID-19. Patients with diabetes may get macular edema upon" exact="fingolimod" post="treatment [100]. A clinical trial has been registered to"/>
   <result pre="treatment [100]. A clinical trial has been registered to use" exact="fingolimod" post="at a dose of 0.5 mg daily for three"/>
   <result pre="(NCT04280588). 5. Other Anti-Infective Agents Repurposed to Treat COVID-19 5.1." exact="Chloroquine" post="and Hydroxychloroquine Both chloroquine (CQ) and hydroxychloroquine (HCQ) are"/>
   <result pre="Other Anti-Infective Agents Repurposed to Treat COVID-19 5.1. Chloroquine and" exact="Hydroxychloroquine" post="Both chloroquine (CQ) and hydroxychloroquine (HCQ) are antimalarial drugs"/>
   <result pre="Agents Repurposed to Treat COVID-19 5.1. Chloroquine and Hydroxychloroquine Both" exact="chloroquine" post="(CQ) and hydroxychloroquine (HCQ) are antimalarial drugs that are"/>
   <result pre="Treat COVID-19 5.1. Chloroquine and Hydroxychloroquine Both chloroquine (CQ) and" exact="hydroxychloroquine" post="(HCQ) are antimalarial drugs that are also prescribed in"/>
   <result pre="in treating autoimmune diseases [101]. According to the literature, both" exact="chloroquine" post="and hydroxychloroquine possess antiviral activity against several viruses. CQ,"/>
   <result pre="autoimmune diseases [101]. According to the literature, both chloroquine and" exact="hydroxychloroquine" post="possess antiviral activity against several viruses. CQ, through the"/>
   <result pre="the SARS-CoV-2 spike protein [108]. To date, clinical studies investigating" exact="hydroxychloroquine" post="or chloroquine have been limited, and their role in"/>
   <result pre="spike protein [108]. To date, clinical studies investigating hydroxychloroquine or" exact="chloroquine" post="have been limited, and their role in COVID-19 treatment"/>
   <result pre="versus 12.5%, respectively) [111]. In this study, the use of" exact="azithromycin" post="in combination with HCQ was apparently associated with a"/>
   <result pre="study were a concern, and the biologic basis for using" exact="azithromycin" post="in this setting is unclear. Another small observational study"/>
   <result pre="the activity of the non-structural enzyme 3 helicase [113]. Moreover," exact="ivermectin" post="inhibits dengue viruses and interrupts virus replication [114]. Ivermectin"/>
   <result pre="which mediates the nuclear transport of several RNA viruses. Thus," exact="ivermectin" post="blocks the nuclear trafficking of RNA viral proteins. Ivermectin"/>
   <result pre="polymerase in dengue viruses [115,116]. To investigate the effect of" exact="ivermectin" post="on SARS-CoV-2, Vero/hSLAM cells with SARS-CoV-2 that were isolated"/>
   <result pre="cells with SARS-CoV-2 that were isolated Australia/VIC01/2020 were treated with" exact="ivermectin" post="[117]. Ivermectin administration resulted in a successful viral loss"/>
   <result pre="in viral RNA at 72 h. The authors hypothesized that" exact="ivermectin" post="exerts its antiviral activity by inhibiting the nuclear import"/>
   <result pre="importinÎ±/Î²1â€&quot;the same mechanism discussed before for other RNA viruses. 5.3." exact="Azithromycin" post="Macrolides are a unique class of antibiotics that include"/>
   <result pre="effects. Lately, the anti-viral effects of macrolides have been investigated." exact="Erythromycin" post="is the first macrolide proved to have efficacy in"/>
   <result pre="of rhinovirus and influenza virus [118]. On the other hand," exact="clarithromycin" post="and azithromycin have shown higher effectivity towards rhinovirus, respiratory"/>
   <result pre="and influenza virus [118]. On the other hand, clarithromycin and" exact="azithromycin" post="have shown higher effectivity towards rhinovirus, respiratory syncytial virus,"/>
   <result pre="and Ebola viruses have been shown to be inhibited by" exact="azithromycin" post="[120,121]. During the early phase of influenza virus infection,"/>
   <result pre="azithromycin [120,121]. During the early phase of influenza virus infection," exact="azithromycin" post="has been found to block influenza virus endocytosis into"/>
   <result pre="might be an effective treatment for COVID-19. The mechanism of" exact="azithromycin" post="against SARS-CoV-2 is unclear; however, it may be similar"/>
   <result pre="[111]. Several pathways for the suspected antiviral effects found with" exact="azithromycin" post="have been suggested. Firstly, as mentioned regarding CQ and"/>
   <result pre="have been suggested. Firstly, as mentioned regarding CQ and HCQ," exact="azithromycin" post="is a weak base that could inhibit endocytosis, thus"/>
   <result pre="inhibit endocytosis, thus limiting viral entry and replication [122]. Secondly," exact="azithromycin" post="directly affects the activity of bronchial epithelial cells and"/>
   <result pre="improving lung function [123]. Thirdly, there is evidence suggesting that" exact="azithromycin" post="increases the production of IFN via the stimulation of"/>
   <result pre="to a reduction of viral replication [124]. Lastly and recently," exact="azithromycin" post="was shown to directly intervene with the SARS-CoV-2 host"/>
   <result pre="viral spread and pathogenesis in an infected host [16,138], and" exact="camostat" post="mesylate is a serine protease inhibitor that inhibits SARS-CoV"/>
   <result pre="of both influenza and parainfluenza viruses. In experimentally infected mice," exact="camostat" post="was also found to prevent the development of pneumonia"/>
   <result pre="prevent the development of pneumonia and viral myocarditis [140]. Moreover," exact="camostat" post="mesylate has been found to help to slow down"/>
   <result pre="the treatment of chronic pancreatitis patients in Japan [141]. Therefore," exact="camostat" post="mesylate could also be of benefit in patients infected"/>
   <result pre="model of MERS-CoV infectionProc. Natl. Acad. Sci. USA20201176771677610.1073/pnas.192208311732054787 20.WangM.CaoR.ZhangL.YangX.LiuJ.XuM.ShiZ.HuZ.ZhongW.XiaoG.Remdesivir and" exact="chloroquine" post="effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in"/>
   <result pre="studies of drug repurposing and synergism of lopinavir, oseltamivir and" exact="ritonavir" post="binding with SARS-CoV-2 Protease against COVID-19J. Biomol. Struct. Dyn.20201710.1080/07391102.2020.1752802"/>
   <result pre="81.FangW.YangY.MaY.HongS.LinL.HeX.XiongJ.LiP.ZhaoH.HuangY.et al.Camrelizumab (SHR-1210) alone or in combination with gemcitabine plus" exact="cisplatin" post="for nasopharyngeal carcinoma: Results from two single-arm, phase 1"/>
   <result pre="in multiple sclerosisAnn. Neurol.20116975977710.1002/ana.2242621520239 100.CoppesO.J.M.GutierrezI.RederA.T.KsiazekS.BernardJ.Severe early bilateral macular edema following" exact="fingolimod" post="therapyMult. Scler. Relat. Disord.2013225625810.1016/j.msard.2012.11.00425877733 101.LeeS.J.SilvermanE.BargmanJ.M.The role of antimalarial agents"/>
   <result pre="IL-6 from lipopolysaccharide-stimulated human monocytes/macrophages by different modesRheumatology20064570371010.1093/rheumatology/kei28216418198 107.SavarinoA.BoelaertJ.R.CassoneA.MajoriG.CaudaR.Effects of" exact="chloroquine" post="on viral infections: An old drug against todayâ€™s diseases?Lancet"/>
   <result pre="vitro antiviral activity and projection of optimized dosing design of" exact="hydroxychloroquine" post="for the treatment of severe acute respiratory syndrome Coronavirus"/>
   <result pre="Dis. Off. Publ. Infect. Dis. Soc. Am.202010.1093/cid/ciaa237 109.JieZ.HeH.XiH.ZhiZ.Expert consensus on" exact="chloroquine" post="phosphate for the treatment of novel coronavirus pneumoniaChin. J."/>
   <result pre="COVID-192020Available online: https://www.acc.org/latest-in-cardiology/articles/2020/03/27/14/00/ventricular-arrhythmia-risk-due-to-hydroxychloroquine-azithromycin-treatment-for-covid-19(accessed on 20 April 2020) 111.GautretP.LagierJ.-C.ParolaP.HoangV.T.MeddebL.MailheM.DoudierB.CourjonJ.GiordanengoV.VieiraV.E.et al.Hydroxychloroquine and" exact="azithromycin" post="as a treatment of COVID-19: Results of an open-label"/>
   <result pre="rapid antiviral clearance or clinical benefit with the combination of" exact="hydroxychloroquine" post="and azithromycin in patients with severe COVID-19 infectionMed. Mal."/>
   <result pre="clearance or clinical benefit with the combination of hydroxychloroquine and" exact="azithromycin" post="in patients with severe COVID-19 infectionMed. Mal. Infect.202010.1016/j.medmal.2020.03.00632240719 113.BurgR.W.MillerB.M.BakerE.E.BirnbaumJ.CurrieS.A.HartmanR.KongY.L.MonaghanR.L.OlsonG.PutterI.et"/>
   <result pre="replication of HIV-1 and dengue virusBiochem. J.201244385185610.1042/BJ2012015022417684 117.CalyL.DruceJ.D.CattonM.G.JansD.A.WagstaffK.M.The FDA-approved drug" exact="ivermectin" post="inhibits the replication of SARS-CoV-2 in vitroAntivir. Res.202017810478710.1016/j.antiviral.2020.10478732251768 118.MinJ.Y.JangY.J.Macrolide"/>
   <result pre="impair phagocytosis in J774 macrophagesExp. Cell Res.20022818610010.1006/excr.2002.561312441132 123.CramerC.L.PattersonA.AlchakakiA.SoubaniA.O.Immunomodulatory indications of" exact="azithromycin" post="in respiratory disease: A concise review for the clinicianPostgrad."/>
   <result pre="and III interferon responsesAntimicrob. Agents Chemother.20196310.1128/AAC.00394-19 125.SandeepS.McGregorK.Energetics based modeling of" exact="hydroxychloroquine" post="and azithromycin binding to the SARS-CoV-2 spike (S)proteinâ€&quot;ACE2 ComplexChemRxiv202010.26434/chemrxiv.12015792.v2"/>
   <result pre="interferon responsesAntimicrob. Agents Chemother.20196310.1128/AAC.00394-19 125.SandeepS.McGregorK.Energetics based modeling of hydroxychloroquine and" exact="azithromycin" post="binding to the SARS-CoV-2 spike (S)proteinâ€&quot;ACE2 ComplexChemRxiv202010.26434/chemrxiv.12015792.v2 126.KubaK.ImaiY.Ohto-NakanishiT.PenningerJ.M.Trilogy of"/>
   <result pre="influenzaAntivir. Res.201192273610.1016/j.antiviral.2011.07.01421802447 141.JiaD.TaguchiM.OtsukiM.Preventive and therapeutic effects of the protease inhibitor" exact="camostat" post="on pancreatic fibrosis and atrophy in CCK-1 receptor-deficient ratsPancreas200530546115632700"/>
   <result pre="ACE 2 (rhACE2). Potential pharmacotherapeutic approaches include the use of" exact="camostat" post="mesylate (which is a TMPRSS2 inhibitor) to block the"/>
   <result pre="elevated ALT/AST. Known hypersensitivity CYP2C8 and aldehyde oxidase inhibitor https://clinicaltrials.gov/ct2/show/NCT04376814" exact="Ribavirin" post="Inhibits viral RdRp Oral Flu-like symptoms, depression, suicide, insomnia,"/>
   <result pre="depression or suicidal ideation, and liver failure. Inhibits metabolism of" exact="zidovudine" post="https://clinicaltrials.gov/ct2/show/NCT04350684(IFNÎ²-1)https://clinicaltrials.gov/ct2/show/NCT04276688(IFNÎ²-1)https://clinicaltrials.gov/ct2/show/NCT04350671(IFNÎ²-1)https://clinicaltrials.gov/ct2/show/NCT04343976(IFN-Î») Immuno-Modulatory Agents Baricitinib JAK-1 and JAK-2 inhibitor Oral"/>
   <result pre="(minor), OAT1/3, and P-glycoprotein/ABCB1. Potentially significant interactions may exist https://clinicaltrials.gov/ct2/show/NCT04358614https://clinicaltrials.gov/ct2/show/NCT04340232https://clinicaltrials.gov/ct2/show/NCT04346147https://clinicaltrials.gov/ct2/show/NCT04320277https://clinicaltrials.gov/ct2/show/NCT04373044https://clinicaltrials.gov/ct2/show/NCT04321993https://clinicaltrials.gov/ct2/show/NCT04345289" exact="Ruxolitinib" post="JAK1 and JAK2 inhibitor Oral Uncontrolled HIV infection, active"/>
   <result pre="who developed these infections were taking concomitant immunosuppressants, such as" exact="methotrexate" post="or corticosteroids. Known or expected to have allergic reactions"/>
   <result pre="â‰¥ 500 msec, heart block, CAD, pregnancy, and known hypersensitivity" exact="Ketoconazole" post="increases the drug level; vaccination may be less effective"/>
   <result pre="less effective https://clinicaltrials.gov/ct2/show/NCT04280588 Other Anti-Infective Agents Repurposed to Treat COVID-19" exact="Chloroquine" post="and hydroxychloroquine Inhibits viral entry and endocytosis Oral QTc"/>
   <result pre="https://clinicaltrials.gov/ct2/show/NCT04280588 Other Anti-Infective Agents Repurposed to Treat COVID-19 Chloroquine and" exact="hydroxychloroquine" post="Inhibits viral entry and endocytosis Oral QTc prolongation, hypoglycemia,"/>
   <result pre="myalgia, blurred vision, and Mazzotti reaction (with onchocerciasis) Hypersensitivity to" exact="ivermectin" post="Warfarin https://clinicaltrials.gov/ct2/show/NCT04360356https://clinicaltrials.gov/ct2/show/NCT04351347https://clinicaltrials.gov/ct2/show/NCT04374019 Azithromycin Inhibits viral entry and endocytosis Oral"/>
   <result pre="blurred vision, and Mazzotti reaction (with onchocerciasis) Hypersensitivity to ivermectin" exact="Warfarin" post="https://clinicaltrials.gov/ct2/show/NCT04360356https://clinicaltrials.gov/ct2/show/NCT04351347https://clinicaltrials.gov/ct2/show/NCT04374019 Azithromycin Inhibits viral entry and endocytosis Oral QTc"/>
   <result pre="and Mazzotti reaction (with onchocerciasis) Hypersensitivity to ivermectin Warfarin https://clinicaltrials.gov/ct2/show/NCT04360356https://clinicaltrials.gov/ct2/show/NCT04351347https://clinicaltrials.gov/ct2/show/NCT04374019" exact="Azithromycin" post="Inhibits viral entry and endocytosis Oral QTc prolongation, diarrhea,"/>
   <result pre="angioedema and hereditary or idiopathic angioedemaCoadministration of neprilysin inhibitors with" exact="aliskiren" post="in patients with diabetes mellitus or with renal impairment"/>
   <result pre="Member/ Multidrug Resistance Protein; ACEi: angiotensin converting enzyme inhibitor; ALT:" exact="alanine" post="transaminase; AST: aspartate transaminase; AV: atrio-ventricular; BCRP/ABCG2: Breast cancer"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7283245\results\search\drug\results.xml">
   <result pre="RepScientific Reports2045-2322Nature Publishing Group UKLondon 66440 doi: 10.1038/s41598-020-66440-9 : Article" exact="Sofosbuvir" post="as a potential alternative to treat the SARS-CoV-2 epidemic"/>
   <result pre="conserved in all these viruses, opening the possibility to use" exact="sofosbuvir" post="against these highly infectious pathogens. Subject terms Molecular medicine"/>
   <result pre="viral diseases, including Favipiravir9 and Remdesivir10. This latter is an" exact="adenosine" post="analogue, which has been shown to be efficacious preventing"/>
   <result pre="â€&quot; green; motif D â€&quot; magenta; motif E â€&quot; cyan." exact="Sofosbuvir" post="(SOF) is a nucleotide analogue targeted against the HCV"/>
   <result pre="virus, yielding very promising results. Figure 2 Conservation of the" exact="Sofosbuvir" post="binding residues in members of the Betacoronavirus genus and"/>
   <result pre="the same as Fig.Â 1; the residues that partake in" exact="Sofosbuvir" post="binding are highlighted in orange, whereas the catalytic aspartates"/>
   <result pre="the active site. The sidechains of the residues partaking in" exact="Sofosbuvir" post="binding are shown, and sofosbuvir is colored orange. With"/>
   <result pre="of the residues partaking in Sofosbuvir binding are shown, and" exact="sofosbuvir" post="is colored orange. With the number of COVID-19 cases"/>
   <result pre="superposition of the hepatitis C virus polymerase NS5B bound to" exact="Sofosbuvir" post="[PDB ID: 4WTG13] with the SARS-coronavirus nsp12 [PDB ID:"/>
   <result pre="and the proofreading exonucleasemBio.20189e002211810.1128/mBio.00221-1829511076 12.Wang, M. et al. Remdesivir and" exact="chloroquine" post="effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in"/>
   <result pre="15.MesciPet al.Blocking Zika virus vertical transmissionSci. Rep.20188121810.1038/s41598-018-19526-429352135 16.DragoniFet al.Evaluation of" exact="sofosbuvir" post="activity and resistance profile against West Nile virus in"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7284144\results\search\drug\results.xml">
   <result pre="studies of drug repurposing and synergism of lopinavir, oseltamivir and" exact="ritonavir" post="binding with SARS-CoV-2 protease against COVID-19. Journal of Biomolecular"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7284148\results\search\drug\results.xml">
   <result pre="with Cyclocytidine hydrochloride (anti-viral and anti-cancer), Trifluridine (anti-viral), Adonitol, and" exact="Meropenem" post="(anti-bacterial), and Penciclovir (anti-viral) bound with a good docking"/>
   <result pre="(anti-viral and anti-cancer), Trifluridine (anti-viral), Adonitol, and Meropenem (anti-bacterial), and" exact="Penciclovir" post="(anti-viral) bound with a good docking score ranging from"/>
   <result pre="found to catalyze the transfer of methyl group SAM or" exact="AdoMet" post="to RNA substrate and produce S-adenosyl-L-homocysteine as a byproduct"/>
   <result pre="[12]. Moreover, it has also been shown that the anti-virals" exact="Velpatasvir" post="and Ledipasvir are particularly attractive as therapeutics to combat"/>
   <result pre="Our result highlighted that; Cyclocytidine, Hydrochloride, Trifluridine, Adonitol Meropenem, and" exact="Penciclovir" post="yielded a preeminent dock score with the main Protease"/>
   <result pre="âˆ’5.7â€‰Kcal/mol. Cyclocytidine hydrochloride (anti-viral and anti-cancer), Trifluridine (anti-viral), Adonitol (anti-bacterial)," exact="Meropenem" post="(antibiotic and anti-bacterial), and Penciclovir (anti-viral) yielded a good"/>
   <result pre="anti-cancer), Trifluridine (anti-viral), Adonitol (anti-bacterial), Meropenem (antibiotic and anti-bacterial), and" exact="Penciclovir" post="(anti-viral) yielded a good docking score with the main"/>
   <result pre="methyltransferase; (c) Daphnetin- NSP10/NSP16 methyltransferase; (d) Amoxicillin- NSP10/NSP16 methyltransferase; (e)" exact="Tetracycline" post="hydrochloride- NSP10/NSP16 methyltransferase. Figure 2. Ribbon presentation of Protease"/>
   <result pre="Trifluridine âˆ’6.09 3 Methylgallate âˆ’6.02 Adonitol âˆ’5.58 4 2-deoxy-D-glucose âˆ’5.85" exact="Meropenem" post="âˆ’5.20 5 Daphnetin âˆ’5.78 Penciclovir âˆ’5.14 3.2. Interactions between"/>
   <result pre="Adonitol âˆ’5.58 4 2-deoxy-D-glucose âˆ’5.85 Meropenem âˆ’5.20 5 Daphnetin âˆ’5.78" exact="Penciclovir" post="âˆ’5.14 3.2. Interactions between the proteins and compounds Protein-ligands"/>
   <result pre="methyltransferase; (c) Daphnetin- NSP10/NSP16 methyltransferase; (d) Amoxicillin- NSP10/NSP16 methyltransferase; (e)" exact="Tetracycline" post="hydrochloride- NSP10/NSP16 methyltransferase. Figure 4. Protein-ligand interactions profile of"/>
   <result pre="Pro108; Pro132; Pro293; Ile200; Val202 Pro108; Asn203; Glu240; Gln110 4" exact="Meropenem" post="Phe112; Ile106; Val104; Tyr154; Phe8; Phe294 Lys102; asn151; Asp153;"/>
   <result pre="Val104; Tyr154; Phe8; Phe294 Lys102; asn151; Asp153; Thr111; Gln110 5" exact="Penciclovir" post="Phe8; Phe294; Pro293; Ile249 Thr111; Gln110; Asn151 A good"/>
   <result pre="Compounds(Main protease) DG binding free energy 1 Oxytetracycline dihydrate âˆ’52.55" exact="Penciclovir" post="âˆ’42.90 2 TYZEKA (Telbivudine) âˆ’51.56 Cyclocytidine hydrochloride âˆ’33.61 3"/>
   <result pre="2 TYZEKA (Telbivudine) âˆ’51.56 Cyclocytidine hydrochloride âˆ’33.61 3 2-deoxy-D-glucose âˆ’41.18" exact="Meropenem" post="âˆ’30.36 4 Daphnetin âˆ’38.47 Trifluridine âˆ’30.18 5 Methylgallate âˆ’37.61"/>
   <result pre="âˆ’0.39 âˆ’1.833 8.5 5 116.056 âˆ’1.571 2 âˆ’2.772 343.539 C17H25N3O2O5S" exact="Meropenem" post="383.462 âˆ’1.52 âˆ’1.357 9.7 2 3.353 âˆ’1.491 2 âˆ’1.869"/>
   <result pre="âˆ’1.52 âˆ’1.357 9.7 2 3.353 âˆ’1.491 2 âˆ’1.869 651.295 C10H15N5O3" exact="Penciclovir" post="253.26 âˆ’1.76 âˆ’1.443 8.9 5 20.823 âˆ’2.494 2 âˆ’4.113"/>
   <result pre="âˆ’1.76 âˆ’1.443 8.9 5 20.823 âˆ’2.494 2 âˆ’4.113 488.808 C10H14N2O5" exact="Telbivudine" post="242.231 âˆ’1.88 âˆ’1.058 8.6 3 59.067 âˆ’1.595 2 âˆ’4.089"/>
   <result pre="with Cyclocytidine hydrochloride (anti-viral and anti-cancer), Trifluridine (anti-viral), Adonitol (anti-bacterial)," exact="Meropenem" post="(antibiotic and anti-bacterial), and Penciclovir (anti-viral) bound with a"/>
   <result pre="anti-cancer), Trifluridine (anti-viral), Adonitol (anti-bacterial), Meropenem (antibiotic and anti-bacterial), and" exact="Penciclovir" post="(anti-viral) bound with a good docking score ranging from"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7284455\results\search\drug\results.xml">
   <result pre="reducing SARS-CoV-2 viral replication. He received a 1-week course of" exact="prednisolone" post="and valacyclovir for treatment of facial palsy. Upon review"/>
   <result pre="viral replication. He received a 1-week course of prednisolone and" exact="valacyclovir" post="for treatment of facial palsy. Upon review 1â€‰week later,"/>
   <result pre="prompt treatment re-initiation is particularly important in the cases of" exact="fingolimod" post="and natalizumab, in order to minimize the risk of"/>
   <result pre="that may be tested and used against SARS-CoV-2. For example," exact="hydroxychloroquine" post="sulphate has been associated with headache, dizziness and extrapyramidal"/>
   <result pre="when patients with disorders of the neuromuscular junction are prescribed" exact="hydroxychloroquine" post="sulphate, especially with co-administration of aminoglycoside antibiotics. Certain drug"/>
   <result pre="aminoglycoside antibiotics. Certain drug databases report additional minor interactions of" exact="chloroquine" post="with anti-Xa inhibitors, resulting in a decrease of their"/>
   <result pre="All direct oral anticoagulants also interact with the antiviral agent" exact="ritonavir" post="(a protease inhibitor used in conjunction with another PI"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7286259\results\search\drug\results.xml">
   <result pre="Original Article In silico screening of FDA approved drugs reveals" exact="ergotamine" post="and dihydroergotamine as potential coronavirus main protease enzyme inhibitors"/>
   <result pre="In silico screening of FDA approved drugs reveals ergotamine and" exact="dihydroergotamine" post="as potential coronavirus main protease enzyme inhibitors GurungArun Bahadurarunbgurung@gmail.comaâ�ŽAliMohammad"/>
   <result pre="for each enzyme target. Interestingly, the anti-migraine drugs such as" exact="ergotamine" post="and its derivative, dihydroergotamine were found to bind to"/>
   <result pre="Interestingly, the anti-migraine drugs such as ergotamine and its derivative," exact="dihydroergotamine" post="were found to bind to all the three target"/>
   <result pre="drug candidates. Keywords Coronaviruses Coronaviral main protease FDA approved drugs" exact="Ergotamine" post="Dihydroergotamine COVID-19 SARS-CoV-2 SARS-CoV MERS-CoV 2019-nCoV 1 Introduction Coronaviruses"/>
   <result pre="candidates. Keywords Coronaviruses Coronaviral main protease FDA approved drugs Ergotamine" exact="Dihydroergotamine" post="COVID-19 SARS-CoV-2 SARS-CoV MERS-CoV 2019-nCoV 1 Introduction Coronaviruses are"/>
   <result pre="The top five lead molecules identified for SARS-CoV-2 Mpro were" exact="Dihydroergotamine" post="(ZINC000003978005), Avodart (ZINC000003932831), Irinotecan (ZINC000001612996), Ergotamine (ZINC000052955754) and Olysio"/>
   <result pre="molecules identified for SARS-CoV-2 Mpro were Dihydroergotamine (ZINC000003978005), Avodart (ZINC000003932831)," exact="Irinotecan" post="(ZINC000001612996), Ergotamine (ZINC000052955754) and Olysio (ZINC000164760756) with binding energies"/>
   <result pre="for SARS-CoV-2 Mpro were Dihydroergotamine (ZINC000003978005), Avodart (ZINC000003932831), Irinotecan (ZINC000001612996)," exact="Ergotamine" post="(ZINC000052955754) and Olysio (ZINC000164760756) with binding energies of âˆ’9.4Â"/>
   <result pre="and âˆ’9.2Â kcal/mol respectively (Table 1). The best lead molecule" exact="Dihydroergotamine" post="(ZINC000003978005) binds to a pocket within the Cys145-His41 dyad"/>
   <result pre="Binding Energy (kcal/mol) Molecular Interactions Hydrogen bonds Hydrophobic interactions ZINC000003978005" exact="Dihydroergotamine" post="âˆ’9.4 O1â€¦..N(Gly143) [3.13Â Ã…]O4â€¦..N(Gly143) [2.80Â Ã…] Thr25, His41, Cys44,"/>
   <result pre="Glu166, Pro168, Arg188, Gln189 and Thr190 (NÂ =Â 10) ZINC000001612996" exact="Irinotecan" post="âˆ’9.3 N4â€¦..O(Thr26) [3.00Â Ã…]O3â€¦..NE2(Gln192) [2.90Â Ã…] Thr24, Thr25, His41,"/>
   <result pre="Met165, Glu166, Pro168, Gln189 and Thr190 (NÂ =Â 13) ZINC000052955754" exact="Ergotamine" post="âˆ’9.3 O4â€¦..N(Gly143) [3.13Â Ã…] Thr25, His41, Cys44, Met49, Asn142,"/>
   <result pre="wireframe representation) and molecular interaction between SARS-CoV-2 Mpro and (A)" exact="Dihydroergotamine" post="(ZINC000003978005) (B) Î±-ketoamide 13b inhibitor (O6K). The hydrophobic interactions"/>
   <result pre="second target-SARS-CoV Mpro, the top 5 lead molecules identified were" exact="Saquinavir" post="(ZINC000026985532), Ergotamine (ZINC000052955754), Nilotinib (ZINC000006716957), Raltegravir (ZINC000013831130) and Dihydroergotamine"/>
   <result pre="Mpro, the top 5 lead molecules identified were Saquinavir (ZINC000026985532)," exact="Ergotamine" post="(ZINC000052955754), Nilotinib (ZINC000006716957), Raltegravir (ZINC000013831130) and Dihydroergotamine (ZINC000003978005) with"/>
   <result pre="top 5 lead molecules identified were Saquinavir (ZINC000026985532), Ergotamine (ZINC000052955754)," exact="Nilotinib" post="(ZINC000006716957), Raltegravir (ZINC000013831130) and Dihydroergotamine (ZINC000003978005) with binding energies"/>
   <result pre="were Saquinavir (ZINC000026985532), Ergotamine (ZINC000052955754), Nilotinib (ZINC000006716957), Raltegravir (ZINC000013831130) and" exact="Dihydroergotamine" post="(ZINC000003978005) with binding energies of âˆ’9.6Â kcal/mol, âˆ’9.5Â kcal/mol,"/>
   <result pre="and âˆ’9.2Â kcal/mol respectively (Table 2). The best lead molecule-" exact="Saquinavir" post="(ZINC000026985532) exhibits four hydrogen bonds (Three bonds with the"/>
   <result pre="Binding Energy (kcal/mol) Molecular Interactions Hydrogen bonds Hydrophobic interactions ZINC000026985532" exact="Saquinavir" post="âˆ’9.6 O6â€¦..N(Glu166) [2.83Â Ã…]N5â€¦..OE1(Gln189) [3.06Â Ã…]O2â€¦..O(Leu141) [2.75Â Ã…]O1â€¦..N(Gly143) [2.89Â"/>
   <result pre="His164, Met165, Leu167, Thr190 and Gln192 (NÂ =Â 12) ZINC000052955754" exact="Ergotamine" post="âˆ’9.5 O1â€¦..N(Gly143)O4â€¦..N(Gly143) Thr25, His41, Met49, Asn142, Cys145, His164, Met165,"/>
   <result pre="Cys145, His164, Met165, Glu166 and Gln189 (NÂ =Â 9) ZINC000006716957" exact="Nilotinib" post="âˆ’9.4 N4â€¦..OD(Asn142) [3.03Â Ã…]N1â€¦..O(His164) [3.15Â Ã…] Thr25, His41, Cys44,"/>
   <result pre="Leu141, Gly143, Asp187, Arg188 and Gln189, (NÂ =Â 10) ZINC000003978005" exact="Dihydroergotamine" post="âˆ’9.2 O4â€¦..N(Ser144) [3.34Â Ã…]O4â€¦..N(Gly143) [2.67Â Ã…]O1â€¦..N(Gly143) [2.98Â Ã…] Thr25,"/>
   <result pre="red wireframe representation) between SARS-CoV Mpro lead compounds and. (A)" exact="Saquinavir" post="(ZINC000026985532) (B) inhibitor SG85 (G85). The hydrophobic interactions are"/>
   <result pre="leads for the third target-MERS-CoV Mpro were found to be" exact="Ergotamine" post="(ZINC000052955754), Ak-Fluor (ZINC000003860453), Avodart (ZINC000003932831), Dihydroergotamine (ZINC000003978005) and Saquinavir"/>
   <result pre="were found to be Ergotamine (ZINC000052955754), Ak-Fluor (ZINC000003860453), Avodart (ZINC000003932831)," exact="Dihydroergotamine" post="(ZINC000003978005) and Saquinavir (ZINC000026664090) with binding energies of âˆ’9.6Â"/>
   <result pre="be Ergotamine (ZINC000052955754), Ak-Fluor (ZINC000003860453), Avodart (ZINC000003932831), Dihydroergotamine (ZINC000003978005) and" exact="Saquinavir" post="(ZINC000026664090) with binding energies of âˆ’9.6Â kcal/mol, âˆ’9.4Â kcal/mol,"/>
   <result pre="and âˆ’8.1Â kcal/mol respectively (Table 3). The best lead molecule-" exact="Ergotamine" post="(ZINC000052955754) binds to a region within the Cys148-His41 catalytic"/>
   <result pre="Binding Energy (kcal/mol) Molecular Interactions Hydrogen bonds Hydrophobic interactions ZINC000052955754" exact="Ergotamine" post="âˆ’9.6 O3â€¦..SG(Cys148) [3.23Â Ã…] Met25, His41, Leu49, Leu144, Cys145,"/>
   <result pre="Met168, Glu169, Asp190, Lys191 and Gln192 (NÂ =Â 10) ZINC000003978005" exact="Dihydroergotamine" post="âˆ’9.3 O1â€¦..SG(Cys145) [3.35Â Ã…] Met25, His41, Leu49, Leu144, Cys148,"/>
   <result pre="Glu169, Asp190, Lys191, Gln192 and His194 (NÂ =Â 11) ZINC000026664090" exact="Saquinavir" post="âˆ’9.3 O2â€¦..SG(Cys145) [3.21Â Ã…]O3â€¦..NE2(His41) [2.97Â Ã…]N3â€¦..OE1(Gln192) [3.13Â Ã…]N5â€¦..OE1 (Gln192)"/>
   <result pre="wireframe representation) between MERS-CoV Mpro and lead compounds and (A)" exact="Ergotamine" post="(ZINC000052955754) (B) inhibitor GC813 (AW4). The hydrophobic interactions are"/>
   <result pre="and green dashed lines correspond to hydrogen bonds. The molecules-" exact="Dihydroergotamine" post="(ZINC000003978005) and Ergotamine (ZINC000052955754) were identified to be common"/>
   <result pre="lines correspond to hydrogen bonds. The molecules- Dihydroergotamine (ZINC000003978005) and" exact="Ergotamine" post="(ZINC000052955754) were identified to be common leads interacting with"/>
   <result pre="the favourable number of hydrogen bonds and hydrophobic interactions. Both" exact="Ergotamine" post="and its derivative, Dihydroergotamine have been used in clinical"/>
   <result pre="hydrogen bonds and hydrophobic interactions. Both Ergotamine and its derivative," exact="Dihydroergotamine" post="have been used in clinical practice for the treatment"/>
   <result pre="of pharmacological binding with several receptors such as 5-HT (5-hydroxytryptamine)," exact="dopamine" post="and noradrenaline receptors and are potent vasoconstrictors (Bigal and"/>
   <result pre="binding with several receptors such as 5-HT (5-hydroxytryptamine), dopamine and" exact="noradrenaline" post="receptors and are potent vasoconstrictors (Bigal and Tepper, 2003,"/>
   <result pre="docking approach. Our study suggests that anti-migraine drugs such as" exact="Ergotamine" post="(ZINC000052955754) and its derivative, Dihydroergotamine (ZINC000003978005) are the most"/>
   <result pre="that anti-migraine drugs such as Ergotamine (ZINC000052955754) and its derivative," exact="Dihydroergotamine" post="(ZINC000003978005) are the most potent lead molecules which can"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7287466\results\search\drug\results.xml">
   <result pre="cascade abnormalities reported in ECoVs, testing for C-reactive protein, serum" exact="creatine" post="kinase, and D-dimer level is mandatory. Presently, there is"/>
   <result pre="are linked to the high incidence of thrombotic complexities, while" exact="methylprednisolone" post="is associated with myopathy. Future studies expected to apply"/>
   <result pre="majority of the initial cases. Keywords COVID-19 Ageusia Myalgia Anticoagulants" exact="Methylprednisolone" post="1 Introduction The emergence of an infectious disorder usually"/>
   <result pre="years lady, SE presented with reappearing seizures not responding to" exact="phenytoin" post="treatment and extended episodes up to 30Â min accompanied"/>
   <result pre="features; namely, generalized flaccid paresis, linked risk factors, raised serum" exact="creatine" post="kinase, and histological features. Besides, the nonexistence of myofiber"/>
   <result pre="exhibiting with significant myofiber atrophy particularly for cases in whom" exact="hydrocortisone" post="administered. Never the less, in a most recent prospective"/>
   <result pre="regimen, lopinavir-ritonavir (LPV/r) have anti-CoV action in vitro, and IFN-" exact="alpha" post="is a broad-spectrum antiviral medicine [37]. Similarly, there is"/>
   <result pre="clinical experiments; importantly, for SARS-CoV-2, according to the guidelines, IFN-" exact="alpha" post="and LPV/r are recommended as antiviral therapy [75]. Neurologically,"/>
   <result pre="with seizures managed by propofol, phenytoin, and Levetiracetam. Valproate and" exact="midazolam" post="also employed in addition to antibiotics hydroxychloroquine or antiviral"/>
   <result pre="Levetiracetam. Valproate and midazolam also employed in addition to antibiotics" exact="hydroxychloroquine" post="or antiviral [16], [51], [52], [53], [54]. Similarly, a"/>
   <result pre="corticosteroid on mortality rather than prolonged viral clearing [16]. Intravenous" exact="methylprednisolone" post="has been used supportively in ECoV neurological cases [60]."/>
   <result pre="musculoskeletal. On lab examination, the focus should be on serum" exact="creatine" post="kinase level as 44â€&quot;60% of ECoV cases presents with"/>
   <result pre="of LMWH are linked high frequency of thrombotic complexities while" exact="methylprednisolone" post="is associated with myopathy. Future inter-continental studies, exploring prognosis,"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7287479\results\search\drug\results.xml">
   <result pre="of fentany, and several counties are already reporting spikes in" exact="fentanyl" post="and opioid overdose rates (AmericanÂ Medical Association,Â 2020). People"/>
   <result pre="sterile drug use equipment, medication-assisted treatment and overdose education and" exact="naloxone" post="distribution. These are vital for reducing the risk of"/>
   <result pre="from https://www.cdc.gov/coronavirus/2019-ncov/community/correction-detention/guidance-correctional-detention.html. CerdÃ¡M.TracyM.GaleaS.A prospective population based study of changes in" exact="alcohol" post="use and binge drinking after a mass traumatic eventDrug"/>
   <result pre="use and binge drinking after a mass traumatic eventDrug and" exact="alcohol" post="dependence1151â€&quot;220111820977977 FlaggA.NeffJ.Why jails are so important in the fight"/>
   <result pre="North Carolina inmates: 2000â€&quot;2015American Journal of Public Health108920181207121330024795 RichmanJ.A.WislarJ.S.FlahertyJ.A.FendrichM.RospendaK.M.Effects on" exact="alcohol" post="use and anxiety of the September 11, 2001, attacks"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7290442\results\search\drug\results.xml">
   <result pre="address this challenge. The drugs included in this trial are" exact="lopinavir" post="and ritonavir, lopinavir and ritonavir plus interferon beta as"/>
   <result pre="The drugs included in this trial are lopinavir and ritonavir," exact="lopinavir" post="and ritonavir plus interferon beta as well as chloroquine,"/>
   <result pre="included in this trial are lopinavir and ritonavir, lopinavir and" exact="ritonavir" post="plus interferon beta as well as chloroquine, and remdesivir."/>
   <result pre="virus particle maturation, a late step in HIV-1 replication, while" exact="ritonavir" post="helps boost the activity of lopinavir by inhibiting CYP3A"/>
   <result pre="in HIV-1 replication, while ritonavir helps boost the activity of" exact="lopinavir" post="by inhibiting CYP3A enzymes that slows down the rate"/>
   <result pre="inhibiting CYP3A enzymes that slows down the rate at which" exact="lopinavir" post="is broken down in the liver [69]. Findings from"/>
   <result pre="used either on its own or in combination with either" exact="alpha" post="interferon (China) or chloroquine/hydroxychloroquine (South Korea) for COVID-19 treatment"/>
   <result pre="as the first anti-COVID-19 drug in the country [66]. Chloroquine/Hydroxychloroquine:" exact="Chloroquine" post="is an inexpensive drug for the treatment of malaria"/>
   <result pre="as an anti-inflammatory agent for the treatment of autoimmune diseases." exact="Chloroquine" post="is thought to inhibit virus replication by increasing endosomal"/>
   <result pre="However, a recent study showed that the anti-inflammatory effects of" exact="chloroquine" post="are mediated by upregulation of the cyclin-dependent kinase inhibitor,"/>
   <result pre="exacerbation of pneumonia and acceptable safety margin with use of" exact="chloroquine" post="for treatment of COVID-19 [10]. Hydroxychloroquine is an analogue"/>
   <result pre="margin with use of chloroquine for treatment of COVID-19 [10]." exact="Hydroxychloroquine" post="is an analogue of chloroquine which is more stable"/>
   <result pre="for treatment of COVID-19 [10]. Hydroxychloroquine is an analogue of" exact="chloroquine" post="which is more stable with better clinical safety profile"/>
   <result pre="patients and used successfully in combination with the macrolide antibiotic" exact="azithromycin" post="[84]. A recent clinical trial, however, has shown disappointing"/>
   <result pre="trial, however, has shown disappointing results with the combination of" exact="azithromycin" post="with hydroxychloroquine in critically-ill COVID-19 patients [85], suggesting that"/>
   <result pre="has shown disappointing results with the combination of azithromycin with" exact="hydroxychloroquine" post="in critically-ill COVID-19 patients [85], suggesting that larger studies"/>
   <result pre="be made for chloroquine/hydroxychloroquine in the treatment of COVID-19. Interestingly," exact="chloroquine" post="and hydroxychloroquine are zinc ionophores and zinc has been"/>
   <result pre="for chloroquine/hydroxychloroquine in the treatment of COVID-19. Interestingly, chloroquine and" exact="hydroxychloroquine" post="are zinc ionophores and zinc has been shown to"/>
   <result pre="infection facilitates the rapid dissemination of novel coronavirus (SARS-CoV2)Science202036848949310.1126/science.abb322132179701 10.GaoJ.TianZ.YangX.Breakthrough:" exact="Chloroquine" post="phosphate has shown apparent efficacy in treatment of COVID-19"/>
   <result pre="and its Associated Congenital Microcephaly in MiceEBioMedicine20172418919410.1016/j.ebiom.2017.09.03429033372 82.OhS.ShinJ.H.JangE.J.WonH.Y.KimH.K.JeongM.G.KimK.S.HwangE.S.Anti-inflammatory activity of" exact="chloroquine" post="and amodiaquine through p21-mediated suppression of T cell proliferation"/>
   <result pre="proliferation and Th1 cell differentiationBiochem. Biophys. Res. Commun.201647434535010.1016/j.bbrc.2016.04.10527109480 83.WangM.CaoR.ZhangL.YangX.LiuJ.XuM.ShiZ.HuZ.ZhongW.XiaoG.Remdesivir and" exact="chloroquine" post="effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in"/>
   <result pre="emerged novel coronavirus (2019-nCoV) in vitroCell Res.20203026927110.1038/s41422-020-0282-032020029 84.GautretP.LagierJ.C.ParolaP.MeddebL.MailheM.DoudierB.CourjonJ.GiordanengoV.VieiraV.E.DupontH.T.et al.Hydroxychloroquine and" exact="azithromycin" post="as a treatment of COVID-19: Results of an open-label"/>
   <result pre="rapid antiviral clearance or clinical benefit with the combination of" exact="hydroxychloroquine" post="and azithromycin in patients with severe COVID-19 infectionMed. Mal."/>
   <result pre="clearance or clinical benefit with the combination of hydroxychloroquine and" exact="azithromycin" post="in patients with severe COVID-19 infectionMed. Mal. Infect.2020in press10.1016/j.medmal.2020.03.00632240719"/>
   <result pre="of Alzheimerâ€™s DiseaseACS Med. Chem. Lett.201561025102910.1021/acsmedchemlett.5b0028126396692 88.ShittuM.O.AfolamiO.I.Improving the efficacy of" exact="Chloroquine" post="and Hydroxychloroquine against SARS-CoV-2 may require Zinc additivesâ€&quot;A better"/>
   <result pre="DiseaseACS Med. Chem. Lett.201561025102910.1021/acsmedchemlett.5b0028126396692 88.ShittuM.O.AfolamiO.I.Improving the efficacy of Chloroquine and" exact="Hydroxychloroquine" post="against SARS-CoV-2 may require Zinc additivesâ€&quot;A better synergy for"/>
   <result pre="press10.1016/j.ijantimicag.2020.105954 99.ZhaoM.Cytokine storm and immunomodulatory therapy in COVID-19: Role of" exact="chloroquine" post="and anti-IL-6 monoclonal antibodiesInt. J. Antimicrob. Agents2020in press10.1016/j.ijantimicag.2020.105982 100.CellinaM.OrsiM.BombaciF.SalaM.MarinoP.OlivaG.Favorable"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7290740\results\search\drug\results.xml">
   <result pre="courier ; font-style : italic;} VirusesVirusesvirusesViruses1999-4915MDPI doi: 10.3390/v12050557viruses-12-00557 : Article" exact="Ethanol" post="Extract of Caesalpinia decapetala Inhibits Influenza Virus Infection In"/>
   <result pre="host and virus factors. In this study, we identified the" exact="ethanol" post="extract of Caesalpinia decapetala (Roth) Alston (EEC) as an"/>
   <result pre="There are many problems with the present anti-influenza drugs [4]." exact="Amantadine" post="and amantadine, inhibitors of the M2 ion channel, have"/>
   <result pre="Hubei province, China. By screening the extract library comprising the" exact="ethanol" post="extracts of the 600 plants in a U937 cell"/>
   <result pre="model against influenza virus infection [16], we found that the" exact="ethanol" post="extract of Caesalpinia decapetala (Roth) Alston (EEC) has antiviral"/>
   <result pre="infective dose (TCID50) assay in MDCK cells. 2.2. Preparation of" exact="Ethanol" post="Extracts of Plants The 600 plants were collected from"/>
   <result pre="and branches of C. decapetala were extracted with 75% aqueous" exact="ethanol" post="at room temperature overnight. After filtration, the ethanol extract"/>
   <result pre="75% aqueous ethanol at room temperature overnight. After filtration, the" exact="ethanol" post="extract of C. decapetala was stored at 4 Â°C"/>
   <result pre="the Chinese Academy of Sciences (WIVA08201601). Mice were anesthetized with" exact="pentobarbital" post="sodium and then infected with the influenza virus through"/>
   <result pre="for natural products of plants with anti-influenza activity, we made" exact="ethanol" post="extracts of about 600 plant species from Shen Nong"/>
   <result pre="China. By screening these plant extracts, we found that the" exact="ethanol" post="extract of C. decapetala (EEC) inhibits the replication of"/>
   <result pre="as oseltamivir (data not shown), but comparable to that of" exact="ribavirin" post="(Figure S1). In addition to human influenza A viruses"/>
   <result pre="antiviral activity and cytotoxicity from that extracted with 75% aqueous" exact="ethanol" post="(data not shown). This observation suggests that the extraction"/>
   <result pre="can be found at https://www.mdpi.com/1999-4915/12/5/557/s1. Figure S1: Antiviral effects of" exact="ribavirin" post="against influenza virus PR 8 were determined in A"/>
   <result pre="105TCID50/mL was mixed with 5 Î¼L of serially diluted EEC," exact="ribavirin" post="or oseltamivir, respectively. Each reaction was conducted at 37"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7291183\results\search\drug\results.xml">
   <result pre="remedies to treat the disease, doctors are repurposing drugs like" exact="chloroquine" post="and remdesivir to treat COVID-19 patients. In parallel, research"/>
   <result pre="remsdesivir, developed by Gilead Inc. USA, and an antimalarial drug," exact="chloroquine" post="(CQ)/hydroxychloroquine (HCQ), for the treatment of COVID-19.Â An array"/>
   <result pre="Rajasthan, India, have started using antiviral drugs in combination with" exact="chloroquine" post="(Colson et al.2020; Lai et al.2020; Liu et al.2020)."/>
   <result pre="dependent RNA polymerase, (2) a combination of two HIV drugs," exact="lopinavir" post="and ritonavir, (3) lopinavir and ritonavir plus interferon beta,"/>
   <result pre="a combination of two HIV drugs, lopinavir and ritonavir, (3)" exact="lopinavir" post="and ritonavir plus interferon beta, and (4) the antimalarial"/>
   <result pre="of two HIV drugs, lopinavir and ritonavir, (3) lopinavir and" exact="ritonavir" post="plus interferon beta, and (4) the antimalarial drugs chloroquine"/>
   <result pre="and ritonavir plus interferon beta, and (4) the antimalarial drugs" exact="chloroquine" post="or hydroxychloroquine (tableÂ 1B). Coronavirus being a RNA virus,"/>
   <result pre="plus interferon beta, and (4) the antimalarial drugs chloroquine or" exact="hydroxychloroquine" post="(tableÂ 1B). Coronavirus being a RNA virus, retroviral drugs"/>
   <result pre="of Tat-mediated transactivation (Jiang et al.1996; Savarino et al.2001). Moreover," exact="chloroquine" post="can also increase the pH of endosomes (Mauthe et"/>
   <result pre="virus inside the host cell, it is more likely that" exact="chloroquine" post="stops viral spread by blocking the process of uncoating"/>
   <result pre="viral replication Hepatitis C, Ebola virus, Marburg virus Â 36791-04-5" exact="Ribavirin" post="Inosine monophosphate dehydrogenase Inhibition of Inosine monophosphate dehydrogenase(induction of"/>
   <result pre="protozoal, and viral infection-caused diarrhoea B Â 54-05-7 Â 118-42-3" exact="Chloroquine" post="Hydroxchloroquine Endosome or ACE2 A drug that can elevate"/>
   <result pre="ACE2 glycosylation Material parasite infection Â 192725-17-0 Â 155213-67-3 Lopinavir" exact="Ritonavir" post="3CLpro &amp;amp; PLpro- viral proteases Protease inhibitors that may"/>
   <result pre="in treating, as observed in the case of ganciclovir. Although" exact="ganciclovir" post="is successful in treating patients with acquired immunodeficiency syndrome-related"/>
   <result pre="came into use and is presently a successful drug. Similarly," exact="aspirin" post="is toxic to rhesus monkeys and paracetamol is toxic"/>
   <result pre="HA hemagglutinin WHO World Health Organization VLP virus-like particles CQ" exact="chloroquine" post="HCQ hydroxychloroquine FDA Food And Drug Administration NIAID National"/>
   <result pre="WHO World Health Organization VLP virus-like particles CQ chloroquine HCQ" exact="hydroxychloroquine" post="FDA Food And Drug Administration NIAID National Institute of"/>
   <result pre="disease pathogenesis and transmissibility. Clin. Infect. Dis. 10.1093/cid/ciaa325 ColsonPRolainJ-MLagierJ-CBrouquiPRaoultDChloroquine and" exact="hydroxychloroquine" post="as available weapons to fight COVID-192020IntJ. Antimicrob. Agents EnkirchTvon"/>
   <result pre="enhancement of viral infectionsVaccine20092750551210.1016/j.vaccine.2008.10.08719022319 JiangMCLinJKChenSSInhibition of HIV-1 Tat-mediated transactivation by" exact="quinacrine" post="and chloroquineBiochem. Biophys. Res. Commun.19962261710.1006/bbrc.1996.13028806583 KimYIKimSGKimSEKimEHParkSJYuKWChangJHet al.Infection and rapid"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7291249\results\search\drug\results.xml">
   <result pre="virus-infected lungs [124]. These cells induce the robust production of" exact="nitric oxide" post="synthase 2, and deficiency in CCR2 leads to attenuation"/>
   <result pre="Biol.20101753053810.1038/nsmb.177920383144 38.LiS.SiebenC.LudwigK.HoferC.T.ChiantiaS.HerrmannA.EghiaianF.SchaapI.A.pH-Controlled two-step uncoating of influenza virusBiophys. J.20141061447145610.1016/j.bpj.2014.02.01824703306 39.GrambasS.BennettM.S.HayA.J.Influence of" exact="amantadine" post="resistance mutations on the pH regulatory function of the"/>
   <result pre="activity of influenza A virus M2 protein: Characterization of the" exact="amantadine" post="blockJ. Virol.1993675585559410.1128/JVI.67.9.5585-5594.19937688826 41.DiasA.BouvierD.CrepinT.McCarthyA.A.HartD.J.BaudinF.CusackS.RuigrokR.W.The cap-snatching endonuclease of influenza virus polymerase"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7291320\results\search\drug\results.xml">
   <result pre="small single-arm study from France has tested the effect of" exact="hydroxychloroquine" post="(an analogue of chloroquine) and azithromycin on the respiratory"/>
   <result pre="tested the effect of hydroxychloroquine (an analogue of chloroquine) and" exact="azithromycin" post="on the respiratory viral loads in patients with COVID-19"/>
   <result pre="viral loads in patients with COVID-19 [105]. Patients treated with" exact="hydroxychloroquine" post="showed a significant reduction in viral carriage by day"/>
   <result pre="favipiravir) have been applied, without clinical efficacy data available. Lastly," exact="methylprednisolone" post="is another drug under investigation (NCT04323592) that is currently"/>
   <result pre="which results in decreased serum concentrations of active metabolites of" exact="clopidogrel" post="and prasugrel and increased serum concentration of ticagrelor. Cardiac"/>
   <result pre="Careful QT monitoring is recommended especially when a combination of" exact="hydroxychloroquine" post="and azithromycin is used [109]. Lastly, the use of"/>
   <result pre="monitoring is recommended especially when a combination of hydroxychloroquine and" exact="azithromycin" post="is used [109]. Lastly, the use of corticosteroid is"/>
   <result pre="Adults Hospitalized with Severe Covid-19N. Engl. J. Med.20203821787179910.1056/NEJMoa200128232187464 104.WangM.CaoR.ZhangL.YangX.LiuJ.XuM.ShiZ.HuZ.ZhongW.XiaoG.Remdesivir and" exact="chloroquine" post="effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in"/>
   <result pre="emerged novel coronavirus (2019-nCoV) in vitroCell Res.20203026927110.1038/s41422-020-0282-032020029 105.GautretP.LagierJ.C.ParolaP.HoangV.T.MeddebL.MailheM.DoudierB.CourjonJ.GiordanengoV.VieiraV.E.et al.Hydroxychloroquine and" exact="azithromycin" post="as a treatment of COVID-19: Results of an open-label"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7291595\results\search\drug\results.xml">
   <result pre="IL-15Â and IL-17) [6,50] Treatment medicine Corticosteroids, remdesivir, combination of" exact="lopinavir" post="and ritonavir, type I interferon and so on Lopinavir"/>
   <result pre="and so on Lopinavir and ritonavir, corticosteroids, IFN-Î±, IVIG IFN-Î²," exact="lopinavir" post="and ritonavir, mycophenolic acid [67,83] ACE2: Angiotensin-converting enzyme 2;"/>
   <result pre="Lopinavir and ritonavir, corticosteroids, IFN-Î±, IVIG IFN-Î², lopinavir and ritonavir," exact="mycophenolic acid" post="[67,83] ACE2: Angiotensin-converting enzyme 2; CT: Computed tomography;Â DPP4:"/>
   <result pre="patients are given empirical antibiotic or antiviral drugs. Moxifloxacin or" exact="levofloxacin" post="are empirically used to treat early coinfections with bacteria"/>
   <result pre="are empirically used to treat early coinfections with bacteria [65]." exact="Linezolid" post="is effective against Streptococcus pneumoniae and Staphylococcus aureus and"/>
   <result pre="nemonoxacin in cases of severe infection [65]. A combination of" exact="lopinavir" post="and ritonavir has been used to treat COVID-19 because"/>
   <result pre="cases of severe infection [65]. A combination of lopinavir and" exact="ritonavir" post="has been used to treat COVID-19 because the lopinavir/ritonavir"/>
   <result pre="used to inhibit COVID-19 in China [45,70]. Other neuraminidase inhibitors," exact="zanamivir" post="and peramivir, are also effective treatments for MERS-CoV [71]."/>
   <result pre="are all empirical therapies for COVID-19. However, whether oseltamivir or" exact="zanamivir" post="are effective treatments for COVID-19 also needs further study."/>
   <result pre="lupus and rheumatoid arthritisÂ [76]. A recent study indicates that" exact="chloroquine" post="and the antiviral drug RDV-inhibited SARS-CoV-2 in vitro [77]."/>
   <result pre="SARS-CoV-2 in vitro [77]. Clinical symptoms of patients treated with" exact="chloroquine" post="were obviously relieved: for example, more rapid decline in"/>
   <result pre="rapid decline in fever and improvement of lung CT [77]." exact="Chloroquine" post="was suggested to treat COVID-19 in the SARS-CoV-2 treatment"/>
   <result pre="in the SARS-CoV-2 treatment guidelines by the Chinese medical advisory." exact="Chloroquine" post="has been highly effective in reducing SARS-CoV-2 viral replication"/>
   <result pre="and interfering with the glycosylation of cellular receptors [76]. Moreover," exact="chloroquine" post="was probably the first molecule to be used to"/>
   <result pre="have been developed. Therefore, empirical antiviral drugs (lopinavir/ritonavir, favipiravir, oseltamivir," exact="zanamivir" post="and peramivir, arbidol), antibiotic drugs (moxifloxacin, levofloxacin, linezolid), chloroquine/hydroxychloroquine,"/>
   <result pre=", ColsonP , RaoultDNew insights on the antiviral effects of" exact="chloroquine" post="against coronavirus: what to expect for COVID-19?Int. J. Antimicrob."/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7293728\results\search\drug\results.xml">
   <result pre="vitro). Oseltamivir was obtained from Roche Co., Ltd. (Basel, Switzerland)." exact="Ribavirin" post="was purchased from Star Lake Bioscience Co., Ltd. (Zhaoqing"/>
   <result pre="tosyl-phenylalanine chloromethyl-ketone (TPCK) treated trypsin (Sigma), 100â€‰U/ml penicillin, and 100â€‰Î¼g/ml" exact="streptomycin" post="(Gibco). The plate was incubated at 34Â°C, 5% CO2,"/>
   <result pre="infected mice, 60 mice were divided into 6 groups (placebo," exact="ribavirin" post="75â€‰mg/kg/day, LQ 100/200/400â€‰mg/kg/day, uninfected control, nâ€‰=â€‰10): 5 groups (placebo,"/>
   <result pre="ribavirin 75â€‰mg/kg/day, LQ 100/200/400â€‰mg/kg/day, uninfected control, nâ€‰=â€‰10): 5 groups (placebo," exact="ribavirin" post="75â€‰mg/kg/day, LQ 100/200/400â€‰mg/kg/day) were inoculated with 5-fold 50% lethal"/>
   <result pre="days after IBV infection (Figure 5(b)). In the positive control," exact="ribavirin" post="treated mice (Figure 5(c)), there were a few inflammatory"/>
   <result pre="(average valueâ€‰=â€‰log 4.5 TCID50/g). Interestingly, viral load of 75â€‰mg/kg/day of" exact="ribavirin" post="treated mice (average valueâ€‰=â€‰log 3.17 TCID50/g) was lower than"/>
   <result pre="10â€‰mg/kg/day of oseltamivir treated mice (Figure 7(h)) and 75â€‰mg/kg/day of" exact="ribavirin" post="treated mice (Figure 7(b)), and mild pneumonia was observed"/>
   <result pre="many studies evaluating combinations of agents, including amantadine, oseltamivir, and" exact="ribavirin" post="[28â€&quot;30] antiviral therapy with anti-inflammatory drugs or antioxidant [31â€&quot;33],"/>
   <result pre="severe influenzaThe Lancet Infectious Diseases201414121259127010.1016/s1473-3099(14)70821-725213733 28BeigelJ. H.BaoY.BeelerJ.et al.Oseltamivir, amantadine, and" exact="ribavirin" post="combination antiviral therapy versus oseltamivir monotherapy for the treatment"/>
   <result pre="F.BarnardD. L.et al.Efficacy of combined therapy with amantadine, oseltamivir, and" exact="ribavirin" post="in vivo against susceptible and amantadine-resistant influenza A virusesPLoS"/>
   <result pre="A virusesPLoS One20127110.1371/journal.pone.0031006 30SmeeD. F.WongM.-H.BaileyK. W.SidwellR. W.Activities of oseltamivir and" exact="ribavirin" post="used alone and in combination against infections in mice"/>
   <result pre="mice without prior adaptation and responds to a combination of" exact="zanamivir" post="and COX-2 inhibitorPLoS One20149910.1371/journal.pone.0107966 32OttoliniM.BlancoJ.PorterD.PetersonL.CurtisS.PrinceG.Combination anti-inflammatory and antiviral therapy"/>
   <result pre="influenza in a cotton rat modelPediatric Pulmonology200336429029410.1002/ppul.1032012950040 33GhezziP.UngheriD.Synergistic combination of" exact="N-acetylcysteine" post="and ribavirin to protect from lethal influenza viral infection"/>
   <result pre="a cotton rat modelPediatric Pulmonology200336429029410.1002/ppul.1032012950040 33GhezziP.UngheriD.Synergistic combination of N-acetylcysteine and" exact="ribavirin" post="to protect from lethal influenza viral infection in a"/>
   <result pre="Medicine2010361334110.1007/s00134-009-1727-619924393 35ZhangA. J. X.LiC.ToK. K. W.et al.Toll-like receptor 7 agonist" exact="imiquimod" post="in combination with influenza vaccine expedites and augments humoral"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7294848\results\search\drug\results.xml">
   <result pre="that inserts into the membrane. The potential beneficial effect of" exact="chloroquine" post="on SARS-CoV-2 is due to its effect on the"/>
   <result pre="AngII on the platelets was not reversible by application of" exact="aspirin" post="(Jagroop and Mikhailidis, 2000). At the cellular level, angiotensin"/>
   <result pre="al., 2006). Ang II is a potent activator of nicotinamide" exact="adenine" post="dinucleotide phosphate (NADPH) oxidase and hence an inducer of"/>
   <result pre="flux to the affected tissues and inhibits the production of" exact="nitric oxide" post="and hence promotes vascular injury (Kato et al., 1996;"/>
   <result pre="Experimental data suggested that at micromolar concentration of remdesivir and" exact="chloroquine" post="potentially blocked virus infection (Wang M. et al., 2020)."/>
   <result pre="the efficacy of remdesivir treatment alone or in conjunction with" exact="chloroquine" post="in SARS-CoV-2 infection. Because hydroxychloroquine and chloroquine are considered"/>
   <result pre="alone or in conjunction with chloroquine in SARS-CoV-2 infection. Because" exact="hydroxychloroquine" post="and chloroquine are considered inhibitors of endosomal trafficking of"/>
   <result pre="in conjunction with chloroquine in SARS-CoV-2 infection. Because hydroxychloroquine and" exact="chloroquine" post="are considered inhibitors of endosomal trafficking of SARS-CoV-2, these"/>
   <result pre="outcomes of SARS. CMAJ171, 1349â€&quot;1352. 10.1503/cmaj.104039815557587 CinatlJ.MichaelisM.MorgensternB.DoerrH. W. (2005). High-dose" exact="hydrocortisone" post="reduces expression of the pro-inflammatory chemokines CXCL8 and CXCL10"/>
   <result pre="1â€&quot;10. 10.1186/s40779-020-00240-032169119 GustafssonF.Holstein-RathlouN.-H. (1999). Angiotensin II modulates conducted vasoconstriction to" exact="norepinephrine" post="and local electrical stimulation in rat mesenteric arterioles. Cardiovasc."/>
   <result pre="V.BrecherP. (1996). Effects of angiotensin II infusion and inhibition of" exact="nitric oxide" post="synthase on the rat aorta. Hypertension28, 153â€&quot;158. 10.1161/01.HYP.28.2.1538707375 KirchdoerferR."/>
   <result pre="Mol. Physiol.295, L178â€&quot;L185. 10.1152/ajplung.00009.200818441099 LiuX.LiZ.LiuS.ChenZ.ZhaoZ.HuangY.-y.et al. (2020). Therapeutic effects of" exact="dipyridamole" post="on COVID-19 patients with coagulation dysfunction. medRxiv. 10.1101/2020.02.27.20027557 LorenzJ."/>
   <result pre="Hypertension48, 1050â€&quot;1057. 10.1161/01.HYP.0000248135.97380.7617043157 MagagnoliJ.NarendranS.PereiraF.CummingsT.HardinJ. W.SuttonS. S.et al. (2020). Outcomes of" exact="hydroxychloroquine" post="usage in United States veterans hospitalized with Covid-19. medRxiv."/>
   <result pre="Circul. Res.112, 1307â€&quot;1309. 10.1161/CIRCRESAHA.113.30127123661710 MartinR. E.MarchettiR. V.CowanA. I.HowittS. M.BrÃ¶erS.KirkK. (2009)." exact="Chloroquine" post="transport via the malaria parasite's chloroquine resistance transporter. Science325,"/>
   <result pre="V.CowanA. I.HowittS. M.BrÃ¶erS.KirkK. (2009). Chloroquine transport via the malaria parasite's" exact="chloroquine" post="resistance transporter. Science325, 1680â€&quot;1682. 10.1126/science.117566719779197 MenterT.HaslbauerJ. D.NienholdR.SavicS.HopferH.DeigendeschN.et al.. (2020)."/>
   <result pre="ACE2 ratio. Endocrinology148, 2453â€&quot;2457. 10.1210/en.2006-128717303661 WangM.CaoR.ZhangL.YangX.LiuJ.XuM.et al.. (2020). Remdesivir and" exact="chloroquine" post="effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7294857\results\search\drug\results.xml">
   <result pre="medium, provided the original author and source are credited.https://www.cureus.com/articles/31798-pathological-findings-and-management-of-covid-19-patients-a-brief-overview-of-modern-day-pandemic Abstract" exact="Today" post="the world is facing one of the deadliest pandemics"/>
   <result pre="self-limiting. There is no definitive treatment, although a combination of" exact="hydroxychloroquine" post="and azithromycin have shown good results, and passive immunization"/>
   <result pre="is no definitive treatment, although a combination of hydroxychloroquine and" exact="azithromycin" post="have shown good results, and passive immunization also shows"/>
   <result pre="to be studied in detail. coronavirus covid-19 ards viral pneumonia" exact="hydroxychloroquine" post="pandemic corona pandemic passive immunization The content published in"/>
   <result pre="role of remdesivir, and five studies discussed the role of" exact="chloroquine" post="in these patients which showed some positive effects however"/>
   <result pre="and is a widely used anti-viral. Arabi et al. found" exact="zanamivir" post="and Panamivir to be as effective as oseltamivir in"/>
   <result pre="report by Lim et al. showed that the combination of" exact="lopinavir" post="and ritonavir significantly reduced the viral load in a"/>
   <result pre="Lim et al. showed that the combination of lopinavir and" exact="ritonavir" post="significantly reduced the viral load in a 54-year-old patient"/>
   <result pre="[11]. Elfiky showed in a study that Sofosbuvir, Remdesivir, and" exact="Ribavirin" post="showed that they could help manage and treat this"/>
   <result pre="be administered to cover common bacterial pathogens.Â Immune modulator drugs:" exact="Chloroquine" post="and hydroxychloroquine, the immune modulator drugs used as antimalarials,"/>
   <result pre="study testing the efficacy of broad-spectrum anti-virals like remdesivir, favipiravir," exact="ribavirin" post="penciclovir, and chloroquine showed that chloroquine and remdesivir were"/>
   <result pre="efficacy of broad-spectrum anti-virals like remdesivir, favipiravir, ribavirin penciclovir, and" exact="chloroquine" post="showed that chloroquine and remdesivir were effective against COVID-19"/>
   <result pre="anti-virals like remdesivir, favipiravir, ribavirin penciclovir, and chloroquine showed that" exact="chloroquine" post="and remdesivir were effective against COVID-19 virus in-vitro [13]."/>
   <result pre="also showed similar results; it showed an increased efficacy of" exact="chloroquine" post="in preventing symptom exacerbation, preventing progression to severe pneumonia,"/>
   <result pre="and improving radiological findings without any serious side effects [26]." exact="Chloroquine" post="has both anti-viral and immune-modulating properties, which increase its"/>
   <result pre="Monitored by Quantitative RT-PCRJ Korean Med SciLimJJeonSShinHYet al.7910352020 13Remdesivir and" exact="chloroquine" post="effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in"/>
   <result pre="treatmentBiosci TrendsWangZChenXLuYChenFZhangW646814202032037389 25Anti-HCV, nucleotide inhibitors, repurposing against COVID-19Life SciElfikyAA117477248202032119961 26Breakthrough:" exact="Chloroquine" post="phosphate has shown apparent efficacy in treatment of COVID-19"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7295489\results\search\drug\results.xml">
   <result pre="toroviruses. All identified CoVs are categorized into four different genera" exact="alpha" post="coronaviruses, beta coronaviruses, gammacoronaviruses, and delta coronaviruses. The human"/>
   <result pre="gammacoronaviruses, and delta coronaviruses. The human infecting CoVs belongs to" exact="alpha" post="coronaviruses and beta coronaviruses, whereas gammacoronaviruses, and delta coronaviruses"/>
   <result pre="along with COVID-19 antibiotics are found beneficial. We may use" exact="chloroquine" post="and hydroxychloroquine having synergistic effects, but further studies needed"/>
   <result pre="COVID-19 antibiotics are found beneficial. We may use chloroquine and" exact="hydroxychloroquine" post="having synergistic effects, but further studies needed (De Wit"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7295552\results\search\drug\results.xml">
   <result pre="do not recommend NSAIDs being avoided when clinically indicated [4]." exact="Acetaminophen" post="should be used as the preferred antipyretic agent for"/>
   <result pre="be low, and courses should be short (e.g., intravenous (IV)" exact="dexamethasone" post="20 mg once daily for 5 days, then 10"/>
   <result pre="of the COVID-19 patients in a study in China [13]." exact="Acetaminophen" post="is the recommended antipyretic in COVID-19. It can also"/>
   <result pre="report of NSAID use and worsening of COVID-19 severity [3]." exact="Aspirin" post="causes Reye syndrome, and should be avoided in children."/>
   <result pre="supplement to this article (Supplementary Material 1, www.jocmr.org). Hydroxychloroquine/chloroquine and" exact="azithromycin" post="Mechanism of action (MOA) Hydroxychloroquine and chloroquine block entry"/>
   <result pre="Material 1, www.jocmr.org). Hydroxychloroquine/chloroquine and azithromycin Mechanism of action (MOA)" exact="Hydroxychloroquine" post="and chloroquine block entry of the virus into human"/>
   <result pre="www.jocmr.org). Hydroxychloroquine/chloroquine and azithromycin Mechanism of action (MOA) Hydroxychloroquine and" exact="chloroquine" post="block entry of the virus into human cells by"/>
   <result pre="in host cells, along with dissipating cytokine production and inhibition." exact="Azithromycin" post="is an antibacterial macrolide and works through binding to"/>
   <result pre="of subsequent Rho-kinase activation in human airway epithelial cells [22]." exact="Azithromycin" post="was shown to inhibit replication in Zika and Ebola"/>
   <result pre="in Zika and Ebola viruses [23, 24]. Pros and cons" exact="Chloroquine" post="and hydroxychloroquine are relatively well tolerated and has been"/>
   <result pre="and Ebola viruses [23, 24]. Pros and cons Chloroquine and" exact="hydroxychloroquine" post="are relatively well tolerated and has been used for"/>
   <result pre="effects (&amp;lt; 10%), like hypoglycemia, retinopathy, psychiatric effects, QTc prolongation." exact="Azithromycin" post="is a commonly used macrolide for respiratory bacterial infections."/>
   <result pre="bacterial infections. Gautret et al concluded that combination therapy with" exact="azithromycin" post="and hydroxychloroquine cured 100% of patients virologically on day"/>
   <result pre="Gautret et al concluded that combination therapy with azithromycin and" exact="hydroxychloroquine" post="cured 100% of patients virologically on day 6 compared"/>
   <result pre="on day 6 compared to 57.1% in patients treated with" exact="hydroxychloroquine" post="only, and 12.5% in the control group (P ="/>
   <result pre="study among 368 USA veterans found no benefit, rather touted" exact="hydroxychloroquine" post="to be more harmful due to its side effect"/>
   <result pre="to its side effect profile [27]. Proposed dose for COVID-19" exact="Hydroxychloroquine" post="dose most used is 400 mg twice daily orally"/>
   <result pre="400 mg daily orally for a total of 5 days." exact="Chloroquine" post="dose suggested by FDA is 1 g on day"/>
   <result pre="7 days total. Remdesivir MOA Remdesivir, or GS-5734, is an" exact="adenosine" post="monophosphate prodrug that metabolizes to an active C-adenosine nucleoside"/>
   <result pre="are nausea, vomiting, and reversible rise in aspartate aminotransferase and" exact="alanine" post="transaminase. Proposed dose for COVID-19 The current dose under"/>
   <result pre="medications has been used for experimental purposes. Lopinavir/ritonavir MOA The" exact="lopinavir" post="component binds to the site of viral protease activity"/>
   <result pre="results in the formation of immature, noninfectious viral particles. The" exact="ritonavir" post="component inhibits the cytochrome P450 3A (CYP3A) metabolism of"/>
   <result pre="in mind. The most frequently reported reactions in patients receiving" exact="lopinavir" post="therapy are asthenia, diarrhea, and nausea. Elevated total bilirubin,"/>
   <result pre="many of the COVID-19 survivors had chronic heartburn and took" exact="famotidine" post="rather than omeprazole, which is more expensive when he"/>
   <result pre="who recovered and found a slightly higher number in the" exact="famotidine" post="group, but was not high enough to be statistically"/>
   <result pre="effects of immunosuppression could diminish the clinical expression of disease." exact="Tacrolimus" post="and cyclosporine are the most commonly used drugs for"/>
   <result pre="immunosuppression could diminish the clinical expression of disease. Tacrolimus and" exact="cyclosporine" post="are the most commonly used drugs for maintenance immunosuppression"/>
   <result pre="IFN beta-1b, lopinavir/ritonavir, mainly used for the treatment of HIV," exact="ribavirin" post="mainly used in combination with IFN for the treatment"/>
   <result pre="Other drugs under a further investigation like favipiravir costs $1.45/day," exact="hydroxychloroquine" post="$0.08/day, azithromycin $0.10/day, lopinavir/ritonavir $0.39/day. If the repurposed drugs"/>
   <result pre="under a further investigation like favipiravir costs $1.45/day, hydroxychloroquine $0.08/day," exact="azithromycin" post="$0.10/day, lopinavir/ritonavir $0.39/day. If the repurposed drugs demonstrate efficacy"/>
   <result pre="2World Health Organization. https://www.who.int/emergencies/diseases/novel-coronavirus-2019. Accessed on June 1, 2020 3DayMCovid-19:" exact="ibuprofen" post="should not be used for managing symptoms, say doctors"/>
   <result pre="virus inhibitors for drug repurposingACS Infect Dis20151731732610.1021/acsinfecdis.5b0003027622822 25GautretPLagierJCParolaPHoangVTMeddebLMailheMDoudierBet al.Hydroxychloroquine and" exact="azithromycin" post="as a treatment of COVID-19: results of an open-label"/>
   <result pre="arrhythmia risk due to hydroxychloroquine-azithromycin treatment for COVID-19Cardiology2020 27MagagnoliJNarendranSPereiraFCummingsTHardinJWSuttonSSAmbatiJOutcomes of" exact="hydroxychloroquine" post="usage in United States veterans hospitalized with Covid-19medRxiv202010.1101/2020.04.16.20065920 28Food"/>
   <result pre="therapeutic potentials for treatment of immune-related diseasesInt Immunopharmacol20197015616610.1016/j.intimp.2019.02.02630802678 38Kapinska-MrowieckaMTurowskiG[Efficacy of" exact="cimetidine" post="in treatment of Herpes zoster in the first 5"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7296288\results\search\drug\results.xml">
   <result pre="(CDI). A recent Cochrane review emphasized increased symptomatic cure with" exact="vancomycin" post="when compared to metronidazole, fidaxomicin compared to vancomycin, and"/>
   <result pre="emphasized increased symptomatic cure with vancomycin when compared to metronidazole," exact="fidaxomicin" post="compared to vancomycin, and possibly teicoplanin compared to vancomycin"/>
   <result pre="metronidazole, fidaxomicin compared to vancomycin, and possibly teicoplanin compared to" exact="vancomycin" post="[24] in CDI patients. Importantly, no recent studies looked"/>
   <result pre="few stories of success over the yearsâ€&quot;anti-community MRSA armamentarium includes" exact="doxycycline" post="and trimethoprim-sulfamethoxazole, while the new research focuses on testing"/>
   <result pre="class Names and notes Indications Select side effects Comments Aminomethylcyclines" exact="Omadacycline" post="Skin and soft tissue infections, pneumonia caused by Gram-positive"/>
   <result pre="Fragilis, Legionella, and Chlamydia Similar to newer tetracyclines such as" exact="doxycycline" post="In trials for pneumonia treatment mortality rate was higher"/>
   <result pre="treatment of acne vulgaris. Similar to newer tetracyclines such as" exact="doxycycline" post="Tetracyclines Eravacycline Complicated intraabdominal infections have broad-spectrum activity for"/>
   <result pre="acne vulgaris. Similar to newer tetracyclines such as doxycycline Tetracyclines" exact="Eravacycline" post="Complicated intraabdominal infections have broad-spectrum activity for treatment of"/>
   <result pre="treatment of Gram+ and Gramâˆ’ intraabdominal infections Infusion site reaction," exact="tetracycline" post="class adverse reactions Related to tigecycline. Not approved for"/>
   <result pre="Related to tigecycline. Not approved for urinary tract infections Aminoglycoside" exact="Plazomicin" post="Complicated UTI and ventilator-associated pneumonia [28] caused by Gram-negative"/>
   <result pre="non-responsive with multidrug-resistant M. tuberculosis infection only in combination with" exact="bedaquiline" post="and linezolid Hepatotoxicity, myelosuppression, neurotoxicity, QT prolongation, lactic acidosis,"/>
   <result pre="multidrug-resistant M. tuberculosis infection only in combination with bedaquiline and" exact="linezolid" post="Hepatotoxicity, myelosuppression, neurotoxicity, QT prolongation, lactic acidosis, multiple drug-drug"/>
   <result pre="Complicated UTIs caused by Gram-negative organisms Risk of seizures with" exact="meropenem" post="in patients with CNS disorders, reduced valproic acid serum"/>
   <result pre="through Strategic national Stockpile. Unknown efficacy in humans Endonuclease inhibitor" exact="Baloxavir marboxil" post="Influenza up to 48Â h in duration in patients"/>
   <result pre="with antacids, laxatives, or oral supplements Non-nucleoside reverse transcriptase inhibitor" exact="Doravirine" post="Combination therapy for HIV infection Uncommon; immune reconstitution inflammatory"/>
   <result pre="result in fulminant hepatitis, case reports of severe bradycardia when" exact="amiodarone" post="is co-administered; headache Not recommended in patients with moderate"/>
   <result pre="old antibiotics [23, 31] Name Explored new indications Comments Gentamicin," exact="kanamycin" post="N. gonorrhoeae infections Ertapenem N. gonorrhoeae infections Fosfomycin N."/>
   <result pre="Name Explored new indications Comments Gentamicin, kanamycin N. gonorrhoeae infections" exact="Ertapenem" post="N. gonorrhoeae infections Fosfomycin N. gonorrhoeae infections Spectinomycin N."/>
   <result pre="Comments Gentamicin, kanamycin N. gonorrhoeae infections Ertapenem N. gonorrhoeae infections" exact="Fosfomycin" post="N. gonorrhoeae infections Spectinomycin N. gonorrhoeae infections First developed"/>
   <result pre="gonorrhoeae infections Ertapenem N. gonorrhoeae infections Fosfomycin N. gonorrhoeae infections" exact="Spectinomycin" post="N. gonorrhoeae infections First developed in 1960, abandoned after"/>
   <result pre="Ramoplanin Clostridium difficile Not absorbed from oral administration Minocycline MRSA" exact="Mecillinam" post="[32] MDR Enterobacteriaceae Not available in the USA Tetracyclines,"/>
   <result pre="Parkinsonâ€™s disease [33] Exploring anti-inflammatory properties Nebulized antibiotics formulations Amikacin," exact="ciprofloxacin" post="for ventilator-associated pneumonia [28] Currently only colistin, aztreonam, and"/>
   <result pre="ciprofloxacin for ventilator-associated pneumonia [28] Currently only colistin, aztreonam, and" exact="tobramycin" post="improved for use exclusively in patients with cystic fibrosis"/>
   <result pre="ESBL Enterobacteriaceae, and N. gonorrhoeae Cephalosporin/vancomycin heterodimer Cefilavancin Gram-positive pathogens" exact="Ethambutol" post="SQ 109 M. tuberculosis Non-absorbable small molecule antibiotic Ridinilazole"/>
   <result pre="13.Kristen M, Bullard-Feibelman, Jennifer Govero, ZheZhu etc The FDA-approved drug" exact="sofosbuvir" post="inhibits Zika virus infection Antiviral Research Vol. 137. 2017;137:134â€&quot;140"/>
   <result pre="20.FriedmanNDTemkinECarmeliYThe negative impact of antibiotic resistanceClin Microbiol Infect201622541642210.1016/j.cmi.2015.12.00226706614 21.DupontJPratDSztrymfBLinezolid versus" exact="vancomycin" post="in Methicillin Resistant Staphylococcus aureus nosocomial pneumonia in the"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7296524\results\search\drug\results.xml">
   <result pre="of necessary drugs (antihistamine, corticosteroid, and adrenaline) and two available" exact="adrenaline" post="auto-injectors. In children with food allergies (FA), the avoidance"/>
   <result pre="of necessary drugs (antihistamine, corticosteroid, and adrenaline) and two available" exact="adrenaline" post="auto-injectors. The child/adolescent suffering from food allergies must consume"/>
   <result pre="prevalence of 0.07â€&quot;0.7% in children [33]. In the case of" exact="Azithromycin" post="hypersensitivity, an antibiotic of the same class (i.e., clarithromycin)"/>
   <result pre="low grade of cross-reactivity after ascertaining tolerance under medical surveillance." exact="Hydroxychloroquine" post="exposes some patients to the risk of rare but"/>
   <result pre="patients to the risk of rare but potentially fatal SCARs." exact="Azithromycin" post="and Hydroxychloroquine co-treatment can be safely performed after a"/>
   <result pre="the risk of rare but potentially fatal SCARs. Azithromycin and" exact="Hydroxychloroquine" post="co-treatment can be safely performed after a cardiological evaluation"/>
   <result pre="used to identify safe alternative heparin. In patients with assessed" exact="chlorhexidine" post="hypersensitivity, the use of this disinfectant is contraindicated during"/>
   <result pre="disinfectant is contraindicated during the COVID-19 pandemic. Low concentrations of" exact="chlorhexidine" post="should be used to prevent sensitization. Chlorhexidine is used"/>
   <result pre="Low concentrations of chlorhexidine should be used to prevent sensitization." exact="Chlorhexidine" post="is used as disinfectant and antiseptic, but it is"/>
   <result pre="dermatitis can be provoked by its frequent use [35]. Moreover," exact="chlorhexidine" post="can cause immediate systemic reactions such as anaphylaxis [36]."/>
   <result pre="immediate systemic reactions such as anaphylaxis [36]. Higher concentrations of" exact="chlorhexidine" post="irritate the skin and increase the risk of sensitization"/>
   <result pre="health workers during the COVID-19 pandemic, an increased incidence of" exact="Chlorhexidine" post="allergy could develop. The use of low concentrations of"/>
   <result pre="Chlorhexidine allergy could develop. The use of low concentrations of" exact="chlorhexidine" post="(0.5â€&quot;2% weight/volume) is suggested to prevent sensitization. Patients with"/>
   <result pre="unresponsive to 2nd generation H1-antihistamines and omalizumab, ongoing treatment with" exact="cyclosporine" post="A should not be stopped during the COVID-19 pandemic."/>
   <result pre="CSU. However, due to a higher incidence of adverse effects," exact="cyclosporine" post="A is not recommended as a standard treatment in"/>
   <result pre="adolescents with CSU unresponsive to 2nd generation H1-antihistamines and omalizumab," exact="cyclosporine" post="A is suggested as a therapeutic option [38]. Similar"/>
   <result pre="a therapeutic option [38]. Similar to patients undergoing immunosuppressive treatment," exact="cyclosporine" post="A should not be stopped during COVID-19 pandemic and"/>
   <result pre="generation H1-antihistamines and omalizumab, we suggest delaying the beginning of" exact="cyclosporine" post="A treatment consistently with health conditions. Ongoing treatment with"/>
   <result pre="timely evaluation should be carried out on time. Moreover, an" exact="adrenaline" post="auto-injector should be promptly prescribed, and venom immunotherapy (VIT)"/>
   <result pre="[44â€&quot;46]. Thus, the appropriate diagnostic workup, the prescription of an" exact="adrenaline" post="auto-injector, and VITâ€™s performance are critical services, and they"/>
   <result pre="by inhalation spray or powder, anti-leukotriene agents, biological drugs, intramuscular" exact="adrenaline" post="should be administered according to the individual therapeutic plan"/>
   <result pre="the food in question; emergency therapy, self-injectable intramuscular adrenaline, and" exact="salbutamol" post="spray, according to the individual therapeutic plan [82]. During"/>
   <result pre="del Giudice M, Peroni D, et al. focus on the" exact="cetirizine" post="use in clinical practice: a reappraisal 30 years later."/>
   <result pre="Med. 2020; (in press). 13.James L. Olds, Kabbani N. Is" exact="nicotine" post="exposure linked to cardiopulmonary vulnerability to COVID-19 in the"/>
   <result pre="infections: individual participant data meta-analysisHealth Technol Assess20192314410.3310/hta23020 17.VorilhonPArpajouBVaillant RousselHMerlinEPereiraBCabaillotAEfficacy of" exact="vitamin C" post="for the prevention and treatment of upper respiratory tract"/>
   <result pre="Am Acad Dermatol. 2020; (in press). 21.Magdaleno-TapialJMartÃ­nez-DomÃ©nechAValenzuela-OÃ±ateCFerrer-GuillÃ©nBEsteve-MartÃ­nezAZaragoza-NinetVAllergic contact dermatitis to" exact="chlorhexidine" post="in pediatric patientsPediatr Dermatol20193654054110.1111/pde.1380830838689 22.Stone TE, Kunaviktikul W, Omura"/>
   <result pre="Covid-19. N Enl J Med. 2020; (in press). 33.XuPSafety of" exact="azithromycin" post="in pediatrics: a systematic review protocolBMJ Paediatr Open201931e00046910.1136/bmjpo-2019-000469 34.Gonzalez-DelgadoPFernandezJHypersensitivity"/>
   <result pre="Dermatologists guidelines for the safe and effective prescribing of oral" exact="ciclosporin" post="in dermatology 2018Br J Dermatol20181801312133810.1111/bjd.17587 40.collab: British Association of"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7297930\results\search\drug\results.xml">
   <result pre="process called â€œrepurposingâ€� or â€œrepositioningâ€� [2]. Notably, in case reports," exact="hydroxychloroquine" post="(HCQ) has been regarded as an effective regimen reducing"/>
   <result pre="doses of the drug might be administered without documented cardiotoxicities." exact="Atazanavir" post="Mechanisms Using a deep learning-based drug-target interaction model called"/>
   <result pre="cleaving into the working form. In recent in vitro experiments," exact="atazanavir" post="inhibited SARS-CoV-2 replication and pro-inflammatory cytokines [14]. Clinical trials"/>
   <result pre="of CYP3A4 and UGT1A1 and a strong inhibitor of OATP1B1," exact="atazanavir" post="may increase the plasma concentrations of other drugs such"/>
   <result pre="as proton-pump inhibitors, antacids, and H2-receptor antagonists. Statins such as" exact="simvastatin" post="and atorvastatin are also known as CYP3A4 isoenzyme substrates"/>
   <result pre="inhibitors, antacids, and H2-receptor antagonists. Statins such as simvastatin and" exact="atorvastatin" post="are also known as CYP3A4 isoenzyme substrates [16]. Cardiovascular"/>
   <result pre="Cardiovascular Risks Dose-related asymptomatic prolongation in the PR interval with" exact="atazanavir" post="has been observed in clinical studies [17, 18]. It"/>
   <result pre="require dose reductions or avoidance of CYP3A-mediated drugs such as" exact="rivaroxaban" post="and apixaban. Ritonavir/lopinavir can also influence the activity of"/>
   <result pre="results in decreased serum concentrations of the active metabolites of" exact="clopidogrel" post="and prasugrel and increased serum concentrations of ticagrelor. The"/>
   <result pre="CYP450-based interaction with lopinavir/ritonavir is expected. Otherwise, atorvastatin, pravastatin, and" exact="pitavastatin" post="can also be considered at a low starting dose."/>
   <result pre="(THDMS-COVID-19) combining various regimens including protease inhibitors, oseltamivir, favipiravir, and" exact="hydroxychloroquine" post="was initiated to test whether the cocktail formula is"/>
   <result pre="prolongation risk of favipiravir is considered to be low [36]." exact="Ribavirin" post="Mechanisms Similar to remdesivir, ribavirin functions as an RNA-dependent"/>
   <result pre="considered to be low [36]. Ribavirin Mechanisms Similar to remdesivir," exact="ribavirin" post="functions as an RNA-dependent RNA polymerase inhibitor and is"/>
   <result pre="approved for the treatment of RSV and HCV [37]. Although" exact="ribavirin" post="was recommended for COVID-19 treatment according to Chinese guidelines,"/>
   <result pre="to evaluate the therapeutic effects on COVID-19 [25]. Drug Interactions" exact="Ribavirin" post="is metabolized by a reversible phosphorylation pathway or a"/>
   <result pre="potential for P450 enzyme-based interactions. However, case reports showed that" exact="ribavirin" post="has variable effects on warfarin dosing [40]. The detailed"/>
   <result pre="However, case reports showed that ribavirin has variable effects on" exact="warfarin" post="dosing [40]. The detailed mechanism has yet to be"/>
   <result pre="ascariasis, and lymphatic filariasis [42, 43]. Beyond its anti-parasite effects," exact="ivermectin" post="has also been identified as an inhibitor of interactions"/>
   <result pre="response [45]. An in vitro study showed that a single" exact="ivermectin" post="treatment reduced SARS-CoV-2 by 5000-fold at 48Â h in"/>
   <result pre="have been documented in case reports [47, 48]. Immune-Modulating Drugs" exact="Hydroxychloroquine" post="(HCQ; Plaquenil) Mechanisms Hydroxychloroquine has actions, pharmacokinetics, and metabolism"/>
   <result pre="case reports [47, 48]. Immune-Modulating Drugs Hydroxychloroquine (HCQ; Plaquenil) Mechanisms" exact="Hydroxychloroquine" post="has actions, pharmacokinetics, and metabolism similar to those of"/>
   <result pre="Hydroxychloroquine has actions, pharmacokinetics, and metabolism similar to those of" exact="chloroquine" post="[49]. As an anti-malarial and anti-autoimmune agent, by sequestering"/>
   <result pre="France demonstrated a positive effect of HCQ in combination with" exact="azithromycin" post="[5]. Upon this finding, although the US FDA issued"/>
   <result pre="although the US FDA issued an Emergency Use Authorization for" exact="hydroxychloroquine" post="in treating COVID-19, the trial design has been questioned."/>
   <result pre="toxicities including cardiomyopathy and fatal arrhythmia [7, 8]. Drug Interactions" exact="Chloroquine" post="and HCQ undergo CYP-mediated metabolism by CYPs 2C8, 3A4,"/>
   <result pre="as azithromycin, metabolic derangements, and renal failure [55]. Of note," exact="hydroxychloroquine" post="has a long half-life of 40Â days [56]. ECG"/>
   <result pre="published study of 15 patients with COVID-19, tocilizumab combined with" exact="methylprednisolone" post="ameliorated increased CRP and IL-6, but the result was"/>
   <result pre="multiple sclerosis [76]. By structurally resembling the lipid sphingosine-1-phosphate (S1P)," exact="fingolimod" post="can act as a highly potent functional antagonist of"/>
   <result pre="T cells [76]. Similar to the immunomodulatory properties of IFN-I," exact="fingolimod" post="is regarded as a method of treating the SARS-CoV-2"/>
   <result pre="and open-label study is preparing to evaluate the efficacy of" exact="fingolimod" post="for treating COVID-19 [78]. Drug Interactions Fingolimod is primarily"/>
   <result pre="by CYP4F2 [79]. Since few drugs are metabolized by CYP4F2," exact="fingolimod" post="is expected to have a relatively low potential for"/>
   <result pre="and beta-blockers [80]. CYP4F2 genotypes were observed contributing to both" exact="warfarin" post="clearance and sensitivity differences [79]. Cardiovascular Risks Given that"/>
   <result pre="retinal vein occlusion [76, 81]. Conversely, upon its atheroprotective effects," exact="fingolimod" post="diminishes atherosclerosis plaque volume and macrophage and collagen content"/>
   <result pre="kinase (Pak1), a pivotal regulator of channel activity and contractility," exact="fingolimod" post="resists load stress-induced murine hypertrophic remodeling without deterioration of"/>
   <result pre="Anti-viral drugs Â Â Remdesivir A nucleotide prodrug, transforming to" exact="adenosine" post="analogue, causing RNA pre-mature termination and inhibiting viral replication"/>
   <result pre="reported Liver toxicity (rare) 14, 15, 17, 73 Â Â" exact="Atazanavir" post="An analog of the peptide chain substrate binding to"/>
   <result pre="into the working form. Binding to SARS-CoV-2 3C-like proteinase (3CLpro);" exact="Atazanavir" post="inhibits SARS-CoV-2 replication and pro-inflammatory cytokine in vitro experiments"/>
   <result pre="2nd or 3rd degree AVB; lopinavir/ritonavir; decreased serum concentrations of" exact="clopidogrel" post="and prasugrel but increase statins, ticagrelor, rivaroxaban, and apixaban"/>
   <result pre="of clopidogrel and prasugrel but increase statins, ticagrelor, rivaroxaban, and" exact="apixaban" post="Liver toxicity, pancreatitis, GI upset, neurotoxicity 22, 26, 28,"/>
   <result pre="Minimal clinically significant drug interactions Not reported 34â€&quot;38 Â Â" exact="Ribavirin" post="A nucleoside inhibitor, stopping viral RNA synthesis and mRNA"/>
   <result pre="No report of cytochrome P450 enzyme mediated metabolism of ribavirin." exact="Ribavirin" post="has no characterized direct CV toxicity; ribavirin has variable"/>
   <result pre="metabolism of ribavirin. Ribavirin has no characterized direct CV toxicity;" exact="ribavirin" post="has variable effects on warfarin dosing Liver toxicity, hematologic"/>
   <result pre="no characterized direct CV toxicity; ribavirin has variable effects on" exact="warfarin" post="dosing Liver toxicity, hematologic disorder 40, 43, 44 Â"/>
   <result pre="the lymph node T cells As an effective immunology modulator," exact="fingolimod" post="with potentials of anti-SARS-CoV-2 Multiple sclerosis, refractory NCT04280588 Metabolism"/>
   <result pre="Parola P, Hoang VT, Meddeb L, Mailhe M, et al." exact="Hydroxychloroquine" post="and azithromycin as a treatment of COVID-19: results of"/>
   <result pre="Hoang VT, Meddeb L, Mailhe M, et al. Hydroxychloroquine and" exact="azithromycin" post="as a treatment of COVID-19: results of an open-label"/>
   <result pre="Parola P, Meddeb L, Mailhe M, Doudier B, et al." exact="Hydroxychloroquine" post="and azithromycin as a treatment of COVID-19: results of"/>
   <result pre="Meddeb L, Mailhe M, Doudier B, et al. Hydroxychloroquine and" exact="azithromycin" post="as a treatment of COVID-19: results of an open-label"/>
   <result pre="disease 2019 (COVID-19) pandemic. J Am Coll Cardiol. 2020;75:2352â€&quot;71. 7.ChenC-YWangF-LLinC-CChronic" exact="hydroxychloroquine" post="use associated with QT prolongation and refractory ventricular arrhythmiaClin"/>
   <result pre="SM, et al. A prospective evaluation of the effect of" exact="atazanavir" post="on the QTc interval and QTc dispersion in HIV-positive"/>
   <result pre="ME. Prolonged QT interval and torsades de pointes associated with" exact="atazanavir" post="therapy. Clin Infect Dis. 2007;44(6):e67â€&quot;8. 20.FengH-PCaroLFandozziCChuXGuoZTalatyJet al.Pharmacokinetic interactions between"/>
   <result pre="al.Pharmacokinetic interactions between the hepatitis C virus inhibitors elbasvir and" exact="grazoprevir" post="and HIV protease inhibitors ritonavir, atazanavir, lopinavir, and darunavir"/>
   <result pre="Zhu WY, Wang Y, Wang GQ. A systematic review of" exact="lopinavir" post="therapy for SARS coronavirus and MERS coronavirus-a possible reference"/>
   <result pre="hospitalized with severe Covid-19. N Engl J Med. 2020;382:1787â€&quot;99. 25.Lopinavir/Ritonavir," exact="Ribavirin" post="and IFN-beta Combination for nCoV Treatment. 2020;NCT04276688. 26.van der"/>
   <result pre="(COVID-19). 2020;ChiCTR2000029600. 34.Various Combination of Protease Inhibitors, Oseltamivir, Favipiravir, and" exact="Hydroxychloroquine" post="for Treatment of COVID-19 : A Randomized Control Trial"/>
   <result pre="MG, Liang TJ. The application and mechanism of action of" exact="ribavirin" post="in therapy of hepatitis C. Antivir Chem Chemother. 2012;23(1):1â€&quot;12."/>
   <result pre="forms: ribavirin. J Pharm Sci. 2016;105(4):1362â€&quot;9. 40.Schulman S. Inhibition of" exact="warfarin" post="activity by ribavirin. Ann Pharmacother. 2002;36(1):72â€&quot;4. 41.Atif M, Estrada-Mondragon"/>
   <result pre="Nguyen B, Lynch JW, Keramidas A. Effects of glutamate and" exact="ivermectin" post="on single glutamate-gated chloride channels of the parasitic nematode"/>
   <result pre="Diau J, Asugeni R, MacLaren D, et al. Impact of" exact="ivermectin" post="administered for scabies treatment on the prevalence of head"/>
   <result pre="DG, Prospere R, Roberts JM, Lammie PJ. Assessment of combined" exact="ivermectin" post="and albendazole for treatment of intestinal helminth and Wuchereria"/>
   <result pre="JD, Catton MG, Jans DA, Wagstaff KM. The FDA-approved drug" exact="ivermectin" post="inhibits the replication of SARS-CoV-2 in vitro. Antivir Res."/>
   <result pre="Neca J, Soucek P, Havlasova J, et al. Effect of" exact="ivermectin" post="on activities of cytochrome P450 isoenzymes in mouflon (Ovis"/>
   <result pre="Loustaud-Ratti V, Vidal E, Bedane C. Systemic adverse reactions with" exact="ivermectin" post="treatment of scabies. Ann Dermatol Venereol. 2006;133(10):784â€&quot;7. 48.Goa KL,"/>
   <result pre="49.Manic G, Obrist F, Kroemer G, Vitale I, Galluzzi L." exact="Chloroquine" post="and hydroxychloroquine for cancer therapy. Mol Cell Oncol. 2014;1(1):e29911."/>
   <result pre="Obrist F, Kroemer G, Vitale I, Galluzzi L. Chloroquine and" exact="hydroxychloroquine" post="for cancer therapy. Mol Cell Oncol. 2014;1(1):e29911. 50.Schrezenmeier E,"/>
   <result pre="Oncol. 2014;1(1):e29911. 50.Schrezenmeier E, Dorner T. Mechanisms of action of" exact="hydroxychloroquine" post="and chloroquine: implications for rheumatology. Nat Rev Rheumatol. 2020;16(3):155â€&quot;66."/>
   <result pre="Benjannet S, Erickson BR, Rollin PE, Ksiazek TG, et al." exact="Chloroquine" post="is a potent inhibitor of SARS coronavirus infection and"/>
   <result pre="Shokouhi S, Saffaei A. Aminoquinolines against coronavirus disease 2019 (COVID-19):" exact="chloroquine" post="or hydroxychloroquine. Int J Antimicrob Agents. 2020;105945:105945. 54.Colson P,"/>
   <result pre="54.Colson P, Rolain JM, Lagier JC, Brouqui P, Raoult D." exact="Chloroquine" post="and hydroxychloroquine as available weapons to fight COVID-19. Int"/>
   <result pre="Rolain JM, Lagier JC, Brouqui P, Raoult D. Chloroquine and" exact="hydroxychloroquine" post="as available weapons to fight COVID-19. Int J Antimicrob"/>
   <result pre="Kalla M, Yavari A, Mirams GR, Douglas G, et al." exact="Hydroxychloroquine" post="reduces heart rate by modulating the hyperpolarization-activated current If:"/>
   <result pre="56.Tett SE, Cutler DJ, Day RO, Brown KF. Bioavailability of" exact="hydroxychloroquine" post="tablets in healthy volunteers. Br J Clin Pharmacol. 1989;27(6):771â€&quot;9."/>
   <result pre="X, Kivitz AJ, Grange S. Disease-drug-drug interaction involving tocilizumab and" exact="simvastatin" post="in patients with rheumatoid arthritis. Clin Pharmacol Ther. 2011;89(5):735â€&quot;40."/>
   <result pre="novel, first oral therapy for multiple sclerosis: the development of" exact="fingolimod" post="(FTY720, Gilenya)Discov Med2011126421322821955849 77.Rosa SGV, Santos WC. Clinical trials"/>
   <result pre="R, Ferratini M, Toccafondi A, et al. 6-Month effects of" exact="fingolimod" post="on indexes of cardiovascular autonomic control in multiple sclerosis."/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7298161\results\search\drug\results.xml">
   <result pre="SARS-CoV-2 COVID-19 novel coronavirus pneumonia therapeutic drugs anti-SARS-CoV-2 agents favipiravir" exact="hydroxychloroquine" post="traditional Chinese medicine Introduction In December 2019, a new"/>
   <result pre="Emtritabine HIV Reverse transcriptase inhibitor Azvudine HIV Reverse transcriptase inhibitor" exact="Ribavirin" post="HCV RdRpa inhibitor Danorevir HCV HCV protease inhibitor Ganovo"/>
   <result pre="Ganovo HCV HCV protease inhibitor Tenofovir HBV Reverse transcriptase inhibitor" exact="Triazavirin" post="Flu RdRp inhibitor Favipiravir Flu RdRp inhibitor Baloxavir Marboxil"/>
   <result pre="Chloroquineb Malaria Heme biocrystallization inhibitor Suramin Trypanosomes infection Multiple targets" exact="Ruxolitinib" post="Myelofibrosis JAK1/JAK2 signaling inhibition Leflunomide Rheumatoid arthritis Pyrimidine synthesis"/>
   <result pre="Suramin Trypanosomes infection Multiple targets Ruxolitinib Myelofibrosis JAK1/JAK2 signaling inhibition" exact="Leflunomide" post="Rheumatoid arthritis Pyrimidine synthesis inhibitor Tranilast Bronchial asthma, Allergic"/>
   <result pre="Myelofibrosis JAK1/JAK2 signaling inhibition Leflunomide Rheumatoid arthritis Pyrimidine synthesis inhibitor" exact="Tranilast" post="Bronchial asthma, Allergic disorders Hematopoietic prostaglandin D synthase inhibitor"/>
   <result pre="daily Aerosol inhalation Lopinavir/ritonavir 400â€‰mg/100â€‰mg Twice daily Oral â‰¤10 days" exact="Ribavirin" post="500â€‰mg 2â€&quot;3 times daily Intravenous injection â‰¤10 days Combination"/>
   <result pre="times daily Intravenous injection â‰¤10 days Combination with interferon or" exact="lopinavir" post="/ritonavir recommended Chloroquine phosphate 500â€‰mg Twice daily Oral 7"/>
   <result pre="injection â‰¤10 days Combination with interferon or lopinavir /ritonavir recommended" exact="Chloroquine" post="phosphate 500â€‰mg Twice daily Oral 7 days 18â€&quot;65 years"/>
   <result pre="Twice daily Oral 7 days 18â€&quot;65 years old, weight 50â€‰kg" exact="Chloroquine" post="phosphate 500â€‰mg Day 1â€&quot;2 twice daily; Day 3â€&quot;7 once"/>
   <result pre="a protease inhibitor and is usually used in combination with" exact="ritonavir" post="to increase its half-life through the inhibition of cytochrome"/>
   <result pre="shown that lopinavir/ritonavir treatment has no significant effect [26, 27]." exact="Ribavirin" post="Ribavirin is a purine nucleoside analog with a broad-spectrum"/>
   <result pre="that lopinavir/ritonavir treatment has no significant effect [26, 27]. Ribavirin" exact="Ribavirin" post="is a purine nucleoside analog with a broad-spectrum antiviral"/>
   <result pre="[29] and in combination with interferon for hepatitis C [30]." exact="Ribavirin" post="was widely used in 2003 to treat SARS-CoV infection,"/>
   <result pre="effect and caused significant hemolysis in many patients [31â€&quot;34]. When" exact="ribavirin" post="was combined with IFN-Î², it had good antiviral activity"/>
   <result pre="studies have shown that in patients with severe MERS-CoV infection," exact="ribavirin" post="combined with IFN-Î±-2a treatment can significantly improve patient 14-day"/>
   <result pre="14-day survival [36]. Preliminary in vitro test results demonstrate that" exact="ribavirin" post="can inhibit SARS-CoV-2 in a human cell line. In"/>
   <result pre="Protocol for Novel Coronavirus Pneumoniaâ€�, it is recommended to use" exact="ribavirin" post="at a dose of 500â€‰mg each time for adults"/>
   <result pre="The course of treatment does not exceed 10 days [13]." exact="Chloroquine" post="phosphate Chloroquine phosphate is an antimalarial drug that has"/>
   <result pre="of treatment does not exceed 10 days [13]. Chloroquine phosphate" exact="Chloroquine" post="phosphate is an antimalarial drug that has been on"/>
   <result pre="to the ACE2 receptor to mediate SARS-CoV-2 infection [9, 40]." exact="Chloroquine" post="phosphate has been reported to interfere with the glycosylation"/>
   <result pre="of SARS-CoV to cells and achieving therapeutic goals [41]. Therefore," exact="chloroquine" post="phosphate is used to treat COVID-19, and in vitro"/>
   <result pre="used to treat COVID-19, and in vitro experiments show that" exact="chloroquine" post="phosphate does inhibit SARS-CoV-2 and that its EC50 is"/>
   <result pre="EC50 is 1.13â€‰Î¼M [39]. Apart from the above antiviral mechanism," exact="chloroquine" post="phosphate can continue to exert antiviral effects after SARS-CoV-2"/>
   <result pre="has immunomodulatory activity to strengthen the antiviral effect [42]. Therefore," exact="chloroquine" post="phosphate has been included in the â€œDiagnosis and Treatment"/>
   <result pre="Protocol for Novel Coronavirus Pneumoniaâ€� and is undergoing clinical trials." exact="Chloroquine" post="phosphate is used for the treatment of COVID-19 in"/>
   <result pre="56], and the triphosphate form of remdesivir will compete with" exact="adenosine" post="triphosphate, leading to delayed chain termination and inhibiting viral"/>
   <result pre="the study, which will be randomized, double-blind and placebo-controlled [62]." exact="Hydroxychloroquine" post="As a derivative of chloroquine, hydroxychloroquine has similar efficacy"/>
   <result pre="double-blind and placebo-controlled [62]. Hydroxychloroquine As a derivative of chloroquine," exact="hydroxychloroquine" post="has similar efficacy and few adverse reactions. Based on"/>
   <result pre="on its characteristics of immunomodulation, antithrombotic activity, and improved inflammation," exact="hydroxychloroquine" post="has been used in the clinical treatment of systemic"/>
   <result pre="used in the clinical treatment of systemic lupus erythematosus [63]." exact="Hydroxychloroquine" post="has been shown to have anti-SARS-CoV activity in vitro"/>
   <result pre="activity in vitro [64], and it is clinically safer than" exact="chloroquine" post="[65, 66]. Some clinical studies have found that after"/>
   <result pre="hydroxychloroquine, the viral load significantly decreases or even disappears, and" exact="azithromycin" post="can enhance the antiviral effect [67, 68]. Traditional Chinese"/>
   <result pre="SARS: initial virological and clinical findingsThorax200459252614985565 23.KimUJWonE-JKeeS-JJungS-IJangH-CCombination therapy with lopinavir/ritonavir," exact="ribavirin" post="and interferon-Î± for Middle East respiratory syndromeAntivir Ther201621455926492219 24.WuC-YJanJ-TMaS-HKuoC-JJuanH-FChengY-SEet"/>
   <result pre="multiple effects on virus replication and propagation. Molecular basis of" exact="ribavirin" post="resistanceCurr Opin Virol2014810524846716 29.TrangTPWhalenMHilts-HoreczkoADoernbergSBLiuCComparative effectiveness of aerosolized versus oral"/>
   <result pre="ribavirin resistanceCurr Opin Virol2014810524846716 29.TrangTPWhalenMHilts-HoreczkoADoernbergSBLiuCComparative effectiveness of aerosolized versus oral" exact="ribavirin" post="for the treatment of respiratory syncytial virus infections: a"/>
   <result pre="coronavirus infection: a retrospective cohort studyLancet Infect Dis2014141090525278221 37.SavarinoAUse of" exact="chloroquine" post="in viral diseasesLancet Infect Dis201111653421550312 38.SavarinoABoelaertJRCassoneAMajoriGCaudaREffects of chloroquine on"/>
   <result pre="37.SavarinoAUse of chloroquine in viral diseasesLancet Infect Dis201111653421550312 38.SavarinoABoelaertJRCassoneAMajoriGCaudaREffects of" exact="chloroquine" post="on viral infections: an old drug against todayâ€™s diseases?Lancet"/>
   <result pre="old drug against todayâ€™s diseases?Lancet Infect Dis20033722714592603 39.WangMCaoRZhangLYangXLiuJXuMet al.Remdesivir and" exact="chloroquine" post="effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in"/>
   <result pre="cellsJ Infect Dis2015212 Suppl 2S160626038396 63.RainsfordKDParkeALClifford-RashotteMKeanWFTherapy and pharmacological properties of" exact="hydroxychloroquine" post="and chloroquine in treatment of systemic lupus erythematosus, rheumatoid"/>
   <result pre="Dis2015212 Suppl 2S160626038396 63.RainsfordKDParkeALClifford-RashotteMKeanWFTherapy and pharmacological properties of hydroxychloroquine and" exact="chloroquine" post="in treatment of systemic lupus erythematosus, rheumatoid arthritis and"/>
   <result pre="vitro antiviral activity and projection of optimized dosing design of" exact="hydroxychloroquine" post="for the treatment of severe acute respiratory syndrome Coronavirus"/>
   <result pre="Infect Dis 2020;Â pii: ciaa237. 10.1093/cid/ciaa237. 66.MarmorMFKellnerULaiTYYMellesRBMielerWFRecommendations on Screening for" exact="Chloroquine" post="and Hydroxychloroquine Retinopathy (2016 Revision)Ophthalmology201612313869426992838 67.Gautret P, Lagier JC,"/>
   <result pre="2020;Â pii: ciaa237. 10.1093/cid/ciaa237. 66.MarmorMFKellnerULaiTYYMellesRBMielerWFRecommendations on Screening for Chloroquine and" exact="Hydroxychloroquine" post="Retinopathy (2016 Revision)Ophthalmology201612313869426992838 67.Gautret P, Lagier JC, Parola P,"/>
   <result pre="Parola P, Hoang VT, Meddeb L, Mailhe M, et al." exact="Hydroxychloroquine" post="and azithromycin as a treatment of COVID-19: results of"/>
   <result pre="Hoang VT, Meddeb L, Mailhe M, et al. Hydroxychloroquine and" exact="azithromycin" post="as a treatment of COVID-19: results of an open-label"/>
   <result pre="Jiang S, Han S, Yan D, et al. Efficacy of" exact="hydroxychloroquine" post="in patients with COVID-19: results of a randomized clinical"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7300636\results\search\drug\results.xml">
   <result pre="reduction services. The popular press has documented limited availability of" exact="fentanyl" post="and other synthetic opioids due to closings of chemical"/>
   <result pre="effect on their wellbeing. In addition, harm reduction programmes, including" exact="naloxone" post="distribution and syringe exchange, have become increasingly difficult to"/>
   <result pre="70 countries worldwide have introduced syringe exchange programmes [20] and" exact="naloxone" post="has saved tens of thousands of lives in the"/>
   <result pre="consider implementing governmentâ€�supported programmes to purchase and allocate syringes. WHOâ€�endorsed" exact="naloxone" post="distribution and training programmes should be reâ€�considered in contexts"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7300672\results\search\drug\results.xml">
   <result pre="origin of the virus, we then discuss the effect of" exact="ibuprofen" post="and nicotine on the severity of the disease. We"/>
   <result pre="the virus, we then discuss the effect of ibuprofen and" exact="nicotine" post="on the severity of the disease. We highlight the"/>
   <result pre="the existence of more pathogenic cohorts of SARSâ€�CoVâ€�2. COVIDâ€�19 SARSâ€�CoVâ€�2" exact="ibuprofen" post="viral transmission nicotine vitamin D coronavirus coronavirus viral susceptibility"/>
   <result pre="more pathogenic cohorts of SARSâ€�CoVâ€�2. COVIDâ€�19 SARSâ€�CoVâ€�2 ibuprofen viral transmission" exact="nicotine" post="vitamin D coronavirus coronavirus viral susceptibility risk factors fig-count:"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7301781\results\search\drug\results.xml">
   <result pre="changes 34 141 92 19 286 (28.9) Increased smoking and" exact="alcohol" post="Yes 35 101 87 38 261(26.3) No 82 350"/>
   <result pre="an alarm, as isolation might lead to an escalation in" exact="alcohol" post="misuse and probable development of alcohol use disorder in"/>
   <result pre="to an escalation in alcohol misuse and probable development of" exact="alcohol" post="use disorder in high-risk persons during and after the"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7301795\results\search\drug\results.xml">
   <result pre="for 14 days) were started together with antibiotic therapy (intravenous" exact="ceftriaxone" post="2 gr and oral azithromycin 500 mg per day)"/>
   <result pre="together with antibiotic therapy (intravenous ceftriaxone 2 gr and oral" exact="azithromycin" post="500 mg per day) and intravenous methylprednisolone (40 mg"/>
   <result pre="gr and oral azithromycin 500 mg per day) and intravenous" exact="methylprednisolone" post="(40 mg twice daily for 5 days with tapered"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7301903\results\search\drug\results.xml">
   <result pre="beta, gamma, and delta.2 Coronaviruses infecting humans are categorized within" exact="alpha" post="and beta, among which originated two major epidemics: severe"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7302922\results\search\drug\results.xml">
   <result pre="non-infectious virus particles [45, 46]. It has been confirmed that" exact="ritonavir" post="is an active peptidomimetic inhibitor against HIV-1 and HIV-2"/>
   <result pre="concentration of the combining drugs, which increases the adverse reaction." exact="Ribavirin" post="Ribavirin is a synthetic nucleoside antiviral drug with broad-spectrum"/>
   <result pre="of the combining drugs, which increases the adverse reaction. Ribavirin" exact="Ribavirin" post="is a synthetic nucleoside antiviral drug with broad-spectrum antiviral"/>
   <result pre="[43, 51â€&quot;53]. It was recommended that the combined use of" exact="ribavirin" post="and Î±-interferon or lopinavir, 500Â mg/time for adults with"/>
   <result pre="for the reason that the incidence of adverse reactions of" exact="ribavirin" post="is high and the individualized differences are obvious [54]."/>
   <result pre="individualized differences are obvious [54]. Studies on the effect of" exact="ribavirin" post="in vitro showed that ribavirin could reduce viral infection"/>
   <result pre="Studies on the effect of ribavirin in vitro showed that" exact="ribavirin" post="could reduce viral infection [55]. However, the effectiveness and"/>
   <result pre="reduce viral infection [55]. However, the effectiveness and safety of" exact="ribavirin" post="for COVID-19 still need further clinical trials to confirm."/>
   <result pre="of the virus at concentration of 300Â Î¼mol/L [32, 54]." exact="Emtricitabine" post="and Denofovir Alafenamide Emtricitabine is a nucleoside reverse transcriptase"/>
   <result pre="concentration of 300Â Î¼mol/L [32, 54]. Emtricitabine and Denofovir Alafenamide" exact="Emtricitabine" post="is a nucleoside reverse transcriptase inhibitor which is used"/>
   <result pre="[77, 80]. It has been reported that the combination of" exact="emtricitabine" post="and denofovir alafenamide in clinical trial for the treatment"/>
   <result pre="treatment of COVID-19 was applied with great therapeutic effects [32]." exact="Chloroquine" post="Phosphate Chloroquine phosphate is mainly used in the treatment"/>
   <result pre="COVID-19 was applied with great therapeutic effects [32]. Chloroquine Phosphate" exact="Chloroquine" post="phosphate is mainly used in the treatment of malaria"/>
   <result pre="broad-spectrum antiviral effect [84]. Recently, it has been found that" exact="chloroquine" post="phosphate could effectively inhibit the infection of coronavirus at"/>
   <result pre="recommended for antiviral treatment of the COVID-19 as well [88]." exact="Hydroxychloroquine" post="Hydroxychloroquine was developed as an antimalarial drug and has"/>
   <result pre="for antiviral treatment of the COVID-19 as well [88]. Hydroxychloroquine" exact="Hydroxychloroquine" post="was developed as an antimalarial drug and has been"/>
   <result pre="arthritis and lupus erythematosus [89â€&quot;91]. Due to its antiviral activity," exact="hydroxychloroquine" post="has also been used as an adjuvant therapy for"/>
   <result pre="adjuvant therapy for AIDS [92â€&quot;94]. It has been confirmed that" exact="hydroxychloroquine" post="also has therapeutic effect against Ebola virus and dengue"/>
   <result pre="reported that some COVID-19 patients benefited from the treatment with" exact="hydroxychloroquine" post="[96â€&quot;99]. Moreover, its effect for virus elimination could be"/>
   <result pre="Moreover, its effect for virus elimination could be reinforced by" exact="azithromycin" post="[97]. Biological Medicine Interferon Î± Interferon (IFN) is a"/>
   <result pre="2019:2020. 55.FeldJJBernsteinDEYounesZVlierbergheHVLarsenLTatschFFerenciPRibavirin dose management in HCV patients receiving ombitasvir/paritaprevir/ritonavir and" exact="dasabuvir" post="with ribavirinLiver Int20183891571157529377566 56.BlaisingJPolyakSJPÃ©cheurEIArbidol as a broad-spectrum antiviral: an"/>
   <result pre="against MERS-CoV. Nat Commun 2020, 11, (1), 222. 65.WangMCaoRZhangLYangXLiuJXuMShiZHuZZhongWXiaoGRemdesivir and" exact="chloroquine" post="effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in"/>
   <result pre="for the treatment of Plasmodium vivax malariaPLoS One20171211e018737629121061 83.BaruahUKGowthamarajanKRavisankarVKarriVSimhadriPKSinghVOptimisation of" exact="chloroquine" post="phosphate loaded nanostructured lipid carriers using Box-Behnken design and"/>
   <result pre="vitro antiviral activity and projection of optimized dosing design of" exact="hydroxychloroquine" post="for the treatment of severe acute respiratory syndrome coronavirus"/>
   <result pre="respiratory syndrome coronavirus 2 (SARS-CoV-2). Clin Infect Dis 2020. 86.GaoJTianZYangXBreakthrough:" exact="chloroquine" post="phosphate has shown apparent efficacy in treatment of COVID-19"/>
   <result pre="COVID-19 associated pneumonia in clinical studiesBiosci Trends2020141727332074550 87.Expert consensus on" exact="chloroquine" post="phosphate for the treatment of novel coronavirus pneumonia. Zhonghua"/>
   <result pre="Bethesda (MD), 2012. 90.HuCLuLWanJPWenCThe pharmacological mechanisms and therapeutic activities of" exact="hydroxychloroquine" post="in rheumatic and related diseasesCurr Med Chem201724202241224928302011 91.SchrezenmeierEDÃ¶rnerTMechanisms of"/>
   <result pre="rheumatic and related diseasesCurr Med Chem201724202241224928302011 91.SchrezenmeierEDÃ¶rnerTMechanisms of action of" exact="hydroxychloroquine" post="and chloroquine: implications for rheumatologyNat Rev Rheumatol202016315516632034323 92.PlantoneDKoudriavtsevaTCurrent and"/>
   <result pre="implications for rheumatologyNat Rev Rheumatol202016315516632034323 92.PlantoneDKoudriavtsevaTCurrent and future use of" exact="chloroquine" post="and hydroxychloroquine in infectious, immune, neoplastic, and neurological diseases:"/>
   <result pre="rheumatologyNat Rev Rheumatol202016315516632034323 92.PlantoneDKoudriavtsevaTCurrent and future use of chloroquine and" exact="hydroxychloroquine" post="in infectious, immune, neoplastic, and neurological diseases: a mini-reviewClin"/>
   <result pre="94.KhaliliHDastanFDehghan ManshadiSAA case report of hearing loss post use of" exact="hydroxychloroquine" post="in a HIV-infected patientDaru20142212024450358 95.CaoBParnellLADiamondMSMysorekarIUInhibition of autophagy limits vertical"/>
   <result pre="96.Colson P; Rolain JM; Lagier JC; Brouqui P; Raoult D," exact="Chloroquine" post="and hydroxychloroquine as available weapons to fight COVID-19. Int"/>
   <result pre="Rolain JM; Lagier JC; Brouqui P; Raoult D, Chloroquine and" exact="hydroxychloroquine" post="as available weapons to fight COVID-19. Int J Antimicrob"/>
   <result pre="E; La Scola B; Rolain JM; Brouqui P; Raoult D," exact="Hydroxychloroquine" post="and azithromycin as a treatment of COVID-19: results of"/>
   <result pre="Scola B; Rolain JM; Brouqui P; Raoult D, Hydroxychloroquine and" exact="azithromycin" post="as a treatment of COVID-19: results of an open-label"/>
   <result pre="Shokouhi S; Saffaei A, Aminoquinolines against coronavirus disease 2019 (COVID-19):" exact="chloroquine" post="or hydroxychloroquine. Int J Antimicrob Agents 2020, 105945. 100.SnellLMMcGahaTLBrooksDGType"/>
   <result pre="Varicella-Zoster virus. J Virol 2018, 92, (21). 102.LiHSKuokDITCheungMCNgMMTNgKCHuiKPYPeirisJSMChanMCWNichollsJMEffect of interferon" exact="alpha" post="and cyclosporine treatment separately and in combination on Middle"/>
   <result pre="J Virol 2018, 92, (21). 102.LiHSKuokDITCheungMCNgMMTNgKCHuiKPYPeirisJSMChanMCWNichollsJMEffect of interferon alpha and" exact="cyclosporine" post="treatment separately and in combination on Middle East respiratory"/>
   <result pre="in-vitro and ex-vivo culture modelAntivir Res2018155899629772254 103.SnyderBGoebelSKoideFPtakRKalkeriRSynergistic antiviral activity of" exact="sofosbuvir" post="and type-I interferons (Î± and Î²) against Zika virusJ"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7303642\results\search\drug\results.xml">
   <result pre="LLC, Waltham, MA) also found increased overall infection risk with" exact="prednisone" post="&amp;gt;10Â mg/d in patients with rheumatoid arthritis (incidence rate"/>
   <result pre="of stay in oxygen requiring or ventilated patients treated with" exact="dexamethasone" post="6 mg daily for 10 days as compared with"/>
   <result pre="indicates that daily doses of systemic corticosteroids &amp;gt;10 mg of" exact="prednisone" post="equivalent are associated with an increased susceptibility to overall"/>
   <result pre="evidence from a large RCT suggests that the use of" exact="dexamethasone" post="reduces mortality in hospitalized COVID-19 patients. Further data are"/>
   <result pre="complications of systemic corticosteroid use in the setting of COVID-19." exact="Methotrexate" post="In clinical trials, methotrexate increased infection risk in patients"/>
   <result pre="use in the setting of COVID-19. Methotrexate In clinical trials," exact="methotrexate" post="increased infection risk in patients with rheumatoid arthritis (risk"/>
   <result pre="spondylitis, and scleroderma.20 Robust data for adverse events related to" exact="methotrexate" post="come from a recent clinical trial evaluating the efficacy"/>
   <result pre="from a recent clinical trial evaluating the efficacy of low-dose" exact="methotrexate" post="for the treatment of atherosclerosis in patients with cardiovascular"/>
   <result pre="infections.21 Conclusions A modestly increased risk of infection associated with" exact="methotrexate" post="has been suggested in some studies. Further data are"/>
   <result pre="studies. Further data are needed to understand the impact of" exact="methotrexate" post="on SARS-CoV-2 infection. Antimalarial drugs When used for their"/>
   <result pre="the treatment of SARS-CoV-2 infection. Although inÂ vitro data suggest" exact="chloroquine" post="and hydroxychloroquine both inhibit coronavirus,24,25 available clinical data do"/>
   <result pre="of SARS-CoV-2 infection. Although inÂ vitro data suggest chloroquine and" exact="hydroxychloroquine" post="both inhibit coronavirus,24,25 available clinical data do not suggest"/>
   <result pre="or clinical trial is cautioned against.31 Oral small molecules (azathioprine," exact="mycophenolate mofetil," post="and cyclosporine) Using claims data, Schneeweiss etÂ al32 examined"/>
   <result pre="opportunistic infections in patients with atopic dermatitis. Compared with methotrexate," exact="cyclosporine" post="A had a 58% higher risk of overall infection"/>
   <result pre="(adjusted RR, 1.58; 95% CI, 1.17-2.15). In the same study," exact="azathioprine" post="had double the infection risk (RR, 1.78; 95% CI,"/>
   <result pre="double the infection risk (RR, 1.78; 95% CI, 0.98-3.25), whereas" exact="mycophenolate mofetil" post="tripled the risk (RR, 3.31; 95% CI, 1.94-5.64). A"/>
   <result pre="study comparing patients with systemic lupus erythematosus newly treated with" exact="mycophenolate mofetil" post="or azathioprine found no differences in rates of serious"/>
   <result pre="with systemic lupus erythematosus newly treated with mycophenolate mofetil or" exact="azathioprine" post="found no differences in rates of serious infections.33 Studies"/>
   <result pre="potential in COVID-19 Some authors have suggested the use of" exact="cyclosporine" post="in the treatment of COVID-1937 based on its ability"/>
   <result pre="no ongoing clinical trials in patients with COVID-19. Conclusions Azathioprine," exact="mycophenolate mofetil," post="and cyclosporine A increase the risk of infection relative"/>
   <result pre="trials in patients with COVID-19. Conclusions Azathioprine, mycophenolate mofetil, and" exact="cyclosporine" post="A increase the risk of infection relative to reference"/>
   <result pre="caution and discussion with patients regarding starting or continuing therapy." exact="Apremilast" post="Long-term safety data from open-label extension studies in psoriasis"/>
   <result pre="a low risk of infection associated with the use of" exact="apremilast" post="and, therefore, low potential for harm in COVID-19 infection."/>
   <result pre="regarding Janus kinase (JAK) inhibitors comes from the use of" exact="tofacitinib" post="in rheumatoid arthritis. Analysis of the most recent tofacitinib"/>
   <result pre="of tofacitinib in rheumatoid arthritis. Analysis of the most recent" exact="tofacitinib" post="data from randomized controlled trials and long-term extension studies"/>
   <result pre="and nonselective JAK inhibitors.46, 47, 48 Therapeutic potential in COVID-19" exact="Ruxolitinib" post="(NCT04362137) and baricitinib (NCT04280705) are currently being evaluated in"/>
   <result pre="patients critically ill with COVID-19.10,49 Moreover, unlike tofacitinib, baricitinib and" exact="ruxolitinib" post="have demonstrated antiviral activity via inhibition of receptor-mediated endocytosis"/>
   <result pre="direct antiviral and anti-inflammatory effects in COVID-19, seemingly unique to" exact="ruxolitinib" post="and baricitinib. Taken together, there are insufficient data at"/>
   <result pre="similar overall rates of infections when rituximab is compared with" exact="methotrexate" post="plus placebo.60,61 Long-term observational studies also show that this"/>
   <result pre="8 (1.5) csDMARD MTX: 17 (20) 69 (63) 110 (21)" exact="Hydroxychloroquine" post="8 (9) N/A 0 Hospitalization 14 (16) 39 (35)"/>
   <result pre="systemic steroids should be tapered to daily doses &amp;lt;10Â mg" exact="prednisone" post="equivalent, if safe to do so. b.Patients on recurrent"/>
   <result pre="doses of systemic corticosteroids over high-dose regimens (eg, &amp;lt;20Â mg" exact="prednisone" post="equivalent daily for &amp;lt;2Â weeks); if needed for maintenance"/>
   <result pre="include mucous membrane blistering disorders. d.If possible, use alternatives to" exact="cyclosporine" post="and other agents requiring intensive toxicity/safety monitoring. Patients with"/>
   <result pre="agents (eg, apremilast, antimalarials, and retinoids), and anti-inflammatory medications (eg," exact="tetracycline" post="or macrolide class antibiotics). b.High-dose systemic corticosteroids should be"/>
   <result pre="in patients with newly diagnosed autoimmune diseaseMedicine (Baltimore)925201328529323982055 13GreenbergJ.D.ReedG.KremerJ.M.Association of" exact="methotrexate" post="and tumour necrosis factor antagonists with risk of infectious"/>
   <result pre="a systematic review and meta-analysisCrit Care23120199930917856 20IbrahimA.AhmedM.ConwayR.CareyJ.J.Risk of infection with" exact="methotrexate" post="therapy in inflammatory diseases: a systematic review and meta-analysisJ"/>
   <result pre="vitro antiviral activity and projection of optimized dosing design of" exact="hydroxychloroquine" post="for the treatment of severe acute respiratory syndrome coronavirus"/>
   <result pre="acute respiratory syndrome coronavirus by chloroquineBiochem Biophys Res Commun3231200426426815351731 26PastickK.A.OkaforE.C.WangF.Review:" exact="hydroxychloroquine" post="and chloroquine for treatment of SARS-CoV-2 (COVID-19)Open Forum Infect"/>
   <result pre="syndrome coronavirus by chloroquineBiochem Biophys Res Commun3231200426426815351731 26PastickK.A.OkaforE.C.WangF.Review: hydroxychloroquine and" exact="chloroquine" post="for treatment of SARS-CoV-2 (COVID-19)Open Forum Infect Dis742020ofaa13032363212 27MahevasM.TranV.-T.RoumierM.No"/>
   <result pre="(COVID-19)Open Forum Infect Dis742020ofaa13032363212 27MahevasM.TranV.-T.RoumierM.No evidence of clinical efficacy of" exact="hydroxychloroquine" post="in patients hospitalized for COVID-19 infection with oxygen requirement:"/>
   <result pre="data to emulate a target trial [preprint]medRxiv202010.1101/2020.04.10.20060699 28GelerisJ.SunY.PlattJ.Observational study of" exact="hydroxychloroquine" post="in hospitalized patients with Covid-19N Engl J Med3822520202411241832379955 29MagagnoliJ.NarendranS.PereiraF.Outcomes"/>
   <result pre="in hospitalized patients with Covid-19N Engl J Med3822520202411241832379955 29MagagnoliJ.NarendranS.PereiraF.Outcomes of" exact="hydroxychloroquine" post="usage in United States veterans hospitalized with Covid-19 [preprint]medRxiv202010.1101/2020.04.16.20065920"/>
   <result pre="trialBMJ3692020m184932409561 31US Food and Drug AdministrationFDA cautions against use of" exact="hydroxychloroquine" post="or chloroquine for COVID-19 outside of the hospital setting"/>
   <result pre="Food and Drug AdministrationFDA cautions against use of hydroxychloroquine or" exact="chloroquine" post="for COVID-19 outside of the hospital setting or a"/>
   <result pre="Mofetil Renal Transplantation Study GroupA blinded, randomized clinical trial of" exact="mycophenolate mofetil" post="for the prevention of acute rejection in cadaveric renal"/>
   <result pre="coronavirus replication by cyclophilin inhibitorsViruses5520131250126023698397 40CrowleyJ.ThaÃ§iD.JolyP.Long-term safety and tolerability of" exact="apremilast" post="in patients with psoriasis: pooled safety analysis for â‰¥156"/>
   <result pre="(ESTEEM 1 and 2)J Am Acad Dermatol7722017310317.e128416342 41KavanaughA.GladmanD.D.EdwardsC.J.Long-term experience with" exact="apremilast" post="in patients with psoriatic arthritis: 5-year results from a"/>
   <result pre="PALACE 1â€&quot;3 pooled analysisArthritis Res Ther211201911831077258 42WollenhauptJ.LeeE.-B.CurtisJ.R.Safety and efficacy of" exact="tofacitinib" post="for up to 9.5â€‰years in the treatment of rheumatoid"/>
   <result pre="network meta-analysisClin Ther3812201626282641.e527889300 44StrandV.AhadiehS.DeMasiR.THU0211 Meta-analysis of serious infections with baricitinib," exact="tofacitinib" post="and biologic DMARDs in rheumatoid arthritis [abstract]Ann Rheum Dis76Suppl"/>
   <result pre="naÃ¯ve with active rheumatoid arthritis and an inadequate response to" exact="methotrexate" post="(Study Evaluating Rituximab's Efficacy in MTX iNadequate rEsponders (SERENE))Ann"/>
   <result pre="observational studyArthritis Care Res (Hoboken)71820199931003 64JolyP.Maho-VaillantM.Prost-SquarcioniC.First-line rituximab combined with short-term" exact="prednisone" post="versus prednisone alone for the treatment of pemphigus (Ritux"/>
   <result pre="Care Res (Hoboken)71820199931003 64JolyP.Maho-VaillantM.Prost-SquarcioniC.First-line rituximab combined with short-term prednisone versus" exact="prednisone" post="alone for the treatment of pemphigus (Ritux 3): a"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7305479\results\search\drug\results.xml">
   <result pre="pivaloyloxymethyl group, which may hydrolyze to free pivalate, thus inhibiting" exact="L-carnitine" post="metabolism in cells [17]. The EC50 values for all"/>
   <result pre="uridine (5.00 g, 20.48 mmol) and 4-dimethylaminopyridine (20 mg) in" exact="dried" post="pyridine (35 mL), isobutyric anhydride (10.2 mL, 61.43 mmol)"/>
   <result pre="dissolved in dichloromethane (200 mL), and washed with saturated aqueous" exact="NaHCO3" post="(2 Ã— 150 mL) and brine (150 mL). The"/>
   <result pre="150 mL) and brine (150 mL). The organic phase was" exact="dried" post="with Na2SO4, filtered, and evaporated in a vacuum. The"/>
   <result pre="phase was separated, washed with 5% aqueous NaHSO3 (100 mL)," exact="dried" post="over Na2SO4, filtered, and evaporated to dryness. The residue"/>
   <result pre="in ethyl acetate (30 mL), washed with water (20Â mL)," exact="NaHCO3" post="saturated water (20 mL), and brine (20 mL). The"/>
   <result pre="(20 mL), and brine (20 mL). The organic phase was" exact="dried" post="over Na2SO4, filtered, and evaporated in a vacuum. The"/>
   <result pre="precipitate was filtered off, washed three times (water 5 mL," exact="ethanol" post="2 mL, diethyl ether 5 mL), and dried in"/>
   <result pre="5 mL, ethanol 2 mL, diethyl ether 5 mL), and" exact="dried" post="in a vacuum to yield product (IV) (151 mg,"/>
   <result pre="CO2). MTT solution was removed, slurry was dissolved in 96%" exact="ethyl alcohol," post="and optical densities of solutions were determined at 535"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7305759\results\search\drug\results.xml">
   <result pre="(&amp;gt;1Â Î¼g/mL), elevated prothrombin time, elevation of troponin, increase in" exact="creatine" post="phosphokinase levels, and also acute kidney injury (Guan etÂ"/>
   <result pre="dual treatment, lopinavir/ritonavir dual treatment with interferon beta 1-alpha, and" exact="chloroquine" post="or hydroxychloroquine (paused temporarily due to the concerns raised"/>
   <result pre="lopinavir/ritonavir dual treatment with interferon beta 1-alpha, and chloroquine or" exact="hydroxychloroquine" post="(paused temporarily due to the concerns raised about the"/>
   <result pre="protease inhibitor HCV Favipiravir Avigan Nucleoside analog Broad-spectrum antiviral Lopinavir/ritonavir" exact="Kaletra" post="Protease inhibitorsRitonavir is also a cytochrome P450 and P-gp"/>
   <result pre="fusion inhibition with the targeted membrane Influenza,SARS-CoV Various well-known drugs" exact="Azithromycin" post="Zithromax, Azithrocin, others Inhibition translation of mRNA Macrolide antibiotic"/>
   <result pre="Macrolide antibiotic Carrimycin â€&quot; Inhibition translation of mRNA Macrolide antibiotic" exact="Doxycycline" post="Doxylin, others Inhibition bacterial protein synthesis Tetracycline antibiotic Chloroquine"/>
   <result pre="mRNA Macrolide antibiotic Doxycycline Doxylin, others Inhibition bacterial protein synthesis" exact="Tetracycline" post="antibiotic Chloroquine and hydroxychloroquine Aralen, Plaquenil, Quineprox, others Increase"/>
   <result pre="antibiotic Doxycycline Doxylin, others Inhibition bacterial protein synthesis Tetracycline antibiotic" exact="Chloroquine" post="and hydroxychloroquine Aralen, Plaquenil, Quineprox, others Increase of lysosomal"/>
   <result pre="Doxylin, others Inhibition bacterial protein synthesis Tetracycline antibiotic Chloroquine and" exact="hydroxychloroquine" post="Aralen, Plaquenil, Quineprox, others Increase of lysosomal pH in"/>
   <result pre="type 1 antagonist Hypertension Tetrandrine â€&quot; Calcium channel blocker Hypertension" exact="Spironolactone" post="Aldactone, others Potassium-sparing diuretic Hypertension Bromhexine Bisolvon, others Increasing"/>
   <result pre="Calcium channel blocker Hypertension Spironolactone Aldactone, others Potassium-sparing diuretic Hypertension" exact="Bromhexine" post="Bisolvon, others Increasing lysosomal activity Mucolytic Dornase alfa Pulmozyme"/>
   <result pre="Mucolytic Dornase alfa Pulmozyme Recombinant human deoxyribonuclease I Cystic fibrosis" exact="Dexmedetomidine" post="Precedex Selective alpha-2 adrenoceptor agonist Sedation Fluoxetine Prozac, others"/>
   <result pre="Sedation Fluoxetine Prozac, others Selective serotonin reuptake inhibitor Antidepressant Immunosuppressors" exact="Ruxolitinib" post="Jakafi, Jakavi JAK inhibition Rheumatoid arthritis Tocilizumab Actemra, RoActemra"/>
   <result pre="Prozac, others Selective serotonin reuptake inhibitor Antidepressant Immunosuppressors Ruxolitinib Jakafi," exact="Jakavi" post="JAK inhibition Rheumatoid arthritis Tocilizumab Actemra, RoActemra Interleukin-6 receptor"/>
   <result pre="C5 Paroxysmal nocturnal hemoglobinuria, atypical hemolytic uremic syndrome, neuromyelitis optica" exact="Methylprednisolone" post="Medrol, Meprolone, others Inhibition of proinflammatory cytokine production Inflammation,"/>
   <result pre="Recombinant granulocyte macrophage colony-stimulating factor Non-Hodgkin lymphoma, acute lymphocytic leukemia" exact="Lenalidomide" post="Revlimid Induces tumor cell apoptosis Multiple myeloma P-gp, P-glycoprotein;"/>
   <result pre="al., 2020). As examples of the most common treatment options," exact="chloroquine" post="and hydroxychloroquine, both antimalarial agents with anti-inflammatory and immunomodulatory"/>
   <result pre="a macrolide antibiotic, was found to raise the efficacy of" exact="hydroxychloroquine" post="as a complementary therapy (Gautret etÂ al., 2020). Preclinical"/>
   <result pre="with ritonavir, it is a potent CYP3A4 inhibitor that boosts" exact="lopinavir" post="concentrations, could block the main protease of SARS-CoV-1, and"/>
   <result pre="et al., 2020). Remdesivir, an investigational monophosphoramidate prodrug of an" exact="adenosine" post="analog, was developed between 2014 and 2016 in response"/>
   <result pre="Zika infections (Xu etÂ al., 2016). Another interesting candidate is" exact="chloroquine" post="and its derivatives, which are normally indicated for malaria"/>
   <result pre="Curr.8201610.1371/currents.outbreaks.aa1f2b60e8d43939b43fbd93e1a63a94 CortegianiA.IngogliaG.IppolitoM.GiarratanoA.EinavS.A systematic review on the efficacy and safety of" exact="chloroquine" post="for the treatment of COVID-19J.Â Crit. Care57202027928332173110 De ClercqE.LiG.Approved"/>
   <result pre="discovery: applications to targets and beyondBr. J. Pharmacol.1522007213717549046 GautretP.LagierJ.-C.ParolaP.MeddebL.MailheM.DoudierB.CourjonJ.GiordanengoV.VieiraV.E.DupontH.T.Hydroxychloroquine and" exact="azithromycin" post="as a treatment of COVID-19: results of an open-label"/>
   <result pre="COVID-19 in ItalyJAMA202010.1001/jama.2020.4683 OpreaT.I.BaumanJ.E.BologaC.G.BurandaT.ChigaevA.EdwardsB.S.JarvikJ.W.GreshamH.D.HaynesM.K.HjelleB.Drug repurposing from an academic perspectiveDrug Discov." exact="Today" post="Ther. Strateg.82011616922368688 PatelA.B.VermaA.COVID-19 and angiotensin-converting enzyme inhibitors and angiotensin"/>
   <result pre="cancer using genome-scale metabolic modeling and drug repositioningEBioMedicine42201938639630905848 WangM.CaoR.ZhangL.YangX.LiuJ.XuM.ShiZ.HuZ.ZhongW.XiaoG.Remdesivir and" exact="chloroquine" post="effectively inhibit the recently emerged novel coronavirus (2019-nCoV) inÂ"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7306310\results\search\drug\results.xml">
   <result pre="agents, antiviral drugs such as remdesivir,3 lopinavir/ritonavir,4 the antimalarial agent" exact="hydroxychloroquine" post="in combination with azithromycin,5 and monoclonal antibodies, such the"/>
   <result pre="with severe Covid-19. N Engl J Med.2020;382:1787â€&quot;1799.32187464 5.GautretPLagierJCParolaPet al.Hydroxychloroquine and" exact="azithromycin" post="as a treatment of COVID-19: results of an open-label"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7306646\results\search\drug\results.xml">
   <result pre="neutrophil percentage, platelet count, lymphocyte count, C-reactive protein, aspartate transaminase," exact="creatine" post="kinase, albumin, and fibrinogen values were significantly different between"/>
   <result pre="bilirubin (DBIL), indirect bilirubin (IBIL), albumin (ALB), aspartate transaminase (AST)," exact="alanine" post="transaminase (ALT), creatine kinase (CK), creatine kinase isoenzyme (CK-MB),"/>
   <result pre="bilirubin (IBIL), albumin (ALB), aspartate transaminase (AST), alanine transaminase (ALT)," exact="creatine" post="kinase (CK), creatine kinase isoenzyme (CK-MB), D-dimer, and fibrinogen"/>
   <result pre="(ALB), aspartate transaminase (AST), alanine transaminase (ALT), creatine kinase (CK)," exact="creatine" post="kinase isoenzyme (CK-MB), D-dimer, and fibrinogen (Fib), prothrombin time"/>
   <result pre="are from Ï‡2 or Mann-Whitney U test. ALB albumin, ALT" exact="alanine" post="transaminase, AST aspartate transaminase, BUN blood urea nitrogen, CK"/>
   <result pre="alanine transaminase, AST aspartate transaminase, BUN blood urea nitrogen, CK" exact="creatine" post="kinase, CK-MB creatine kinase isoenzyme, Cr creatinine, CRP C-reactive"/>
   <result pre="aspartate transaminase, BUN blood urea nitrogen, CK creatine kinase, CK-MB" exact="creatine" post="kinase isoenzyme, Cr creatinine, CRP C-reactive protein, DBIL direct"/>
   <result pre="0.003 OR odds ratio, CI confidence interval, ALB albumin, ALT" exact="alanine" post="transaminase, AST aspartate transaminase, BUN blood urea nitrogen, CK"/>
   <result pre="alanine transaminase, AST aspartate transaminase, BUN blood urea nitrogen, CK" exact="creatine" post="kinase, CK-MB creatine kinase isoenzyme, Cr creatinine, CRP C-reactive"/>
   <result pre="aspartate transaminase, BUN blood urea nitrogen, CK creatine kinase, CK-MB" exact="creatine" post="kinase isoenzyme, Cr creatinine, CRP C-reactive protein, DBIL direct"/>
   <result pre="therapy are required. Abbreviations ALB Albumin ALT Alanine transaminase AST" exact="Aspartate" post="transaminase ARDS Acute Respiratory Distress Syndrome AUC Area under"/>
   <result pre="characteristic curve BUN Blood urea nitrogen CI Confidence interval CK" exact="Creatine" post="kinase CK-MB Creatine kinase isoenzyme Cr Creatinine CRP C-reactive"/>
   <result pre="Blood urea nitrogen CI Confidence interval CK Creatine kinase CK-MB" exact="Creatine" post="kinase isoenzyme Cr Creatinine CRP C-reactive protein CT Computed"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7306893\results\search\drug\results.xml">
   <result pre="ChengG, SungJJY. Retrospective comparison of convalescent plasma with continuing high-dose" exact="methylprednisolone" post="treatment in SARS patients. Clinical Microbiology and Infection. 2004."/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7306998\results\search\drug\results.xml">
   <result pre="use as an arterial thromboembolic prophylaxis agent in combination with" exact="aspirin" post="or warfarin.109 Dipyridamole has recently been shown to suppress"/>
   <result pre="arterial thromboembolic prophylaxis agent in combination with aspirin or warfarin.109" exact="Dipyridamole" post="has recently been shown to suppress human neutrophil and"/>
   <result pre="suppress human neutrophil and T-cell activation, upstream of cytokine effectors.58,110" exact="Dipyridamole" post="induces a type I interferon response, which is necessary"/>
   <result pre="vitro by inhibiting a critical viral replication complex.111,112 Administered orally," exact="dipyridamole" post="has a favorable safety profile, and a small clinical"/>
   <result pre="and safety of monoclonal antibody to human tumor necrosis factor" exact="alpha" post="in patients with sepsis syndrome. A randomized, controlled, double-blind,"/>
   <result pre="Engl J Med2014; 370: 2191â€&quot;2200.24835849 99BernardGRWheelerAPRussellJA, et al.The effects of" exact="ibuprofen" post="on the physiology and survival of patients with sepsis."/>
   <result pre="on the physiology and survival of patients with sepsis. The" exact="Ibuprofen" post="in Sepsis Study Group. N Engl J Med1997; 336:"/>
   <result pre="Engl J Med2016; 375: 534â€&quot;544.27232649 105CohenATSpiroTESpyropoulosAC; collab: MAGELLAN Steering Committee." exact="Rivaroxaban" post="for thromboprophylaxis in acutely ill medical patients. N Engl"/>
   <result pre="Inc.122019. 110MacatangayBJCJacksonEKAbebeKZ, et al.A randomized, placebo-controlled, pilot clinical trial of" exact="dipyridamole" post="to decrease HIV-associated chronic inflammation. J Infect Dis2020; 221:"/>
   <result pre="Pharmacother. 1984; 38: 412â€&quot;413.6084526 113LiuXLiZLiuS, et al.Potential therapeutic effects of" exact="dipyridamole" post="in the severely ill patients with COVID-19. Acta Pharm"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7307799\results\search\drug\results.xml">
   <result pre="new to India [8]. Malaria is endemic and antimalarials like" exact="Chloroquine" post="are often started empirically for resistant fever. The same"/>
   <result pre="fever. The same is the case with Macrolide antibiotics like" exact="Azithromycin" post="for lower respiratory tract infections. Unsurprisingly, these two drugs,"/>
   <result pre="norms (white circles) as they stand in queue to buy" exact="alcohol" post="after authorities permitted the opening of liquor stores during"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7307801\results\search\drug\results.xml">
   <result pre="drugs are potential candidates for meeting all the requirements above:" exact="Chloroquine" post="(CH), its analogue Hydroxychloroquine (HCH), and the combination Lopinavir"/>
   <result pre="for meeting all the requirements above: Chloroquine (CH), its analogue" exact="Hydroxychloroquine" post="(HCH), and the combination Lopinavir (LPV) / Ritonavir (RTV)."/>
   <result pre="its analogue Hydroxychloroquine (HCH), and the combination Lopinavir (LPV) /" exact="Ritonavir" post="(RTV). These drugs have been shown to have good"/>
   <result pre="vitro antiviral activity and projection of optimized dosing design of" exact="hydroxychloroquine" post="for the treatment of Severe Acute Respiratory Syndrome Coronavirus"/>
   <result pre="10.5582/bst.2020.0307232281583 31GautretPLagierJCParolaPHoangVTMeddebLSevestreJet al.Clinical and microbiological effect of a combination of" exact="hydroxychloroquine" post="and azithromycin in 80 COVID-19 patients with at least"/>
   <result pre="al.Clinical and microbiological effect of a combination of hydroxychloroquine and" exact="azithromycin" post="in 80 COVID-19 patients with at least a six-day"/>
   <result pre="pilot observational study.Travel Med Infect Dis. 2020;34:101663. 10.1016/j.tmaid.2020.10166332289548 32MehraMRDesaiSSRuschitzkaFPatelANHydroxychloroquine or" exact="chloroquine" post="with or without a macrolide for treatment of COVID-19:"/>
   <result pre="COVID-19: a multinational registry analysis.Lancet. 2020:S0140-6736(20)31180-6.32450107 33MarmorMFKellnerULaiTYMellesRBMielerWFRecommendations on screening for" exact="chloroquine" post="and hydroxychloroquine retinopathy (2016 Revision).Ophthalmology. 2016;123:1386-94. 10.1016/j.ophtha.2016.01.05826992838 34Garcia-CremadesMSolansBPHughesEErnestJPWallenderEAweekaFet al.Optimizing"/>
   <result pre="multinational registry analysis.Lancet. 2020:S0140-6736(20)31180-6.32450107 33MarmorMFKellnerULaiTYMellesRBMielerWFRecommendations on screening for chloroquine and" exact="hydroxychloroquine" post="retinopathy (2016 Revision).Ophthalmology. 2016;123:1386-94. 10.1016/j.ophtha.2016.01.05826992838 34Garcia-CremadesMSolansBPHughesEErnestJPWallenderEAweekaFet al.Optimizing hydroxychloroquine dosing"/>
   <result pre="chloroquine and hydroxychloroquine retinopathy (2016 Revision).Ophthalmology. 2016;123:1386-94. 10.1016/j.ophtha.2016.01.05826992838 34Garcia-CremadesMSolansBPHughesEErnestJPWallenderEAweekaFet al.Optimizing" exact="hydroxychloroquine" post="dosing for patients with COVID-19: An integrative modeling approach"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7307812\results\search\drug\results.xml">
   <result pre="we propose new interventions, including the use of amiodarone, simvastatin," exact="pioglitazone" post="and curcumin. In mild infections (sore throat, cough) we"/>
   <result pre="ARDS but also less likely to die; and ii) administering" exact="methylprednisolone" post="to patients with ARDS was associated with lower risk"/>
   <result pre="statins in ARDS may be explained by their solubility: while" exact="simvastatin" post="is lipid-soluble, rosuvastatin is water-soluble, with important consequences on"/>
   <result pre="before vasopressors they are likely to benefit from administration of" exact="sodium bicarbonate" post="(increments of 100 ml of 8.4% solution). Treatment-wise, after"/>
   <result pre="few antivirals were proposed and tested and among these are" exact="mycophenolic acid," post="cyclosporine at low concentrations, chloroquine; chlorpromazine, loperamide, and lopinavir,"/>
   <result pre="were proposed and tested and among these are mycophenolic acid," exact="cyclosporine" post="at low concentrations, chloroquine; chlorpromazine, loperamide, and lopinavir, found"/>
   <result pre="polymerase inhibitor) as specific treatment for COVID-19; different protocols use" exact="chloroquine" post="(500 mg q 12 h); hydroxychloroquine (200 mg q"/>
   <result pre="COVID-19; different protocols use chloroquine (500 mg q 12 h);" exact="hydroxychloroquine" post="(200 mg q 12 h); lopinavir/ritonavir (400/100 mg every"/>
   <result pre="survival (26). Hence, it has been proposed that the sulphone" exact="dapsone" post="may show efficacy in COVID-19 related ARDS, as the"/>
   <result pre="burst in a variety of therapeutic contexts (27). Efficacy of" exact="Dapsone" post="in the treatment of Pneumocystis pneumonia suggests it will"/>
   <result pre="The haemotoxicity of the drug can be ameliorated with concomitant" exact="cimetidine" post="administration (27,28). Overall, the major clinical manifestations: sore throat,"/>
   <result pre="antiviral response (38) which relies on heme-containing enzymes such as" exact="nitric oxide" post="synthase (detailed below); also increases viral permeation of tissues"/>
   <result pre="depress viral cell entry; however, a combination of two substances," exact="camostat" post="and EST, a cathespsin inhibitor effectively blocked the viral"/>
   <result pre="effective in vitro for SARS, both pre- and post-exposure, are" exact="chloroquine" post="and hydroxychloroquine; since they were extensively studied and shown"/>
   <result pre="extensively studied and shown to exert pleiotropic antiviral actions (58)." exact="Chloroquine" post="is a weakly basic substance and upon entering cells"/>
   <result pre="S protein-induced viral fusion (59), and the PlPro protease (60)" exact="chloroquine" post="can benefit patients with porphirin extravasation (Fig. 2) by"/>
   <result pre="replication, such as the RNA-dependent RNA polymerase (RdRp) inhibited by" exact="ribavirin" post="(which also inhibits viral mRNA capping); the 3C-like protease"/>
   <result pre="main active substances, nigellidine and Î±-Hederin compare positively to either" exact="chloroquine" post="or hydroxychloroquine based on their binding energy with viral"/>
   <result pre="substances, nigellidine and Î±-Hederin compare positively to either chloroquine or" exact="hydroxychloroquine" post="based on their binding energy with viral proteases (68),"/>
   <result pre="induced specific molecules: IFN-Î±, somatic cytochrome c; hepatitis C-associated p44;" exact="pyridoxal" post="kinase; and lysosomal acid lipase (LIPA); IFN-Î², clathrin-like protein,"/>
   <result pre="the S protein entry into host cells. Furthermore, NH4Cl and" exact="chloroquine" post="(also a weak base) impair the glycosylation of ACE2,"/>
   <result pre="process blocked by constituent hydrolaze CH25H, methyl-Î²-cyclodextrin, a cholesterol-sequestering drug," exact="simvastatin" post="and possibly other lipophilic statins. Low pH is affecting"/>
   <result pre="shown with mycobacteria (122) and probably also in SARS-CoV2 infection." exact="Arginine" post="also directly stimulates transcription/translation of the iNOS gene leading"/>
   <result pre="its causes are strongly linked to arginine and ascorbate deficiencies." exact="Arginine" post="is known to improve lymphocyte-based immunity (136). Arginine depletion"/>
   <result pre="ascorbate deficiencies. Arginine is known to improve lymphocyte-based immunity (136)." exact="Arginine" post="depletion due to upregulation of Arg1 in myeloid-derived suppressor"/>
   <result pre="of CD3+ and the proliferation of CD8+ T lymphocytes (138)." exact="Arginine" post="is also critical for B-lymphocyte differentiation; in transgenic mice"/>
   <result pre="spread of vaccinia virus and tanapox virus to neighboring cells." exact="Nitric oxide" post="from arginine directly enhances the stimulation of ascorbic acid"/>
   <result pre="M2 activities, despite the high levels of inflammatory cytokines (82,127,148)." exact="Arginine" post="corrects the pH and its increased extracellular concentration helps"/>
   <result pre="from citrulline in the urea cycle, ~10% is used for" exact="creatine" post="synthesis and 1% for NO generation (133). Pharmacological doses"/>
   <result pre="(155) an effective antiviral regimen is the combination arginine+extended release" exact="vitamin C," post="in doses of 1,000 mg L-arginine and 250-500 mg"/>
   <result pre="calcium/sodium ascorbate (Ester-C) or Cetebe (GSK) or other modified release" exact="vitamin C," post="at least 3 times a day each. We have"/>
   <result pre="is associated with hyper-inflammation in ARDS patients, and administration of" exact="sodium bicarbonate" post="for balancing pH can be limited by electrolyte imbalance"/>
   <result pre="pH can be limited by electrolyte imbalance and/or cardiovascular pathology." exact="Arginine" post="administration can improve pH via the buffering action of"/>
   <result pre="adrenal synthesis of hormones and neurotransmitters including cathecholamines (norepinephrine) and" exact="vasopressin" post="(131), physiological vasopressors which otherwise need to be administered."/>
   <result pre="or thrombomodulin (for vascular integrity) (167). However, patients treated with" exact="vitamin C" post="had a significant benefit in 28-day mortality, transfer from"/>
   <result pre="change color) - chloroquine, amodiaquine, curcumin; for tachycardic, tachyarrhythmic patients" exact="amiodarone" post="400 mg qd for a maximum 7 days; for"/>
   <result pre="7 days; for all patients and especially with high cholesterol," exact="simvastatin" post="for asthma patients, Montelukast and/or fexofenadine or other lipophilic"/>
   <result pre="patients and especially with high cholesterol, simvastatin for asthma patients," exact="Montelukast" post="and/or fexofenadine or other lipophilic antihistaminic and anti- inflammatory,"/>
   <result pre="KT203 (which decrease macrophage activation and pain-inflicting CCXl-2 with allodynia);" exact="rabeprazole" post="for preventing gastritis and for possible antiviral effects; methylprednisolone"/>
   <result pre="allodynia); rabeprazole for preventing gastritis and for possible antiviral effects;" exact="methylprednisolone" post="was shown to be of benefit in COVID-19 (4),"/>
   <result pre="has an advantage in tired or stressed individuals (with high" exact="cortisol" post="and lactate/LDH levels) and by repeated exposure which increases"/>
   <result pre="of Boswellia serrata (400 mg tid) as anti-inflammatory and analgesic;" exact="artemisinin" post="can be a good substitute for chloroquine or amiodarone"/>
   <result pre="anti-inflammatory and analgesic; artemisinin can be a good substitute for" exact="chloroquine" post="or amiodarone in patients with prolonged QT interval, COPD"/>
   <result pre="analgesic; artemisinin can be a good substitute for chloroquine or" exact="amiodarone" post="in patients with prolonged QT interval, COPD or lung"/>
   <result pre="Seattle region - case seriesN Engl J Med38220122022202010.1056/NEJMoa200450032227758 11FarsalinosKNiauraRLe HouezecJBarbouniATsatsakisAKouretasDVantarakisAPoulasKEditorial:" exact="Nicotine" post="and SARS-CoV-2: COVID-19 may be a disease of the"/>
   <result pre="as treatment adjunct in ARDSExp Lung Res46157161202010.1080/01902148.2020.175326632286085 28ColemanMDRhodesLEScottAKVerbovJLFriedmannPSBreckenridgeAMParkBKThe use of" exact="cimetidine" post="to reduce dapsone-dependent methaemoglobinaemia in dermatitis herpetiformis patientsBr J"/>
   <result pre="SARS coronavirus infection and spreadVirol J269200510.1186/1743-422X-2-6916115318 59SamarthSMcGregorKEnergetics based modeling of" exact="hydroxychloroquine" post="and azithromycin binding to the SARS-CoV-2 spike (S)protein -"/>
   <result pre="infection and spreadVirol J269200510.1186/1743-422X-2-6916115318 59SamarthSMcGregorKEnergetics based modeling of hydroxychloroquine and" exact="azithromycin" post="binding to the SARS-CoV-2 spike (S)protein - ACE2 complexChemRxiv2020Preprint."/>
   <result pre="silico structure-based virtual screening approachChemRxiv202010.26434/chemrxiv.12005988 63FaragAWangPBoysINEitsonJOhlsonMBFanWMcDougalMBAhmedMSchogginsJWIdentification of atovaquone, quabain and" exact="mebendazole" post="as FDA approved drugs Tar-geting SARS-CoV-2 (Version 4)2020ChemRxivPreprint 10.26434/chemrxiv.12003930.v4"/>
   <result pre="RanstMInhibition of SARS-coronavirus infection in vitro by S-nitroso-N- acetylpenicillamine, a" exact="nitric oxide" post="donor compoundInternational Journal of Infectious Diseases Int J Infect"/>
   <result pre="SARS with human interferonsLancet362293294200310.1016/S0140-6736(03)13973-612892961 126KarupiahGXieQWBullerRMLNathanCDuarteCMacMickingJDInhibition of viral replication by interferon-Î³-induced" exact="nitric oxide" post="synthaseScience26114451448199310.1126/science.76901567690156 127BurrackKSMorrisonTEThe role of myeloid cell activation and arginine"/>
   <result pre="T-cell functions by human granulocyte arginaseBlood10816271634200610.1182/blood-2006-11-01038916709924 129RackÃ©KWarnkenML-Arginine metabolic pathwaysThe Open" exact="Nitric Oxide" post="Journal29192010https://benthamopen.com/contents/pdf/TONOJ/TONOJ-2-9.pdf10.2174/1875042701002020009 130GournasCPapageorgiouIDiallinasGThe nucleobaseascorbate transporter (NAT) family: Genomics, evolution, structure-function"/>
   <result pre="in young adults: A cross-sectional studyNutr Metab (Lond)9102201210.1186/1743-7075-9-10223158971 133WuGMorrisSMJrArginine metabolism:" exact="Nitric oxide" post="and beyondBiochem J336117199810.1042/bj33600019806879 134ScheitKBauerGSynergistic effects between catalase inhibitors and"/>
   <result pre="beyondBiochem J336117199810.1042/bj33600019806879 134ScheitKBauerGSynergistic effects between catalase inhibitors and modulators of" exact="nitric oxide" post="metabolism on tumor cell apoptosisAnticancer Res3453375350201425275027 135ThomasSRMohrDStockerRNitric oxide inhibits"/>
   <result pre="dietary arginine enhances wound healing in normal but not inducible" exact="nitric oxide" post="synthase knockout miceSurgery128374378200010.1067/msy.2000.10737210923019 137RodriguezPCQuicenoDGOchoaACL-arginine availability regulates T-lymphocyte cell-cycle progressionBlood10915681573200710.1182/blood-2006-06-03185617023580"/>
   <result pre="Radic Biol Med467077200910.1016/j.freeradbiomed.2008.09.03018952164 150KimWYJungJWChoiJCShinJWKimJYSubphenotypes in patients with septic shock receiving" exact="vitamin C," post="hydrocortisone, and thiamine: A retrospective cohort analysisNutrients1111201910.3390/nu11122976 151Grahame HardieDRegulation"/>
   <result pre="Care Med28643648200010.1097/00003246-200003000-0000710752808 160LuikingYCPoezeMDeutzNEArginine infusion in patients with septic shock increases" exact="nitric oxide" post="production without haemodynamic instabilityClin Sci (Lond)1285767201510.1042/CS2014034325036556 161GoughMSMorganMAMMackCMDarlingDCFrasierLMDoolinKPApostolakosMJStewartJCGravesBTArningEet al.The ratio"/>
   <result pre="protects against impaired arteriolar constriction in sepsis by inhibiting inducible" exact="nitric oxide" post="synthase expressionFree Radic Biol Med3712821289200410.1016/j.freeradbiomed.2004.06.02515451067 166WangYLinHLinBWLinJDEffects of different ascorbic"/>
   <result pre="critically ill patients: a meta-analysisAnn Intensive Care958201910.1186/s13613-019-0532-931111241 167FowlerAAIIITruwitJDHiteRDMorrisPEDeWildeCPridayAFisherBThackerLRIINatarajanRBrophyDFet al.Effect of" exact="vitamin C" post="infusion on organ failure and biomarkers of inflammation and"/>
   <result pre="(FACCT study) Conservative administration of fluids Liberal administration of fluids" exact="Simvastatin" post="administration has benefit on 28- and 90-day survival (HARP-2)"/>
   <result pre="mechanism Method and/or software used for testing FDA approved drugs" exact="Hydroxychloroquine" post="and azithromycin (59) Spike (S) Protein - binding motifs"/>
   <result pre="and/or software used for testing FDA approved drugs Hydroxychloroquine and" exact="azithromycin" post="(59) Spike (S) Protein - binding motifs of ACE2"/>
   <result pre="respective protease in KJ/mol cloperastine (-10.4) 3CLpro (PDB ID 6LU7)" exact="vigabatrin" post="(-10.2) methotrexate (-6.9) Remdesivir (-18.6 KJ/mol) Protease Used PyRx"/>
   <result pre="in KJ/mol cloperastine (-10.4) 3CLpro (PDB ID 6LU7) vigabatrin (-10.2)" exact="methotrexate" post="(-6.9) Remdesivir (-18.6 KJ/mol) Protease Used PyRx for loading"/>
   <result pre="Used PyRx for loading and visualising the SDF files for" exact="vigabatrin" post="(-12.1) 6Y84 - main protease with the ligands and"/>
   <result pre="and 6Y84 from PDB goline (-9.0) phenazo- pyridine (-8.4) (64)" exact="Pemirolast" post="(65) Protease; RNA Replicase inhibitor Using COVID-19 Docking Server"/>
   <result pre="Pemirolast (65) Protease; RNA Replicase inhibitor Using COVID-19 Docking Server" exact="Chloroquine" post="(37) Accessory proteins prevents binding of orf1ab, ORF3a, ORF10"/>
   <result pre="by MVD (Molegro Virtual Docker) For 6LU7: Nigellidine -6.29 Kcal/mol;" exact="chloroquine" post="-6.29; OH-chloroquine -5.57; favipiravir -4.23; For 2GTB: Î±-Hederin -6.50"/>
   <result pre="-6.29; OH-chloroquine -5.57; favipiravir -4.23; For 2GTB: Î±-Hederin -6.50 kcal/mol;" exact="chloroquine" post="-6.20; OH-chloroquine -5.51; favipiravir -4.12 (68) Proteases (3CLpro andMpro)"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7307834\results\search\drug\results.xml">
   <result pre="as whole grains, and micronutrients including vitamin A, vitamin D," exact="vitamin C," post="vitamin E, B vitamins, zinc, selenium and iron, as"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7309195\results\search\drug\results.xml">
   <result pre="I/II completed studies Disease or conditions Interventions Colorectal cancer Drug:" exact="Capecitabine" post="and Aflibercept Metastatic breast cancer Drug: Tivozanib (AV-951)â€‰+â€‰paclitaxel Bladder"/>
   <result pre="Colorectal cancer Drug: Capecitabine and Aflibercept Metastatic breast cancer Drug:" exact="Tivozanib" post="(AV-951)â€‰+â€‰paclitaxel Bladder cancer Biological: Vesigenurtaclel-1 (HS-410) Biological: Placebo Biological:"/>
   <result pre="Drug: Carboplatinâ€&quot;Phase 2 Non-small cell lung cancer Drug: Pazopanib Drug:" exact="Paclitaxel" post="Non small lung cancer Drug: Pemetrexed Drug: Cisplatin Drug:"/>
   <result pre="of the study demonstrated that treatment with a â€œcocktailâ€� of" exact="dabrafenib" post="and trametinib, designed to target cancers that have specific"/>
   <result pre="27.Updated data from phase 3 trial of Ibrance (palbocicilib) plus" exact="letrozole" post="in ER+, HER2âˆ’ metastatic breast cancer confirm improvement in"/>
   <result pre="Mar 2020. 28.Taylor-StokesGMitraDWallerJGibsonKMilliganGIyerSTreatment patterns and clinical outcomes among patients receiving" exact="palbociclib" post="in combination with an aromatase inhibitor or fulvestrant for"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7309305\results\search\drug\results.xml">
   <result pre="molecular dynamics simulation and total binding free energy revealed that" exact="Saquinavir" post="and TCM5280805 target the catalytic dyad (His41 and Cys145)"/>
   <result pre="these compounds should be tested experimentally against the SARS-COV-2 as" exact="Saquinavir" post="has been reported to inhibit HIV protease experimentally. Considering"/>
   <result pre="Barton, 2010). This approach was fruitful in the case of" exact="sildenafil" post="for leprosy, erectile dysfunction, and pulmonary hypertension, and multiple"/>
   <result pre="for leprosy, erectile dysfunction, and pulmonary hypertension, and multiple myeloma" exact="thalidomide" post="(Hernandez et al., 2017). Literature mining was carried out"/>
   <result pre="HIV-1 HIV-II HBV HTLV-1 Enfuvirtide DB00109 âœ&quot; X X X" exact="Nelfinavir" post="DB00220 âœ&quot; X X X Indinavir DB00224 âœ&quot; X"/>
   <result pre="âœ&quot; X X X Indinavir DB00224 âœ&quot; X X âœ&quot;" exact="Nevirapine" post="DB00238 âœ&quot; X X X Tenofovirdisoproxil DB00300 âœ&quot; X"/>
   <result pre="âœ&quot; X X X Tenofovirdisoproxil DB00300 âœ&quot; X X X" exact="Zidovudine" post="DB00495 âœ&quot; X X X Ritonavir DB00503 âœ&quot; X"/>
   <result pre="âœ&quot; X X X Zidovudine DB00495 âœ&quot; X X X" exact="Ritonavir" post="DB00503 âœ&quot; X X X Efavirenz DB00625 âœ&quot; X"/>
   <result pre="âœ&quot; X X X Ritonavir DB00503 âœ&quot; X X X" exact="Efavirenz" post="DB00625 âœ&quot; X X X Stavudine DB00649 âœ&quot; X"/>
   <result pre="âœ&quot; X X X Efavirenz DB00625 âœ&quot; X X X" exact="Stavudine" post="DB00649 âœ&quot; X X X Amprenavir DB00701 âœ&quot; âœ&quot;"/>
   <result pre="âœ&quot; âœ&quot; X X Delavirdine DB00705 âœ&quot; X X X" exact="Lamivudine" post="DB00709 âœ&quot; X âœ&quot; X Emtricitabine DB00879 âœ&quot; X"/>
   <result pre="âœ&quot; X X X Lamivudine DB00709 âœ&quot; X âœ&quot; X" exact="Emtricitabine" post="DB00879 âœ&quot; X X X Didanosine DB00900 âœ&quot; X"/>
   <result pre="âœ&quot; X X X Didanosine DB00900 âœ&quot; X X X" exact="Tipranavir" post="DB00932 âœ&quot; X X X Zalcitabine DB00943 âœ&quot; X"/>
   <result pre="âœ&quot; X X X Tipranavir DB00932 âœ&quot; X X X" exact="Zalcitabine" post="DB00943 âœ&quot; X X X Abacavir DB01048 âœ&quot; X"/>
   <result pre="âœ&quot; X X X Zalcitabine DB00943 âœ&quot; X X X" exact="Abacavir" post="DB01048 âœ&quot; X X X Atazanavir DB01072 âœ&quot; X"/>
   <result pre="âœ&quot; X X X Abacavir DB01048 âœ&quot; X X X" exact="Atazanavir" post="DB01072 âœ&quot; X X X Saquinavir DB01232 âœ&quot; X"/>
   <result pre="âœ&quot; X X X Atazanavir DB01072 âœ&quot; X X X" exact="Saquinavir" post="DB01232 âœ&quot; X X X Darunavir DB01264 âœ&quot; âœ&quot;"/>
   <result pre="âœ&quot; X X X Darunavir DB01264 âœ&quot; âœ&quot; X X" exact="Fosamprenavir" post="DB01319 âœ&quot; X X X Lopinavir DB01601 âœ&quot; X"/>
   <result pre="âœ&quot; X X X Maraviroc DB04835 âœ&quot; X X X" exact="Etravirine" post="DB06414 âœ&quot; X X X Raltegravir DB06817 âœ&quot; X"/>
   <result pre="âœ&quot; X X X Dolutegravir DB08930 âœ&quot; X X X" exact="Cobicistat" post="DB09065 âœ&quot; X X X Elvitegravir DB09101 âœ&quot; X"/>
   <result pre="score âˆ’9.09â€‰kcal/mol was reported for the HIV protease inhibitor drug" exact="Saquinavir" post="(Figure 2). This drug has been reported to inhibit"/>
   <result pre="the HIV proteinase enzymes too. In this case, (SARS-COV-2), the" exact="Saquinavir" post="formed six hydrogen bonds, including two with the central"/>
   <result pre="also formed. Thus, we speculate that the clinical testing of" exact="Saquinavir" post="should be done at the earliest. It is also"/>
   <result pre="used against the recent coronavirus. Figure 2. Interaction pattern of" exact="Saquinavir" post="with the SARS-COV-2 proteinase. The left panes show the"/>
   <result pre="Saquinavir with the SARS-COV-2 proteinase. The left panes show the" exact="Saquinavir" post="drug in 2D, while the right panel shows the"/>
   <result pre="in 2D, while the right panel shows the interaction of" exact="Saquinavir" post="with the critical active site residues, including His41 and"/>
   <result pre="by comparing with the experimentally tested compounds showed that the" exact="Saquinavir" post="and TCM5280805 possess a similar scaffold with Myricetrin and"/>
   <result pre="protease target. From the scores it can be seen that" exact="Saquinavir" post="with score 0.40 possesses strong inhibitory effects against the"/>
   <result pre="against the 3CLpro of SARS-COV-2. Recently published results also shortlisted" exact="Saquinavir" post="as a potential candidate, but they only performed 20â€‰ns"/>
   <result pre="given in Table 3, thus these results strongly suggest that" exact="Saquinavir" post="and TCM5280805 should be tested experimentally against the SARS-COV-2"/>
   <result pre="of the entire article stressed the potential inhibitory role of" exact="Saquinavir" post="and TCM5280805, which are based on computer-based virtual drug"/>
   <result pre="addition, the bioactivity of these compounds were predicted which reported" exact="Saquinavir" post="as strong potential inhibitor followed by the others.Binding Free"/>
   <result pre="receptor. Thus, here from all the analyses, we suggest that" exact="Saquinavir" post="and TCM5280805 should be tested experimentally for possible treatment"/>
   <result pre="AlmakhlafiG. A., AlbarrakM. M., MemishZ. A., &amp;amp; AlbarrakA. M. (2014)." exact="Ribavirin" post="and interferon alfa-2a for severe Middle East respiratory syndrome"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7309518\results\search\drug\results.xml">
   <result pre="between COVID-19â€&quot;bearing gangliosides and peripheral nerve glycolipids was addressed. Elevated" exact="Creatine" post="Kinase (&amp;gt;10,000) is reported in 10% of COVID-19â€&quot;infected patients;"/>
   <result pre="have been hypogeusia (in 5.6%), hyposmia (5.1%), and very high" exact="creatine" post="kinase (CK) levels, with myalgia (in 19.3%) indicating potential"/>
   <result pre="targeted cells.15 If benefit is confirmed and safety is established," exact="chloroquine" post="may be of added therapeutic value in future patients"/>
   <result pre="Most autoimmune neuromuscular patients are maintained on steroids, mycophenolate, or" exact="azathioprine" post="while most chronic inflammatory demyelinating polyneuropathy receive monthly IVIg."/>
   <result pre="acute inflammatory demyelinating polyneuropathy AMAN acute motor axonal neuropathy CK" exact="creatine" post="kinase CRP C-reactive protein GBS Guillain-BarrÃ© syndrome ICU intensive"/>
   <result pre="molecular modeling studies reveal a new mechanism of action of" exact="chloroquine" post="and hydroxychloroquine against SARS-CoV-2 infection. Int J Antimicrob Agents202010.1016/j.ijantimicag.2020.105960."/>
   <result pre="studies reveal a new mechanism of action of chloroquine and" exact="hydroxychloroquine" post="against SARS-CoV-2 infection. Int J Antimicrob Agents202010.1016/j.ijantimicag.2020.105960. 16.VaduganathanM, VardenyO,"/>
   <result pre="34.DalakasMC, IllaI, PezeshkpourGH, LaukaitisJP, CohenB, GriffinJMitochondrial myopathy caused by long-term" exact="zidovudine" post="therapy. N Engl J Med1990;332:1098â€&quot;1105. 35.DalakasMCPeripheral neuropathy and antiretroviral"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7310596\results\search\drug\results.xml">
   <result pre="al. and Li et al. have described increased levels of" exact="creatine" post="kinaseâ€&quot;myocardial band (CK-MB), myoglobin, and NT-pro-BNP in COVID patients,"/>
   <result pre="and the potential for pro-arrhythmia. Although data on outcomes with" exact="hydroxychloroquine" post="are not available, it is widely used in hospitals"/>
   <result pre="Society released recently in collaboration with the ACC and AHA," exact="hydroxychloroquine" post="use must be closely monitored in certain patient groups."/>
   <result pre="the known strategies to counter them. Among the treatments employed," exact="chloroquine" post="and hydroxychloroquine, antiretrovirals (lopinavir and ritonavir), ribavarin, remdesivir, corticosteroids,"/>
   <result pre="inhibitors), and immunoglobulin therapy (convalescent plasma) have been prominent [92]." exact="Chloroquine" post="and hydroxychloroquine have been used to treat patients with"/>
   <result pre="immunoglobulin therapy (convalescent plasma) have been prominent [92]. Chloroquine and" exact="hydroxychloroquine" post="have been used to treat patients with COVID-19 in"/>
   <result pre="is useful to monitor [65]. A detailed treatment workflow with" exact="hydroxychloroquine" post="is provided in Fig.Â 3. Lopinavir and ritonavir also"/>
   <result pre="workflow with hydroxychloroquine is provided in Fig.Â 3. Lopinavir and" exact="ritonavir" post="also have the potential to cause QTc prolongation [93]."/>
   <result pre="ritonavir also have the potential to cause QTc prolongation [93]." exact="Ribavirin" post="has the potential to cause hemolytic anemia in high"/>
   <result pre="CV adverse effects of experimental therapies. Fig. 3 Workflow for" exact="hydroxychloroquine" post="therapy in COVID-19 patients Table 3 Treatment modalities used"/>
   <result pre="adverse effects Therapy Rationale in CoVID-19 patients Cardiovascular adverse effects" exact="Chloroquine" post="and hydroxychloroquine 1. Inhibits the viral entry through endosomal"/>
   <result pre="Therapy Rationale in CoVID-19 patients Cardiovascular adverse effects Chloroquine and" exact="hydroxychloroquine" post="1. Inhibits the viral entry through endosomal trafficking 2."/>
   <result pre="ventricular arrhythmias, Torsades de pointe Lopinavir/ritonavir Lopinavir inhibits viral protease" exact="Ritonavir" post="inhibits CYP3A metabolism, increasing the half-life of lopinavir Conduction"/>
   <result pre="viral protease Ritonavir inhibits CYP3A metabolism, increasing the half-life of" exact="lopinavir" post="Conduction abnormalities Remdesivir Viral RNA polymerase inhibitor No serious"/>
   <result pre="Remdesivir Viral RNA polymerase inhibitor No serious cardiac adverse effects" exact="Ribavirin" post="Inhibits viral RNA and DNA replication Hemolytic anemia Corticosteroids"/>
   <result pre="18 May 2020. 66.US FDA. FDA cautions against use of" exact="hydroxychloroquine" post="or chloroquine for COVID-19 outside of the hospital setting"/>
   <result pre="2020. 66.US FDA. FDA cautions against use of hydroxychloroquine or" exact="chloroquine" post="for COVID-19 outside of the hospital setting or a"/>
   <result pre="haemophilia therapies in COVID-19J Thromb Haemost.202010.1111/jth.1484132558075 80.AsakuraHOgawaHPotential of heparin and" exact="nafamostat" post="combination therapy for COVID-19J Thromb Haemost.202010.1111/jth.1485832302456 81.LlitjosJFLeclercMChochoisCMonsallierJMRamakersMAuvrayMet al.High incidence"/>
   <result pre="treatments for coronavirus disease 2019 (COVID-19): a reviewJAMA20203231818241836 93.US FDA." exact="Kaletra" post="prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/021251s046_021906s039lbl.pdf. Accessed 18 May 2020. 94.Al-TawfiqJAAl-HomoudAHMemishZARemdesivir as"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7310912\results\search\drug\results.xml">
   <result pre="to 2019, seven new strains of CoV belong to genus" exact="alpha" post="and beta coronaviruses are being identified to cause human"/>
   <result pre="[18]. In the beginning of epidemics, antiviral treatments such as" exact="lopinavir" post="and ritonavir oseltamivir and ganciclovir along with corticosteroids were"/>
   <result pre="the beginning of epidemics, antiviral treatments such as lopinavir and" exact="ritonavir" post="oseltamivir and ganciclovir along with corticosteroids were used that"/>
   <result pre="epidemics, antiviral treatments such as lopinavir and ritonavir oseltamivir and" exact="ganciclovir" post="along with corticosteroids were used that already were practiced"/>
   <result pre="injury or shock [22]. In addition, antibacterial including moxifloxacin, ceftriaxone," exact="azithromycin" post="and glucocorticoid therapy have been used because vaccine preparation"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7313527\results\search\drug\results.xml">
   <result pre="A number of antiviral drugs such as Ribavirin, Remdesivir, Lopinavir/ritonavir," exact="Azithromycin" post="and Doxycycline have been recommended or are being used"/>
   <result pre="of antiviral drugs such as Ribavirin, Remdesivir, Lopinavir/ritonavir, Azithromycin and" exact="Doxycycline" post="have been recommended or are being used to treat"/>
   <result pre="these drugs, rationale and evidence have been presented to use" exact="chloroquine" post="to treat COVID-19, arguably with certain precautions and criticism."/>
   <result pre="could be useful as a complement to COVID-19 treatment. Keywords" exact="Chloroquine" post="SARS-CoV-2 RNA dependent RNA polymerase Thymoquinone Zinc transporter Pneumocytes"/>
   <result pre="2020; Chen et al., 2020a; Wong and Lee, 2020), (ii)" exact="Ribavirin" post="a nucleoside analogue that inhibits MERS-CoV replication (Falzarano et"/>
   <result pre="RNA polymerase of pathogenic virus (Furuta et al., 2009), (v)" exact="azithromycin" post="and doxycycline - commonly used antibiotics to inhibit viral"/>
   <result pre="of pathogenic virus (Furuta et al., 2009), (v) azithromycin and" exact="doxycycline" post="- commonly used antibiotics to inhibit viral replication and"/>
   <result pre="(Conti et al., 2020). In addition to these treatment strategies," exact="chloroquine" post="and hydroxychloroquine (Fig. 1 ) have been recommended as"/>
   <result pre="al., 2020). In addition to these treatment strategies, chloroquine and" exact="hydroxychloroquine" post="(Fig. 1 ) have been recommended as potential candidates"/>
   <result pre="is sufficient pre-clinical rationale and evidence regarding the effectiveness of" exact="chloroquine" post="for treatment of COVID-19 as well as evidence of"/>
   <result pre="long-time use in clinical practice for other indications.â€� Use of" exact="chloroquine" post="to treat COVID-19 patients in China also showed clinical"/>
   <result pre="also showed clinical and virologic benefit (Gao et al., 2020)." exact="Chloroquine" post="administered transplacentally or via maternal milk was shown to"/>
   <result pre="HCoV-OC43 infection in newborn C57BL/6 mice (Keyaerts et al., 2009)." exact="Chloroquine" post="at a reasonably low concentration (EC90 = 6.90 Î¼M)"/>
   <result pre="cells with standard oral dosing (Wang et al., 2020b). However," exact="hydroxychloroquine" post="having relatively higher potency against SARS-CoV-2 (Colson et al.,"/>
   <result pre="analysing the potential benefits, based on a systematic review, both" exact="chloroquine" post="and hydroxychloroquine were suggested to treat COVID-19 patients with"/>
   <result pre="potential benefits, based on a systematic review, both chloroquine and" exact="hydroxychloroquine" post="were suggested to treat COVID-19 patients with or without"/>
   <result pre="without diabetes (Singh et al., 2020). Fig. 1 Structure of" exact="chloroquine" post="and hydroxychloroquine. Chloroquine was further hypothesized to interfere with"/>
   <result pre="et al., 2020). Fig. 1 Structure of chloroquine and hydroxychloroquine." exact="Chloroquine" post="was further hypothesized to interfere with SARS-CoV-2â€²s abiity to"/>
   <result pre="binding of SARS-CoV-2. Among the other possible mode of protection," exact="chloroquine" post="has been hypothesized to modulate the acidification of endosomes"/>
   <result pre="autophagosome. Through reduction of cellular mitogen-activated protein (MAP) kinase activation," exact="chloroquine" post="may also inhibit virus replication. Moreover, chloroquine could alter"/>
   <result pre="(MAP) kinase activation, chloroquine may also inhibit virus replication. Moreover," exact="chloroquine" post="could alter M protein maturation and interfere with virion"/>
   <result pre="7 Black seed from Nigella sativa: a natural alternative to" exact="Chloroquine" post="Black seed from an annual flowering plant Nigella sativa"/>
   <result pre="extract (Nickavar et al., 2003). Thymoquinone, dithymoquinone (nigellone), thymohydroquinone, and" exact="thymol" post="are considered the main active constituents. Thymoquinone is the"/>
   <result pre="of bioactive components such as nigellimine share structural similarities with" exact="chloroquine" post="and hydroxychloroquine. Fig. 2 Major bioactive terpenes of black"/>
   <result pre="availability of Zn in pneumocytes. Earlier it was proven that" exact="chloroquine" post="can enhance the uptake of Zn by lysosomes -"/>
   <result pre="an in vitro condition, A2780 cells treated with 100â€&quot;300 Î¼M" exact="chloroquine" post="showed increased uptake of ZnCl2 by doubling intracellular Zn"/>
   <result pre="dose dependent manner (Xue et al., 2014). In other words," exact="chloroquine" post="can act as ionophore for Zn to enter in"/>
   <result pre="in Wuhan, China: a descriptive studyLancet (London, England)395202050751310.1016/S0140-6736(20)30211-7 ColsonP.RolainJ.-M.LagierJ.-C.BrouquiP.RaoultD.Chloroquine and" exact="hydroxychloroquine" post="as available weapons to fight COVID-19Int. J. Antimicrob. Agents202010.1016/j.ijantimicag.2020.105932"/>
   <result pre="Agents202010.23812/Editorial-Conti-2 CortegianiA.IngogliaG.IppolitoM.GiarratanoA.EinavS.A systematic review on the efficacy and safety of" exact="chloroquine" post="for the treatment of COVID-19J. Crit. Care202010.1016/j.jcrc.2020.03.005 CousinsR.J.DunnM.A.LeinartA.S.YedinakK.C.DiSilvestroR.A.Coordinate regulation"/>
   <result pre="multiple proteolytic eventsVirology189199227428410.1016/0042-6822(92)90703-r1318604 DevauxC.A.RolainJ.-M.ColsonP.RaoultD.New insights on the antiviral effects of" exact="chloroquine" post="against coronavirus: what to expect for COVID-19?Int. J. Antimicrob."/>
   <result pre="compounds: novel broad-spectrum inhibitors of RNA viral infectionsAntiviral Res.8220099510210.1016/j.antiviral.2009.02.19819428599 GaoJ.TianZ.YangX.Breakthrough:" exact="chloroquine" post="phosphate has shown apparent efficacy in treatment of COVID-19"/>
   <result pre="of viral RNA-dependent RNA polymeraseJ. Virol.20179110.1128/JVI.00754-17 KeyaertsE.LiS.VijgenL.RysmanE.VerbeeckJ.Van RanstM.MaesP.Antiviral activity of" exact="chloroquine" post="against human coronavirus OC43 infection in newborn miceAntimicrob. Agents"/>
   <result pre="Chromatogr.2620121157116210.1002/bmc.267122290690 LiuzziJ.P.YooC.Role of zinc in the regulation of autophagy during" exact="ethanol" post="exposure in human hepatoma cellsBiol. Trace Elem. Res.156201335035610.1007/s12011-013-9816-324061963 LubkeT.LobelP.SleatD.E.Proteomics"/>
   <result pre="of altered resistance to infectionAm. J. Clin. Nutr.681998447S463S9701160 SinghA.K.SinghA.ShaikhA.SinghR.MisraA.Chloroquine and" exact="hydroxychloroquine" post="in the treatment of COVID-19 with or without diabetes:"/>
   <result pre="replication of these viruses in cell culturePLoS Pathog.62010e100117610.1371/journal.ppat.100117621079686 TouretF.de LamballerieX.Of" exact="chloroquine" post="and COVID-19Antiviral Res.177202010476210.1016/j.antiviral.2020.10476232147496 UchideN.OhyamaK.BesshoT.YuanB.YamakawaT.Effect of antioxidants on apoptosis induced"/>
   <result pre="and prognostic factors based on 4-week follow-upJ. Infect.202010.1016/j.jinf.2020.03.019 WangM.CaoR.ZhangL.YangX.LiuJ.XuM.ShiZ.HuZ.ZhongW.XiaoG.Remdesivir and" exact="chloroquine" post="effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in"/>
   <result pre="vitro antiviral activity and projection of optimized dosing design of" exact="hydroxychloroquine" post="for the treatment of severe acute respiratory syndrome coronavirus"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7313828\results\search\drug\results.xml">
   <result pre="household contacts. Viruses2020; 12(2):171.. 19.CoreyL, WaldA, PatelR, et al.; collab:" exact="Valacyclovir" post="HSV Transmission Study GroupOnce-daily valacyclovir to reduce the risk"/>
   <result pre="WaldA, PatelR, et al.; collab: Valacyclovir HSV Transmission Study GroupOnce-daily" exact="valacyclovir" post="to reduce the risk of transmission of genital herpes."/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7314063\results\search\drug\results.xml">
   <result pre="response includes AngII activation.10,18 Active AngII inhibits the production of" exact="nitric oxide" post="(NO), which results in a marked inflammatory reaction.19 Absence"/>
   <result pre="ideally prevent viral uptake and replication, while preserving ACE2 functions." exact="Chloroquine" post="The antiviral mechanism by which chloroquine exerts its action"/>
   <result pre="while preserving ACE2 functions. Chloroquine The antiviral mechanism by which" exact="chloroquine" post="exerts its action is by disruption of the glycosylation"/>
   <result pre="to ACE2 will be impeded. Vincent et al. found that" exact="chloroquine" post="was effective in preventing or diminishing viral uptake shortly"/>
   <result pre="treatment with chloroquine. As soon as the host is infected," exact="chloroquine" post="might prevent replication. Wang et al. showed that SARS-CoV"/>
   <result pre="assumed to be cured.33 Therefore, it might be postulated that" exact="chloroquine" post="appears to be unsuitable for the treatment of a"/>
   <result pre="equilibrium, due to the gycosylation on ACE2. Therefore, research on" exact="chloroquine" post="as a preventive treatment option should be inititated before"/>
   <result pre="be inititated before it can be introduced and indeed several" exact="chloroquine" post="prevention trials in healthcare personnel have already been started."/>
   <result pre="Laboratorio Elea S.A.C.I.F. y A. Clinical trial, open label, randomized" exact="Telmisartan" post="80 mg t.d. Standard care Hospitalized Proven SARS-CoV-2 infection"/>
   <result pre="351 Yes NCT04356495 University Hospital, Bordeaux Multicentre, open label, randomized" exact="Telmisartan" post="20 mg o.d. Vitamin complex Non-hospitalized Proven SARS-CoV-2 infection"/>
   <result pre="LiuC, ZhengJ, YangR.Engineering a nanolab for the determination of lysosomal" exact="nitric oxide" post="by the rational design of a pH-activatable fluorescent probe."/>
   <result pre="probe. Chem Sci2016;7:1920â€&quot;1925.29899916 25AkerstromS, GunalanV, KengCT, TanYJ, MirazimiA.Dual effect of" exact="nitric oxide" post="on SARS-CoV replication: viral RNA production and palmitoylation of"/>
   <result pre="the S protein are affected. Virology2009;395:1â€&quot;9.19800091 26NiedbalaW, CaiB, LiewFY.Role of" exact="nitric oxide" post="in the regulation of T cell functions. Ann Rheum"/>
   <result pre="Suppl 3:iii37â€&quot;iii40.17038470 27SafariT, NematbakhshM.Role of angiotensin type 2 receptor on" exact="nitric oxide" post="production response to angiotensin II administration in ovariectomised rats"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7314230\results\search\drug\results.xml">
   <result pre="increased ACE2 expression in rat myocardial tissue after 12â€‰days of" exact="lisinopril" post="and losartan, similar to the findings of Ocaranza et"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7315394\results\search\drug\results.xml">
   <result pre="in the subfamily Coronaviridae. CoVs are divided into four genera:" exact="alpha" post="(Î±), beta (Î²), gamma (Î³), and delta (Î´) (Figure"/>
   <result pre="of 10-30â€‰Î¼M [128]. Chloroquine, also a small molecule, is a" exact="quinine" post="analog used to prevent and treat malaria. Similar to"/>
   <result pre="analog used to prevent and treat malaria. Similar to umifenovir," exact="chloroquine" post="exhibits its inhibitory effect on influenza by pH stabilization."/>
   <result pre="chloroquine exhibits its inhibitory effect on influenza by pH stabilization." exact="Chloroquine" post="is a weak base and becomes protonated intracellularly in"/>
   <result pre="It can raise lysosomal pH to facilitate autophagy intracellularly [130â€&quot;132]." exact="Chloroquine" post="also alters the signaling pathway of enzymes, causing enzyme"/>
   <result pre="in host cells [133, 134]. Liu et al. claimed that" exact="chloroquine" post="could inhibit SARS-CoV entry by changing glycosylation of the"/>
   <result pre="vitro on primate cells and human rectal cells [136, 137]." exact="Hydroxychloroquine" post="is a derivative of chloroquine with an additional hydroxyl"/>
   <result pre="human rectal cells [136, 137]. Hydroxychloroquine is a derivative of" exact="chloroquine" post="with an additional hydroxyl group. These two chloroquines share"/>
   <result pre="Both have shown in vitro antiviral activities toward 2019-nCoV [138â€&quot;140]." exact="Hydroxychloroquine" post="was more effective than chloroquine in inhibiting 2019-nCoV in"/>
   <result pre="antiviral activities toward 2019-nCoV [138â€&quot;140]. Hydroxychloroquine was more effective than" exact="chloroquine" post="in inhibiting 2019-nCoV in vitro on primate cells [141]."/>
   <result pre="inhibiting 2019-nCoV in vitro on primate cells [141]. Until now," exact="chloroquine" post="has shown apparent efficiency and safety against 2019-nCoV in"/>
   <result pre="against 2019-nCoV in clinical trials conducted in China [139]. Currently," exact="chloroquine" post="or hydroxychloroquine has been administered to hospitalized 2019-nCoV patients"/>
   <result pre="in clinical trials conducted in China [139]. Currently, chloroquine or" exact="hydroxychloroquine" post="has been administered to hospitalized 2019-nCoV patients on an"/>
   <result pre="and the USA [42]. However, it must be noted that" exact="chloroquine" post="and hydroxychloroquine cause ocular toxicity [142]. Hydroxychloroquine is reportedly"/>
   <result pre="USA [42]. However, it must be noted that chloroquine and" exact="hydroxychloroquine" post="cause ocular toxicity [142]. Hydroxychloroquine is reportedly less toxic"/>
   <result pre="be noted that chloroquine and hydroxychloroquine cause ocular toxicity [142]." exact="Hydroxychloroquine" post="is reportedly less toxic than chloroquine, making it more"/>
   <result pre="In vivo studies on rats with pancreatic fibrosis showed that" exact="camostat" post="mesylate inhibits inflammation, cytokine expression, and fibrosis in the"/>
   <result pre="the viral MERS-CoV particle [156]. Zhou et al. claimed that" exact="camostat" post="mesylate displays an inhibitory effect in mice for SARS-CoV"/>
   <result pre="treatment [113]. Unfortunately, in vitro and in vivo data for" exact="camostat" post="mesylate against coronaviruses are limited. More investigation is required"/>
   <result pre="against coronaviruses are limited. More investigation is required to evaluate" exact="camostat" post="mesylate as a potential therapeutic against COVID-19. Lopinavir-ritonavir is"/>
   <result pre="a coformulated antiretroviral drug with excellent efficacy against HIV-1. The" exact="lopinavir" post="has a core molecular structure identical to ritonavir. The"/>
   <result pre="to ritonavir. The 5-thiazolyl end group and 2-isopropylthiazolyl group in" exact="ritonavir" post="are replaced by the phenoxyacetyl group and a modified"/>
   <result pre="the amino terminus has six-membered cyclic urea attached. In brief," exact="lopinavir" post="is a potent protease inhibitor developed from ritonavir with"/>
   <result pre="In brief, lopinavir is a potent protease inhibitor developed from" exact="ritonavir" post="with high specificity for HIV-1 protease [103]. It represents"/>
   <result pre="the production of noncontagious viral particles. On the other hand," exact="ritonavir" post="binds to HIV-1 protease, interrupting the maturation and production"/>
   <result pre="Hong Kong has shown that the combination of lopinavir-ritonavir and" exact="ribavirin" post="treatment for 152 patients against SARS-CoV had an overall"/>
   <result pre="attractive therapeutic target to prevent host cells from producing viruses." exact="Ribavirin" post="is a synthetic guanosine nucleoside analog that mimics purines,"/>
   <result pre="nucleoside analog that mimics purines, including inosine and adenosine, and" exact="ribavirin" post="has been used in the treatment of respiratory syncytial"/>
   <result pre="at the heterocyclic base, compared with guanine's two rings. Notably," exact="ribavirin" post="has a ribose sugar moiety with a hydroxyl group"/>
   <result pre="2â€²-carbon position, enabling preferential activity in RNA-related metabolism [168, 169]." exact="Ribavirin" post="inhibits cellular enzyme and inosine monophosphate dehydrogenase involved in"/>
   <result pre="inosine monophosphate dehydrogenase involved in purine nucleotide biosynthesis [170, 171]." exact="Ribavirin" post="is also known for its inhibitory effect on viruses"/>
   <result pre="catastrophically error-prone. It is likely that as a nucleoside analog," exact="ribavirin" post="is incorporated by RdRp into the newly synthesized viral"/>
   <result pre="synthesized viral genome, where it induces mutagenesis [170, 172]. Although" exact="ribavirin" post="has proven effective against viral infections, its mechanism of"/>
   <result pre="proposed mechanisms of action that require further validation [168, 173]." exact="Ribavirin" post="was initially used in treating SARS; however, ribavirin treatment"/>
   <result pre="[168, 173]. Ribavirin was initially used in treating SARS; however," exact="ribavirin" post="treatment lacked an in vitro antiviral effect and caused"/>
   <result pre="effects including anemia, hypoxemia, and decreased hemoglobin levels [174]. However," exact="ribavirin" post="was used as the primary treatment during the MERS"/>
   <result pre="during the MERS outbreak [175]. In general, clinical studies of" exact="ribavirin" post="treatment for SARS and MERS did not show strong"/>
   <result pre="studies of ribavirin's efficacy against COVID-19. Therefore, the use of" exact="ribavirin" post="remains controversial and requires more investigation for a better"/>
   <result pre="in which it shares the same carboxamide moiety [180]. While" exact="ribavirin" post="interacts with the viral polymerase directly, favipiravir must be"/>
   <result pre="and safety in 2019-nCoV treatment. Remdesivir is a trial synthetic" exact="adenosine" post="analog that has not yet been clinically approved [185]."/>
   <result pre="therapeutic efficacy against coronavirus outbreaks, umifenovir, chloroquine, hydroxychloroquine, lopinavir-ritonavir, and" exact="ribavirin" post="have been recommended in the latest guidelines for diagnosis"/>
   <result pre="as a possible treatment for COVID-19. On the other hand," exact="ivermectin" post="is originally a medication used to treat parasite infestation."/>
   <result pre="nuclear protein import cycle [196]. Caly et al. reported that" exact="ivermectin" post="successfully inhibited 2019-nCoV in vitro but the mechanism of"/>
   <result pre="vitro but the mechanism of action is unclear [197]. Since" exact="ivermectin" post="is an approved drug, it shows great potential as"/>
   <result pre="reported that the Smabucus Formosana Nakai (a traditional medicinal herb)" exact="ethanol" post="stem extract displayed strong anti-HCoV-NL63 activity [227]. Moreover, TCM"/>
   <result pre="coronavirus disease 2019 (COVID-19)Drug Discoveries &amp;amp; Therapeutics2020141586010.5582/ddt.2020.0101232147628 129SavarinoA.BoelaertJ. R.CassoneA.MajoriG.CaudaR.Effects of" exact="chloroquine" post="on viral infections: an old drug against today's diseasesThe"/>
   <result pre="mouse peritoneal macrophagesJournal of Cell Biology198190366566910.1083/jcb.90.3.6656169733 131SchrezenmeierE.DÃ¶rnerT.Mechanisms of action of" exact="hydroxychloroquine" post="and chloroquine: implications for rheumatologyNature Reviews Rheumatology202016315516610.1038/s41584-020-0372-x32034323 132MautheM.OrhonI.RocchiC.et al.Chloroquine"/>
   <result pre="coronavirus by chloroquineBiochemical and Biophysical Research Communications2004323126426810.1016/j.bbrc.2004.08.08515351731 138WangM.CaoR.ZhangL.et al.Remdesivir and" exact="chloroquine" post="effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in"/>
   <result pre="the recently emerged novel coronavirus (2019-nCoV) in vitroCell Research202030326927110.1038/s41422-020-0282-032020029 139GaoJ.TianZ.YangX.Breakthrough:" exact="chloroquine" post="phosphate has shown apparent efficacy in treatment of COVID-19"/>
   <result pre="of COVID-19 associated pneumonia in clinical studiesBioScience Trends2020141727310.5582/bst.2020.0104732074550 140ColsonP.RolainJ.-M.LagierJ.-C.BrouquiP.RaoultD.Chloroquine and" exact="hydroxychloroquine" post="as available weapons to fight COVID-19International Journal of Antimicrobial"/>
   <result pre="vitro antiviral activity and projection of optimized dosing design of" exact="hydroxychloroquine" post="for the treatment of severe acute respiratory syndrome coronavirus"/>
   <result pre="2 (SARS-CoV-2)Clinical Infectious Diseases202010.1093/cid/ciaa237 142PasadhikaS.FishmanG. A.Effects of chronic exposure to" exact="hydroxychloroquine" post="or chloroquine on inner retinal structuresEye201024234034610.1038/eye.2009.6519373270 143McChesneyE. W.Animal toxicity"/>
   <result pre="Infectious Diseases202010.1093/cid/ciaa237 142PasadhikaS.FishmanG. A.Effects of chronic exposure to hydroxychloroquine or" exact="chloroquine" post="on inner retinal structuresEye201024234034610.1038/eye.2009.6519373270 143McChesneyE. W.Animal toxicity and pharmacokinetics"/>
   <result pre="on inner retinal structuresEye201024234034610.1038/eye.2009.6519373270 143McChesneyE. W.Animal toxicity and pharmacokinetics of" exact="hydroxychloroquine" post="sulfateThe American Journal of Medicine1983751111810.1016/0002-9343(83)91265-26408923 144KonvalinkaJ.KrÃ¤usslichH.-G.MÃ¼llerB.Retroviral proteases and their"/>
   <result pre="al.Protease inhibitors targeting coronavirus and filovirus entryAntiviral Research2015116768410.1016/j.antiviral.2015.01.01125666761 153AshizawaN.HashimotoT.MiyakeT.ShizukuT.ImaokaT.KinoshitaY.Efficacy of" exact="camostat" post="mesilate compared with famotidine for treatment of functional dyspepsia:"/>
   <result pre="and filovirus entryAntiviral Research2015116768410.1016/j.antiviral.2015.01.01125666761 153AshizawaN.HashimotoT.MiyakeT.ShizukuT.ImaokaT.KinoshitaY.Efficacy of camostat mesilate compared with" exact="famotidine" post="for treatment of functional dyspepsia: is camostat mesilate effective?Journal"/>
   <result pre="mesilate compared with famotidine for treatment of functional dyspepsia: is" exact="camostat" post="mesilate effective?Journal of Gastroenterology and Hepatology200621476777110.1111/j.1440-1746.2005.04041.x16677167 154GiboJ.ItoT.KawabeK.et al.Camostat mesilate"/>
   <result pre="and pancreatic stellate cells activityLaboratory Investigation2005851758910.1038/labinvest.370020315531908 155IshikuraH.NishimuraS.MatsunamiM.et al.The proteinase inhibitor" exact="camostat" post="mesilate suppresses pancreatic pain in rodentsLife Sciences200780211999200410.1016/j.lfs.2007.02.04417433371 156ShiratoK.KawaseM.MatsuyamaS.Middle East"/>
   <result pre="Medicine20203821787179910.1056/NEJMoa200128232187464 162ChenJ.LiangZ.WangW.YiC.ZhangS.ZhangQ.Revealing origin of decrease in potency of darunavir and" exact="amprenavir" post="against HIV-2 relative to HIV-1 protease by molecular dynamics"/>
   <result pre="America201411133122341223910.1073/pnas.140002711125092296 164LinS.ShenR.HeJ.LiX.GuoX.Molecular modeling evaluation of the binding effect of ritonavir," exact="lopinavir" post="and darunavir to severe acute respiratory syndrome coronavirus 2"/>
   <result pre="Virology202092669369710.1002/jmv.2576132167173 168ThomasE.GhanyM. G.LiangT. J.The application and mechanism of action of" exact="ribavirin" post="in therapy of hepatitis CAntiviral Chemistry and Chemotherapy201223111210.3851/IMP212522592135 169CrottyS.MaagD.ArnoldJ."/>
   <result pre="CAntiviral Chemistry and Chemotherapy201223111210.3851/IMP212522592135 169CrottyS.MaagD.ArnoldJ. J.et al.The broad-spectrum antiviral ribonucleoside" exact="ribavirin" post="is an RNA virus mutagenNature Medicine20006121375137910.1038/82191 170DulinD.ArnoldJ. J.van LaarT.et"/>
   <result pre="United States of America200198126895690010.1073/pnas.11108559811371613 173TeH. S.RandallG.JensenD. M.Mechanism of action of" exact="ribavirin" post="in the treatment of chronic hepatitis CGastroenterology &amp;amp; Hepatology20073321822521960835"/>
   <result pre="dengue virusBiochemical Journal2012443385185610.1042/BJ2012015022417684 197CalyL.DruceJ. D.CattonM. G.JansD. A.WagstaffK. M.The FDA-approved drug" exact="ivermectin" post="inhibits the replication of SARS-CoV-2 in vitroAntiviral Research2020178, article"/>
   <result pre="Clinical Virology200841212212810.1016/j.jcv.2007.10.01118036887 227WengJ.-R.LinC. S.LaiH. C.et al.Antiviral activity of Sambucus FormosanaNakai" exact="ethanol" post="extract and related phenolic acid constituents against human coronavirus"/>
   <result pre="with favipiravir (see favipiravir) Currently being evaluated in China Chloroquine," exact="hydroxychloroquine" post="Entry receptor Antiviral drug on malaria; not yet tested"/>
   <result pre="Not known None Lopinavir-ritonavir Viral protease Used in combination with" exact="ribavirin" post="for SARS and MERS N/A 199 hospitalized patients, Wuhan,"/>
   <result pre="drug; not yet tested for coronaviruses N/A Not known None" exact="Ribavirin" post="Genome replication Used in combination with lopinavir-ritonavir for SARS"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7315836\results\search\drug\results.xml">
   <result pre="with IC50 values of around 50 and 6 Î¼M, respectively." exact="Glycine" post="linkage of peptide P4 (residue 22â€&quot;47) with an ACE2"/>
   <result pre="SARS-CoV pseudotyped virus, cytotoxicity data is not available to date.66" exact="Chloroquine" post="(4) currently has applications for malaria and amoebiasis treatment."/>
   <result pre="malaria and amoebiasis treatment. Interestingly, Nichol et al. showed that" exact="chloroquine" post="could also block the interaction of RBD of SARS-CoV"/>
   <result pre="and a CC50 &amp;gt; 100 Î¼M in Vero E6 cells.68" exact="Chloroquine" post="possibly increases endosomal pH required for virus/cell fusion as"/>
   <result pre="the affinity of SARS-CoV/SARS-CoV-2 to ACE2. Besides its antiviral activity," exact="chloroquine" post="may synergistically enhance its antiviral effect with immune-modulating activity"/>
   <result pre="its antiviral effect with immune-modulating activity in vivo.68 At present," exact="chloroquine" post="is carried out in clinical research in China for"/>
   <result pre="of chloroquine, which shares the same mechanism of action as" exact="chloroquine" post="but displays a more tolerable safety profile.70 Yao et"/>
   <result pre="pseudotyped viruses when treated with a combination of (23,25)trans-epoxysuccinyl- l-leucylamindo-3-methylbutane" exact="ethyl ester" post="(EST, a cathepsin inhibitor) and 22. The results suggested"/>
   <result pre="of 75 Î¼M in HEK-293T cells. Furthermore, when cathepsin inhibitor" exact="camostat" post="was used in combination with 23, a significant inhibition"/>
   <result pre="23, a significant inhibition in infectivity was characterized compared to" exact="camostat" post="alone.20 Recently, Bestle et al., showed that the potent"/>
   <result pre="Targeting Host Factors and Unknown Targets Machamer et al. found" exact="imatinib" post="(28), an Abelson kinase signaling pathway inhibitor that could"/>
   <result pre="effects in Vero cells at 100 Î¼M.123,124 Another Abl inhibitor," exact="dasatinib" post="(29), was active against both MERS-CoV and SARS-CoV, with"/>
   <result pre="CaoR.; ZhangL.; YangX.; LiuJ.; XuM.; ShiZ.; HuZ.; ZhongW.; XiaoG.Remdesivir and" exact="chloroquine" post="effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in"/>
   <result pre="in Vitro. Cell Res.2020, 30, 269â€&quot;271. 10.1038/s41422-020-0282-0.32020029 GaoJ.; TianZ.; YangX.Breakthrough:" exact="chloroquine" post="phosphate has shown apparent efficacy in treatment of COVID-19"/>
   <result pre="D.; ParkeA. L.; Clifford-RashotteM.; KeanW. F.Therapy and pharmacological properties of" exact="hydroxychloroquine" post="and chloroquine in treatment of systemic lupus erythematosus, rheumatoid"/>
   <result pre="L.; Clifford-RashotteM.; KeanW. F.Therapy and pharmacological properties of hydroxychloroquine and" exact="chloroquine" post="in treatment of systemic lupus erythematosus, rheumatoid arthritis and"/>
   <result pre="vitro antiviral activity and projection of optimized dosing design of" exact="hydroxychloroquine" post="for the treatment of severe acute respiratory syndrome coronavirus"/>
   <result pre="coronavirus 2 (SARS-CoV-2). Clin. Infect. Dis.2020, ciaa23710.1093/cid/ciaa237.32150618 ChenC.; WangF.; LinC.Chronic" exact="hydroxychloroquine" post="use associated with qt prolongation and refractory ventricular arrhythmia."/>
   <result pre="e80â€&quot;e82. 10.1016/j.ijcard.2007.04.055.17590456 YaylaliS. A.; SadigovF.; ErbilH.; EkinciA.; AkcakayaA. A.Chloroquine and" exact="hydroxychloroquine" post="retinopathy-related risk factors in a turkish cohort. Int. Ophthalmol.2013,"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7315944\results\search\drug\results.xml">
   <result pre="clinical blood samples from Wuhan, researchers found eleven (bilirubin total," exact="creatine" post="kinase isoenzyme, GLU, creatinine, kalium, lactate dehydrogenase, platelet distribution"/>
   <result pre="diagnosis was the main objective along with augmentation of accuracy." exact="Prompt" post="and early detection reduce the spread of the disease"/>
   <result pre="suggested eight drugs, i.e., vismodegib, gemcitabine, clofazimine, celecoxib, brequinar, conivaptan," exact="bedaquiline" post="and tolcapone are found virtually effective against feline infectious"/>
   <result pre="drugs, i.e., vismodegib, gemcitabine, clofazimine, celecoxib, brequinar, conivaptan, bedaquiline and" exact="tolcapone" post="are found virtually effective against feline infectious peritonitis coronavirus."/>
   <result pre="Furthermore, other five drugs like homoharringtonine, salinomycin, boceprevir, tilorone and" exact="chloroquine" post="are also found operational during AI experimental environment. A"/>
   <result pre="Furthermore, results revealed that some medications like darunavir, ritonavir, and" exact="lopinavir" post="were outlined to tackle viral proteinases. It was also"/>
   <result pre="proteinases. It was also found that various antiviral compounds like" exact="Kaletra" post="might be utilized for the medicine of Covid-19 human"/>
   <result pre="of the Ebola virus. The study proposed an amodiaquine and" exact="chloroquine" post="compound popularly used to treat the malaria virus. Furthermore,"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7317260\results\search\drug\results.xml">
   <result pre="TNF-Î±, IL-1 Î², and IL-10 in 60 patients with T2DM;" exact="sitagliptin" post="treatment significantly decreased the high levels of pro-inflammatory TNF-Î±,"/>
   <result pre="of current smoking among hospitalized COVID-19 patients in China: could" exact="nicotine" post="be a therapeutic option?Intern Emerg Med202010.1007/s11739-020-02355-732385628 2.DengSQPengHJCharacteristics of and"/>
   <result pre="CD26 expressing U937 cellsImmunobiology199419212113610.1016/S0171-2985(11)80412-27750986 17.KawasakiTChenWHtweYMTatsumKDudekSMSome of the protective effects of" exact="sitagliptin" post="could be mediated through extra-glycemic action, as modulating DPP4/CD26"/>
   <result pre="action, as modulating DPP4/CD26 in rats, the DPP4 inhibition of" exact="sitagliptin" post="improves LPS-induced lung injuryAm J Physiol Lung Cell Mol"/>
   <result pre="injuryAm J Physiol Lung Cell Mol Physiol2018315L834L84510.1152/ajplung.0003130188745 18.TelikaniZSheikhVZamaniAet al.Effect of" exact="sitagliptin" post="on serum levels of TNF-Î±, IL-1Î² and IL-10 in"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7318922\results\search\drug\results.xml">
   <result pre="Drugs used to treat COVID suspected of causing exanthems are" exact="hydroxychloroquine" post="(morbilliform) and azithromycin (morbilliform, urticarial) Young and Fernandez, 2020"/>
   <result pre="treat COVID suspected of causing exanthems are hydroxychloroquine (morbilliform) and" exact="azithromycin" post="(morbilliform, urticarial) Young and Fernandez, 2020 High variability is"/>
   <result pre="to protect against infection and spread (Schmitt, 2020). Avoidance of" exact="ibuprofen" post="and other nonsteroidal anti-inflammatory drugs (NSAIDs) has been suggested"/>
   <result pre="(FitzGerald, 2020, Giollo et al., 2020). Switching from NSAIDs to" exact="acetaminophen" post="is a reasonable alternative in healthy individuals who require"/>
   <result pre="workplace areas are recommended to be frequently disinfected using 75%" exact="alcohol" post="products or disinfecting wipes. Examples of places to clean"/>
   <result pre="seconds or using a hand sanitizer with at least 60%" exact="alcohol" post="Avoid touching your eyes, nose, and mouth Cover your"/>
   <result pre="et al., 2006). That said, a new clinical trial of" exact="methylprednisolone" post="has recently been approved to determine whether COVID-19 cases"/>
   <result pre="of antiviral medications to help suppress viral replication, and both" exact="ritonavir" post="and lopinavir are being studied in clinical trials (Shionogi,"/>
   <result pre="medications to help suppress viral replication, and both ritonavir and" exact="lopinavir" post="are being studied in clinical trials (Shionogi, Toyama Chemical;"/>
   <result pre="SARS epidemic (Chu et al., 2004). Remdesivir (Gilead Pharmaceuticals Inc," exact="Foster" post="City, CA) is an investigational drug that was considered"/>
   <result pre="cascade (Tang et al., 2012). A nonrandomized clinical trial combining" exact="azithromycin" post="and hydroxychloroquine initially showed promising therapeutic potential (Gautret et"/>
   <result pre="et al., 2012). A nonrandomized clinical trial combining azithromycin and" exact="hydroxychloroquine" post="initially showed promising therapeutic potential (Gautret et al., 2020)."/>
   <result pre="the combination of drugs can potentiate cardiac arrythmias. Most recently," exact="hydroxychloroquine" post="has fallen out of favor as a therapy of"/>
   <result pre="benefit, followed by the retraction of a Lancet article supporting" exact="hydroxychloroquine" post="(Chorin et al., 2020, Mehra et al., 2020). Additionally,"/>
   <result pre="CuiY.SongY.Genome and evolution of yersinia pestisAdv Exp Med Biol918201617119227722863 DayM.Covid-19:" exact="Ibuprofen" post="should not be used for managing symptoms, say doctors"/>
   <result pre="study in Spain with 375 casesBr J Dermatol18312020717732348545 GautretP.LagierJ.C.ParolaP.HoangV.T.MeddebL.MailheM.Hydroxychloroquine and" exact="azithromycin" post="as a treatment of COVID-19: results of an open-label"/>
   <result pre="livedo reticularisJ Am Acad DermatolS0190â€&quot;96222020203055830562 McEvedyC.The bubonic plagueSci Am258219881181233055286 MehraM.R.DesaiS.S.RuschitzkaF.PatelA.N.Retracted:" exact="Hydroxychloroquine" post="or chloroquine with or without a macrolide for treatment"/>
   <result pre="Am Acad DermatolS0190â€&quot;96222020203055830562 McEvedyC.The bubonic plagueSci Am258219881181233055286 MehraM.R.DesaiS.S.RuschitzkaF.PatelA.N.Retracted: Hydroxychloroquine or" exact="chloroquine" post="with or without a macrolide for treatment of COVID-19:"/>
   <result pre="Pediatric 2020 [Epub ahead of publication]. SchrezenmeierE.DÃ¶rnerT.Mechanisms of action of" exact="hydroxychloroquine" post="and chloroquine: implications for rheumatologyNat Rev Rheumatol16202015516632034323 SchwartzD.A.GrahamA.L.Potential maternal"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7319607\results\search\drug\results.xml">
   <result pre="divided into four genera: Î±-CoVs, Î²-CoVs, Î³-CoVs, and Î´-CoVs, only" exact="alpha" post="and beta can infect mammals [1]. After binding to"/>
   <result pre="that vary from 0.1 to 0.5Â mg/mL [24]. For example," exact="Albuterol" post="(manufactured by Dey Laboratories) contained 300Â Î¼g of EDTA,"/>
   <result pre="To study off-target bronchoconstriction by EDTA, it was found that" exact="Albuterol" post="(1Â Âµg/kg IV) significantly attenuated Na2EDTA-induced bronchoconstriction in canines"/>
   <result pre="drop in FEV1 and adding concentrated EDTA to a standard" exact="Albuterol" post="nebulizer set-up should mitigate most EDTA induced bronchoconstriction. As"/>
   <result pre="aliquots and sterilize by autoclaving. It is noteworthy that the" exact="disodium salt" post="of EDTA will not go into solution until the"/>
   <result pre="from other pathogenic virusesEmerg Microbes Infect912020 Mar 1455857032172672 37See PubChem" exact="Ethylenediaminetetraacetic acid" post="disodium salt (Compound); &amp;lt;https://pubchem.ncbi.nlm.nih.gov/compound/Ethylenediaminetetraacetic-acid-disodium-salt#section=Absorption-Distribution-and-Excretion&amp;gt;. 38MontoA.S.CowlingB.J.PeirisJ.S.CoronavirusesViral Infect Humans272014199223 39CallowK.A.ParryH.F.SergeantM.TyrrellD.A.J.The time"/>
   <result pre="pathogenic virusesEmerg Microbes Infect912020 Mar 1455857032172672 37See PubChem Ethylenediaminetetraacetic acid" exact="disodium salt" post="(Compound); &amp;lt;https://pubchem.ncbi.nlm.nih.gov/compound/Ethylenediaminetetraacetic-acid-disodium-salt#section=Absorption-Distribution-and-Excretion&amp;gt;. 38MontoA.S.CowlingB.J.PeirisJ.S.CoronavirusesViral Infect Humans272014199223 39CallowK.A.ParryH.F.SergeantM.TyrrellD.A.J.The time course of"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7319644\results\search\drug\results.xml">
   <result pre="that somehow demonstrated effectiveness against MERS-CoV and/or SARS-CoV infections are:" exact="Ribavirin" post="[109], Nitazoxanide [110], Remdesivir [111] and Lopinavir, although the"/>
   <result pre="the efficacy and safety of some drugs remain controversial [108,112]." exact="Ribavirin" post="is an approved drug developed to treat HCV and"/>
   <result pre="[113] in vivo studies performed with combinations of lopinavir/ribavirin (LPV/r)," exact="Ribavirin" post="and interferon resulted in the cure of a 64-year-old"/>
   <result pre="in Saudi Arabia to MERS patients [114]. Lopinavir combined with" exact="ribavirin" post="also presents a synergistic effect being able to inhibit"/>
   <result pre="to MERS-CoV and SARS-CoV, the use of high doses of" exact="ribavirin" post="is worrying, since it can trigger side effects such"/>
   <result pre="can trigger side effects such as anemia [119]. In addition," exact="ribavirin" post="is contraindicated during pregnancy, due to its potential teratogenicity"/>
   <result pre="[120]. Controversially, several evidences demonstrate that the teratogenicity effect of" exact="ribavirin" post="associated with humans is not significant, as observed when"/>
   <result pre="associated with humans is not significant, as observed when the" exact="Ribavirin" post="Pregnancy Registry was established in 2003 [121]. However, more"/>
   <result pre="[121]. However, more information on possible placental interference caused by" exact="ribavirin" post="is needed to ensure its use. Chloroquine (CQ) and"/>
   <result pre="interference caused by ribavirin is needed to ensure its use." exact="Chloroquine" post="(CQ) and hydroxychloroquine (HCQ) are used to treat mainly"/>
   <result pre="ribavirin is needed to ensure its use. Chloroquine (CQ) and" exact="hydroxychloroquine" post="(HCQ) are used to treat mainly malaria and rheumatic"/>
   <result pre="MERS-CoV, no clinical data are available on the success of" exact="chloroquine" post="to patients [125]. In a recent in vitro study"/>
   <result pre="% of a patient group treated with HQ combined with" exact="Azithromycin" post="had no detectable viral load after 6 days of"/>
   <result pre="ensure patient safety [127]. In this case, the use of" exact="chloroquine" post="is still controversial and needs more clinical trials. In"/>
   <result pre="and retinotoxic in the fetal phase for individuals exposed to" exact="chloroquine" post="raises concerns about its use [129,130]. In contrast, many"/>
   <result pre="that normalize after discontinuing treatment. In addition, serum estradiol and" exact="progesterone" post="levels were decreased in women treated with IFN [138]."/>
   <result pre="21KeyaertsE.VijgenL.ChenL.MaesP.HedenstiernaG.Van RanstM.Inhibition of SARS-coronavirus infection in vitro by S-nitroso-N-acetylpenicillamine, a" exact="nitric oxide" post="donor compoundInt J Infect Dis84200422322610.1016/j.ijid.2004.04.01215234326 22LipsitchM.CohenT.CooperB.RobinsJ.M.MaS.JamesL.Transmission dynamics and control"/>
   <result pre="(MERS): a reviewJ Infect Public Health111201891710.1016/j.jiph.2017.08.00928864360 108YaoT.T.QianJ.D.ZhuW.Y.WangY.WangG.Q.A systematic review of" exact="lopinavir" post="therapy for SARS coronavirus and MERS coronavirusâ€&quot;A possible reference"/>
   <result pre="2 ProteasesbioRxiv0131202092969510.1101/2020.01.31.929695 119Dieterich, DT. Method of treating anemia caused by" exact="ribavirin" post="treatment of hepatitis C using erythropoietin alpha. U.S. Patent"/>
   <result pre="multiple modes of action and possible future perspectivesFuture Virol143201915316010.2217/fvl-2018-0166 121SinclairS.M.JonesJ.K.MilerR.K.GreeneM.F.KwoP.Y.MaddreyW.C.The" exact="Ribavirin" post="Pregnancy Registry: an interim analysis of potential teratogenicity at"/>
   <result pre="modalities for Middle East respiratory syndromeJ Antimicrob Chemother711220163340335010.1093/jac/dkw33827585965 126GautretP.LagierJ.C.ParolaP.HoangV.T.MeddebL.MailheM.Hydroxychloroquine and" exact="azithromycin" post="as a treatment of COVID-19: results of an open-label"/>
   <result pre="the mother during pregnancyBull Soc Ophtalmol Fr6919694664675403305 130KaplanY.C.OzsarfatiJ.NickelC.KorenG.Reproductive outcomes following" exact="hydroxychloroquine" post="use for autoimmune diseases: a systematic review and metaanalysisBr"/>
   <result pre="a systematic review and metaanalysisBr J Clin Pharmacol815201683584810.1111/bcp.1287226700396 131KaplanY.C.KorenG.Use of" exact="hydroxychloroquine" post="during pregnancy and breastfeeding: an update for the recent"/>
   <result pre="the recent coronavirus pandemic (COVID-19)Motherisk Int J2020 132SperberK.HomC.ChaoC.P.ShapiroD.AshJ.Systematic review of" exact="hydroxychloroquine" post="use in pregnant patients with autoimmune diseasesPediatr Rheumatol Online"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7319650\results\search\drug\results.xml">
   <result pre="and has evidence of a synergistic in vitro effect with" exact="ribavirin" post="[[57], [58], [59]]; has been used for years as"/>
   <result pre="it may interfere with the dosage of anticoagulants such as" exact="ribavirin" post="[56]. Moreover, it may also interact with HMG-CoA reductase"/>
   <result pre="no cytotoxicity or adverse reactions related [[51], [52], [53], [54]]." exact="Ribavirin" post="that binds to the active site on RdRp has"/>
   <result pre="of the active metabolites of and increased serum concentrations [56]." exact="Hydroxychloroquine" post="(HCQ) was originally developed and used for the treatment"/>
   <result pre="[69], [70]], a French study evaluated 26 patients treated with" exact="hydroxychloroquine" post="and 16 control patients, all positive for the virus"/>
   <result pre="showed that the effect of the drug was enhanced by" exact="azithromycin" post="[71]. The experimental protocol included 200 mg of oral"/>
   <result pre="azithromycin [71]. The experimental protocol included 200 mg of oral" exact="hydroxychloroquine" post="sulfate, three times a day for ten days in"/>
   <result pre="based on clinical judgment. The authors documented the efficacy of" exact="hydroxychloroquine" post="in reducing the viral load at day 7. Although"/>
   <result pre="rule out a cardiotoxic effect. Recent studies have shown that" exact="azithromycin" post="(AZM), and the closely related drug roxithromycin, both act"/>
   <result pre="replication of other viruses, such as Ebola and HIV-1 [69,80,81]." exact="Azithromycin" post="has been linked to an increased risk of ventricular"/>
   <result pre="that the risk of ventricular arrhythmia with the use of" exact="azithromycin" post="is likely to be due to the patient's health"/>
   <result pre="without symptoms of hepatic impairmentTher. Drug Monit.36April (2)201419220110.1097/FTD.0b013e3182a28c6a24632753 56MueckW.KubitzaD.BeckaM.Co-administration of" exact="rivaroxaban" post="with drugs that share its elimination pathways: pharmacokinetic effects"/>
   <result pre="A ReviewJAMA13202010.1001/jama.2020.6019Apr 61MorganR.E.CampbellS.E.SuehiraK.SponsellerC.A.YuC.Y.MedlockM.M.Effects of steady-state lopinavir/ritonavir on the pharmacokinetics of" exact="pitavastatin" post="in healthy adult volunteersJ. Acquir. Immune Defic. Syndr.60Junuary1(2)201215816410.1097/QAI.0b013e318251addb22627182 62AlarcÃ³nG.S.McGwinG.BertoliA.M.FesslerB.J.Calvo-AlÃ©nJ.BastianH.M.VilÃ¡L.M.ReveilleJ.D.LUMINA"/>
   <result pre="adult volunteersJ. Acquir. Immune Defic. Syndr.60Junuary1(2)201215816410.1097/QAI.0b013e318251addb22627182 62AlarcÃ³nG.S.McGwinG.BertoliA.M.FesslerB.J.Calvo-AlÃ©nJ.BastianH.M.VilÃ¡L.M.ReveilleJ.D.LUMINA Study GroupEffect of" exact="hydroxychloroquine" post="on the survival of patients with systemic lupus erythematosus:"/>
   <result pre="multiethnic US cohort (LUMINA L)Ann. Rheum. Dis.6620071168117217389655 63WillisR.SeifA.M.Jr McGwinG.Martinez-MartinezL.A.GonzÃ¡lezE.B.DangN.PapalardoE.LiuJ.VilÃ¡L.M.ReveilleJ.D.AlarcÃ³nG.S.PierangeliS.S.Effect of" exact="hydroxychloroquine" post="treatment on pro-inflammatory cytokines and disease activity in SLE"/>
   <result pre="Plasmodium in reticulocytes can occur without hemozoin formation, resulting in" exact="chloroquine" post="resistanceJ. Exp. Med.212June 1 (6)201589390310.1084/jem.2014173125941254 67TÃ¶nnesmannE.KandolfR.LewalterT.Chloroquine cardiomyopathy - a"/>
   <result pre="cardiomyopathy - a review of the literatureImmunopharmacol. Immunotoxicol.35June (3)201343444210.3109/08923973.2013.78007823635029 68GaoJ.TianZ.YangX.Breakthrough:" exact="chloroquine" post="phosphate has shown apparent efficacy in treatment of COVID-19"/>
   <result pre="vitro antiviral activity and projection of optimized dosing design of" exact="hydroxychloroquine" post="for the treatment of severe acute respiratory syndrome coronavirus"/>
   <result pre="coronavirus 2 (SARS-CoV-2)Clin. Infect. Dis.9202010.1093/cid/ciaa237Mar pii: ciaa237 71GautretP.LagierJ.C.ParolaP.HoangV.T.MeddebL.MailheM.DoudierB.CourjonJ.GiordanengoV.VieiraV.E.DupontH.T.HonorÃ©S.ColsonP.ChabriÃ¨reE.La ScolaB.RolainJ.M.BrouquiP.RaoultD.Hydroxychloroquine and" exact="azithromycin" post="as a treatment of COVID-19: results of an open-label"/>
   <result pre="an open-label non-randomized clinical trialInt. J. Antimicrob. Agents20202010594910.1016/j.ijantimicag.2020.105949Mar 72PetriM.Use of" exact="hydroxychloroquine" post="to prevent thrombosis in systemic lupus erythematosus and in"/>
   <result pre="73WhiteN.J.Cardiotoxicity of antimalarial drugsLancet Infect. Dis.7200754955817646028 74WozniackaA.CygankiewiczI.ChudzickM.The cardiac safety of" exact="chloroquine" post="phosphate treatment in patients with systemic lupus erythematosus: the"/>
   <result pre="in systemic lupus erythematosusClin. Exp. Rheumatol.36July-August (4)201854555129652656 76CairoliE.DaneseN.TelizM.BruzzoneM.J.FerreiraJ.RebellaM.CayotaA.Cumulative dose of" exact="hydroxychloroquine" post="is associated with a decrease of resting heart rate"/>
   <result pre="patients with systemic lupus erythematosus: a pilot studyLupus2420151204120910.1177/096120331558087025852050 77OzsvariB.NuttallJ.R.SotgiaF.LisantiM.P.Azithromycin and" exact="Roxithromycin" post="define a new family of &quot;senolytic&quot; drugs that target"/>
   <result pre="(Albany NY)1020183294330710.18632/aging.10163330428454 78AvedissianS.N.RhodesN.J.NgT.N.H.RaoA.P.BeringerP.M.The potential for QT interval prolongation with chronic" exact="azithromycin" post="therapy in adult cystic fibrosis patientsPharmacotherapy39201971872310.1002/phar.227031045258 79TangF.LiR.XueJ.LanJ.XuH.LiuY.ZhouL.LuY.Azithromycin attenuates acute"/>
   <result pre="inhibitors for drug repurposingACS Infect. Dis.1July 10 (7)201531732610.1021/acsinfecdis.5b0003027622822 81RoyJ.PaquetteJ.S.FortinJ.F.TremblayM.J.The immunosuppressant" exact="rapamycin" post="represses human immunodeficiency virus type 1 replicationAntimicrob. Agents Chemother.46November(11)20023447345512384349"/>
   <result pre="azithromycinCardiovasc. Toxicol.17October (4)201743444010.1007/s12012-017-9401-728213753 83LeeR.A.GuytonA.KunzD.CutterG.R.HoesleyC.J.Evaluation of baseline corrected QT interval and" exact="azithromycin" post="prescriptions in an academic medical centerJ. Hosp. Med.11January (1)2016152010.1002/jhm.244826287278"/>
   <result pre="(1)2016152010.1002/jhm.244826287278 84PatelH.CalipG.S.Di DomenicoR.J.SchumockG.T.SudaK.J.LeeT.A.Prevalence of cardiac risk factors in patients prescribed" exact="azithromycin" post="before and after the 2012 FDA warning on the"/>
   <result pre="heart rhythmsPharmacotherapy40202010711510.1002/phar.235531867748 85AvedissianS.N.RhodesN.J.NgT.N.M.RaoA.P.BeringerP.M.The potential for QT interval prolongation with chronic" exact="azithromycin" post="therapy in adult cystic fibrosis patientsPharmacotherapy39201971872310.1002/phar.227031045258 86FangL.KarakiulakisG.RothM.Are patients with"/>
   <result pre="Respir. Med.6September (9)201869169810.1016/S2213-2600(18)30177-230078618 94McAuleyD.F.LaffeyJ.G.Oâ€™KaneC.M.PerkinsG.D.MullanB.TrinderT.J.JohnstonP.HopkinsP.A.JohnstonA.J.McDowellC.McNally; HARP-2C.Investigators; Irish Critical Care Trials Group." exact="Simvastatin" post="in the acute respiratory distress syndromeN. Engl. J. Med.371October"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7320698\results\search\drug\results.xml">
   <result pre="WHO, SOLIDARITY, to research available therapies for Covid-19, including remdesivir," exact="chloroquine" post="and hydroxychloroquine, lopinavir and ritonavir, and lopinavirâ€‰+â€‰ritonavirâ€‰+â€‰interferon-beta. There is"/>
   <result pre="research available therapies for Covid-19, including remdesivir, chloroquine and hydroxychloroquine," exact="lopinavir" post="and ritonavir, and lopinavirâ€‰+â€‰ritonavirâ€‰+â€‰interferon-beta. There is widespread interest to"/>
   <result pre="were excluded from the study. In addition to supportive treatment," exact="hydroxychloroquine" post="and azithromycin were administered to all patients and then"/>
   <result pre="from the study. In addition to supportive treatment, hydroxychloroquine and" exact="azithromycin" post="were administered to all patients and then favipravir. Convalescant"/>
   <result pre="options used in the current treatment of Covid-19 are hydroxychloroquine," exact="lopinavir" post="/ ritonavir, azithromycin, favipiravir and Interleukin-6 (IL-6) inhibitors. Remdesivir,"/>
   <result pre="Acad Sci1171720209490949632253318 12SooY.Retrospective comparison of convalescent plasma with continuing highâ€�dose" exact="methylprednisolone" post="treatment in SARS patientsClin Microbiol Infect107200467667815214887 13FDAInvestigational COVID-19 convalescent"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7320840\results\search\drug\results.xml">
   <result pre="authorization for the investigational antiviral drug remdesivir and antimalarial drug" exact="hydroxychloroquine" post="for the treatment of suspected or laboratory-confirmed COVID-19 in"/>
   <result pre="pneumonia in a recent clinical trial in China [52]. Recently," exact="hydroxychloroquine" post="and chloroquine had been reported to be of importance"/>
   <result pre="a recent clinical trial in China [52]. Recently, hydroxychloroquine and" exact="chloroquine" post="had been reported to be of importance in relevance"/>
   <result pre="in vitro activity against SARS-CoV, SARS-CoV-2, and other coronaviruses, with" exact="hydroxychloroquine" post="having relatively higher potency against SARS-CoV-2 [51, 53, 54]."/>
   <result pre="SARS-CoV-2 [51, 53, 54]. A study in China reported that" exact="chloroquine" post="treatment of COVID-19 patients had the clinical and virologic"/>
   <result pre="in China [55]. In the USA, several clinical trials of" exact="hydroxychloroquine" post="for prophylaxis or treatment of SARS-CoV-2 infection are going"/>
   <result pre="and zoonotic coronaviruses. Sci Transl Med. 2017;9. 10.1126/scitranslmed.aal3653 51.WangMCaoRZhangLYangXLiuJXuMShiZHuZZhongWXiaoGRemdesivir and" exact="chloroquine" post="effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in"/>
   <result pre="by minimally invasive autopsiesZhonghua Bing Li Xue Za Zhi202049E009 55.GaoJTianZYangXBreakthrough:" exact="chloroquine" post="phosphate has shown apparent efficacy in treatment of COVID-19"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7321236\results\search\drug\results.xml">
   <result pre="ribavirin, remdesivir and galidesivir act as RDRP inhibitors while lopinavir," exact="ritonavir" post="[5,6] and danoprevir are viral protease inhibitors. In addition,"/>
   <result pre="of the viral particles have been proposed, such as chloroquine," exact="hydroxychloroquine" post="[7] and APN01 [8]. Lopinavir and ritonavir designed and"/>
   <result pre="such as chloroquine, hydroxychloroquine [7] and APN01 [8]. Lopinavir and" exact="ritonavir" post="designed and approved for the treatment of AIDS were"/>
   <result pre="and dolutegravir [13] and the HIV-1 protease inhibitors, darunavir and" exact="saquinavir" post="[14]. According to a more recent in silico research,"/>
   <result pre="silico research, published on April 15th, the HCV protease inhibitors," exact="simeprevir" post="and faldaprevir as well as the HIV-1 protease inhibitors"/>
   <result pre="faldaprevir as well as the HIV-1 protease inhibitors indinavir and" exact="tipranavir" post="along with saquinavir were predicted to act as better"/>
   <result pre="as the HIV-1 protease inhibitors indinavir and tipranavir along with" exact="saquinavir" post="were predicted to act as better Mpro inhibitors compared"/>
   <result pre="predicted to act as better Mpro inhibitors compared to the" exact="lopinavir" post="and ritonavir used in clinical practice [15]. Danoprevir was"/>
   <result pre="act as better Mpro inhibitors compared to the lopinavir and" exact="ritonavir" post="used in clinical practice [15]. Danoprevir was the first"/>
   <result pre="the random selection was made for the HIV-1 inhibitors where" exact="lopinavir" post="and ritonavir were selected because they have already been"/>
   <result pre="selection was made for the HIV-1 inhibitors where lopinavir and" exact="ritonavir" post="were selected because they have already been proposed for"/>
   <result pre="of the drugs that were selected are the anti-HCV drugs" exact="telaprevir" post="and boceprevir, the DPP-4 inhibitor sitagliptin, the renin inhibitor"/>
   <result pre="inhibitor alisliren, the ACE inhibitor captopril, the thrombin direct inhibitors" exact="argatroban" post="and dabigatran and the coagulation Factor Xa inhibitor rivaroxaban."/>
   <result pre="compounds, with the exception of the ACE and renin inhibitors," exact="captopril" post="and aliskiren, for which the calculated free binding energy"/>
   <result pre="The best results were obtained for the HCV protease inhibitors" exact="telaprevir" post="and boceprevir, with free binding energies of âˆ’10.05 and"/>
   <result pre="âˆ’9.03 and âˆ’8.80 kcal molâˆ’1, respectively. The HIV-1 protease inhibitors" exact="ritonavir" post="and lopinavir showed a little lower predicted activity, with"/>
   <result pre="âˆ’8.80 kcal molâˆ’1, respectively. The HIV-1 protease inhibitors ritonavir and" exact="lopinavir" post="showed a little lower predicted activity, with free binding"/>
   <result pre="active site is the second preferred binding site of lopinavir," exact="ritonavir" post="and boceprevir. According to this observation, the expected inhibitory"/>
   <result pre="the DPP-4 inhibitors. In the group of anti-coagulants, inogartan and" exact="argatroban" post="of the first randomly selected compounds were the most"/>
   <result pre="at the S1 subsite such as the 7-methoxy-8-methyl-quinoline moiety of" exact="simeprevir" post="[15] or the oxadiazole group of raltegravir, which adopts"/>
   <result pre="role in complex stabilization of many compounds including raltegravir and" exact="ribavirin" post="[12]. Most inhibitors used in this study do not"/>
   <result pre="protease inhibitors, teneligliptin and gemigliptin but also trelagliptin, evogliptin and" exact="gosogliptin" post="among the DPP-4 inhibitors, inogatran and melagatran of Î±-thrombin"/>
   <result pre="approved drugs characterized as well tolerated in subjects. Compared to" exact="lopinavir" post="and ritonavir, most of the evaluated compounds showed better"/>
   <result pre="TechniquesMath. Oper. Res.19816193010.1287/moor.6.1.19 41.A Phase 3 Study in Combination with" exact="BMS-790052" post="and BMS-650032 in Japanese Hepatitis C Virus (HCV) PatientsAvailable"/>
   <result pre="coagulation Factor Xa heavy chain (B). Figure 3 Docking of" exact="linagliptin" post="(A,C) and gemigliptin (B,D) at the SARS-CoV-2 structure 6M2N."/>
   <result pre="indinavir, lasinavir, lopinavir, mozenavir, nelfinavir, palinavir, ritonavir, saquinavir, telinavir, and" exact="tipranavir" post="HCV Protease asunaprevir, boceprevir, ciluprevir, danoprevir, faldaprevir, narlaprevir, neceprevir,"/>
   <result pre="gemigliptin, gosogliptin, linagliptin, melogliptin, omarigliptin, saxagliptin, sitagliptin, teneligliptin, trelagliptin, and" exact="vildagliptin" post="Renin aliskiren, ciprokiren, ditekiren, enalkiren, remikiren, terlakiren, and zankiren"/>
   <result pre="pivopril, quinapril, ramipril, rentiapril, spirapril, temocapril, trandolapril, utibapril, zabicipril, and" exact="zofenopril" post="Thrombin direct inhibitors: argatroban, inogatran, melagatran and its pro-drug"/>
   <result pre="Active Site (kcal molâˆ’1) HIV-1 protease inhibitors Lopinavir âˆ’8.65 (2nd)" exact="Ritonavir" post="âˆ’8.96 (2nd) HCV protease inhibitors Telaprevir âˆ’9.23 Boceprevir âˆ’9.16"/>
   <result pre="inhibitors Lopinavir âˆ’8.65 (2nd) Ritonavir âˆ’8.96 (2nd) HCV protease inhibitors" exact="Telaprevir" post="âˆ’9.23 Boceprevir âˆ’9.16 (2nd) DPP-4 inhibitor Sitagliptin âˆ’8.80 Thrombin"/>
   <result pre="HCV protease inhibitors Telaprevir âˆ’9.23 Boceprevir âˆ’9.16 (2nd) DPP-4 inhibitor" exact="Sitagliptin" post="âˆ’8.80 Thrombin inhibitors Argatroban âˆ’9.03 Dabigatran âˆ’6.57 Factor Xa"/>
   <result pre="âˆ’8.80 Thrombin inhibitors Argatroban âˆ’9.03 Dabigatran âˆ’6.57 Factor Xa inhibitor" exact="Rivaroxaban" post="âˆ’7.97 ACE inhibitor Captopril âˆ’5.17 Renin inhibitor Aliskiren âˆ’4.66"/>
   <result pre="âˆ’9.03 Dabigatran âˆ’6.57 Factor Xa inhibitor Rivaroxaban âˆ’7.97 ACE inhibitor" exact="Captopril" post="âˆ’5.17 Renin inhibitor Aliskiren âˆ’4.66 molecules-25-02529-t003_Table 3Table 3 Estimated"/>
   <result pre="âˆ’6.02 Evogliptin âˆ’8.38 âˆ’8.74 âˆ’9.84 Narlaprevir âˆ’5.70 âˆ’6.11 âˆ’12.38 âˆ’6.90" exact="Gosogliptin" post="âˆ’8.30 âˆ’8.75 âˆ’9.18 Sovaprevir âˆ’8.17 âˆ’8.53 âˆ’10.45 âˆ’4.80 Gemigliptin"/>
   <result pre="Teneligliptin âˆ’9.58 âˆ’9.16âˆ’9.52 * âˆ’9.87 âˆ’6.55 Trelagliptin âˆ’8.92 âˆ’8.41 âˆ’9.30" exact="Vildagliptin" post="âˆ’8.55 âˆ’8.21 âˆ’8.67 4FFW initial ligand (sitagliptin) âˆ’10.78 Î±-Thrombin"/>
   <result pre="6M2N 1DWE 6LU7 6M2N 4BTI Inogatran âˆ’10.30 (3rd) âˆ’8.32 âˆ’10.39" exact="Apixaban" post="âˆ’7.53 âˆ’7.11 Melagatran âˆ’8.64 âˆ’8.70 âˆ’10.35 Betrixaban âˆ’9.25 âˆ’8.44"/>
   <result pre="Fast Track status from FDA in 2012 Achillion Pharmaceuticals -" exact="Telaprevir" post="ChEMBL231813 Approved 2011 Vertex Pharmaceuticals and Johnson &amp;amp; Johnson"/>
   <result pre="Gemigliptin - Approved 2011 LG Life Sciences Generally well tolerated" exact="Gosogliptin" post="- Approved in Russia 2016 Pfizer Hypoglycemia [48] Linagliptin"/>
   <result pre="AstraZeneca Upper respiratory tract infection, may cause joint pain [49,50]" exact="Sitagliptin" post="ChEMBL1422 Approved 2006 Merck &amp;amp; Co. Headache, swelling of"/>
   <result pre="Trelagliptin - Approved in Japan 2015 Takeda Generally well tolerated" exact="Vildagliptin" post="ChEMBL142703 Approved 2007 Novartis Nausea, hypoglycemia, headache, dizziness [52]"/>
   <result pre="tolerated Melagatran AstraZeneca Dabigatran ChEMBL539697 Approved 2010 Boehringer-Ingelheim Gastrointestinal [54]" exact="Apixaban" post="ChEMBL231779 Approved 2014 Bristol-Myers Squibb and Pfizer Bleeding, bausea"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7323073\results\search\drug\results.xml">
   <result pre="in Covidâ€�19 vaccine and treatment trials. For instance, the drug" exact="hydroxychloroquine" post="was one of the first pharmaceutical agents under investigation"/>
   <result pre="fetal or maternal complications. Initial studies have not concluded that" exact="hydroxychloroquine" post="is an effective treatment for SARSâ€�CoVâ€�2, and, thus, the"/>
   <result pre="priority is among antiretrovirals (HIV protease inhibitors). The combination of" exact="lopinavir" post="and ritonavir has been widely used in HIVâ€�positive pregnant"/>
   <result pre="among antiretrovirals (HIV protease inhibitors). The combination of lopinavir and" exact="ritonavir" post="has been widely used in HIVâ€�positive pregnant women. Nevertheless,"/>
   <result pre="al., â€œAntibodies in Infants.â€� 11Gautret, P., et al., â€œHydroxychloroquine and" exact="Azithromycin" post="as a Treatment of Covid-19: Results of an Open-Label"/>
   <result pre="of print]): doi:10.1016/j.ijantimicag.2020.105949. 12Sperber, K., et al., â€œSystematic Review of" exact="Hydroxychloroquine" post="Use in Pregnant Patients with Autoimmune Diseases,â€� Pediatric Rheumatology"/>
   <result pre="Journal7 (2009): doi:10.1186/1546-0096-7-9; Sciascia, S., et al., â€œThe Impact of" exact="Hydroxychloroquine" post="Treatment on Pregnancy Outcome in Women with Antiphospholipid Antibodies,â€�"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7323156\results\search\drug\results.xml">
   <result pre="resolution triggers a prolonged phase of immune suppression through COXâ€�1/mPGESâ€�1â€�derived" exact="prostaglandin E2." post="Cell Reports, 20, 3162â€&quot;3175. 10.1016/j.celrep.2017.08.09828954232 Norris, P. C., Libreros,"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7323229\results\search\drug\results.xml">
   <result pre="randomized clinical trials (RCT) for the treatment of COVIDâ€�19 disease." exact="Chloroquine" post="(an old antimalarial medication), and hydroxychloroquine (used in treating"/>
   <result pre="treatment of COVIDâ€�19 disease. Chloroquine (an old antimalarial medication), and" exact="hydroxychloroquine" post="(used in treating some rheumatologic conditions) showed good inâ€�vitro"/>
   <result pre="the RCTs so far have not shown any benefit for" exact="chloroquine" post="or hydroxychloroquine, rather, a study had to be stopped"/>
   <result pre="in six continents, Mehra and colleagues30 found no benefit of" exact="Hydroxychloroquine" post="or chloroquine, when used alone or with a macrolide,"/>
   <result pre="poor outcomes in COVIDâ€�19 patients and in contrast, one NSAID," exact="Indomethacin" post="has shown in vitro evidence of inhibition of RNA"/>
   <result pre="countries have suggested that in patients with respiratory tract infections," exact="acetaminophen" post="should be used in preference to NSAIDs for control"/>
   <result pre="SampaioVS, et al. Effect of high vs low doses of" exact="chloroquine" post="diphosphate as adjunctive therapy for patients hospitalized with severe"/>
   <result pre="(SARSâ€�CoVâ€�2) infection. JAMA Netw Open. 2020;3(4):e208857. 30MehraMR, DesaiSS, RuschitzkaF, PatelAN." exact="Hydroxychloroquine" post="or chloroquine with or without a macrolide for treatment"/>
   <result pre="JAMA Netw Open. 2020;3(4):e208857. 30MehraMR, DesaiSS, RuschitzkaF, PatelAN. Hydroxychloroquine or" exact="chloroquine" post="with or without a macrolide for treatment of COVIDâ€�19:"/>
   <result pre="Arch Med Sci. 2020;16(3):490â€�496. https://pubmed.ncbi.nlm.nih.gov/32399094.32399094 38QiaoW, WangC, ChenB, et al." exact="Ibuprofen" post="attenuates cardiac fibrosis in streptozotocinâ€�induced diabetic rats. Cardiol. 2015;131(2):97â€�106."/>
   <result pre="diabetic rats. Cardiol. 2015;131(2):97â€�106. 39AmiciC, di CaroA, CiucciA, et al." exact="Indomethacin" post="has a potent antiviral activity against SARS coronavirus. Antivir"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7323526\results\search\drug\results.xml">
   <result pre="and meningococcal PCR, and treated empirically with intravenous or intramuscular" exact="ceftriaxone" post="(100 mg/kg/day) until their results were available. Additional investigations"/>
   <result pre="case-patients, this testing was necessary to obtain a diagnosis because" exact="ceftriaxone" post="had been administered before blood or CSF collection. For"/>
   <result pre="(median 4.7 hours) (Table 2). For the patient who received" exact="ceftriaxone" post="55 hours after first arrival, the patient received daily"/>
   <result pre="fever was on day 3 of illness, at which point" exact="ceftriaxone" post="was administered and the patient was transferred to Alice"/>
   <result pre="The patient was given a diagnosis of isolated meningococcemia, given" exact="ceftriaxone" post="for 5 days, and showed a full recovery. Seven"/>
   <result pre="mean time from initial clinic arrival to first dose of" exact="ceftriaxone" post="was significantly longer for these patients compared with patients"/>
   <result pre="significantly longer for these patients compared with patients who received" exact="ceftriaxone" post="as first-line treatment (26.1 hours vs. 6.0 hours; p"/>
   <result pre="patients who initially received penicillin compared with patients who received" exact="ceftriaxone" post="as first-line therapy (25.6 days vs. 6.4 days, p"/>
   <result pre="interval from initial clinic arrival to the first dose of" exact="ceftriaxone" post="for this patient was 16.8 hours. Benzathine penicillin had"/>
   <result pre="years; p = 0.08) or the time interval to receiving" exact="ceftriaxone" post="(mean 11.5 hours vs. 11.5 hours; p = 0.30)"/>
   <result pre="presentation to a clinic and receiving their first dose of" exact="ceftriaxone" post="(20.8 hours for the patient with meningitis and 39.2"/>
   <result pre="occurred if treatment had been delayed. The empiric administration of" exact="ceftriaxone" post="to all patients who had fever during the early"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7323662\results\search\drug\results.xml">
   <result pre="social exchange, maintain appropriate lifestyles and social contacts, avoid smoking," exact="alcohol" post="and other drugs, seek out health workers help when"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7326413\results\search\drug\results.xml">
   <result pre="Cole (2015) demonstrated that social instability adversely impacted metabolites of" exact="epinephrine" post="and norepinephrine, and expression of immune response genes, as"/>
   <result pre="response to social stimulus following both acute and chronic isolation." exact="Dopamine" post="levels were also reduced in fish exposed to social"/>
   <result pre="2018). Socioeconomic disadvantage was also associated with greater accumulation of" exact="cortisol" post="in hair in both parents and children, and that"/>
   <result pre="socioeconomic status was associated with heightened ambulatory blood pressure and" exact="cortisol" post="output over the working day, which may reflect stress-related"/>
   <result pre="late-life gene expression profilesAm. J. Epidemiol.1865201750350910.1093/aje/kwx14728911009 LiuC.H.FinkG.BrentaniH.BrentaniA.An assessment of hair" exact="cortisol" post="among postpartum Brazilian mothers and infants from a high-risk"/>
   <result pre="J. Div. Health Psychol. Am. Psychol. Assoc.371120181077108010.1037/hea0000675 UrsacheA.MerzE.C.MelvinS.MeyerJ.NobleK.G.Socioeconomic status, hair" exact="cortisol" post="and internalizing symptoms in parents and childrenPsychoneuroendocrinology78201714215010.1016/j.psyneuen.2017.01.02028199857 VolacoA.CavalcantiA.M.FilhoR.P.PrÃ©comaD.B.Socioeconomic status:"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7326458\results\search\drug\results.xml">
   <result pre="the initialy planned duration in four patients, two because of" exact="alanine" post="aminotransferase elevations (3 to 5 normal range) and two"/>
   <result pre="therapeutic agents for SARS-CoV-2, with controversial results. These agents include" exact="ribavirin" post="and interferon alpha 2b (IFNÎ±-2b) (Martinez, 2020), lopinavir/ritonavir (Chu"/>
   <result pre="SARS-CoV-2, with controversial results. These agents include ribavirin and interferon" exact="alpha" post="2b (IFNÎ±-2b) (Martinez, 2020), lopinavir/ritonavir (Chu et al., 2004,"/>
   <result pre="lopinavir/ritonavir (Chu et al., 2004, Arabi et al., 2020), and" exact="hydroxychloroquine" post="(Savarino et al., 2006, Chen et al., 2020, Gautret"/>
   <result pre="of illness) and was stopped on day 15, due to" exact="alanine" post="aminotransferase (ALT) elevation (195 IU/l versus 46 IU/l before"/>
   <result pre="recursive two-stage group sequential randomized controlled trialTrials21January (1)2020831900204 ChenZ.HuJ.ZhangZ.JiangS.HanS.YanD.Efficacy of" exact="hydroxychloroquine" post="in patients with COVID-19: results of a randomized clinical"/>
   <result pre="17, 20202020Available from: https://www.who.int/docs/default-source/coronaviruse/protocol-v2-1.pdf?sfvrsn=a9ef618c_2. [Cited 22 June 2020]. MarGautretP.LagierJ.-C.ParolaP.HoangV.T.MeddebL.MailheM.Hydroxychloroquine and" exact="azithromycin" post="as a treatment of COVID-19: results of an open-label"/>
   <result pre="inhibits both epidemic and zoonotic coronavirusesSci Transl Med93962017 WangM.CaoR.ZhangL.YangX.LiuJ.XuM.Remdesivir and" exact="chloroquine" post="effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7328712\results\search\drug\results.xml">
   <result pre="Lopinavirâ€&quot;ritonavir Lopinavirâ€&quot;ritonavir is a combination therapy used to treat HIV." exact="Ritonavir" post="is an inhibitor of cytochrome P450 and is used"/>
   <result pre="gastrointestinal intolerance, hepatotoxicity, pancreatitis, and QT prolongation. The use of" exact="ritonavir" post="can cause severe drugâ€&quot;drug interactions in medications metabolised through"/>
   <result pre="lopinavirâ€&quot;ritonavir combined with different drugs and different combinations such as" exact="ritonavir" post="and interferon 1b.39,56 Early use of lopinavirâ€&quot;ritonavir as an"/>
   <result pre="trial is ongoing and results have yet to be published.60" exact="Ribavirin" post="Ribavirin is a guanosine analogue that interferes with the"/>
   <result pre="is ongoing and results have yet to be published.60 Ribavirin" exact="Ribavirin" post="is a guanosine analogue that interferes with the replication"/>
   <result pre="replication of RNA and DNA viruses.61In vitro antiviral activities of" exact="Ribavirin" post="have been demonstrated in SARS-CoV and MERS-CoV.61,62 From the"/>
   <result pre="and MERS-CoV.61,62 From the experiences of SARS-CoV, the use of" exact="ribavirin" post="as a monotherapy was limited as it required high"/>
   <result pre="as it required high concentration to inhibit viral replication, and" exact="ribavirin" post="usage was associated with dose-dependent haemolysis and liver toxicity.63,64"/>
   <result pre="and liver toxicity.63,64 In the treatment of SARS and MERS," exact="ribavirin" post="is used in combination with interferon or lopinavir/ritonavir.11,65 The"/>
   <result pre="used in combination with interferon or lopinavir/ritonavir.11,65 The use of" exact="ribavirin" post="in combination with interferon or lopinavir/ritonavir is recommended in"/>
   <result pre="viral shedding and hospital stay in patients with mild-to-moderate COVID-19.67" exact="Chloroquine" post="and hydroxychloroquine Chloroquine and hydroxychloroquine are widely used for"/>
   <result pre="and hospital stay in patients with mild-to-moderate COVID-19.67 Chloroquine and" exact="hydroxychloroquine" post="Chloroquine and hydroxychloroquine are widely used for the treatment"/>
   <result pre="hospital stay in patients with mild-to-moderate COVID-19.67 Chloroquine and hydroxychloroquine" exact="Chloroquine" post="and hydroxychloroquine are widely used for the treatment of"/>
   <result pre="in patients with mild-to-moderate COVID-19.67 Chloroquine and hydroxychloroquine Chloroquine and" exact="hydroxychloroquine" post="are widely used for the treatment of malaria and"/>
   <result pre="safety profile and are readily available at relatively low cost." exact="Hydroxychloroquine" post="sulphate has been demonstrated to be less toxic than"/>
   <result pre="Hydroxychloroquine sulphate has been demonstrated to be less toxic than" exact="chloroquine" post="phosphate in animal studies.68 Both these drugs have been"/>
   <result pre="China involving more than 100 patients with Covid-19 showed that" exact="chloroquine" post="was better able to inhibit exacerbation of pneumonia and"/>
   <result pre="recent small open-label nonrandomised clinical trial showed patients given daily" exact="hydroxychloroquine" post="had significantly reduced viral load measured by nasopharyngeal swab"/>
   <result pre="factors, as some patients also received azithromycin.71 The combination of" exact="hydroxychloroquine" post="and azithromycin should be used with caution in patients"/>
   <result pre="some patients also received azithromycin.71 The combination of hydroxychloroquine and" exact="azithromycin" post="should be used with caution in patients at risk"/>
   <result pre="in patients at risk for QT prolongation. The use of" exact="chloroquine" post="alone is also a risk factor for QT prolongation."/>
   <result pre="IIb clinical trial assessing the safety and efficacy of high-dose" exact="chloroquine" post="was terminated early due to prolonged QTc (&amp;gt;500 ms)"/>
   <result pre="a multinational registry of 96,032 hospitalised COVID-19 patients revealed that" exact="hydroxychloroquine" post="or chloroquine was associated with decreased in-hospital survival (mortality"/>
   <result pre="registry of 96,032 hospitalised COVID-19 patients revealed that hydroxychloroquine or" exact="chloroquine" post="was associated with decreased in-hospital survival (mortality of 11.1"/>
   <result pre="led to retraction of the article.74 Other adverse effects of" exact="chloroquine" post="include retinopathy, rash, nausea, glucose fluctuation and diarrhoea, and"/>
   <result pre="retinopathy, rash, nausea, glucose fluctuation and diarrhoea, and use of" exact="chloroquine" post="is contraindicated in patients with porphyria. Chloroquine or hydroxychloroquine"/>
   <result pre="and use of chloroquine is contraindicated in patients with porphyria." exact="Chloroquine" post="or hydroxychloroquine should not be used to treat COVID-19"/>
   <result pre="of chloroquine is contraindicated in patients with porphyria. Chloroquine or" exact="hydroxychloroquine" post="should not be used to treat COVID-19 until they"/>
   <result pre="to determine the optimal dosage to balance efficacy and safety." exact="Chloroquine" post="or hydroxychloroquine has been suggested as candidate prophylactics for"/>
   <result pre="the optimal dosage to balance efficacy and safety. Chloroquine or" exact="hydroxychloroquine" post="has been suggested as candidate prophylactics for COVID-19 in"/>
   <result pre="for COVID-19 currently undergoing clinical trials include protease inhibitors (nelfinavir," exact="camostat" post="mesilate, ritonavir, danoprevir, darunavir, flavopiridol, relacatib), nucleoside analogues (galidesivir),"/>
   <result pre="targeting the immune system Corticosteroids Corticosteroid therapies such as intravenous" exact="methylprednisolone" post="are currently being tested as a treatment for COVID-19.77"/>
   <result pre="methylprednisolone are currently being tested as a treatment for COVID-19.77" exact="Methylprednisolone" post="has already been used in COVID-19 patients in combination"/>
   <result pre="and colleagues reported that corticosteroid therapy using methylprednisolone, dexamethasone, and" exact="hydrocortisone" post="was beneficial in treating SARS-CoV patients,78 and significantly prolonged"/>
   <result pre="treated with a combination therapy of moxifloxacin, lopinavir, interferon, and" exact="methylprednisolone" post="(given to only ICU patients) showed good treatment effects"/>
   <result pre="case report of a 45-year-old woman with COVID-19 treated with" exact="thalidomide" post="(100 mg orally once a day) and methylprednisolone (40"/>
   <result pre="treated with thalidomide (100 mg orally once a day) and" exact="methylprednisolone" post="(40 mg intravenously bid for 3 days then reduced"/>
   <result pre="option for the COVID-19Travel Med Infect Dis202010.1016/j.tmaid.2020.101615 45WangMCaoRZhangLet al.Remdesivir and" exact="chloroquine" post="effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in"/>
   <result pre="replication in vitroAntiviral Res2020178March10478610.1016/j.antiviral.2020.10478632251767 56collab: US National Library of MedicineLopinavir/ritonavir," exact="ribavirin" post="and IFN-beta combination for nCoV treatmenthttps://clinicaltrials.gov/ct2/show/NCT04276688. Published 2020Accessed April"/>
   <result pre="17, 2020 67HungIF-NLungK-CTsoEY-Ket al.Triple combination of interferon beta-1b, lopinavirâ€&quot;ritonavir, and" exact="ribavirin" post="in the treatment of patients admitted to hospital with"/>
   <result pre="open-label, randomised, phase 2 trialLancet202010.1016/S0140-6736(20)31042-4 68McChesneyEWAnimal toxicity and pharmacokinetics of" exact="hydroxychloroquine" post="sulfateAm J Med1983751 PART 1111810.1016/0002-9343(83)91265-26408923 69CortegianiAIngogliaGIppolitoMGiarratanoAEinavSA systematic review on"/>
   <result pre="1111810.1016/0002-9343(83)91265-26408923 69CortegianiAIngogliaGIppolitoMGiarratanoAEinavSA systematic review on the efficacy and safety of" exact="chloroquine" post="for the treatment of COVID-19J Crit Care20203710.1016/j.jcrc.2020.03.005 70GaoJTianZYangXBreakthrough: chloroquine"/>
   <result pre="of chloroquine for the treatment of COVID-19J Crit Care20203710.1016/j.jcrc.2020.03.005 70GaoJTianZYangXBreakthrough:" exact="chloroquine" post="phosphate has shown apparent efficacy in treatment of COVID-19"/>
   <result pre="COVID-19 associated pneumonia in clinical studiesBiosci Trends2020141727310.5582/bst.2020.0104732074550 71GautretPLagierJ-CParolaPet al.Hydroxychloroquine and" exact="azithromycin" post="as a treatment of COVID-19: results of an open-label"/>
   <result pre="results of a randomized, double-blinded, phase IIb clmedRxiv202010.1101/2020.04.07.20056424 73MehraMRDesaiSSRuschitzkaFPatelANHydroxychloroquine or" exact="chloroquine" post="with or without a macrolide for treatment of COVID-19:"/>
   <result pre="for treatment of COVID-19: a multinational registry analysisLancet202010.1016/S0140-6736(20)31180-6 74MehraMRRuschitzkaFPatelANRetraction-Hydroxychloroquine or" exact="chloroquine" post="with or without a macrolide for treatment of COVID-19:"/>
   <result pre="macrolide for treatment of COVID-19: a multinational registry analysisLancet202010.1016/S0140-6736(20)31324-6 75PrincipiNEspositoSCorrespondence" exact="chloroquine" post="or hydroxychloroquine for prophylaxis of COVID-19Lancet Infect Dis20203099203029610.1016/S1473-3099(20)30296-6 76collab:"/>
   <result pre="treatment of COVID-19: a multinational registry analysisLancet202010.1016/S0140-6736(20)31324-6 75PrincipiNEspositoSCorrespondence chloroquine or" exact="hydroxychloroquine" post="for prophylaxis of COVID-19Lancet Infect Dis20203099203029610.1016/S1473-3099(20)30296-6 76collab: World Health"/>
   <result pre="US National Library of MedicineOutcomes related to COVID-19 treated with" exact="hydroxychloroquine" post="among in-patients with symptomatic diseasehttps://clinicaltrials.gov/ct2/show/NCT04332991. Published 2020Accessed April 19,"/>
   <result pre="19, 2020 114collab: US National Library of MedicineThe impact of" exact="camostat" post="mesilate on COVID-19 infection (CamoCO-19)https://clinicaltrials.gov/ct2/show/NCT04321096?term=camostat+mesilate&amp;amp;cond=COVID&amp;amp;draw=2&amp;amp;rank=4. Published 2020Accessed April 22,"/>
   <result pre="Library of MedicineVarious combination of protease inhibitors, oseltamivir, favipiravir, and" exact="hydroxychloroquine" post="for treatment of COVID-19: a randomized control trial (THDMS-COVID-19)"/>
   <result pre="mg PO daily for 5 days QT prolongationNausea and vomitingRetinopathyRashHypoglycaemia" exact="Hydroxychloroquine" post="sulfate64,113 Adult: 400 mg PO every 12 hours for"/>
   <result pre="PO every 12 hours for 4 days. Protease inhibitor76,114â€&quot;116 Nelfinavir," exact="camostat" post="mesilate, ritonavir, danoprevir, darunavir, flavopiridol, relacatib PO LipodystrophyMetabolic effects"/>
   <result pre="side effectsHeadache Pharmacological therapies targeting the immune system Corticosteroids66,77,110,120 Adult:" exact="methylprednisolone" post="40 mg IV every 12 hours for 5 days"/>
   <result pre="annua 12 g, Polygonum cuspidatum 20 g, verbena 30 g," exact="dried" post="reed root 30 g, gardenia 15 g, orange red"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7331074\results\search\drug\results.xml">
   <result pre="10% inactivated fetal bovine serum (Gibco) and antibiotics (100 U/mL" exact="penicillin G" post="and 100 Î¼g/mL streptomycin) (Gibco). The cells were incubated"/>
   <result pre="for an additional 4 h. Formazan precipitates were dissolved with" exact="dimethyl sulfoxide" post="(150 Î¼L/well), and then, the absorbance was measured at"/>
   <result pre="Cell2010, 140, 805â€&quot;820. 10.1016/j.cell.2010.01.022.20303872 LinR.-J.; LiaoC.-L.; LinE.; LinY.-L.Blocking of the" exact="alpha" post="interferon-induced Jak-Stat signaling pathway by Japanese encephalitis virus infection."/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7331567\results\search\drug\results.xml">
   <result pre="show the highest degree of conservation amongst the cleavage sites.63" exact="Glutamine" post="in P1 is highly conserved in all polyprotein cleavage"/>
   <result pre="as viral serine protease warheads in the approved HCV drugs" exact="telaprevir" post="and boceprevir.62 Compound 1 has previously been investigated as"/>
   <result pre="hydrophobic cyclohexyl (1, 2) or smaller cyclopropyl (3) groups as" exact="leucine" post="mimetics and P1â€² contains cyclopropyl (2) or benzyl (1,"/>
   <result pre="Mpro inhibition and reduction of cytopathic effect were the Î±-ketoamides" exact="boceprevir" post="(KiÂ =Â 1.18 Î¼Îœ, EC50Â =Â 1.31Â Î¼M) and"/>
   <result pre="4 are covalent modifiers with precedents in approved drugs (e.g." exact="telaprevir" post="or afatinib).62, 105 Potential problems associated with limited drug-likeness"/>
   <result pre="Attempts to repurpose the approved combination of HIV protease inhibitors," exact="ritonavir" post="and lopinavir, was unsuccessful in clinical studies, which is"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7332457\results\search\drug\results.xml">
   <result pre="distal enterocytes coexpress dipeptidyl peptidase-4 (the receptor for MERS-CoV) and" exact="alanine" post="aminopeptidase (the receptor for hCoV-229E) (Liang etÂ al., 2020)."/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7332875\results\search\drug\results.xml">
   <result pre="the three drugs through molecular dynamics simulation studies for 50â€‰ns." exact="Zidovudine" post="shows a very stable interaction with fluctuation starting at"/>
   <result pre="0 0.00 Disallowed regions 0 0.00 The end residues (excluding" exact="Glycine" post="and Proline) 8 Â Proline 64 Â Glycine 40"/>
   <result pre="0.00 The end residues (excluding Glycine and Proline) 8 Â" exact="Proline" post="64 Â Glycine 40 Â Total number of residues"/>
   <result pre="residues (excluding Glycine and Proline) 8 Â Proline 64 Â" exact="Glycine" post="40 Â Total number of residues 499 100 This"/>
   <result pre="PubChem databases and their docking score on each sites are" exact="Zidovudine" post="(âˆ’11.08, âˆ’9.09, âˆ’9.75), Valganciclovir (âˆ’8.102, âˆ’5.40, âˆ’8.30) and Ribavirin"/>
   <result pre="docking score on each sites are Zidovudine (âˆ’11.08, âˆ’9.09, âˆ’9.75)," exact="Valganciclovir" post="(âˆ’8.102, âˆ’5.40, âˆ’8.30) and Ribavirin (âˆ’8.59, âˆ’6.38, âˆ’7.94). Further"/>
   <result pre="are Zidovudine (âˆ’11.08, âˆ’9.09, âˆ’9.75), Valganciclovir (âˆ’8.102, âˆ’5.40, âˆ’8.30) and" exact="Ribavirin" post="(âˆ’8.59, âˆ’6.38, âˆ’7.94). Further ranking of these molecules was"/>
   <result pre="on each sites (Site 1, Site 2, Site 3) are" exact="Zidovudine" post="(âˆ’23.50, âˆ’16.37, âˆ’44.64), Valganciclovir (âˆ’49.88, âˆ’39.44, âˆ’48.05) and Ribavirin"/>
   <result pre="1, Site 2, Site 3) are Zidovudine (âˆ’23.50, âˆ’16.37, âˆ’44.64)," exact="Valganciclovir" post="(âˆ’49.88, âˆ’39.44, âˆ’48.05) and Ribavirin (âˆ’40.92, âˆ’47.82, âˆ’44.96) (Table"/>
   <result pre="are Zidovudine (âˆ’23.50, âˆ’16.37, âˆ’44.64), Valganciclovir (âˆ’49.88, âˆ’39.44, âˆ’48.05) and" exact="Ribavirin" post="(âˆ’40.92, âˆ’47.82, âˆ’44.96) (Table 6). Further ranking of these"/>
   <result pre="of drug molecules PubChem Id Indication Mechanism of action 1" exact="Zidovudine" post="72187 Antiviral drug used for the treatment of human"/>
   <result pre="activity against Human Immunodeficiency Virus Type 1 (HIV-1) (https://www.drugbank.ca/drugs/DB00495) 2" exact="Valganciclovir" post="135413534 Antiviral drug used for the treatment of cytomegalovirus"/>
   <result pre="incorporation with viral DNA&amp;amp; inhibits viral DNA polymerases (https://www.drugbank.ca/drugs/DB01610) 3" exact="Ribavirin" post="37542 Used for the treatment of chronic Hepatitis C"/>
   <result pre="water bridges (Figure 6(B)). Figure 5(C) shows the interaction of" exact="Zidovudine" post="with the target protein. It shows a very stable"/>
   <result pre="The RMSF fluctuation is also very low in case of" exact="Zidovudine" post="(0.8 minimum to 4.3) as compared to two other"/>
   <result pre="has been used in one earlier study that has shown" exact="theophylline" post="and pyrimidine groups of drugs as promisable interactions (Sarma"/>
   <result pre="have antiviral activities and drugs from PubChem databases are Zidovudine," exact="Valganciclovir" post="and Ribavirin. Thus, anti-HIV drugs as well as anti-Herpes"/>
   <result pre="MD simulation to find final three drugs. Out of those," exact="Zidovudine" post="has stronger and more stable interaction with this protein"/>
   <result pre="stable interaction with this protein structure. Therefore, the drugs especially" exact="Zidovudine" post="can be further explored in the clinical trial as"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7332877\results\search\drug\results.xml">
   <result pre="first clinical trial to investigate the efficacy of Remdesivir, an" exact="adenosine" post="analog which can cause pre-mature RNA termination of the"/>
   <result pre="Various provinces of China and India have initiated trials using" exact="Chloroquine" post="or hydroxychloroquine, known anti-malarial agent, as a heme polymerase"/>
   <result pre="inhibited the 2019-nCoV at a low-micromolar concentration. Further, Remdesivir and" exact="Chloroquine" post="were also found to be potently blocking virus infection"/>
   <result pre="study is to dock the antiviral drugs (1) Remdesivir (2)" exact="Chloroquine" post="(3) Favipiravir (4) Baloxavir Marboxil (5) Ribavirin (6) Penciclovir"/>
   <result pre="(1) Remdesivir (2) Chloroquine (3) Favipiravir (4) Baloxavir Marboxil (5)" exact="Ribavirin" post="(6) Penciclovir (7) Nafamostat (8) Nitazoxanide (9) Oseltamivir and"/>
   <result pre="(2) Chloroquine (3) Favipiravir (4) Baloxavir Marboxil (5) Ribavirin (6)" exact="Penciclovir" post="(7) Nafamostat (8) Nitazoxanide (9) Oseltamivir and (10) Zanamivir"/>
   <result pre="(3) Favipiravir (4) Baloxavir Marboxil (5) Ribavirin (6) Penciclovir (7)" exact="Nafamostat" post="(8) Nitazoxanide (9) Oseltamivir and (10) Zanamivir with Mpro"/>
   <result pre="(6) Penciclovir (7) Nafamostat (8) Nitazoxanide (9) Oseltamivir and (10)" exact="Zanamivir" post="with Mpro to understand their effectiveness against 2019-nCoV. The"/>
   <result pre="Chloroquine, Favipiravir, Baloxavir Marboxil, Ribavirin, Penciclovir, Nafamostat, Nitazoxanide, Oseltamivir and" exact="Zanamivir" post="ae chosen for the molecular docking analysis and the"/>
   <result pre="His163:NH â†’ Câ€‰=â€‰O 2.13 His164:Ï€-Ï€ â€&quot; Met165:NH â†’ Câ€‰=â€‰O 3.50" exact="Baloxavir marboxil" post="âˆ’7.8 His41: Ï€-cation â€&quot; Thr25, Thr26, Leu27, His41, Met49,"/>
   <result pre="Glu166, Gln189 Cys145:NH â†’ CO 2.61 Glu166:NH â†’ CO 2.26" exact="Nafamostat" post="âˆ’7.7 Tyr54:CO â†� NH 1.38 Leu27, Pro39, Arg40, His41,"/>
   <result pre="Cys145, His164, Met165, Asp187 His164:NH â†� NO 2.71 Â Â" exact="Penciclovir" post="âˆ’6.5 Tyr54:CO â†� HN 2.64 Thr26, Leu27, His41, Met49,"/>
   <result pre="His172, Gln189 Cys145:Câ€‰=â€‰O â†’ OH 2.48 Cys145:NH â†� CO 1.54" exact="Zanamivir" post="âˆ’6.5 His41:Câ€‰=â€‰O â†� NH 2.23 Thr25, Thr26, Leu27, Asn28,"/>
   <result pre="OH 2.38 Cys145:Câ€‰=â€‰O â†� OH 2.58 His164:Câ€‰=â€‰O â†� NH 2.23" exact="Ribavirin" post="âˆ’6.2 Ser144:NH â†’ CO 2.80 His41, Met49, Leu141, Asn142,"/>
   <result pre="Arg188, Gln189 Cys145:NH â†’ CO 2.74 Glu166:NH â†’ CO 2.33" exact="Chloroquine" post="âˆ’5.7 Cys:145:CS â†� NH 1.23 Leu27, Pro39, His41, Met49,"/>
   <result pre="better binding score to least binding score: Remdesivirâ€‰&amp;gt;â€‰Baloxavir marboxil &amp;gt;" exact="Nafamostat" post="&amp;gt; Nitazoxanide &amp;gt; Penciclovir &amp;gt; Zanamivirâ€‰&amp;gt;â€‰Ribavirinâ€‰&amp;gt;â€‰Oseltamivirâ€‰&amp;gt; Chloroquine &amp;gt; Favipiravir"/>
   <result pre="least binding score: Remdesivirâ€‰&amp;gt;â€‰Baloxavir marboxil &amp;gt; Nafamostat &amp;gt; Nitazoxanide &amp;gt;" exact="Penciclovir" post="&amp;gt; Zanamivirâ€‰&amp;gt;â€‰Ribavirinâ€‰&amp;gt;â€‰Oseltamivirâ€‰&amp;gt; Chloroquine &amp;gt; Favipiravir (Table 1 and Figure"/>
   <result pre="Remdesivirâ€‰&amp;gt;â€‰Baloxavir marboxil &amp;gt; Nafamostat &amp;gt; Nitazoxanide &amp;gt; Penciclovir &amp;gt; Zanamivirâ€‰&amp;gt;â€‰Ribavirinâ€‰&amp;gt;â€‰Oseltamivirâ€‰&amp;gt;" exact="Chloroquine" post="&amp;gt; Favipiravir (Table 1 and Figure 5A and B)."/>
   <result pre="Dynamics, 32(2), 171â€&quot;185. 10.1080/07391102.2012.75805623383626 RathiS., IshP., KalantriA., &amp;amp; KalantriS. (2020)." exact="Hydroxychloroquine" post="prophylaxis for COVID-19 contacts in India. Lancet Infectious Diseases."/>
   <result pre="Discovery and synthesis of a phosphoramidate prodrug of a pyrrolo[2,1-f][triazin-4-amino]" exact="adenine" post="C-nucleoside (GS-5734) for the treatment of Ebola and emerging"/>
   <result pre="RollinP. E., KsiazekT. G., SeidahN. G., &amp;amp; NicholS. T. (2005)." exact="Chloroquine" post="is a potent inhibitor of SARS coronavirus infection and"/>
   <result pre="LiuJ., XuM., ShiZ., HuZ., ZhongW., &amp;amp; XiaoG. (2020). Remdesivir and" exact="chloroquine" post="effectively inhibit the recently emerged novel coronavirus (2019-nCoV) inÂ"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7332961\results\search\drug\results.xml">
   <result pre="CHIKV infectivity in Ae. albopictus in the presence of either" exact="alanine" post="or valine at position 226 in E1 protein. This"/>
   <result pre="C.YoungA. R.MonteK.HedbergM. L.ShimakR. M.et al. (2019). Distinct roles of interferon" exact="alpha" post="and beta in controlling Chikungunya. Virus replication and modulating"/>
   <result pre="22, 2020). Moller-TankS.KondratowiczA. S.DaveyR. A.RennertP. D.MauryW. (2013). Role of the" exact="phosphatidylserine" post="receptor TIM-1 in enveloped-virus entry.J. Virol.878327â€&quot;8341. 10.1128/JVI.01025-1323698310 MylesK. M.KellyC."/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7334951\results\search\drug\results.xml">
   <result pre="phase 2 trial examining the combination of IFN-Î²1b, lopinavir/ritonavir and" exact="ribavirin" post="compared with lopinavir/ritonavir alone, the investigators observed significant symptoms"/>
   <result pre="interests. References References 1HungI.F.-N.LungK.-C.TsoE.Y.-K.LiuR.ChungT.W.-H.ChuM.-Y.NgY.-Y.LoJ.ChanJ.TamA.R.ShumH.-P.ChanV.WuA.K.-L.SinK.-M.LeungW.-S.LawW.-L.LungD.C.SinS.YeungP.YipC.C.-Y.ZhangR.R.FungA.Y.-F.YanE.Y.-W.LeungK.-H.IpJ.D.ChuA.W.-H.ChanW.-M.NgA.C.-K.LeeR.FungK.YeungA.WuT.-C.ChanJ.W.-M.YanW.-W.ChanW.-M.ChanJ.F.-W.LieA.K.-W.TsangO.T.-Y.ChengV.C.-C.QueT.-L.LauC.-S.ChanK.-H.ToK.K.-W.YuenK.-Y.Triple combination of interferon beta-1b, lopinavirâ€&quot;ritonavir, and" exact="ribavirin" post="in the treatment of patients admitted to hospital with"/>
   <result pre="the monkey nervous system following intranasal administrationNeuroscience.152200878579710.1016/j.neuroscience.2008.01.01318304744 59BennettA.L.SmithD.W.CumminsM.J.JacobyP.A.CumminsJ.M.BeilharzM.W.Low-dose oral interferon" exact="alpha" post="as prophylaxis against viral respiratory illness: a double-blind, parallel"/>
   <result pre="of Interferon?Clin. Pharmacokinet.21199141141710.2165/00003088-199121060-000021723667 61MengZ.WangT.LiC.ChenX.LiL.QinX.LiH.LuoJ.An experimental trial of recombinant human interferon" exact="alpha" post="nasal drops to prevent coronavirus disease 2019 in medical"/>
   <result pre="LieA.Tak-Yin TsangO.Chi-Chung ChengV.QueT.-L.LauC.-S.ChanK.-H.Kai-Wang ToK.YuenK.-Y.HungI.F.-N.LungK.-C.TsoE.Y.-K.LiuR.ChungT.W.-H.ChuM.-Y.NgY.-Y.LoJ.ChanJ.W.TamA.R.ShumH.-P.ChanV.WuA.K.-L.SinK.-M.LeungW.-S.LawW.-L.LungD.C.SinS.YeungP.YipC.C.-Y.ZhangR.R.FungA.Y.-F.YanE.Y.-W.LeungK.-H.IpJ.D.ChuA.W.-H.ChanW.-M.W.-M.NgA.C.-K.LeeR.FungK.YeungA.WuT.-C.ChanJ.W.YanW.-W.ChanW.-M.W.-M.ChanJ.W.LieA.K.-W.TsangO.T.-Y.ChengV.C.-C.QueT.-L.LauC.-S.ChanK.-H.ToK.K.-W.YuenK.-Y.Triple combination of interferon beta-1b, lopinavirâ€&quot;ritonavir, and" exact="ribavirin" post="in the treatment of patients admitted to hospital with"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7335243\results\search\drug\results.xml">
   <result pre="the lipid or sterol metabolism, regulation of neurotransmitters, kinase signaling," exact="estrogen" post="receptors, and DNA synthesis/repair) [70], [71], [72], [73]. It"/>
   <result pre="Manufacturer Status of clinical trials Nucleoside Analogs Pegylated interferon with" exact="ribavirin" post="[77] / Valeant Under clinical trial for COVID-19 (ChiCTR2000029387)"/>
   <result pre="Under clinical trial for COVID-19 (ChiCTR2000029548) Remdesivir [79] (GS-5734) An" exact="adenine" post="analog with a similar chemical structure to the approved"/>
   <result pre="similar chemical structure to the approved HIV reverse transcriptase inhibitor" exact="tenofovir alafenamide." post="Gilead Phase II clinical trial for Ebola(NCT03719586);Under phase III"/>
   <result pre="of COVID-19 in the early stage Protease inhibitors Lopinavir and" exact="ritonavir" post="[76] Protease inhibitors approved as anti-HIV drugs Abbott Under"/>
   <result pre="clinical trials for SARS; Under clinical trial for COVID-19 (ChiCTR2000029539)" exact="Chloroquine" post="Chloroquine and hydroxychloroquine [81] Oral prescription drugs for treatment"/>
   <result pre="trials for SARS; Under clinical trial for COVID-19 (ChiCTR2000029539) Chloroquine" exact="Chloroquine" post="and hydroxychloroquine [81] Oral prescription drugs for treatment of"/>
   <result pre="SARS; Under clinical trial for COVID-19 (ChiCTR2000029539) Chloroquine Chloroquine and" exact="hydroxychloroquine" post="[81] Oral prescription drugs for treatment of malaria and"/>
   <result pre="RdRp, nucleoside analogs are responsible for viral RNA replication [84]." exact="Ribavirin" post="is a guanine analog among approved nucleoside analogs used"/>
   <result pre="and has been harnessed to cure patients with SARS [85]." exact="Ribavirin" post="was extensively leveraged for patients with or without concomitant"/>
   <result pre="reactions like anemia in high doses [77]. In COVID-19 therapy," exact="ribavirin" post="was utilized with pegylated interferon for stimulating the innate"/>
   <result pre="with other antiviral drugs like baloxavir marboxil [88]. As an" exact="adenine" post="analogue with a similar chemical structure to the approved"/>
   <result pre="similar chemical structure to the approved HIV reverse transcriptase inhibitor" exact="tenofovir alafenamide," post="remdesivir (GS-5734) exhibits broad-spectrum antiviral activity against several RNA"/>
   <result pre="It also possesses outstanding in vitro antiviral activity compared with" exact="lopinavir" post="and ritonavir [90]. In the United States, the first"/>
   <result pre="possesses outstanding in vitro antiviral activity compared with lopinavir and" exact="ritonavir" post="[90]. In the United States, the first case of"/>
   <result pre="of IFN-Î± via vapor inhalation in patients twice daily with" exact="ribavirin" post="as combined therapy [96]. In the detailed study of"/>
   <result pre="to the standard-care group. Further, Baden and Rubin unraveled that" exact="lopinavir" post="simply was not particularly potent against SARS-CoV-2. The concentration"/>
   <result pre="SARS-CoV, indicating an alternative therapeutic option for COVID-19 [76]. 5.3.2" exact="Chloroquine" post="and hydroxychloroquine Chloroquine, as a drug extensively utilized in"/>
   <result pre="an alternative therapeutic option for COVID-19 [76]. 5.3.2 Chloroquine and" exact="hydroxychloroquine" post="Chloroquine, as a drug extensively utilized in anti-malaria and"/>
   <result pre="of SARS-CoV cell receptors [101]. Gao et al. revealed that" exact="chloroquine" post="was effective in the therapy of COVID-19-associated pneumonia [102]."/>
   <result pre="of around 1â€¯Î¼M [88]. Although several trials had verified that" exact="chloroquine" post="suppresses the exacerbation of COVID-19, the optimal dosage of"/>
   <result pre="chloroquine suppresses the exacerbation of COVID-19, the optimal dosage of" exact="chloroquine" post="will require to be evaluated in future trials [102]."/>
   <result pre="chloroquine will require to be evaluated in future trials [102]." exact="Hydroxychloroquine" post="is an analog of chloroquine, and there are few"/>
   <result pre="few studies on its interaction [103]. In previous SARS outbreaks," exact="hydroxychloroquine" post="was found to possess anti-SARS-CoV capacity in vitro[104]. In"/>
   <result pre="by applying a physiologically based pharmacokinetic model, they found that" exact="hydroxychloroquine" post="is more effective than chloroquine in Vero cells infected"/>
   <result pre="pharmacokinetic model, they found that hydroxychloroquine is more effective than" exact="chloroquine" post="in Vero cells infected with SARS-CoV-2 [105]. Of note,"/>
   <result pre="in turn cause multiple organ failure and death [49]. Both" exact="chloroquine" post="and hydroxychloroquine possess immunomodulatory effects and can inhibit such"/>
   <result pre="cause multiple organ failure and death [49]. Both chloroquine and" exact="hydroxychloroquine" post="possess immunomodulatory effects and can inhibit such immune responses"/>
   <result pre="may relate with the determination of whether the benefit of" exact="chloroquine" post="treatment is hinged on the age of the patients"/>
   <result pre="[107]. Recently, a multinational registry analysis of the application of" exact="hydroxychloroquine" post="or chloroquine unraveled that there might be an increased"/>
   <result pre="a multinational registry analysis of the application of hydroxychloroquine or" exact="chloroquine" post="unraveled that there might be an increased frequency of"/>
   <result pre="treatment of COVID-19 diseases [108]. The WHO has also suspended" exact="hydroxychloroquine" post="treatment in COVID-19 solidarity trial in terms of the"/>
   <result pre="of SARS: initial virological and clinical findingsThorax59200425225614985565 76YamamotoN.YangR.YoshinakaY.AmariS.NakanoT.CinatlJ.HIV protease inhibitor" exact="nelfinavir" post="inhibits replication of SARS-associated coronavirusBiochem Biophys Res Commun318200471972515144898 77Al-TawfiqJ.A.MomattinH.DibJ.MemishZ.A.Ribavirin"/>
   <result pre="depletion of cellular GTP pools and is moderately synergistic with" exact="alpha" post="interferonAntimicrob Agents Chemother58201426727324145541 85SoL.K.Y.LauA.C.W.YamL.Y.C.CheungT.M.T.PoonE.YungR.W.H.Development of a standard treatment protocol"/>
   <result pre="animal and human cell linesBiochem Biophys Res Commun326200590590815607755 88WangM.CaoR.ZhangL.YangX.LiuJ.XuM.Remdesivir and" exact="chloroquine" post="effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in"/>
   <result pre="potent inhibitor of SARS coronavirus infection and spreadVirol J220056916115318 102GaoJ.TianZ.YangX.Breakthrough:" exact="chloroquine" post="phosphate has shown apparent efficacy in treatment of COVID-19"/>
   <result pre="COVID-19 associated pneumonia in clinical studiesBiosci Trends4120207273 103JallouliM.GalicierL.ZahrN.AumaitreO.FrancesC.Le GuernV.Determinants of" exact="hydroxychloroquine" post="blood concentration variations in systemic lupus erythematosusArthritis Rheumatol6720152176218425989906 104BiotC.DaherW.ChavainN.FandeurT.KhalifeJ.DiveD.Design"/>
   <result pre="vitro antiviral activity and projection of optimized dosing design of" exact="hydroxychloroquine" post="for the treatment of severe acute respiratory syndrome coronavirus"/>
   <result pre="syndrome coronavirus 2 (SARS-CoV-2)Clin Infect Dis2020ciaa237 106SchrezenmeierE.DÃ¶rnerT.Mechanisms of action of" exact="hydroxychloroquine" post="and chloroquine: implications for rheumatologyNat Rev Rheumatol16202015516632034323 107TouretF.de LamballerieX.Of"/>
   <result pre="hydroxychloroquine and chloroquine: implications for rheumatologyNat Rev Rheumatol16202015516632034323 107TouretF.de LamballerieX.Of" exact="chloroquine" post="and COVID-19Antiviral Res2020104762 108MehraM.R.DesaiS.S.RuschitzkaF.PatelA.N.Hydroxychloroquine or chloroquine with or without"/>
   <result pre="Rev Rheumatol16202015516632034323 107TouretF.de LamballerieX.Of chloroquine and COVID-19Antiviral Res2020104762 108MehraM.R.DesaiS.S.RuschitzkaF.PatelA.N.Hydroxychloroquine or" exact="chloroquine" post="with or without a macrolide for treatment of COVID-19:"/>
   <result pre="treatment of COVID-19: a multinational registry analysisLancet202010.1016/S0140-6736(20)31180-6 109Kunzmann K.A.WHO suspends" exact="hydroxychloroquine" post="treatment in COVID-19 solidarity trial2020. https://www.contagionlive.com/news/who-hydroxychloroquine-treatment-covid-19-solidarity-trial. 110JeanS.S.LeeP.I.HsuehP.R.Treatment options for"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7335248\results\search\drug\results.xml">
   <result pre="HIV (human immunodeficiency virus) spread causing acquired immune deficiency syndrome." exact="Zidovudine" post="(AZT) was the first anti-HIV drug approved in the"/>
   <result pre="9.60) showed anti-influenza activities, even if with higher IC50 than" exact="ribavirin" post="and oseltamivir acid, used as positive controls for the"/>
   <result pre="oligomer with an IC50 value eightfold lower than that of" exact="ribavirin" post="(IC50=5.54Â Î¼g/mL). Notably, the methoxy group in isorhapontigenin (IC50Â"/>
   <result pre="with nucleoside analogue reverse transcriptase inhibitors (NRTIs) such as tenofovir," exact="didanosine" post="and zidovudine, resveratrol seemed to improve the inhibition of"/>
   <result pre="al. studied the synergistic effect of resveratrol in combination with" exact="decitabine" post="(5-aza-2â€²-deoxycytidine, 5-aza-dC), a deoxyribonucleoside analogue able to lethally mutagenize"/>
   <result pre="in 2016 the same authors studied combinations of resveratrol and" exact="5-azacytidine" post="(5-aza-C), the decitabine riboside analogue, and they found that"/>
   <result pre="same authors studied combinations of resveratrol and 5-azacytidine (5-aza-C), the" exact="decitabine" post="riboside analogue, and they found that the synergistic activity"/>
   <result pre="and transmission to new hosts [17,96]. Nucleoside analogues, such as" exact="acyclovir" post="and pencyclovir, are administered as therapeutic agents against HSV."/>
   <result pre="to the growth of herpes simplex virus strains resistant to" exact="acyclovir" post="[100]. An exhaustive overview on resveratrol as novel anti-herpes"/>
   <result pre="of HSV-2 replication to hopeaphenol and shoreaketone in comparison with" exact="acyclovir" post="(ACV). The two oligostilbenoids acted as potent virucidal when"/>
   <result pre="of ribonucleotide reductaseFEBS Lett.421199827727910.1016/S0014-5793(97)01572-X9468322 86RawsonJ.M.O.RothM.E.XieJ.DalyM.B.ClouserC.L.LandmanS.R.ReillyC.S.BonnacL.KimB.PattersonS.E.ManskyL.M.Synergistic reduction of HIV-1 infectivity by" exact="5-azacytidine" post="and inhibitors of ribonucleotide reductaseBioorg. Med. Chem.2420162410242210.1016/j.bmc.2016.03.05227117260 87HanY.QuashieP.K.MesplÃ¨deT.XuH.QuanY.JaegerW.SzekeresT.WainbergM.A.AÂ resveratrol"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7335730\results\search\drug\results.xml">
   <result pre="aggressive therapy and of rescue ventilatory strategies, such as inhaled" exact="nitric oxide," post="prone positioning, and extracorporeal membrane oxygenation [18]. Stroke During"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7336121\results\search\drug\results.xml">
   <result pre="with RVG (a 29 amino acid peptide) specifically for nicotinic" exact="acetylcholine" post="receptor (nAchR) binding in the CNS. The molecule entered"/>
   <result pre="Biol. Ther.27200276376912387675 61RizzaS.A.BhatiaR.ZeuliJ.TemesgenZ.Ibalizumab for the treatment of multidrug-resistant HIV-1 infectionDrugs" exact="Today" post="(Barcelona, Spain: 1998)55120192534 62SimÃµesE.A.F.BontL.ManzoniP.FaurouxB.PaesB.Figueras-AloyJ.Past, present and future approaches to"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7337839\results\search\drug\results.xml">
   <result pre="endocrine disorders who develop COVID-19, several factors warrant management decisions." exact="Hydrocortisone" post="dose adjustments are required in patients with adrenal insufficiency."/>
   <result pre="be associated with postviral hypocortisolism and are dramatically improved with" exact="cortisol" post="replacement [41]. Furthermore, insertion/deletion polymorphisms in the ACE gene"/>
   <result pre="[52] Hypernatremia Impaired level of consciousness Monitor electrolytes Replacement Convert" exact="desmopressin" post="to parenteral form [52] Hypokalemia Gastrointestinal losses [52] Upregulation"/>
   <result pre="Persistently low blood pressure Hyperkalemia and hyponatremia Serum 9 am" exact="cortisol" post="Cosyntropin test Hydrocortisone therapy Thyroid Hypothyroidism Destruction of follicular"/>
   <result pre="low blood pressure Hyperkalemia and hyponatremia Serum 9 am cortisol" exact="Cosyntropin" post="test Hydrocortisone therapy Thyroid Hypothyroidism Destruction of follicular and"/>
   <result pre="pressure Hyperkalemia and hyponatremia Serum 9 am cortisol Cosyntropin test" exact="Hydrocortisone" post="therapy Thyroid Hypothyroidism Destruction of follicular and parafollicular cells"/>
   <result pre="regarding possible electrolyte imbalances and should titrate any corticosteroid or" exact="desmopressin" post="doses accordingly. If intranasal desmopressin cannot be administered because"/>
   <result pre="should titrate any corticosteroid or desmopressin doses accordingly. If intranasal" exact="desmopressin" post="cannot be administered because of impaired consciousness, it can"/>
   <result pre="COVID-19 Endocrine Condition Management Diabetes insipidus Titrate the dose of" exact="desmopressin" post="according to serum sodium, and osmolality. Convert to parenteral"/>
   <result pre="parenteral form (IV/IM) if intranasal route is not feasible [52]" exact="Desmopressin" post="dose equivalents [138] Tablets Spray Injections 100 Âµg 2.5"/>
   <result pre="established GH deficiency [58] Hypoadrenalism Double the morning dose of" exact="hydrocortisone" post="and continue 20 mg 4 times daily, or give"/>
   <result pre="continue 20 mg 4 times daily, or give doubled usual" exact="hydrocortisone" post="dose (â€œsick day ruleâ€�), depending on the infection severity"/>
   <result pre="patient characteristics [64] During an adrenal crisis, IM or IV" exact="hydrocortisone" post="100 mg stat followed by 200 mg over 24-hour"/>
   <result pre="infusion [66] Patients with primary hypoadrenalism do not require increasing" exact="fludrocortisone" post="dose [65] Critical illness-related corticosteroid insufficiency (CIRCI): IV hydrocortisone"/>
   <result pre="increasing fludrocortisone dose [65] Critical illness-related corticosteroid insufficiency (CIRCI): IV" exact="hydrocortisone" post="400 mg daily for 3 days or longer depending"/>
   <result pre="syndrome Continue medical management in those with active disease IV" exact="etomidate" post="at a rate of 0.04 to 0.05 mg/kg/h for"/>
   <result pre="to 0.05 mg/kg/h for those with severe illness targeting a" exact="cortisol" post="level 500-800 nmol/L [78, 79] Anticoagulation to be considered"/>
   <result pre="hypocalcemia increases the risk of QT prolongation with chloroquine/hydroxychloroquine and" exact="azithromycin" post="[112] Vitamin D deficiency Vitamin D supplements to achieve"/>
   <result pre="10 000 IU depending on the requirement [131, 132] Hypogonadism" exact="Testosterone" post="Temporary discontinuation may be possible if medication is not"/>
   <result pre="changing to an alternative is possible (e.g., intramuscular injections to" exact="testosterone" post="gel) Estrogen Conversion to transdermal formulations when applicable as"/>
   <result pre="an alternative is possible (e.g., intramuscular injections to testosterone gel)" exact="Estrogen" post="Conversion to transdermal formulations when applicable as the thrombosis"/>
   <result pre="the thrombosis risk is lower with transdermal compared to oral" exact="estrogen" post="Based on the currently available evidence, patients with preexisting"/>
   <result pre="the currently available evidence, patients with preexisting hyperprolactinemia may continue" exact="dopamine" post="receptor agonist (DRA) therapy during the pandemic and during"/>
   <result pre="the clinical significance of higher plasma bromocriptine levels is uncertain." exact="Cabergoline" post="is less affected by such enzyme modulations because only"/>
   <result pre="temporary discontinuation of DRAs in severe COVID-19 should be considered." exact="Chloroquine" post="is not known to adversely interact with DRAs. In"/>
   <result pre="cell apoptosis in pituitary tumors when used in combination with" exact="cabergoline" post="in animal studies [57]. However, these beneficial effects are"/>
   <result pre="would be on steroid replacement in physiological doses, usually with" exact="hydrocortisone" post="which needs continuation without disruption. Patients should have a"/>
   <result pre="have a â€œsteroid emergency cardâ€� and bracelet with details of" exact="hydrocortisone" post="dosing during an infection. Standard guidelines suggest doubling the"/>
   <result pre="continuous inflammation [63, 64]. Therefore, an immediate dose of doubled" exact="hydrocortisone" post="morning dose, followed by replacement dose of 20 mg"/>
   <result pre="features of acute adrenal insufficiency would warrant IV or IM" exact="hydrocortisone" post="treatment with 100 mg given immediately, followed by 200"/>
   <result pre="[66]. Patients with primary adrenal insufficiency would not require additional" exact="fludrocortisone" post="in this setting as hydrocortisone doses above 50 mg"/>
   <result pre="insufficiency would not require additional fludrocortisone in this setting as" exact="hydrocortisone" post="doses above 50 mg per day are known to"/>
   <result pre="and improve the outcomes in these patients. The decision on" exact="hydrocortisone" post="treatment and the appropriate dose can be guided by"/>
   <result pre="treatment and the appropriate dose can be guided by baseline" exact="cortisol" post="level, and the target level expected in severely ill"/>
   <result pre="or sepsis, this response may be inadequate because of impaired" exact="cortisol" post="secretion or cortisol resistance caused by abnormalities in glucocorticoid"/>
   <result pre="response may be inadequate because of impaired cortisol secretion or" exact="cortisol" post="resistance caused by abnormalities in glucocorticoid receptors, known as"/>
   <result pre="[69, 70]. Based on the available evidence, a random serum" exact="cortisol" post="of less than 275 nmol/L (10 Âµg/dL) or a"/>
   <result pre="of less than 275 nmol/L (10 Âµg/dL) or a serum" exact="cortisol" post="rise by less than 248 nmol/L (9 Âµg/dL) at"/>
   <result pre="Furthermore, one needs to be aware that threshold levels of" exact="cortisol" post="will vary according to assay. These assay-related variations can"/>
   <result pre="ill patients because of the presence of heterophile antibodies and" exact="cortisol" post="metabolites, and can impact the diagnosis of CIRCI [69,"/>
   <result pre="can be considered based on clinical parameters, regardless of the" exact="cortisol" post="response, following a discussion between the treating intensivist and"/>
   <result pre="and endocrinologist. Patients with CIRCI can be treated with IV" exact="hydrocortisone" post="(up to 400 mg/day) for 3 days or longer"/>
   <result pre="once the patientâ€™s condition is stable [70]. The decision regarding" exact="hydrocortisone" post="treatment should be made cautiously, and it is also"/>
   <result pre="to be mindful about the possible drug interactions as well." exact="Ritonavir" post="is known to inhibit the cytochrome P4503A enzyme and"/>
   <result pre="settles and they are stable to undergo definitive therapy. Intravenous" exact="etomidate" post="can be considered in patients with severe illness needing"/>
   <result pre="glucocorticoid-lowering therapy with careful dose adjustments to achieve a target" exact="cortisol" post="level. If the patient has coexisting acute kidney injury,"/>
   <result pre="If nonthyroidal illness syndrome is suspected, therapy with thyroxine or" exact="liothyronine" post="is not currently recommended because of lack of clinical"/>
   <result pre="on immunosuppressants [90]. However, patients who are on glucocorticoids and" exact="mycophenolate mofetil" post="for thyroid eye disease should especially adhere to social"/>
   <result pre="is advisable. There might be difficulty in accessing medications including" exact="testosterone" post="injections. It may be reasonable to postpone replacement in"/>
   <result pre="substitution of the alternative dosage forms is an option. If" exact="testosterone" post="gel preparation is substituted for injections, the gel can"/>
   <result pre="can be commenced from the due date of the next" exact="testosterone" post="injection [58]. In the case of female hormone replacement,"/>
   <result pre="critical illness-related corticosteroid insufficiency COVID-19 coronavirus-19 CS Cushing syndrome DRA" exact="dopamine" post="receptor agonist FGF2 fibroblast growth factor 2 HPA hypothalamo-pituitary-adrenal"/>
   <result pre="Metab.2018;62(2):236-263.29768629 49.VardasK, ApostolouK, BriassouliE, et al.Early response roles for prolactin" exact="cortisol" post="and circulating and cellular levels of heat shock proteins"/>
   <result pre="57.LinSJ, WuZR, CaoL, et al.Pituitary tumor suppression by combination of" exact="cabergoline" post="and chloroquine. J Clin Endocrinol Metab.2017;102(10):3692-3703.28973192 58.COVID-19 resources for"/>
   <result pre="Endocr Connect.2016;5(5):G1-G3.27935813 63.PreteA, TaylorAE, BancosI, et al.Prevention of adrenal crisis:" exact="cortisol" post="responses to major stress compared to stress dose hydrocortisone"/>
   <result pre="crisis: cortisol responses to major stress compared to stress dose" exact="hydrocortisone" post="delivery. J Clin Endocrinol Metab. 2020;105(7). doi:10.1210/clinem/dgaa133 64.ArltW, BaldewegSE,"/>
   <result pre="2017. Crit Care Med.2017;45(12):2078-2088.28938253 71.CohenJ, WardG, PrinsJ, JonesM, VenkateshBVariability of" exact="cortisol" post="assays can confound the diagnosis of adrenal insufficiency in"/>
   <result pre="McKiernanFIatrogenic Cushing syndrome and adrenal insufficiency during concomitant therapy with" exact="ritonavir" post="and fluticasone. Springerplus.2015;4:455.26322261 73.PivonelloR, FerrignoR, IsidoriAM, BillerBMK, GrossmanAB, ColaoACovid-19"/>
   <result pre="al.Self-care for common colds: the pivotal role of vitamin D," exact="vitamin C," post="ainc, and echinacea in three main immune interactive clusters"/>
   <result pre="Clin Nutr. 2020. doi:10.1038/s41430-020-0558-y 133.HeaneyRP, DaviesKM, ChenTC, HolickMF, Barger-LuxMJHuman serum" exact="25-hydroxycholecalciferol" post="response to extended oral dosing with cholecalciferol. Am J"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7338124\results\search\drug\results.xml">
   <result pre="the virus present in the respiratory tract despite oseltamivir and" exact="peramivir" post="treatment. Through the neuraminidase inhibition assay, both viruses were"/>
   <result pre="variation S31N in the matrix gene, the M2 proton-channel blockers" exact="amantadine" post="and rimantadine are no longer clinically applied [4]. The"/>
   <result pre="in the matrix gene, the M2 proton-channel blockers amantadine and" exact="rimantadine" post="are no longer clinically applied [4]. The Korea Centers"/>
   <result pre="with acute hematologic cancer not exhibiting recovery despite oseltamivir and" exact="peramivir" post="administration; these were characterized genetically and antigenically following isolation."/>
   <result pre="out using the Agpath ID One-step RT-PCR system (Applied Biosystems," exact="Foster" post="City, CA, USA) [10]. TableÂ 1 lists multiplex (A/B/IPC"/>
   <result pre="influenza viruses to NAI was characterized using oseltamivir, zanamivir, and" exact="peramivir" post="at concentrations that inhibited the NA activity by 50%"/>
   <result pre="and A/Korea/S0002/2019 viruses exhibited significantly reduced inhibition by oseltamivir and" exact="peramivir" post="with &amp;gt;â€‰100 IC50 fold-changes relative to drug-sensitive virus, but"/>
   <result pre="fold-changes relative to drug-sensitive virus, but were normally susceptible to" exact="zanamivir" post="(TableÂ 6). However, every isolate collected from the KINRESS"/>
   <result pre="Virus Type (Subtype) Genotype NAI resistance (IC50 fold change) Oseltamivir" exact="Zanamivir" post="Peramivir A/Korea/S0003/2019 A(H1N1)pdm09 Variant (H275Y) HRI 179.33 NI 2.56"/>
   <result pre="Type (Subtype) Genotype NAI resistance (IC50 fold change) Oseltamivir Zanamivir" exact="Peramivir" post="A/Korea/S0003/2019 A(H1N1)pdm09 Variant (H275Y) HRI 179.33 NI 2.56 HRI"/>
   <result pre="the IC50 for oseltamivir and peramivir, but not zanamivir. Thus," exact="zanamivir" post="might be an option for immunocompromised patients when oseltamivir"/>
   <result pre="might be an option for immunocompromised patients when oseltamivir and" exact="peramivir" post="are not effective. These findings also indicate the necessity"/>
   <result pre="Respiratory Viruses Surveillance System SARI Severe Acute Respiratory Infection H" exact="Histidine" post="Y Tyrosine NAIs Neuraminidase inhibitors NA Neuraminidase HA Hemagglutinin"/>
   <result pre="immunocompromised vs nonimmunocompromised hostsClin Infect Dis20135821422410.1093/cid/cit72524186906 19.TrebbienRPedersenSSVorborgKFranckKTFischerTKDevelopment of oseltamivir and" exact="zanamivir" post="resistance in influenza a (H1N1) pdm09 virus, Denmark, 2014Euro"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7338588\results\search\drug\results.xml">
   <result pre="pattern recognition receptors, namely the Toll-like receptors (TLRs) and the" exact="retinoic acid" post="inducible gene I (RIG-I)-like receptors (RLRs). These receptors recognize"/>
   <result pre="In the cytosol the virus may be recognized by the" exact="retinoic acid" post="inducible receptor (RIG)-I or the melanoma differentiation-associated protein (MDA)5."/>
   <result pre="therapeutic options, namely remdesivir, lopinavir/ritonavir with and without IFN-Î², and" exact="chloroquine" post="or hydroxychloroquine (171). Remdesivir, already early suggested to be"/>
   <result pre="namely remdesivir, lopinavir/ritonavir with and without IFN-Î², and chloroquine or" exact="hydroxychloroquine" post="(171). Remdesivir, already early suggested to be the most"/>
   <result pre="most promising compound (172, 173), is a pro-drug of an" exact="adenosine" post="nucleotide analog, which upon incorporation in the growing RNA"/>
   <result pre="licensed for HIV treatment (184, 185), as well as for" exact="chloroquine" post="and hydroxychloroquine presently used in the treatment of malaria"/>
   <result pre="HIV treatment (184, 185), as well as for chloroquine and" exact="hydroxychloroquine" post="presently used in the treatment of malaria and autoimmune"/>
   <result pre="in vivo benefits of lopinavir/ritonavir (188). Similarly, clinical trials on" exact="chloroquine" post="and hydroxychloroquine have identified methodological limitations and conflicting results,"/>
   <result pre="benefits of lopinavir/ritonavir (188). Similarly, clinical trials on chloroquine and" exact="hydroxychloroquine" post="have identified methodological limitations and conflicting results, even suggesting"/>
   <result pre="limitations and conflicting results, even suggesting a negative effect of" exact="hydroxychloroquine" post="(189â€&quot;195). In May 2020, a multinational analysis reported the"/>
   <result pre="In May 2020, a multinational analysis reported the use of" exact="hydroxychloroquine" post="or chloroquine, with or without a macrolide, for treatment"/>
   <result pre="Notably, the study was retracted shortly after publication, whereas the" exact="hydroxychloroquine" post="studies currently continue after evaluation of the safety data"/>
   <result pre="host are also potentially valuable treatment options. Interestingly, the agent" exact="camostat" post="mesylate has been reported to block the cellular serine"/>
   <result pre="Biol Chem. (2020) 295: 4773â€&quot;9. 10.1074/jbc.AC120.01305632094225 175.WangMCaoRZhangLYangXLiuJXuMet al.. Remdesivir and" exact="chloroquine" post="effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in"/>
   <result pre="vitro antiviral activity and projection of optimized dosing design of" exact="hydroxychloroquine" post="for the treatment of severe acute respiratory syndrome Coronavirus"/>
   <result pre="382:1787â€&quot;99. 10.1056/NEJMc200804332187464 189.BorbaMGSValFFASampaioVSAlexandreMAAMeloGCBritoMet al.Effect of high vs low doses of" exact="chloroquine" post="diphosphate as adjunctive therapy for patients hospitalized with severe"/>
   <result pre="JAMA Netw Open. (2020) 3:e20885710.1001/jamanetworkopen.2020.8857 190.MahevasMTranVTRoumierMChabrolAPauleRGuillaudCet al.. Clinical efficacy of" exact="hydroxychloroquine" post="in patients with covid-19 pneumonia who require oxygen: observational"/>
   <result pre="data. BMJ. (2020) 369:m1844. 10.1136/bmj.m184432409486 191.BoulwareDRPullenMFBangdiwalaASPastickKALofgrenSMOkaforECet al.A randomized trial of" exact="hydroxychloroquine" post="as postexposure prophylaxis for Covid-19. N Engl J Med."/>
   <result pre="[Epub ahead of print]. 10.1056/NEJMoa2016638. 192.GelerisJSunYPlattJZuckerJBaldwinMHripcsakGet al.. Observational study of" exact="hydroxychloroquine" post="in hospitalized patients with Covid-19. N Engl J Med."/>
   <result pre="J Med. (2020) 382:2411â€&quot;8. 10.1056/NEJMoa201241032379955 193.RosenbergESDufortEMUdoTWilberschiedLAKumarJTesorieroJet al.Association of treatment with" exact="hydroxychloroquine" post="or azithromycin with in-hospital mortality in patients with COVID-19"/>
   <result pre="(2020) 382:2411â€&quot;8. 10.1056/NEJMoa201241032379955 193.RosenbergESDufortEMUdoTWilberschiedLAKumarJTesorieroJet al.Association of treatment with hydroxychloroquine or" exact="azithromycin" post="with in-hospital mortality in patients with COVID-19 in New"/>
   <result pre="JAMA. (2020). [Epub ahead of print]. 10.1001/jama.2020.8630. 194.GautretPLagierJCParolaPHoangVTMeddebLMailheMet al.Hydroxychloroquine and" exact="azithromycin" post="as a treatment of COVID-19: results of an open-label"/>
   <result pre="chloroquine. J Mol Cell Biol. (2020) 12:322â€&quot;5. 10.1093/jmcb/mjaa01432236562 196.MehraMRDesaiSSRuschitzkaFPatelANHydroxychloroquine or" exact="chloroquine" post="with or without a macrolide for treatment of COVID-19:"/>
   <result pre="protocol for a randomized controlled trial on the assessment of" exact="camostat" post="treatment in chronic pancreatitis (TACTIC). Trials. (2019) 20:501. 10.1186/s13063-019-3606-y31412955"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7339094\results\search\drug\results.xml">
   <result pre="options Respiratory syncitial virus 1â€&quot;50 11â€&quot;47 S, C, D Pavilizumab" exact="Ribavirin" post="aerosol Influenza 1.3â€&quot;40 8â€&quot;28 S, D Seasonal influenza immunization"/>
   <result pre="S, C ND Parainfluenza virus 3â€&quot;27 10â€&quot;50 S, A, D" exact="Ribavirin" post="Cidofovir Bocavirus 1â€&quot;3 Not reported S, C, D ND"/>
   <result pre="C ND Parainfluenza virus 3â€&quot;27 10â€&quot;50 S, A, D Ribavirin" exact="Cidofovir" post="Bocavirus 1â€&quot;3 Not reported S, C, D ND Adenovirus"/>
   <result pre="significant reduction in the progression from URTI to LRTI [5]." exact="Ribavirin" post="has been proven effective in hindering the progression from"/>
   <result pre="70 to 35%) in onco-hematological patients [5]. The lack of" exact="ribavirin" post="aerosol therapy has increased the risk of mortality in"/>
   <result pre="increased the risk of mortality in patients with HSCT [49];" exact="ribavirin" post="aerosol is the only approved treatment for severe RSV-related"/>
   <result pre="myeloma, routine treatment of RSV infection is not recommended [13]." exact="Ribavirin" post="therapy is recommended in patients with leukemia and patients"/>
   <result pre="HSCT at high risk of complications [5]. The co-administration of" exact="ribavirin" post="with intravenous immunoglobulins (IVIG), with specific anti-RSV immunoglobulins or"/>
   <result pre="neither intravenous administration of immunoglobulins nor the use of aerosol" exact="ribavirin" post="are useful strategies for the effective reduction of the"/>
   <result pre="required [43]. Promising results following the use of IVIG and" exact="ribavirin" post="have been obtained in vitro; however, these data have"/>
   <result pre="vitro regarding the use of antiviral drugs such as cidofovir," exact="ganciclovir" post="and other antiretroviral drugs (zalzitabine, alovudine, stavudine) but there"/>
   <result pre="but there are not as many validations in vivo [48]." exact="Cidofovir" post="has been shown to reduce mortality, but it is"/>
   <result pre="the application of this measure [29]. The use of aerosol" exact="ribavirin" post="and pavilizumab as preventive strategies in patients with URTI"/>
   <result pre="in lymphopenic patients [48]. Regarding PiV, the real impact of" exact="ribavirin" post="and of experimental anti-viral agents such as DAS 181"/>
   <result pre="occurs in immunocompromised patients. Retrospective studies demonstrate positive outcomes with" exact="ribavirin" post="(alone or in combination with immunomodulators) for the treatment"/>
   <result pre="hematopoietic cell transplant recipientsBr J Haematol2008143445546710.1111/j.1365-2141.2008.07295.x18785968 49.ShahDPet al.Impact of aerosolized" exact="ribavirin" post="on mortality in 280 allogeneic haematopoietic stem cell transplant"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7339606\results\search\drug\results.xml">
   <result pre="of RdRp of SARS-CoV-2. However, in virtual screening, Remdesivir and" exact="Sofosbuvir" post="do not provided us with novel compounds against SARS-CoV-2"/>
   <result pre="RMSD 1. Remdesivir âˆ’â€‰14.06038 2.357701 2. Galidesivir âˆ’â€‰12.5338 1.0217 3." exact="Ribavirin" post="âˆ’â€‰11.8884 0.9554 4. Sofosbuvir âˆ’â€‰11.132 2.08 5. Penciclovir âˆ’â€‰10.9772"/>
   <result pre="2.357701 2. Galidesivir âˆ’â€‰12.5338 1.0217 3. Ribavirin âˆ’â€‰11.8884 0.9554 4." exact="Sofosbuvir" post="âˆ’â€‰11.132 2.08 5. Penciclovir âˆ’â€‰10.9772 0.9461 6. Chloroquine âˆ’â€‰10.3804"/>
   <result pre="1.0217 3. Ribavirin âˆ’â€‰11.8884 0.9554 4. Sofosbuvir âˆ’â€‰11.132 2.08 5." exact="Penciclovir" post="âˆ’â€‰10.9772 0.9461 6. Chloroquine âˆ’â€‰10.3804 1.6397 7. Nitazoxanide âˆ’â€‰9.7636"/>
   <result pre="0.9554 4. Sofosbuvir âˆ’â€‰11.132 2.08 5. Penciclovir âˆ’â€‰10.9772 0.9461 6." exact="Chloroquine" post="âˆ’â€‰10.3804 1.6397 7. Nitazoxanide âˆ’â€‰9.7636 2.4603 8. Nafamostat âˆ’â€‰9.76403"/>
   <result pre="0.9461 6. Chloroquine âˆ’â€‰10.3804 1.6397 7. Nitazoxanide âˆ’â€‰9.7636 2.4603 8." exact="Nafamostat" post="âˆ’â€‰9.76403 2.4605 9. Interferon âˆ’â€‰9.62582 1.7336 10. Favipiravir âˆ’â€‰9.36643"/>
   <result pre="et al. reported that nucleoside analogs such as Remdesivir and" exact="Sofosbuvir" post="strongly binds with ASP760, ASP761 and ASP618 residues to"/>
   <result pre="also been reported which are in clinical trials including Remdesivir," exact="Sofosbuvir" post="Galidesivir etc., for which we have already tested with"/>
   <result pre="Shi Z, Hu Z, Zhong W, Xiao G. Remdesivir and" exact="chloroquine" post="effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in"/>
   <result pre="activity of the IMP dehydrogenase inhibitor VX-497: a comparison with" exact="Ribavirin" post="and demonstration of antiviral additivity with alpha interferonAntimicrob Agents"/>
   <result pre="a comparison with Ribavirin and demonstration of antiviral additivity with" exact="alpha" post="interferonAntimicrob Agents Chemother20004485986610722482 50.WangMCaoRZhangLYangXLiuJXuMet al.Remdesivir and chloroquine effectively inhibit"/>
   <result pre="antiviral additivity with alpha interferonAntimicrob Agents Chemother20004485986610722482 50.WangMCaoRZhangLYangXLiuJXuMet al.Remdesivir and" exact="chloroquine" post="effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7340244\results\search\drug\results.xml">
   <result pre="poorly understood. Treatment of KD requires intravenous immunoglobulin (IVIG) and" exact="aspirin" post="during the first ten days of illness, and its"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7341697\results\search\drug\results.xml">
   <result pre="the different kinds of outbreaks of avian influenza and Ebola." exact="Today" post="we are confronted with completely new issues endangering our"/>
   <result pre="since it might be harmful for patients. Drugs, such as" exact="hydroxychloroquine" post="have well-documented risks; administering the drug outside of any"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7342332\results\search\drug\results.xml">
   <result pre="that include but not limited to lopinavirâ€&quot;ritonavir, remdesivir, danoprevir, darunavirâ€&quot;cobicistat," exact="ribavirin" post="and interferon beta, chloroquine, hydroxychloroquine, oseltamivir, umifenovir, pirfenidone, bevacizumab,"/>
   <result pre="28-day mortality. One reason for the lack of efficacy of" exact="lopinavir" post="could be high concentration required to inhibit viral replication"/>
   <result pre="from pneumonia and SARS.[1] In contrast, French clinical trial of" exact="hydroxychloroquine" post="and azithromycin in COVID-19 included hospitalized patients who were"/>
   <result pre="and SARS.[1] In contrast, French clinical trial of hydroxychloroquine and" exact="azithromycin" post="in COVID-19 included hospitalized patients who were asymptomatic or"/>
   <result pre="â€&quot; a large global trial of four drugs â€&quot; remdesivir," exact="chloroquine" post="and hydroxychloroquine, lopinavirâ€&quot;ritonavir, and lopinavir-ritonavir plus interferon-beta.[8] Its simple"/>
   <result pre="outbreaks through an expedited review or unscheduled full committee meetings.[9]" exact="Hydroxychloroquine" post="trial was approved by the French EC within 1"/>
   <result pre="controlled, single-arm proof-of-concept trial in guineaPLoS Med201613e100196726930627 5GautretPLagierJCParolaPHoangVTMeddebLMailheMet al.Hydroxychloroquine and" exact="azithromycin" post="as a treatment of COVID-19: Results of an open-label"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7343578\results\search\drug\results.xml">
   <result pre="by COVID-19: 1) Pituitary: possible hypothalamic-pituitary disfunction and alterations in" exact="antidiuretic hormone" post="metabolism. 2) Thyroid: sick euthyroid syndrome; 3) Adrenal: probable"/>
   <result pre="appear, especially high fever and potential dehydration. Oral agents, particularly" exact="metformin" post="and sodium glucose cotransporter-2 inhibitors need to be stopped"/>
   <result pre="of DDP-4 with the current antidiabetic drugs such as sitagliptin," exact="vildagliptin" post="or linagliptin may impair the virus/DPP-4 interaction, thereby protecting"/>
   <result pre="with the current antidiabetic drugs such as sitagliptin, vildagliptin or" exact="linagliptin" post="may impair the virus/DPP-4 interaction, thereby protecting the cell"/>
   <result pre="be to avoid hyponatremia [70]. This can be performed delaying" exact="desmopressin" post="to allow regular periods of free water clearance to"/>
   <result pre="during the SARS outbreak in 2003 had reported that serum" exact="Triiodothyronine" post="and thyroxine levels were lower in patients with SARS"/>
   <result pre="Adrenal insufficiency Life-long replacement treatment aiming to mimic physiologic plasma" exact="cortisol" post="concentrations is not easy to be achieved in adrenal"/>
   <result pre="Many circumstances, either organic and/or psychological, might unbalance the physiologic" exact="cortisol" post="requirements. COVID-19 pandemic may be a new reason for"/>
   <result pre="patients have a more severe course of COVID-19 [76]. Regarding" exact="cortisol" post="dynamics, autopsy studies performed on patients who died from"/>
   <result pre="cytopathic effect of the virus. Hence, it is likely that" exact="cortisol" post="dynamics may be altered in patients with SARS (and"/>
   <result pre="the host adrenocorticotropic hormone (ACTH). This could blunt the stress-induced" exact="cortisol" post="rise, as antibodies produced against the viral particles will"/>
   <result pre="be accounted by an insufficient compensatory self-adjusted rise of the" exact="hydrocortisone" post="dosage at the time of the beginning of an"/>
   <result pre="to have sufficient stock at home of steroid pills and" exact="hydrocortisone" post="injections if social confinement is required during the COVID-19"/>
   <result pre="antiandrogen compound did not affect the morbidity and mortality; conversely," exact="estrogen" post="depletion by ovariectomy or treatment with an estrogen receptor"/>
   <result pre="mortality; conversely, estrogen depletion by ovariectomy or treatment with an" exact="estrogen" post="receptor antagonist dramatically increased both morbidity and mortality suggesting"/>
   <result pre="both morbidity and mortality suggesting a protective effect for the" exact="estrogen" post="receptor signaling pathway [92]. In addition, in animal experiments,"/>
   <result pre="estrogen receptor signaling pathway [92]. In addition, in animal experiments," exact="estrogen" post="treatment upregulated estrogen receptor signaling, silenced the cytokine storm"/>
   <result pre="pathway [92]. In addition, in animal experiments, estrogen treatment upregulated" exact="estrogen" post="receptor signaling, silenced the cytokine storm and lead to"/>
   <result pre="primary prostate cancer [95]. The modulation of TMPRSS2 expression by" exact="testosterone" post="has been postulated to contribute to male predominance of"/>
   <result pre="interleukins levels [106]. Of particular interest to Covid-19, is the" exact="nitric oxide," post="which is a key signaling molecule acting as a"/>
   <result pre="postulated as a prospective therapeutic agent for Covid-19. Use of" exact="melatonin" post="in COVID 19 Viruses induce an explosion of inflammatory"/>
   <result pre="which might also be beneficial for COVID-19 patients. In addition," exact="melatonin" post="could be an adjuvant to prevent pulmonary fibrosis [108]."/>
   <result pre="could be an adjuvant to prevent pulmonary fibrosis [108]. Notably," exact="melatonin" post="has a high safety profile [109]. There are no"/>
   <result pre="profile [109]. There are no reports on the use of" exact="melatonin" post="in COVID-19 to date [108]. Publisherâ€™s note Springer Nature"/>
   <result pre="immunologic activityJ Neuroimmunol201528915216126616885 108.Shneider A, Kudriavtsev A, Vakhrusheva A. Can" exact="melatonin" post="reduce the severity of COVID-19 pandemic? Int Rev Immunol."/>
   <result pre="L, Di X, Ma B, Niu S, et al. COVID-19:" exact="melatonin" post="as a potential adjuvant treatment. Life Sci. 2020;117583."/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7344048\results\search\drug\results.xml">
   <result pre="plays a critical role in the viral replication [13]. K11777," exact="camostat" post="and EST, are cysteine protease inhibitors, which have been"/>
   <result pre="accelerate the targeted drug discovery efforts. Two HIV-1 proteinase inhibitors," exact="lopinavir" post="and ritonavir, have been considered to target SARS-CoV [17]."/>
   <result pre="âˆ’â€‰8.14 1.09 âˆ’â€‰10.82 âˆ’â€‰10.52 âˆ’â€‰0.30 âˆ’â€‰3.51 +â€‰2.68 âˆ’â€‰3.51 34.77 8" exact="Chloroquine" post="âˆ’â€‰4.95 233.3 âˆ’â€‰7.34 âˆ’â€‰6.96 âˆ’â€‰0.38 âˆ’â€‰1.34 +â€‰2.39 âˆ’â€‰1.34 30.78"/>
   <result pre="âˆ’â€‰5.77 58.47 âˆ’â€‰8.76 âˆ’â€‰8.53 âˆ’â€‰0.23 âˆ’â€‰0.68 +â€‰2.98 âˆ’â€‰0.68 30.56 10" exact="Artemisinin" post="âˆ’â€‰6.40 20.22 âˆ’â€‰6.70 âˆ’â€‰6.50 âˆ’â€‰0.20 +â€‰0.06 +â€‰0.30 +â€‰0.06 31.94"/>
   <result pre="âˆ’â€‰4.15 905.42 âˆ’â€‰4.45 âˆ’â€‰4.31 âˆ’â€‰0.14 âˆ’â€‰0.09 +â€‰0.30 âˆ’â€‰0.09 32.27 16" exact="Ritonavir" post="âˆ’â€‰7.45 3.49 âˆ’â€‰13.11 âˆ’â€‰13.15 +â€‰0.03 âˆ’â€‰3.46 +â€‰5.67 âˆ’â€‰5.67 28.61"/>
   <result pre="(grey), bilobetin (brown) and ginkgetin (white) (b) anti-malarial (chloroquine (green)," exact="hydroxychloroquine" post="(golden yellow) and artemisinin (blue) (c) anti-viral remdesivir (yellow),"/>
   <result pre="ginkgetin (white) (b) anti-malarial (chloroquine (green), hydroxychloroquine (golden yellow) and" exact="artemisinin" post="(blue) (c) anti-viral remdesivir (yellow), darunavir (blue), lopinavir (red),"/>
   <result pre="yellow) and artemisinin (blue) (c) anti-viral remdesivir (yellow), darunavir (blue)," exact="lopinavir" post="(red), galidesivir (dark pink), favipiravir (light blue), ritonavir (light"/>
   <result pre="darunavir (blue), lopinavir (red), galidesivir (dark pink), favipiravir (light blue)," exact="ritonavir" post="(light pink) and umifenovir (green) and d vitamins [vitamin"/>
   <result pre="Ser144, Cys145 7 Ginkgetin (PubChem CID:5271805) Thr26, Gly143, His163 8" exact="Chloroquine" post="(PubChem CID:2719) His41, Gly143, Cys145 9 Hydroxychloroquine (PubChem CID:3652)"/>
   <result pre="Gly143, His163 8 Chloroquine (PubChem CID:2719) His41, Gly143, Cys145 9" exact="Hydroxychloroquine" post="(PubChem CID:3652) Thr26, Asn142, Glu166 10 Artemisinin (PubChem CID:68827)"/>
   <result pre="Gly143, Cys145 9 Hydroxychloroquine (PubChem CID:3652) Thr26, Asn142, Glu166 10" exact="Artemisinin" post="(PubChem CID:68827) His41, Leu141, Asn142, Gly143, Ser144, Glu166 11"/>
   <result pre="Glu166 15 Favipiravir (PubChem CID:492405) Ser144, His163, His164, Glu166 16" exact="Ritonavir" post="(PubChem CID:392622) Thr26, His41, Cys145 17 Umifenovir (PubChem CID:131411)"/>
   <result pre="drug (red) in SARS-CoV-2 3CLpro (green) substrate binding pocket. b" exact="Artemisinin" post="drug (blue) binding mode in SARS-CoV-2 3CLpro (pink) substrate"/>
   <result pre="3CLpro (pink) substrate binding pocket. c Binding mode of the" exact="Ritonavir" post="drug (magenta) in SARS-CoV-2 3CLpro (cyan) substrate binding pocket."/>
   <result pre="the highest docking score (âˆ’â€‰6.40Â kcal/mol) as compared to O6K," exact="chloroquine" post="(-4.95Â kcal/mol) and hydroxychloroquine (âˆ’â€‰5.77Â kcal/mol) anti-malarial molecules. Importantly,"/>
   <result pre="(âˆ’â€‰6.40Â kcal/mol) as compared to O6K, chloroquine (-4.95Â kcal/mol) and" exact="hydroxychloroquine" post="(âˆ’â€‰5.77Â kcal/mol) anti-malarial molecules. Importantly, Artemisinin has demonstrated broad"/>
   <result pre="chloroquine (-4.95Â kcal/mol) and hydroxychloroquine (âˆ’â€‰5.77Â kcal/mol) anti-malarial molecules. Importantly," exact="Artemisinin" post="has demonstrated broad anti-viral activity against human cytomegalovirus, herpes"/>
   <result pre="virus, hepatitis C virus, and bovine viral diarrhea virus [47]." exact="Artemisinin" post="was shown to exhibit hydrogen bonding with His41, Leu141,"/>
   <result pre="3CLpro amino-acid residues (Fig.Â 7b). Amongst the seven antiviral drugs," exact="Ritonavir" post="showed the highest binding energy (-7.45Â kcal/mol) and lowest"/>
   <result pre="(-7.45Â kcal/mol) and lowest inhibitory constant Ki value (3.49Â ÂµM)." exact="Ritonavir" post="produced hydrogen bond interactions with Thr26, His41 and Cys145"/>
   <result pre="acids (Fig.Â 7c). A combination of two HIV-1 protease inhibitors," exact="lopinavir" post="and ritonavir, were given to critically ill SARS-CoV 2"/>
   <result pre="SARS-CoV 2 infected patients [48]. However, the combination therapy of" exact="lopinavir" post="and ritonavir was also stopped early in 13 patients"/>
   <result pre="infected patients [48]. However, the combination therapy of lopinavir and" exact="ritonavir" post="was also stopped early in 13 patients (total recruitment"/>
   <result pre="[49, 50]. Therefore, we selected vitamins, ascorbic acid (vitamin C)," exact="cholecalciferol" post="(vitamin D) and alpha-tocopherol (vitamin E) to investigate their"/>
   <result pre="Ki (âˆ’â€‰7.75Â kcal/mol and 2.08Â ÂµM respectively) as compared to" exact="vitamin C" post="and vitamin E. Amino acid residues Thr24, Thr26, His41"/>
   <result pre="signalling changes through phosphorylation changes, and here we observed that" exact="cholecalciferol" post="formed a strong hydrogen bond with Thr residues and"/>
   <result pre="antivirals are currently being used clinically in SARS-CoV-2 treatment, including" exact="lopinavir" post="[59], ritonavir [60], remdesivir [61], and oseltamivir [62]. However,"/>
   <result pre="currently being used clinically in SARS-CoV-2 treatment, including lopinavir [59]," exact="ritonavir" post="[60], remdesivir [61], and oseltamivir [62]. However, in the"/>
   <result pre="a drug-resistance event. Moreover, other classes of drugs, such as" exact="chloroquine" post="and hydroxychloroquine have shown antiviral properties by blocking viral"/>
   <result pre="event. Moreover, other classes of drugs, such as chloroquine and" exact="hydroxychloroquine" post="have shown antiviral properties by blocking viral entry into"/>
   <result pre="design of improved alpha-ketoamide inhibitorsScience202036840941232198291 17.NukoolkarnVLeeVSMalaisreeMAruksakulwongOHannongbuaSMolecular dynamic simulations analysis of" exact="ritonavir" post="and lopinavir as SARS-CoV 3CL(pro) inhibitorsJ Theor Biol200825486186718706430 18.XueXYuHYangHXueFWuZShenWLiJZhouZDingYZhaoQet"/>
   <result pre="improved alpha-ketoamide inhibitorsScience202036840941232198291 17.NukoolkarnVLeeVSMalaisreeMAruksakulwongOHannongbuaSMolecular dynamic simulations analysis of ritonavir and" exact="lopinavir" post="as SARS-CoV 3CL(pro) inhibitorsJ Theor Biol200825486186718706430 18.XueXYuHYangHXueFWuZShenWLiJZhouZDingYZhaoQet al.Structures of"/>
   <result pre="chemical toolboxJ Cheminform201133321982300 37.ChitranshiNDheerYKumarSGrahamSLGuptaVMolecular docking, dynamics, and pharmacology studies on" exact="bexarotene" post="as an agonist of ligand-activated transcription factors, retinoid X"/>
   <result pre="displaying SARS-CoV 3CL(pro) inhibitionBioorg Med Chem2010187940794720934345 47.EfferthTRomeroMRWolfDGStammingerTMarinJJMarschallMThe antiviral activities of" exact="artemisinin" post="and artesunateClin Infect Dis20084780481118699744 48.Cao B, Wang Y, Wen"/>
   <result pre="nsp3 in its pathogenesisJ Med Virol202092658458832083328 59.YaoTTQianJDZhuWYWangYWangGQA systematic review of" exact="lopinavir" post="therapy for SARS coronavirus and MERS coronavirus-A possible reference"/>
   <result pre="Pharmacol Sci2020244572457532373997 63.ZhouDDaiSMTongQCOVID-19: a recommendation to examine the effect of" exact="hydroxychloroquine" post="in preventing infection and progressionJ Antimicrob Chemother2020757 64.BasavarajappaDKGuptaVKDigheRRajalaARajalaRVPhosphorylated Grb14"/>
   <result pre="factor is involved in the regulation of glycogen synthase kinase" exact="3beta" post="(GSK3beta) signallingBiochem Biophys Res Commun201445438138625451258 66.HadfieldJMegillCBellSMHuddlestonJPotterBCallenderCSagulenkoPBedfordTNeherRANextstrain: real-time tracking of"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7344049\results\search\drug\results.xml">
   <result pre="Antiviral agents Status Target pathogens RefS. SARS-CoV-2; MERS-CoV Spike glycoprotein" exact="Nafamostat" post="Approved Anticoagulant therapy in Asian countries [99, 100] SARS-CoV-2;"/>
   <result pre="1b), chronic granulomatous disease (IFN-Î³) SARS-CoV-2; SARS-CoV; MERS-CoV Endosomal acidification" exact="Chloroquine" post="Approved Malaria and certain amoeba infections [99, 104â€&quot;106] Open-label"/>
   <result pre="109] Randomized trial SARS-CoV-2 SARS-CoV; SARS-CoV-2; RSV; HCV MERS-CoV RdRp" exact="Ribavirin" post="Approved HCV and RSV [99] Randomized trial SARS SARS-CoV-2"/>
   <result pre="HCV and RSV [99] Randomized trial SARS SARS-CoV-2 SARS-CoV-2 RdRp" exact="Penciclovir" post="Approved HSV [99] SARS-CoV-2; MERS-CoV; SARS-CoV Remdesivir (GS-5734) Phase"/>
   <result pre="host protein for influenza A virus and is inhibited by" exact="paroxetine" post="acting as virion un-coating can reduce viral load in"/>
   <result pre="if used with or without modification against COVID-19 after investigation." exact="Mesalazine" post="and celecoxib are COX inhibitors having wide-ranging clinical applications"/>
   <result pre="with or without modification against COVID-19 after investigation. Mesalazine and" exact="celecoxib" post="are COX inhibitors having wide-ranging clinical applications for having"/>
   <result pre="because of rapid free radicals release, use of antioxidants like" exact="vitamin C" post="can play a role in COVID-19 management [83]. A"/>
   <result pre="pro-inflammatory cytokine expression in some viruses. Statin in combination with" exact="caffeine" post="is more effective in viral replication inhibition and alleviation"/>
   <result pre="alleviation of lung injury and has a similar activity like" exact="ribavirin" post="and oseltamivir [85]. Since we have no report found"/>
   <result pre="pneumonia: a randomized controlled trialCrit Care Med2019479e735e74331162191 33.LiQLiZYZhangJGuoWNXuXMSunFXet al.Xiyanping Plus" exact="Azithromycin" post="Chemotherapy in Pediatric Patients with Mycoplasma pneumoniae Pneumonia: a"/>
   <result pre="immune regulationCurrent opinion in virology201616314026812607 43.CookLELockeMCYoungARMonteKHedbergMLShimakRMet al.Distinct roles of interferon" exact="alpha" post="and beta in controlling chikungunya virus replication and modulating"/>
   <result pre="Yanagisawa A, Levy T, Saul A. early large dose intravenous" exact="vitamin C" post="is the treatment of choice for 2019-nCov pneumonia. 84.LiuYYangYZhangCHuangFWangFYuanJet"/>
   <result pre="Yang X, Liu J, Xu M, et al. Remdesivir and" exact="chloroquine" post="effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in"/>
   <result pre="in JapanJ Gastroenterol Hepatol201631118018926110395 101.FalzaranoDDe WitERasmussenALFeldmannFOkumuraAScottDPet al.Treatment with interferon-Î±2b and" exact="ribavirin" post="improves outcome in MERS-CoVâ€&quot;infected rhesus macaquesNat Med201319101313131724013700 102.ChanJFChanK-HKaoRYToKKZhengB-JLiCPet al.Broad-spectrum"/>
   <result pre="respiratory syndrome coronavirusJ Infect201367660661624096239 103.KimUJWonE-JKeeS-JJungS-IJangH-CCase report combination therapy with lopinavir/ritonavir," exact="ribavirin" post="and interferon-Î± for Middle East respiratory syndromeAntiviral Ther201621455459 104.de"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7344768\results\search\drug\results.xml">
   <result pre="humans [26]. The drugs included in the SOLIDARITY trial are" exact="lopinavir" post="and ritonavirplus interferon beta as well as chloroquine, and"/>
   <result pre="have shown positive responses to treatments with a combination of" exact="lopinavir" post="and ritonavir [2]. Remdesivir has shown high efficacy against"/>
   <result pre="positive responses to treatments with a combination of lopinavir and" exact="ritonavir" post="[2]. Remdesivir has shown high efficacy against other coronaviruses"/>
   <result pre="include immunoglobulins, remdesivir, arbidol hydrochloride combined with interferon atomisation, hydroxychloroquine," exact="ritonavir" post="plus oseltamivir and many more [2]. Hydroxychloroquine, an anti-malarial"/>
   <result pre="of 80 individuals showed improvement in symptoms upon administration of" exact="hydroxychloroquine" post="and azithromycin [48]. However, there are still no convincing"/>
   <result pre="individuals showed improvement in symptoms upon administration of hydroxychloroquine and" exact="azithromycin" post="[48]. However, there are still no convincing studies to"/>
   <result pre="[48]. However, there are still no convincing studies to establish" exact="hydroxychloroquine" post="as the therapeutic candidate for SARS-CoV-2 and further investigations"/>
   <result pre="Epidemiol.202011010.1093/ije/dyaa03331828333 48.GautretP.LagierJ.-C.ParolaP.HoangV.T.MeddebL.SevestreJ.MailheM.DoudierB.AubryC.AmraneS.et al.Clinical and microbiological effect of a combination of" exact="hydroxychloroquine" post="and azithromycin in 80 COVID-19 patients with at least"/>
   <result pre="al.Clinical and microbiological effect of a combination of hydroxychloroquine and" exact="azithromycin" post="in 80 COVID-19 patients with at least a six-day"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7344926\results\search\drug\results.xml">
   <result pre="drugs, including Food and Drug Administration (FDA)-approved drugs, such as" exact="hydroxychloroquine" post="and chloroquine [10,11]. However, these drugs may not be"/>
   <result pre="Food and Drug Administration (FDA)-approved drugs, such as hydroxychloroquine and" exact="chloroquine" post="[10,11]. However, these drugs may not be suitable for"/>
   <result pre="inhibitor of the hepatitis C virus, while another antimalarial drug," exact="chloroquine" post="showed weak efficacy against HIV infection [12,13,14]. Although antimalarial"/>
   <result pre="clinical trial to test the efficacy of the antimalarial drugs" exact="chloroquine" post="and hydroxychloroquine alone and in combination with another drug,"/>
   <result pre="to test the efficacy of the antimalarial drugs chloroquine and" exact="hydroxychloroquine" post="alone and in combination with another drug, the antibiotic"/>
   <result pre="hydroxychloroquine alone and in combination with another drug, the antibiotic" exact="azithromycin" post="[15]. These drugs are currently being tested on COVID-19"/>
   <result pre="COVID-19 hospitalized patients at the Barnes-Jewish Hospital. In addition to" exact="hydroxychloroquine" post="and chloroquine, Remdesivir (GS-5734) is another drug that is"/>
   <result pre="shield immunity to reduce COVID-19 epidemic spreadNat. Med.202020201610.1038/s41591-020-0895-3 10.TouretF.De LamballerieX.Of" exact="chloroquine" post="and COVID-19Antivir. Res.202017710476210.1016/j.antiviral.2020.10476232147496 11.MahÃ©vasM.TranV.-T.RoumierM.ChabrolA.PauleR.GuillaudC.FoisE.LepeuleR.SzwebelT.-A.LescureF.-X.et al.Clinical efficacy of hydroxychloroquine in"/>
   <result pre="10.TouretF.De LamballerieX.Of chloroquine and COVID-19Antivir. Res.202017710476210.1016/j.antiviral.2020.10476232147496 11.MahÃ©vasM.TranV.-T.RoumierM.ChabrolA.PauleR.GuillaudC.FoisE.LepeuleR.SzwebelT.-A.LescureF.-X.et al.Clinical efficacy of" exact="hydroxychloroquine" post="in patients with covid-19 pneumonia who require oxygen: Observational"/>
   <result pre="ferroquine is an inhibitor of hepatitis C virusHepatology201358869710.1002/hep.2627323348596 14.NeelyM.KalyesubulaI.BagendaD.MyersC.OlnessK.Effect of" exact="chloroquine" post="on human immunodeficiency virus (HIV) vertical transmissionAfr. Health Sci.20033616712913796"/>
   <result pre="Subjects With COVID-19ClinicalTrials.govBethesda, ML, USA2020 25.VargheseF.KaukinenP.GlÃ¤skerS.BespalovM.HanskiL.WennerbergK.KÃ¼mmererB.M.AholaT.Discovery of berberine, abamectin and" exact="ivermectin" post="as antivirals against chikungunya and other alphavirusesAntivir. Res.201612611712410.1016/j.antiviral.2015.12.01226752081 26.CalyL.DruceJ.D.CattonM.G.JansD.A.WagstaffK.M.The"/>
   <result pre="antivirals against chikungunya and other alphavirusesAntivir. Res.201612611712410.1016/j.antiviral.2015.12.01226752081 26.CalyL.DruceJ.D.CattonM.G.JansD.A.WagstaffK.M.The FDA-approved drug" exact="ivermectin" post="inhibits the replication of SARS-CoV-2 in vitroAntivir. Res.202017810478710.1016/j.antiviral.2020.10478732251768 27.collab:"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7345039\results\search\drug\results.xml">
   <result pre="promising inhibitory effects are remdesivir and chloroquine. Remdesivir is an" exact="adenosine" post="analogue that cause premature termination of viral replication and"/>
   <result pre="progress to evaluate the efficacy and safety of the drug." exact="Chloroquine" post="is an antimalarial drug, known to exert a potent"/>
   <result pre="of cellular receptors of SARS-CoV [62]. A study demonstrated that" exact="chloroquine" post="could function at both, entry and at post-entry stages"/>
   <result pre="which may synergistically enhance its antiviral effect in vivo [39]." exact="Hydroxychloroquine" post="is an antirheumatic drug with a similar chemical structure"/>
   <result pre="is an antirheumatic drug with a similar chemical structure to" exact="chloroquine" post="and exhibits a strong immunomodulatory capacity, which prevents inflammation"/>
   <result pre="the overactivation of the immune system triggered by CoVID-19 infection," exact="hydroxychloroquine" post="can be suggested to attenuate the progression of the"/>
   <result pre="every 15â€&quot;20 min [29], use of hand sanitizers with â‰¥60%" exact="alcohol" post="content, wearing face masks, encouraging people to cover their"/>
   <result pre="systematic reviewAnn. Rheum. Dis.201069202810.1136/ard.2008.10176619103632 64.van den BorneB.E.DijkmansB.A.de RooijH.H.le CessieS.VerweijC.L.Chloroquine and" exact="hydroxychloroquine" post="equally affect tumor necrosis factor-alpha, interleukin 6, and interferon-gamma"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7345143\results\search\drug\results.xml">
   <result pre="mortality [2,3]. Whereas smoking, physical activities, unhealthy nutrients and excessive" exact="alcohol" post="consumption have been linked to health outcomes due to"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7346995\results\search\drug\results.xml">
   <result pre="systemic infections, and so do other immunosuppressive agents such as" exact="methotrexate" post="and cyclosporin.18 Fortunately, the advent of biologic agents, such"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7347348\results\search\drug\results.xml">
   <result pre="steroid treatment includes continuous therapy with &amp;gt;10 mg daily of" exact="prednisone" post="equivalent, lasting for more than 1-month period. *only for"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7348116\results\search\drug\results.xml">
   <result pre="Chin Med (Xi Bu Zhong Yi Yao)201932298100 11.YinQZhangJXYuTHLiSMClinical effect of" exact="ribavirin" post="injection combined with Tanreqing ultrasonic atomization in treating viral"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7349555\results\search\drug\results.xml">
   <result pre="activation and apoptosis from inflammatory cytokines, especially tumor necrosis factor" exact="alpha" post="(TNFÎ±) [34]. According to recent unpublished data from autopsies,"/>
   <result pre="protective immunity and inflammation is crucial to overcome the infection." exact="Prompt" post="recruitment and expansion of virus-specific lymphocytes can lead to"/>
   <result pre="membrane-fusion inhibitor active against influenza [148]. More trials are underway." exact="Ribavirin" post="has been empirically included into various treatment protocols for"/>
   <result pre="even though there is little evidence for its efficacy [149]." exact="Ribavirin" post="is a nucleoside analogue that inhibits viral RNA-dependent RNA"/>
   <result pre="with in vitro activity against SARS-CoV only at high concentrations." exact="Ribavirin" post="has been used for the treatment of SARS and"/>
   <result pre="MERS, mostly in combination with IFNs. Of 30 trials evaluating" exact="ribavirin" post="in patients with SARS, 26 were classified as inconclusive"/>
   <result pre="a high proportion of treated patients [150]. With these premises" exact="ribavirin" post="likely has limited value for the treatment of Covid-19."/>
   <result pre="likely has limited value for the treatment of Covid-19. 6.2." exact="Chloroquine" post="and Hydroxychloroquine Chloroquine and hydroxychloroquine inhibit in vitro SARS-CoV-2"/>
   <result pre="limited value for the treatment of Covid-19. 6.2. Chloroquine and" exact="Hydroxychloroquine" post="Chloroquine and hydroxychloroquine inhibit in vitro SARS-CoV-2 [151]. These"/>
   <result pre="value for the treatment of Covid-19. 6.2. Chloroquine and Hydroxychloroquine" exact="Chloroquine" post="and hydroxychloroquine inhibit in vitro SARS-CoV-2 [151]. These agents"/>
   <result pre="the treatment of Covid-19. 6.2. Chloroquine and Hydroxychloroquine Chloroquine and" exact="hydroxychloroquine" post="inhibit in vitro SARS-CoV-2 [151]. These agents appear to"/>
   <result pre="alternatives, the use of hydroxychloroquine, alone or in combination with" exact="azithromycin" post="(an antibiotic added mainly for its anti-inflammatory effects possibly"/>
   <result pre="clinical outcome. At day 6, 70% of patients who received" exact="hydroxychloroquine" post="(n = 20) achieved viral clearance compared to 12.5%"/>
   <result pre="out the potential synergistic effect of the concomitant use of" exact="azithromycin" post="since all the patients receiving the combination achieved viral"/>
   <result pre="were observed including the fact that six patients in the" exact="hydroxychloroquine" post="group that met the inclusion criteria were removed from"/>
   <result pre="still unpublished small clinical trial randomized 62 patients to receive" exact="hydroxychloroquine" post="or placebo and found a reduction of time to"/>
   <result pre="and the need for mechanical ventilation based on exposure to" exact="hydroxychloroquine" post="alone or with azithromycin, placing a cautionary note. In"/>
   <result pre="an increased overall mortality was identified in patients treated with" exact="hydroxychloroquine" post="alone [155]. Similarly, in a retrospective analysis of hospitalized"/>
   <result pre="probability of treatment weighting approach, did not find evidence of" exact="hydroxychloroquine" post="efficacy [156]. On 21 April, the National Institute of"/>
   <result pre="against the use, outside clinical trials, of the combination of" exact="hydroxychloroquine" post="plus azithromycin, because of the potential for toxicities. Also,"/>
   <result pre="Also, it was recommended to pay attention toward patients receiving" exact="chloroquine" post="or hydroxychloroquine for adverse effects, especially prolonged QTc interval."/>
   <result pre="was recommended to pay attention toward patients receiving chloroquine or" exact="hydroxychloroquine" post="for adverse effects, especially prolonged QTc interval. 6.3. SARS-CoV2-Specific"/>
   <result pre="SARS and MERS on the combined use of IFN and" exact="ribavirin" post="failed to show any improvement in mortality or viral"/>
   <result pre="recent COVID-19 series found that patients with ARDS treated with" exact="methylprednisolone" post="exhibited lower mortality (46% vs. 62%, hazard ratio for"/>
   <result pre="Adults Hospitalized with Severe Covid-19N. Engl. J. Med.20203821787179910.1056/NEJMoa200128232187464 144.WangM.CaoR.ZhangL.YangX.LiuJ.XuM.ShiZ.HuZ.ZhongW.XiaoG.Remdesivir and" exact="chloroquine" post="effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in"/>
   <result pre="in inhibiting SARS-CoV-2 infection in vitroCell Discov.2020610.1038/s41421-020-0156-0 152.GautretP.LagierJ.C.ParolaP.HoangV.T.MeddebL.MailheM.DoudierB.CourjonJ.GiordanengoV.VieiraV.E.et al.Hydroxychloroquine and" exact="azithromycin" post="as a treatment of COVID-19: Results of an open-label"/>
   <result pre="Dissemination of Results and Its Consequences Regarding the Use of" exact="Hydroxychloroquine" post="for COVID-19Ann. Intern. Med.202010.7326/M20-122332227189 154.ChenZ.HuJ.ZhangZ.Shan JiangS.HanS.YanD.ZhuangR.HuB.ZhangZ.Efficacy of hydroxychloroquine in"/>
   <result pre="Use of Hydroxychloroquine for COVID-19Ann. Intern. Med.202010.7326/M20-122332227189 154.ChenZ.HuJ.ZhangZ.Shan JiangS.HanS.YanD.ZhuangR.HuB.ZhangZ.Efficacy of" exact="hydroxychloroquine" post="in patients with COVID-19: Results of a randomized clinical"/>
   <result pre="with COVID-19: Results of a randomized clinical trialmedRxiv202010.1101/2020.03.22.20040758 155.MagagnoliJ.NarendranS.PereiraF.CummingsT.HardinJ.W.SuttonS.S.AmbatiJ.Outcomes of" exact="hydroxychloroquine" post="usage in United States veterans hospitalized with Covid-19medRxiv202010.1101/2020.04.16.20065920 156.MahevasM.TranV.-T.RoumierM.ChabrolA.PauleR.GuillaudC.GallienS.LepeuleR.SzwebelT.-A.LescureX.et"/>
   <result pre="hospitalized with Covid-19medRxiv202010.1101/2020.04.16.20065920 156.MahevasM.TranV.-T.RoumierM.ChabrolA.PauleR.GuillaudC.GallienS.LepeuleR.SzwebelT.-A.LescureX.et al.No evidence of clinical efficacy of" exact="hydroxychloroquine" post="in patients hospitalized for COVID-19 infection with oxygen requirement:"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7350360\results\search\drug\results.xml">
   <result pre="had liver injury indicated by abnormal liver function testsâ€&quot;mainly elevated" exact="alanine" post="aminotransferase (ALT), hypoalbuminemia, and elevated gamma-glutamyl transferase (GGT) [22,23,24]."/>
   <result pre="injury seen in COVID-19 patients. They show that patients given" exact="lopinavir" post="or ritonavir after admission presented higher incidence of liver"/>
   <result pre="in COVID-19 patients. They show that patients given lopinavir or" exact="ritonavir" post="after admission presented higher incidence of liver injury and"/>
   <result pre="their liver in the first place. Though recent evidence suggests" exact="lopinavir" post="and ritonavir had no clinical effect on SARS-CoV-2, perhaps"/>
   <result pre="in the first place. Though recent evidence suggests lopinavir and" exact="ritonavir" post="had no clinical effect on SARS-CoV-2, perhaps future application"/>
   <result pre="Several drugs have been trialled on SARS-CoV-2 patients such as" exact="hydroxychloroquine" post="and azithromycin with ambiguous results on the virus but"/>
   <result pre="have been trialled on SARS-CoV-2 patients such as hydroxychloroquine and" exact="azithromycin" post="with ambiguous results on the virus but possibly exacerbating"/>
   <result pre="values [11,30]. Patients with SARS-CoV-2 have exhibited increased levels of" exact="creatine" post="kinase, lactate dehydrogenase, ferritin, C-reactive protein, and myoglobin alongside"/>
   <result pre="enzymes and liver dysfunction in SARS-CoV-2 patients presenting with elevated" exact="alanine" post="transaminase (ALT), gamma-glutamyl transferase (GGT), bilirubin, and monocyte chemoattractant"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7351052\results\search\drug\results.xml">
   <result pre="2 weeks after the onset of symptoms. At that time," exact="methylprednisolone" post="was able to reduce levels of IL-8, MCP-1, and"/>
   <result pre="(Th2 response). In parallel, a letter reported that use of" exact="methylprednisolone" post="(1â€&quot;2â€‰mg/kg/day for 5â€&quot;7 days) in 26 patients with severe"/>
   <result pre="trial of critically ill patients with COVID-19 demonstrated benefit of" exact="dexamethasone" post="(orally or intravenously, 6â€‰mg once daily for 10 days)"/>
   <result pre="treatment. Alternatively, pregnant or breastfeeding women were randomized to receive" exact="prednisolone" post="(orally, 40â€‰mg) or hydrocortisone (intravenously, 80â€‰mg twice daily). The"/>
   <result pre="breastfeeding women were randomized to receive prednisolone (orally, 40â€‰mg) or" exact="hydrocortisone" post="(intravenously, 80â€‰mg twice daily). The RECOVERY trial enrolled 6425"/>
   <result pre="institutes of health are updating their guidelines to recommend that" exact="dexamethasone" post="be administered to COVID-19-patients with hypoxemic respiratory failure (World"/>
   <result pre="to advise glucocorticoids rather than no glucocorticoids (preferably dexamethasone, alternatively" exact="methylprednisolone" post="or prednisone) in hospitalized patients with severe COVID-19. Steroid"/>
   <result pre="A study of 30 patients with SARS-CoV-1 infection treated with" exact="methylprednisolone" post="showed that the initial stage of the disease is"/>
   <result pre="infections. Finally, in a study of SARS-CoV-1 patients in which" exact="ribavirin" post="and hydrocortisone therapy were compared versus placebo, suggested that"/>
   <result pre="in a study of SARS-CoV-1 patients in which ribavirin and" exact="hydrocortisone" post="therapy were compared versus placebo, suggested that corticosteroid administration"/>
   <result pre="(iv) the dose administered should be low to moderate (â‰¤0.5âˆ’1â€‰mg/kg/day" exact="methylprednisolone" post="or equivalent), and the duration short (â‰¤7 days). Additionally,"/>
   <result pre="Also, clinicians should be aware of possible drugâ€&quot;drug interactions, since" exact="dexamethasone" post="is a moderate inducer of cytochrome P450 (CYP)3A4, and"/>
   <result pre="septic shockN. Engl. J. Med.378201879780829347874 WangY.JiangW.HeQ.WangC.WangB.ZhouP.DongN.TongQ.A retrospective cohort study of" exact="methylprednisolone" post="therapy in severe patients with COVID-19 pneumoniaSig. Transduct. Target"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7351566\results\search\drug\results.xml">
   <result pre="several repurposed candidates in the drug development pipeline. Galidesivir and" exact="Sofosbuvir" post="are both nucleoside analog antivirals originally used to treat"/>
   <result pre="for the treatment of YF [95, 96]. Both Galidesivir and" exact="Sofosbuvir" post="were found to inhibit YF replication in vitro and"/>
   <result pre="patients presenting with acute liver failure were treated off-label with" exact="Sofosbuvir" post="for a week as compassionate use and displayed marked"/>
   <result pre="we?Trends Microbiol2018261086587610.1016/j.tim.2018.04.00429759926 95.SacramentoCQde MeloGRde FreitasCSRochaNHoelzLVMirandaMet al.The clinically approved antiviral drug" exact="sofosbuvir" post="inhibits Zika virus replicationSci Rep201774092010.1038/srep4092028098253 96.XuHTColby-GerminarioSPHassounahSAFogartyCOsmanNPalanisamyNHanYOliveiraMQuanYWainbergMAEvaluation of Sofosbuvir (beta-D-2â€²-deoxy-2â€²-alpha-fluoro-2â€²-beta-C-methyluridine)"/>
   <result pre="antiviral drug sofosbuvir inhibits Zika virus replicationSci Rep201774092010.1038/srep4092028098253 96.XuHTColby-GerminarioSPHassounahSAFogartyCOsmanNPalanisamyNHanYOliveiraMQuanYWainbergMAEvaluation of" exact="Sofosbuvir" post="(beta-D-2â€²-deoxy-2â€²-alpha-fluoro-2â€²-beta-C-methyluridine) as an inhibitor of dengue virus replicationSci Rep201771634510.1038/s41598-017-06612-228740124"/>
   <result pre="98.de FreitasCSHigaLMSacramentoCQFerreiraACReisPADelvecchioRMonteiroFLBarbosa-LimaGJames WestgarthHVieiraYRMattosMRochaNHoelzLVBLemeRPPBastosMML. RodriguesGOM. LopesCEQueiroz-JuniorCMLimaCXCostaVVTeixeiraMMBozzaFABozzaPTBoechatNTanuriASouzaTMLYellow fever virus is susceptible to" exact="sofosbuvir" post="both in vitro and in vivoPLoS Negl Trop Dis2019131e000707210.1371/journal.pntd.000707230699122"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7352498\results\search\drug\results.xml">
   <result pre="potential antiviral agent carriers. For instance, antiviral drugs such as" exact="ribavirin" post="and isoprinosine have been chemically linked on a single-walled"/>
   <result pre="animals in lethal models of endotoxemia. The selective delivery of" exact="adenosine" post="and antioxidants together could serve as an innovative method"/>
   <result pre="of H1N1 influenza virus-induced apoptosis by functionalized selenium nanoparticles with" exact="amantadine" post="through ROS-mediated AKT signaling pathwaysInt. J. Nanomed.201813200510.2147/IJN.S155994 32.LiY.LinZ.GuoM.XiaY.ZhaoM.WangC.XuT.ChenT.ZhuB.Inhibitory activity"/>
   <result pre="enhanced drug deliverySci. Adv.20195eaax078010.1126/sciadv.aax078031453334 36.Ã–ztÃ¼rkA.A.KÄ±rÄ±mlÄ±oÄŸluG.Y.Preparation and in vitro of characterization" exact="lamivudine" post="loaded nanoparticles prepared by acid or ester terminated PLGA"/>
   <result pre="antiretroviral therapyJ. Res. Pharm.201923897913 37.VenkateshD.N.BaskaranM.KarriV.V.S.R.MannemalaS.S.RadhakrishnaK.GotiS.Fabrication and in vivo evaluation of" exact="Nelfinavir" post="loaded PLGA nanoparticles for enhancing oral bioavailability and therapeutic"/>
   <result pre="oral bioavailability and therapeutic effectSaudi Pharm. J.20152366767410.1016/j.jsps.2015.02.02126702262 38.ShahL.K.AmijiM.M.Intracellular delivery of" exact="saquinavir" post="in biodegradable polymeric nanoparticles for HIV/AIDSPharm. Res.2006232638264510.1007/s11095-006-9101-716969696 39.TangX.LiangY.LiuX.ZhouS.LiuL.ZhangF.XieC.CaiS.WeiJ.ZhuY.PLGA-PEG nanoparticles"/>
   <result pre="nodes and blood in primatesAIDS Res. Hum. Retrovir.20153110711410.1089/aid.2014.021025402233 45.DuanJ.FreelingJ.P.KoehnJ.ShuC.HoR.J.Y.Evaluation of" exact="atazanavir" post="and darunavir interactions with lipids for developing pH-responsive anti-HIV"/>
   <result pre="Drug DeliverySpringerBerlin, Germany201138 114.ChiappettaD.A.FacorroG.de CelisE.R.SosnikA.Synergistic encapsulation of the anti-HIV agent" exact="efavirenz" post="within mixed poloxamine/poloxamer polymeric micellesNanomed. Nanotechnol. Biol. Med.2011762463710.1016/j.nano.2011.01.017 115.Santos-MartinezM.J.RahmeK.CorbalanJ.J.FaulknerC.HolmesJ.D.TajberL.MedinaC.RadomskiM.W.Pegylation"/>
   <result pre="for therapeutic applicationsNat. Rev. Drug Discov.2010961562710.1038/nrd259120616808 140.MaurerP.JenningsG.T.WillersJ.RohnerF.LindmanY.RoubicekK.RennerW.A.MÃ¼llerP.BachmannM.F.A therapeutic vaccine for" exact="nicotine" post="dependence: Preclinical efficacy, and Phase I safety and immunogenicityEur."/>
   <result pre="less cytotoxic (~90%) than free AgNPs (65%) or AM (56%)" exact="Amantadine" post="(AM) H1N1 [30] Selenium (Se) Uniformly spherical Se@AM (70"/>
   <result pre="antiviral activity towards the NP drugs than the free drugs" exact="Diphyllin" post="&amp;amp; Bafilomycin [33] PLGA Uniform, spherical/smooth surface NPs (116âˆ’143"/>
   <result pre="interaction between polymer and LAM confirmed by FTIR and DSC" exact="Lamivudine" post="(LAM) HIV [36] PLGA Spherical/smooth surface NFV NPs (~185"/>
   <result pre="PLGA Spherical/smooth surface NFV NPs (~185 nm); almost narrow distribution" exact="Efavirenz" post="(EFV) [37] PEO-PCL Spherical PEO-PCL NPs (~200âˆ’270 nm)with smooth"/>
   <result pre="NPs (~200âˆ’270 nm)with smooth surface; SQV is encapsulated into NPs" exact="Saquinavir" post="(SQV) [38] PLGA-PEG Spherical shape (~125 nm) for those"/>
   <result pre="loaded with SAHA; ~118 nm for NPs loaded with NFV" exact="Suberoylanilide hydroxamic acid" post="(SAHA) and NFV [39] Hybrid NPs (PLGA, PLA, MMA-SPM,"/>
   <result pre="DNA Electrochemical 0.4 pM, 1.0 nMâˆ’5.0 pM 20 Spherical, 3" exact="Daunorubicin" post="Scanometric 10 pM, 10 pMâˆ’100 nM 20 Spherical, 1.4"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7353929\results\search\drug\results.xml">
   <result pre="are likely to emerge in the near future. 4-aminoquinolines Both" exact="chloroquine" post="and hydroxychloroquine have been demonstrated to inhibit CoV-2 in"/>
   <result pre="to emerge in the near future. 4-aminoquinolines Both chloroquine and" exact="hydroxychloroquine" post="have been demonstrated to inhibit CoV-2 in vitro. Hydroxychloroquine"/>
   <result pre="and hydroxychloroquine have been demonstrated to inhibit CoV-2 in vitro." exact="Hydroxychloroquine" post="acts by increasing the pH of endosomes and lysosomes"/>
   <result pre="of the coronavirus. As per Chinese experience, the use of" exact="chloroquine" post="has been associated with decreased duration of symptoms and"/>
   <result pre="and reduced progression of the disease.[18] In the French study," exact="hydroxychloroquine" post="was associated with increased effectiveness in combination with azithromycin.[19]"/>
   <result pre="has serious methodological limitations and was based on improper rationale." exact="Chloroquine" post="and hydroxychloroquine are also being seen as promising agents"/>
   <result pre="methodological limitations and was based on improper rationale. Chloroquine and" exact="hydroxychloroquine" post="are also being seen as promising agents for prophylaxis"/>
   <result pre="outbreak in ChinaInfection202048151332185635 18DevauxCARolainJMColsonPRaoultDNew insights on the antiviral effects of" exact="chloroquine" post="against coronavirus: What to expect for COVID-19Int J Antimicrob"/>
   <result pre="on 2020 Apr 07In PressAvailable from: https://doiorg/101016/jijantimicag2020105938 19GautretPLagierJCParolaPHoangVTMeddebLMailheMet al.Hydroxychloroquine and" exact="azithromycin" post="as a treatment of COVID-19: Results of an open-label"/>
   <result pre="from: https://doiorg/101016/jijantimicag2020105949 20ZhouDDaiSMTongQCOVID-19: A recommendation to examine the effect of" exact="hydroxychloroquine" post="in preventing infection and progressionJ Antimicrob Chemother2020Last accessed on"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7354743\results\search\drug\results.xml">
   <result pre="vaccines made it to Phase I clinical trials before funding" exact="dried" post="up because the virus was eradicated from the human"/>
   <result pre="Issues Mol Biol201722798827705898 68.GhaffarifarFPlasmid DNA vaccines: where are we now?Drugs" exact="Today" post="Barc20185431533329911696 69.GeallAJMandlCWUlmerJBRNA: the new revolution in nucleic acid vaccinesSemin"/>
   <result pre="disappear during the evolution of influenza virus in humans increase" exact="alpha" post="interferon secretion by plasmacytoid dendritic cellsJ Virol2011853893390421307198 104.KriegAMWagnerHCausing a"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7356537\results\search\drug\results.xml">
   <result pre="deliver medical interventions in the pre-hospital or in-hospital setting [70]." exact="Prompt" post="activation of emergency medical services (EMS) is crucial, since"/>
   <result pre="ACS patients, care should be taken when administering antiplatelet therapy." exact="Clopidogrel" post="and ticagrelor have specific interactions with lopinavirâ€&quot;ritonavir, a combination"/>
   <result pre="care should be taken when administering antiplatelet therapy. Clopidogrel and" exact="ticagrelor" post="have specific interactions with lopinavirâ€&quot;ritonavir, a combination of antiviral"/>
   <result pre="benefit [99]. Lopinavirâ€&quot;ritonavir should not be used in combination with" exact="clopidogrel" post="or ticagrelor due to their potent CYP3A4 inhibition [100],"/>
   <result pre="Lopinavirâ€&quot;ritonavir should not be used in combination with clopidogrel or" exact="ticagrelor" post="due to their potent CYP3A4 inhibition [100], which results"/>
   <result pre="CYP3A4 inhibition [100], which results in a diminished effect of" exact="clopidogrel" post="and an increased effect of ticagrelor; prasugrel should be"/>
   <result pre="utilization, or quality of life in patients with Covid-19 using" exact="aspirin" post="and other non-steroidal anti-inflammatory drugs (NSAIDS) has been provided,"/>
   <result pre="by the WHO [103]. It may be assumed that low-dose" exact="aspirin" post="can be safely used as antiplatelet drug in Covid-19"/>
   <result pre="be safely used as antiplatelet drug in Covid-19 patients. Additionally," exact="atorvastatin" post="and rosuvastatin should be started at the lowest possible"/>
   <result pre="statins [101]. Beta-blockersâ€&quot;especially metoprololâ€&quot;should be administered cautiously in patients consuming" exact="chloroquine" post="or hydroxychloroquine due to CYP2D6 inhibition [104] and the"/>
   <result pre="Beta-blockersâ€&quot;especially metoprololâ€&quot;should be administered cautiously in patients consuming chloroquine or" exact="hydroxychloroquine" post="due to CYP2D6 inhibition [104] and the potential role"/>
   <result pre="due to CYP2D6 inhibition [104] and the potential role of" exact="hydroxychloroquine" post="in reducing heart rate [105]. Reninâ€&quot;angiotensinâ€&quot;aldosterone system (RAAS)-related drugs"/>
   <result pre="case reports have highlighted the necessity of augmented doses of" exact="warfarin" post="in patients treated with ribavirin; the international normalized ratio"/>
   <result pre="is involved in the hepatic clearance of some novel OACs," exact="rivaroxaban" post="should be avoided and apixaban should be administered at"/>
   <result pre="clearance of some novel OACs, rivaroxaban should be avoided and" exact="apixaban" post="should be administered at 50% of the standard dose"/>
   <result pre="SARS: Initial virological and clinical findingsThorax200410.1136/thorax.2003.01265814985565 98.KimU.J.WonE.J.KeeS.J.JungS.I.JangH.C.Combination therapy with lopinavir/ritonavir," exact="ribavirin" post="and interferon-a for Middle East respiratory syndromeAntivir. Ther.20162145545910.3851/IMP300226492219 99.CaoB.WangY.WenD.LiuW.WangJ.FanG.RuanL.SongB.CaiY.WeiM.et"/>
   <result pre="with severe covid-19N. Engl. J. Med.202010.1056/NEJMoa200128232187464 100.DuangchaemkarnK.ReisfeldB.LohitnavyM.A pharmacokinetic model of" exact="lopinavir" post="in combination with ritonavir in humanProceedings of the 36th"/>
   <result pre="J. Med.202010.1056/NEJMoa200128232187464 100.DuangchaemkarnK.ReisfeldB.LohitnavyM.A pharmacokinetic model of lopinavir in combination with" exact="ritonavir" post="in humanProceedings of the 36th Annual International Conference of"/>
   <result pre="with COVID-19Available online: https://www.who.int/news-room/commentaries/detail/the-use-of-non-steroidal-anti-inflammatory-drugs-(nsaids)-in-patients-with-covid-19(accessed on 18 May 2020) 104.SomerM.KallioJ.PesonenU.PyykkÃ¶K.HuupponenR.ScheininM.Influence of" exact="hydroxychloroquine" post="on the bioavailability of oral metoprololBr. J. Clin. Pharmacol.200010.1046/j.1365-2125.2000.00197.x"/>
   <result pre="treatments for coronavirus disease 2019 (COVID-19): A reviewJAMA202010.1001/jama.2020.6019 109.PetersonD.Van ErmenA.Increased" exact="warfarin" post="requirements in a patient with chronic hepatitis C infection"/>
   <result pre="requirements in a patient with chronic hepatitis C infection receiving" exact="sofosbuvir" post="and ribavirinAm. J. Health Pharm.20177488889210.2146/ajhp16073028596225 110.PuglisiG.M.SmithS.M.JankovichR.D.AshbyC.R.JodlowskiT.Z.Paritaprevir/ritonavir/ombitasvir+dasabuvir plus ribavirin therapy"/>
   <result pre="infection receiving sofosbuvir and ribavirinAm. J. Health Pharm.20177488889210.2146/ajhp16073028596225 110.PuglisiG.M.SmithS.M.JankovichR.D.AshbyC.R.JodlowskiT.Z.Paritaprevir/ritonavir/ombitasvir+dasabuvir plus" exact="ribavirin" post="therapy and inhibition of the anticoagulant effect of warfarin:"/>
   <result pre="coadministered with lopinavirâ€&quot;ritonavir, diminished effect of clopidogrel, increased effect of" exact="ticagrelor" post="[101]. Consider using prasugrel if no contraindications [101].Contraindications to"/>
   <result pre="[112].Contraindications for ticagrelor: previous intracranial hemorrhage or ongoing bleeds [112]." exact="Aspirin" post="- Lack of evidence on discontinuation of aspirin in"/>
   <result pre="bleeds [112]. Aspirin - Lack of evidence on discontinuation of" exact="aspirin" post="in Covid-19 patients. Low-dose aspirin can be assumed to"/>
   <result pre="of evidence on discontinuation of aspirin in Covid-19 patients. Low-dose" exact="aspirin" post="can be assumed to be safe as antiplatelet drug"/>
   <result pre="-Lovastatin -Simvastatin Lopinavirâ€&quot;Ritonavir When coadministered with lopinavirâ€&quot;ritonavir, increased effect of" exact="atorvastatin" post="and rosuvastatin [101]. Start at lowest possible dose of"/>
   <result pre="rosuvastatin [101]. Start at lowest possible dose of rosuvastatin and" exact="atorvastatin" post="and titrate, otherwise use pravastatin [101]. Beta-blockers: -Metoprolol -Carvedilol"/>
   <result pre="possible dose of rosuvastatin and atorvastatin and titrate, otherwise use" exact="pravastatin" post="[101]. Beta-blockers: -Metoprolol -Carvedilol -Propranolol -Labetalol Chloroquineâ€&quot;Hydroxychloroquine Fingolimod Hydroxychloroquine"/>
   <result pre="use pravastatin [101]. Beta-blockers: -Metoprolol -Carvedilol -Propranolol -Labetalol Chloroquineâ€&quot;Hydroxychloroquine Fingolimod" exact="Hydroxychloroquine" post="has a potential role in reducing heart rate and"/>
   <result pre="and may increase effect of beta-blockers [105]. When coadministered with" exact="chloroquine" post="or hydroxychloroquine, beta-blockers dose reduction may be required [105]."/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7356583\results\search\drug\results.xml">
   <result pre="mechanical ventilation. Makris et al. [45] investigated the impact of" exact="pravastatin" post="therapy on ventilator-associated pneumonia (VAP) frequency and mortality. The"/>
   <result pre="pneumonia (VAP) frequency and mortality. The authors showed that the" exact="pravastatin" post="group had significantly increased probability of survival compared to"/>
   <result pre="However, this study was limited by a short duration of" exact="simvastatin" post="administration, which was probably administered too late to see"/>
   <result pre="the recent clinical trialsCurr. Pharm. Des.2012181519153010.2174/13816121279950480322364136 29.Bielecka-DabrowaA.MikhailidisD.P.RizzoM.von HaehlingS.RyszJ.BanachM.The influence of" exact="atorvastatin" post="on parameters of inflammation left ventricular function, hospitalizations and"/>
   <result pre="Is Suspected2020Available online: https://www.who.int/publications-detail/clinical-management-of-severe-acute-respiratory-infection-when-novel-coronavirus-(ncov)-infection-is-suspected(accessed on 11 April 2020) 45.MakrisD.ManoulakasE.KomnosA.PapakrivouE.TzovarasN.HovasA.ZintzarasE.ZakynthinosE.Effect of" exact="pravastatin" post="on the frequency of ventilator-associated pneumonia and on intensive"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7356825\results\search\drug\results.xml">
   <result pre="safety for use in pregnant women [126]. 4.1.4. Quinine/Quinine Sulfate" exact="Quinine" post="is a natural compound extracted from the bark of"/>
   <result pre="drug discovery and development [133]. Of the four drugs examined," exact="quinine" post="markedly decreased DENV replication by inhibiting DENV RNA replication,"/>
   <result pre="its specific antiviral mechanism could not be determined [109]. As" exact="quinine" post="is reported to act on host cells rather than"/>
   <result pre="to the compound could be minimized [131]. The effects of" exact="quinine" post="in the human body is well studied as it"/>
   <result pre="for the treatment of malaria. It has been reported that" exact="quinine" post="produces mild to severe side effects at therapeutic concentrations"/>
   <result pre="vomiting, loss of vision, and marked auditory loss [130]. Identifying" exact="quinine" post="as an antiviral drug is a good starting point,"/>
   <result pre="of bioflavonoid against dengue virus type-2Virol. J.2011856010.1186/1743-422X-8-56022201648 109.MalakarS.SreelathaL.DechtawewatT.NoisakranS.YenchitsomanusP.-T.ChuJ.J.H.LimjindapornT.Drug repurposing of" exact="quinine" post="as antiviral against dengue virus infectionVirus Res.201825517117810.1016/j.virusres.2018.07.01830055216 110.MohdA.ZainalN.TanK.-K.AbubakarS.Resveratrol affects"/>
   <result pre="Role in the treatment of malariaMalar. J.20111014410.1186/1475-2875-10-14421609473 131.BaroniA.PaolettiI.RuoccoE.AyalaF.CorradoF.WolfR.TufanoM.A.DonnarummaG.Antiviral effects of" exact="quinine" post="sulfate on HSV-1 HaCat cells infected: Analysis of the"/>
   <result pre="against extracellular CHIKV particles -Time-of-addition assay, inactivation assay [95] 15" exact="Quinine" post="Cinchona tree DEN-1 to -4 -Inhibits viral replication by"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7356962\results\search\drug\results.xml">
   <result pre="shuanghuanglian, a Chinese herbal medication that includes substances from the" exact="dried" post="fruit lianqiao (Forsythiae fructus), which has reportedly been used"/>
   <result pre="medicine) that tonifies and enhances the spleenâ€�. It is the" exact="dried" post="rhizome of Atractylodes lancea (Thunb.), Atractylodes chinensis Koidz, or"/>
   <result pre="that patients should receive KaletraÂ® (a combination of antiviral drugs" exact="lopinavir" post="and ritonavir) very early and should also be treated"/>
   <result pre="corylifoliaJ. Enzym. Inhib. Med. Chem.201429596310.3109/14756366.2012.75359123323951 58.WengJ.R.LinC.S.LaiH.C.LinY.P.WangC.Y.TsaiY.C.LinC.W.Antiviral activity of Sambucus FormosanaNakai" exact="ethanol" post="extract and related phenolic acid constituents against human coronavirus"/>
   <result pre="COVID-19 Patients in Northeast ChongqingJ. Med. Virol.2020779780610.1002/jmv.25783 106.McMahonM.A.SilicianoJ.D.LaiJ.LiuJ.O.StiversJ.T.SilicianoR.F.KohliR.M.The antiherpetic drug" exact="acyclovir" post="inhibits HIV replication and selects the V75I reverse transcriptase"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7357070\results\search\drug\results.xml">
   <result pre="remdesivir as well as antiretroviral drugs including darunavir, lopinavir, and" exact="ritonavir" post="are suggested to be effective in treating disorders caused"/>
   <result pre="C, HIV-1, influenza, etc., along with host-targeted drugs such as" exact="hydroxychloroquine" post="and azithromycin [4,5,6,7,8,9]. Overcoming the challenges of novel viral"/>
   <result pre="influenza, etc., along with host-targeted drugs such as hydroxychloroquine and" exact="azithromycin" post="[4,5,6,7,8,9]. Overcoming the challenges of novel viral infections requires"/>
   <result pre="such as remdesivir, chloroquine, umifenovir, and some antiretroviral drugs (darunavir," exact="lopinavir" post="in combination with ritonavir) [30]. The therapeutic effects of"/>
   <result pre="those of some other drugs such as antiretroviral drugs (darunavir," exact="lopinavir" post="in combination with ritonavir) [32] on SARS-CoV-2 have generated"/>
   <result pre="MERS or COVID-19: Initial assessmentJ. Int. AIDS Soc.202023e2548910.1002/jia2.2548932293807 12.KimJ.-W.KimE.J.KwonH.H.JungC.Y.KimK.C.ChoeJ.-Y.HongH.-L.Lopinavir-ritonavir versus" exact="hydroxychloroquine" post="for viral clearance and clinical improvement in patients with"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7358098\results\search\drug\results.xml">
   <result pre="al48 assessed the safety and efficacy of PD-1 inhibition by" exact="pembrolizumab" post="with different predisposing conditions (n=8). In this small cohort,"/>
   <result pre="Nevertheless, it seems that early and short-time use of low-dose" exact="methylprednisolone" post="may be one feasible approach in SARS-COV-2-related pneumonitis and"/>
   <result pre="syndrome.83 Hence, possible ICI-induced irAEs could be safely managed with" exact="methylprednisolone" post="in the setting of COVID-19. Based on the observation"/>
   <result pre="to compare the efficacy of the combined administration of a" exact="chloroquine" post="analog, nivolumab, and tocilizumab versus standard of care in"/>
   <result pre="randomized into two different cohorts: (1) asymptomatic or mild symptoms:" exact="chloroquine" post="analog versus nivolumab versus standard of care (1:1:1); (2)"/>
   <result pre="versus nivolumab versus standard of care (1:1:1); (2) moderate/severe symptoms:" exact="chloroquine" post="analog versus tocilizumab versus standard of care (1:1:1). It"/>
   <result pre="of care (1:1:1). It has to be stressed, however, that" exact="hydroxychloroquine" post="use has been reported to be ineffective or even"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7358456\results\search\drug\results.xml">
   <result pre="is regulated by the major control complex mammalian target of" exact="rapamycin" post="(mTOR) (15, 16). Interestingly, trehalose induces autophagy independent of"/>
   <result pre="mammalian cell cultures, trehalose treatment can enhance the clearance of" exact="denatured" post="huntingtin and denatured Î±-synuclein, both autophagy substrates associated with"/>
   <result pre="trehalose treatment can enhance the clearance of denatured huntingtin and" exact="denatured" post="Î±-synuclein, both autophagy substrates associated with Huntington's and Parkinson's"/>
   <result pre="on mTOR substrates, which are reduced by the mTOR inhibitor" exact="rapamycin" post="(14). Later, the transcription factor EB (TFEB) was identified"/>
   <result pre="virion maturation, regulating cellular autophagy with autophagy modulators such as" exact="chloroquine" post="(CQ) or trehalose is of great importance in the"/>
   <result pre="New triple antiviral therapy combination of interferon beta-1b, lopinavir-ritonavir, and" exact="ribavirin" post="in the treatment of mild to moderate COVID-19 patients"/>
   <result pre="limitations to this trial (56). CQ and its structural analog" exact="hydroxychloroquine" post="(HCQ), FDA approved drugs used as antimalarial agents with"/>
   <result pre="proves these drugs to be effective against the disease. Interestingly," exact="azithromycin" post="and erythromycin, macrolide antibiotics, have specific antiviral effects that"/>
   <result pre="patients treated with CQ-azithromycin (65, 66). Remdesivir, lopinavir/ritonavir, CQ, and" exact="azithromycin" post="have shown to be effective in inhibiting SARS-CoV-2 replication"/>
   <result pre="10.1056/NEJMoa200128232187464 56.HungIFLungKTsoEYLiuRChungTWChuMYet al.. Triple combination of inferferon beta-1b, lopinavir-ritonavir, and" exact="ribavirin" post="in the treatment of patients admitted to hospital with"/>
   <result pre="2 trial. Lancet. (2020) 395:1695â€&quot;704. 10.1016/S0140-6736(20)31042-432401715 57.WangMCaoRZhangLYangXLiuJXuMet al.. Remdesivir and" exact="chloroquine" post="effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in"/>
   <result pre="(2019-nCoV) in vitro. Cell Res. (2020) 30:269â€&quot;71. 10.1038/s41422-020-0282-032020029 58.MautheMOrhonIRocchiCZhouXLuhrMHijlkemaKJet al.." exact="Chloroquine" post="inhibits autophagic flux by decreasing autophagosome-lysosome fusion. Autophagy. (2018)"/>
   <result pre="fusion. Autophagy. (2018) 14:1435â€&quot;55. 10.1080/15548627.2018.147431429940786 59.Al-BariMAA. Targeting endosomal acidification by" exact="chloroquine" post="analogs as a promising strategy for the treatment of"/>
   <result pre="Pathog. (2014) 10:e1004502. 10.1371/journal.ppat.100450225375324 62.Emergency Use Authorization for Use of" exact="Chloroquine" post="Phosphate or Hydroxychloroquine Sulfate Supllied From the Strategic National"/>
   <result pre="10.1371/journal.ppat.100450225375324 62.Emergency Use Authorization for Use of Chloroquine Phosphate or" exact="Hydroxychloroquine" post="Sulfate Supllied From the Strategic National Stockpile for Treatmetn"/>
   <result pre="63.KakeyaHSekiMIzumikawaKKosaiKMorinagaYKuriharaSet al.. Efficacy of combination therapy with oseltamivir phosphate and" exact="azithromycin" post="for influenza: a multicenter, open-label, randomized study. PLoS ONE."/>
   <result pre="open-label, randomized study. PLoS ONE. (2014) 9:e91293. 10.1371/journal.pone.009129324632748 64.GautretPLagierJCParolaPHoangVTMeddebLMailheMet al.." exact="Hydroxychloroquine" post="and azithromycin as a treatment of COVID-19: results of"/>
   <result pre="study. PLoS ONE. (2014) 9:e91293. 10.1371/journal.pone.009129324632748 64.GautretPLagierJCParolaPHoangVTMeddebLMailheMet al.. Hydroxychloroquine and" exact="azithromycin" post="as a treatment of COVID-19: results of an open-label"/>
   <result pre="print]. 10.1016/j.ijantimicag.2020.10594932205204 65.BorbaMGSValFFASampaioVSAlexandreMAAMeloGCBritoMet al.Effect of high vs low doses of" exact="chloroquine" post="diphosphate as adjunctive therapy for patients hospitalized with severe"/>
   <result pre="66.MercuroNJYenCFShimDJMaherTRMcCoyCMZimetbaumPJet al.Risk of QT interval prolongation associated with use of" exact="hydroxychloroquine" post="with or without concomitant azithromycin among hospitalized patients testing"/>
   <result pre="prolongation associated with use of hydroxychloroquine with or without concomitant" exact="azithromycin" post="among hospitalized patients testing positive for coronavirus disease 2019"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7359800\results\search\drug\results.xml">
   <result pre="For the treatment of affected people, limited urgent use of" exact="chloroquine" post="and hydroxychloroquine have been approved by the United States"/>
   <result pre="treatment of affected people, limited urgent use of chloroquine and" exact="hydroxychloroquine" post="have been approved by the United States Food and"/>
   <result pre="in the second phase, they should attempt to suppress it." exact="Vitamin B3" post="should be used immediately after the coughing begins because"/>
   <result pre="developed remdesivir, and it is a phosphoramidate prodrug of an" exact="adenosine" post="C-nucleoside and a broad spectrum antiviral agent [65]. Hydroxychloroquine"/>
   <result pre="an adenosine C-nucleoside and a broad spectrum antiviral agent [65]." exact="Hydroxychloroquine" post="and chloroquine are other drugs that have a long"/>
   <result pre="C-nucleoside and a broad spectrum antiviral agent [65]. Hydroxychloroquine and" exact="chloroquine" post="are other drugs that have a long history of"/>
   <result pre="another drug, which was administered and marketed in combination with" exact="ritonavir" post="by Abbott under the brand name Kaletra in 2000."/>
   <result pre="in combination with ritonavir by Abbott under the brand name" exact="Kaletra" post="in 2000. Lopinavir is a protease inhibitor with high"/>
   <result pre="[92]. Table 3 Drug Class Target Dosage References Camostat mesilate" exact="Serine" post="protease inhibitor TMPRSS2 200Â mg three times daily, for"/>
   <result pre="mg three times daily, for 2 weeks, per oral [73,74]" exact="Nafamostat" post="mesilate Serine protease inhibitor TMPRSS2 240Â mg daily, for"/>
   <result pre="times daily, for 2 weeks, per oral [73,74] Nafamostat mesilate" exact="Serine" post="protease inhibitor TMPRSS2 240Â mg daily, for 5 days,"/>
   <result pre="TMPRSS2 240Â mg daily, for 5 days, per oral [75]" exact="Chloroquine" post="phosphate Antimalarial drug ACE2 250Â mg daily until clinical"/>
   <result pre="ACE2 250Â mg daily until clinical convalescence, per oral [78,79]" exact="Hydroxychloroquine" post="Antimalarial drug Endosome, pH elevation 400Â mg loading dose"/>
   <result pre="[[83], [84], [85]] Lopinavir/ritonavir Antiviral drug Viral proteases 400Â mg" exact="lopinavir" post="and 100 mg ritonavir twice daily, for 14 days,"/>
   <result pre="Antiviral drug Viral proteases 400Â mg lopinavir and 100 mg" exact="ritonavir" post="twice daily, for 14 days, per oral [[86], [87],"/>
   <result pre="[123]. Although there is no registered medicine for COVID-19 treatment," exact="hydroxychloroquine" post="and remdesivir are prescribed and are partially effective [124].&amp;lt;--"/>
   <result pre="65SiegelD.HuiH.C.DoerfflerE.ClarkeM.O.ChunK.ZhangL.Discovery and synthesis of a phosphoramidate prodrug of a pyrrolo[2,1-f][triazin-4-amino]" exact="adenine" post="C-nucleoside (GS-5734) for the treatment of Ebola and emerging"/>
   <result pre="is blocked by a clinically proven protease receptorCell2020(March) 74SaiJ.K.SuyamaM.KubokawaY.MatsumuraY.InamiK.WatanabeS.Efficacy of" exact="camostat" post="mesilate against dyspepsia associated with non-alcoholic mild pancreatic diseaseJ"/>
   <result pre="regional arterial infusion versus intravenous administration of the protease inhibitor" exact="nafamostat" post="mesilate for predicted severe acute pan-creatitis: a multicenter, randomized,"/>
   <result pre="vitro antiviral activity and pro-jection of optimized dosing design of" exact="hydroxychloroquine" post="for the treatment of severe acute respiratory syndrome coronavirus"/>
   <result pre="acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Clin Infect Dis2020(March) 79GautretP.LagierJ.C.ParolaP.HoangV.T.MeddebL.MailheM.Hydroxychloro-quine and" exact="azithromycin" post="as a tratment of COVID-19: results of an open-label"/>
   <result pre="an open-label non-randomized clinical trialInt J Antimicrob Agents2020105949(March) 80ChenZ.HuJ.ZhangZ.JiangS.HanS.YanD.Efficacy of" exact="hydroxychloroquine" post="in patients with COVID-19: results of a randomized clinical"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7360125\results\search\drug\results.xml">
   <result pre="with COVID-19 include arthralgia, myalgia, and proximal weakness with elevated" exact="creatine" post="kinase (CK) level [21, 22]. Some of these manifestations"/>
   <result pre="myocarditis was noticed following treatment with hydroxychloroquine, lopinavir/ritonavir, and intravenous" exact="methylprednisolone" post="[25, 26]. An increase in the incidence of Kawasaki"/>
   <result pre="and proximal muscle weakness preceded respiratory symptom of COVID-19 Elevate" exact="Creatine" post="kinase (CK) level (25,384Â IU/L) MRI showed muscle edema"/>
   <result pre="acute myocarditis Improved with supportive care, hydroxychloroquine, lopinavir/ritonavir, and intravenous" exact="methylprednisolone" post="[25, 26] Multisystem autoinflammatory syndrome Â Cytokine storm/Secondary Hemophagocytic"/>
   <result pre="Myopathy and neuromyopathy can rarely occur following long-term treatment with" exact="chloroquine" post="and hydroxychloroquine [33]. Favipiravir can lead to hyperuricemia [34]."/>
   <result pre="neuromyopathy can rarely occur following long-term treatment with chloroquine and" exact="hydroxychloroquine" post="[33]. Favipiravir can lead to hyperuricemia [34]. Lopinavir-ritonavir-related rheumatic"/>
   <result pre="adverse events include arthralgia, back pain, osteonecrosis, and vasculitis [35]." exact="Ribavirin" post="can cause arthralgia, back pain, myositis, and exacerbation of"/>
   <result pre="adverse effects Drugs Antiviral mechanisms Rheumatic musculoskeletal adverse events Refs." exact="Chloroquine" post="and hydroxychloroquine Inhibit pH-dependent internalization and fusion of the"/>
   <result pre="Drugs Antiviral mechanisms Rheumatic musculoskeletal adverse events Refs. Chloroquine and" exact="hydroxychloroquine" post="Inhibit pH-dependent internalization and fusion of the virus with"/>
   <result pre="fusion as well as virus-endosome fusion Not reported Galidesivir Antiviral" exact="adenosine" post="nucleoside analog Not reported Ribavirin Interfere with polymerases, RNA"/>
   <result pre="fusion Not reported Galidesivir Antiviral adenosine nucleoside analog Not reported" exact="Ribavirin" post="Interfere with polymerases, RNA capping, and inosine monophosphate dehydrogenase"/>
   <result pre="(higher incidence in combination with interferon Î±) [36] Camostat mesylate" exact="Serine" post="protease inhibitor Not reported Interferon Î± and Î² Inhibit"/>
   <result pre="activates the surrounding macrophages to release reactive oxygen species and" exact="nitric oxide" post="resulting in bystander killing of surrounding uninfected cells [67]."/>
   <result pre="antiphospholipid antibody syndrome (APS), and an autoinflammatory syndrome, deficiency of" exact="adenosine" post="deaminase-2 (DADA-2) [81]. In COVID-19, a rise in neutrophil"/>
   <result pre="receptorâ€‰&amp;gt;â€‰tocilizumab, sarilumab. (8) Anti IFN Î³â€&quot;&amp;gt;â€‰emapalumab. (9) JAK inhibitorâ€&quot;&amp;gt;â€‰baricitinib, ruxolitinib," exact="tofacitinib" post="(multi-cytokine targeted therapy). CCL2 chemokine (Câ€&quot;C motif) ligand 2,"/>
   <result pre="infection: a reviewTher Clin Risk Manag2008451023103319209283 36.NaikGSTyagiMGA pharmacological profile of" exact="ribavirin" post="and monitoring of its plasma concentration in Chronic Hepatitis"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7360901\results\search\drug\results.xml">
   <result pre="also suggested aÂ possible beneficial effect of the antimalarial drugs" exact="chloroquine" post="and hydroxychloroquine on COVID-19 progression, which may at least"/>
   <result pre="aÂ possible beneficial effect of the antimalarial drugs chloroquine and" exact="hydroxychloroquine" post="on COVID-19 progression, which may at least in part"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7361075\results\search\drug\results.xml">
   <result pre="in transplant recipients. The role of steroids, calcineurin inhibitors and" exact="mycophenolic acid" post="has been explored more in detail. A pointâ€�inâ€�time snapshot"/>
   <result pre="here for the physicians dealing with immunocompromised patients. Coronavirus COVIDâ€�19" exact="cyclosporine" post="SARS steroids tacrolimus fig-count: table-count: page-count: word-count: This article"/>
   <result pre="physicians dealing with immunocompromised patients. Coronavirus COVIDâ€�19 cyclosporine SARS steroids" exact="tacrolimus" post="fig-count: table-count: page-count: word-count: This article has been accepted"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7361119\results\search\drug\results.xml">
   <result pre="world is frantically looking to repurpose existing drugs, such as" exact="chloroquine" post="and hydroxychloroquine, which is premature and, according to at"/>
   <result pre="[30]. The first nonrepurposed drugs approved by the FDA were" exact="lamivudine" post="(a non-nucleoside reverse transcriptase inhibitor) and saquinavir (a protease"/>
   <result pre="the FDA were lamivudine (a non-nucleoside reverse transcriptase inhibitor) and" exact="saquinavir" post="(a protease inhibitor), both approved in 1995, nearly 15"/>
   <result pre="into Epidemic Response: The Ebola Experience2017National Academies Press 24FernerR.E.AronsonJ.K.Chloroquine and" exact="hydroxychloroquine" post="in COVID-19BMJ3692020m143232269046 25DuanY.Advance of promising targets and agents against"/>
   <result pre="Hospital of Wenzhou Medical UniversityEvaluating the Efficacy and Safety of" exact="Bromhexine" post="Hydrochloride Tablets Combined With Standard Treatment/ Standard Treatment in"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7361338\results\search\drug\results.xml">
   <result pre="conducted by Soo et al, 40 SARS patients refractory to" exact="ribavirin" post="and 1.5 g of pulsed methylprednisolone received either 200â€�400â€‰mL"/>
   <result pre="SARS patients refractory to ribavirin and 1.5 g of pulsed" exact="methylprednisolone" post="received either 200â€�400â€‰mL CP (n = 19) or a"/>
   <result pre="CP (n = 19) or a further dose of pulsed" exact="methylprednisolone" post="(n = 21). In patients who received CP, higher"/>
   <result pre="WongR, et al. Retrospective comparison of convalescent plasma with continuinghighâ€�dose" exact="methylprednisolone" post="treatment in SARS patients. Clin Microbiol Infect. 2004;10:676â€�678.15214887 9YehKM,"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7361468\results\search\drug\results.xml">
   <result pre="28HungIF, LungKC, TsoEYet alTriple combination of interferon betaâ€�1b, Lopinavirâ€�Ritonavir, and" exact="Ribavirin" post="in the treatment of patients admitted to hospital with"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7361534\results\search\drug\results.xml">
   <result pre="can only be controlled through surface disinfestation procedures by applying" exact="ethanol" post="(62â€�71%), 1â€�propanol (70%), 2â€�propanol (70%), H2O2 (0.5%), and sodium"/>
   <result pre="most of the countries on the trial basis, hydroxychlroquine with" exact="azithromycin" post="have been used to cure the infected people. Further,"/>
   <result pre="alone than in combination with the azithromycin. Although, hydroxychlroquine and" exact="azithromycin" post="have toxicity to heart and hydroxychloroquine showed toxic effect"/>
   <result pre="azithromycin. Although, hydroxychlroquine and azithromycin have toxicity to heart and" exact="hydroxychloroquine" post="showed toxic effect on eye.39, 77 A biological preparation"/>
   <result pre="quantum dots (CdTe QDs) mixed with sandwiched complexes, NH2â€�reporter, and" exact="biotin" post="receptor and target DNA accelerating the research for developing"/>
   <result pre="intensive care unit. Various nonspecific drugs such as hydroxychloroquine, ribavirin," exact="lopinavir" post="etc. are used for treating COVIDâ€�19; however, their actual"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7361641\results\search\drug\results.xml">
   <result pre="on viral replication processes. (1) ACE2 and spike complex inhibitors:" exact="Azithromycin" post="and Chloroquine, interrupt in ACE2 and S protein complex"/>
   <result pre="cleavage and activation of the S protein; (3) Targeting endosomes:" exact="chloroquine" post="and its derivatives increase pH and inhibit viral RNA"/>
   <result pre="thereby inhibit viral replication; (5) Targeting RdRp: Favipiravir, Remdesivir, and" exact="Ribavirin" post="block RdRp and cause premature termination of RNA synthesis;"/>
   <result pre="al., 2006) and the efficacy of PLpro inhibitors such as" exact="chloroquine" post="and formoterol have been investigated recently for the treatment"/>
   <result pre="and the efficacy of PLpro inhibitors such as chloroquine and" exact="formoterol" post="have been investigated recently for the treatment of COVIDâ€�19"/>
   <result pre="Feng, Porter, &amp;amp; GÃ¶tte, 2019). Remdesivir (GSâ€�5734), a prodrug and" exact="adenosine" post="analog, can be incorporated into nascent viral RNA, and"/>
   <result pre="of TMPRSS2 in the pathogenesis of this viral disease. Previously," exact="Bromhexine" post="hydrochloride, an FDA approved component in mucolytic cough suppressants,"/>
   <result pre="reduction of the progression of metastasis (Lucas et al., 2014)." exact="Bromhexine" post="hydrochloride might be repurposed as a TMPRSS2 inhibitor for"/>
   <result pre="a potential strategy. Preliminary results from a study suggest that" exact="Hydroxychloroquine" post="might have antiâ€�cytokine storm properties (Yao et al., 2020)."/>
   <result pre="applicable Renmin Hospital of Wuhan University, Ansun Biopharma, Inc. NCT04324489" exact="Serine" post="protease inhibitor Camostat Mesilate Phase 1, phase 2 University"/>
   <result pre="1, phase 2 University of Aarhus NCT04321096 Endosome Endosomal acidification" exact="Chloroquine" post="diphosphate Phase 2 FundaÃƒÂ§ÃƒÂ£o de Medicina Tropical Dr. Heitor"/>
   <result pre="MourÃƒÂ£o, Ludmila AbrahÃƒÂ£o Hajjar, Jorge Souza MendonÃƒÂ§a NCT04323527 Endosomal acidification" exact="Chloroquine" post="or Hydroxychloroquine Not applicable University of Oxford NCT04303507 Endosomal"/>
   <result pre="AbrahÃƒÂ£o Hajjar, Jorge Souza MendonÃƒÂ§a NCT04323527 Endosomal acidification Chloroquine or" exact="Hydroxychloroquine" post="Not applicable University of Oxford NCT04303507 Endosomal acidification Colchicine"/>
   <result pre="Montreal Heart Institute, DACIMA Software NCT04322565, NCT04322682 Lysosome â€ 1" exact="Bromhexine" post="hydrochloride tablets â€ 2 Arbidol hydrochloride â€ 3 Recombinant"/>
   <result pre="Wenzhou Medical University, WanBangDe Pharmaceutical Group Co., Ltd. NCT04273763 Lysosome" exact="Hydroxychloroquine" post="Early Phase 1, Phase 2, Phase 3 National Institute"/>
   <result pre="Health Clinical Center NCT04315896, NCT04318444, NCT04318015, NCT04308668, NCT04323631, NCT04261517 Lysosome" exact="Hydroxychloroquine" post="sulfate Phase 4 University Hospital, Akershus NCT04316377 Lysosome Thalidomide"/>
   <result pre="Lysosome Hydroxychloroquine sulfate Phase 4 University Hospital, Akershus NCT04316377 Lysosome" exact="Thalidomide" post="Phase 2 First Affiliated Hospital of Wenzhou Medical University,"/>
   <result pre="Medicine, Jingmen No.1 PeopleÃ¢â‚¬â&quot;¢s Hospital, Tongji Hospital NCT04279197 Spike glycoprotein" exact="Nitric oxide" post="Phase 2 Massachusetts General Hospital, Xijing Hospital, Fondazione IRCCS"/>
   <result pre="Ca' Granda, Ospedale Maggiore Policlinico NCT04305457, NCT04306393, NCT04312243 Spike glycoprotein" exact="Nitric oxide" post="0.5%/nitrogen 99.5% gas for Inhalation Phase 2 University of"/>
   <result pre="intervention 3CLpro, interferon receptor (IFNAR) â€ 1 Lopinavir/ritonavir â€ 2" exact="Ribavirin" post="â€ 3 Interferon Betaâ€�1B Phase 2 The University of"/>
   <result pre="NCT04275388 ACE2 and spike binding complex, Endosomal acidification â€ 1" exact="Azithromycin" post="â€ 2 Chloroquine Phase 3 Population Health Research Institute"/>
   <result pre="spike binding complex, Endosomal acidification â€ 1 Azithromycin â€ 2" exact="Chloroquine" post="Phase 3 Population Health Research Institute NCT04324463 ACE2 and"/>
   <result pre="NCT04324463 ACE2 and spike binding complex, Endosomal acidification â€ 1" exact="Azithromycin" post="â€ 2 Hydroxychloroquine Phase 4 Chronic Obstructive Pulmonary Disease"/>
   <result pre="spike binding complex, Endosomal acidification â€ 1 Azithromycin â€ 2" exact="Hydroxychloroquine" post="Phase 4 Chronic Obstructive Pulmonary Disease Trial Network, Denmark"/>
   <result pre="NCT04322396 ACE2 and spike binding complex, Endosomal acidification â€ 1" exact="Hydroxychloroquine" post="+ azithromycin â€ 2 Hydroxychloroquine Phase 3 Hospital Israelita"/>
   <result pre="and spike binding complex, Endosomal acidification â€ 1 Hydroxychloroquine +" exact="azithromycin" post="â€ 2 Hydroxychloroquine Phase 3 Hospital Israelita Albert Einstein,"/>
   <result pre="complex, Endosomal acidification â€ 1 Hydroxychloroquine + azithromycin â€ 2" exact="Hydroxychloroquine" post="Phase 3 Hospital Israelita Albert Einstein, EMS, Hospital do"/>
   <result pre="Care Network, EMS NCT04321278, NCT04322123 Endosomal acidification, RdRp â€ 1" exact="Hydroxychloroquine" post="â€ 2 Remdesivir Phase 2, Phase 3 Oslo University"/>
   <result pre="â€ 1 Carrimycin â€ 2 lopinavir/ritonavir tablets or Arbidol or" exact="chloroquine" post="phosphate Phase 4 Beijing YouAn Hospital, Shenyang Tonglian Group"/>
   <result pre="might be a potential therapeutic strategy. Several therapeutics such as" exact="Chloroquine" post="(CQ), a wellâ€�studied lysosomotropic antimalarial drug, and its derivatives"/>
   <result pre="Chloroquine (CQ), a wellâ€�studied lysosomotropic antimalarial drug, and its derivatives" exact="hydroxychloroquine" post="and colchicine would be an option for blocking this"/>
   <result pre="(Savarino, Boelaert, Cassone, Majori, &amp;amp; Cauda, 2003). Although CQ and" exact="hydroxychloroquine" post="were found to be effective against SARSâ€�CoVâ€�2 (Gautret et"/>
   <result pre="evidence claimed some unprecedented effects. A recent study reported that" exact="hydroxychloroquine" post="(either alone or in combination with azithromycin) showed no"/>
   <result pre="2020), instead was linked with increased overall mortality (27.8% in" exact="hydroxychloroquine" post="and 22.1% in hydroxychloroquine plus azithromycin versus 11.4% in"/>
   <result pre="with increased overall mortality (27.8% in hydroxychloroquine and 22.1% in" exact="hydroxychloroquine" post="plus azithromycin versus 11.4% in the control group). A"/>
   <result pre="overall mortality (27.8% in hydroxychloroquine and 22.1% in hydroxychloroquine plus" exact="azithromycin" post="versus 11.4% in the control group). A multinational, observational,"/>
   <result pre="observational, realâ€�world study of patients with COVIDâ€�19 also claimed that" exact="hydroxychloroquine" post="or chloroquine showed no evidence of benefit, rather it"/>
   <result pre="study of patients with COVIDâ€�19 also claimed that hydroxychloroquine or" exact="chloroquine" post="showed no evidence of benefit, rather it was associated"/>
   <result pre="Moreover, a recent systematic review found no difference between the" exact="hydroxychloroquine" post="treated group and an untreated group of COVIDâ€�19 patients"/>
   <result pre="al., 2020). WHO had recently postponed further clinical trials on" exact="hydroxychloroquine" post="due to unexpected results in previous trials, however, this"/>
   <result pre="treating COVIDâ€�19 (Tables 1 and 2). ASC09/Ritonavir, Lopinavir/Ritonavir, ASC09Fâ€‰+â€‰Oseltamivir, and" exact="Ritonavir" post="+ Oseltamivir are some protease inhibitor drug candidates that"/>
   <result pre="(Table 1). For example, monotherapy or combination of Lopinavir and" exact="Ritonavir" post="has been studied against MERSâ€�CoV both in vitro and"/>
   <result pre="al., 2014). Studies showed that the combination of Lopinavir and" exact="Ritonavir" post="with Ribavirin and Interferon alfa (IFNâ€�Î±) resulted in the"/>
   <result pre="Studies showed that the combination of Lopinavir and Ritonavir with" exact="Ribavirin" post="and Interferon alfa (IFNâ€�Î±) resulted in the survival of"/>
   <result pre="evaluate and compare the efficacy and safety of Lopinavir and" exact="Ritonavir" post="for COVIDâ€�19 patients (Table 3). A recent case report"/>
   <result pre="Pharmaceuticals Co., Ltd. NCT04261907 3CLpro â€ 1 ASC09Fâ€‰+â€‰Oseltamivir â€ 2" exact="Ritonavir" post="+ Oseltamivir â€ 3 Oseltamivir Phase 3 Tongji Hospital"/>
   <result pre="3 Oseltamivir Phase 3 Tongji Hospital NCT04261270 3CLpro Darunavir and" exact="Cobicistat" post="Phase 3 Shanghai Public Health Clinical Center NCT04252274 3CLpro"/>
   <result pre="3 Shanghai Public Health Clinical Center NCT04252274 3CLpro Ganovo +" exact="ritonavir" post="Â± interferon nebulization Phase 4 The Ninth Hospital of"/>
   <result pre="Co. Ltd. NCT04321174, NCT04295551 3CLpro â€ 1 Lopinavir/ritonavir â€ 2" exact="Hydroxychloroquine" post="sulfate Phase 2 Asan Medical Center NCT04307693 3CLpro â€"/>
   <result pre="Asan Medical Center NCT04307693 3CLpro â€ 1 Lopinavir/ritonavir â€ 2" exact="Hydroxychloroquine" post="sulfate â€ 3 Baricitinib (Janus kinase inhibitor) â€ 4"/>
   <result pre="(NIAID) NCT04323761, NCT04302766, NCT04315948, NCT04252664, NCT04257656, NCT04292899, NCT04292730, NCT04280705 RdRp" exact="Ribavirin" post="Not applicable Jiangsu Famous Medical Technology Co., Ltd. NCT04306497"/>
   <result pre="National Institute of Allergy and Infectious Diseases (NIAID) NCT03891420 RdRp" exact="Triazavirin" post="Phase 3 Health Commission of Heilongjiang province ChiCTR2000030001 Note:"/>
   <result pre="with the control arm (Cai et al., 2020). Remdesivir, an" exact="adenosine" post="nucleoside analog prodrug and developed by Gilead Sciences (Foster"/>
   <result pre="trials are undergoing to study the efficacy of Remdesivir and" exact="Ribavirin" post="for the treatment of SARSâ€�CoVâ€�2 as alone or in"/>
   <result pre="Negrin University Hospital, Li Ka Shing Knowledge Institute NCT04325061 Cytokine" exact="Methylprednisolone" post="Phase 2, Phase 3, Phase 4 Beijing Chao Yang"/>
   <result pre="(IFNAR) â€ 1 Recombinant human interferon Alphaâ€�1b â€ 2 thymosin" exact="alpha" post="1 Phase 3 Shanghai Jiao Tong University School of"/>
   <result pre="+ standard treatment Phase 2 Southeast University, China NCT04268537 Prostaglandins" exact="Naproxen" post="Phase 3 Assistance Publique â€� HÃƒÂ´pitaux de Paris NCT04325633"/>
   <result pre="need to be evaluated against SARSâ€�CoVâ€�2. However, recent hype on" exact="hydroxychloroquine" post="or chloroquine, for example, as COVIDâ€�19 therapy should be"/>
   <result pre="V. T., Meddeb, L., Mailhe, M., &amp;amp; Raoult, D. (2020)." exact="Hydroxychloroquine" post="and azithromycin as a treatment of COVIDâ€�19: Results of"/>
   <result pre="Meddeb, L., Mailhe, M., &amp;amp; Raoult, D. (2020). Hydroxychloroquine and" exact="azithromycin" post="as a treatment of COVIDâ€�19: Results of an openâ€�label"/>
   <result pre="I., &amp;amp; Jang, H. C. (2016). Combination therapy with lopinavir/ritonavir," exact="ribavirin" post="and interferonâ€�Î± for Middle East respiratory syndrome. Antiviral Therapy,"/>
   <result pre="W., Sutton, S. S., &amp;amp; Ambati, J. (2020). Outcomes of" exact="hydroxychloroquine" post="usage in United States veterans hospitalized with Covidâ€�19. medRxiv"/>
   <result pre="Desai, S. S., Ruschitzka, F., &amp;amp; Patel, A. N. (2020)." exact="Hydroxychloroquine" post="or chloroquine with or without a macrolide for treatment"/>
   <result pre="S., Ruschitzka, F., &amp;amp; Patel, A. N. (2020). Hydroxychloroquine or" exact="chloroquine" post="with or without a macrolide for treatment of COVIDâ€�19:"/>
   <result pre="rapid antiviral clearance or clinical benefit with the combination of" exact="hydroxychloroquine" post="and azithromycin in patients with severe COVIDâ€�19 infection. MÃ©decine"/>
   <result pre="clearance or clinical benefit with the combination of hydroxychloroquine and" exact="azithromycin" post="in patients with severe COVIDâ€�19 infection. MÃ©decine et Maladies"/>
   <result pre="Cassone, A., Majori, G., &amp;amp; Cauda, R. (2003). Effects of" exact="chloroquine" post="on viral infections: An old drug against today's diseases?The"/>
   <result pre="Discovery and synthesis of a Phosphoramidate Prodrug of a Pyrrolo[2,1â€�f][triazinâ€�4â€�amino]" exact="adenine" post="Câ€�nucleoside (GSâ€�5734) for the treatment of Ebola and emerging"/>
   <result pre="Y. N., &amp;amp; Hong, Z. (2001). Mechanisms of action of" exact="ribavirin" post="in antiviral therapies. Antiviral Chemistry and Chemotherapy, 12(5), 261â€&quot;272."/>
   <result pre="Liu, J., Xu, M., &amp;amp; Xiao, G. (2020). Remdesivir and" exact="chloroquine" post="effectively inhibit the recently emerged novel coronavirus (2019â€�nCoV) in"/>
   <result pre="vitro antiviral activity and projection of optimized dosing Design of" exact="Hydroxychloroquine" post="for the treatment of severe acute respiratory syndrome coronavirus"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7362761\results\search\drug\results.xml">
   <result pre="and TNFÎ±; (21)], a high serum aspartate aminotransferase (AST) or" exact="alanine" post="aminotransferase (ALT), procalcitonin and ferritin levels (21, 22), decreased"/>
   <result pre="MIP1, Macrophage Inflammatory Protein 1; MCP-1, monocyte chemotactic protein-1; ALT," exact="alanine" post="transaminase; AST, aspartate transaminase; CRP, C-reactive protein. Potential Therapeutic"/>
   <result pre="showed faster virus clearance in patients with COVID-19 who received" exact="hydroxychloroquine" post="(33). Initial dose: 600 mg (of chloroquine) followed by"/>
   <result pre="vitro study in a mouse model demonstrated the efficacy of" exact="camostat" post="in protecting mice from death from a lethal SARS-CoV"/>
   <result pre="that doses of 600 mg (200 mg, three times) of" exact="camostat" post="daily are expected to reduce SARS-CoV-2 infection; but human"/>
   <result pre="protease inhibitor used to treat HIV infection in combination with" exact="ritonavir" post="to increase its availability. Lopinavir has some degree of"/>
   <result pre="molecules that could inhibit ACE2 have been identified, of which" exact="ruxolitinib" post="is included in a clinical study together with mesenchymal"/>
   <result pre="of the complications of COVID-19 with frequent fatal consequences (42)." exact="Chloroquine" post="[(N4-(7-Chloro-4-quinolinyl)-N1,N1-diethyl-1,4-pentanediamine)], a conventional drug for the treatment of malaria,"/>
   <result pre="applied in several studies against CoVs. In an early report," exact="chloroquine" post="was found to be effective in preventing the spread"/>
   <result pre="be effective in preventing the spread of SARS-CoV-2 in vitro." exact="Chloroquine" post="was assumed to elevate endosomal pH and to interfere"/>
   <result pre="of mild upper respiratory tract infections. Research findings showed that" exact="chloroquine" post="inhibits HCoV-OC43 replication in HRT-18 cells with LD50 effective"/>
   <result pre="Î¼M and an IC50 of 419 Î¼M (45). In addition," exact="chloroquine" post="(15 mg/kg) could prevent the HCoV-OC43-induced death in newborn"/>
   <result pre="rate (98.6%) of the pups (46). This report advocated that" exact="chloroquine" post="can be highly effective against HCoVs and it may"/>
   <result pre="the penetration of the virus into cellsâ€&quot;transmembrane proteinase TMPRSS2. The" exact="camostat" post="molecule, a synthetic serine protease inhibitor approved in Japan"/>
   <result pre="agent and is approved for the treatment of cystic fibrosis." exact="Nafamostat" post="has mucolytic action and can prevent the deterioration of"/>
   <result pre="/Ritonavir Combination The combination of lopinavir/ritonavir protease inhibitors (marketed as" exact="Kaletra" post="for the treatment of HIV infection), with or without"/>
   <result pre="addition to supportive treatment, the guide includes the use of" exact="lopinavir" post="+ ritonavir + IFN, which is, however, supported by"/>
   <result pre="supportive treatment, the guide includes the use of lopinavir +" exact="ritonavir" post="+ IFN, which is, however, supported by only a"/>
   <result pre="the two protease inhibitors are also administered in studies with" exact="ribavirin" post="(a guanosine analog and RNA synthesis inhibitor that could"/>
   <result pre="who are not pregnant (59). Neuraminidase Inhibitors Oseltamivir, peramivir, or" exact="zanamivir" post="are not justified for the treatment of COVID-19, because"/>
   <result pre="The combination of lopinavir/ritonavir protease inhibitors (marketed under the name" exact="Kaletra" post="for the treatment of HIV infection), with or without"/>
   <result pre="addition to supportive treatment, the guide includes the use of" exact="lopinavir" post="+ ritonavir + IFN, which is supported, however, by"/>
   <result pre="supportive treatment, the guide includes the use of lopinavir +" exact="ritonavir" post="+ IFN, which is supported, however, by only a"/>
   <result pre="protease inhibitors are administered in studies and in combination with" exact="ribavirin" post="(guanosine analog and RNA synthesis inhibitor, which within SARS-COV-2"/>
   <result pre="between lopinavir/ritonavir (with or without interferon beta), and remdesivir and" exact="chloroquine" post="(or hydroxychloroquine). Spain and Norway are the countries that"/>
   <result pre="evolution of the infection (71). To test the impact of" exact="camostat" post="mesilate on COVID-19 Infection (CamoCO-19), an Investigator-initiated Randomized, Placebo-controlled,"/>
   <result pre="be announced in December this year (72). The efficacy of" exact="nafamostat" post="in patients with Covid-19 (RACONA study), is the subject"/>
   <result pre="of the RACONA study is to test the hypothesis that" exact="nafamostat" post="is useful in the treatment of COVID-19 lung damage."/>
   <result pre="of the coagulation cascade, pulmonary embolism, and bacterial superinfections (73)." exact="Chloroquine" post="phosphate displayed apparent efficacy and acceptable safety against SARS-COV-2"/>
   <result pre="of the People's Republic of China. Another recent study suggested" exact="chloroquine" post="phosphate tablet (500 mg twice per day for 10"/>
   <result pre="twice per day for 10 days) against SARS-COV-2 (74). Although" exact="chloroquine" post="has long been used to treat malaria and amebiasis,"/>
   <result pre="developed widespread resistance to it (75). Furthermore, an overdose of" exact="chloroquine" post="was known to cause acute poisoning and death (76)"/>
   <result pre="and death (76) which limits its utilization in clinical practices." exact="Hydroxychloroquine" post="is a derivative of chloroquine, and significantly less (~40%)"/>
   <result pre="derivative of chloroquine, and significantly less (~40%) toxic (77). Recently," exact="hydroxychloroquine" post="was found to efficiently inhibit the SARS-CoV-2 infection in"/>
   <result pre="viral loads was evaluated using SARS-COV-2 patients from France (78)." exact="Hydroxychloroquine" post="(600 mg daily) was administered to patients and their"/>
   <result pre="significant reduction of the viral load. Interestingly, the addition of" exact="azithromycin" post="to hydroxychloroquine significantly eliminated the virus as compared to"/>
   <result pre="of the viral load. Interestingly, the addition of azithromycin to" exact="hydroxychloroquine" post="significantly eliminated the virus as compared to a single"/>
   <result pre="to a single therapy (79). This clinical survey demonstrated that" exact="hydroxychloroquine" post="treatment is significantly associated with viral load reduction in"/>
   <result pre="infected patients, with better results obtained by the addition of" exact="azithromycin" post="(78). This might be a milestone preventive option in"/>
   <result pre="useful in severe lung injury), and in the case of" exact="chloroquine" post="there is insufficient evidence to substantiate the studies. However,"/>
   <result pre="can bring about clinical improvements, such as statins, heparin, and" exact="vitamin C." post="In addition to the molecules described by WHO, recent"/>
   <result pre="extracts of plants and plant parts Gentiana scabra Bunge (the" exact="dried" post="rhizome), Dioscorea polystachya Turcz. (the tuber), Senna tora (L.)"/>
   <result pre="Dioscorea polystachya Turcz. (the tuber), Senna tora (L.) Roxb. (the" exact="dried" post="seed), Taxillus chinensis (DC.) Danser (the dried stem with"/>
   <result pre="(L.) Roxb. (the dried seed), Taxillus chinensis (DC.) Danser (the" exact="dried" post="stem with leaf), and Cibotium barometz (L.) J.Sm. (the"/>
   <result pre="dried stem with leaf), and Cibotium barometz (L.) J.Sm. (the" exact="dried" post="rhizome) were found to be potent inhibitors of SARS-CoV-2"/>
   <result pre="+RNA replication complexes. Viruses. (2015) 7:4385â€&quot;413. 10.3390/v708282526287230 12.FarsalinosKNiauraRLe HouezecJBarbouniATsatsakisAKouretasDet al.." exact="Nicotine" post="and SARS-CoV-2: COVID-19 may be a disease of the"/>
   <result pre="24.DoceaAOGofitÄƒECalinaDZaharieSValceaDIMitru?PAutoimmune disorders due to double antiviral therapy with Peginterferon and" exact="Ribavirin" post="in patients with hepatitis C virus infection. Farmacia J."/>
   <result pre="Biol. (2020) 12:322â€&quot;5. 10.1093/jmcb/mjaa01432236562 33.ChenJLiuDLiuLLiuPXuQXiaLet al.. [A pilot study of" exact="hydroxychloroquine" post="in treatment of patients with moderate COVID-19]. Zhejiang Da"/>
   <result pre="vitro antiviral activity and projection of optimized dosing design of" exact="hydroxychloroquine" post="for the treatment of severe acute respiratory syndrome coronavirus"/>
   <result pre="Dis. (2020) ciaa237. 10.1093/cid/ciaa237. [Epub ahead of print]. 44.VincentMJBergeronEBenjannetSEricksonBRRollinPEKsiazekTGet al.." exact="Chloroquine" post="is a potent inhibitor of SARS coronavirus infection and"/>
   <result pre="Chem. (2020) 295:4773â€&quot;9. 10.1074/jbc.AC120.01305632094225 46.KeyaertsELiSVijgenLRysmanEVerbeeckJVan RanstMet al.. Antiviral activity of" exact="chloroquine" post="against human coronavirus OC43 infection in newborn mice. Antimicrob"/>
   <result pre="vitro. Cell Discov. (2020) 6:16. 10.1038/s41421-020-0156-032194981 49.YamamotoMMatsuyamaSLiXTakedaMKawaguchiYInoueJIet al.. Identification of" exact="nafamostat" post="as a potent inhibitor of middle east respiratory syndrome"/>
   <result pre="findings. Thorax. (2004) 59:252â€&quot;6. 10.1136/thorax.2003.01265814985565 55.YaoTTQianJDZhuWYWangYWangGQ. A systematic review of" exact="lopinavir" post="therapy for SARS coronavirus and MERS coronavirus-A possible reference"/>
   <result pre="https://clinicaltrials.gov/ (accessed April 10, 2020). 73.collab: University Hospital PadovaEfficacy of" exact="Nafamostat" post="in Covid-19 Patients (RACONA Study) (RACONA). NCT04352400 (2020). Available"/>
   <result pre="April 10, 2020). 74.collab: Health Commission of Guangdong Province for" exact="Chloroquine" post="in the Treatment of Novel Coronavirus[Expert consensus on chloroquine"/>
   <result pre="for Chloroquine in the Treatment of Novel Coronavirus[Expert consensus on" exact="chloroquine" post="phosphate for the treatment of novel coronavirus pneumonia]. Zhonghua"/>
   <result pre="Cryptolepis, and Tabebuia genera. Phytother Res. (2020) 1â€&quot;14. 10.1002/ptr.662832022345 76.StokkermansTJGoyalABansalPTrichonasG." exact="Chloroquine" post="And Hydroxychloroquine Toxicity. In: StatPearls. Treasure Island: StatPearls Publishing"/>
   <result pre="Tabebuia genera. Phytother Res. (2020) 1â€&quot;14. 10.1002/ptr.662832022345 76.StokkermansTJGoyalABansalPTrichonasG. Chloroquine And" exact="Hydroxychloroquine" post="Toxicity. In: StatPearls. Treasure Island: StatPearls Publishing (2020). 77.McChesneyEW."/>
   <result pre="Island: StatPearls Publishing (2020). 77.McChesneyEW. Animal toxicity and pharmacokinetics of" exact="hydroxychloroquine" post="sulfate. Am J Med. (1983) 75:11â€&quot;8. 10.1016/0002-9343(83)91265-26408923 78.GautretPLagierJ-CParolaPHoangVTMeddebLMailheMet al.."/>
   <result pre="hydroxychloroquine sulfate. Am J Med. (1983) 75:11â€&quot;8. 10.1016/0002-9343(83)91265-26408923 78.GautretPLagierJ-CParolaPHoangVTMeddebLMailheMet al.." exact="Hydroxychloroquine" post="and azithromycin as a treatment of COVID-19: results of"/>
   <result pre="Am J Med. (1983) 75:11â€&quot;8. 10.1016/0002-9343(83)91265-26408923 78.GautretPLagierJ-CParolaPHoangVTMeddebLMailheMet al.. Hydroxychloroquine and" exact="azithromycin" post="as a treatment of COVID-19: results of an open-label"/>
   <result pre="SARS-coronavirus. J Med Chem. (2005) 48:1256â€&quot;9. 10.1021/jm049300815715493 113.AmiciCDi CaroACiucciAChiappaLCastillettiCMartellaVet al.." exact="Indomethacin" post="has a potent antiviral activity against SARS coronavirus. Antivir"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7362831\results\search\drug\results.xml">
   <result pre="in an additive manner with the clinically used antiviral drug" exact="ribavirin" post="[10]. This antiviral activity was also manifested inÂ vivo."/>
   <result pre="related bioactive compounds from Aglaia speciesNat. Prod. Rep.312014924939 2BernardY.RibeiroN.ThuaudF.TurkeriG.DirrR.BoulberdaaM.NebigilC.G.DesaubryL.Flavaglines alleviate" exact="doxorubicin" post="cardiotoxicity: implication of Hsp27PloS One62011e25302 3QureshiR.YildirimO.GasserA.BasmadjianC.ZhaoQ.WilmetJ.P.DesaubryL.NebigilC.G.FL3, a synthetic flavagline"/>
   <result pre="flavagline and ligand of prohibitins, protects cardiomyocytes via STAT3 from" exact="doxorubicin" post="toxicityPloS One102015e0141826 4RibeiroN.ThuaudF.BernardY.GaiddonC.CresteilT.HildA.HirschE.C.MichelP.P.NebigilC.G.DesaubryL.Flavaglines as potent anticancer and cytoprotective agentsJ.Â"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7362842\results\search\drug\results.xml">
   <result pre="OxideNitric Oxide1089-86031089-8611Elsevier Inc. pmcid: 7362842S1089-8603(20)30170-1 doi: 10.1016/j.niox.2020.07.003 : Article Harnessing" exact="nitric oxide" post="for preventing, limiting and treating the severe pulmonary consequences"/>
   <result pre="critical role for patients and health systems during this pandemic." exact="Nitric oxide" post="is an antimicrobial and anti-inflammatory molecule with key roles"/>
   <result pre="pulmonary disease states. This article reviews the rationale for exogenous" exact="nitric oxide" post="use for the pathogenesis of COVID-19 and highlights its"/>
   <result pre="of literature identifies several mechanisms that may be targeted with" exact="nitric oxide." post="â€¢Reported proofs of concept for inhaled nitric oxide treating"/>
   <result pre="targeted with nitric oxide. â€¢Reported proofs of concept for inhaled" exact="nitric oxide" post="treating COVID-19 demonstrate the need for randomized control trials."/>
   <result pre="treating COVID-19 demonstrate the need for randomized control trials. Keywords" exact="Nitric oxide" post="COVID-19 ARDS 1 Introduction Coronaviruses (CoVs) are RNA viruses"/>
   <result pre="spread of the virus. Here we review the potential for" exact="nitric oxide" post="in limiting the density of virus within the lungs,"/>
   <result pre="balance is crucial for normal vascular function. NO is an" exact="endothelium-derived relaxing factor" post="that plays key roles in vascular signaling, regulation of"/>
   <result pre="may contribute to pathogenesis of ARDS. Anti-inflammatory molecules such as" exact="N-acetylcysteine" post="can potentially attenuate cellular damage by ROS [33], and"/>
   <result pre="cellular damage by reoxygenation and reperfusion. 3 The rationale for" exact="nitric oxide" post="use Nitric oxide (NO) is a gas produced from"/>
   <result pre="reoxygenation and reperfusion. 3 The rationale for nitric oxide use" exact="Nitric oxide" post="(NO) is a gas produced from arginine in mammalian"/>
   <result pre="cells by three enzymes: neuronal (nNOS), endothelial (eNOS) and inducible" exact="nitric oxide" post="synthase (iNOS) [34]. In host cells iNOS is commonly"/>
   <result pre="of a patient with COVID-19 using their proprietary INOpulseÂ® inhaled" exact="nitric oxide" post="system [52], and on May 11 the FDA accepted"/>
   <result pre="unchecked inflammation are likely at the root of severe illness." exact="Nitric oxide" post="has demonstrated promise in similar respiratory disease models in"/>
   <result pre="is illustrated as therapeutics firms seek its indication for COVID-19," exact="nitric oxide" post="treatment can be pivotal in the world's fight against"/>
   <result pre="Pathobiology2009AcademicCambridge, MA 16AkaikeT.MaedaH.Nitric oxide and virus infectionImmunology101200030030811106932 17TejeroJ.ShivaS.GladwinM.T.Sources of vascular" exact="nitric oxide" post="and reactive oxygen species and their regulationPhysiol. Rev.9912019 Jan"/>
   <result pre="a novel diagnostic and therapeutic target in sepsisCrit. Care23120191630654825 33LeeT.F.JantzieL.L.ToddK.G.CheungP.Y.Postresuscitation" exact="N-acetylcysteine" post="treatment reduces cerebral hydrogen peroxide in the hypoxic piglet"/>
   <result pre="of severe acute respiratory syndrome coronavirusJ. Virol.7920051966196915650225 36CabralesP.TsaiA.G.FrangosJ.A.IntagliettaM.Role of endothelial" exact="nitric oxide" post="in microvascular oxygen delivery and consumptionFree Radic. Biol. Med.39920051229123716214038"/>
   <result pre="in microvascular oxygen delivery and consumptionFree Radic. Biol. Med.39920051229123716214038 37RossaintR.FalkeK.J.LÃ³pezF.SlamaK.PisonU.ZapolW.M.Inhaled" exact="nitric oxide" post="for the adult respiratory distress syndromeN. Engl. J. Med.328619933994058357359"/>
   <result pre="the adult respiratory distress syndromeN. Engl. J. Med.328619933994058357359 38ChenL.LiuP.GaoH.Inhalation of" exact="nitric oxide" post="in the treatment of severe acute respiratory syndrome: a"/>
   <result pre="aging endothelial cellsFree Radic. Biol. Med.1132017263528916474 40CsomaB.BikovA.NagyL.Dysregulation of the endothelial" exact="nitric oxide" post="pathway is associated with airway inflammation in COPDRespir. Res.201201915631311549"/>
   <result pre="43ThatcherG.R.An introduction to NO-related therapeutic agentsCurr. Top. Med. Chem.57200559760116101422 44DarwishI.MillerC.KainK.C.LilesW.C.Inhaled" exact="nitric oxide" post="therapy fails to improve outcome in experimental severe influenzaInt."/>
   <result pre="improve outcome in experimental severe influenzaInt. J. Med. Sci.92201215716222253563 45AfshariA.BrokJ.MÃ¸llerA.M.WetterslevJ.Inhaled" exact="nitric oxide" post="for acute respiratory distress syndrome and acute lung injury"/>
   <result pre="review with meta-analysis and trial sequential analysisAnesth. Analg.11220111411142121372277 46AdhikariN.K.J.BurnsK.E.A.FriedrichJ.O.GrantonJ.T.CookD.J.MeadeM.O.Effect of" exact="nitric oxide" post="on oxygenation and mortality in acute lung injury: systematic"/>
   <result pre="Chem.112020042679269015544469 48KeyaertsE.VijgenL.ChenL.Inhibition of SARS-coronavirus infection in vitro by S-nitroso-N-acetylpenicillamine, a" exact="nitric oxide" post="donor compoundInt. J. Infect. Dis.84200422322615234326 49AkerstrÃ¶mS.GunalanV.KengC.T.TanY.J.MirazimiA.Dual effect of nitric"/>
   <result pre="nitric oxide donor compoundInt. J. Infect. Dis.84200422322615234326 49AkerstrÃ¶mS.GunalanV.KengC.T.TanY.J.MirazimiA.Dual effect of" exact="nitric oxide" post="on SARS-CoV replication: viral RNA production and palmitoylation of"/>
   <result pre="are affectedVirology395120091919800091 50NavatiM.S.LucasA.LiongC.BarrosM.JayadevaJ.T.FriedmanJ.M.CabralesP.Reducing ischemia/reperfusion Injury by the targeted delivery of" exact="nitric oxide" post="from magnetic-field-induced localization of S-nitrosothiol-coated paramagnetic nanoparticlesACS Appl. Bio"/>
   <result pre="Oxide273201215016022705913 52Bellerophon Therapeutics announces first patient treated with INOpulseÂ® inhaled" exact="nitric oxide" post="therapy for COVID-19BioSpaceMarch 30, 2020www.biospace.com/article/releases 53Bellerophon Therapeutics Announces FDA"/>
   <result pre="FDA Clears Initiation of Phase 3 Study for INOpulseÂ® Inhaled" exact="Nitric Oxide" post="Therapy to Treat COVID-19May 11, 2020Globe Newswirewww.globenewswire.com/news-release 54FDA Grants"/>
   <result pre="2020Globe Newswirewww.globenewswire.com/news-release 54FDA Grants Expanded Emergency Use Access for COVID-19" exact="Nitric Oxide" post="TreatmentMarch 26, 2020PR Newswirewww.prnewsire.com 55ZamanianR.T.PollackC.V.Jr.GentileM.A.Outpatient inhaled nitric oxide in"/>
   <result pre="for COVID-19 Nitric Oxide TreatmentMarch 26, 2020PR Newswirewww.prnewsire.com 55ZamanianR.T.PollackC.V.Jr.GentileM.A.Outpatient inhaled" exact="nitric oxide" post="in a patient with vasoreactive IPAH and COVID-19 infectionAm."/>
   <result pre="2] Abbreviations CoVs coronaviruses SARS severe acute respiratory syndrome NO" exact="nitric oxide" post="MERS Middle East respiratory syndrome, MERS COVID-19 coronavirus disease"/>
   <result pre="I/R Ischemia/Reperfusion nNOS, eNOS and iNOS neuronal, endothelial and inducible" exact="nitric oxide" post="synthase iNO Inhaled NO RSNO S-nitrosothiols containing molecules SNAP"/>
   <result pre="iNO Inhaled NO RSNO S-nitrosothiols containing molecules SNAP S-nitroso-N-acetylpenicillamine NO-np" exact="nitric oxide" post="releasing nanoparticles FDA Food and Drug Administration ICU intensive"/>
   <result pre="or published in any other publication before its appearance in" exact="Nitric Oxide." post="Category 1 Conception and design of study: Joel Friedman,"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7362854\results\search\drug\results.xml">
   <result pre="incomparable with the danger of the disease. However, remdesivir (1)," exact="lopinavir" post="(2) and ritonavir (3), favipiravir (4), chloroquine (5) and"/>
   <result pre="danger of the disease. However, remdesivir (1), lopinavir (2) and" exact="ritonavir" post="(3), favipiravir (4), chloroquine (5) and hydroxychloroquine (6) (Fig.Â"/>
   <result pre="However, remdesivir (1), lopinavir (2) and ritonavir (3), favipiravir (4)," exact="chloroquine" post="(5) and hydroxychloroquine (6) (Fig.Â 1 A) and their"/>
   <result pre="lopinavir (2) and ritonavir (3), favipiravir (4), chloroquine (5) and" exact="hydroxychloroquine" post="(6) (Fig.Â 1 A) and their combinations [[45], [46],"/>
   <result pre="it is administrated only intravenously [[49], [50], [51]]. Anti-HIV drug" exact="lopinavir" post="is developed from ritonavir. Both are created against HIV-1"/>
   <result pre="2014 for treating viral strains unresponsive to current antivirals [54,55]." exact="Chloroquine" post="(ResochinÂ®, AralenÂ®) and hydroxychloroquine (DolquineÂ®, PlaquenilÂ®, AxemalÂ®) are antimalarial"/>
   <result pre="strains unresponsive to current antivirals [54,55]. Chloroquine (ResochinÂ®, AralenÂ®) and" exact="hydroxychloroquine" post="(DolquineÂ®, PlaquenilÂ®, AxemalÂ®) are antimalarial drugs. The latter drug"/>
   <result pre="the following chemical entities of umifenovir 7, agent EIDD-2801 8," exact="ribavirin" post="9, ruxolitinib 10, ingavirin 11, azithromycin 12, ivermectin 13"/>
   <result pre="chemical entities of umifenovir 7, agent EIDD-2801 8, ribavirin 9," exact="ruxolitinib" post="10, ingavirin 11, azithromycin 12, ivermectin 13 and danoprevir"/>
   <result pre="7, agent EIDD-2801 8, ribavirin 9, ruxolitinib 10, ingavirin 11," exact="azithromycin" post="12, ivermectin 13 and danoprevir 14 (Fig.Â 1B) must"/>
   <result pre="EIDD-2801 8, ribavirin 9, ruxolitinib 10, ingavirin 11, azithromycin 12," exact="ivermectin" post="13 and danoprevir 14 (Fig.Â 1B) must be considered"/>
   <result pre="This drug candidate can be taken in pill form [62,63]." exact="Ribavirin" post="(RebetolÂ®, VirazoleÂ®, etc.) is a synthetic nucleoside antiviral drug,"/>
   <result pre="with a range of dosing regimens in different clinical settings." exact="Ribavirin" post="was found clinically effective against influenza, herpesvirus infections, hemorrhagic"/>
   <result pre="ineffective against Ebola and Marburg viruses [[64], [65], [66], [67]]." exact="Ruxolitinib" post="(AkaviÂ®) is approved in 2011 to treat certain rare"/>
   <result pre="metapneumoviruses, enteroviruses, including Coxsackie virus and rhinovirus [[70], [71], [72]]." exact="Azithromycin" post="(ZithromaxÂ®) is an inexpensive semisynthetic antibiotic drug used for"/>
   <result pre="as a drug in combination with ritonavir, peginterferon alfa and" exact="ribavirin" post="for the treatment of treatment-naive patients with non-cirrhotic genotype"/>
   <result pre="and 1,2,4-triazole 9), which resemble the respective RNA bases of" exact="adenosine" post="and cytidine, two are so-called peptide-heterocyclic chimera derivatives (comp."/>
   <result pre="the RO5, failing two or three criteria. The case of" exact="chloroquine" post="(5) is a border zone; although it has small"/>
   <result pre="of the immune system. mUN, unknown detailed anti-influenza virus mechanism;" exact="azithromycin" post="does not affect attachment of viruses onto the cell"/>
   <result pre="(less than 5) for Lipinskiâ€™s rule, excluding two drugs, i.e.," exact="lopinavir" post="(2) and ritonavir (3), which are highly lipophilic molecules"/>
   <result pre="for Lipinskiâ€™s rule, excluding two drugs, i.e., lopinavir (2) and" exact="ritonavir" post="(3), which are highly lipophilic molecules with respective cLogP"/>
   <result pre="and 7.14. In contrast, the drugs favipiravir (4), EIDD-2801 (8)," exact="ribavirin" post="(9), ruxolitinib (10) and ingavirin (11) are highly hydrophilic"/>
   <result pre="In contrast, the drugs favipiravir (4), EIDD-2801 (8), ribavirin (9)," exact="ruxolitinib" post="(10) and ingavirin (11) are highly hydrophilic molecules with"/>
   <result pre="proteins. Interestingly, three macrocyclic compounds displaying an appropriate lipophilicity, i.e.," exact="azithromycin" post="(12), ivermectin (13) and danoprevir (14), are less lipophilic"/>
   <result pre="three macrocyclic compounds displaying an appropriate lipophilicity, i.e., azithromycin (12)," exact="ivermectin" post="(13) and danoprevir (14), are less lipophilic than lopinavir"/>
   <result pre="(12), ivermectin (13) and danoprevir (14), are less lipophilic than" exact="lopinavir" post="(2) and ritonavir (3), which possess an alicyclic peptide"/>
   <result pre="and danoprevir (14), are less lipophilic than lopinavir (2) and" exact="ritonavir" post="(3), which possess an alicyclic peptide backbone. All of"/>
   <result pre="5 and 6, although they have almost identical molecular volumes," exact="hydroxychloroquine" post="is more polar, less lipophilic, and thus encounters more"/>
   <result pre="small nitrogen-containing molecule drugs such as favipiravir (4), umifenovir (7)," exact="ruxolitinib" post="(10) and ingavirin (11) also demonstrated good absorption (76â€&quot;90%),"/>
   <result pre="ring increases the TPSA parameter of nucleoside-based drugs EIDD-2801 (8)," exact="ribavirin" post="(9) and remdesivir (1) (TPSAÂ =Â 143.15â€&quot;203.57Â Ã…2). Increased"/>
   <result pre="Increased TPSA values are also observed for macrocyclic molecule drugs" exact="azithromycin" post="(12), ivermectin (13) and danoprevir (14). Among these three"/>
   <result pre="values are also observed for macrocyclic molecule drugs azithromycin (12)," exact="ivermectin" post="(13) and danoprevir (14). Among these three drugs, ivermectin"/>
   <result pre="(12), ivermectin (13) and danoprevir (14). Among these three drugs," exact="ivermectin" post="is the most hydrophilic molecule, is well resorbed after"/>
   <result pre="be transferred in the presence of efflux pumps, for which" exact="ivermectin" post="is a substrate [102]. In addition, these drugs have"/>
   <result pre="flexibility (ROTBÂ =Â 7â€&quot;8) according to the Veberâ€™s rule. Curiously," exact="chloroquine" post="(5) and hydroxychloroquine (6) show the same capacity, and"/>
   <result pre="7â€&quot;8) according to the Veberâ€™s rule. Curiously, chloroquine (5) and" exact="hydroxychloroquine" post="(6) show the same capacity, and remdesivir (1), lopinavir"/>
   <result pre="and hydroxychloroquine (6) show the same capacity, and remdesivir (1)," exact="lopinavir" post="(2) and ritonavir (3) are much more flexible molecules"/>
   <result pre="show the same capacity, and remdesivir (1), lopinavir (2) and" exact="ritonavir" post="(3) are much more flexible molecules (ROTBÂ =Â 15â€&quot;17)."/>
   <result pre="ABSÂ 1â€&quot;3, 8, 9, 13 and 14), except for the" exact="azithromycin" post="molecule, which exhibits a 8.63 value of pKa, and"/>
   <result pre="is noteworthy that as ACE2 inhibitors, two small drugs of" exact="chloroquine" post="(5) and hydroxychloroquine (6), with respective pKa values of"/>
   <result pre="as ACE2 inhibitors, two small drugs of chloroquine (5) and" exact="hydroxychloroquine" post="(6), with respective pKa values of 10.06 and 9.22,"/>
   <result pre="ChemDraw program do not supply a second ionization constant for" exact="chloroquine" post="and hydroxychloroquine. However, in practice, it was found that"/>
   <result pre="chloroquine and hydroxychloroquine. However, in practice, it was found that" exact="chloroquine" post="has two basic groups corresponding to the quinoline-ring nitrogen"/>
   <result pre="Moreover, at a physiologic pH of 7.4 (plasma), 18% of" exact="chloroquine" post="is monoprotonated but still soluble in lipid and able"/>
   <result pre="lysosome (pHÂ âˆ¼Â 4â€&quot;5), it is biprotonated [103,104]. In practice," exact="chloroquine" post="is administered as a phosphate salt, whereas hydroxychloroquine is"/>
   <result pre="In practice, chloroquine is administered as a phosphate salt, whereas" exact="hydroxychloroquine" post="is processed as a sulfate, and both drugs are"/>
   <result pre="5.24) and less soluble in water (LogSÂ =Â âˆ’6.04) than" exact="chloroquine" post="and hydroxychloroquine drugs (LogSÂ =Â âˆ’4.53 andÂ âˆ’3.77, respectively)"/>
   <result pre="less soluble in water (LogSÂ =Â âˆ’6.04) than chloroquine and" exact="hydroxychloroquine" post="drugs (LogSÂ =Â âˆ’4.53 andÂ âˆ’3.77, respectively) (TableÂ 1)."/>
   <result pre="different chemical natures and modes of action, i.e., umifenovir (7)," exact="azithromycin" post="(12) and ivermectin (13), that do not virtually alter"/>
   <result pre="and modes of action, i.e., umifenovir (7), azithromycin (12) and" exact="ivermectin" post="(13), that do not virtually alter any vital proteins,"/>
   <result pre="drugs that interact with one human target, i.e., remdesivir (1)," exact="lopinavir" post="(2), ritonavir (3) and danoprevir (14), which bind to"/>
   <result pre="interact with one human target, i.e., remdesivir (1), lopinavir (2)," exact="ritonavir" post="(3) and danoprevir (14), which bind to protease enzymes,"/>
   <result pre="treatment for COVID-19 in the USA (remdesivir) and Japan (favipiravir)." exact="Ruxolitinib" post="(10), an anticancer drug tested for its potential to"/>
   <result pre="recent work on control of the SARS-CoV-2 infection inÂ vitro," exact="hydroxychloroquine" post="was less toxic and more efficient as a viral"/>
   <result pre="less toxic and more efficient as a viral inhibitor than" exact="chloroquine" post="[106], which confirms the current in silico calculation, but"/>
   <result pre="of (hydroxy) chloroquine, offers a cautiously optimistic report that (hydroxy)" exact="chloroquine" post="might have a prophylactic and/or therapeutic effect against COVID-19"/>
   <result pre="[113]. Special attention has been focused on use of (hydroxy)" exact="chloroquine" post="drugs for a COVID-19 cure. Both drugs, which show"/>
   <result pre="T-cell stimulators and inflammatory molecules [114]. It is noteworthy that" exact="hydroxychloroquine" post="has been found to be a more potent SARS-CoV-2"/>
   <result pre="COVID-19 treatment in several countries. Recently, it was found that" exact="dexamethasone" post="(glucocorticoid) reduced deaths in hospitalized patients with severe COVID-19"/>
   <result pre="criterions of drug selection are still debatable. The story with" exact="hydroxychloroquine" post="tests is very meaningful [[146], [147], [148], [149]], itâ€™s"/>
   <result pre="open drug discovery for SARS-CoV-2, Drug DiscovToday Off.2552020928941 45GautretP.LagierJ.C.ParolaP.MeddebL.MailheM.DoudierB.Hydroxychloroquine and" exact="azithromycin" post="as a treatment of COVID-19: results of an open-label"/>
   <result pre="rapid antiviral clearance or clinical benefit with the combination of" exact="hydroxychloroquine" post="and azithromycin in patients with severe COVID-19 infectionMed. Maladies"/>
   <result pre="clearance or clinical benefit with the combination of hydroxychloroquine and" exact="azithromycin" post="in patients with severe COVID-19 infectionMed. Maladies Infect.5042020384 47WangM.CaoR.ZhangL.YangX.LiuJ.XuM.Remdesivir"/>
   <result pre="in patients with severe COVID-19 infectionMed. Maladies Infect.5042020384 47WangM.CaoR.ZhangL.YangX.LiuJ.XuM.Remdesivir and" exact="chloroquine" post="effectively inhibit the recently emerged novel coronavirus (2019-nCoV) inÂ"/>
   <result pre="for old drugsCurr. Med. Chem.252420182797281028901270 57PlantoneD.KoudriavtsevaT.Current and future use of" exact="chloroquine" post="and hydroxychloroquine in infectious, immune, neoplastic, and neurological diseases:"/>
   <result pre="drugsCurr. Med. Chem.252420182797281028901270 57PlantoneD.KoudriavtsevaT.Current and future use of chloroquine and" exact="hydroxychloroquine" post="in infectious, immune, neoplastic, and neurological diseases: a mini-reviewClin."/>
   <result pre="neoplastic, and neurological diseases: a mini-reviewClin. Drug Invest.3882018653671 58TouretF.de LamballerieX.Of" exact="chloroquine" post="and COVID-19Antivir. Res.177202010476210.1016/j.antiviral.2020.104762 59YazdanyJ.KimA.H.J.Use of hydroxychloroquine and chloroquine during"/>
   <result pre="Drug Invest.3882018653671 58TouretF.de LamballerieX.Of chloroquine and COVID-19Antivir. Res.177202010476210.1016/j.antiviral.2020.104762 59YazdanyJ.KimA.H.J.Use of" exact="hydroxychloroquine" post="and chloroquine during the COVID-19 pandemic: what every clinician"/>
   <result pre="58TouretF.de LamballerieX.Of chloroquine and COVID-19Antivir. Res.177202010476210.1016/j.antiviral.2020.104762 59YazdanyJ.KimA.H.J.Use of hydroxychloroquine and" exact="chloroquine" post="during the COVID-19 pandemic: what every clinician should knowAnn."/>
   <result pre="poised for COVID-19 clinical trialsAvailable at:https://cen.acs.org/biological-chemistry/infectious-disease/Emory-discovered-antiviral-poised-COVID/98/i122020 64GraciJ.D.CameronC.E.Mechanisms of action of" exact="ribavirin" post="against distinct virusesRev. Med. Virol.1612006374816287208 65Loustaud-RattiV.RousseauA.MarquetP.DenisF.AlainS.Ribavirin in chronic hepatitis"/>
   <result pre="drug repurposing on the fast trackNat. Biotechnol.384202037939132205870 88RajeshkumarN.V.YabuuchiS.PaiS.G.MaitraA.HidalgoM.DangC.V.Fatal toxicity of" exact="chloroquine" post="or hydroxychloroquine with metformin in miceBioRxiv202010.1101/2020.03.31.018556 89FoucquierJ.GuedjM.Analysis of drug"/>
   <result pre="on the fast trackNat. Biotechnol.384202037939132205870 88RajeshkumarN.V.YabuuchiS.PaiS.G.MaitraA.HidalgoM.DangC.V.Fatal toxicity of chloroquine or" exact="hydroxychloroquine" post="with metformin in miceBioRxiv202010.1101/2020.03.31.018556 89FoucquierJ.GuedjM.Analysis of drug combinations: current"/>
   <result pre="fast trackNat. Biotechnol.384202037939132205870 88RajeshkumarN.V.YabuuchiS.PaiS.G.MaitraA.HidalgoM.DangC.V.Fatal toxicity of chloroquine or hydroxychloroquine with" exact="metformin" post="in miceBioRxiv202010.1101/2020.03.31.018556 89FoucquierJ.GuedjM.Analysis of drug combinations: current methodological landscapePharm."/>
   <result pre="molecular properties and bioactivity scoreAvailable at:http://www.Molinspiration.com2011 99FerrariV.CutlerD.J.Kinetics and thermodynamics of" exact="chloroquine" post="and hydroxychloroquine transport across the human erythrocyte membraneBiochem. Pharmacol.411199123301986742"/>
   <result pre="and bioactivity scoreAvailable at:http://www.Molinspiration.com2011 99FerrariV.CutlerD.J.Kinetics and thermodynamics of chloroquine and" exact="hydroxychloroquine" post="transport across the human erythrocyte membraneBiochem. Pharmacol.411199123301986742 100CaoY.C.DengQ.X.DaiS.X.Remdesivir for"/>
   <result pre="and pharmacodynamic considerations regarding efficacy and safetyMalar. J.161201716128434401 103BrowningD.J.BrowningD.J.Hydroxychloroquine and" exact="Chloroquine" post="Retinopathy in: Hydroxychloroquine and Chloroquine Retinopathy2014Springer Science+Business Media New"/>
   <result pre="regarding efficacy and safetyMalar. J.161201716128434401 103BrowningD.J.BrowningD.J.Hydroxychloroquine and Chloroquine Retinopathy in:" exact="Hydroxychloroquine" post="and Chloroquine Retinopathy2014Springer Science+Business Media New York3563 104TitusE.O.Recent developments"/>
   <result pre="and safetyMalar. J.161201716128434401 103BrowningD.J.BrowningD.J.Hydroxychloroquine and Chloroquine Retinopathy in: Hydroxychloroquine and" exact="Chloroquine" post="Retinopathy2014Springer Science+Business Media New York3563 104TitusE.O.Recent developments in the"/>
   <result pre="and mechanism of action of chloroquine, TherDrug Monit1141989369379 105TettS.E.CutlerD.J.DayR.O.BrownK.F.Bioavailability of" exact="hydroxychloroquine" post="tablets in healthy volunteers, BritJ.Â Clin. Pharm.2761989771779 106LiuJ.CaoR.XuM.WangX.ZhangH.HuH.Hydroxychloroquine, a"/>
   <result pre="inhibiting SARS-CoV-2 infection inÂ vitroCell Discov6120201610.1038/s41421-020-0156-032194981 107MarmorM.F.KellnerU.LaiT.Y.MellesR.B.MielerW.F.Recommendations on screening for" exact="chloroquine" post="and hydroxychloroquine retinopathy (2016 revision)Ophthalmol. Times1236201613861394 108VerbaanderdC.MaesH.SchaafM.B.SukhatmeV.P.PantziarkaP.SukhatmeV.Repurposing drugs in"/>
   <result pre="infection inÂ vitroCell Discov6120201610.1038/s41421-020-0156-032194981 107MarmorM.F.KellnerU.LaiT.Y.MellesR.B.MielerW.F.Recommendations on screening for chloroquine and" exact="hydroxychloroquine" post="retinopathy (2016 revision)Ophthalmol. Times1236201613861394 108VerbaanderdC.MaesH.SchaafM.B.SukhatmeV.P.PantziarkaP.SukhatmeV.Repurposing drugs in oncology (ReDO)-chloroquine"/>
   <result pre="retinopathy (2016 revision)Ophthalmol. Times1236201613861394 108VerbaanderdC.MaesH.SchaafM.B.SukhatmeV.P.PantziarkaP.SukhatmeV.Repurposing drugs in oncology (ReDO)-chloroquine and" exact="hydroxychloroquine" post="as anti-cancer agentsEcancermedicalscience11201778129225688 109McGreadyR.ThwaiK.L.ChoT.LooareesuwanS.WhiteN.J.NostenF.The effects of quinine and chloroquine"/>
   <result pre="oncology (ReDO)-chloroquine and hydroxychloroquine as anti-cancer agentsEcancermedicalscience11201778129225688 109McGreadyR.ThwaiK.L.ChoT.LooareesuwanS.WhiteN.J.NostenF.The effects of" exact="quinine" post="and chloroquine antimalarial treatments in the first trimester of"/>
   <result pre="and hydroxychloroquine as anti-cancer agentsEcancermedicalscience11201778129225688 109McGreadyR.ThwaiK.L.ChoT.LooareesuwanS.WhiteN.J.NostenF.The effects of quinine and" exact="chloroquine" post="antimalarial treatments in the first trimester of pregnancyTrans. R."/>
   <result pre="pregnancyTrans. R. Soc. Trop. Med. Hyg.962200218018412055810 110HuT.Y.FriemanM.WolframJ.Insights from nanomedicine into" exact="chloroquine" post="efficacy against COVID-19Nat. Nanotechnol.154202024724932203437 111CortegianiA.IngogliaG.IppolitoM.GiarratanoA.EinavS.AÂ systematic review on the"/>
   <result pre="Nanotechnol.154202024724932203437 111CortegianiA.IngogliaG.IppolitoM.GiarratanoA.EinavS.AÂ systematic review on the efficacy and safety of" exact="chloroquine" post="for the treatment of COVID-19J.Â Crit. Care202010.1016/j.jcrc.2020.03.005 112LianN.XieH.LinS.HuangJ.ZhaoJ.LinQ.Umifenovir treatment"/>
   <result pre="drug ArbidolProc. Natl. Acad. Sci. U.S.A.1142201720621428003465 114SchrezenmeierE.DÃ¶rnerT.Mechanisms of action of" exact="hydroxychloroquine" post="and chloroquine: implications for rheumatologyNat. Rev. Rheumatol.16202015516632034323 115DevauxC.A.RolainJ.M.ColsonP.RaoultD.New insights"/>
   <result pre="rheumatologyNat. Rev. Rheumatol.16202015516632034323 115DevauxC.A.RolainJ.M.ColsonP.RaoultD.New insights on the antiviral effects of" exact="chloroquine" post="against coronavirus: what to expect for COVID-19?Int. J. Antimicrob."/>
   <result pre="vitro antiviral activity and projection of optimized dosing design of" exact="hydroxychloroquine" post="for the treatment of severe acute respiratory syndrome coronavirus"/>
   <result pre="synthesis of a phosphoramidate prodrug of a pyrrolo [2, 1-f][triazin-4-amino]" exact="adenine" post="C-nucleoside (GS-5734) for the treatment of Ebola and emerging"/>
   <result pre="COVID-19? Not so fastJ.Â Biol. Regul. Homeost. Agents343202010.23812/20-EDITORIAL_1-5 146MehraM.R.DesaiS.S.RuschitzkaF.PatelA.N.Hydroxychloroquine or" exact="chloroquine" post="with or without a macrolide for treatment of COVID-19:"/>
   <result pre="for treatment of COVID-19: a multinational registry analysisLancet2020 147Funck-BrentanoC.SalemJ.E.Chloroquine or" exact="hydroxychloroquine" post="for COVID-19: why might they be hazardous?Lancet202010.1016/S0140-6736(20)31174-0 148MahaseE.Covid-19: 146"/>
   <result pre="might they be hazardous?Lancet202010.1016/S0140-6736(20)31174-0 148MahaseE.Covid-19: 146 researchers raise concerns over" exact="chloroquine" post="study that halted WHO trialBMJ369202010.1136/bmj.m2197 149GelerisJ.SunY.PlattJ.ZuckerJ.BaldwinM.HripcsakG.Observational study of hydroxychloroquine"/>
   <result pre="over chloroquine study that halted WHO trialBMJ369202010.1136/bmj.m2197 149GelerisJ.SunY.PlattJ.ZuckerJ.BaldwinM.HripcsakG.Observational study of" exact="hydroxychloroquine" post="in hospitalized patients with Covid-19N.Â Engl. J. Med.38220202411241832379955 Acknowledgements"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7364167\results\search\drug\results.xml">
   <result pre="an important protein needed for coronavirus replication, and its inhibitor" exact="cyclosporine" post="A has the ability to suppress coronavirus on a"/>
   <result pre="of the SARS-CoV-2 virus to enter the host cells. However," exact="cyclosporine" post="A has immunosuppressive effects, so the conditions for its"/>
   <result pre="use as an antiviral drug are limited. As a result," exact="cyclosporine" post="A analogues without immunosuppressive side effects have attracted lots"/>
   <result pre="of coronavirus infection, especially coronavirus disease 2019 (COVID-19), and non-immunosuppressive" exact="cyclosporine" post="analogues. Keywords cyclophilin A cyclosporine A COVID-19 SARS-CoV2 Coronavirus"/>
   <result pre="disease 2019 (COVID-19), and non-immunosuppressive cyclosporine analogues. Keywords cyclophilin A" exact="cyclosporine" post="A COVID-19 SARS-CoV2 Coronavirus (CoV) is the general name"/>
   <result pre="isomerase (PPIase) activity. Cell receptors originally found as immunosuppressive drug" exact="cyclosporine" post="A (CsA) were found [7,8]. At this stage, CsA"/>
   <result pre="protein can enhance NFAT activities with Ca2+. CaN, calcineurin; CsA," exact="cyclosporin A;" post="CyPA, cyclophilin A; Nsp1, non-structure protein 1; IL-2, interleukin-2;"/>
   <result pre="a possible target for CoV, and also noted that non-immunosuppressive" exact="cyclosporine" post="derivatives may have the potential to become a panCoV"/>
   <result pre="block SARS-CoV and MERS-CoV replication. Combination treatment with alisporivir and" exact="ribavirin" post="increases the anti-MERS-CoV activity in vitro[39]. Gastrointestinal disorders: PreclinicalChronic"/>
   <result pre="of MERS and SARS CoVs, and in cell-based infection models," exact="ribavirin" post="further enhances alisporivir's antiviral effect [39]. 3 Conclusions and"/>
   <result pre="action in cell signaling pathwaysCell70319923653681379518 28SchreiberS.L.CrabtreeG.R.The mechanism of action of" exact="cyclosporin A" post="and FK506Immunol Today13419921361421374612 29PeelM.ScribnerA.Cyclophilin inhibitors as antiviral agentsBioorg Med"/>
   <result pre="both cyclophilin A and cyclophilin BJ Gen Virol982201719020027902373 35Ma-LauerY.ZhengY.MaleÅ¡eviÄ‡M.Influences of" exact="cyclosporin A" post="and non-immunosuppressive derivatives on cellular cyclophilins and viral nucleocapsid"/>
   <result pre="coronavirus NL63 replication is cyclophilin A-dependent and inhibited by non-immunosuppressive" exact="cyclosporine" post="A-derivatives including AlisporivirVirus Res1842014445324566223 39De WildeA.H.FalzaranoD.Zevenhoven-DobbeJ.C.Alisporivir inhibits MERS- and"/>
   <result pre="activity against hepatitis C virus alone or in combination with" exact="alpha" post="interferonAntimicrob Agents Chemother50920062976298216940091 41HopkinsS.ScorneauxB.HuangZ.SCY-635, a novel nonimmunosuppressive analog of"/>
   <result pre="alpha interferonAntimicrob Agents Chemother50920062976298216940091 41HopkinsS.ScorneauxB.HuangZ.SCY-635, a novel nonimmunosuppressive analog of" exact="cyclosporine" post="that exhibits potent inhibition of hepatitis C virus RNA"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7366108\results\search\drug\results.xml">
   <result pre="scientifically approved vaccines/drugs for COVID-19. Nonetheless, few broad-spectrum antiviral drugs," exact="azithromycin" post="were tested against COVID-19 in clinical trials, and finally,"/>
   <result pre="to wield anti-inflammatory and antifibrotic actions, stimulate the release of" exact="nitric oxide," post="and decrease blood pressure [43,44]. ACE-2 has shown a"/>
   <result pre="Clinical phase (sample size) Findings Status Clinical trial identifier 1." exact="Hydroxychloroquine" post="Block viral entry by inhibiting glycosylation of host receptors,"/>
   <result pre="IV(11) No Result Posted for this study Completed NCT04291729 6." exact="Methylprednisolone" post="Immunomodulatory effect Phase 2 &amp;amp; Phase 3(80) No Result"/>
   <result pre="is an antiviral drug, act as nucleotide analog, specifically an" exact="adenosine" post="analogue, which inserts into viral RNA chains, causing their"/>
   <result pre="and treat scurvy, a disease caused by a lack of" exact="vitamin C" post="National Clinical Trial Identifier:(NCT04264533) 9. Combination of Azithromycin and"/>
   <result pre="of vitamin C National Clinical Trial Identifier:(NCT04264533) 9. Combination of" exact="Azithromycin" post="and Hydroxychloroquine Azithromycin: Antibacterial with some in-vitro activity against"/>
   <result pre="C National Clinical Trial Identifier:(NCT04264533) 9. Combination of Azithromycin and" exact="Hydroxychloroquine" post="Azithromycin: Antibacterial with some in-vitro activity against some viruses"/>
   <result pre="contribute to an antiinflammatory response in patients with viral infections" exact="Azithromycin" post="is clinically used as adjunctive therapy to management of"/>
   <result pre="other inflammatory conditions National Clinical Trial Identifier:(NCT04327401), (NCT04344730), (NCT04348305) 12." exact="Nitric oxide" post="Selective pulmonary vasodilator; may be useful in the adjunctive"/>
   <result pre="a potential complication of COVID-19 National Clinical Trial Identifier:(NCT04306393) 13." exact="Ruxolitinib" post="Janus kinase (JAK) 1 and 2 inhibitor; 7 may"/>
   <result pre="proinflammatory cytokines, including interferon, during viral infections such as COVID-19" exact="Ruxolitinib" post="is a clinically approved Janus-associated kinase (JAK) inhibitor with"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7366994\results\search\drug\results.xml">
   <result pre="not responded to tolvaptan. Among tolvaptan-responsive participants, adding Oryeong-san to" exact="tolvaptan" post="decreased the frequency of rehospitalization and improved BNP level"/>
   <result pre="Cardiol175202025926032139904 14TamanoM.ToyodaS.KatoS.AsakoO.AsabuH.AkiraT.A clinical study of combined effect of Goreisan with" exact="tolvaptan" post="in non-responsive patients with heart failureProg Med3762017777782 15LiY.L.JuJ.Q.YangC.H.JiangH.Q.XuJ.W.ZhangS.J.Oral Chinese"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7367788\results\search\drug\results.xml">
   <result pre="with standard treatment regimen. Various antineoplastic drugs (etoposide, methotrexate, melphalan," exact="isotretinoin" post="plus tamoxifen, nintedanib, lenalidomide, etc.) and drugs like thalidomide,"/>
   <result pre="like thalidomide, oxytocin, chlorpromazine, montelukast, povidone-iodine, famotidine, cholecalciferol, N-acetylcysteine, and" exact="pyridostigmine" post="bromide have also been studied in clinical trials for"/>
   <result pre="respiratory distress associated with COVID-19, the role of drugs like" exact="valsartan" post="and sirolimus is being investigated in various clinical trials."/>
   <result pre="associated with COVID-19, the role of drugs like valsartan and" exact="sirolimus" post="is being investigated in various clinical trials. There is"/>
   <result pre="action for use in COVID-19 Disease indication (Approved/Investigational)* Remdesivir (antiviral," exact="adenosine" post="nucleotide analog) Phase 2/3 Target RdRp and inhibit it,"/>
   <result pre="inhibits viral RNA synthesis Approved to treat influenza in Japan" exact="Ribavirin" post="(antiviral, guanine nucleotide analog) Phase 1/2 Target RdRp and"/>
   <result pre="mRNA capping Chronic hepatitis C virus (HCV) infection Galidesivir (antiviral," exact="adenosine" post="nucleoside analog) Phase 1 Target and bind to viral"/>
   <result pre="maturation Approved for HIV-1 infection Darunavir (antiviral, protease inhibitor) and" exact="Cobicistat" post="(Pharmacokinetic enhancer) Phase 1 Target protease enzyme, inhibits protein"/>
   <result pre="viral DNA into the nucleus Investigational drug for hepatitis B" exact="Chloroquine" post="and hydroxychloroquine (antimalarial, aminoquinolone derivative, antiviral and immunomodulatory properties)"/>
   <result pre="into the nucleus Investigational drug for hepatitis B Chloroquine and" exact="hydroxychloroquine" post="(antimalarial, aminoquinolone derivative, antiviral and immunomodulatory properties) Phase 2/3/4"/>
   <result pre="of cytokines and growth factors Rheumatoid arthritis in adult patients" exact="Ruxolitinib" post="(kinase inhibitor) Phase 1/2/3 Target JAK kinase receptor, JAK"/>
   <result pre="cascades of cytokines and growth factors Intermediate or high-risk myelofibrosis" exact="Acalabrutinib" post="(kinase inhibitor) Phase 2 A selective inhibitor of Brutonâ€™s"/>
   <result pre="a protein encoded by SARS-CoV-2 genes Severe recalcitrant nodular acne" exact="Naproxen" post="(anti-inflammatory) (studied in combination with antiviral) Phase 3 Inhibit"/>
   <result pre="gouty arthritis, primary dysmenorrhea, for inflammation and pain in musculoskeletal" exact="Azithromycin" post="(broad-spectrum macrolide antibiotic (studied alone or in combination with"/>
   <result pre="Azithromycin (broad-spectrum macrolide antibiotic (studied alone or in combination with" exact="hydroxychloroquine" post="or amoxicillin/clavulanic acid)) Phase 2/3/4 Target bacterial ribosomes, inhibits"/>
   <result pre="and IL-6, prevents cytokine storm Gout and familial Mediterranean fever" exact="Deferoxamine" post="(iron chelator) Phase 1/2/3 Manages excess iron levels in"/>
   <result pre="of clot formation in indwelling intravenous lines for hemodialysis Inhaled" exact="nitric oxide" post="(INO) (pulmonary vasodilator) Phase 1/2 Targets heme molecule of"/>
   <result pre="Directions Antiviral Drugs Remdesivir (GS-5734) It is an investigational nucleotide" exact="adenosine" post="analog developed by Gilead Sciences, USA, and is a"/>
   <result pre="drugâ€&quot;drug interactions among individuals of a different region. Lopinavir and" exact="Ritonavir" post="These protease inhibitors are widely used for human immunodeficiency"/>
   <result pre="required to conclude the efficacy of LPV/RTV in COVID-19 patients." exact="Chloroquine" post="and Hydroxychloroquine They are amino-quinolines known for their anti-malarial"/>
   <result pre="conclude the efficacy of LPV/RTV in COVID-19 patients. Chloroquine and" exact="Hydroxychloroquine" post="They are amino-quinolines known for their anti-malarial and immunomodulatory"/>
   <result pre="established as a wide spectrum antiviral drug [36, 37]. Recently," exact="chloroquine" post="has demonstrated the efficacy against SARS-CoV-2 in Vero E6"/>
   <result pre="receiving standard supportive care. The authors also reported that including" exact="azithromycin" post="with HCQ for the treatment of 6 patients has"/>
   <result pre="based on their structural moiety, classical example being emetine, and" exact="quinine" post="[74]. WHO also supports and welcomes innovations around the"/>
   <result pre="such as Nigella sativa, natural honey, artemisinin, curcumin, Boswellia, and" exact="vitamin C" post="are in a clinical trial for COVID-19 [13]. Although"/>
   <result pre="a highly divergent RNA dependent RNA polymeraseAntivir Res2019169110 19.WangMCaoRZhangLYangXLiuJXuMShiZHuZZhongWXiaoGRemdesivir and" exact="chloroquine" post="effectively inhibit the recently emerged novel coronavirus ( 2019-nCoV"/>
   <result pre="al. Triple combination of interferon beta-1b , lopinavirâ€&quot;ritonavir , and" exact="ribavirin" post="in the treatment of patients admitted to hospital with"/>
   <result pre="into the antiviral effects of chloroquineLancet Infect Dis20066676916439323 37.YanYZouZSunYLiXXuKFWeiYJinNJiangCAnti-malaria drug" exact="chloroquine" post="is highly effective in treating avian influenza A H5N1"/>
   <result pre="potent inhibitor of SARS coronavirus infection and spreadVirol J2005211015631631 39.GaoJTianZYangXBreakthrough:" exact="Chloroquine" post="phosphate has shown apparent efficacy in treatment of COVID-19"/>
   <result pre="Parola P, Hoang VT, Meddeb L, Mailhe M, et al." exact="Hydroxychloroquine" post="and azithromycin as a treatment of COVID-19: results of"/>
   <result pre="Hoang VT, Meddeb L, Mailhe M, et al. Hydroxychloroquine and" exact="azithromycin" post="as a treatment of COVID-19: results of an open-"/>
   <result pre="J Antimicrob Agents. 2020. 10.1016/j.ijantimicag.2020.105949. 41.JunCHENDanpingLIULiLIUPingLIUQingnianXULXet al.A pilot study of" exact="hydroxychloroquine" post="in treatment of patients with moderate COVID-19Zhejiang Da Xue"/>
   <result pre="Z, Han M, Wang Z, Chen J SW et al." exact="Hydroxychloroquine" post="in patients mainly with mild to moderate COVIDâ€&quot;19: an"/>
   <result pre="Sampaio VS, Alexandre MAA, Melo GC, Brito M, et al." exact="Chloroquine" post="diphosphate in two different dosages as adjunctive therapy of"/>
   <result pre="2020;10.1101/2020.04.07.20056424. 44.Mehra MR, Desai SS, Ruschitzka F, Patel AN. Articles" exact="Hydroxychloroquine" post="or chloroquine with or without a macrolide for treatment"/>
   <result pre="MR, Desai SS, Ruschitzka F, Patel AN. Articles Hydroxychloroquine or" exact="chloroquine" post="with or without a macrolide for treatment of COVID-19:"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7368942\results\search\drug\results.xml">
   <result pre="â€ƒLeflunomide 17 (10) â€&quot; â€&quot; â€ƒSulfasalazine 5 (3) â€&quot; â€&quot;" exact="Prednisone" post="49 (29) â€&quot; â€&quot; CHIK symptoms 51 (30) 21"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7369569\results\search\drug\results.xml">
   <result pre="related to ACE2. The binding affinities of remdesivir, chloroquine, Ciclenosid," exact="Niclosamide" post="and Lopinavirus to ACE2 were determined and compared. Methods"/>
   <result pre="800 Treatment No cure, vaccine, or specific treatment Combination of" exact="lopinavir" post="and ritonavir or only ribavirin or IFN-Î±1 plus corticosteroids"/>
   <result pre="No cure, vaccine, or specific treatment Combination of lopinavir and" exact="ritonavir" post="or only ribavirin or IFN-Î±1 plus corticosteroids Combination of"/>
   <result pre="or specific treatment Combination of lopinavir and ritonavir or only" exact="ribavirin" post="or IFN-Î±1 plus corticosteroids Combination of ribavirin (or ritonavir)"/>
   <result pre="ritonavir or only ribavirin or IFN-Î±1 plus corticosteroids Combination of" exact="ribavirin" post="(or ritonavir) and interferon alpha-2b ACE2 Angiotensin converting enzyme"/>
   <result pre="(ClinicalTrials.gov) investigating therapeutic agents for COVID-19. Five studies on hydroxychloroquine," exact="lopinavir" post="plus ritonavir and arbidol, mesenchymal stem cells, traditional Chinese"/>
   <result pre="therapeutic agents for COVID-19. Five studies on hydroxychloroquine, lopinavir plus" exact="ritonavir" post="and arbidol, mesenchymal stem cells, traditional Chinese medicine and"/>
   <result pre="treatment, antibiotic therapy, corticosteroid therapy and other medications, such as" exact="ibuprofen" post="as an antipyretic, nutrition support treatment, H2 receptor antagonists"/>
   <result pre="clinical manifestations and epidemiology in children with COVID-19 treated with" exact="lopinavir" post="and ritonavir and without glucocorticoids and immunoglobulin, all 20"/>
   <result pre="and epidemiology in children with COVID-19 treated with lopinavir and" exact="ritonavir" post="and without glucocorticoids and immunoglobulin, all 20 patients improved"/>
   <result pre="Binding energy Antiviral Remdesivir LEU129, PHE123, MET124, VAL439, LEU443 -5.62" exact="Chloroquine" post="MET124, LEU127, ILE472, TRP481, LEU485, VAL589 -4.2 Ciclesonide MET124,"/>
   <result pre="LEU443 -5.62 Chloroquine MET124, LEU127, ILE472, TRP481, LEU485, VAL589 -4.2" exact="Ciclesonide" post="MET124, LEU127, ILE472, LEU485, ILE469, ILE588, VAL589 -5.53 Niclosamide"/>
   <result pre="-4.2 Ciclesonide MET124, LEU127, ILE472, LEU485, ILE469, ILE588, VAL589 -5.53" exact="Niclosamide" post="LYS112, LEU116,MET124, LEU446, TYR600 -4.31 Lopinavirus TYR231, ILE309, PHE312,"/>
   <result pre="shown in TableÂ 2 and Fig.Â 2, we found that" exact="chloroquine" post="and ciclesonide share similar binding amino acid residues (MET124,"/>
   <result pre="acid residues (MET124, LEU127, ILE472 and VAL589). Likewise, remdesivir and" exact="niclosamide" post="also possess MET124. Taken together, we might therefore hypothesize"/>
   <result pre="further studies are needed to elucidate the molecular mechanism of" exact="lopinavir" post="treatment of COVID-19. Conclusions The SARS-CoV-2 has a certain"/>
   <result pre="string RNA ACE2 Angiotensin converting enzyme 2, LEU Leucine PHE" exact="Phenylalanine" post="MET Methionine VAL Valine ILE isoleucine TRP Tryptophan TYR"/>
   <result pre="ACE2 Angiotensin converting enzyme 2, LEU Leucine PHE Phenylalanine MET" exact="Methionine" post="VAL Valine ILE isoleucine TRP Tryptophan TYR Tyrosine Xue-Yan"/>
   <result pre="converting enzyme 2, LEU Leucine PHE Phenylalanine MET Methionine VAL" exact="Valine" post="ILE isoleucine TRP Tryptophan TYR Tyrosine Xue-Yan Zhang, Hao-Jie"/>
   <result pre="Leucine PHE Phenylalanine MET Methionine VAL Valine ILE isoleucine TRP" exact="Tryptophan" post="TYR Tyrosine Xue-Yan Zhang, Hao-Jie Huang and Dong-Lin Zhuang"/>
   <result pre="protein to HIV-1 gp120 and gag2020 50.XuJShiPYLiHZhouJBroad Spectrum antiviral agent" exact="Niclosamide" post="and its therapeutic potentialACS Infect Dis2020690991532125140 51.WangMCaoRZhangLYangXLiuJXuMShiZHuZZhongWXiaoGRemdesivir and chloroquine"/>
   <result pre="agent Niclosamide and its therapeutic potentialACS Infect Dis2020690991532125140 51.WangMCaoRZhangLYangXLiuJXuMShiZHuZZhongWXiaoGRemdesivir and" exact="chloroquine" post="effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7369591\results\search\drug\results.xml">
   <result pre="Acronyms COVID-19, coronavirus disease 2019 CPT, convalescent plasma therapy CQ," exact="chloroquine" post="EC50, half-maximal effective concentration HCQ, hydroxychloroquine ICU, intensive care"/>
   <result pre="convalescent plasma therapy CQ, chloroquine EC50, half-maximal effective concentration HCQ," exact="hydroxychloroquine" post="ICU, intensive care unit IL-6, interleukin 6 JAK, Janus"/>
   <result pre="14, 15, 16, 17, 18, 19Clinical trial: 20, 21, 22" exact="Adenosine" post="analogue that causes termination of RNA synthesis Antiviral Favipiravir"/>
   <result pre="inhibitor/selective inhibitors of Janus kinases/modulation of immune responses Anti-inflammatory Chloroquine," exact="hydroxychloroquine" post="Preclinical: 77, 78, 98, 99Case series: 91Cohort: 81, 82,"/>
   <result pre="distress syndrome coronavirusÂ 2. bNonâ€&quot;peer-reviewed publications. Remdesivir Remdesivir is an" exact="adenosine" post="analogue developed to treat Ebola. Its effects derive from"/>
   <result pre="its usefulness in treating COVID-19 and its widespread use with" exact="ribavirin" post="in the management of COVID-19 in China. The reported"/>
   <result pre="did a randomized trial in 22 patients comparing LPV/RTV with" exact="chloroquine" post="(CQ).40 A study of LPV/RTV pharmacokinetic properties in 8"/>
   <result pre="of COVID-19. Janus kinase (JAK) inhibitors such as baricitinib and" exact="ruxolitinib" post="are also being considered for treating COVID-19â€&quot;associated cytokine storm."/>
   <result pre="of 10056 and 8557 patients receiving tocilizumab plus LPV/RTV or" exact="hydroxychloroquine" post="(HCQ) compared with LPV/RTV or HCQ alone, respectively, found"/>
   <result pre="randomized trial of a different JAK inhibitor, ruxolitinib, patients receiving" exact="ruxolitinib" post="had numerically faster, but not statistically significant (P=.147), time"/>
   <result pre="58% decline in inflammation scores 7 days after treatment with" exact="ruxolitinib" post="(P&amp;lt;.01) and 76% of patients had clinical improvement on"/>
   <result pre="stay.67 However, a 6425-patient open-label RCT of low- to moderate-dose" exact="dexamethasone" post="reported reductions in 28-day mortality in one-third of patients"/>
   <result pre="ventilation (rate ratio, 0.82; 95% confidence interval, 0.72 to 0.94).68" exact="Chloroquine" post="and Hydroxychloroquine Hydroxychloroquine and CQ are quinine analogues that"/>
   <result pre="ratio, 0.82; 95% confidence interval, 0.72 to 0.94).68 Chloroquine and" exact="Hydroxychloroquine" post="Hydroxychloroquine and CQ are quinine analogues that have been"/>
   <result pre="0.82; 95% confidence interval, 0.72 to 0.94).68 Chloroquine and Hydroxychloroquine" exact="Hydroxychloroquine" post="and CQ are quinine analogues that have been widely"/>
   <result pre="0.72 to 0.94).68 Chloroquine and Hydroxychloroquine Hydroxychloroquine and CQ are" exact="quinine" post="analogues that have been widely used in the treatment"/>
   <result pre="0.4 to 2.1)82 who received HCQ or HCQ added to" exact="azithromycin" post="or who were unexposed to HCQ. Likewise, in a"/>
   <result pre="1.04, 95% confidence interval, 0.82 to 1.32)83 or HCQ and" exact="azithromycin" post="use and mortality.84 The first double-blind, RCT of postexposure"/>
   <result pre="12.5% of control patients (P&amp;lt;.001).86 Although a follow-up study of" exact="azithromycin" post="combined with HCQ in 80 additional French patients with"/>
   <result pre="corrected QT measurements greater than 500 ms after HCQ plus" exact="azithromycin" post="treatment.97 One arm of a double-blind randomized trial of"/>
   <result pre="resultant pulmonary inflammation and edema118 as well as evaluation of" exact="ivermectin" post="based on its inÂ vitro antiâ€&quot;SARS-CoV-2 effects.119TableÂ 2 Clinical"/>
   <result pre="None 48 (75) Single 1 (2) Multi 15 (23) Chloroquine," exact="hydroxychloroquine" post="134 Global 123 (92) None 65 (49) Single 10"/>
   <result pre="National Institutes of Healthâ€™s Outcomes Related to COVID-19 treated with" exact="hydroxychloroquine" post="among in-patients with symptomatic Disease study (ORCHID) was halted"/>
   <result pre="Oxford SoCÂ + LPV/RTVSoCÂ + IFN Î²-1aSoCÂ + HCQSoCÂ +" exact="dexamethasone" post="SoC Phase II/III, adaptive, open-label RCT â‰¥18 y and"/>
   <result pre="d of randomizationHospital length of stayNumber of patients needing ventilation" exact="Hydroxychloroquine" post="Versus Placebo in COVID-19 Patients at Risk for Severe"/>
   <result pre="length of stay COVID-19Â = coronavirus disease 2019; CQ/HCQÂ =" exact="chloroquine" post="or hydroxychloroquine; FiO2Â = fraction of inspired oxygen; ICUÂ"/>
   <result pre="clinical efficacy. The preliminary results of the low- to moderate-dose" exact="dexamethasone" post="arm of the Randomised Evaluation of COVID-19 Therapy (RECOVERY)"/>
   <result pre="such as cancer, obesity, Alzheimer disease, diabetes, or opioid and" exact="alcohol" post="addiction. The COVID-19 pandemic is a formidable health care"/>
   <result pre="MERS-CoV infectionProc Natl Acad Sci U S A1171220206771677632054787 12WangM.CaoR.ZhangL.Remdesivir and" exact="chloroquine" post="effectively inhibit the recently emerged novel coronavirus (2019-nCoV) inÂ"/>
   <result pre="ahead of print April 15, 2020]medRxivhttps://doi.org/10.1101/2020.03.17.20037432 27KimU.J.WonE.J.KeeS.J.JungS.I.JangH.C.Combination therapy with lopinavir/ritonavir," exact="ribavirin" post="and interferon-Î± for Middle East respiratory syndromeAntivir Ther215201645545926492219 28SpanakisN.TsiodrasS.HaagmansB.L.Virological"/>
   <result pre="Med Pharmacol Sci24620203390339632271456 35HungI.F.N.LungK.C.TsoE.Y.K.Triple combination of interferon beta-1b, lopinavir-ritonavir, and" exact="ribavirin" post="in the treatment of patients admitted to hospital with"/>
   <result pre="10.1016/j.medj.2020.04.001/S2666-6340(20)30001-5. 40HuangM.TangT.PangP.Treating COVID-19 with chloroquineJÂ Mol Cell Biol124202032232532236562 41SchoergenhoferC.JilmaB.StimpflT.KarolyiM.ZoufalyA.Pharmacokinetics of" exact="lopinavir" post="and ritonavir in patients hospitalized with coronavirus disease 2019"/>
   <result pre="COVID-19 with chloroquineJÂ Mol Cell Biol124202032232532236562 41SchoergenhoferC.JilmaB.StimpflT.KarolyiM.ZoufalyA.Pharmacokinetics of lopinavir and" exact="ritonavir" post="in patients hospitalized with coronavirus disease 2019 (COVID-19) [published"/>
   <result pre="trialJÂ Allergy Clin Immunol14612020137146.e14332470486 66La RosÃ©eF.BremerH.C.GehrkeI.The Janus kinase 1/2 inhibitor" exact="ruxolitinib" post="in COVID-19 with severe systemic hyperinflammationLeukemia34720201805181532518419 67LuS.ZhouQ.HuangL.Effectiveness and safety"/>
   <result pre="antiviral agentsProc Natl Acad Sci U S A7861981360536096115382 71ShimizuY.YamamotoS.HommaM.IshidaN.Effect of" exact="chloroquine" post="on the growth of animal virusesArch Gesamte Virusforsch3611972931044335025 72KeyaertsE.VijgenL.MaesP.NeytsJ.Van"/>
   <result pre="respiratory syndrome coronavirus by chloroquineBiochem Biophys Res Commun3231200426426815351731 73TouretF.de LamballerieX.Of" exact="chloroquine" post="and COVID-19Antiviral Res177202010476232147496 74PatonN.I.LeeL.XuY.Chloroquine for influenza prevention: a randomised,"/>
   <result pre="placebo controlled trialLancet Infect Dis119201167768321550310 75TricouV.MinhN.N.VanT.P.AÂ randomized controlled trial of" exact="chloroquine" post="for the treatment of dengue in Vietnamese adults [published"/>
   <result pre="2012;6(6)]PLoS Negl Trop Dis482010e78520706626 76De LamballerieX.BoissonV.ReynierJ.C.On chikungunya acute infection and" exact="chloroquine" post="treatmentVector Borne jDis862008837840 77LiuJ.CaoR.XuM.Hydroxychloroquine, a less toxic derivative of"/>
   <result pre="vitro antiviral activity and projection of optimized dosing design of" exact="hydroxychloroquine" post="for the treatment of severe acute respiratory syndrome coronavirus"/>
   <result pre="syndrome coronavirus 2 (SARS-CoV-2)Clin Infect Dis7115202073273932150618 79ChenJ.LiuD.LiuL.AÂ pilot study of" exact="hydroxychloroquine" post="in treatment of patients with common coronavirus disease-19 (COVID-19)JÂ"/>
   <result pre="coronavirus disease 2019: open label, randomised controlled trialBMJ3692020m184932409561 81MagagnoliJ.NarendranS.PereiraF.Outcomes of" exact="hydroxychloroquine" post="usage in United States veterans hospitalized with COVID-19 [published"/>
   <result pre="online ahead of print April 21, 2020]medRxivhttps://doi.org/10.1101/2020.04.16.20065920 82MahÃ©vasM.TranV.T.RoumierM.Clinical efficacy of" exact="hydroxychloroquine" post="in patients with covid-19 pneumonia who require oxygen: observational"/>
   <result pre="observational comparative study using routine care dataBMJ3692020m184432409486 83GelerisJ.SunY.PlattJ.Observational study of" exact="hydroxychloroquine" post="in hospitalized patients with Covid-19NÂ Engl J Med3822520202411241832379955 84RosenbergE.S.DufortE.M.UdoT.Association"/>
   <result pre="patients with Covid-19NÂ Engl J Med3822520202411241832379955 84RosenbergE.S.DufortE.M.UdoT.Association of treatment with" exact="hydroxychloroquine" post="or azithromycin with in-hospital mortality in patients with COVID-19"/>
   <result pre="Covid-19NÂ Engl J Med3822520202411241832379955 84RosenbergE.S.DufortE.M.UdoT.Association of treatment with hydroxychloroquine or" exact="azithromycin" post="with in-hospital mortality in patients with COVID-19 in New"/>
   <result pre="with COVID-19 in New York stateJAMA3232420202493250232392282 85BoulwareD.R.PullenM.F.BangdiwalaA.S.AÂ randomized trial of" exact="hydroxychloroquine" post="as postexposure prophylaxis for Covid-19NÂ Engl J Med3836202051752532492293 86GautretP.LagierJ.-C.ParolaP.Hydroxychloroquine"/>
   <result pre="as postexposure prophylaxis for Covid-19NÂ Engl J Med3836202051752532492293 86GautretP.LagierJ.-C.ParolaP.Hydroxychloroquine and" exact="azithromycin" post="as a treatment of COVID-19: results of an open-label"/>
   <result pre="Antimicrob Agents561202010594932205204 87GautretP.LagierJ.-C.ParolaP.Clinical and microbiological effect of a combination of" exact="hydroxychloroquine" post="and azithromycin in 80 COVID-19 patients with at least"/>
   <result pre="87GautretP.LagierJ.-C.ParolaP.Clinical and microbiological effect of a combination of hydroxychloroquine and" exact="azithromycin" post="in 80 COVID-19 patients with at least a six-day"/>
   <result pre="up: an observational studyTravel Med Infect Dis34202010166332289548 88DahleyD.GatesS.OrrisT.Statistical review of" exact="hydroxychloroquine" post="and azithromycin as a treatment of COVID-19: results of"/>
   <result pre="observational studyTravel Med Infect Dis34202010166332289548 88DahleyD.GatesS.OrrisT.Statistical review of hydroxychloroquine and" exact="azithromycin" post="as a treatment of COVID-19: results of an open-label"/>
   <result pre="online ahead of print March 2020]ResearchGatehttps://doi.org/10.13140/RG.2.2.24669.36325 90Statement on IJAA paper:" exact="Hydroxychloroquine" post="and azithromycin as a treatment of COVID-19: results of"/>
   <result pre="of print March 2020]ResearchGatehttps://doi.org/10.13140/RG.2.2.24669.36325 90Statement on IJAA paper: Hydroxychloroquine and" exact="azithromycin" post="as a treatment of COVID-19: results of an open-label"/>
   <result pre="rapid antiviral clearance or clinical benefit with the combination of" exact="hydroxychloroquine" post="and azithromycin in patients with severe COVID-19 infectionMed Mal"/>
   <result pre="clearance or clinical benefit with the combination of hydroxychloroquine and" exact="azithromycin" post="in patients with severe COVID-19 infectionMed Mal Infect504202038432240719 92MillionM.LagierJ.-C.GautretP.Early"/>
   <result pre="COVID-19 infectionMed Mal Infect504202038432240719 92MillionM.LagierJ.-C.GautretP.Early treatment of COVID-19 patients with" exact="hydroxychloroquine" post="and azithromycin: a retrospective analysis of 1061 cases in"/>
   <result pre="cases in Marseille, FranceTravel Med Infect Dis35202010173832387409 93YuB.LiC.ChenP.Low dose of" exact="hydroxychloroquine" post="reduces fatality of critically ill patients with COVID-19 [published"/>
   <result pre="Sci. June 18, 2020. doi:10.1007/s11427-020-1751-3]Sci China Life Scihttps://doi.org/10.1007/s11427-020-1732-2 94ChenZ.HuJ.ZhangZ.Efficacy of" exact="hydroxychloroquine" post="in patients with COVID-19: results of a randomized clinical"/>
   <result pre="trial [published online ahead of print April 10, 2020]medRxivhttps://doi.org/10.1101/2020.03.22.20040758 95MehraM.R.DesaiS.S.RuschitzkaF.PatelA.N.RETRACTED:" exact="Hydroxychloroquine" post="or chloroquine with or without a macrolide for treatment"/>
   <result pre="online ahead of print April 10, 2020]medRxivhttps://doi.org/10.1101/2020.03.22.20040758 95MehraM.R.DesaiS.S.RuschitzkaF.PatelA.N.RETRACTED: Hydroxychloroquine or" exact="chloroquine" post="with or without a macrolide for treatment of COVID-19:"/>
   <result pre="Therhttps://doi.org/10.1002/cpt.1968 98BorbaM.G.S.ValF.F.A.SampaioV.S.collab: CloroCovid-19 TeamEffect of high vs low doses of" exact="chloroquine" post="diphosphate as adjunctive therapy for patients hospitalized with severe"/>
   <result pre="online ahead of print June 8, 2020]medRxivhttps://doi.org/10.1101/2020.06.03.20116988 119CalyL.DruceJ.D.CattonM.G.JansD.A.WagstaffK.M.The FDA-approved drug" exact="ivermectin" post="inhibits the replication of SARS-CoV-2 inÂ vitroAntiviral Res178202010478732251768 120â€œSolidarityâ€�"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7369612\results\search\drug\results.xml">
   <result pre="measures for COVID-19 infections Mitigation measures for COVID-19 deaths Slope" exact="Intercept" post="RMSE Slope Intercept RMSE Los Angeles, California 16.31 âˆ’22.57"/>
   <result pre="infections Mitigation measures for COVID-19 deaths Slope Intercept RMSE Slope" exact="Intercept" post="RMSE Los Angeles, California 16.31 âˆ’22.57 617.21 âˆ’0.25 7.00"/>
   <result pre="7StebbingJ.PhelanA.GriffinI.TuckerC.OechsleO.SmithD.COVID-19: combining antiviral and anti-inflammatory treatmentsLancet Infect Dis204202040040232113509 8TouretF.de LamballerieX.Of" exact="chloroquine" post="and COVID-19Antiviral Res177202010476232147496 9RanneyM.L.GriffethV.JhaA.K.Critical supply shortages - the need"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7369980\results\search\drug\results.xml">
   <result pre="young women in South Africa: A cohort studyLancet2010376414810.1016/S0140-6736(10)60548-X20557928 18.LanC.W.Scott-SheldonL.A.CareyK.B.JohnsonB.T.CareyM.P.Prevalence of" exact="Alcohol" post="Use, Sexual Risk Behavior, and HIV Among Russians in"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7370876\results\search\drug\results.xml">
   <result pre="priming by TMPRSS2 (a target of the serine protease inhibitor" exact="camostat" post="mesylate), membrane fusion and endocytosis (a target of the"/>
   <result pre="membrane fusion and endocytosis (a target of the antimalarial drug" exact="chloroquine" post="and anti-influenza drug umifenovir) and RNA replication by RdRP"/>
   <result pre="that have been proposed as treatments for COVID-19 such as" exact="hydroxychloroquine" post="and azithromycin have pro-arrhythmic effects. AF, atrial fibrillation; VF,"/>
   <result pre="been proposed as treatments for COVID-19 such as hydroxychloroquine and" exact="azithromycin" post="have pro-arrhythmic effects. AF, atrial fibrillation; VF, ventricular fibrillation;"/>
   <result pre="Inhibitors of endocytosis Camostat mesylate Inhibition of TMPRSS2 Not common" exact="Chloroquine" post="and hydroxychloroquine Blockade of virus entry by multiple mechanisms"/>
   <result pre="endocytosis Camostat mesylate Inhibition of TMPRSS2 Not common Chloroquine and" exact="hydroxychloroquine" post="Blockade of virus entry by multiple mechanisms QT interval"/>
   <result pre="Remdesivir Inhibition of RdRP Not common, but limited clinical data" exact="Ribavirin" post="Inhibition of RdRP Not common Others Azithromycin Macrolide antibiotic;"/>
   <result pre="limited clinical data Ribavirin Inhibition of RdRP Not common Others" exact="Azithromycin" post="Macrolide antibiotic; used in combination with chloroquine or hydroxychloroquine"/>
   <result pre="Not common Others Azithromycin Macrolide antibiotic; used in combination with" exact="chloroquine" post="or hydroxychloroquine QT interval prolongation Tocilizumab IL-6 inhibition Hypertension"/>
   <result pre="Others Azithromycin Macrolide antibiotic; used in combination with chloroquine or" exact="hydroxychloroquine" post="QT interval prolongation Tocilizumab IL-6 inhibition Hypertension ACE2, angiotensin-converting"/>
   <result pre="disease 2019; RdRP, RNA-dependent RNA polymerase; S protein, spike protein." exact="Hydroxychloroquine" post="and azithromycin Chloroquine and hydroxychloroquine have been widely touted"/>
   <result pre="RdRP, RNA-dependent RNA polymerase; S protein, spike protein. Hydroxychloroquine and" exact="azithromycin" post="Chloroquine and hydroxychloroquine have been widely touted as potential"/>
   <result pre="RNA-dependent RNA polymerase; S protein, spike protein. Hydroxychloroquine and azithromycin" exact="Chloroquine" post="and hydroxychloroquine have been widely touted as potential treatment"/>
   <result pre="polymerase; S protein, spike protein. Hydroxychloroquine and azithromycin Chloroquine and" exact="hydroxychloroquine" post="have been widely touted as potential treatment strategies for"/>
   <result pre="been widely touted as potential treatment strategies for COVID-19 (refs143â€&quot;145)." exact="Chloroquine" post="and hydroxychloroquine can potentially block virus entry into cells,"/>
   <result pre="touted as potential treatment strategies for COVID-19 (refs143â€&quot;145). Chloroquine and" exact="hydroxychloroquine" post="can potentially block virus entry into cells, particularly via"/>
   <result pre="involving 36 patients with COVID-19 reported improved virus clearance with" exact="hydroxychloroquine" post="treatment144. Furthermore, combining hydroxychloroquine with azithromycin in six patients"/>
   <result pre="COVID-19 reported improved virus clearance with hydroxychloroquine treatment144. Furthermore, combining" exact="hydroxychloroquine" post="with azithromycin in six patients resulted in even better"/>
   <result pre="improved virus clearance with hydroxychloroquine treatment144. Furthermore, combining hydroxychloroquine with" exact="azithromycin" post="in six patients resulted in even better virus clearance"/>
   <result pre="in even better virus clearance than with the use of" exact="hydroxychloroquine" post="alone144. Importantly, however, several concerns have been raised regarding"/>
   <result pre="with COVID-19 in China, patients in the treatment group received" exact="hydroxychloroquine" post="(400â€‰mg per day) for 5 days, whereas patients in"/>
   <result pre="antiviral agents, antibacterial agents and immunoglobulin, with or without corticosteroids)143." exact="Hydroxychloroquine" post="improved the time to clinical recovery, body temperature recovery"/>
   <result pre="with COVID-19, mortality was significantly lower among patients treated with" exact="hydroxychloroquine" post="plus standard treatment (which included other antiviral drugs and"/>
   <result pre="large observational study involving 1,376Â patients from New York City," exact="hydroxychloroquine" post="treatment did not alter the risk of the composite"/>
   <result pre="or death149. These inconsistent results show that the efficacy of" exact="hydroxychloroquine" post="is still controversial and needs to be validated in"/>
   <result pre="and needs to be validated in large, randomized studies150. Although" exact="chloroquine" post="and hydroxychloroquine have a long history of clinical use"/>
   <result pre="to be validated in large, randomized studies150. Although chloroquine and" exact="hydroxychloroquine" post="have a long history of clinical use for numerous"/>
   <result pre="induce arrhythmias41,142,151. Azithromycin, which has been assessed in combination with" exact="hydroxychloroquine" post="as a treatment for COVID-19, is also known to"/>
   <result pre="a cohort study of 90 patients with COVID-19 who received" exact="hydroxychloroquine" post="(withÂ or without azithromycin), those who received a combination"/>
   <result pre="(withÂ or without azithromycin), those who received a combination of" exact="hydroxychloroquine" post="and azithromycin had greater QT interval prolongation than those"/>
   <result pre="without azithromycin), those who received a combination of hydroxychloroquine and" exact="azithromycin" post="had greater QT interval prolongation than those taking hydroxychloroquine"/>
   <result pre="and azithromycin had greater QT interval prolongation than those taking" exact="hydroxychloroquine" post="alone151. Furthermore, in a retrospective cohort study of 1,438"/>
   <result pre="patients hospitalized with COVID-19 in New York, treatment with hydroxychloroquine," exact="azithromycin" post="or both was compared with neither treatment153. None of"/>
   <result pre="of cardiac arrest was more likely in patients receiving both" exact="hydroxychloroquine" post="and azithromycin than in patients receiving neither drug153. Given"/>
   <result pre="arrest was more likely in patients receiving both hydroxychloroquine and" exact="azithromycin" post="than in patients receiving neither drug153. Given that some"/>
   <result pre="electrocardiographic evaluation should be strongly considered in patients treated with" exact="hydroxychloroquine" post="and/or azithromycin. Remdesivir Remdesivir is a promising investigational nucleotide"/>
   <result pre="combination with ritonavir, which functions to slow the breakdown of" exact="lopinavir" post="by inhibiting cytochrome P450 3A4 (ref.41). In a randomized,"/>
   <result pre="of ventricular dysfunction in myocardial infarcted ratHypertension20064857257816908757 133.LuqueMet al.Effects of" exact="captopril" post="related to increased levels of prostacyclin and angiotensin-(1â€&quot;7) in"/>
   <result pre="in exploratory COVID-19 treatmentCirculation2020141e906e90732267732 143.Chen, Z. et al. Efficacy of" exact="hydroxychloroquine" post="in patients with COVID-19: results of a randomized clinical"/>
   <result pre="clinical trial. Preprint at medRxiv10.1101/2020.03.22.20040758 (2020). 144.Gautret, P. et al." exact="Hydroxychloroquine" post="and azithromycin as a treatment of COVID-19: results of"/>
   <result pre="Preprint at medRxiv10.1101/2020.03.22.20040758 (2020). 144.Gautret, P. et al. Hydroxychloroquine and" exact="azithromycin" post="as a treatment of COVID-19: results of an open-label"/>
   <result pre="Int. J. Antimicrob. Agents, 105949, 10.1016/j.ijantimicag.2020.105949 (2020). 145.WangMet al.Remdesivir and" exact="chloroquine" post="effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in"/>
   <result pre="recently emerged novel coronavirus (2019-nCoV) in vitroCell Res.20203026927132020029 146.SavarinoABoelaertJRCassoneAMajoriGCaudaREffects of" exact="chloroquine" post="on viral infections: an old drug against todayâ€™s diseases?Lancet"/>
   <result pre="International Society of Antimicrobial Chemotherapyhttps://www.isac.world/news-and-publications/isac-elsevier-statement (2020). 148.YuBet al.Low dose of" exact="hydroxychloroquine" post="reduces fatality of critically ill patients with COVID-19Sci. China"/>
   <result pre="patients with COVID-19Sci. China Life. Sci.202010.1007/s11427-020-1732-232676969 149.GelerisJet al.Observational study of" exact="hydroxychloroquine" post="in hospitalized patients with COVID-19N. Engl. J. Med.20203822411241832379955 150.FihnSDPerencevichEBradleySMCaution"/>
   <result pre="COVID-19N. Engl. J. Med.20203822411241832379955 150.FihnSDPerencevichEBradleySMCaution needed on the use of" exact="chloroquine" post="and hydroxychloroquine for coronavirus disease 2019JAMA Netw. Open.20203e20903532330276 151.MercuroNJet"/>
   <result pre="J. Med.20203822411241832379955 150.FihnSDPerencevichEBradleySMCaution needed on the use of chloroquine and" exact="hydroxychloroquine" post="for coronavirus disease 2019JAMA Netw. Open.20203e20903532330276 151.MercuroNJet al.Risk of"/>
   <result pre="151.MercuroNJet al.Risk of QT interval prolongation associated with use of" exact="hydroxychloroquine" post="with or without concomitant azithromycin among hospitalized patients testing"/>
   <result pre="prolongation associated with use of hydroxychloroquine with or without concomitant" exact="azithromycin" post="among hospitalized patients testing positive for coronavirus disease 2019"/>
   <result pre="case reportsTher. Adv. Infect. Dis.2013115516525165550 153.RosenbergESet al.Association of treatment with" exact="hydroxychloroquine" post="or azithromycin with in-hospital mortality in patients with COVID-19"/>
   <result pre="Adv. Infect. Dis.2013115516525165550 153.RosenbergESet al.Association of treatment with hydroxychloroquine or" exact="azithromycin" post="with in-hospital mortality in patients with COVID-19 in New"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7371486\results\search\drug\results.xml">
   <result pre="Res Clin Obstet Gynaecol2020;63:87â€&quot;110. 10.1016/j.bpobgyn.2019.08.00231859163 21FosterAM, ArnottG, HobstetterMCommunity-based distribution of" exact="misoprostol" post="for early abortion: evaluation of a program along the"/>
   <result pre="BaumSE, AndjelicD, et al.A harm-reduction model of abortion counseling about" exact="misoprostol" post="use in Peru with telephone and in-person follow-up: a"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7371569\results\search\drug\results.xml">
   <result pre="130 257 040 Atracurium 135 000 11 475 91 800" exact="Rocuronium" post="130 500 22 185 177 480 ICU, intensive care"/>
   <result pre="5000 55 000 600 70 85% 1.5 Red 1.2 Red" exact="Rocuronium" post="1 000 000 1 500 000 2 500 000"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7372203\results\search\drug\results.xml">
   <result pre="dexamethasone, interferons, statins, angiotensin pathway modulators, macrolides (e.g. azithromycin, clarithromycin)," exact="hydroxychloroquine" post="and chloroquine, colchicine, and prostaglandin D2 modulators such as"/>
   <result pre="as endorsement for use of such agents. The use of" exact="hydroxychloroquine" post="and azithromycin in COVID-19 patients may be associated with"/>
   <result pre="for use of such agents. The use of hydroxychloroquine and" exact="azithromycin" post="in COVID-19 patients may be associated with harm. Whether"/>
   <result pre="who received tocilizumab (80â€&quot;600Â mg per dose) in combination with" exact="methylprednisolone" post="in 8 of the patients. Five patients received two"/>
   <result pre="the management of CRS in severely ill COVID-19 patients [32]." exact="Ruxolitinib" post="(JakafiÂ®) is a potent and selective oral inhibitor of"/>
   <result pre="high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease [33]." exact="Ruxolitinib" post="interrupts signaling downstream of multiple proinflammatory cytokines, which constitute"/>
   <result pre="againstÂ viruses [34]. In addition, severe reactions afterÂ initiationÂ ofÂ" exact="ruxolitinib" post="were reported in two COVID-19 patients, and required drug"/>
   <result pre="of ritonavir, a CYP3A4 inhibitor, leading to an increase in" exact="ruxolitinib" post="plasma concentrations. Thus, the role and safety of this"/>
   <result pre="currently no published clinical trials to support the use of" exact="ruxolitinib" post="or other JAK inhibitors in COVID-19. Two ongoing phase"/>
   <result pre="randomized clinical trials are evaluating the efficacy and safety of" exact="ruxolitinib" post="plus standard of care, compared with standard-of-care therapy alone,"/>
   <result pre="high-titer neutralizing antibodies (NAT of 80â€&quot;480) in conjunction with continued" exact="methylprednisolone" post="and antiviral treatment [73]. Before transfusion, patients displayed continuously"/>
   <result pre="with ARDS, providing that a low dose (â‰¤â€‰0.5â€&quot;1Â mg/kg/day of" exact="methylprednisolone" post="or equivalent) and short duration (â‰¤â€‰7Â days) are used"/>
   <result pre="on preliminary results from the RECOVERY trial, which showed that" exact="dexamethasone" post="reduces mortality among COVID-19 patients with severe respiratory complications"/>
   <result pre="mortality among COVID-19 patients with severe respiratory complications [97]. Low-dose" exact="dexamethasone" post="(6Â mg once daily, orally or intravenously) for 10Â"/>
   <result pre="multicenter, randomized controlled trial (DEXA-ARDS) studied the effects of intravenous" exact="dexamethasone" post="at a dose of 20Â mg once daily on"/>
   <result pre="[98]. Compared with those receiving conventional treatment, the addition of" exact="dexamethasone" post="to the therapy regimen lead to a reduction in"/>
   <result pre="with confirmed COVID-19 infection has commenced (NCT04325061). Compared with methylprednisolone," exact="dexamethasone" post="has less mineralocorticoid activity and is less likely to"/>
   <result pre="a concern in this patient population [90]. The use of" exact="methylprednisolone" post="in severe COVID-19 patients was evaluated in several retrospective,"/>
   <result pre="pneumonia that progressed to acute respiratory failure, the use of" exact="methylprednisolone" post="1â€&quot;2Â mg/kg daily intravenously for 5â€&quot;7Â days in 26"/>
   <result pre="whom received methylprednisolone. Wu et al. showed that treatment with" exact="methylprednisolone" post="decreased the risk of death (HR 0.38, 95% CI"/>
   <result pre="0.20â€&quot;0.72, pâ€‰=â€‰0.003) among patients with ARDS [6]. Higher doses of" exact="methylprednisolone" post="have been recommended for managing the cytokine storm: methylprednisolone"/>
   <result pre="of methylprednisolone have been recommended for managing the cytokine storm:" exact="methylprednisolone" post="60â€&quot;125Â mg every 6Â h for up to 3Â"/>
   <result pre="retrospective cohort study of 44 patients investigated the use of" exact="ribavirin" post="and INFÎ±-2a compared with ribavirin alone for the management"/>
   <result pre="patients investigated the use of ribavirin and INFÎ±-2a compared with" exact="ribavirin" post="alone for the management of severe MERS. The study"/>
   <result pre="therapy should be started or continued. Macrolides Macrolides, such as" exact="azithromycin" post="and clarithromycin, are antibiotics with immunomodulatory and anti-inflammatory effects"/>
   <result pre="the exact mechanisms of these effects are not fully illuminated." exact="Azithromycin" post="has been used as an adjunctive therapy to provide"/>
   <result pre="al., patients with moderate or severe ARDS who received adjunctive" exact="azithromycin" post="manifested a significant improvement in 90-day survival [129]. In"/>
   <result pre="to draw any firm conclusions about the benefits of adjunctive" exact="azithromycin" post="in COVID-19 patients. Furthermore, this antibiotic is known to"/>
   <result pre="outpatients receiving this therapy in combination with other QT-prolonging therapies." exact="Hydroxychloroquine" post="and Chloroquine It has been postulated that hydroxychloroquine and"/>
   <result pre="this therapy in combination with other QT-prolonging therapies. Hydroxychloroquine and" exact="Chloroquine" post="It has been postulated that hydroxychloroquine and chloroquine exhibit"/>
   <result pre="QT-prolonging therapies. Hydroxychloroquine and Chloroquine It has been postulated that" exact="hydroxychloroquine" post="and chloroquine exhibit immunomodulatory effects that theoretically may confer"/>
   <result pre="Hydroxychloroquine and Chloroquine It has been postulated that hydroxychloroquine and" exact="chloroquine" post="exhibit immunomodulatory effects that theoretically may confer an anti-inflammatory"/>
   <result pre="open-label, randomized trial indicated the potentially beneficial anti-inflammatory effect of" exact="hydroxychloroquine" post="in patients with COVID-19 [143]. While adding hydroxychloroquine to"/>
   <result pre="effect of hydroxychloroquine in patients with COVID-19 [143]. While adding" exact="hydroxychloroquine" post="to the standard of care did not increase virus"/>
   <result pre="from hydroxychloroquine. If these findings are confirmed in larger studies," exact="hydroxychloroquine" post="may be indicated to decrease the risk of progressive"/>
   <result pre="agent also prolongs the QT interval, and the combination of" exact="hydroxychloroquine" post="and azithromycin could produce additive and potentially dangerous QT"/>
   <result pre="prolongs the QT interval, and the combination of hydroxychloroquine and" exact="azithromycin" post="could produce additive and potentially dangerous QT prolongation [144]."/>
   <result pre="data of 1376 patients who received hydroxychloroquine, 811 (58.9%) received" exact="hydroxychloroquine" post="and 565 (41.1%) did not. The primary endpoint was"/>
   <result pre="346 patients (25.1%), and there was no significant association between" exact="hydroxychloroquine" post="use and the composite primary endpoint (HR 1.04, 95%"/>
   <result pre="trial by Boulware et al. [146] evaluated the use of" exact="hydroxychloroquine" post="as a potential agent for post-exposure prophylaxis in 821"/>
   <result pre="was to identify new COVID-19 infections between patients who received" exact="hydroxychloroquine" post="or placebo. Within 4Â days of exposure, patients were"/>
   <result pre="exposure, patients were randomized to either a 5-day regimen of" exact="hydroxychloroquine" post="or placebo. While there were slightly fewer infections in"/>
   <result pre="or placebo. While there were slightly fewer infections in the" exact="hydroxychloroquine" post="arm (11.8% vs. 14.3%), the difference was not statistically"/>
   <result pre="15 June 2020. The basis of this decision is that" exact="hydroxychloroquine" post="or chloroquine are unlikely to be effective in treating"/>
   <result pre="2020. The basis of this decision is that hydroxychloroquine or" exact="chloroquine" post="are unlikely to be effective in treating COVID-19, above"/>
   <result pre="consistently replicated. Preliminary results from the RECOVERY trial reported that" exact="hydroxychloroquine" post="did not provide a significant difference in the primary"/>
   <result pre="difference in the primary endpoint of 28-day mortalityâ€&quot;25.7% in the" exact="hydroxychloroquine" post="arm and 23.5% in the usual-care arm (HR 1.11,"/>
   <result pre="the ORCHID study, which evaluated the safety and effectiveness of" exact="hydroxychloroquine" post="for the treatment of COVID-19 in hospitalized adults, was"/>
   <result pre="et al. evaluated the efficacy and safety of two different" exact="chloroquine" post="dosages as adjunctive therapy in hospitalized patients with severe"/>
   <result pre="The 81 enrolled patients were randomized to receive either high-dose" exact="chloroquine" post="(i.e. 600Â mg twice daily for 10Â days) or"/>
   <result pre="(i.e. 600Â mg twice daily for 10Â days) or low-dose" exact="chloroquine" post="(i.e. 450Â mg twice daily on day 1 and"/>
   <result pre="the treatment of severe COVID-19, particularly in patients also receiving" exact="azithromycin" post="and oseltamivir. The study continues to evaluate the low-dose"/>
   <result pre="of CYP3A4 substrates Safety during pregnancy and lactation is unknown" exact="Ruxolitinib" post="Various regimens under investigation 5Â mg bid for 14Â"/>
   <result pre="increased macrophage-dependent infection, tuberculosis, opportunistic infections, injection site reactions, increased" exact="creatine" post="phosphokinase, headache, rash None Avoid use with anakinra due"/>
   <result pre="with the smallest possible effective dose for the shortest duration" exact="Methylprednisolone" post="0.5â€&quot;1Â mg/kg daily or 1â€&quot;2Â mg/kg daily (of methylprednisolone"/>
   <result pre="duration Methylprednisolone 0.5â€&quot;1Â mg/kg daily or 1â€&quot;2Â mg/kg daily (of" exact="methylprednisolone" post="or equivalent) have been proposed Higher doses (cytokine storm):"/>
   <result pre="patients with pre-existing heart disease and organ transplant Miscellaneous Statins" exact="Simvastatin" post="40Â mg od for 14Â days, simvastatin 80Â mg"/>
   <result pre="transplant Miscellaneous Statins Simvastatin 40Â mg od for 14Â days," exact="simvastatin" post="80Â mg od, atorvastatin 40Â mg od PO Anti-inflammatory"/>
   <result pre="40Â mg od for 14Â days, simvastatin 80Â mg od," exact="atorvastatin" post="40Â mg od PO Anti-inflammatory and immunomodulatory effects Hepatotoxicity,"/>
   <result pre="in COVID-19 patients with severe rhabdomyolysis ACEi/ARB Various dosing regimens:" exact="telmisartan" post="80Â mg bid, telmisartan 40Â mg bid, ramipril 2.5Â"/>
   <result pre="severe rhabdomyolysis ACEi/ARB Various dosing regimens: telmisartan 80Â mg bid," exact="telmisartan" post="40Â mg bid, ramipril 2.5Â mg od for 14Â"/>
   <result pre="dosing regimens: telmisartan 80Â mg bid, telmisartan 40Â mg bid," exact="ramipril" post="2.5Â mg od for 14Â days, losartan 100Â mg"/>
   <result pre="2.5Â mg od for 14Â days, losartan 100Â mg od," exact="valsartan" post="80 or 160Â mg for 14Â days (max: 160Â"/>
   <result pre="or 160Â mg for 14Â days (max: 160Â mg bid)," exact="captopril" post="25Â mg, losartan 25Â mg od, losartan 50Â mg"/>
   <result pre="indication for ACEi/ARB; abrupt withdrawal may lead to clinical instability" exact="Azithromycin" post="500Â mg on day 1, then 250Â mg od"/>
   <result pre="on days 2â€&quot;5 in conjunction with a 10-day regimen of" exact="hydroxychloroquine" post="PO Anti-inflammatory and immunomodulatory effects QTc prolongation and ventricular"/>
   <result pre="and ventricular arrhythmias, diarrhea, nausea, abdominal pain, vomiting Hypersensitivity to" exact="azithromycin" post="or other macrolides, history of cholestatic jaundice/hepatic dysfunction associated"/>
   <result pre="other macrolides, history of cholestatic jaundice/hepatic dysfunction associated with prior" exact="azithromycin" post="use InhibitsÂ P-gp/ABCB1 Elderly patients may be more susceptible"/>
   <result pre="be more susceptible to development of Torsades de pointes arrhythmias" exact="Hydroxychloroquine" post="400Â mg bid on day 1, then 200Â mg"/>
   <result pre="component of the formulation CYP2D6, CYP2C8, CYP3A4, CYP3A5 Coadministration of" exact="chloroquine" post="phosphate or hydroxychloroquine sulfate and remdesivir may result in"/>
   <result pre="formulation CYP2D6, CYP2C8, CYP3A4, CYP3A5 Coadministration of chloroquine phosphate or" exact="hydroxychloroquine" post="sulfate and remdesivir may result in reduced antiviral activity"/>
   <result pre="with renal or hepatic function ACEi angiotensin-converting enzyme inhibitors, ALT" exact="alanine" post="aminotransferase, ARB angiotensin II receptor blockers, AST aminotransferase, bid"/>
   <result pre="for the treatment of COVID-19. Recent studies have demonstrated that" exact="hydroxychloroquine" post="and chloroquine may not be effective in treating COVID-19,"/>
   <result pre="treatment of COVID-19. Recent studies have demonstrated that hydroxychloroquine and" exact="chloroquine" post="may not be effective in treating COVID-19, and the"/>
   <result pre="do not outweigh their known and potential risks. However, low-dose" exact="dexamethasone" post="(6Â mg once daily, orally or intravenously, for 10Â"/>
   <result pre="anti-inflammatory and immunosuppressive activity of ruxolitinibFront Oncol20199118610.3389/fonc.2019.0118631788449 35.GaspariVZengariniCGrecoSVangeliVMastroianniASide effects of" exact="ruxolitinib" post="in patients with SARS-CoV-2 infection: two case reportsInt J"/>
   <result pre="Rev202019710255410.1016/j.autrev.2020.10255432380316 69.SooYOChengYWongRet al.Retrospective comparison of convalescent plasma with continuing high-dose" exact="methylprednisolone" post="treatment in SARS patientsClin Microbiol Infect200410767667810.1111/j.1469-0691.2004.00956.x15214887 70.ArabiYBalkhyHHajeerAHet al.Feasibility, safety,"/>
   <result pre="asked questions and answers. https://www.cdc.gov/coronavirus/2019-ncov/hcp/faq.html. Accessed 7 Apr 2020. 97.Low-cost" exact="dexamethasone" post="reduces death by up to one third in hospitalised"/>
   <result pre="2020;15(4):e0231911]PLoS ONE2020152e022839110.1371/journal.pone.022839132084142 106.HungIFLungKCTsoEYet al.Triple combination of interferon beta-1b, lopinavirâ€&quot;ritonavir, and" exact="ribavirin" post="in the treatment of patients admitted to hospital with"/>
   <result pre="meta-analysis of randomized controlled trialsMicrobiol Immunol20196334334910.1111/1348-0421.12726)31283028 129.KawamuraKIchikadoKTakakiMet al.Adjunctive therapy with" exact="azithromycin" post="for moderate and severe acute respiratory distress syndrome: a"/>
   <result pre="symptoms reliefExpert Rev Respir Med202014553354110.1080/17476348.2020.173018032053044 134.SchoglerAKopfBSEdwardsMRet al.Novel antiviral properties of" exact="azithromycin" post="in cystic fibrosis airway epithelial cellsEur Respir J20154542843910.1183/09031936.0010201425359346 135.LeeNWongCKChanMCWet"/>
   <result pre="J Med2012366201881189010.1056/NEJMoa100383322591294 137.DevauxCARolainJMColsonPet al.New insights on the antiviral effects of" exact="chloroquine" post="against coronavirus: what to expect for COVID-19?Int J Antimicrob"/>
   <result pre="vitro antiviral activity and projection of optimized dosing design of" exact="hydroxychloroquine" post="for the treatment of severe acute respiratory syndrome coronavirus"/>
   <result pre="(SARS-CoV-2)Clin Infect Dis202010.1093/cid/ciaa23732613227 139.SahraeiZShabaniMShokouhiSet al.Aminoquinolines against coronavirus disease 2019 (COVID-19):" exact="chloroquine" post="or hydroxychloroquineInt J Antimicrob Agents202055410594510.1016/j.ijantimicag.2020.10594532194152 140.ZhouDDaiSMTongQCOVID-19: a recommendation to"/>
   <result pre="Antimicrob Agents202055410594510.1016/j.ijantimicag.2020.10594532194152 140.ZhouDDaiSMTongQCOVID-19: a recommendation to examine the effect of" exact="hydroxychloroquine" post="in preventing infection and progressionJ Antimicrob Chemother20207571667167010.1093/jac/dkaa11432196083 141.Ben-ZviIKivitySLangevitzPShoenfeldYHydroxychloroquine: from"/>
   <result pre="coronavirus disease 19 (COVID-19)Mayo Clin Proc202010.1016/j.mayocp.2020.03.02432359771 145.GelerisJSunYPlattJet al.Observational study of" exact="hydroxychloroquine" post="in hospitalized patients with covid-19N Engl J Med2020382252411241810.1056/NEJMoa201241032379955 146.BoulwareDRPullenMFBangdiwalaASet"/>
   <result pre="with covid-19N Engl J Med2020382252411241810.1056/NEJMoa201241032379955 146.BoulwareDRPullenMFBangdiwalaASet al.A randomized trial of" exact="hydroxychloroquine" post="as postexposure prophylaxis for covid-19N Engl J Med.202010.1056/NEJMoa201663832492293 147.Letter"/>
   <result pre="prophylaxis for covid-19N Engl J Med.202010.1056/NEJMoa201663832492293 147.Letter revoking EUA for" exact="chloroquine" post="phosphate and hydroxychloroquine sulfate. 2020. https://www.fda.gov/media/138945/download. Accessed 20 Jun"/>
   <result pre="Engl J Med.202010.1056/NEJMoa201663832492293 147.Letter revoking EUA for chloroquine phosphate and" exact="hydroxychloroquine" post="sulfate. 2020. https://www.fda.gov/media/138945/download. Accessed 20 Jun 2020. 148.Low-cost dexamethasone"/>
   <result pre="and hydroxychloroquine sulfate. 2020. https://www.fda.gov/media/138945/download. Accessed 20 Jun 2020. 148.Low-cost" exact="dexamethasone" post="reduces death by up to one third in hospitalised"/>
   <result pre="Jun 2020. 150.BorbaMGSValFFASampaioVSet al.Effect of high vs low doses of" exact="chloroquine" post="diphosphate as adjunctive therapy for patients hospitalized with severe"/>
   <result pre="an anti-inflammatory and cardioprotective agentExpert Opin Drug Metab Toxicol201511111781179410.1517/17425255.2015.107639126239119 153.GendelmanOAmitalHBragazziNLWatadAChodickGContinuous" exact="hydroxychloroquine" post="or colchicine therapy does not prevent infection with SARS-CoV-2:"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7374000\results\search\drug\results.xml">
   <result pre="cells, as they can be considered host cellâ€&quot;originating substitutes including" exact="cortisol" post="and serum IgG [62]. The beneficial effects of corticosteroid"/>
   <result pre="as tuberculous meningitis and typhoid fever, are well known. Furthermore," exact="methylprednisolone" post="pulse therapy (30 mg/kg/day or 1 g/day for adults)"/>
   <result pre="cell physiology and diseaseAm J Physiol Cell Physiol2018314C2112729118026 56DaniJANeuronal nicotinic" exact="acetylcholine" post="receptor structure and function and response to nicotineInt Rev"/>
   <result pre="pneumonia caused by 2009 H1N1 influenza virusCrit Care20111541321457512 105LeeKYLeeHSHongJHLeeMHLeeJSBurgnerDLeeBCRole of" exact="prednisolone" post="treatment in severe Mycoplasma pneumoniae pneumonia in childrenPediatr Pulmonol200641263816437541"/>
   <result pre="a systematic review of the literatureFront Med (Lausanne)2020717032391369 114BlumCANigroNBrielMSchuetzPUllmerESuter-WidmerIet al.Adjunct" exact="prednisone" post="therapy for patients with community-acquired pneumonia: a multicentre, double-blind,"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7375387\results\search\drug\results.xml">
   <result pre="basic biology but also antiviral drug development, including that of" exact="chloroquine" post="(12â€&quot;14, 20). Here, we sought to verify whether HAE"/>
   <result pre="heat-inactivated fetal bovine serum (FBS; Thermo Fisher Scientific, Poland) and" exact="streptomycin" post="(100â€‰Î¼g/ml), penicillin (100 U/ml), and ciprofloxacin (5â€‰Î¼g/ml). A549_ACE2+ cell"/>
   <result pre="Fisher Scientific, Poland) and streptomycin (100â€‰Î¼g/ml), penicillin (100 U/ml), and" exact="ciprofloxacin" post="(5â€‰Î¼g/ml). A549_ACE2+ cell cultures were supplemented with G418 (5â€‰mg/ml;"/>
   <result pre="h. The supernatant was discarded, and cells were stained with" exact="crystal violet" post="to visualize the plaques. RNA fluorescent in situ hybridization"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7376323\results\search\drug\results.xml">
   <result pre="medical history included syphilis, which was cured. The ART is" exact="Efavirenz" post="600Â mg, Zidovudine 300Â mg, and Lamivudine 150Â mg."/>
   <result pre="syphilis, which was cured. The ART is Efavirenz 600Â mg," exact="Zidovudine" post="300Â mg, and Lamivudine 150Â mg. After that, she"/>
   <result pre="The ART is Efavirenz 600Â mg, Zidovudine 300Â mg, and" exact="Lamivudine" post="150Â mg. After that, she continued the ART regularly."/>
   <result pre="and traditional Chinese medicine to interferon atomization (5 million bid)," exact="ribavirin" post="(150Â mg TID), and abidol (200Â mg TID) for"/>
   <result pre="specific antiviral drugs for SARS-CoV-2. This patient was treated with" exact="ribavirin" post="and abidol, which may not inhibit the replication of"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7376974\results\search\drug\results.xml">
   <result pre="to silver ions present in solution, the antiviral activity of" exact="silver sulfadiazine" post="(AgSD) and silver nitrate (known antibacterial silver salts) was"/>
   <result pre="silver ions present in solution, the antiviral activity of silver" exact="sulfadiazine" post="(AgSD) and silver nitrate (known antibacterial silver salts) was"/>
   <result pre="Oseltamivir inhibition of the activity of neuraminidase and hemagglutinin (34)" exact="Amantadine" post="(35) Zanamivir (36) inhibition of accumulation of reactive oxygen"/>
   <result pre="of the activity of neuraminidase and hemagglutinin (34) Amantadine (35)" exact="Zanamivir" post="(36) inhibition of accumulation of reactive oxygen species (ROS)"/>
   <result pre="Zhu et al. prepared AgNPs surface-modified with oseltamivir, amantadine, and" exact="zanamivir" post="(Ag@OTV,34 Ag@AM,35 and Ag@ZNV36), by chemical methods. The results"/>
   <result pre="acid derivatives) were explored. C60 functionalized with aminobutyric acid and" exact="aminocaproic acid" post="was able to inhibit HIV viral replication at subnanomolar"/>
   <result pre="ox-CNTs functionalized with cyclodextrin were used for the delivery of" exact="acyclovir" post="(a prodrug inhibitor of the viral DNA polymerases) for"/>
   <result pre="for the treatment of HSV-1. Preliminary results showed that when" exact="acyclovir" post="was delivered via the nanotubes, the viral antireplicative effect"/>
   <result pre="herpes virus using cyclodextrin and PEI-functionalized CNTs for co-delivery of" exact="cidofovir" post="and plasmid DNA. However, the antiviral effect of the"/>
   <result pre="satisfactory.111 Functionalized CNTs have been also used for delivery of" exact="ribavirin" post="in vivo using grass carp as an animal model"/>
   <result pre="ox-CNTs were first functionalized via amidation with BSA, and then" exact="ribavirin" post="was covalently bound to the protein via esterification (Figure"/>
   <result pre="of mice with influenza A decreased the concentration of lung" exact="glutathione" post="and the antioxidant vitamin C, providing evidence that the"/>
   <result pre="A decreased the concentration of lung glutathione and the antioxidant" exact="vitamin C," post="providing evidence that the viral infection was associated with"/>
   <result pre="applied for the treatment of H1N1 virus. Notably, SeNPs with" exact="ribavirin" post="(administered via intranasal absorption every 24 h for 3"/>
   <result pre="Figure 13 In vivo antiviral efficiency of SeNPs functionalized with" exact="ribavirin" post="(Se@RBV). (a) Mice infected by H1N1 virus were treated"/>
   <result pre="ZhuB.; LiuG. L.; LingF.; WangG. X.Carbon Nanotube-Based Nanocarrier Loaded with" exact="Ribavirin" post="against Grass Carp Reovirus. Antiviral Res.2015, 118, 29â€&quot;38. 10.1016/j.antiviral.2015.03.006.25796971"/>
   <result pre="of H1N1 Influenza Virus Infection by Selenium Nanoparticles Loaded with" exact="Ribavirin" post="via Resisting Caspase-3 Apoptotic Pathway. Int. J. Nanomed.2018, 13,"/>
   <result pre="ZhuB.Inhibition of H1N1 Influenza Virus by Selenium Nanoparticles Loaded with" exact="Zanamivir" post="through P38 and JNK Signaling Pathways. RSC Adv.2017, 7,"/>
   <result pre="of H1N1 Influenza Virus-Induced Apoptosis by Functionalized Selenium Nanoparticles with" exact="Amantadine" post="through ROS-Mediated AKT Signaling Pathways. Int. J. Nanomed.2018, 13,"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7377207\results\search\drug\results.xml">
   <result pre="and detoxification by Chinese medicine [33]. Clinical trials have demonstrated" exact="Chloroquine" post="was proved to be effective in the control and"/>
   <result pre="associated with shorter time-to-viral-clearance (median 4 versus 11â€‰days, Pâ€‰ 44]." exact="Chloroquine" post="and Hydroxychloroquine Chloroquine (CQ) is a drug that widely"/>
   <result pre="shorter time-to-viral-clearance (median 4 versus 11â€‰days, Pâ€‰ 44]. Chloroquine and" exact="Hydroxychloroquine" post="Chloroquine (CQ) is a drug that widely used against"/>
   <result pre="time-to-viral-clearance (median 4 versus 11â€‰days, Pâ€‰ 44]. Chloroquine and Hydroxychloroquine" exact="Chloroquine" post="(CQ) is a drug that widely used against malaria"/>
   <result pre="drug has an antiviral potential [46]. The function mechanism of" exact="Chloroquine" post="is increasing the endosomal pH. With a pH higher"/>
   <result pre="receptors of sars-cov-2 which bind to their targets [47]. Therefore," exact="Chloroquine" post="can inhibit a pre-entry step of the viral cycle"/>
   <result pre="out by a Chinese researchers group about the efficiency of" exact="chloroquine" post="in in-vitro studies, using Vero E6 cells infected by"/>
   <result pre="by SARS-CoV-2 at a multiplicity of infection (MOI) of 0.05," exact="Chloroquine" post="was highly effective in decreasing viral replication and it"/>
   <result pre="concentration (CC50) larger than 100â€‰Î¼M) [49]. Another article indicated that" exact="Chloroquine" post="can inhibit in-vitro replication of HCoV-229E in epithelial lung"/>
   <result pre="effective against Middle East respiratory syndrome coronavirus (MERS-CoV) in-vitro [52]." exact="Hydroxychloroquine" post="(HCQ) with a very similar chemical structure to Chloroquine"/>
   <result pre="[52]. Hydroxychloroquine (HCQ) with a very similar chemical structure to" exact="Chloroquine" post="is one of the disease-modifying antirheumatic drugs that use"/>
   <result pre="capacity which prevents inflammation flare-ups and organ damage [53]. Both" exact="Chloroquine" post="and Hydroxychloroquine can raise the intracellular pH and inhibit"/>
   <result pre="prevents inflammation flare-ups and organ damage [53]. Both Chloroquine and" exact="Hydroxychloroquine" post="can raise the intracellular pH and inhibit the fusion"/>
   <result pre="antiviral outcomes [54]. In one case, the pharmacological activity of" exact="chloroquine" post="and hydroxychloroquine was checked out, the Vero cells were"/>
   <result pre="[54]. In one case, the pharmacological activity of chloroquine and" exact="hydroxychloroquine" post="was checked out, the Vero cells were infected with"/>
   <result pre="checked out, the Vero cells were infected with SARS-CoV-2 and" exact="Hydroxychloroquine" post="(EC50â€‰=â€‰0.72â€‰Î¼M) was found to be more potent than chloroquine"/>
   <result pre="and Hydroxychloroquine (EC50â€‰=â€‰0.72â€‰Î¼M) was found to be more potent than" exact="chloroquine" post="(EC50â€‰=â€‰5.47â€‰Î¼M) in-vitro because of smaller EC value [55]. On"/>
   <result pre="â€˜We have concluded that there is no beneficial effect of" exact="hydroxychloroquine" post="in patients hospitalized with COVID-19. We have therefore decided"/>
   <result pre="We have therefore decided to stop enrolling participants to the" exact="hydroxychloroquine" post="arm of the RECOVERY Trial with immediate effect. We"/>
   <result pre="public health. â€˜A total of 1542 patients were randomized to" exact="Hydroxychloroquine" post="and compared with 3132 patients randomized to usual care"/>
   <result pre="significant difference in the primary endpoint of 28-day mortality (25.7%" exact="Hydroxychloroquine" post="vs. 23.5% usual care; hazard ratio 1.11 [95% confidence"/>
   <result pre="available as soon as possible [56]. Remdesivir Remdesivir is an" exact="adenosine" post="nucleotide analog that is similar to tenofovir alafenamide -"/>
   <result pre="Remdesivir is an adenosine nucleotide analog that is similar to" exact="tenofovir alafenamide" post="- a nucleotide analog of adenosine 5-monophosphate - with"/>
   <result pre="is similar to tenofovir alafenamide - a nucleotide analog of" exact="adenosine" post="5-monophosphate - with antiviral activity against hepatitis B virus,"/>
   <result pre="analysis from the oropharyngeal swab was negative for SARS-CoV-2 [59]." exact="Ribavirin" post="Ribavirin is a nucleotides derivative competing with physiological nucleotide"/>
   <result pre="from the oropharyngeal swab was negative for SARS-CoV-2 [59]. Ribavirin" exact="Ribavirin" post="is a nucleotides derivative competing with physiological nucleotide for"/>
   <result pre="[60, 61]. Through the outbreak of SARS in Hong Kong," exact="ribavirin" post="was widely used for patients with or without the"/>
   <result pre="simultaneous use of steroids [62]. The EC50 against COVID-19 for" exact="Ribavirin" post="determined at 109.5â€‰Î¼M [63]. Based on previous studies about"/>
   <result pre="on previous studies about SARS and MERS, the combination of" exact="ribavirin" post="and IFN-Î², decreases the viral replication and disease severity"/>
   <result pre="models [64]. Due to unfavorable reactions, the proper dose of" exact="ribavirin" post="in the clinical application should be given carefully. Losartan"/>
   <result pre="in December 2019. Angiotensin receptor blockers (i.e., AT1R), like losartan," exact="olmesartan" post="and valsartan can inhibit Ang II-mediated vasoconstriction. Besides, aldosterone"/>
   <result pre="2019. Angiotensin receptor blockers (i.e., AT1R), like losartan, olmesartan and" exact="valsartan" post="can inhibit Ang II-mediated vasoconstriction. Besides, aldosterone inhibitors (e.g.,"/>
   <result pre="lopinavir, and interferon to non-ICU patients and the addition of" exact="methylprednisolone" post="to the above treatment for ICU patients resulted in"/>
   <result pre="the previous coronavirus such as SARS-CoV infections [72]. Lopinavir â€&quot;" exact="Ritonavir" post="Three anti-HIV drugs, ritonavir, lopinavir, and darunavir, might have"/>
   <result pre="2019 (COVID-19). It is implied that the therapeutic effect of" exact="ritonavir" post="and lopinavir on COVID-19 may be largely due to"/>
   <result pre="It is implied that the therapeutic effect of ritonavir and" exact="lopinavir" post="on COVID-19 may be largely due to their inhibitory"/>
   <result pre="to their inhibitory impact on CEP_C30 (coronavirus endopeptidase C30), while" exact="ritonavir" post="may have greater ability; the inhibitory impact of darunavir"/>
   <result pre="(CYP3A) isoenzyme in the liver. It is always used with" exact="ritonavir" post="to reduce the dose of lopinavir and enhance the"/>
   <result pre="is always used with ritonavir to reduce the dose of" exact="lopinavir" post="and enhance the plasma levels of lopinavir as ritonavir"/>
   <result pre="the dose of lopinavir and enhance the plasma levels of" exact="lopinavir" post="as ritonavir inhibits CYP3A isoenzyme. Lopinavir and ritonavir are"/>
   <result pre="of lopinavir and enhance the plasma levels of lopinavir as" exact="ritonavir" post="inhibits CYP3A isoenzyme. Lopinavir and ritonavir are antiretroviral protease"/>
   <result pre="levels of lopinavir as ritonavir inhibits CYP3A isoenzyme. Lopinavir and" exact="ritonavir" post="are antiretroviral protease inhibitors used in combination as a"/>
   <result pre="studies Table 5 Interaction between drugs [87] Therapy Specific interaction" exact="Ribavirin" post="-Anticoagulants Warfarin Lopinavir/Ritonavir -Anticoagulants Apixaban Rivaroxaban -Antiplatelets Clopidogrel Ticagrelor"/>
   <result pre="5 Interaction between drugs [87] Therapy Specific interaction Ribavirin -Anticoagulants" exact="Warfarin" post="Lopinavir/Ritonavir -Anticoagulants Apixaban Rivaroxaban -Antiplatelets Clopidogrel Ticagrelor -Statin Atorvastatin"/>
   <result pre="drugs [87] Therapy Specific interaction Ribavirin -Anticoagulants Warfarin Lopinavir/Ritonavir -Anticoagulants" exact="Apixaban" post="Rivaroxaban -Antiplatelets Clopidogrel Ticagrelor -Statin Atorvastatin Rosuvastatin Lovastatin Simvastatin"/>
   <result pre="[87] Therapy Specific interaction Ribavirin -Anticoagulants Warfarin Lopinavir/Ritonavir -Anticoagulants Apixaban" exact="Rivaroxaban" post="-Antiplatelets Clopidogrel Ticagrelor -Statin Atorvastatin Rosuvastatin Lovastatin Simvastatin -Antiarrhythmics"/>
   <result pre="Specific interaction Ribavirin -Anticoagulants Warfarin Lopinavir/Ritonavir -Anticoagulants Apixaban Rivaroxaban -Antiplatelets" exact="Clopidogrel" post="Ticagrelor -Statin Atorvastatin Rosuvastatin Lovastatin Simvastatin -Antiarrhythmics QT-prolonging medication"/>
   <result pre="interaction Ribavirin -Anticoagulants Warfarin Lopinavir/Ritonavir -Anticoagulants Apixaban Rivaroxaban -Antiplatelets Clopidogrel" exact="Ticagrelor" post="-Statin Atorvastatin Rosuvastatin Lovastatin Simvastatin -Antiarrhythmics QT-prolonging medication Digoxin"/>
   <result pre="Lopinavir/Ritonavir -Anticoagulants Apixaban Rivaroxaban -Antiplatelets Clopidogrel Ticagrelor -Statin Atorvastatin Rosuvastatin" exact="Lovastatin" post="Simvastatin -Antiarrhythmics QT-prolonging medication Digoxin Chloroquine/Hydroxychloroquine -Beta-blockers Metoprolol, carvedilol,"/>
   <result pre="-Anticoagulants Apixaban Rivaroxaban -Antiplatelets Clopidogrel Ticagrelor -Statin Atorvastatin Rosuvastatin Lovastatin" exact="Simvastatin" post="-Antiarrhythmics QT-prolonging medication Digoxin Chloroquine/Hydroxychloroquine -Beta-blockers Metoprolol, carvedilol, propranolol,"/>
   <result pre="Clopidogrel Ticagrelor -Statin Atorvastatin Rosuvastatin Lovastatin Simvastatin -Antiarrhythmics QT-prolonging medication" exact="Digoxin" post="Chloroquine/Hydroxychloroquine -Beta-blockers Metoprolol, carvedilol, propranolol, labetalol -Antiarrhythmics QT-prolonging agents"/>
   <result pre="Simvastatin -Antiarrhythmics QT-prolonging medication Digoxin Chloroquine/Hydroxychloroquine -Beta-blockers Metoprolol, carvedilol, propranolol," exact="labetalol" post="-Antiarrhythmics QT-prolonging agents Digoxin Additionally, itâ€™s noted that Hydroxychloroquine"/>
   <result pre="Digoxin Chloroquine/Hydroxychloroquine -Beta-blockers Metoprolol, carvedilol, propranolol, labetalol -Antiarrhythmics QT-prolonging agents" exact="Digoxin" post="Additionally, itâ€™s noted that Hydroxychloroquine consumption is better than"/>
   <result pre="propranolol, labetalol -Antiarrhythmics QT-prolonging agents Digoxin Additionally, itâ€™s noted that" exact="Hydroxychloroquine" post="consumption is better than chloroquine (during long-term use) due"/>
   <result pre="Digoxin Additionally, itâ€™s noted that Hydroxychloroquine consumption is better than" exact="chloroquine" post="(during long-term use) due to its fewer side effects."/>
   <result pre="severe disease classification Critical Critical Critical Critical Critical Treatments â€ƒSteroids" exact="Methylprednisolone" post="Methylprednisolone Methylprednisolone Methylprednisolone Methylprednisolone â€ƒAntivirals Lopinavir/ritonavir; Interferon alfa-1b; favipiravir"/>
   <result pre="disease classification Critical Critical Critical Critical Critical Treatments â€ƒSteroids Methylprednisolone" exact="Methylprednisolone" post="Methylprednisolone Methylprednisolone Methylprednisolone â€ƒAntivirals Lopinavir/ritonavir; Interferon alfa-1b; favipiravir Lopinavir/ritonavir;"/>
   <result pre="classification Critical Critical Critical Critical Critical Treatments â€ƒSteroids Methylprednisolone Methylprednisolone" exact="Methylprednisolone" post="Methylprednisolone Methylprednisolone â€ƒAntivirals Lopinavir/ritonavir; Interferon alfa-1b; favipiravir Lopinavir/ritonavir; Arbidol;"/>
   <result pre="Critical Critical Critical Critical Critical Treatments â€ƒSteroids Methylprednisolone Methylprednisolone Methylprednisolone" exact="Methylprednisolone" post="Methylprednisolone â€ƒAntivirals Lopinavir/ritonavir; Interferon alfa-1b; favipiravir Lopinavir/ritonavir; Arbidol; darunavir"/>
   <result pre="Critical Critical Critical Critical Treatments â€ƒSteroids Methylprednisolone Methylprednisolone Methylprednisolone Methylprednisolone" exact="Methylprednisolone" post="â€ƒAntivirals Lopinavir/ritonavir; Interferon alfa-1b; favipiravir Lopinavir/ritonavir; Arbidol; darunavir Lopinavir/ritonavir;"/>
   <result pre="that in cell culture soluble ACE2 fused to Ig or" exact="camostat" post="mesylate which is a nonspecific protease inhibitor can inhibit"/>
   <result pre="Pseudovirus bearing the S protein of SARS-CoV-2. High doses of" exact="camostat" post="mesylate were indicated to partially reduce SARS-CoV-2 growth [123]."/>
   <result pre="Ribonucleic Acid DNA Deoxyribonucleic Acid WHO World Health Organization CQ" exact="Chloroquine" post="MOI Multiplicity of Infection EC50 half-maximal Effective Concentration CC50"/>
   <result pre="of Infection EC50 half-maximal Effective Concentration CC50 Half-Cytotoxic Concentration HCQ" exact="Hydroxychloroquine" post="HIV Human Immunodeficiency Viruses RAAS Renin-Angiotensin-Aldosterone System AT1R Angiotensin"/>
   <result pre="version)Military Med Res2020714 34.Gao J, Tian Z, Yang X. Breakthrough:" exact="Chloroquine" post="phosphate has shown apparent efficacy in treatment of COVID-19"/>
   <result pre="2 and its inhibition by the antimalarial quinolinesBiochemistry200443154538454715078100 49.WangMCaoRZhangLYangXLiuJXuMShiZHuZZhongWXiaoGRemdesivir and" exact="chloroquine" post="effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in"/>
   <result pre="2010 Jan 1;69(01):20â€&quot;8.doi: 10.1136/ard.2008.101766. 54.Fox RI. Mechanism of action of" exact="hydroxychloroquine" post="as an antirheumatic drug. In Seminars in arthritis and"/>
   <result pre="vitro antiviral activity and projection of optimized dosing design of" exact="hydroxychloroquine" post="for the treatment of severe acute respiratory syndrome coronavirus"/>
   <result pre="activity of the IMP dehydrogenase inhibitor VX-497: a comparison with" exact="ribavirin" post="and demonstration of antiviral additivity with alpha interferon. Antimicrob"/>
   <result pre="a comparison with ribavirin and demonstration of antiviral additivity with" exact="alpha" post="interferon. Antimicrob Agents Chemother. 2000;44(4):859â€&quot;66. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC89783/. 64.KimUJWonEJKeeSJJungSIJangHCCase report combination"/>
   <result pre="Agents Chemother. 2000;44(4):859â€&quot;66. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC89783/. 64.KimUJWonEJKeeSJJungSIJangHCCase report combination therapy with lopinavir/ritonavir," exact="ribavirin" post="and interferon-Î± for Middle East respiratory syndromeAntivir Ther20162145545910.3851/IMP300226492219 65.ZeinalianMSalari-JaziAJannesariAKhanahmadHA"/>
   <result pre="preprint arXiv:2003.00751. 2020 Mar 2.doi: 10.1159/000508278. 71.Frie K, Gbinigie K." exact="Chloroquine" post="and hydroxychloroquine: current evidence for their effectiveness in treating"/>
   <result pre="X. Molecular modeling evaluation of the binding effect of ritonavir," exact="lopinavir" post="and darunavir to severe acute respiratory syndrome coronavirus 2"/>
   <result pre="with severe 2009 influenza A (H1N1) infectionChest2013144246447323450336 78.Day M. Covid-19:" exact="ibuprofen" post="should not be used for managing symptoms, say doctors"/>
   <result pre="Courjon J, Giordanengo V, Vieira VE, Dupont HT, HonorÃ© S." exact="Hydroxychloroquine" post="and azithromycin as a treatment of COVID-19: results of"/>
   <result pre="Giordanengo V, Vieira VE, Dupont HT, HonorÃ© S. Hydroxychloroquine and" exact="azithromycin" post="as a treatment of COVID-19: results of an open-label"/>
   <result pre="20:105949.doi: 10.1016/j.ijantimicag.2020.105949. 89.SooYOChengYWongRHuiDSLeeCKTsangKKNgMHChanPChengGSungJJRetrospective comparison of convalescent plasma with continuing high-dose" exact="methylprednisolone" post="treatment in SARS patientsClin Microbiol Infect200410767667815214887 90.LaiSTTreatment of severe"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7380217\results\search\drug\results.xml">
   <result pre="loss prevention strategies (eg, minimizing blood draws or treatment with" exact="tranexamic acid" post="if clinically permissible) should be maximized [10]. The use"/>
   <result pre="15, 2020, the US Food and Drug Administration (FDA) revoked" exact="chloroquine" post="and hydroxychloroquine's emergency use authorization in response to the"/>
   <result pre="and other potential serious side effects, the potential benefits of" exact="chloroquine" post="and hydroxychloroquine do not outweigh the risks of their"/>
   <result pre="potential serious side effects, the potential benefits of chloroquine and" exact="hydroxychloroquine" post="do not outweigh the risks of their use. The"/>
   <result pre="Agents that likely will not work, according to the literature" exact="Azithromycin" post="Tested in a French trial and found to reinforce"/>
   <result pre="French trial and found to reinforce the positive effect of" exact="hydroxychloroquine" post="on the COVID-19 viral load [41]. Used as a"/>
   <result pre="enhanced if used concurrently with full-dose azithromycin, chloroquine, or both." exact="Chloroquine" post="and hydroxychloroquine Best evidence thus far has failed to"/>
   <result pre="used concurrently with full-dose azithromycin, chloroquine, or both. Chloroquine and" exact="hydroxychloroquine" post="Best evidence thus far has failed to demonstrate benefit"/>
   <result pre="no benefit and association with higher mortality in patients receiving" exact="hydroxychloroquine" post="[43]. Other studies have shown no benefit and potential"/>
   <result pre="arrhythmias 44, 45, 46, 47. Concerns about increased toxicity with" exact="cyclosporine" post="and imatinib (used in chronic GVHD), such as myopathies."/>
   <result pre="45, 46, 47. Concerns about increased toxicity with cyclosporine and" exact="imatinib" post="(used in chronic GVHD), such as myopathies. Agents that"/>
   <result pre="Castleman's disease Use only in the context of clinical trials." exact="Ruxolitinib" post="Possible role in hemophagocytic lymphohistiocytosis due to COVID-19 (trials"/>
   <result pre="patients; thus, cautious use in clinical trials only is recommended." exact="Ibrutinib" post="Reported as perhaps beneficial for COVID-19 in a retrospective"/>
   <result pre="the reported study were already on ibrutinib. Caution against using" exact="ibrutinib" post="solely for COVID-19 infection in HCT recipients until trial"/>
   <result pre="on in ARDS due to COVID-19 Interactions with other drugs" exact="Voriconazole" post="and posaconazole No known role in COVID-19 Commonly used"/>
   <result pre="ARDS due to COVID-19 Interactions with other drugs Voriconazole and" exact="posaconazole" post="No known role in COVID-19 Commonly used in GVHD."/>
   <result pre="posaconazole No known role in COVID-19 Commonly used in GVHD." exact="Azithromycin" post="interaction with the CYP3A4 inducers. CAR T cells (cryopreserved"/>
   <result pre="COVID-2019 infectionClin Chem Lab Med5820201131113432119647 17Principi N, Esposito S.Chloroquine or" exact="hydroxychloroquine" post="for prophylaxis of COVID-19 [e-pub ahead of print]. Lancet"/>
   <result pre="2020. 18CortegianiAIngogliaGIppolitoMGiarratanoAEinavS.A systematic review on the efficacy and safety of" exact="chloroquine" post="for the treatment of COVID-19J Crit Care57202027928332173110 19ZhangLZhuFXieLClinical characteristics"/>
   <result pre="therapy in severe COVID-19 patients: a pilot studymedRxiv202003.16.20036145 41GautretPLagierJCParolaPHydroxychloroquine and" exact="azithromycin" post="as a treatment of COVID-19: results of an open-label"/>
   <result pre="an open-label non-randomized clinical trialInt J Antimicrob Agents562020105949 42ChenZHuJZhangZEfficacy of" exact="hydroxychloroquine" post="in patients with COVID-19: results of a randomized clinical"/>
   <result pre="with COVID-19: results of a randomized clinical trialmedRxiv202003.22.20040758 43MagagnoliJNarendranSPereiraFOutcomes of" exact="hydroxychloroquine" post="usage in United States veterans hospitalized with COVID-19medRxiv202004.16.20065920 44GelerisJSunYPlattJObservational"/>
   <result pre="in United States veterans hospitalized with COVID-19medRxiv202004.16.20065920 44GelerisJSunYPlattJObservational study of" exact="hydroxychloroquine" post="in hospitalized patients with Covid-19N Engl J Med38220202411241832379955 45RosenbergESDufortEMUdoTAssociation"/>
   <result pre="patients with Covid-19N Engl J Med38220202411241832379955 45RosenbergESDufortEMUdoTAssociation of treatment with" exact="hydroxychloroquine" post="or azithromycin with in-hospital mortality in patients with COVID-19"/>
   <result pre="Covid-19N Engl J Med38220202411241832379955 45RosenbergESDufortEMUdoTAssociation of treatment with hydroxychloroquine or" exact="azithromycin" post="with in-hospital mortality in patients with COVID-19 in New"/>
   <result pre="trialBMJ3692020m184932409561 47Mehra MR, Desai SS, Ruschitzka F, Patel AN. RETRACTED:" exact="Hydroxychloroquine" post="or chloroquine with or without a macrolide for treatment"/>
   <result pre="MR, Desai SS, Ruschitzka F, Patel AN. RETRACTED: Hydroxychloroquine or" exact="chloroquine" post="with or without a macrolide for treatment of COVID-19:"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7381894\results\search\drug\results.xml">
   <result pre="the trialed antiviral drugs, remdesivir alone or in combination with" exact="chloroquine" post="or interferon beta showed effectiveness against the COVID-19 infection"/>
   <result pre="or interferon beta showed effectiveness against the COVID-19 infection [39]." exact="Chloroquine" post="efficacy against the COVID-19 may be linked with its"/>
   <result pre="world, while China based preliminary data has demonstrated benefits of" exact="chloroquine" post="in patients with pneumonia, as the drug significantly eliminatied"/>
   <result pre="Treatment of COVID-19 disease, Chinese National Health Commission [41,42]. However," exact="chloroquine" post="is also known to have toxicity and side effects"/>
   <result pre="them were reported clinically recovered [43]. Therfore, both remdesivir and" exact="chloroquine" post="should further be evaluated for their suitability against COVID-19."/>
   <result pre="of clinical trials are necessary to evaluate its effectiveness Furthermore," exact="ritonavir" post="and lopinavir are promising protease inhibitors, which have been"/>
   <result pre="trials are necessary to evaluate its effectiveness Furthermore, ritonavir and" exact="lopinavir" post="are promising protease inhibitors, which have been included in"/>
   <result pre="of anti-COVID-19 drugs. Although, earlier treatment of COVID-19 patients with" exact="ritonavir" post="and lopinavir in Wuhan, China, did not indicate sufficient"/>
   <result pre="drugs. Although, earlier treatment of COVID-19 patients with ritonavir and" exact="lopinavir" post="in Wuhan, China, did not indicate sufficient benefits of"/>
   <result pre="of circadian rhythms, sleep and healthHum Mol Genet262017R1283810.1093/hmg/ddx24028977444 39WangM.CaoR.ZhangL.YangX.LiuJ.XuM.Remdesivir and" exact="chloroquine" post="effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in"/>
   <result pre="mediated by the viral polymerase and the proofreading exoribonucleaseMBio9201811510.1128/mBio.00221-18 41GaoJ.TianZ.YangX.Breakthrough:" exact="Chloroquine" post="phosphate has shown apparent efficacy in treatment of COVID-19"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7383122\results\search\drug\results.xml">
   <result pre="Based on in vitro data and a controversial recent trial," exact="hydroxychloroquine" post="has gained widespread adoption as part of institutional protocols"/>
   <result pre="institutional protocols to manage the COVID-19 infection [49, 50]. Both" exact="chloroquine" post="and hydroxychloroquine block a potassium channel that can prolong"/>
   <result pre="to manage the COVID-19 infection [49, 50]. Both chloroquine and" exact="hydroxychloroquine" post="block a potassium channel that can prolong the QTc"/>
   <result pre="with the other currently suggested treatments including the QTc prolonging" exact="azithromycin" post="and lopinavir/ritonavir (all three medications are on CredibleMeds QTc"/>
   <result pre="Suggested COVID-19 medication Potential HF and transplant patient medication Interaction" exact="Hydroxychloroquine" post="Beta blockers Hydroxychloroquine inhibits CYP2D6 increasing beta blocker concentration"/>
   <result pre="Potential HF and transplant patient medication Interaction Hydroxychloroquine Beta blockers" exact="Hydroxychloroquine" post="inhibits CYP2D6 increasing beta blocker concentration âž&quot; monitor for"/>
   <result pre="(amiodarone, dofetilide) Higher risk of QTc prolongation and TdP Cyclosporine" exact="Hydroxychloroquine" post="may increase serum concentration of cyclosporine through unknown mechanisms"/>
   <result pre="prolongation and TdP Cyclosporine Hydroxychloroquine may increase serum concentration of" exact="cyclosporine" post="through unknown mechanisms Digoxin Hydroxychloroquine may inhibit p-glycoprotein-mediated digoxin"/>
   <result pre="Hydroxychloroquine may increase serum concentration of cyclosporine through unknown mechanisms" exact="Digoxin" post="Hydroxychloroquine may inhibit p-glycoprotein-mediated digoxin transport âž&quot; may increase"/>
   <result pre="may increase serum concentration of cyclosporine through unknown mechanisms Digoxin" exact="Hydroxychloroquine" post="may inhibit p-glycoprotein-mediated digoxin transport âž&quot; may increase digoxin"/>
   <result pre="of cyclosporine through unknown mechanisms Digoxin Hydroxychloroquine may inhibit p-glycoprotein-mediated" exact="digoxin" post="transport âž&quot; may increase digoxin concentration Lopinavir/ritonavir (Lpv/R) Antiarrhythmic"/>
   <result pre="Digoxin Hydroxychloroquine may inhibit p-glycoprotein-mediated digoxin transport âž&quot; may increase" exact="digoxin" post="concentration Lopinavir/ritonavir (Lpv/R) Antiarrhythmic medications (amiodarone, dofetilide) Lpv/R inhibits"/>
   <result pre="âž&quot; increase in antiarrhythmic concentration, side effects, and QTc prolongation" exact="Eplerenone" post="Lpv/R inhibits CYP3A4 âž&quot; increase in concentration of eplerenone"/>
   <result pre="Eplerenone Lpv/R inhibits CYP3A4 âž&quot; increase in concentration of eplerenone" exact="Ivabradine" post="Lpv/R inhibits CYP3A4 âž&quot; increase in concentration of ivabradine"/>
   <result pre="eplerenone Ivabradine Lpv/R inhibits CYP3A4 âž&quot; increase in concentration of" exact="ivabradine" post="Cyclosporine Lpv/R inhibits CYP3A4 âž&quot; increase in concentration of"/>
   <result pre="ivabradine Cyclosporine Lpv/R inhibits CYP3A4 âž&quot; increase in concentration of" exact="tacrolimus" post="Tacrolimus Lpv/R inhibits CYP3A4 âž&quot; increase in concentration of"/>
   <result pre="Cyclosporine Lpv/R inhibits CYP3A4 âž&quot; increase in concentration of tacrolimus" exact="Tacrolimus" post="Lpv/R inhibits CYP3A4 âž&quot; increase in concentration of tacrolimus"/>
   <result pre="tacrolimus Tacrolimus Lpv/R inhibits CYP3A4 âž&quot; increase in concentration of" exact="tacrolimus" post="Warfarin (VKA) Lpv/R may decrease VKA concentration through induction"/>
   <result pre="Tacrolimus Lpv/R inhibits CYP3A4 âž&quot; increase in concentration of tacrolimus" exact="Warfarin" post="(VKA) Lpv/R may decrease VKA concentration through induction of"/>
   <result pre="Lung Transplantation (ISHLT) guidelines suggest holding the immunosuppressive drugs like" exact="mycophenolate mofetil" post="or azathioprine in moderate to severe presentations of COVID-19"/>
   <result pre="guidelines suggest holding the immunosuppressive drugs like mycophenolate mofetil or" exact="azathioprine" post="in moderate to severe presentations of COVID-19 [69]. For"/>
   <result pre="mortality in Covid-19. N Engl J Med 382(25):e102. 10.1056/NEJMoa2007621 7.NgTMToewsMLImpaired" exact="norepinephrine" post="regulation of monocyte inflammatory cytokine balance in heart failureWorld"/>
   <result pre="2020. Available from: https://www.acc.org/latest-in-cardiology/articles/2020/03/17/08/59/hfsa-acc-aha-statement-addresses-concerns-re-using-raas-antagonists-in-covid-19. Accessed 27 Apr 2020 49.WangMCaoRZhangLYangXLiuJXuMShiZHuZZhongWXiaoGRemdesivir and" exact="chloroquine" post="effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in"/>
   <result pre="J, Giordanengo V, Vieira VE, Dupont HT, HonorÃ© S (2020)" exact="Hydroxychloroquine" post="and azithromycin as a treatment of COVID-19: results of"/>
   <result pre="V, Vieira VE, Dupont HT, HonorÃ© S (2020) Hydroxychloroquine and" exact="azithromycin" post="as a treatment of COVID-19: results of an open-label"/>
   <result pre="products on P-glycoprotein mediated effluxEur J Pharm Sci2006291708116846720 56.SomerMKallioJPesonenUPyykkÃ¶KHuupponenRScheininMInfluence of" exact="hydroxychloroquine" post="on the bioavailability of oral metoprololBr J Clin Pharmacol200049654955410848718"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7384729\results\search\drug\results.xml">
   <result pre="monitoring theÂ corrected QT interval (QTc) in hospitalized patients using" exact="hydroxychloroquine" post="(HCQ) and azithromycin. It is noteworthy that this drug"/>
   <result pre="of 90 hospitalized patients with COVID-19, patients taking HCQ and" exact="azithromycin" post="had greater QTÂ interval prolongation than those taking HCQ"/>
   <result pre="in 68% of the patients in the remdesivir group [28]." exact="Ribavirin" post="and lopinavir/ritonavir are also under investigation in numerous clinical"/>
   <result pre="al. Risk of QT interval prolongation associated with use of" exact="hydroxychloroquine" post="with or without concomitant azithromycin among hospitalized patients testing"/>
   <result pre="prolongation associated with use of hydroxychloroquine with or without concomitant" exact="azithromycin" post="among hospitalized patients testing positive for coronavirus disease 2019"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7385132\results\search\drug\results.xml">
   <result pre="2; SARS-CoV-2, Severe Acute Respiratory Syndrome Coronavirus 2; TMPRSS2, Transmembrane" exact="Serine" post="Protease 2. After binding to ACE2, the cellular transmembrane"/>
   <result pre="the absence of anti-inflammatory agents (see below). In some patients," exact="tacrolimus" post="reduction may be preferred over complete withdrawal (67, 69)"/>
   <result pre="showed no benefit compared to control group (87) Chloroquine/Hydroxychloroquine Â±" exact="azithromycin" post="Increases endosomal pH Not reduced risk of death in"/>
   <result pre="548 patients (93). In a retrospective study on 201 patients" exact="methylprednisolone" post="was beneficial in those with severe disease (94) IVIg"/>
   <result pre="with target membrane Not improvement in a retrospective study (99)" exact="Bromhexine" post="hydrochloride Transmembrane protease serine inhibitor Ongoing trials Danoprevir HCV"/>
   <result pre="Broad spectrum antivirals RCT proved benefit in triple therapy (101)" exact="Nitric Oxide" post="Gas Inhibits viral protein and RNA synthesis Ongoing trials"/>
   <result pre="NLRP3 inflammasome Ongoing trials Fingolimod Sphingosine-1-phosphate receptor regulator Ongoing trials" exact="Naproxen" post="Inhibitor of both COX-2 of Influenza A virus NP"/>
   <result pre="NP Ongoing trials Pirfenidone Inhibits IL-1Î² and IL-4 Ongoing trials" exact="Ruxolitinib" post="JAK 1 and JAK 2 inhibitor Ongoing trials Sarilumab"/>
   <result pre="monoclonal Ab Decrease inflammatory markers in a retrospective study (104)" exact="Thalidomide" post="Reduces TNFÎ± Ongoing trials Ulinastatin Reduces TNFÎ±, IL-6, and"/>
   <result pre="animal models (109, 110). Lopinavir is used in combination with" exact="ritonavir" post="because it increases the plasma half-life of lopinavir inhibiting"/>
   <result pre="combination with ritonavir because it increases the plasma half-life of" exact="lopinavir" post="inhibiting the cytochrome P450 (111). Despite these promising results,"/>
   <result pre="alone in the time to clinical improvement or mortality (87)." exact="Hydroxychloroquine" post="SARS-CoV-2 needs an acidic endosomal pH for processing and"/>
   <result pre="internalization (8). In vitro data indicate that the antimalarial drug" exact="chloroquine" post="exerts antiviral effects by increasing endosomal pH and abrogating"/>
   <result pre="pH and abrogating virus-endosome fusion. Antiviral effects in vivo of" exact="hydroxychloroquine" post="may be enhanced by the immune-modulating activity that this"/>
   <result pre="efficacy of hydroxychloroquine, particularly combined with azithromycin, in viral clearance." exact="Hydroxychloroquine" post="is often administered in conjunction with azithromycin, but caution"/>
   <result pre="of 62 COVID-19 positive patients (not peer-reviewed) patients treated with" exact="hydroxychloroquine" post="treatment showed an improvement in the clinical recovery and"/>
   <result pre="one observational study of 1,376 patients with COVID-19 treated with" exact="hydroxychloroquine" post="showed no difference in the risk of being intubated"/>
   <result pre="intubated or death compared to patients who did not receive" exact="hydroxychloroquine" post="(88). The quick evolution of the COVID-19 pandemic and"/>
   <result pre="Remdesivir Remdesivir has broad-spectrum antiviral activity because it is an" exact="adenosine" post="analog that can determine pre-mature termination of viral RNA"/>
   <result pre="of COVID-19. JAK-STAT Inhibitors JAK-STAT inhibitors, like baricitinib, fedratinib, and" exact="ruxolitinib" post="are potent anti-inflammatory drugs that are approved for rheumatoid"/>
   <result pre="and recommendations. Lancet Respir Med. (2020) 8:506â€&quot;17. 10.1016/S2213-2600(20)30161-232272080 34.GautretPLagierJCParolaPHoangVTMeddebLMailheMet al.." exact="Hydroxychloroquine" post="and azithromycin as a treatment of COVID-19: results of"/>
   <result pre="Lancet Respir Med. (2020) 8:506â€&quot;17. 10.1016/S2213-2600(20)30161-232272080 34.GautretPLagierJCParolaPHoangVTMeddebLMailheMet al.. Hydroxychloroquine and" exact="azithromycin" post="as a treatment of COVID-19: results of an open-label"/>
   <result pre="J Med. (2020) 382:1787â€&quot;99. 10.1056/NEJMoa200128232187464 88.GelerisJSunYPlattJZuckerJBaldwinMHripcsakGet al.. Observational study of" exact="hydroxychloroquine" post="in hospitalized patients with Covid-19. N Engl J Med."/>
   <result pre="print]. 101.HungIFNLungKCTsoEYKLiuRChungTWHChuMYet al.. Triple combination of interferon beta-1b, lopinavirâ€&quot;ritonavir, and" exact="ribavirin" post="in the treatment of patients admitted to hospital with"/>
   <result pre="(2019-nCoV). Biosci Trends. (2020) 14:69â€&quot;71. 10.5582/bst.2020.0102031996494 112.WangMCaoRZhangLYangXLiuJXuMet al.. Remdesivir and" exact="chloroquine" post="effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in"/>
   <result pre="in vitro. Cell Res. (2020) 30:269â€&quot;71. 10.1038/s41422-020-0282-032020029 113.ChenZHuJZhangZJiangSHanSYanDet al.Efficacy of" exact="hydroxychloroquine" post="in patients with COVID-19: results of a randomized clinical"/>
   <result pre="trial. medRxiv. (2020). 10.1101/2020.03.22.20040758. [Epub ahead of print]. 114.MehraMRRuschitzkaFPatelANRetractionâ€&quot;Hydroxychloroquine or" exact="chloroquine" post="with or without a macrolide for treatment of COVID-19:"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7385229\results\search\drug\results.xml">
   <result pre="lowering pro-inflammatory cytokine production, notably IL-6 and tumor necrosis factor" exact="alpha" post="(TNFÎ±). Ang1-7 has also shown beneficial effects in inflammation"/>
   <result pre="and intubation risk during COVID-19 among elderly patients treated with" exact="nifedipine" post="or amlodipine (84), although the study sample was small"/>
   <result pre="preventing and treating metabolic syndrome. Peptides. (2014) 59:34â€&quot;41. 10.1016/j.peptides.2014.07.00225017239 84.SolaimanzadehI." exact="Nifedipine" post="and Amlodipine Are Associated With Improved Mortality and Decreased"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7388682\results\search\drug\results.xml">
   <result pre="CoVs in the fields of vaccination, diagnosis and therapy. Keywords:â€‚" exact="chloroquine" post="coronavirus COVID-19 nanomedicine remdesivir SARS-CoV-2 page-count: Based on the"/>
   <result pre="III trials [9,48,91â€&quot;95]. Additionally, guanine analogs such as favipiravir and" exact="ribavirin" post="have been tested against CoVs in combination with interferons"/>
   <result pre="against CoVs in combination with interferons [9,96,97]. The protease inhibitors" exact="lopinavir" post="and ritonavir, which inhibit viral replication through binding to"/>
   <result pre="of neutralizing antibodies, which increased significantly with adjuvants such as" exact="aluminum hydroxide" post="(15-fold) or Matrix M1 (68-fold) [1]. Adjuvants might also"/>
   <result pre="Gold NP; CAuNP: Chiroplasmonic AuNP; CoV: Coronavirus; E: Envelope; FITC:" exact="Fluorescein" post="isothiocyanate; MERS-CoV: Middle East respiratory syndrome coronavirus; MNP: Magnetic"/>
   <result pre="was amplified by RT-LAMP and the amplicons were labeled with" exact="fluorescein" post="isothiocyanate (FITC) and biotin to bind streptavidin-AuNPs conjugates forming"/>
   <result pre="and the amplicons were labeled with fluorescein isothiocyanate (FITC) and" exact="biotin" post="to bind streptavidin-AuNPs conjugates forming complex. This FITC-labeled complex"/>
   <result pre="nanomedicine against the new SARS-CoV-2. Repositioning of drugs, such as" exact="chloroquine" post="and remdesivir, is a rapid process to reach safe"/>
   <result pre="Medical Institute. Antiviral agents Repositioned drugs such as remdesivir, favipiravir," exact="ribavirin" post="and chloroquine have been tested clinically against COVID-19. Nanomedicine"/>
   <result pre="Antiviral agents Repositioned drugs such as remdesivir, favipiravir, ribavirin and" exact="chloroquine" post="have been tested clinically against COVID-19. Nanomedicine &amp;amp; CoVs"/>
   <result pre="Acta186(4), 224 (2019).30847572 9.WangM , CaoR , ZhangLet al.Remdesivir and" exact="chloroquine" post="effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in"/>
   <result pre="1787â€&quot;1799 (2020).32187464 101.HuTY , FriemanM , WolframJInsights from nanomedicine into" exact="chloroquine" post="efficacy against COVID-19. Nat. Nanotechnol.15(4), 247â€&quot;249 (2020).32203437 102.GaoJ ,"/>
   <result pre="COVID-19. Nat. Nanotechnol.15(4), 247â€&quot;249 (2020).32203437 102.GaoJ , TianZ , YangXBreakthrough:" exact="chloroquine" post="phosphate has shown apparent efficacy in treatment of COVID-19"/>
   <result pre="Dis.6(2), 67â€&quot;69 (2006).16439323 105.YanY , ZouZ , SunYet al.Anti-malaria drug" exact="chloroquine" post="is highly effective in treating avian influenza A H5N1"/>
   <result pre="Virol. J.2(1), 69 (2005).16115318 107.RolainJM , ColsonP , RaoultDRecycling of" exact="chloroquine" post="and its hydroxyl analogue to face bacterial, fungal and"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7391015\results\search\drug\results.xml">
   <result pre="been reported from other countries, allowing to speculate on pharmaceutical" exact="nicotine" post="as a potential treatment option in COVID-19 [24]. To"/>
   <result pre="on off-label use of old drugs, such as antimalarial drugs" exact="chloroquine" post="(CQ) and hydroxychloroquine (HCQ) and antiretroviral lopinavir/ritonavir and darunavir/cobicistat"/>
   <result pre="of old drugs, such as antimalarial drugs chloroquine (CQ) and" exact="hydroxychloroquine" post="(HCQ) and antiretroviral lopinavir/ritonavir and darunavir/cobicistat [26]. Unfortunately, conclusive"/>
   <result pre="et al. on the efficacy of the combination use of" exact="hydroxychloroquine" post="and azithromycin, which had great resonance and influenced treatment"/>
   <result pre="of current smoking among hospitalized COVID-19 patients in China: could" exact="nicotine" post="be a therapeutic option?Intern Emerg Med202010.1007/s11739-020-02355-732385628 24.PolosaRCaciGCOVID-19: counter-intuitive data"/>
   <result pre="COVID-19: a multidisciplinary point of viewClin Rheumatol20203972077208410.1007/s10067-020-05179-032472459 27.FaninACalegariJBeverinaAet al.Hydroxychloroquine and" exact="azithromycin" post="as a treatment of COVID-19Intern Emerg Med202010.1007/s11739-020-02388-y32474851 28.GautretPLagierJCParolaPet al.Clinical"/>
   <result pre="Med202010.1007/s11739-020-02388-y32474851 28.GautretPLagierJCParolaPet al.Clinical and microbiological effect of a combination of" exact="hydroxychloroquine" post="and azithromycin in 80 COVID-19 patients with at least"/>
   <result pre="al.Clinical and microbiological effect of a combination of hydroxychloroquine and" exact="azithromycin" post="in 80 COVID-19 patients with at least a six-day"/>
   <result pre="new treatment strategies for COVID-19: is there a role for" exact="bromhexine" post="as add-on therapy?Intern Emerg Med202010.1007/s11739-020-02383-332458206 30.LandiADe ServiSThe burden of"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7391235\results\search\drug\results.xml">
   <result pre="studyBrain Behav. Immun.20175926026427638184 163.BersaniFSet al.Global arginine bioavailability, a marker of" exact="nitric oxide" post="synthetic capacity, is decreased in PTSD and correlated with"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7392152\results\search\drug\results.xml">
   <result pre="rather for a general mechanism of viral infection. For instance," exact="chloroquine" post="and hydroxychloroquine have been reported to affect endosomes, the"/>
   <result pre="a general mechanism of viral infection. For instance, chloroquine and" exact="hydroxychloroquine" post="have been reported to affect endosomes, the critical point"/>
   <result pre="antiviral activity [5]. Regardless, in a recent small clinical trial" exact="hydroxychloroquine" post="demonstrated moderate effectiveness in treatment of COVID-19 patients, and"/>
   <result pre="the effect was even more pronounced in co-treatment with antibacterial" exact="azithromycin" post="[6]. This led both drugs to numerous currently ongoing"/>
   <result pre="their potential benefits, mechanisms and safety. The mentioned drugs, chloroquine," exact="hydroxychloroquine" post="and azithromycin, highly accumulate in lysosomes/endosomes and their membranes,"/>
   <result pre="lysosomes). We propose that the antiviral activity of (hydroxy)chloroquine and" exact="azithromycin" post="is shared among all strong lysosomotropic drugs and is"/>
   <result pre="and have been extensively summarized by Salata et al. [22]." exact="Chloroquine" post="and amiodarone have so far been amongst the most"/>
   <result pre="been extensively summarized by Salata et al. [22]. Chloroquine and" exact="amiodarone" post="have so far been amongst the most widely studied"/>
   <result pre="amodiaquine, mefloquine, quinacrine); channel blockers (amiodarone, verapamil, manidipine); antibacterial (azithromycin);" exact="estrogen" post="receptor modulators (tamoxifen, raloxifene, toremifene); two antivirals, the only"/>
   <result pre="COVID-19 could be their potential anti-inflammatory effects, which was for" exact="azithromycin" post="and chloroquine as well as for a number of"/>
   <result pre="be their potential anti-inflammatory effects, which was for azithromycin and" exact="chloroquine" post="as well as for a number of tool drugs"/>
   <result pre="are: promethazine, amodiaquine, chloroquine, mefloquine, tilorone, hydroxychloroquine, arbidol (umifenovir) and" exact="nelfinavir" post="[23] (https://drugvirus.info/). The drugs that passed all applied lysosomotropism"/>
   <result pre="applied lysosomotropism criteria are: azithromycin, promethazine, cyclizine, chloroquine, clemastine, hydroxyzine," exact="rifabutin" post="and vicriviroc, and drugs that do not have data"/>
   <result pre="and thereby preventing infection of the cell. The third antiviral," exact="nelfinavir" post="is a protease inhibitor drug approved for treatment of"/>
   <result pre="primary inclusion criteria. Three of them target respiratory system (bromhexine," exact="ambroxol" post="and formoterol), but should be cautiously assessed at which"/>
   <result pre="tested in numerous ongoing clinical trials on COVID-19, with chloroquine," exact="hydroxychloroquine" post="and azithromycin being most widely studied. FDA has recently"/>
   <result pre="numerous ongoing clinical trials on COVID-19, with chloroquine, hydroxychloroquine and" exact="azithromycin" post="being most widely studied. FDA has recently revoked the"/>
   <result pre="has recently revoked the emergency use authorization (EUA) to use" exact="hydroxychloroquine" post="and chloroquine to treat COVID-19 outside clinical trials due"/>
   <result pre="revoked the emergency use authorization (EUA) to use hydroxychloroquine and" exact="chloroquine" post="to treat COVID-19 outside clinical trials due to the"/>
   <result pre="CADs are also being clinically tested, such as amiodarone, fluoxetine," exact="chlorpromazine" post="and fluvoxamine, but also other drugs with possible CAD"/>
   <result pre="other drugs with possible CAD properties such as imatinib, bromhexine," exact="formoterol" post="[41]. The number of clinical trials and diversity of"/>
   <result pre="the past 50 yearsClin. Microbiol. Rev.29201669574727281742 2Al-BariM.A.A.Targeting endosomal acidification by" exact="chloroquine" post="analogs as a promising strategy for the treatment of"/>
   <result pre="the treatment of emerging viral diseasesPharmacol. Res. Perspect.52017e00293 3SavarinoA.BoelaertJ.R.CassoneA.MajoriG.CaudaR.Effects of" exact="chloroquine" post="on viral infections: an old drug against todayâ€™s diseases?Lancet"/>
   <result pre="interaction map reveals targets for drug repurposingNature2020 6GautretP.LagierJ.C.ParolaP.HoangV.T.MeddebL.MailheM.DoudierB.CourjonJ.GiordanengoV.VieiraV.E.DupontH.T.HonorÃ©S.ColsonP.ChabriÃ¨reE.La ScolaB.RolainJ.M.BrouquiP.RaoultD.Hydroxychloroquine and" exact="azithromycin" post="as a treatment of COVID-19: results of an open-label"/>
   <result pre="endo-/lysosomal system in rat hepatocytesDrug Metab. Dispos.472019495730409837 10TogamiK.ChonoS.MorimotoK.Subcellular distribution of" exact="azithromycin" post="and clarithromycin in rat alveolar macrophages (NR8383) in vitroBiol."/>
   <result pre="in rat hepatocytesDrug Metab. Dispos.472019495730409837 10TogamiK.ChonoS.MorimotoK.Subcellular distribution of azithromycin and" exact="clarithromycin" post="in rat alveolar macrophages (NR8383) in vitroBiol. Pharm. Bull.3620131494149923995662"/>
   <result pre="by decreasing autophagosome-lysosome fusionAutophagy1420181435145529940786 17NujiÄ‡K.BanjanacM.MuniÄ‡V.PolanÄ�ecD.ErakoviÄ‡ HaberV.Impairment of lysosomal functions by" exact="azithromycin" post="and chloroquine contributes to anti-inflammatory phenotypeCell. Immunol.2792012788623099154 18LoganR.FunkR.S.AxcellE.KriseJ.P.Drug-drug interactions"/>
   <result pre="autophagosome-lysosome fusionAutophagy1420181435145529940786 17NujiÄ‡K.BanjanacM.MuniÄ‡V.PolanÄ�ecD.ErakoviÄ‡ HaberV.Impairment of lysosomal functions by azithromycin and" exact="chloroquine" post="contributes to anti-inflammatory phenotypeCell. Immunol.2792012788623099154 18LoganR.FunkR.S.AxcellE.KriseJ.P.Drug-drug interactions involving lysosomes:"/>
   <result pre="Research Information on Drug-Induced Liver Injury [Online].Available: https://www.ncbi.nlm.nih.gov/books/NBK547852/ [Accessed]2012 37LentiniG.CavalluzziM.M.HabtemariamS.COVID-19," exact="chloroquine" post="repurposing, and cardiac safety concern: chirality might helpMolecules202025 38GriloL.S.CarruptP.A.AbrielH.Stereoselective"/>
   <result pre="stimulated Raman scatteringNat. Chem.6201461462224950332 43Fda. Fda cautions against use of" exact="hydroxychloroquine" post="or chloroquine for COVID-19 outside of the hospital setting"/>
   <result pre="scatteringNat. Chem.6201461462224950332 43Fda. Fda cautions against use of hydroxychloroquine or" exact="chloroquine" post="for COVID-19 outside of the hospital setting or a"/>
   <result pre="during a five-year period. Incidence and prognosisActa Med. Scand.18219674915016054829 47ChenC.Y.WangF.L.LinC.C.Chronic" exact="hydroxychloroquine" post="use associated with QT prolongation and refractory ventricular arrhythmiaClin."/>
   <result pre="&amp;amp; immunology and dermatologyComprehensiv Med. Chem. II2007 52KrishnaS.WhiteN.J.Pharmacokinetics of quinine," exact="chloroquine" post="and amodiaquine. Clinical implicationsClin. Pharmacokinet.3019962632998983859 53Oâ€™maraE.KasserraC.HuddlestoneJ.R.WanY.SoniP.CaceresM.MedlockM.MorrisonR.DevinskyO.Effect of vicriviroc on"/>
   <result pre="single-component and combination formulationsJ. Clin. Pharmacol.3619969119228930778 56SchrezenmeierE.DÃ¶rnerT.Mechanisms of action of" exact="hydroxychloroquine" post="and chloroquine: implications for rheumatologyNat. Rev. Rheumatol.16202015516632034323 57ShiJ.MontayG.BhargavaV.O.Clinical pharmacokinetics"/>
   <result pre="first ketolide antibacterialClin. Pharmacokinet.44200591593416122280 58StanatS.J.CarltonC.G.CrumbW.J.Jr.AgrawalK.C.ClarksonC.W.Characterization of the inhibitory effects of" exact="erythromycin" post="and clarithromycin on the HERG potassium channelMol. Cell. Biochem.25420031714674677"/>
   <result pre="antibacterialClin. Pharmacokinet.44200591593416122280 58StanatS.J.CarltonC.G.CrumbW.J.Jr.AgrawalK.C.ClarksonC.W.Characterization of the inhibitory effects of erythromycin and" exact="clarithromycin" post="on the HERG potassium channelMol. Cell. Biochem.25420031714674677 59TaylorG.HoustonJ.B.ShafferJ.MawerG.Pharmacokinetics of"/>
   <result pre="61Van HaarstA.D.Vanâ€™ T KloosterG.A.Van GervenJ.M.SchoemakerR.C.Van OeneJ.C.BurggraafJ.CoeneM.C.CohenA.F.The influence of cisapride and" exact="clarithromycin" post="on QT intervals in healthy volunteersClin. Pharmacol. Ther.6419985425469834046 62WalkerR.B.KanferI.Pharmacokinetics"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7392210\results\search\drug\results.xml">
   <result pre="Dosage in Current Trials Supportive Evidence Caveats References Remdesivir(2014) Antiviral;" exact="Adenosine" post="nucleotide analogue Acts as an RNA-chain terminator by binding"/>
   <result pre="and safety for the treatment of COVID-19 [34], [52], [53]" exact="Ribavirin" post="(1986) Antiviral; Nucleoside analogue Inhibits viral RNA synthesis and"/>
   <result pre="animal model for SARS-CoV infection Limited data available. [57], [58]" exact="Hydroxychloroquine" post="/ chloroquine (HCQ/CQ) (1955/1934) Antimalarial Block viral entry into"/>
   <result pre="for SARS-CoV infection Limited data available. [57], [58] Hydroxychloroquine /" exact="chloroquine" post="(HCQ/CQ) (1955/1934) Antimalarial Block viral entry into cells by"/>
   <result pre="10.1.1 Antivirals 10.1.1.1 Remdesivir Remdesivir, a monophosphate prodrug of an" exact="adenosine" post="analog, was originally developed to combat the Ebola outbreak"/>
   <result pre="gets rapidly catabolized by the Cytochrome P450 enzyme system) [44]," exact="ritonavir" post="(a CYP3A4 inhibitor) is added to increase its plasma"/>
   <result pre="SARS-CoV [45], it was far less potent than Remdesivir and" exact="Chloroquine" post="in-vitro [46]. In a randomized open-label study of 199"/>
   <result pre="significant benefit in mild and moderate COVID-19 cases [56]. 10.1.1.5" exact="Ribavirin" post="Ribavirin, a guanosine analog prescribed for viral hemorrhagic fever"/>
   <result pre="viral S protein for entry into human cells. In mice," exact="camostat" post="mesylate showed a 60% survival rate following SARS-CoV infection,"/>
   <result pre="COVID-19 are currently underway around the globe. 10.1.3 Antimalarial 10.1.3.1" exact="Hydroxychloroquine" post="/ Chloroquine (HCQ/CQ) These are antimalarial drugs which are"/>
   <result pre="currently underway around the globe. 10.1.3 Antimalarial 10.1.3.1 Hydroxychloroquine /" exact="Chloroquine" post="(HCQ/CQ) These are antimalarial drugs which are also believed"/>
   <result pre="=Â 14) group. All six patients in the HCQ plus" exact="Azithromycin" post="group had significantly better viral clearance [60]. However, six"/>
   <result pre="an increased occurrence of ventricular arrhythmias in patients who received" exact="hydroxychloroquine" post="or chloroquine, when used alone or in conjunction with"/>
   <result pre="on 2541 patients, treatment with HCQ alone and HCQÂ +Â" exact="Azithromycin" post="demonstrated a significant reduction in mortality among hospitalized COVID-19"/>
   <result pre="be effective in preventing COVID-19 after a high-risk exposure [64]." exact="Hydroxychloroquine" post="was discontinued from the RECOVERY trial owing to no"/>
   <result pre="or clinical improvement outcomes [65]. The WHO also discontinued the" exact="Hydroxychloroquine" post="trial arm of the SOLIDARITY trial as it did"/>
   <result pre="thus ineffective in COVID-19 patients requiring mechanical ventilation [71]. 10.2.1.3" exact="Ruxolitinib" post="Ruxolitinib has been found to be effective against inflammatory"/>
   <result pre="ineffective in COVID-19 patients requiring mechanical ventilation [71]. 10.2.1.3 Ruxolitinib" exact="Ruxolitinib" post="has been found to be effective against inflammatory and"/>
   <result pre="promising results in the earlier phases [72]. 10.3 Corticosteroids 10.3.1" exact="Methylprednisolone" post="It is a corticosteroid with potent anti-inflammatory properties which"/>
   <result pre="are expected in November 2020. 10.4.3 Aspirin, Clopidogrel, Rivaroxaban, Atorvastatin," exact="omeprazole" post="These drugs are being trialled to study their cardioprotective"/>
   <result pre="COVID-19: a Prospective, Randomized Controlled Trial Experimental: standard careÂ +Â" exact="Methylprednisolone" post="40Â mg q12h for 5Â daysVSPlacebo Comparator: standard care"/>
   <result pre="lung injury score NCT04291729 Evaluation of Ganovo (Danoprevir) Combined With" exact="Ritonavir" post="in the Treatment of SARS-CoV-2 Infection Experimental: GanovoÂ +Â"/>
   <result pre="Ritonavir in the Treatment of SARS-CoV-2 Infection Experimental: GanovoÂ +Â" exact="ritonavir" post="with or without interferon nebulization Phase 4 Single Group"/>
   <result pre="TimeÂ Frame:Â 14Â daysÂ ] NCT04261517 Efficacy and Safety of" exact="Hydroxychloroquine" post="for Treatment of COVID-19 Experimental: HCQ (400Â mg per"/>
   <result pre="rate. [Â TimeÂ Frame:Â 2Â weeksÂ ] NCT04276688 Lopinavir/ Ritonavir," exact="Ribavirin" post="and IFN-beta Combination for nCoV Treatment Study group: LPV/r"/>
   <result pre="LPV/r 400Â mg/100Â mg twice daily for 14Â daysÂ +Â" exact="Ribavirin" post="400Â mg twice daily for 14Â days + IF"/>
   <result pre="A Compassionate Use Protocol Experimental: 25Â Âµg/kg of body weight" exact="tirofiban" post="as bolus IV injection (3Â min) followed by continuous"/>
   <result pre="of 75Â mg daily for 30Â days.A loading dose of" exact="clopidogrel" post="300Â mg PO, followed by 75Â mg daily for"/>
   <result pre="] NCT04273321 Efficacy and Safety of Corticosteroids in COVID-19 Experimental:" exact="Methylprednisolone" post="1Â mg/kg/day ivgtt for 7Â days Not Applicable Single"/>
   <result pre="Testing, treatment and prophylaxis of SARS-CoV-2Study 1 â€&quot; Contacts receive" exact="Hydroxychloroquine" post="prophylaxis. Contacts will complete a survey collecting demographic, epidemiological"/>
   <result pre="day 14. Contacts will be offered a prophylactic regimen of" exact="hydroxychloroquine" post="(200Â mg tablets) 800Â mg on day 1, and"/>
   <result pre="3, and 7. Cases will be offered a therapeutic regimen" exact="hydroxychloroquine" post="(200Â mg tablets) 800Â mg on day 1, and"/>
   <result pre="care therapyOseltamivir 75Â mg 12 hourly for 5â€&quot;10Â days and" exact="Hydroxychloroquine" post="400Â mg 12 hourly day âˆ’1 followed by 200Â"/>
   <result pre="negativization NCT04345276 Efficacy and Safety of Ganovo (Danoprevir) Combined With" exact="Ritonavir" post="in the Treatment of SARS-CoV-2 Infection Experimental: DanoprevirÂ +Â"/>
   <result pre="Ritonavir in the Treatment of SARS-CoV-2 Infection Experimental: DanoprevirÂ +Â" exact="Ritonavir" post="groupDanoprevir 100Â mg, one tablet each time, twice per"/>
   <result pre="tablet each time, twice per day, up to 10Â days." exact="Ritonavir" post="100Â mg, one tablet each time, twice per day,"/>
   <result pre="(IVM) 12Â mg /weeklyÂ +Â Hydroxychloroquin (HCQ) 400Â mg/dailyÂ +Â" exact="Azithromycin" post="(AZT) 500Â mg dailyVSNo Intervention: Hydroxychloroquine 400Â mg/dailyÂ +Â"/>
   <result pre="(HCQ) 400Â mg/dailyÂ +Â Azithromycin (AZT) 500Â mg dailyVSNo Intervention:" exact="Hydroxychloroquine" post="400Â mg/dailyÂ +Â azithromycin 500Â mg daily Phase 1"/>
   <result pre="Azithromycin (AZT) 500Â mg dailyVSNo Intervention: Hydroxychloroquine 400Â mg/dailyÂ +Â" exact="azithromycin" post="500Â mg daily Phase 1 Randomized; Double blind 100(â‰¥18)"/>
   <result pre="two arms [Â TimeÂ Frame:Â One-monthÂ ] NCT04376814 Favipiravir Plus" exact="Hydroxychloroquine" post="and Lopinavir/Ritonavir Plus Hydroxychloroquine in COVID-19 Experimental: Test GroupIn"/>
   <result pre="Frame:Â One-monthÂ ] NCT04376814 Favipiravir Plus Hydroxychloroquine and Lopinavir/Ritonavir Plus" exact="Hydroxychloroquine" post="in COVID-19 Experimental: Test GroupIn this group, Patients will"/>
   <result pre="times per day for 7Â days, plus 200Â mg of" exact="Hydroxychloroquine" post="two times per day will be given to patients"/>
   <result pre="Patients will be given a stat dose of 400Â mg" exact="Hydroxychloroquine" post="tablets plus 200/50Â mg of Lopinavir/Ritonavirtwo times per day"/>
   <result pre="day 1, 4, 7, 28 after first transfusionÂ ] NCT04342650" exact="Chloroquine" post="Diphosphate in the Prevention of SARS in Covid-19 Infection"/>
   <result pre="donation set.VSControl groupThe control group of COVID-19 patients were given" exact="Hydroxychloroquine" post="400Â mg PO twice per day for 5Â days"/>
   <result pre="400Â mg PO twice per day for 5Â days and" exact="Azithromycin" post="once PO 500Â mg per day for 5Â days."/>
   <result pre="Up to 8Â weeksÂ ] NCT04321278 Safety and Efficacy of" exact="Hydroxychloroquine" post="Associated With Azithromycin in SARS-CoV2 Virus (Coalition Covid-19 Brasil"/>
   <result pre="weeksÂ ] NCT04321278 Safety and Efficacy of Hydroxychloroquine Associated With" exact="Azithromycin" post="in SARS-CoV2 Virus (Coalition Covid-19 Brasil II) Experimental: HydroxychloroquineÂ"/>
   <result pre="Experimental: HydroxychloroquineÂ +Â azithromycinHydroxychloroquine [400Â mg 2Ã—/day, 12/12Â h]Â +Â" exact="azithromycin" post="[500Â mg 1Ã—/day]VSActive Comparator: HydroxychloroquineHydroxychloroquine [400Â mg 2Ã—/day, 12/12Â"/>
   <result pre="status [Â TimeÂ Frame:Â 15Â days after randomizationÂ ] NCT04323527" exact="Chloroquine" post="Diphosphate for the Treatment of Severe Acute Respiratory Syndrome"/>
   <result pre="Respiratory Syndrome Secondary to SARS-CoV2 (CloroCOVID19) Active Comparator: Low Dose" exact="Chloroquine" post="Diphosphate (5Â days)Low dose chloroquine group consists of 450Â"/>
   <result pre="(CloroCOVID19) Active Comparator: Low Dose Chloroquine Diphosphate (5Â days)Low dose" exact="chloroquine" post="group consists of 450Â mg bid (3 tablets of"/>
   <result pre="tube in case of orotracheal intubation. VSActive Comparator: High Dose" exact="Chloroquine" post="Diphosphate (10Â days) consists of 600Â mg bid (4"/>
   <result pre="reduced in cancer drug discovery?Expert Opin. Drug Discov.8201336336823373702 34WangM.Remdesivir and" exact="chloroquine" post="effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in"/>
   <result pre="studied in RECOVERY, https://www.recoverytrial.net/news/no-clinical-benefit-from-use-of-lopinavir-ritonavir-in-hospitalised-covid-19-patients-studied-in-recovery. Accessed 19 July 2020. 49WHO discontinues" exact="hydroxychloroquine" post="and lopinavir/ritonavir treatment arms for COVID-19, https://www.who.int/news-room/detail/04-07-2020-who-discontinues-hydroxychloroquine-and-lopinavir-ritonavir-treatment-arms-for-covid-19. Accessed 19"/>
   <result pre="modeling and docking studies of TMPRSS2 with experimentally known inhibitors" exact="camostat" post="mesylate, nafamostat and bromhexine hydrochloride to control SARS-Coronavirus-2. (2020)."/>
   <result pre="docking studies of TMPRSS2 with experimentally known inhibitors camostat mesylate," exact="nafamostat" post="and bromhexine hydrochloride to control SARS-Coronavirus-2. (2020). doi:10.26434/chemrxiv.12162360.v1. 58ZhouY.Protease"/>
   <result pre="of TMPRSS2 with experimentally known inhibitors camostat mesylate, nafamostat and" exact="bromhexine" post="hydrochloride to control SARS-Coronavirus-2. (2020). doi:10.26434/chemrxiv.12162360.v1. 58ZhouY.Protease inhibitors targeting"/>
   <result pre="vitro antiviral activity and projection of optimized dosing design of" exact="hydroxychloroquine" post="for the treatment of severe acute respiratory syndrome coronavirus"/>
   <result pre="acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Clin. Infect. Dis.202010.1093/cid/ciaa237 60GautretP.Hydroxychloroquine and" exact="azithromycin" post="as a treatment of COVID-19: results of an open-label"/>
   <result pre="non-randomized clinical trialInt. J. Antimicrob. Agents105949202010.1016/j.ijantimicag.2020.105949 61M.G.S. Borba, et al.," exact="Chloroquine" post="diphosphate in two different dosages as adjunctive therapy of"/>
   <result pre="(CloroCovid-19 Study), Infect. Diseases (except HIV/AIDS), (2020). doi:10.1101/2020.04.07.20056424. 62MehraM.R.DesaiS.S.RuschitzkaF.PatelA.N.Hydroxychloroquine or" exact="chloroquine" post="with or without a macrolide for treatment of COVID-19:"/>
   <result pre="Infect. Diseases97202039640332623082 64D.R. Boulware, et al., A randomized trial of" exact="hydroxychloroquine" post="as postexposure prophylaxis for Covid-19, N. Engl. J. Med."/>
   <result pre="Med. NEJMoa2016638 (2020). doi:10.1056/NEJMoa2016638. 65No clinical benefit from use of" exact="hydroxychloroquine" post="in hospitalised patients with COVID-19, https://www.recoverytrial.net/news/statement-from-the-chief-investigators-of-the-randomised-evaluation-of-covid-19-therapy-recovery-trial-on-hydroxychloroquine-5-june-2020-no-clinical-benefit-from-use-of-hydroxychloroquine-in-hospitalised-patients-with-covid-19. Accessed 18 July"/>
   <result pre="https://www.recoverytrial.net/news/statement-from-the-chief-investigators-of-the-randomised-evaluation-of-covid-19-therapy-recovery-trial-on-hydroxychloroquine-5-june-2020-no-clinical-benefit-from-use-of-hydroxychloroquine-in-hospitalised-patients-with-covid-19. Accessed 18 July 2020. 66FDA cautions against use of" exact="hydroxychloroquine" post="or chloroquine for COVID-19 outside of the hospital setting"/>
   <result pre="18 July 2020. 66FDA cautions against use of hydroxychloroquine or" exact="chloroquine" post="for COVID-19 outside of the hospital setting or a"/>
   <result pre="corticosteroids for 2019-nCoV pneumoniaLancet395202068368432122468 75P. Horby, et al., Effect of" exact="dexamethasone" post="in hospitalized patients with COVID-19: preliminary report, Infect. Diseases"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7393415\results\search\drug\results.xml">
   <result pre="at â€œwarp speedâ€�. Key Words accelerated approval COVID-19 emergency use" exact="hydroxychloroquine" post="operation warp speed pandemic vaccine approval Abbreviations and Acronyms"/>
   <result pre="about â€œmoving too fast.â€� Two stories include the use of" exact="hydroxychloroquine" post="for COVID-19 infections, and the implementation of the Operation"/>
   <result pre="Vaccine Initiative (OWSVI). Hydroxychloroquine: Moving Too Fast in Every Direction" exact="Hydroxychloroquine" post="was proposed as a treatment for COVID-19 prior to"/>
   <result pre="success in treating 24 COVID-19 patients with a combination of" exact="hydroxychloroquine" post="and azithromycin (2). A few days later, President Trump"/>
   <result pre="treating 24 COVID-19 patients with a combination of hydroxychloroquine and" exact="azithromycin" post="(2). A few days later, President Trump touted the"/>
   <result pre="you have to lose?â€� (3). An almost immediate shortage of" exact="hydroxychloroquine" post="resulted as the U.S. government stockpiled the drug, doctors"/>
   <result pre="it off-label, and some patients began hoarding. Patients who needed" exact="hydroxychloroquine" post="for its proven indications began to run out. By"/>
   <result pre="its proven indications began to run out. By March 28," exact="hydroxychloroquine" post="received conditional approval via the FDAâ€™s Emergency Use Pathway"/>
   <result pre="later, the FDA approved a phase III clinical trial of" exact="hydroxychloroquine" post="for COVID-19 treatment, sponsored by Novartis. Results of clinical"/>
   <result pre="COVID-19 treatment, sponsored by Novartis. Results of clinical trials of" exact="hydroxychloroquine" post="for COVID-19 were published quickly, sometimes in â€œpreprintâ€� form"/>
   <result pre="published in The Lancet indicating that COVID-19 patients who received" exact="hydroxychloroquine" post="had significantly higher mortality than did those who did"/>
   <result pre="funding agencies stopped or paused many of the 131 registered" exact="hydroxychloroquine" post="COVID-19 trials that were underway, and the World Health"/>
   <result pre="was published from the University of Minnesota, which found that" exact="hydroxychloroquine" post="failed to prevent COVID-19 (8). As of this writing,"/>
   <result pre="to prevent COVID-19 (8). As of this writing, shortages of" exact="hydroxychloroquine" post="continue, although it has not been reliably shown to"/>
   <result pre="June 15, the FDA revoked its Emergency Use Authorization for" exact="hydroxychloroquine" post="due to lack of efficacy evidence. A Vaccine at"/>
   <result pre="phase II (14). Such EUAs have authorized the use of" exact="hydroxychloroquine" post="and chloroquine, convalescent plasma, hyperimmune globulin, remdesivir, and Fresenius"/>
   <result pre="top medical journals may be unraveling. ScienceAvailable at:https://www.sciencemag.org/news/2020/06/mysterious-company-s-coronavirus-papers-top-medical-journals-may-be-unraveling 5MehraM.R.RuschitzkaF.PatelA.N.Retractionâ€&quot;hydroxychloroquine or" exact="chloroquine" post="with or without macrolide for treatment of COVID-19: a"/>
   <result pre="details in scandal emerge. STATAvailable at:https://www.statnews.com/2020/06/07/researcher-involved-in-retracted-lancet-study-has-faculty-appointment-terminated-as-details-in-scandal-emerge/ 8BoulwareD.R.PullenM.F.BangdiwalaK.A.AÂ randomized trial of" exact="hydroxychloroquine" post="as postexposure prophylaxis for Covid-19NÂ Engl J Med2020 Jun"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7396720\results\search\drug\results.xml">
   <result pre="the viral family, composed mainly of hydrophobic residues, such as" exact="glycine" post="(G) or alanine (A), which anchor to the target"/>
   <result pre="composed mainly of hydrophobic residues, such as glycine (G) or" exact="alanine" post="(A), which anchor to the target membrane when the"/>
   <result pre="and pseudovirus infection [65]. In addition to peptide fusion inhibitors," exact="nelfinavir" post="mesylate (Viracept), a currently prescribed anti-HIV protease inhibitor, suppresses"/>
   <result pre="inhibitor, suppresses both SARS-CoV-2 S and SARS-CoV S-mediated cellâ€&quot;cell fusion." exact="Viracept" post="is the first reported small molecule fusion inhibitor in"/>
   <result pre="molecule fusion inhibitor in addition to peptide fusion inhibitors. Moreover," exact="nelfinavir" post="may inhibit the function of TMPRSS2 involved in activation"/>
   <result pre="been demonstrated that SARS-CoV-2 cellular entry can be blocked by" exact="camostat" post="mesilate [18, 67]. There are currently five clinical trials"/>
   <result pre="currently five clinical trials registered to evaluate the efficacy of" exact="camostat" post="mesilate (ClinicalTrials.gov Identifier: NCT04321096, NCT04353284, NCT04338906, NCT04355052, NCT04374019). In"/>
   <result pre="[81]. Mutation of the aspartate (D) at position 614 to" exact="glycine" post="(G614) results in a more pathogenic strain of SARS-CoV-2"/>
   <result pre="R, Chouljenko T, Jois SD, et al. The anti-HIV drug" exact="Nelfinavir" post="Mesylate (Viracept) is a potent inhibitor of cell fusion"/>
   <result pre="79.LuYHardesKDahmsSOBottcher-FriebertshauserESteinmetzerTThanMEet al.Peptidomimetic furin inhibitor MI-701 in combination with oseltamivir and" exact="ribavirin" post="efficiently blocks propagation of highly pathogenic avian influenza viruses"/>
   <result pre="the novel coronavirus SARS-CoV-2Int J Biol Sci20201617182332226289 84.WangMLCaoRYZhangLKYangXLLiuJXuMYet al.Remdesivir and" exact="chloroquine" post="effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7397939\results\search\drug\results.xml">
   <result pre="higher levels of perceived stress. In this survey the Cronbach's" exact="alpha" post="was .884. 2.3.3The Coping Orientation to the Problems Experienced-New"/>
   <result pre="easier to administer. In this study the value of Cronbach's" exact="alpha" post="was .801. 2.4 Data analysis The distribution of all"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7400054\results\search\drug\results.xml">
   <result pre="Therefore, the WHO recommended two hand rub formulations based on" exact="ethanol" post="and 2-propanol [51]. Such alcohol-based hand rub formulations were"/>
   <result pre="levels of lactate dehydrogenase and creatinine kinase, increased levels of" exact="alanine" post="aminotransferase or aspartate aminotransferase as indicators of irregular liver"/>
   <result pre="for the treatment of COVID-19 patients. Furthermore, a combination of" exact="lopinavir" post="and ritonavir has been reported to significantly improve the"/>
   <result pre="treatment of COVID-19 patients. Furthermore, a combination of lopinavir and" exact="ritonavir" post="has been reported to significantly improve the conditions of"/>
   <result pre="in South Korea [126]. Similar to remdisivir, a combination of" exact="lopinavir" post="and ritonavir was developed to treat HIV-1 infections in"/>
   <result pre="Korea [126]. Similar to remdisivir, a combination of lopinavir and" exact="ritonavir" post="was developed to treat HIV-1 infections in adults. However,"/>
   <result pre="to treat HIV-1 infections in adults. However, the combination of" exact="lopinavir" post="and ritonavir failed to serve its initial purpose when"/>
   <result pre="HIV-1 infections in adults. However, the combination of lopinavir and" exact="ritonavir" post="failed to serve its initial purpose when used for"/>
   <result pre="of the prevention and control of COVID-19. Sanitizers containing 60â€&quot;70%" exact="ethanol" post="or 70% isopropanol are effective against SARS-CoV-2. Similarly, household"/>
   <result pre="to 28 days. Surface disinfection with 0.1% hypochlorite or 62-71%" exact="ethanol" post="was found to be effective in reducing the infectivity"/>
   <result pre="hospitalized with severe COVID-19N. Engl. J. Med.20203821787179910.1056/NEJMoa200128232187464 129.GautretP.LagierJ.C.ParolaP.HoangV.T.MeddebL.MailheM.DoudierB.CourjonJ.GiordanengoV.VieiraV.E.et al.Hydroxychloroquine and" exact="azithromycin" post="as a treatment of COVID-19: Results of an open-label"/>
   <result pre="by NMPA, China Inhibition of RNA-dependent RNA polymerase of SARS-CoV-2" exact="Hydroxychloroquine" post="and azithromycin USA Clinical trials are under progress Both"/>
   <result pre="China Inhibition of RNA-dependent RNA polymerase of SARS-CoV-2 Hydroxychloroquine and" exact="azithromycin" post="USA Clinical trials are under progress Both have shown"/>
   <result pre="progress Developed for treatment of Ebola virus infection Lopinavir +" exact="Ritonavir" post="AbbVie, USA Further research is under process Developed to"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7400365\results\search\drug\results.xml">
   <result pre="inject drugsSubst. Use Misuse2016511218122310.3109/10826084.2016.116105427219274 2.DoreG.J.ConwayB.LuoY.JanczewskaE.KnyszB.LiuY.PodsadeckiT.Efficacy and safety of ombitasvir/paritaprevir/r and" exact="dasabuvir" post="compared to IFN-containing regimens in genotype 1 HCV patients:"/>
   <result pre="drug use: An integrated analysis of 7 phase III studiesDrug" exact="Alcohol" post="Depend.201919448749410.1016/j.drugalcdep.2018.11.00730529905 21.HuangM.LiuW.SuL.WuC.WuP.YangS.ChangS.Hepatitis C virus re-infection after viral clearance of"/>
   <result pre="regimensLiver Int.20183882183310.1111/liv.1359628941023 25.RockstrohJ.K.OrkinC.VianiR.M.WylesD.LuetkemeyerA.F.LazzarinA.LazzarinA.Soto-MalaveR.NelsonM.R.BhaganiS.R.et al.Safety and efficacy of ombitasvir, paritaprevir with" exact="ritonavir" post="Â± dasabuvir with or without ribavirin in patients with"/>
   <result pre="25.RockstrohJ.K.OrkinC.VianiR.M.WylesD.LuetkemeyerA.F.LazzarinA.LazzarinA.Soto-MalaveR.NelsonM.R.BhaganiS.R.et al.Safety and efficacy of ombitasvir, paritaprevir with ritonavir Â±" exact="dasabuvir" post="with or without ribavirin in patients with human immunodeficiency"/>
   <result pre="of ombitasvir, paritaprevir with ritonavir Â± dasabuvir with or without" exact="ribavirin" post="in patients with human immunodeficiency virus-1 and hepatitis C"/>
   <result pre="Time(Participant Range if Given) Attrition Rate (Loss to Follow-Up) 1" exact="Foster" post="et al., 2019 [20] Integrated analysis of clinical trials"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7402078\results\search\drug\results.xml">
   <result pre="Canada, Greenland Bed rest; ample fluids; nourishing food; treatment through" exact="alcohol" post="to quinine, salicylates Sixth cholera pandemic 1910â€&quot;1911 Cholera/800,000 Middle"/>
   <result pre="given to all COVID-19 patients to boost general immunity: (1)" exact="vitamin C" post="in warm water with half a lemon at regular"/>
   <result pre="studies of drug repurposing and synergism of lopinavir, oseltamivir and" exact="ritonavir" post="binding with SARS-CoV-2 protease against COVID-19J Biomol Struct Dyn20201416"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7402116\results\search\drug\results.xml">
   <result pre="viruses and include alpha, beta, delta, and gamma subgroups, with" exact="alpha" post="and beta affecting humans [2]. The early presenting signs"/>
   <result pre="including smoking, cytokines, hypoxia, heme, oxidative stress, heat shock, ROS," exact="nitric oxide" post="(NO), cAMP, and oxidized lipids [6]. 2. COVID-19 Increases"/>
   <result pre="transport chain (ETC) of the mitochondria. Hemoproteins include hemoglobin, myoglobin," exact="nitric oxide" post="(NO) synthetase, catalase, and the cytochromes of the ETC"/>
   <result pre="synthetase, NO levels decrease. Recent studies have tried using inhaled" exact="nitric oxide" post="to mitigate the severity of COVID-19 to supplement the"/>
   <result pre="II (ANG-II), and thromboxane A, act as opposing molecules to" exact="nitric oxide" post="(NO) [6]. Cytochrome P450 (CYP) enzymes are hemoproteins [43,44]."/>
   <result pre="COVID-19 are CYP inhibitors, which include Azithromycin, Lopinavir, Hydroxychloroquine, and" exact="Chloroquine" post="[27]. Catalase and cytochrome enzymes require heme. Catalase is"/>
   <result pre="complexes (Iâ€&quot;IV) embedded in the inner mitochondrial membrane to create" exact="adenosine" post="triphosphate (ATP) cofactors, nicotinamide adenine dinucleotide (NADH) and flavin"/>
   <result pre="inner mitochondrial membrane to create adenosine triphosphate (ATP) cofactors, nicotinamide" exact="adenine" post="dinucleotide (NADH) and flavin adenine dinucleotide (FADH2) [73,74]. Electrons"/>
   <result pre="create adenosine triphosphate (ATP) cofactors, nicotinamide adenine dinucleotide (NADH) and" exact="flavin adenine dinucleotide" post="(FADH2) [73,74]. Electrons from reduced cofactors (NADH and FADH2)"/>
   <result pre="adenosine triphosphate (ATP) cofactors, nicotinamide adenine dinucleotide (NADH) and flavin" exact="adenine" post="dinucleotide (FADH2) [73,74]. Electrons from reduced cofactors (NADH and"/>
   <result pre="Other uncoupling proteins such as uncoupling proteins 1â€&quot;3 (UCPs) and" exact="adenine" post="nucleotide translocases (ANTs) are also activated by ROS to"/>
   <result pre="cells (Figure 7). In severe cytokine storm you have inducible" exact="nitric oxide" post="synthetase (iNOS), NO which will convert superoxides to peroxynitrite"/>
   <result pre="and the inflammatory response. 8. Cytochrome 2D6 Genetic Polymorphisms COVID-19" exact="Chloroquine" post="was first introduced in 1934. Hydroxychloroquine/chloroquine are both 4-aminoquinolones"/>
   <result pre="and animal studies where they proved beneficial, the use of" exact="chloroquine" post="was based on evidence of it being a potent"/>
   <result pre="more common. Slow metabolizers allow toxic levels of drugs like" exact="hydroxychloroquine" post="to accumulate resulting in increased cardiac complications like prolonged"/>
   <result pre="study in Lupus patients in Korea showed significant variability in" exact="hydroxychloroquine" post="levels due to CYP2D6 polymorphisms [110]. Another study in"/>
   <result pre="metoprolol [115,116]. This polymorphism affect many other drugs such as" exact="Isoniazid" post="(INH), barbiturates, omeprazole, selective serotonin reuptake inhibitors (SSRIâ€™s), sulfasalazine,"/>
   <result pre="cardiac arrest in the treatment group, especially when combined with" exact="Azithromycin" post="[117,118]. 9. Therapeutic Strategies-COVID-19 9.1. Antivirals Remdesivir, a CYP3A4"/>
   <result pre="used in clinical trials to treat COVID-19. It is an" exact="adenosine" post="analogue that inserts itself into the RNA virus, terminating"/>
   <result pre="downregulated by the acute phase reactant IL-6 and upregulated by" exact="dexamethasone" post="[122]. As a result, concomitant use of steroids along"/>
   <result pre="treatment arm has shown promising results with the use of" exact="dexamethasone" post="[143]. In the patients who were critically ill on"/>
   <result pre="heme content in the kidney [150]. Heme arginate also increases" exact="Nitric Oxide" post="(NO) while decreasing adhesion molecules in HIV infected stem"/>
   <result pre="other naturally occurring substances such as resveratrol, curcumin, statins, and" exact="aspirin" post="[19]. 11. ACE Genetic Polymorphisms ACE levels are under"/>
   <result pre="MERS middle East respiratory syndrome ROS reactive oxygen species NO" exact="nitric oxide" post="cAMP cyclic adenosine monophosphate TMPRSS-2 transmembrane serine protease 2"/>
   <result pre="syndrome ROS reactive oxygen species NO nitric oxide cAMP cyclic" exact="adenosine" post="monophosphate TMPRSS-2 transmembrane serine protease 2 ETC electron transport"/>
   <result pre="low-density lipoprotein IL interleukins TNF tumor necrosis factor NADH nicotinamide" exact="adenine" post="dinucleotide FADH2 flavin adenine dinucleotide ANTs adenine nucleotide translocases"/>
   <result pre="interleukins TNF tumor necrosis factor NADH nicotinamide adenine dinucleotide FADH2" exact="flavin adenine dinucleotide" post="ANTs adenine nucleotide translocases UCP uncoupling proteins INOS inducible"/>
   <result pre="TNF tumor necrosis factor NADH nicotinamide adenine dinucleotide FADH2 flavin" exact="adenine" post="dinucleotide ANTs adenine nucleotide translocases UCP uncoupling proteins INOS"/>
   <result pre="factor NADH nicotinamide adenine dinucleotide FADH2 flavin adenine dinucleotide ANTs" exact="adenine" post="nucleotide translocases UCP uncoupling proteins INOS inducible nitric oxide"/>
   <result pre="dinucleotide ANTs adenine nucleotide translocases UCP uncoupling proteins INOS inducible" exact="nitric oxide" post="synthetase ALT aspartate transaminase AST alanine aminotransferase CRP c-reactive"/>
   <result pre="proteins INOS inducible nitric oxide synthetase ALT aspartate transaminase AST" exact="alanine" post="aminotransferase CRP c-reactive protein LPV/RTV Lopinavir/ritonavir RTC randomized clinical"/>
   <result pre="desensitization to oxidant damageProc. Natl. Acad. Sci. USA1993909285928910.1073/pnas.90.20.92858415693 38.MartelJ.KoY.F.YoungJ.D.OjciusD.M.Could nasal" exact="nitric oxide" post="help to mitigate the severity of COVID-19?Microbes Infect.20202216817110.1016/j.micinf.2020.05.00232387333 39.LeiC.SuB.DongH.FakhrB.S.GrassiL.G.Di"/>
   <result pre="39.LeiC.SuB.DongH.FakhrB.S.GrassiL.G.Di FenzaR.GianniS.PinciroliR.VassenaE.MoraisC.C.A.et al.Protocol for a randomized controlled trial testing inhaled" exact="nitric oxide" post="therapy in spontaneously breathing patients with COVID-19medRxiv202010.1101/2020.03.10.20033522 40.HedenstiernaG.ChenL.HedenstiernaM.LiebermanR.FineD.H.Nitric oxide"/>
   <result pre="(Oxf.)200618743344610.1111/j.1748-1716.2006.01582.x16866775 43.SzilagyiJ.T.MishinV.HeckD.E.JanY.H.AleksunesL.M.RichardsonJ.R.HeindelN.D.LaskinD.L.LaskinJ.D.Selective Targeting of Heme Protein in Cytochrome P450 and" exact="Nitric Oxide" post="Synthase by DiphenyleneiodoniumToxicol. Sci.201615115015910.1093/toxsci/kfw03126880746 44.OlsonK.R.GaoY.DeLeonE.R.ArifM.ArifF.AroraN.StraubK.D.Catalase as a sulfide-sulfur oxido-reductase:"/>
   <result pre="Force: Mitochondrial Uncoupling and Reactive Oxygen SpeciesJ. Mol. Biol.20184303873389110.1016/j.jmb.2018.03.02529626541 80.SinghS.P.SchragenheimJ.CaoJ.FalckJ.R.AbrahamN.G.BellnerL.PGC-1" exact="alpha" post="regulates HO-1 expression, mitochondrial dynamics and biogenesis: Role of"/>
   <result pre="J.2005517318210.1038/sj.tpj.650030515768052 110.LeeJ.Y.VinayagamoorthyN.HanK.KwokS.K.JuJ.H.ParkK.S.JungS.H.ParkS.W.ChungY.J.ParkS.H.Association of Polymorphisms of Cytochrome P450 2D6 with Blood" exact="Hydroxychloroquine" post="Levels in Patients with Systemic Lupus ErythematosusArthritis Rheumatol.20166818419010.1002/art.3940226316040 111.WahieS.DalyA.K.CordellH.J.GoodfieldM.J.JonesS.K.LovellC.R.CarmichaelA.J.CarrM.M.DrummondA.NatarajanS.et"/>
   <result pre="ErythematosusArthritis Rheumatol.20166818419010.1002/art.3940226316040 111.WahieS.DalyA.K.CordellH.J.GoodfieldM.J.JonesS.K.LovellC.R.CarmichaelA.J.CarrM.M.DrummondA.NatarajanS.et al.Clinical and pharmacogenetic influences on response to" exact="hydroxychloroquine" post="in discoid lupus erythematosus: A retrospective cohort studyJ. Investig."/>
   <result pre="DenusS.Pharmacogenomics of heart failure: A systematic reviewPharmacogenomics2016171817185810.2217/pgs-2016-011827813451 117.QaseemA.YostJ.Etxeandia-IkobaltzetaI.MillerM.C.AbrahamG.M.ObleyA.J.ForcieaM.A.JokelaJ.A.HumphreyL.L.Should Clinicians Use" exact="Chloroquine" post="or Hydroxychloroquine Alone or in Combination with Azithromycin for"/>
   <result pre="heart failure: A systematic reviewPharmacogenomics2016171817185810.2217/pgs-2016-011827813451 117.QaseemA.YostJ.Etxeandia-IkobaltzetaI.MillerM.C.AbrahamG.M.ObleyA.J.ForcieaM.A.JokelaJ.A.HumphreyL.L.Should Clinicians Use Chloroquine or" exact="Hydroxychloroquine" post="Alone or in Combination with Azithromycin for the Prophylaxis"/>
   <result pre="Clinicians Use Chloroquine or Hydroxychloroquine Alone or in Combination with" exact="Azithromycin" post="for the Prophylaxis or Treatment of COVID-19?Ann. Intern. Med.202010.7326/M20-199832422063"/>
   <result pre="or Treatment of COVID-19?Ann. Intern. Med.202010.7326/M20-199832422063 118.GelerisJ.SunY.PlattJ.ZuckerJ.BaldwinM.HripcsakG.LabellaA.MansonD.K.KubinC.BarrR.G.et al.Observational Study of" exact="Hydroxychloroquine" post="in Hospitalized Patients with Covid-19N. Engl. J. Med.20203822411241810.1056/NEJMoa201241032379955 119.AgostiniM.L.AndresE.L.SimsA.C.GrahamR.L.SheahanT.P.LuX.SmithE.C.CaseJ.B.FengJ.Y.JordanR.et"/>
   <result pre="treatmentJAMA200629681582610.1001/jama.296.7.81516905787 139.ZhaoM.Cytokine storm and immunomodulatory therapy in COVID-19: Role of" exact="chloroquine" post="and anti-IL-6 monoclonal antibodiesInt. J. Antimicrob. Agents202010598210.1016/j.ijantimicag.2020.10598232305588 140.CharyM.A.BarbutoA.F.IzadmehrS.HayesB.D.BurnsM.M.COVID-19: Therapeutics"/>
   <result pre="active. Key: p38 mitogen-activated protein kinases = P38 MAPK, nicotinamide" exact="adenine" post="dinucleotide phosphate (NADP+/NADPH). Figure 4 The porphyrin synthesis pathway"/>
   <result pre="formation of ROS. Molecules such as uncoupling proteins (UCPs), and" exact="adenine" post="nucleotide translocases (ANTs) uncouple these reactions counteracting ATPaseâ€™s increased"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7402212\results\search\drug\results.xml">
   <result pre="no treatment benefit for severely infected patients by SARS-CoV-2 [77]." exact="Ribavirin" post="is a guanosine analogue, used to treat several viral"/>
   <result pre="when receiving ventilation, compared to 5% when not receiving [82]." exact="Chloroquine" post="and hydroxychloroquine Chloroquine is antimalarial and autoimmune disease drug."/>
   <result pre="ventilation, compared to 5% when not receiving [82]. Chloroquine and" exact="hydroxychloroquine" post="Chloroquine is antimalarial and autoimmune disease drug. It blocks"/>
   <result pre="compared to 5% when not receiving [82]. Chloroquine and hydroxychloroquine" exact="Chloroquine" post="is antimalarial and autoimmune disease drug. It blocks viral"/>
   <result pre="as interfering with the glycosylation of cellular receptor ACE2 [83]." exact="Hydroxychloroquine" post="is an analog of chloroquine. Both drugs have immunomodulatory"/>
   <result pre="response to SARS-CoV-2 [84]. Clinical controlled trials have shown that" exact="chloroquine" post="was proved to be effective in the treatment of"/>
   <result pre="perception, communication and managementSoc Sci Med6320063113312316978751 75YaoT.T.QianJ.D.ZhuW.Y.WangY.WangG.Q.A systematic review of" exact="lopinavir" post="therapy for SARS coronavirus and MERS coronavirus-A possible reference"/>
   <result pre="syndrome coronavirus 2 with high potencyJ Biol Chem2952020206785679732284326 81WangM.CaoR.ZhangL.YangX.LiuJ.XuM.Remdesivir and" exact="chloroquine" post="effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in"/>
   <result pre="inhibitor of SARS coronavirus infection and spreadVirol J220056916115318 84SavarinoA.BoelaertJ.R.CassoneA.MajoriG.CaudaR.Effects of" exact="chloroquine" post="on viral infections: an old drug against todayâ€™s diseases?Lancet"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7402395\results\search\drug\results.xml">
   <result pre="have four subfamilies including alpha, beta, gamma, and delta. The" exact="alpha" post="and beta coronaviruses originate from mammals, while gamma and"/>
   <result pre="adjunctive agents such as zinc, vitamin D, Azithromycin, Ascorbic acid," exact="Nitric oxide," post="Corticosteroids, IL-6 antagonists. Because the viral load reaches its"/>
   <result pre="be specifically linked to 2019-nCoV RBD [87]. Other examples are" exact="Chloroquine" post="and Hydroxychloroquine, that have been used as antimalaria for"/>
   <result pre="[88], but several clinical studies have reported that administration of" exact="chloroquine" post="and hydroxychloroquine is associated with an increased risk of"/>
   <result pre="several clinical studies have reported that administration of chloroquine and" exact="hydroxychloroquine" post="is associated with an increased risk of heart problems"/>
   <result pre="inhibitor of SARS coronavirus infection and spreadVirol J200526916115318 89.SinghAKSinghAShaikhASinghRMisraAChloroquine and" exact="hydroxychloroquine" post="in the treatment of COVID-19 with or without diabetes:"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7402641\results\search\drug\results.xml">
   <result pre="influenza A virus infection when compared to the DAA drug" exact="Zanamivir" post="(100%) in parallel (Cheung et al., 2017). Another two"/>
   <result pre="CC50/EC50. As shown in Fig.Â 1D, the antiviral effect of" exact="Leflunomide" post="is hardly detectable at the cell culture level (EC50"/>
   <result pre="Â± 67.69 SI 5.10 65.38 53.13 3.14 32.26 141.75 32.64" exact="Leflunomide" post="EC50 &amp;gt;25.00 â€&quot; â€&quot; â€&quot; â€&quot; â€&quot; 41.49 Â±"/>
   <result pre="stronger than Favipiravir (EC50 = 66.85 Î¼mol/L), whereas its pro-drug" exact="Leflunomide" post="showed less inhibition of EC50 = 41.49 Î¼mol/L. Additionally,"/>
   <result pre="of Remdesivir (EC50 = 0.77 Î¼mol/L, SI &amp;gt; 129.87) and" exact="Chloroquine" post="(EC50 = 1.13 Î¼mol/L, SI &amp;gt; 88.50) (Wang et"/>
   <result pre="had much greater EC50 and SI values (66.5-fold stronger than" exact="Chloroquine" post="in EC50) against SARS-CoV-2. To determine more carefully the"/>
   <result pre="data in Fig.Â 2B clearly showed that all DHODHi including" exact="Leflunomide" post="(200 Î¼mol/L), Teriflunomide (67 Î¼mol/L), Brequinar (10 Î¼mol/L), S312"/>
   <result pre="dose of 5 mg/kg in the following experiments. FigureÂ 3" exact="Thein" post="vivoantiviral activity of S312 in influenza A virus-infected mice."/>
   <result pre="influenza and COVID-19, always induce pathogenic immunity as cytokine/chemokine storms." exact="Leflunomide" post="and Teriflunomide are already clinically used in autoimmune disease"/>
   <result pre="al., 2009; Gao et al., 2013; Hung et al., 2013)." exact="Leflunomide" post="and its active metabolite Teriflunomide have been approved for"/>
   <result pre="exist in COVID-19 patients. The active metabolite A771726 (Teriflunomide) of" exact="Leflunomide" post="inhibited the proliferation of PHA mitogen-stimulated human lymphocytes with"/>
   <result pre="46 Âµmol/L (Fox et al., 1999). The recommended dosage of" exact="Leflunomide" post="in treating rheumatoid arthritis (RA) is loading 100 mg/day"/>
   <result pre="0.05; EC50 = 6.00 Î¼mol/L at MOI = 0.03). As" exact="Leflunomide" post="has been widely used and proved to treat RA"/>
   <result pre="of data qualityActa Crystallogr Sect D200662728216369096 FoxRIHerrmannMLFrangouCGWahlGMMorrisREStrandVKirschbaumBJMechanism of action for" exact="leflunomide" post="in rheumatoid arthritisClin Immunol19999319820810600330 GaoGFFrom â€œAâ€�IV to â€œZâ€�IKV: attacks"/>
   <result pre="J200636316945126 MatsuokaYLamirandeEWSubbaraoKThe mouse model for influenzaCurr Protoc Microbiol20091315G-3 McNichollIRMcNichollJJNeuraminidase inhibitors:" exact="zanamivir" post="and oseltamivirAnn Pharmacother200135577011197587 Mei-jiaoGShi-fangLYan-yanCJun-junSYue-fengSTing-tingRYong-guangZHui-yunCAntiviral effects of selected IMPDH and"/>
   <result pre="virus through suppression of host pyrimidine biosynthesisJ Virol2011856548655621507975 WangMCaoRZhangLYangXLiuJXuMShiZHuZZhongWXiaoGRemdesivir and" exact="chloroquine" post="effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7402643\results\search\drug\results.xml">
   <result pre="hand sanitizer (æ´—æ‰‹æ¶²), disinfectant (æ¶ˆæ¯’æ¶²/æ¶ˆæ¯’å‰‚/æ¶ˆæ¯’æ°´), thermometer (ä½&quot;æ¸©è®¡) Rumors Worldwide chloroquine," exact="hydroxychloroquine" post="China radix isatidis (æ�¿è&quot;�æ ¹), Shuanghuanglian (å�Œé»&quot;è¿ž), garlic (å¤§è’œ)"/>
   <result pre="on specific terms is standardized as 100%). The antimalarial drugs" exact="chloroquine" post="and hydroxychloroquine have been repeatedly mentioned by world-leading politicians"/>
   <result pre="terms is standardized as 100%). The antimalarial drugs chloroquine and" exact="hydroxychloroquine" post="have been repeatedly mentioned by world-leading politicians as treatments"/>
   <result pre="5 shows the Google Trends data for the antimalarial drugs" exact="chloroquine" post="and hydroxychloroquine worldwide. Public searches for chloroquine started to"/>
   <result pre="the Google Trends data for the antimalarial drugs chloroquine and" exact="hydroxychloroquine" post="worldwide. Public searches for chloroquine started to increase and"/>
   <result pre="the antimalarial drugs chloroquine and hydroxychloroquine worldwide. Public searches for" exact="chloroquine" post="started to increase and reached a small peak in"/>
   <result pre="started to spread in Italy. The increase in searches for" exact="chloroquine" post="was observed during this time only in Asian and"/>
   <result pre="and limitations in health and health policy researchHealth Policy20193123333834110.1016/j.healthpol.2019.01.00130660346 21RobertsonATrumpâ€™s" exact="chloroquine" post="hype is a misinformation problem bigger than social mediaThe"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7403001\results\search\drug\results.xml">
   <result pre="litonavir), RNA polymerase inhibitors (e.g., remdesivir), neuraminidase inhibitors (oseltamivir), and" exact="chloroquine" post="phosphate have been shown to have therapeutic effects.44, 45,"/>
   <result pre="options for severe acute respiratory infections caused by 2019-nCoVChembiochem21202073073832022370 47GaoJ.TianZ.YangX.Breakthrough:" exact="chloroquine" post="phosphate has shown apparent efficacy in treatment of COVID-19"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7403098\results\search\drug\results.xml">
   <result pre="cells, IL2, IL-12, interferon gamma (IFN-Î³), and transforming growth factor" exact="alpha" post="(TGF-Î±), effector cells produce antibodies to destroy the infected"/>
   <result pre="the trialed antiviral drugs, remdesivir alone or in combination with" exact="chloroquine" post="or interferon beta showed effectiveness against COVID-19 infection (Sheahan"/>
   <result pre="effectiveness against COVID-19 infection, ganciclovir, acyclovir, ribavirin, oseltamivir, peramivir, and" exact="zanamivir" post="are not promising options to treat COVID-19. However, remdesivir,"/>
   <result pre="infection (Chan et al., 2020). Previous studies have shown that" exact="chloroquine" post="(broadly used antimalarial drug) exhibits antiviral properties against several"/>
   <result pre="SARS-CoV-2 (Colson et al., 2020). However, the toxic effects of" exact="chloroquine" post="such as increasing the risk for cardiovascular disorders have"/>
   <result pre="the Chinese Clinical Trial Registry (www.chictr.org.cn), proposing the use of" exact="chloroquine" post="in controlling COVID-19 (under registration numbers: ChiCTR-20000-29542, 29559, 29609,"/>
   <result pre="could be a target to prevent viral entry. Moreover, Transmembrane" exact="Serine" post="Protease 2 (TMPRSS2) is helper membrane protein for the"/>
   <result pre="Human Coronavirus SARS-CoV-2 and Bat-SARSr-CoV RaTG13bioRxiv20209690062020.2002, 2027 MatsuyamaS.KawaseM.NaoN.ShiratoK.UjikeM.KamitaniW.ShimojimaM.FukushiS.The Inhaled Corticosteroid" exact="Ciclesonide" post="Blocks Coronavirus RNA Replication by Targeting Viral NSP15bioRxiv202010.1101/03.11.9870162020 MengL.HuaF.BianZ.Coronavirus"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7404079\results\search\drug\results.xml">
   <result pre="and gastrointestinal tract illnesses [19]. Sirtuins, a family of nicotinamide" exact="adenine" post="dinucleotide (NAD)+ dependent deacetylases, play an important role in"/>
   <result pre="virus-receptor interaction [33]. Promoter hypermethylation downregulates APN gene expression and" exact="azacitidine" post="(5-azaC) induces APN protein expression [34]. In melanoma cells,"/>
   <result pre="to inhibit the activity of 3CLpro including the anti-HIV drug" exact="lopinavir" post="[16]. The structural viral proteins (NP, M, E, and"/>
   <result pre="favipiravir, ribavirin, galidesivir, and its salt form (BCX-4430) targeting RdRp;" exact="ritonavir" post="and darunavir targeting viral proteases (3CLpro or PLpro) in"/>
   <result pre="darunavir targeting viral proteases (3CLpro or PLpro) in addition to" exact="camostat" post="mesylate which is a serine protease inhibitor directly acting"/>
   <result pre="and S protein showed efficacy against SARS-CoV-2 as well as" exact="chloroquine" post="which possesses an antiviral and an anti-inflammatory effect [16]."/>
   <result pre="and depsipeptide [63, 66, 67]. Other potent HDACi such as" exact="vorinostat" post="or suberanilohydroxamic acid (SAHA), belinostat, romidepsin, and panobinostat were"/>
   <result pre="[63, 66, 67]. Other potent HDACi such as vorinostat or" exact="suberanilohydroxamic acid" post="(SAHA), belinostat, romidepsin, and panobinostat were already used for"/>
   <result pre="the contrary, a possible synergism was revealed combining BIX-01294 with" exact="vorinostat" post="and DZNep with vorinostat [71]. BRD4, a chief gene"/>
   <result pre="synergism was revealed combining BIX-01294 with vorinostat and DZNep with" exact="vorinostat" post="[71]. BRD4, a chief gene expression regulator, is involved"/>
   <result pre="NFÎºB pathway [58]. Panobinostat + antivirals or (rapamycin, selumetinib, trametinib)" exact="Belinostat" post="and domatinostat Enhanced TGF-Î² expression [58]. Belinostat or domatinostat"/>
   <result pre="(rapamycin, selumetinib, trametinib) Belinostat and domatinostat Enhanced TGF-Î² expression [58]." exact="Belinostat" post="or domatinostat + antivirals or (rapamycin, selumetinib, trametinib) HKMT"/>
   <result pre="cellular antiviral state and reduced viral yields [57]. DZNep +" exact="vorinostat" post="HKMT G9a BIX-01294 Enhancing antiviral state [57]. BIX-01294 +"/>
   <result pre="vorinostat HKMT G9a BIX-01294 Enhancing antiviral state [57]. BIX-01294 +" exact="vorinostat" post="HMT Suv39H1 Chaetocin Permanent cell cycle arrest and RNA"/>
   <result pre="and TGF-Î² [58]. 5-azadC + antivirals or (rapamycin, selumetinib, trametinib)" exact="Azacitidine" post="Viral mimicry [62]. Azacitidine + antivirals or (rapamycin, selumetinib,"/>
   <result pre="+ antivirals or (rapamycin, selumetinib, trametinib) Azacitidine Viral mimicry [62]." exact="Azacitidine" post="+ antivirals or (rapamycin, selumetinib, trametinib) BET proteins (BRD4)"/>
   <result pre="Besides, 5-azadC induced IL-10 marker and TGF-Î² [58, 70, 93]." exact="Belinostat" post="and domatinostat enhanced the expression of TGF-Î² [58]. Moreover,"/>
   <result pre="were clinically recovered after the administration of remdesivir combined with" exact="chloroquine" post="(CQ) or IFN-Î² due to the significant blockade of"/>
   <result pre="potency of antiviral therapy was achieved after the fusion of" exact="ribavirin" post="and IFN with immunomodulating agents such as intravenous N-acetylcysteine"/>
   <result pre="of ribavirin and IFN with immunomodulating agents such as intravenous" exact="N-acetylcysteine" post="[94]. Few synergistic combinations resulting from a network-based analysis"/>
   <result pre="[94]. Few synergistic combinations resulting from a network-based analysis include" exact="sirolimus" post="and dactinomycin, an approved RNA synthesis inhibitor, target HCoV-associated"/>
   <result pre="combined with other host-targeting molecules such as peroxisome proliferator-activated receptor" exact="alpha" post="(PPAR-Î±) agonists [11]. In a retrospective analysis, ribavirin was"/>
   <result pre="proliferator-activated receptor alpha (PPAR-Î±) agonists [11]. In a retrospective analysis," exact="ribavirin" post="was tested in combination with corticosteroids, immunoglobulins, and/or antibiotics"/>
   <result pre="SARS-CoV; no efficacy and high fatality rates were shown. Since" exact="ribavirin" post="treatment did not improve patient outcome health, Canada stopped"/>
   <result pre="the use of ribavirin. Additional studies tested the activity of" exact="ribavirin" post="jointly with lopinavir against SARS-CoV. Compared to the control"/>
   <result pre="ribavirin. Additional studies tested the activity of ribavirin jointly with" exact="lopinavir" post="against SARS-CoV. Compared to the control groups, confirmed SARS-CoV"/>
   <result pre="consequences. In another retrospective analysis, patients were treated with oral" exact="ribavirin" post="and SC pegylated IFN-Î±2a for 2 weeks. At day"/>
   <result pre="either alfacon-1, a recombinant consensus IFN-Î±, or protease inhibitors and" exact="ribavirin" post="were found to improve patientsâ€™ health [56]. Patients with"/>
   <result pre="Chromatin immuno-precipitation COVID-19 Coronavirus infectious disease 2019 CoVs Coronaviruses CQ" exact="Chloroquine" post="DCs Dendritic cells DDR DNA damage response DENV Dengue"/>
   <result pre="array MyD88 Myeloid differentiation primary response gene 88 NAD Nicotinamide" exact="adenine" post="dinucleotide NP Nucleocapsid Nsp Non-structural proteins ORF Open reading"/>
   <result pre="of International Concern PLpro Papain-like protease PPAR-Î± Peroxisome proliferator-activated receptor" exact="alpha" post="PRR Prorenin receptor P-TEFb Positive transcription elongation factor beta"/>
   <result pre="COVID-19 susceptibility and severity in lupus patientsClin Immunol.202021510841032276140 84.LedfordHCoronavirus breakthrough:" exact="dexamethasone" post="is first drug shown to save livesNature.202058246932546811 85.Horby P,"/>
   <result pre="of coronavirus disease (COVID-19) outbreakJ Autoimmun.202010910243332113704 96.Principi N, Esposito S." exact="Chloroquine" post="or hydroxychloroquine for prophylaxis of COVID-19. Lancet Infect Dis."/>
   <result pre="disease (COVID-19) outbreakJ Autoimmun.202010910243332113704 96.Principi N, Esposito S. Chloroquine or" exact="hydroxychloroquine" post="for prophylaxis of COVID-19. Lancet Infect Dis. 2020;S1473309920302966. 97.SinghAKSinghAShaikhASinghRMisraAChloroquine"/>
   <result pre="for prophylaxis of COVID-19. Lancet Infect Dis. 2020;S1473309920302966. 97.SinghAKSinghAShaikhASinghRMisraAChloroquine and" exact="hydroxychloroquine" post="in the treatment of COVID-19 with or without diabetes:"/>
   <result pre="developing countriesDiabetes Metab Syndr Clin Res Rev.202014241246 98.WangMCaoRZhangLYangXLiuJXuMet al.Remdesivir and" exact="chloroquine" post="effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7404132\results\search\drug\results.xml">
   <result pre="values of total bilirubin, creatinine, cardiac troponins, aspartate aminotransferase (AST)," exact="alanine" post="aminotransferase (ALT), prothrombin time (PT), and procalcitonin were detected"/>
   <result pre="the HIV (Human Immunodeficiency Virus) protease inhibitor ASC09F, ritonavir, and" exact="cobicistat" post="[52]. There is, so far, a lack of supportive"/>
   <result pre="can potentially treat COVID-19. The use of HIV protease inhibitor" exact="lopinavir" post="in association with ritonavir in recent Chinese trials on"/>
   <result pre="The use of HIV protease inhibitor lopinavir in association with" exact="ritonavir" post="in recent Chinese trials on SARS-CoV2 patients requires further"/>
   <result pre="combination with other antiviral drugs, such as lopinavir, ritonavir, or" exact="ribavirin" post="[60]. In the study by Hung et al. (2020)"/>
   <result pre="the efficacy and safety of IFN Î²1b, lopinavir, ritonavir, and" exact="ribavirin" post="was assessed in a multicenter, prospective, open-label, randomized, phase"/>
   <result pre="of moderate forms of COVID-19. IFN Î²1a in combination with" exact="hydroxychloroquine" post="and lopinavir/ritonavir was effective in reducing disease symptoms at"/>
   <result pre="and other factors may lead to disseminated intravascular coagulation [14]." exact="Chloroquine" post="(CQ) and hydroxychloroquine (HCQ) have been used for prevention"/>
   <result pre="may lead to disseminated intravascular coagulation [14]. Chloroquine (CQ) and" exact="hydroxychloroquine" post="(HCQ) have been used for prevention and treatment of"/>
   <result pre="conducted in China demonstrated apparent efficacy and acceptable safety of" exact="chloroquine" post="or hydroxychloroquine in the treatment of COVID-19 associated pneumonia"/>
   <result pre="China demonstrated apparent efficacy and acceptable safety of chloroquine or" exact="hydroxychloroquine" post="in the treatment of COVID-19 associated pneumonia [70]. Regarding"/>
   <result pre="Adenovirus 5 ALT Alanine aminotransferase ARDS Acute-respiratory disease syndrome AST" exact="Aspartate" post="aminotransferase AT1R Angiotensin type-1 receptor CAR Chimeric antigen receptor"/>
   <result pre="CoV Coronavirus COVID-19 Coronavirus disease 2019 CP Convalescent plasma CQ" exact="Chloroquine" post="CRP C reactive protein CRS Cytokine release syndrome CTL"/>
   <result pre="Dendritic cells ESR Erythrocyte sedimentation rate hAds Human adenoviruses HCQ" exact="Hydroxychloroquine" post="HIV Human Immunodeficiency Virus IDV Immune-derived vaccines iPSC Induced"/>
   <result pre="questionsCell Biosci.202010404510.1186/s13578-020-00404-432190290 60.HungI.F.-N.LungK.-C.TsoE.Y.-K.LiuR.ChungT.W.-H.ChuM.-Y.NgY.-Y.LoJ.ChanJ.TamA.R.et al.Triple combination of interferon beta-1b, lopinavirâ€&quot;ritonavir, and" exact="ribavirin" post="in the treatment of patients admitted to hospital with"/>
   <result pre="beta-1a for COVID-19: A non-controlled prospective trialInt. Immunopharmacol.20208510668810.1016/j.intimp.2020.10668832544867 63.YanY.ZouZ.SunY.LiX.XuK.-F.WeiY.NingyiJ.JiangC.Anti-malaria drug" exact="chloroquine" post="is highly effective in treating avian influenza A H5N1"/>
   <result pre="modelCell Res.20122330030210.1038/cr.2012.16523208422 64.ZhouD.DaiS.-M.TongQ.COVID-19: A recommendation to examine the effect of" exact="hydroxychloroquine" post="in preventing infection and progressionJ. Antimicrob. Chemother.2020751667167010.1093/jac/dkaa11432196083 65.BorneB.E.V.D.DijkmansB.A.de RooijH.H.le"/>
   <result pre="preventing infection and progressionJ. Antimicrob. Chemother.2020751667167010.1093/jac/dkaa11432196083 65.BorneB.E.V.D.DijkmansB.A.de RooijH.H.le CessieS.VerweijC.L.Chloroquine and" exact="hydroxychloroquine" post="equally affect tumor necrosis factor-alpha, interleukin 6, and interferon-gamma"/>
   <result pre="Production through Blockade of Cyclic GMP-AMP Synthaseâ€&quot;DNA InteractionJ. Immunol.20151944089409310.4049/jimmunol.140279325821216 70.GaoJ.TianZ.YangX.Breakthrough:" exact="Chloroquine" post="phosphate has shown apparent efficacy in treatment of COVID-19"/>
   <result pre="associated pneumonia in clinical studiesBiosci. Trends202014727310.5582/bst.2020.0104732074550 71.SchrezenmeierE.DornerT.Mechanisms of action of" exact="hydroxychloroquine" post="and chloroquine: Implications for rheumatologyNat. Rev. Rheumatol.20201615516610.1038/s41584-020-0372-x32034323 72.BaronS.A.DevauxC.ColsonP.RaoultD.RolainJ.-M.Teicoplanin: An"/>
   <result pre="[60] AssociationIFN alpha2b/Umifenovir SARS anti-CoV2 activity [61] Association IFN beta1a" exact="hydroxychloroquine" post="Lopinavir/Ritonavir SARS anti-CoV2 activity [62] Chloroquine and hydroxychloroquine Endosomal"/>
   <result pre="[61] Association IFN beta1a hydroxychloroquine Lopinavir/Ritonavir SARS anti-CoV2 activity [62]" exact="Chloroquine" post="and hydroxychloroquine Endosomal acidification/Acting on a lysosomotropic base that"/>
   <result pre="IFN beta1a hydroxychloroquine Lopinavir/Ritonavir SARS anti-CoV2 activity [62] Chloroquine and" exact="hydroxychloroquine" post="Endosomal acidification/Acting on a lysosomotropic base that appears to"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7404498\results\search\drug\results.xml">
   <result pre="pmcid: 7404498 doi: 10.1111/eci.13358ECI13358 : Letter: Letters High doses of" exact="hydroxychloroquine" post="do not affect viral clearance in patients with SARSâ€�CoVâ€�2"/>
   <result pre="of the public health emergency.file:ECI-9999-e13358.pdf Abstract Abstract The use of" exact="hydroxychloroquine" post="(HCQ) has been considered a therapeutic option by international"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7404911\results\search\drug\results.xml">
   <result pre="18% of previously treated cases developed multidrug-resistant TB (MDR-TB) or" exact="rifampicin" post="(RFP)-resistant TB (RR/TB) in 2018 [1]. Drug-resistant TB (DR-TB)"/>
   <result pre="resistance to more than one first-line anti-TB drug, other than" exact="isoniazid" post="(INH) and RFP [22]. RR-TB is considered susceptible to"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7405164\results\search\drug\results.xml">
   <result pre="in both the host and the virus. Drugs such as" exact="chloroquine" post="may contribute to increased intracellular zinc. Moreover, clinical trials"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7405322\results\search\drug\results.xml">
   <result pre="4â€�drug, weightâ€�appropriate, TB regimen at diagnosis. He did not receive" exact="prednisone" post="at the time as the airway obstruction was deemed"/>
   <result pre="rifampicin, isoniazid, pyrazinamide, and ethambutol, was continued and adjuvant oral" exact="prednisone" post="2â€‰mg/kg was added before the diagnosis of COVIDâ€�19, interrupted"/>
   <result pre="5, followed by selfâ€�isolation. He received two doses of oral" exact="prednisone" post="before the diagnosis of COVIDâ€�19. The airway obstruction will"/>
   <result pre="decision either to treat medically with antituberculous drugs and oral" exact="prednisone" post="or intervene surgically.10 As bronchoscopy is a very highâ€�risk"/>
   <result pre="airway obstruction due to COVIDâ€�19, which subsequently rapidly improved. Oral" exact="prednisone" post="at 2â€‰mg/kg for TB airway obstruction was continued for"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7405402\results\search\drug\results.xml">
   <result pre="The efficiency of seven antiâ€�viral drugs (ribavirin, nafamostat, nitazoxanide, penciclovir," exact="chloroquine" post="(CQ) remdesivir and favipiravir) on only a single clinical"/>
   <result pre="TableÂ 1. The cell culture investigations showed that the compounds" exact="chloroquine" post="(CQ) and remdesivir (RDV) effectively inhibited the infection by"/>
   <result pre="Target Antiâ€�viral mechanism of action References Remdesivir RNA polymerase An" exact="adenine" post="analogue that participates into nascent viral RNA chains and"/>
   <result pre="chains and causes in preâ€�mature termination Wang etÂ al.Â (2020)" exact="Baloxavir marboxil" post="RNA polymerase Capâ€�dependent endonuclease inhibitor HarrisonÂ (2020) Triazavirin RNA"/>
   <result pre="(2020) Baloxavir marboxil RNA polymerase Capâ€�dependent endonuclease inhibitor HarrisonÂ (2020)" exact="Triazavirin" post="RNA polymerase A guanosine nucleotide analogue that inhibits RNA"/>
   <result pre="polymerase Inhibits RNAâ€�dependent RNA polymerase (RdRp) Wang etÂ al.Â (2020)" exact="Ribavirin" post="RNA polymerase Inhibits viral RNA synthesis and mRNA capping"/>
   <result pre="and mRNA capping Khalili, Zhu, Mak, Yan, and ZhuÂ (2020)" exact="Penciclovir" post="RNA polymerase Inhibits RNAâ€�dependent RNA polymerase (RdRp) Wang etÂ"/>
   <result pre="by terminating nonâ€�obligate RNA chain Li and De ClercqÂ (2020)" exact="Ritonavir" post="Protease Inhibits 3CLpro StowerÂ (2020) ASC09F Protease A combination"/>
   <result pre="+ ritonavir/ Oseltamivir Li and De ClercqÂ (2020) Camostat Protease" exact="Serine" post="protease inhibitor with activity against the host TMPRSS2 protease"/>
   <result pre="potent HCV protease (NS3/4A) inhibitor Shah, Modi, and SagarÂ (2020)" exact="Nelfinavir" post="Protease Inhibits chymotrypsinâ€�like protease (3CLpro) Xu et al. (2020)"/>
   <result pre="Epoprostenol Protease Inhibits chymotrypsinâ€�like protease (3CLpro) Liu and WangÂ (2020)" exact="Vapreotide" post="Protease Inhibits chymotrypsinâ€�like protease (3CLpro) Liu and WangÂ (2020)"/>
   <result pre="LiuÂ (2020) Beclabuvir Protease Inhibits chymotrypsinâ€�like protease (3CLpro) TalluriÂ (2020)" exact="Saquinavir" post="Protease Inhibits chymotrypsinâ€�like protease (3CLpro) TalluriÂ (2020) Î±â€�ketoamide Protease"/>
   <result pre="ContiniÂ (2020) Indinavir Protease Inhibits chymotrypsinâ€�like protease (3CLpro) ContiniÂ (2020)" exact="Cobicistat" post="Protease Inhibits chymotrypsinâ€�like protease (3CLpro) ContiniÂ (2020) Atazanavir Protease"/>
   <result pre="ContiniÂ (2020) Cobicistat Protease Inhibits chymotrypsinâ€�like protease (3CLpro) ContiniÂ (2020)" exact="Atazanavir" post="Protease Inhibits chymotrypsinâ€�like protease (3CLpro) ContiniÂ (2020) Mycophenolic acid"/>
   <result pre="Grazoprevir Protease Inhibits papainâ€�like protease (PLpro) Elfiky and IbrahimÂ (2020)" exact="Formoterol" post="Protease Inhibits papainâ€�like protease (PLpro) Arya, Das, Prashar, and"/>
   <result pre="Inhibits papainâ€�like protease (PLpro) Arya, Das, Prashar, and KumarÂ (2020)" exact="Telaprevir" post="Protease Inhibits papainâ€�like protease (PLpro) Elfiky and IbrahimÂ (2020)"/>
   <result pre="viral spike protein interaction Yang, Li, Bai, and HouÂ (2020)" exact="Molsidomine" post="ACE2 Decrease the expression of ACE2 Yang etÂ al.Â"/>
   <result pre="an important regulator of clathrinâ€�mediated endocytosis. Richardson etÂ al.Â (2020)" exact="Ruxolitinib" post="Kinase Janusâ€�associated kinase (JAK) inhibitor blocking ACE2â€�mediated endocytosis Stebbing"/>
   <result pre="innate immune response to produce interferons Wang etÂ al.Â (2020)" exact="Nafamostat" post="Spike glycoprotein Inhibits the membrane fusion Wang etÂ al.Â"/>
   <result pre="L in the late endosomes Zhang, Ma, et al. (2020))" exact="Ciclesonide" post="Endoribonuclease A corticosteroid that inhibits replication via inhibition of"/>
   <result pre="humanized monoclonal antibody (mAb) targeting PDâ€�1 AminJafari and GhasemiÂ (2020)" exact="Emtricitabine" post="Reverse transcriptase Nonâ€�nucleoside reverse transcriptase inhibitor HarrisonÂ (2020) Tenofovir"/>
   <result pre="transcriptase Experimental reverse transcriptase inhibitor drug against HIVâ€�1/AIDS HarrisonÂ (2020)" exact="Methylprednisolone" post="Nuclear receptors Synthetic corticosteroid that binds to nuclear receptors"/>
   <result pre="(2020) Tocilizumab ILâ€�6 receptor Immunosuppressive antiâ€�ILâ€�6 receptor mAb HarrisonÂ (2020)" exact="Amantadine" post="Viroporin E Inhibits the uncounting stage Aranda Abreu etÂ"/>
   <result pre="E Inhibits the uncounting stage Aranda Abreu etÂ al.Â (2020)" exact="Thalidomide" post="ND Regulating immunity, inhibiting the inflammatory cytokine surge Dastan"/>
   <result pre="targeting the viral entry Li and De ClercqÂ (2020) Chloroquine/" exact="hydroxychloroquine" post="ND 1. Elevate the pH of acidic intracellular organelles,"/>
   <result pre="(2020) Fingolimod ND Sphingosineâ€�1â€�phosphate receptor regulator Rosa and SantosÂ (2020)" exact="Dipyridamole" post="ND Adenosine deaminase and phosphodiesterase inhibitor AlyÂ (2020) Abbreviation:"/>
   <result pre="ND Sphingosineâ€�1â€�phosphate receptor regulator Rosa and SantosÂ (2020) Dipyridamole ND" exact="Adenosine" post="deaminase and phosphodiesterase inhibitor AlyÂ (2020) Abbreviation: ND, not"/>
   <result pre="drug candidates in clinical trials Remdesivir (RDV, GSâ€�5734) is an" exact="adenosine" post="analogue that has completed the clinical trial phase III"/>
   <result pre="II NCT04280588 Fingolimod Modulation of Sphingosine 1â€�phosphate receptor II NCT04273529" exact="Thalidomide" post="Inhibition of Inflammatory cells and cytokines II NCT04288102 Biological:"/>
   <result pre="function II NCT04317092 Tocilizumab ILâ€�6â€�mediated signalling inhibition II NCT04321993 Lopinavir/ritonavir;" exact="Hydroxychloroquine" post="sulphate; Baricitinib (janus kinase inhibitor); Sarilumab (antiâ€�ILâ€�6 receptor) Protease"/>
   <result pre="of the S protein binding to the cell II NCT04279197" exact="Acetylcysteine" post="Mucolytic agent II NCT04311177 Losartan Angiotensin II receptor blocker"/>
   <result pre="receptor blocker II NCT04292899 Remdesivir RNA polymerase inhibition III NCT04325633" exact="Naproxen" post="Prostaglandin G/H synthase inhibition III NCT04304313 Sildenafil citrate cGMPâ€�specific"/>
   <result pre="inhibition III NCT04320615 Tocilizumab (TCZ) ILâ€�6â€�mediated signalling inhibition III NCT04315896" exact="Hydroxychloroquine" post="Accumulation and raising the pH of the vacuole III"/>
   <result pre="III NCT04324021 Emapalumab Neutralizing the interferonâ€�gamma III NCT04252274 Darunavir and" exact="cobicistat" post="Protease inhibitionâ€� cytochrome P450 3A (CYP3A) isoforms inhibition III"/>
   <result pre="Hydrochloride combined with Interferon atomization Dualâ€�acting direct antiâ€�viral/hostâ€�targeting IV NCT04263402" exact="Methylprednisolone" post="Corticosteroid IV NCT04252885 Umifenovir (Arbidol) Dualâ€�acting direct antiâ€�viral/hostâ€�targeting IV"/>
   <result pre="ND Integrins ND Spike protein* EK1C4 Uncoating Ion channel proteins" exact="Amantadine" post="Replicase Protein Expression Papainâ€�like proteinase (PLpro) Mycophenolic acid, Grazoprevir,"/>
   <result pre="Atazanavir, Replication ofÂ viral genome RNAâ€�dependent RNA polymerase (RdRp)* Remdesivir," exact="Baloxavir marboxil," post="Triazavirin, Favipiravir (Avigan), Ribavirin, Penciclovir, Acyclovir fleximer analogue, Galidesivir"/>
   <result pre="the treatment of acute coronary syndrome with the small molecule" exact="tirofiban" post="(Î±IIbÎ²3 blocker) are examples of approved drugs based on"/>
   <result pre="enteroviruses (Yamauchi &amp;amp; Greber,Â 2016). In accordance with this approach," exact="rimantadine" post="inhibits the capsid disintegration by blocking the ion channel"/>
   <result pre="Abreu et al. They proposed an in situ models of" exact="amantadine" post="as a drug to relieve the effects of SARSâ€�CoVâ€�2"/>
   <result pre="2020), etc have also been reported. Another PLpro inhibitor named" exact="disulfiram" post="has been identified to block the function of this"/>
   <result pre="computational drug repositioning research, five drugs, namely eravacycline, valrubicin, carfilzomib," exact="lopinavir" post="and elbasvir, have speculated to exhibit blocking activities on"/>
   <result pre="(Wang,Â 2020). According to another computational prediction, bortezomib, flurazepam, ponatinib," exact="sorafenib" post="and dasatinib are five other potent potential inhibitors of"/>
   <result pre="According to another computational prediction, bortezomib, flurazepam, ponatinib, sorafenib and" exact="dasatinib" post="are five other potent potential inhibitors of 3Cl pro"/>
   <result pre="et al., 2020). The antiâ€�viral agents of remdesivir, favipiravir and" exact="penciclovir" post="can block the RNAâ€�dependent RNA polymerase (RdRp) of many"/>
   <result pre="2020; Zhang, Lin, et al., 2020). The high concentrations of" exact="penciclovir" post="(EC50Â =Â 95.96Â Î¼M) and favipiravir (EC50Â =Â 61.88Â"/>
   <result pre="during the protein folding. The PPIase activity is blocked by" exact="cyclosporin A" post="and its different analogues which are nonâ€�immunosuppressive agents (de"/>
   <result pre="rather resistant to many nucleoside analogues including favipiravir (guanine analogue)," exact="ribavirin" post="(guanosine analogue) and 5â€�fluorouracil (pyrimidine analogue) (Harrison,Â 2020). Remdesivir,"/>
   <result pre="in the society. Drugs like zanamivir, oseltamivir, laninamivir octanoate and" exact="peramivir" post="inhibit this step by targeting viral neuraminidase to block"/>
   <result pre="Informa Pharma Intelligence. Nevertheless, HIV protease inhibitors (ritonavir/lopinavir/ASC09), favipiravir and" exact="chloroquine" post="need further investigations. 5 FUTURE DIRECTIONS As we proceed"/>
   <result pre="reveals the potential of aliskiren, dipyridamole, mopidamol, rosuvastatin, rolitetracycline and" exact="metamizole" post="to inhibit COVIDâ€�19 virus main protease. ChemRxiv. Preprint. 10.26434/chemrxiv.12061302.v1"/>
   <result pre="M. E., Herrera Covarrubias, D., &amp;amp; Rojas DurÃ¡n, F. (2020)." exact="Amantadine" post="as a drug to mitigate the effects of COVIDâ€�19."/>
   <result pre="coronavirus NL63 replication is cyclophilin Aâ€�dependent and inhibited by nonâ€�immunosuppressive" exact="cyclosporine" post="Aâ€�derivatives including Alisporivir. Virus Research, 184, 44â€&quot;53. 10.1016/j.virusres.2014.02.01024566223 Cascella,"/>
   <result pre="A., Hashemian, S. M., Tavakoliâ€�Ardakani, M., &amp;amp; Saffaei, A. (2020)." exact="Thalidomide" post="against coronavirus disease 2019 (COVIDâ€�19): A medicine with a"/>
   <result pre="â€¦ Ribeill, Y. (2010). SCYâ€�635, a novel nonimmunosuppressive analog of" exact="cyclosporine" post="that exhibits potent inhibition of hepatitis C virus RNA"/>
   <result pre="G., (2010). Structural basis for the nonâ€�immunosuppressive character of the" exact="cyclosporin A" post="analogue Debio 025. Biochemistry, 49, 4679â€&quot;4686. 10.1021/bi100326620423153 Lemmon, M."/>
   <result pre="305â€&quot;306. 10.1038/d41573-020-00073-5 Touret, F., &amp;amp; de Lamballerie, X. (2020). Of" exact="chloroquine" post="and COVIDâ€�19. Antiviral Research, 177, 10476210.1016/j.antiviral.2020.10476232147496 Tugizov, S. M.,"/>
   <result pre="Liu, J., Xu, M., â€¦ Xiao, G. (2020). Remdesivir and" exact="chloroquine" post="effectively inhibit the recently emerged novel coronavirus (SARSâ€�COVâ€�2) in"/>
   <result pre="Zhu, Z., Mu, K., Wang, X., &amp;amp; Zhu, W. (2020)." exact="Nelfinavir" post="was predicted to be a potential inhibitor of 2019â€�nCov"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7405496\results\search\drug\results.xml">
   <result pre="IKK IÎºB kinase MEK MAPK kinase mTOR mammalian target of" exact="rapamycin" post="RAS renin angiotensin system TMPRSS2 transmembrane protease, serine 2"/>
   <result pre="Sampson, Brown, &amp;amp; Denton,Â 2013). Interestingly, transgender males exposed to" exact="oestrogen" post="(estradiol) and androgen deprivation (spironolactone) therapies display significantly higher"/>
   <result pre="BBOX1 and MYLK were downâ€�regulated. Four DEGs were regulated by" exact="oestrogen" post="receptorâ€�Î±, with C3 and EDN1 genes being upâ€�regulated and"/>
   <result pre="with YRPW motif protein; MYLK, myosin light chain kinase; PDK4," exact="pyruvate" post="dehydrogenase lipoamide kinase isozyme 4; SOX9, sexâ€�determining region Y"/>
   <result pre="limiting SARSâ€�CoV replication directly (Channappanavar et al.,Â 2017). Therefore, exogenous" exact="oestrogen" post="administration has been proposed for both male and female"/>
   <result pre="(Zhang et al.,Â 2020). Indeed, a preliminary study showed that" exact="dexamethasone" post="was able to reduce 28â€�day mortality among COVIDâ€�19 patients"/>
   <result pre="al.,Â 2020). Promising drugs are blockers of TMPRSS2, such as" exact="camostat" post="mesylate and nafamostat mesylate (see Zhou, Fang, et al.,Â"/>
   <result pre="drugs are blockers of TMPRSS2, such as camostat mesylate and" exact="nafamostat" post="mesylate (see Zhou, Fang, et al.,Â 2020). Coagulopathies are"/>
   <result pre="not clear. In this study, targeting the mammalian target of" exact="rapamycin" post="(mTOR) pathway using sirolimus appeared to be a promising"/>
   <result pre="study, targeting the mammalian target of rapamycin (mTOR) pathway using" exact="sirolimus" post="appeared to be a promising therapeutic approach to fight"/>
   <result pre="A. (2017). Protective regulation of the ACE2/ACE gene expression by" exact="estrogen" post="in human atrial tissue from elderly men. Experimental Biology"/>
   <result pre="L., â€¦ collab: RECOVERY Collaborative Group . (2020). Effect of" exact="dexamethasone" post="in hospitalized patients with COVIDâ€�19: Preliminary report. medRxiv. 10.1101/2020.06.22.20137273"/>
   <result pre="Suba, Z. (2020). Prevention and therapy of COVIDâ€�19 via exogenous" exact="estrogen" post="treatment for both male and female patients; an opinion"/>
   <result pre="Yazdany, J., &amp;amp; Kim, A. H. J. (2020). Use of" exact="hydroxychloroquine" post="and chloroquine during the COVIDâ€�19 pandemic: What every clinician"/>
   <result pre="&amp;amp; Kim, A. H. J. (2020). Use of hydroxychloroquine and" exact="chloroquine" post="during the COVIDâ€�19 pandemic: What every clinician should know."/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7405653\results\search\drug\results.xml">
   <result pre="inflammatory component (arthritis/tenosynovitis), corticosteroid use after 14 days is effective." exact="Prednisone" post="0.5 milligram per kilogram per day (maximum dose being"/>
   <result pre="use. In older patients, amitriptyline may lead to sedation, therefore," exact="gabapentin" post="is often preferred starting at low doses. Patients with"/>
   <result pre="Patients with a history of arrhythmia should also be administered" exact="gabapentin" post="instead of amitriptyline. Approximately 30% of CHIKV patients may"/>
   <result pre="The drugs of choice at this stage are antimalarials, preferably" exact="hydroxychloroquine" post="(HCQ). In this guideline, methotrexate (MTX) is an option"/>
   <result pre="this stage are antimalarials, preferably hydroxychloroquine (HCQ). In this guideline," exact="methotrexate" post="(MTX) is an option for inflammatory joint disease (moderate"/>
   <result pre="reviewArthritis Care ResHoboken2018701015011508 22DeLamballerie XBoissonVReynierJ-CEnaultSCharrelRNFlahaultAet al.On Chikungunya Acute Infection and" exact="Chloroquine" post="TreatmentVector-Borne Zoonotic Dis20088683784018620511 23PandyaSMethotrexate and hydroxychloroquine combination therapy in"/>
   <result pre="Chikungunya Acute Infection and Chloroquine TreatmentVector-Borne Zoonotic Dis20088683784018620511 23PandyaSMethotrexate and" exact="hydroxychloroquine" post="combination therapy in chronic chikungunya arthritis: A 16 week"/>
   <result pre="parallel-group studyIndian J Rheumatol2009439410110.1016/S0973-3698(10)60189-6 25RavindranVAliasGEfficacy of combination DMARD therapy vs." exact="hydroxychloroquine" post="monotherapy in chronic persistent chikungunya arthritis: a 24-week randomized"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7405836\results\search\drug\results.xml">
   <result pre="protein within the ORF3 band, a secreted protein with an" exact="alpha" post="helix and beta-sheet with six strands encoded by ORF8"/>
   <result pre="(244), hypoalbuminemia, and an increase of lactate dehydrogenase, aspartate transaminase," exact="alanine" post="aminotransferase, bilirubin, and, especially, D-dimer (244). Middle-aged and elderly"/>
   <result pre="consequences with regard to the high spread of this virus." exact="Ethanol" post="and disinfectants containing chlorine or bleach are effective against"/>
   <result pre="additional clinical trials (187, 281). A controlled trial of ritonavir-boosted" exact="lopinavir" post="and interferon alpha 2b treatment was performed on COVID-19"/>
   <result pre="(187, 281). A controlled trial of ritonavir-boosted lopinavir and interferon" exact="alpha" post="2b treatment was performed on COVID-19 hospitalized patients (ChiCTR2000029308)"/>
   <result pre="COVID-19 hospitalized patients (ChiCTR2000029308) (188). In addition, the use of" exact="hydroxychloroquine" post="and tocilizumab for their potential role in modulating inflammatory"/>
   <result pre="to remdesivir and favipiravir (broad-spectrum antiviral drugs) revealed remdesivir and" exact="chloroquine" post="to be highly effective against SARS-CoV-2 infection in vitro"/>
   <result pre="in vitro to lessen the viral infection. Both remdesivir and" exact="chloroquine" post="are being used in humans to treat other diseases,"/>
   <result pre="identified that drugs such as ribavirin, remdesivir, galidesivir, tenofovir, and" exact="sofosbuvir" post="bind RdRp tightly, indicating their vast potential to be"/>
   <result pre="study has proven that remdesivir has better antiviral activity than" exact="lopinavir" post="and ritonavir. Further, in vivo studies conducted in mice"/>
   <result pre="of disease in the event of a new coronavirus outbreak." exact="Chloroquine" post="is an antimalarial drug known to possess antiviral activity"/>
   <result pre="a recent multicenter clinical trial that was conducted in China," exact="chloroquine" post="phosphate was found to exhibit both efficacy and safety"/>
   <result pre="drug, gave promising results. The COVID-19 patients received 600â€‰mg of" exact="hydroxychloroquine" post="daily along with azithromycin as a single-arm protocol. This"/>
   <result pre="The COVID-19 patients received 600â€‰mg of hydroxychloroquine daily along with" exact="azithromycin" post="as a single-arm protocol. This protocol was found to"/>
   <result pre="of the main disadvantages that limit the clinical utility of" exact="ivermectin" post="is its potential to cause cytotoxicity. However, altering the"/>
   <result pre="modified, thereby having significant control over the systemic concentration of" exact="ivermectin" post="(338). Based on the pharmacokinetic simulation, it was also"/>
   <result pre="Based on the pharmacokinetic simulation, it was also found that" exact="ivermectin" post="may have limited therapeutic utility in managing COVID-19, since"/>
   <result pre="large-scale antiviral response against SARS-CoV-2 (341). Further, a combination of" exact="ivermectin" post="and hydroxychloroquine might have a synergistic effect, since ivermectin"/>
   <result pre="response against SARS-CoV-2 (341). Further, a combination of ivermectin and" exact="hydroxychloroquine" post="might have a synergistic effect, since ivermectin reduces viral"/>
   <result pre="of ivermectin and hydroxychloroquine might have a synergistic effect, since" exact="ivermectin" post="reduces viral replication, while hydroxychloroquine inhibits the entry of"/>
   <result pre="have a synergistic effect, since ivermectin reduces viral replication, while" exact="hydroxychloroquine" post="inhibits the entry of the virus in the host"/>
   <result pre="as well as the clinical utility of this promising drug." exact="Nafamostat" post="is a potent inhibitor of MERS-CoV that acts by"/>
   <result pre="doi:10.1126/science.1087139.12958366 79.Monchatre-LeroyE, BoueF, BoucherJM, RenaultC, MoutouF, Ar GouilhM, UmhangG2017Identification of" exact="alpha" post="and beta coronavirus in wildlife species in France: bats,"/>
   <result pre="BushmakerT, MartellaroC, BaselerL, BeneckeAG, KatzeMG, MunsterVJ, FeldmannH2013Treatment with interferon-Î±2b and" exact="ribavirin" post="improves outcome in MERS-CoV-infected rhesus macaques. Nat Med19:1313â€&quot;1317. doi:10.1038/nm.3362.24013700"/>
   <result pre="CaoR, ZhangL, YangX, LiuJ, XuM, ShiZ, HuZ, ZhongW, XiaoG2020Remdesivir and" exact="chloroquine" post="effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in"/>
   <result pre="coronavirus infection and spread. Virol J2:69. doi:10.1186/1743-422X-2-69.16115318 197.GaoJ, TianZ, YangX2020Breakthrough:" exact="chloroquine" post="phosphate has shown apparent efficacy in treatment of COVID-19"/>
   <result pre="J Med Virol92:667â€&quot;674. doi:10.1002/jmv.25762.32167180 261.ColsonP, RolainJM, LagierJC, BrouquiP, RaoultD2020Chloroquine and" exact="hydroxychloroquine" post="as available weapons to fight COVID-19. Int J Antimicrob"/>
   <result pre="GiarratanoA, EinavS2020A systematic review on the efficacy and safety of" exact="chloroquine" post="for the treatment of COVID-19. Crit Care57:279â€&quot;283. doi:10.1016/j.jcrc.2020.03.005. 263.DevauxCA,"/>
   <result pre="263.DevauxCA, RolainJM, ColsonP, RaoultD2020New insights on the antiviral effects of" exact="chloroquine" post="against coronavirus: what to expect for COVID-19?Int J Antimicrob"/>
   <result pre="doi:10.1016/j.ijantimicag.2020.105938.32171740 264.SahraeiZ, ShabaniM, ShokouhiS, SaffaeiA2020Aminoquinolines against coronavirus disease 2019 (COVID-19):" exact="chloroquine" post="or hydroxychloroquine. Int J Antimicrob Agents55:105945. doi:10.1016/j.ijantimicag.2020.105945.32194152 265.TouretF, de"/>
   <result pre="or hydroxychloroquine. Int J Antimicrob Agents55:105945. doi:10.1016/j.ijantimicag.2020.105945.32194152 265.TouretF, de LamballerieX2020Of" exact="chloroquine" post="and COVID-19. Antiviral Res177:104762. doi:10.1016/j.antiviral.2020.104762.32147496 266.YaoX, YeF, ZhangM, CuiC,"/>
   <result pre="vitro antiviral activity and projection of optimized dosing design of" exact="hydroxychloroquine" post="for the treatment of severe acute respiratory syndrome coronavirus"/>
   <result pre="267.ZhouD, DaiSM, TongQ2032020COVID-19: a recommendation to examine the effect of" exact="hydroxychloroquine" post="in preventing infection and progression. J Antimicrob Chemother doi:10.1093/jac/dkaa114."/>
   <result pre="of Guangdong Province and Health Commission of Guangdong Province for" exact="Chloroquine" post="in the Treatment of Novel Coronavirus. 2020Expert consensus on"/>
   <result pre="Chloroquine in the Treatment of Novel Coronavirus. 2020Expert consensus on" exact="chloroquine" post="phosphate for the treatment of novel coronavirus pneumonia. Zhonghua"/>
   <result pre="DupontHT, HonorÃ©S, ColsonP, ChabriÃ¨reE, La ScolaB, RolainJM, BrouquiP, RaoultD2032020Hydroxychloroquine and" exact="azithromycin" post="as a treatment of COVID-19: results of an open-label"/>
   <result pre="rapid antiviral clearance or clinical benefit with the combination of" exact="hydroxychloroquine" post="and azithromycin in patients with severe COVID-19 infection. Med"/>
   <result pre="clearance or clinical benefit with the combination of hydroxychloroquine and" exact="azithromycin" post="in patients with severe COVID-19 infection. Med Mal Infect50:384."/>
   <result pre="Mal Infect50:384. doi:10.1016/j.medmal.2020.03.006.32240719 308.CalyL, DruceJD, CattonMG, JansDA, WagstaffKM2020The FDA-approved drug" exact="ivermectin" post="inhibits the replication of SARS-CoV-2 in vitro. Antiviral Res178:104787."/>
   <result pre="Am Acad Dermatol82:e221. doi:10.1016/j.jaad.2020.04.017.32283237 340.SchmithVD, ZhouJJ, LohmerLR2020The approved dose of" exact="ivermectin" post="alone is not the ideal dose for the treatment"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7409030\results\search\drug\results.xml">
   <result pre="of viral infection, and clinical impact was portrayed. SARS-CoV-2 remdesivir" exact="chloroquine" post="hydroxychloroquine lopinavir/ritonavir convalescent plasma 1. Introduction Since the beginning"/>
   <result pre="viral infection, and clinical impact was portrayed. SARS-CoV-2 remdesivir chloroquine" exact="hydroxychloroquine" post="lopinavir/ritonavir convalescent plasma 1. Introduction Since the beginning of"/>
   <result pre="protein (IP10), monocyte chemoattractant protein (MCP1), macrophage inflammatory protein 1" exact="alpha" post="(MIP1A), platelet derived growth factor (PDGF), tumor necrosis factor"/>
   <result pre="selected for the SOLIDARITY trial: remdesivir (RDV), an experimental antiviral;" exact="chloroquine" post="(CQ), an antimalarial agent (or hydroxychloroquineâ€&quot;HCQ); a combination of"/>
   <result pre="chloroquine (CQ), an antimalarial agent (or hydroxychloroquineâ€&quot;HCQ); a combination of" exact="lopinavir" post="and ritonavir (LPV/r), an anti-HIV medication; and lopinavir +"/>
   <result pre="an antimalarial agent (or hydroxychloroquineâ€&quot;HCQ); a combination of lopinavir and" exact="ritonavir" post="(LPV/r), an anti-HIV medication; and lopinavir + ritonavir +"/>
   <result pre="combination of lopinavir and ritonavir (LPV/r), an anti-HIV medication; and" exact="lopinavir" post="+ ritonavir + interferon-beta (an antiviral and modulator of"/>
   <result pre="lopinavir and ritonavir (LPV/r), an anti-HIV medication; and lopinavir +" exact="ritonavir" post="+ interferon-beta (an antiviral and modulator of the immune"/>
   <result pre="to fill the gaps in the RDV toxicological profile. 3.2." exact="Chloroquine" post="and Hydroxychloroquine Chloroquine (CQâ€&quot;Figure 7A, see brief description in"/>
   <result pre="the gaps in the RDV toxicological profile. 3.2. Chloroquine and" exact="Hydroxychloroquine" post="Chloroquine (CQâ€&quot;Figure 7A, see brief description in Table 2),"/>
   <result pre="gaps in the RDV toxicological profile. 3.2. Chloroquine and Hydroxychloroquine" exact="Chloroquine" post="(CQâ€&quot;Figure 7A, see brief description in Table 2), a"/>
   <result pre="been recently reported as a potential broad-spectrum antiviral drug [61,81]." exact="Hydroxychloroquine" post="(HCQâ€&quot;Figure 7B, see brief description in Table 2) is"/>
   <result pre="(HCQâ€&quot;Figure 7B, see brief description in Table 2) is a" exact="chloroquine" post="analogue [82], one of the antimalarials and other anti-inflammatory"/>
   <result pre="SARS-CoV-2 protein targets. Among the results, the authors showed that" exact="chloroquine" post="can target nonstructural proteins such as Nsp3b, exhibiting suitable"/>
   <result pre="was not statistically relevant [92]; (ii) coadministration of HCQ with" exact="azithromycin" post="determined the decrease of viral load in COVID-19 patients"/>
   <result pre="healthcare Israelian database analysis) [97]. The association of HCQ and" exact="azithromycin" post="for the treatment COVID-19 patients was based on several"/>
   <result pre="for the treatment COVID-19 patients was based on several premises:" exact="azithromycin" post="proved in vitro activity against Ebola and Zika viruses,"/>
   <result pre="[93], but further studies confirmed the efficacy of HCQ and" exact="azithromycin" post="combination [98]. CQ and HCQ are also evaluated in"/>
   <result pre="should be noted that melanin-containing cells bind strongly to the" exact="chloroquine" post="process, explaining the retinal toxicity of both compounds [82,90]."/>
   <result pre="are not considered robust [102], and EMA did not approve" exact="chloroquine" post="for standard use in COVID-19 pathology and restricted its"/>
   <result pre="by WHO on 17 June 2020 regarding the assessment of" exact="hydroxychloroquine" post="as a treatment for COVID-19 infection notifies that this"/>
   <result pre="was suspended based on the evidence gathered according to which" exact="hydroxychloroquine" post="had no impact on decreasing the mortality of hospitalized"/>
   <result pre="which also stopped their study [107]. 3.3. Lopinavir/Ritonavir Lopinavir and" exact="ritonavir" post="(LPV/r) (Figure 8, see brief description in Table 2)"/>
   <result pre="with the best scores for potential viral protease inhibition were" exact="lopinavir" post="and ritonavir [111]. In accordance with previous studies, to"/>
   <result pre="best scores for potential viral protease inhibition were lopinavir and" exact="ritonavir" post="[111]. In accordance with previous studies, to investigate a"/>
   <result pre="COVID-19 to test the efficacy and safety of the oral" exact="lopinavir" post="(400 mg) associated with ritonavir (200 mg) in SARS-CoV-2"/>
   <result pre="and safety of the oral lopinavir (400 mg) associated with" exact="ritonavir" post="(200 mg) in SARS-CoV-2 infection. At the end of"/>
   <result pre="parameters: (1) a good absorption rate after oral administration, (2)" exact="lopinavir" post="presents a high affinity for serum proteins (98â€&quot;99% bound"/>
   <result pre="proteins, mainly of alpha-1-acid glycoprotein (AAG)), (3) hepatic biotransformation of" exact="lopinavir" post="is almost exclusively by isozyme CYP3A (ritonavir is a"/>
   <result pre="(iv) rare: Stevensâ€&quot;Johnson syndrome and erythema multiforme [114]. As both" exact="lopinavir" post="and ritonavir are CYP3A enzyme inhibitors, multiple drugâ€&quot;drug interactions"/>
   <result pre="Stevensâ€&quot;Johnson syndrome and erythema multiforme [114]. As both lopinavir and" exact="ritonavir" post="are CYP3A enzyme inhibitors, multiple drugâ€&quot;drug interactions were described,"/>
   <result pre="triazolam, cisapride, domperidone, sirolimus, lovastatin, simvastatin, budesonide, fluticasone, mometasone, and" exact="triamcinolone" post="[114]. In light of the toxicological profile of LPV/r"/>
   <result pre="effects after the lopinavir/ritonavir treatment and 37 patients (17.1%) after" exact="chloroquine" post="use. The adverse effects related to LPV/r use consisted"/>
   <result pre="via hydrogen and hydrophobic bonds, manifesting a synergistic activity with" exact="lopinavir" post="and ritonavir. The authors concluded that the effect of"/>
   <result pre="oseltamivir may be a safe candidate for clinical testing. 4.2." exact="Ribavirin" post="Ribavirin (Figure 11) is a nucleoside analog antiviral agent."/>
   <result pre="may be a safe candidate for clinical testing. 4.2. Ribavirin" exact="Ribavirin" post="(Figure 11) is a nucleoside analog antiviral agent. Structurally,"/>
   <result pre="Ribavirin (Figure 11) is a nucleoside analog antiviral agent. Structurally," exact="ribavirin" post="was modified so that the nucleobase part was replaced"/>
   <result pre="a carboxamide group in the third position. ADME profile wise," exact="ribavirin" post="is a highly soluble, highly polar rigid molecule, suited"/>
   <result pre="mechanism of action, after being metabolized to its triphosphate form," exact="ribavirin" post="competes with the physiological nucleoside (adenosine/guanosine) for the RdRp"/>
   <result pre="infection [124]. Using docking experiments, a research team demonstrated that" exact="ribavirin" post="and other FDA-approved antiviral drugs (galidesivir, remdesivir, tenofovir, sofosbuvir)"/>
   <result pre="conducted in order to explore the specific antiviral activity of" exact="Ribavirin" post="against SARS-CoV-2; the results concluded that high concentrations of"/>
   <result pre="the viral infection, as the EC50 value (109.50 Î¼M) of" exact="ribavirin" post="was higher than that of other antivirals such as"/>
   <result pre="natural compounds and comparable to some FDA-approved drugs such as" exact="nelfinavir" post="and lopinavir [133]. Betulinic acid (3Î²-hydroxy-lup-20(29)-en-28-oic acidâ€&quot;Figure 13) (BA)"/>
   <result pre="and comparable to some FDA-approved drugs such as nelfinavir and" exact="lopinavir" post="[133]. Betulinic acid (3Î²-hydroxy-lup-20(29)-en-28-oic acidâ€&quot;Figure 13) (BA) is a"/>
   <result pre="Î©-undecanoic amides and ionic derivatives of betulinic acid conjugated with" exact="glycine" post="intervene during the fusion of the virus to the"/>
   <result pre="classes able to reduce inflammation include non-steroidal anti-inflammatory medication, glucocorticoids," exact="chloroquine" post="and hydroxychloroquine, immunosuppressants, and inflammatory cytokines antagonists (IL-6R monoclonal"/>
   <result pre="includes the inhibition of enzymes involved in the clathrin-mediated endocytosis;" exact="tofacitinib" post="is an example of drug that produces no inhibition"/>
   <result pre="already associated with known drugs such as nimesulide, didanosine, thiabendazole," exact="fluticasone" post="propionate, and Photofrin, and their role as a key"/>
   <result pre="drugs, tocilizumab should not be administered with the following agents:" exact="metamizole" post="(high risk of hematological toxicity), immunosuppressants (adalimumab and basiliximab),"/>
   <result pre="with other investigated agents for COVID-19 therapy such as chloroquine," exact="hydroxychloroquine" post="(potential additive toxicity), and ribavirin (risk of hematological toxicity)"/>
   <result pre="COVID-19 therapy such as chloroquine, hydroxychloroquine (potential additive toxicity), and" exact="ribavirin" post="(risk of hematological toxicity) requires close monitoring and possible"/>
   <result pre="the subcutaneous use of INF beta-1a in combination therapy with" exact="hydroxychloroquine" post="and lopinavir/ritonavir. The early results showed a positive response"/>
   <result pre="clinical impact of the triple combination, IFN beta-1b, lopinavirâ€&quot;ritonavir, and" exact="ribavirin" post="[155]. The authors showed that treatment with the triple"/>
   <result pre="drug interactions study developed by Liverpool University, both heparin and" exact="argatroban" post="are not susceptible to determine interactions with the investigational"/>
   <result pre="the administration of this compound should be performed under surveillance." exact="Chloroquine" post="and hydroxychloroquine are recommended for compassionate use in mild-to-moderate"/>
   <result pre="of this compound should be performed under surveillance. Chloroquine and" exact="hydroxychloroquine" post="are recommended for compassionate use in mild-to-moderate (as single"/>
   <result pre="adverse events and drugâ€&quot;drug interactions, the significance was reached (both" exact="lopinavir" post="and ritonavir are CYP3A inhibitors and are subjected to"/>
   <result pre="and drugâ€&quot;drug interactions, the significance was reached (both lopinavir and" exact="ritonavir" post="are CYP3A inhibitors and are subjected to multiple drugâ€&quot;drug"/>
   <result pre="Remdesivir for Treating SARS-CoV-2 InfectionsInt. J. Antimicrob. Agents20205510593310.1016/j.ijantimicag.2020.10593332147516 61.WangM.CaoR.ZhangL.YangX.LiuJ.XuM.ShiZ.HuZ.ZhongW.XiaoG.Remdesivir and" exact="Chloroquine" post="Effectively Inhibit the Recently Emerged Novel Coronavirus (2019-nCoV) in"/>
   <result pre="online: https://www.covid19-druginteractions.org/(accessed on 25 April 2020) 81.HuT.Y.FriemanM.WolframJ.Insights from Nanomedicine into" exact="Chloroquine" post="Efficacy Against COVID-19Nat. Nanotechnol.20201524724910.1038/s41565-020-0674-932203437 82.YaoX.YeF.ZhangM.CuiC.HuangB.NiuP.LiuX.ZhaoL.DongE.SongC.et al.Optimized Dosing Design of"/>
   <result pre="Chloroquine Efficacy Against COVID-19Nat. Nanotechnol.20201524724910.1038/s41565-020-0674-932203437 82.YaoX.YeF.ZhangM.CuiC.HuangB.NiuP.LiuX.ZhaoL.DongE.SongC.et al.Optimized Dosing Design of" exact="Hydroxychloroquine" post="for the Treatment of Severe Acute Respiratory Syndrome Coronavirus"/>
   <result pre="March 2020Available online: http://arxiv.org/abs/2003.10642(accessed on 25 April 2020) 85.ColsonP.RolainJ.M.LagierJ.C.BrouquiP.RaoultD.Chloroquine and" exact="hydroxychloroquine" post="as available weapons to fight COVID-19Int. J. Antimicrob. Agents20205510593210.1016/j.ijantimicag.2020.10593232145363"/>
   <result pre="April 2020) 91.ChowdhuryM.S.RathodJ.GernsheimerJ.A Rapid Systematic Review of Clinical Trials Utilizing" exact="Chloroquine" post="and Hydroxychloroquine as a Treatment for COVID-19Acad. Emerg. Med.202010.1111/acem.14005"/>
   <result pre="91.ChowdhuryM.S.RathodJ.GernsheimerJ.A Rapid Systematic Review of Clinical Trials Utilizing Chloroquine and" exact="Hydroxychloroquine" post="as a Treatment for COVID-19Acad. Emerg. Med.202010.1111/acem.14005 92.ChenJ.LiuD.LiuL.LiuP.XuQ.XiaL.LingY.HuangD.SongS.ZhangD.et al.A"/>
   <result pre="Treatment for COVID-19Acad. Emerg. Med.202010.1111/acem.14005 92.ChenJ.LiuD.LiuL.LiuP.XuQ.XiaL.LingY.HuangD.SongS.ZhangD.et al.A Pilot Study of" exact="Hydroxychloroquine" post="in Treatment of Patients with Moderate COVID-19Zhejiang Da Xue"/>
   <result pre="Da Xue Xue Bao Yi Xue Ban20204921521932391667 93.GautretP.LagierJ.C.ParolaP.HoangV.T.MeddebL.MailheM.DoudierB.CourjonJ.GiordanengoV.VieiraV.E.et al.Hydroxychloroquine and" exact="Azithromycin" post="as a Treatment of COVID-19: Results of an Open-Label"/>
   <result pre="of an Open-Label Non-Randomized Clinical TrialInt. J. Antimicrob. Agents202010594910.1016/j.ijantimicag.2020.10594932205204 94.GaoJ.TianZ.YangX.Breakthrough:" exact="Chloroquine" post="Phosphate Has Shown Apparent Efficacy in Treatment of COVID-19"/>
   <result pre="StudiesBiosci. Trends202014727310.5582/bst.2020.0104732074550 95.ZhouD.DaiS.M.TongQ.COVID-19: A Recommendation to Examine the Effect of" exact="Hydroxychloroquine" post="in Preventing Infection and ProgressionJ. Antimicrob. Chemother.202010.1093/jac/dkaa114 96.MeoS.A.KlonoffD.C.AkramJ.Efficacy of"/>
   <result pre="Hydroxychloroquine in Preventing Infection and ProgressionJ. Antimicrob. Chemother.202010.1093/jac/dkaa114 96.MeoS.A.KlonoffD.C.AkramJ.Efficacy of" exact="Chloroquine" post="and Hydroxychloroquine in the Treatment of COVID-19Eur. Rev. Med."/>
   <result pre="Preventing Infection and ProgressionJ. Antimicrob. Chemother.202010.1093/jac/dkaa114 96.MeoS.A.KlonoffD.C.AkramJ.Efficacy of Chloroquine and" exact="Hydroxychloroquine" post="in the Treatment of COVID-19Eur. Rev. Med. Pharmacol. Sci.2020244539454710.26355/eurrev_202004_2103832373993"/>
   <result pre="in the Treatment of COVID-19Eur. Rev. Med. Pharmacol. Sci.2020244539454710.26355/eurrev_202004_2103832373993 97.GendelmanO.AmitalH.BragazziN.L.WatadA.ChodickG.Continuous" exact="Hydroxychloroquine" post="or Colchicine Therapy Does Not Prevent Infection with SARS-CoV-2:"/>
   <result pre="Large Healthcare Database AnalysisAutoimmun. Rev.202010256610.1016/j.autrev.2020.10256632380315 98.SunJ.ChenY.FanX.WangX.HanQ.LiuZ.Advances in the Use of" exact="Chloroquine" post="and Hydroxychloroquine for the Treatment of COVID-19Postgrad. Med.202010.1080/00325481.2020.177898232496926 99.ShuklaA.M.ArchibaldL.K.ShuklaA.W.MehtaH.J.CherabuddiK.Chloroquine"/>
   <result pre="Database AnalysisAutoimmun. Rev.202010256610.1016/j.autrev.2020.10256632380315 98.SunJ.ChenY.FanX.WangX.HanQ.LiuZ.Advances in the Use of Chloroquine and" exact="Hydroxychloroquine" post="for the Treatment of COVID-19Postgrad. Med.202010.1080/00325481.2020.177898232496926 99.ShuklaA.M.ArchibaldL.K.ShuklaA.W.MehtaH.J.CherabuddiK.Chloroquine and Hydroxychloroquine"/>
   <result pre="and Hydroxychloroquine for the Treatment of COVID-19Postgrad. Med.202010.1080/00325481.2020.177898232496926 99.ShuklaA.M.ArchibaldL.K.ShuklaA.W.MehtaH.J.CherabuddiK.Chloroquine and" exact="Hydroxychloroquine" post="in the Context of COVID-19Drugs Context2020910.7573/dic.2020-4-5 100.Van den EyndeJ.J.COVID-19:"/>
   <result pre="EyndeJ.J.COVID-19: An Update about the Discovery Clinical TrialPharmaceuticals2020139810.3390/ph13050098 101.PastickK.A.OkaforE.C.WangF.LofgrenS.M.SkipperC.P.NicolM.R.PullenM.F.RajasinghamR.McDonaldE.G.LeeT.C.et al.Review:" exact="Hydroxychloroquine" post="and Chloroquine for Treatment of SARS-CoV-2 (COVID-19)Open Forum Infect."/>
   <result pre="Update about the Discovery Clinical TrialPharmaceuticals2020139810.3390/ph13050098 101.PastickK.A.OkaforE.C.WangF.LofgrenS.M.SkipperC.P.NicolM.R.PullenM.F.RajasinghamR.McDonaldE.G.LeeT.C.et al.Review: Hydroxychloroquine and" exact="Chloroquine" post="for Treatment of SARS-CoV-2 (COVID-19)Open Forum Infect. Dis.2020710.1093/ofid/ofaa130 102.MeyerowitzE.A.VannierA.FriesenM.SchoenfeldS.GelfandJ.A.CallahanM.V.KimA.Y.ReevesP.M.PoznanskyM.C.Rethinking"/>
   <result pre="of SARS-CoV-2 (COVID-19)Open Forum Infect. Dis.2020710.1093/ofid/ofaa130 102.MeyerowitzE.A.VannierA.FriesenM.SchoenfeldS.GelfandJ.A.CallahanM.V.KimA.Y.ReevesP.M.PoznanskyM.C.Rethinking the Role of" exact="Hydroxychloroquine" post="in the Treatment of COVID-19FASEB J.2020346027603710.1096/fj.20200091932350928 103.RuamviboonsukP.LaiT.ChangA.LaiC.C.MielerW.F.LamD.collab: Asia-Pacific Vitreo-Retina"/>
   <result pre="the Treatment of COVID-19FASEB J.2020346027603710.1096/fj.20200091932350928 103.RuamviboonsukP.LaiT.ChangA.LaiC.C.MielerW.F.LamD.collab: Asia-Pacific Vitreo-Retina SocietyChloroquine and" exact="Hydroxychloroquine" post="Retinal Toxicity Consideration in the Treatment of COVID-19Asia Pac."/>
   <result pre="in a patient with coronavirus disease 2019Heart Rhythm2020304203042310.1016/j.hrthm.2020.04.04632380291 106.collab: EMACOVID-19:" exact="Chloroquine" post="and Hydroxychloroquine Only to be Used in Clinical Trials"/>
   <result pre="patient with coronavirus disease 2019Heart Rhythm2020304203042310.1016/j.hrthm.2020.04.04632380291 106.collab: EMACOVID-19: Chloroquine and" exact="Hydroxychloroquine" post="Only to be Used in Clinical Trials or Emergency"/>
   <result pre="Studies of Drug Repurposing and Synergism of Lopinavir, Oseltamivir and" exact="Ritonavir" post="Binding with SARS-CoV-2 Protease against COVID-19J. Biomol. Struct. Dyn.202010.1080/07391102.2020.175280232248766"/>
   <result pre="Antimicrob. Chemother.20106510.1093/jac/dkq015 123.ThomasE.GhanyM.G.LiangT.J.Review the application and mechanism of action of" exact="ribavirin" post="in therapy of hepatitis CAntivir. Chem. Chemother.20122311210.3851/IMP212522592135 124.ElfikyA.A.Anti-HCV, nucleotide"/>
   <result pre="TrialInt. Immunopharmacol.20208510668810.1016/j.intimp.2020.10668832544867 155.HungI.F.N.LungK.C.TsoE.Y.K.LiuR.ChungT.W.H.ChuM.Y.NgY.Y.LoJ.ChanJ.TamA.R.et al.Triple Combination of Interferon Beta-1b, Lopinavir-Ritonavir, and" exact="Ribavirin" post="in the Treatment of Patients Admitted to Hospital with"/>
   <result pre="green, and nucleotides in orange. Figure 7 Chemical structure of" exact="chloroquine" post="(A) and hydroxychloroquine (B) ADME profile was achieved using"/>
   <result pre="in orange. Figure 7 Chemical structure of chloroquine (A) and" exact="hydroxychloroquine" post="(B) ADME profile was achieved using the free web"/>
   <result pre="nausea, pain in the extremities elevation of hepatic enzymes values" exact="Chloroquine" post="(CQ) 4-aminoquinoline Mild-to-moderate and severeâ€&quot;depending on the guideline applied"/>
   <result pre="adverse effects have a lower intensity, but are not absent" exact="Hydroxychloroquine" post="(HCQ) 4-aminoquinoline Mild-to-moderate and severeâ€&quot;depending on the guideline applied"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7409838\results\search\drug\results.xml">
   <result pre="is referred to the Web version of this article.) 4.5" exact="Serine" post="derivatives To develop nonpeptidic inhibitors that interact with the"/>
   <result pre="the literature and exhibit potent biological activity, were linked to" exact="L-serine" post="for the design of serine derivatives (61.62), as shown"/>
   <result pre="Further SAR studies revealed that compound 75c, which has a" exact="nitro" post="at the C-4 position, is the most potent inhibitor"/>
   <result pre="by 2.0Â Ã…. The orientation of the ligand has a" exact="nitro" post="phenyl group situated in the S1 pocket, and the"/>
   <result pre="nitro phenyl group situated in the S1 pocket, and the" exact="nitro" post="group points towards the surface of the protein. The"/>
   <result pre="towards the surface of the protein. The oxygen of the" exact="nitro" post="group forms a hydrogen bond with Gly143 and Cys145,"/>
   <result pre="characteristics are significantly superior to those of the traditional drug" exact="telaprevir" post="[107]. Thus, we propose that the existing 3CLpro inhibitors"/>
   <result pre="respiratory distress syndrome in humansmBio32012e00473-00412 10NukoolkarnV.LeeV.S.MalaisreeM.AruksakulwongO.HannongbuaS.Molecular dynamic simulations analysis of" exact="ritonavir" post="and lopinavir as SARS-CoV 3CL(pro) inhibitorsJ.Â Theor. Biol.254200886186718706430 11XuX.ChenP.WangJ.FengJ.ZhouH.LiX.ZhongW.HaoP.Evolution"/>
   <result pre="syndrome in humansmBio32012e00473-00412 10NukoolkarnV.LeeV.S.MalaisreeM.AruksakulwongO.HannongbuaS.Molecular dynamic simulations analysis of ritonavir and" exact="lopinavir" post="as SARS-CoV 3CL(pro) inhibitorsJ.Â Theor. Biol.254200886186718706430 11XuX.ChenP.WangJ.FengJ.ZhouH.LiX.ZhongW.HaoP.Evolution of the"/>
   <result pre="of the human Cereblon-DDB1-lenalidomide complex reveals basis for responsiveness to" exact="thalidomide" post="analogsNat. Struct. Mol. Biol.21201480380925108355 103FischerE.S.BÃ¶hmK.LydeardJ.R.YangH.StadlerM.B.CavadiniS.NagelJ.SerlucaF.AckerV.LingarajuG.M.TichkuleR.B.SchebestaM.ForresterW.C.SchirleM.HassiepenU.OttlJ.HildM.BeckwithR.E.HarperJ.W.JenkinsJ.L.ThomÃ¤N.H.Structure of the DDB1-CRBN E3"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7409942\results\search\drug\results.xml">
   <result pre="Ebola and Marburg virus infection, acting as an analog of" exact="adenosine" post="nucleotide to confuse viral RNA polymerase and evade proofreading"/>
   <result pre="infection is characterized by over-exuberant inflammatory response. Baricitinib, fedratinib and" exact="ruxolitinib" post="that are known to inhibit JAK-STAT signaling pathway might"/>
   <result pre="discharged from hospital with COVID-19 in chongqing, ChinamedRxiv202010.1101/2020.02.20.200255362020.02.20.20025536 86WangM.CaoR.ZhangL.YangX.LiuJ.XuM.Remdesivir and" exact="chloroquine" post="effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7410019\results\search\drug\results.xml">
   <result pre="higher risk of infection. Based on these considerations, we suggest" exact="ibrutinib" post="or acalabrutinib and, for logistical reasons, venetoclax for patients"/>
   <result pre="of infection. Based on these considerations, we suggest ibrutinib or" exact="acalabrutinib" post="and, for logistical reasons, venetoclax for patients not fitting"/>
   <result pre="considerations, we suggest ibrutinib or acalabrutinib and, for logistical reasons," exact="venetoclax" post="for patients not fitting for BTK inhibitors. We use"/>
   <result pre="or obinutuzumab combinations and delay combining anti-CD20 monoclonal antibodies with" exact="venetoclax" post="until later in the course of treatment when safer."/>
   <result pre="in the course of treatment when safer. Ibrutinib, acalabrutinib, and" exact="venetoclax" post="prolong progression-free and overall survival with lower risk of"/>
   <result pre="compared to chemo(immuno)therapy.43â€&quot;46,54,56,58,59 The percentage of opportunistic infections reported for" exact="ibrutinib" post="is low (4.1%) and similar to that reported for"/>
   <result pre="ibrutinib is low (4.1%) and similar to that reported for" exact="venetoclax" post="(3.1%).79â€&quot;82 Compared to chemo(immuno)therapy, ibrutinib and acalabrutinib do not"/>
   <result pre="similar to that reported for venetoclax (3.1%).79â€&quot;82 Compared to chemo(immuno)therapy," exact="ibrutinib" post="and acalabrutinib do not produce lymphopenia, a known risk"/>
   <result pre="that reported for venetoclax (3.1%).79â€&quot;82 Compared to chemo(immuno)therapy, ibrutinib and" exact="acalabrutinib" post="do not produce lymphopenia, a known risk factor for"/>
   <result pre="of any â‰¥3 grade adverse events does not differ between" exact="ibrutinib" post="(41%â€&quot;77%), acalabrutinib (50%), and venetoclax (78%), indicating that the"/>
   <result pre="â‰¥3 grade adverse events does not differ between ibrutinib (41%â€&quot;77%)," exact="acalabrutinib" post="(50%), and venetoclax (78%), indicating that the frequency of"/>
   <result pre="events does not differ between ibrutinib (41%â€&quot;77%), acalabrutinib (50%), and" exact="venetoclax" post="(78%), indicating that the frequency of unplanned visits for"/>
   <result pre="visits for tumor lysis management during the ramp up phase." exact="Ibrutinib" post="treatment requires few routine treatment visits and lab assessments.54"/>
   <result pre="a few reports from uncontrolled clinical cases.86,87 The disadvantage of" exact="ibrutinib" post="treatment during SARS-CoV-2 outbreak is the continuous schedule not"/>
   <result pre="the continuous schedule not allowing treatment free intervals. However, if" exact="ibrutinib" post="is discontinued because of an adverse event while CLL"/>
   <result pre="to normal levels within an average of 60 days from" exact="venetoclax" post="discontinuation.83,91 The disadvantage of venetoclax treatment is the need"/>
   <result pre="average of 60 days from venetoclax discontinuation.83,91 The disadvantage of" exact="venetoclax" post="treatment is the need for frequent access to the"/>
   <result pre="ramp-up phase to prevent tumor lysis syndrome (TLS).58 In addition," exact="venetoclax" post="treatment has a relatively high risk of neutropenia during"/>
   <result pre="higher drug discontinuation rate due to adverse events compared to" exact="acalabrutinib" post="treated patients.59 Treatment with rituximab or obinutuzumab produces a"/>
   <result pre="do not apply prophylactic interruption or dose reductions of ibrutinib," exact="acalabrutinib" post="or venetoclax based on the reasoning that once treatment"/>
   <result pre="apply prophylactic interruption or dose reductions of ibrutinib, acalabrutinib or" exact="venetoclax" post="based on the reasoning that once treatment has started,"/>
   <result pre="maximum benefit. This is illustrated by the evidence that temporary" exact="ibrutinib" post="dose interruptions associate with shorter progression free survival, suggesting"/>
   <result pre="phase III study. J Clin Oncol.2019;37:269â€&quot;277.30523712 47.BurgerJASivinaMJainNet al.Randomized trial of" exact="ibrutinib" post="vs ibrutinib plus rituximab in patients with chronic lymphocytic"/>
   <result pre="study. J Clin Oncol.2019;37:269â€&quot;277.30523712 47.BurgerJASivinaMJainNet al.Randomized trial of ibrutinib vs" exact="ibrutinib" post="plus rituximab in patients with chronic lymphocytic leukemia. Blood.2019;133:1011â€&quot;1019.30530801"/>
   <result pre="in patients with chronic lymphocytic leukemia. Blood.2019;133:1011â€&quot;1019.30530801 48.RobertsAWMaSKippsTJet al.Efficacy of" exact="venetoclax" post="in relapsed chronic lymphocytic leukemia is influenced by disease"/>
   <result pre="49.ByrdJCHillmenPOâ€™BrienSet al.Long-term follow-up of the RESONATE phase 3 trial of" exact="ibrutinib" post="vs ofatumumab. Blood.2019;133:2031â€&quot;2042.30842083 50.ByrdJCFurmanRRCoutreSEet al.Ibrutinib treatment for first-line and"/>
   <result pre="study in patients with previously treated CLL/SLL. Leukemia.2018;32:83â€&quot;91.28592889 52.Oâ€™BrienSFurmanRRCoutreSet al.Single-agent" exact="ibrutinib" post="in treatment-naive and relapsed/refractory chronic lymphocytic leukemia: a 5-year"/>
   <result pre="analysis from RESONATE: Up to six years of follow-up on" exact="ibrutinib" post="in patients with previously treated chronic lymphocytic leukemia or"/>
   <result pre="Am J Hematol.2019;94:1353â€&quot;1363.31512258 54.BurgerJABarrPMRobakTet al.Long-term efficacy and safety of first-line" exact="ibrutinib" post="treatment for patients with CLL/SLL: 5 years of follow-up"/>
   <result pre="phase 3 trial. Lancet.2020;395:1278â€&quot;1291.32305093 57.FlinnIWHillmenPMontilloMet al.The phase 3 DUO trial:" exact="duvelisib" post="vs ofatumumab in relapsed and refractory CLL/SLL. Blood.2018;132:2446â€&quot;2455.30287523 58.FischerKAl-SawafOBahloJet"/>
   <result pre="lymphocytic leukemia. Blood Cancer J.2018;8:10.29339727 79.DavidsMSHallekMWierdaWet al.Comprehensive safety analysis of" exact="venetoclax" post="monotherapy for patients with relapsed/refractory chronic lymphocytic leukemia. Clin"/>
   <result pre="treated with ibrutinib. Blood.2015;126:2213â€&quot;2219.26337493 81.VarugheseTTaurYCohenNet al.Serious infections in patients receiving" exact="ibrutinib" post="for treatment of lymphoid cancer. Clin Infect Dis.2018;67:687â€&quot;692.29509845 82.RogersKAMousaLZhaoQet"/>
   <result pre="cancer. Clin Infect Dis.2018;67:687â€&quot;692.29509845 82.RogersKAMousaLZhaoQet al.Incidence of opportunistic infections during" exact="ibrutinib" post="treatment for B-cell malignancies. Leukemia.2019;33:2527â€&quot;2530.31086260 83.de WeerdtIHoflandTde BoerRet al.Distinct"/>
   <result pre="node and peripheral blood of CLL patients is reshaped during" exact="venetoclax" post="treatment. Blood Adv.2019;3:2642â€&quot;2652.31506282 84.LongMBeckwithKDoPet al.Ibrutinib treatment improves T cell"/>
   <result pre="patients with chronic lymphocytic leukemia. J Immunol.2017;198:1740â€&quot;1747.28077600 86.TreonSPCastilloJSkarbnikAPet al.The BTK-inhibitor" exact="ibrutinib" post="may protect against pulmonary injury in COVID-19 infected patients."/>
   <result pre="chronic lymphocytic leukemia. N Engl J Med.2019;381:432â€&quot;443.31365801 89.Oâ€™BrienSMByrdJCHillmenPet al.Outcomes with" exact="ibrutinib" post="by line of therapy and post-ibrutinib discontinuation in patients"/>
   <result pre="90.ParikhSAAchenbachSJCallTGet al.The impact of dose modification and temporary interruption of" exact="ibrutinib" post="on outcomes of chronic lymphocytic leukemia patients in routine"/>
   <result pre="in routine clinical practice. Cancer Med.2020;9:3390â€&quot;3399.32187452 91.DaveNGopalakrishnanSMensingSet al.Model-informed dosing of" exact="venetoclax" post="in healthy subjects: an exposure-response analysis. Clin Transl Sci.2019;12:625â€&quot;632.31268229"/>
   <result pre="24, 2020. 10.1016/S2666-5247(20)30009-4. 114.HampelPJDingWCallTGet al.Rapid disease progression following discontinuation of" exact="ibrutinib" post="in patients with chronic lymphocytic leukemia treated in routine"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7410516\results\search\drug\results.xml">
   <result pre="and psychiatric drugs are reported in Table 1. Among these," exact="chloroquine" post="and hydroxychloroquine have been administered in COVID-19 even in"/>
   <result pre="drugs are reported in Table 1. Among these, chloroquine and" exact="hydroxychloroquine" post="have been administered in COVID-19 even in milder forms"/>
   <result pre="that there was insufficient evidence for recommending the use of" exact="hydroxychloroquine" post="and chloroquine in this group of patients. Different organizations,"/>
   <result pre="was insufficient evidence for recommending the use of hydroxychloroquine and" exact="chloroquine" post="in this group of patients. Different organizations, including the"/>
   <result pre="the Italian Medicines Agency (AIFA), have suspended the employment of" exact="hydroxychloroquine" post="outside clinical trials [61]. Seizures have been observed in"/>
   <result pre="been observed in the past in some patients treated with" exact="chloroquine" post="[62]. Moreover, due to their association with QT prolongation,"/>
   <result pre="(e.g. NMD-related heart failure). Furthermore according to Russo et al.," exact="chloroquine" post="and hydroxychloroquine, as well as Remdesivir, an antiviral agent"/>
   <result pre="COVID-19 [63, 64], should not be co-administered with carbamazepine, phenytoin," exact="phenobarbital" post="and primidone, for the risk of drug interactions and"/>
   <result pre="drug interactions and enzymatic induction of inhibition [65]. Lopinavir and" exact="ritonavir" post="have been employed in COVID-19 treatment [66], although contradictory"/>
   <result pre="been observed and their effectiveness is still debatable [67]. Moreover," exact="ritonavir" post="may promote the metabolism of phenytoin and other antiepileptic"/>
   <result pre="still debatable [67]. Moreover, ritonavir may promote the metabolism of" exact="phenytoin" post="and other antiepileptic and antipsychotic drugs due to the"/>
   <result pre="antipsychotic drugs due to the induction of CYP450 [68]. Furthermore," exact="azithromycin" post="has proven efficacy in COVID-19 in association with hydroxychloroquine"/>
   <result pre="Furthermore, azithromycin has proven efficacy in COVID-19 in association with" exact="hydroxychloroquine" post="[57]. Nonetheless, patients with myasthenia gravis taking macrolides should"/>
   <result pre="felbamate; PER perampanel; HLP haloperidol; CPZ chlorpromazine; RSP risperidone; OLP" exact="olanzapine" post="Neurological involvement in children COVID-19 seems to have a"/>
   <result pre="act little on the cytochrome P450, such as citalopram, escitalopram," exact="olanzapine" post="and valproate, to avoid interactions with antivirals, which are"/>
   <result pre="75 56.CortegianiAIngogliaGIppolitoMGiarratanoAEinavSA systematic review on the efficacy and safety of" exact="chloroquine" post="for the treatment of COVID-19J Crit Care20205727928332173110 57.Gautret P,"/>
   <result pre="Care20205727928332173110 57.Gautret P, Lagier JC, Parola P, et al (2020)" exact="Hydroxychloroquine" post="and azithromycin as a treatment of COVID-19: results of"/>
   <result pre="P, Lagier JC, Parola P, et al (2020) Hydroxychloroquine and" exact="azithromycin" post="as a treatment of COVID-19: results of an open-label"/>
   <result pre="Han Q, Liu Z (2020) Advances in the use of" exact="chloroquine" post="and hydroxychloroquine for the treatment of COVID-19. Postgrad Med:1â€&quot;10."/>
   <result pre="Liu Z (2020) Advances in the use of chloroquine and" exact="hydroxychloroquine" post="for the treatment of COVID-19. Postgrad Med:1â€&quot;10. 10.1080/00325481.2020.1778982 59.ChenJLiuDLiuLLiuPXuQXiaLLingYHuangDSongSZhangDQianZLiTShenYLuHA"/>
   <result pre="treatment of COVID-19. Postgrad Med:1â€&quot;10. 10.1080/00325481.2020.1778982 59.ChenJLiuDLiuLLiuPXuQXiaLLingYHuangDSongSZhangDQianZLiTShenYLuHA pilot study of" exact="hydroxychloroquine" post="in treatment of patients with moderate COVID-19Zhejiang Da Xue"/>
   <result pre="62.MulhauserPAllemannYRegameyCChloroquine and nonconvulsive status epilepticusAnn Intern Med1995123176777762925 63.WangMCaoRZhangLYangXLiuJXuMet al.Remdesivir and" exact="chloroquine" post="effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in"/>
   <result pre="88.ZambrelliECaneviniMGambiniODâ€™AgostinoADelirium and sleep disturbances in COVID-19: a possible role for" exact="melatonin" post="in hospitalized patients?Sleep Med20207011132361215"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7411102\results\search\drug\results.xml">
   <result pre="Society has come up with document regarding cardiovascular risks of" exact="hydroxychloroquine" post="in treatment and prophylaxis of COVID-19 patients and recommendations"/>
   <result pre="prolongation in hospitalized patientsCirc Cardiovasc Qual Outcomes6201347948723716032 46KapoorA.PandurangiU.AroraV.Cardiovascular risks of" exact="hydroxychloroquine" post="in treatment and prophylaxis of COVID-19 patients: a scientific"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7412427\results\search\drug\results.xml">
   <result pre="7412427 doi: 10.3390/v12070703viruses-12-00703 : Article Combinatory Treatment with Oseltamivir and" exact="Itraconazole" post="Targeting Both Virus and Host Factors in Influenza A"/>
   <result pre="treatment. The second class of approved antivirals are the adamantanes" exact="amantadine" post="and rimantadine, which both inhibit the IAV proton channel"/>
   <result pre="IAV subtypes already acquired resistance against the approved antiviral drug" exact="amantadine" post="and there is increasing evidence that the commonly used"/>
   <result pre="reached at 20.56 nM (pdm09) and 23.41 nM (Panama), respectively." exact="Itraconazole" post="EC50 was 0.47 ÂµM for pdm09 and 0.37 ÂµM"/>
   <result pre="[24] on the replication efficiency of two different IAV strains." exact="Itraconazole" post="has been identified as a direct inhibitor of the"/>
   <result pre="the relevance of pharmacokinetic interactionsClin. Microbiol. Infect.2006129710616460557 35.ShinJ.H.ChoiK.Y.KimY.C.LeeM.G.Dose-Dependent Pharmacokinetics of" exact="Itraconazole" post="after Intravenous or Oral Administration to Rats: Intestinal First-Pass"/>
   <result pre="fungal infectionsExpert Opin. Drug Metab. Toxicol.2013991192610.1517/17425255.2013.79478523641752 38.BaeS.K.ParkS.-J.ShimE.-J.MunJ.-H.KimE.-Y.ShinJ.-G.ShonJ.-H.Increased Oral Bioavailability of" exact="Itraconazole" post="and Its Active Metabolite, 7-Hydroxyitraconazole, When Coadministered With a"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7413162\results\search\drug\results.xml">
   <result pre="COVID-19 in adults. From the reported patients, two recovered with" exact="methylprednisolone" post="and intravenous immunoglobulins [120,121] and two of them died"/>
   <result pre="other one was a 58-year-old man who was treated with" exact="dexamethasone" post="and died as consequence of status epilepticus. [123] (Figure."/>
   <result pre="and chaotic saccadic ocular movements. DaT-SPECT confirmed bilateral decreased presynaptic" exact="dopamine" post="uptake asymmetrically involving bilateral putamen. Parkinsonian symptoms in this"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7413836\results\search\drug\results.xml">
   <result pre="other nine medicines, brincidofovir, an ether lipid ester analog of" exact="cidofovir" post="with potent antiviral activity, showed the highest docking scores"/>
   <result pre="(PDB codeâ€‰=â€‰1Q2W) Drug name Ligand Receptor Interaction Distance E (kcal/mol)" exact="Atovaquone" post="6-ring CD PRO 122 (B) pi-H 4.11 âˆ’Â 0.5"/>
   <result pre="Atovaquone 6-ring CD PRO 122 (B) pi-H 4.11 âˆ’Â 0.5" exact="Chloroquine" post="O 5 NZ LYS 5 (A) H-acceptor 3.34 âˆ’Â"/>
   <result pre="0.6 6-ring CA GLY 2 (B) pi-H 3.49 âˆ’Â 0.5" exact="Doxycycline" post="N 6 N GLN 127 (A) H-acceptor 3.27 âˆ’Â"/>
   <result pre="N 9 N GLN 127 (B) H-acceptor 3.32 âˆ’Â 2.3" exact="Ribavirin" post="O 1 O PHE 3 (B) H-donor 2.98 âˆ’Â"/>
   <result pre="receptor (PDB codeâ€‰=â€‰6M0J) Drug Ligand Receptor Interaction Distance E (kcal/mol)" exact="Atovaquone" post="6-ring CA VAL 209 (A) pi-H 3.90 âˆ’ 1.0"/>
   <result pre="Atovaquone 6-ring CA VAL 209 (A) pi-H 3.90 âˆ’ 1.0" exact="Chloroquine" post="N 17 O GLU 208 (A) H-donor 3.16 âˆ’"/>
   <result pre="0.6 6-ring N ASN 210 (A) pi-H 3.62 âˆ’ 0.6" exact="Doxycycline" post="O 24 OE1 GLU 208 (A) H-donor 3.01 âˆ’"/>
   <result pre="O 12 NZ LYS 94 (A) H-acceptor 3.12 âˆ’ 3.5" exact="Ribavirin" post="O 15 NZ LYS 562 (A) H-acceptor 3.03 âˆ’"/>
   <result pre="3.01 âˆ’ 1.2 Table 5 Docking score and energy of" exact="ivermectin" post="drug and 1Q2W of COVID-19 with site 1 of"/>
   <result pre="protease (PDB codeâ€‰=â€‰1Q2W) Table 6 Docking score and energy of" exact="ivermectin" post="drug with ACE-2 receptor (PDB codeâ€‰=â€‰6M0J) Fig.Â 1 3d"/>
   <result pre="with ACE-2 RECEPTOR (PDB CODEâ€‰=â€‰6M0J) Fig.Â 5 Chemical structure of" exact="ivermectin" post="Brincidofovir (BCV) is an orally bioavailable, long-acting nucleotide analog"/>
   <result pre="with an enhanced cellular penetration prodrug of cidofovir, wherein the" exact="cidofovir" post="acyclic nucleoside monophosphate is conjugated through its phosphonate group"/>
   <result pre="particle, the compound ensures better and higher intracellular releases of" exact="cidofovir" post="and lower plasma concentrations of the active drug, effectively"/>
   <result pre="effectively increasing its antiviral activity. When intracellular, the released free" exact="cidofovir" post="from the BCV is phosphorylated to its active metabolite"/>
   <result pre="cidofovir from the BCV is phosphorylated to its active metabolite" exact="cidofovir" post="diphosphate, which, due to its structural similarity to the"/>
   <result pre="investigations using molecular docking to check the binding interaction between" exact="ivermectin" post="and the SARS-CoV-2 protease and receptor. We got comparable"/>
   <result pre="better recommended because for its high lipophilicity â€œ5.54â€�, whereas for" exact="ivermectin" post="it is â€œ2.01â€�. In conclusion, molecular modeling tools were"/>
   <result pre="SARS coronavirus main proteaseWorldw Protein Data Bank200310.2210/pdb1q2w/pdb CalyLDruceJDCattonMGJansDAWagstaffKMThe FDA-approved drug" exact="ivermectin" post="inhibits the replication of SARS-CoV-2 in vitroAntivir Res202017810478710.1016/j.antiviral.2020.10478732251768 ChiangC-MFaculty"/>
   <result pre="dsDNA virusesExpert Rev Anti-infect Ther2014121171117810.1586/14787210.2014.94884725120093 FramptonJETafenoquine: first global approvalDrugs2018781517152310.1007/s40265-018-0979-230229442 GaoJTianZYangXBreakthrough:" exact="chloroquine" post="phosphate has shown apparent efficacy in treatment of COVID-19"/>
   <result pre="of therapeutic intervention with an oral ether lipid analogue of" exact="cidofovir" post="(CMX001) in a lethal mousepox modelAntivir Res200878A61A6210.1016/j.antiviral.2008.01.132 ParkerSet al.Efficacy"/>
   <result pre="al.Efficacy of therapeutic intervention with an oral etherâ€&quot;lipid analogue of" exact="cidofovir" post="(CMX001) in a lethal mousepox modelAntiviral Res200877394910.1016/j.antiviral.2007.08.00317904231 Schepers J."/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7414693\results\search\drug\results.xml">
   <result pre="about this earlier HIV epidemic and the well-documented relationship between" exact="heroin" post="use and injection drug use (IDU) along with condomless"/>
   <result pre="nonmedical use and abuse of prescription opioids, an increase in" exact="heroin" post="use,2 a large number of opioid overdose deaths,3 and"/>
   <result pre="In particular the concern is the increase of illicitly manufactured" exact="fentanyl" post="used in isolation or with other drugs, such as"/>
   <result pre="was a marked increase in deaths caused by illicitly manufactured" exact="fentanyl" post="overdoses, especially in people who used multiple illicit opioids"/>
   <result pre="people who used multiple illicit opioids and nonopioids. Illicitly manufactured" exact="fentanyl" post="was involved in approximately two-thirds of opioid deaths during"/>
   <result pre="soft tissue infections, and bone and joint infections.10,13,16, 17, 18" exact="Fentanyl" post="or heroin combined with stimulants such as cocaine and"/>
   <result pre="infections, and bone and joint infections.10,13,16, 17, 18 Fentanyl or" exact="heroin" post="combined with stimulants such as cocaine and methamphetamine have"/>
   <result pre="17, 18 Fentanyl or heroin combined with stimulants such as" exact="cocaine" post="and methamphetamine have led to new HIV outbreaks among"/>
   <result pre="HIV epidemic associated with IDU was related to injection of" exact="heroin" post="and cocaine and affected persons predominantly living in urban"/>
   <result pre="associated with IDU was related to injection of heroin and" exact="cocaine" post="and affected persons predominantly living in urban centers and"/>
   <result pre="linked directly to both sharing contaminated IDU works when injecting" exact="oxymorphone" post="(Opana) as well as through condomless sexual intercourse.27 Over"/>
   <result pre="a change from addiction to prescription opioids to a new" exact="heroin" post="epidemic across the country, which was predominantly found to"/>
   <result pre="to involve the rapidly available and less expensive black tar" exact="heroin" post="coming from Mexico,28 which in turn led to another"/>
   <result pre="remember that the early HIV epidemic was associated with white" exact="heroin" post="from Asia, which had low supply levels in the"/>
   <result pre="fulfilled by the less expensive and easily available black tar" exact="heroin" post="that was supplied through Mexico and now the illicitly"/>
   <result pre="and overdose, and they reduce transmission of HIV and HCV33,52;" exact="buprenorphine" post="and XR-NTX also improve HIV viral suppression in PLWH,53,"/>
   <result pre="removal of the DATA 2000 X-waiver mandatory training to provide" exact="buprenorphine" post="and removal of limitations of numbers of persons with"/>
   <result pre="treat it. Thus, services must expand to provide clean syringes," exact="fentanyl" post="testing, and naloxone distribution. Further, federal dollars should be"/>
   <result pre="services must expand to provide clean syringes, fentanyl testing, and" exact="naloxone" post="distribution. Further, federal dollars should be released to states"/>
   <result pre="be released to states to fund provision of the syringes," exact="fentanyl" post="test strips, and naloxone, along with the staff to"/>
   <result pre="the United States, 2003-2013JAMA31420151468147826461997 3Botticelli M. Americaâ€™s Addiction to Opioids:" exact="Heroin" post="and Prescription Drug Abuse. 2014. Available at: http://www.drugcaucus.senate.gov/sites/default/files/Botticelli%20Testimony.pdf. 4Substance"/>
   <result pre="Deaths by Opioid Type and Presence of Benzodiazepines, Cocaine, and" exact="Methamphetamine" post="- 25 States, July-December 2017 to January-June 2018MMWR Morb"/>
   <result pre="the United StatesInt J Drug Policy702019404631079029 9KariisaM.SchollL.WilsonN.Drug overdose deaths involving" exact="cocaine" post="and psychostimulants with abuse potential - United States, 2003-2017MMWR"/>
   <result pre="to its rootsNature5732019S10S1231511672 27PetersP.J.PontonesP.HooverK.W.HIV infection linked to injection use of" exact="oxymorphone" post="in Indiana, 2014-2015NÂ Engl J Med375201622923927468059 28QuinonesS.Dreamland1st edition2015Bloomsbury PressNew"/>
   <result pre="2014-2015NÂ Engl J Med375201622923927468059 28QuinonesS.Dreamland1st edition2015Bloomsbury PressNew York 29RuddR.A.PaulozziL.J.BauerM.J.Increases in" exact="heroin" post="overdose deaths - 28 States, 2010 to 2012MMWR Morb"/>
   <result pre="inject drugs: an international systematic review of high seroprevalence areasDrug" exact="Alcohol" post="Depend12420129510722257753 33collab: SAMHSATip 63: medications for opioid use disorder-executive"/>
   <result pre="abuse treatment outcomes for released HIV-infected prisoners: the impact of" exact="buprenorphine" post="treatmentJÂ Urban Health87201059260220177974 54SpringerS.A.Di PaolaA.AzarM.M.Extended-release naltrexone improves viral suppression"/>
   <result pre="double-blind, placebo-controlled randomized trialJÂ Acquir Immune Defic Syndr782018435329373393 55SpringerS.A.QiuJ.Saber-TehraniA.S.Retention on" exact="buprenorphine" post="is associated with high levels of maximal viral suppression"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7414743\results\search\drug\results.xml">
   <result pre="indicates a sharp drop among people with a history of" exact="heroin" post="use in 2011 (from approximately 4000â€&quot;4600 per year across"/>
   <result pre="JY, Yoo BK. Meta-analysis of the efficacy and safety of" exact="sofosbuvir" post="for the treatment of hepatitis C virus infection. (2210â€&quot;7711"/>
   <result pre="of hepatitis C virus infection. (2210â€&quot;7711 (Electronic)). 3.NaggieSCooperCSaagMWorkowskiKRuanePTownerWJet al.Ledipasvir and" exact="Sofosbuvir" post="for HCV in patients Coinfected with HIV-1N Engl J"/>
   <result pre="Hutchinson Sj Fau - Lima VD, Lima Vd Fau -" exact="Foster" post="GR, et al. Hepatitis C virus treatment for prevention"/>
   <result pre="C, et al. Ombitasvir, paritaprevir co-dosed with ritonavir, dasabuvir, and" exact="ribavirin" post="for hepatitis C in patients co-infected with HIV-1: a"/>
   <result pre="Kottilil S, Daar ES, Ruane P, Workowski K, et al." exact="Sofosbuvir" post="and Velpatasvir for the Treatment of Hepatitis C Virus"/>
   <result pre="Daar ES, Ruane P, Workowski K, et al. Sofosbuvir and" exact="Velpatasvir" post="for the Treatment of Hepatitis C Virus in Patients"/>
   <result pre="An Open-Label, Phase 3 Study. (1537â€&quot;6591 (Electronic)). 12.WylesDLRuanePJSulkowskiMSDieterichDLuetkemeyerAMorganTRet al.Daclatasvir plus" exact="Sofosbuvir" post="for HCV in patients Coinfected with HIV-1N Engl J"/>
   <result pre="1950 to 2100. https://www.populationpyramid.net/spain/2010. Accessed 17 Apr 2018. 40.Martin NK," exact="Foster" post="Gr Fau - Vilar J, Vilar J Fau -"/>
   <result pre="between 2004 and 2011 in Spain. (1365â€&quot;2893 (Electronic)). 61.Martin NK," exact="Foster" post="Gr VJ, Ryder S, Cramp ME, Gordon F, Dillon"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7414935\results\search\drug\results.xml">
   <result pre="detergent before entering the workplace followed by disinfection with 75%" exact="alcohol" post="or disinfection with 50 ppm of available chlorine. Operators"/>
   <result pre="Coronavirus pseudoparticles formed with recombinant M and E proteins induce" exact="alpha" post="interferon synthesis by leukocytes. J Virol. 1998;72:8636â€&quot;8643. doi:10.1128/JVI.72.11.8636-8643.19989765403 13.HuangC,"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7416109\results\search\drug\results.xml">
   <result pre="till date to evaluate the safety and effectiveness of the" exact="dexamethasone" post="(a corticosteroid) for the management of SARS-CoV-2 infection (https://clinicaltrials.gov/ct2/results?cond=covid-19&amp;amp;term=dexamethasone&amp;amp;cntry=&amp;amp;state=&amp;amp;city=&amp;amp;dist=)."/>
   <result pre="(a corticosteroid) for the management of SARS-CoV-2 infection (https://clinicaltrials.gov/ct2/results?cond=covid-19&amp;amp;term=dexamethasone&amp;amp;cntry=&amp;amp;state=&amp;amp;city=&amp;amp;dist=). Recently," exact="dexamethasone" post="was declared as the world's first treatment proven effective"/>
   <result pre="investigate several potential COVID-19 treatments on hospitalized patients [3]. Moreover," exact="dexamethasone" post="has been proven to significantly reduce the mortality risk"/>
   <result pre="as much as 35% and 20%, respectively. After that, the" exact="dexamethasone" post="has been authorized by the UK government for the"/>
   <result pre="hospitalized COVID-19 patients, not on oxygen or ventilation [4]. The" exact="dexamethasone" post="(synthetic pregnane corticosteroid; a cortisol derivative) is a well-known"/>
   <result pre="oxygen or ventilation [4]. The dexamethasone (synthetic pregnane corticosteroid; a" exact="cortisol" post="derivative) is a well-known lifesaving drug and commonly used"/>
   <result pre="of different anti-inflammatory cytokines [5]. Fig. 1 An overview of" exact="dexamethasone" post="and its mode of action in COVID-19 patients. Additionally,"/>
   <result pre="pneumonia [6]. In this context, the anti-inflammatory effect of the" exact="dexamethasone" post="is suggested to probably counter the cytokine storm caused"/>
   <result pre="launched to test the hypothesis of whether early administration of" exact="dexamethasone" post="along with IV-IG and IFN-Î² can reduce the harmful"/>
   <result pre="cytokine storm in critically ill COVID-19 patients or not. Moreover," exact="dexamethasone" post="is approved by the FDA as a broad-spectrum immunosuppressant"/>
   <result pre="with an added advantage of longer duration of action. Furthermore," exact="dexamethasone" post="is suggested to limit the production of inflammatory cytokines"/>
   <result pre="concern and needs further investigation [6]. The breakthrough discovery of" exact="dexamethasone" post="as the first drug to save lives is very"/>
   <result pre="of the general population [6]. However, finding effective drugs like" exact="dexamethasone" post="will transform the global impact of the COVID-19 pandemic"/>
   <result pre="with 2019 novel coronavirus in Wuhan, ChinaLancet39510223202049750610.1016/S0140-6736(20)3018331986264 3MahaseE.Covid-19: demand for" exact="dexamethasone" post="surges as RECOVERY trial publishes preprintBMJ3692020m251210.1136/bmj.m2512 4LedfordH.Coronavirus breakthrough: dexamethasone"/>
   <result pre="for dexamethasone surges as RECOVERY trial publishes preprintBMJ3692020m251210.1136/bmj.m2512 4LedfordH.Coronavirus breakthrough:" exact="dexamethasone" post="is first drug shown to save livesNature202010.1038/d41586-020-01824-5 5RhenT.CidlowskiJ.A.Anti-inflammatory action"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7416802\results\search\drug\results.xml">
   <result pre="effective against CoVs, as are organic solvents such as ether," exact="alcohol" post="(60â€&quot;95%), chloroform, and disinfectants with a high concentration of"/>
   <result pre="in phase I of testing [11]. Four antiviral drugs, including" exact="hydroxychloroquine" post="(or chloroquine), favipiravir, lopinavir, and remdesivir, have entered phase"/>
   <result pre="and are briefly described below. Remdesivir Remdesivir (GS-5734) is an" exact="adenosine" post="analog drug that was produced for the treatment of"/>
   <result pre="CYP-3A4, indicating a possible interaction with related inhibitors such as" exact="ritonavir" post="and voriconazole. It has also been suggested that the"/>
   <result pre="efficacy on a wide scale in the fight against COVID-19." exact="Chloroquine" post="and hydroxychloroquine Chloroquine is an anti-parasitic drug that is"/>
   <result pre="a wide scale in the fight against COVID-19. Chloroquine and" exact="hydroxychloroquine" post="Chloroquine is an anti-parasitic drug that is used against"/>
   <result pre="wide scale in the fight against COVID-19. Chloroquine and hydroxychloroquine" exact="Chloroquine" post="is an anti-parasitic drug that is used against malaria"/>
   <result pre="potential use in treating COVID-19. The potential antiviral activity of" exact="chloroquine" post="against COVID-19 was first reported by Wang et al."/>
   <result pre="rationale for using this dosage remains vague. The use of" exact="chloroquine" post="has been associated with stability in patients, with better"/>
   <result pre="countries like the USA. As a substitute, another drug called" exact="hydroxychloroquine" post="is being investigated. It differs from chloroquine by the"/>
   <result pre="another drug called hydroxychloroquine is being investigated. It differs from" exact="chloroquine" post="by the presence of an additional hydroxyl group. It"/>
   <result pre="is assumed that this drug will be more effective than" exact="chloroquine" post="for treating COVID-19, the prolonged use of which has"/>
   <result pre="in rheumatic disorders. The current data regarding the activity of" exact="hydroxychloroquine" post="against CoVs are still inadequate. However, in 2006, a"/>
   <result pre="was examined by Biot et al. [91], who demonstrated that" exact="chloroquine" post="had superior antiviral activity against SARS-CoV-1 compared to hydroxychloroquine."/>
   <result pre="the findings were the opposite of the previous ones, with" exact="hydroxychloroquine" post="being more effective than chloroquine against SARS-CoV-2 when the"/>
   <result pre="of the previous ones, with hydroxychloroquine being more effective than" exact="chloroquine" post="against SARS-CoV-2 when the â€œratio of the free lung"/>
   <result pre="(RLTEC) values were compared [65]. The reported efficacious dosage of" exact="chloroquine" post="was more than 400Â mg, and therefore, the dosage"/>
   <result pre="was more than 400Â mg, and therefore, the dosage of" exact="hydroxychloroquine" post="was set accordingly in another study [61], which found"/>
   <result pre="following days. This dosage resulted in higher RLTEC values for" exact="hydroxychloroquine" post="than chloroquine. The second dosage gave similar results, suggesting"/>
   <result pre="dosage gave similar results, suggesting that a lower dosage of" exact="hydroxychloroquine" post="was also effective [65]. However, it is important to"/>
   <result pre="and analyzed from the PBPK data for a dosage of" exact="hydroxychloroquine" post="less than 1000Â mg and varying regimens, RLTEC values"/>
   <result pre="consecutive days, which would vary drastically from the dosage of" exact="chloroquine" post="taken two times every day with RLTEC values. The"/>
   <result pre="reported the effect of oral administration of 200Â mg of" exact="hydroxychloroquine" post="after the passage of eight hours in patients infected"/>
   <result pre="stronger reduction in the viral load than the use of" exact="hydroxychloroquine" post="alone. This finding, although significant, is not sufficient, as"/>
   <result pre="viral load was noteworthy. The study included 26 patients receiving" exact="hydroxychloroquine" post="therapy, six of which were excluded from the study"/>
   <result pre="indicate that caution is needed in the administration of both" exact="chloroquine" post="and hydroxychloroquine, initial studies conducted in China have been"/>
   <result pre="has been addressed [94]. In the meantime, the administration of" exact="hydroxychloroquine" post="needs to be approached with caution. Lopinavir/ritonavir Lopinavir is"/>
   <result pre="effectiveness of the drug. The reported course of action of" exact="lopinavir" post="is the inhibition of the protease enzyme of the"/>
   <result pre="drugs against SARS-CoV-1 during its outbreak, and the administration of" exact="lopinavir" post="and ribavirin was observed to block replication of the"/>
   <result pre="SARS-CoV-1 during its outbreak, and the administration of lopinavir and" exact="ribavirin" post="was observed to block replication of the virus after"/>
   <result pre="efficacy when used in combination [96]. The potent activity of" exact="lopinavir" post="against SARS-CoV-1 was also reported by de Wilde et"/>
   <result pre="in subjects who had contracted HIV [98]. The potency of" exact="lopinavir" post="in combination with ritonavir was compared to that of"/>
   <result pre="contracted HIV [98]. The potency of lopinavir in combination with" exact="ritonavir" post="was compared to that of interferon beta (INF-Î²) against"/>
   <result pre="symptoms in animals infected with MERS-CoV after combined therapy with" exact="lopinavir" post="and ritonavir [99]. At present, a controlled study of"/>
   <result pre="animals infected with MERS-CoV after combined therapy with lopinavir and" exact="ritonavir" post="[99]. At present, a controlled study of combined therapy"/>
   <result pre="Chu et al. [96], in which it was used with" exact="ribavirin" post="and corticosteroid drugs. The subjects undergoing lopinavir/ritonavir therapy were"/>
   <result pre="The subjects undergoing lopinavir/ritonavir therapy were compared with subjects receiving" exact="ribavirin" post="along with corticosteroids, after which a considerable decrease in"/>
   <result pre="should be considered that their activity compared to remdesivir and" exact="chloroquine" post="in the case of SARS-CoV-1 was below average, and"/>
   <result pre="and chest imaging, may consider glucocorticoid that is equivalent to" exact="methylprednisolone" post="1â€&quot;2Â mg/kg/day for 3â€&quot;5Â days or less. Note that"/>
   <result pre="Chinese Thoracic Society recommends a lower dose,â€‰â‰¤â€‰0.5â€&quot;1Â mg/kg per day" exact="methylprednisolone" post="forâ€‰â‰¤â€‰7Â days in select patients, after careful consideration of"/>
   <result pre="and benefits [125]. Pharmacological treatments in which risks outweigh benefits" exact="Ribavirin" post="with or without interferon Ribavirin was approved in the"/>
   <result pre="in which risks outweigh benefits Ribavirin with or without interferon" exact="Ribavirin" post="was approved in the 1980s for viral hemorrhagic fever,"/>
   <result pre="transcription by inhibiting the synthesis of RNA. The combination of" exact="ribavirin" post="with corticosteroids and/or interferon against SARS-CoV-1 did not show"/>
   <result pre="and cytopenia [129]. Despite these observations, the Chinese guidelines recommend" exact="ribavirin" post="500Â mg IV 2â€&quot;3 times daily in combination with"/>
   <result pre="lack of experimental trials, it is not safe to use" exact="ribavirin" post="at the moment for the treatment of COVID-19. Oseltamivir"/>
   <result pre="The same is true for other neuraminidase inhibitors such as" exact="zanamivir" post="and peramivir. Currently, the available data also do not"/>
   <result pre="registered yet Darunavir/cobicistat Anti-retroviral HIV-1 protease inhibitor Not registered yet" exact="Disulfiram" post="Thiuram derivative Blocks alcohol oxidation Not registered yet Eculizumab"/>
   <result pre="HIV-1 protease inhibitor Not registered yet Disulfiram Thiuram derivative Blocks" exact="alcohol" post="oxidation Not registered yet Eculizumab Humanized, monoclonal IgG antibody"/>
   <result pre="Griffithsin Anti-HIV microbicide Potent HIV entry inhibitor Not registered yet" exact="Nelfinavir" post="Anti-retroviral An HIV-1 protease inhibitor Not registered yet Niclosamide"/>
   <result pre="yet Nelfinavir Anti-retroviral An HIV-1 protease inhibitor Not registered yet" exact="Niclosamide" post="Anthelminthic Not registered yet REGN3048 Human monoclonal antibody Binds"/>
   <result pre="monoclonal antibody/ used against rheumatoid arthritis IL-6 receptor antagonist USA" exact="Sofosbuvir" post="Antiviral A nucleotide analog inhibitor of hepatitis C virus"/>
   <result pre="against COVID-19 at various levels of infection and disease progression" exact="Nitric oxide" post="therapy against COVID-19 Nitric oxide gas is a human-friendly"/>
   <result pre="of infection and disease progression Nitric oxide therapy against COVID-19" exact="Nitric oxide" post="gas is a human-friendly gas due to the following"/>
   <result pre="2002â€&quot;2003. Critically ill patients can be treated by giving them" exact="nitric oxide" post="gas, which not only improves lung function but also"/>
   <result pre="Apr 2020 59.Request for emergency use authorization for use of" exact="chloroquine" post="phosphate or hydroxychloroquine sulfate supplied from the Strategic National"/>
   <result pre="for emergency use authorization for use of chloroquine phosphate or" exact="hydroxychloroquine" post="sulfate supplied from the Strategic National Stockpile for Treatment"/>
   <result pre="2020 60.CortegianiAIngogliaGIppolitoMGiarratanoAEinavSA systematic review on the eicacy and safety of" exact="chloroquine" post="for the treatment of COVID-19J Crit Care20205727928332173110 61.Gao J,"/>
   <result pre="Crit Care20205727928332173110 61.Gao J, Tian Z, Yang X (2020) Breakthrough:" exact="chloroquine" post="phosphate has shown apparent efficacy in treatment of COVID-19"/>
   <result pre="of Guangdong Province and Health Commission of Guangdong Province for" exact="Chloroquine" post="in the Treatment of Novel Coronavirus PneumoniaExpert Consens Chloroquine"/>
   <result pre="for Chloroquine in the Treatment of Novel Coronavirus PneumoniaExpert Consens" exact="Chloroquine" post="Phosphate Treat Novel Coronavirus Pneumonia [in Chinese]202020201010011939 63.Physicians work"/>
   <result pre="vitro antiviral activity and projection of optimized dosing design of" exact="hydroxychloroquine" post="for the treatment of severe acute respiratory syndrome coronavirus"/>
   <result pre="to treat coronavirus disease 2019 (COVID-19)Drug Discov Ther2020141586032147628 78.WangMCaoRZhangLYangXLiuJXuMShiZHuZZhongWXiaoGRemdesivir and" exact="chloroquine" post="effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in"/>
   <result pre="synthesis of a phosphoramidate prodrug of a pyrrolo [2, 1-f][triazin4-amino]" exact="adenine" post="C-nucleoside (GS-5734) for the treatment of ebola and emerging"/>
   <result pre="the United States. https://www.medrxiv.org/content/10.1101/2020.03.09.20032896v1.full.pdf. Retrieved 14 Mar 2020 90.ColsonPRolainJ-MLagierJ-CBrouquiPRaoultDChloroquine and" exact="hydroxychloroquine" post="as available weapons to fight COVID-19Int J Antimicrob Agents202055410593232145363"/>
   <result pre="92.TettSEClinical pharmacokinetics of slow-acting antirheumatic drugsClin Pharmacokinet19932553924077904547 93.GautretPLagierJ-CParolaPMeddebLMailheMDoudierBet al.Hydroxychloroquine and" exact="azithromycin" post="as a treatment of COVID19: results of an open-label"/>
   <result pre="an open-label non-randomized clinical trialInt J Antimicrob Agents202056110594932205204 94.TouretFde LamballerieXOf" exact="chloroquine" post="and COVID-19Antiviral Res202017710476232147496 95.RatiaKPeganSTakayamaJSleemanKCoughlinMBalijiSChaudhuriRFuWPrabhakarBSJohnsonMEA noncovalent class of papain-like protease/deubiquitinase"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7417167\results\search\drug\results.xml">
   <result pre="causing cell damage. Based on prior in-vitro studies on SARS-CoV," exact="amiodarone" post="and other cationic amphiphilic drugs like dronedarone, verapamil, and"/>
   <result pre="Many of the â€œoff-labelâ€� COVID-19 therapies including (hydroxy)chloroquine, lopinavir/ritonavir and" exact="azithromycin" post="have either known or possible risk of TdP due"/>
   <result pre="due to their effect on QT prolongation (59). (Hydroxy)chloroquine and" exact="azithromycin" post="inhibit the hERG-K+ channel, which causes prolongation of action"/>
   <result pre="cohort study of 90 hospitalized COVID-19 patients, the administration of" exact="hydroxychloroquine" post="with or without azithromycin was associated with an increased"/>
   <result pre="hospitalized COVID-19 patients, the administration of hydroxychloroquine with or without" exact="azithromycin" post="was associated with an increased risk of QTc prolongation"/>
   <result pre="drugs, or myocardial ischemia. In patients with supraventricular tachycardia, intravenous" exact="adenosine" post="can be used for acute termination, although further validation"/>
   <result pre="are hemodynamically stable, consider discontinuing antiarrhythmic drugs (AADs) especially sotalol," exact="flecainide" post="and likely amiodarone and propafenone given serious drug-drug interactions"/>
   <result pre="consider discontinuing antiarrhythmic drugs (AADs) especially sotalol, flecainide and likely" exact="amiodarone" post="and propafenone given serious drug-drug interactions with antiviral drugs"/>
   <result pre="antiarrhythmic drugs (AADs) especially sotalol, flecainide and likely amiodarone and" exact="propafenone" post="given serious drug-drug interactions with antiviral drugs and to"/>
   <result pre="close monitoring with caution is recommended with the use of" exact="amiodarone" post="in patients undergoing treatment with fingolimod. Propafenone or flecainide"/>
   <result pre="the use of amiodarone in patients undergoing treatment with fingolimod." exact="Propafenone" post="or flecainide is preferred in structurally normal hearts who"/>
   <result pre="of amiodarone in patients undergoing treatment with fingolimod. Propafenone or" exact="flecainide" post="is preferred in structurally normal hearts who are on"/>
   <result pre="flecainide is preferred in structurally normal hearts who are on" exact="fingolimod" post="(63). Transthoracic echocardiography (TTE) is recommended only in hemodynamically"/>
   <result pre="the previously mentioned causes, the first choice of therapy is" exact="amiodarone" post="or intravenous lidocaine, especially if underlying myocardial infarction is"/>
   <result pre="recommended that all patients with COVID-19 self-medicate with paracetamol or" exact="acetaminophen" post="if they develop fever. High-risk BrS patients who develop"/>
   <result pre="administered with great caution in critically ill patients. BBs and" exact="flecainide" post="should be continued while monitoring interactions with antiviral drugs."/>
   <result pre="days) versus high-dose (600Â mg twice daily for 10Â days)" exact="chloroquine" post="in addition to azithromycin in severe COVID-19 patients showed"/>
   <result pre="mg twice daily for 10Â days) chloroquine in addition to" exact="azithromycin" post="in severe COVID-19 patients showed lethality in the higher"/>
   <result pre="to 10.6) and thus recommended against the use of high-dose" exact="chloroquine" post="in severe cases (68). Traditionally, the Tisdale risk score,"/>
   <result pre="Clinic for patients in whom QTc-prolonging drugs like (hydroxy)chloroquine Â±" exact="azithromycin" post="or lopinavir/ritonavirÂ are under consideration recommend to obtain a"/>
   <result pre="â‰¥60Â ms, 2 to 3Â h after a dose of" exact="hydroxychloroquine" post="or other QT-prolonging agent, we recommend re-evaluation of the"/>
   <result pre="etÂ al. (72) reports a possible benefit of addition of" exact="lidocaine" post="or mexiletine to allow combination therapy with azithromycin and"/>
   <result pre="addition of lidocaine or mexiletine to allow combination therapy with" exact="azithromycin" post="and chloroquine in patients with a prolonged QT interval."/>
   <result pre="lidocaine or mexiletine to allow combination therapy with azithromycin and" exact="chloroquine" post="in patients with a prolonged QT interval. Class Ib"/>
   <result pre="amiodarone, propafenone, flecainide, quinidine, and some novel oral anticoagulants including" exact="apixaban" post="and rivaroxaban, which are metabolized mainly by different CP450"/>
   <result pre="for COVID-19 Therapy With Cardiac Drugs Treatment Select Drug-Drug Interactionsâˆ—" exact="Azithromycin" post="â†&quot; in HR, â†‘ PR interval, â†‘â†‘ in QTc"/>
   <result pre="of TdP.AAD drug interactions: Severe: amiodarone, disopyramide, dofetilide, flecainide, sotalol," exact="propafenone" post="Moderate: BBs, digoxin (Hydroxy) chloroquine â†&quot; in HR, â†‘"/>
   <result pre="interactions: Severe: amiodarone, disopyramide, dofetilide, flecainide, sotalol, propafenone Moderate: BBs," exact="digoxin" post="(Hydroxy) chloroquine â†&quot; in HR, â†‘ PR interval, â†‘â†‘"/>
   <result pre="amiodarone, disopyramide, dofetilide, flecainide, sotalol, propafenone Moderate: BBs, digoxin (Hydroxy)" exact="chloroquine" post="â†&quot; in HR, â†‘ PR interval, â†‘â†‘ in QTc"/>
   <result pre="risk of TdP.AAD drug interactions: Severe: amiodarone, flecainide, mexiletine, sotalol," exact="dofetilide" post="Moderate: disopyramide, propafenone, quinidine, digoxin Mild: metoprolol, nebivolol, propranolol,"/>
   <result pre="Severe: amiodarone, flecainide, mexiletine, sotalol, dofetilide Moderate: disopyramide, propafenone, quinidine," exact="digoxin" post="Mild: metoprolol, nebivolol, propranolol, timolol, verapamil Lopinavir/ritonavir â†‘ PR"/>
   <result pre="Moderate: disopyramide, propafenone, quinidine, digoxin Mild: metoprolol, nebivolol, propranolol, timolol," exact="verapamil" post="Lopinavir/ritonavir â†‘ PR interval, â†‘â†‘ in QTc interval with"/>
   <result pre="risk of TdP.AAD interactions: Moderate: BBs, CCBs, ivabradine, amiodarone, flecainide," exact="propafenone" post="Ribavirin Unknown Tocilizumab No ECG changes describedAAD interactions: Mild:"/>
   <result pre="of TdP.AAD interactions: Moderate: BBs, CCBs, ivabradine, amiodarone, flecainide, propafenone" exact="Ribavirin" post="Unknown Tocilizumab No ECG changes describedAAD interactions: Mild: amiodarone,"/>
   <result pre="Unknown Tocilizumab No ECG changes describedAAD interactions: Mild: amiodarone, quinidine" exact="Methylprednisolone" post="Unknown Interferon alfa-1 Unknown â†‘/â†&quot;Â =Â mild increase/decrease; â†‘â†‘/â†&quot;â†&quot;Â"/>
   <result pre="Proc9520201213122132359771 60MercuroN.J.YenC.F.ShimD.J.Risk of QT interval prolongation associated with use of" exact="hydroxychloroquine" post="with or without concomitant azithromycin among hospitalized patients testing"/>
   <result pre="prolongation associated with use of hydroxychloroquine with or without concomitant" exact="azithromycin" post="among hospitalized patients testing positive for coronavirus disease 2019"/>
   <result pre="arrhythmia syndromesHeart Rhythm2020 Mar 31[E-pub ahead of print] 67RamireddyA.ChughH.S.ReinierK.Experience with" exact="hydroxychloroquine" post="and azithromycin in the COVID-19 pandemic: implications for QT"/>
   <result pre="Rhythm2020 Mar 31[E-pub ahead of print] 67RamireddyA.ChughH.S.ReinierK.Experience with hydroxychloroquine and" exact="azithromycin" post="in the COVID-19 pandemic: implications for QT interval monitoringJÂ"/>
   <result pre="Am Heart Assoc92020e017144 68BorbaM.G.S.ValF.F.A.SampaioV.S.Effect of high vs low doses of" exact="chloroquine" post="diphosphate as adjunctive therapy for patients hospitalized with severe"/>
   <result pre="prolongation in coronavirus disease 2019 (COVID-19) patients treated with either" exact="chloroquine" post="or hydroxychloroquine in conjunction with azithromycin: Possible benefits of"/>
   <result pre="coronavirus disease 2019 (COVID-19) patients treated with either chloroquine or" exact="hydroxychloroquine" post="in conjunction with azithromycin: Possible benefits of intravenous lidocaineHeartRhythm"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7419580\results\search\drug\results.xml">
   <result pre="available that reference secondary infections showed that most clinicians prescribed" exact="meropenem" post="and linezolid to children with a rate of prophylactic"/>
   <result pre="reference secondary infections showed that most clinicians prescribed meropenem and" exact="linezolid" post="to children with a rate of prophylactic treatment between"/>
   <result pre="commonly used antibiotics were moxifloxacin (n = 452, 39.2%) and" exact="azithromycin" post="(n = 294, 30.7%). Others include ceftriaxone, vancomycin, cefepime,"/>
   <result pre="maxipime, azithromycin, amoxicillin-clavulanate, cefoperazone/sulbactam, quinolone plus azithromycin, levofloxacin, moxifloxacin, and" exact="ceftriaxone" post="plus azithromycin, and most commonly azithromycin (n = 206,"/>
   <result pre="azithromycin, levofloxacin, moxifloxacin, and ceftriaxone plus azithromycin, and most commonly" exact="azithromycin" post="(n = 206, 74.6%). Of the four studies that"/>
   <result pre="in three studies, administering amoxicillin-clavulanate, clarithromycin, azithromycin, levofloxacin, moxifloxacin and" exact="ceftriaxone" post="plus azithromycin (47, 49, 51). In total, 12 patients"/>
   <result pre="studies, administering amoxicillin-clavulanate, clarithromycin, azithromycin, levofloxacin, moxifloxacin and ceftriaxone plus" exact="azithromycin" post="(47, 49, 51). In total, 12 patients out of"/>
   <result pre="Sixty eight patients were treated with the antibiotics piperacillin-tazobactam, azithromycin," exact="ceftriaxone" post="and trimethoprim- sulfamethoxazole, levofloxacin, imipenem and other broad-spectrum antibiotics"/>
   <result pre="(96.6%) (65â€&quot;67, 71, 72). The most commonly used antibiotics were" exact="vancomycin" post="(n = 317, 46.2%) and imipenem/meropenem (n = 243,"/>
   <result pre="= 243, 54.7%). Others were azithromycin, ceftriaxone, cephalosporin, piperacillin-tazobactam, linezolid," exact="vancomycin" post="plus cefepime, vancomycin plus meropenem, clarithromycin, levofloxacin and dicloxacillin."/>
   <result pre="Others were azithromycin, ceftriaxone, cephalosporin, piperacillin-tazobactam, linezolid, vancomycin plus cefepime," exact="vancomycin" post="plus meropenem, clarithromycin, levofloxacin and dicloxacillin. In total, 223"/>
   <result pre="cephalosporin, piperacillin-tazobactam, linezolid, vancomycin plus cefepime, vancomycin plus meropenem, clarithromycin," exact="levofloxacin" post="and dicloxacillin. In total, 223 patients of 910 (24.5%)"/>
   <result pre="one of the studies reported the use of azithromycin, vancomycin," exact="ceftriaxone" post="and cephalosporin (65). In general, all eight case studies"/>
   <result pre="multicenter descriptive study. Clin Infect Dis. (2020) 29:ciaa19910.1093/cid/ciaa199 35.GautretPLagierJCParolaPMeddebLMailheMDoudierBet al.." exact="Hydroxychloroquine" post="and azithromycin as a treatment of COVID-19: results of"/>
   <result pre="study. Clin Infect Dis. (2020) 29:ciaa19910.1093/cid/ciaa199 35.GautretPLagierJCParolaPMeddebLMailheMDoudierBet al.. Hydroxychloroquine and" exact="azithromycin" post="as a treatment of COVID-19: results of an open-label"/>
   <result pre="syndrome coronavirus infection. Ann Intern Med. (2014) 160:389â€&quot;97. 10.7326/M13-248624474051 56.Al-TawfiqJAMomattinHDibJMemishZA." exact="Ribavirin" post="and interferon therapy in patients infected with the middle"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7423503\results\search\drug\results.xml">
   <result pre="cause respiratory tract infections in humans. Coronaviruses classify into either" exact="alpha" post="and beta subtypes that infect humans, or into gamma"/>
   <result pre="interferon production culminating in the release of IL-6 and TNF" exact="alpha" post="cytokines [37]. This immune cascade results in extensive tracheobronchial"/>
   <result pre="virus. Liver injury is linked to multiple etiologies such as" exact="alcohol" post="consumption, toxins, bile duct dysfunction, and viral infections. Epidemiologists"/>
   <result pre="development of new drugs and clinical assessment. The antiviral medication" exact="Amantadine" post="is no longer recommended due to the increase in"/>
   <result pre="treatments have demonstrated efficacy for the treatment of COVID-19 including" exact="lopinavir" post="and ritonavir, chloroquine, and hydroxychloroquine that may help to"/>
   <result pre="the treatment of COVID-19 including lopinavir and ritonavir, chloroquine, and" exact="hydroxychloroquine" post="that may help to alleviate symptoms in patients. With"/>
   <result pre="available therapeutic drugs to treat patients with the SARS-CoV-2 infection." exact="Hydroxychloroquine" post="and chloroquine are antiviral drugs that possess similar chemical"/>
   <result pre="drugs to treat patients with the SARS-CoV-2 infection. Hydroxychloroquine and" exact="chloroquine" post="are antiviral drugs that possess similar chemical structures and"/>
   <result pre="action involve targeting lysosome to control graft-versus-host disease in humans." exact="Chloroquine" post="can inhibit the entry of SARS-CoV-2 and prevent virus-host"/>
   <result pre="its binding with SP. This suggests the potential use of" exact="chloroquine" post="in the early stages of infection before the virus"/>
   <result pre="the virus can reduce ACE2 expression and activity [89]. Both" exact="hydroxychloroquine" post="and chloroquine can inhibit certain cellular functions and molecular"/>
   <result pre="can reduce ACE2 expression and activity [89]. Both hydroxychloroquine and" exact="chloroquine" post="can inhibit certain cellular functions and molecular pathways involved"/>
   <result pre="Food and Drug Administration (FDA) has authorized the use of" exact="chloroquine" post="and hydroxychloroquine for emergency treatment of COVID-19 and has"/>
   <result pre="Drug Administration (FDA) has authorized the use of chloroquine and" exact="hydroxychloroquine" post="for emergency treatment of COVID-19 and has the potential"/>
   <result pre="COVID-19 is lopinavir/ritonavir (LPV/r). Lopinavir is a protease inhibitor and" exact="ritonavir" post="is a booster and they are commonly used to"/>
   <result pre="in combination. In vitro studies have demonstrated the ability of" exact="lopinavir" post="in inhibiting SARS-CoV, reducing symptoms such as diarrhea and"/>
   <result pre="the risk of acute respiratory distress syndrome with LPV/r and" exact="ribavirin" post="[88]. The use of LPV/r for treatment of COVID-19"/>
   <result pre="acute kidney injury and secondary infections [90]. A combination of" exact="lopinavir" post="and ritonavir has significantly improved the clinical condition of"/>
   <result pre="injury and secondary infections [90]. A combination of lopinavir and" exact="ritonavir" post="has significantly improved the clinical condition of SARS-CoV patients"/>
   <result pre="effectiveness of oseltamivir against COVD-19 and also in combinations with" exact="chloroquine" post="and favipiravir. However, a study in Wuhan reported no"/>
   <result pre="the entry of the virus. The antimalarial drugs, chloroquine, and" exact="hydroxychloroquine" post="have been shown to inhibit terminal phosphorylation of ACE2"/>
   <result pre="and serve as candidate drugs against the COVID-19 disease [90]." exact="Chloroquine" post="has inhibition activity against SARS-CoV-2Â at relatively high doses"/>
   <result pre="antiviral drugs being explored including hydroxychloroquine, chloroquine, remdesivir, favipiravir, and" exact="lopinavir" post="and ritonavir may be able to limit the spread"/>
   <result pre="being explored including hydroxychloroquine, chloroquine, remdesivir, favipiravir, and lopinavir and" exact="ritonavir" post="may be able to limit the spread of the"/>
   <result pre="From recent clinical trials, the antiviral drugs remdesivir, favipivir, and" exact="lopinavir" post="and ritonavir can be administered for the treatment of"/>
   <result pre="clinical trials, the antiviral drugs remdesivir, favipivir, and lopinavir and" exact="ritonavir" post="can be administered for the treatment of severe COVID-19"/>
   <result pre="the growth and development by interfering with SP and ACE2." exact="Azithromycin" post="targets SP directly, preventing viral uptake, while hydroxychloroquine interferes"/>
   <result pre="and ACE2. Azithromycin targets SP directly, preventing viral uptake, while" exact="hydroxychloroquine" post="interferes with ACE2 terminal glycosylation, thus weakening SP-ACE2 binding"/>
   <result pre="doses of WJ-MSCs (50*10e6 cells) along with standardized treatment of" exact="hydroxychloroquine" post="and Lopinavir/Ritonavir or Azithromycin and ventilator support. Mortality rate,"/>
   <result pre="cells) along with standardized treatment of hydroxychloroquine and Lopinavir/Ritonavir or" exact="Azithromycin" post="and ventilator support. Mortality rate, sequential organ failure assessment"/>
   <result pre="Chahinian, H., &amp;amp; Yahi, N. (2020). Synergistic antiviral effect of" exact="hydroxychloroquine" post="and azithromycin in combination against SARS-CoV-2: what molecular dynamics"/>
   <result pre="&amp;amp; Yahi, N. (2020). Synergistic antiviral effect of hydroxychloroquine and" exact="azithromycin" post="in combination against SARS-CoV-2: what molecular dynamics studies of"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7424135\results\search\drug\results.xml">
   <result pre="newer antiviral drugs/vaccines under investigation. Keywords Angiotensin Angiotensin converting enzyme" exact="Chloroquine" post="Corona virus COVID-19 Cytokine storm RNA-dependent RNA polymerase Spike"/>
   <result pre="water by the kidney, and also attenuate inflammation through the" exact="nitric oxide" post="production (Fig.Â 4) [36]. On the contrary, ACE converts"/>
   <result pre="to exert anti-inflammatory and anti-fibrotic actions, stimulate the release of" exact="nitric oxide" post="and reduce blood pressure. SARS-CoV-2 binds to ACE2 to"/>
   <result pre="of smokers and patients with COPD express higher ACE2 receptor." exact="Nicotine" post="binds and enhances nicotinic acetylcholine receptors (nAChR), specifically the"/>
   <result pre="COPD express higher ACE2 receptor. Nicotine binds and enhances nicotinic" exact="acetylcholine" post="receptors (nAChR), specifically the Î±7subtype (Î±7-nAChR) in lungs and"/>
   <result pre="growing interest in the use of anti-malaria and anti-amebiasis drugs" exact="chloroquine" post="(CQ, N4-(7-Chloro-4-quinolinyl)-N1,N1-diethyl-1,4-pentanediamine) and hydroxychloroquine (HCQ), as potential treatments for"/>
   <result pre="use of anti-malaria and anti-amebiasis drugs chloroquine (CQ, N4-(7-Chloro-4-quinolinyl)-N1,N1-diethyl-1,4-pentanediamine) and" exact="hydroxychloroquine" post="(HCQ), as potential treatments for COVID-19. Chloroquine inhibits quinone"/>
   <result pre="(CQ, N4-(7-Chloro-4-quinolinyl)-N1,N1-diethyl-1,4-pentanediamine) and hydroxychloroquine (HCQ), as potential treatments for COVID-19." exact="Chloroquine" post="inhibits quinone reductase 2, which is involved in the"/>
   <result pre="the â€˜cytokine stormâ€™ through controlling the T lymphocyte activation [85]." exact="Azithromycin" post="together with HCQ was reported considerably more efficient for"/>
   <result pre="considered in different clinical trials [87]. Remdesivir, an analogue of" exact="adenosine" post="with broad-spectrum antiviral agent has shown a high capacity"/>
   <result pre="[89]. Recently, the mixture of three drugs, lopinavir, oseltamivir and" exact="ritonavir" post="has been proposed to mitigate the virulence to a"/>
   <result pre="of homocysteine-dependent trans-sulfuration pathway in COVID-19 infection. Hence, Vitamin B6," exact="folic acid," post="and Vitamin B12 should also be included in the"/>
   <result pre="pathway in COVID-19 infection. Hence, Vitamin B6, folic acid, and" exact="Vitamin B12" post="should also be included in the treatment regimen for"/>
   <result pre="molecular modeling studies reveal a new mechanism of action of" exact="chloroquine" post="and hydroxychloroquine against SARS-CoV-2 infectionInt J Antimicrob Agents202055510596032251731 35.QiuYZhaoYBWangQLiJYZhouZJLiaoCHet"/>
   <result pre="studies reveal a new mechanism of action of chloroquine and" exact="hydroxychloroquine" post="against SARS-CoV-2 infectionInt J Antimicrob Agents202055510596032251731 35.QiuYZhaoYBWangQLiJYZhouZJLiaoCHet al.Predicting the"/>
   <result pre="responses in retort to SARS-CoV-2 in an ageing population, consider" exact="N-acetylcysteine" post="as early therapeutic intervention. Version 2Toxicol Rep2020776877132632359 41.XiongYLiuYCaoLWangDGuoMJiangAet al.Transcriptomic"/>
   <result pre="the road not takenEur J Clin Invest202010e1333910.1111/eci.13339 51.HasanagicSSerdarevicFPotential role of" exact="memantine" post="in the prevention and treatment of COVID-19: its antagonism"/>
   <result pre="the prevention and treatment of COVID-19: its antagonism of nicotinic" exact="acetylcholine" post="receptors (nAChR) and beyondEur Respir J202018200161010.1183/13993003.01610-2020 52.WangBLiRLuZHuangYDoes comorbidity increase"/>
   <result pre="for tetracyclines in the treatment of COVID-19Pharmacotherapy202040548748832267566 74.CalyLDruceJDCattonMGJansDAWagstaffKMThe FDA-approved drug" exact="ivermectin" post="inhibits the replication of SARS-CoV-2 in vitroAntivir Res202017810478732251768 75.WanYShangJSunSTaiWChenJGengQet"/>
   <result pre="studiesJ Biomol Struct Dyn20201111210.1080/07391102.2020.1776157 82.OrtegaJTSerranoMLJastrzebskaBClass A G protein-coupled receptor antagonist" exact="famotidine" post="as a therapeutic alternative against SARS-CoV2: an in silico"/>
   <result pre="in silico analysisBiomolecules2020106954 83.DevauxCARolainJMColsonPRaoultDNew insights on the antiviral effects of" exact="chloroquine" post="against coronavirus: what to expect for COVID-19?Int J Antimicrob"/>
   <result pre="vitroCell Discov202061632194981 85.ZhouDDaiSMTongQCOVID-19: a recommendation to examine the effect of" exact="hydroxychloroquine" post="in preventing infection and progressionJ Antimicrob Chemother20207571667167032196083 86.GautretPLagierJCParolaPHoangVTMeddebLMailheMet al.Hydroxychloroquine"/>
   <result pre="in preventing infection and progressionJ Antimicrob Chemother20207571667167032196083 86.GautretPLagierJCParolaPHoangVTMeddebLMailheMet al.Hydroxychloroquine and" exact="azithromycin" post="as a treatment of COVID-19: results of an open-label"/>
   <result pre="studies of drug repurposing and synergism of lopinavir, oseltamivir and" exact="ritonavir" post="binding with SARS-CoV-2 Protease against COVID-19J Biomol Struct Dyn2020161610.1080/07391102.2020.1752802"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7425093\results\search\drug\results.xml">
   <result pre="effective against SARS-CoV-2. Remdesivir is a phosphoramidate prodrug of an" exact="adenosine" post="C-nucleoside. By entrance into respiratory epithelial cells in human,"/>
   <result pre="RNA-dependent RNA polymerase (RdRp) by competing with the usual counterpart" exact="adenosine" post="triphosphate (ATP). The nucleoside analog is incorporated into the"/>
   <result pre="including ribavirin, favipiravir, penciclovir, galidesivir, remdesivir, 6Ê¹-fluorinated aristeromycin analogs and" exact="acyclovir" post="fleximer analogs are available.4 In clinical trials associated with"/>
   <result pre="Mechanism of Action Remdesivir is a phosphoramidate prodrug of an" exact="adenosine" post="C-nucleoside (Figure 1A).12 By entrance into respiratory epithelial cells"/>
   <result pre="structures of (A) remdesivir as the phosphoramidate prodrug of an" exact="adenosine" post="C-nucleoside and (B) pharmacologically active nucleoside triphosphate (NTP) as"/>
   <result pre="RNA-dependent RNA polymerase (RdRp) by competing with the usual counterpart" exact="adenosine" post="triphosphate (ATP). The nucleoside analog is incorporated into the"/>
   <result pre="and inhibits the enzyme by competing with the usual counterpart" exact="adenosine" post="triphosphate (ATP). The nucleoside analog is incorporated into the"/>
   <result pre="Results of data screening showed that GS-441,524 (a 1Ê¹-CN modified" exact="adenosine" post="C-nucleoside hit) along with GS-5734 (a prodrug form of"/>
   <result pre="remdesivir and interferon-beta have a superior antiviral activity compared to" exact="lopinavir" post="and ritonavir against MERS-CoV in vitro. In mice, both"/>
   <result pre="interferon-beta have a superior antiviral activity compared to lopinavir and" exact="ritonavir" post="against MERS-CoV in vitro. In mice, both prophylactic and"/>
   <result pre="clinical trial focused on evaluating simultaneous administration of remdesivir and" exact="dexamethasone" post="in patients on ventilators with COVID-19. The World Health"/>
   <result pre="initial clinical trial results from the United Kingdom that showed" exact="dexamethasone" post="could reduce mortality by one-third in patients on ventilators"/>
   <result pre="ventilators with COVID-19. For patients requiring only oxygen, administration of" exact="dexamethasone" post="decreased the mortality rate by about one-fifth.42 Evaluating the"/>
   <result pre="by about one-fifth.42 Evaluating the efficacy of remdesivir along with" exact="dexamethasone" post="in patients on ventilators with COVID-19 may be interesting."/>
   <result pre="Discovery and synthesis of a phosphoramidate prodrug of a Pyrrolo[2,1-f][triazin-4-amino]" exact="adenine" post="C-nucleoside (GS-5734) for the treatment of Ebola and emerging"/>
   <result pre="Med. 2017;9(396):eaal3653. doi:10.1126/scitranslmed.aal365328659436 18.WangM, CaoR, ZhangL, et al. Remdesivir and" exact="chloroquine" post="effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7426275\results\search\drug\results.xml">
   <result pre="in PBS at room temperature for 20Â min, or 95%" exact="ethanol" post="and 5% glacial acetic acid at âˆ’20Â Â°C for"/>
   <result pre="corresponding YFV proteins when the cells were fixed with 95%" exact="ethanol" post="and 5% glacial acetic acid (Fig. 2B). All these"/>
   <result pre="min and permeabilized with 1% Triton X-100 (A), or 95%" exact="ethanol" post="and 5% glacial acetic acid at âˆ’20Â Â°C for"/>
   <result pre="The cells were fixed with either 3.5% paraformaldehyde or 95%" exact="ethanol" post="and 5% glacial acetic acid as indicated in Fig."/>
   <result pre="cells were either mock treated (Act D-) or treated with" exact="Actinomycin D" post="(Act D+) for 2Â h followed by EU labelling"/>
   <result pre="in Fig. 7B, consistent with published in vitro antiviral data," exact="Sofosbuvir" post="inhibits YFV at EC50 of 8.82Â Î¼M and EC90"/>
   <result pre="of 32.4Â Î¼M (de Freitas et al., 2019). Combination of" exact="Sofosbuvir" post="and BDAA, resulted in significant synergistic effect of inhibiting"/>
   <result pre="and negative control wells. (B) Synergistic effect between BDAA and" exact="Sofosbuvir" post="identified using high-content imaging-based HTS assay. Huh-7Â cells were"/>
   <result pre="Infect. Dis.2220161859186027479749 de FreitasC.S.HigaL.M.SacramentoC.Q.FerreiraA.C.ReisP.A.DelvecchioR.MonteiroF.L.Barbosa-LimaG.James WestgarthH.VieiraY.R.MattosM.RochaN.HoelzL.V.B.LemeR.P.P.BastosM.M.RodriguesG.O.L.LopesC.E.M.Queiroz-JuniorC.M.LimaC.X.CostaV.V.TeixeiraM.M.BozzaF.A.BozzaP.T.BoechatN.TanuriA.SouzaT.M.L.Yellow fever virus is susceptible to" exact="sofosbuvir" post="both in vitro and in vivoPLoS Neglected Trop. Dis.132019e0007072"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7426442\results\search\drug\results.xml">
   <result pre="virus particle, and inhibits PLpro or 3CLpro in SARS-CoV-2. (138)" exact="Ritonavir" post="CYP3a (target unknown for coronavirus) HIV protease inhibitor. No"/>
   <result pre="polymerase Purine analog blocking viral RNA synthesis. (140) Remdesivir (141)" exact="Ribavirin" post="Guanosine nucleoside binds to nucleoside binding pocket of the"/>
   <result pre="nucleoside binding pocket of the enzyme. (133, 140, 142) Galidesivir" exact="Adenosine" post="analog, effective against Ebola, Zika, and other RNA viruses."/>
   <result pre="infections in both in-vitro and in-vivo models (138, 149â€&quot;151). This" exact="adenosine" post="analog gets incorporated into the newly synthesized viral RNA,"/>
   <result pre="effectiveness against SARS-CoV-2 (141, 155). It has been reported that" exact="chloroquine" post="immuno-modulates the host microenvironment and also interferes with the"/>
   <result pre="contact with potential COVID-19 patients, the individuals were given either" exact="hydroxychloroquine" post="or placebo as a prophylactic measure. The results revealed"/>
   <result pre="or placebo as a prophylactic measure. The results revealed that" exact="hydroxychloroquine" post="treatment had the same effect as did the placebo"/>
   <result pre="same effect as did the placebo group. The usage of" exact="hydroxychloroquine" post="resulted in minor side effects (40.1%) as compared to"/>
   <result pre="complications were observed (158). Based on the putative function of" exact="hydroxychloroquine" post="on the endosomal acidification, whereby it is presumed to"/>
   <result pre="disease. Numerous clinical trials to further explore the usage of" exact="hydroxychloroquine" post="in different combinations are in the pipeline and will"/>
   <result pre="In clinical trials, some of the combinational antiviral drugs like" exact="lopinavir" post="+ ritonavir and blockers like angiotensin receptor blocker that"/>
   <result pre="trials, some of the combinational antiviral drugs like lopinavir +" exact="ritonavir" post="and blockers like angiotensin receptor blocker that were thought"/>
   <result pre="diseases. Virol Sin. (2020) 35:12250. 10.1007/s12250-020-00204-732048130 141.WangMCaoRZhangLYangXLiuJXuMet al.. Remdesivir and" exact="chloroquine" post="effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in"/>
   <result pre="(2019-nCoV) in vitro. Cell Res. (2020) 30:269â€&quot;71. 10.1038/s41422-020-0282-032020029 142.OmraniASSaadMMBaigKBahloulAAbdul-MatinMAlaidaroosAYet al.." exact="Ribavirin" post="and interferon alfa-2a for severe Middle East respiratory syndrome"/>
   <result pre="508:402â€&quot;5. 10.1038/nature1302724590073 144.DevauxCARolainJMColsonPRaoultD. New insights on the antiviral effects of" exact="chloroquine" post="against coronavirus: what to expect for COVID-19?Int J Antimicrob"/>
   <result pre="Antimicrob Agents. (2020) 55:105938. 10.1016/j.ijantimicag.2020.10593832171740 145.SchrezenmeierEDÃ¶rnerT. Mechanisms of action of" exact="hydroxychloroquine" post="and chloroquine: implications for rheumatology. Nat Rev Rheumatol. (2020)"/>
   <result pre="Rheumatol. (2020) 16:155â€&quot;66. 10.1038/s41584-020-0372-x32034323 146.collab: ClinicalTrials.govThe Efficacy of Lopinavir Plus" exact="Ritonavir" post="and Arbidol Against Novel Coronavirus Infection. (2020). Available online"/>
   <result pre="Chem - An Asian J. (2019) 14:3962â€&quot;8. 10.1002/asia.20190084131389664 155.AguiarACCMurceECortopassiWAPimentelASAlmeidaMMFSBarrosDCSet al.." exact="Chloroquine" post="analogs as antimalarial candidates with potent in vitro and"/>
   <result pre="J Parasitol Drugs Drug Resist. (2018) 8:459â€&quot;64. 10.1016/j.ijpddr.2018.10.00230396013 156.VincentMJBergeronEBenjannetSEricksonBRRollinPEKsiazekTGet al.." exact="Chloroquine" post="is a potent inhibitor of SARS coronavirus infection and"/>
   <result pre="and spread. Virol J. (2005) 2:1â€&quot;10. 10.1186/1743-422X-2-6915631631 157.SavarinoABoelaertJRCassoneAMajoriGCaudaR. Effects of" exact="chloroquine" post="on viral infections: an old drug against today's diseases?Lancet"/>
   <result pre="Infect Dis. (2003) 3:722â€&quot;7. 10.1016/S1473-3099(03)00806-514592603 158.BoulwareDRPullenMFBangdiwalaASPastickKALofgrenSMOkaforECet al.A randomized trial of" exact="hydroxychloroquine" post="as postexposure prophylaxis for covid-19. N Engl J Med."/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7426550\results\search\drug\results.xml">
   <result pre="of different drugs were proposed. For example, chloroquine, hydroxychloroquine, and" exact="azithromycin" post="all inhibit the uncoating of the invading endosomes. On"/>
   <result pre="Smallpox Tecovirimatâ€ Measles Vitamin A Plague Doxycyclineâ€¡ Cholera Massive rehydration;" exact="doxycycline" post="(in adults)â€¡; azithromycin (in children)â€¡ Yellow fever None Influenza"/>
   <result pre="Vitamin A Plague Doxycyclineâ€¡ Cholera Massive rehydration; doxycycline (in adults)â€¡;" exact="azithromycin" post="(in children)â€¡ Yellow fever None Influenza H1N1 OseltamivirÂ§ Influenza"/>
   <result pre="type of mutation: AUUU, a segment of the viral genome" exact="Adenine" post="Uracil Uracil Uracil; AUCU, same segment of the genome"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7426727\results\search\drug\results.xml">
   <result pre="the immune system include: -Lifestyle (e.g., sedentary lifestyle, tobacco smoking," exact="alcohol" post="intake, drugs of abuse, Western-pattern diet (high-fat diet, ultraprocessed"/>
   <result pre="sleep deprivation, etc.); -Iatrogenic (e.g., immunosuppressants, non-steroidal anti-inflammatory drugs (NSAIDs)," exact="acetaminophen" post="(paracetamol), surgical stress, anesthesia, psychotropic drugs (antidepressants, antiepileptic and"/>
   <result pre="Disease Prevention and Control)Epidemiology of COVID-19Available online at:https://www.ecdc.europa.eu/en/covid-19/latest-evidence/epidemiologyupdated FarsalinosK.NiauraR.Le HouezecJ.BarbouniA.TsatsakisA.KouretasD.VantarakisA.PoulasK.Editorial:" exact="nicotine" post="and SARS-CoV-2: COVID-19 may be a disease of the"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7428753\results\search\drug\results.xml">
   <result pre="synergistically amplifying the risk of cardiac arrhythmias. Drugs such as" exact="azithromycin" post="and hydroxychloroquine are associated with QT prolongation [32,33]. Azithromycin"/>
   <result pre="the risk of cardiac arrhythmias. Drugs such as azithromycin and" exact="hydroxychloroquine" post="are associated with QT prolongation [32,33]. Azithromycin is known"/>
   <result pre="as azithromycin and hydroxychloroquine are associated with QT prolongation [32,33]." exact="Azithromycin" post="is known to prolong the QT interval [34] and"/>
   <result pre="and increase the risk of cardiovascular death [35]. The anti-malarial" exact="chloroquine" post="is associated with prolonged QT interval with or without"/>
   <result pre="based on the study of case reports201315516610.1177/2049936113501816 33KapoorA.PandurangiU.AroraV.GuptaA.JaswalA.NabarA.Cardiovascular risks of" exact="hydroxychloroquine" post="in treatment and prophylaxis of COVID-19 patients: a scientific"/>
   <result pre="Indian Heart Rhythm SocietyIndian Pacing Electrophysiol J20202011712010.1016/j.ipej.2020.04.00332278018 34MosholderA.D.MathewJ.AlexanderJ.J.SmithH.NambiarS.Cardiovascular risks with" exact="azithromycin" post="and other antibacterial drugsNÂ Engl J Med36820131665166810.1056/NEJMp130272623635046 35RayW.A.MurrayK.T.HallK.ArbogastP.G.SteinC.M.Azithromycin and"/>
   <result pre="deathNÂ Engl J Med36620121881189010.1056/NEJMoa100383322591294 36collab: Pfizer LabsZithromax (azithromycin tablets) and" exact="azithromycin" post="for oral suspension2013 37ReyskensK.M.S.E.FisherT.L.SchislerJ.C.Oâ€™ConnorW.G.RogersA.B.WillisM.S.The maladaptive effects of HIV protease"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7428924\results\search\drug\results.xml">
   <result pre="of myocarditis, as well as due to the application of" exact="chloroquine" post="and hydroxychloroquine, especially if combined with azithromycin. This therapy"/>
   <result pre="2020 in the Lancet, did not prove the benefit of" exact="hydroxychloroquine" post="or chloroquine used as monotherapy or in combination with"/>
   <result pre="the Lancet, did not prove the benefit of hydroxychloroquine or" exact="chloroquine" post="used as monotherapy or in combination with second-generation macrolides,"/>
   <result pre="chloroquine used as monotherapy or in combination with second-generation macrolides," exact="azithromycin" post="or clarithromycin. At the same time, there were ventricular"/>
   <result pre="dehydrogenase (LDH), CRP, interleukin 1, interleukin 6, tumor necrosis factor" exact="alpha" post="(TNF-alpha) and lymphopenia (12). A significant number of people"/>
   <result pre="namely remdesivir, lopinavir/ritonavir, lopinavir/ritonavir in combination with interferon beta-1; and" exact="chloroquine" post="or hydroxychloroquine. 14. REMDESIVIR I COVID-19 Remdesivir is the"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7429403\results\search\drug\results.xml">
   <result pre="SARS-CoV viruses. For this reason, in a study, Arbidol and" exact="Kaletra" post="(lopinavir/ritonavir) were used against COVID-19, and according to the"/>
   <result pre="Oral administration of ritonavir, lopinavir, oseltamivir, and intravenous administration of" exact="ganciclovir" post="for 3â€&quot;14 days were also helpful in 75 patients.73"/>
   <result pre="3â€&quot;14 days were also helpful in 75 patients.73 In addition," exact="chloroquine" post="has been shown to have an immune-suppressive activity and"/>
   <result pre="may be considered as an effective treatment for COVID-19.82 Combining" exact="thalidomide" post="(an immunomodulatory and anti-inflammatory agent) with a low-dose of"/>
   <result pre="candidates for SARS-CoV-2 infection.65 The WHO recommends that steroids and" exact="methylprednisolone" post="can be used for patients with COVID-19 only in"/>
   <result pre="a descriptive study. Lancet. 2020;395(10223):507â€&quot;513. doi:10.1016/S0140-6736(20)30211-732007143 74.GaoJ, TianZ, YangX. Breakthrough:" exact="chloroquine" post="phosphate has shown apparent efficacy in treatment of COVID-19"/>
   <result pre="Trends. 2020;14(1):72â€&quot;73. doi:10.5582/bst.2020.0104732074550 75.WangM, CaoR, ZhangL, et al. Remdesivir and" exact="chloroquine" post="effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in"/>
   <result pre="YanWH. [Effect of combined treatment of Shuanghuanglian and recombinant interferon" exact="alpha" post="2a on coxsackievirus B3 replication in vitro]. Zhongguo Zhong"/>
   <result pre="Opin Ther Pat. 2013;23(10):1337â€&quot;1348. doi:10.1517/13543776.2013.82315923905913 86.ChenC, QiF, ShiK, et al." exact="Thalidomide" post="combined with low-dose glucocorticoid in the treatment of COVID-19"/>
   <result pre="et al. Retrospective comparison of convalescent plasma with continuing high-dose" exact="methylprednisolone" post="treatment in SARS patients. Clin Microbiol Infect. 2004;10(7):676â€&quot;678. doi:10.1111/j.1469-0691.2004.00956.x15214887"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7429453\results\search\drug\results.xml">
   <result pre="Protocol A multi-centre open-label two-arm randomised superiority clinical trial of" exact="azithromycin" post="versus usual care in ambulatory COVID-19: study protocol for"/>
   <result pre="stated in a credit line to the data. Abstract Background" exact="Azithromycin" post="is an orally active synthetic macrolide antibiotic with a"/>
   <result pre="a potential candidate therapy for pandemic coronavirus disease 2019 (COVID-19)." exact="Azithromycin" post="was widely used to treat severe SARS-CoV and MERS-CoV,"/>
   <result pre="coronavirus infections. Other ongoing trials are exploring short courses of" exact="azithromycin" post="either in early disease, within the first 7â€‰days of"/>
   <result pre="II/III, multi-centre, prospective, open-label, two-arm randomised superiority clinical trial of" exact="azithromycin" post="versus standard care for adults presenting to hospital with"/>
   <result pre="randomised in a 1:1 ratio to usual care or to" exact="azithromycin" post="500â€‰mg orally daily for 14â€‰days with telephone follow-up at"/>
   <result pre="biomarkers. Discussion This trial will determine the clinical utility of" exact="azithromycin" post="in patients with moderately severe, clinically diagnosed COVID-19 and"/>
   <result pre="for accrual on 29 May 2020. Keywords COVID-19 Coronavirus SAR-CoV-2" exact="Azithromycin" post="Macrolide Randomised controlled trial Respiratory failure Mortality Trial Funding"/>
   <result pre="Biomedical Research Centre Funding Oxford University Funding http://dx.doi.org/10.13039/100008648Pfizer Foundation Background" exact="Azithromycin" post="(AZM) is an orally active synthetic macrolide antibiotic with"/>
   <result pre="to treat 1/3 of severe cases of MERS-CoV [1], and" exact="azithromycin" post="has been tried in COVID-19 infection [2] although RCT"/>
   <result pre="data for any coronavirus disease are lacking [3]. Antiviral properties" exact="Azithromycin" post="has well-documented, broad antiviral properties in vitro. Numerous studies"/>
   <result pre="vitro, being shown to reduce viral replication in combination with" exact="hydroxychloroquine" post="[10]. Azithromycin was also associated with a reduced viral"/>
   <result pre="shown to reduce viral replication in combination with hydroxychloroquine [10]." exact="Azithromycin" post="was also associated with a reduced viral load of"/>
   <result pre="receiving some other drugs including fluoroquinolones such as moxifloxacin and" exact="levofloxacin" post="and in patients with ongoing proarrhythmic conditions. Due to"/>
   <result pre="Rationale for design This trial is designed to determine whether" exact="azithromycin" post="is effective in preventing progression to severe respiratory failure"/>
   <result pre="aim is to test the hypothesis that the use of" exact="azithromycin" post="500â€‰mg once daily for 14â€‰days is effective in preventing"/>
   <result pre="objective The primary objective is to compare the effect of" exact="azithromycin" post="in participants with a clinical diagnosis of COVID-19 in"/>
   <result pre="objectives The secondary objectives are to compare the effect of" exact="azithromycin" post="in participants with a PCR-confirmed diagnosis of COVID-19 in"/>
   <result pre="open-label two-arm randomised superiority clinical trial of standard care versus" exact="azithromycin" post="with standard care alone for those presenting to hospital"/>
   <result pre="therapeutic benefit, then this is also essential information to disseminate." exact="Azithromycin" post="is an extremely useful drug for a wide variety"/>
   <result pre="inflammatory cytokines to have a potentially clinically meaningful beneficial effect." exact="Azithromycin" post="is safe and well tolerated. Even in long-term administration"/>
   <result pre="macrolides have a class warning for potential cardiac QT prolongation," exact="azithromycin" post="does not show this effect under experimental conditions [52]."/>
   <result pre="interact with CYP3A4, despite a minor interaction with the anti-coagulant" exact="warfarin" post="[54]. In the large AMAZES RCT, there was no"/>
   <result pre="risk of cardiovascular death of 47 extra deaths/million compared with" exact="amoxicillin" post="(relative risk (RR) for cardiovascular death 2.49 [55], and"/>
   <result pre="LINK Additional file 4. LINK Additional file 5. Abbreviations AZM" exact="Azithromycin" post="BTS British Thoracic Society COVID-19 Coronavirus disease 2019 CURB-65"/>
   <result pre="urea &amp;gt;â€‰7.0 mmol/L, respiratory rate â‰¥â€‰30 breaths/min, blood pressure EDTA" exact="Ethylenediaminetetraacetic acid" post="ePR Electronic patient record IMV Invasive mechanical ventilation MERS"/>
   <result pre="Middle East Respiratory SyndromeInt J Infect Dis20198118419030690213 2.GautretPLagierJParolaPHoangVTMeddebLMailheMet al.Hydroxychloroquine and" exact="azithromycin" post="as a treatment of COVID-19: results of an open-label"/>
   <result pre="bronchial epithelial cellsEur Respir J201036364665420150207 5.SchoglerAKopfBSEdwardsMRJohnstonSLCasaultaCKieningerEet al.Novel antiviral properties of" exact="azithromycin" post="in cystic fibrosis airway epithelial cellsEur Respir J201545242843925359346 6.PorterJDWatsonJRobertsLRGillSKGrovesHDhariwalJet"/>
   <result pre="IFN-augmenting activity in airway epitheliumJ Antimicrob Chemother201671102767278127494903 7.GibsonPGYangIAUphamJWReynoldsPNHodgeSJamesALet al.Effect of" exact="azithromycin" post="on asthma exacerbations and quality of life in adults"/>
   <result pre="Med19961543 Pt 16546608810601 10.AndreaniJLe BideauMDuflotIJardotPRollandCBoxbergerMet al.In vitro testing of combined" exact="hydroxychloroquine" post="and azithromycin on SARS-CoV-2 shows synergistic effectMicrob Pathog202014510422832344177 11.Doan"/>
   <result pre="16546608810601 10.AndreaniJLe BideauMDuflotIJardotPRollandCBoxbergerMet al.In vitro testing of combined hydroxychloroquine and" exact="azithromycin" post="on SARS-CoV-2 shows synergistic effectMicrob Pathog202014510422832344177 11.Doan T, Hinterwirth"/>
   <result pre="Zhong L, et al. Reduction of coronavirus burden with mass" exact="azithromycin" post="distribution. Clin Infect Dis. 2020:ciaa606. 10.1093/cid/ciaa606. 12.Touret F, Gilles"/>
   <result pre="Deng YQ, Li D, Parvatiyar K, Quanquin N, et al." exact="Azithromycin" post="protects against Zika virus infection by upregulating virus-induced type"/>
   <result pre="repurposing screen of approved drugsEmerg Microbes Infect2014312e8426038505 18.KawamuraKIchikadoKTakakiMEguchiYAnanKSugaMAdjunctive therapy with" exact="azithromycin" post="for moderate and severe acute respiratory distress syndrome: a"/>
   <result pre="cellsAm J Physiol Lung Cell Mol Physiol20062901L75L8516085674 33.HuiDYanFChenRHThe effects of" exact="azithromycin" post="on patients with diffuse panbronchiolitis: a retrospective study of"/>
   <result pre="Respir Crit Care Med19981576 Pt 1182918329620913 35.NagaiHShishidoHYonedaRYamaguchiETamuraAKurashimaALong-term low-dose administration of" exact="erythromycin" post="to patients with diffuse panbronchiolitisRespiration.1991583â€&quot;41451491745845 36.WengDWuQChenXQDuYKChenTLiHet al.Azithromycin treats diffuse"/>
   <result pre="Cell Mol Biol200941559060219244203 41.BanjanacMMunic KosVNujicKVrancicMBelamaricDCrnkovicSet al.Anti-inflammatory mechanism of action of" exact="azithromycin" post="in LPS-stimulated J774A.1 cellsPharmacol Res201266435736222766077 42.KhanAASliferTRAraujoFGRemingtonJSEffect of clarithromycin and"/>
   <result pre="action of azithromycin in LPS-stimulated J774A.1 cellsPharmacol Res201266435736222766077 42.KhanAASliferTRAraujoFGRemingtonJSEffect of" exact="clarithromycin" post="and azithromycin on production of cytokines by human monocytesInt"/>
   <result pre="azithromycin in LPS-stimulated J774A.1 cellsPharmacol Res201266435736222766077 42.KhanAASliferTRAraujoFGRemingtonJSEffect of clarithromycin and" exact="azithromycin" post="on production of cytokines by human monocytesInt J Antimicrob"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7429937\results\search\drug\results.xml">
   <result pre="Care1364-85351466-609XBioMed CentralLondon pmcid: 74299373222 doi: 10.1186/s13054-020-03222-9 : Research Letter Inhaled" exact="nitric oxide" post="in patients admitted to intensive care unit with COVID-19"/>
   <result pre="however, there are no data regarding the use of inhaled" exact="nitric oxide" post="(iNO). We report herein our experience of iNO administration"/>
   <result pre="potentialCirculation20041093106311110.1161/01.CIR.0000134595.80170.6215226227 4.Gebistorf F, Karam O, Wetterslev J, Afshari A. Inhaled" exact="nitric oxide" post="for acute respiratory distress syndrome (ARDS) in children and"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7429942\results\search\drug\results.xml">
   <result pre="drugs for SARS-CoV2 infection under investigation impair neuromuscular function significantly;" exact="chloroquine" post="and azithromycin are not recommended in myasthenia gravis without"/>
   <result pre="SARS-CoV2 infection under investigation impair neuromuscular function significantly; chloroquine and" exact="azithromycin" post="are not recommended in myasthenia gravis without available ventilatory"/>
   <result pre="atrophy, polymyositis, and immune-mediated neuropathies) that present impaired production of" exact="choline" post="acetyltransferase and acetylcholinesterase, and reduced concentration of acetylcholine at"/>
   <result pre="production of choline acetyltransferase and acetylcholinesterase, and reduced concentration of" exact="acetylcholine" post="at the endplate [59]. As concerns sedation, intravenous anaesthetics"/>
   <result pre="SARS-CoV-2 infection Drug Results so far Potential NMD-relevant side effects" exact="Chloroquine" post="(CQ)/Hydroxychloroquine (HCQ) Open label studies of HCQâ€‰+â€‰azithromycin found an"/>
   <result pre="Myalgias in healthy controls [67] Elevation in liver enzymes [66]" exact="Azithromycin" post="Open label studies of HCQâ€‰+â€‰azithromycin found increased rate of"/>
   <result pre="ECZ [68] Myalgias and arthralgias Elevation in liver enzymes CK" exact="creatine" post="kinase, CQ chloroquine, CRP C-reactive protein, ECZ eculizumab, HCQ"/>
   <result pre="lopinavir/ritonavir, MG myasthenia gravis, SSC standard supportive care, TCZ tociluzumab" exact="Chloroquine" post="(CQ) and its less toxic derivative, hydroxychloroquine (HCQ), have"/>
   <result pre="care, TCZ tociluzumab Chloroquine (CQ) and its less toxic derivative," exact="hydroxychloroquine" post="(HCQ), have been developed as antimalarial drugs; nowadays, they"/>
   <result pre="studies are now underway to better clarify Remdesivir efficacy (www.clinicaltrials.gov)." exact="Azithromycin" post="is a macrolide antibiotic that may be able to"/>
   <result pre="many drugs that are now used against COVID, such as" exact="azithromycin" post="and lopinavir/ritonavir, hold potential for QTc prolongation [85], which"/>
   <result pre="these agents, regular monitoring of serum CK levels. HCQ and" exact="azithromycin" post="also have the potential to cause the onset or"/>
   <result pre="upper and lower extremities [47]. This patient was treated with" exact="prednisone" post="(increased from 20 to 40Â mg twice daily), pyridostigmine,"/>
   <result pre="al. (2020) Clinical and microbiological effect of a combination of" exact="hydroxychloroquine" post="and azithromycin in 80 COVID-19 patients with at least"/>
   <result pre="Clinical and microbiological effect of a combination of hydroxychloroquine and" exact="azithromycin" post="in 80 COVID-19 patients with at least a six-day"/>
   <result pre="P, Hoang VT, Meddeb L, Mailhe M, et al. (2020)" exact="Hydroxychloroquine" post="and azithromycin as a treatment of COVID-19: results of"/>
   <result pre="VT, Meddeb L, Mailhe M, et al. (2020) Hydroxychloroquine and" exact="azithromycin" post="as a treatment of COVID-19: results of an open-label"/>
   <result pre="Agents 105949 62.BorbaMGSValFFASampaioVSAlexandreMAAMeloGCBritoMet al.Effect of high vs low doses of" exact="chloroquine" post="diphosphate as adjunctive therapy for patients hospitalized with severe"/>
   <result pre="of Guangdong Province and Health Commission of Guangdong Province for" exact="chloroquine" post="in the treatment of novel coronavirus pneumoniaExpert Consens Chloroquine"/>
   <result pre="for chloroquine in the treatment of novel coronavirus pneumoniaExpert Consens" exact="Chloroquine" post="Phosphate Treat Novel Coronavirus Pneumonia202043185188 73.WangMCaoRZhangLYangXLiuJXuMet al.Remdesivir and chloroquine"/>
   <result pre="Consens Chloroquine Phosphate Treat Novel Coronavirus Pneumonia202043185188 73.WangMCaoRZhangLYangXLiuJXuMet al.Remdesivir and" exact="chloroquine" post="effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in"/>
   <result pre="the recently emerged novel coronavirus (2019-nCoV) in vitroCell Res20203026927132020029 74.GaoJTianZYangXBreakthrough:" exact="chloroquine" post="phosphate has shown apparent efficacy in treatment of COVID-19"/>
   <result pre="rapid antiviral clearance or clinical benefit with the combination of" exact="hydroxychloroquine" post="and azithromycin in patients with severe COVID-19 infection. Med"/>
   <result pre="clearance or clinical benefit with the combination of hydroxychloroquine and" exact="azithromycin" post="in patients with severe COVID-19 infection. Med Mal Infect"/>
   <result pre="the STAT1 and NF-ÎºB signaling pathwaysJ Immunol20192031021103031263039 79.KawamuraKIchikadoKTakakiMEguchiYAnanKSugaMAdjunctive therapy with" exact="azithromycin" post="for moderate and severe acute respiratory distress syndrome: a"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7430223\results\search\drug\results.xml">
   <result pre="have become modern medicines. Few notable examples include morphine, digoxin," exact="artemisinin" post="and colchicine. As many herbs are found to have"/>
   <result pre="Krimighna 2. Dalchini Cinnamomum zeylanicum Breyn. Stem Bark Cinnamaldehyde, cuminaldehyde," exact="Eugenol" post="Katu, Tikta, Madhura Ushna Kapha-vatashamaka Pitta vardhaka Deepana, Pachana,"/>
   <result pre="and it was able to suppress both the production of" exact="nitric oxide" post="(NO) and up regulation of surface levels of co-stimulatory"/>
   <result pre="adverse effects and should be observed clinically. 5.3 Sunthi An" exact="alcohol" post="extract increases the immunological status of mice with increased"/>
   <result pre="Med Rev142009161171Available from:https://www.ncbi.nlm.nih.gov/pubmed/1959422519594225 38LoA.-H.LiangY.-C.Lin-ShiauS.-Y.HoC.-T.LinJ.-K.Carnosol, an antioxidant in rosemary, suppresses inducible" exact="nitric oxide" post="synthase through down-regulating nuclear factor-kappaB in mouse macrophagesCarcinogenesis23200298399110.1093/carcin/23.6.98312082020 39MondalS.Antimicrobial"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7431281\results\search\drug\results.xml">
   <result pre="pandemic, possible repositioning of various antiviral and antiparasitic drugs including" exact="hydroxychloroquine" post="and chloroquine, remdesivir, protease inhibitorsâ€&quot;lopinavir and ritonavir, etc. previously"/>
   <result pre="Isotretinoin in Treatment of COVID-19 Not yet recruiting COVID-19 Drug:" exact="isotretinoin" post="only product in oral dose form 28 Convalescent Plasma"/>
   <result pre="Study Not yet recruiting Coronavirus Coronavirus infection Drug: plasma Drug:" exact="hydroxychloroquine" post="â€¢ Universidad del Rosario, Bogota, Cundinamarca, Colombia 33 Methodist"/>
   <result pre="in Outpatients Infected with COVID-19 Not yet recruiting COVID-19 Drug:" exact="melatonin" post="Other: placebo (methylcellulose) capsule â€¢ University at Buffalo, Buffalo,"/>
   <result pre="of Wisconsin, Madison, WI, USA 51 Safety and Efficacy Of" exact="Hydroxychloroquine" post="for At Risk Population (SHARP) Against COVID-19 Not yet"/>
   <result pre="Risk Population (SHARP) Against COVID-19 Not yet recruiting Coronavirus infection" exact="Hydroxychloroquine" post="adverse reaction Drug: hydroxychloroquine sulfate 200Â mg (mg) tab"/>
   <result pre="COVID-19 Not yet recruiting Coronavirus infection Hydroxychloroquine adverse reaction Drug:" exact="hydroxychloroquine" post="sulfate 200Â mg (mg) tab 52 Validation of COVID-19"/>
   <result pre="plasma â€¢ Hospital ClÃ­nico Universidad CatÃ³lica, Santiago, Chile 61 Will" exact="Hydroxychloroquine" post="Impede or Prevent COVID-19 Recruiting COVID-19 Coronavirus Coronavirus infections"/>
   <result pre="USA 62 Various Combination of Protease Inhibitors, Oseltamivir, Favipiravir, and" exact="Hydroxychloroquine" post="for Treatment of COVID-19: a Randomized Control Trial Not"/>
   <result pre="diagnostic PCR â€¢ Seda Yilmaz Semerci, Istanbul, Turkey 77 Inhaled" exact="Nitric Oxide" post="for Preventing Progression in COVID-19 Recruiting COVID-19 Drug: nitric"/>
   <result pre="Nitric Oxide for Preventing Progression in COVID-19 Recruiting COVID-19 Drug:" exact="nitric oxide" post="â€¢ Tufts Medical Center, Boston, MA, USA 78 Cohort"/>
   <result pre="mechanical trombectomy â€¢ Uhmontpellier, Montpellier, France 81 Pre-exposure Prophylaxis with" exact="Hydroxychloroquine" post="for High- Risk Healthcare Workers During the COVID-19 Pandemic"/>
   <result pre="Risk Healthcare Workers During the COVID-19 Pandemic Suspended COVID-19 Drug:" exact="hydroxychloroquine" post="Drug: placebos â€¢ ISGlobal, Barcelona, Spain 82 Evaluating Clinical"/>
   <result pre="Franca SAS, MedellÃ­n, Antioquia, Colombia 100 Safety and Efficacy of" exact="Tramadol" post="in COVID-19 Egyptian Patients Not yet recruiting COVID-19 Drug:"/>
   <result pre="Drug: tramadol Other: standard care delivered in the isolation hospitals" exact="Hydroxychloroquine" post="is FDA-approved to prevent and treat malaria, as well"/>
   <result pre="Lung and Blood Institute, evaluating the safety and effectiveness of" exact="hydroxychloroquine" post="for treatment of adults hospitalized with COVID-19. The preliminary"/>
   <result pre="of adults hospitalized with COVID-19. The preliminary studies indicate that" exact="chloroquine" post="and hydroxychloroquine have the potential to improve disease outcomes"/>
   <result pre="hospitalized with COVID-19. The preliminary studies indicate that chloroquine and" exact="hydroxychloroquine" post="have the potential to improve disease outcomes and possibly"/>
   <result pre="vitro and clinical studies demonstrated that the antiviral action of" exact="hydroxychloroquine" post="might be effective in limiting SARS-CoV-2 infection [49, 50]."/>
   <result pre="in limiting SARS-CoV-2 infection [49, 50]. Further, a combination of" exact="hydroxychloroquine" post="and azithromycin has also been used against the pathophysiology"/>
   <result pre="SARS-CoV-2 infection [49, 50]. Further, a combination of hydroxychloroquine and" exact="azithromycin" post="has also been used against the pathophysiology of COVID-19"/>
   <result pre="COVID-19 [51] and is under clinical trial against SARS-CoV-2. The" exact="chloroquine" post="drug appears to interfere with terminal glycosylation of ACE2"/>
   <result pre="coronaviruses showing a strong impact on SARS-CoV infection [52â€&quot;55]. Moreover," exact="chloroquine" post="and hydroxychloroquine are known to modulate the immune response"/>
   <result pre="a strong impact on SARS-CoV infection [52â€&quot;55]. Moreover, chloroquine and" exact="hydroxychloroquine" post="are known to modulate the immune response in some"/>
   <result pre="effects of the SARS-CoV-2 infection. A preliminary clinical trial of" exact="chloroquine" post="repurposing against SARS-CoV-2 infection has shown some positive results,"/>
   <result pre="Institutes of Health (NIH), USA, stopped the clinical trial of" exact="hydroxychloroquine" post="as a potential therapy for COVID-19 because some studies"/>
   <result pre="now emerging. Recent systematic studies demonstrated no significant benefit of" exact="hydroxychloroquine" post="drug in COVID-19 treatment [57, 58]. Besides, the clinical"/>
   <result pre="respiratory distress, and then multiple organ failure. Nutritional interventions including" exact="vitamin C" post="and D and antioxidants are also used to boost"/>
   <result pre="in vivo activityInt J Parasitol Drugs Drug Resist20188345946430396013 35.WangMCaoRZhangLYangXLiuJXuMShiZHuZZhongWXiaoGRemdesivir and" exact="chloroquine" post="effectively inhibit the recently emerged novel coronavirus (2019- nCoV)"/>
   <result pre="emerged novel coronavirus (2019- nCoV) in vitroCell Res202030326927132020029 36.YazdanyJKimAHJUse of" exact="hydroxychloroquine" post="and chloroquine during the COVID-19 pandemic: what every clinician"/>
   <result pre="coronavirus (2019- nCoV) in vitroCell Res202030326927132020029 36.YazdanyJKimAHJUse of hydroxychloroquine and" exact="chloroquine" post="during the COVID-19 pandemic: what every clinician should knowAnn"/>
   <result pre="P, Rolain JM, Lagier JC, Brouqui P, Raoult D (2020)" exact="Chloroquine" post="and hydroxychloroquine as available weapons to fight COVID-19. Int"/>
   <result pre="JM, Lagier JC, Brouqui P, Raoult D (2020) Chloroquine and" exact="hydroxychloroquine" post="as available weapons to fight COVID-19. Int J Antimicrob"/>
   <result pre="weapons to fight COVID-19. Int J Antimicrob Agents:105932. 10.1016/j.ijantimicag.2020.105932 38.GuastalegnameMValloneACould" exact="chloroquine" post="/hydroxychloroquine be harmful in coronavirus disease 2019 (COVID-19) treatment?Clin"/>
   <result pre="coronavirus (2019-nCoV)Nat Rev Drug Discov202019314915032127666 44.RainsfordKParkeALClifford-RashotteMKeanWTherapy and pharmacological properties of" exact="hydroxychloroquine" post="and chloroquine in treatment of systemic lupus erythematosus, rheumatoid"/>
   <result pre="Rev Drug Discov202019314915032127666 44.RainsfordKParkeALClifford-RashotteMKeanWTherapy and pharmacological properties of hydroxychloroquine and" exact="chloroquine" post="in treatment of systemic lupus erythematosus, rheumatoid arthritis and"/>
   <result pre="vitro antiviral activity and projection of optimized dosing design of" exact="hydroxychloroquine" post="for the treatment of severe acute respiratory syndrome coronavirus"/>
   <result pre="La Scola B, Rolain JM, Brouqui P, Raoult D (2020)" exact="Hydroxychloroquine" post="and azithromycin as a treatment of COVID-19: results of"/>
   <result pre="B, Rolain JM, Brouqui P, Raoult D (2020) Hydroxychloroquine and" exact="azithromycin" post="as a treatment of COVID-19: results of an open-label"/>
   <result pre="inhibitor of SARS coronavirus infection and spreadVirol J200526916115318 53.RolainJMColsonPRaoultDRecycling of" exact="chloroquine" post="and its hydroxyl analogue to face bacterial, fungal and"/>
   <result pre="Raoult D (2020) New insights on the antiviral effects of" exact="chloroquine" post="against coronavirus: what to expect for COVID-19? Int J"/>
   <result pre="expect for COVID-19? Int J Antimicrob Agents:105938. 10.1016/j.ijantimicag.2020.105938 55.SavarinoABoelaertJRCassoneAMajoriGCaudaREffects of" exact="chloroquine" post="on viral infections: an old drug against today's diseases?Lancet"/>
   <result pre="AV, Roman YM, Pasupuleti V, Barboza JJ, White CM (2020)" exact="Hydroxychloroquine" post="or chloroquine for treatment or prophylaxis of COVID-19: a"/>
   <result pre="YM, Pasupuleti V, Barboza JJ, White CM (2020) Hydroxychloroquine or" exact="chloroquine" post="for treatment or prophylaxis of COVID-19: a living systematic"/>
   <result pre="systematic review. Ann Intern Med. 10.7326/M20-2496 58.BoulwareDRPullenMFBangdiwalaASPastickKALofgrenSMOkaforECSkipperCPNasceneAANicolMRAbassiMEngenNWChengMPLaBarDLotherSAMacKenzieLJDrobotGMartenNZarychanskiRKellyLESchwartzISMcDonaldEGRajasinghamRLeeTCHullsiekKHA randomized trial of" exact="hydroxychloroquine" post="as postexposure prophylaxis for Covid-19N Engl J Med202038351752532492293 59.National"/>
   <result pre="blockade for cytokine stormImmunotherapy20168895997027381687 81.immunomodulatory therapy in COVID-19: role of" exact="chloroquine" post="and anti-IL-6 monoclonal antibodies. Int J Antimicrob Agents:105982 10.1016/j.ijantimicag.2020.105982"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7432271\results\search\drug\results.xml">
   <result pre="date, therapies with proven benefit in certain groups include remdesivir," exact="dexamethasone" post="and convalescent plasma [3,4,5]. This review describes the structure"/>
   <result pre="in the Nidovirales order. The subgroups of the family are" exact="alpha" post="(Î±), beta (Î²), gamma (Î³) and delta (Î´) coronaviruses"/>
   <result pre="a promising candidate for treatment of COVID19. RDV is an" exact="adenosine" post="nucleotide analogue with broad-spectrum antiviral activity against RNA viruses"/>
   <result pre="[107,108] by inhibiting viral proteases including 3CLpro or PLpro [108]." exact="Ritonavir" post="is used in combination with Lopinavir to increase LPV"/>
   <result pre="performance and safety of favipiravir in combination with oseltamivir and" exact="chloroquine" post="among 80 participants with COVID-19 in Rajavithi Hospital in"/>
   <result pre="however caution is required as it is teratogenic [119]. 8.1.4." exact="Ribavirin" post="Ribavirin (1-Î²-D-ribofuranosyl-1,2,4-triazole-3-carboxamide) is a synthetic guanosine analogue with broad-spectrum"/>
   <result pre="caution is required as it is teratogenic [119]. 8.1.4. Ribavirin" exact="Ribavirin" post="(1-Î²-D-ribofuranosyl-1,2,4-triazole-3-carboxamide) is a synthetic guanosine analogue with broad-spectrum activity"/>
   <result pre="B and in combination with interferon-Î± for hepatitis C [126]." exact="Ribavirin" post="has multiple mechanisms of action-including interference with RNA capping,"/>
   <result pre="response [127]. The in vitro anti SARS-CoV activity reported for" exact="ribavirin" post="differs widely depending on the cell lines used for"/>
   <result pre="lines used for the antiviral assays. It is possible that" exact="ribavirin" post="may be more effective when co-administrated with IFN as"/>
   <result pre="single treatment alone [128]. Similarly, the combination of IFN-Î±2b and" exact="ribavirin" post="in vitro decreased the inhibitory concentration against MERS-CoV to"/>
   <result pre="of SARS-CoV-2, in vitro studies revealed that high concentrations of" exact="ribavirin" post="(EC50 of 109.5 ÂµM) are required to reduce the"/>
   <result pre="109.5 ÂµM) are required to reduce the viral infection and" exact="ribavirin" post="is 100 times less potent than remdesivir [101]. Administration"/>
   <result pre="less potent than remdesivir [101]. Administration of high doses of" exact="ribavirin" post="in SARS trials was associated with serious adverse reactions"/>
   <result pre="data evaluating the efficacy of this compound, the administration of" exact="ribavirin" post="for the treatment of COVID-19 is not recommended. An"/>
   <result pre="in China (ChiCTR2000029387) is evaluating the efficacy and safety of" exact="ribavirin" post="and LPV/r in combination with interferon alpha-1b for SARS-CoV-2"/>
   <result pre="demonstrated that serine proteases cause the spread of SARS-CoV and" exact="camostat" post="effectively prevents this step, suggesting it may be an"/>
   <result pre="treating SARS and potentially MERS [141]. Another study demonstrated that" exact="camostat" post="partially blocked SARS-CoV and human coronavirus NL63 (HCoV-NL63) infection"/>
   <result pre="the ACE2 receptor and TMPRSS2 [142]. Additionally, the effect of" exact="camostat" post="mesylate in blocking SARS-CoV-2 infection of human lung Calu-3"/>
   <result pre="double-blind randomized controlled clinical trial is evaluating the efficacy of" exact="camostat" post="mesylate for treatment of COVID-19 (NCT04353284), but more studies"/>
   <result pre="the virus can be attained in a patientâ€™s lung. 8.1.7." exact="Nafamostat" post="Mesylate Nafamostat mesylate (6-amidino-2-naphthyl p guanidinobenzoate dimethanesulfonate) is a"/>
   <result pre="can be attained in a patientâ€™s lung. 8.1.7. Nafamostat Mesylate" exact="Nafamostat" post="mesylate (6-amidino-2-naphthyl p guanidinobenzoate dimethanesulfonate) is a synthetic serine"/>
   <result pre="for the treatment of inflammatory-related diseases such as pancreatitis [144,145]." exact="Nafamostat" post="is a potent inhibitor of S-mediated membrane fusion of"/>
   <result pre="MERS-CoV infection in vitro [22]. The anti MERS-CoV activity of" exact="nafamostat" post="is through inhibition of the host protease TMPRSS2, which"/>
   <result pre="study in lung cell culture tested the inhibitory effect of" exact="gabexate" post="mesylate, nafamostat mesylate and camostat mesylate on SARS-CoV-2 infection"/>
   <result pre="lung cell culture tested the inhibitory effect of gabexate mesylate," exact="nafamostat" post="mesylate and camostat mesylate on SARS-CoV-2 infection and demonstrated"/>
   <result pre="tested the inhibitory effect of gabexate mesylate, nafamostat mesylate and" exact="camostat" post="mesylate on SARS-CoV-2 infection and demonstrated that nafamostat mesylate"/>
   <result pre="mesylate and camostat mesylate on SARS-CoV-2 infection and demonstrated that" exact="nafamostat" post="mesylate inhibited S-mediated entry of SARS-CoV-2 into host cells"/>
   <result pre="of SARS-CoV-2 into host cells 15 times more effectively that" exact="camostat" post="mesylate, with an EC50 in the low nanomolar range"/>
   <result pre="EC50 in the low nanomolar range [146]. In another study," exact="nafamostat" post="was tested in vitro against a clinical SARS-CoV-2 isolate"/>
   <result pre="target. Despite these promising in vitro data, the efficacy of" exact="nafamostat" post="as a COVID-19 treatment needs to be tested in"/>
   <result pre="to be tested in clinical trials. 8.2. Anti-Parasites 8.2.1. Chloroquine/Hydroxychloroquine" exact="Chloroquine" post="(N4-(7-Chloro-4-quinolinyl)-N1,N1-diethyl-1,4-pentanediamine) has long been used to prevent and treat"/>
   <result pre="and herpes simplex virus [147]. Sometimes the antiviral activities of" exact="chloroquine" post="described in vitro have been confirmed in virus-infected patients,"/>
   <result pre="the results have not always been reproduced in clinical trials." exact="Chloroquine" post="possesses different mechanisms of action depending on the pathogen"/>
   <result pre="the pathogen studied. In vitro studies on SARS-CoV showed that" exact="chloroquine" post="can interfere with glycosylation of ACE2, in Vero cells"/>
   <result pre="Since SARS-CoV-2 uses a similar receptor, it is expected that" exact="chloroquine" post="may prevent SARS-CoV-2 attachment to target cells by the"/>
   <result pre="SARS-CoV-2 attachment to target cells by the same mechanism. Moreover," exact="chloroquine" post="can induce autophagosome formation resulting in spike protein degradation"/>
   <result pre="changing the pH of lysosomes and inhibition of cathepsins. Furthermore," exact="chloroquine" post="interferes with viral assembly, budding and proteolytic processing of"/>
   <result pre="(MAPK) [149]. Previous studies have reported the potential use of" exact="chloroquine" post="for treatment of SARS-CoV [150]. The potent efficacy of"/>
   <result pre="treatment of SARS-CoV [150]. The potent efficacy of remdesivir and" exact="chloroquine" post="were evaluated in Vero E6; chloroquine was effective in"/>
   <result pre="efficacy of remdesivir and chloroquine were evaluated in Vero E6;" exact="chloroquine" post="was effective in controlling SARS-CoV-2 infection in vitro with"/>
   <result pre="the lung [101]. There is safety concern in administration of" exact="chloroquine" post="due to the risk of macular retinopathy and cardiomyopathy"/>
   <result pre="in vitro efficiency of chloroquine, the clinical outcomes are uncertain." exact="Hydroxychloroquine" post="sulfate, a derivative form of chloroquine, was first synthesized"/>
   <result pre="two to three times less toxicity in animals compared to" exact="chloroquine" post="[154]. Hydroxychloroquine likely has the same mechanism of action"/>
   <result pre="three times less toxicity in animals compared to chloroquine [154]." exact="Hydroxychloroquine" post="likely has the same mechanism of action on viruses"/>
   <result pre="the same mechanism of action on viruses as that of" exact="chloroquine" post="and acts as a weak base compound, changing the"/>
   <result pre="[155]. There is limited published evidence supporting the activity of" exact="hydroxychloroquine" post="against coronaviruses. An in vitro study in Vero cells"/>
   <result pre="An in vitro study in Vero cells showed that the" exact="chloroquine" post="was approximately 5-fold more potent (EC50 of 6.5 Â±"/>
   <result pre="potent (EC50 of 6.5 Â± 3.2 Î¼M) than that of" exact="hydroxychloroquine" post="(EC50 of 34 Â± 5 Î¼M) against SARS-CoV [156]."/>
   <result pre="Â± 5 Î¼M) against SARS-CoV [156]. Conversely, the potency of" exact="hydroxychloroquine" post="in Vero cells infected with SARS-CoV-2 (EC50 of 0.72"/>
   <result pre="SARS-CoV-2 (EC50 of 0.72 Î¼M) was greater than that of" exact="chloroquine" post="(EC50 of 5.47 Î¼M) [157]. In a non-randomized open-label"/>
   <result pre="[157]. In a non-randomized open-label trial in France, administration of" exact="hydroxychloroquine" post="significantly reduced the viral load in COVID-19 patients, alone"/>
   <result pre="as well as enrolment of asymptomatic individuals. Widespread administration of" exact="hydroxychloroquine" post="is likely to cause rare adverse effects in patients,"/>
   <result pre="with azithromycin) [159]. It has been shown the combination of" exact="hydroxychloroquine" post="and azithromycin in COVID-19 patients is associated with increased"/>
   <result pre="[159]. It has been shown the combination of hydroxychloroquine and" exact="azithromycin" post="in COVID-19 patients is associated with increased risk of"/>
   <result pre="the FDA does not recommend combination therapy of remdesivir with" exact="chloroquine" post="phosphate or hydroxychloroquine sulfate as it might result in"/>
   <result pre="not recommend combination therapy of remdesivir with chloroquine phosphate or" exact="hydroxychloroquine" post="sulfate as it might result in a reduced antiviral"/>
   <result pre="of remdesivir [162]. Moreover, the FDA announced the use of" exact="hydroxychloroquine" post="and chloroquine for treatment of hospitalized COVID-19 patients can"/>
   <result pre="[162]. Moreover, the FDA announced the use of hydroxychloroquine and" exact="chloroquine" post="for treatment of hospitalized COVID-19 patients can cause serious"/>
   <result pre="withdrew the emergency use authorization it issued in March for" exact="chloroquine" post="and hydroxychloroquine as COVID-19 treatments. The FDA made this"/>
   <result pre="emergency use authorization it issued in March for chloroquine and" exact="hydroxychloroquine" post="as COVID-19 treatments. The FDA made this determination based"/>
   <result pre="the Chinese clinical trial registry (http://www.chictr.org.cn) testing the efficacy of" exact="chloroquine" post="and hydroxychloroquine. In addition, hydroxychloroquine is now under evaluation"/>
   <result pre="(http://www.chictr.org.cn) testing the efficacy of chloroquine and hydroxychloroquine. In addition," exact="hydroxychloroquine" post="is now under evaluation in the U.S. (NCT04308668) as"/>
   <result pre="guidelines panel for COVID-19 treatment recommended against the use of" exact="chloroquine" post="or hydroxychloroquine for the treatment of COVID-19, except in"/>
   <result pre="for COVID-19 treatment recommended against the use of chloroquine or" exact="hydroxychloroquine" post="for the treatment of COVID-19, except in a clinical"/>
   <result pre="trial. The panel also recommends against the use of high-dose" exact="chloroquine" post="(600 mg twice daily for 10 days) for the"/>
   <result pre="on Vero-hSLAM cell lines infected with SARS-CoV-2 has shown that" exact="ivermectin" post="can reduce viral RNA up to 5000-fold, equal to"/>
   <result pre="h [166]. Momekov et al. using available pharmacokinetic data from" exact="ivermectin" post="showed that its inhibitory concentrations against the SARS-CoV-2 is"/>
   <result pre="unlikely attainable in humans [169]. Overall, the possible efficacy of" exact="ivermectin" post="against SARS-CoV-2 infection needs data to support it. 9."/>
   <result pre="virus titer in animal models [215]. 10. Adjunctive/Supportive Therapy 10.1." exact="Azithromycin" post="Azithromycin (9-deoxo-9a-aza-9a-methyl-9a-homoerythromycin) is a widely used macrolide antibiotic which"/>
   <result pre="titer in animal models [215]. 10. Adjunctive/Supportive Therapy 10.1. Azithromycin" exact="Azithromycin" post="(9-deoxo-9a-aza-9a-methyl-9a-homoerythromycin) is a widely used macrolide antibiotic which can"/>
   <result pre="bacteria by targeting 23S ribosomal RNA. Beside its antibacterial activity," exact="azithromycin" post="has immunomodulatory and anti-viral effects. Previous studies have suggested"/>
   <result pre="anti-viral effects. Previous studies have suggested an antiviral function for" exact="azithromycin" post="in Ebola virus infection, both in vitro and in"/>
   <result pre="Ebola virus infection, both in vitro and in mice [216]." exact="Azithromycin" post="(but not other macrolides like erythromycin or telithromycin) can"/>
   <result pre="and in mice [216]. Azithromycin (but not other macrolides like" exact="erythromycin" post="or telithromycin) can inhibit rhinovirus replication and release in"/>
   <result pre="expression of interferon and pro-inflammatory cytokines (IL-6 and IL-8) [217]." exact="Azithromycin" post="also shows dose dependent antiviral activity against Zika virus"/>
   <result pre="responses [218]. Interestingly, Tran et al. reported antiviral activity of" exact="azithromycin" post="against Influenza (H1N1) virus; treatment prior to infection inhibited"/>
   <result pre="cells, without changing viral attachment [219]. Moreover, intranasal administration of" exact="azithromycin" post="to infected mice reduced the viral load in affected"/>
   <result pre="COVID-19 patients (n = 36), Gautret et al. reported that" exact="azithromycin" post="co-administered with hydroxychloroquine reduced the viral load more efficiently"/>
   <result pre="= 36), Gautret et al. reported that azithromycin co-administered with" exact="hydroxychloroquine" post="reduced the viral load more efficiently than hydroxychloroquine alone"/>
   <result pre="co-administered with hydroxychloroquine reduced the viral load more efficiently than" exact="hydroxychloroquine" post="alone [158]. Patients were administered hydroxychloroquine (600 mg/day), with"/>
   <result pre="load more efficiently than hydroxychloroquine alone [158]. Patients were administered" exact="hydroxychloroquine" post="(600 mg/day), with or without azithromycin (500 mg day"/>
   <result pre="[158]. Patients were administered hydroxychloroquine (600 mg/day), with or without" exact="azithromycin" post="(500 mg day one, followed by 250 mg/day for"/>
   <result pre="combination group (6/6) were virologically cured (negative swab), compared to" exact="hydroxychloroquine" post="alone (57.1%) or untreated controls (12.5%) [158]. However, this"/>
   <result pre="was not randomized, patients were not well matched and adding" exact="azithromycin" post="to hydroxychloroquine may increase the risk of cardiac arrhythmias."/>
   <result pre="randomized, patients were not well matched and adding azithromycin to" exact="hydroxychloroquine" post="may increase the risk of cardiac arrhythmias. There are"/>
   <result pre="are now several larger clinical trials investigating the efficacy of" exact="azithromycin" post="in COVID-19 patients (e.g., NCT04332107, NCT04336332, NCT04329832), but until"/>
   <result pre="(e.g., NCT04332107, NCT04336332, NCT04329832), but until these results are available," exact="Azithromycin" post="cannot be recommended for routine use in COVID-19. 10.2."/>
   <result pre="observational study of SARS-CoV-2 infected patients treated with 40 mg" exact="methylprednisolone" post="once or twice daily, there was no significant association"/>
   <result pre="of hospitalization [226]. Similarly, Fang et al. reported that low-dose" exact="methylprednisolone" post="by injection (median hydrocortisone-equivalent dose, 250 mg/day) or orally"/>
   <result pre="randomized evaluation of COVID-19 therapy (RECOVERY) trial (NCT04381936) found that" exact="dexamethasone" post="(6 milligrams/day for 10 days) can save lives in"/>
   <result pre="benefit, the NIH COVID-19 treatment guidelines panel recommended administration of" exact="dexamethasone" post="(6 mg/day for up to 10 days) for mechanically"/>
   <result pre="hypoglycemia should be considered by the treating clinicians [2]. 10.3." exact="Nitric Oxide" post="Nitric Oxide (NO) is a free radical with vasodilator"/>
   <result pre="be considered by the treating clinicians [2]. 10.3. Nitric Oxide" exact="Nitric Oxide" post="(NO) is a free radical with vasodilator properties. In"/>
   <result pre="[231]. In vitro studies have reported antiviral activity of the" exact="nitric oxide" post="donor compound S-nitroso-N-acetylpenicillamine for inhibition of SARS-Co-V replication in"/>
   <result pre="for inhibition of SARS-Co-V replication in Vero E6 cells [232,233]." exact="Nitric oxide" post="inhalation has also been shown to have long term"/>
   <result pre="after treatment) in ARDS with regard to pulmonary function [234]." exact="Nitric oxide" post="can inhibit both RNA and protein synthesis of SARS-CoV"/>
   <result pre="RNA and protein synthesis of SARS-CoV in vitro [232]. Moreover," exact="nitric oxide" post="or its derivatives can inhibit palmitoylation of the viral"/>
   <result pre="binding to its receptor ACE2 and inhibiting SARS-Co-V replication [235]." exact="Nitric oxide" post="inhalation has been successfully used to treat SARS patients,"/>
   <result pre="are several clinical trials currently investigating the therapeutic potential of" exact="nitric oxide" post="therapy in patients with COVID-19 (NCT04358588, NCT04305457), as more"/>
   <result pre="critically ill COVID-19 patients and the NIH panel recommends using" exact="dexamethasone" post="at proven doses in COVID-19 patients who are mechanically"/>
   <result pre="are not mechanically ventilated [2]. Early data on administration of" exact="hydroxychloroquine" post="often in combination with azithromycin were promising, however studies"/>
   <result pre="Early data on administration of hydroxychloroquine often in combination with" exact="azithromycin" post="were promising, however studies were very low quality, with"/>
   <result pre="from the Solidarity Trialâ€™s International Steering Committee to discontinue the" exact="hydroxychloroquine" post="arm in the trial. The fusion inhibitor umifenovir and"/>
   <result pre="in the trial. The fusion inhibitor umifenovir and protease inhibitor" exact="lopinavir" post="/ritonavir were also regarded initially as likely effective candidates"/>
   <result pre="media. The widespread empiric use of unproven agents such as" exact="hydroxychloroquine" post="can lead to supply shortages for people who rely"/>
   <result pre="programmed death-1 CDC left for disease control and prevention NO" exact="nitric oxide" post="cGMP cyclic guanosine monophosphate GM-CSF granulocyte-monocyte stimulating factor References"/>
   <result pre="coronavirus S1 region and its monoclonal antibodyGenes Genom.20143638739710.1007/s13258-014-0186-9 22.YamamotoM.MatsuyamaS.LiX.TakedaM.KawaguchiY.InoueJ.-I.MatsudaZ.Identification of" exact="Nafamostat" post="as a Potent Inhibitor of Middle East Respiratory Syndrome"/>
   <result pre="inhibits both epidemic and zoonotic coronavirusesSci. Transl. Med.20179eaal365310.1126/scitranslmed.aal365328659436 101.WangM.CaoR.ZhangL.YangX.LiuJ.XuM.ShiZ.HÃºZ.ZhongW.XiaoG.Remdesivir and" exact="chloroquine" post="effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in"/>
   <result pre="1-f8-D-ribofuranosyl-1, 2, 4-triazole-3-carboxamideScience197217770570610.1126/science.177.4050.7054340949 126.ThomasE.GhanyM.G.LiangT.J.The application and mechanism of action of" exact="ribavirin" post="in therapy of hepatitis CAntivir. Chem. Chemother.20122311210.3851/IMP212522592135 127.GraciJ.D.CameronC.E.Mechanisms of"/>
   <result pre="therapy of hepatitis CAntivir. Chem. Chemother.20122311210.3851/IMP212522592135 127.GraciJ.D.CameronC.E.Mechanisms of action of" exact="ribavirin" post="against distinct virusesRev. Med. Virol.200516374810.1002/rmv.483 128.MorgensternB.MichaelisM.BaerP.C.DoerrH.W.CinatlJ.CinatlJ.Ribavirin and interferon-Î² synergistically"/>
   <result pre="ribavirinSci. Rep.20133srep0168610.1038/srep0168623594967 130.KnowlesS.R.PhillipsE.J.DresserL.MatukasL.Common Adverse Events Associated with the Use of" exact="Ribavirin" post="for Severe Acute Respiratory Syndrome in CanadaClin. Infect. Dis.2003371139114210.1086/37830414523782"/>
   <result pre="142.KawaseM.ShiratoK.Van Der HoekL.TaguchiF.MatsuyamaS.Simultaneous Treatment of Human Bronchial Epithelial Cells with" exact="Serine" post="and Cysteine Protease Inhibitors Prevents Severe Acute Respiratory Syndrome"/>
   <result pre="by a Clinically Proven Protease InhibitorCell202018127128010.1016/j.cell.2020.02.05232142651 144.IwakiM.InoY.MotoyoshiA.OzekiM.SatoT.KurumiM.AoyamaT.Pharmacological studies of FUT-175," exact="nafamostat" post="mesilate. V. Effects on the pancreatic enzymes and experimental"/>
   <result pre="145.ChenX.XuZ.ZengS.WangX.LiuW.QianL.WeiJ.YangX.ShenQ.GongZ.et al.The Molecular Aspect of Antitumor Effects of Protease Inhibitor" exact="Nafamostat" post="Mesylate and Its Role in Potential Clinical ApplicationsFront. Oncol.2019985210.3389/fonc.2019.0085231552177"/>
   <result pre="COVID-19Antimicrob. Agents Chemother.20206410.1128/AAC.00754-20 147.DevauxC.A.RolainJ.-M.ColsonP.RaoultD.New insights on the antiviral effects of" exact="chloroquine" post="against coronavirus: What to expect for COVID-19?Int. J. Antimicrob."/>
   <result pre="inhibitor of SARS coronavirus infection and spreadVirol. J.200526910.1186/1743-422X-2-6916115318 149.SinghA.K.SinghA.ShaikhA.SinghR.MisraA.Chloroquine and" exact="hydroxychloroquine" post="in the treatment of COVID-19 with or without diabetes:"/>
   <result pre="other developing countriesDiabetes Metab. Syndr. Clin. Res. Rev.20201424124610.1016/j.dsx.2020.03.01132247211 150.SavarinoA.BoelaertJ.R.CassoneA.MajoriG.CaudaR.Effects of" exact="chloroquine" post="on viral infections: An old drug against todayâ€™s diseasesLancet"/>
   <result pre="An old drug against todayâ€™s diseasesLancet Infect. Dis.2003372272710.1016/S1473-3099(03)00806-514592603 151.ColsonP.RolainJ.-M.LagierJ.-C.BrouquiP.RaoultD.Chloroquine and" exact="hydroxychloroquine" post="as available weapons to fight COVID-19Int. J. Antimicrob. Agents20205510593210.1016/j.ijantimicag.2020.10593232145363"/>
   <result pre="J. Antimicrob. Agents20205510593210.1016/j.ijantimicag.2020.10593232145363 152.BernsteinH.N.Ocular safety of hydroxychloroquineAnn. Ophthalmol.1991232922961952638 153.RatliffN.B.EstesM.L.MylesJ.L.ShireyE.K.McMahonJ.T.Diagnosis of" exact="Chloroquine" post="Cardiomyopathy by Endomyocardial BiopsyN. Engl. J. Med.198731619119310.1056/NEJM1987012231604053796692 154.McChesneyE.W.Animal toxicity"/>
   <result pre="Endomyocardial BiopsyN. Engl. J. Med.198731619119310.1056/NEJM1987012231604053796692 154.McChesneyE.W.Animal toxicity and pharmacokinetics of" exact="hydroxychloroquine" post="sulfateAm. J. Med.198375111810.1016/0002-9343(83)91265-26408923 155.Al-BariM.A.A.Targeting endosomal acidification by chloroquine analogs"/>
   <result pre="pharmacokinetics of hydroxychloroquine sulfateAm. J. Med.198375111810.1016/0002-9343(83)91265-26408923 155.Al-BariM.A.A.Targeting endosomal acidification by" exact="chloroquine" post="analogs as a promising strategy for the treatment of"/>
   <result pre="Vitro Antiviral Activity and Projection of Optimized Dosing Design of" exact="Hydroxychloroquine" post="for the Treatment of Severe Acute Respiratory Syndrome Coronavirus"/>
   <result pre="Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)Clin. Infect. Dis.202010.1093/cid/ciaa237 158.GautretP.LagierJ.-C.ParolaP.HoangV.T.MeddebL.MailheM.DoudierB.CourjonJ.GiordanengoV.VieiraV.E.et al.Hydroxychloroquine and" exact="azithromycin" post="as a treatment of COVID-19: Results of an open-label"/>
   <result pre="an open-label non-randomized clinical trialInt. J. Antimicrob. Agents2020202010594910.1016/j.ijantimicag.2020.105949 159.FernerR.E.AronsonJ.K.Chloroquine and" exact="hydroxychloroquine" post="in covid-19BMJ2020369m143210.1136/bmj.m143232269046 160.LiewD.RobertsD.HillC.Hydroxychloroquine for COVID-19: A Cautionary Tale. InSight+Available"/>
   <result pre="15 June 2020) 163.collab: Administration FaDFDA Cautions Against Use of" exact="Hydroxychloroquine" post="or Chloroquine for COVID-19 Outside of the Hospital Setting"/>
   <result pre="2020) 163.collab: Administration FaDFDA Cautions Against Use of Hydroxychloroquine or" exact="Chloroquine" post="for COVID-19 Outside of the Hospital Setting or a"/>
   <result pre="on 1 July 2020) 164.No Clinical Benefit from Use of" exact="Hydroxychloroquine" post="in Hospitalised Patients with COVID-19562020Available online: https://www.ox.ac.uk/news/2020-06-05-no-clinical-benefit-use-hydroxychloroquine-hospitalised-patients-covid-19(accessed on 5"/>
   <result pre="Guidelines1662020Available online: https://www.covid19treatmentguidelines.nih.gov/(accessed on 30 July 2020) 166.CalyL.DruceJ.D.CattonM.G.JansD.A.WagstaffK.M.The FDA-approved drug" exact="ivermectin" post="inhibits the replication of SARS-CoV-2 in vitroAntivir. Res.202017810478710.1016/j.antiviral.2020.10478732251768 167.WagstaffK.M.RawlinsonS.M.HearpsA.C.JansD.A.An"/>
   <result pre="Inhibitors of Nuclear ImportJ. Biomol. Screen.20111619220010.1177/108705711039036021297106 168.YangS.N.AtkinsonS.C.WangC.LeeA.BogoyevitchM.A.BorgN.A.JansD.A.The broad spectrum antiviral" exact="ivermectin" post="targets the host nuclear transport importin Î±/Î²1 heterodimerAntivir. Res.202017710476010.1016/j.antiviral.2020.10476032135219"/>
   <result pre="233.KeyaertsE.VijgenL.ChenL.MaesP.HedenstiernaG.Van RanstM.Inhibition of SARS-coronavirus infection in vitro by S-nitroso-N-acetylpenicillamine, a" exact="nitric oxide" post="donor compoundInt. J. Infect. Dis.2004822322610.1016/j.ijid.2004.04.01215234326 234.DellingerR.P.TrzeciakS.CrinerG.ZimmermanJ.L.TaylorR.W.UsanskyH.YoungJ.GoldsteinB.Association between inhaled nitric"/>
   <result pre="nitric oxide donor compoundInt. J. Infect. Dis.2004822322610.1016/j.ijid.2004.04.01215234326 234.DellingerR.P.TrzeciakS.CrinerG.ZimmermanJ.L.TaylorR.W.UsanskyH.YoungJ.GoldsteinB.Association between inhaled" exact="nitric oxide" post="treatment and long-term pulmonary function in survivors of acute"/>
   <result pre="survivors of acute respiratory distress syndromeCrit. Care201216R3610.1186/cc1121522386043 235.Ã…kerstrÃ¶mS.GunalanV.KengC.T.TanY.-J.MirazimiA.Dual effect of" exact="nitric oxide" post="on SARS-CoV replication: Viral RNA production and palmitoylation of"/>
   <result pre="and palmitoylation of the S protein are affectedVirology20093951910.1016/j.virol.2009.09.00719800091 236.ChenL.LiuP.GaoH.SunB.ChaoD.WangF.ZhuY.HedenstiernaG.WangC.G.Inhalation of" exact="Nitric Oxide" post="in the Treatment of Severe Acute Respiratory Syndrome: A"/>
   <result pre="NCT04321616 [237] Lopinavir/Ritonavir Viral protease Anti-viral Oral administration 400 mg" exact="lopinavir" post="and 100 mg ritonavir twice a day for 14"/>
   <result pre="protease Anti-viral Oral administration 400 mg lopinavir and 100 mg" exact="ritonavir" post="twice a day for 14 days, peroral ACTRN12620000445976, NCT02735707,"/>
   <result pre="a day on day 2âˆ’14. 2020-001435-27, NCT04359615, NCT04303299, NCT04402203 [120]" exact="Ribavirin" post="viral RNA Anti-viral 500 mg each time, 2 to"/>
   <result pre="TMPRSS2 Anti-viral 600 mg (200 mg, three times) NCT04353284 [240]" exact="Nafamostat" post="TMPRSS2 Anti-viral 240 mg daily, for 5 days, peroral"/>
   <result pre="Anti-viral 240 mg daily, for 5 days, peroral NCT04418128 [138]" exact="Chloroquine" post="Phosphate ACE2 Anti-parasite 500 mg (300 mg for chloroquine)"/>
   <result pre="chloroquine) each time, 2 times/day NCT04303507, NCT04324463, NCT04353336, NCT04328493 [238]" exact="Hydroxychloroquine" post="Endosome, pH elevation Anti-parasite 200 mg, three times per"/>
   <result pre="for 3 days NCT04343092, NCT04392427 [242] Tocilizumab IL-6 receptor subunit" exact="alpha" post="Monoclonal antibody 400 mg intravenous or 8 mg/kg Ã—"/>
   <result pre="250 mg/day for the next four days (in combination with" exact="hydroxychloroquine" post="NCT04359316, NCT04332107, NCT04336332, NCT04329832 [158] Corticosteroides Binds glucocorticoid receptor"/>
   <result pre="Corticosteroides Binds glucocorticoid receptor and suppress inflammation Anti-Inflammation 40 mg" exact="methylprednisolone" post="once or twice daily NCT04273321 [226] Dexamethasone Binds glucocorticoid"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7434367\results\search\drug\results.xml">
   <result pre="povidone-iodine. Inhibition of other coronaviruses was described for lactoferrin, ethanol," exact="hydroxychloroquine" post="and quaternary ammonium compound. No treatment has been tested"/>
   <result pre="randomized controlled clinical trials thus far. However, interferon-alpha, lactoferrin and" exact="hydroxychloroquine" post="were tested in one-arm open label uncontrolled clinical trial."/>
   <result pre="papers dealt with drugs against methicillin resistant Staphylococcus aureus (generally," exact="mupirocin" post="in nose associated with either chlorhexidine or hexachlorophene body"/>
   <result pre="resistant Staphylococcus aureus (generally, mupirocin in nose associated with either" exact="chlorhexidine" post="or hexachlorophene body wash). The pharmacological agents relevant for"/>
   <result pre="aureus (generally, mupirocin in nose associated with either chlorhexidine or" exact="hexachlorophene" post="body wash). The pharmacological agents relevant for the present"/>
   <result pre="hypothiocyanite (OSCNâˆ’), lactoferrin (LF), N-chlorotaurine (NCT), interferon-alpha (IFN-Î±), polyvinylpyrrolidone-iodine (PVPâ€&quot;I)," exact="hydroxychloroquine" post="(HCQ), quaternary ammonium compounds and alcohol-based nasal antiseptics. 3.1"/>
   <result pre="open-label prospective study tested nasal drops of recombinant human interferon" exact="alpha" post="(rhIFN-Î±) on 2944 health care workers in China during"/>
   <result pre="disinfectant during and after labour (Casteels et al., 2000). 3.6" exact="Hydroxychloroquine" post="Hydroxychloroquine (HCQ), a less toxic derivative of chloroquine (CQ),"/>
   <result pre="during and after labour (Casteels et al., 2000). 3.6 Hydroxychloroquine" exact="Hydroxychloroquine" post="(HCQ), a less toxic derivative of chloroquine (CQ), at"/>
   <result pre="2000). 3.6 Hydroxychloroquine Hydroxychloroquine (HCQ), a less toxic derivative of" exact="chloroquine" post="(CQ), at micromolar concentration proved anti-viral activity against SARS-CoV-2"/>
   <result pre="enveloped viruses relatively easy to inactivate by exposure to alcohols." exact="Ethanol" post="62â€&quot;71% is among the reagents already proven effective to"/>
   <result pre="minute (Kampf et al., 2020). Sanitizers with at least 60%" exact="ethanol" post="are recommended by the USA Centre for Disease Control"/>
   <result pre="the general public too (CDC, 2020). In a recent study" exact="ethanol" post="at concentration &amp;gt;30% efficiently inactivated SARS-CoV-2 in suspension in"/>
   <result pre="log10Â reduction) (Leslie et al, 2020). Saline nasal irrigations and" exact="ethanol" post="oral rinses have been suggested as potential topical measures"/>
   <result pre="in both latter studies. The safety-tested formulation was composed of" exact="ethanol" post="active combined with a mixture of natural oil emollients"/>
   <result pre="placebo treatment control. Whilst 3 nasal applications of the latter" exact="alcohol" post="based antiseptic over 8 hours significantly reduced the nasal"/>
   <result pre="et al., 2019). Shintake recently proposed a controlled inhalation of" exact="ethanol" post="vapor obtained from readily available alcoholic beverages (whisky or"/>
   <result pre="vitro inhibition of other coronaviruses was reported for LF, HCQ," exact="ethanol" post="and AQCs. No treatment was tested against SARS-CoV-2 in"/>
   <result pre="He Lin Chuang Bing Du Xue Za Zhi193200520721016261198 GautretP.LagierJ.-C.ParolaP.Hydroxychloroquine and" exact="azithromycin" post="as a treatment of COVID-19: results of an open-"/>
   <result pre="Infect. Dis.2692020 Sep22762278 MengZ.WangT.LiC.ChenX.LiL.QinX.LiH.LuoJ.An experimental trial of recombinantX human interferon" exact="alpha" post="nasal drops to prevent coronavirus disease 2019 in medical"/>
   <result pre="coli and some gram-negative pathogensInfect. Immun.1319768008075374 RosenbergE.S.DufortE.M.UdoT.Association of treatment with" exact="hydroxychloroquine" post="or azithromycin with in-hospital mortality in patients with COVID-19"/>
   <result pre="some gram-negative pathogensInfect. Immun.1319768008075374 RosenbergE.S.DufortE.M.UdoT.Association of treatment with hydroxychloroquine or" exact="azithromycin" post="with in-hospital mortality in patients with COVID-19 in New"/>
   <result pre="Disinfection of SARS-CoV-2 (COVID-19) in Human Respiratory Tract by Controlled" exact="Ethanol" post="Vapor Inhalation. ArXiv - Cornell UniversityAvailable from:https://arxiv.org/abs/2003.12444 SteedL.L.CostelloJ.LohiaS.JonesT.SpannhakeE.W.NguyenS.Reduction of"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7435473\results\search\drug\results.xml">
   <result pre="1970s when 75% of all masks being used were disposable." exact="Today" post="the use of a muslin or gauze mask is"/>
   <result pre="methods of decontamination using a rice cooker treatment, autoclave, bleach," exact="ethanol" post="and isopropanol. In this study, pressure drop (âˆ†p) and"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7435512\results\search\drug\results.xml">
   <result pre="envelope protein ExoN exonuclease FDA Food and Drug Administration HCQ" exact="hydroxychloroquine" post="HIV human immunodeficiency virus IFN interferon IL interleukin M"/>
   <result pre="hydrochloride Endocytosis/inhibition membrane fusion (38, 39, 40) NCT04252885 (41, 42)" exact="Ribavirin" post="RNA polymerase/inhibition (43, 44) No data Remdesivir RNA polymerase/inhibition"/>
   <result pre="Trial (42, 51) Î²â€�dâ€�N4â€�hydroxycytidine RNA polymerase/inhibition (52, 53) No data" exact="Sofosbuvir" post="RNA polymerase/inhibition (54) No data Î±â€�ketoamide inhibitor Proteases/inhibition (55)"/>
   <result pre="polymerase/inhibition (54) No data Î±â€�ketoamide inhibitor Proteases/inhibition (55) No data" exact="Ritonavir" post="Proteases/inhibition (56) NCT04252885 (41, 49, 57, 58, 59) Lopinavir"/>
   <result pre="Lopinavir Proteases/inhibition (56, 60) NCT04252885 (41, 49, 57, 58, 59)" exact="Nelfinavir" post="Proteases/inhibition (61) No data Dolutegravir Proteases/inhibition (39) No data"/>
   <result pre="the first clinical trials reported that lopinavir, combined with the" exact="ritonavir" post="that boosts lopinavir levels by interfering with cytochrome P450"/>
   <result pre="trials reported that lopinavir, combined with the ritonavir that boosts" exact="lopinavir" post="levels by interfering with cytochrome P450 metabolism, does not"/>
   <result pre="Indeed, in vitro studies show that SARSâ€�CoV polymerase can incorporate" exact="ribavirin" post="triphosphate during replication, but this purine NA is detected"/>
   <result pre="mechanism.68 This might partly explain the poor antiviral effect of" exact="ribavirin" post="in SARSâ€� and MERSâ€�CoV infection.43, 70 On the other"/>
   <result pre="hepatitis C virus infection management. A recent study showed that" exact="sofosbuvir" post="triphosphate is incorporated by recombinant SARSâ€�CoVâ€�2 RdRp during RNA"/>
   <result pre="analysis of their results reveals that some compounds, such as" exact="chloroquine" post="derivatives, have been identified in different experimental conditions. Moreover,"/>
   <result pre="Compounds Target/MoA Tests in vitro (CoV) Clinical trials SARSâ€�CoVâ€�2 Antivirals" exact="Nafamostat" post="mesylate TMPRSS2/inhibitor (92) No data Camostat mesylate TMPRSS2/inhibitor (39,"/>
   <result pre="(92) No data Camostat mesylate TMPRSS2/inhibitor (39, 92) No data" exact="Chloroquine" post="Hydroxychloroquine pH increases in endosomal compartment (39, 48, 93,"/>
   <result pre="No data Camostat mesylate TMPRSS2/inhibitor (39, 92) No data Chloroquine" exact="Hydroxychloroquine" post="pH increases in endosomal compartment (39, 48, 93, 94,"/>
   <result pre="93, 94, 95, 96) â€œSolidarity,â€� â€œDiscoveryâ€� NCT04358068 (49, 97, 98)" exact="Azithromycin" post="(antibiotic) pH increases in endosomal compartment/immunomodulator (39) NCT04358068 (98)"/>
   <result pre="Azithromycin (antibiotic) pH increases in endosomal compartment/immunomodulator (39) NCT04358068 (98)" exact="Omeprazole" post="PPI (39) No data Vonoprazan PPI (39) No data"/>
   <result pre="approved for clinical use, blocks S protein processing inâ€‰vitro.92 Moreover," exact="camostat" post="mesylate and its derivative nafamostat mesylate can inhibit (in"/>
   <result pre="S protein processing inâ€‰vitro.92 Moreover, camostat mesylate and its derivative" exact="nafamostat" post="mesylate can inhibit (in the nM to Î¼M range)"/>
   <result pre="protein priming blocks ACE2â€�mediated entry. However, the inhibition observed with" exact="camostat" post="mesylate and nafamostat mesylate in VeroE6 cells infected by"/>
   <result pre="ACE2â€�mediated entry. However, the inhibition observed with camostat mesylate and" exact="nafamostat" post="mesylate in VeroE6 cells infected by SARSâ€�CoVâ€�2 is lower"/>
   <result pre="lower and probably not enough for a therapeutic utilization of" exact="camostat" post="mesylate. The picture is further complicated because other cellular"/>
   <result pre="Two recent studies showed that proton pump inhibitors, such as" exact="omeprazole" post="and vonoprazan, reduce the infection of cells by SARSâ€�CoVâ€�2.39,"/>
   <result pre="reduce the infection of cells by SARSâ€�CoVâ€�2.39, 64 In addition," exact="chloroquine" post="and hydroxychloroquine (HCQ), which have been extensively used for"/>
   <result pre="infection of cells by SARSâ€�CoVâ€�2.39, 64 In addition, chloroquine and" exact="hydroxychloroquine" post="(HCQ), which have been extensively used for the treatment"/>
   <result pre="levels and does not protect macaques against SARSâ€�CoV infection.108 Moreover," exact="chloroquine" post="derivatives have immunosuppressive effects and inhibit the activation of"/>
   <result pre="have also suggested the therapeutic effect of the HCQâ€�azithromycin combination.98" exact="Azithromycin" post="is an antibiotic that has also antiviral activity in"/>
   <result pre="antiviral activity in respiratory viral infections.111 Interestingly, the MoA of" exact="azithromycin" post="and HCQ may be related to the modulation of"/>
   <result pre="of the endosomal and transâ€�Golgi network pH.112, 113 In addition," exact="azithromycin" post="plays a role in regulating interleukin production that might"/>
   <result pre="control the immune response and prevent symptom worsening.114, 115, 116" exact="Azithromycin" post="may also inhibit viral invasion by interfering with the"/>
   <result pre="have removed their support for the use of HCQ and" exact="chloroquine" post="for COVIDâ€�19, consequently the status of ongoing trials must"/>
   <result pre="must be questioned. More recently, it has been reported that" exact="ivermectin" post="inhibits SARSâ€�CoVâ€�2 with an ~5000â€�fold reduction in viral RNA"/>
   <result pre="S A. 2020;117(12):6771â€�6776.32054787 48WangM, CaoR, ZhangL, et al. Remdesivir and" exact="chloroquine" post="effectively inhibit the recently emerged novel coronavirus (2019â€�nCoV) in"/>
   <result pre="Chemother. 2014;58(8):4875â€�4884.24841269 61YamamotoN, YangR, YoshinakaY, et al. HIV protease inhibitor" exact="nelfinavir" post="inhibits replication of SARSâ€�associated coronavirus. Biochem Biophys Res Commun."/>
   <result pre="2020. 65CrottyS, MaagD, ArnoldJJ, et al. The broadâ€�spectrum antiviral ribonucleoside" exact="ribavirin" post="is an RNA virus mutagen. Nat Med. 2000;6(12):1375â€�1379.11100123 66PruijssersAJ,"/>
   <result pre="Virol. 2019;35:57â€�62.31125806 67FeldJJ, HoofnagleJH. Mechanism of action of interferon and" exact="ribavirin" post="in treatment of hepatitis C. Nature. 2005;436(7053):967â€�972.16107837 68FerronF, SubissiL,"/>
   <result pre="et al. Structural and molecular basis of mismatch correction and" exact="ribavirin" post="excision from coronavirus RNA. Proc Natl Acad Sci U"/>
   <result pre="Antimicrob Agents Chemother. 2002;46(4):977â€�981.11897578 74KimJâ€�A, SeongRâ€�K, KumarM, ShinOS. Favipiravir and" exact="ribavirin" post="inhibit replication of Asian and African strains of Zika"/>
   <result pre="strategies. J Biol Regul Homeost Agents. 2020;34(2). 91LedfordH. Coronavirus breakthrough:" exact="dexamethasone" post="is first drug shown to save lives. Nature. 2020;582:46932546811"/>
   <result pre="save lives. Nature. 2020;582:46932546811 92HoffmannM, SchroederS, Kleineâ€�WeberH, MÃ¼llerMA, DrostenC, PÃ¶hlmannS." exact="Nafamostat" post="Mesylate Blocks Activation of SARSâ€�CoVâ€�2: New Treatment Option. The"/>
   <result pre="http://aac.asm.org/. Accessed April 27, 2020. 93VincentMJ, BergeronE, BenjannetS, et al." exact="Chloroquine" post="is a potent inhibitor of SARS coronavirus infection and"/>
   <result pre="vitro antiviral activity and projection of optimized dosing design of" exact="hydroxychloroquine" post="for the treatment of severe acute respiratory syndrome coronavirus"/>
   <result pre="infection in vitro. Cell Discov. 2020;6(1):16.32194981 97GaoJ, TianZ, YangX. Breakthrough:" exact="chloroquine" post="phosphate has shown apparent efficacy in treatment of COVIDâ€�19"/>
   <result pre="clinical studies. Biosci Trends. 2020;14(1):72â€�73.32074550 98GautretP, LagierJâ€�C, ParolaP, et al." exact="Hydroxychloroquine" post="and azithromycin as a treatment of COVIDâ€�19: results of"/>
   <result pre="Biosci Trends. 2020;14(1):72â€�73.32074550 98GautretP, LagierJâ€�C, ParolaP, et al. Hydroxychloroquine and" exact="azithromycin" post="as a treatment of COVIDâ€�19: results of an openâ€�label"/>
   <result pre="and mortality. JAMA. 2020;126:1671â€&quot;1681. 104HoffmannM, SchroederS, Kleineâ€�WeberH, MÃ¼llerMA, DrostenC, PÃ¶hlmannS." exact="Nafamostat" post="mesylate blocks activation of SARSâ€�CoVâ€�2: new treatment option for"/>
   <result pre="Cell. 2020;181:271â€&quot;280. 32142651 106SavarinoA, BoelaertJR, CassoneA, MajoriG, CaudaR. Effects of" exact="chloroquine" post="on viral infections: an old drug against today's diseases."/>
   <result pre="J Antimicrob Agents. 2020;106028http://dx.doi/10.1016/j.ijantimicag.2020.10602832450198 109SchrezenmeierE, DÃ¶rnerT. Mechanisms of action of" exact="hydroxychloroquine" post="and chloroquine: implications for rheumatology. Nat Rev Rheumatol. 2020;16(3):155â€�166.32034323"/>
   <result pre="Antimicrobial Chemotherapy. https://www.isac.world/news-and-publications/official-isac-statement. Accessed April 30, 2020. 111GielenV, JohnstonSL, EdwardsMR." exact="Azithromycin" post="induces antiâ€�viral responses in bronchial epithelial cells. Eur Respir"/>
   <result pre="in bronchial epithelial cells. Eur Respir J. 2010;36(3):646â€�654.20150207 112DereticV, TimminsGS." exact="Azithromycin" post="and ciprofloxacin have a chloroquineâ€�like effect on respiratory epithelial"/>
   <result pre="epithelial cells. Eur Respir J. 2010;36(3):646â€�654.20150207 112DereticV, TimminsGS. Azithromycin and" exact="ciprofloxacin" post="have a chloroquineâ€�like effect on respiratory epithelial cells. bioRxiv."/>
   <result pre="113PaniA, LauriolaM, RomandiniA, ScaglioneF. Macrolides and viral infections: focus on" exact="azithromycin" post="in COVIDâ€�19 pathology. Int J Antimicrob Agents. 2020;106053.32534189 114AghaiZH,"/>
   <result pre="Int J Antimicrob Agents. 2020;106053.32534189 114AghaiZH, KodeA, SaslowJG, et al." exact="Azithromycin" post="suppresses activation of nuclear factorâ€�kappa B and synthesis of"/>
   <result pre="cells from premature infants. Pediatr Res. 2007;62(4):483â€�488.17667842 115TaylorSP, SellersE, TaylorBT." exact="Azithromycin" post="for the prevention of COPD exacerbations: the good, bad,"/>
   <result pre="and ugly. Am J Med. 2015;128(12):1362. 116BouwmanJJ, VisserenFL, BouterPK, DieperslootRJ." exact="Azithromycin" post="inhibits interleukinâ€�6 but not fibrinogen production in hepatocytes infected"/>
   <result pre="CD147 as a target for COVIDâ€�19 treatment: suggested effects of" exact="azithromycin" post="and stem cell engagement. Stem Cell Rev Reports. 2020;16:434â€&quot;440."/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7435532\results\search\drug\results.xml">
   <result pre="suitable for treating COVIDâ€�19. Those three medicines are, namely, favilavir," exact="chloroquine" post="phosphate, and remdesivir. Hydroxychloroquine combined with azithromycin enhances the"/>
   <result pre="Those three medicines are, namely, favilavir, chloroquine phosphate, and remdesivir." exact="Hydroxychloroquine" post="combined with azithromycin enhances the reduction of the viral"/>
   <result pre="are, namely, favilavir, chloroquine phosphate, and remdesivir. Hydroxychloroquine combined with" exact="azithromycin" post="enhances the reduction of the viral load in COVIDâ€�19"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7436557\results\search\drug\results.xml">
   <result pre="on the society. Several independent studies have convincingly shown that" exact="cyclosporine" post="inhibit replication of several different coronaviruses in vitro. The"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7436575\results\search\drug\results.xml">
   <result pre="patient had no history of other preexisting pathological conditions except" exact="amoxicillin" post="allergy. The results of physical examination on March 20"/>
   <result pre="and V1â€&quot;V2 leads When admitted, the patient was treated with" exact="dexamethasone" post="(12â€‰mg iv), hydroxychloroquine (200â€‰mg twice daily), antiviral drugs (lopinavir/ritonavirâ€&quot;2"/>
   <result pre="When admitted, the patient was treated with dexamethasone (12â€‰mg iv)," exact="hydroxychloroquine" post="(200â€‰mg twice daily), antiviral drugs (lopinavir/ritonavirâ€&quot;2 tablets 200/50â€‰mg twice"/>
   <result pre="daily), oxygen support (Venturi mask FiO2 40%), antibiotic prophylaxis with" exact="ceftriaxone" post="(2â€‰g iv), and venous thromboembolic (VTE) prophylaxis with enoxaparin"/>
   <result pre="enoxaparin (4,000â€‰U.I. sc). After 48â€‰hr, nâ€�acetylcysteine (600â€‰mg twice daily) and" exact="furosemide" post="(20â€‰mg iv twice daily) were administered. During the first"/>
   <result pre="percutaneous coronary intervention (PCI). The patient was treated with a" exact="ticagrelor" post="oral loading dose of 180â€‰mg, ASA 150â€‰mg, and heparin"/>
   <result pre="where a more extensive thrombus was present and even after" exact="adenosine" post="and nitroprusside intracoronary injection (Figure 3eâ€&quot;h). At the end"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7438223\results\search\drug\results.xml">
   <result pre="is mandatory. For adolescents with type 2 diabetes treated with" exact="metformin" post="or other antidiabetic drugs, oral agents may need to"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7438224\results\search\drug\results.xml">
   <result pre="FerreiraM.E.Zika virus and pregnant women: a psychological approachPsychol. Health327201779880910.1080/08870446.2017.130736928343414 GaoJ.TianZ.YangX.Breakthrough:" exact="chloroquine" post="phosphate has shown apparent efficacy in treatment of COVID-19"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7438404\results\search\drug\results.xml">
   <result pre="nM HCoV-NL63 Replication 0.08â€&quot;0.3 Î¼M SARS-CoV-2 Replication 0.024 Î¼M MERS-CoV" exact="Ribavirin" post="Replication 20 Î¼g mLâ€&quot;1 SARS-CoV Synthetic molecule, highly tolerated,"/>
   <result pre="al., 2005; Barnard et al., 2006 Acyclic sugar scaffold of" exact="acyclovir" post="Replication 23 Î¼M MERS-CoV Synthetic molecule, highly tolerated, easily"/>
   <result pre="Acyclovir, easily produced, but there are no in vivo assays" exact="Niclosamide" post="Replication 0.1 Î¼M SARS-CoV Drug already in use to"/>
   <result pre="people, and the drug has some adverse effects. Lopinavir and" exact="Ritonavir" post="Inhibited SARS-CoV and MERS-CoV Replication (protease inhibitor) NE Clinical"/>
   <result pre="storms, improving antiviral response, and providing the best clinical outcomes." exact="Chloroquine" post="Inhibited HIV, CHIKV, SARS-CoV, and SARS-CoV-2 Entry Improved outcomes"/>
   <result pre="are being conducted Impairs virus replication and has anti-inflammatory activities" exact="Chloroquine" post="possesses important side effects and is indicated only in"/>
   <result pre="trials are being conducted Less toxic option, impairs virus replication" exact="Hydroxychloroquine" post="improved patientsâ€™ outcomes, including when associated with azithromycin. Less"/>
   <result pre="outcomes, including when associated with azithromycin. Less toxic option than" exact="chloroquine" post="treatment, but there are studies with contrasting results regarding"/>
   <result pre="nM and CC50 of 80 Î¼M (Pyrc et al., 2006)." exact="Ribavirin" post="is a synthetic nucleoside analog of guanosine used for"/>
   <result pre="hepatitis C virus (HCV) (PubChem, 2005c). The antiviral activities of" exact="ribavirin" post="against several RNA viruses have been described, and it"/>
   <result pre="mice (Barnard et al., 2006). The in vitro decrease of" exact="ribavirin" post="efficacy was demonstrated to be associated with the excision"/>
   <result pre="by conserved coronavirus proofreading mechanisms (Ferron et al., 2017). Moreover," exact="ribavirin" post="showed good results for the treatment of critical MERS-CoV"/>
   <result pre="patients (Al-Tawfiq et al., 2014), and the combined treatment of" exact="ribavirin" post="with type I Interferons (IFN-I) in primate models improved"/>
   <result pre="models improved MERS disease symptoms (Falzarano et al., 2013b). Although" exact="ribavirin" post="has been given as part of treatment regimens for"/>
   <result pre="a nucleoside analog based on the acyclic sugar scaffold of" exact="acyclovir" post="showed antiviral potential against coronaviruses (Tan et al., 2004)."/>
   <result pre="of Niclosamide, a drug used in antihelminthic treatment (Katz, 1977)." exact="Niclosamide" post="presented antiviral activity on post-entry steps of SARS-CoV infection"/>
   <result pre="E6 cells (Wen et al., 2007). Both authors suggested that" exact="Niclosamide" post="impairs post-entry steps. However, this effect seems to not"/>
   <result pre="to an interaction with 3CLpro. An additional potential compound is" exact="mycophenolic acid" post="(MPA), an antibiotic derived from penicillium fungal species (PubChem,"/>
   <result pre="hand, are a class of adamantane-based compounds conjugated with a" exact="pyridoxal" post="moiety (vitamin B6) (Kesel, 2003). These molecules showed effective"/>
   <result pre="al., 2011, 2013; Pfefferle et al., 2011). Alisporivir, a non-immunosuppressive" exact="cyclosporin A" post="analog, inhibited the replication of SARS-CoV in Vero E6"/>
   <result pre="assays (de Wilde et al., 2014; Kim et al., 2015)." exact="Ritonavir" post="also demonstrated anti-MERS-CoV activities with an EC50 of 24.9"/>
   <result pre="In clinical assays for MERS-CoV, the association of Lopinavir with" exact="Ritonavir" post="reduced adverse clinical outcomes and viral load in infected"/>
   <result pre="Yao et al., 2020a). In particular, for SARS-CoV, Lopinavir and" exact="Ritonavir" post="presented a low to medium antiviral activity in vitro,"/>
   <result pre="performed yet (Yao et al., 2020a). In addition, Lopinavir and" exact="Ritonavir" post="played an important role in the clinical outcome of"/>
   <result pre="The authors proposed that the low efficacy of Lopinavir with" exact="Ritonavir" post="might be associated with the time of administration, since"/>
   <result pre="al., 2020b). Later, it was shown that the association of" exact="lopinavir" post="and ritonavir with interferon-Î²1 and ribavirin to treat mild"/>
   <result pre="Later, it was shown that the association of lopinavir and" exact="ritonavir" post="with interferon-Î²1 and ribavirin to treat mild to moderate"/>
   <result pre="that the association of lopinavir and ritonavir with interferon-Î²1 and" exact="ribavirin" post="to treat mild to moderate COVID-19 patients alleviated symptoms"/>
   <result pre="(Kobayashi et al., 1993). There are two subtypes of IFN-I," exact="alpha" post="(IFN-Î±) and beta (IFN-Î²) (Samuel, 2001). IFN-Î² is associated"/>
   <result pre="in clinical trials, improving outcomes in COVID-19 patients as in" exact="lopinavir" post="or ribavirin (Hung et al., 2020). COVID-19 patients with"/>
   <result pre="trials, improving outcomes in COVID-19 patients as in lopinavir or" exact="ribavirin" post="(Hung et al., 2020). COVID-19 patients with mild to"/>
   <result pre="improve symptoms in COVID-19 patients (Zha et al., 2020). Moreover," exact="dexamethasone" post="emerged as a potential drug for treating COVID-19 patients,"/>
   <result pre="controlled, open-lab, and multicenter trial that assessed the effects of" exact="dexamethasone" post="in 454 patients, described to date in pre-print findings"/>
   <result pre="in pre-print findings (Horby et al., 2020). Data suggested that" exact="dexamethasone" post="reduced death in one-third of patients in invasive mechanical"/>
   <result pre="considering the preliminary results, the WHO suggested that treatment with" exact="dexamethasone" post="may be applied during the third phase of COVID-19,"/>
   <result pre="and associated with significant clinical improvement (Toniati et al., 2020)." exact="Chloroquine" post="is a 9-aminoquinole that increases the pH in acidic"/>
   <result pre="HIV and other viruses (Jacobson et al., 2016; Al-Bari, 2017)." exact="Chloroquine" post="was described as an entry inhibitor of SARS-CoV infection"/>
   <result pre="an in vivo study in cats demonstrated that treatment with" exact="chloroquine" post="improved the clinical score of treated groups when compared"/>
   <result pre="when compared to the untreated group (Takano et al., 2013)." exact="Chloroquine" post="also had its anti-CoV activities tested in Vero cells"/>
   <result pre="al., 2020b; Yao et al., 2020b). Despite the performance of" exact="chloroquine" post="in vitro, clinical studies conducted in China and France"/>
   <result pre="2020; Molina et al., 2020). Gao and collaborators indicated that" exact="chloroquine" post="phosphate was recommended to treat COVID-19-associated pneumonia only during"/>
   <result pre="of its antiviral and anti-inflammatory activities (Gao et al., 2020)." exact="Hydroxychloroquine" post="is an analog of chloroquine that was described as"/>
   <result pre="activities (Gao et al., 2020). Hydroxychloroquine is an analog of" exact="chloroquine" post="that was described as having antiviral activity, inhibiting SARS-CoV-2"/>
   <result pre="an open-label non-randomized study by Gautret and colleagues affirmed that" exact="hydroxychloroquine" post="reduced symptoms from SARS-CoV-2 patients and that association with"/>
   <result pre="hydroxychloroquine reduced symptoms from SARS-CoV-2 patients and that association with" exact="azithromycin" post="could reinforce its effects (Gautret et al., 2020). However,"/>
   <result pre="(Juurlink, 2020). Recent studies have been contradicting the safety of" exact="chloroquine" post="and hydroxychloroquine use, as these drugs presented severe side"/>
   <result pre="Recent studies have been contradicting the safety of chloroquine and" exact="hydroxychloroquine" post="use, as these drugs presented severe side effects that"/>
   <result pre="an effect that may be enhanced by concomitant use of" exact="azithromycin" post="(Chorin et al., 2020). Both chloroquine and hydroxychloroquine interfere"/>
   <result pre="by concomitant use of azithromycin (Chorin et al., 2020). Both" exact="chloroquine" post="and hydroxychloroquine interfere with ventricular repolarization, leading to prolongation"/>
   <result pre="use of azithromycin (Chorin et al., 2020). Both chloroquine and" exact="hydroxychloroquine" post="interfere with ventricular repolarization, leading to prolongation of the"/>
   <result pre="polymorphisms of hepatic cytochrome P450 enzyme 2D6 (CYP2D6), responsible for" exact="chloroquine" post="metabolization) (Kirchheiner et al., 2008; Lee et al., 2016)."/>
   <result pre="for the treatment (Smith, 2020). Recently, the WHO stopped the" exact="hydroxychloroquine" post="arm of the Solidarity trial to treat COVID-19 based"/>
   <result pre="2020c). Besides, the FDA also cautioned against the administration of" exact="hydroxychloroquine" post="or chloroquine in COVID-19 patients, mainly due to the"/>
   <result pre="the FDA also cautioned against the administration of hydroxychloroquine or" exact="chloroquine" post="in COVID-19 patients, mainly due to the risk of"/>
   <result pre="survival of animals. In addition, Saracatinib, Tizoxanide, Nitazoxanide, Niclosamide, and" exact="Ribavirin" post="are molecules licensed to treat diseases such as those"/>
   <result pre="not reduce symptoms and/or decrease viral load. Tocilizumab, Chloroquine, and" exact="Hydroxychloroquine" post="have been demonstrated to inhibit SARS-CoV-2 in vitro and,"/>
   <result pre="viral load in patients despite the strong adverse effects of" exact="Chloroquine" post="(Table 2). Even so, recent studies are contradicting the"/>
   <result pre="Even so, recent studies are contradicting the safety profiles of" exact="Chloroquine" post="and Hydroxychloroquine, since they might cause arrhythmia in patients,"/>
   <result pre="2020). In addition, previous studies demonstrated that the use of" exact="Chloroquine" post="analogs for decades against malaria has established chloroquine-resistant Plasmodium"/>
   <result pre="However, there is a possibility that prophylactic exposure to pro-apoptotic" exact="chloroquine" post="drugs caused natural selection for strains of viruses and"/>
   <result pre="C.MurceE.CortopassiW. A.PimentelA. S.AlmeidaM. M. F. S.BarrosD. C. S.et al. (2018)." exact="Chloroquine" post="analogs as antimalarial candidates with potent in vitro and"/>
   <result pre="print. 10.1002/jmv.2596432369191 Al-BariM. A. A. (2017). Targeting endosomal acidification by" exact="chloroquine" post="analogs as a promising strategy for the treatment of"/>
   <result pre="emerging viral diseases.Pharmacol. Res. Perspect.51â€&quot;13. 10.1002/prp2.29328596841 Al-TawfiqJ. A.MomattinH.DibJ.MemishZ. A. (2014)." exact="Ribavirin" post="and interferon therapy in patients infected with the Middle"/>
   <result pre="10.3390/v406101122816037 CalyL.DruceJ. D.CattonM. G.JansD. A.WagstaffK. M. (2020). The FDA-approved drug" exact="ivermectin" post="inhibits the replication of SARS-CoV-2 in vitro.Antiviral Res.178:104787. 10.1016/j.antiviral.2020.10478732251768"/>
   <result pre="Med. Virol.92418â€&quot;423. 10.1002/jmv.2568131967327 ChenJ.LiuD.LiuL.LiuP.XuQ.XiaL.et al. (2020). [A pilot study of" exact="hydroxychloroquine" post="in treatment of patients with moderate COVID-19].Zhejiang Xue Xue"/>
   <result pre="Overview.Curr. Trop. Med. Rep.31â€&quot;4. 10.1007/s40475-020-00201-632219057 ChenZ.HuJ.ZhangZ.JiangS.HanS.YanD.et al. (2020). Efficacy of" exact="hydroxychloroquine" post="in patients with COVID-19: results of a randomized clinical"/>
   <result pre="induces severe in vitro cytopathology and is strongly inhibited by" exact="cyclosporin A" post="or interferon-Î± treatment.J. Gen. Virol.941749â€&quot;1760. 10.1099/vir.0.052910-023620378 de WildeA. H.Zevenhoven-DobbeJ."/>
   <result pre="FalzaranoD.de WitE.RasmussenA. L.FeldmannF.OkumuraA.ScottD. P.et al. (2013b). Treatment with interferon-Î±2b and" exact="ribavirin" post="improves outcome in MERS-CoVâ€&quot;infected rhesus macaques.Nat. Med.191313â€&quot;1317. 10.1038/nm.336224013700 collab:"/>
   <result pre="Med.191313â€&quot;1317. 10.1038/nm.336224013700 collab: FDA (2020). FDA Cautions Against use of" exact="Hydroxychloroquine" post="or Chloroquine for COVID-19 Outside of the Hospital Setting"/>
   <result pre="collab: FDA (2020). FDA Cautions Against use of Hydroxychloroquine or" exact="Chloroquine" post="for COVID-19 Outside of the Hospital Setting or a"/>
   <result pre="al. (2017). Structural and molecular basis of mismatch correction and" exact="ribavirin" post="excision from coronavirus RNA.Proc. Natl. Acad. Sci. U S.A.115E162â€&quot;E171."/>
   <result pre="P. (Cambridge, MA: Academic Press), 1â€&quot;42. 10.1016/B978-0-12-815422-9.00001-2 GaoJ.TianZ.YangX. (2020). Breakthrough:" exact="chloroquine" post="phosphate has shown apparent efficacy in treatment of COVID-19"/>
   <result pre="Ebola virus infection.Transfus. Apher. Sci.5631â€&quot;34. 10.1016/j.transci.2016.12.01428094110 GautretP.LagierJ.-C.ParolaP.HoangV. T.MeddebL.MailheM.et al. (2020)." exact="Hydroxychloroquine" post="and azithromycin as a treatment of COVID-19: results of"/>
   <result pre="infection.Transfus. Apher. Sci.5631â€&quot;34. 10.1016/j.transci.2016.12.01428094110 GautretP.LagierJ.-C.ParolaP.HoangV. T.MeddebL.MailheM.et al. (2020). Hydroxychloroquine and" exact="azithromycin" post="as a treatment of COVID-19: results of an open-label"/>
   <result pre="GirijalaR. L.SiddiqiI.KwakY.WrightD.PatelD. B.GoldbergL. H. (2019). Pustular DRESS syndrome secondary to" exact="hydroxychloroquine" post="with EBV reactivation.J. Drugs Dermatol. JDD18207â€&quot;209.30811149 GorbalenyaA. E.BakerS. C.BaricR."/>
   <result pre="entry.J. Virol.8112029â€&quot;12039. 10.1128/JVI.00315-0717715238 HartB. J.DyallJ.PostnikovaE.ZhouH.KindrachukJ.JohnsonR. F.et al. (2014). Interferon-Î² and" exact="mycophenolic acid" post="are potent inhibitors of middle east respiratory syndrome coronavirus"/>
   <result pre="Engl. J. Med.382929â€&quot;936. 10.1056/NEJMoa200119132004427 HorbyP.LimW. S.EmbersonJ.MafhamM.BellJ.LinsellL.et al. (2020). Effect of" exact="dexamethasone" post="in hospitalized patients with COVID-19: preliminary report.medRxiv [Preprint]10.1101/2020.06.22.20137273 HsuL."/>
   <result pre="W.-H.ChuM.-Y.et al. (2020). Triple combination of interferon beta-1b, lopinavir-ritonavir, and" exact="ribavirin" post="in the treatment of patients admitted to hospital with"/>
   <result pre="JacobsonJ. M.BosingerS. E.KangM.Belaunzaran-ZamudioP.MatiningR. M.WilsonC. C.et al. (2016). The effect of" exact="chloroquine" post="on immune activation and interferon signatures associated with HIV-1.AIDS"/>
   <result pre="Agents Chemother.64e00819â€&quot;e00820. 10.1128/AAC.00819-2032366720 JuurlinkD. N. (2020). Safety considerations with chloroquine," exact="hydroxychloroquine" post="and azithromycin in the management of SARS-CoV-2 infection.CMAJ192E450â€&quot;E453. 10.1503/cmaj.20052832269021"/>
   <result pre="10.1128/AAC.00819-2032366720 JuurlinkD. N. (2020). Safety considerations with chloroquine, hydroxychloroquine and" exact="azithromycin" post="in the management of SARS-CoV-2 infection.CMAJ192E450â€&quot;E453. 10.1503/cmaj.20052832269021 KaepplerU.StieflN.SchillerM.VicikR.BreuningA.SchmitzW.et al."/>
   <result pre="protease.Antiviral Res.97161â€&quot;168. 10.1016/j.antiviral.2012.11.00523219425 KimU. J.WonE.-J.KeeS.-J.JungS.-I.JangH.-C. (2015). Combination therapy with lopinavir/ritonavir," exact="ribavirin" post="and interferon-Î± for Middle East respiratory syndrome: a case"/>
   <result pre="(2016). Association of polymorphisms of cytochrome P450 2D6 with blood" exact="hydroxychloroquine" post="levels in patients with systemic lupus erythematosus.Arthritis Rheumatol.68184â€&quot;190. 10.1002/art.3940226316040"/>
   <result pre="TMPRSS2-expressing cells.Proc. Natl. Acad. Sci. U.S.A.1177001â€&quot;7003. 10.1073/pnas.200258911732165541 MautheM.OrhonI.RocchiC.ZhouX.LuhrM.HijlkemaK.-J.et al. (2018)." exact="Chloroquine" post="inhibits autophagic flux by decreasing autophagosome-lysosome fusion.Autophagy141435â€&quot;1455. 10.1080/15548627.2018.147431429940786 McDonaghP.SheehyP."/>
   <result pre="lopinavir/ritonavir in treatment-naive, HIV-1-infected patients: 96-week analysis.AIDS231679â€&quot;1688. 10.1097/QAD.0b013e32832d735019487905 MohanD.MohandasE.RajatR. (1981)." exact="Chloroquine" post="psychosis: a chemical psychosis?J. Natl. Med. Assoc.731073â€&quot;1076.7310924 MolinaJ. M.DelaugerreC.Le"/>
   <result pre="rapid antiviral clearance or clinical benefit with the combination of" exact="hydroxychloroquine" post="and azithromycin in patients with severe COVID-19 infection.Med. Mal."/>
   <result pre="clearance or clinical benefit with the combination of hydroxychloroquine and" exact="azithromycin" post="in patients with severe COVID-19 infection.Med. Mal. Infect.50:384. 10.1016/j.medmal.2020.03.00632240719"/>
   <result pre="Randomized dose-ranging controlled trial of AQ-13, a candidate antimalarial, and" exact="chloroquine" post="in healthy volunteers.PLoS Clin. Trials2:e6. 10.1371/journal.pctr.002000617213921 collab: National Research"/>
   <result pre="10.1016/j.bbrc.2003.12.08114715271 PreobrazhenskayaM. N.OlsufyevaE. N. (2004). Patents on glycopeptides of the" exact="vancomycin" post="family and their derivatives as antimicrobials: January 1999 â€&quot;"/>
   <result pre="MA: Springer), 597â€&quot;600. 10.1007/978-0-387-33012-9_108 RoquesP.ThibervilleS.-D.Dupuis-MaguiragaL.LumF.-M.LabadieK.MartinonF.et al. (2018). Paradoxical effect of" exact="chloroquine" post="treatment in enhancing chikungunya virus infection.Viruses10:268. 10.3390/v1005026829772762 RossignolJ.-F. (2014)."/>
   <result pre="Dis.6920â€&quot;28. 10.1136/ard.2008.10176619103632 SaijoM.MorikawaS.FukushiS.MizutaniT.HasegawaH.NagataN.et al. (2005). Inhibitory effect of mizoribine and" exact="ribavirin" post="on the replication of severe acute respiratory syndrome (SARS)-associated"/>
   <result pre="A.RaynesK. J.BrayP. G.ParkB. K.Oâ€™NeillP. M.WardS. A. (2002). Novel short chain" exact="chloroquine" post="analogues retain activity against chloroquine resistant K1 plasmodium falciparum.J."/>
   <result pre="A. (2002). Novel short chain chloroquine analogues retain activity against" exact="chloroquine" post="resistant K1 plasmodium falciparum.J. Med. Chem.454975â€&quot;4983. 10.1021/jm010870712408708 StruckA.-W.AxmannM.PfefferleS.DrostenC.MeyerB. (2012)."/>
   <result pre="inhibitor and vaccine.Cell. Mol. Immunol.17613â€&quot;620. 10.1038/s41423-020-0400-432203189 TakanoT.KatohY.DokiT.HohdatsuT. (2013). Effect of" exact="chloroquine" post="on feline infectious peritonitis virus infection in vitro and"/>
   <result pre="herpes simplex virus proliferation.Oncotarget103209â€&quot;3226. 10.18632/oncotarget.2690731143369 UnÃ¼bolM.AyhanM.GuneyE. (2011). Hypoglycemia induced by" exact="hydroxychloroquine" post="in a patient treated for rheumatoid arthritis.J. Clin. Rheumatol."/>
   <result pre="Pract. Rep. Rheum. Musculoskelet. Dis.1746â€&quot;47. 10.1097/RHU.0b013e3182098e1f21169846 UrsingJ.RomboL.EksborgS.LarsonL.BruvollA.TarningJ.et al. (2020). High-dose" exact="chloroquine" post="for uncomplicated plasmodium falciparum malaria is well tolerated and"/>
   <result pre="well tolerated and causes similar QT interval prolongation as standard-dose" exact="chloroquine" post="in children.Antimicrob. Agents Chemother.64:e01846-19. 10.1128/AAC.01846-1931907183 van DoremalenN.BushmakerT.MorrisD. H.HolbrookM. G.GambleA.WilliamsonB."/>
   <result pre="10.1056/NEJMc200497332182409 VargheseF. S.KaukinenP.GlÃ¤skerS.BespalovM.HanskiL.WennerbergK.et al. (2016). Discovery of berberine, abamectin and" exact="ivermectin" post="as antivirals against chikungunya and other alphaviruses.Antiviral Res.126117â€&quot;124. 10.1016/j.antiviral.2015.12.01226752081"/>
   <result pre="dengue viruses.Bioinformation8519â€&quot;522. 10.6026/9732063000851922829722 VincentM. J.BergeronE.BenjannetS.EricksonB. R.RollinP. E.KsiazekT. G.et al. (2005)." exact="Chloroquine" post="is a potent inhibitor of SARS coronavirus infection and"/>
   <result pre="blocking SARS-CoV-2 infection.Nat. Commun.11:2251. 10.1038/s41467-020-16256-y32366817 WangM.CaoR.ZhangL.YangX.LiuJ.XuM.et al. (2020b). Remdesivir and" exact="chloroquine" post="effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in"/>
   <result pre="online at: https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports(accessed July 04, 2020) collab: WHO (2020c). Q&amp;amp;A:" exact="Hydroxychloroquine" post="and COVID-19. Available online at: https://www.who.int/news-room/q-a-detail/q-a-hydroxychloroquine-and-covid-19(accessed July 5, 2020)"/>
   <result pre="5â€™ ends.Virus Res.206120â€&quot;133. 10.1016/j.virusres.2015.02.02525736566 YaoT.-T.QianJ.-D.ZhuW.-Y.WangY.WangG.-Q. (2020a). A systematic review of" exact="lopinavir" post="therapy for SARS coronavirus and MERS coronavirusâ€&quot;A possible reference"/>
   <result pre="vitro antiviral activity and projection of optimized dosing design of" exact="hydroxychloroquine" post="for the treatment of severe acute respiratory syndrome coronavirus"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7438974\results\search\drug\results.xml">
   <result pre="patterns in chronic hepatitis delta determine early response to interferon" exact="alpha" post="therapyJÂ Viral Hepat2520181384139429888837 29YurdaydinC.New treatment options for delta virus:"/>
   <result pre="30WedemeyerH.PortK.DeterdingK.WrankeA.KirschnerJ.BrunoB.PS-039 - a phase 2 dose-escalation study of lonafarnib plus" exact="ritonavir" post="in patients with chronic hepatitis D: final results from"/>
   <result pre="with chronic hepatitis D: final results from the Lonafarnib with" exact="ritonavir" post="in HDV-4 (LOWR HDV-4) studyJÂ Hepatol662017S24 31WedemeyerH.SchoeneweisK.BogomolovP.O.VoronkovaN.V.ChulanovV.StepanovaT.Interim results of"/>
   <result pre="safety and efficacy of Myrcludex B in combination with Peg-Interferon" exact="alpha" post="2a in patients with chronic HBV/HDV co-infectionHepatology68201811A 32BazinetM.PÃ¢nteaV.CebotarescuV.CojuhariL.JimbeiP.AlbrechtJ.Treatment of"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7439087\results\search\drug\results.xml">
   <result pre="such as prostaglandin-endoperoxide synthase 2 (PTGS2), heat shock protein 90" exact="alpha" post="family class a member 1 (HSP90AA1), and estrogen receptor"/>
   <result pre="protein 90 alpha family class a member 1 (HSP90AA1), and" exact="estrogen" post="receptor 1 (ESR1) to inhibit COVID-19. On the other"/>
   <result pre="combine with ACE2 binding to PTGS2, heat shock protein 90" exact="alpha" post="family class b member 1 (HSP90AB1), calmodulin regulated spectrin"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7441141\results\search\drug\results.xml">
   <result pre="drug therapy, and mortality in Covid-19N Engl J Med2020382258210.1056/NEJMoa2007621 25.MehraMRDesaiiSSRuschitzkaFPatelANRETRACTED:" exact="hydroxychloroquine" post="or chloroquine with or without a macrolide for treatment"/>
   <result pre="and mortality in Covid-19N Engl J Med2020382258210.1056/NEJMoa2007621 25.MehraMRDesaiiSSRuschitzkaFPatelANRETRACTED: hydroxychloroquine or" exact="chloroquine" post="with or without a macrolide for treatment of COVID-19:"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7441224\results\search\drug\results.xml">
   <result pre="COVID-19, the potential of several existing medications (including remdesivir, lopinavir/ritonavir," exact="hydroxychloroquine" post="and tocilizumab) is of interest. During the influenza A(H1N1)pdm09"/>
   <result pre="Approved for acute uncomplicated influenza, expanded under EUA April 2009" exact="Zanamivir" post="54 368 2 (1â€&quot;9) Approved for acute uncomplicated influenza,"/>
   <result pre="Approved for acute uncomplicated influenza, expanded under EUA April 2009" exact="Peramivir" post="14 403 1 (1â€&quot;3) Unapproved, eIND in April 2009,"/>
   <result pre="1 (1â€&quot;3) Unapproved, eIND in April 2009, EUA October 2009" exact="Amantadine" post="11 86 3 (1â€&quot;13) Approved for acute uncomplicated influenza,"/>
   <result pre="Approved for acute uncomplicated influenza, but resistance to A(H1N1)pdm09 demonstrated" exact="Rimantadine" post="5 32 3 (1â€&quot;13) Approved for acute uncomplicated influenza,"/>
   <result pre="Approved for acute uncomplicated influenza, but resistance to A(H1N1)pdm09 demonstrated" exact="Ribavirin" post="5 34 2 (1â€&quot;6) Not approved for influenza Intravenous"/>
   <result pre="Aug. 2009 Oct. 2010 Apr. 2016 (Unp) â€ƒNCT00957996 Phase 3" exact="Peramivir" post="300 127 94 Oct. 2009 Oct. 2010 Aug. 2013"/>
   <result pre="Oct. 2009 Oct. 2010 Aug. 2013 [10] â€ƒNCT01199744 Prospective cohort" exact="Zanamivir" post="N/R 1575 Unknown Nov. 2009 Apr. 2010 Mar. 2011(Unp)"/>
   <result pre="Unknown Nov. 2009 Apr. 2010 Mar. 2011(Unp) â€ƒNCT01014988 Phase 2" exact="Zanamivir" post="150 130 92 Nov. 2009 Sep. 2011 Feb. 2014"/>
   <result pre="A(H1N1) infectionChest.2013144246447310.1378/chest.12-290723450336 7.WangCHChungFTLinSMHuangSYChouCLLeeKYet al.Adjuvant treatment with a mammalian target of" exact="rapamycin" post="inhibitor, sirolimus, and steroids improves outcomes in patients with"/>
   <result pre="children aged &amp;lt;2 years with influenzaJ Infect Dis2013207570972010.1093/infdis/jis76523230059 10.IsonMGFraizJHellerBJaureguiLMillsGOâ€™RiordanWet al.Intravenous" exact="peramivir" post="for treatment of influenza in hospitalized patientsAntivir Ther201419434936110.3851/IMP268023985625 11.MartyFMManCYvan"/>
   <result pre="patientsAntivir Ther201419434936110.3851/IMP268023985625 11.MartyFMManCYvan der HorstCFrancoisBGarotDManezRet al.Safety and pharmacokinetics of intravenous" exact="zanamivir" post="treatment in hospitalized adults with influenza: an open-label, multicenter,"/>
   <result pre="Parola P, Hoang VT, Meddeb L, Mailhe M, et al." exact="Hydroxychloroquine" post="and azithromycin as a treatment of COVID-19: results of"/>
   <result pre="Hoang VT, Meddeb L, Mailhe M, et al. Hydroxychloroquine and" exact="azithromycin" post="as a treatment of COVID-19: results of an open-label"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7441399\results\search\drug\results.xml">
   <result pre="spontaneously reversible hypokinetic rigid syndrome, with DaTscan showing reduction of" exact="dopamine" post="transporter uptake in the putamen as well as hyposmia119."/>
   <result pre="(PTSD) as observed in previous SARS and MERS pandemics38. Increased" exact="levodopa" post="requirement during acute admissions and need for non-oral dopaminergic"/>
   <result pre="such patients may be on non-oral therapies (subcutaneous apomorphine, intrajejunal" exact="levodopa" post="infusion, and deep brain stimulation (DBS)) for advanced PD151."/>
   <result pre="vulnerable, with high mortality rates and may have an increased" exact="levodopa" post="requirement during the acute illness45,46. Pre-existing dyspnea of PD152,155,"/>
   <result pre="molecular modelling studies reveal a new mechanism of action of" exact="chloroquine" post="and hydroxychloroquine against SARS-CoV-2 infection. Int. J. Antimicrob. Agents.10.1016/j.ijantimicag.2020.105960"/>
   <result pre="studies reveal a new mechanism of action of chloroquine and" exact="hydroxychloroquine" post="against SARS-CoV-2 infection. Int. J. Antimicrob. Agents.10.1016/j.ijantimicag.2020.105960 (2020). 65.Milanetti,"/>
   <result pre="162.Smieszek, S. P., Przychodzen, B. P. &amp;amp; Polymeropoulos, M. H." exact="Amantadine" post="disrupts lysosomal gene expression: a hypothesis for COVID19 treatment."/>
   <result pre="Y. M., Chaudhuri, K. R. &amp;amp; Jenner, P. Stress and" exact="cortisol" post="in Parkinsonâ€™s disease. Int. Rev. Neurobiol. 10.1016/bs.irn.2020.01.005 (2020)."/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7441762\results\search\drug\results.xml">
   <result pre="recovery but with insignificant clinical benefits and the antimalarial drug," exact="hydroxychloroquine" post="has been red flagged by USFDA for use as"/>
   <result pre="Remdesivir, a nucleotide analogue inhibitor of RdRp and antimalarial drug" exact="chloroquine" post="effectively inhibited the SARS-CoV-2 infection inÂ vitro (M. Wang"/>
   <result pre="vitro (M. Wang etÂ al., 2020). Hydroxychloroquine, an analogue of" exact="chloroquine" post="is also a drug candidate after inÂ vitro (Yao"/>
   <result pre="pose and binding interactions of N3 (i), GS-441524 (ii) and" exact="Hydroxychloroquine" post="(iii) with SARS-Cov-2 Mpro. Figure 2. Docked pose and"/>
   <result pre="pose and binding interactions of MLN-4765 (i), GS-441524 (ii) and" exact="Hydroxychloroquine" post="(iii) with ACE2. Table 1. Docking scores of N3/MLN-4760"/>
   <result pre="SARS-CoV-2 infected patients (Rhoades, 2020). Remdesivir is a prodrug of" exact="adenosine" post="triphosphate (ATP) analog, GS-441524 that interferes with the action"/>
   <result pre="The 2D and 3D docking pose of both remdesivir and" exact="hydroxychloroquine" post="in SARS-CoV-2 Mpro and ACE2 is presented in Figure"/>
   <result pre="- PubMed - NCBI, n.d.). Avicularin elevated the sensitivity of" exact="cisplatin" post="in drug resistant gastric cancer cells in inÂ vitro"/>
   <result pre="crude extract have less bioavailability as compared to encapsulated spray" exact="dried" post="formulations. Like delphinidin 3,5-diglucoside the next two leads (Scutellarein"/>
   <result pre="Triglycosides from Buddleja Madagascariensis.Phytochemistry, 48(4), 739â€&quot;42. 10.1016/S0031-9422(97)01043-1. collab: FDA (2020)." exact="Hydroxychloroquine" post="fact sheet for health care providers, 1â€&quot;7. FilipiakK., HidalgoM.,"/>
   <result pre="HonorÃ©S., ColsonP., ChabriÃ¨reE., La ScolaB., RolainJ.-M., BrouquiP., &amp;amp; RaoultD. (2020)." exact="Hydroxychloroquine" post="and azithromycin as a treatment of COVID-19: Results of"/>
   <result pre="ChabriÃ¨reE., La ScolaB., RolainJ.-M., BrouquiP., &amp;amp; RaoultD. (2020). Hydroxychloroquine and" exact="azithromycin" post="as a treatment of COVID-19: Results of an open-label"/>
   <result pre="LiuJ., XuM., ShiZ., HuZ., ZhongW., &amp;amp; XiaoG. (2020). Remdesivir and" exact="chloroquine" post="effectively inhibit the recently emerged novel coronavirus (2019-NCoV) inÂ"/>
   <result pre="vitro antiviral activity and projection of optimized dosing design of" exact="hydroxychloroquine" post="for the treatment of severe acute respiratory syndrome coronavirus"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7441776\results\search\drug\results.xml">
   <result pre="(RMSF) and root mean square deviation (RMSD) values for backbone," exact="alpha" post="carbon and heavy atoms were recorded. For more accuracy,"/>
   <result pre="1. According to best binding affinities, Simeprevir, Ergotamine, Bromocriptine and" exact="Tadalafil" post="are selected for further analysis (Figure 2). Remdesivir and"/>
   <result pre="with SARS-CoV-2 Mpro. Drug Binding affinity (kcal/mol) GOLD fitting score" exact="Simeprevir" post="â€&quot;10.3 73.83 ZINC000164760756 Ergotamine â€&quot;9.8 81.8 ZINC000052955754 Bromocriptine â€&quot;9.6"/>
   <result pre="Binding affinity (kcal/mol) GOLD fitting score Simeprevir â€&quot;10.3 73.83 ZINC000164760756" exact="Ergotamine" post="â€&quot;9.8 81.8 ZINC000052955754 Bromocriptine â€&quot;9.6 70.66 ZINC000053683151 Tadalafil â€&quot;9.5"/>
   <result pre="73.83 ZINC000164760756 Ergotamine â€&quot;9.8 81.8 ZINC000052955754 Bromocriptine â€&quot;9.6 70.66 ZINC000053683151" exact="Tadalafil" post="â€&quot;9.5 59.32 ZINC000003993855 Dihydroergotamine â€&quot;9.2 75.46 ZINC000003978005 Perampanel â€&quot;9.2"/>
   <result pre="81.8 ZINC000052955754 Bromocriptine â€&quot;9.6 70.66 ZINC000053683151 Tadalafil â€&quot;9.5 59.32 ZINC000003993855" exact="Dihydroergotamine" post="â€&quot;9.2 75.46 ZINC000003978005 Perampanel â€&quot;9.2 74.57 ZINC000030691797 Nilotinib â€&quot;9.2"/>
   <result pre="70.66 ZINC000053683151 Tadalafil â€&quot;9.5 59.32 ZINC000003993855 Dihydroergotamine â€&quot;9.2 75.46 ZINC000003978005" exact="Perampanel" post="â€&quot;9.2 74.57 ZINC000030691797 Nilotinib â€&quot;9.2 84.77 ZINC000006716957 Rolapitant â€&quot;9.1"/>
   <result pre="59.32 ZINC000003993855 Dihydroergotamine â€&quot;9.2 75.46 ZINC000003978005 Perampanel â€&quot;9.2 74.57 ZINC000030691797" exact="Nilotinib" post="â€&quot;9.2 84.77 ZINC000006716957 Rolapitant â€&quot;9.1 72.66 ZINC000003816514 Naldemedine â€&quot;8.9"/>
   <result pre="84.77 ZINC000006716957 Rolapitant â€&quot;9.1 72.66 ZINC000003816514 Naldemedine â€&quot;8.9 70.68 ZINC000100378061" exact="Irinotecan" post="ZINC000001612996 â€&quot;8.9 72.3 Raltegravir â€&quot;8.9 64.33 ZINC000013831130 Lumacaftor â€&quot;8.8"/>
   <result pre="64.33 ZINC000013831130 Lumacaftor â€&quot;8.8 68.84 ZINC000064033452 Eltrombopag â€&quot;8.8 69.34 ZINC000011679756" exact="Saquinavir" post="â€&quot;8.7 87.79 ZINC000003914596 Sildenafil â€&quot;8.7 80.21 ZINC000019796168 Pimozide â€&quot;8.6"/>
   <result pre="69.34 ZINC000011679756 Saquinavir â€&quot;8.7 87.79 ZINC000003914596 Sildenafil â€&quot;8.7 80.21 ZINC000019796168" exact="Pimozide" post="â€&quot;8.6 77.44 ZINC000004175630 Paliperidone â€&quot;8.5 62.18 ZINC000004214700 Suvorexant â€&quot;8.5"/>
   <result pre="87.79 ZINC000003914596 Sildenafil â€&quot;8.7 80.21 ZINC000019796168 Pimozide â€&quot;8.6 77.44 ZINC000004175630" exact="Paliperidone" post="â€&quot;8.5 62.18 ZINC000004214700 Suvorexant â€&quot;8.5 62.23 ZINC000049036447 Nintedanib â€&quot;8.5"/>
   <result pre="77.44 ZINC000004175630 Paliperidone â€&quot;8.5 62.18 ZINC000004214700 Suvorexant â€&quot;8.5 62.23 ZINC000049036447" exact="Nintedanib" post="â€&quot;8.5 79.48 ZINC000100014909 Maraviroc â€&quot;8.5 74.25 ZINC000100003902 Paliperidone â€&quot;8.4"/>
   <result pre="62.23 ZINC000049036447 Nintedanib â€&quot;8.5 79.48 ZINC000100014909 Maraviroc â€&quot;8.5 74.25 ZINC000100003902" exact="Paliperidone" post="â€&quot;8.4 58.75 ZINC000001481956 Conivaptan â€&quot;8.4 69.76 ZINC000012503187 Pazopanib â€&quot;8.4"/>
   <result pre="58.75 ZINC000001481956 Conivaptan â€&quot;8.4 69.76 ZINC000012503187 Pazopanib â€&quot;8.4 66.93 ZINC000011617039" exact="Ibrutinib" post="â€&quot;8.4 76.69 ZINC000035328014 Tipranavir â€&quot;8.4 79.31 ZINC000100022637 Dabrafenib ZINC000068153186"/>
   <result pre="69.76 ZINC000012503187 Pazopanib â€&quot;8.4 66.93 ZINC000011617039 Ibrutinib â€&quot;8.4 76.69 ZINC000035328014" exact="Tipranavir" post="â€&quot;8.4 79.31 ZINC000100022637 Dabrafenib ZINC000068153186 â€&quot;8.3 68.28 Telotristat â€&quot;8.3"/>
   <result pre="66.93 ZINC000011617039 Ibrutinib â€&quot;8.4 76.69 ZINC000035328014 Tipranavir â€&quot;8.4 79.31 ZINC000100022637" exact="Dabrafenib" post="ZINC000068153186 â€&quot;8.3 68.28 Telotristat â€&quot;8.3 74.89 ZINC000084758235 Teniposide â€&quot;8.2"/>
   <result pre="79.31 ZINC000100022637 Dabrafenib ZINC000068153186 â€&quot;8.3 68.28 Telotristat â€&quot;8.3 74.89 ZINC000084758235" exact="Teniposide" post="â€&quot;8.2 58.82 ZINC000004099009 Apixaban â€&quot;8.2 72.74 ZINC000011677837 Rifaximin â€&quot;7.7"/>
   <result pre="â€&quot;8.3 68.28 Telotristat â€&quot;8.3 74.89 ZINC000084758235 Teniposide â€&quot;8.2 58.82 ZINC000004099009" exact="Apixaban" post="â€&quot;8.2 72.74 ZINC000011677837 Rifaximin â€&quot;7.7 42.56 ZINC000169621200 Lifitegrast â€&quot;7.5"/>
   <result pre="74.89 ZINC000084758235 Teniposide â€&quot;8.2 58.82 ZINC000004099009 Apixaban â€&quot;8.2 72.74 ZINC000011677837" exact="Rifaximin" post="â€&quot;7.7 42.56 ZINC000169621200 Lifitegrast â€&quot;7.5 73.73 ZINC000084668739 Montelukast (Contini,"/>
   <result pre="72.74 ZINC000011677837 Rifaximin â€&quot;7.7 42.56 ZINC000169621200 Lifitegrast â€&quot;7.5 73.73 ZINC000084668739" exact="Montelukast" post="(Contini, 2020) â€&quot;8.3 93.62 GHRP-2 (Contini, 2020) â€&quot;8.1 95.49"/>
   <result pre="GHRP-2 (Contini, 2020) â€&quot;8.1 95.49 Indinavir (Contini, 2020) â€&quot;8 88.35" exact="Cobicistat" post="(Contini, 2020) â€&quot;7.5 86.53 Angiotensin II (Contini, 2020) â€&quot;6.9"/>
   <result pre="Ergotamine, (c) Bromocriptine, and (d) Tadalafil. Simeprevir, Ergotamine, Bromocriptine and" exact="Tadalafil" post="form a number of hydrogen bonds and hydrophobic interactions"/>
   <result pre="active site residues are categorized as hydrophobic (Table 2). Both" exact="Simeprevir" post="and Ergotamine form a hydrogen bond with at least"/>
   <result pre="residues are categorized as hydrophobic (Table 2). Both Simeprevir and" exact="Ergotamine" post="form a hydrogen bond with at least one of"/>
   <result pre="Câ€‰=â€‰Carbon Hydrogen bond. Interacting residue Distance Bond category Bond type" exact="Simeprevir" post="CYS145 2.7202 H CH GLN189 2.29 H CH GLY143"/>
   <result pre="Hydrophobic Pi-Alkyl ALA191 4.47775 Hydrophobic Pi-Alkyl PRO168 3.91598 Hydrophobic Pi-Alkyl" exact="Ergotamine" post="HIS41 2.88425 H C MET165 1.89419 H C MET165"/>
   <result pre="Pi-Alkyl GLN189 2.38092 Hydrophobic Pi-Sigma HIS41 5.13653 Hydrophobic Pi-Pi-T Shaped" exact="Tadalafil" post="ASN142 2.16312 H C GLY143 2.66564 H C MET165"/>
   <result pre="Hydrophobic Pi-Alkyl MET49 4.6017 Hydrophobic Pi-Alkyl HIS41 5.18874 Hydrophobic Pi-Alkyl" exact="Simeprevir" post="is observed to show three hydrophobic interactions with Pro168,"/>
   <result pre="Leu50 and one with each of the Thr190 and Ala191." exact="Ergotamine" post="exhibits one piâ€&quot;alkyl and one piâ€&quot;pi T-shaped hydrophobic interaction"/>
   <result pre="one with each of the Met49, Cys145 and Gln189 residues." exact="Tadalafil" post="exhibits hydrophobic interactions with both catalytic residues. Both Ergotamine"/>
   <result pre="residues. Tadalafil exhibits hydrophobic interactions with both catalytic residues. Both" exact="Ergotamine" post="and Tadalafil show one piâ€&quot;sulfur interaction with Met165 and"/>
   <result pre="exhibits hydrophobic interactions with both catalytic residues. Both Ergotamine and" exact="Tadalafil" post="show one piâ€&quot;sulfur interaction with Met165 and Met49 residues,"/>
   <result pre="selected drugs and apoâ€&quot;form is performed for 100â€‰ns. RMSD of" exact="alpha" post="carbon atoms, RMSF of all amino acid residues, solvent"/>
   <result pre="over the phase of 100â€‰ns, (b) RMSF values of the" exact="alpha" post="carbon over the entire simulation, where the ordinate is"/>
   <result pre="apoâ€&quot;Mpro complex experienced a fluctuation in Rg value during 80â€&quot;90â€‰ns." exact="Ergotamine" post="showed structural compactness all over the simulation time with"/>
   <result pre="structure of Mpro is shown in beige color with (a)" exact="Simeprevir" post="(cyan), (b) Ergotamine (green), (c) Bromocriptine (blue) and (d)"/>
   <result pre="is shown in beige color with (a) Simeprevir (cyan), (b)" exact="Ergotamine" post="(green), (c) Bromocriptine (blue) and (d) Tadalafil (orange red)."/>
   <result pre="Simeprevir (cyan), (b) Ergotamine (green), (c) Bromocriptine (blue) and (d)" exact="Tadalafil" post="(orange red). 3.4. Principal components analysis PCA is applied"/>
   <result pre="apoâ€&quot;Mpro and Simeprevirâ€&quot;Mpro complex. Thus, by forming a complex with" exact="Ergotamine" post="and Tadalafil, Mpro showed a similar structural profile compared"/>
   <result pre="Therefore, it is evident from the PCA scoring plot that" exact="Simeprevir" post="has the best binding stability with Mpro, while Ergotamine"/>
   <result pre="that Simeprevir has the best binding stability with Mpro, while" exact="Ergotamine" post="and Tadalafil also demonstrate almost similar behavior in MD"/>
   <result pre="has the best binding stability with Mpro, while Ergotamine and" exact="Tadalafil" post="also demonstrate almost similar behavior in MD simulation. Figure"/>
   <result pre="(D2, D3 and D5) containing indole ring, amide group and" exact="alcohol" post="group are clustered together on the fourth quadrant of"/>
   <result pre="SARS-CoV-2. Among the 1615 studied drugs, Simeprevir, Ergotamine, Bromocriptine and" exact="Tadalafil" post="are found to have the highest binding affinity. As"/>
   <result pre="of the catalytic residues. Furthermore, MD simulations exhibit that Simeprevir," exact="Ergotamine" post="and Bromocriptine drugs with Mpro protein preserve the structural"/>
   <result pre="reveals that drugs containing an indole ring, amide group and" exact="alcohol" post="group are clustered together in the fourth quadrant and"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7442131\results\search\drug\results.xml">
   <result pre="the four most promising COVID-19 treatment regimens: (1) remdesivir (2)" exact="chloroquine" post="phosphate and hydroxychloroquine (3) lopinavir + ritonavir (4) lopinavir"/>
   <result pre="promising COVID-19 treatment regimens: (1) remdesivir (2) chloroquine phosphate and" exact="hydroxychloroquine" post="(3) lopinavir + ritonavir (4) lopinavir + ritonavir +"/>
   <result pre="treatment regimens: (1) remdesivir (2) chloroquine phosphate and hydroxychloroquine (3)" exact="lopinavir" post="+ ritonavir (4) lopinavir + ritonavir + interferon. The"/>
   <result pre="(1) remdesivir (2) chloroquine phosphate and hydroxychloroquine (3) lopinavir +" exact="ritonavir" post="(4) lopinavir + ritonavir + interferon. The four treatment"/>
   <result pre="(2) chloroquine phosphate and hydroxychloroquine (3) lopinavir + ritonavir (4)" exact="lopinavir" post="+ ritonavir + interferon. The four treatment regimens will"/>
   <result pre="phosphate and hydroxychloroquine (3) lopinavir + ritonavir (4) lopinavir +" exact="ritonavir" post="+ interferon. The four treatment regimens will be widely"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7443229\results\search\drug\results.xml">
   <result pre="of antioxidant molecules such as ascorbic acid, carotenoids, and reduced" exact="glutathione" post="(GSH) [30â€&quot;32]. Wu et al. reported that glucose-6-phosphate dehydrogenase-"/>
   <result pre="pyrrolidine dithiocarbamate or N-acetylcysteine, significantly inhibits coronavirus-induced apoptosis [43]. Moreover," exact="melatonin" post="promotes downregulation of acute lung oxidative injury due to"/>
   <result pre="by H2O2 [48], promotes an increase in SOD, CAT, and" exact="glutathione" post="peroxidase (GPx), and reduces lipid peroxidation in rats with"/>
   <result pre="in oxidative stress through reductions in parameters such as indirect" exact="nitric oxide" post="synthesis and status total oxidative, as well as an"/>
   <result pre="12 days in an experimental model of cardiotoxicity induced by" exact="doxorubicin" post="in rats promoted cardioprotection by reducing levels of malondialdehyde"/>
   <result pre="injury induced by D-galactosamine by increasing levels of SOD, GSH," exact="glutathione" post="reductase, and glutathione S-transferase [80, 81]. Rhoifolin is found"/>
   <result pre="D-galactosamine by increasing levels of SOD, GSH, glutathione reductase, and" exact="glutathione" post="S-transferase [80, 81]. Rhoifolin is found in citrus fruits,"/>
   <result pre="the initial treatment of SARS-CoV with antiviral agents such as" exact="ribavirin" post="and corticosteroids did not achieve very satisfactory results, mainly"/>
   <result pre="and cellular immune systems [108, 109]. Other drugs such as" exact="pentoxifylline" post="were considered for the treatment of SARS due to"/>
   <result pre="alveolar damage DPPH: 2,2-Diphenyl-1-picrylhydrazyl FRAP: Ferric reducing antioxidant power GSH:" exact="Reduced glutathione" post="GPx: Glutathione peroxidase HCoVs: Human coronaviruses HKU1: Human coronavirus-HKU1"/>
   <result pre="damage DPPH: 2,2-Diphenyl-1-picrylhydrazyl FRAP: Ferric reducing antioxidant power GSH: Reduced" exact="glutathione" post="GPx: Glutathione peroxidase HCoVs: Human coronaviruses HKU1: Human coronavirus-HKU1"/>
   <result pre="2,2-Diphenyl-1-picrylhydrazyl FRAP: Ferric reducing antioxidant power GSH: Reduced glutathione GPx:" exact="Glutathione" post="peroxidase HCoVs: Human coronaviruses HKU1: Human coronavirus-HKU1 LRTIs: Lower"/>
   <result pre="gastroenteritis virus-activated apoptotic signalingBiochemical and Biophysical Research Communications20134421â€&quot;2333710.1016/j.bbrc.2013.10.16424225120 44ZhangR.WangX.NiL.et al.COVID-19:" exact="melatonin" post="as a potential adjuvant treatmentLife Sciences2020250, article 11758310.1016/j.lfs.2020.117583 45WuS.ZhangY.RenF.et"/>
   <result pre="International20202020710.1155/2020/821643532258148 48KimG. N.JangH. D.Protective mechanism of quercetin and rutin using" exact="glutathione" post="metabolism on H2O2-induced oxidative stress in HepG2 cellsAnnals of"/>
   <result pre="luteolin and quercetin 3-Î²-d-glucoside identified from Passiflora subpeltata leaves against" exact="acetaminophen" post="induced hepatotoxicity in ratsBiomedicine &amp;amp; Pharmacotherapy2016831278128510.1016/j.biopha.2016.08.04427567587 53JayachandranM.WuZ.GanesanK.KhalidS.ChungS. M.XuB.Isoquercetin upregulates"/>
   <result pre="streptozotocin-nicotinamide-induced diabetic ratsBiomedicine &amp;amp; Pharmacotherapy20179436237310.1016/j.biopha.2017.07.12928772214 64SeeramN. P.HenningS. M.NiuY.LeeR.ScheullerH. S.HeberD.Catechin and" exact="caffeine" post="content of green tea dietary supplements and correlation with"/>
   <result pre="Journal of Molecular Sciences2019209p. 214810.3390/ijms2009214831052292 72ZareM. F. R.RakhshanK.AboutalebN.et al.Apigenin attenuates" exact="doxorubicin" post="induced cardiotoxicity via reducing oxidative stress and apoptosis in"/>
   <result pre="MoraisA. T.et al.Structural and molecular basis of mismatch correction and" exact="ribavirin" post="excision from coronavirus RNAProceedings of the National Academy of"/>
   <result pre="gallate Rats with streptozotocin-induced diabetes mellitus 2.5â€‰mg/100â€‰g (i.p.) Reduces indirect" exact="nitric oxide" post="synthesis and total oxidative statusIncreased levels of CAT and"/>
   <result pre="12.2â€‰Î¼molâ€‰Fe2+/mmol, respectively Scavenging of free radicals [71] Cardiotoxicity induced by" exact="doxorubicin" post="in rats 25â€‰mg/kg (p.o.) Reduces levels of MDA, increases"/>
   <result pre="rats 10 and 20â€‰mg/kg (p.o.) Increases levels of SOD, GSH," exact="glutathione" post="reductase, and glutathione S-transferase [80] Rhoifolin ORAC Approximately 10"/>
   <result pre="20â€‰mg/kg (p.o.) Increases levels of SOD, GSH, glutathione reductase, and" exact="glutathione" post="S-transferase [80] Rhoifolin ORAC Approximately 10 Trolox equivalents (Î¼M)"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7443335\results\search\drug\results.xml">
   <result pre="been proposed such as lopinavir/ritonavir (400/100Â mg every 12Â h)," exact="chloroquine" post="(500Â mg every 12Â h), and hydroxyl-chloroquine (200Â mg"/>
   <result pre="given treatment of FPV and 45 patients were treated with" exact="lopinavir" post="and ritonavir (LPV/RTV) combination. It was found that those"/>
   <result pre="of FPV and 45 patients were treated with lopinavir and" exact="ritonavir" post="(LPV/RTV) combination. It was found that those treated with"/>
   <result pre="the attention, such as ribavirin, favipiravir, oseltamivir and umifenovir [44]." exact="Ribavirin" post="(Tribavirin) is a broad-spectrum guanosine analogue against RNA and"/>
   <result pre="and DNA viruses such as hepatitis C and E [45]." exact="Ribavirin" post="in conjunction with interferon showed synergistic activity in in"/>
   <result pre="activity in in vitro antiviral study. This result suggested that" exact="ribavirin" post="elicits antiviral activity at lower concentration with interferon. Therefore,"/>
   <result pre="concentration with interferon. Therefore, a combination therapy of interferon and" exact="ribavirin" post="were widely used due to synergistic effect. Simultaneous use"/>
   <result pre="sputum specimens remain negative for more than three times [46]." exact="Chloroquine" post="and hydroxychloroquine (HC) had received intense attention because of"/>
   <result pre="remain negative for more than three times [46]. Chloroquine and" exact="hydroxychloroquine" post="(HC) had received intense attention because of viral enzymes"/>
   <result pre="events and other potential side effects. The potential benefits of" exact="chloroquine" post="and HC no longer outweigh the potential risks for"/>
   <result pre="risks for the authorized use [47]. HC is superior to" exact="chloroquine" post="and reported positive results in some pre-clinical data in"/>
   <result pre="of severity [48]. Philippe Gautret et al. conducted study on" exact="hydroxychloroquine" post="and azithromycin as a treatment toCOVID-19. It was found"/>
   <result pre="[48]. Philippe Gautret et al. conducted study on hydroxychloroquine and" exact="azithromycin" post="as a treatment toCOVID-19. It was found that patients"/>
   <result pre="a treatment toCOVID-19. It was found that patients treated with" exact="hydroxychloroquine" post="showed significant reduction in viral infection as compared to"/>
   <result pre="significant reduction in viral infection as compared to the control." exact="Hydroxychloroquine" post="in combination with azithromycin were more effective in the"/>
   <result pre="infection as compared to the control. Hydroxychloroquine in combination with" exact="azithromycin" post="were more effective in the elimination of virus [49]."/>
   <result pre="Magagnoli et al. conducted study to study the outcomes of" exact="hydroxychloroquine" post="in COVID-19 patients. This study was carried out on"/>
   <result pre="pandemic. Anticoagulants like Vitamin K antagonists, dabigatran, apixaban, betrixaban, edoxaban," exact="rivaroxaban" post="and antiplatelets like clopidogrel, prasugrel ticagrelor, cilostazol may have"/>
   <result pre="apixaban, betrixaban, edoxaban, rivaroxaban and antiplatelets like clopidogrel, prasugrel ticagrelor," exact="cilostazol" post="may have interactions with COVID âˆ’19 investigational drug. Therefore,"/>
   <result pre="produce inhalable SLMs with stealth effect and deep lung deposition," exact="cisplatin" post="microcrystals were prepared by high pressure homogenization (HPH) in"/>
   <result pre="PEGylated components (DSPE-methyl-PEG conjugate-2000, DSPE-mPEG-2000) or D-Î±-Tocopherol polyethylene glycol 1000" exact="succinate" post="(TPGS) via spray-drying technique. SLMs was explained by the"/>
   <result pre="technique. SLMs was explained by the increased solubilization of un-entrapped" exact="cisplatin" post="microcrystals on SLM surface by PEGylated fractions leading to"/>
   <result pre="or use at targeted site. Joshy et al. reported the" exact="zidovudine" post="loaded polyvinylpyrrolidone (PVP)/stearic acid (SA)-polyethylene glycol (PEG) nanoparticles led"/>
   <result pre="anti-SARS or anti-MARS reagents based on Ag2S NCs [148] 4" exact="Amantadine" post="(Ada), on the outermost layer of PVPâ€&quot;PEG-coated silver nanorods"/>
   <result pre="cytotoxic lymphocytes to produce around eightfold stronger tumor necrosis factor" exact="alpha" post="in vivo Surface modifications of nanomaterials in fundamentally improving"/>
   <result pre="viral protein Nontoxic drug-loaded nanoaggregates inhibit HCV replication at low" exact="camptothecin" post="concentration. [152] 8 Modified dendrimer NPs Venezuelan equine encephalitis"/>
   <result pre="2020). 47Coronavirus (COVID-19) update: FDA revokes emergency use authorization for" exact="chloroquine" post="and hydroxychloroquine|FDA, (n.d). https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-revokes-emergency-use-authorization-chloroquine-and (accessed August 10, 2020). 48PooladandaV.ThatikondaS.GoduguC.The"/>
   <result pre="potential therapeutic options to combat COVID-19Life Sci.254202011776510.1016/j.lfs.2020.117765 49GautretP.LagierJ.C.ParolaP.HoangV.T.MeddedL.MailheM.DoudierB.CourjonJ.GiordanengoV.VieiraV.E.DupontH.T.HonoreS.ColsonP.ChabriereE.La ScolaB.RolainJ.M.BrouquiP.RaoultD.Hydroxychloroquine and" exact="azithromycin" post="as a treatment of COVID-19: preliminary results of an"/>
   <result pre="preliminary results of an open-label non-randomized clinical trialMedRxiv.202010.1101/2020.03.16.200371352020.03.16.20037135 50MagagnoliJ.NarendranS.PereiraF.CummingsT.HardinJ.W.SuttonS.S.AmbatiJ.Outcomes of" exact="hydroxychloroquine" post="usage in United States veterans hospitalized with Covid-19MedRxiv.202010.1101/2020.04.16.200659202020.04.16.20065920 51COVID-19"/>
   <result pre="rodents using large porous particlesAerosol Sci. Technol.32200042143310.1080/027868200303551 71LevetV.RosiÃ¨reR.MerlosR.FusaroL.BergerG.AmighiK.WauthozN.Development of controlled-release" exact="cisplatin" post="dry powders for inhalation against lung cancersInt. J. Pharm.515201620922010.1016/j.ijpharm.2016.10.01927737810"/>
   <result pre="vaccineViral Immunol.312018475410.1089/vim.2017.002429328884 152LancelotA.ClaverÃ­a-GimenoR.VelÃ¡zquez-CampoyA.AbianO.SerranoJ.L.SierraT.Nanostructures based on ammonium-terminated amphiphilic Janus dendrimers as" exact="camptothecin" post="carriers with antiviral activityEur. Polym. J.90201713614910.1016/j.eurpolymj.2017.03.012 153ChahalJ.S.FangT.WoodhamA.W.KhanO.F.LingJ.AndersonD.G.PloeghH.L.An RNA nanoparticle"/>
   <result pre="virus infectionsMater. Sci. Eng. C.89201841342110.1016/j.msec.2018.04.005 157KumarP.LakshmiY.S.KondapiA.K.Triple drug combination of Zidovudine," exact="Efavirenz" post="and lamivudine loaded Lactoferrin nanoparticles: an effective Nano first-line"/>
   <result pre="Sci. Eng. C.89201841342110.1016/j.msec.2018.04.005 157KumarP.LakshmiY.S.KondapiA.K.Triple drug combination of Zidovudine, Efavirenz and" exact="lamivudine" post="loaded Lactoferrin nanoparticles: an effective Nano first-line regimen for"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7445016\results\search\drug\results.xml">
   <result pre="two subfamilies: Orthocoronavirinae and Torovirinae. Subfamily Orthocoronavirinae encompasses four genera:" exact="alpha" post="coronavirus, beta coronavirus, gamma coronavirus, and delta coronavirus [1]."/>
   <result pre="includes drugs like protease inhibitors (lopinavir/ritonavir; darunavir + ritonavir; darunavir/cobicistat);" exact="chloroquine" post="or hydroxychloroquine; tocilizumab, monoclonal antibody against chimeric antigen receptor"/>
   <result pre="receptor T cells; nucleotide inhibitor like remdesivir (a broad-spectrum antiviral);" exact="methylprednisolone" post="20Â mgâ€‰Ã—â€‰2/day; and antibiotic therapy using third-generation cephalosporin, clarithromycin,"/>
   <result pre="20Â mgâ€‰Ã—â€‰2/day; and antibiotic therapy using third-generation cephalosporin, clarithromycin, or" exact="azithromycin" post="or alternatively fluoroquinolones in case of secondary bacterial infections"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7445120\results\search\drug\results.xml">
   <result pre="patients with diabetes. In addition, previous studies have reported that" exact="metformin" post="could increase ACE-2 expression and improve its stability by"/>
   <result pre="than diabetes, white cell count, the percentage of neutrophils, lymphopenia," exact="alanine" post="aminotransferase, aspartate aminotransferase, Î³-glutamyl transferase, creatinine, C-reactive protein (CRP),"/>
   <result pre="(188.0â€&quot;323.0) 0.849 Alanine aminotransferase, U/L 20.0 (13.0â€&quot;33.0) 23.0 (13.3â€&quot;37.0) 0.534" exact="Aspartate" post="aminotransferase, U/L 23.0 (18.0â€&quot;33.0) 25.0 (17.3â€&quot;35.5) 0.479 Alkaline phosphatase,"/>
   <result pre="(166.3â€&quot;312.5) 0.305 Alanine aminotransferase, U/L 23.0 (13.0â€&quot;35.0) 24.0 (16.0â€&quot;39.5) 0.582" exact="Aspartate" post="aminotransferase, U/L 25.0 (16.0â€&quot;33.0) 30.0 (20.5â€&quot;37.0) 0.331 Total bilirubin,"/>
   <result pre="diabetes, 52 (81.3%) patients received antidiabetic treatment during hospitalization, including" exact="metformin" post="(18/52 [34.6%]), insulin (22/52 [42.3%]), Î±-glucosidase inhibitors (26/52 [50.0%]),"/>
   <result pre="metformin (18/52 [34.6%]), insulin (22/52 [42.3%]), Î±-glucosidase inhibitors (26/52 [50.0%])," exact="pioglitazone" post="(6/52 [11.5%]), sulfonylureas (6/52 [11.5%]), dipeptidyl peptidase-4 inhibitors (6/52"/>
   <result pre="[38.9%]), calcium channel blockers (CCBs) (27/36 [75.0%]), Î²-receptor blockers(9/36 [25.0%])," exact="spironolactone" post="(4/36 [11.1%]). Moreover, 10 (10/64 [15.6%]) patients received statins"/>
   <result pre="[17]. Special considerations were also recommended on the use of" exact="metformin" post="due to the lactic acidosis associated with it [26]."/>
   <result pre="However, considering the risk of acute metabolic decompensation caused by" exact="metformin" post="in COVID-19 patients with severe symptoms as well as"/>
   <result pre="in-hospital glycemic control, the safety of the in-hospital use of" exact="metformin" post="needs more studies to explore. There were some limitations"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7446744\results\search\drug\results.xml">
   <result pre="validated by trial results. To target the inflammatory cascade, low-dose" exact="dexamethasone" post="appears to be helpful in moderate to severe cases"/>
   <result pre="(IP10), monocyte chemoattractant protein 1 (MCP1), macrophage inflammatory protein 1" exact="alpha" post="(MIP1A), macrophage inflammatory protein 1 beta (MIP1B), platelet-derived growth"/>
   <result pre="1 beta (MIP1B), platelet-derived growth factor (PDGF), tumor necrosis factor" exact="alpha" post="(TNFÎ±), and vascular endothelial growth factor (VEGF) concentrations on"/>
   <result pre="on clinical outcomes in COVID-19 27 centers, Germany RCT of" exact="rivaroxaban" post="vs. SOC heparin prophylaxis Any thrombosis, all-cause mortality, or"/>
   <result pre="ACTION Trial Multiple centers, Brazil RCT of therapeutic anticoagulation with" exact="rivaroxaban" post="or enoxaparin vs. prophylactic enoxaparin Composite endpoint of mortality,"/>
   <result pre="of full dose or prophylactic dose heparin with or without" exact="clopidogrel" post="Any thrombosis at 28Â days post randomization 750 May"/>
   <result pre="Randomised Controlled Trial Charing Cross Hospital, London, UK RCT of" exact="aspirin" post="or clopidogrel or rivaroxaban with atorvastatin and omeprazole All-cause"/>
   <result pre="Trial Charing Cross Hospital, London, UK RCT of aspirin or" exact="clopidogrel" post="or rivaroxaban with atorvastatin and omeprazole All-cause mortality at"/>
   <result pre="Cross Hospital, London, UK RCT of aspirin or clopidogrel or" exact="rivaroxaban" post="with atorvastatin and omeprazole All-cause mortality at 30Â days"/>
   <result pre="London, UK RCT of aspirin or clopidogrel or rivaroxaban with" exact="atorvastatin" post="and omeprazole All-cause mortality at 30Â days after admission"/>
   <result pre="RCT of aspirin or clopidogrel or rivaroxaban with atorvastatin and" exact="omeprazole" post="All-cause mortality at 30Â days after admission 3170 March"/>
   <result pre="of COVID-19 disease. Unfortunately, the first randomized controlled trial of" exact="methylprednisolone" post="against standard of care in Beijing, China (NCT04244591) had"/>
   <result pre="conducted in the United Kingdom provided preliminary data that low-dose" exact="dexamethasone" post="reduced deaths by one-third in ventilated patients and by"/>
   <result pre="of non-steroidal anti-inflammatory drugs (NSAIDS) as therapy is extremely controversial." exact="Ibuprofen" post="is a commonly used NSAID, which is used for"/>
   <result pre="which is used for fever control, usually with acetaminophen. However," exact="ibuprofen" post="increases the synthesis of ACE2 enzyme and may potentially"/>
   <result pre="Agency (EMA) guidelines published on March 31, 2020 suggest using" exact="acetaminophen" post="for fever but also had advised not to stop"/>
   <result pre="acetaminophen for fever but also had advised not to stop" exact="ibuprofen" post="if the patient is on it for other reasons"/>
   <result pre="there are ongoing trials to assess the efficacy of inhaled" exact="ibuprofen" post="(NCT04382768) and also oral lipid formulation of ibuprofen (LIBERATE"/>
   <result pre="of inhaled ibuprofen (NCT04382768) and also oral lipid formulation of" exact="ibuprofen" post="(LIBERATE trial, Lipid ibuprofen versus standard of care for"/>
   <result pre="and also oral lipid formulation of ibuprofen (LIBERATE trial, Lipid" exact="ibuprofen" post="versus standard of care for acute hypoxemic respiratory failure"/>
   <result pre="in combination with direct-acting anti-viral agents like lopinavir, remdesivir, and" exact="ritonavir" post="to decrease the viral replication, infectivity, as well as"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7447002\results\search\drug\results.xml">
   <result pre="interact with other substances to further compromise the immune system.9,10" exact="Alcohol" post="and other drug use also suppresses immune responses,11â€&quot;13 particularly"/>
   <result pre="(alpha = 0.87) and the 3-item consumption subscale of the" exact="Alcohol" post="Use Disorders Identification Test (AUDIT-C).24,25 To assess food insecurity,"/>
   <result pre="(viral load), participants provided 80 ÂµL of fingerstick blood for" exact="dried" post="blood spots collected in HemaSpot HF devices that were"/>
   <result pre="typically smoked, posing specific risks for compromised lung function.32 For" exact="alcohol" post="use, we used the 500 ng/mL cutoff for ethyl"/>
   <result pre="J Med Virol.2020. doi: 10.1002/jmv.25889. 9.KarolyHCBidwellLCMuellerRLet al.Investigating the relationships between" exact="alcohol" post="consumption, cannabis use, and circulating cytokines: a preliminary analysis."/>
   <result pre="alcohol consumption, cannabis use, and circulating cytokines: a preliminary analysis." exact="Alcohol" post="Clin Exp Res.2018;42:531â€&quot;539.29286537 10.ShoptawSStallRBordonJet al.Cumulative exposure to stimulants and"/>
   <result pre="Cohort Study. Int J STD AIDS.2012;23:576â€&quot;580.22930295 11.BarrTHelmsCGrantKet al.Opposing effects of" exact="alcohol" post="on the immune system. Prog Neuropsychopharmacol Biol Psychiatry.2016;65:242â€&quot;251.26375241 12.CarricoAWHorvathKJGrovCet"/>
   <result pre="antiretroviral therapy. Curr HIV Res.2018;16:143â€&quot;150.29968539 14.MonnigMAImmune activation and neuroinflammation in" exact="alcohol" post="use and HIV infection: evidence for shared mechanisms. Am"/>
   <result pre="and HIV infection: evidence for shared mechanisms. Am J Drug" exact="Alcohol" post="Abuse.2017;43:7â€&quot;23.27532935 15.GaydosJMcNallyAGuoRet al.Alcohol abuse and smoking alter inflammatory mediator"/>
   <result pre="and protocols. AIDS Behav.2020. doi: 10.1007/s10461-020-02837-x. 24.SaundersJBAaslandOGBaborTFet al.Development of the" exact="Alcohol" post="Use Disorders Identification Test (AUDIT): WHO collaborative project on"/>
   <result pre="WHO collaborative project on early detection of persons with harmful" exact="alcohol" post="consumption II. Addictions.1993;88:791â€&quot;804. 25.MaistoSAConigliaroJMcNeilMet al.An empirical investigation of the"/>
   <result pre="EtG and EtS in urine and PEth species in capillary" exact="dried" post="blood spots to assess the alcohol consumption in driver's"/>
   <result pre="PEth species in capillary dried blood spots to assess the" exact="alcohol" post="consumption in driver's licence regranting cases. Drug Alcohol Depend.2016;165:191â€&quot;197.27364378"/>
   <result pre="assess the alcohol consumption in driver's licence regranting cases. Drug" exact="Alcohol" post="Depend.2016;165:191â€&quot;197.27364378 34.HumeniukRAliRBaborTFet al.Validation of the alcohol, smoking and substance"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7448857\results\search\drug\results.xml">
   <result pre="to cause epidemics worldwide. Different compounds, such as remdesivir and" exact="chloroquine" post="have been reported to inhibit SARS-CoV-2 replication effectively in"/>
   <result pre="lycorine and oxysophoridine against SARS-CoV-2 infection in cell culture, and" exact="chloroquine" post="was used as a positive control [1]. Vero-E6 cells"/>
   <result pre="exhibited dose-dependent inhibition of 2019-CoV replication in infected cells as" exact="chloroquine" post="(Figure 1(A)). The EC50 values of gemcitabine, lycorine, oxysophoridine"/>
   <result pre="(Figure 1(A)). The EC50 values of gemcitabine, lycorine, oxysophoridine and" exact="chloroquine" post="were 1.24, 0.31, 0.18 and 1.36â€…Î¼M, respectively. To confirm"/>
   <result pre="CaoR, ZhangL, YangX, LiuJ, XuM, ShiZ, HuZ, ZhongW, XiaoG.2020Remdesivir and" exact="chloroquine" post="effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7449072\results\search\drug\results.xml">
   <result pre="with high-level resistance to all NRTIs, first generation NNRTIs, all" exact="ritonavir" post="boosted protease inhibitors (PI/r), and all INSTI, while viral"/>
   <result pre="a false positive rate (FPR) of 60.9% suggesting effectiveness of" exact="maraviroc" post="(MRV). The third GRT showed high-level resistance to NRTI,"/>
   <result pre="for 14 years (since 2006). His initial ART regimen was" exact="stavudine" post="(d4T)â€‰+â€‰lamivudine (3TC)â€‰+â€‰nevirapine (NVP) from August 2006 to August 2007."/>
   <result pre="August 2006 to August 2007. NVP was subsequently replaced by" exact="efavirenz" post="(EFV) from August 2007 to August 2009. From August"/>
   <result pre="Following clinical assessment, he received a regimen consisting of super-boosted" exact="ritonavir" post="with darunavir (DRV/r)â€‰+â€‰raltegravir (RAL)â€‰+â€‰tenofovir (TDF) +3TC (unclear start date)"/>
   <result pre="clinical assessment, he was re-initiated with a regimen consisting of" exact="ritonavir" post="boosted darunavir (DRV/r)â€‰+â€‰raltegravir (RAL)â€‰+â€‰tenofovir (TDF) +3TC (unclear start date)"/>
   <result pre="mutational profile suggested DRV/r(600â€‰mg Ã—â€‰2/day)â€‰+â€‰DTG(50â€‰mg Ã—â€‰2/day), possibly associated with ritonavir-boosted" exact="atazanavir" post="(ATV/r) for its potential capacity to enhance DTG concentrations"/>
   <result pre="E157Q, to integrase strand transfer inhibitors (INSTI) including raltegravir, dolutegravir," exact="bictegravir" post="and elvitegravir. Viral tropism revealed a CCR5-tropic virus, defined"/>
   <result pre="a false positive rate (FPR) of 60.9%, suggesting eligibility for" exact="maraviroc" post="(MRV). The third GRT (August 08, 2019), encompassing PR,"/>
   <result pre="drugs in resource-limited settings with similar ART landscapes. Abbreviations 3TC" exact="Emtricitabine" post="ABC Abacavir ADR Acquired drug resistance AIDS Acquired Immunodeficiency"/>
   <result pre="resource-limited settings with similar ART landscapes. Abbreviations 3TC Emtricitabine ABC" exact="Abacavir" post="ADR Acquired drug resistance AIDS Acquired Immunodeficiency Syndrome ART"/>
   <result pre="drug resistance AIDS Acquired Immunodeficiency Syndrome ART Antiretroviral therapy ATV/r" exact="Ritonavir" post="boosted Atazanavir CCR5 C-C chemokine receptor type 5 CD4"/>
   <result pre="AIDS Acquired Immunodeficiency Syndrome ART Antiretroviral therapy ATV/r Ritonavir boosted" exact="Atazanavir" post="CCR5 C-C chemokine receptor type 5 CD4 Cluster of"/>
   <result pre="of differentiation four CRF18_cpx Circulating recombinant form complex 18 D4T" exact="Stavudine" post="DRV/r Ritonavir boosted Darunavir DTG Dolutegravir EFV Efavirenz FPR"/>
   <result pre="four CRF18_cpx Circulating recombinant form complex 18 D4T Stavudine DRV/r" exact="Ritonavir" post="boosted Darunavir DTG Dolutegravir EFV Efavirenz FPR False positive"/>
   <result pre="18 D4T Stavudine DRV/r Ritonavir boosted Darunavir DTG Dolutegravir EFV" exact="Efavirenz" post="FPR False positive rate GP 120 Envelope glycoprotein 120"/>
   <result pre="drug resistance IN Integrase INSTI Integrase strand transfer inhibitor LPV/r" exact="Ritonavir" post="boosted Lopinavir MRV Maraviroc NNRTI Non-nucleoside reverse-transcriptase inhibitor NRTI"/>
   <result pre="Maraviroc NNRTI Non-nucleoside reverse-transcriptase inhibitor NRTI Nucleoside reverse-transcriptase inhibitor NVP" exact="Nevirapine" post="PDR Pretreatment drug resistance PI/r ritonavir boosted protease inhibitor"/>
   <result pre="Nucleoside reverse-transcriptase inhibitor NVP Nevirapine PDR Pretreatment drug resistance PI/r" exact="ritonavir" post="boosted protease inhibitor Pol Polymerase PR Protease RAL Raltegravir"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7449407\results\search\drug\results.xml">
   <result pre="Sciences : Pharmacology : Behavioral Pharmacology : Recreational Drug Use:" exact="Heroin" post=": Medicine and Health Sciences : Pharmacology : Drugs"/>
   <result pre="study identifies and characterizes user-generated messages related to opioid abuse," exact="heroin" post="injection drug use, and HIV status using natural language"/>
   <result pre="risk factors related to HIV transmission stemming from opioid and" exact="heroin" post="abuse for priority populations, and also help identify community"/>
   <result pre="health community about the dangerous connection between prescription opioid abuse," exact="heroin" post="injection drug use (IDU), lack of access to needle"/>
   <result pre="detect, classify and characterize Twitter messages associated with opioid abuse," exact="heroin" post="injection drug use, and HIV user behaviors and attitudes."/>
   <result pre="our dataset for common â€œstreetâ€� or â€œslangâ€� terms associated with" exact="heroin" post="and IDU and prescription opioid drug abuse (see Table"/>
   <result pre="Keywords used for filtering. Category: Keywords: HIV HIV, AIDS, HIV/AIDS" exact="Heroin" post="Heroin, smack, speedball, screwball, tar, black tar, skag, china"/>
   <result pre="or product sourcing, self-reported injection drug use or mention of" exact="heroin" post="use, self-report of HIV-risk related behaviors (e.g. unprotected sex,"/>
   <result pre="Indiana that included keywords related to HIV (n = 487)," exact="heroin" post="(n = 592), injection drug use (271), and opioids"/>
   <result pre="associated with HIV, 37.2% (n = 133) were associated with" exact="heroin" post="IDU, and 20.9% (n = 75) were associated with"/>
   <result pre="a total of 133 tweets were identified as related to" exact="heroin" post="IDU, and 75 tweets were related to opioid use"/>
   <result pre="included specific discussion of types of opioid use, mention of" exact="heroin" post="injection behavior, reporting of HIV status, and public sentiment"/>
   <result pre="Heroin:Â Â Â Â 1. People in garrett are mixing" exact="heroin" post="and meth and shooting it upâ€¦upper and a downer"/>
   <result pre="weed as I walked in the door. And then for" exact="heroin" post="as I left. (Usage)Â Â Â Â 3. apparently"/>
   <result pre="heroin as I left. (Usage)Â Â Â Â 3. apparently" exact="heroin" post="is the new cute to do lmao (Usage)Â Â"/>
   <result pre="to hit me up almost daily got arrested for dealing" exact="heroin" post="last weekâ€¦glad I attract scumbags (Diversion)Â Â Â Â"/>
   <result pre="Â Â Â 5. Iâ€™m gnoing home and ovredsoing on" exact="heroin" post="and cOCaine (Overdose)Â Â Â Â 6. Such a"/>
   <result pre="6. Such a fucked up world anymore I can get" exact="heroin" post="10 times easier than weed (Diversion)Â Â Â Â"/>
   <result pre="weed (Diversion)Â Â Â Â 7. Lol people were doing" exact="Heroin" post="at Bridge 11. Never again (Usage) Heroin (street/slang):Â Â"/>
   <result pre="people were doing Heroin at Bridge 11. Never again (Usage)" exact="Heroin" post="(street/slang):Â Â Â Â 1. In need of a"/>
   <result pre="AND I have HIV EWWWWWW (Status)Â Â Â Â 4." exact="Today" post="in class I talked about how the government spread"/>
   <result pre="documenting or alleging substance use by other users, self-reporting future" exact="heroin" post="or prescription drug abuse, and commenting about substance use"/>
   <result pre="about heroin-related overdose, and 11 tweets specifically reported injection of" exact="heroin" post="by users. Importantly, tweets related specifically to injection reported"/>
   <result pre="signal tweets in Indiana. In addition, we found tweets self-reporting" exact="heroin" post="and prescription drug abuse-related behavior from the neighboring Clark"/>
   <result pre="Such tweets included: â€œI just witnessed someone die of a" exact="heroin" post="overdoseâ€� (October 2014); â€œNow thats it 2015 im finally"/>
   <result pre="â€œNow thats it 2015 im finally going to kick my" exact="heroin" post="addiction #newyearnewmeâ€� (January 2015); and â€œin for the meth"/>
   <result pre="detect messages related to user behavior associated with opioid abuse," exact="heroin" post="injection drug use, and HIV, critical elements of the"/>
   <result pre="the most common theme identified was opioid use, followed by" exact="heroin" post="abuse. In Indiana, between 2005 and 2014, hospital admissions"/>
   <result pre="abuse. In Indiana, between 2005 and 2014, hospital admissions for" exact="heroin" post="and prescription drug abuse increased 413% and 155% respectively,"/>
   <result pre="state [22]. In our dataset, we detected tweets self-reporting both" exact="heroin" post="and opioid use, including examples of IDU and reports"/>
   <result pre="rural users [2]. This epidemiological profile is similar to current" exact="heroin" post="users in the United States, potentially indicating that the"/>
   <result pre="users at higher risk for transition from opioid abuse to" exact="heroin" post="injection drug use [2]. Our study design identified behavioral"/>
   <result pre="drug use [2]. Our study design identified behavioral tweets reporting" exact="heroin" post="injection drug use, opioid use, and HIV status, and"/>
   <result pre="remain to interrupting the dangerous transition from opioid abuse to" exact="heroin" post="injection drug use and its associated HIV transmission risks,"/>
   <result pre="PontonesP, HooverKW, et al.HIV infection linked to injection use of" exact="oxymorphone" post="in Indiana, 2014â€&quot;2015. N Engl J Med. 20167;375:229â€&quot;39. 10.1056/NEJMoa151519527468059"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7449465\results\search\drug\results.xml">
   <result pre="the efficacy of BCG vaccine in COVID-19 patients [76]. Similarly," exact="vitamin C" post="could also be used as an adjunct therapy since"/>
   <result pre="hypoxia [77]. A clinical trial to study the efficacy of" exact="vitamin C" post="infusion for COVID-19 patients with severe pneumonia is also"/>
   <result pre="treated with triple therapy of IFN-Î²1b, and antivirals lopinavir-ritonavir and" exact="ribavirin" post="[87]. Similarly, IL-6 blockade could attenuate immune cell mediated"/>
   <result pre="10.1016/j.jcyt.2015.01.004 .25747742 78CarrAC. A new clinical trial to test high-dose" exact="vitamin C" post="in patients with COVID-19. Crit Care. 2020;24(1):133 Epub 2020/04/09."/>
   <result pre="ChungTWH, ChuMY, et al.Triple combination of interferon beta-1b lopinavir-ritonavir, and" exact="ribavirin" post="in the treatment of patients admitted to hospital with"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7449622\results\search\drug\results.xml">
   <result pre="antiviral drugs such as oseltamivir, zanamivir, and baloxavir. Oseltamivir and" exact="zanamivir" post="are approved neuraminidase (NA) inhibitors (4). Using standard in"/>
   <result pre="vitro NA inhibition assays, we determined that both oseltamivir and" exact="zanamivir" post="potently inhibit the NA activity of WSN/33-Renilla IAV-like particles"/>
   <result pre="drug sensitivities similar to those of authentic IAVs. Oseltamivir and" exact="zanamivir" post="sensitivity of WSN/33 and WSN/33-Renilla IAV particles (A and"/>
   <result pre="in vitro NA inhibition assays revealed that both oseltamivir and" exact="zanamivir" post="inhibit the NA activity of Viet/04-T-Renilla IAV-like particles with"/>
   <result pre="reporter with gain-of-function HA amino acid substitutions. Oseltamivir carboxylate and" exact="zanamivir" post="sensitivity of Viet/04-Renilla and Viet/04-T-Renilla IAV particles (A and"/>
   <result pre="concentrations of oseltamivir carboxylate (no. sc-212484; Santa Cruz Biotechnology) or" exact="zanamivir" post="(no. SML0492; Sigma-Aldrich), and chemiluminescence was measured with the"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7451040\results\search\drug\results.xml">
   <result pre="of the original COVID-19 outbreak has recommended the use of" exact="chloroquine" post="for treatment of mild, moderate and severe pneumonia during"/>
   <result pre="of Guangdong Province and Health Commission of Guangdong Province for" exact="chloroquine" post="in the treatment of novel coronavirus pneumonia[Expert consensus on"/>
   <result pre="chloroquine in the treatment of novel coronavirus pneumonia[Expert consensus on" exact="chloroquine" post="phosphate for the treatment of novel coronavirus pneumonia]Chinese Journal"/>
   <result pre="Disease202043E01910.3760/cma.j.issn.1001-0939.2020.001932075365 25.CortegianiAIngogliaGIppolitoMGiarratanoAEinavSA systematic review on the efficacy and safety of" exact="chloroquine" post="for the treatment of COVID-19J Crit Care202010:S0883-9441(20)30390-710.1016/j.jcrc.2020.03.005 26AhmedSFQuadeerAAMcKayMRPreliminary identification"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7451056\results\search\drug\results.xml">
   <result pre="taken into account when battling a viral infection. For instance," exact="camostat" post="mesylate, a TMPRSS2 inhibitor and drug used to treat"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7451121\results\search\drug\results.xml">
   <result pre="as to restriction, are most suitableâ€� [1]. The antimalarial drug" exact="chloroquine" post="and its safer derivative hydroxy-chloroquine (C18H26ClN3O) have been used"/>
   <result pre="lupus erythematosus (SLE), rheumatoid arthritis (RA) and SjÃ¶gren syndrome [2]." exact="Chloroquine" post="and hydroxy-chloroquine appear to block viral entry into cells"/>
   <result pre="in host cells [3], [4], [5], [6]. The use of" exact="chloroquine" post="and of hydroxy-chloroquine-related compounds in the treatment of COVID-19"/>
   <result pre="showed antiviral activity (in vitro) against SARS coronavirus [8]. Recently" exact="chloroquine" post="[9] and hydroxyl-chloroquine [10] have also been found to"/>
   <result pre="reported to be due to misuse of hydroxy-chloroquine, or even" exact="chloroquine" post="(although this drug is not part of the therapeutic"/>
   <result pre="overdose of aspirin; official dosage recommendations are clearly excessive [21]." exact="Amantadine" post="was originally introduced as an antiviral drug to treat"/>
   <result pre="patients noticed relief in their Parkinson disease symptoms after taking" exact="amantadine" post="for influenza. This clinical observation sparked an initial interest,"/>
   <result pre="eventually led to a new indication of this drug. Interestingly" exact="amantadine" post="is discarded as influenza medication nowadays for lack of"/>
   <result pre="Aphorisms 1,6. LittrÃ© edition [Translation by the authors]. 2SavarinoA.BoelaertJ.R.CassoneA.MajoriG.CaudaR.Effects of" exact="chloroquine" post="on viral infections: an old drug against today's diseases?Lancet"/>
   <result pre="in press] 4ZhouD.DaiS.M.TongQ.COVID-19: a recommendation to examine the effect of" exact="hydroxychloroquine" post="in preventing infection and progressionJ Antimicrob Chemother2020dkaa11410.1093/jac/dkaa114[Published online March"/>
   <result pre="online March 11, 2020. Article in press] 6OwenB.2020, Excitement around" exact="hydroxychloroquine" post="for treating COVID-19 causes challenges for rheumatologyLancet202010.1016/S2665-9913(20)30089-8[Published online April"/>
   <result pre="inhibitor of SARS coronavirus infection and spreadVirol J220056910.1186/1743-422X-2-6916115318 9WangM.CaoR.ZhangL.Remdesivir and" exact="chloroquine" post="effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in"/>
   <result pre="vitro antiviral activity and projection of optimized dosing design of" exact="hydroxychloroquine" post="for the treatment of Severe Acute Respiratory Syndrome Coronavirus"/>
   <result pre="Syndrome Coronavirus 2 (SARS-CoV-2)Clin Infect Dis202010.1093/cid/ciaa237[Article in press] 11GautretP.LagierJ.C.ParolaP.Hydroxychloroquine and" exact="azithromycin" post="as a treatment of COVID-19: results of an open"/>
   <result pre="non-randomised clinical trialInt J Antimicrob Agents202010594910.1016/j.ijantimicag.2020.105949[Article in press] 12RolainJ.-M.ColsonP.RaoultD.Recycling of" exact="chloroquine" post="and its hydroxyl analogue to face bacterial, fungal and"/>
   <result pre="infections in the 21st centuryInt J Antimicrobial Agents302007297308 13ColsonP.RolainJ.-M.LagierJ.-C.BrouquiP.RaoultD.Chloroquine and" exact="hydroxychloroquine" post="as available weapons to fight COVID-19Int J Antimicrobial Agents202010.1016/j.ijantimicag.2020.105932[Article"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7452913\results\search\drug\results.xml">
   <result pre="of the Food and Drug Administration (FDA) approved antiviral drugs." exact="Simeprevir" post="(SMV), Paritaprevir (PTV) and Grazoprevir (GZR) were the common"/>
   <result pre="Food and Drug Administration (FDA) approved antiviral drugs. Simeprevir (SMV)," exact="Paritaprevir" post="(PTV) and Grazoprevir (GZR) were the common leads identified"/>
   <result pre="non-structural proteins PDB, protein data bank PLpro, papain-like proteinase PTV," exact="Paritaprevir" post="RdRp, RNA-dependent RNA polymerase RMSD, root mean square deviation"/>
   <result pre="2 SAVES, Structure Analysis and Verification Server SF, Sinefungin SMV," exact="Simeprevir" post="TMHs, transmembrane helices ZBD, zinc binding domain Keywords SARS-CoV-2"/>
   <result pre="docking studies. Table 1 Drugs Abbreviation PubChem ID Inhibitors class" exact="Idoxuridine" post="IDU 5905 5-Substituted 2â€²-deoxyuridine analogues Trifluridine TFT 6256 Brivudine"/>
   <result pre="5905 5-Substituted 2â€²-deoxyuridine analogues Trifluridine TFT 6256 Brivudine BVDU 446727" exact="Vidarabine" post="VDR 21704 Nucleoside analogues Entecavir ETV 135398508 Telbivudine LdT"/>
   <result pre="TFT 6256 Brivudine BVDU 446727 Vidarabine VDR 21704 Nucleoside analogues" exact="Entecavir" post="ETV 135398508 Telbivudine LdT 159269 Foscarnet PFA 3415 Pyrophosphate"/>
   <result pre="BVDU 446727 Vidarabine VDR 21704 Nucleoside analogues Entecavir ETV 135398508" exact="Telbivudine" post="LdT 159269 Foscarnet PFA 3415 Pyrophosphate analogues Zidovudine AZT"/>
   <result pre="ETV 135398508 Telbivudine LdT 159269 Foscarnet PFA 3415 Pyrophosphate analogues" exact="Zidovudine" post="AZT 35370 Nucleoside reverse transcriptase (RT) inhibitors (NRTIs) Didanosine"/>
   <result pre="35370 Nucleoside reverse transcriptase (RT) inhibitors (NRTIs) Didanosine ddI 135398739" exact="Zalcitabine" post="ddC 24066 Stavudine d4T 18283 Lamivudine 3TC 60825 Abacavir"/>
   <result pre="transcriptase (RT) inhibitors (NRTIs) Didanosine ddI 135398739 Zalcitabine ddC 24066" exact="Stavudine" post="d4T 18283 Lamivudine 3TC 60825 Abacavir ABC 441300 Emtricitabine"/>
   <result pre="(NRTIs) Didanosine ddI 135398739 Zalcitabine ddC 24066 Stavudine d4T 18283" exact="Lamivudine" post="3TC 60825 Abacavir ABC 441300 Emtricitabine (âˆ’)FTC 60877 Nevirapine"/>
   <result pre="135398739 Zalcitabine ddC 24066 Stavudine d4T 18283 Lamivudine 3TC 60825" exact="Abacavir" post="ABC 441300 Emtricitabine (âˆ’)FTC 60877 Nevirapine NVP 4463 Nonnucleoside"/>
   <result pre="24066 Stavudine d4T 18283 Lamivudine 3TC 60825 Abacavir ABC 441300" exact="Emtricitabine" post="(âˆ’)FTC 60877 Nevirapine NVP 4463 Nonnucleoside reverse transcriptase inhibitors"/>
   <result pre="18283 Lamivudine 3TC 60825 Abacavir ABC 441300 Emtricitabine (âˆ’)FTC 60877" exact="Nevirapine" post="NVP 4463 Nonnucleoside reverse transcriptase inhibitors (NNRTIs) Delavirdine DLV"/>
   <result pre="NVP 4463 Nonnucleoside reverse transcriptase inhibitors (NNRTIs) Delavirdine DLV 5625" exact="Efavirenz" post="EFV 64139 Etravirine ETR 193962 Rilpivirine RPV 6451164 Saquinavir"/>
   <result pre="reverse transcriptase inhibitors (NNRTIs) Delavirdine DLV 5625 Efavirenz EFV 64139" exact="Etravirine" post="ETR 193962 Rilpivirine RPV 6451164 Saquinavir SQV 441243 Protease"/>
   <result pre="5625 Efavirenz EFV 64139 Etravirine ETR 193962 Rilpivirine RPV 6451164" exact="Saquinavir" post="SQV 441243 Protease inhibitors Ritonavir RTV 392622 Indinavir IDV"/>
   <result pre="ETR 193962 Rilpivirine RPV 6451164 Saquinavir SQV 441243 Protease inhibitors" exact="Ritonavir" post="RTV 392622 Indinavir IDV 5362440 Nelfinavir NFV 64143 Amprenavir"/>
   <result pre="SQV 441243 Protease inhibitors Ritonavir RTV 392622 Indinavir IDV 5362440" exact="Nelfinavir" post="NFV 64143 Amprenavir APV 65016 Atazanavir ATV 148192 Fosamprenavir"/>
   <result pre="392622 Indinavir IDV 5362440 Nelfinavir NFV 64143 Amprenavir APV 65016" exact="Atazanavir" post="ATV 148192 Fosamprenavir FPV 131536 Tipranavir TPV 54682461 Darunavir"/>
   <result pre="5362440 Nelfinavir NFV 64143 Amprenavir APV 65016 Atazanavir ATV 148192" exact="Fosamprenavir" post="FPV 131536 Tipranavir TPV 54682461 Darunavir DRV 213039 Telaprevir"/>
   <result pre="64143 Amprenavir APV 65016 Atazanavir ATV 148192 Fosamprenavir FPV 131536" exact="Tipranavir" post="TPV 54682461 Darunavir DRV 213039 Telaprevir TVR 3010818 Boceprevir"/>
   <result pre="148192 Fosamprenavir FPV 131536 Tipranavir TPV 54682461 Darunavir DRV 213039" exact="Telaprevir" post="TVR 3010818 Boceprevir BOC 10324367 Simeprevir SMV 24873435 Asunaprevir"/>
   <result pre="54682461 Darunavir DRV 213039 Telaprevir TVR 3010818 Boceprevir BOC 10324367" exact="Simeprevir" post="SMV 24873435 Asunaprevir ASV 16076883 Paritaprevir PTV 45110509 Grazoprevir"/>
   <result pre="3010818 Boceprevir BOC 10324367 Simeprevir SMV 24873435 Asunaprevir ASV 16076883" exact="Paritaprevir" post="PTV 45110509 Grazoprevir GZR 44603531 Raltegravir RAL 54671008 Integrase"/>
   <result pre="inhibitors Maraviroc MVC 3002977 Acyclovir ACV 135398513 Acyclic guanosine analogues" exact="Ganciclovir" post="GCV 135398740 Famciclovir FCV 3324 Valacyclovir VACV 135398742 Penciclovir"/>
   <result pre="3002977 Acyclovir ACV 135398513 Acyclic guanosine analogues Ganciclovir GCV 135398740" exact="Famciclovir" post="FCV 3324 Valacyclovir VACV 135398742 Penciclovir PCV 135398748 Valganciclovir"/>
   <result pre="135398513 Acyclic guanosine analogues Ganciclovir GCV 135398740 Famciclovir FCV 3324" exact="Valacyclovir" post="VACV 135398742 Penciclovir PCV 135398748 Valganciclovir VGCV 135413535 Cidofovir"/>
   <result pre="analogues Ganciclovir GCV 135398740 Famciclovir FCV 3324 Valacyclovir VACV 135398742" exact="Penciclovir" post="PCV 135398748 Valganciclovir VGCV 135413535 Cidofovir CDV 60613 Acyclic"/>
   <result pre="135398740 Famciclovir FCV 3324 Valacyclovir VACV 135398742 Penciclovir PCV 135398748" exact="Valganciclovir" post="VGCV 135413535 Cidofovir CDV 60613 Acyclic nucleoside phosphonate analogues"/>
   <result pre="3324 Valacyclovir VACV 135398742 Penciclovir PCV 135398748 Valganciclovir VGCV 135413535" exact="Cidofovir" post="CDV 60613 Acyclic nucleoside phosphonate analogues Amantadine AMT 2130"/>
   <result pre="Valganciclovir VGCV 135413535 Cidofovir CDV 60613 Acyclic nucleoside phosphonate analogues" exact="Amantadine" post="AMT 2130 Influenza virus inhibitors Ribavirin RBV 37542 Rimantadine"/>
   <result pre="Acyclic nucleoside phosphonate analogues Amantadine AMT 2130 Influenza virus inhibitors" exact="Ribavirin" post="RBV 37542 Rimantadine RIM 5071 Zanamivir ZAN 60855 Oseltamivir"/>
   <result pre="analogues Amantadine AMT 2130 Influenza virus inhibitors Ribavirin RBV 37542" exact="Rimantadine" post="RIM 5071 Zanamivir ZAN 60855 Oseltamivir OTV 65028 Laninamivir"/>
   <result pre="2130 Influenza virus inhibitors Ribavirin RBV 37542 Rimantadine RIM 5071" exact="Zanamivir" post="ZAN 60855 Oseltamivir OTV 65028 Laninamivir octanoate LO 9847629"/>
   <result pre="Zanamivir ZAN 60855 Oseltamivir OTV 65028 Laninamivir octanoate LO 9847629" exact="Peramivir" post="PRV 154234 Favipiravir FPV 492405 2.10 Preparation of protein"/>
   <result pre="that 17.64%, 26.29% and 56.07% of residues are present in" exact="alpha" post="helix, extended strand and random coil respectively (Suppl. Table"/>
   <result pre="protein, 13.85%, 29.79% and 56.36% of residues are present in" exact="alpha" post="helix, extended strand and random coil respectively. 3.3 TMHMM"/>
   <result pre="al., 2012b; Yu et al., 2012). Three lead molecules-Simeprevir (SMV)," exact="Paritaprevir" post="(PTV) and Grazoprevir (GZR) for SARS-CoV-2 Nsp13 helicase enzyme"/>
   <result pre="Structure SARS-CoV-2 Nsp13 helicase Binding energy (kcal/mol) Inhibition constant (Ki)" exact="Simeprevir" post="(SMV) Image 1 âˆ’10.42 23.00Â nM Paritaprevir (PTV) Image"/>
   <result pre="Inhibition constant (Ki) Simeprevir (SMV) Image 1 âˆ’10.42 23.00Â nM" exact="Paritaprevir" post="(PTV) Image 2 âˆ’9.70 78.25Â nM Grazoprevir (GZR) Image"/>
   <result pre="and molecular interaction between SARS-CoV-2 Nsp13 helicase enzyme and (B)" exact="Simeprevir" post="(SMV) (C) Paritaprevir (PTV) (D) Grazoprevir (GZR) (E) Scutellarin"/>
   <result pre="between SARS-CoV-2 Nsp13 helicase enzyme and (B) Simeprevir (SMV) (C)" exact="Paritaprevir" post="(PTV) (D) Grazoprevir (GZR) (E) Scutellarin (control inhibitor). The"/>
   <result pre="Molecule Structure SARS-CoV-2 Nsp14 Binding energy (kcal/mol) Inhibition constant (Ki)" exact="Paritaprevir" post="(PTV) Image 8 âˆ’13.29 181.23 pM Simeprevir (SMV) Image"/>
   <result pre="Inhibition constant (Ki) Paritaprevir (PTV) Image 8 âˆ’13.29 181.23 pM" exact="Simeprevir" post="(SMV) Image 9 âˆ’13.26 190.01 pM Grazoprevir (GZR) Image"/>
   <result pre="binding conformation and molecular interaction between SARS-CoV-2 Nsp14 and (B)" exact="Paritaprevir" post="(PTV) (C) Simeprevir (SMV) (D) Grazoprevir (GZR) (E) Sinefungin"/>
   <result pre="molecular interaction between SARS-CoV-2 Nsp14 and (B) Paritaprevir (PTV) (C)" exact="Simeprevir" post="(SMV) (D) Grazoprevir (GZR) (E) Sinefungin (control inhibitor). The"/>
   <result pre="(De Clercq and Li, 2016). Interestingly, the top 3 hits-" exact="Simeprevir" post="(SMV), Paritaprevir (PTV) and Grazoprevir (GZR) were also the"/>
   <result pre="and Li, 2016). Interestingly, the top 3 hits- Simeprevir (SMV)," exact="Paritaprevir" post="(PTV) and Grazoprevir (GZR) were also the top leads"/>
   <result pre="a set of FDA approved antiviral drugs. Three potential inhibitors-" exact="Simeprevir" post="(SMV), Paritaprevir (PTV) and Grazoprevir (GZR) were identified which"/>
   <result pre="of FDA approved antiviral drugs. Three potential inhibitors- Simeprevir (SMV)," exact="Paritaprevir" post="(PTV) and Grazoprevir (GZR) were identified which show dual"/>
   <result pre="screening identifies Pranlukast as a potential inhibitor against Plasmodium falciparum" exact="Adenosine" post="Deaminase enzymeGene Rep.62017546610.1016/j.genrep.2016.12.003 HalgrenT.A.Merck molecular force field. I. Basis,"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7453465\results\search\drug\results.xml">
   <result pre="various cell lines and in rhesus macaques. Interferon-alpha 2b and" exact="ribavirin" post="have a synergistic effect on SARS-CoV-1 and MERS-CoV in"/>
   <result pre="releases specific inflammatory and acute phase response biomolecules (aspartate transaminase," exact="alanine" post="transaminase, bilirubin, C-reactive Protein [CRP], fibrinogen and IL-6) that"/>
   <result pre="erythrocyte sedimentation rate, IL-6, lactate dehydrogenase, D-dimer, ferritin, troponin and" exact="creatine" post="kinase-MB. Imaging investigations are typically computed tomography scans: in"/>
   <result pre="in response to tissue damage (elevated levels of D-dimer, ferritin," exact="creatine" post="kinase-MB, and troponin) have been associated with higher mortality"/>
   <result pre="overload. To reduce fever, antipyretic drugs such as paracetamol or" exact="acetaminophen" post="can be administered. Drugs such as remdesivir, chloroquine, ritonavir,"/>
   <result pre="effectiveness has not yet been confirmed.88â€&quot;93 Unfortunately, the use of" exact="chloroquine" post="and derivatives such as hydroxychloroquine, alone or in combination"/>
   <result pre="is currently in phase 2 clinical trials. The protein inhibitor" exact="ritonavir" post="has also been proposed for the treatment of COVID-19."/>
   <result pre="of cellular stress responses.99 The ligands haloperidol, PB28, PD-144418, and" exact="hydroxychloroquine" post="are currently undergoing clinical trials in COVID-19 patients.100 These"/>
   <result pre="after viral entry has occurred. The lack of selectivity of" exact="chloroquine" post="and hydroxychloroquine, including off-target effects on the human Ether-Ã"/>
   <result pre="84LiJYDuanXFWangLP, et al.Selective depletion of regulatory T cell subsets by" exact="docetaxel" post="treatment in patients with non-small cell lung cancer. J"/>
   <result pre="2019-new coronavirus (2019-nCoV).Biosci Trends2020; 14: 69â€&quot;71.31996494 89WangMCaoRZhangL, et al.Remdesivir and" exact="chloroquine" post="effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in"/>
   <result pre="coronavirus SARS-CoV-2. Int J Antimicrob Agents2020; 55: 105923.32070753 93KapoorKMKapoorA.Role of" exact="chloroquine" post="and hydroxychloroquine in the treatment of COVID-19 infection â€&quot;"/>
   <result pre="Int J Antimicrob Agents2020; 55: 105923.32070753 93KapoorKMKapoorA.Role of chloroquine and" exact="hydroxychloroquine" post="in the treatment of COVID-19 infection â€&quot; a systematic"/>
   <result pre="â€&quot; a systematic literature review. medRxiv2020. 94MehraMRDesaiSSRuschitzkaF, et al.Hydroxychloroquine or" exact="chloroquine" post="with or without a macrolide for treatment of COVID-19:"/>
   <result pre="congenital microcephaly in mice.EBioMedicine2017; 24: 189â€&quot;194.29033372 96LiuXChenGShangY, et al.Efficacy of" exact="chloroquine" post="versus lopinavir/ritonavir in mild/general COVID-19 infection: A prospective, open-label,"/>
   <result pre="vitro antiviral activity and projection of optimized dosing design of" exact="hydroxychloroquine" post="for the treatment of severe acute respiratory syndrome coronavirus"/>
   <result pre="Commun2011; 415: 519â€&quot;525.22079628 100ThompsonBT. Outcomes related to COVID-19 treated with" exact="hydroxychloroquine" post="among in-patients with symptomatic disease. https://clinicaltrialsgov/ct2/show/NCT04332991. 2020. 101WhiteNJ.Cardiotoxicity of"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7453598\results\search\drug\results.xml">
   <result pre="in the Lancet, issued a warning that the anti-malarial drugs" exact="chloroquine" post="and hydroxychloroquine endangered the lives of coronavirus patients. Notably,"/>
   <result pre="Lancet, issued a warning that the anti-malarial drugs chloroquine and" exact="hydroxychloroquine" post="endangered the lives of coronavirus patients. Notably, the second"/>
   <result pre="rebuke the US President, Mr Donald Trump, who vigorously endorsed" exact="hydroxychloroquine" post="as both preventive and curative treatment for COVID-19 (34)."/>
   <result pre="(53,Brecht B: In Praise of dialectics). In Praise of Dialectics" exact="Today" post="injustice goes with a certain stride, The oppressors move"/>
   <result pre="Prestigious Medical JournalsThe New York TimesNew York, NY2020https://www.nytimes.com/2020/06/14/health/virus-journals.html6142020 35MehraMRRuschitzkaFPatelANRetraction-Hydroxychloroquine or" exact="chloroquine" post="with or without a macrolide for treatment of COVID-19:"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7454523\results\search\drug\results.xml">
   <result pre="TNFR-antagonists (TNFR-Ig), or GM-CSF antagonists (Lenizulumab) act as potential therapeutics." exact="Hydroxychloroquine" post="(HCQ) can interfere with viral entry and replication; and"/>
   <result pre="subset 17; Th0, naÃ¯ve T cells; TNFR-Ig, tumor necrosis factor" exact="alpha" post="receptor-immunoglobulin fusion protein; SARS-CoV-2, severe acute respiratory syndrome coronavirus"/>
   <result pre="as Interferon-gamma (IFN- Î³), Interleukin-1 (IL-1) and tumor necrosis factor" exact="alpha" post="(TNF- Î±) were also found to be elevated in"/>
   <result pre="COVID-19 infection was contradictory: Results from some trials suggested that" exact="hydroxychloroquine" post="is effective in facilitating viral elimination and decreasing time"/>
   <result pre="were mildly symptomatic. One trial found no significant efficacy of" exact="hydroxychloroquine" post="in combination with azithromycin in severe cases of COVID-19"/>
   <result pre="trial found no significant efficacy of hydroxychloroquine in combination with" exact="azithromycin" post="in severe cases of COVID-19 and was discontinued due"/>
   <result pre="severe side effects (Molina etÂ al. 2020). The efficacy of" exact="hydroxychloroquine" post="is still a matter of controversy, suggesting the need"/>
   <result pre="Shao Shang Za Zhi. 2020;36:E005. ChenZ, HuJ, ZhangZet al.Efficacy of" exact="hydroxychloroquine" post="in patients with COVID-19: results of a randomized clinical"/>
   <result pre="infection. A novel syndrome?Rhinol. 2020;58:3â€&quot;0. GautretP, LagierJ, ParolaPet al.Hydroxychloroquine and" exact="azithromycin" post="as a treatment of COVID-19: results of an open-label"/>
   <result pre="rapid antiviral clearance or clinical benefit with the combination of" exact="hydroxychloroquine" post="and azithromycin in patients with severe COVID-19 infection. Med"/>
   <result pre="clearance or clinical benefit with the combination of hydroxychloroquine and" exact="azithromycin" post="in patients with severe COVID-19 infection. Med Mal Infect."/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7454939\results\search\drug\results.xml">
   <result pre="Sciences : Pharmacology : Behavioral Pharmacology : Recreational Drug Use:" exact="Heroin" post="HIV-1 phylodynamic analysis among people who inject drugs in"/>
   <result pre="time-stamped data were performed on HIV-1 pol sequences generated from" exact="dried" post="blood spots collected from 1,453 PWID as part of"/>
   <result pre="the cityâ€™s estimated 2,500 PWID with easy access to inexpensive" exact="heroin" post="(www.unodc.org/documents/wdr/WDR_2010/World_Drug_Report_2010_lo-res.pdf) [4]. Large sharing networks and unusual injection practices"/>
   <result pre="In this study, using HIV-1 sequence data from HIV-1 positive" exact="dried" post="blood spot (DBS) specimens collected as part of a"/>
   <result pre="such behaviors. Currently, Afghanistan produces approximately 80% of the worldâ€™s" exact="heroin" post="supply [30]. Most of the heroin is trafficked through"/>
   <result pre="80% of the worldâ€™s heroin supply [30]. Most of the" exact="heroin" post="is trafficked through Pakistan before reaching its final destination"/>
   <result pre="regional trafficking routes. Once inside Pakistan, a significant amount of" exact="heroin" post="is trafficked south along main roads and railways southward"/>
   <result pre="explanations for the observed migration patterns. Initially, high quality powder" exact="heroin" post="was abundant in Pakistan with smoking being the primary"/>
   <result pre="heroin. It is widely known that the Taliban relies on" exact="heroin" post="production and trafficking to fund operations. Consistent with this,"/>
   <result pre="cards (GE Healthcare Life Sciences, Mississauga, ON), DBS were air" exact="dried" post="for a minimum of 3 hours at ambient temperature"/>
   <result pre="8MonleauM, ButelC, DelaporteE, BoillotF, PeetersM. Effect of storage conditions of" exact="dried" post="plasma and blood spots on HIV-1 RNA quantification and"/>
   <result pre="9PirilloMF, Recordon-PinsonP, AndreottiM, ManciniMG, AmiciR, GiulianoM. Quantification of HIV-RNA from" exact="dried" post="blood spots using the Siemens VERSANT HIV-1 RNA (kPCR)"/>
   <result pre="Health Organization. WHO manual for HIV drug resistance testing using" exact="dried" post="blood spot specimens. Geneva, Switzerland: 2012. 26WoodsCK, BrummeCJ, LiuTF,"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7456638\results\search\drug\results.xml">
   <result pre=": Original Article Pharmacological inhibition of poly (ADP-ribose) polymerase by" exact="olaparib" post="ameliorates influenza-virus-induced pneumonia in mice LiuWeiliuwei19801116@163.com1RenXiaojuan2WangQian2ZhangYan2DuJunfeng3[1], grid.452270.60000 0004 0614"/>
   <result pre="This study aimed to explore the effects of PARP-1 inhibitor" exact="olaparib" post="on IAV-induced lung injury and the underlying mechanisms. Male"/>
   <result pre="intranasally infected with IAV strain H1N1 to mimic pneumonia experimentally." exact="Olaparib" post="at different doses was intraperitoneally injected 2Â days before"/>
   <result pre="lavage fluid (BALF) were sampled for histological and biochemical analyses." exact="Olaparib" post="increased the survival rate of IAV mice dose-dependently. Olaparib"/>
   <result pre="analyses. Olaparib increased the survival rate of IAV mice dose-dependently." exact="Olaparib" post="remarkably reduced IAV mRNA expression, myeloperoxidase (MPO) level, and"/>
   <result pre="(MPO) level, and inflammatory cell infiltration in IAV lungs. Moreover," exact="olaparib" post="significantly reduced the level of interleukin (IL)-1Î², tumor necrosis"/>
   <result pre="IL-6, and IL-4 and increased IL-10 in IAV lungs. Also," exact="olaparib" post="efficiently reduced IL-6, monocyte chemotactic protein (MCP)-1, granulocyte colony-stimulating"/>
   <result pre="T cell expressed and secreted (RANTES) release in IAV BALF." exact="Olaparib" post="decreased PARylated protein content and p65, IÎºBÎ± phosphorylation in"/>
   <result pre="This study successfully constructed the pneumonia murine model using IAV." exact="Olaparib" post="decreased IAV-induced mortality in mice, lung injury, and cytokine"/>
   <result pre="is available to authorized users. Keywords Influenza A virus PARP" exact="Olaparib" post="Pneumonia Cytokines Introduction Influenza is an acute infectious disease"/>
   <result pre="by elastase and LPS [9, 12]. Yet the role of" exact="olaparib" post="on IAV-induced lung injury has rarely been reported. This"/>
   <result pre="study aimed to explore the effects of PARP inhibition by" exact="olaparib" post="on IAV infection. Methods and materials Animals Specific-pathogen-free 8-"/>
   <result pre="to previously described [13]. Briefly, ketamine (50Â mg/kg weight) and" exact="pentobarbital" post="(30Â mg/kg weight) were intraperitoneally injected to induce the"/>
   <result pre="virusâ€‰+â€‰normal saline), and the IAVâ€‰+â€‰Ola group (H1N1 virusâ€‰+â€‰10Â mg/kg olaparib)." exact="Olaparib" post="(Selleck Chemicals, Houston, TX, USA) at different doses was"/>
   <result pre="0.75-mM hydrogen peroxide (80Â Î¼l), 2.9-mM TMB dissolved in 14.5%" exact="dimethyl sulfoxide" post="(110Â Î¼l), and 150-mM sodium phosphate buffer (pHÂ 5.4)"/>
   <result pre="test using the SPSS software (Chicago, IL, USA). pâ€‰ Results" exact="Olaparib" post="decreased IAV-induced mortality in mice This study aimed to"/>
   <result pre="IAV-induced mortality in mice This study aimed to investigate whether" exact="olaparib" post="(chemical structure in Fig.Â 1a) possessed protective effects against"/>
   <result pre="in the IAV-only group. To the expectations, mice in the" exact="olaparib" post="group showed higher survival rate compared with that in"/>
   <result pre="in the IAV group in a dose-dependent manner, indicating that" exact="olaparib" post="could powerfully protect against influenza virus challenge in mice."/>
   <result pre="side effects (Fig. S1). Also, the dose of 10Â mg/kg" exact="olaparib" post="was chosen for further investigation as a result of"/>
   <result pre="as a result of the highest survival rate among all" exact="olaparib" post="groups. Fig. 1 Effects of olaparib on influenza virus"/>
   <result pre="survival rate among all olaparib groups. Fig. 1 Effects of" exact="olaparib" post="on influenza virus challenge-induced mortality in mice. (a) Chemical"/>
   <result pre="15 consecutive days. Oseltamivir was used as positive control. Ola," exact="olaparib" post="group; IAV, influenza A virus-infected group. nâ€‰=â€‰20 in each"/>
   <result pre="influenza A virus-infected group. nâ€‰=â€‰20 in each group. *pâ€‰**pâ€‰ ***pâ€‰" exact="Olaparib" post="relieved IAV-induced lung injury in mice As olaparib treatment"/>
   <result pre="*pâ€‰**pâ€‰ ***pâ€‰ Olaparib relieved IAV-induced lung injury in mice As" exact="olaparib" post="treatment evidently reduced the virus-induced mortality, pathological changes were"/>
   <result pre="pathological changes were further explored to assess the influences of" exact="olaparib" post="on the lung injury severity. In comparison with the"/>
   <result pre="was significantly higher than that in the control group, and" exact="olaparib" post="treatment remarkably reduced the lung index, suggesting that olaparib"/>
   <result pre="and olaparib treatment remarkably reduced the lung index, suggesting that" exact="olaparib" post="could alleviate the pulmonary edema induced by IVA infection"/>
   <result pre="MPO levels compared with that in the control group, whereas" exact="olaparib" post="evidently reduced MPO levels, illustrating that olaparib reduced leucocyte"/>
   <result pre="control group, whereas olaparib evidently reduced MPO levels, illustrating that" exact="olaparib" post="reduced leucocyte infiltration to the lungs of IAV mice."/>
   <result pre="might lead to the breathing difficulty in infected mice. And" exact="olaparib" post="treatment attenuated the pathological abnormalities in IAV lungs. Lung"/>
   <result pre="abnormalities in IAV lungs. Lung histopathological grading numerically pointed that" exact="olaparib" post="rectified the lung injury caused by IAV infection (Fig."/>
   <result pre="caused by IAV infection (Fig. 2e). Fig. 2 Effects of" exact="olaparib" post="on influenza virus challenge-induced lung injuries at day 6"/>
   <result pre="group). Data were presented as meanâ€‰Â±â€‰SD. ##pâ€‰ ###pâ€‰ *pâ€‰ **pâ€‰" exact="Olaparib" post="reduced IAV-induced cytokine release in murine lungs Virus-infected pneumonia"/>
   <result pre="inflammatory cytokines in lung homogenate was detected to investigate whether" exact="olaparib" post="could influence the release of inflammatory cytokines in lung"/>
   <result pre="cytokine, IL-10, was remarkably descended in the IAV group, while" exact="olaparib" post="treatment obviously rectified the abnormal release of the above"/>
   <result pre="the abnormal release of the above inflammatory cytokines, meaning that" exact="olaparib" post="might possess anti-inflammatory effect in murine lung tissue under"/>
   <result pre="lung tissue under the IAV context. Fig. 3 Effects of" exact="olaparib" post="on influenza virus challenge-induced cytokine release in lung homogenate"/>
   <result pre="ELISA. Data were presented as meanâ€‰Â±â€‰SD. ##pâ€‰ ###pâ€‰ *pâ€‰ **pâ€‰" exact="Olaparib" post="reduced IAV-induced cytokine release in murine BALF The detection"/>
   <result pre="IAV group compared with those in the control group, while" exact="olaparib" post="treatment significantly reduced the abnormal increased levels of the"/>
   <result pre="obtained from lung tissue (Fig.Â 4a-h). Fig. 4 Effects of" exact="olaparib" post="on influenza virus challenge-induced cytokine and chemokine release in"/>
   <result pre="by ELISA. Data were presented as meanâ€‰Â±â€‰SD. ###pâ€‰ *pâ€‰**pâ€‰ ***pâ€‰" exact="Olaparib" post="decreased PARylated protein content and p65, IÎºBÎ± phosphorylation in"/>
   <result pre="tissues To explore the mechanisms underlying the protective effect of" exact="olaparib" post="against IAV-induced injury to murine lungs, western blot was"/>
   <result pre="homogenate samples compared with the control group, while PARP inhibitor" exact="olaparib" post="significantly reduced the PARylated protein content in IAV-infected samples"/>
   <result pre="c). NF-ÎºB genes are reported to be the targets of" exact="olaparib" post="in the context of LPS stimulation to the lungs"/>
   <result pre="lung homogenates compared with those of the control group, while" exact="olaparib" post="obviously decreased the abnormal increase of the two proteins,"/>
   <result pre="decreased the abnormal increase of the two proteins, suggesting that" exact="olaparib" post="inhibits the activation of NF-ÎºB signaling pathway in the"/>
   <result pre="IkBa among different groups (Fig. 5b). Fig. 5 Effects of" exact="olaparib" post="on influenza virus challenge-induced PARylated protein content and p65,"/>
   <result pre="study investigated for the first time the possible role of" exact="olaparib" post="on IAV infection in a murine model and found"/>
   <result pre="infection in a murine model and found that PARP-1 inhibitor" exact="olaparib" post="remarkably relieved IAV-induced lung injury and lung inflammation possibly"/>
   <result pre="injury induced by ALI [34]. As a potent PARP inhibitor," exact="olaparib" post="has already been approved to be used in cancer"/>
   <result pre="used in cancer patients for clinical trials with acceptable toxicity." exact="Olaparib" post="downregulates NF-ÎºB-related genes including TNF-Î± and IL-1Î², decreases neutrophil,"/>
   <result pre="edema of LPS-stimulated murine lungs [12]. Our study found that" exact="olaparib" post="possesses protective effects against IAV-induced lung inflammation, suggesting that"/>
   <result pre="damages to patients. Our study explored the protective effects of" exact="olaparib" post="in experimental virus-induced pneumonia, suggesting its possible application in"/>
   <result pre="We did not perform toxicity analysis about the influence of" exact="olaparib" post="on normal physiology of mice. The relationship between PARP-1/NF-ÎºB"/>
   <result pre="present study successfully constructed the pneumonia murine model using IAV." exact="Olaparib" post="decreased IAV-induced mortality in mice, lung injury, and cytokine"/>
   <result pre="PARP-1/NF-ÎºB axis. This study indicates the non-specific anti-inflammatory effect of" exact="olaparib" post="in lung disorders and would shine light on the"/>
   <result pre="of NF-kappaB and p38 MAPK pathwayJ Pharm Anal202010213014610.1016/j.jpha.2019.09.00532373385 12.KapoorKSinglaESahuBNauraASPARP inhibitor," exact="olaparib" post="ameliorates acute lung and kidney injury upon intratracheal administration"/>
   <result pre="Biochem20154001â€&quot;215316210.1007/s11010-014-2271-425404465 13.HatayamaKNosakaNYamadaMYashiroMFujiiYTsukaharaHLiuKNishiboriMMatsukawaAMorishimaTCombined effect of anti-high-mobility group box-1 monoclonal antibody and" exact="peramivir" post="against influenza A virus-induced pneumonia in miceJ Med Virol201991336136910.1002/jmv.2533030281823"/>
   <result pre="myeloperoxidase activity in biological samplesPLoS One201387e6797610.1371/journal.pone.006797623861842 17.LiYCPengSZChenHMZhangFXXuPPXieJHHeJJChenJNLaiXPSuZROral administration of patchouli" exact="alcohol" post="isolated from Pogostemonis Herba augments protection against influenza viral"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7457578\results\search\drug\results.xml">
   <result pre="being used by the majority (50.5%) was DMARDs (methotrexate and" exact="sulfasalazine" post="alone or in combination). Immunosuppressant therapy (cyclophosphamide, mycophenolate mofetil,"/>
   <result pre="(methotrexate and sulfasalazine alone or in combination). Immunosuppressant therapy (cyclophosphamide," exact="mycophenolate mofetil," post="or azathioprine) and biological agents (adalimumab, etanercept, or tofacitinib)"/>
   <result pre="those with symptomatic infections only. Some commonly used drugs like" exact="hydroxychloroquine" post="might have some role in inhibition of SARS-CoV-19 by"/>
   <result pre="Dis. 2020;23(6):717â€&quot;722. doi:10.1111/1756-185X.1386332462761 14.WangM, CaoR, ZhangL, et al. Remdesivir and" exact="chloroquine" post="effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7457942\results\search\drug\results.xml">
   <result pre="RNA and glycoproteins are also potential targets [15]. For example," exact="acyclovir" post="disturbs some key herpes virus enzymes that have an"/>
   <result pre="clinical trials, several of which are commercially available. For example," exact="vidarabine" post="is currently used for the treatment of HSV infection,"/>
   <result pre="novel violapyrones (VLPs), VLPs Qâ€&quot;T (2â€&quot;5, Fig.Â 4) [34]. Using" exact="ribavirin" post="as a positive control, anti-influenza A [H1N1 (A/Virginia/ATCC1/2009) and"/>
   <result pre="respectively (ribavirin as a positive control, IC50Â =Â 24.6Â Î¼g/mL;" exact="Zanamivir" post="as a positive control, IC50Â =Â 28.4Â Î¼g/mL) [38]."/>
   <result pre="Fig.Â 7), paxilline (35, Fig.Â 7) [43]. When compared with" exact="ribavirin" post="(IC50Â =Â 113.1Â Î¼M), compounds 27â€&quot;35 displayed significant activities"/>
   <result pre="At present, clinically effective anti-herpes virus drugs such as acyclovir," exact="valacyclovir" post="and other nucleoside analogues are mainly used as nucleoside"/>
   <result pre="values of 39.0 and 16.1Â Î¼M, respectively [27]. Moreover, though" exact="efavirenz" post="(positive control) displaying stronger activity than the data raising"/>
   <result pre="the collected compounds (IC50Â &amp;gt;Â 100Â Î¼M) in comparison with" exact="efavirenz" post="(IC50Â =Â 40.6Â Î¼M) suggested that these compounds were"/>
   <result pre="displayed anti-EV71 activity with IC50 value of 9.4Â Î¼M [46]." exact="Ribavirin" post="was used as the positive control against EV71 virus"/>
   <result pre="The Western Equine Encephalitis Virus (WEEV) belongs to the encephalitic" exact="alpha" post="viruses, which can directly infect neurons leading to CNS"/>
   <result pre="there are currently no licensed vaccines or antivirus drugs for" exact="alpha" post="virus infections [80]. Chemical investment of the extract of"/>
   <result pre="D68-2Apro as an antiviral drug target and the discovery of" exact="telaprevir" post="as a potent D68-2Apro inhibitorJ.Â Virol.932019e02221 14NovikovaM.ZhangY.FreedE.O.PengK.Multiple roles of"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7458227\results\search\drug\results.xml">
   <result pre="for the 2019-new coronavirus (2019-nCoV). Biosci Trends2020;14:6971.31996494 [9]WangMCaoRZhangLet al.Remdesivir and" exact="chloroquine" post="effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7459861\results\search\drug\results.xml">
   <result pre="other drugs such as arbidol (ChiCTR2000029621), a haemagglutinin inhibitor and" exact="chloroquine" post="phosphate, a traditional antimalarial drug, have been added to"/>
   <result pre="8I) (http://www.nhc.gov.cn). In particular, in vitro studies have demonstrated that" exact="chloroquine" post="as well as hydroxychloroquine could impair the endosome-mediated viral"/>
   <result pre="in vitro studies have demonstrated that chloroquine as well as" exact="hydroxychloroquine" post="could impair the endosome-mediated viral entry or later stages"/>
   <result pre="entry or later stages of viral replication [173]. Combination of" exact="hydroxychloroquine" post="and azithromycin has also been suggested as a valid"/>
   <result pre="later stages of viral replication [173]. Combination of hydroxychloroquine and" exact="azithromycin" post="has also been suggested as a valid approach since"/>
   <result pre="approach since it showed more rapid resolution of infection than" exact="hydroxychloroquine" post="alone [174]; however, the combined use of azithromycin and"/>
   <result pre="infection than hydroxychloroquine alone [174]; however, the combined use of" exact="azithromycin" post="and hydroxychloroquine seems to be associated with at increased"/>
   <result pre="hydroxychloroquine alone [174]; however, the combined use of azithromycin and" exact="hydroxychloroquine" post="seems to be associated with at increased risk of"/>
   <result pre="(Figure 8II) [175]. Moreover, four additional molecules including prulifloxacin, tegobuvir," exact="bictegravir" post="and nelfinavir, detected by high-throughput screening, showed reasonable binding"/>
   <result pre="that deserve further consideration. Among these, the antivirals Ledipasvir or" exact="Velpatasvir" post="proved to be particularly attracting as therapeutics to combat"/>
   <result pre="study on 201 patients with ARDS showed that treatment with" exact="methylprednisolone" post="decreased the risk of death (hazard ratio 0.38, 95%"/>
   <result pre="virus entry and are potential drug targetsJ. Virol.2015894387440410.1128/JVI.02705-1425653444 173.SavarinoA.BoelaertJ.R.CassoneA.MajoriG.CaudaR.Effects of" exact="chloroquine" post="on viral infections: An old drug against todayâ€™s diseases?Lancet"/>
   <result pre="Vitro Antiviral Activity and Projection of Optimized Dosing Design of" exact="Hydroxychloroquine" post="for the Treatment of Severe Acute Respiratory Syndrome Coronavirus"/>
   <result pre="Potential against Novel Respiratory 2019 CoronavirusAntimicrob. Agents Chemother.20206410.1128/AAC.00399-20 179.WangM.CaoR.ZhangL.YangX.LiuJ.XuM.ShiZ.HuZ.ZhongW.XiaoG.Remdesivir and" exact="chloroquine" post="effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7460442\results\search\drug\results.xml">
   <result pre="in progress has been delineated. COVID-19 cytokine storm clinical features" exact="dexamethasone" post="epidemiology life cycle pathogenesis RT-PCR remdesivir SARS-CoV-2 therapeutics vaccines"/>
   <result pre="to manage the fever is acetaminophen, while expectorants such as" exact="guaifenesin" post="are used for non-productive cough [90]. Patients with SARS,"/>
   <result pre="a nucleotide analog and is metabolized in the cell to" exact="adenosine" post="triphosphate analog, which inhibits the viral RNA polymerases. Remdesivir"/>
   <result pre="edition of treatment guidelines for combating COVID-19. Later, arbidol and" exact="chloroquine" post="phosphate have also been added in the 6th edition,"/>
   <result pre="beyond standard care [108]. On the basis of the guidelines," exact="ritonavir" post="is used as a booster to enhance the efficacy"/>
   <result pre="possibly useful and can be employed [59]. A glucocorticoids-based drug" exact="dexamethasone" post="may be employed against COVID-19. Dexamethasone is a synthetic"/>
   <result pre="COVID-19 patients [112]. A recent controlled open-label, randomized trial of" exact="dexamethasone" post="in hospitalized patients, concluded that the use of dexamethasone"/>
   <result pre="of dexamethasone in hospitalized patients, concluded that the use of" exact="dexamethasone" post="with the aid of mechanical ventilation or oxygen alone"/>
   <result pre="dose of 6 mg once daily for 10 days. However," exact="dexamethasone" post="was not effective in those patients who were not"/>
   <result pre="been updated to recommend the use of glucocorticoids such as" exact="dexamethasone" post="in hospitalized patients with COVID-19 [114,115]. As discussed earlier,"/>
   <result pre="the infection and are supposed to be less effective [90]." exact="Chloroquine" post="and its derivative hydroxychloroquine are considered to be effective"/>
   <result pre="supposed to be less effective [90]. Chloroquine and its derivative" exact="hydroxychloroquine" post="are considered to be effective against COVID-19 and are"/>
   <result pre="of treatment [116]. An open-label, non-randomized clinical trial showed that" exact="hydroxychloroquine" post="(600 mg/day) treatment is magnificently related to a decreased"/>
   <result pre="viral replication in patients, and its effectiveness is reinforced by" exact="azithromycin" post="(500 mg/day) [116]. Hydroxychloroquine showed superior sensitivity over chloroquine"/>
   <result pre="and its effectiveness is reinforced by azithromycin (500 mg/day) [116]." exact="Hydroxychloroquine" post="showed superior sensitivity over chloroquine against COVID-19 [117]. Contrary"/>
   <result pre="by azithromycin (500 mg/day) [116]. Hydroxychloroquine showed superior sensitivity over" exact="chloroquine" post="against COVID-19 [117]. Contrary to the previous results, at"/>
   <result pre="open-label, randomized controlled clinical trial showed that the use of" exact="hydroxychloroquine" post="alone or with azithromycin did not improve the clinical"/>
   <result pre="trial showed that the use of hydroxychloroquine alone or with" exact="azithromycin" post="did not improve the clinical status of hospitalized patients"/>
   <result pre="can be controlled with the use of protease inhibitors, including" exact="camostat" post="and nafamostat, which target TMPRSS2, and thereby inhibit the"/>
   <result pre="the clinical results of the patients. These broad-spectrum antibiotics, including" exact="azithromycin" post="and fluoroquinolones, can be given as empirical therapy to"/>
   <result pre="bacteria are cleared from the body. The combination therapy of" exact="azithromycin" post="with hydroxychloroquine showed significant activity against COVID-19 infection [124]."/>
   <result pre="cleared from the body. The combination therapy of azithromycin with" exact="hydroxychloroquine" post="showed significant activity against COVID-19 infection [124]. Table 5"/>
   <result pre="potential therapeutics against COVID-19. Some researchers recommend the use of" exact="vitamin C" post="supplements that may help to treat the clinical symptoms"/>
   <result pre="pneumonia; however, this requires more clinical evaluation [131]. Supplements of" exact="vitamin D3" post="can also be useful for combating the infection. While"/>
   <result pre="have been used for antiviral or anti-parasite ones such as" exact="chloroquine" post="phosphate and lopinavir/ritonavir. Among them, remdesivir has been approved"/>
   <result pre="89.SinghalT.A review of coronavirus disease-2019 (COVID-19)Indian J. Pediatr.20208728128610.1007/s12098-020-03263-632166607 90.WangM.CaoR.ZhangL.YangX.LiuJ.XuM.ShiZ.HuZ.ZhongW.XiaoG.Remdesivir and" exact="chloroquine" post="effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in"/>
   <result pre="Treatment GuidelinesAvailable online: https://www.covid19treatmentguidelines.nih.gov/dexamethasone/(accessed on 30 July 2020) 116.GautretP.LagierJ.-C.ParolaP.MeddebL.MailheM.DoudierB.CourjonJ.GiordanengoV.VieiraV.E.DupontH.T.Hydroxychloroquine and" exact="azithromycin" post="as a treatment of COVID-19: Results of an open-label"/>
   <result pre="vitro antiviral activity and projection of optimized dosing design of" exact="hydroxychloroquine" post="for the treatment of severe acute respiratory syndrome coronavirus"/>
   <result pre="coronavirus 2 (SARS-CoV-2)Clin. Infect. Dis.2020210.1093/cid/ciaa23732150618 118.CavalcantiA.B.ZampieriF.G.RosaR.G.AzevedoL.C.VeigaV.C.AvezumA.DamianiL.P.MarcadentiA.Kawano-DouradoL.LisboaT.et al.Hydroxychloroquine with or without" exact="Azithromycin" post="in Mild-to-Moderate Covid-19N. Engl. J. Med.202010.1056/NEJMoa2019014 119.KlokF.KruipM.Van der MeerN.ArbousM.GommersD.KantK.KapteinF.Van"/>
   <result pre="rapid antiviral clearance or clinical benefit with the combination of" exact="hydroxychloroquine" post="and azithromycin in patients with severe COVID-19 infectionMed. Mal."/>
   <result pre="clearance or clinical benefit with the combination of hydroxychloroquine and" exact="azithromycin" post="in patients with severe COVID-19 infectionMed. Mal. Infect.2020300853008810.1016/j.medmal.2020.03.006 125.JinY.YangH.JiW.WuW.ChenS.ZhangW.DuanG.Virology,"/>
   <result pre="the dysfunctional immune response, cells may undergo pyroptosis and release" exact="adenosine" post="triphosphate (ATP), nucleic acids, and ASC oligomer. These impaired-associated"/>
   <result pre="day. Drug Regimen Dosage Route of Administration Length of Therapy" exact="Ribavirin" post="500 mg, t.i.d, combination therapy with lopinavir/ritonavir IV infusion"/>
   <result pre="mg, t.i.d, combination therapy with lopinavir/ritonavir IV infusion â‰¤10 days" exact="Chloroquine" post="phosphate 500 mg one time, b.i.d Orally â‰¤10 days"/>
   <result pre="provides protective antibodies against SARS-CoV-2 Clinical trials have been conducted" exact="Chloroquine" post="Hydroxychloroquine Anti-malaria Inhibition of endosomal acidified fusion and also"/>
   <result pre="protective antibodies against SARS-CoV-2 Clinical trials have been conducted Chloroquine" exact="Hydroxychloroquine" post="Anti-malaria Inhibition of endosomal acidified fusion and also have"/>
   <result pre="antiviral property, as it also enhances the therapeutic activity of" exact="hydroxychloroquine" post="Clinical trials have been conducted Enoxaparin Low molecular weight"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7461160\results\search\drug\results.xml">
   <result pre="Golgi fragmentation observed in PD results in reduced delivery of" exact="dopamine" post="transporter [101] and impaired axonal synapses and dendrite trafficking."/>
   <result pre="induces severe in vitro cytopathology and is strongly inhibited by" exact="cyclosporin A" post="or interferon-alpha treatmentJ General Virol201394Pt 817491760 24.van der MeerYSnijderEJDobbeJCet"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7461401\results\search\drug\results.xml">
   <result pre="of psychiatric disorders, such as faceâ€�toâ€�face bullying, using drugs and" exact="alcohol" post="and engaging in risky behaviour. Although some evidence indicates"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7462115\results\search\drug\results.xml">
   <result pre="the laboratory: 1.211â€‰g tris, 8.5â€‰g sodium chloride, 1.1â€‰g calcium chloride" exact="anhydrous" post="or 1.47â€‰g calcium chloride-containing crystalline water, dissolved into 800â€‰ml"/>
   <result pre="the detection of HIV-1 tat proteinBioelectrochemistry200567213514116027048 101.NgSet al.Optical aptasensors for" exact="adenosine" post="triphosphateTheranostics2016610168327446501 102.ChenCet al.Functionalized magnetic microparticle-based colorimetric platform for influenza"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7462603\results\search\drug\results.xml">
   <result pre="disease time-course and reduce the severity of symptoms. Adamantane derivatives," exact="amantadine" post="(Symmetrel) and rimantadine (Flumadine), are small molecule inhibitors that"/>
   <result pre="reduce the severity of symptoms. Adamantane derivatives, amantadine (Symmetrel) and" exact="rimantadine" post="(Flumadine), are small molecule inhibitors that target M2 proteins"/>
   <result pre="influenza A viruses. [111]. Orally delivered oseltamivir (Tamiï¬‚u), intranasally administered" exact="zanamivir" post="(Relenza), and intravenously injected peramivir (Rapivab) are FDA approved"/>
   <result pre="delivered oseltamivir (Tamiï¬‚u), intranasally administered zanamivir (Relenza), and intravenously injected" exact="peramivir" post="(Rapivab) are FDA approved NA inhibitors that prevent the"/>
   <result pre="virus release from infected host cells. In 2018, FDA approved" exact="Baloxavir marboxil" post="(Xofluza) for influenza A and B. Xofluza inhibits polymerase"/>
   <result pre="FDA approved Baloxavir marboxil (Xofluza) for influenza A and B." exact="Xofluza" post="inhibits polymerase acidic endonuclease, an enzyme essential for viral"/>
   <result pre="used extensively, WHO has recommends the orally administrated tenofovir or" exact="entecavir" post="for the treatment of CHB due to their minimal"/>
   <result pre="due to their minimal drug resistance and side effects [209]." exact="Entecavir" post="is an off-patent drug. The two tenofovir blockbusters for"/>
   <result pre="They are the antidiabetic insulin sensitizer Rosiglitazone, the leukotriene inhibitor" exact="zafirlukast" post="for asthma, antihistamines, and decongestants TRIAC targeting thyroid hormone"/>
   <result pre="for asthma, antihistamines, and decongestants TRIAC targeting thyroid hormone receptor," exact="glutathione" post="transferase inhibitor sulfasalazine for inflammation, and pain and vital"/>
   <result pre="and decongestants TRIAC targeting thyroid hormone receptor, glutathione transferase inhibitor" exact="sulfasalazine" post="for inflammation, and pain and vital dye Chicago Sky"/>
   <result pre="of drug prevention or therapy [214]. During the SARS outbreak," exact="ribavirin" post="was most frequently used to inhibit viral RNA synthesis"/>
   <result pre="was most frequently used to inhibit viral RNA synthesis [74]." exact="Ribavirin" post="is a guanosine analog that inhibits guanosine-triphosphate (GTP) synthesis,"/>
   <result pre="capping, and viral RNA-dependent RNA polymerase [49,20]. At the time," exact="ribavirin" post="was used for Hepatitis C virus (HCV) therapy [233]"/>
   <result pre="respiratory syncytial viral (RSV) infection [42]. The reported uses of" exact="ribavirin" post="in SARS cases showed conflicting results with numerous methodological"/>
   <result pre="distinguished from other treatments such as corticosteroids or other antivirals." exact="Ribavirin" post="treatment for SARS was not tested in clinical trials,"/>
   <result pre="the reliability and sensitivityJ. Virol. Methods1732201135335621419168 74GraciJ.D.CameronC.E.Mechanisms of action of" exact="ribavirin" post="against distinct virusesRev. Med. Virol.1612006374816287208 75GrimmD.ThimmeR.BlumH.E.HBV life cycle and"/>
   <result pre="immunity against multiple influenza serotypesEur. J. Immunol.37920072441244917668898 191TapiaG.HÃ¸jenJ.F.Ã–kvistM.OlesenR.LethS.NissenS.K.Sequential vacc-4x and" exact="romidepsin" post="during combination antiretroviral therapy (cART): immune responses to vacc-4x"/>
   <result pre="on p24 and changes in HIV reservoirsJ. Infect.756201755557128917661 192TassopoulosN.C.VolpesR.PastoreG.HeathcoteJ.ButiM.GoldinR.D.Efficacy of" exact="lamivudine" post="in patients with hepatitis B e antigen-negative/hepatitis B virus"/>
   <result pre="e antigen-negative/hepatitis B virus DNA-positive (precore mutant) chronic hepatitis B." exact="lamivudine" post="precore mutant study groupHepatology293199988989610051494 193TayM.Z.PohC.M.ReniaL.MacAryP.A.NgL.F.P.The trinity of COVID-19: immunity,"/>
   <result pre="A.8921199210537105411438243 212WinckelmannA.MorcillaV.ShaoW.SchleimannM.H.HojenJ.F.SchlubT.E.Genetic characterization of the HIV-1 reservoir after Vacc-4x and" exact="romidepsin" post="therapy in HIV-1-infected individualsAids321320181793180229762162 213WongJ.H.LegowskaA.RolkaK.NgT.B.HuiM.ChoC.H.Effects of cathelicidin and its"/>
   <result pre="as potent inhibitors of SARS-associated coronavirusAntivir. Ther.103200539340315918330 233ZhouS.LiuR.BaroudyB.M.MalcolmB.A.ReyesG.R.The effect of" exact="ribavirin" post="and IMPDH inhibitors on hepatitis C virus subgenomic replicon"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7462660\results\search\drug\results.xml">
   <result pre="on ACE RAAS inhibitors (RAASi) with the possible exception of" exact="aliskiren" post="(a direct inhibitor of renin), which is infrequently used,"/>
   <result pre="II receptor blockers on cardiac angiotensin-converting enzyme 2Circulation2005111202605261010.1161/CIRCULATIONAHA.104.51046115897343 18.KarramTAbbasiAKeidarSGolombEHochbergIWinaverJHoffmanAAbassiZEffects of" exact="spironolactone" post="and eprosartan on cardiac remodeling and angiotensin-converting enzyme isoforms"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7462898\results\search\drug\results.xml">
   <result pre="viral entry, as inhibition of TMPRSS2 with serine protease inhibitor" exact="camostat" post="mesylate blocks entry of SARS-CoV-2 into the epithelial cells"/>
   <result pre="infection with viruses similar to SARS-CoV-2 [48]. Camostat mesylate and" exact="nafamostat" post="mesylate are serine protease inhibitors, which are commercially available"/>
   <result pre="pancreatitis and cystic fibrosis, respectively. Preclinical studies show treatment with" exact="camostat" post="mesylate blocks entry of SARS-CoV-2 into the epithelial cells"/>
   <result pre="blocks entry of SARS-CoV-2 into the epithelial cells [12]. Likewise," exact="nafamostat" post="has been reported to reduce TMPRSS2-dependent fusion of MERS-CoV"/>
   <result pre="to case reports suggesting clinical efficacy [50]. Potential efficacy of" exact="camostat" post="and the more potent nafamostat in the treatment of"/>
   <result pre="efficacy [50]. Potential efficacy of camostat and the more potent" exact="nafamostat" post="in the treatment of patients with COVID-19 is being"/>
   <result pre="SARS-CoV-2 entry into the host cells, anti-androgenic agents, such as" exact="bicalutamide" post="and enzalutamide are being tested in prospective phase 2"/>
   <result pre="into the host cells, anti-androgenic agents, such as bicalutamide and" exact="enzalutamide" post="are being tested in prospective phase 2 clinical trials"/>
   <result pre="others. There has been considerable interest in the use of" exact="chloroquine" post="and its less toxic version hydroxychloroquine, because of the"/>
   <result pre="[51]). However, the initial enthusiasm for the potential efficacy of" exact="hydroxychloroquine" post="(alone or in combination with azithromycin) in the treatment"/>
   <result pre="trials [52]. There were no beneficial effects of treatment with" exact="hydroxychloroquine" post="in the Randomised Evaluation of COVID-19 Therapy (RECOVERY) study"/>
   <result pre="(Table 1 ), which randomized 1,542 hospitalized patients to the" exact="hydroxychloroquine" post="and 3,132 patients to the usual care (https://www.recoverytrial.net/results/hydroxychloroquine-results). The"/>
   <result pre="to the usual care (https://www.recoverytrial.net/results/hydroxychloroquine-results). The 28-day mortality in the" exact="hydroxychloroquine" post="group was 25.7% as compared to 23.5% in the"/>
   <result pre="randomized clinical trials are still ongoing to test efficacy of" exact="hydroxychloroquine" post="in the treatment of patients with COVID-19. Table 1"/>
   <result pre="(95% CI: 0.67-0.96)No benefit in those not requiring respiratory support" exact="Hydroxychloroquine" post="(HCQ) Viral entry by endocytosis Impairs lysosome function HCQ:"/>
   <result pre="RNA synthesis upon incorporation. Among the nucleoside analogues, remdesivir, an" exact="adenosine" post="analogue, which was originally developed for treatment of Ebola"/>
   <result pre="requiring respiratory support in the RECOVERY study [69]. Thus far," exact="dexamethasone" post="is the only drug shown to reduce COVID-19 mortality"/>
   <result pre="for influenza H1N1 virus pathogenesis in micePLoS Pathog92013e1003774 49YamamotoMMatsuyamaSLiXTakedaMKawaguchiYInoueJIIdentification of" exact="nafamostat" post="as a potent inhibitor of middle east respiratory syndrome"/>
   <result pre="cell-cell fusion assayAntimicrob Agents Chemother6020166532653927550352 50JangSRheeJY.Three cases of treatment with" exact="nafamostat" post="in elderly patients with COVID-19 pneumonia who need oxygen"/>
   <result pre="of chloroquine/hydroxychloroquine for COVID-19J Crit Care59202017619032683212 52CavalcantiABZampieriFGRosaRGAzevedoLCPVeigaVCAvezumAHydroxychloroquine with or without" exact="Azithromycin" post="in Mild-to-Moderate Covid-19N Engl J Med2020, NEJMoa2019014 53ChorinEDaiMShulmanEWadhwaniLBar-CohenRBarbhaiyaCThe QT"/>
   <result pre="NEJMoa2019014 53ChorinEDaiMShulmanEWadhwaniLBar-CohenRBarbhaiyaCThe QT interval in patients with COVID-19 treated with" exact="hydroxychloroquine" post="and azithromycinNat Med26202080880932488217 54WangQWuJWangHGaoYLiuQMuAStructural basis for RNA replication by"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7463036\results\search\drug\results.xml">
   <result pre="SARS-CoV-2 replication, with half-inhibitory concentration (IC50) value above 100Â Î¼M." exact="Chloroquine" post="was selected as a positive control, which can inhibit"/>
   <result pre="copy numbers in the cell supernatant were quantified by qRT-PCR." exact="Chloroquine" post="was selected as the positive group. Data from the"/>
   <result pre="scoring function, efficient optimization, and multithreadingJ. Comput. Chem.3122010 24WangM.CaoR.ZhangL.Remdesivir and" exact="chloroquine" post="effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7463108\results\search\drug\results.xml">
   <result pre="Commonwealth University, [5], grid.224260.00000 0004 0458 8737Institute for Drug and" exact="Alcohol" post="Studies, Virginia Commonwealth University, epub: 2020-9-9pmc-release: 2020-9-9144received: 2020-2-26accepted: 2020-7-2(C)"/>
   <result pre="penetration of specific drugs. Keywords Antiretroviral therapy Astrocyte Blood-brain barrier" exact="Buprenorphine" post="C-C motif chemokine receptor 5 (CCR5) COVID-19 Cytochrome P450"/>
   <result pre="likelihood for abuse (Bell and Strang 2020), the use of" exact="buprenorphine" post="via telemedicine has become advantageous for managing OUD during"/>
   <result pre="CDC 2017). The second phase began in 2010 in which" exact="heroin" post="took the lead as the principal cause of overdose"/>
   <result pre="in 2013 in which highly potent synthetic opioids, such as" exact="fentanyl" post="and its analogs became the main cause of mortality"/>
   <result pre="mortality (Kolodyny et al. 2015; CDC 2017). The entry of" exact="fentanyl" post="and its analogs into the clandestine market has changed"/>
   <result pre="Laboratory Information System of the U.S. Drug Enforcement Administration (DEA)," exact="fentanyl" post="accounted for one-third of the illicit opioids seized in"/>
   <result pre="in proinflammatory cytokines and inflammatory mediators, including TNF-Î±, IL-1Î², and" exact="nitric oxide" post="synthase (NOS) (Dyuizen and Lamash 2009). Opiates especially drive"/>
   <result pre="(Hauser and Knapp 2014; McLane et al. 2018). For delayed" exact="heroin" post="overdose death after a survival period of 5Â h"/>
   <result pre="al. 2015) and cognitive impairment (Gruber et al. 2007). Moreover," exact="heroin" post="use is associated with symmetric T2 and fluid-attenuated inversion"/>
   <result pre="al. 2012, 2016; Hahn et al. 2016). Antagonizing CCR5 with" exact="maraviroc" post="reinstates morphine potency in an antinociceptive assay and restores"/>
   <result pre="encephalitis (HIVE) (Bell et al. 1998, 2002). In Indonesian injection" exact="heroin" post="abusers who lacked access to cART, CD4 counts (a"/>
   <result pre="of HIV progression) were reduced compared to PWH not using" exact="heroin" post="(Meijerink et al. 2014). However, with the introduction of"/>
   <result pre="plasma Human (Ryan et al. 2004) HIV ARV naive Reported" exact="heroin" post="use â€¢ â†&quot; MIP-1Î±, MIP-1Î², MCP-2 in blood after"/>
   <result pre="recall Human, female (Meyer et al. 2013) HIV cART Reported" exact="heroin" post="use â€¢ â†&quot; Recall memory â€¢ â†&quot; Working memory"/>
   <result pre="women, irrespective of HIV status â€¢ â†‘ Response time with" exact="cocaine" post="use Human (Martin et al. 2018) Visual and cognitive"/>
   <result pre="and Booth 2001) HIV cART OST â€¢ â†&quot; Frequency of" exact="heroin" post="injection â€¢ â†‘ On ARV Human (Pettes et al."/>
   <result pre="SUD C17T MOR polymorphism correlates with â†‘ risk of cocaine," exact="alcohol" post="&amp;amp; tobacco (but not opiate) use Human (Crystal et"/>
   <result pre="q.i.d., â‰¤ 4Â years) â€¢ â†‘ Survival time â€¢ â†‘" exact="Creatine" post="in white matter (SIVâ€‰+â€‰morphine only) â€¢ â†‘ Myo-inositol in"/>
   <result pre="tg, males (Fitting et al. 2016) Locomotor function Tat1â€&quot;86 No" exact="Oxycodone" post="(0â€&quot;10Â mg/kg, i.p., 15Â min prior behavioral assay) â†‘"/>
   <result pre="Motor skill Rhesus macaques (Marcario et al. 2016) Tat1â€&quot;86 No" exact="Oxycodone" post="(acute, 0.1â€&quot;10Â mg/kg, i.p.) â†‘ Psychomotor effects Mouse, Tat"/>
   <result pre="5Â days) â†&quot; Dolutegravir and abacavir, but no change in" exact="lamivudine" post="in brains of morphine-treated animals Mouse, Tat tg females"/>
   <result pre="CSF, cerebrospinal fluid; DAMGO [D-Ala2, N-MePhe4, Gly-ol]-enkephalin; DRD2L, type 2" exact="dopamine" post="receptor; DTG, dolutegravir; HIVE, HIV encephalitis (typically seen pre-cART);"/>
   <result pre="use disorder; tg, transgenic; t.i.d., three times a day; ZDV," exact="zidovudine" post="For practicality, Tables 1 and 2 are limited to"/>
   <result pre="al. 1995) HIVSF162 No â€¢ 8-CAC, U50,488 (KOR agonists) â€¢" exact="Cocaine" post="â€¢ KOR agonist â†&quot; p24; blocked by KOR antagonists"/>
   <result pre="tenofovir; TUNEL, terminal deoxynucleotidyl transferase dUTP nick end labeling; ZDV," exact="zidovudine" post="For practicality, the table is limited to key studies"/>
   <result pre="in [Ca2+]i were not attenuated by ryanodine, whereas ryanodine and" exact="pyruvate" post="attenuate combined Tat and morphine-induced increases in [Ca2+]i. Nimodipine"/>
   <result pre="and pyruvate attenuate combined Tat and morphine-induced increases in [Ca2+]i." exact="Nimodipine" post="(L-type Ca2+ channel blocker) and dantrolene did not show"/>
   <result pre="exposure, morphine significantly reduced the levels of dolutegravir (f) and" exact="abacavir" post="(g), but not lamivudine (h), within the striatum, as"/>
   <result pre="the levels of dolutegravir (f) and abacavir (g), but not" exact="lamivudine" post="(h), within the striatum, as compared to placebo. (*"/>
   <result pre="(El-Hage et al. 2006b). Co-exposure of Tat and morphine or" exact="buprenorphine" post="to a BBB model increases monocyte transmigration in response"/>
   <result pre="the duration of opiate dependence (Ivers et al. 2018). Chronic" exact="oxycodone" post="exposure in rats causes some axonopathies and reduces the"/>
   <result pre="caspase-3 activation and TUNEL reactivity in OLs and reversible by" exact="naloxone" post="or naltrexone, respectively (Hauser et al. 2009). Although OLs"/>
   <result pre="immunoneutralizing antibodies (Hahn et al. 2012) or the selective antagonist," exact="maraviroc" post="(Balinang et al. 2017), were able to significantly attenuate"/>
   <result pre="et al. 2010). Similarly, the production of the inflammatory mediators" exact="prostaglandin E2" post="and the thromboxane A2 receptor by astrocytes is more"/>
   <result pre="MOR were noted when using a bivalent ligand derivative of" exact="maraviroc" post="linked to an opioid antagonist, naltrexone, with HIV-1 entry"/>
   <result pre="both astrocytes and microglia when morphine is present suggesting that" exact="maraviroc" post="therapy may not be effective with opiate co-exposure. Importantly,"/>
   <result pre="5 Differential inhibition of HIV-1 entry into human glia by" exact="maraviroc" post="and a bivalent CCR5-MOR antagonist (BVL) with cell-specific interactions"/>
   <result pre="morphine interactions (Kim et al. 2018). Similarly, short-duration (5 d)" exact="maraviroc" post="pre-treatment also eliminated neurotoxicity and attenuated neuronal increases in"/>
   <result pre="enhanced Tat-induced toxicity over a 72-h period (**pÂ pÂ c)." exact="Naloxone" post="or morphine by themselves had no effect on neuronal"/>
   <result pre="of Tat, restoring MSN survival to control levels. Pre-treatment with" exact="naloxone" post="re-established Tat toxicity, suggesting that the paradoxical protective effects"/>
   <result pre="stress-responsive hypothalamic-pituitary-adrenal (HPA) axis, the endogenous opioid system, and the" exact="dopamine" post="system (Kreek 1973; Kreek et al. 2002; George et"/>
   <result pre="Blendy 2008). Alternatively, chronic self-administration of short-acting opiates suppresses diurnal" exact="cortisol" post="rhythmicity (Facchinetti et al. 1984; Vuong et al. 2010),"/>
   <result pre="NAc shell demonstrates molecular and structural changes associated with intravenous" exact="heroin" post="self-administration (Jacobs et al. 2005). Moreover, earlier studies have"/>
   <result pre="including the NAc, frontal cortex, and striatum, and encompassed increased" exact="dopamine" post="and norepinephrine levels and turnover, which are central in"/>
   <result pre="NAc, frontal cortex, and striatum, and encompassed increased dopamine and" exact="norepinephrine" post="levels and turnover, which are central in opiate reward"/>
   <result pre="are central in opiate reward processes (Smith et al. 1982)." exact="Heroin" post="abuse is known to downregulate dopaminergic activity in the"/>
   <result pre="the NAc and may reflect a compensatory reduction in of" exact="dopamine" post="biosynthesis in response to excessive dopaminergic stimulation resulting from"/>
   <result pre="et al. 2001). Additionally, HIV is known to interfere with" exact="dopamine" post="neurotransmission (Nath et al. 2000b; Gaskill et al. 2017)"/>
   <result pre="al. 2000b; Gaskill et al. 2017) causing reductions in presynaptic" exact="dopamine" post="terminals and dopamine transport in the striatum (Wang et"/>
   <result pre="et al. 2017) causing reductions in presynaptic dopamine terminals and" exact="dopamine" post="transport in the striatum (Wang et al. 2004; Chang"/>
   <result pre="al. 2008; Midde et al. 2012, 2015). The decline in" exact="dopamine" post="function may exacerbate opioid abuse tendencies and drug-seeking behaviors"/>
   <result pre="of Selective/Biased Agonism in neuroHIV Pathogenesis Although morphine, methadone, and" exact="buprenorphine" post="all activate MOR, each can impart different signals through"/>
   <result pre="of KOR (Noble and Marie 2018). In comparison to methadone," exact="buprenorphine" post="has been shown to have fewer pharmacodynamic interactions with"/>
   <result pre="et al. 2010), and we found that morphine, methadone, and" exact="buprenorphine" post="differentially increase ROS and [Ca2+]i alone or following Tat"/>
   <result pre="metabolized primarily by cytochrome P450 (CYP) 3A4 and 2C8. Both" exact="buprenorphine" post="and its active metabolite, norbuprenorphine, are glucuronidated by UDP-glucuronosyltransferase"/>
   <result pre="UGT 1A1, leading to increases in overall systemic exposure of" exact="buprenorphine" post="and norbuprenorphine and also results in symptoms of opioid"/>
   <result pre="and impaired cognition (McCance-Katz et al. 2007). Dose adjustments of" exact="buprenorphine" post="are recommended when initiating therapy with atazanavir to avoid"/>
   <result pre="Dose adjustments of buprenorphine are recommended when initiating therapy with" exact="atazanavir" post="to avoid symptoms of opioid excess. Methadone is a"/>
   <result pre="(Bruce et al. 2006; Meemken et al. 2015). In contrast," exact="efavirenz" post="and nevirapine induce CYP 3A4, resulting in decreased systemic"/>
   <result pre="al. 2006; Meemken et al. 2015). In contrast, efavirenz and" exact="nevirapine" post="induce CYP 3A4, resulting in decreased systemic concentrations of"/>
   <result pre="avoid opioid withdrawal, increased methadone dosing is recommended when either" exact="efavirenz" post="or nevirapine therapy is initiated (Marzolini et al. 2000;"/>
   <result pre="withdrawal, increased methadone dosing is recommended when either efavirenz or" exact="nevirapine" post="therapy is initiated (Marzolini et al. 2000; Clarke et"/>
   <result pre="al. 2000; Clarke et al. 2001; Meemken et al. 2015)." exact="Oxycodone" post="metabolism is inhibited by lopinavir/ritonavir, increasing oxycodone concentrations as"/>
   <result pre="et al. 2015). Oxycodone metabolism is inhibited by lopinavir/ritonavir, increasing" exact="oxycodone" post="concentrations as well as the self-reported drug effects (Nieminen"/>
   <result pre="d continuous exposure to morphine on ARV brain concentrations (dolutegravir," exact="lamivudine" post="and abacavir) and demonstrated that morphine exposure resulted in"/>
   <result pre="2017). Another study measured intracellular concentrations of dolutegravir, tenofovir and" exact="emtricitabine" post="in primary human astrocytes, microglia, pericytes and BMECs (Patel"/>
   <result pre="improved ART adherence for HIV-infected women who use illicit drugsDrug" exact="Alcohol" post="Depend202020610767031711873 AdlerMWGellerEBRogersTJHendersonEEEisensteinTKOpioids, receptors, and immunityAdv Exp Med Biol199333513208237587 AlaeeAZarghamiMFarniaSKhademlooMKhoddadTComparison"/>
   <result pre="in human lymphocytesAIDS2011251126112821422985 BabaMOishiRSaekiKEnhancement of blood-brain barrier permeability to sodium" exact="fluorescein" post="by stimulation of mu opioid receptors in miceNaunyn Schmiedeberg's"/>
   <result pre="damage in the brain: potential role of the thiol antioxidant" exact="N-acetylcysteine" post="amide. Free Radic Biol Med 48:1388â€&quot;1398 Banerjee A, Strazza"/>
   <result pre="dependence and HIV-1 infection on pattern shift visual evoked potentialsDrug" exact="Alcohol" post="Depend1998501471559649966 Becker WC, Fiellin DA (2020) When epidemics collide:"/>
   <result pre="receptorsProc Natl Acad Sci U S A199390539153938390660 BruceRDMcCance-KatzEKharaschEDMoodyDEMorseGDPharmacokinetic interactions between" exact="buprenorphine" post="and antiretroviral medicationsClin Infect Dis200643Suppl 4S216S22317109308 BruehlSApkarianAVBallantyneJCBergerABorsookDChenWGFarrarJTHaythornthwaiteJAHornSDIadarolaMJInturrisiCELaoLMackeySMaoJSawczukAUhlGRWitterJWoolfCJZubietaJKLinYPersonalized medicine and"/>
   <result pre="immunodeficiency virus type 1 transgenic rat modelJ Virol2007818406841117553897 ChangLWangGJVolkowNDErnstTTelangFLoganJFowlerJSDecreased brain" exact="dopamine" post="transporters are related to cognitive deficits in HIV patients"/>
   <result pre="related to cognitive deficits in HIV patients with or without" exact="cocaine" post="abuseNeuroImage20084286987818579413 ChaoCCGekkerGShengWSHuSPortoghesePSPetersonPKEndogenous opioid peptides suppress cytokine-mediated upregulation of HIV-1"/>
   <result pre="effect of HIV-1 coat protein gp120 on corticotropin-releasing hormone and" exact="arginine vasopressin" post="in the rat hypothalamus: involvement of nitric oxideExp Neurol200016637638411085902"/>
   <result pre="of HIV-1 coat protein gp120 on corticotropin-releasing hormone and arginine" exact="vasopressin" post="in the rat hypothalamus: involvement of nitric oxideExp Neurol200016637638411085902"/>
   <result pre="use in African American womenAddict Biol20121718119121070507 Culpepper-MorganJAKreekMJHypothalamic-pituitary-adrenal axis hypersensitivity to" exact="naloxone" post="in opioid dependence: a case of naloxone-induced withdrawalMetab Clin"/>
   <result pre="in progression of HIV-1 infections to AIDSJ Neuroimmunol19988377879610676 DonahoeRMFalekAMaddenJJNicholsonJKBokosPGallegosKVeitREffects of" exact="cocaine" post="and other drugs of abuse on immune functionAdv Exp"/>
   <result pre="http://www.healthdata.org/gbd/gbd-2017-resources. FacchinettiFGrassoAPetragliaFParriniDVolpeAGenazzaniARImpaired circadian rhythmicity of beta-lipotrophin, beta-endorphin and ACTH in" exact="heroin" post="addictsActa Endocrinol19841051491556320568 FalekADonahoeRMMaddenJJShaferDAOpiates as immunosuppressive and genotoxic agentsDrugs of"/>
   <result pre="notch ligand and activation of notch signaling pathwayJ Neurosci201636113621137327807176 FanRSchrottLMArnoldTSnellingSRaoMGrahamDCorneliusAKorneevaNLChronic" exact="oxycodone" post="induces axonal degeneration in rat brainBMC Neurosci2018191529571287 FauciASRedfieldRRSigounasGWeahkeeMDGiroirBPEnding the"/>
   <result pre="KJ, Geiger JD, Jordan-Sciutto KL, Grinspan JB (2019) Protease inhibitors," exact="saquinavir" post="and darunavir, inhibit oligodendrocyte maturation: Implications for Lysosomal Stress."/>
   <result pre="Gamble-George J, Yano H, Khoshbouei H (2017) HIV, Tat and" exact="dopamine" post="transmission. Neurobiol Dis 105:51â€&quot;73 Gandhi N, Saiyed ZM, Napuri"/>
   <result pre="human immunodeficiency virus type 1 (HIV-1) clade-specific Tat protein and" exact="cocaine" post="in blood-brain barrier dysfunction: Implications for HIV-1â€&quot;associated neurocognitive disorder."/>
   <result pre="Endocr Metab Disord20131410511223728720 GeorgeOLe MoalMKoobGFAllostasis and addiction: role of the" exact="dopamine" post="and corticotropin-releasing factor systemsPhysiol Behav2012106586422108506 GerettiAMHIV-1 subtypes: epidemiology and"/>
   <result pre="Neurol1994535215348083694 GrayFScaravilliFEverallIChretienFAnSBocheDAdle-BiassetteHWingertsmannLDurigonMHurtrelBChiodiFBellJLantosPNeuropathology of early HIV-1 infectionBrain Pathol199661158866743 GrayLRTachedjianGEllettAMRocheMJChengWJGuilleminGJBrewBJTurvilleSGWesselinghSLGorryPRChurchillMJThe NRTIs lamivudine," exact="stavudine" post="and zidovudine have reduced HIV-1 inhibitory activity in astrocytesPLoS"/>
   <result pre="of early HIV-1 infectionBrain Pathol199661158866743 GrayLRTachedjianGEllettAMRocheMJChengWJGuilleminGJBrewBJTurvilleSGWesselinghSLGorryPRChurchillMJThe NRTIs lamivudine, stavudine and" exact="zidovudine" post="have reduced HIV-1 inhibitory activity in astrocytesPLoS One20138e6219623614033 GrimmMCBen-BaruchATaubDDHowardOMResauJHWangJMAliHRichardsonRSnydermanROppenheimJJOpiates"/>
   <result pre="Biol20182330431227739172 JacobsEHSmitABde VriesTJSchoffelmeerANLong-term gene expression in the nucleus accumbens following" exact="heroin" post="administration is subregion-specific and depends on the nature of"/>
   <result pre="Morgello S (2013) HIV-related cognitive impairment shows bi-directional association with" exact="dopamine" post="receptor DRD1 and DRD2 polymorphisms in substance-dependent and substance-independent"/>
   <result pre="and substance-independent populations. J Neurovirol 19:495â€&quot;504 JankovicBDHorvatJDjordjijevicDRamahAFridmanVSpahicOBrain-associated autoimmune features in" exact="heroin" post="addicts: correlation to HIV infection and dementiaThe International journal"/>
   <result pre="cortex cultureArch Virol199413781997526826 KishSJKalasinskyKSDerkachPSchmunkGAGuttmanMAngLAdamsVFurukawaYHaycockJWStriatal dopaminergic and serotonergic markers in human" exact="heroin" post="usersNeuropsychopharmacology20012456156711282256 Knapp PE, Hauser KF (1996) Î¼-Opioid receptor activation"/>
   <result pre="for active efflux transportersDrug Metab Dispos20144298398924644297 KolodynyACourtwrightDTHwangCSKreinerPEadieJLClarkTWAlexanderGCThe prescription opioid and" exact="heroin" post="crisis: a public health approach to an epidemic of"/>
   <result pre="Drug Discov2002171072612209151 KreekMJBartGLillyCLaForgeKSNielsenDAPharmacogenetics and human molecular genetics of opiate and" exact="cocaine" post="addictions and their treatmentsPharmacol Rev20055712615734726 KringenMKChalabianlooFBernardJPBramnessJGMoldenEHoisethGCombined effect of CYP2B6"/>
   <result pre="clade dependent. J Neurosci 28:12190â€&quot;12198 LiWLiQZhuJQinYZhengYChangHZhangDWangHWangLWangYWangWWhite matter impairment in chronic" exact="heroin" post="dependence: a quantitative DTI studyBrain Res20131531586423895765 LiGHAndersonCJaegerLDoTMajorEONathACell-to-cell contact facilitates"/>
   <result pre="task performance in SIV-infected rhesus macaquesJ NeuroImmune Pharmacol20161134835727039332 MarinhoATMirandaJPCaixasUCharneiraCGoncalves-DiasCMarquesMMMonteiroECAntunesAMMPereiraSASingularities of" exact="nevirapine" post="metabolism: from sex-dependent differences to idiosyncratic toxicityDrug Metab Rev201951769030712401"/>
   <result pre="between opioids and antiretroviral agentsClin Infect Dis200541Suppl 1S89S9516265622 McCance-KatzEFMoodyDEMorseGDMaQDiFrancescoRFriedlandGPadePRaineyPMInteraction between" exact="buprenorphine" post="and atazanavir or atazanavir/ritonavirDrug Alcohol Depend20079126927817643869 McDermottDHBeecroftMJKleebergerCAAl-SharifFMOllierWEZimmermanPABoatinBALeitmanSFDetelsRHajeerAHMurphyPMChemokine RANTES promoter"/>
   <result pre="and antiretroviral agentsClin Infect Dis200541Suppl 1S89S9516265622 McCance-KatzEFMoodyDEMorseGDMaQDiFrancescoRFriedlandGPadePRaineyPMInteraction between buprenorphine and" exact="atazanavir" post="or atazanavir/ritonavirDrug Alcohol Depend20079126927817643869 McDermottDHBeecroftMJKleebergerCAAl-SharifFMOllierWEZimmermanPABoatinBALeitmanSFDetelsRHajeerAHMurphyPMChemokine RANTES promoter polymorphism affects"/>
   <result pre="Infect Dis200541Suppl 1S89S9516265622 McCance-KatzEFMoodyDEMorseGDMaQDiFrancescoRFriedlandGPadePRaineyPMInteraction between buprenorphine and atazanavir or atazanavir/ritonavirDrug" exact="Alcohol" post="Depend20079126927817643869 McDermottDHBeecroftMJKleebergerCAAl-SharifFMOllierWEZimmermanPABoatinBALeitmanSFDetelsRHajeerAHMurphyPMChemokine RANTES promoter polymorphism affects risk of both"/>
   <result pre="inhibition of sheep erythrocyte binding to T lymphocytes: reversal by" exact="naloxone" post="and cyclic nucleotidesNIDA Res Monogr1981341591656783926 McLaneVDCaoLWillisCLMorphine increases hippocampal viral"/>
   <result pre="NM, Gomez AM, Zhu J (2012) HIV-1 Tat protein decreases" exact="dopamine" post="transporter cell surface expression and vesicular monoamine transporter-2 function"/>
   <result pre="at tyrosine 88, lysine 92 and tyrosine 470 of human" exact="dopamine" post="transporter result in an attenuation of HIV-1 Tat-induced inhibition"/>
   <result pre="transporter result in an attenuation of HIV-1 Tat-induced inhibition of" exact="dopamine" post="transport. J NeuroImmune Pharmacol 10:122â€&quot;135 MirsattariSMPowerCNathAPrimary headaches with HIV"/>
   <result pre="sleep, and cancer-related fatigueMed Hypotheses200258778211863402 Morales OdiaYJinkaMZiaiWCSevere leukoencephalopathy following acute" exact="oxycodone" post="intoxicationNeurocrit Care201013939720440598 MorganMMChristieMJAnalysis of opioid efficacy, tolerance, addiction and"/>
   <result pre="drugsAIDS2017311181119028323752 MullerUJTruebnerKSchiltzKKuhnJMawrinCDobrowolnyHBernsteinHGBogertsBSteinerJPostmortem volumetric analysis of the nucleus accumbens in male" exact="heroin" post="addicts: implications for deep brain stimulationEur Arch Psychiatry Clin"/>
   <result pre="MullerUJSchiltzKMawrinCDobrowolnyHFrodlTBernsteinHGBogertsBTruebnerKSteinerJTotal hypothalamic volume is reduced in postmortem brains of male" exact="heroin" post="addictsEur Arch Psychiatry Clin Neurosci201826824324828534187 MullerUJMawrinCFrodlTDobrowolnyHBusseSBernsteinHGBogertsBTruebnerKSteinerJReduced volumes of the"/>
   <result pre="volumes of the external and internal globus pallidus in male" exact="heroin" post="addicts: a postmortem studyEur Arch Psychiatry Clin Neurosci201926931732430173319 MurphyABarbaroJMartinez-AguadoPChilundaVJaureguiberry-BravoMBermanJWThe"/>
   <result pre="drugs of abuse and HIV infectionNeuroAIDS19992112 NathAJonesMMaragosWBoozeRMactutusCBellJHauserKFMattsonMNeurotoxicity and dysfunction of" exact="dopamine" post="systems associated with AIDS dementiaPsychopharmacol200014222227 NathAAndersonCJonesMMaragosWBoozeRMactutusCBellJHauserKFMattsonMNeurotoxicity and dysfunction of"/>
   <result pre="NieminenTHHagelbergNMSaariTINeuvonenMNeuvonenPJLaineKOlkkolaKTOxycodone concentrations are greatly increased by the concomitant use of" exact="ritonavir" post="or lopinavir/ritonavirEur J Clin Pharmacol20106697798520697700 NobleFMarieNManagement of opioid addiction"/>
   <result pre="Cell Biochem200830816917517934700 PetersPJet al.HIV infection linked to injection use of" exact="oxymorphone" post="in Indiana, 2014-2015N Engl J Med201637522923927468059 PetersonPKSharpBMGekkerGPortoghesePSSannerudKBalfourHHJrMorphine promotes the"/>
   <result pre="NeuroImmune Pharmacol2012787789122101471 PolliJWJarrettJLStudenbergSDHumphreysJEDennisSWBrouwerKRWoolleyJLRole of P-glycoprotein on the CNS disposition of" exact="amprenavir" post="(141W94), an HIV protease inhibitorPharm Res1999161206121210468021 PriceRWBrewBSidtisJRosenblumMScheckACClearyPThe brain in"/>
   <result pre="HIV-1 infection and AIDS dementia complexScience19882395865923277272 ProtassLMDelayed postanoxic encephalopathy after" exact="heroin" post="useAnn Intern Med1971747387395559439 ProudnikovDRandesiMLevranOCrystalHDornMOttJHoAKreekMJAssociation of polymorphisms of the mu"/>
   <result pre="persistenceAIDS Rev201921112230899112 QiuYJiangGSuHLvXZhangXTianJZhuoFProgressive white matter microstructure damage in male chronic" exact="heroin" post="dependent individuals: a DTI and TBSS studyPLoS One20138e6321223650554 Qureshi"/>
   <result pre="Dis 49:780â€&quot;786 Salahuddin MF, Qrareya AN, Mahdi F, Jackson D," exact="Foster" post="M, Vujanovic T, Box JG, Paris JJ (2020) Combined"/>
   <result pre="T, Box JG, Paris JJ (2020) Combined HIV-1 Tat and" exact="oxycodone" post="activate the hypothalamic-pituitary-adrenal and -gonadal axes and promote psychomotor,"/>
   <result pre="Med 14:e8â€&quot;e9. 10.1097/ADM.0000000000000685 SanchezESBigbeeJWFobbsWRobinsonSESato-BigbeeCOpioid addiction and pregnancy: perinatal exposure to" exact="buprenorphine" post="affects myelination in the developing brainGlia2008561017102718381654 SarkisyanDHussainMZWatanabeHKononenkoOBazovIZhouXYamskovaOKrishtalOKarpyakVMYakovlevaTBakalkinGDownregulation of the"/>
   <result pre="Determination that a public health emergency exists. https://www.hhs.gov/sites/default/files/opioid%20PHE%20Declaration-no-sig.pdf SerafiniRAPryceKDZachariouVThe mesolimbic" exact="dopamine" post="system in chronic pain and associated affective comorbiditiesBiol Psychiatry202087647331806085"/>
   <result pre="turnover correlated with morphine-seeking behavior of ratsPharmacol Biochem Behav1982165095196123120 SmithJECoCLaneJDLimbic" exact="acetylcholine" post="turnover rates correlated with rat morphine-seeking behaviorsPharmacol Biochem Behav1984204294426538688"/>
   <result pre="Biol2003741074108212972507 SzetoCYTangNLLeeDTStadlinAAssociation between mu opioid receptor gene polymorphisms and Chinese" exact="heroin" post="addictsNeuroreport2001121103110611338173 TakahashiKYiHLiuCHLiuSKashiwagiYPatinDJHaoSSpinal bromodomain-containing protein 4 contributes to neuropathic pain"/>
   <result pre="attenuates the (âˆ’)-morphine-produced conditioned place preference and the mu-opioid receptor-mediated" exact="dopamine" post="increase in the posterior nucleus accumbens of the ratEur"/>
   <result pre="of the Toll-like receptor 4 antagonist (+)-naltrexone on incubation of" exact="heroin" post="craving. Biol Psychiatry 73:729â€&quot;737 ThompsonAROpioids and their proper use"/>
   <result pre="abuse. Cellular and molecular life sciences 64:2120â€&quot;2132 VenutoCSMollanKMaQDaarESSaxPEFischlMCollierACSmithKYTierneyCMorseGDSex differences in" exact="atazanavir" post="pharmacokinetics and associations with time to clinical events: AIDS"/>
   <result pre="opioid use disorder: a research synthesis and meta-analysisAm J Drug" exact="Alcohol" post="Abuse201945112530359116 Wu DT, Woodman SE, Weiss JM, McManus CM,"/>
   <result pre="spliced mu opioid receptor variants: mMOR-1A, mMOR-1O, and mMOR-1PSynapse20146814415224375714 XuJLuZXuMPanLDengYXieXLiuHDingSHurdYLPasternakGWKleinRJCartegniLZhouWPanYXA" exact="heroin" post="addiction severity-associated intronic single nucleotide polymorphism modulates alternative pre-mRNA"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7464065\results\search\drug\results.xml">
   <result pre="have beneficial effects in COVID-19 therapy [111, 134]. Remdesivir and" exact="chloroquine" post="have been reported to inhibit SARS-CoV-2 in vitro [35]"/>
   <result pre="proved enough efficacy in clinical trials. In the case of" exact="chloroquine" post="and hydroxychloroquine, although initially was thought to be useful"/>
   <result pre="is insufficient evidence to support the effectiveness or safety of" exact="hydroxychloroquine" post="or chloroquine for the treatment of COVID-19 in hospitalized"/>
   <result pre="evidence to support the effectiveness or safety of hydroxychloroquine or" exact="chloroquine" post="for the treatment of COVID-19 in hospitalized patients as"/>
   <result pre="but its clinical utility remains to be confirmed [142â€&quot;144]. Remdesivir," exact="chloroquine" post="and hydroxychloroquine though being used in COVID-19 patients under"/>
   <result pre="clinical utility remains to be confirmed [142â€&quot;144]. Remdesivir, chloroquine and" exact="hydroxychloroquine" post="though being used in COVID-19 patients under the common"/>
   <result pre="have RCTs, then no conclusions yet can be made [155]." exact="Ribavirin" post="and favipiravir are RNA polymerase inhibitors and have been"/>
   <result pre="or in combination with IFN-Î± in COVID-19 patients [156]. Tocilizumab," exact="ivermectin" post="does not have RCTs yet, although they have preclinical"/>
   <result pre="[167, 168]. During the SARS outbreak, HIV protease inhibitors like" exact="lopinavir" post="and ritonavir had positive efficacy [169]. In vitro and"/>
   <result pre="During the SARS outbreak, HIV protease inhibitors like lopinavir and" exact="ritonavir" post="had positive efficacy [169]. In vitro and in vivo"/>
   <result pre="better anti-viral efficacy as compared to the combined formula of" exact="lopinavir" post="and ritonavir in treating MERS-CoV infections [173]. Since the"/>
   <result pre="efficacy as compared to the combined formula of lopinavir and" exact="ritonavir" post="in treating MERS-CoV infections [173]. Since the novel coronavirus"/>
   <result pre="the Peopleâ€™s Republic of China has advocated the inclusion of" exact="chloroquine" post="phosphate for the cure of COVID-19 patients, in its"/>
   <result pre="[177]. Chen et al. [18] have used oseltamivir (75 mg)," exact="lopinavir" post="(500 mg), ritonavir (500 mg) per os twice daily"/>
   <result pre="al. [18] have used oseltamivir (75 mg), lopinavir (500 mg)," exact="ritonavir" post="(500 mg) per os twice daily followed by ganciclovir"/>
   <result pre="mg), ritonavir (500 mg) per os twice daily followed by" exact="ganciclovir" post="(0.25 g) intravenously for 3â€&quot;14 days in COVID-19 infected"/>
   <result pre="[178]. Anti-viral proteases Anti-coronavirus protease activity was exhibited by the" exact="lopinavir" post="(LPV), and it is proposed as a treatment option"/>
   <result pre="evaluated. Chen et al. [18] have used oseltamivir, lopinavir, ritonavir," exact="ganciclovir" post="in COVID-19 infected patients with excellent results; however, the"/>
   <result pre="controversial [165]. Other medications used are antibiotics (cephalosporins, quinolones, carbapenems," exact="tigecycline" post="against methicillin-resistant Staphylococcus aureus, linezolid, moxifloxacin or levofloxacin, azithromycin"/>
   <result pre="carbapenems, tigecycline against methicillin-resistant Staphylococcus aureus, linezolid, moxifloxacin or levofloxacin," exact="azithromycin" post="or amoxicillin, and antifungal drugs), corticosteroids (prednisolone, dexamethasone), antipyretics"/>
   <result pre="135, 165, 189, 190]. Huang et al. [25] used antibiotics," exact="methylprednisolone" post="corticosteroid (40â€&quot;120 mg per day), and oseltamivir (orally 75"/>
   <result pre="192]. National Health Commission of China recommended a combination of" exact="ribavirin" post="and interferon-Î± as a treatment regimen for COVID-19 in"/>
   <result pre="SARS-CoV in combination with antibiotics (moxifloxacin or levofloxacin, nemonoxacin, linezolid," exact="azithromycin" post="or amoxicillin), corticosteroids and oxygen therapy has been used"/>
   <result pre="promising candidates, including as mentioned combination therapies, including remdesivir, and" exact="ivermectin" post="[115]. Many newer drugs or candidates are being evaluated"/>
   <result pre="is disclosed, which comprises: administering a first effective amount of" exact="phenol" post="red and a second effective amount of an organic"/>
   <result pre="a vaccine composition Kim [265] 2017-01-19 WO2017010835A1 Drug/treatment Use of" exact="radotinib" post="for prevention or treatment of viral respiratory disease The"/>
   <result pre="the race for patents. These include remdesivir of Gilead SciencesÂ®," exact="hydroxychloroquine" post="of SanofiÂ® and Kaletra (Lopinavir+Ritonavir) of AbbvieÂ®. They are"/>
   <result pre="These include remdesivir of Gilead SciencesÂ®, hydroxychloroquine of SanofiÂ® and" exact="Kaletra" post="(Lopinavir+Ritonavir) of AbbvieÂ®. They are patented for use against"/>
   <result pre="242]. Chinese were first to evaluate the effectiveness of remdesivir," exact="chloroquine" post="and Kaletra in treating COVID-19 patients [25, 136]. However,"/>
   <result pre="were first to evaluate the effectiveness of remdesivir, chloroquine and" exact="Kaletra" post="in treating COVID-19 patients [25, 136]. However, simultaneous intentions"/>
   <result pre="and recent developmentsVet Q202040111231858882 101.collab: Health Commission ChinaExpert consensus on" exact="chloroquine" post="phosphate for the treatment of novel coronavirus pneumoniaChin J"/>
   <result pre="of COVID-19 pneumonia in a patient from Colombia after receiving" exact="chloroquine" post="and clarithromycinAnn Clin Microbiol Antimicrob20201911632331519 115.SandersJMMonogueMLJodlowskiTZCutrellJBPharmacologic Treatments for Coronavirus"/>
   <result pre="and pathogenesis of coronavirus disease (COVID-19) outbreakJ Autoimmun202010910243332113704 136.WangMCaoRZhangLYangXLiuJXuMShiZHuZZhongWXiaoGRemdesivir and" exact="chloroquine" post="effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in"/>
   <result pre="controlled trialBMJ2020369m184932409561 138.BorbaMGSValFFASampaioVSAlexandreMAAMeloGCBritoMMouraoMPGBrito-SousaJDBaia-da-SilvaDGuerraMVFet al.Effect of High vs Low Doses of" exact="Chloroquine" post="Diphosphate as Adjunctive Therapy for Patients Hospitalized With Severe"/>
   <result pre="Infection: A Randomized Clinical TrialJAMA Netw Open202034e20885732339248 139.LiuXChenHShangYZhuHChenGChenYLiuSZhouYHuangMHongZet al.Efficacy of" exact="chloroquine" post="versus lopinavir/ritonavir in mild/general COVID-19 infection: a prospective, open-label,"/>
   <result pre="Roman YM, Pasupuleti V, Barboza JJ, White CM. Update Alert:" exact="Hydroxychloroquine" post="or Chloroquine for the Treatment or Prophylaxis of COVID-19."/>
   <result pre="Pasupuleti V, Barboza JJ, White CM. Update Alert: Hydroxychloroquine or" exact="Chloroquine" post="for the Treatment or Prophylaxis of COVID-19. Ann Intern"/>
   <result pre="141.Hernandez AV, Roman YM, Pasupuleti V, Barboza JJ, White CM." exact="Hydroxychloroquine" post="or Chloroquine for Treatment or Prophylaxis of COVID-19: A"/>
   <result pre="Roman YM, Pasupuleti V, Barboza JJ, White CM. Hydroxychloroquine or" exact="Chloroquine" post="for Treatment or Prophylaxis of COVID-19: A Living Systematic"/>
   <result pre="Report. N Engl J Med. 2020. 146.GeversSKwaMSGWijnansEvan NieuwkoopCSafety considerations for" exact="chloroquine" post="and hydroxychloroquine in the treatment of COVID-19Clin Microbiol Infect20202691276127732422406"/>
   <result pre="Engl J Med. 2020. 146.GeversSKwaMSGWijnansEvan NieuwkoopCSafety considerations for chloroquine and" exact="hydroxychloroquine" post="in the treatment of COVID-19Clin Microbiol Infect20202691276127732422406 147.LiLWangXWangRHuYJiangSLuXAntiviral Agent"/>
   <result pre="Remdesivir for COVID-19: Data to Date. Cardiology. 2020. 149.LedfordHCoronavirus breakthrough:" exact="dexamethasone" post="is first drug shown to save livesNature2020582781346932546811 150.PatelSKSaikumarGRanaJDhamaJYatooMITiwariRRodrÃ­guez-MoralesAJDhamaKDexamethasone: A"/>
   <result pre="critically ill COVID-19 patients?Travel Med Infect Dis20203710184410184432791213 151.MahaseECovid-19: Demand for" exact="dexamethasone" post="surges as RECOVERY trial publishes preprintBMJ2020369m251232576548 152.Group RC, Horby"/>
   <result pre="a randomized controlled trialTrials2018191818129382391 171.FalzaranoDde WitERasmussenALFeldmannFOkumuraAScottDPBriningDBushmakerTMartellaroCBaselerLet al.Treatment with interferon-Î±2b and" exact="ribavirin" post="improves outcome in MERS-CoV-infected rhesus macaquesNat Med201319101313131724013700 172.WangZChenXLuYChenFZhangWClinical characteristics"/>
   <result pre="and interferon beta against MERS-CoVNat Commun202011122231924756 174.YaoT-TQianJ-DZhuW-YWangYWangG-QA systematic review of" exact="lopinavir" post="therapy for SARS coronavirus and MERS coronavirus-A possible reference"/>
   <result pre="possible reference for coronavirus disease-19 treatment optionJ Med Virol202010.1002/jmv.2572932648948 175.GaoJTianZYangXBreakthrough:" exact="Chloroquine" post="phosphate has shown apparent efficacy in treatment of COVID-19"/>
   <result pre="Ahn CA, Bang HY, Song SE, Park JS. Use of" exact="radotinib" post="for prevention or treatment of viral respiratory disease. 2017."/>
   <result pre="the future. J Am Pharm Assoc. 2020. 254.DellapianaGNaqviMLeggettCTholemeierLBurwickRMPreferential use of" exact="dexamethasone" post="for fetal lung maturation in severe COVID-19Am J Obst"/>
   <result pre="Chen Z, Deng K-Q, Lin L, Chen M-M et al:" exact="Metformin" post="use is associated with increased incidence of acidosis but"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7464173\results\search\drug\results.xml">
   <result pre="structure have an important place. Examples of such drugs include" exact="cidofovir" post="(active against herpes simplex virus HSV-1 and HSV-2, as"/>
   <result pre="and Methods 2.1. Synthesis All solvents used in reactions were" exact="dried" post="and purified according to standard procedures. The progress of"/>
   <result pre="of hexane and ethyl acetate (3:2, v/v) or chloroform and" exact="ethanol" post="(15:1, v/v). The spots were visualized by spraying them"/>
   <result pre="mL) was added to the residue and washed with saturated" exact="sodium bicarbonate" post="solution and water. The organic layer was dried with"/>
   <result pre="saturated sodium bicarbonate solution and water. The organic layer was" exact="dried" post="with anhydrous sodium sulphate (VI), then concentrated until dry."/>
   <result pre="bicarbonate solution and water. The organic layer was dried with" exact="anhydrous" post="sodium sulphate (VI), then concentrated until dry. The product"/>
   <result pre="hydrochloric acid solution and with water. The organic layer was" exact="dried" post="with anhydrous sodium sulphate (VI) and concentrated until dry"/>
   <result pre="solution and with water. The organic layer was dried with" exact="anhydrous" post="sodium sulphate (VI) and concentrated until dry in a"/>
   <result pre="For toxic/side effect study we used crystal structure of the" exact="pyruvate" post="kinase (PDB ID: 6NU1), aconitase (PDB ID: 1C96), cytochrome"/>
   <result pre="= 42.156, Y = âˆ’15.872 and Z = 28.523 for" exact="pyruvate" post="kinase, X = 69.590, Y = 67.860 and Z"/>
   <result pre="available for SARS-CoV-2-related diseases. Studies of remdesivir, phosphoramidate of an" exact="adenosine" post="C-nucleoside analog, have brought attention to the possible application"/>
   <result pre="5-azacytosine acyclic nucleoside phosphonates using NMR spectroscopyBioorg. Med. Chem.2008166778678210.1016/j.bmc.2008.05.05818554916 8.BroganelliP.ChiarettaA.FragnelliB.BernengoM.G.Intralesional" exact="cidofovir" post="for the treatment of multiple and recalcitrant cutaneous viral"/>
   <result pre="by a ligand-protein inverse docking approachJ. Mol. Graph.20012019921810.1016/S1093-3263(01)00109-7 44.ZanellaA.BianchiP.Red cell" exact="pyruvate" post="kinase deficiency: From genetics to clinical manifestationsBest. Pract. Res."/>
   <result pre="Cytochrome c in apoptosis: Increased sensitivity to tumor necrosis factor" exact="alpha" post="is associated with respiratory defects but not with lack"/>
   <result pre="Spike Glycoprotein with Saikosaponin, a triterpenoid natural productChemRxiv202010.26434/chemrxiv.12033774.v1 57.WangM.CaoR.ZhangL.YangX.LiuJ.XuM.ShiZ.HuZ.ZhongW.XiaoG.Remdesivir and" exact="chloroquine" post="effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in"/>
   <result pre="Protein Physiological Function Site of Action Effect of Deficiency/Inhibition Ref." exact="pyruvate" post="kinase glycolysis cytosol hemolytic anemia [44] aconitase citric acid"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7464234\results\search\drug\results.xml">
   <result pre="a rapidly progressive and widespread alveolar damage [11]. Transmembrane Protease," exact="Serine" post="2 (TMPRSS2) by contrast, is a transmembrane serine protease"/>
   <result pre="the female gender. Genetic hormonal differences have been reported, and" exact="testosterone" post="seems to favor a more severe evolution of the"/>
   <result pre="consists of off-label or compassionate therapies, antiparasitic agents including chloroquine," exact="hydroxychloroquine" post="and nitazoxanide, antibiotics, antiretroviral agents, anti-inflammatory and anti-coagulant compounds"/>
   <result pre="RNA-Dependent RNA Polymerase Inhibitors (RdRp), there is Remdesivir (RDV), an" exact="adenosine" post="analog previously used as anti-Ebola virus drug recently approved"/>
   <result pre="of COVID-19 [59]. The TMPRSS2 cell entry of SARS-CoV-2 inhibitors" exact="camostat" post="mesylate, nafamostat, and bromhexine may treat COVID-19 [60]. Anti-inflammatory"/>
   <result pre="TMPRSS2 cell entry of SARS-CoV-2 inhibitors camostat mesylate, nafamostat, and" exact="bromhexine" post="may treat COVID-19 [60]. Anti-inflammatory molecules potentially efficacy against"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7465216\results\search\drug\results.xml">
   <result pre="around this topic. Increases in the levels of the antioxidant" exact="glutathione" post="(GSH) plays a critical role in maintaining dendritic cell"/>
   <result pre="a significant role in M. tb infection. Furthermore, in vitro" exact="glutathione" post="(GSH) treatment of immune cells isolated from Mycobacterium bovis"/>
   <result pre="this results in advancement of active TB infection [95]. 10." exact="Glutathione" post="with Dendritic Cells to Improve Immune Response Studies have"/>
   <result pre="the functions of DCs against both TB and HIV infections." exact="Glutathione" post="(Î³- l-glutamyl- l-cysteinyl-glycine) is a tripeptide antioxidant composed of"/>
   <result pre="as well as many prokaryotic cells [99,100]. The synthesis of" exact="glutathione" post="is driven by system xcâˆ’ (Sxcâˆ’), an amino acid"/>
   <result pre="consists of the balance of reduced (GSH) and oxidized (GSSG)" exact="glutathione" post="[102]. When exposed to reactive oxygen species (ROS), two"/>
   <result pre="and induces an antioxidant response. It also enhances system xcâˆ’-dependent" exact="cystine" post="uptake, leading to increased GSH synthesis, export, and finally,"/>
   <result pre="HIV+ individuals. This reduction was coupled with decreased levels of" exact="cystine" post="in plasma, thereby affecting DC functionality [111,113]. The net"/>
   <result pre="stress linked with increased viral replication [114]. The addition of" exact="N-acetylcysteine" post="(NAC), a prodrug that supplies bioavailable cysteine, replenishes whole"/>
   <result pre="Harb. Perspect. Med.20145a01779810.1101/cshperspect.a01779825359550 4.ChangC.C.CraneM.ZhouJ.MinaM.PostJ.J.CameronB.A.LloydA.R.JaworowskiA.FrenchM.A.LewinS.R.HIV and co-infectionsImmunol. Rev.201325411414210.1111/imr.1206323772618 5.LawnS.D.WoodR.De CockK.M.KranzerK.LewisJ.J.ChurchyardG.J.Antiretrovirals and" exact="isoniazid" post="preventive therapy in the prevention of HIV-associated tuberculosis in"/>
   <result pre="molecular pharmacology and roles within the CNSBr. J. Pharmacol.2012165203410.1111/j.1476-5381.2011.01480.x21564084 102.KamideY.UtsugiM.DobashiK.OnoA.IshizukaT.HisadaT.KogaY.UnoK.HamuroJ.MoriM.Intracellular" exact="glutathione" post="redox status in human dendritic cells regulates IL-27 production"/>
   <result pre="Natl. Acad. Sci. USA2002991491149610.1073/pnas.02263029911792859 111.BenharM.ShytajI.L.StamlerJ.S.SavarinoA.Dual targeting of the thioredoxin and" exact="glutathione" post="systems in cancer and HIVJ. Clin. Investig.20161261630163910.1172/JCI8533927135880 112.IvanovA.V.Valuev-EllistonV.T.IvanovaO.N.KochetkovS.N.StarodubovaE.S.BartoschB.IsaguliantsM.G.Oxidative Stress"/>
   <result pre="B transcription factor and HIV-1EMBO J.1991102247225810.1002/j.1460-2075.1991.tb07761.x2065663 115.De RosaS.C.ZaretskyM.D.DubsJ.G.RoedererM.AndersonM.GreenA.MitraD.WatanabeN.NakamuraH.TjioeI.et al.N-acetylcysteine replenishes" exact="glutathione" post="in HIV infectionEur. J. Clin. Investig.20003091592910.1046/j.1365-2362.2000.00736.x11029607 Figure 1 Dendritic"/>
   <result pre="robust immune response. Figure 3 The addition of the antioxidant" exact="glutathione" post="maintains redox homeostasis of DCs. This leads to an"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7466376\results\search\drug\results.xml">
   <result pre="and acute lung injury are known. It improves oxygenation rates," exact="glutathione" post="levels and strengthens the immune response. It reduces mechanical"/>
   <result pre="should be selected avoiding subsequent collateral damage for the patient." exact="Chloroquine" post="and Hydroxychloroquine Chloroquine has been proposed for COVID-19 treatment."/>
   <result pre="selected avoiding subsequent collateral damage for the patient. Chloroquine and" exact="Hydroxychloroquine" post="Chloroquine has been proposed for COVID-19 treatment. This drug"/>
   <result pre="avoiding subsequent collateral damage for the patient. Chloroquine and Hydroxychloroquine" exact="Chloroquine" post="has been proposed for COVID-19 treatment. This drug has"/>
   <result pre="is not expensive and has a well-established clinical safety profile." exact="Chloroquine" post="and hydroxychloroquine are nowadays employed against autoimmune disease and"/>
   <result pre="expensive and has a well-established clinical safety profile. Chloroquine and" exact="hydroxychloroquine" post="are nowadays employed against autoimmune disease and in the"/>
   <result pre="of some DNA and RNA viruses, such as SARS-CoV-1 [46]." exact="Chloroquine" post="is a form of quinine consisting of an acidotropic"/>
   <result pre="viruses, such as SARS-CoV-1 [46]. Chloroquine is a form of" exact="quinine" post="consisting of an acidotropic amine. It was synthesized in"/>
   <result pre="Bayer and surged as an efficient replacement for natural quinine." exact="Quinine" post="is found in Cinchona trees that grow in Peru."/>
   <result pre="found in Cinchona trees that grow in Peru. In vitro," exact="chloroquine" post="is a versatile bioactive agent that has antiviral activity"/>
   <result pre="and the hepatitis B virus which are DNA viruses [46]." exact="Chloroquine" post="suppresses the entrance of viruses into host cells and"/>
   <result pre="into host cells and inhibits glycosylation of viral proteins [47]." exact="Chloroquine" post="was effective in decreasing viral replication, in a concentration"/>
   <result pre="it easily penetrates in tissues, such as the lung [47]." exact="Chloroquine" post="blocks viral infection by alkalinizing the endosomal pH in"/>
   <result pre="the nucleic acid and the required enzymes for replication [48]." exact="Chloroquine" post="also alters the immune system functioning through activation of"/>
   <result pre="through activation of cell signaling and pro-inflammatory cytokine control [49]." exact="Chloroquine" post="suppresses phosphorylation of caspase-1 and of the p38 mitogen-activated"/>
   <result pre="the viruses to replicate. In the model of HCoV-229 coronavirus," exact="chloroquine" post="inhibited the virus by suppression of p38 mitogen-activated protein"/>
   <result pre="the virus by suppression of p38 mitogen-activated protein kinase. Moreover," exact="chloroquine" post="reduced IL-1Î² release and diminished interleukin IL-1Î² mRNA expression"/>
   <result pre="release and diminished interleukin IL-1Î² mRNA expression in THP-1 cells." exact="Chloroquine" post="also decreased IL-6 and IL-1 in monocytes and macrophages"/>
   <result pre="Clinical studies have recommended a dose of 500 mg of" exact="chloroquine" post="twice per day for 10 days, in patients with"/>
   <result pre="no contraindications to the drug. In adults 600 mg of" exact="chloroquine" post="can be given and then 300 mg after 12"/>
   <result pre="effects, the drug has a long half-life (30 h) [52]." exact="Chloroquine" post="was efficient against SARS-CoV-2 in Vero E6 cells using"/>
   <result pre="and EC90 values) of 1.13 Î¼M and 6.90 Î¼M. Therefore," exact="chloroquine" post="improves the evolution of pneumonia in COVID-19 patients [53]."/>
   <result pre="chloroquine improves the evolution of pneumonia in COVID-19 patients [53]." exact="Chloroquine" post="also diminishes the activity of the enzyme quinone reductase"/>
   <result pre="on cell transmembrane proteins that participate in ligand recognition. When" exact="chloroquine" post="interferes with the biosynthesis of sialic acid could be"/>
   <result pre="such as the orthomyxoviruses and the human coronavirus HCoV-O43 [55]." exact="Hydroxychloroquine" post="is different from chloroquine since it has hydroxyl group"/>
   <result pre="and the human coronavirus HCoV-O43 [55]. Hydroxychloroquine is different from" exact="chloroquine" post="since it has hydroxyl group at the end of"/>
   <result pre="the side chain. This molecule can be ingested orally as" exact="hydroxychloroquine" post="sulfate. The pharmacokinetics of hydroxychloroquine resembles that of chloroquine,"/>
   <result pre="can be ingested orally as hydroxychloroquine sulfate. The pharmacokinetics of" exact="hydroxychloroquine" post="resembles that of chloroquine, having a rapid gastrointestinal absorption"/>
   <result pre="having a rapid gastrointestinal absorption and elimination by the kidney." exact="Hydroxychloroquine" post="has a good tolerance and can be used in"/>
   <result pre="[56]. In the present global infection of SARS-CoV-2, treatment with" exact="hydroxychloroquine" post="combined with azithromycin, a macrolide antibiotic, resulted in 100%"/>
   <result pre="cured in contrast with only 57.1% of subjects treated with" exact="hydroxychloroquine" post="alone and 12.5% with the control group. It was"/>
   <result pre="12.5% with the control group. It was therefore concluded that" exact="chloroquine" post="and hydroxychloroquine should be used in patients suffering from"/>
   <result pre="the control group. It was therefore concluded that chloroquine and" exact="hydroxychloroquine" post="should be used in patients suffering from pneumonia caused"/>
   <result pre="be used in patients suffering from pneumonia caused by SARS-CoV-2." exact="Chloroquine" post="has also been proposed as a preventative treatment for"/>
   <result pre="[57]. In that study the authors gave 600 mg of" exact="chloroquine" post="for 14 days and found a 50% efficacy of"/>
   <result pre="the viral load at day 7. They also reported that" exact="hydroxychloroquine" post="failed in two patients (mother and son) and concluded"/>
   <result pre="side effects of the drug administration [58]. 4. Drawbacks of" exact="Chloroquine" post="and Hydroxychloroquine Cardiovascular side effects, particularly prolongation of the"/>
   <result pre="of the drug administration [58]. 4. Drawbacks of Chloroquine and" exact="Hydroxychloroquine" post="Cardiovascular side effects, particularly prolongation of the QT interval"/>
   <result pre="clinical trials registered on the effects of the use of" exact="chloroquine" post="and hydroxychloroquine. There is a Clinical Trial in which"/>
   <result pre="currents. In autoimmune disease patients, drug-induced arrhythmias, caused by chloroquine," exact="methotrexate" post="and corticosteroids may also appear [60]. Therefore, the use"/>
   <result pre="showed that Remdesivir and INF-Î² were more effective than lopinavir," exact="ritonavir" post="and INF-Î² in-vitro and in a MERS-CoV mouse model."/>
   <result pre="In the treatment of SARS-CoV-2, antivirals which include oseltamivir, lopinavir/ritonavir," exact="ganciclovir" post="and ribavirin have been employed [65]. 5. Anti-Inflammatory Drugs"/>
   <result pre="treatment of SARS-CoV-2, antivirals which include oseltamivir, lopinavir/ritonavir, ganciclovir and" exact="ribavirin" post="have been employed [65]. 5. Anti-Inflammatory Drugs The release"/>
   <result pre="the IL-18RÎ± receptor. IL-37 acts on mTOR thus elevating the" exact="adenosine" post="monophosphate kinase that has immunosuppressive activity. By inhibiting IL-6,"/>
   <result pre="may be combined with antivirals that act directly (lopinavir or" exact="ritonavir" post="and Remdesivir) and which are now being tested in"/>
   <result pre="in the liver and most of the metabolites produced from" exact="chloroquine" post="and hydroxychloroquine sulfate, oseltamivir, ribavirin and lopinavir/ritonavir, are eliminated"/>
   <result pre="liver and most of the metabolites produced from chloroquine and" exact="hydroxychloroquine" post="sulfate, oseltamivir, ribavirin and lopinavir/ritonavir, are eliminated in urine."/>
   <result pre="of the metabolites produced from chloroquine and hydroxychloroquine sulfate, oseltamivir," exact="ribavirin" post="and lopinavir/ritonavir, are eliminated in urine. Therefore, their metabolism"/>
   <result pre="treat non-cirrhotic genotype 1b chronic hepatitis C, combined with ribavirin," exact="ritonavir" post="and peginterferon-Î± [75]. Currently, a trial study has been"/>
   <result pre="which, when combined with ritonavir, predisposes to severe hypotension [78]." exact="Ritonavir" post="increases the concentration of alfuzosine and may constitute a"/>
   <result pre="are also being treated for arrhythmias [79]. The use of" exact="amiodarone" post="increases its plasmatic concentrations and increases the risk of"/>
   <result pre="is also common in elderly patients. Their use together with" exact="ritonavir" post="and pimozide increases the risk of severe hematologic diseases."/>
   <result pre="common in elderly patients. Their use together with ritonavir and" exact="pimozide" post="increases the risk of severe hematologic diseases. The use"/>
   <result pre="increases the risk of severe hematologic diseases. The use of" exact="ritonavir" post="with antihistaminic drugs such as astemizol, terfenadine or with"/>
   <result pre="The use of ritonavir with antihistaminic drugs such as astemizol," exact="terfenadine" post="or with drugs that control the gastric motility increases"/>
   <result pre="to arrhythmias [77]. Furthermore, the use of sedatives such as" exact="sildenafil" post="which is also used to control pulmonary arterial hypertension"/>
   <result pre="combined with ritonavir. Moreover, the concentration and clinical effects of" exact="lopinavir" post="and ritonavir may be decreased in patients that use"/>
   <result pre="ritonavir. Moreover, the concentration and clinical effects of lopinavir and" exact="ritonavir" post="may be decreased in patients that use alternative medicine"/>
   <result pre="the following antioxidant compounds for the treatment of COVID-19. 11." exact="N-acetylcysteine" post="Preclinical studies have proposed the administration of N-acetylcysteine (NAC),"/>
   <result pre="COVID-19. 11. N-acetylcysteine Preclinical studies have proposed the administration of" exact="N-acetylcysteine" post="(NAC), a precursor of glutathione, as a strategy to"/>
   <result pre="stress lung injury since it increases the content of intracellular" exact="glutathione" post="[89]. A central feature of many lung diseases is"/>
   <result pre="many lung diseases is the alterations of the metabolism of" exact="glutathione" post="that occurs both in the alveoli and lung tissue"/>
   <result pre="alveoli and lung tissue [90]. NAC increases the synthesis of" exact="glutathione" post="synthesis, elevates glutathione-S-transferase activity and has a direct action"/>
   <result pre="tissue myeloperoxidase activity or 3-nitrotyrosine levels [91]. The application of" exact="N-acetylcysteine" post="decreases the levels of IL-8, IL-6, ICAM and the"/>
   <result pre="absorbed at the intestinal level through the sodium-dependent transporter of" exact="vitamin C," post="filtered freely in the glomerulus and reabsorbed at the"/>
   <result pre="of leukocytes in the microcirculation [104]. Decreased plasma levels of" exact="vitamin C" post="may be due to inadequate intake, acute or chronic"/>
   <result pre="increased oxidative stress or increased loss [105]. Low levels of" exact="vitamin C" post="have been documented in critically ill patients in several"/>
   <result pre="and mortality [107]. In a study where the safety of" exact="vitamin C" post="administration in patients with severe sepsis was evaluated and"/>
   <result pre="with severe sepsis was evaluated and two different doses of" exact="vitamin C" post="were compared (50 mg/kg/24 h and 200 mg/kg/24 h)"/>
   <result pre="No adverse effects were reported in the patients who received" exact="vitamin C" post="infusion. The patients who received vitamin C had a"/>
   <result pre="patients who received vitamin C infusion. The patients who received" exact="vitamin C" post="had a greater decrease in the SOFA score compared"/>
   <result pre="group. Decreased C-reactive protein and procalcitonin were reported in the" exact="vitamin C" post="group. Lower levels of thrombomodulin were found in the"/>
   <result pre="C group. Lower levels of thrombomodulin were found in the" exact="vitamin C" post="group compared to placebo. 28-day mortality was also lower"/>
   <result pre="to placebo. 28-day mortality was also lower in the low-dose" exact="vitamin C" post="group (38.1%) compared to the high-dose group (50.6%) and"/>
   <result pre="days or days of ICU stay. A 96-h infusion of" exact="vitamin C" post="in contrast to placebo did not improve vascular injury,"/>
   <result pre="further research was necessary to evaluate the potential role of" exact="vitamin C" post="for other outcomes in ARDS [108]. However, diets enriched"/>
   <result pre="diets enriched with antioxidants (320 IU/L vitamin E, 840 mg/L" exact="vitamin C" post="and 320 mg/L taurine), eicosapentaenoic acid (4.5 g/L) and"/>
   <result pre="vitamin E, 840 mg/L vitamin C and 320 mg/L taurine)," exact="eicosapentaenoic acid" post="(4.5 g/L) and gamma-linolenic acid (4.3 g/L) showed a"/>
   <result pre="patients receiving 60 IU/L Î±-tocopherol (vitamin E) and 340 mg/L" exact="vitamin C" post="through an oro-gastric tube. There was a lower multiple"/>
   <result pre="There was a lower multiple organ failure. Vitamin E and" exact="vitamin C" post="administration also decreased the length of ICU stay. However,"/>
   <result pre="and fewer days of mechanical ventilation in patients treated with" exact="vitamin C" post="and vitamin E. Another randomized, double-blind, placebo-controlled study found"/>
   <result pre="days of mechanical ventilation in patients who were treated with" exact="vitamin C" post="and vitamin E [113]. The combined effect of therapy"/>
   <result pre="[113]. The combined effect of therapy with vitamin E and" exact="vitamin C" post="in severe post-operative patients resulted in a decrease in"/>
   <result pre="which results from COVID-19 [115]. 13. Melatonin N-acetyl-5-methoxytryptamine also called" exact="melatonin" post="(MT) is the main endogenous product of secretion of"/>
   <result pre="[119] and reduce levels of hydroperoxide in mitochondria by restoring" exact="glutathione" post="homeostasis and mitochondrial function in organelles under oxidative stress"/>
   <result pre="stimulate gamma-glutamyl cysteine synthase; therefore, it can increase the intracellular" exact="glutathione" post="synthesis [121]. Another of its antioxidant mechanisms is through"/>
   <result pre="the use of diclofenac, celecoxib, fluvastatin, glipizide, ibuprofen, irbesartan, losartan" exact="phenytoin" post="and others with cytochrome p450 2C9 substrate (CYP2C9) and"/>
   <result pre="(CYP2C9) and with p450 2C (CYP2C8) such as paclitaxel, rosiglitazone," exact="amiodarone" post="and verapamil. However, QRC is currently a promise as"/>
   <result pre="be considered is potentially effective as an antiviral [131]. 15." exact="Pentoxifylline" post="Pentoxifylline is a xanthine indicated in some severe cases"/>
   <result pre="considered is potentially effective as an antiviral [131]. 15. Pentoxifylline" exact="Pentoxifylline" post="is a xanthine indicated in some severe cases of"/>
   <result pre="blood cells rendering it more malleable, thus improving blood perfusion." exact="Pentoxifylline" post="exerts several antioxidant and anti-inflammatory activities; it restores glutathione"/>
   <result pre="perfusion. Pentoxifylline exerts several antioxidant and anti-inflammatory activities; it restores" exact="glutathione" post="levels, it maintains mitochondrial viability, it inhibits TNF-Î± production,"/>
   <result pre="with a mean gestational age of 30 weeks, administration of" exact="pentoxifylline" post="(5 mg/kg/h iv for 6 h for 6 days)"/>
   <result pre="no difference in short-term morbidity was observed between treated with" exact="pentoxifylline" post="and untreated neonates with sepsis [135]. In a meta-analysis"/>
   <result pre="sepsis [135]. In a meta-analysis involving 6 studies, with the" exact="pentoxifylline" post="administration of in septic infants, pentoxifylline was shown to"/>
   <result pre="6 studies, with the pentoxifylline administration of in septic infants," exact="pentoxifylline" post="was shown to be effective in decreasing length of"/>
   <result pre="in a subgroup analysis that resulted in the conclusion that" exact="pentoxifylline" post="may be a beneficial adjuvant treatment in sepsis [136]"/>
   <result pre="[136] and could also be used in COVID-19. Treatment with" exact="pentoxifylline" post="is contraindicated in patients with recent cerebral or retinal"/>
   <result pre="supplementation has been reported to cause better oxygenation rates, increased" exact="glutathione" post="and a stronger immune response. There is a reduction"/>
   <result pre="in ALI/ARDS, have been reported. It improves oxygenation rates; increases" exact="glutathione" post="and promotes a stronger immune response. There is a"/>
   <result pre="of a window of opportunityCMAJ20051731054106510.1503/cmaj.05063216247103 42.ClappB.R.HingoraniA.D.KharbandaR.K.Mohamed-AliV.StephensJ.W.VallanceP.MacAllisterR.J.Inflammation-induced endothelial dysfunction involves reduced" exact="nitric oxide" post="bioavailability and increased oxidant stressCardiovasc. Res.20046417217810.1016/j.cardiores.2004.06.02015364625 43.PÃ©rez-TorresI.Manzano-PechL.Rubio-RuÃ­zM.E.SotoM.E.Guarner-LansV.Nitrosative stress and"/>
   <result pre="mitochondrial dysfunction in sepsis-induced organ failureCrit. Care20061022823210.1186/cc501416953900 46.DanL.XiaodanL.YonggangZ.JoeyK.LingL.YiyiZ.XuC.LiQ.SunX.TianH.et al.Chloroquine and" exact="hydroxychloroquine" post="are associated with reduced cardiovascular risk: A systematic review"/>
   <result pre="the 2019 novel coronavirus SARS-CoV-2Int. J. Antimicrob. Agents20205510592310.1016/j.ijantimicag.2020.10592332070753 48.TouretF.de LamballerieX.Of" exact="chloroquine" post="and COVID-19Antivir. Res.202017710476210.1016/j.antiviral.2020.10476232147496 49.Al-BariM.A.A.Targeting endosomal acidification by chloroquine analogs"/>
   <result pre="48.TouretF.de LamballerieX.Of chloroquine and COVID-19Antivir. Res.202017710476210.1016/j.antiviral.2020.10476232147496 49.Al-BariM.A.A.Targeting endosomal acidification by" exact="chloroquine" post="analogs as a promising strategy for the treatment of"/>
   <result pre="the treatment of emerging viral diseasesPharmacol. Res. Perspec.201750029310.1002/prp2.293 50.RoutyJ.P.AngelJ.B.PatelM.KanagarathamC.RadziochD.KemaI.GilmoreN.AncutaP.SingerJ.JenabianM.A.Assessment of" exact="chloroquine" post="as a modulator of immune activation to improve CD4"/>
   <result pre="receiving antiretroviral therapyHIV Med.201516485610.1111/hiv.1217124889179 51.Van den BorneB.E.DijkmansB.A.de RooijH.H.le CessieS.VerweijC.L.Chloroquine and" exact="hydroxychloroquine" post="equally affect tumor necrosis factor-alpha, interleukin 6 and interferon-gamma"/>
   <result pre="mononuclear cellsJ. Rheumatol.19972455609002011 52.DevauxC.A.RolainJ.ColsonP.RaoultD.New insights on the antiviral effects of" exact="chloroquine" post="against coronavirus: What to expect for COVID-19Int. J. Antimicrob."/>
   <result pre="Agents202010593810.1016/j.ijantimicag.2020.10593832171740 53.CortegianiA.IngogliaG.IppolitoM.GiarratanoA.EinavS.A systematic review on the efficacy and safety of" exact="chloroquine" post="for the treatment of COVID-19J. Crit. Care20205727928310.1016/j.jcrc.2020.03.00532173110 54.ColsonP.RolainJ.M.LagierJ.C.BrouquiP.RaoultD.Chloroquine and"/>
   <result pre="chloroquine for the treatment of COVID-19J. Crit. Care20205727928310.1016/j.jcrc.2020.03.00532173110 54.ColsonP.RolainJ.M.LagierJ.C.BrouquiP.RaoultD.Chloroquine and" exact="hydroxychloroquine" post="as available weapons to fight COVID-19Int. J. Antimicrob. Agents20205510593210.1016/j.ijantimicag.2020.10593232145363"/>
   <result pre="infectionsAdv. Carbohydr. Chem. Biochem.2019766511130851744 57.SahraeiZ.ShabaniM.ShokouhiS.SaffaeiA.Aminoquinolines against coronavirus disease 2019 (COVID-19):" exact="Chloroquine" post="or hydroxychloroquineInt. J. Antimicrob. Agents20205510594510.1016/j.ijantimicag.2020.10594532194152 58.GautretP.LagierJ.C.ParolaP.HoangV.T.MeddebL.MailheM.DoudierB.CourjonJ.GiordanengoV.VieiraV.E.Hydroxychloroquine and azithromycin as"/>
   <result pre="2019 (COVID-19): Chloroquine or hydroxychloroquineInt. J. Antimicrob. Agents20205510594510.1016/j.ijantimicag.2020.10594532194152 58.GautretP.LagierJ.C.ParolaP.HoangV.T.MeddebL.MailheM.DoudierB.CourjonJ.GiordanengoV.VieiraV.E.Hydroxychloroquine and" exact="azithromycin" post="as a treatment of COVID-19: Results of an open-label"/>
   <result pre="effect of oxime derivatives in isolated rat aorta: Role of" exact="nitric oxide" post="(NO) formation in smooth muscleBiochem. Pharmacol.2004671203121410.1016/j.bcp.2003.11.01215006555 85.SingerM.DeutschmanC.S.SeymourC.W.Shankar-HariM.DjillaliB.M.BauerM.BellomoR.BernardG.R.ChicheJ.D.CoopersmithC.M.et al.The third"/>
   <result pre="elastase in acute lung injuryEur. J. Pharmacol.200245111010.1016/S0014-2999(02)02182-912223222 91.RahmanI.MacNeeW.Regulation of redox" exact="glutathione" post="levels and gene transcription in lung inflammation: Therapeutic approachesFree"/>
   <result pre="oleic acid-induced lung injuryPulm. Pharmacol. Ther.20041726327010.1016/j.pupt.2004.05.00215477121 93.SciutoA.M.StricklandP.T.KennedyT.P.GurtnerG.H.Protective effects of N" exact="acetylcysteine" post="treatment after phosgene exposure in rabbitsAm. J. Respir. Crit."/>
   <result pre="cardiac performance in patients with septic shockCrit. Care Med.1996241302131010.1097/00003246-199608000-000068706483 98.SpapenH.ZhangH.DemanetC.VleminckxW.VincentJ.L.HuyghensL.Does" exact="N-acetyl-L-cysteine" post="influence cytokine response during early human septic shockChest19981131616162410.1378/chest.113.6.16169631802 99.MolnÃ¡rZ.ShearerE.LoweD.N-Acetylcysteine"/>
   <result pre="a prospective, randomized, double-blind studyCrit. Care Med.200023799380710.1097/00003246-200012000-00006 101.PatersonR.L.GalleyH.F.WebsterN.R.The effect of" exact="N-acetylcysteine" post="on nuclear factor-kappa B activation, interleukin-6, interleukin-8 and intercellular"/>
   <result pre="in patients with sepsisCrit. Care Med.2003312574257810.1097/01.CCM.0000089945.69588.1814605526 102.BernardG.R.WheelerA.P.AronsM.M.MorrisP.E.PazH.L.RussellJ.A.WrightP.E.A trial of antioxidants" exact="N-acetylcysteine" post="and procysteine in ARDS. The Antioxidant in ARDS Study"/>
   <result pre="in ARDS Study GroupChest199711216417210.1378/chest.112.1.1649228372 103.BergerM.M.VitaminC.requirements in parenteral nutritionGastroenterology2009137707810.1053/j.gastro.2009.08.012 104.MayJ.M.HarrisonF.E.Role of" exact="vitamin C" post="in the function of the vascular endotheliumAntioxid. Redox Signal.2013192068208310.1089/ars.2013.520523581713"/>
   <result pre="Metab. Care20151819320110.1097/MCO.000000000000014825635594 106.Oudemans-van StraatenH.M.Spoelstra-de ManA.M.de WaardM.C.Vitamin C revisitedCrit. Care20141846010.1186/s13054-014-0460-x25185110 107.SchorahC.J.DowningC.PiripitsiA.GallivanL.Al-HazaaA.H.SandersonM.J.BodenhamA.Total" exact="vitamin C," post="ascorbic acid and dehydroascorbic acid concentrations in plasma of"/>
   <result pre="patientsAm. J. Clin. Nutr.19966376076510.1093/ajcn/63.5.7608615361 108.Spoelstra-de ManA.M.E.de GroothH.J.ElbersP.W.G.Oudemans-van StraatenH.M.Response to Adjuvant" exact="vitamin C" post="in cardiac arrest patients undergoing renal replacement therapy: An"/>
   <result pre="An appeal for a higher high-doseCrit. Care20182235010.1186/s13054-018-2200-030567557 109.FowlerA.A.TruwitJ.D.HiteR.D.MorrisP.E.DeWildeC.PridayA.FisherB.ThackerL.R.NatarajanR.BrophyD.F.et al.Effect of" exact="vitamin C" post="infusion on organ failure and biomarkers of inflammation and"/>
   <result pre="The CITRIS-ALI randomized clinical trialJAMA20193221261127031573637 110.Pontes-ArrudaA.AragÃ£oA.M.AlbuquerqueJ.D.Effects of enteral feeding with" exact="eicosapentaenoic acid," post="gammalinolenic acid and antioxidants in mechanically ventilated patients with"/>
   <result pre="randomized controlled trialPediatr. Infect. Dis. J.20153414314810.1097/INF.0000000000000698 135.AkdagA.DilmenU.HaqueK.DilliD.ErdeveO.GoekmenT.Role of IgM-enriched intravenous" exact="pentoxifylline" post="and/or immunoglobulin in the treatment of neonatal sepsisAm. J."/>
   <result pre="renin-angiotensin-aldosterone system, ATR1 = receptor type 1 losartan. ALT =" exact="alanine" post="aminotransferase, AST = aspartate aminotransferase. Figure 4 Ultrastructural features"/>
   <result pre="addressed in this review. Treatment Mechanism of Action Adverse Effect" exact="Chloroquine" post="and Hydroxychloroquine â†&quot; IL-1Î² mRNA expression in THP-1 cells."/>
   <result pre="this review. Treatment Mechanism of Action Adverse Effect Chloroquine and" exact="Hydroxychloroquine" post="â†&quot; IL-1Î² mRNA expression in THP-1 cells. Cardiovascular effects,"/>
   <result pre="Treatment Antioxidant Effect Clinical Effect NAC â†‘ The synthesis of" exact="glutathione" post="and glutathione-S-transferase activity [100]. Lipid peroxidation, chloramine concentration, damage"/>
   <result pre="[108,109]. The combined effect of therapy with vitamin E and" exact="vitamin C" post="in severe post-operative patients resulted in a decrease in"/>
   <result pre="protein phosphatase 2A and TNF-Î± [109,110,111,112]. MT â†‘ The intracellular" exact="glutathione" post="synthesis [122]. Melatonin enhances the immune response by improving"/>
   <result pre="protection. â†&quot; The levels of hydroperoxide in mitochondria by restoring" exact="glutathione" post="homeostasis and mitochondrial function in organelles under oxidative stress"/>
   <result pre="[126,127,128]. It has antiviral, cardioprotective, antioxidant, anti-inflammatory and anti-carcinogenic effects." exact="Pentoxifylline" post="â†‘ The glutathione levels, it maintains mitochondrial viability [133]."/>
   <result pre="antiviral, cardioprotective, antioxidant, anti-inflammatory and anti-carcinogenic effects. Pentoxifylline â†‘ The" exact="glutathione" post="levels, it maintains mitochondrial viability [133]. Decreases duration of"/>
   <result pre="total cholesterol, HDL, LDL, triglycerides, D dimer, troponins, natriuretic peptide," exact="creatine" post="phosphokinase, Cl, Na, K, magnesium, phosphorus. Evaluation of hepatic"/>
   <result pre="the pulmonary function is compromised, a combination of NAC and" exact="vitamin C" post="is suggested. (This applies to all cases). NAC dose:"/>
   <result pre="used together with some antihypertensive drugs. Sedatives, Luvox contraceptives and" exact="cocaine" post="increase the effect of MT. Verapamil, nifedipine, caffeine, alcohol"/>
   <result pre="and cocaine increase the effect of MT. Verapamil, nifedipine, caffeine," exact="alcohol" post="and immunosuppressors decrease the MT effect. Vit C dose:"/>
   <result pre="mellitus, hypertension, or Parkinsonâ€™s disease. Aluminum, estrogens, protease inhibitors, antivirals:" exact="nelfinavir" post="amprenavir, ritonavir, saquinavir, statins, glimepiride, glipizide, metformin, pioglitazone, rosiglitazone,"/>
   <result pre="It should not be used when retinitis pigmentosa is present." exact="Simvastatin" post="and niacin, chemotherapy, anticoagulants and antiplatelet agents and non-steroidal"/>
   <result pre="Measures that are jointly evaluated according to the initial evaluation." exact="Pentoxifylline" post="(vasodilator, inhibitor of IL-6), at a dose of 400"/>
   <result pre="not tolerate it. (The doses of the elected antioxidants and/or" exact="pentoxifylline" post="are similar in all cases. The selection must be"/>
   <result pre="E + pentoxifylline.Monitor if the patient uses antiplatelet or anticoagulant" exact="digoxin" post="or has an arrhythmia. Ischemic Heart DiseaseNAC or MT"/>
   <result pre="choice except contraindication ArrhythmiasNAC or MT or QRC or +" exact="Pentoxifylline" post="Chronic Obstructive Pulmonary DiseaseNAC or MT or QRC or"/>
   <result pre="+ PentoxifyllineSmokingNAC or MT or QRC or Vit C +" exact="Pentoxifylline" post="ImmuneSuppressionNAC or Vit E (if anticoagulants are not being"/>
   <result pre="N-acetylcysteine, MT = melatonin, QRC = quercetin, vit C =" exact="vitamin C," post="vit E = vitamin E, SAH = systemic arterial"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7466926\results\search\drug\results.xml">
   <result pre="(MIP1Î±), MIP1Î² and monocyte chemoattractant protein-1 (MCP1), tumor necrosis factor" exact="alpha" post="(TNF-Î±), etc. in course of the viral pathogenesis during"/>
   <result pre="days, several anti-viral drugs like the neuraminidase inhibitors oseltamivir and" exact="zanamivir" post="are employed prophylactically in the outbreak situations [9, 23]."/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7467230\results\search\drug\results.xml">
   <result pre="prescription opioid pills to injection of illicitly produced opioids, including" exact="heroin" post="and fentanyl, with concomitant increasing injection of stimulants including"/>
   <result pre="heroin and fentanyl, with concomitant increasing injection of stimulants including" exact="cocaine" post="and methamphetamine [1â€&quot;3]. As a result, the incidence of"/>
   <result pre="and soft tissue infections, is rising [2, 4â€&quot;11]. Injection of" exact="fentanyl" post="or heroin alone and in combination with stimulants have"/>
   <result pre="tissue infections, is rising [2, 4â€&quot;11]. Injection of fentanyl or" exact="heroin" post="alone and in combination with stimulants have led to"/>
   <result pre="extended-release naltrexone (XR-NTX). Methadone is a full opioid agonist and" exact="buprenorphine" post="is a partial opioid agonist, while XR-NTX is an"/>
   <result pre="craving, overdose, and HIV and HCV transmission [14, 15]; and" exact="buprenorphine" post="and XR-NTX also improve HIV viral suppression in people"/>
   <result pre="[16, 17]. Of the 3 MOUDs, access to methadone and" exact="buprenorphine" post="are limited by regulations. Prescribing requires special training outside"/>
   <result pre="waiver from the Drug Enforcement Agency in the case of" exact="buprenorphine" post="or treatment in a federally certified opioid treatment program"/>
   <result pre="about 5% of the nationâ€™s physicians have waivers to prescribe" exact="buprenorphine" post="and most substance use treatment programs do not have"/>
   <result pre="of MOUDs, and for cotreatment of related infections. 7.â€ƒEliminate the" exact="buprenorphine" post="waiver, remove patient caps, and offer grant funding for"/>
   <result pre="the requirement for clinicians to obtain a waiver to prescribe" exact="buprenorphine" post="[24]. As outlined in this paper, urgent policy action"/>
   <result pre="infections. One innovative care model combined outpatient parenteral therapy with" exact="buprenorphine" post="treatment and showed similar clinical and drug use outcomes"/>
   <result pre="identified as a major barrier preventing some physicians from integrating" exact="buprenorphine" post="into their practice for the treatment of OUD [49]."/>
   <result pre="Clinical Tools and Resources for Infectious Disease and HIV Clinicians" exact="Buprenorphine" post="practitioner locator https://www.samhsa.gov/medication-assisted-treatment/practitioner-program-data/treatment-practitioner-locator Buprenorphine waiver and training resources https://www.samhsa.gov/medication-assisted-treatment/training-materials-resources/apply-for-practitioner-waiver"/>
   <result pre="for Infectious Disease and HIV Clinicians Buprenorphine practitioner locator https://www.samhsa.gov/medication-assisted-treatment/practitioner-program-data/treatment-practitioner-locator" exact="Buprenorphine" post="waiver and training resources https://www.samhsa.gov/medication-assisted-treatment/training-materials-resources/apply-for-practitioner-waiver Behavioral health treatment services"/>
   <result pre="use disorder treatment https://www.projectshout.org In addition, a reorganization of the" exact="buprenorphine" post="prescribing system is needed. In order to increase the"/>
   <result pre="prescribe MOUD and improve patient access, we recommend eliminating the" exact="buprenorphine" post="waiver requirement, removing the patient caps, and dedicating grant"/>
   <result pre="B. reports providing waiver training courses for providers to become" exact="buprenorphine" post="prescribers through the Providers Clinical Support System. A. W."/>
   <result pre="Cochrane Database Syst Rev2011; (8):CD004145. 16.SpringerSA, QiuJ, Saber-TehraniAS, AlticeFLRetention on" exact="buprenorphine" post="is associated with high levels of maximal viral suppression"/>
   <result pre="use of detoxification services. N Engl J Med2006; 354:2512â€&quot;4.16760459 39.collab:" exact="Alcohol" post="and Drug Foundation. Medically supervised injecting centreshttps://adf.org.au/insights/medically-supervised-injecting-centres/. Accessed 3"/>
   <result pre="376:367â€&quot;87.20650518 48.FanucchiLC, WalshSL, ThorntonAC, NuzzoPA, LofwallMROutpatient parenteral antimicrobial therapy plus" exact="buprenorphine" post="for opioid use disorder and severe injection-related infections [published"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7468341\results\search\drug\results.xml">
   <result pre="in SARS-CoV-2-infected Calu-3 cells involved in C-Myc pathway, transcription, anticoagulation," exact="estrogen" post="signaling, lipid biosynthesis, ciliary landscape, nasal septum abnormality, and"/>
   <result pre="known to be involved in the C-Myc pathway, transcription, anticoagulation," exact="estrogen" post="signaling, lipid biosynthesis, ciliary landscape, nasal septum abnormality, and"/>
   <result pre="Interestingly, Massachusetts General Hospital has initiated a clinical trial of" exact="nitric oxide" post="(NO; NCT04305457) in these patient populations. Similar trials are"/>
   <result pre="NO in SARS-CoV-2 patients. Likewise, an iron chelator and antioxidant" exact="deferoxamine" post="(phase I/phase II): (NCT04333550) is reported to be tested"/>
   <result pre="of clinical trials have recently been initiated employing anti-inflammatory drugs," exact="naproxen" post="(phase III): (NCT04325633), and hydroxychloroquine (Phase III): (NCT04329611). Therefore,"/>
   <result pre="been initiated employing anti-inflammatory drugs, naproxen (phase III): (NCT04325633), and" exact="hydroxychloroquine" post="(Phase III): (NCT04329611). Therefore, it is likely that depending"/>
   <result pre="regulates the expression of proinflammatory cytokines including tumor necrosis factor" exact="alpha" post="(TNF-Î±), interleukin 1 Î² (IL-1Î²), and IL-8. Similarly, UPS"/>
   <result pre="Mol. Sci.1920181122 ChristiansenA.DyrskjotL.The functional role of the novel biomarker karyopherin" exact="alpha" post="2 (KPNA2) in cancerCancer Lett.3312013182323268335 DaviesN.G.KlepacP.LiuY.PremK.JitM.groupC.C.-w.EggoR.M.Age-dependent effects in the"/>
   <result pre="forms a complex with poly(ADP-ribose) polymerase 1 and elongation factor" exact="1alpha" post="and regulates interferon-gamma gene transcription in Th1 cellsClin. Exp."/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7472103\results\search\drug\results.xml">
   <result pre="by host pathogen recognition receptors (PRRs), including Toll-like receptors (TLRs)," exact="retinoic acid" post="inducible gene-I (RIG-I) receptors (RLRs), and NOD-like receptors (NLRs);"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7472261\results\search\drug\results.xml">
   <result pre="of HIV infection: Raltegravir (RAL), elvitegravir (EVG), dolutegravir (DTG), and" exact="bictegravir" post="(BIC). RAL was the first INSTI drug approved for"/>
   <result pre="clinical trial showed that a long-acting regimen of CAB and" exact="rilpivirine" post="(RPV) is noninferior for HIV maintenance therapy compared to"/>
   <result pre="(RPV) is noninferior for HIV maintenance therapy compared to DTG," exact="abacavir" post="(ABC), and lamivudine (3TC) in naÃ¯ve patients. However, 3"/>
   <result pre="for HIV maintenance therapy compared to DTG, abacavir (ABC), and" exact="lamivudine" post="(3TC) in naÃ¯ve patients. However, 3 participants experienced virological"/>
   <result pre="antiretroviral potency of newer integrase strand transfer inhibitors cabotegravir and" exact="bictegravir" post="in HIV-1 non-B subtypesAIDS20173246947610.1097/QAD.000000000000172629239896 41.FoleyB.LeitnerT.ParaskevisD.PeetersM.Primate immunodeficiency virus classification and"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7472297\results\search\drug\results.xml">
   <result pre="remains limited. Currently, only the combination of interferon (IFN)-Î± and" exact="zidovudine" post="showed some benefits in patients with T cell leukemia,"/>
   <result pre="leukemia, and the underlying mechanism and the antiviral contribution of" exact="zidovudine" post="require further investigation (as reviewed by Marino-Merlo et al."/>
   <result pre="enzyme activity in vitro. NtRTIs including abacavir, tenofovir, lamivudine, and" exact="stavudine" post="showed significant and dose-dependent inhibition, whereas NNtRTIs including efavirenz,"/>
   <result pre="significant and dose-dependent inhibition, whereas NNtRTIs including efavirenz, etravirine, and" exact="nevirapine" post="also showed a significant inhibitory effect. Both drug groups"/>
   <result pre="in the presence of RT inhibitors. RT inhibitors such as" exact="abacavir" post="and zidovudine both exhibited an inhibitory effect on HML2"/>
   <result pre="presence of RT inhibitors. RT inhibitors such as abacavir and" exact="zidovudine" post="both exhibited an inhibitory effect on HML2 infection in"/>
   <result pre="activity was halted by the use of NNtRTIs, such as" exact="nevirapine" post="and efavirenz, and RT-encoding LINE-1 elements were downregulated by"/>
   <result pre="has also been investigated. Protease inhibitors such as darunavir and" exact="lopinavir" post="readily docked to the protease catalytic site, thereby inhibiting"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7474329\results\search\drug\results.xml">
   <result pre="nanotechnology Classification Carrier system Matrix Properties References Article NanoFilm Polyvinyl" exact="alcohol" post="(PVA) Polyolefin (POD) Sodium chlorite (NaClO2) The authors obtained"/>
   <result pre="bacteria by modifying these molecules [69] NanoStructure Cellulose The high" exact="alcohol" post="content of hand sanitizer products currently on the market"/>
   <result pre="fluoride (PVDF) or nylon resin Facemasks produced by nanofibres containing" exact="chlorhexidine" post="gluconate or polyhexamethylene biguanide (PHMB) as an antimicrobial [102]"/>
   <result pre="L A product containing silver nanoparticles and the active compounds" exact="thiabendazole" post="and zinc pyrithione Mapa Spontex- United Kingdom PADYCAREÂ® Product"/>
   <result pre="Product coated with silver nanoparticles with antibacterial effect TEXAMEDÂ® GmbH-Germany" exact="Chlorhexidine" post="wash gloves A product containing silver nanoparticles and 2%"/>
   <result pre="are poorly water-soluble, which limits their successful use. For example," exact="chloroquine" post="and hydroxychloroquine have been associated with cardiotoxicity, as well"/>
   <result pre="water-soluble, which limits their successful use. For example, chloroquine and" exact="hydroxychloroquine" post="have been associated with cardiotoxicity, as well as hepatotoxicity"/>
   <result pre="with cardiotoxicity, as well as hepatotoxicity and nephrotoxicity [136], while" exact="ribavirin" post="is associated to haemolytic anaemia [137]. Most side effects"/>
   <result pre="endogenous lipid for preparing nanoparticles loaded with the anti-inflammatory drugs" exact="adenosine" post="and alpha-tocopherol (vitamin E), for targeted action in regions"/>
   <result pre="inflammation. In addition, it was observed that the encapsulation of" exact="adenosine" post="increased its half-life and consequently increased its therapeutic effect"/>
   <result pre="compared to non-encapsulated drugs. Due to the targeted delivery of" exact="adenosine" post="to the loci of inflammation, combined with the ability"/>
   <result pre="safety, and costs of a treatment switch to dolutegravir plus" exact="rilpivirine" post="dual therapy in treatment-experienced HIV patientsAnn Pharmacother201852111828836468 27.Mohammadi PourPFakhriSAsgarySFarzaeiMHEcheverrÃ­aJThe"/>
   <result pre="anticancer agentInorg Chem Commun2020112107712 76.SZALAY SFD. Skin sanitizer compositions comprising" exact="alcohol" post="based emulsion. 2013. https://patents.google.com/patent/EP2654670A2/en. Accessed 26 Apr 2020. 77.Hu"/>
   <result pre="diseasesJ Antimicrob Chemother2015701608162125693996 137.ThomasEGhanyMGLiangTJThe application and mechanism of action of" exact="ribavirin" post="in therapy of hepatitis CAntivir Chem Chemother.20122311222592135 138.SofiasAMAndreassenTHakSNanoparticle ligand-decoration"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7476354\results\search\drug\results.xml">
   <result pre="antiviral properties and are already used in daily practice. Recently," exact="hydroxychloroquine" post="and baricitinib have been proposed as potential drugs for"/>
   <result pre="fact, there are other immunosuppressants known with antiviral activities, including" exact="cyclosporine" post="A, hydroxyurea, minocycline, mycophenolic acid, mycophenolate mofetil, leflunomide, tofacitinib,"/>
   <result pre="immunosuppressants known with antiviral activities, including cyclosporine A, hydroxyurea, minocycline," exact="mycophenolic acid," post="mycophenolate mofetil, leflunomide, tofacitinib, and thalidomide. The inherent antiviral"/>
   <result pre="with antiviral activities, including cyclosporine A, hydroxyurea, minocycline, mycophenolic acid," exact="mycophenolate mofetil," post="leflunomide, tofacitinib, and thalidomide. The inherent antiviral activity could"/>
   <result pre="for viruses other than SARS-CoV-2 in part II. baricitinib COVID-19" exact="hydroxychloroquine" post="immunosuppressant thalidomide virus Introduction Infections are a common concern"/>
   <result pre="other than SARS-CoV-2 in part II. baricitinib COVID-19 hydroxychloroquine immunosuppressant" exact="thalidomide" post="virus Introduction Infections are a common concern of immunosuppressive"/>
   <result pre="search of the PubMed database using the keywords (chloroquine OR" exact="hydroxychloroquine" post="OR baricitinib OR cyclosporine OR hydroxyurea OR minocycline OR"/>
   <result pre="database using the keywords (chloroquine OR hydroxychloroquine OR baricitinib OR" exact="cyclosporine" post="OR hydroxyurea OR minocycline OR mycophenolic acid OR mycophenolate"/>
   <result pre="the keywords (chloroquine OR hydroxychloroquine OR baricitinib OR cyclosporine OR" exact="hydroxyurea" post="OR minocycline OR mycophenolic acid OR mycophenolate mofetil OR"/>
   <result pre="hydroxychloroquine OR baricitinib OR cyclosporine OR hydroxyurea OR minocycline OR" exact="mycophenolic acid" post="OR mycophenolate mofetil OR leflunomide OR tofacitinib OR thalidomide)"/>
   <result pre="OR cyclosporine OR hydroxyurea OR minocycline OR mycophenolic acid OR" exact="mycophenolate mofetil" post="OR leflunomide OR tofacitinib OR thalidomide) AND (virus OR"/>
   <result pre="hydroxyurea OR minocycline OR mycophenolic acid OR mycophenolate mofetil OR" exact="leflunomide" post="OR tofacitinib OR thalidomide) AND (virus OR viral) was"/>
   <result pre="minocycline OR mycophenolic acid OR mycophenolate mofetil OR leflunomide OR" exact="tofacitinib" post="OR thalidomide) AND (virus OR viral) was performed from"/>
   <result pre="of potential anti-SARS-CoV-2 activity and for modulating the cytokine storm." exact="Chloroquine" post="and hydroxychloroquine Chloroquine (CQ) and hydroxychloroquine (HCQ), both derivatives"/>
   <result pre="anti-SARS-CoV-2 activity and for modulating the cytokine storm. Chloroquine and" exact="hydroxychloroquine" post="Chloroquine (CQ) and hydroxychloroquine (HCQ), both derivatives of 4-aminoquinoline,"/>
   <result pre="activity and for modulating the cytokine storm. Chloroquine and hydroxychloroquine" exact="Chloroquine" post="(CQ) and hydroxychloroquine (HCQ), both derivatives of 4-aminoquinoline, are"/>
   <result pre="modulating the cytokine storm. Chloroquine and hydroxychloroquine Chloroquine (CQ) and" exact="hydroxychloroquine" post="(HCQ), both derivatives of 4-aminoquinoline, are indicated to treat"/>
   <result pre="compared with control arms.7â€&quot;12 Based on the inhibitory effect of" exact="azithromycin" post="against Ebola and Zika viruses in vitro, and the"/>
   <result pre="tract infections, two French trials which combined the use of" exact="azithromycin" post="and HCQ revealed better efficacy.7,9 However, further studies are"/>
   <result pre="reversed by calcineurin inhibitors MMFMPA Inhibit DHODH and IMPDH âœ&quot;" exact="Thalidomide" post="Suppress pro-inflammatory cytokines (TNF-Î±, IL-8) through inhibition of NF-ÎºB"/>
   <result pre="COVID-19 by artificial intelligence. Intriguingly, other JAK inhibitors such as" exact="tofacitinib" post="and upadacitinib did not illustrate affinities to NAKs.13,16 A"/>
   <result pre="were given either baricitinib 4â€‰mg/day plus lopinavirâ€&quot;ritonavir or antiretroviral plus" exact="hydroxychloroquine" post="(control group) for 2 weeks. Significant improvement of symptoms"/>
   <result pre="as a modulator for cytokine storm syndrome in COVID-19 infections.25" exact="Mycophenolate mofetil" post="and mycophenolic acid Mycophenolic acid (MPA), an active metabolite"/>
   <result pre="for cytokine storm syndrome in COVID-19 infections.25 Mycophenolate mofetil and" exact="mycophenolic acid" post="Mycophenolic acid (MPA), an active metabolite of mycophenolate mofetil"/>
   <result pre="and mycophenolic acid Mycophenolic acid (MPA), an active metabolite of" exact="mycophenolate mofetil" post="(MMF), inhibits inosine monophosphate dehydrogenase (IMPDH), an essential enzyme"/>
   <result pre="might control viral infection by depleting the intracellular pyrimidine pools.28" exact="Thalidomide" post="Thalidomide, a derivative of glutamic acid, is approved for"/>
   <result pre="45-year-old woman with critical symptoms of COVID-19 was treated by" exact="thalidomide" post="100â€‰mg every 24â€‰h. After the first day use of"/>
   <result pre="all decreased to normal range.15 Proposed mechanisms are as follows:" exact="thalidomide" post="inhibits NF-ÎºB, which further suppresses the production of pro-inflammatory"/>
   <result pre="the production of pro-inflammatory cytokines such as tumor necrosis factor" exact="alpha" post="(TNF-Î±) and IL-8, and prevents the cytokine surge. It"/>
   <result pre="and T-cell receptors. Moreover, the sedative and antiemetic property of" exact="thalidomide" post="helps anxious patients calm down, which reduces oxygen consumption.15"/>
   <result pre="has been conducted to investigate the efficacy and safety of" exact="thalidomide" post="as an adjuvant therapy for COVID-19 pneumonia.29 Part II:"/>
   <result pre="immune-based diseases concomitant with viral infection. DrugsVirus Chloroquine/HCQ Baricitinib CsA" exact="Hydroxyurea" post="Minocycline MMF/MPA Leflunomide Tofacitinib Thalidomide Retrovirus â€ƒHIV â–³ â–³"/>
   <result pre="with viral infection. DrugsVirus Chloroquine/HCQ Baricitinib CsA Hydroxyurea Minocycline MMF/MPA" exact="Leflunomide" post="Tofacitinib Thalidomide Retrovirus â€ƒHIV â–³ â–³ â€¢ â€¢ â€¢"/>
   <result pre="infection. DrugsVirus Chloroquine/HCQ Baricitinib CsA Hydroxyurea Minocycline MMF/MPA Leflunomide Tofacitinib" exact="Thalidomide" post="Retrovirus â€ƒHIV â–³ â–³ â€¢ â€¢ â€¢ â€ƒHTLV-1 â€¢"/>
   <result pre="positive and negative results. BKV, BK virus; CMV, cytomegalovirus; CsA," exact="cyclosporine" post="A; DMARDs, disease-modifying anti-rheumatic drugs; DNA, deoxyribonucleic acid; GAK,"/>
   <result pre="Interrupt life cycle from:(1)â€ƒviral protein synthesis(2)â€ƒgag and envelope assembly(3)â€ƒparticle budding" exact="Hydroxyurea" post="HIV (1)â€ƒInhibit DNA synthesis, slowing production of viral DNA(2)â€ƒDeplete"/>
   <result pre="and protein expression via inhibition of cellular IMPDH MERS-CoV Unknown" exact="Leflunomide" post="HSV, HIV, molluscum and verruca, CMV, BKV, RSV Inhibit"/>
   <result pre="assembling Tofacitinib HTLV-1 HTLV-1-induced ATLL is associated with JAK3 mutations;" exact="tofacitinib" post="inhibits JAK3 Thalidomide HHV-8 Unknown, suspect anti-angiogenesis and make"/>
   <result pre="HTLV-1-induced ATLL is associated with JAK3 mutations; tofacitinib inhibits JAK3" exact="Thalidomide" post="HHV-8 Unknown, suspect anti-angiogenesis and make immune system able"/>
   <result pre="et al.,61 Barrows et al.62 Betaretrovirus âœ&quot; Montano-Loza et al.63" exact="Hydroxyurea" post="HIV âœ&quot; Lori and Lisziewicz64 âœ&quot; RCT (nâ€‰=â€‰57): greater"/>
   <result pre="and fatal disease; higher viral loads than the untreated animals96" exact="Leflunomide" post="HSV âœ&quot; Knight et al.97 âœ&quot; nâ€‰=â€‰1: 42 years,"/>
   <result pre="âœ&quot; Viral loads reduced109 Tofacitinib HTLV-1 âœ&quot; Prolong survival duration110" exact="Thalidomide" post="HHV-8 âœ&quot; Phase II (nâ€‰=â€‰17): 35% partial response rate111âœ&quot;"/>
   <result pre="and 10% stable disease112 AD, atopic dermatitis; CMV, cytomegalovirus; CsA," exact="cyclosporine" post="A; DENV, dengue virus; DMARDs, disease-modifying anti-rheumatic drugs; HAART,"/>
   <result pre="cell lymphotrophic virus-1; MERS-CoV, Middle East respiratory syndrome coronavirus; MMF," exact="mycophenolate mofetil;" post="PCT, porphyria cutanea tarda; RCT, randomized-controlled trial; RSV, respiratory"/>
   <result pre="virus; RNA, ribonucleic acid; SARS-CoV, severe acute respiratory syndrome coronavirus." exact="Leflunomide" post="Leflunomide is approved for rheumatoid arthritis and psoriatic arthritis"/>
   <result pre="RNA, ribonucleic acid; SARS-CoV, severe acute respiratory syndrome coronavirus. Leflunomide" exact="Leflunomide" post="is approved for rheumatoid arthritis and psoriatic arthritis (not"/>
   <result pre="rheumatoid arthritis and psoriatic arthritis (not in the United States)." exact="Leflunomide" post="inhibits the synthesis of pyrimidine via acting on the"/>
   <result pre="dividing cells, especially lymphocytes, are suppressed. On the other hand," exact="leflunomide" post="showed antiviral activity at least for CMV, BKV, and"/>
   <result pre="HSV-2 lesions in an acyclovir-resistant HIV patient significantly improved with" exact="leflunomide" post="40â€‰mg, twice a day.98 Another HIV patient with HSV-1/HSV-2"/>
   <result pre="9â€‰months of leflunomide, complete regression of the lesions was noted." exact="Leflunomide" post="has both immunomodulation and antiviral activities in the HSV"/>
   <result pre="in HIV patients.99 Human immunodeficiency virus An RCT (nâ€‰=â€‰18) demonstrated" exact="leflunomide" post="decreased the activation and cycling of CD4+ T cells."/>
   <result pre="Molluscum and verruca Three patients with atopic dermatitis treated with" exact="azathioprine" post="developed multiple verrucae and molluscum contagiosum. Due to treatment"/>
   <result pre="developed multiple verrucae and molluscum contagiosum. Due to treatment resistance," exact="azathioprine" post="was switched to leflunomide (100â€‰mg loading 3â€‰days, then 20â€‰mg/day)."/>
   <result pre="molluscum contagiosum. Due to treatment resistance, azathioprine was switched to" exact="leflunomide" post="(100â€‰mg loading 3â€‰days, then 20â€‰mg/day). All the lesions subsided"/>
   <result pre="All the lesions subsided in three patients within 2â€‰months of" exact="leflunomide" post="treatment.103 Multiple recalcitrant verrucae in three and molluscum in"/>
   <result pre="renal allograft recipients cleared after switching from MMF to leflunomide.104" exact="Leflunomide" post="can serve as a potential option for patients with"/>
   <result pre="was given. The result showed 15 patients (88%) responded to" exact="leflunomide" post="with involved organ healing and viremia clearance.113 Leflunomide was"/>
   <result pre="responded to leflunomide with involved organ healing and viremia clearance.113" exact="Leflunomide" post="was regarded as an add-on treatment for multi-drug-resistance CMV"/>
   <result pre="treatment for multi-drug-resistance CMV infection. In vitro anti-CMV properties of" exact="leflunomide" post="were not through blocking the replication of viral DNA,"/>
   <result pre="the administration of potent immunosuppressants such as MMF and tacrolimus." exact="Leflunomide" post="is now generally accepted as a second choice after"/>
   <result pre="II RCT (nâ€‰=â€‰46), viremia was decreased in the group of" exact="leflunomide" post="active metabolites, but no significant improvement of renal function"/>
   <result pre="Treatment options for RSV are limited to supportive care or" exact="ribavirin" post="with only marginal effectiveness. Leflunomide showed a potent, dose-dependent"/>
   <result pre="limited to supportive care or ribavirin with only marginal effectiveness." exact="Leflunomide" post="showed a potent, dose-dependent anti-RSV activity in cell cultures.92"/>
   <result pre="cotton rats, even if there was a 3-day delay of" exact="leflunomide" post="administration after viral inoculation.109 Leflunomide offers a dual benefit"/>
   <result pre="was a 3-day delay of leflunomide administration after viral inoculation.109" exact="Leflunomide" post="offers a dual benefit of both viral-load reduction and"/>
   <result pre="uveitis. Ex vivo and animal studies revealed positive results of" exact="tofacitinib" post="for ATLL and HAM.110 HTLV-1-encoded tax protein activates IL-2,"/>
   <result pre="of JAK3 in the pathophysiology of ATLL.114 As a result," exact="tofacitinib" post="targeting JAK3 has been suggested as a therapeutic strategy"/>
   <result pre="has been suggested as a therapeutic strategy in future studies." exact="Hydroxyurea" post="Hydroxyurea, a deoxyribonucleic acid (DNA)-synthesis inhibitor, belongs to the"/>
   <result pre="major and common adverse effect of hydroxyurea. Human immunodeficiency virus" exact="Hydroxyurea" post="demonstrated promising results in reducing HIV RNA viral loads"/>
   <result pre="loads in five placebo-controlled clinical trials. Among all the trials," exact="hydroxyurea" post="was combined with didanosine, a nucleoside analog reverse-transcriptase inhibitor"/>
   <result pre="In vitro studies demonstrated the antiviral modes of hydroxyurea. First," exact="hydroxyurea" post="depletes deoxynucleoside triphosphate (dNTP) pools, which impedes DNA synthesis"/>
   <result pre="in turn slows down the production of viral DNA. Second," exact="hydroxyurea" post="enhances NRTI phosphorylation and reduces resistance to NRTIs. This"/>
   <result pre="to NRTIs. This may partially explain the benefits of adding" exact="hydroxyurea" post="to NRTI for viral control. Finally, cytotoxic effect of"/>
   <result pre="hydroxyurea to NRTI for viral control. Finally, cytotoxic effect of" exact="hydroxyurea" post="makes cellular division of CD4+ T cells decline. This"/>
   <result pre="makes cellular division of CD4+ T cells decline. This enables" exact="hydroxyurea" post="to block HIV proliferation, because HIV could only replicate"/>
   <result pre="(HSV), parvovirus B19 (B19V) Although the mode of action of" exact="hydroxyurea" post="for HCV, HBV, HSV, and B19V is unknown, viral"/>
   <result pre="HSV, and B19V is unknown, viral replications were inhibited by" exact="hydroxyurea" post="in in vitro studies.70,74â€&quot;76 Small-scaled clinical trials showed significant"/>
   <result pre="of blood transfusion and attenuation of clinical symptoms when using" exact="hydroxyurea" post="in patients with B19V infection.77 Minocycline Minocycline, a second-generation"/>
   <result pre="minocycline caused the exacerbation of encephalomyelitis and higher mortality rate.92" exact="Chloroquine" post="and hydroxychloroquine Severe acute respiratory syndrome coronavirus (SARS-CoV) CQ"/>
   <result pre="the exacerbation of encephalomyelitis and higher mortality rate.92 Chloroquine and" exact="hydroxychloroquine" post="Severe acute respiratory syndrome coronavirus (SARS-CoV) CQ and HCQ"/>
   <result pre="transplantation. Earlier and more severe recurrence of PBC occurred with" exact="tacrolimus" post="compared with CsA as an immunosuppressant. This may be"/>
   <result pre="viral protein synthesis, gag and envelope assembly, and particle budding.63" exact="Mycophenolate mofetil" post="and mycophenolic acid Human immunodeficiency virus The combination of"/>
   <result pre="gag and envelope assembly, and particle budding.63 Mycophenolate mofetil and" exact="mycophenolic acid" post="Human immunodeficiency virus The combination of MMF and highly"/>
   <result pre="all marmosets treated with MMF experienced severe and fatal disease.96" exact="Thalidomide" post="Human herpesvirus 8 (HHV-8) HHV-8 is the cause of"/>
   <result pre="of Kaposiâ€™s sarcoma (KS). Case reports showed encouraging experience of" exact="thalidomide" post="in all types of KS (classic, iatrogenic, and HIV"/>
   <result pre="of HHV-8 were decreased in all patients.111,112 The effectiveness of" exact="thalidomide" post="for KS might be related to anti-angiogenesis, and experts"/>
   <result pre="ahead of print 2722020 DOI: 10.1016/j.apsb.2020.02.008. 4Al-BariMAATargeting endosomal acidification by" exact="chloroquine" post="analogs as a promising strategy for the treatment of"/>
   <result pre="diseases. Pharmacol Res Perspect2017; 5: e00293.28596841 5WangMCaoRZhangL, et al.Remdesivir and" exact="chloroquine" post="effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in"/>
   <result pre="novel coronavirus (2019-nCoV) in vitro. Cell Res2020; 30: 269â€&quot;271.32020029 6GaoJTianZYangX.Breakthrough:" exact="chloroquine" post="phosphate has shown apparent efficacy in treatment of COVID-19"/>
   <result pre="clinical studies. Biosci Trends2020; 14: 72â€&quot;73.32074550 7GautretPLagierJCParolaP, et al.Hydroxychloroquine and" exact="azithromycin" post="as a treatment of COVID-19: results of an open-label"/>
   <result pre="print 2032020. DOI: 1016/j.ijantimicag.2020.105949. 8ChenJLiuDLiuL, et al.A pilot study of" exact="hydroxychloroquine" post="in treatment of patients with moderate COVID-19. Zhejiang Da"/>
   <result pre="9GautretPLagierJCParolaP, et al.Clinical and microbiological effect of a combination of" exact="hydroxychloroquine" post="and azithromycin in 80 COVID-19 patients with at least"/>
   <result pre="al.Clinical and microbiological effect of a combination of hydroxychloroquine and" exact="azithromycin" post="in 80 COVID-19 patients with at least a six-day"/>
   <result pre="Travel Med Infect Dis2020; 34: 101663.32289548 10ChenZHuJZhangZ, et al.Efficacy of" exact="hydroxychloroquine" post="in patients with COVID-19: results of a randomized clinical"/>
   <result pre="Dis. Epub ahead of print 342020 DOI: 10.1016/S1473-3099(20)30270-X. 22Sanchez-PernauteORomero-BuenoFISelva-Oâ€™CallaghanA.Why choose" exact="cyclosporin A" post="as first-line therapy in COVID-19 pneumonia. Reumatol Clin. Epub"/>
   <result pre="Nature2005; 434: 658â€&quot;662.15800627 25GoDJParkJKKangEH, et al.Survival benefit associated with early" exact="cyclosporine" post="treatment for dermatomyositis-associated interstitial lung disease. Rheumatol Int2016; 36:"/>
   <result pre="lung disease. Rheumatol Int2016; 36: 125â€&quot;131.26223808 26GarcÃ­aFPlanaMArnedoM, et al.Effect of" exact="mycophenolate mofetil" post="on immune response and plasma and lymphatic tissue viral"/>
   <result pre="US National Library of Medicine. The efficacy and safety of" exact="thalidomide" post="in the adjuvant treatment of moderate new coronavirus (COVID-19)"/>
   <result pre="additive in vitro anti-HIV-1 effect of chloroquine, when combined with" exact="zidovudine" post="and hydroxyurea. Biochem Pharmacol2001; 61: 1531â€&quot;1535.11377382 35SperberKLouieMKrausT, et al.Hydroxychloroquine"/>
   <result pre="type 1. Clin Ther1995; 17: 622â€&quot;636.8565026 36NeelyMKalyesubulaIBagendaD, et al.Effect of" exact="chloroquine" post="on human immunodeficiency virus (HIV) vertical transmission. Afr Health"/>
   <result pre="Sci2003; 3: 61â€&quot;67.12913796 37MurraySMDownCMBoulwareDR, et al.Reduction of immune activation with" exact="chloroquine" post="therapy during chronic HIV infection. J Virol2010; 84: 12082â€&quot;12086.20844049"/>
   <result pre="therapy-treated immunologic nonresponders. Blood2011; 118: 3263â€&quot;3272.21576701 39PatonNIGoodallRLDunnDT, et al.Effects of" exact="hydroxychloroquine" post="on immune activation and disease progression among HIV-infected patients"/>
   <result pre="randomized controlled trial. JAMA2012; 308: 353â€&quot;361.22820788 40RoutyJPAngelJBPatelM, et al.Assessment of" exact="chloroquine" post="as a modulator of immune activation to improve CD4"/>
   <result pre="C6/36 cells. ScientificWorldJournal2013; 2013: 282734.23431254 42FariasKJMachadoPRMunizJA, et al.Antiviral activity of" exact="chloroquine" post="against dengue virus type 2 replication in Aotus monkeys."/>
   <result pre="Cruz2013; 108: 596â€&quot;599.23903975 44TricouVMinhNNVanTP, et al.A randomized controlled trial of" exact="chloroquine" post="for the treatment of dengue in Vietnamese adults. PLoS"/>
   <result pre="66: 217â€&quot;218.6087474 47De LamballerieXBoissonVReynierJC, et al.On chikungunya acute infection and" exact="chloroquine" post="treatment. Vector Borne Zoonotic Dis2008; 8: 837â€&quot;839.18620511 48FedsonDS.Confronting an"/>
   <result pre="be done?Lancet Infect Dis2008; 8: 571â€&quot;576.18420459 49YanYZouZSunY, et al.Anti-malaria drug" exact="chloroquine" post="is highly effective in treating avian influenza A H5N1"/>
   <result pre="et al.Long-term follow-up of HIV positive asymptomatic patients having received" exact="cyclosporin A." post="Adv Exp Med Biol1995; 374: 229â€&quot;234.7572396 57CalabreseLHLedermanMMSpritzlerJ, et al.Placebo-controlled"/>
   <result pre="Mol Cell2005; 19: 111â€&quot;122.15989969 60InoueKSekiyamaKYamadaM, et al.Combined interferon alpha2b and" exact="cyclosporin A" post="in the treatment of chronic hepatitis C: controlled trial."/>
   <result pre="cirrhosis. Liver Int2010; 30: 871â€&quot;877.20492501 64LoriFLisziewiczJ.Rationale for the use of" exact="hydroxyurea" post="as an anti-human immunodeficiency virus drug. Clin Infect Dis2000;"/>
   <result pre="Hum Retroviruses1997; 13: 1403â€&quot;1409.9359660 66RutschmannOTOpravilMItenA, et al.A placebo-controlled trial of" exact="didanosine" post="plus stavudine, with and without hydroxyurea, for HIV infection."/>
   <result pre="combination of reverse transcriptase inhibitors versus the same regimen plus" exact="hydroxyurea" post="or hydroxyurea and interleukin-2 in HIV-infected patients failing protease"/>
   <result pre="reverse transcriptase inhibitors versus the same regimen plus hydroxyurea or" exact="hydroxyurea" post="and interleukin-2 in HIV-infected patients failing protease inhibitor-based combinations."/>
   <result pre="3: 263â€&quot;271.12187499 68FrankIBoschRJFiscusS, et al.Activity, safety, and immunological effects of" exact="hydroxyurea" post="added to didanosine in antiretroviral-naive and experienced HIV type"/>
   <result pre="et al.Activity, safety, and immunological effects of hydroxyurea added to" exact="didanosine" post="in antiretroviral-naive and experienced HIV type 1-infected subjects: a"/>
   <result pre="69StebbingJNelsonMOrkinC, et al.A randomized trial to investigate the recycling of" exact="stavudine" post="and didanosine with and without hydroxyurea in salvage therapy"/>
   <result pre="al.A randomized trial to investigate the recycling of stavudine and" exact="didanosine" post="with and without hydroxyurea in salvage therapy (RESTART). J"/>
   <result pre="investigate the recycling of stavudine and didanosine with and without" exact="hydroxyurea" post="in salvage therapy (RESTART). J Antimicrob Chemother2004; 53: 501â€&quot;505.14762056"/>
   <result pre="HCV replication in humans: a phase I trial of oral" exact="hydroxyurea" post="in chronic hepatitis C patients. Antivir Ther2010; 15: 1179â€&quot;1183.21149925"/>
   <result pre="patients. Antivir Ther2010; 15: 1179â€&quot;1183.21149925 72KashaniHHVossoughiAAdibiP, et al.Amazing results with" exact="hydroxyurea" post="therapy in chronic hepatitis B: a preliminary report. Hepat"/>
   <result pre="73WatanabeNYasudaHAotaY, et al.Reactivation of hepatitis B virus during treatment with" exact="hydroxyurea" post="in an elderly patient with essential thrombocythemia. Geriatr Gerontol"/>
   <result pre="Antimicrob Agents Chemother1973; 3: 325â€&quot;331.4364174 75SergerieYBoivinG.Hydroxyurea enhances the activity of" exact="acyclovir" post="and cidofovir against herpes simplex virus type 1 resistant"/>
   <result pre="Chemother1973; 3: 325â€&quot;331.4364174 75SergerieYBoivinG.Hydroxyurea enhances the activity of acyclovir and" exact="cidofovir" post="against herpes simplex virus type 1 resistant strains harboring"/>
   <result pre="B19 infection in children with sickle cell disease in the" exact="hydroxyurea" post="era. Exp Biol Med (Maywood)2016; 241: 749â€&quot;754.26940953 78SiQCosenzaMKimMO, et"/>
   <result pre="mice. J Virol2007; 81: 6248â€&quot;6253.17409147 93ChapuisAGPaolo RizzardiGDâ€™AgostinoC, et al.Effects of" exact="mycophenolic acid" post="on human immunodeficiency virus infection in vitro and in"/>
   <result pre="treatment of acyclovir-resistant herpes simplex virus type 2 proctitis with" exact="leflunomide" post="in an HIV-infected man. J Clin Virol2012; 54: 276â€&quot;278.22465339"/>
   <result pre="199â€&quot;201.11588518 101SchlapferEFischerMOttP, et al.Anti-HIV-1 activity of leflunomide: a comparison with" exact="mycophenolic acid" post="and hydroxyurea. AIDS2003; 17: 1613â€&quot;1620.12853743 102ReadSWDeGreziaMCicconeEJ, et al.The effect"/>
   <result pre="and hydroxyurea. AIDS2003; 17: 1613â€&quot;1620.12853743 102ReadSWDeGreziaMCicconeEJ, et al.The effect of" exact="leflunomide" post="on cycling and activation of T-cells in HIV-1-infected participants."/>
   <result pre="14: 111â€&quot;120.22093814 106ChongASZengHKnightDA, et al.Concurrent antiviral and immunosuppressive activities of" exact="leflunomide" post="in vivo. Am J Transplant2006; 6: 69â€&quot;75.16433758 107VerkaikNJHoekRAVan BergeijkH,"/>
   <result pre="ATL and HAM/TSP. Blood2011; 117: 1938â€&quot;1946.21106989 111FifeKHowardMRGracieF, et al.Activity of" exact="thalidomide" post="in AIDS-related Kaposiâ€™s sarcoma and correlation with HHV8 titre."/>
   <result pre="Int J STD AIDS1998; 9: 751â€&quot;755.9874123 112LittleRFWyvillKMPludaJM, et al.Activity of" exact="thalidomide" post="in AIDS-related Kaposiâ€™s sarcoma. J Clin Oncol2000; 18: 2593â€&quot;2602.10893291"/>
   <result pre="Clin Oncol2000; 18: 2593â€&quot;2602.10893291 113JohnGTManivannanJChandyS, et al.A prospective evaluation of" exact="leflunomide" post="therapy for cytomegalovirus disease in renal transplant recipients. Transplant"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7476961\results\search\drug\results.xml">
   <result pre="RNA genome into the cytoplasm (endocytic pathway). Alternatively, Transmembrane Protease" exact="Serine" post="type 2 (TMPRSS2) is also involved in priming of"/>
   <result pre="the inhibitory potential of EK1C, further derivatives were designed with" exact="glycine" post="/ serine-based linkers (GSG) and PEG-based spacers. The peptides"/>
   <result pre="and was blocked by a clinically known inhibitor of TMRSS2," exact="camostat" post="[33]. Hence, TMPRSS2 based therapeutics could prove to be"/>
   <result pre="to SARS CoV-2 nsp12, was investigated based on modeling with" exact="sofosbuvir" post="bound to hepatitis C virus (HCV) ns5b. The nsp12"/>
   <result pre="polymerase and selectively binding catalytic site of the HCV polymerase." exact="Sofosbuvir" post="has been approved for the treatment of chronic HCV"/>
   <result pre="Fintelman-Rodrigues and co-workers shed light on the promising potential of" exact="atazanavir" post="and atazanavir/ritonavir combination for the treatment of COVID-19 [76]."/>
   <result pre="[76]. Through a combination of molecular docking and molecular dynamics," exact="atazanavir" post="was shown to bind to the active site of"/>
   <result pre="was also shown to inhibit the enzyme through zymographic studies." exact="Atazanavir" post="and atazanavir/ritonavir combination were evaluated for their inhibitory potential"/>
   <result pre="in both the cell lines potently. The EC50 values of" exact="atazanavir" post="and atazanavir/ritonavir combination against SARS-CoV-2 in Vero E6 cells"/>
   <result pre="and A549 cells are shown in Fig. 16 . Furthermore," exact="atazanavir" post="and atazanavir/ritonavir also prevented pro-inflammatory cytokine production in monocytes"/>
   <result pre="lactate dehydrogenase (LDH) and Interleukin-6 (IL-6). Fig. 16 Structure of" exact="atazanavir" post="and ritonavir. 2.6 Papain like protease (PLpro) Papain like"/>
   <result pre="screened it against a library of 2525 FDA approved drugs." exact="Praziquantel" post="(anti-parasitic), cinacalcet (anti-hyperparathyroidism), procainamide (anti-arrhythmic), terbinafine (antifungal) and pethidine"/>
   <result pre="library of 2525 FDA approved drugs. Praziquantel (anti-parasitic), cinacalcet (anti-hyperparathyroidism)," exact="procainamide" post="(anti-arrhythmic), terbinafine (antifungal) and pethidine (opioid analgesic) were identified"/>
   <result pre="17 ). No major adverse effects have been reported for" exact="praziquantel" post="and cinacalcet. However, procainamide, terbinafine, and pethidine have major"/>
   <result pre="for COVID-19 3.1 Antivirals 3.1.1 Remdesivir Remdesivir, a prodrug of" exact="adenosine" post="analog GS-441524 (Fig. 18 ), is an investigational antiviral"/>
   <result pre="18), it incorporates into the RNA strand after fending off" exact="Adenosine" post="triphosphate (ATP), the natural nucleotide incorporated in this process"/>
   <result pre="RNA synthesis [85], [86], [95] 3.1.2 Lopinavir/ritonavir combination Lopinavir and" exact="ritonavir" post="are two structurally related protease inhibitors that were developed"/>
   <result pre="due to metabolic inactivation by cytochrome P-450 (CYP) enzymes [96]." exact="Ritonavir" post="inhibits cytochrome P-450-3A4 (CYP3A4) at sub-therapeutic levels and hence"/>
   <result pre="(CYP3A4) at sub-therapeutic levels and hence is always co-administered with" exact="lopinavir" post="to prevent its metabolic degradation [97]. Lopinavir was found"/>
   <result pre="against SARS-CoV-2. A study on analysis of molecular complexation between" exact="lopinavir" post="and ritonavir with SARS-CoV-2 3CLpro suggested interaction of these"/>
   <result pre="A study on analysis of molecular complexation between lopinavir and" exact="ritonavir" post="with SARS-CoV-2 3CLpro suggested interaction of these drugs with"/>
   <result pre="the appropriate doses and course of treatment for COVID-19. 3.1.4" exact="Ribavirin" post="Ribavirin, a guanosine analog, has been used for the"/>
   <result pre="active metabolite [110]. Past studies have highlighted the combination of" exact="ribavirin" post="and interferon therapy as an effective treatment strategy for"/>
   <result pre="[112], [113]. Recently, Wang et al. highlighted the potential of" exact="ribavirin" post="to inhibit SARS-CoV-2 in vitro in Vero E6 cells"/>
   <result pre="ÂµM). Clinical trials are underway to evaluate the efficacy of" exact="ribavirin" post="in the treatment of COVID-19 [62]. 3.1.5 Other antiviral"/>
   <result pre="a protease inhibitor approved for the treatment of HIV, and" exact="cobicistat" post="prevents the catabolism of darunavir [116]. Clinical trials are"/>
   <result pre="further evidence is required to support such a claim. 3.2.2" exact="Azithromycin" post="Azithromycin is a broad-spectrum antibiotic that is used for"/>
   <result pre="evidence is required to support such a claim. 3.2.2 Azithromycin" exact="Azithromycin" post="is a broad-spectrum antibiotic that is used for the"/>
   <result pre="). A recently conducted clinical trial highlighted the importance of" exact="azithromycin" post="for the management of SARS-CoV-2 infection [117]. A total"/>
   <result pre="received chloroquine, and 16 patients served as control. Among the" exact="chloroquine" post="treated patients, six patients received azithromycin as a precautionary"/>
   <result pre="as control. Among the chloroquine treated patients, six patients received" exact="azithromycin" post="as a precautionary measure against bacterial superinfection. At the"/>
   <result pre="end of day 6, 100% of the patients treated with" exact="chloroquine" post="and azithromycin were cured off the virus while only"/>
   <result pre="day 6, 100% of the patients treated with chloroquine and" exact="azithromycin" post="were cured off the virus while only 57.1% of"/>
   <result pre="while only 57.1% of the patients were cured who received" exact="chloroquine" post="alone (negative PCR results). These outcomes should be further"/>
   <result pre="results). These outcomes should be further dwelled on to consider" exact="azithromycin" post="as viable adjuvant therapy for SARS-CoV-2 infection. Fascinatingly, azithromycin"/>
   <result pre="consider azithromycin as viable adjuvant therapy for SARS-CoV-2 infection. Fascinatingly," exact="azithromycin" post="has been reported to be active against other RNA"/>
   <result pre="mechanism of action of this drug. 3.3 Antiprotozoal drugs 3.3.1" exact="Chloroquine" post="and hydroxychloroquine Chloroquine and hydroxychloroquine belonging to the class"/>
   <result pre="action of this drug. 3.3 Antiprotozoal drugs 3.3.1 Chloroquine and" exact="hydroxychloroquine" post="Chloroquine and hydroxychloroquine belonging to the class of 4-aminoquinolines"/>
   <result pre="of this drug. 3.3 Antiprotozoal drugs 3.3.1 Chloroquine and hydroxychloroquine" exact="Chloroquine" post="and hydroxychloroquine belonging to the class of 4-aminoquinolines are"/>
   <result pre="drug. 3.3 Antiprotozoal drugs 3.3.1 Chloroquine and hydroxychloroquine Chloroquine and" exact="hydroxychloroquine" post="belonging to the class of 4-aminoquinolines are primarily used"/>
   <result pre="the class of 4-aminoquinolines are primarily used as antimalarials. Structurally," exact="hydroxychloroquine" post="differs from chloroquine by the presence of one extra"/>
   <result pre="4-aminoquinolines are primarily used as antimalarials. Structurally, hydroxychloroquine differs from" exact="chloroquine" post="by the presence of one extra hydroxyl group. Besides"/>
   <result pre="presence of one extra hydroxyl group. Besides its antimalarial prowess," exact="chloroquine" post="has established itself as a broad-spectrum antiviral agent exhibiting"/>
   <result pre="DNA and RNA viruses [120], [121], [122], [123]. Concerning coronaviruses," exact="chloroquine" post="has been reported to be potent against the SARS-CoV-1"/>
   <result pre="Wang et al. shed light on the antiviral prowess of" exact="chloroquine" post="against the SARS-CoV-2. Chloroquine effectively blocked the viral infection"/>
   <result pre="light on the antiviral prowess of chloroquine against the SARS-CoV-2." exact="Chloroquine" post="effectively blocked the viral infection with a high selectivity"/>
   <result pre="[62]. Gao et al., in a recent publication, disclosed that" exact="chloroquine" post="treatment offered superior efficacy than control treatment in a"/>
   <result pre="patients [125]. Now answering the elephant in the room- Can" exact="hydroxychloroquine" post="also be used for the treatment of Covid-19? A"/>
   <result pre="for the treatment of Covid-19? A recent report demonstrated that" exact="hydroxychloroquine" post="is also effective against the SARS-CoV-2, and a study"/>
   <result pre="effective against the SARS-CoV-2, and a study also highlighted that" exact="hydroxychloroquine" post="is more potent against SARS-CoV-2 than chloroquine [126], [127]."/>
   <result pre="also highlighted that hydroxychloroquine is more potent against SARS-CoV-2 than" exact="chloroquine" post="[126], [127]. More arguments favor the use of hydroxychloroquine"/>
   <result pre="than chloroquine [126], [127]. More arguments favor the use of" exact="hydroxychloroquine" post="over chloroquine. Firstly, the presence of an extra hydroxyl"/>
   <result pre="clearance lessening the risk of retinal toxicity than chloroquine. Secondly," exact="hydroxychloroquine" post="is a safer option than chloroquine with respect to"/>
   <result pre="toxicity than chloroquine. Secondly, hydroxychloroquine is a safer option than" exact="chloroquine" post="with respect to therapeutic window and safety margins. Thirdly,"/>
   <result pre="and safety margins. Thirdly, owing to its proven immunomodulatory properties," exact="hydroxychloroquine" post="can act as an ideal treatment intervention in severely"/>
   <result pre="[128]. Recently, a controversial observational study on the effectiveness of" exact="chloroquine" post="or hydroxychloroquine with or without a macrolide for the"/>
   <result pre="a controversial observational study on the effectiveness of chloroquine or" exact="hydroxychloroquine" post="with or without a macrolide for the treatment of"/>
   <result pre="data from over 600 hospitals in six continents concluded that" exact="chloroquine" post="or hydroxychloroquine treatment afforded no protection to COVID-19 patients"/>
   <result pre="over 600 hospitals in six continents concluded that chloroquine or" exact="hydroxychloroquine" post="treatment afforded no protection to COVID-19 patients and was"/>
   <result pre="clinical trials like solidarity trials, RECOVERY trials have demonstrated that" exact="hydroxychloroquine" post="offers no benefit to COVID-19 patients [130], [131]. USFDA"/>
   <result pre="[131]. USFDA has also withdrawn its EUA status given to" exact="chloroquine" post="and hydroxychloroquine in view of the recent developments [132]."/>
   <result pre="has also withdrawn its EUA status given to chloroquine and" exact="hydroxychloroquine" post="in view of the recent developments [132]. 3.3.1.1 Mechanism"/>
   <result pre="of the recent developments [132]. 3.3.1.1 Mechanism of action of" exact="chloroquine" post="Chloroquine is claimed to act via two mechanisms. Chloroquine,"/>
   <result pre="the recent developments [132]. 3.3.1.1 Mechanism of action of chloroquine" exact="Chloroquine" post="is claimed to act via two mechanisms. Chloroquine, in"/>
   <result pre="of endosomal-lysosomal enzymes. By raising the pH of the vesicles," exact="chloroquine" post="can effectively inhibit the entry and replication process [133]."/>
   <result pre="chloroquine can effectively inhibit the entry and replication process [133]." exact="Chloroquine" post="indirectly interferes with the interaction between the SARS-CoV-1 spike"/>
   <result pre="protein is necessary for the viral entry into the cell." exact="Chloroquine" post="impairs the Golgi mediated N-terminal glycosylation of ACE-2, which"/>
   <result pre="the replication of SARS-CoV-2 in vitro[139]. A single treatment of" exact="ivermectin" post="at the dose of 5Â ÂµM resulted in an"/>
   <result pre="about 5000-fold reduction in viral titers following 48Â h of" exact="ivermectin" post="treatment. The safety profile of ivermectin is well established,"/>
   <result pre="following 48Â h of ivermectin treatment. The safety profile of" exact="ivermectin" post="is well established, and hence ivermectin can be potentially"/>
   <result pre="The safety profile of ivermectin is well established, and hence" exact="ivermectin" post="can be potentially repurposed against COVID-19. Fig. 21 Antiprotozoal"/>
   <result pre="by inhibiting TMPRSS2 [33]. Having already established its safety profile," exact="camostat" post="might prove to be a valuable drug in the"/>
   <result pre="to prove its efficacy for the treatment of COVID-19. 3.4.2" exact="Nafamostat" post="Following the footsteps of camostat is nafamostat (Fig. 22"/>
   <result pre="the treatment of COVID-19. 3.4.2 Nafamostat Following the footsteps of" exact="camostat" post="is nafamostat (Fig. 22 ), a serine protease inhibitor"/>
   <result pre="of COVID-19. 3.4.2 Nafamostat Following the footsteps of camostat is" exact="nafamostat" post="(Fig. 22 ), a serine protease inhibitor used as"/>
   <result pre="), a serine protease inhibitor used as an anticoagulant [140]." exact="Nafamostat" post="has been shown to inhibit the entry of MERS-CoV"/>
   <result pre="the entry of MERS-CoV by inhibiting cellular TMPRSS2 [141]. Recently," exact="nafamostat" post="was also shown to inhibit the novel SARS-CoV-2 in"/>
   <result pre="of Medical Science, the University of Tokyo, have disclosed that" exact="nafamostat" post="prevents the entry of novel SARS-CoV-2 by potently binding"/>
   <result pre="novel SARS-CoV-2 by potently binding to the transmembrane protease TMPRSS2." exact="Nafamostat" post="was able to achieve the fusion inhibition at less"/>
   <result pre="inhibition at less than one-tenth of the concentration required by" exact="camostat" post="[142]. Nafamostat can also be repurposed for therapeutic utility"/>
   <result pre="less than one-tenth of the concentration required by camostat [142]." exact="Nafamostat" post="can also be repurposed for therapeutic utility against COVID-19."/>
   <result pre="repurposed for therapeutic utility against COVID-19. Fig. 22 Fusion inhibitors-" exact="camostat" post="and nafamostat. 3.5 Immunomodulators and anti-inflammatory drugs A coordinated"/>
   <result pre="a clinical trial is underway to evaluate the efficacy of" exact="dexamethasone" post="in patients with ARDS secondary to SARS-CoV-2 infection (NCT04325061)."/>
   <result pre="RdRp inhibitor Teratogenic Phase 3 clinical trials (NCT04336904) [62], [164]" exact="Ribavirin" post="Antiviral 106.5 RdRp inhibitor Teratogenic, hemolytic anemia Phase 3"/>
   <result pre="available on the adverse effects associated with teicoplanin â€&quot; [47]" exact="Azithromycin" post="Antibiotic â€&quot; â€&quot; QT interval prolongation, severe hypersensitivity reactions"/>
   <result pre="data is available on Carrimycin Phase 4 clinical trial (NCT04286503)" exact="Chloroquine" post="Antiprotozoal 1.13 Raises the pH in the endocytic vesicles,"/>
   <result pre="hypoglycemia, neuropsychiatric effects Phase 3 clinical trial (NCT04303507) [62], [170]" exact="Hydroxychloroquine" post="Antiprotozoal 0.72 Raises the pH in the endocytic vesicles,"/>
   <result pre="available on the adverse events Phase 2 clinical trial (NCT04374019)" exact="Nafamostat" post="Anticoagulant 22.5 TMPRSS2 inhibitor Hyperkalemia, agranulocytosis, anaphylaxis Phase 2"/>
   <result pre="61ZumlaA.ChanJ.F.W.AzharE.I.HuiD.S.C.YuenK.Y.Coronaviruses-drug discovery and therapeutic optionsNat. Rev. Drug Discov.15201632734710.1038/nrd.2015.3726868298 62WangM.CaoR.ZhangL.YangX.LiuJ.XuM.ShiZ.HuZ.ZhongW.XiaoG.Remdesivir and" exact="chloroquine" post="effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in"/>
   <result pre="designJ. Virol.8220082515252710.1128/jvi.02114-0718094151 73E. Lynch, J. Kil, Development of ebselen, a" exact="glutathione" post="peroxidase mimic, for the prevention and treatment of noise-induced"/>
   <result pre="N. Carels, C.R. Alves, M.M. Siqueira, P.T. Bozza, T.M.L. Souza," exact="Atazanavir" post="inhibits SARS-CoV-2 replication and pro-inflammatory cytokine production, BioRxiv. (2020)"/>
   <result pre="marmosetJ. Infect. Dis.21220151904191310.1093/infdis/jiv39226198719 100NukoolkarnV.LeeV.S.MalaisreeM.AruksakulwongO.HannongbuaS.Molecular dynamic simulations analysis of ritronavir and" exact="lopinavir" post="as SARS-CoV 3CLpro inhibitorsJ. Theor. Biol.254200886186710.1016/j.jtbi.2008.07.03018706430 101NuthoB.MahalapbutrP.HengphasatpornK.PattaranggoonN.C.SimanonN.ShigetaY.HannongbuaS.RungrotmongkolT.Why are lopinavir"/>
   <result pre="and lopinavir as SARS-CoV 3CLpro inhibitorsJ. Theor. Biol.254200886186710.1016/j.jtbi.2008.07.03018706430 101NuthoB.MahalapbutrP.HengphasatpornK.PattaranggoonN.C.SimanonN.ShigetaY.HannongbuaS.RungrotmongkolT.Why are" exact="lopinavir" post="and ritonavir effective against the newly emerged Coronavirus 2019?:"/>
   <result pre="as SARS-CoV 3CLpro inhibitorsJ. Theor. Biol.254200886186710.1016/j.jtbi.2008.07.03018706430 101NuthoB.MahalapbutrP.HengphasatpornK.PattaranggoonN.C.SimanonN.ShigetaY.HannongbuaS.RungrotmongkolT.Why are lopinavir and" exact="ritonavir" post="effective against the newly emerged Coronavirus 2019?: Atomistic insights"/>
   <result pre="trials for 2019-nCoV infectionClin. Pharmacol. Ther.202010.1002/cpt.1844 110GraciJ.D.CameronC.E.Mechanisms of action of" exact="ribavirin" post="against distinct virusesRev. Med. Virol.162006374810.1002/rmv.48316287208 111FalzaranoD.De WitE.RasmussenA.L.FeldmannF.OkumuraA.ScottD.P.BriningD.BushmakerT.MartellaroC.BaselerL.BeneckeA.G.KatzeM.G.MunsterV.J.FeldmannH.Treatment with interferon-Î±2b"/>
   <result pre="against distinct virusesRev. Med. Virol.162006374810.1002/rmv.48316287208 111FalzaranoD.De WitE.RasmussenA.L.FeldmannF.OkumuraA.ScottD.P.BriningD.BushmakerT.MartellaroC.BaselerL.BeneckeA.G.KatzeM.G.MunsterV.J.FeldmannH.Treatment with interferon-Î±2b and" exact="ribavirin" post="improves outcome in MERS-CoV-infected rhesus macaquesNat. Med.1920131313131710.1038/nm.336224013700 112OmraniA.S.SaadM.M.BaigK.BahloulA.Abdul-MatinM.AlaidaroosA.Y.AlmakhlafiG.A.AlbarrakM.M.MemishZ.A.AlbarrakA.M.Ribavirin and"/>
   <result pre="high genetic barrier to resistanceExpert Opin. Pharmacother.1620152689270210.1517/14656566.2015.110963226612518 117GautretP.LagierJ.-C.ParolaP.HoangV.T.MeddebL.MailheM.DoudierB.CourjonJ.GiordanengoV.VieiraV.E.DupontT.HonorÃ©S.ColsonP.ChabriÃ¨reE.La ScolaB.RolainJ.-M.BrouquiP.RaoultD.Hydroxychloroquine and" exact="azithromycin" post="as a treatment of COVID-19: results of an open-label"/>
   <result pre="agent, inhibits zika virus infection in different cell modelsViruses8201610.3390/v8120322 121FreibergA.N.WorthyM.N.LeeB.HolbrookM.R.Combined" exact="chloroquine" post="and ribavirin treatment does not prevent death in a"/>
   <result pre="zika virus infection in different cell modelsViruses8201610.3390/v8120322 121FreibergA.N.WorthyM.N.LeeB.HolbrookM.R.Combined chloroquine and" exact="ribavirin" post="treatment does not prevent death in a hamster model"/>
   <result pre="potent inhibitor of SARS coronavirus infection and spreadVirol. J.2200510.1186/1743-422X-2-69 125GaoJ.TianZ.YangX.Breakthrough:" exact="Chloroquine" post="phosphate has shown apparent efficacy in treatment of COVID-19"/>
   <result pre="vitro antiviral activity and projection of optimized dosing design of" exact="hydroxychloroquine" post="for the treatment of severe acute respiratory syndrome coronavirus"/>
   <result pre="acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Clin. Infect. Dis.202010.1093/cid/ciaa237 128SinghA.K.SinghA.ShaikhA.SinghR.MisraA.Chloroquine and" exact="hydroxychloroquine" post="in the treatment of COVID-19 with or without diabetes:"/>
   <result pre="other developing countriesDiabetes Metab. Syndr. Clin. Res. Rev.202010.1016/j.dsx.2020.03.011 129MehraM.R.DesaiS.S.RuschitzkaF.PatelA.N.Hydroxychloroquine or" exact="chloroquine" post="with or without a macrolide for treatment of COVID-19:"/>
   <result pre="of the RECOVERY Trial, No clinical benefit from use of" exact="hydroxychloroquine" post="in hospitalised patients with COVID-19, Recover. Trial. (2020). https://www.recoverytrial.net/news/statement-from-the-chief-investigators-of-the-randomised-evaluation-of-covid-19-therapy-recovery-trial-on-hydroxychloroquine-5-june-2020-no-clinical-benefit-from-use-of-hydroxychloroquine-in-hospitalised-patients-with-co"/>
   <result pre="2020). 132Coronavirus (COVID-19) Update: FDA Revokes Emergency Use Authorization for" exact="Chloroquine" post="and Hydroxychloroquine | FDA, (n.d.). https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-revokes-emergency-use-authorization-chloroquine-and (accessed June 20,"/>
   <result pre="(COVID-19) Update: FDA Revokes Emergency Use Authorization for Chloroquine and" exact="Hydroxychloroquine" post="| FDA, (n.d.). https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-revokes-emergency-use-authorization-chloroquine-and (accessed June 20, 2020). 133Al-BariM.A.A.Targeting"/>
   <result pre="(n.d.). https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-revokes-emergency-use-authorization-chloroquine-and (accessed June 20, 2020). 133Al-BariM.A.A.Targeting endosomal acidification by" exact="chloroquine" post="analogs as a promising strategy for the treatment of"/>
   <result pre="Sierra Vega, J.J. GarcÃ­a Vieitez, The pharmacokinetics and interactions of" exact="ivermectin" post="in humans - A mini-review, AAPS J. 10 (2008)"/>
   <result pre="replication of HIV-1 and dengue virusBiochem. J.443201285185610.1042/BJ2012015022417684 139CalyL.DruceJ.D.CattonM.G.JansD.A.WagstaffK.M.The FDA-approved drug" exact="ivermectin" post="inhibits the replication of SARS-CoV-2 in vitroAntiviral Res.178202010478710.1016/j.antiviral.2020.104787 140Al-HoraniR.A.DesaiU.R.Recent"/>
   <result pre="for the treatment of fibrinolysis-related disordersMed. Res. Rev.3420141168121610.1002/med.2131524659483 141YamamotoM.MatsuyamaS.LiX.TakedaM.KawaguchiY.InoueJ.I.MatsudaZ.Identification of" exact="nafamostat" post="as a potent inhibitor of middle east respiratory syndrome"/>
   <result pre="- PubChem, (n.d.). https://pubchem.ncbi.nlm.nih.gov/compound/Darunavir#section=Drug-Warnings (accessed June 22, 2020). 169F.S. Structures," exact="Azithromycin" post="_ C38H72N2O12 - PubChem, (2020). https://pubchem.ncbi.nlm.nih.gov/compound/Azithromycin (accessed June 22,"/>
   <result pre="(2020). https://pubchem.ncbi.nlm.nih.gov/compound/Azithromycin (accessed June 22, 2020). 170JuurlinkD.N.Safety considerations with chloroquine," exact="hydroxychloroquine" post="and azithromycin in the management of SARS-CoV-2 infectionCMAJ1922020E450E45310.1503/cmaj.20052832269021 171Nafamostat"/>
   <result pre="(accessed June 22, 2020). 170JuurlinkD.N.Safety considerations with chloroquine, hydroxychloroquine and" exact="azithromycin" post="in the management of SARS-CoV-2 infectionCMAJ1922020E450E45310.1503/cmaj.20052832269021 171Nafamostat | C19H17N5O2"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7478670\results\search\drug\results.xml">
   <result pre="anti-inflammatory activity and metabolic programming. Biomed Pharmacother2020;110281.32554251 [8]GautretPLagierJCParolaPet al.Hydroxychloroquine and" exact="azithromycin" post="as a treatment of COVID-19: results of an open-label"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7479232\results\search\drug\results.xml">
   <result pre="forms of COVID-19 in the United States and Europe, while" exact="dexamethasone" post="is also recommended in specific situations and umifenovir, Î±-interferon,"/>
   <result pre="recommended in specific situations and umifenovir, Î±-interferon, lopinavir/ritonavir, ribavirin, and" exact="chloroquine" post="phosphate has been added to the Guidelines for the"/>
   <result pre="TMPRSS, transmembrane protease serine 2 (); mTORC1, mammalian target of" exact="rapamycin" post="complex 1 (); RLR, RIG-I-like receptors; ACE2, angiotensin converting"/>
   <result pre="RNA release in the presence of the mammalian target of" exact="rapamycin" post="complex 1 protein (rapamycin complex 1) (mTORC1) (4); RNA"/>
   <result pre="currently approached the antiviral role of endosomal-tropic agents such as" exact="hydroxychloroquine" post="sulfate or umifenovir (arbidol) (Yang and Shen, 2020). SARS-CoV-2"/>
   <result pre="complex enzymatic system, also controlled by the mammalian target of" exact="rapamycin" post="complex 1 (mTORC1). While it is still unclear how"/>
   <result pre="repurposing of previously known drugs such as cloroquine (Cq) and" exact="hydroxychloroquine" post="(Hq). Chloroquine phosphate, is an antimalarial drug which acts"/>
   <result pre="previously known drugs such as cloroquine (Cq) and hydroxychloroquine (Hq)." exact="Chloroquine" post="phosphate, is an antimalarial drug which acts through complex"/>
   <result pre="and nafmostat, approved by FDA for other non-viral indications. Additionally," exact="camostat" post="mesylate, a protease inhibitor approved by the FDA in"/>
   <result pre="ChiCTR2000029544 and ChiCTR2000029600) (Coomes and Haghbayan, 2020). Remdesivir is an" exact="adenosine" post="analogue which also controls mTORC1 signalling and has a"/>
   <result pre="has shown in vitro activity against SARS-CoV-2 in combination with" exact="chloroquine" post="(Wang M. et al., 2020) or in monotherapy, as"/>
   <result pre="nucleosidic analogues were recently disproved by clinical studies. These include" exact="ribavirin" post="(ChiCTR200002938) and protease inhibitors targeting PLpro and 3CLpro, such"/>
   <result pre="convincing clinical trials on this matter. Furthermore, the administration of" exact="azithromycin" post="also poses multiple cardiovascular risks (Ray et al., 2012)"/>
   <result pre="(Gautret et al., 2020) on the association between Hq and" exact="azithromycin" post="(NCR04321278) have been questioned by the International Society of"/>
   <result pre="2020). Biological treatment Study identifier number, locations IFN-beta, cholchicine, rivaroxaban," exact="aspirin" post="NCT04331899, Canada IFN-beta, remdesivir, chloroquine, hydroxychloroquine, lopinavir/ritonavir ISRCTN83971151 (Solidarity),"/>
   <result pre="NCT04315948 (DisCoVeRy), multi-centre (Europe) IFN-beta1a NCT04385095, UK IFN-beta1a, lopinavir, ritonavir," exact="hydroxychloroquine" post="NCT04350671 (IB1aIC), Iran IFN-beta1a, lopinavir, ritonavir, hydroxychloroquine NCT04350684 (UAIIC),"/>
   <result pre="IFN-beta1a, lopinavir, ritonavir, hydroxychloroquine NCT04350671 (IB1aIC), Iran IFN-beta1a, lopinavir, ritonavir," exact="hydroxychloroquine" post="NCT04350684 (UAIIC), Iran IFN-beta1b, hydroxychloroquine NCT04350281, Hong Kong IFN-alfa"/>
   <result pre="(IB1aIC), Iran IFN-beta1a, lopinavir, ritonavir, hydroxychloroquine NCT04350684 (UAIIC), Iran IFN-beta1b," exact="hydroxychloroquine" post="NCT04350281, Hong Kong IFN-alfa (aerosols), lopinavir/ritonavir, traditional Chinese medicines"/>
   <result pre="NCT04251871, China Recombinant human IFN-alpha1b ChiCTR2000030480, ChinaÂ IFN-alpha aerosol inhalation," exact="lopinavir" post="ChiCTR2000030535,Â China IFN-alpha, ribavirin, lopinavir/ritonavir ChiCTR2000029387, China IFN-alpha atomization,"/>
   <result pre="ChiCTR2000029756, China IFN-alpha aerosol/lopinavir/ritonavir ChiCTR2000031196, China IFN-alpha2b, tocilizumab, losartan, remdesivir," exact="hydroxychloroquine" post="+ combinations, methylprednisolone, convalescent serum NCT04349410 (FMTVDM), SUA Recombinant"/>
   <result pre="human IFN-alpha 1b ChiCTR2000030922, ChinaÂ Recombinant human IFN-alpha-1b (nasal drops)/thymosin" exact="alpha" post="1 NCT04320238, China PegIFN-Î±2b atomization, arbidol hydrochloride NCT04254874, China"/>
   <result pre="China PegIFN-Î±2b atomization, arbidol hydrochloride NCT04254874, China Long-acting IFN-alpha2a plus" exact="ribavirin" post="ChiCTR2000030922, China PegIFN-lambda-1a NCT04331899, SUA PegIFN-lambda1a NCT04354259 (ILIAD), Canada"/>
   <result pre="on their efficiency in viral or autoimune diseases, such as" exact="thalidomide" post="(NCT04273529, NCT04273581) or fingolimod (NCT04280588). Additionally, experimental data on"/>
   <result pre="viral or autoimune diseases, such as thalidomide (NCT04273529, NCT04273581) or" exact="fingolimod" post="(NCT04280588). Additionally, experimental data on the efficiency of these"/>
   <result pre="RECOVERY trial NCT04381936) have reported a positive effect of intravenous" exact="dexamethasone" post="administration in the treatment of COVID-19. The study showed"/>
   <result pre="study showed that a 10-day treatment with low doses of" exact="dexamethasone" post="(6 mg/day) reduced the mortality in patients who required"/>
   <result pre="MSC (called PLX-PAD) NCT04389450 (140), SUA MSC in combination with" exact="ruxolitinib" post="ChiCTR2000029580, ChinaÂ Allogeneic human dental pulp derived-stem cells NCT04336254,"/>
   <result pre="antiCD147 receptor) (Wang K. et al., 2020) NCT04275245 Clathrin-mediated endocytosis" exact="Hydroxychloroquine" post="(Hq) sulphate (Picot et al., 1993; Jang et al.,"/>
   <result pre="1993; Jang et al., 2006; Bender et al., 2020) and" exact="Chloroquine" post="phosphate (Savarino et al., 2003; Vincent et al., 2005)*multiple"/>
   <result pre="(Hung et al., 2020)Controversial results (Gandhi, 2020) See Table 1" exact="Ruxolitinib" post="(anti-Janus kinase inhibitor) (Gaspari et al., 2020; Yeleswaram et"/>
   <result pre="cytokines, Th2 response, regeneration of damaged cell See Table 2" exact="Thalidomide" post="NCT04273529, NCT04273581 Fingolimod NCT04280588 Neutralizing antibodies Convalescent plasma (Rogers"/>
   <result pre="C.BritoM.et al. (2020). Effect of High vs Low Doses of" exact="Chloroquine" post="Diphosphate as Adjunctive Therapy for Patients Hospitalized With Severe"/>
   <result pre="Therapy for COVID-19. NEJM J. Watch2020. 10.1056/NEJM-JW.NA51564 GaspariV.ZengariniC.GrecoS.VangeliV.MastroianniA.Side effects of" exact="ruxolitinib" post="in patients with SARS-CoV-2 infection: Two case reports. Int."/>
   <result pre="J. Antimicrob. Agents56 (2), 106023. 10.1016/J.IJANTIMICAG.2020.106023 GautretP.LagierJ.-C.ParolaP.HoangV. T.MeddebL.MailheM.et al. (2020)." exact="Hydroxychloroquine" post="and azithromycin as a treatment of COVID-19: results of"/>
   <result pre="Agents56 (2), 106023. 10.1016/J.IJANTIMICAG.2020.106023 GautretP.LagierJ.-C.ParolaP.HoangV. T.MeddebL.MailheM.et al. (2020). Hydroxychloroquine and" exact="azithromycin" post="as a treatment of COVID-19: results of an open-label"/>
   <result pre="Agents56 (1), 105949. 10.1016/j.ijantimicag.2020.10594932205204 GelerisJ.SunY.PlattJ.ZuckerJ.BaldwinM.HripcsakG.et al. (2020). Observational Study of" exact="Hydroxychloroquine" post="in Hospitalized Patients with Covid-19. N. Engl. J. Med.382"/>
   <result pre="W.-H.ChuM.-Y.et al. (2020). Triple combination of interferon beta-1b, lopinavir-ritonavir, and" exact="ribavirin" post="in the treatment of patients admitted to hospital with"/>
   <result pre="Chemother.26 (6), 625â€&quot;632. 10.1016/j.jiac.2020.04.00732362440 JangC. H.ChoiJ. H.ByunM. S.JueD. M. (2006)." exact="Chloroquine" post="inhibits production of TNF-alpha, IL-1beta and IL-6 from lipopolysaccharide-stimulated"/>
   <result pre="(6), e46â€&quot;e47. 10.1016/S2213-2600(20)30216-232353251 JuurlinkD. N. (2020). Safety considerations with chloroquine," exact="hydroxychloroquine" post="and azithromycin in the management of SARS-CoV-2 infection. CMAJ192"/>
   <result pre="10.1016/S2213-2600(20)30216-232353251 JuurlinkD. N. (2020). Safety considerations with chloroquine, hydroxychloroquine and" exact="azithromycin" post="in the management of SARS-CoV-2 infection. CMAJ192 (17), E4540â€&quot;E453."/>
   <result pre="JAMA323 (8), 725. 10.1001/jama.2019.22525 RayW. A.MurrayK. T.HallK.ArbogastP. G.SteinC. M. (2012)." exact="Azithromycin" post="and the Risk of Cardiovascular Death. N. Engl. J."/>
   <result pre="COVID-19. Antiviral Res.178, 104791. 10.1016/j.antiviral.2020.10479132275914 SavarinoA.BoelaertJ. R.CassoneA.MajoriG.CaudaR. (2003). Effects of" exact="chloroquine" post="on viral infections: an old drug against todayâ€™s diseases?"/>
   <result pre="Infect. Dis.3 (11), 722â€&quot;727. 10.1016/S1473-3099(03)00806-514592603 ShamshirianA.HessamiA.HeydariK.Alizadeh-NavaeiR.EbrahimzadehM. A.YIPG. W.et al. (2020)." exact="Hydroxychloroquine" post="Versus COVID-19: A Periodic Systematic Review and Meta-Analysis. medRxiv.2020.04.14.20065276."/>
   <result pre="(7), 2657. 10.3390/ijms21072657 VincentM. J.BergeronE.BenjannetS.EricksonB. R.RollinP. E.KsiazekT. G.et al. (2005)." exact="Chloroquine" post="is a potent inhibitor of SARS coronavirus infection and"/>
   <result pre="Nat. Commun.11 (1), 2251. 10.1038/s41467-020-16256-y32366817 WangM.CaoR.ZhangL.YangX.LiuJ.XuM.et al. (2020). Remdesivir and" exact="chloroquine" post="effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in"/>
   <result pre="Acad. Sci.117 (20), 10970â€&quot;10975. 10.1073/PNAS.200561511732350134 YamamotoM.MatsuyamaS.LiX.TakedaM.KawaguchiY.InoueJ.-I.et al. (2016). Identification of" exact="Nafamostat" post="as a Potent Inhibitor of Middle East Respiratory Syndrome"/>
   <result pre="Vitro Antiviral Activity and Projection of Optimized Dosing Design of" exact="Hydroxychloroquine" post="for the Treatment of Severe Acute Respiratory Syndrome Coronavirus"/>
   <result pre="732â€&quot;739. 10.1093/cid/ciaa23732150618 YeleswaramS.SmithP.BurnT.CovingtonM.JuvekarA.LiY.et al. (2020). Inhibition of cytokine signaling by" exact="ruxolitinib" post="and implications for COVID-19 treatment. Clin. Immunol.218, 108517. 10.1016/j.clim.2020.10851732585295"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7479474\results\search\drug\results.xml">
   <result pre="redexivir, favivir, ribavirin, nitrazine, and chloroquine/hydroxychloroquine, are evaluated [13, 68]." exact="Chloroquine" post="and hydroxychloroquine have been shown to shorten the duration"/>
   <result pre="ribavirin, nitrazine, and chloroquine/hydroxychloroquine, are evaluated [13, 68]. Chloroquine and" exact="hydroxychloroquine" post="have been shown to shorten the duration of SARS-CoV-2"/>
   <result pre="of SARS-CoV-2 viremia by reducing the viral load [68]. However," exact="hydroxychloroquine" post="has also been associated with a higher risk of"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7480504\results\search\drug\results.xml">
   <result pre="slightly impaired in cold weather as both vitamin D and" exact="melatonin" post="are depleted due to shorter daylight [22]. Early in"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7480628\results\search\drug\results.xml">
   <result pre="may include thrombocytopenia, anemia, abnormal liver and kidney function, elevated" exact="creatine" post="kinase and prothrombin time, increased lactate dehydrogenase and D-dimer."/>
   <result pre="care, and to minimize complications. Non-steroidal anti-inflammatory drugs (NSAIDs), including" exact="ibuprofen" post="use, have been reported with clinical deterioration in some"/>
   <result pre="indicated an increase of viral shedding [40]. However, treatment with" exact="methylprednisolone" post="may be beneficial for patients who develop acute respiratory"/>
   <result pre="have currently been conducted investigating the potential cure effect, including" exact="hydroxychloroquine" post="in combination with azithromycin, immune therapy, remdesivir, different antiviral"/>
   <result pre="serious cardiac side effects, treating physicians must be aware of." exact="Chloroquine" post="and hydroxychloroquine, which is the more potent synthetic form"/>
   <result pre="of COVID-19 based on a small French trial [42, 43]." exact="Chloroquine" post="can cause atrioventricular (AV) block and, along with azithromycin,"/>
   <result pre="atrioventricular (AV) block and, along with azithromycin, prolonged QT interval." exact="Hydroxychloroquine" post="can similarly produce conduction problems in the heart. Additive"/>
   <result pre="[49]. A recent multicenter, open-label, randomized controlled trial (RCT) of" exact="hydroxychloroquine" post="involving 150 adults admitted to hospital for COVID-19 reported"/>
   <result pre="the active metabolites of clopidogrel, prasugrel while increasing that of" exact="ticagrelor" post="as well as increasing statins levels with risk of"/>
   <result pre="Lopinavir/ritonavir potentiates the effects of factor Xa inhibitors such as" exact="apixaban" post="and rivaroxaban through the inhibition of CYP3A4, thereby increasing"/>
   <result pre="the effects of factor Xa inhibitors such as apixaban and" exact="rivaroxaban" post="through the inhibition of CYP3A4, thereby increasing bleeding risk"/>
   <result pre="treatment benefit [51]. Remdesivir is a monophosphoramidate prodrug of an" exact="adenosine" post="analogue that inhibits viral RNA synthesis with a broad"/>
   <result pre="with COVID-19 in Wuhan, China. JAMA Cardiol. 2020. 10.1001/jamacardio.2020.0950. 39.DayMCovid-19:" exact="ibuprofen" post="should not be used for managing symptoms, say doctors"/>
   <result pre="vitro antiviral activity and projection of optimized dosing design of" exact="hydroxychloroquine" post="for the treatment of severe acute respiratory syndrome coronavirus"/>
   <result pre="2020:ciaa237 10.1093/cid/ciaa237. 43.Gautret P, Lagier JC, Parola P, et al." exact="Hydroxychloroquine" post="and azithromycin as a treatment of COVID-19: results of"/>
   <result pre="43.Gautret P, Lagier JC, Parola P, et al. Hydroxychloroquine and" exact="azithromycin" post="as a treatment of COVID-19: results of an open-label"/>
   <result pre="a scientific statement from the American Heart AssociationCirculation.2016134e32e6910.1161/CIR.000000000000042627400984 48.SvanstrÃ¶mHPasternakBHviidAUse of" exact="azithromycin" post="and death from cardiovascular causesN Engl J Med20133681704171210.1056/NEJMoa130079923635050 49.XiongTYRedwoodSPrendergastBChenMCoronaviruses"/>
   <result pre="Heart J2020191798180010.1093/eurheartj/ehaa231 50.Tang W, Cao Zhu, Han M, et al." exact="Hydroxychloroquine" post="in patients with COVID-19: an open-label, randomized, controlled trial."/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7481143\results\search\drug\results.xml">
   <result pre="(PT), followed by increase in bilirubin levels, aspartate transaminase (AST)," exact="alanine" post="transaminase (ALT), creatinine, lactate dehydrogenase (LDH), protein C reactive"/>
   <result pre="et al.54 The latter suggest monitoring of serum levels of" exact="testosterone" post="and Vitamin D in infected patients for a better"/>
   <result pre="acids Proline, Leucine, Lysine, Asparagine, Phenylalanine, Glycine, Threonine, Glutamine, Alanine," exact="Methionine" post="and Tyrosine. One of the best ligands was the"/>
   <result pre="host's innate immunity. Analysis of the docking model showed that" exact="ribavirin" post="formed Hydrogen bonds with residues Gly164, Gln270, Tyr274, Asp303"/>
   <result pre="interactions between Tyr265 and the PLpro residue. These results indicate" exact="ribavirin" post="as a powerful PLpro enzyme inhibitor, which means it"/>
   <result pre="(5), uracil (6) and thymine (7) and pyrimidine derivatives drugs:" exact="5-Fluorouracil" post="(8); Gemcitabine (9); Baricitinib (10); Sunitinib (11); Erlotinib (12);"/>
   <result pre="Gemcitabine (9); Baricitinib (10); Sunitinib (11); Erlotinib (12); Galidesivir (13);" exact="Sofosbuvir" post="(14); Telbivudine (15). Regarding antiviral activity, there are several"/>
   <result pre="Baricitinib (10); Sunitinib (11); Erlotinib (12); Galidesivir (13); Sofosbuvir (14);" exact="Telbivudine" post="(15). Regarding antiviral activity, there are several approved drugs"/>
   <result pre="and causes low cellular permeability and low oral bioavailability.90 5.1.1" exact="5-Fluorouracil" post="(5-FU) One compound appointed as potential anti-SARS-CoV-2 is the"/>
   <result pre="5-Fluorouracil (5-FU) One compound appointed as potential anti-SARS-CoV-2 is the" exact="5-Fluorouracil" post="(8) (5-FU) (Fig. 3), a heterocyclic aromatic amine similar"/>
   <result pre="small-molecule tyrosine kinase inhibitor that competitively blocks the binding of" exact="adenosine" post="triphosphate to its binding site in the tyrosine kinase"/>
   <result pre="and prevents the formation of the RNA elongated strand.105, 106" exact="Adenosine" post="and GSV differ in that galidesivir has one Carbon"/>
   <result pre="the pyrimidine ring and Nitrogen in the ribose ring, whereas" exact="adenosine" post="has one Nitrogen in the former and Oxygen in"/>
   <result pre="required to elucidate its potential activity in advanced testing. 5.1.5" exact="Sofosbuvir" post="(SBV) Next, sofosbuvir (SBV) (14) is an example of"/>
   <result pre="its potential activity in advanced testing. 5.1.5 Sofosbuvir (SBV) Next," exact="sofosbuvir" post="(SBV) (14) is an example of successful nucleotide prodrug,"/>
   <result pre="is also combined with other antiviral drugs, such as ledipasvir," exact="velpatasvir" post="and voxilaprevir.110, 111 The structural similarity between SBV (Fig."/>
   <result pre="the efficacy and safety of SBV (46784) monotherapy or plus" exact="Velpatasvir" post="(46790), Daclatasvir (46463), Ledipasvir (46567) in patients diagnosed with"/>
   <result pre="and safety of SBV (46784) monotherapy or plus Velpatasvir (46790)," exact="Daclatasvir" post="(46463), Ledipasvir (46567) in patients diagnosed with SARS-CoV-2 showing"/>
   <result pre="and, possibly, redirect the repurposing of drugs against COVID-19. 5.1.6" exact="Telbivudine" post="(TBV) Telbivudine (TBV) (15) (Fig. 3) is a thymidine"/>
   <result pre="redirect the repurposing of drugs against COVID-19. 5.1.6 Telbivudine (TBV)" exact="Telbivudine" post="(TBV) (15) (Fig. 3) is a thymidine nucleoside analogue"/>
   <result pre="phosphorylation by cellular kinases, which results in the active metabolite," exact="Telbivudine" post="5â€²â€&quot;triphosphate, enabling DNA polymerase and inhibiting viral replication. The"/>
   <result pre="Mpro. Among other results were Ribavirin, TBV and two vitamins," exact="cyanocobalamin" post="(B12) and nicotinamide (B3). Researchers suggest that these four"/>
   <result pre="essential to life. They are basic constituents of nitrogenous bases" exact="adenine" post="(A) (16) and guanine (G) (17) (Fig. 4 ).83,"/>
   <result pre="and MERS-CoV.128 Fig. 4 Chemical structures of purine nitrogenous bases" exact="adenine" post="(16) and guanine (17) and others nitrogen-based analogue drugs:"/>
   <result pre="and guanine (17) and others nitrogen-based analogue drugs: Remdesivir (18);" exact="Ganciclovir" post="(19); Valganciclovir (20); Tenofovir (21); Ribavirin (22); Favipiravir (23)."/>
   <result pre="(17) and others nitrogen-based analogue drugs: Remdesivir (18); Ganciclovir (19);" exact="Valganciclovir" post="(20); Tenofovir (21); Ribavirin (22); Favipiravir (23). 5.2.1 Remdesivir"/>
   <result pre="analogue drugs: Remdesivir (18); Ganciclovir (19); Valganciclovir (20); Tenofovir (21);" exact="Ribavirin" post="(22); Favipiravir (23). 5.2.1 Remdesivir (RDV) Purine derivatives are"/>
   <result pre="in 2017 under the name of GS-5734. It is an" exact="adenosine" post="analogue prodrug first developed to treat Ebola (EBOV), but"/>
   <result pre="the pharmacologically active GS-443902 nucleoside triphosphate. The latter works as" exact="adenosine" post="triphosphate (ATP) analogue, which means it competes with the"/>
   <result pre="When the clinical symptoms became worse, the patient was given" exact="vancomycin" post="and cefepime. As the symptoms worsened, intravenous treatment with"/>
   <result pre="intravenous treatment with RDV was administered at day 7, and" exact="vancomycin" post="and cefepime were no longer administered. At day 8,"/>
   <result pre="with RDV was administered at day 7, and vancomycin and" exact="cefepime" post="were no longer administered. At day 8, the patient"/>
   <result pre="the FDA for extreme cases in children and adults.129 5.2.2" exact="Ganciclovir" post="(GCV) and Valganciclovir In addition to the promising results"/>
   <result pre="extreme cases in children and adults.129 5.2.2 Ganciclovir (GCV) and" exact="Valganciclovir" post="In addition to the promising results shown by RDV,"/>
   <result pre="by RDV, other purine analogues have been investigated for SARS-CoV-2." exact="Ganciclovir" post="(GCV) (19) also named, according to its chemical structure,"/>
   <result pre="related to Acquired Immunodeficiency Syndrome (AIDS).138 GCV is converted into" exact="ganciclovir" post="triphosphate by cellular kinase, which inhibits dGTP and disrupts"/>
   <result pre="and disrupts viral DNA synthesis due to substitution of various" exact="adenosine" post="bases in the DNA chain.139 Recently, GCV was used"/>
   <result pre="of combined therapy is yet necessary for more robust investigations." exact="Valganciclovir" post="(20) (Fig. 4) is the antiviral prodrug of GCV"/>
   <result pre="great bioavailability and is converted by hydrolysis into ganciclovir. Using" exact="valganciclovir" post="in its oral form enables clinical treatment and makes"/>
   <result pre="143 The mechanism of action is the same of GCV.144" exact="Valganciclovir" post="was computationally evaluated for COVID-19.5 The assay with the"/>
   <result pre="Nsp12 in coronavirus, which is vital for its replication/transcription. Therefore," exact="valganciclovir" post="could be a significant antiviral drug to treat SARS-CoV-2."/>
   <result pre="to treat SARS-CoV-2. But there are no clinical reports on" exact="valganciclovir" post="used to treat COVID-19 in addition to what has"/>
   <result pre="anti-SARS-CoV-2 therapeutic. 5.2.3 Tenofovir (TFV) Tenofovir (TFV) (21) is another" exact="adenine" post="analogue pointed as promising COVID-19 therapeutic (Fig. 4), it"/>
   <result pre="promising in-vitro activity against coronavirus, probably by 3CLPro inhibition.154 5.3.1" exact="Ribavirin" post="Ribavirin (22) (Fig. 4) is a powerful triazole-based antiviral"/>
   <result pre="in-vitro activity against coronavirus, probably by 3CLPro inhibition.154 5.3.1 Ribavirin" exact="Ribavirin" post="(22) (Fig. 4) is a powerful triazole-based antiviral analogue"/>
   <result pre="syncytial virus in children, generally combined with Interferon (INF). However," exact="ribavirin" post="treatment presents undesirable adverse effects, like lowering of haemoglobin,"/>
   <result pre="3 to 10â€¯Î¼g/mL.157 Because of the range of antiviral actions," exact="ribavirin" post="has been thoroughly investigated as an alternative for SARS-CoV,"/>
   <result pre="treatment. Falzarano et al.158 investigated the effects of Interferon-Î±2b and" exact="ribavirin" post="in the replication of nCoV isolate hCoV-EMC/2012 replication in"/>
   <result pre="displayed complete cytopathogenic effect (CPE) at 1000â€…U/ml and above, whereas" exact="ribavirin" post="presented complete CPE at 200â€¯Î¼g/ml and above. The IC50"/>
   <result pre="CPE at 200â€¯Î¼g/ml and above. The IC50 of IFN-Î±2b and" exact="ribavirin" post="was subsequently determined to be 58.08 U/ml and 41.45â€¯Î¼g/ml,"/>
   <result pre="U/ml), reduced infectious titers by 3.97-log. On the other hand," exact="ribavirin" post="treatment, at 200â€¯Î¼g/ml or higher, reduced infectious virus below"/>
   <result pre="decrease of ribavirin. These data suggest that combining IFN-Î±2b and" exact="ribavirin" post="is a likely an alternative treatment. Tests of ribavirin"/>
   <result pre="and ribavirin is a likely an alternative treatment. Tests of" exact="ribavirin" post="against SARS-Cov-2 were conducted either in-silico or in-vitro. Wang"/>
   <result pre="concentrations of the drugs. Results showed that high concentrations of" exact="ribavirin" post="were necessary to reduce viral infection, with EC50â€¯=â€¯109,50â€¯Î¼M and"/>
   <result pre="In addition, Wu et al.5 also conducted in-silico evaluation of" exact="ribavirin" post="against PLpro. It was verified that ribavirin bonds to"/>
   <result pre="in-silico evaluation of ribavirin against PLpro. It was verified that" exact="ribavirin" post="bonds to the enzyme active site similar to other"/>
   <result pre="bonds and Ï€â€&quot;Ï€ stacking were also predicted. These findings suggest" exact="ribavirin" post="as a powerful PLpro inhibitor. Nonetheless, investigation on triazole"/>
   <result pre="under investigation are considered promising to fight COVID-19. The combination" exact="lopinavir" post="(24)/ritonavir (25) (Kaletra) is the most outstanding (Fig. 5"/>
   <result pre="drugs often used in combination to treat HIV patients because" exact="ritonavir" post="increases concentrations of lopinavir in the body. Also, the"/>
   <result pre="combination to treat HIV patients because ritonavir increases concentrations of" exact="lopinavir" post="in the body. Also, the combination of both drugs"/>
   <result pre="of peptide derivatives, amino acids and analogues drugs: Lopinavir (24);" exact="Ritonavir" post="(25); Oseltamivir (26); Nelfinavir (27); Atazanavir (28); Captopril (29);"/>
   <result pre="acids and analogues drugs: Lopinavir (24); Ritonavir (25); Oseltamivir (26);" exact="Nelfinavir" post="(27); Atazanavir (28); Captopril (29); Ciclosporin A (30), Teicoplanin"/>
   <result pre="analogues drugs: Lopinavir (24); Ritonavir (25); Oseltamivir (26); Nelfinavir (27);" exact="Atazanavir" post="(28); Captopril (29); Ciclosporin A (30), Teicoplanin (31). There"/>
   <result pre="Lopinavir (24); Ritonavir (25); Oseltamivir (26); Nelfinavir (27); Atazanavir (28);" exact="Captopril" post="(29); Ciclosporin A (30), Teicoplanin (31). There are several"/>
   <result pre="marmoset. Four groups were established: control, lopinavir/ritonavir treatment, Interferon-Beta-1b and;" exact="mycophenolate mofetil." post="The lopinavir/ritonavir group achieved better clinical results than the"/>
   <result pre="and treated with LPV/ritonavir by mouth (lopinavir 400â€¯mg/ritonavir 10â€¯mg 2*day)," exact="ribavirin" post="and IFN-2a.171 The patient displayed absence of fever and"/>
   <result pre="stage of the disease and a relatively high concentration of" exact="lopinavir" post="was used to inhibit viral replication.167, 172 Different researches"/>
   <result pre="investigated whether the administration of LPV/RTV plus interferon beta-1b and" exact="ribavirin" post="could present better outcomes than the treatment with LPV/RTV"/>
   <result pre="the combination group was given LPV/RTV (400â€¯mg/100â€¯mg respectively) every 12â€¯h," exact="ribavirin" post="(400â€¯mg) each 12â€¯h and subcutaneous injections of 1â€&quot;3 doses"/>
   <result pre="and papain like viral protease (PLVP), suggest that effects of" exact="Kaletra" post="are related to protease C30 inhibition with consequent antiviral"/>
   <result pre="treated with a combination of oseltamivir (75â€¯mg each 12â€¯h oral)," exact="ganciclovir" post="(0.25â€¯g each 12â€¯h, intravenously) and Kaletra (500â€¯mg*2/day, oral) for"/>
   <result pre="(75â€¯mg each 12â€¯h oral), ganciclovir (0.25â€¯g each 12â€¯h, intravenously) and" exact="Kaletra" post="(500â€¯mg*2/day, oral) for 3â€&quot;14â€¯days. Most patients were also treated"/>
   <result pre="studies achieved positive results regarding its use as anti-SARS-CoV-2. 5.4.3" exact="Nelfinavir" post="Nelfinavir (27) (Fig. 5) is a safe anti-retroviral drug"/>
   <result pre="achieved positive results regarding its use as anti-SARS-CoV-2. 5.4.3 Nelfinavir" exact="Nelfinavir" post="(27) (Fig. 5) is a safe anti-retroviral drug largely"/>
   <result pre="used for HIV-1 protease inhibition with strong in-vivo activity.178 Generally," exact="Nelfinavir" post="is combined with other anti-retroviral medication as part of"/>
   <result pre="prescribed for children, young individuals, adults and pregnant women.179, 180" exact="Nelfinavir" post="and its active metabolite M8 strongly bind to serum"/>
   <result pre="the disease. Among the 24 drugs likely to inhibit SARS-CoV," exact="nelfinavir" post="stands out in all assays.180 The mechanism of action"/>
   <result pre="out in all assays.180 The mechanism of action suggested for" exact="nelfinavir" post="involves preventing SARS-CoV replication after its entry in the"/>
   <result pre="virion production. Based on results from previous studies as well," exact="nelfinavir" post="was considered a likely therapy for COVID-19 after its"/>
   <result pre="good binding modes: nelfinavir, praziquantel, pitavastatin, perampanel, eszopiclone, and zopiclone." exact="Nelfinavir" post="was identified as the best drug with predicted binding"/>
   <result pre="âˆ’9.42â€¯Â±â€¯0.04â€¯kcal/mol by SIE, respectively. In addition, the binding model of" exact="nelfinavir" post="in its docking complex turned out to be very"/>
   <result pre="electrostatic interaction performs an important role in the bond between" exact="nelfinavir" post="and the potential target Mpro. 5.4.4 Atazanavir Atazanavir (28)"/>
   <result pre="the bond between nelfinavir and the potential target Mpro. 5.4.4" exact="Atazanavir" post="Atazanavir (28) (Fig. 5) is an antiretroviral drug protease"/>
   <result pre="bond between nelfinavir and the potential target Mpro. 5.4.4 Atazanavir" exact="Atazanavir" post="(28) (Fig. 5) is an antiretroviral drug protease inhibitor"/>
   <result pre="inhibitory concentration of 2,6â€&quot;5,3 nmol. Compared to other protease inhibitors," exact="atazanavir" post="has the advantage of allowing a daily posology regimen"/>
   <result pre="in-vitro atazanavir, which is considered safe and well tolerated.184 The" exact="atazanavir" post="acts to inhibit HIV-1 protease, which is indispensable in"/>
   <result pre="helicase, exonuclease 3â€²â€&quot;5â€², endoRNAse and SARS-CoV-2 2â€²-O-ribose methyltransferase. Results suggested" exact="atazanavir" post="as the best drug because of its strong binding"/>
   <result pre="390,67â€¯nM), and endoRNAse (Kd 50,32â€¯nM). Therefore, it is likely that" exact="atazanavir" post="can inhibit all subunits in the SARS-CoV-2 replication complex"/>
   <result pre="SARS-CoV-2 replication complex at the same time. The potential of" exact="atazanavir" post="was supported by computational assays for SARS-CoV-2 Mpro. Interactions"/>
   <result pre="on binding affinity and binding free energy. Results suggest that" exact="atazanavir" post="is a potent helicase inhibitor with affinity of âˆ’11,28;"/>
   <result pre="GLN331 and the drug was observed. Another relevant characteristic of" exact="atazanavir" post="is meeting the Lipinski rule of five as the"/>
   <result pre="are recommended to confirm efficacy and safety against COVID-19. 5.4.5" exact="Captopril" post="Captopril (29) (Fig. 5) is an angiotensin-converting enzyme inhibitor"/>
   <result pre="recommended to confirm efficacy and safety against COVID-19. 5.4.5 Captopril" exact="Captopril" post="(29) (Fig. 5) is an angiotensin-converting enzyme inhibitor (ACEi)."/>
   <result pre="succinyls/dipeptidase by blocking its zinc catalytic center.188, 189 Tolerance to" exact="captopril" post="has been largely investigated; its single dose by mouth"/>
   <result pre="(10â€&quot;30â€¯min) at the cellular level. This capacity is related to" exact="captopril" post="transport mainly through plasma proteins such as albumins with"/>
   <result pre="less frequent for low doses.188, 189 Some investigations have suggested" exact="captopril" post="as possible COVID-19 treatment. Serafin et al.99 indicated captopril"/>
   <result pre="suggested captopril as possible COVID-19 treatment. Serafin et al.99 indicated" exact="captopril" post="as potential for inhibiting the bond between human SARS-CoV-2"/>
   <result pre="drugs were identified as ligands for the enzyme active site:" exact="captopril" post="and disulfiram. The former binds to the active site"/>
   <result pre="same site with 3CLpro Cys145). It is, thus, suggested that" exact="captopril" post="binds to the same site of N3, obstructing the"/>
   <result pre="site of N3, obstructing the function of Cys145â€&quot;His41 catalytic dyad." exact="Captopril" post="probably inhibits the enzyme in two stages. Initially, it"/>
   <result pre="in a more stable inhibitor complex. The hypothesis is that" exact="captopril" post="can bind covalently to 3CLpro Cys145. Although the potential"/>
   <result pre="can bind covalently to 3CLpro Cys145. Although the potential of" exact="captopril" post="on the enzyme has been demonstrated, therapeutic use against"/>
   <result pre="angiotensin-II receptor blockers, needs analysis to clarify the effects of" exact="captopril" post="in COVID-19 treatment. 5.4.6 Ciclosporin A (CsA) The cyclosporin"/>
   <result pre="of captopril in COVID-19 treatment. 5.4.6 Ciclosporin A (CsA) The" exact="cyclosporin A" post="(CsA) (30) (Fig. 5) is isolated from the fungus"/>
   <result pre="or suspension and is often used with low doses of" exact="ritonavir" post="as part of a combined ART protocol.211 Its mechanism"/>
   <result pre="the concentration of 300â€¯ÂµM.212 Nonetheless, the combination of darunavir and" exact="ritonavir" post="displayed low in-vitro effectiveness against SARS-CoV-2.213 A number of"/>
   <result pre="for replication of this HCoVs. Nevertheless, the authors reported that" exact="dasatinib" post="may be valuable against coronaviruses infections if a dosing"/>
   <result pre="More preclinical and clinical studies are required to prove whether" exact="dasatinib" post="is really promising for COVID-19 patient treatment. 5.6.2 Imatinib"/>
   <result pre="several biological processes.217 In addition to this well-known antitumor effect," exact="imatinib" post="has also shown in-vitro antiviral properties against several virus,"/>
   <result pre="related to SARS-CoV-2.24 In this regard, it is reported that" exact="imatinib" post="has anti-CoV activity in two points of the virus"/>
   <result pre="cell protein required for viral growth.222 Furthermore, evidences suggest that" exact="imatinib" post="can modulate the immune response by sundry mechanisms,223, 224,"/>
   <result pre="treatment alternative for COVID-19 pneumonia. In addition, the use of" exact="imatinib" post="as treatment appears to be reasonable from an economic"/>
   <result pre="protein with 34 antiviral compounds. Based on this study results," exact="imatinib" post="was one of the highly binding affinities performed against"/>
   <result pre="drugs that inhibited SARS-CoV-2 at non-cytotoxic concentrations. The authors indicate" exact="imatinib" post="as one of the hits, since it exhibited IC50"/>
   <result pre="CoVs with cellular membranes, precluding their entry. This result indicates" exact="imatinib" post="use against SARS-CoV-2. However, its efficacy and safety need"/>
   <result pre="is the result of a structural modification in the antiparasitic" exact="niclosamide" post="when a benzene ring is replaced with a nitrothiazole.234,"/>
   <result pre="improve results for patients infected with Î²-CoVs. 5.7 Quinolines 5.7.1" exact="Chloroquine" post="(CQ) and Hydroxychloroquine (HCQ) More recently, molecules with a"/>
   <result pre="patients infected with Î²-CoVs. 5.7 Quinolines 5.7.1 Chloroquine (CQ) and" exact="Hydroxychloroquine" post="(HCQ) More recently, molecules with a quinoline group have"/>
   <result pre="investigated as treatment for the new coronavirus (SARS-CoV-2), such as" exact="Chloroquine" post="(CQ) (37) and Hydroxychloroquine (HCQ) (38) (Fig. 7 )"/>
   <result pre="the new coronavirus (SARS-CoV-2), such as Chloroquine (CQ) (37) and" exact="Hydroxychloroquine" post="(HCQ) (38) (Fig. 7 ) that belong to the"/>
   <result pre="7 Chemical structures of quinolines, macrolides and indole derivatives drugs:" exact="Chloroquine" post="(37); Hydroxychloroquine (38); Ivermectin (39); Arbidol (40); Rizatriptan (41);"/>
   <result pre="structures of quinolines, macrolides and indole derivatives drugs: Chloroquine (37);" exact="Hydroxychloroquine" post="(38); Ivermectin (39); Arbidol (40); Rizatriptan (41); Melatonin (42)."/>
   <result pre="mid-March 2020, verified the efficacy of HCQ with and without" exact="azithromycin" post="in a Retrospective multicentre cohort study with COVID-19 patients"/>
   <result pre="the 1.438 admissions, only patients who received HQ exclusively, or" exact="Azithromycin" post="exclusively, or both drugs had greater chances of developing"/>
   <result pre="neurological diseases, tuberculosis and some cancers.265 It is known that" exact="ivermectin" post="is capable of inhibiting the bond between a virus"/>
   <result pre="replication. There are several studies showing the antiviral activity of" exact="ivermectin" post="against HIV-1 and dengue virus,266 influenza,269 DENV 1â€&quot;4,270 yellow"/>
   <result pre="sequestering IMP Î±/Î²1 on the rough ER/Golgi membrane.273 Considering the" exact="ivermectin" post="nuclear transport inhibitory activity, such drug is widely believed"/>
   <result pre="viral proteins and infecting other healthy cells. At this point," exact="ivermectin" post="bonds to and destabilizes IMP Î±/Î²1, impeding the viral"/>
   <result pre="order to provide further scientific support to the use of" exact="ivermectin" post="against SARS-CoV-2, Caly et al.274 conducted in-vitro experiments on"/>
   <result pre="hours after infection with SARS-CoV-2, a single 5â€¯Î¼M dose of" exact="ivermectin" post="was administered, which reduced in 5,000 times the viral"/>
   <result pre="A different mechanism of action that consolidates the use of" exact="ivermectin" post="against COVID-19 is its immunomodulatory property. The inflammatory response"/>
   <result pre="by Kosyna et al.275, whose lab tests with and without" exact="ivermectin" post="aimed to examine whether the properties of the bond"/>
   <result pre="hypoxia mechanism on the cellular level. The authors concluded that" exact="ivermectin" post="inhibited both IMP Î±/Î²1 and HIF-1Î±. Regarding the proper"/>
   <result pre="the proper time of administration, Yavuz &amp;amp; Unal276 claim that" exact="ivermectin" post="is beneficial if taken in the early stages of"/>
   <result pre="of the disease, when symptoms can change. They concluded that" exact="ivermectin" post="is a viable molecule for urgent antiviral therapies against"/>
   <result pre="A different investigation conducted by PatrÃ¬ &amp;amp; Fabbrocini277 suggested combining" exact="ivermectin" post="and HCQ against COVID-19 on the hypothesis that both"/>
   <result pre="primary shield against the viral penetration through cellular membrane while" exact="ivermectin" post="reduced viral replication. However, there are no randomized clinical"/>
   <result pre="to support either the isolated or the combined effect of" exact="ivermectin" post="as prophylactic or therapeutic drug against COVID-19. This hinders"/>
   <result pre="hinders its indication and clinical decisions. Thus far, data indicate" exact="ivermectin" post="is useful at the early stages of the disease,"/>
   <result pre="combined drug therapy with vitamins and zinc, for example.279 Financially," exact="ivermectin" post="is inexpensive and its doses and protocols are well"/>
   <result pre="6-position, one hydroxyl at 5-position, one trimethyl at 4-position, one" exact="ethyl ester" post="at 3-position and one methylsulfanyl benzene at 2-position. Arbidol"/>
   <result pre="virus at elevated concentrations (50â€¯Î¼M), or drugs like laninamivir, oseltamivir," exact="peramivir" post="and zanamivir were ineffective for anti-SARS-CoV-2 activity. Data also"/>
   <result pre="elevated concentrations (50â€¯Î¼M), or drugs like laninamivir, oseltamivir, peramivir and" exact="zanamivir" post="were ineffective for anti-SARS-CoV-2 activity. Data also show that"/>
   <result pre="methyl at 3-position, the substitution sites are the same of" exact="melatonin" post="(MLT). After virtual triage through molecular dock at spike-ACE2"/>
   <result pre="indole derivative that could be repurposed to treat COVID-19 is" exact="melatonin" post="(MLT) (42) (Fig. 7). MLT is classified as a"/>
   <result pre="medication to fight SARS-CoV-2. One such combination involves MLT plus" exact="mercaptopurine" post="in synergic action against the following targets: PLpro, ACE2,"/>
   <result pre="amides, peptidomimetics and steroid derivatives drugs: Emetine (43); Homoharringtonine (44);" exact="Disulfiram" post="(45); Dexamethasone (46). Another alkaloid candidate to repurpose against"/>
   <result pre="results expected of a COVID-19 therapeutic drug.109 5.11 Thioamide 5.11.1" exact="Disulfiram" post="The first reports on tetraethylthiuram disulfide, disulfiram (DSF) (45)"/>
   <result pre="therapeutic drug.109 5.11 Thioamide 5.11.1 Disulfiram The first reports on" exact="tetraethylthiuram disulfide," post="disulfiram (DSF) (45) (Fig. 8), date back to 1881."/>
   <result pre="5.11 Thioamide 5.11.1 Disulfiram The first reports on tetraethylthiuram disulfide," exact="disulfiram" post="(DSF) (45) (Fig. 8), date back to 1881. However,"/>
   <result pre="enabled treatment of intestinal parasites.305, 306, 307 In 1945, DSF" exact="alcohol" post="sensitivity was discovered accidentally and it was soon used"/>
   <result pre="and it was soon used in the clinical treatment of" exact="alcohol" post="dependence.308, 309 DSF is used to treat alcohol dependence"/>
   <result pre="treatment of alcohol dependence.308, 309 DSF is used to treat" exact="alcohol" post="dependence because it irreversibly inhibits the acetaldehyde dehydrogenase enzyme"/>
   <result pre="Evaluation of COVID-19 therapy.316 More specifically, the study focused on" exact="dexamethasone" post="(46), a corticosteroid with fluorine at 9-position (Fig. 8)."/>
   <result pre="Among purine and pyrimidine derivatives, RDV is the most promising" exact="adenosine" post="analogue for clinical trials, probably due to the importance"/>
   <result pre="silver complexes of 5,7-dimethyl-1,2,4-triazolo[1,5 a]pyrimidineJ Inorg Biochem201910.1016/j.jinorgbio.2019.110810 89TÄƒnaseC.I.DrÄƒghiciC.CojocaruA.New carbocyclic N6-substituted" exact="adenine" post="and pyrimidine nucleoside analogues with a bicyclo[2.2.1]heptane fragment as"/>
   <result pre="animal model of intestinal mucositis induced by the combination of" exact="irinotecan" post="and 5-fluorouracil in miceCancer Chemother Pharmacol77201632333210.1007/s00280-015-2938-x26666645 93AhmadS.I.5-Fluorouracil in combination"/>
   <result pre="SARS-CoV-2 replication in vitroAntiviral Res202010.1016/j.antiviral.2020.104786 110LamA.M.EspirituC.BansalS.Genotype and subtype profiling of" exact="PSI-7977" post="as a nucleotide inhibitor of hepatitis C virusAntimicrob Agents"/>
   <result pre="of PSI-7851 and its diastereoisomer PSI-7977J Biol Chem2852010343373434710.1074/jbc.M110.16180220801890 113XuH.-T.Colby-GerminarioS.P.HassounahS.A.Evaluation of" exact="Sofosbuvir" post="(Î²-D-2â€²-deoxy-2â€²-Î±-fluoro-2â€²-Î²-C-methyluridine) as an inhibitor of Dengue virus replicationSci Rep72017634510.1038/s41598-017-06612-228740124"/>
   <result pre="Sacramento CQ, et al. Yellow fever virus is susceptible to" exact="sofosbuvir" post="both in vitro and in vivo. PLoS Negl Trop"/>
   <result pre="vivo. PLoS Negl Trop Dis 2019;13:e0007072. https://doi.org/10.1371/journal.pntd.0007072. 115Bullard-FeibelmanK.M.GoveroJ.ZhuZ.The FDA-approved drug" exact="sofosbuvir" post="inhibits Zika virus infectionAntiviral Res201713713413714010.1016/j.antiviral.2016.11.023 116Ferreira AC, Reis PA,"/>
   <result pre="Freitas CS, et al. Beyond members of the flaviviridae family," exact="sofosbuvir" post="also inhibits chikungunya virus replication. Antimicrob Agents Chemother 2018;63:e01389-18."/>
   <result pre="Agents Chemother 2018;63:e01389-18. https://doi.org/10.1128/AAC.01389-18. 117Sayad B, Sobhani M, Khodarahmi R." exact="Sofosbuvir" post="as repurposed antiviral drug against COVID-19: why were we"/>
   <result pre="Alegre, Santa Catarina: Artmed Editora; 2016. 122OsbornM.Safety and efficacy of" exact="telbivudine" post="for the treatment of chronic hepatitis BTher Clin Risk"/>
   <result pre="treatments for coronavirus disease 2019 (COVID-19)JAMA202010.1001/jama.2020.6019[Epub ahead of print] 138MartinD.F.KuppermannB.D.WolitzR.A.PalestineA.G.LiH.RobinsonC.A.Oral" exact="ganciclovir" post="for patients with cytomegalovirus retinitis treated with a ganciclovir"/>
   <result pre="138MartinD.F.KuppermannB.D.WolitzR.A.PalestineA.G.LiH.RobinsonC.A.Oral ganciclovir for patients with cytomegalovirus retinitis treated with a" exact="ganciclovir" post="implantN Engl J Med34019991063107010.1056/NEJM19990408340140210194235 139Wishart DS, Feunang YD, Guo"/>
   <result pre="cytomegalovirus infection and disease in patients receiving prophylaxis with oral" exact="valganciclovir" post="or intravenous ganciclovir after umbilical cord blood transplantationBiol Blood"/>
   <result pre="disease in patients receiving prophylaxis with oral valganciclovir or intravenous" exact="ganciclovir" post="after umbilical cord blood transplantationBiol Blood Marrow Transplant15200973074010.1016/j.bbmt.2009.03.00219450758 142WinstonD.J.BadenL.R.GabrielD.A.Pharmacokinetics"/>
   <result pre="after umbilical cord blood transplantationBiol Blood Marrow Transplant15200973074010.1016/j.bbmt.2009.03.00219450758 142WinstonD.J.BadenL.R.GabrielD.A.Pharmacokinetics of" exact="ganciclovir" post="after oral valganciclovir versus intravenous ganciclovir in allogeneic stem"/>
   <result pre="blood transplantationBiol Blood Marrow Transplant15200973074010.1016/j.bbmt.2009.03.00219450758 142WinstonD.J.BadenL.R.GabrielD.A.Pharmacokinetics of ganciclovir after oral" exact="valganciclovir" post="versus intravenous ganciclovir in allogeneic stem cell transplant patients"/>
   <result pre="Marrow Transplant15200973074010.1016/j.bbmt.2009.03.00219450758 142WinstonD.J.BadenL.R.GabrielD.A.Pharmacokinetics of ganciclovir after oral valganciclovir versus intravenous" exact="ganciclovir" post="in allogeneic stem cell transplant patients with graft-versus-host disease"/>
   <result pre="by a combination of interferon-Î±2b and ribavirinSci Rep32013168610.1038/srep0168623594967 159WangM.CaoR.ZhangL.Remdesivir and" exact="chloroquine" post="effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in"/>
   <result pre="model of common marmosetJ Infect Dis21220151904191310.1093/infdis/jiv39226198719 171KimU.J.WonE.-J.KeeS.-J.JungS.-I.JangH.-C.Combination therapy with lopinavir/ritonavir," exact="ribavirin" post="and interferon-alpha for Middle East respiratory syndrome: a case"/>
   <result pre="Engl J Med38220201787179910.1056/NEJMoa200128232187464 173HungI.F.LungK.C.TsoE.Y.K.Triple combination of interferon beta-1b, lopinavirâ€&quot;ritonavir, and" exact="ribavirin" post="in the treatment of patients admitted to hospital with"/>
   <result pre="2 trialLancet20202016951704 174LinS.ShenR.HeJ.LiX.GuoX.Molecular modeling evaluation of the binding abilities of" exact="ritonavir" post="and lopinavir to wuhan pneumonia coronavirus proteasesBioRxiv202010.1101/2020.01.31.929695 175UyekiT.M.Oseltamivir treatment"/>
   <result pre="174LinS.ShenR.HeJ.LiX.GuoX.Molecular modeling evaluation of the binding abilities of ritonavir and" exact="lopinavir" post="to wuhan pneumonia coronavirus proteasesBioRxiv202010.1101/2020.01.31.929695 175UyekiT.M.Oseltamivir treatment of influenza"/>
   <result pre="approachLife Sci2522020117652 178HsiehL.LinC.SuB.Synergistic antiviral effect of Galanthus nivalis agglutinin and" exact="nelfinavir" post="against feline coronavirusAntivir Res882010253020603153 179PerryC.M.FramptonJ.E.MccormackP.L.SiddiquiM.A.A.CvetkovicR.S.NelfinavirDrugs6520052209224416225378 180YamamotoN.YangR.YoshinakaY.HIV protease inhibitor nelfinavir"/>
   <result pre="and nelfinavir against feline coronavirusAntivir Res882010253020603153 179PerryC.M.FramptonJ.E.MccormackP.L.SiddiquiM.A.A.CvetkovicR.S.NelfinavirDrugs6520052209224416225378 180YamamotoN.YangR.YoshinakaY.HIV protease inhibitor" exact="nelfinavir" post="inhibits replication of SARS-associated coronavirusBiochem Biophys Res Commun318200471972515144898 181XuZ.PengC.ShiY.Nelfinavir"/>
   <result pre="for the treatment of human immunodeficiency virus infectionPharmacotherapy12200417321747 183MastanS.K.KumarK.E.Influence of" exact="atazanavir" post="on the pharmacodynamics and pharmacokinetics of gliclazide in animal"/>
   <result pre="infectionPharmacotherapy12200417321747 183MastanS.K.KumarK.E.Influence of atazanavir on the pharmacodynamics and pharmacokinetics of" exact="gliclazide" post="in animal modelsInt J Diabetes Dev Ctries220105660 184HaasD.W.ZalacC.SchraderdS.Therapy with"/>
   <result pre="gliclazide in animal modelsInt J Diabetes Dev Ctries220105660 184HaasD.W.ZalacC.SchraderdS.Therapy with" exact="atazanavir" post="plus saquinavir in patients failing highly active antiretroviral therapy:"/>
   <result pre="animal modelsInt J Diabetes Dev Ctries220105660 184HaasD.W.ZalacC.SchraderdS.Therapy with atazanavir plus" exact="saquinavir" post="in patients failing highly active antiretroviral therapy: a randomized"/>
   <result pre="to therapeutic agentBr J Pharmacol16520121235124521955136 191LiddicoatA.M.LavelleE.C.Modulation of innate immunity by" exact="cyclosporine" post="ABiochem Pharmacol163201947248030880061 192ChighizolaC.B.OngV.H.MeroniP.L.The use of cyclosporine A in rheumatology:"/>
   <result pre="of innate immunity by cyclosporine ABiochem Pharmacol163201947248030880061 192ChighizolaC.B.OngV.H.MeroniP.L.The use of" exact="cyclosporine" post="A in rheumatology: a 2016 comprehensive reviewClin Rev Allergy"/>
   <result pre="coronavirus NL63 replication is cyclophilin A-dependent and inhibited by non-immunosuppressive" exact="cyclosporine" post="A-derivatives including AlisporivirVirus Res1842014445324566223 197de WildeA.H.PhamU.PosthumaC.C.SnijderE.J.Cyclophilins and cyclophilin inhibitors"/>
   <result pre="207KhatriA.MenonR.M.MarburyT.C.Pharmacokinetics and safety of co-administered paritaprevir plus ritonavir, ombitasvir, and" exact="dasabuvir" post="in hepatic impairmentJ Hepatol63201580581226070406 208GentileI.BuonomoA.R.BorgiaG.Dasabuvir: a non-nucleoside inhibitor of"/>
   <result pre="acute lung injuryAm J Physiol Cell Mol Physiol3092015L1294L1304 225BÃ¤rnthalerT.Imatinib stimulates" exact="prostaglandin E2" post="and attenuates cytokine release via EP4 receptor activationJ Allergy"/>
   <result pre="clinical remission in rheumatoid arthritisJ Bone Spine772010372373 227CahillK.N.KatzH.R.CuiJ.KIT inhibition by" exact="imatinib" post="in patients with severe refractory asthmaN Engl J Med37620171911192028514613"/>
   <result pre="asthmaN Engl J Med37620171911192028514613 228MagroF.CostaC.Long-standing remission of Crohnâ€™s disease under" exact="imatinib" post="therapy in a patient with Crohnâ€™s diseaseInflamm Bowel Dis1220061087108917075351"/>
   <result pre="treatment in chronic myeloid leukaemiaLeukemia3020161648167127121688 231MughalT.Principal long-term adverse effects of" exact="imatinib" post="in patients with chronic myeloid leukemia in chronic phaseBiol"/>
   <result pre="of action of an undervalued drugImmunol Lett1532013505723891850 245KapoorA.PandurangiU.AroraV.Cardiovascular risks of" exact="hydroxychloroquine" post="in treatment and prophylaxis of COVID-19 patients: a scientific"/>
   <result pre="the Indian Heart Rhythm SocietyIndian Pacing Electrophysiol J20202011712032278018 246ColsonP.RolainJ.M.LagierJ.C.BrouquiP.RaoultD.Chloroquine and" exact="hydroxychloroquine" post="as available weapons to fight COVID-19Int J Antimicrob Agents.552020105932"/>
   <result pre="effective in inhibiting SARS-CoV-2 infection in vitroCell Discov620201632194981 248TouretF.de LamballerieX.Of" exact="chloroquine" post="and COVID-19Antiviral Res1772020104762 249DrakesmithH.PrenticeA.Viral infection and iron metabolismNat Rev"/>
   <result pre="other amines as antiviral agentsProc Natl Acad Sci781981360536096115382 255ShimizuY.YamamotoS.HommaM.IshidaN.Effect of" exact="chloroquine" post="on the growth of animal virusesArch Gesamte Virusforsch361972931044335025 256KeyaertsE.VijgenL.MaesP.NeytsJ.VanRanst"/>
   <result pre="Commun323200426426815351731 257CortegianiA.IngogliaG.IppolitoM.GiarratanoA.EinavS.A systematic review on the efficacy and safety of" exact="chloroquine" post="for the treatment of COVID-19J Crit Care57202027928332173110 258SinghA.K.SinghA.ShaikhA.SinghR.MisraA.Chloroquine and"/>
   <result pre="chloroquine for the treatment of COVID-19J Crit Care57202027928332173110 258SinghA.K.SinghA.ShaikhA.SinghR.MisraA.Chloroquine and" exact="hydroxychloroquine" post="in the treatment of COVID-19 with or without diabetes:"/>
   <result pre="molecular modelling studies reveal a new mechanism of action of" exact="chloroquine" post="and hydroxychloroquine against SARS-CoV-2 infectionInt J Antimicrob Agents552020105960 260GautretP.LagierJ.C.ParolaP.Hydroxychloroquine"/>
   <result pre="studies reveal a new mechanism of action of chloroquine and" exact="hydroxychloroquine" post="against SARS-CoV-2 infectionInt J Antimicrob Agents552020105960 260GautretP.LagierJ.C.ParolaP.Hydroxychloroquine and azithromycin"/>
   <result pre="and hydroxychloroquine against SARS-CoV-2 infectionInt J Antimicrob Agents552020105960 260GautretP.LagierJ.C.ParolaP.Hydroxychloroquine and" exact="azithromycin" post="as a treatment of COVID-19: results of an open-label"/>
   <result pre="for an evidence baseLancet Respir Med8202053954132304640 262RosenbergE.S.DufortE.M.UdoT.Association of treatment with" exact="hydroxychloroquine" post="or azithromycin with in-hospital mortality in patients with COVID-19"/>
   <result pre="evidence baseLancet Respir Med8202053954132304640 262RosenbergE.S.DufortE.M.UdoT.Association of treatment with hydroxychloroquine or" exact="azithromycin" post="with in-hospital mortality in patients with COVID-19 in New"/>
   <result pre="patients with COVID-19 in New York StateJAMA202010.1001/jama.2020.8630 263GelerisJ.SunY.PlattJ.Observational study of" exact="hydroxychloroquine" post="in hospitalized patients with Covid-19N Engl J Med202010.1056/nejmoa2012410 264Recovery."/>
   <result pre="serotypes by the inhibitor IvermectinAntiviral Res99201330130623769930 271YangS.N.Y.AtkinsonS.C.WangC.The broad spectrum antiviral" exact="ivermectin" post="targets the host nuclear transport importin Î±/Î²1 heterodimerAntiviral Res1772020104760"/>
   <result pre="factors on the rough endoplasmic reticulum/golgi membraneVirology81200798129824 274CalyL.DruceJ.D.CattonM.G.JansD.A.WagstaffK.M.The FDA-approved drug" exact="ivermectin" post="inhibits the replication of SARS-CoV-2 in vitroAntivir Res1782020104787 275KosynaF.K.NagelM.KluxenL.KraushaarK.DeppingR.The"/>
   <result pre="COVID-19 chemoprophylaxis and treatment?J Am Acad Dermatol822020e221 278GonÃ§alvesA.DruceJ.D.CattonM.G.Therapeutic potential of" exact="ivermectin" post="for COVID-19Authorea202010.22541/au.159050476.60928563 279JayawardenaR.SooriyaarachchiP.ChourdakisM.JeewandaraC.RanasingheP.Enhancing immunity in viral infections, with special"/>
   <result pre="in healthy Chinese volunteersInt J Clin Pharmacol Ther51201342343223391367 293VisserW.H.Rizatriptan vs" exact="Sumatriptan" post="in the Acute Treatment of MigraineArch Neurol.53199611328912486 294ArmijoP.R.ReginatoR.D.MaganhinC.C.AÃ§Ã£o da"/>
   <result pre="Melatonin as a potential adjuvant treatmentLife Sci2502020117583 296Ben-NathanD.MaestroniG.J.M.LustigS.ContiA.Protective effects of" exact="melatonin" post="in mice infected with encephalitis virusesArch Virol14019952232307710351 297SilvestriM.RossiG.A.Melatonin: its"/>
   <result pre="COVID-19 infection: protective common molecular mechanisms of vitamin D and" exact="melatonin" post="as a new potential synergistic treatmentLife Sci2542020117808 300TangQ.LiS.DuL.Emetine protects"/>
   <result pre="a treatment option for alcoholismJ Ment Heal Hum Behav20201541 306KrampeH.EhrenreichH.Supervised" exact="disulfiram" post="as adjunct to psychotherapy in alcoholism treatmentCurr Pharm Des1620102076209020482514"/>
   <result pre="psychotherapy in alcoholism treatmentCurr Pharm Des1620102076209020482514 307BanysP.The clinical use of" exact="disulfiram" post="(AntabuseÂ®): a reviewJ Psychoactive Drugs2019882432613069984 308PhillipsM.MalloyG.NedunchezianD.LukrecA.HowardR.G.Disulfiram inhibits the in"/>
   <result pre="vitro growth of methicillin-resistant staphylococcus aureusAntimicrob Agents Chemother3519917857872069390 309HamblinK.A.Flick-SmithH.BarnesK.B.Disulfiram, an" exact="alcohol" post="dependence therapy, can inhibit the in vitro growth of"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7484576\results\search\drug\results.xml">
   <result pre="under the terms of premium subscription. Chloroquine, emodin and promazine" exact="Chloroquine" post="is a 9â€�aminoquinoline that has recently been described as"/>
   <result pre="been described as a potent drug with significant anti-viral activity.41" exact="Chloroquine" post="has been known to be a potent inhibitor of"/>
   <result pre="SARS-CoV.42 Wang et al.43 demonstrated the effective suppression activity of" exact="chloroquine" post="for the newly emerged novel CoVID-19 in vitro. Out"/>
   <result pre="anti-viral agents tested against a new clinical isolate of SARS-CoV-2," exact="chloroquine" post="was observed to be extremely efficacious in preventing and"/>
   <result pre="2003;290(24):3222â€&quot;28. doi:10.1001/jama.290.24.3222.14693875 15.WalmsleyS, BernsteinB, KingM, ArribasJ, BeallG, RuaneP, BrunSLopinavirâ€&quot;ritonavir versus" exact="nelfinavir" post="for the initial treatment of HIV infection. New Engl"/>
   <result pre="17.LinS, ShenR, GuoXMolecular modeling evaluation of the binding abilities of" exact="ritonavir" post="and lopinavir to wuhan pneumonia coronavirus proteases. BioRxiv. 2020."/>
   <result pre="GuoXMolecular modeling evaluation of the binding abilities of ritonavir and" exact="lopinavir" post="to wuhan pneumonia coronavirus proteases. BioRxiv. 2020. doi:10.1101/2020.01.31.929695. 18.ChuCM,"/>
   <result pre="2004;101(8):2536â€&quot;41. doi:10.1073/pnas.0307140101.14983044 41.YanY, ZouZ, SunY, LiX, XuKF, WeiY, JiangCAnti-malaria drug" exact="chloroquine" post="is highly effective in treating avian influenza A H5N1"/>
   <result pre="2005;2(1):69. doi:10.1186/1743-422X-2-69.16115318 43.WangM, CaoR, ZhangL, YangX, LiuJ, XuM, XiaoGRemdesivir and" exact="chloroquine" post="effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in"/>
   <result pre="(2019-nCoV) in vitro. Cell Res. 2020;30(3):269â€&quot;71. doi:10.1038/s41422-020-0282-0.32020029 44.TouretF, de LamballerieXOf" exact="chloroquine" post="and COVID-19. Antiviral Res. 2020;177:104762. doi:10.1016/j.antiviral.2020.104762.32147496 45.AlvesDS, PÃ©rez-FonsL, EstepaA,"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7486771\results\search\drug\results.xml">
   <result pre="example, from decreased air pollution, traffic accidents, and consumption of" exact="alcohol" post="resulting from the economic slowdown. These effects may be"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7486822\results\search\drug\results.xml">
   <result pre="human immunodeficiency virus (HIV) infection.4 Lopinavir has antiviral activity, while" exact="ritonavir" post="acts as a lopinavir enhancer, increasing its plasma concentrations"/>
   <result pre="infection.4 Lopinavir has antiviral activity, while ritonavir acts as a" exact="lopinavir" post="enhancer, increasing its plasma concentrations by inhibiting CYP3A4. A"/>
   <result pre="rate of interaction was inhaled budesonide (11.41%, nâ€¯=â€¯42), followed by" exact="simvastatin" post="(9.51%, nâ€¯=â€¯35) and atorvastatin (7.07%, nâ€¯=â€¯26). The rates of"/>
   <result pre="inhaled budesonide (11.41%, nâ€¯=â€¯42), followed by simvastatin (9.51%, nâ€¯=â€¯35) and" exact="atorvastatin" post="(7.07%, nâ€¯=â€¯26). The rates of interactions by drug, together"/>
   <result pre="(ATC) Risk level N (%) Mechanism Effect Recommendationa Antiemetics Â" exact="Domperidone" post="X 3 (0.82) CYP3A4 inhibition. QT prolongation â†‘ Dc."/>
   <result pre="Cardiovascular toxicity risk, ventricular arrhythmia (TdP) Contraindicated. Consider change to" exact="metoclopramide" post="Antidiabetic Â Glibenclamide C 2 (0.54) CYP3A4 and 2D6"/>
   <result pre="ventricular arrhythmia (TdP) Contraindicated. Consider change to metoclopramide Antidiabetic Â" exact="Glibenclamide" post="C 2 (0.54) CYP3A4 and 2D6 inhibitionb â†‘ Dc."/>
   <result pre="â†‘ Dc. Risk of hypoglycaemia Reduce dosage. Monitor glucose. Â" exact="Gliclazide" post="C 1 (0.27) Induction of CYP2C9 and 2C19b â†&quot;"/>
   <result pre="â†‘ Dc. Risk of hypoglycaemia Reduce dosage. Monitor glucose. Â" exact="Canagliflozin" post="D 1 (0.27) Induction of UGT1A9 and 2B4 â†&quot;"/>
   <result pre="to 200â€¯mg or 300â€¯mg. Monitor glucose. If GFRâ€¯ Anticoagulants Â" exact="Apixaban" post="D 5 (1.36) CYP3A4 inhibition. P-glycoprotein inhibition â†‘ Dc."/>
   <result pre="Risk of bleeding Change to LMWH at therapeutic doses. Â" exact="Rivaroxaban" post="X 3 (0.82) Contraindicated. Change to LMWH at therapeutic"/>
   <result pre="to 30â€¯mg or switch to LMWH at therapeutic doses. Â" exact="Acenocoumarol" post="C 11 (2.99) CYP2C9 induction â†&quot; Dc. Thrombotic risk"/>
   <result pre="Thrombotic risk Change to LMWH at therapeutic doses. Antiplatelet Â" exact="Clopidogrel" post="C 15 (4.08) Inhibition of CYP3A4, (2B6, 2C9 and"/>
   <result pre="Switch to ASA (monotherapy), switch to prasugrel (dual therapy) Â" exact="Ticagrelor" post="X 2 (0.54) CYP3A4 inhibition Dc. Risk of bleeding"/>
   <result pre="AV block Reduce dose 50%. Monitor BP and ECG. Â" exact="Nifedipine" post="D 5 (1.36) Reduce dosage. Monitor BP and ECG."/>
   <result pre="D 5 (1.36) Reduce dosage. Monitor BP and ECG. Â" exact="Manidipine" post="D 3 (0.82) Reduce dosage. Monitor BP and ECG."/>
   <result pre="D 3 (0.82) Reduce dosage. Monitor BP and ECG. Â" exact="Lercanidipine" post="X 2 (0.54) Contraindicated. Change to amlodipine with a"/>
   <result pre="amlodipine with a 50% dose reduction. Other cardiovascular drugs Â" exact="Digoxin" post="D 2 (0.54) P-glycoprotein inhibition. Prolonged PR â†‘ Dc."/>
   <result pre="poisoning Reduce dose between 30%âˆ’50% or reduce frequency. Monitor for" exact="digoxin" post="levels. Â Ivabradine X 1 (0.27) CYP3A4 inhibition â†‘"/>
   <result pre="between 30%âˆ’50% or reduce frequency. Monitor for digoxin levels. Â" exact="Ivabradine" post="X 1 (0.27) CYP3A4 inhibition â†‘ Dc. Bradycardia risk"/>
   <result pre="1 (0.27) CYP3A4 inhibition â†‘ Dc. Bradycardia risk Contraindicated. Â" exact="Ranolazine" post="(C01EB18) X 2 (0.54) CYP3A4 inhibition. QT prolongation â†‘"/>
   <result pre="Risk of bradycardia, hypotension, ventricular arrhythmia (TdP) Contraindicated. Antiarrhythmics Â" exact="Amiodarone" post="X 5 (1.36) CYP3A4 inhibition. QT prolongation â†‘ Dc."/>
   <result pre="Dc. Risk of ventricular arrhythmia Contraindicated. Close monitoring, ECG Â" exact="Flecainide" post="X 1 (0.27) Â Propafenone X 3 (0.82) CYP3A4"/>
   <result pre="Contraindicated. Close monitoring, ECG Â Flecainide X 1 (0.27) Â" exact="Propafenone" post="X 3 (0.82) CYP3A4 and 2D6 inhibitionb Close monitoring,"/>
   <result pre="bradycardia and increased negative inotropic effect Reduce dosage. ECG. Â" exact="Verapamil" post="D 6 (1.63) Lipid-lowering drugs (statins) Â Atorvastatin D"/>
   <result pre="of liver toxicity and rhabdomyolysis Maximum dose 20 mg Â" exact="Lovastatin" post="X 1 (0.27) Contraindicated. Switch to pravastatin or pitavastatin"/>
   <result pre="20 mg Â Lovastatin X 1 (0.27) Contraindicated. Switch to" exact="pravastatin" post="or pitavastatin Â Simvastatin X 35 (9.51) Contraindicated. Switch"/>
   <result pre="Â Lovastatin X 1 (0.27) Contraindicated. Switch to pravastatin or" exact="pitavastatin" post="Â Simvastatin X 35 (9.51) Contraindicated. Switch to pravastatin"/>
   <result pre="X 1 (0.27) Contraindicated. Switch to pravastatin or pitavastatin Â" exact="Simvastatin" post="X 35 (9.51) Contraindicated. Switch to pravastatin or pitavastatin"/>
   <result pre="or pitavastatin Â Simvastatin X 35 (9.51) Contraindicated. Switch to" exact="pravastatin" post="or pitavastatin Â Rosuvastatin D 3 (0.82) BCRP and"/>
   <result pre="Â Simvastatin X 35 (9.51) Contraindicated. Switch to pravastatin or" exact="pitavastatin" post="Â Rosuvastatin D 3 (0.82) BCRP and OATP1B1 transporter"/>
   <result pre="and OATP1B1 transporter inhibition Maximum dose 10 mg Urological Â" exact="Tamsulosin" post="X 18 (4.89) CYP3A4 and 2D6 inhibitionb â†‘ Dc."/>
   <result pre="anticholinergic toxicity Maximum dose 5â€¯mg/day. Monitor anticholinergic effects Corticosteroids Â" exact="Methylprednisolone" post="D 23 (6.25) CYP3A4 inhibition â†‘ Dc. Risk of"/>
   <result pre="inhibition â†‘ Dc. Risk of Cushing's syndrome Reduce dose Â" exact="Prednisone" post="C 5 (1.36) Â Dexamethasone D 1 (0.27) CYP3A4"/>
   <result pre="(LPV/r) CYP3A4 induction (dexamethasone) â†&quot; LPV/r. Decreased efficacy Antimicrobial Â" exact="Clarithromycin" post="D 6 (1.63) CYP3A4 inhibition. QT prolongation â†‘ Dc."/>
   <result pre="If GFR 30âˆ’60â€¯ml/min, reduce dose to 500â€¯mg/24â€¯h If GFRâ€¯ Â" exact="Metronidazole" post="X 1 (0.27) LPV/r oral solution contains alcohol. Disulfiram"/>
   <result pre="Â Metronidazole X 1 (0.27) LPV/r oral solution contains alcohol." exact="Disulfiram" post="reaction risk Contraindicated with the oral solution. No tablets"/>
   <result pre="risk Contraindicated with the oral solution. No tablets Antioestrogens Â" exact="Tamoxifen" post="D 3 (0.82) CYP3A4 and 2D6 inhibitionb â†&quot; AMC."/>
   <result pre="D 3 (0.82) CYP3A4 and 2D6 inhibitionb â†&quot; AMC. Decreased" exact="oestrogen" post="modulating effect Muscle relaxants Â Fentanyl iv D 4"/>
   <result pre="inhibitionb â†&quot; AMC. Decreased oestrogen modulating effect Muscle relaxants Â" exact="Fentanyl" post="iv D 4 (1.09) CYP3A4 inhibition â†‘ Dc. Risk"/>
   <result pre="depression Reduce dose to 25âˆ’50â€¯mcg/h. Monitor pain (ANI, NOL) Â" exact="Midazolam" post="iv D 24 (6.52) â†‘ Dc. Risk of respiratory"/>
   <result pre="exceedâ€¯&amp;gt;â€¯25â€¯mg/kg/h). Monitor depth of sedation (BIS). Opioid pain relievers Â" exact="Fentanyl" post="oral/patch D 2 (0.54) CYP3A4 inhibition â†‘ Dc. Risk"/>
   <result pre="Dc. Risk of sedation and respiratory depression. Reduce dose Â" exact="Oxycodone" post="D 1 (0.27) CYP3A4 and 2D6 inhibitionb â†‘ Dc."/>
   <result pre="â†‘ Dc. Risk of sedation and respiratory depression. Anticonvulsants Â" exact="Carbamazepine" post="D 1 (0.27) CYP3A4 inhibition (LPV/r) â†‘ Dc. CNS"/>
   <result pre="dose. CYP3A4 (carbamazepine) induction â†&quot; LPV/r. Decreased antiviral effect Â" exact="Phenytoin" post="D 1 (0.27) CYP2C9 and 2C19 induction (LPV/r) â†&quot;"/>
   <result pre="2 times a day and consider increasing the dose. Monitor" exact="phenytoin" post="levels and adjust dose CYP3A (phenytoin) induction â†&quot; LPV/r."/>
   <result pre="dose CYP3A (phenytoin) induction â†&quot; LPV/r. Decreased antiviral effect Â" exact="Clonazepam" post="D 5 (1.36) CYP3A4 inhibition â†‘ Dc. Risk of"/>
   <result pre="Dc. Risk of sedation and drowsiness. Reduce dose Hypnotic/sedatives Â" exact="Alprazolam" post="D 10 (2.72) Inhibition of CYP3A4 and P-glycoprotein â†‘"/>
   <result pre="respiratory depression. Start low dose and increase as needed. Â" exact="Clorazepate" post="C 3 (0.82) Reduce dosage. Â Diazepam D 15"/>
   <result pre="as needed. Â Clorazepate C 3 (0.82) Reduce dosage. Â" exact="Diazepam" post="D 15 (4.08) CYP3A4 and C219 inhibitionb Avoid. Reduce"/>
   <result pre="(4.08) CYP3A4 and C219 inhibitionb Avoid. Reduce dosage. Neuroleptics Â" exact="Haloperidol" post="D 8 (2.17) CYP3A4, 2D6b inhibition and glucuronidation (UGT2B7â€¯&amp;gt;â€¯1A4"/>
   <result pre="in the elderly. Reduce dosage. Monitor CNS effects. ECG. Â" exact="Quetiapine" post="D 11 (2.99) CYP3A4 and 2D6 inhibitionb. QT prolongation"/>
   <result pre="Cardiovascular toxicity risk: tachycardia and ventricular arrhythmia (TdP) Contraindicated. Consider" exact="salbutamol" post="Antihistamines Â Ebastine D 1 (0.27) CYP3A4 inhibition â†‘"/>
   <result pre="of drowsiness, xerostomia, and headache Reduce dosage. Consider dexchlorpheniramine ASA:" exact="acetylsalicylic acid;" post="ANI: analgesia nociception index; AV: atrioventricular; Dc: drug concentration;"/>
   <result pre="slow cardiac repolarization and prolong the QT interval.5 In addition," exact="hydroxychloroquine" post="and azithromycin, drugs currently used in combination with LVP/r"/>
   <result pre="associated with developing potential interactions with LPV/r in our study." exact="Simvastatin" post="and atorvastatin were 2 of the drugs with the"/>
   <result pre="developing potential interactions with LPV/r in our study. Simvastatin and" exact="atorvastatin" post="were 2 of the drugs with the highest rate"/>
   <result pre="20 April 2020]. Available from: https://www.mscbs.gob.es/profesionales/saludPublica/ccayes/alertasActual/nCovChina/documentos.htm. 2YaoT.T.QianJ.D.ZhuW.Y.WangY.WangG.Q.A systematic review of" exact="lopinavir" post="therapy for SARS coronavirus and MERS coronavirusâ€&quot;a possible reference"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7488313\results\search\drug\results.xml">
   <result pre="mg/mL) via the intramuscular route, euthanized by intracardiac injection of" exact="pentobarbital" post="overdose (140Â mg/kg body weight, Euthasol 400Â mg/mL) and"/>
   <result pre="enriched with Penicillinâ€&quot;Streptomycin (Thermo Fisher Scientific, Waltham, Massachusetts, USA) and" exact="Nystatin" post="(Sigma-Aldrich, Missouri, USA) at a final concentration of 6%."/>
   <result pre="by one-step Taqman RT-PCR technique in Fast7500 equipment (Applied Biosystems," exact="Foster" post="City, CA, USA), using the same primers and probe"/>
   <result pre="whereas the product is not cut in case of an" exact="adenine" post="(A) at this position. Digestion products were visualized in"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7489051\results\search\drug\results.xml">
   <result pre="clinical trials along with umifenovir (also named Arbidol) and ribavirin." exact="Chloroquine" post="(CQ), a widely used antimalarial and immunomodulatory drug, showed"/>
   <result pre="These findings led to 15 clinical trials of CQ or" exact="hydroxychloroquine" post="(HCQ) in China to test their efficacy and safety"/>
   <result pre="the Guidelines for the Diagnosis and Treatment of COVID-19, glucocorticoid" exact="methylprednisolone" post="was prudently recommended to treat severe patients at a"/>
   <result pre="(200 mg/50 mg per capsule, 2 capsules each time, BID);" exact="ribavirin" post="(500 mg by venoclysis per time, BID, combination treatment"/>
   <result pre="IL-6 level. Â (8) Other therapies, including low dosage of" exact="methylprednisolone" post="(â‰¤1â€&quot;2 mg kgâ€&quot;1 dayâ€&quot;1) and intestinal microecological regulators. aBID,"/>
   <result pre="of action inÂ vitro/inÂ vivo effect CoV type ref 1" exact="Chloroquine" post="(CQ) IncreasesÂ endosomalÂ pH; disrupts intracellular trafficking and viral"/>
   <result pre="and the duration of fever. SARS-CoV-2 Huang et al.39 2" exact="Hydroxychloroquine" post="(HCQ) The same as CQ. In vitro IC50: 0.72"/>
   <result pre="relief for pyrexia and cough. SARS-CoV-2 Chen et al.64 5" exact="Ribavirin" post="Inhibits viral RNA synthesis and mRNA capping. In vitro"/>
   <result pre="In vitro The cytopathic effect of SARS-CoV was inhibited by" exact="ribavirin" post="at 50 Î¼g/mL SARS-CoV Chu et al.66 IC50: 109.5"/>
   <result pre="vitro The cytopathic effect of the SARS-CoV was inhibited by" exact="lopinavir" post="at 4 Î¼g/mL. SARS-CoV Chu et al.66 IC50: 17.1"/>
   <result pre="&amp;gt;37.6 Î¼M; SI: 5.7 HCoV-229E Lopinavir/ritonavir A fixed dose of" exact="ritonavir" post="was used to increase lopinavir half-life through the inhibition"/>
   <result pre="Lopinavir/ritonavir A fixed dose of ritonavir was used to increase" exact="lopinavir" post="half-life through the inhibition of cytochrome P450. Randomized, controlled,"/>
   <result pre="3.1 14 Tingenone 9.9 4.0 15 Iguesterin 2.6 0.8 16" exact="Hesperetin" post="Isatis indigotica 8.3 NT - Lin et al.93 17"/>
   <result pre="produce IFNs. 2.12 &amp;gt;35.5 &amp;gt;16.7 SARS-CoV-2 WangÂ etÂ al.16 49" exact="Nafamostat" post="Inhibits S protein-mediated membrane fusion. 22.5 &amp;gt;100 &amp;gt;4.4 50"/>
   <result pre="Nafamostat Inhibits S protein-mediated membrane fusion. 22.5 &amp;gt;100 &amp;gt;4.4 50" exact="Penciclovir" post="Inhibits RdRp. 95.9 &amp;gt;400 &amp;gt;4.2 aNT, not tested. Table"/>
   <result pre="ipecacuanha 0.30 2.69 9.0 HCoV-OC43 1.43 3.63 2.5 HCoV-NL63 63" exact="Mycophenolate mofetil" post="Derivative 1.58 3.43 2.2 HCoV-OC43 0.23 3.01 13 HCoV-NL63"/>
   <result pre="Fangchinoline 0.91 12.4 11 69 Cepharanthine 0.72 10.5 13 70" exact="Reserpine" post="Rauwolfia serpentina 3.4 25 7.3 SARS-CoV Wu et al.67"/>
   <result pre="MERS-CoV, in cultured cells and mouse models.49 It is an" exact="adenosine" post="analog that is incorporated into nascent viral RNA chains,"/>
   <result pre="clinical studies. 3.1.2 Other Effective CoV Inhibitors Another guanine derivative," exact="ribavirin" post="(4), approved for treating hepatitis C virus (HCV) and"/>
   <result pre="to block the SARS-CoV 3CLpro67 and is usually combined with" exact="ritonavir" post="(6) to increase the half-life of lopinavir by inhibiting"/>
   <result pre="usually combined with ritonavir (6) to increase the half-life of" exact="lopinavir" post="by inhibiting cytochrome P450.68 On January 18, 2020, a"/>
   <result pre="used to treat chronic pancreatitis. Zhou et al. reported that" exact="camostat" post="was effective in protecting mice from a lethal infection"/>
   <result pre="SARS-CoV-2 entry into mouse lung cells.78 These findings suggest that" exact="camostat" post="may be a valuable therapeutic against COVID-19. 3.2 Potential"/>
   <result pre="evaluated for their anti-SARS-CoV 3CLpro activities. Among them, the flavonoid" exact="hesperetin" post="(16, IC50 = 8.3 Î¼M) showed the highest inhibitory"/>
   <result pre="PLpro (IC50, 3.7 Î¼M).107 Kim et al. found that the" exact="ethanol" post="extract of Psoralea corylifolia seeds showed strong activity against"/>
   <result pre="Î¼g/mL). Furthermore, they demonstrated that six flavonoids isolated from the" exact="ethanol" post="extract displayed PLpro inhibition in a dose-dependent manner with"/>
   <result pre="vinyl sulfones is associated with the presence of a basic" exact="piperazine" post="ring at the P3 position, which is consistent with"/>
   <result pre="that nitazoxanide inhibited SARS-CoV-2 with an EC50 of 2.12 Î¼M." exact="Nafamostat" post="(49), a highly efficacious inhibitor of MERS-CoV as it"/>
   <result pre="with an EC50 of 22.5 Î¼M. However, the nucleoside analog" exact="penciclovir" post="(50) was required for viral inhibition, yielding an EC50"/>
   <result pre="and pharmacologically active compounds and identified seven compounds (lycorine (8)," exact="mycophenolic acid" post="(61), emetine (62), mycophenolate mofetil (63), phenazopyridine (64), monensin"/>
   <result pre="identified seven compounds (lycorine (8), mycophenolic acid (61), emetine (62)," exact="mycophenolate mofetil" post="(63), phenazopyridine (64), monensin sodium (65), and pyrvinium pamoate"/>
   <result pre="(lycorine (8), mycophenolic acid (61), emetine (62), mycophenolate mofetil (63)," exact="phenazopyridine" post="(64), monensin sodium (65), and pyrvinium pamoate (66)) as"/>
   <result pre="to identify effective anti-SARS agents. The potent inhibitors found were" exact="reserpine" post="(70), a well-known antihypertensive drug derived from several members"/>
   <result pre="equally as important as antivirals. In fact, glucocorticoids such as" exact="methylprednisolone" post="have been approved to treat some severe COVID-19 patients"/>
   <result pre="that a low-to-moderate dose (6 mg/day for 10 days) of" exact="dexamethasone" post="reduced deaths in hospitalized COVID-19 patients who were on"/>
   <result pre="CaoR.; ZhangL.; YangX.; LiuJ.; XuM.; ShiZ.; HuZ.; ZhongW.; XiaoG.Remdesivir and" exact="chloroquine" post="effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in"/>
   <result pre="in vitro. Cell Res.2020, 30, 269â€&quot;271. 10.1038/s41422-020-0282-0.32020029 GaoJ.; TianZ.; YangX.Breakthrough:" exact="Chloroquine" post="phosphate has shown apparent efficacy in treatment of COVID-19"/>
   <result pre="YanY.; ZouZ.; SunY.; LiX.; XuK. F.; WeiY.; JinN.; JiangC.Anti-malaria drug" exact="chloroquine" post="is highly effective in treating avian influenza A H5N1"/>
   <result pre="KeyaertsE.; LiS.; VijgenL.; RysmanE.; VerbeeckJ.; Van RanstM.; MaesP.Antiviral activity of" exact="chloroquine" post="against human coronavirus OC43 infection in newborn mice. Antimicrob."/>
   <result pre="multicenter prospective observational study of the safety and efficacy of" exact="chloroquine" post="for the treatment of COVID-19. medRxiv2020, 10.1101/2020.04.26.20081059. McChesneyE. W.Animal"/>
   <result pre="of COVID-19. medRxiv2020, 10.1101/2020.04.26.20081059. McChesneyE. W.Animal toxicity and pharmacokinetics of" exact="hydroxychloroquine" post="sulfate. Am. J. Med.1983, 75, 11â€&quot;18. 10.1016/0002-9343(83)91265-2.6408923 GautretP.; LagierJ.-C.;"/>
   <result pre="T.; HonorÃ©S.; ColsonP.; ChabriÃ¨reE.; La ScolaB.; RolainJ.-M.; BrouquiP.; RaoultD.Hydroxychloroquine and" exact="azithromycin" post="as a treatment of COVID-19: results of an open-label"/>
   <result pre="ChenZ.; HuJ.; ZhangZ.; JiangS.; HanS.; YanD.; ZhuangR.; HuB.; ZhangZ.Efficacy of" exact="hydroxychloroquine" post="in patients with COVID-19: results of a randomized clinical"/>
   <result pre="dissemination of results and its consequences regarding the use of" exact="hydroxychloroquine" post="for COVID-19. Ann. Intern. Med.2020, 172, 819â€&quot;821. 10.7326/M20-1223.32227189 TangW.;"/>
   <result pre="KerneisS.; MÃ©nagerP.; MouthonL.; AudureauE.; RavaudP.; GodeauB.; GallienS.; Costedoat-ChalumeauN.Clinical efficacy of" exact="hydroxychloroquine" post="in patients with Covid-19 pneumonia who require oxygen: observational"/>
   <result pre="McDonaldE. G.; RajasinghamR.; LeeT. C.; HullsiekK. H.A randomized trial of" exact="hydroxychloroquine" post="as postexposure prophylaxis for Covid-19. N. Engl. J. Med.2020,"/>
   <result pre="rapid antiviral clearance or clinical benefit with the combination of" exact="hydroxychloroquine" post="and azithromycin in patients with severe COVID-19 infection. Med."/>
   <result pre="clearance or clinical benefit with the combination of hydroxychloroquine and" exact="azithromycin" post="in patients with severe COVID-19 infection. Med. Mal. Infect.2020,"/>
   <result pre="50, 384â€&quot;387. 10.1016/j.medmal.2020.03.006.32240719 MehraM. R.; DesaiS. S.; RuschitzkaF.; PatelA. N.RETRACTED:" exact="Hydroxychloroquine" post="or chloroquine with or without a macrolide for treatment"/>
   <result pre="10.1016/j.medmal.2020.03.006.32240719 MehraM. R.; DesaiS. S.; RuschitzkaF.; PatelA. N.RETRACTED: Hydroxychloroquine or" exact="chloroquine" post="with or without a macrolide for treatment of COVID-19:"/>
   <result pre="vitro antiviral activity and projection of optimized dosing design of" exact="hydroxychloroquine" post="for the treatment of severe acute respiratory syndrome coronavirus"/>
   <result pre="against novel coronavirus (SARS-CoV-2). Pharmacol. Res.2020, 156, 10476110.1016/j.phrs.2020.104761.32205232 LedfordH.Coronavirus breakthrough:" exact="dexamethasone" post="is first drug shown to save lives. Nature2020, 582,"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7491483\results\search\drug\results.xml">
   <result pre="were on maximal doses of statins (rosuvastatin 40Â mg or" exact="atorvastatin" post="80Â mg daily) combined with ezetimibe. Fourteen (41.2%) patients"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7493775\results\search\drug\results.xml">
   <result pre="repurposing of broadly acting antiviral drugs such as IFNs and" exact="ribavirin" post="that have been used for other viral infections or"/>
   <result pre="for the development of novel anti-SARS-CoV-2 therapy. 2.2. RdRp inhibition" exact="Ribavirin" post="is a broad-spectrum antiviral agent that has previously been"/>
   <result pre="RNA and capping of mRNA. During the previous SARS epidemic," exact="ribavirin" post="was widely used for patients in China.15 However, evidence"/>
   <result pre="was widely used for patients in China.15 However, evidence showed" exact="ribavirin" post="might have no significant antiviral activity against SARS-CoV in"/>
   <result pre="vitro and had significant toxicity concern in clinical practice.16,17 Hence," exact="ribavirin" post="usage for SARS-CoV is questionable and has been criticized.18"/>
   <result pre="has been criticized.18 Earlier evidence demonstrated that the combination of" exact="ribavirin" post="and IFN-Î² had a synergistic effect for inhibiting the"/>
   <result pre="of the in vitro efficacy for SARS-CoV, the usage of" exact="ribavirin" post="against SARS-CoV-2 should be carefully considered. Remdesivir, by far,"/>
   <result pre="COVID-19 is ongoing (ChiCTR2000029600). 2.3. Protease inhibition A co-formulation of" exact="lopinavir" post="and ritonavir, which was reported to have in vitro"/>
   <result pre="been tested for the therapy of COVID-19.23â€&quot;25 The component of" exact="lopinavir" post="can bind to HIV-1 protease and block the cleavage"/>
   <result pre="particles. Another component, ritonavir, can increase the plasma level of" exact="lopinavir" post="by inhibiting the CYP3A-mediated metabolism of the latter. It"/>
   <result pre="been shown to inhibit the replication of SARS-CoV.30 In addition," exact="nelfinavir" post="has revealed rational binding conformation with the viral main"/>
   <result pre="with the viral main protease of SARS-CoV-2. (BioRxiv doi:10.1101/2020.01.28.922922.) Therefore," exact="nelfinavir" post="might be a potential therapeutic option for COVID-19. 2.4."/>
   <result pre="developing new drugs to fight COVID-19. 2.5. Viral entry inhibitors" exact="Hydroxychloroquine" post="and chloroquine are aminoquinolines, which have been used to"/>
   <result pre="drugs to fight COVID-19. 2.5. Viral entry inhibitors Hydroxychloroquine and" exact="chloroquine" post="are aminoquinolines, which have been used to treat autoimmune"/>
   <result pre="of the endosomes, which in turn prevent viral entry fusion.35" exact="Chloroquine" post="can also interfere with ACE2 glycosylation of the cellular"/>
   <result pre="ChiCTR2000029609). The preliminary study in France evaluated the efficacy of" exact="hydroxychloroquine" post="in SARS-CoV-2 patients. The results showed that the virologic"/>
   <result pre="is still under investigation. Hence, the benefits and risk of" exact="chloroquine" post="or hydroxychloroquine therapy for COVID-19 remains to be carefully"/>
   <result pre="under investigation. Hence, the benefits and risk of chloroquine or" exact="hydroxychloroquine" post="therapy for COVID-19 remains to be carefully elucidated. 2.6."/>
   <result pre="entry also depends on transmembrane protease serine 2 (TMPRSS2).37 Hence," exact="camostat" post="mesylate, a TMPRSS2 inhibitor, can eliminate SARS-CoV-2 infection in"/>
   <result pre="process. It provides potential target for COVID-19 therapy development. Recently," exact="amantadine" post="was screened for the possibility to downregulate the expression"/>
   <result pre="evidence indicated its poor activity against SARS-CoV.16 At present, the" exact="amantadine" post="and its analog are not recommended for influenza due"/>
   <result pre="effect on lactation due to decrease of serum prolactin.46 Although" exact="amantadine" post="and its analog are not commonly discussed, this aspect"/>
   <result pre="equine encephalitis virus in vitro.69â€&quot;72 Initially, the inhibitory activity of" exact="ivermectin" post="on interaction of virus integrase protein (IN) and the"/>
   <result pre="IMPÎ±/Î²1 on the rough ER/Golgi membrane.81 The evidence suggests that" exact="ivermectin" post="might be used against SARS-CoV-2 through nuclear transport inhibitory"/>
   <result pre="an in vitro experiment showed that a single treatment with" exact="ivermectin" post="resulted in about 5000-fold reduction in SARS-CoV-2 virus.82 The"/>
   <result pre="on its in vitro efficacy and a well-known safety information," exact="ivermectin" post="might be worthy to further evaluate as a potential"/>
   <result pre="with severe Covid-19.N Engl J Med2020;382:1787â€&quot;99.32187464 30.YamamotoNYangRYoshinakaYAmariSNakanoTCinatlJet al.HIV protease inhibitor" exact="nelfinavir" post="inhibits replication of SARS-associated coronavirus.Biochem Biophys Res Commun2004;318:719â€&quot;25.15144898 31.ParkJYJeongHJKimJHKimYMParkSJKimDet"/>
   <result pre="inhibits autophagic flux by decreasing autophagosome-lysosome fusion.Autophagy2018;14:1435â€&quot;55.29940786 36.GautretPLagierJCParolaPHoangVTMeddebLMailheMet al.Hydroxychloroquine and" exact="azithromycin" post="as a treatment of COVID-19: results of an open-label"/>
   <result pre="Res2020;30:189â€&quot;90.32071427 66.Ben AddiALefortAHuaXLibertFCommuniDLedentCet al.Modulation of murine dendritic cell function by" exact="adenine" post="nucleotides and adenosine: involvement of the A(2B) receptor.Eur J"/>
   <result pre="on the rough endoplasmic reticulum/Golgi membrane.J Virol2007;81:9812â€&quot;24.17596301 82.CalyLDruceJDCattonMGJansDAWagstaffKMThe FDA-approved drug" exact="ivermectin" post="inhibits the replication of SARS-CoV-2 in vitro.Antiviral Res2020;178:104787.32251768"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7493780\results\search\drug\results.xml">
   <result pre="related to the cardiovascular field. 4.1. Antiviral therapies Remdesivir (GS-5734)," exact="adenosine" post="analogue, is a prodrug which is metabolized to its"/>
   <result pre="in COVID-19 patients with different disease severity (https://www.gilead.com/purpose/advancing-global-health/covid-19/remdesivir-clinical-trials). Lopinavir and" exact="ritonavir" post="were two protease inhibitor which was used to treat"/>
   <result pre="cardiovascular disease.24 4.2. Chloroquine/hydroxychloroquine Evidences suggested that the antimalarial drugs" exact="chloroquine" post="and hydroxychloroquine might exert potent antiviral and anti-inflammatory effects.40"/>
   <result pre="4.2. Chloroquine/hydroxychloroquine Evidences suggested that the antimalarial drugs chloroquine and" exact="hydroxychloroquine" post="might exert potent antiviral and anti-inflammatory effects.40 Chloroquine and"/>
   <result pre="chloroquine and hydroxychloroquine might exert potent antiviral and anti-inflammatory effects.40" exact="Chloroquine" post="and hydroxychloroquine are rapidly protonated and concentrated in endosomes"/>
   <result pre="hydroxychloroquine might exert potent antiviral and anti-inflammatory effects.40 Chloroquine and" exact="hydroxychloroquine" post="are rapidly protonated and concentrated in endosomes and therefore"/>
   <result pre="of the viral S protein. In vitro study showed both" exact="chloroquine" post="and hydroxychloroquine decrease SARS-CoV-2 replication in cultured cells and"/>
   <result pre="viral S protein. In vitro study showed both chloroquine and" exact="hydroxychloroquine" post="decrease SARS-CoV-2 replication in cultured cells and hydroxychloroquine was"/>
   <result pre="chloroquine and hydroxychloroquine decrease SARS-CoV-2 replication in cultured cells and" exact="hydroxychloroquine" post="was more potent than chloroquine.33,41 In a small single-arm"/>
   <result pre="small single-arm study of patients with confirmed COVID-19, treatment with" exact="hydroxychloroquine" post="was associated with a significant difference in clearing of"/>
   <result pre="to 6 days when compared with untreated controls. Moreover, combining" exact="hydroxychloroquine" post="with azithromycin showed even more efficient virus elimination in"/>
   <result pre="days when compared with untreated controls. Moreover, combining hydroxychloroquine with" exact="azithromycin" post="showed even more efficient virus elimination in present observation.42"/>
   <result pre="accepted worldwide and prophylactic usage had also been discussed recently.44" exact="Chloroquine" post="and hydroxychloroquine can cause QT prolongation, and cautious monitoring"/>
   <result pre="and prophylactic usage had also been discussed recently.44 Chloroquine and" exact="hydroxychloroquine" post="can cause QT prolongation, and cautious monitoring was crucial"/>
   <result pre="monitoring was crucial especially in the combination usage with azithromycin." exact="Chloroquine" post="and hydroxychloroquine can also cause rare complications including cardiomyopathy,"/>
   <result pre="crucial especially in the combination usage with azithromycin. Chloroquine and" exact="hydroxychloroquine" post="can also cause rare complications including cardiomyopathy, both systolic"/>
   <result pre="COVID-19 should be addressed. Evidences suggested that prehospital use of" exact="aspirin" post="use was associated a lower risk of for developing"/>
   <result pre="All P2Y12 inhibitors reduce platelet-leukocyte aggregates and platelet-derived pro-inflammatory cytokines." exact="Ticagrelor" post="is unique in having the most potent anti-inflammatory properties"/>
   <result pre="nucleoside transporter 1 (ENT1), which contributes to inhibition of cellular" exact="adenosine" post="uptake. The XANTHIPPE trial, as well as post hoc"/>
   <result pre="hoc analyses of PLATO study showed encouraging clinical benefit of" exact="ticagrelor" post="in the management of pneumonia by preventing the complications"/>
   <result pre="provide evidence supports a net benefit of aspirin-free strategies (reduce" exact="aspirin" post="duration to 1-3 months) after PCI for patients at"/>
   <result pre="effects of statin should still be monitored since myalgia, increased" exact="creatine" post="phosphokinase, rhabdomyolysis, and acute kidney injury do occur in"/>
   <result pre="and should also be carefully accessed during clinical practice.61 4.6." exact="Amiodarone" post="In a retrospective reviews of COVID-19 patients treated in"/>
   <result pre="in vitro spreading of SARS coronavirus. In vitro study showed" exact="amiodarone" post="inhibited SARS-CoV infection and spreading via altering the late"/>
   <result pre="virus through endosomes.63 Extrapolating current evidence, administration of prophylactic intravenous" exact="amiodarone" post="to mitigate the risk of late sudden cardiac arrest"/>
   <result pre="in COVID-19 cardiogenic shock.Eur J Heart Fail2020;22:911â€&quot;5.32275347 33.WangMCaoRZhangLYangXLiuJXuMet al.Remdesivir and" exact="chloroquine" post="effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in"/>
   <result pre="arbidol for COVID-19: a randomized clinical trial.medRxiv. 2020Doi:10.1101/2020.03.17.20037432. 40.SavarinoABoelaertJRCassoneAMajoriGCaudaREffects of" exact="chloroquine" post="on viral infections: an old drug against todayâ€™s diseases?Lancet"/>
   <result pre="vitro antiviral activity and projection of optimized dosing design of" exact="hydroxychloroquine" post="for the treatment of severe acute respiratory syndrome coronavirus"/>
   <result pre="respiratory syndrome coronavirus 2 (SARS-CoV-2).Clin Infect Dis2020Doi:10.1093/cid/ciaa237. 42.GautretPLagierJCParolaPHoangVTMeddebLMailheMet al.Hydroxychloroquine and" exact="azithromycin" post="as a treatment of COVID-19: results of an open-label"/>
   <result pre="of an open-label non-randomized clinical trial.Int J Antimicrob Agents2020Doi:10.1016/j.ijantimicag.2020.105949. 43.GaoJTianZYangXBreakthrough:" exact="chloroquine" post="phosphate has shown apparent efficacy in treatment of COVID-19"/>
   <result pre="of COVID-19 associated pneumonia in clinical studies.Biosci Trends2020;14:72â€&quot;3.32074550 44.PrincipiNEspositoSChloroquine or" exact="hydroxychloroquine" post="for prophylaxis of COVID-19.Lancet Infect Dis2020Doi:10.1016/S1473-3099(20)30296-6. 45.ChatreCRoubilleFVernhetHJorgensenCPersYMCardiac complications attributed"/>
   <result pre="for prophylaxis of COVID-19.Lancet Infect Dis2020Doi:10.1016/S1473-3099(20)30296-6. 45.ChatreCRoubilleFVernhetHJorgensenCPersYMCardiac complications attributed to" exact="chloroquine" post="and hydroxychloroquine: a systematic review of the literature.Drug Saf2018;41:919â€&quot;31.29858838"/>
   <result pre="50.StoreyRFJamesSKSiegbahnAVarenhorstCHeldCYcasJet al.Lower mortality following pulmonary adverse events and sepsis with" exact="ticagrelor" post="compared to clopidogrel in the PLATO study.Platelets2014;25:517â€&quot;25.24127651 51.YilmazSKiliÃ§OYaylaliYTDiffuse alveolar"/>
   <result pre="following pulmonary adverse events and sepsis with ticagrelor compared to" exact="clopidogrel" post="in the PLATO study.Platelets2014;25:517â€&quot;25.24127651 51.YilmazSKiliÃ§OYaylaliYTDiffuse alveolar hemorrhage associated with"/>
   <result pre="clopidogrel in the PLATO study.Platelets2014;25:517â€&quot;25.24127651 51.YilmazSKiliÃ§OYaylaliYTDiffuse alveolar hemorrhage associated with" exact="ticagrelor" post="therapy after percutaneous coronary intervention.Anatol J Cardiol2018;20:60â€&quot;1.29952365 52.ToyotaTShiomiHMorimotoTNatsuakiMKimuraTShort versus"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7496561\results\search\drug\results.xml">
   <result pre="including remdesivir (RDV), plasma exchange or cytapheresis, hydroxychloroquine, baricitinib, and" exact="lopinavir" post="(LPV), we have tried to detail the principles behind"/>
   <result pre="[5]. These compounds include drugs that alter the neurotransmitter regulation," exact="estrogen" post="receptors, kinase signal transduction, protein processing, and DNA. A"/>
   <result pre="the SARS-CoV-2 PLpro [13]. Protease Inhibitors (PIs) PIs like disulfiram," exact="lopinavir" post="(LPV), and ritonavir have shown activity against SARS and"/>
   <result pre="[13]. Protease Inhibitors (PIs) PIs like disulfiram, lopinavir (LPV), and" exact="ritonavir" post="have shown activity against SARS and MERS. Although disulfiram"/>
   <result pre="and ritonavir have shown activity against SARS and MERS. Although" exact="disulfiram" post="has been reported to inhibit the PLpro of MERS"/>
   <result pre="MERS and SARS in-vitro, it lacks clinical evidence. LPV and" exact="ritonavir" post="were considered to suppress the 3CLpro of SARS and"/>
   <result pre="and, therefore, RDV should not be used in patients with" exact="alanine" post="transaminase (ALT) levels of â‰¥5xÂ ULN (upper limit of"/>
   <result pre="the antiviral effects of RDV is reduced if co-administered with" exact="chloroquine" post="phosphate or hydroxychloroquine sulfate [16]. Multiple clinical trials are"/>
   <result pre="of RDV is reduced if co-administered with chloroquine phosphate or" exact="hydroxychloroquine" post="sulfate [16]. Multiple clinical trials are ongoing on the"/>
   <result pre="ill patients who are frequent recipients of plasma exchange [20]." exact="Chloroquine" post="Current applications: the primary indication for chloroquine and hydroxychloroquine"/>
   <result pre="plasma exchange [20]. Chloroquine Current applications: the primary indication for" exact="chloroquine" post="and hydroxychloroquine is to prevent or treat malaria and"/>
   <result pre="[20]. Chloroquine Current applications: the primary indication for chloroquine and" exact="hydroxychloroquine" post="is to prevent or treat malaria and also in"/>
   <result pre="erythematosus (SLE), antiphospholipid antibody syndrome, rheumatoid arthritis, and SjÃ¶gren's syndrome.Â" exact="Chloroquine" post="and hydroxychloroquine have been found to have anti-inflammatory, immunomodulating,"/>
   <result pre="antiphospholipid antibody syndrome, rheumatoid arthritis, and SjÃ¶gren's syndrome.Â Chloroquine and" exact="hydroxychloroquine" post="have been found to have anti-inflammatory, immunomodulating, anti-infective, antithrombotic,"/>
   <result pre="their strong antiproliferative, antimutagenic, and inhibiting autophagy capacities [24]. MOA:Â" exact="chloroquine" post="and hydroxychloroquine have several mechanisms of action. Since these"/>
   <result pre="antiproliferative, antimutagenic, and inhibiting autophagy capacities [24]. MOA:Â chloroquine and" exact="hydroxychloroquine" post="have several mechanisms of action. Since these drugs are"/>
   <result pre="fusion and inactivation of enzymes required for viral replication [25]." exact="Chloroquine" post="demonstrates broad-spectrum antiviral activity against human coronavirus HCoV-O43 and"/>
   <result pre="is a key enzyme in the synthesis of sialic acids.Â" exact="Chloroquine" post="exerts a potentÂ anti-SARS-CoV-1 effectÂ in vitro, which is"/>
   <result pre="of a cell surface receptor, the ACE2 on Vero cells." exact="Chloroquine" post="has an effect on the immune system by its"/>
   <result pre="signaling is an important step in the viral replication cycle." exact="Chloroquine" post="prevents phosphorylation of p38 MAPK in Tamm-Horsfall protein 1"/>
   <result pre="IL-1, IL-6, TNF-Î± in immune cells [26]. Principle behind use:" exact="chloroquine" post="and hydroxychloroquine are 4-aminoquinolines that are under trial for"/>
   <result pre="TNF-Î± in immune cells [26]. Principle behind use: chloroquine and" exact="hydroxychloroquine" post="are 4-aminoquinolines that are under trial for the treatment"/>
   <result pre="chloroquine, hydroxychloroquine, or these two in combination with other drugs." exact="Chloroquine" post="has been found to affect glycosylation of ACE2, the"/>
   <result pre="cells [25]. Several in-vitro studies have been done in which" exact="chloroquine" post="has acted against both RNA and DNA viruses. Some"/>
   <result pre="virus and herpes simplex virus. Coronavirus being an RNA virus," exact="chloroquine" post="has demonstrated in vitro inhibition of HCoV-229E replication in"/>
   <result pre="with the HCoV-O43 coronavirus could have been prevented by administering" exact="chloroquine" post="through the mother's milk. These studies also exhibited an"/>
   <result pre="mother's milk. These studies also exhibited an antiviral effect of" exact="chloroquine" post="on a recombinant HCoV-O43 coronavirus [26]. Currently, there are"/>
   <result pre="are several ongoing clinical trials to test the efficacy of" exact="chloroquine" post="in combination with multiple drugs.Â On April 27, 2020,"/>
   <result pre="the FDA issued a EUAÂ for the emergency use of" exact="chloroquine" post="to treat adults and adolescents who weigh 50 kg"/>
   <result pre="Dosage: in accordance with various guidelines, the effective dose of" exact="chloroquine" post="for the treatment of COVID-19 infection has been found"/>
   <result pre="challenges: there have been some concerns regarding the safety of" exact="hydroxychloroquine" post="in high doses for treatment in critically ill patients"/>
   <result pre="doses for treatment in critically ill patients with COVID-19 [30]." exact="Hydroxychloroquine" post="can cause serious cutaneous adverse reactions, fulminant hepatic failure,"/>
   <result pre="likeÂ QTc (corrected Q-T interval) prolongation especially when prescribed with" exact="azithromycin" post="[25]. Routine electrocardiogram (ECG) is therefore recommended before starting"/>
   <result pre="and moxifloxacin; LPV/ritonavir and RDV should be avoided. Administration of" exact="hydroxychloroquine" post="and chloroquine requires frequent monitoring of complete blood count,"/>
   <result pre="LPV/ritonavir and RDV should be avoided. Administration of hydroxychloroquine and" exact="chloroquine" post="requires frequent monitoring of complete blood count, which includes"/>
   <result pre="(MI), and QTc of &amp;gt;500 msec [28]. Lopinavir Current application:" exact="lopinavir" post="(LPV) is an HIV-1 protease inhibitor administered in fixed-dose"/>
   <result pre="is an HIV-1 protease inhibitor administered in fixed-dose combination with" exact="ritonavir" post="(LPV/r). Ritonavir is a potent cytochrome P450 3A4 (CYP3A4)"/>
   <result pre="HIV-1 protease inhibitor administered in fixed-dose combination with ritonavir (LPV/r)." exact="Ritonavir" post="is a potent cytochrome P450 3A4 (CYP3A4) inhibitor, which"/>
   <result pre="of hepatotoxicity, hence close laboratoryÂ monitoring may be needed. With" exact="ritonavir" post="being a CYP3A4 inhibitor, it is also a moderate"/>
   <result pre="cases of COVID-19. Baricitinib therapy also increases the levels of" exact="creatine" post="kinase, and this elevation is more common in patients"/>
   <result pre="efficacy of baricitinib against COVID-19 is still under study [43]." exact="Ribavirin" post="Ribavirin is a guanosine analog that interferes with viral"/>
   <result pre="of baricitinib against COVID-19 is still under study [43]. Ribavirin" exact="Ribavirin" post="is a guanosine analog that interferes with viral RNA"/>
   <result pre="shown that while SARS-CoV, MERS-CoV, and HCoV-OC43 were sensitive to" exact="ribavirin" post="in vitro, drug concentrations that significantly impede CoV replication"/>
   <result pre="humans. A reason for the decreased in vitro efficacy of" exact="ribavirin" post="was found to be the excision of ribavirin nucleoside"/>
   <result pre="efficacy of ribavirin was found to be the excision of" exact="ribavirin" post="nucleoside analogs by coronavirus proofreading mechanism. Subsequent in vivo"/>
   <result pre="proofreading mechanism. Subsequent in vivo testing showed that monotherapy with" exact="ribavirin" post="showed restricted activity against SARS-CoV in mouse models. However,"/>
   <result pre="in primate models, improvement of MERS symptoms was seen when" exact="ribavirin" post="was combined with type I Interferons [44]. In a"/>
   <result pre="also demonstrated that the SARS-CoV-2 RdRpÂ model is targeted by" exact="ribavirin" post="[45]. Angiotensin-Converting Enzyme Inhibitor (ACEI) [Renin-Angiotensin System (RAS) Drugs]"/>
   <result pre="ID No. of participants* Duration Phase Sponsor Combination drugs Drug:Â" exact="hydroxychloroquine" post="+ intravenous famotidine NCT04370262 1170 April 2020â€&quot; April 2021"/>
   <result pre="participants* Duration Phase Sponsor Combination drugs Drug:Â hydroxychloroquine + intravenous" exact="famotidine" post="NCT04370262 1170 April 2020â€&quot; April 2021 Phase 3 Northwell"/>
   <result pre="4 National University of Ireland, Galway, Ireland Drug: lopinavir/ritonavir; drug:" exact="hydroxychloroquine" post="sulfate; drug: losartan; drug: placebos NCT04328012 4000 April 2020â€&quot;April"/>
   <result pre="2020â€&quot;June 2021 Phase 2, phase 3 University of Oxford Drug:" exact="hydroxychloroquine" post="sulfate tablets; drug: lopinavir/ritonavir oral tablet; drug: hydroxychloroquine sulfate"/>
   <result pre="Oxford Drug: hydroxychloroquine sulfate tablets; drug: lopinavir/ritonavir oral tablet; drug:" exact="hydroxychloroquine" post="sulfate tablets plus lopinavir/ritonavir oral tablets; drug: placebo NCT04403100"/>
   <result pre="1968 June 2020â€&quot;November 2020 Phase 3 Cardresearch Drug: hydroxychloroquine; drug:" exact="azithromycin" post="NCT04334382 1550 April 2020â€&quot;December 2021 Phase 3 Intermountain Health"/>
   <result pre="2021 Phase 3 Intermountain Health Care, Inc. Drug: hydroxychloroquine; drug:" exact="azithromycin" post="(Azithro); drug: placebo for hydroxychloroquine; drug: placebo for azithromycin"/>
   <result pre="drug: azithromycin (Azithro); drug: placebo for hydroxychloroquine; drug: placebo for" exact="azithromycin" post="NCT04358068 2000 May 2020â€&quot;March 2021 Phase 2 National Institute"/>
   <result pre="mg + 1200 mg) combined with azithromycin; drug: hydroxychloroquine; drug:" exact="hydroxychloroquine" post="combined with azithromycin NCT04411433 1000 May 2020â€&quot;July 2020 Phase"/>
   <result pre="mg) combined with azithromycin; drug: hydroxychloroquine; drug: hydroxychloroquine combined with" exact="azithromycin" post="NCT04411433 1000 May 2020â€&quot;July 2020 Phase 3 Ministry of"/>
   <result pre="May 2020â€&quot;July 2020 Phase 3 Ministry of Health, Turkey Drug:" exact="hydroxychloroquine" post="- daily dosing; drug: hydroxychloroquine - weekly dosing NCT04341441"/>
   <result pre="Ministry of Health, Turkey Drug: hydroxychloroquine - daily dosing; drug:" exact="hydroxychloroquine" post="- weekly dosing NCT04341441 3000 April 2020â€&quot;April 2021 Phase"/>
   <result pre="April 2020â€&quot;April 2021 Phase 3 Henry Ford Health System Drug:" exact="hydroxychloroquine" post="NCT04363827 2300 May 2020â€&quot;March 2021 Phase 2 Istituto Scientifico"/>
   <result pre="Romagnolo per lo Studio e la Cura dei Tumori Drug:" exact="hydroxychloroquine" post="sulfate; drug: ascorbic acid NCT04328961 2000 March 2020â€&quot;October 2020"/>
   <result pre="disoproxil; drug: hydroxychloroquine; drug: placebo: emtricitabine/tenofovir disoproxil placebo; drug: placebo:" exact="hydroxychloroquine" post="NCT04334928 4000 April 2020â€&quot;July 2020 Phase 3 Plan Nacional"/>
   <result pre="Dietary supplement: vitamins; drug: hydroxychloroquine; drug: imatinib; drug: favipiravir; drug:" exact="telmisartan" post="NCT04356495 1057 July 2020â€&quot;January 2021 Phase 3 University Hospital,"/>
   <result pre="2020 Phase 3 Montreal Heart Institute Darunavir Drug: darunavir and" exact="cobicistat" post="NCT04252274 30 January 2020â€&quot;December 2020 Phase 3 Shanghai Public"/>
   <result pre="LLC Arbidol Drug: carrimycin; drug: lopinavir/ritonavir tablets or Arbidol or" exact="chloroquine" post="phosphate; drug: basic treatment NCT04286503 520 February 2020â€&quot;February 2021"/>
   <result pre="for investigational COVID-19 convalescent plasma82020ResearchResearch2020https://www.fda.gov/vaccines-blood-biologics/investigational-new-drug-ind-or-device-exemption-ide-process-cber/recommendations-investigational-covid-19-convalescent-plasma 24Current and future use of" exact="chloroquine" post="and hydroxychloroquine in infectious, immune, neoplastic, and neurological diseases:"/>
   <result pre="COVID-19 convalescent plasma82020ResearchResearch2020https://www.fda.gov/vaccines-blood-biologics/investigational-new-drug-ind-or-device-exemption-ide-process-cber/recommendations-investigational-covid-19-convalescent-plasma 24Current and future use of chloroquine and" exact="hydroxychloroquine" post="in infectious, immune, neoplastic, and neurological diseases: a mini-reviewClin"/>
   <result pre="neoplastic, and neurological diseases: a mini-reviewClin Drug InvestigPlantoneDKoudriavtsevaT653671382018 25Chloroquine and" exact="hydroxychloroquine" post="in covid-19BMJFernerREAronsonJK03692020 26New insights on the antiviral effects of"/>
   <result pre="hydroxychloroquine in covid-19BMJFernerREAronsonJK03692020 26New insights on the antiviral effects of" exact="chloroquine" post="against coronavirus: what to expect for COVID-19?Int J Antimicrob"/>
   <result pre="27FDA: coronavirus (COVID-19) update: FDA revokes emergency use authorization for" exact="chloroquine" post="and hydroxychloroquine82020CommissionerO2020https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-revokes-emergency-use-authorization-chloroquine-and 28Chloroquine and hydroxychloroquine in the treatment of"/>
   <result pre="revokes emergency use authorization for chloroquine and hydroxychloroquine82020CommissionerO2020https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-revokes-emergency-use-authorization-chloroquine-and 28Chloroquine and" exact="hydroxychloroquine" post="in the treatment of COVID-19 with or without diabetes:"/>
   <result pre="and other developing countriesDiabetes Metab SyndrSinghAKSinghAShaikhASinghRMisraA24124614202032247211 29Finding the dose for" exact="hydroxychloroquine" post="prophylaxis for COVID-19: the desperate search for effectiveness (Epub"/>
   <result pre="Pharmacol TherAl-KofahiMJacobsonPBoulwareDRet al.2020 30Effect of high vs low doses of" exact="chloroquine" post="diphosphate as adjunctive therapy for patients hospitalized with severe"/>
   <result pre="treated with multiple drugs. (Article in Italian)Infez MedSabbataniSLegnaniGFulgaroC1824112003https://www.infezmed.it/index.php/article?Anno=2003&amp;amp;numero=1&amp;amp;ArticoloDaVisualizzare=Vol_11_1_2003_1812719666 32Why are" exact="lopinavir" post="and ritonavir effective against the newly emerged coronavirus 2019?"/>
   <result pre="multiple drugs. (Article in Italian)Infez MedSabbataniSLegnaniGFulgaroC1824112003https://www.infezmed.it/index.php/article?Anno=2003&amp;amp;numero=1&amp;amp;ArticoloDaVisualizzare=Vol_11_1_2003_1812719666 32Why are lopinavir and" exact="ritonavir" post="effective against the newly emerged coronavirus 2019? Atomistic insights"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7497732\results\search\drug\results.xml">
   <result pre="conditions determining short life expectancy. Antivirals; low molecular weight heparin;" exact="hydroxychloroquine" post="Â± azithromycin; immunomodulatory agents; high-dose corticosteroids were collected and"/>
   <result pre="Platelets,10^3/Î¼L, median (IQR) 214 (167â€&quot;267) 192 (145â€&quot;261) 204 (159â€&quot;266) 0.007" exact="Creatine" post="phosphokinase, U/L, median (IQR) 82 (52â€&quot;154) 140 (66â€&quot;350) 94"/>
   <result pre="darunavir/c or remdesivir 89 (24.2) 45 (26.2) 134 (24.8) 0.632" exact="Hydroxychloroquine" post="Â± azithromycin 306 (83.8) 121 (69.5) 427 (79.2) &amp;lt;0.001"/>
   <result pre="remdesivir 89 (24.2) 45 (26.2) 134 (24.8) 0.632 Hydroxychloroquine Â±" exact="azithromycin" post="306 (83.8) 121 (69.5) 427 (79.2) &amp;lt;0.001 Heparin prophylaxis"/>
   <result pre="(%) 0.001 No drugs 29 (8.0) 22 (12.6) 51 (9.5)" exact="Hydroxychloroquine" post="+ heparin (Â±lopinavir/r or darunavir/c or azithromycin) 214 (58.6)"/>
   <result pre="or darunavir/c or azithromycin) 214 (58.6) 87 (50.0) 301 (55.8)" exact="Hydroxychloroquine" post="+ lopinavir/r or darunavir/c 41 (11.2) 11 (6.3) 52"/>
   <result pre="+ lopinavir/r or darunavir/c 41 (11.2) 11 (6.3) 52 (9.6)" exact="Hydroxychloroquine" post="Â± azithromycin 49 (13.4) 23 (13.2) 72 (13.4) Heparin"/>
   <result pre="or darunavir/c 41 (11.2) 11 (6.3) 52 (9.6) Hydroxychloroquine Â±" exact="azithromycin" post="49 (13.4) 23 (13.2) 72 (13.4) Heparin only 11"/>
   <result pre="attack or hemiplegia. During hospitalisation, most of the patients received" exact="hydroxychloroquine" post="Â± azithromycin (427, 79.2%) and low weight heparin at"/>
   <result pre="hemiplegia. During hospitalisation, most of the patients received hydroxychloroquine Â±" exact="azithromycin" post="(427, 79.2%) and low weight heparin at prophylactic doses"/>
   <result pre="More than half of the patients were given combinations including" exact="hydroxychloroquine" post="+ heparin Â± lopinavir/r or darunavir/c or azithromycin (301,"/>
   <result pre="combinations including hydroxychloroquine + heparin Â± lopinavir/r or darunavir/c or" exact="azithromycin" post="(301, 55.8%). A total of 117 patients (21.9%) required"/>
   <result pre="&amp;lt;0.001 Thearapy combinations Â No drugs 1.00 1.00 1.00 Â" exact="Hydroxychloroquine" post="+ heparin (Â±lopinavir/r or darunavir/c or azithromycin) 0.33 0.20"/>
   <result pre="&amp;lt;0.001 0.30 0.17 0.50 &amp;lt;0.001 0.28 0.16 0.47 &amp;lt;0.001 Â" exact="Hydroxychloroquine" post="+ lopinavir/r or darunavir/c 0.45 0.22 0.92 0.029 0.42"/>
   <result pre="0.029 0.42 0.20 0.91 0.028 0.42 0.20 0.90 0.025 Â" exact="Hydroxychloroquine" post="or Hydroxychloroquine + azithromycin 0.55 0.31 1.00 0.048 0.57"/>
   <result pre="0.20 0.91 0.028 0.42 0.20 0.90 0.025 Â Hydroxychloroquine or" exact="Hydroxychloroquine" post="+ azithromycin 0.55 0.31 1.00 0.048 0.57 0.30 1.07"/>
   <result pre="0.028 0.42 0.20 0.90 0.025 Â Hydroxychloroquine or Hydroxychloroquine +" exact="azithromycin" post="0.55 0.31 1.00 0.048 0.57 0.30 1.07 0.080 0.53"/>
   <result pre="treatment received. Most of the patients were receiving combinations containing" exact="hydroxychloroquine" post="Â± azithromycin Â± antivirals. The possible effectiveness and toxicity"/>
   <result pre="Most of the patients were receiving combinations containing hydroxychloroquine Â±" exact="azithromycin" post="Â± antivirals. The possible effectiveness and toxicity of hydroxychloroquine"/>
   <result pre="Â± azithromycin Â± antivirals. The possible effectiveness and toxicity of" exact="hydroxychloroquine" post="in Covid-19 disease is debated: laboratory studies showed antiviral"/>
   <result pre="prospective cohort studyLancet39520201763177132442528 DevauxC.A.RolainJ.M.ColsonP.RaoultD.New insights on the antviral effects of" exact="chloroquine" post="against coronavirus: what to expect for COVID-19?Int J Antimicrob"/>
   <result pre="for COVID-19?Int J Antimicrob Agents555202010593810.1016/j.antimicag.2020.105938[Published online 12 March]32171740 GautretF.LagierJ.C.ParolaP.HoangV.T.MeddebL.MailheM.Hydroxychloroquine and" exact="azithromycin" post="as a treatment of COVID-19: results of an open-label"/>
   <result pre="is effective in inhibiting SARS-CoV-2 infection in vitroCell Discov620201632194981 MehraM.R.DesaiS.S.RuschitzkaF.PatelA.N.RETRACTED:" exact="hydroxychloroquine" post="or chloroquine with or without a macrolide for treatment"/>
   <result pre="in inhibiting SARS-CoV-2 infection in vitroCell Discov620201632194981 MehraM.R.DesaiS.S.RuschitzkaF.PatelA.N.RETRACTED: hydroxychloroquine or" exact="chloroquine" post="with or without a macrolide for treatment of COVID-19:"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7498210\results\search\drug\results.xml">
   <result pre="currently become pandemic worldwide. Though drugs like remdesivir, favipiravir, and" exact="dexamethasone" post="found beneficial for COVID-19 management, they have limitations clinically,"/>
   <result pre="hydrophobic, electrostatic interactions. The drugs such as arbutin, terbutaline, barnidipine," exact="tipiracil" post="and aprepitant identified as potential hits. Among the drugs,"/>
   <result pre="interactions. The drugs such as arbutin, terbutaline, barnidipine, tipiracil and" exact="aprepitant" post="identified as potential hits. Among the drugs, tipiracil and"/>
   <result pre="tipiracil and aprepitant identified as potential hits. Among the drugs," exact="tipiracil" post="and aprepitant interacted with the Mpro consistently, and they"/>
   <result pre="aprepitant identified as potential hits. Among the drugs, tipiracil and" exact="aprepitant" post="interacted with the Mpro consistently, and they turned out"/>
   <result pre="repurposing using computer-aided docking tools and the potential roles of" exact="tipiracil" post="and aprepitant, which can be explored further in the"/>
   <result pre="and visual interpretations, the drugs aprepitant, barnidipine, tipiracil, arbutin, and" exact="terbutaline" post="were found to be significantly interacting with Mpro residues"/>
   <result pre="Molecular interactions H-bond-forming interactions Ï€-Ï€ stacking or Ï€-cation interaction 1" exact="Aprepitant" post="Chemotherapy-induced emesis, Postoperative nausea and vomiting âˆ’6.892 - HIE41"/>
   <result pre="HIE41 4 Arbutin Skin-lightening agent, Hyperpigmentation âˆ’6.206 ASN142(2) HIE41 5" exact="Terbutaline" post="Asthma, Wheezing, COPD âˆ’5.846 GLY143, HIS164, GLN189 HIE41 Residues"/>
   <result pre="GLU: Glutamic acid; HIS: Histidine; GLY: Glycine; GLN: Glutamine; HIE:" exact="Histidine" post="(HISÎ­). The drug aprepitant made a Ï€-Ï€ stacking interaction"/>
   <result pre="Histidine; GLY: Glycine; GLN: Glutamine; HIE: Histidine (HISÎ­). The drug" exact="aprepitant" post="made a Ï€-Ï€ stacking interaction with histidine (HIE41) residue"/>
   <result pre="stacking interaction with histidine (HIE41) residue of Mpro. The drug" exact="barnidipine" post="made hydrogen bonding interactions with aspargine (ASN142), cysteine (CYS145),"/>
   <result pre="stacking interaction with HIE41, two hydrogen bonding interaction with ASN142." exact="Terbutaline" post="exhibited hydrogen bonding interactions with glycine (GLY143), HIS164 and"/>
   <result pre="bonding interaction with ASN142. Terbutaline exhibited hydrogen bonding interactions with" exact="glycine" post="(GLY143), HIS164 and glutamine (GLN189) residues of Mpro a"/>
   <result pre="MD-simulation exhibited strong and stable binding with Mpro for the" exact="aprepitant" post="and tipiracil where the RMSD-fluctuations for the ligand and"/>
   <result pre="strong and stable binding with Mpro for the aprepitant and" exact="tipiracil" post="where the RMSD-fluctuations for the ligand and protein remained"/>
   <result pre="for the ligand and protein remained within 2.0Â Ã…. The" exact="barnidipine" post="and terbutaline demonstrated strong binding ability and arbutin demonstrated"/>
   <result pre="ligand and protein remained within 2.0Â Ã…. The barnidipine and" exact="terbutaline" post="demonstrated strong binding ability and arbutin demonstrated the least"/>
   <result pre="protein backbone fluctuations; red colour represents ligand fluctuations. The Mpro-bound" exact="aprepitant" post="exhibited good binding mode during MD-simulation. The plot of"/>
   <result pre="the simulation (FigureÂ 2 ). FigureÂ 2 Interaction diagram of" exact="aprepitant" post="with Mpro. (A) The protein-ligand contacts showing the bonding"/>
   <result pre="protein-ligand contacts showing the bonding interactions fraction. (B) Interaction of" exact="aprepitant" post="with residues in each trajectory frame. The darker colour"/>
   <result pre="higher the interaction or the residues make more contact; (C)" exact="Aprepitant" post="interaction with the protein residues during MD simulation. Interactions"/>
   <result pre="residue (41%) (FigureÂ 3 ). FigureÂ 3 Interaction diagram of" exact="barnidipine" post="with Mpro. (A) The protein-ligand contacts showing the bonding"/>
   <result pre="protein-ligand contacts showing the bonding interactions fraction. (B) Interaction of" exact="barnidipine" post="with residues in each trajectory frame. The darker colour"/>
   <result pre="acid residue (FigureÂ 4 ). FigureÂ 4 Interaction diagram of" exact="tipiracil" post="with Mpro. (A) The protein-ligand contacts showing the bonding"/>
   <result pre="protein-ligand contacts showing the bonding interactions fraction. (B) Interaction of" exact="tipiracil" post="with residues in each trajectory frame. The darker colour"/>
   <result pre="shown are occurring more than 30% during the simulation time." exact="Terbutaline" post="bound to Mpro exhibited polar as well as non-polar"/>
   <result pre="This indicates that the ligand-protein complex was unstable compared to" exact="tipiracil" post="and aprepitant. A bridged hydrogen bonding was observed with"/>
   <result pre="acid residue (FigureÂ 6 ). FigureÂ 6 Interaction diagram of" exact="terbutaline" post="with Mpro. (A) The protein-ligand contacts showing the bonding"/>
   <result pre="protein-ligand contacts showing the bonding interactions fraction. (B) Interaction of" exact="terbutaline" post="with residues in each trajectory frame. The darker colour"/>
   <result pre="higher the interaction or the residues make more contact; (C)" exact="Terbutaline" post="interaction with the protein residues during MD simulation. Interactions"/>
   <result pre="first time reported by us for targeting Mpro. The drug" exact="aprepitant" post="is used as an antiemetic in chemotherapy-induced emesis and"/>
   <result pre="an antiemetic in chemotherapy-induced emesis and post operatives emesis (25)." exact="Aprepitant" post="is an antagonist of Neurokinin 1 receptor (NK-1R), it"/>
   <result pre="adjuvant therapy with anti-HIV drugs (26). In the current studies," exact="aprepitant" post="is found a better drug based on its results"/>
   <result pre="screened for inhibiting replication of SARS-CoV-2 in COVID-19. The drug" exact="tipiracil" post="is currently used along with an anticancer agent trifluridine"/>
   <result pre="agent trifluridine at the cite of action. At therapeutic doses," exact="tipiracil" post="has no reported adverse events (28). In this study,"/>
   <result pre="events (28). In this study, the data infers that the" exact="tipiracil" post="interaction with Mpro is much more durable and stable"/>
   <result pre="both SP-docking and molecular dynamics simulations. Thus, the repurposing of" exact="tipiracil" post="will have advantages compared to other selected molecules. The"/>
   <result pre="be repurposed to treat COVID-19 if explored further. The drug" exact="terbutaline" post="sometimes used to prevent premature labour, is also the"/>
   <result pre="asthma, wheezing and COPD (31). Because of its lung specificity," exact="terbutaline" post="will have advantages if it is found useful in"/>
   <result pre="and favipiravir have been officially approved for COVID-19 treatment. Similarly," exact="dexamethasone" post="is an immunosuppressant is repurposed for COVID-19 to reduce"/>
   <result pre="and whereby reduce the mortality. The anti-HIV drugs such as" exact="ritonavir" post="and nelfinavir, have been proposed for repurposing in COVID-19"/>
   <result pre="Mpro (32). The antiviral drugs such as solutegravir, raltegravir, paritaprevir," exact="bictegravir" post="and dolutegravir were also suggested in another report (33)."/>
   <result pre="in another report (33). Similarly, anti-hepatitis-C virus drugs paritaprevir and" exact="simeprevir" post="was suggested in another report as a covalent inhibitor"/>
   <result pre="In another study, drugs such as simeprevir, ergotamine, bromocriptine and" exact="tadalafil" post="are proposed by the researcher (35). There was a"/>
   <result pre="virtual screening report on peptides drugs such as nafarelin and" exact="icatibant" post="for repurposing to COVD-19 (36). Similarly, the drugs leupeptin,"/>
   <result pre="aprepitant, barnidipine, tipiracil, arbutin and terbutaline. Among these five drug-hits," exact="aprepitant" post="and tipiracil were found strongest in binding Mpro by"/>
   <result pre="tipiracil, arbutin and terbutaline. Among these five drug-hits, aprepitant and" exact="tipiracil" post="were found strongest in binding Mpro by MD-simulation studies."/>
   <result pre="tools and shortlisted five drugs. Further, testing theses drugs, especially" exact="aprepitant" post="and tipiracil, by inÂ vitro Mpro inhibitory activity and"/>
   <result pre="of nausea and vomitingDrugs6920091853187819719336 26BarrettJ.S.SpitsinS.MoorthyG.Pharmacologic rationale for the NK1R antagonist," exact="aprepitant" post="as adjunctive therapy in HIVJ Transl Med14201614827230663 27SakaiT.TeramuraT.OkamiyaH.A review"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7498411\results\search\drug\results.xml">
   <result pre="vivo, in vitro Antiviral agent delivery PLGA NPs loaded with" exact="acyclovir" post="for oral delivery. [20] 180 nm 3D8 scFv antibody"/>
   <result pre="viral infectivity. [35] Au NPs 5, 50, 100 nm Thiol" exact="cysteamine" post="HCV In vivo, in vitro Nanovaccines DNA segment specific"/>
   <result pre="side effects [19]. For instance, as an approved antiviral drug," exact="acyclovir" post="can be used to treat herpes simplex virus (HSV)"/>
   <result pre="clinical application by U.S. Food and Drug Administration. Encapsulation of" exact="acyclovir" post="into PLGA-based NPs for oral administration has been demonstrated"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7498997\results\search\drug\results.xml">
   <result pre="milieus could also be a determinant of viral infections as" exact="estrogen" post="has immunoenhancing effects while testosterone has immunosuppressive effects. The"/>
   <result pre="determinant of viral infections as estrogen has immunoenhancing effects while" exact="testosterone" post="has immunosuppressive effects. The sex-specific severity of COVID-19 infections"/>
   <result pre="it is involved in S protein priming [14, 17, 18]." exact="Serine" post="proteases on the surface of target cell cleave the"/>
   <result pre="therapeutic target to control coronavirus infection [14]. TMPRSS2 inhibitors including" exact="nafamostat" post="and camostat are undergoing clinical trials to determine their"/>
   <result pre="to control coronavirus infection [14]. TMPRSS2 inhibitors including nafamostat and" exact="camostat" post="are undergoing clinical trials to determine their efficacy against"/>
   <result pre="Since TLR7 escapes X chromosome inactivation and is activated by" exact="estrogen" post="[51], females may have a better strategy to overcome"/>
   <result pre="gene activation primes the gonad to secrete testosterone. The secreted" exact="testosterone" post="further helps to differentiate the male reproductive systems. Testosterone"/>
   <result pre="secreted testosterone further helps to differentiate the male reproductive systems." exact="Testosterone" post="is also suggested to reach the brain and organize"/>
   <result pre="also suggested to reach the brain and organize neuronal networks." exact="Testosterone" post="can mediate gene expression directly by binding to the"/>
   <result pre="to the androgen receptor (AR) or indirectly following conversion into" exact="estrogen" post="by the enzyme aromatase [73, 75]. On the other"/>
   <result pre="by the enzyme aromatase [73, 75]. On the other hand," exact="estrogen" post="and progesterone are important hormones in females that lead"/>
   <result pre="enzyme aromatase [73, 75]. On the other hand, estrogen and" exact="progesterone" post="are important hormones in females that lead to differential"/>
   <result pre="There are three different types of estrogens produced in females:" exact="estrone" post="(E1), 17Î²-estradiol (E2), and estriol (E3). E2 is the"/>
   <result pre="of estrogens produced in females: estrone (E1), 17Î²-estradiol (E2), and" exact="estriol" post="(E3). E2 is the predominant form that is produced"/>
   <result pre="of hormones fluctuates during ovulation and pregnancy. Estrogens act through" exact="estrogen" post="receptors (ERs) which exist in two forms, ERÎ± and"/>
   <result pre="in immune response may not be a direct effect of" exact="estrogen" post="but could be indirect through gonadotropin-releasing hormone [78]. Nakada"/>
   <result pre="and females are under the influence of different hormonal milieu." exact="Testosterone" post="has been shown to have immunosuppressive effect while estrogen"/>
   <result pre="milieu. Testosterone has been shown to have immunosuppressive effect while" exact="estrogen" post="has immunoenhancing effect [60]. Testosterone has been found to"/>
   <result pre="to have immunosuppressive effect while estrogen has immunoenhancing effect [60]." exact="Testosterone" post="has been found to inhibit T helper cell differentiation"/>
   <result pre="viral load of Venezuelan equine encephalitis virus in macaques [82]." exact="Testosterone" post="is also known to decrease the responsiveness towards influenza"/>
   <result pre="to decrease the responsiveness towards influenza vaccine [83]. Analysis of" exact="testosterone" post="levels in females showed that the level is usually"/>
   <result pre="including HIV, hepatitis C virus, Ebola, and human cytomegalovirus [91]." exact="Estrogen" post="was shown to inhibit influenza A virus replication in"/>
   <result pre="isolated from female mice [91]. Interestingly, the protective effect of" exact="estrogen" post="was not observed in nasal epithelial cells isolated from"/>
   <result pre="male mice [91]. Since SARS predominantly replicates in airways, higher" exact="estrogen" post="levels in females may increase the protection from SARS"/>
   <result pre="in females. However, gonadectomy or treatment with the AR antagonist" exact="flutamide" post="did not affect morbidity or mortality in male mice"/>
   <result pre="infection [63]. Based on this, it was suggested that the" exact="estrogen" post="receptor signaling plays an important role in coronavirus infection"/>
   <result pre="not play a role in pathogenesis [63]. This suggests that" exact="estrogen" post="signaling is critical in regulating viral infection and could"/>
   <result pre="SARS-CoV-2 showed increased luteinizing hormone (LH), but the ratio of" exact="testosterone" post="to LH and follicle stimulating hormone to LH was"/>
   <result pre="could also play a crucial role in pathogenesis (Fig. 5)." exact="Estrogen" post="in females can have immune-enhancing effects while testosterone secreted"/>
   <result pre="(Fig. 5). Estrogen in females can have immune-enhancing effects while" exact="testosterone" post="secreted by the testis can have immune-suppressive effects. However,"/>
   <result pre="death rate in males. This difference could be due to" exact="testosterone" post="and estrogen differential effect on the immune system. Since"/>
   <result pre="in males. This difference could be due to testosterone and" exact="estrogen" post="differential effect on the immune system. Since females have"/>
   <result pre="Androgen receptor ARB Angiotensin II type 1 receptor blocker ER" exact="Estrogen" post="receptor COVID-19 Coronavirus disease 19 DAMP Damage-associated molecular pattern"/>
   <result pre="responses to viral infectionsJ Immunol20171981782179028223406 73.PhoenixCHGoyRWGerallAAYoungWCOrganizing action of prenatally administered" exact="testosterone propionate" post="on the tissues mediating mating behavior in the female"/>
   <result pre="xy brain cells intrinsically different?Trends Endocrinol Metab20041561114693420 76.NilssonSMakelaSTreuterETujagueMThomsenJAnderssonGet al.Mechanisms of" exact="estrogen" post="actionPhysiol Rev2001811535156511581496 77.KovatsSEstrogen receptors regulate innate immune cells and"/>
   <result pre="receptors regulate innate immune cells and signaling pathwaysCell Immunol2015294636925682174 78.PhielKLHendersonRAAdelmanSJEllosoMMDifferential" exact="estrogen" post="receptor gene expression in human peripheral blood mononuclear cell"/>
   <result pre="al.Systems analysis of sex differences reveals an immunosuppressive role for" exact="testosterone" post="in the response to influenza vaccinationProc Natl Acad Sci"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7499567\results\search\drug\results.xml">
   <result pre="their common and different properties. RNA viruses coronaviruses SARS-Cov-2 influenza" exact="chloroquine" post="serine protease inhibitors heparan sulfate glycoconjugate Funding NIH10.13039/100000002 NINDS10.13039/100000065"/>
   <result pre="Ekins et al. 2020 Oseltamivir Tamiflu Neupane et al. 2020" exact="Ribavirin" post="Copegus, Rebetol, Ribasphere, Vilona, Virazole Neupane et al. 2020"/>
   <result pre="Sliva, Pantzartzi and Votava 2019 Quercetin Zakaryan et al. 2017" exact="Ambroxol" post="Muciclar, Mucosolvan, Mucobrox, Mucol, Lasolvan, Mucoangin, Surbronc, Brontex, Ambolar,"/>
   <result pre="Ambolar, Lysopain Yang etÂ al. 2002; Yamaya et al. 2014" exact="Allopurinol" post="Allohexal, Allosig, Milurit, Alloril, Progout, Ãœrikoliz, Zyloprim, Zyloric, Zyrik"/>
   <result pre="2006; George and Struthers 2009 Melatonin Reiter et al. 2017" exact="Deferoxamine" post="Desferal Borg and Schaich 1986; Klebanoff et al. 1989;"/>
   <result pre="2010 Mexidol Emoxipine, Emoxypin, Epigid Pavelkina, Yerovichenkov and Pak 2010" exact="Chloroquine" post="Chloroquine FNA, Resochin, Dawaquin, Lariago, Delagil Jeon et al."/>
   <result pre="Mexidol Emoxipine, Emoxypin, Epigid Pavelkina, Yerovichenkov and Pak 2010 Chloroquine" exact="Chloroquine" post="FNA, Resochin, Dawaquin, Lariago, Delagil Jeon et al. 2020;"/>
   <result pre="al. 2020; Jin et al. 2020; Liu et al. 2020" exact="Hydroxychloroquine" post="Plaquenil, Hydroquin, Axemal, Dolquine, Quensyl, Quinoric, Immard Liu et"/>
   <result pre="2020; Wang et al. 2020a; Zhang et al. 2020 Ivermectin" exact="Stromectol" post="Caly et al. 2020 The nature of RNA viruses"/>
   <result pre="compound is highly promiscuous and not a good drug candidate." exact="Ambroxol" post="(trans-4-[[(2-amino-3,5-dibromophenyl)methyl] amino]cyclohexanolhydrochlo-ride) also deserves attention as an additional antiviral"/>
   <result pre="(Yang etÂ al. 2002). The in vitro inhibitory effects of" exact="ambroxol" post="on influenza virus were described in 2014 (Yamaya etÂ"/>
   <result pre="diverse effects and high oral bioavailability (Jauch etÂ al. 1978)," exact="ambroxol" post="may be included in a list of medications used"/>
   <result pre="virus-induced pneumonia in daily doses of 5â€&quot;50Â mg/kg have failed." exact="Allopurinol" post="has not shown any effects on the evolution and"/>
   <result pre="and Sharanov 1997). The explanation of this paradox is that" exact="deferoxamine" post="(desferal) has approximately the same affinity constant for ferric"/>
   <result pre="the same time, it seems that ferric ions chelated by" exact="deferoxamine" post="do not completely lose their ability to redox transformation"/>
   <result pre="etÂ al. 2002; Francisco etÂ al. 2010). In contrast, 2-ethyl-6-methyl-3-hydroxypyridine" exact="succinate" post="(mexidol, emoxipine) has noticeable iron chelating activity (Andrusishina etÂ"/>
   <result pre="viral infections (Pavelkina, Yerovichenkov and Pak 2010). In clinical practice," exact="chloroquine" post="has been widely used as a safe, effective and"/>
   <result pre="2012; Jagadeesh, Saivisveswar and Revankar 2014; Son and Chung 2014)." exact="Chloroquine" post="and its many analogs (such as hydroxychloroquine etc.) have"/>
   <result pre="and Chung 2014). Chloroquine and its many analogs (such as" exact="hydroxychloroquine" post="etc.) have properties of weak acidic amines in unprotonated"/>
   <result pre="endosomes or lysosomes) (Vincent etÂ al. 2005). The level of" exact="chloroquine" post="in such compartments may be &amp;gt;100 times higher than"/>
   <result pre="its concentration in the cell (de Duve etÂ al. 1974)." exact="Chloroquine" post="may stay in the isolated intracellular compartments for hundreds"/>
   <result pre="hundreds of hours (Schrezenmeier and DornerÂ 2020). Accumulating in endosomes/lysosomes," exact="chloroquine" post="shifts the pH to alkali (Homewood etÂ al. 1972;"/>
   <result pre="al. 2006; Di Trani etÂ al. 2007). The ability of" exact="chloroquine" post="to inhibit the acidification of endosomes that contain respiratory"/>
   <result pre="genomes and following replication, may partially explain its antiviral activity." exact="Chloroquine" post="also has high antiviral activity against not only influenza"/>
   <result pre="of Golgi apparatus. For this reason, it is important that" exact="chloroquine" post="is able to change the redox status of a"/>
   <result pre="a solution of a broad-spectrum antibiotic, with the addition of" exact="dimethyl sulfoxide" post="(DMSO) and heparin. This approach avoids hemolysis and uses"/>
   <result pre="that have been tested for other indications. This analysis highlighted" exact="chloroquine" post="as one of the most repurposed drugs as it"/>
   <result pre="against hundreds of diseases (Baker et al. 2018). Not surprisingly," exact="chloroquine" post="has also been identified by several groups (in China,"/>
   <result pre="etÂ al. 2020). These cover large natural product molecules like" exact="ivermectin" post="(Caly etÂ al. 2020) through to an array of"/>
   <result pre="care center. Ann Thorac Med. 2019;14:179â€&quot;85.31333767 Al-BariMAATargeting endosomal acidification by" exact="chloroquine" post="analogs as a promising strategy for the treatment of"/>
   <result pre="of ambroxol. Eur J Med Res. 2008;13:557â€&quot;62.19073395 BelloSO, ChikaA, BelloAYIs" exact="chloroquine" post="better than artemisinin combination therapy as first line treatment"/>
   <result pre="J Med Res. 2008;13:557â€&quot;62.19073395 BelloSO, ChikaA, BelloAYIs chloroquine better than" exact="artemisinin" post="combination therapy as first line treatment in adult Nigerians"/>
   <result pre="VilarMJ, daÂ TrindadoÂ NetoPBet al.Double-blind, randomized, controlled clinical trial of" exact="clofazimine" post="compared with chloroquine in patients with systemic lupus erythematosus."/>
   <result pre="NetoPBet al.Double-blind, randomized, controlled clinical trial of clofazimine compared with" exact="chloroquine" post="in patients with systemic lupus erythematosus. Arthritis Rheum. 2005;52:3073â€&quot;8.16200586"/>
   <result pre="erythematosus. Arthritis Rheum. 2005;52:3073â€&quot;8.16200586 BhattacharyyaD, SenPCThe effect of binding of" exact="chlorpromazine" post="and chloroquine to ion transporting ATPases. Mol Cell Biochem."/>
   <result pre="Rheum. 2005;52:3073â€&quot;8.16200586 BhattacharyyaD, SenPCThe effect of binding of chlorpromazine and" exact="chloroquine" post="to ion transporting ATPases. Mol Cell Biochem. 1999;198:179â€&quot;85.10497894 BiemondP,"/>
   <result pre="USA. 2009;106:582â€&quot;7.19124777 Cabral-RomeroC, MartÃ­nez-SanmiguelJJ, ResÃ©ndez-PÃ©rezDet al.Antibacterial and anti-biofilm activities of" exact="ambroxol" post="against oral bacteria. Pharma Innovation J. 2013;2:52â€&quot;8. CainCC, SipeDM,"/>
   <result pre="man. Epidemiol Infect. 1990;105:435â€&quot;46.2170159 CalyL, DruceJD, CattonMGet al.The FDA-approved drug" exact="ivermectin" post="inhibits the replication of SARS-CoV-2 in vitro. Antiviral Res."/>
   <result pre="nitrite to nitric oxide: insights regarding where, when and how." exact="Nitric Oxide." post="2013;34:19â€&quot;26.23454592 CaoJ, WangD, XuFet al.Activation of IL-27 signaling promotes"/>
   <result pre="SikdarRet al.The in vivo inhibition of transport enzyme activities by" exact="chloroquine" post="in different organs of rat is reversible. Mol Cell"/>
   <result pre="reversible. Mol Cell Biochem. 1992;118:15â€&quot;21.1336812 ChangCK, AlbarilloMV, SchumerWTherapeutic effect of" exact="dimethyl sulfoxide" post="on ICAM-1 gene expression and activation of NF-ÎºB and"/>
   <result pre="Nat Commun. 2014;5:4794.25183443 ChinappiM, ViaA, MarcatiliPet al.On the mechanism of" exact="chloroquine" post="resistance in Plasmodium falciparum. PLoS One. 2010;5:e14064.21124966 ChoyKT, WongAY,"/>
   <result pre="with community acquired pneumonia. J Infect. 2012;65:223â€&quot;30.22543245 CohenHG, ReynoldsTBComparison of" exact="metronidazole" post="and chloroquine for the treatment of amoebic liver abscess."/>
   <result pre="acquired pneumonia. J Infect. 2012;65:223â€&quot;30.22543245 CohenHG, ReynoldsTBComparison of metronidazole and" exact="chloroquine" post="for the treatment of amoebic liver abscess. A controlled"/>
   <result pre="CrowleAJ, MayMHInhibition of tubercle bacilli in cultured human macrophages by" exact="chloroquine" post="used alone and in combination with streptomycin, isoniazid, pyrazinamide,"/>
   <result pre="in combination with streptomycin, isoniazid, pyrazinamide, and two metabolites of" exact="vitamin D3." post="Antimicrob Agents Chemother. 1990;34:2217â€&quot;22.2127346 CruveilhierLAction du serum antipneumococcique au"/>
   <result pre="al.Different pH requirements are associated with divergent inhibitory effects of" exact="chloroquine" post="on human and avian influenza A viruses. Virol J."/>
   <result pre="wild birds. PLoS Pathog. 2008;4:e1000076.18516303 DulchavskySA, DavidsonSB, CullenWJet al.Effects of" exact="deferoxamine" post="on H2O2-induced oxidative stress in isolated rat heart. Basic"/>
   <result pre="Methods Mol Biol. 2015;1282:1â€&quot;23.25720466 FeurleGE, MoosV, SchneiderTet al.The combination of" exact="chloroquine" post="and micocycline, a therapeutic option in cerebrospinal infection of"/>
   <result pre="cerebrospinal infection of Whipple`s disease refractory to treatment with ceftriaxone," exact="meropenem" post="and co-trimoxazole. J Antimicrob Chemother. 2012;67:1295â€&quot;6.22287233 ForniD, CaglianiR, ClericiMet"/>
   <result pre="GeorgeJ, StruthersADRole of urate, xanthine oxidase and the effects of" exact="allopurinol" post="in vascular oxidative stress. Vasc Health Risk Manag. 2009;5:265â€&quot;72.19436671"/>
   <result pre="Med. 2010;134:235â€&quot;43.20121613 GiovanellaF, FerreiraGK, deÂ PrÃ¡SDet al.Effects of primaquine and" exact="chloroquine" post="on oxidative stress parameters in rats. An Acad Bras"/>
   <result pre="properties of cell membranes: the molecular mechanism of action of" exact="dimethyl sulfoxide." post="J Phys Chem B. 2007;111:10453â€&quot;60.17661513 HaijemaBJ, VoldersH, RottierPJSwitching species"/>
   <result pre="coronavirus genome. J Virol. 2003;77:4528â€&quot;38.12663759 HallawayPE, EatonJW, PanterSSet al.Modulation of" exact="deferoxamine" post="toxicity and clearance by covalent attachment to biocompatible polymers."/>
   <result pre="mortality. Yale J Biol Med. 2017;90:165â€&quot;181.28656006 JagadeeshK, SaivisveswarKN, RevankarSPEfficacy of" exact="chloroquine" post="against Escherichia Coli and Proteus vulgaris: an in vitro"/>
   <result pre="HuangL, MalkeyRet al.A mammalian functional reductase that regulates nitrite and" exact="nitric oxide" post="homeostasis. Nat Chem Biol. 2008;4:411â€&quot;7.18516050 JauchR, BozlerG, HammerRet al.Ambroxol,"/>
   <result pre="of peroxynitrite-induced DNA strand breakage and hydroxyl radical formation by" exact="dimethyl sulfoxide" post="at very low concentration. Exp Biol Med (Maywood). 2010;235:614â€&quot;22.20463302"/>
   <result pre="endoplasmic reticulum. J Cell Biol. 1989;109:2721â€&quot;9.2556405 KastanMB, SemenkovichCF, SchneiderJUse of" exact="chloroquine" post="to treat metabolic syndrome. United States patent US 20080319010A12008."/>
   <result pre="do they really matter?Front Cell Dev Biol. 2019;7:93.31263697 KernKU, WeiserTTopical" exact="ambroxol" post="for the treatment of neuropathic pain. An initial clinical"/>
   <result pre="hemagglutinin polypeptide. Virology. 1975;68:440â€&quot;54.128196 LeeHJ, ShinS, YoonSGet al.The effect of" exact="chloroquine" post="on the development of dry eye in Sjogren syndrome"/>
   <result pre="host fibronectin. J Virol. 2012;86:10704â€&quot;13.22837202 LiF, WangW, HuLet al.Effect of" exact="ambroxol" post="on pneumonia caused by Pseudomonas aeruginosawith biofilm formation in"/>
   <result pre="a multifunctional protein. Viruses. 2014;6:2991â€&quot;3018.25105276 McGillJB, JohnsonM, HurstSet al.Low dose" exact="chloroquine" post="decreases insulin resistance in human metabolic syndrome but does"/>
   <result pre="infection. Infect Immun. 2006;74:6707â€&quot;21.16982840 MeinÃ£oIM, SatoEI, AndradeLEet al.Controlled trial with" exact="chloroquine" post="diphosphate in systemic lupus erythematosus. Lupus. 1996;5:237â€&quot;41.8803897 MengeshaT, MakonnenEComparative"/>
   <result pre="lupus erythematosus. Lupus. 1996;5:237â€&quot;41.8803897 MengeshaT, MakonnenEComparative efficacy and safety of" exact="chloroquine" post="and alternative antimalarial drugs: a meta-analysis fromsix African countries."/>
   <result pre="models. Sci Rep. 2016;6:31380.27539639 SanmartÃ­n-SuÃ¡rezC, Soto-OteroR, SÃ¡nchez-SelleroIet al.Antioxidant properties of" exact="dimethyl sulfoxide" post="and its viability as a solvent in the evaluation"/>
   <result pre="H2N2 and H3N2. Virology. 1978;87:13â€&quot;20.664248 SchrezenmeierE, DornerTMechanisms of action of" exact="hydroxychloroquine" post="and chloroquine: implications for rheumatology. Nat Rev Rheumatol. 2020;16:155â€&quot;66.32034323"/>
   <result pre="1996;21:641â€&quot;9.8891667 SeifartC, ClostermannU, SeifartUet al.Cell-specific modulation of surfactant proteins by" exact="ambroxol" post="treatment. Toxicol Appl Pharmacol. 2005;203:27â€&quot;35.15694461 SencioV, BarthelemyA, TavaresLPet al.Gut"/>
   <result pre="therapies. Eur J Pharmacol. 2009;625:220â€&quot;33.19836374 SonD, ChungMHIn vitro synergism between" exact="chloroquine" post="and antibiotics against Orientia tsutsugamushi. Infect Chemother. 2014;46:182â€&quot;8.25298907 SpicklerARInfluenza."/>
   <result pre="2019;11:E328.30959796 TanDX, KormazA, ReiterRJet al.Ebola virus disease: potential use of" exact="melatonin" post="as a treatment. J Pineal Res. 2014;57:381â€&quot;4.25262626 TashiroM, CiborowskiP,"/>
   <result pre="action. Psychopharmakol Biol Narkol. 2001;1:2â€&quot;12. WangM, CaoR, ZhangLet al.Remdesivir and" exact="chloroquine" post="effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in"/>
   <result pre="human ACE2. Cell. 2020b:S0092â€&quot;8674(20)30338-X., DOI: 10.1016/j.cell.2020.03.045. WaqarT, KhushdilA, HaqueKEfficacy of" exact="chloroquine" post="as a first line agent in the treatment of"/>
   <result pre="levels. Eur Respir J. 2002;19:952â€&quot;8.12030738 YanY, ZouZ, SunYet al.Anti-malaria drug" exact="chloroquine" post="is highly effective in treating avian influenza A H5N1"/>
   <result pre="systemic review. J Med Virol. 2020;92:479â€&quot;90.32052466 ZhangR, WangX, NiLet al.COVID-19:" exact="melatonin" post="as potential adjuvant treatment. Life Sci. 2020;250:117583.32217117 ZhaoP, SunL,"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7500907\results\search\drug\results.xml">
   <result pre="generations containing alpha, beta, delta, and gamma. Among these generations," exact="alpha" post="and beta are human coronaviruses (HCoVs)1,2 In late December"/>
   <result pre="Novel Coronavirus-induced Pneumonia, have been suggested antiviral agents containing: Interferon" exact="alpha" post="(IFN-Î±), lopinavir/ritonavir, chloroquine phosphate, ribavirin, and arbidol as potential"/>
   <result pre="have been suggested antiviral agents containing: Interferon alpha (IFN-Î±), lopinavir/ritonavir," exact="chloroquine" post="phosphate, ribavirin, and arbidol as potential options in COVID-19"/>
   <result pre="Table 1 Drug Adult Dosage Pediatric Dosage Route of Administration" exact="Chloroquine" post="phosphate 500 mg (300 mg for chloroquine base) twice"/>
   <result pre="Route of Administration Chloroquine phosphate 500 mg (300 mg for" exact="chloroquine" post="base) twice daily25 Not recommended Oral Hydroxychloroquine 200 mg"/>
   <result pre="(300 mg for chloroquine base) twice daily25 Not recommended Oral" exact="Hydroxychloroquine" post="200 mg twice daily26 Not recommended Oral Lopinavir/Ritonavir 400mg/100"/>
   <result pre="â€¢40: 400 mg/100 mg/time, twice daily for 1â€&quot;2 weeks27 Oral" exact="Ribavirin" post="500 mg twice dailyin combination with IFN-Î± or lopinavir/ritonavir25"/>
   <result pre="mg twice daily 26 Not recommended Oral 1Body weight 2Interferon" exact="alpha" post="Table 2 Classification of drugs that have been considered"/>
   <result pre="COVID-19 Investigational and/or hypothesis 1. Desferrioxamine34,352. Teicoplanin313. Etoposide36 - 1Interferon" exact="alpha" post="2Interferon alpha 2b 3Interferon beta 1a 4Extracorporeal membrane oxygenation"/>
   <result pre="and/or hypothesis 1. Desferrioxamine34,352. Teicoplanin313. Etoposide36 - 1Interferon alpha 2Interferon" exact="alpha" post="2b 3Interferon beta 1a 4Extracorporeal membrane oxygenation Chloroquine/Hydroxychloroquine Chloroquine"/>
   <result pre="2Interferon alpha 2b 3Interferon beta 1a 4Extracorporeal membrane oxygenation Chloroquine/Hydroxychloroquine" exact="Chloroquine" post="and hydroxychloroquine are immunomodulant antimalarial agents with broad-spectrum antiviral"/>
   <result pre="2b 3Interferon beta 1a 4Extracorporeal membrane oxygenation Chloroquine/Hydroxychloroquine Chloroquine and" exact="hydroxychloroquine" post="are immunomodulant antimalarial agents with broad-spectrum antiviral effects which"/>
   <result pre="which have been considered for potential benefits in COVID-19 treatment." exact="Hydroxychloroquine" post="is a common drug in many autoimmune disorders such"/>
   <result pre="COVID-19.37,38 Previous in vitro studies confirmed the antiviral activity of" exact="chloroquine" post="against COVID-19. Also, a recent publication from a Chinese"/>
   <result pre="from a Chinese clinical trial reported that the use of" exact="chloroquine" post="phosphate in patients with COVID-19 is superior and have"/>
   <result pre="its beneficial effect in COVID-19 treatment.37 The recommended dose of" exact="chloroquine" post="in patients with mild, moderate, or severe COVID-19 pneumonia"/>
   <result pre="moderate, or severe COVID-19 pneumonia is 500 mg twice daily." exact="Chloroquine" post="is a safe, available, and clinically applicable drug for"/>
   <result pre="safe, available, and clinically applicable drug for COVID-19 patients. Since" exact="hydroxychloroquine" post="has the same mechanism of action to chloroquine, so"/>
   <result pre="effects in the treatment of COVID-19 pneumonia.39 750 mg of" exact="chloroquine" post="is equal to 1200 mg of hydroxychloroquine.38 The recommended"/>
   <result pre="equal to 1200 mg of hydroxychloroquine.38 The recommended dose of" exact="hydroxychloroquine" post="in COVID-19 is 200 mg twice daily. Chloroquine and"/>
   <result pre="dose of hydroxychloroquine in COVID-19 is 200 mg twice daily." exact="Chloroquine" post="and hydroxychloroquine have been considered as potential candidates against"/>
   <result pre="hydroxychloroquine in COVID-19 is 200 mg twice daily. Chloroquine and" exact="hydroxychloroquine" post="have been considered as potential candidates against COVID-19 pneumonia.40,41"/>
   <result pre="candidates against COVID-19 pneumonia.40,41 An open-label non-randomized clinical trial on" exact="hydroxychloroquine" post="and azithromycin co-administration in COVID-19 patients was performed in"/>
   <result pre="COVID-19 pneumonia.40,41 An open-label non-randomized clinical trial on hydroxychloroquine and" exact="azithromycin" post="co-administration in COVID-19 patients was performed in France. Results"/>
   <result pre="in COVID-19 patients was performed in France. Results revealed that" exact="hydroxychloroquine" post="could significantly reduce the viral load and azithromycin could"/>
   <result pre="revealed that hydroxychloroquine could significantly reduce the viral load and" exact="azithromycin" post="could reinforce its clinical effect, but the main limitation"/>
   <result pre="management.43 Results of a systematic review on the efficacy of" exact="hydroxychloroquine" post="or chloroquine on the prevention or treatment of COVID-19"/>
   <result pre="of a systematic review on the efficacy of hydroxychloroquine or" exact="chloroquine" post="on the prevention or treatment of COVID-19 revealed that"/>
   <result pre="and meta-analysis on 53 randomized clinical trials on administration of" exact="hydroxychloroquine" post="in COVID-19 management revealed that hydroxychloroquine administration (case group)"/>
   <result pre="trials on administration of hydroxychloroquine in COVID-19 management revealed that" exact="hydroxychloroquine" post="administration (case group) was significantly associated with higher incidence"/>
   <result pre="of action in coronavirus treatment Recently published studies revealed that" exact="chloroquine" post="could highly reduce COVID-19 replication with an acceptable effective"/>
   <result pre="of 500 mg twice daily. The most important advantage of" exact="chloroquine" post="in COVID-19 treatment is good penetration to tissues especially"/>
   <result pre="tissues especially lungs which are highly affected in COVID-19 pneumonia." exact="Chloroquine" post="could stop viral infection by enhancing the pH of"/>
   <result pre="modification of COVID-19 viruses (inhibition of entry and post-entry stages).40" exact="Chloroquine" post="is a weak base that could be entrapped in"/>
   <result pre="and have low-pH, so interfering with their acidification process. Therefore" exact="chloroquine" post="could inhibit pH-dependent viral fusion and replication. Also, it"/>
   <result pre="endoplasmic reticulum-Golgi intermediate like structures.47 Another possible antiviral mechanism of" exact="chloroquine" post="is its immunomodulatory effect through cell signaling pathways and"/>
   <result pre="from COVID-19-induced ARDS by attenuating the pro-inflammatory cytokines and receptors.47" exact="Hydroxychloroquine" post="can enhance intracellular pH and avoid lysosomal activity in"/>
   <result pre="immune system over-activation, caused by COVID-19. According to this mechanism," exact="hydroxychloroquine" post="could alleviate symptoms of mild to severe COVID-19 pneumonia.38"/>
   <result pre="symptoms of mild to severe COVID-19 pneumonia.38 Chloroquine/Hydroxychloroquine adverse reactions" exact="Chloroquine" post="has different adverse reactions such as cardiovascular adverse reactions"/>
   <result pre="results of a systematic review on dermatologic adverse effects of" exact="hydroxychloroquine" post="emphasized that the most common dermatologic reactions due to"/>
   <result pre="hydroxychloroquine emphasized that the most common dermatologic reactions due to" exact="hydroxychloroquine" post="administration were rash, SJS,toxic epidermal necrolysis (TEN), pruritus, hyperpigmentation,"/>
   <result pre="mostly occurred after cumulative dosages of hydroxychloroquine.51 In overall, since" exact="hydroxychloroquine" post="has lower tissue accumulation potential in comparison with chloroquine,"/>
   <result pre="reactions and would be better choice.38 Chloroquine/Hydroxychloroquine contraindications Contraindications in" exact="chloroquine" post="use contains hypersensitivity to chloroquine (4-aminoquinolone compounds) and the"/>
   <result pre="choice.38 Chloroquine/Hydroxychloroquine contraindications Contraindications in chloroquine use contains hypersensitivity to" exact="chloroquine" post="(4-aminoquinolone compounds) and the presence of retinal or visual"/>
   <result pre="the presence of retinal or visual field changes.52 Chloroquine/Hydroxychloroquine pharmacokinetics" exact="Chloroquine" post="and hydroxychloroquine can distribute widely in the whole body"/>
   <result pre="of retinal or visual field changes.52 Chloroquine/Hydroxychloroquine pharmacokinetics Chloroquine and" exact="hydroxychloroquine" post="can distribute widely in the whole body after oral"/>
   <result pre="can distribute widely in the whole body after oral administration." exact="Hydroxychloroquine" post="has incomplete and variable (about 70%) absorption, while chloroquine"/>
   <result pre="administration. Hydroxychloroquine has incomplete and variable (about 70%) absorption, while" exact="chloroquine" post="has rapid and almost complete absorption. Both have moderate"/>
   <result pre="Both have moderate plasma protein binding. Both have hepatic metabolism." exact="Chloroquine" post="has an elimination half-life of 4 to 5 days"/>
   <result pre="has an elimination half-life of 4 to 5 days while" exact="hydroxychloroquine" post="has an elimination half-life of about 40 days. The"/>
   <result pre="acidification.52 Patients with predisposing diseases and special conditions Cardiovascular diseases" exact="Chloroquine" post="and hydroxychloroquine have a narrow therapeutic index and poisoning"/>
   <result pre="with predisposing diseases and special conditions Cardiovascular diseases Chloroquine and" exact="hydroxychloroquine" post="have a narrow therapeutic index and poisoning could be"/>
   <result pre="cardiovascular disease.37 Long-term exposure to these drugs could induce cardiomyopathy.38" exact="Chloroquine" post="in patients consuming heparin, prone the patients to risk"/>
   <result pre="consuming heparin, prone the patients to risk of bleeding. Also," exact="chloroquine" post="in patients with digitalization (using digoxin) could cause cardiac"/>
   <result pre="block.27 Liver diseases There is no dosage adjustment available for" exact="chloroquine" post="or hydroxychloroquine in patients with hepatic failure but it"/>
   <result pre="diseases There is no dosage adjustment available for chloroquine or" exact="hydroxychloroquine" post="in patients with hepatic failure but it should be"/>
   <result pre="caution.52 Kidney diseases There is no dosage adjustments available for" exact="chloroquine" post="in patients with renal failure from the manufacture's labeling"/>
   <result pre="adjustment is required. There is no dosage adjustments available for" exact="hydroxychloroquine" post="in renal failure but it should be used with"/>
   <result pre="showed a low risk of congenital abnormalities in patients receiving" exact="chloroquine" post="during pregnancy because of the lack of a pattern"/>
   <result pre="that the benefits of its use are higher than risks.53" exact="Hydroxychloroquine" post="use during pregnancy could not be accompanied by risks"/>
   <result pre="But patient monitoring during pregnancy is required.53 In general, since" exact="chloroquine" post="may induce severe side effects during fetal development, so"/>
   <result pre="chloroquine may induce severe side effects during fetal development, so" exact="hydroxychloroquine" post="would be a better option in pregnant women with"/>
   <result pre="during pregnancy.38 Lactation According to the American Academy of Pediatrics," exact="chloroquine" post="is compatible with breastfeeding. Although it could be excreted"/>
   <result pre="for nursing infants.53 According to the American Academy of Pediatrics," exact="hydroxychloroquine" post="is compatible with breastfeeding. Small amounts of hydroxychloroquine could"/>
   <result pre="of Pediatrics, hydroxychloroquine is compatible with breastfeeding. Small amounts of" exact="hydroxychloroquine" post="could be excreted to the milk, but because of"/>
   <result pre="and the possibility of drug accumulation and toxicity, breastfeeding during" exact="hydroxychloroquine" post="therapy should be done with caution.53 Umifenovir (ArbidolÂ®) Umifenovir"/>
   <result pre="in administration for a few days up to one month.55" exact="Ribavirin" post="Ribavirin is a nucleoside antihepaciviral agent (anti-HCV) which has"/>
   <result pre="administration for a few days up to one month.55 Ribavirin" exact="Ribavirin" post="is a nucleoside antihepaciviral agent (anti-HCV) which has been"/>
   <result pre="antihepaciviral agent (anti-HCV) which has been suggested for COVID-19 treatment." exact="Ribavirin" post="is a direct-acting antiviral (DAA) agent.56 Ribavirin mechanism of"/>
   <result pre="for COVID-19 treatment. Ribavirin is a direct-acting antiviral (DAA) agent.56" exact="Ribavirin" post="mechanism of action in coronavirus treatment Ribavirin is a"/>
   <result pre="antiviral (DAA) agent.56 Ribavirin mechanism of action in coronavirus treatment" exact="Ribavirin" post="is a nucleoside analog that has antiviral action against"/>
   <result pre="of RNA and DNA viruses. The potential antiviral activity of" exact="ribavirin" post="is inhibition of inosine monophosphate dehydrogenase (IMPDH) cellular protein"/>
   <result pre="viral growth might be stopped. Another possible antiviral activity of" exact="ribavirin" post="is its immunomodulatory effects by suppression of IL-10.57 Ribavirin"/>
   <result pre="of ribavirin is its immunomodulatory effects by suppression of IL-10.57" exact="Ribavirin" post="also could inhibit RNA polymerase activity and therefore inhibition"/>
   <result pre="initiation and elongation, so viral protein synthesis could be inhibited." exact="Ribavirin" post="adverse reactions The most common adverse reactions of ribavirin"/>
   <result pre="inhibited. Ribavirin adverse reactions The most common adverse reactions of" exact="ribavirin" post="are CNS adverse reactions (headache, fatigue, insomnia, nervousness, etc.),"/>
   <result pre="reactions are cardiovascular events such as chest pain and flushing.52" exact="Ribavirin" post="contraindications Ribavirin is contraindicated in patients with hypersensitivity to"/>
   <result pre="cardiovascular events such as chest pain and flushing.52 Ribavirin contraindications" exact="Ribavirin" post="is contraindicated in patients with hypersensitivity to ribavirin, pregnant"/>
   <result pre="major hemoglobinopathies such as sickle cell anemia and major thalassemia.52" exact="Ribavirin" post="pharmacokinetics Ribavirin distribution could significantly prolonged in erythrocytes for"/>
   <result pre="such as sickle cell anemia and major thalassemia.52 Ribavirin pharmacokinetics" exact="Ribavirin" post="distribution could significantly prolonged in erythrocytes for about 16"/>
   <result pre="16 to 40 days, which is responsible for ribavirin-induced anemia.58" exact="Ribavirin" post="has hepatic metabolism. Its oral bioavailability (F) is about"/>
   <result pre="has hepatic metabolism. Its oral bioavailability (F) is about 64%." exact="Ribavirin" post="elimination half-life (t Â½) in the normal population is"/>
   <result pre="So because of its prolonged half-life and potential overdose toxicity," exact="ribavirin" post="is contraindicated in patients with hepatic failure (Child-Pugh class"/>
   <result pre="(Tmax) after oral administration is between 2 to 3 hours." exact="Ribavirin" post="excretion could take place through both urine and feces"/>
   <result pre="Cardiovascular diseases One of the most important side effects of" exact="ribavirin" post="is hemolytic anemia which could worsen cardiac disease in"/>
   <result pre="could induce fatal or non-fatal myocardial infarction in them. So" exact="ribavirin" post="should be avoided in patients with a history of"/>
   <result pre="a history of unstable or severe cardiac diseases. Liver diseases" exact="Ribavirin" post="is contraindicated in patients with hepatic decompensation (Child-Pugh class"/>
   <result pre="with hepatic decompensation (Child-Pugh class B and C). Kidney diseases" exact="Ribavirin" post="dosage adjustment in patients with renal failure highly depends"/>
   <result pre="if serum creatinine level rises over 2 mg/dl during administration," exact="ribavirin" post="should be discontinued promptly.27Table 3. Ribavirin dose adjustment based"/>
   <result pre="2 mg/dl during administration, ribavirin should be discontinued promptly.27Table 3." exact="Ribavirin" post="dose adjustment based on renal function. Table 3 Ribavirin"/>
   <result pre="3. Ribavirin dose adjustment based on renal function. Table 3" exact="Ribavirin" post="formulations GFR â‰¥ 50 ml/min GFR 30 to 50"/>
   <result pre="daily 200 mg once daily 1End stage renal disease Pregnancy" exact="Ribavirin" post="has teratogenic and mutagenic effects. So it is a"/>
   <result pre="drug accumulation in tissue compartments for up to 6 months," exact="ribavirin" post="administration is contraindicated in pregnant women and also in"/>
   <result pre="partner. It was suggested that pregnancy should be avoided during" exact="ribavirin" post="therapy and at least 6 months after completion of"/>
   <result pre="months after completion of therapy in women or men.53 Lactation" exact="Ribavirin" post="because of the prolonged plasma elimination half-life and molecular"/>
   <result pre="no human data available.53 Patients have undergone solid organ transplantation" exact="Ribavirin" post="may precipitate hematologic adverse effects of organ transplantation regimen"/>
   <result pre="agents (anti-HIV). Previous researches proved the in vitro efficacy of" exact="lopinavir" post="against SARS-CoV.59 Ritonavir can enhance lopinavir's elimination half-life (t"/>
   <result pre="researches proved the in vitro efficacy of lopinavir against SARS-CoV.59" exact="Ritonavir" post="can enhance lopinavir's elimination half-life (t Â½) by inhibition"/>
   <result pre="against MERS-CoV.60 Also, results revealed that lopinavir/ritonavir in combination with" exact="ribavirin" post="and IFN-Î± could promote viral clearance and enhance patientsâ€™"/>
   <result pre="clinical efficacy against COVID-19 infection. The recommended daily dose of" exact="lopinavir" post="/ritonavir is 400 and 100 mg respectively twice daily."/>
   <result pre="with the underlying disease who are infected with COVID-19.62 Also," exact="lopinavir" post="would be a promising drug of choice in children"/>
   <result pre="a critical enzyme in viral maturation and infectivity. Low dose" exact="ritonavir" post="in combination with lopinavir act as a pharmacokinetic enhancer"/>
   <result pre="viral maturation and infectivity. Low dose ritonavir in combination with" exact="lopinavir" post="act as a pharmacokinetic enhancer by inhibition of lopinavir"/>
   <result pre="with lopinavir act as a pharmacokinetic enhancer by inhibition of" exact="lopinavir" post="inactivation metabolism.63 Lopinavir/Ritonavir adverse reactions The most common adverse"/>
   <result pre="hypokalemia in patients with COVID-19 infection.64 Lopinavir/Ritonavir drug interactions Since" exact="lopinavir" post="undergoes hepatic metabolism through CYP3A4 enzyme, potential drug-drug interactions"/>
   <result pre="inhibitors or inducers of CYP3A4 enzyme and P-glycoprotein inhibitors. Also," exact="ritonavir" post="has hepatic metabolism via CYP3A4 and CYP2D6. Ritonavir has"/>
   <result pre="inhibitors. Also, ritonavir has hepatic metabolism via CYP3A4 and CYP2D6." exact="Ritonavir" post="has serious and life-threatening drug interactions with sedative-hypnotic agents,"/>
   <result pre="drugs, and ergot alkaloid agents because of the effect of" exact="ritonavir" post="on their hepatic metabolism through CYP3A4 AND CYP2D6. Concurrent"/>
   <result pre="through CYP3A4 AND CYP2D6. Concurrent use of these agents with" exact="ritonavir" post="is absolutely contraindicated and should be avoided.52 Lopinavir/Ritonavir contraindications"/>
   <result pre="with underlying kidney disease and it could be administered safely.52" exact="Ritonavir" post="also has high protein binding (about 98 to 99"/>
   <result pre="and undergo hepatic metabolism through CYP3A4 and CYP2D6. Low-dose of" exact="ritonavir" post="in combination with lopinavir as a fixed-dose agent (1:4"/>
   <result pre="through CYP3A4 and CYP2D6. Low-dose of ritonavir in combination with" exact="lopinavir" post="as a fixed-dose agent (1:4 ratio) acts as a"/>
   <result pre="(1:4 ratio) acts as a pharmacokinetic enhancer by inhibition of" exact="lopinavir" post="inactivation metabolism through inhibition of liver and intestinal CYP3A4"/>
   <result pre="liver and intestinal CYP3A4 and inhibition of P-glycoprotein efflux pump.65" exact="Ritonavir" post="could induce high serum and lymph node concentration with"/>
   <result pre="in fasting state to 4 hours in the fed state." exact="Ritonavir" post="also has small renal elimination so dosage adjustment is"/>
   <result pre="severe hepatic failure, there is no dosage adjustments available but" exact="lopinavir" post="has primary liver metabolism and its AUC will be"/>
   <result pre="and should not be stopped during pregnancy.53 Lactation Lopinavir and" exact="ritonavir" post="with a molecular weight of 629 and 721 Da"/>
   <result pre="has been suggested that during COVID-19 treatment, calcineurin inhibitors (ex." exact="cyclosporine" post="and tacrolimus) and mTOR inhibitors (ex. sirolimus and everolimus)"/>
   <result pre="calcineurin inhibitors (ex. cyclosporine and tacrolimus) and mTOR inhibitors (ex." exact="sirolimus" post="and everolimus) could be discontinued and replaced with lopinavir/ritonavir"/>
   <result pre="count and the number of cytokines such as IL-6.70 Interferon" exact="alpha" post="(IFN-Î±) IFN-Î± is a broad-spectrum antiviral agent that is"/>
   <result pre="Another concern about the administration of IFN-Î± in combination with" exact="ritonavir" post="in children is inhibition of development and growth which"/>
   <result pre="further randomized clinical trials are required to confirm its efficacy.31" exact="Azithromycin" post="Azithromycin is a macrolide antibiotic. Previous in vitro studies"/>
   <result pre="randomized clinical trials are required to confirm its efficacy.31 Azithromycin" exact="Azithromycin" post="is a macrolide antibiotic. Previous in vitro studies revealed"/>
   <result pre="antibiotic. Previous in vitro studies revealed the antiviral activity of" exact="azithromycin" post="and also it could prevent severe viral respiratory tract"/>
   <result pre="patients infected with respiratory viruses. A recent publication showed that" exact="azithromycin" post="in combination with hydroxychloroquine could have synergistic effects against"/>
   <result pre="viruses. A recent publication showed that azithromycin in combination with" exact="hydroxychloroquine" post="could have synergistic effects against COVID-19 infection. But the"/>
   <result pre="open-label non-randomized clinical trial in France revealed that co-administration of" exact="azithromycin" post="with hydroxychloroquine in COVID-19 patients was accompanied by reinforcement"/>
   <result pre="clinical trial in France revealed that co-administration of azithromycin with" exact="hydroxychloroquine" post="in COVID-19 patients was accompanied by reinforcement of the"/>
   <result pre="COVID-19 patients was accompanied by reinforcement of the effect of" exact="hydroxychloroquine" post="monotherapy, but the main limitation of this clinical trial"/>
   <result pre="data available on its efficacy against COVID-19. Remdesivir is an" exact="adenosine" post="analog with antiviral activity. A possible mechanism of antiviral"/>
   <result pre="treatment of COVID-19. A possible disadvantage of NSAIDs such as" exact="Ibuprofen" post="in COVID-19 infection is their potential effects in over-expression"/>
   <result pre="of a previous meta-analysis revealed that high dose intravenous (IV)" exact="vitamin C" post="would be a promising agent in sepsis and septic"/>
   <result pre="a life-threatening consequence of sepsis or septic shock. High dose" exact="vitamin C" post="has dual effects; it can act as a pro-oxidant"/>
   <result pre="antioxidant agent for lung epithelial cells. Another possible mechanism of" exact="vitamin C" post="is inhibition of lactate secretion from immune cells and"/>
   <result pre="of alveolar epithelial cells type II.79 So high dose IV" exact="vitamin C" post="would be a promising option in COVID-19-induced ARDS management."/>
   <result pre="promising option in COVID-19-induced ARDS management. The recommended dose of" exact="vitamin C" post="in patients with severe COVID-19 pneumonia is 50 mg/kg"/>
   <result pre="IV every 6 hours for 4 days. In this protocol," exact="hydrocortisone" post="(50 mg IV every 6 hours for 7 days)"/>
   <result pre="and safety in COVID-19 patients. Some recent studies revealed that" exact="vitamin C" post="could have a preventive role in COVID-19 lower respiratory"/>
   <result pre="respiratory tract infection. So supplementation with a moderate amount of" exact="vitamin C" post="has been suggested as a promising preventive option.80 Extracorporeal"/>
   <result pre="who develop cardiac arrhythmia and septic shock during COVID-19 pneumonia.81" exact="Deferoxamine" post="Iron toxicity has a multi-stage clinical course. First patients"/>
   <result pre="obstructive pulmonary disease, hypertension, etc.) In this group, lopinavir/ritonavir plus" exact="chloroquine" post="or hydroxychloroquine would be considered. Also according to the"/>
   <result pre="disease, hypertension, etc.) In this group, lopinavir/ritonavir plus chloroquine or" exact="hydroxychloroquine" post="would be considered. Also according to the therapeutic protocol"/>
   <result pre="48 hours. In this group, a combination of remdesivir plus" exact="chloroquine" post="or hydroxychloroquine or monotherapy of remdesivir are considered as"/>
   <result pre="In this group, a combination of remdesivir plus chloroquine or" exact="hydroxychloroquine" post="or monotherapy of remdesivir are considered as the first"/>
   <result pre="the first choice. If remdesivir is not available, lopinavir/ritonavir plus" exact="chloroquine" post="has been suggested as a second choice of therapy."/>
   <result pre="multi-organ failure. In this group, a combination of remdesivir plus" exact="chloroquine" post="or hydroxychloroquine or monotherapy of remdesivir are considered as"/>
   <result pre="In this group, a combination of remdesivir plus chloroquine or" exact="hydroxychloroquine" post="or monotherapy of remdesivir are considered as the first"/>
   <result pre="the first choice. If remdesivir is not available, lopinavir/ritonavir plus" exact="chloroquine" post="has been suggested as a second choice of therapy."/>
   <result pre="angiotensin receptor blockers (ARBs) could enhance ACE2 level. Thiazolidinediones and" exact="Ibuprofen" post="might also enhance the ACE2 level.83 So the potential"/>
   <result pre="36HamiziKAouidaneSBelaalouiGEtoposid-based therapy for severe forms of COVID-19Med Hypo2020109826 37TouretFde LamballerieXOf" exact="chloroquine" post="and COVID-19Antiviral Res1772020104762 38ZhouDDaiSMTongQCOVID-19: a recommendation to examine the"/>
   <result pre="COVID-19Antiviral Res1772020104762 38ZhouDDaiSMTongQCOVID-19: a recommendation to examine the effect of" exact="hydroxychloroquine" post="in preventing infection and progressionJ Antimicrob Chemother2020 39ColsonPRolainJMLagierJCBrouquiPRaoultDChloroquine and"/>
   <result pre="hydroxychloroquine in preventing infection and progressionJ Antimicrob Chemother2020 39ColsonPRolainJMLagierJCBrouquiPRaoultDChloroquine and" exact="hydroxychloroquine" post="as available weapons to fight COVID-19Int J Antimicrob Agents2020105932"/>
   <result pre="J Antimicrob Agents2020105932 40DevauxCARolainJMColsonPRaoultDNew insights on the antiviral effects of" exact="chloroquine" post="against coronavirus: what to expect for COVID-19?Int J Antimicrob"/>
   <result pre="coronavirus: what to expect for COVID-19?Int J Antimicrob Agents2020105938 41GaoJTianZYangXBreakthrough:" exact="Chloroquine" post="phosphate has shown apparent efficacy in treatment of COVID-19"/>
   <result pre="of COVID-19 associated pneumonia in clinical studiesBiosci Trends1412020727332074550 42GautretPLagierJ-CParolaPMeddebLMailheMDoudierBHydroxychloroquine and" exact="azithromycin" post="as a treatment of COVID-19: results of an open-label"/>
   <result pre="an open-label non-randomized clinical trialInt J Antimicrob Agents2020105949 43SchluenzLARamos-OteroGPNawarskasJJChloroquine or" exact="hydroxychloroquine" post="for management of coronavirus disease 2019: friend or Foe?Cardiol"/>
   <result pre="of coronavirus disease 2019: friend or Foe?Cardiol Rev285202026627132769401 44HernandezAVRomanYMPasupuletiVBarbozaJJWhiteCMHydroxychloroquine or" exact="chloroquine" post="for treatment or prophylaxis of COVID-19: a living systematic"/>
   <result pre="45ChenC, PanK, WuB, LiX, ChenZ, XuQ, etÂ al. Safety of" exact="hydroxychloroquine" post="in COVID-19 and other diseases: a systematic review and"/>
   <result pre="controversial treatment for COVID-19Arch Pharmacal Res202018 47HuTYFriemanMWolframJInsights from nanomedicine into" exact="chloroquine" post="efficacy against COVID-19Nat Nanotech1542020247249 48CortegianiAIngogliaGIppolitoMGiarratanoAEinavSA systematic review on the"/>
   <result pre="Nanotech1542020247249 48CortegianiAIngogliaGIppolitoMGiarratanoAEinavSA systematic review on the efficacy and safety of" exact="chloroquine" post="for the treatment of COVID-19J Crit Care2020 49WangMCaoRZhangLYangXLiuJXuMRemdesivir and"/>
   <result pre="chloroquine for the treatment of COVID-19J Crit Care2020 49WangMCaoRZhangLYangXLiuJXuMRemdesivir and" exact="chloroquine" post="effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in"/>
   <result pre="antiviral compoundsJ Clin Virol3112004697515288617 60KimUJWonE-JKeeS-JJungS-IJangH-CCase report Combination therapy with lopinavir/ritonavir," exact="ribavirin" post="and interferon-Î± for Middle East respiratory syndromeAntiviral Therapy21201645545926492219 61CaoBWangYWenDLiuWWangJFanGA"/>
   <result pre="COVID-19 progressionInt J Infect Dis2020 65MoltÃ³JBarbanojMJMirandaCBlancoASantosJRNegredoESimultaneous population pharmacokinetic model for" exact="lopinavir" post="and ritonavir in HIV-infected adultsClin Pharmacokinet4710200868169218783298 66PericoLBenigniARemuzziGShould COVID-19 concern"/>
   <result pre="J Infect Dis2020 65MoltÃ³JBarbanojMJMirandaCBlancoASantosJRNegredoESimultaneous population pharmacokinetic model for lopinavir and" exact="ritonavir" post="in HIV-infected adultsClin Pharmacokinet4710200868169218783298 66PericoLBenigniARemuzziGShould COVID-19 concern nephrologists? Why"/>
   <result pre="of etiology, pathogenesis, diagnosis, and ongoing clinical trialsCureus1252020 79ErolA.High-dose intravenous" exact="vitamin C" post="treatment for COVID-19. 2020. 80WangL-sWangY-rYeD-wLiuQ-qA review of the 2019"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7501082\results\search\drug\results.xml">
   <result pre="polymerase Hel, helicase S protein, Spike protein TMPRSS2, Trans-Membrane Protease" exact="Serine" post="Protease-2 TMPRSS4, Trans-Membrane Protease Serine Protease-4 HAT, Human Airway"/>
   <result pre="Spike protein TMPRSS2, Trans-Membrane Protease Serine Protease-2 TMPRSS4, Trans-Membrane Protease" exact="Serine" post="Protease-4 HAT, Human Airway Trypsin-like protease TGN, Trans-Golgi Network"/>
   <result pre="CMK, Chloro-Methyl-Ketone Dec, Decanoyl Phac, Phenyl-Acetyl TTSP, Type II Transmembrane" exact="Serine" post="Proteases family HPV, Human Papillomavirus HBV, Hepatitis B virus"/>
   <result pre="sulphonyl fluoride BHH, BromHexine Hydrochloride PCSK, Pro-protein Convertase Subtilisin/Kexin AMPK," exact="Adenosine" post="Monophosphate-activated Protein Kinase HCoV-NL63, Human Coronavirus â€&quot; NL63 HCoV-229E,"/>
   <result pre="of non-peptidic inhibitors, such as streptamine-based compounds. Upon addition of" exact="guanidine" post="residues, streptamine derivatives mimic the cationic furin cleavage site"/>
   <result pre="Three-dimensional model of TMPRSS2 in complex with the standard inhibitor" exact="camostat" post="mesylate [90]. The catalytic triad (i.e., His296, Asp345, Ser441)"/>
   <result pre="triad (i.e., His296, Asp345, Ser441) and the predicted interactions of" exact="camostat" post="with the active site residues (i.e., Asp187, Asn346, Cys348,"/>
   <result pre="3.2.3 TMPRSS2 inhibitors Alpha-1-antitrypsin (A1AT), 4-(2-aminomethyl)-benzene-sulfonyl fluoride (AEBSF), Camostat mesylate," exact="Nafamostat" post="and Bromhexine hydrochloride are the best experimentally validated inhibitors"/>
   <result pre="inhibitors Alpha-1-antitrypsin (A1AT), 4-(2-aminomethyl)-benzene-sulfonyl fluoride (AEBSF), Camostat mesylate, Nafamostat and" exact="Bromhexine" post="hydrochloride are the best experimentally validated inhibitors of TMPRSS2,"/>
   <result pre="inhibits also the fusion of the mouse hepatitis coronavirus [95]." exact="Bromhexine" post="hydrochloride (BHH) is a drug used as a mucolytic"/>
   <result pre="of the ligand. Asn450 forms two hydrogen bonds with the" exact="anhydrous" post="carbonyl oxygen, with side chain acceptor and backbone acceptor."/>
   <result pre="the TMPRSS2 catalytic triad (i.e., His296 and Ser441) (Fig. 5C)." exact="Nafamostat" post="and Camostat mesylate bind in the same pocket of"/>
   <result pre="(Fig. 5C). The binding energy of TMPRSS2 with Camostat mesylate," exact="Nafamostat" post="and Bromhexine hydrochloride is of âˆ’7.94Â kcal/mol, âˆ’7.21Â kcal/mol,"/>
   <result pre="The binding energy of TMPRSS2 with Camostat mesylate, Nafamostat and" exact="Bromhexine" post="hydrochloride is of âˆ’7.94Â kcal/mol, âˆ’7.21Â kcal/mol, and âˆ’5.96Â"/>
   <result pre="kcal/mol respectively. Similarly, the inhibition constant (Ki) of Camostat mesylate," exact="Nafamostat" post="and Bromhexine hydrochloride are 1.51Â ÂµM, 5.17Â ÂµM and"/>
   <result pre="Similarly, the inhibition constant (Ki) of Camostat mesylate, Nafamostat and" exact="Bromhexine" post="hydrochloride are 1.51Â ÂµM, 5.17Â ÂµM and 43Â ÂµM,"/>
   <result pre="effect in combination with interferon [105]. The antiviral action of" exact="nitric oxide" post="(NO) has been reported for the treatment of several"/>
   <result pre="actual coronavirus pandemia, selected drugs, like favipiravir, amodiaquine, 2â€²-fluoro-2â€²-deoxycytidine, and" exact="ribavirin" post="are not classified as protease inhibitors, but they were"/>
   <result pre="that Î±-ketoamide analogues bind the Mpro more tightly than the" exact="amoxicillin" post="used as control [128]. One of them, synthesized and"/>
   <result pre="âˆ’8.07Â kcal/mol, respectively) with respect to the control shikonin and" exact="lopinavir" post="(around âˆ’5.4Â kcal/mol) [132]. Bonducellpin D from Caesalpinia bonduc"/>
   <result pre="an alkaloid from the seeds of Lepidium sativum, and (iii)" exact="folic acid," post="which all bind tightly the enzyme forming hydrogen bonds"/>
   <result pre="was performed against the SARS-CoV-2 Mpro, giving the glecaprevir and" exact="maraviroc" post="as the best inhibitors [143]. Further, also selected anti-HIV"/>
   <result pre="simeprevir, faldaprevir, and asunaprevir) were docked against SARS-CoV-2 Mpro. Indeed," exact="simeprevir" post="(Fig. 7D), an approved HCV NS3/4A protease inhibitor, seems"/>
   <result pre="fluvastatin may be novel molecules with inhibitory properties. In fact," exact="pitavastatin" post="(Fig. 7E) has a binding energy greater than that"/>
   <result pre="has a binding energy greater than that of protease inhibitors" exact="nelfinavir" post="and lopinavir, reported in the same study [149]. Potential"/>
   <result pre="kcal/mol), even though the best score was found for the" exact="eszopiclone" post="(âˆ’10.0Â kcal/mol) (Fig. 7F) a drug used for the"/>
   <result pre="of insomnia [151]. Further, the antibiotic talampicillin and the anti-psychotic" exact="lurasidone" post="have been identified by virtual screening as potential drugs"/>
   <result pre="similar score of âˆ’6.4Â kcal/mol [153]. Notably, remdesivir, GS-441524 and" exact="entecavir" post="might be multi-target potential inhibitors for both RNA-dependent RNA-polymerase"/>
   <result pre="6.5Â kcal/mol, respectively) while a lower score was found for" exact="chloroquine" post="and hydroxychloroquine with âˆ’5.0Â kcal/mol and âˆ’5.9Â kcal/mol, respectively"/>
   <result pre="respectively) while a lower score was found for chloroquine and" exact="hydroxychloroquine" post="with âˆ’5.0Â kcal/mol and âˆ’5.9Â kcal/mol, respectively [153]. 4.3.1.2.2"/>
   <result pre="activity of baicalin or baicalein is close to that of" exact="chloroquine" post="(EC50Â =Â 2.71Â ÂµM) and hydroxychloquine (EC50Â =Â 4.51Â"/>
   <result pre="Respiratory tract infection [154] Baicalein 2.94 Respiratory tract infection [154]" exact="Chloroquine" post="2.71/5.47 Malaria [155], [162] Hydroxychloroquine 0.7/4.51 Malaria [162], [155]"/>
   <result pre="2.94 Respiratory tract infection [154] Chloroquine 2.71/5.47 Malaria [155], [162]" exact="Hydroxychloroquine" post="0.7/4.51 Malaria [162], [155] Remdesivir 23.15 Ebolavirus [161] Boceprevir"/>
   <result pre="Î¼M, 9.35Â Î¼M, 1.55Â Î¼M, and 1.82Â Î¼M respectively [124]." exact="Dipyridamole" post="binds Mpro through hydrogen bonds and hydrophobic interactions, showing"/>
   <result pre="0.55Â Î¼M) better than other drugs tested, such as the" exact="disulfiram" post="(4.67Â Î¼M), which was taken as positive control for"/>
   <result pre="was taken as positive control for the bioassay [158]. Furthermore," exact="dipyridamole" post="and montelukast sodium showed a global inhibitory function on"/>
   <result pre="as positive control for the bioassay [158]. Furthermore, dipyridamole and" exact="montelukast" post="sodium showed a global inhibitory function on NF-kB signalling"/>
   <result pre="(lopinavir), 2.55Â Î¼M (homorringtonine), and 0.46Â Î¼M (emetine hydrochloride), while" exact="ribavirin" post="and favipiravir showed no inhibition at 100Â Î¼M. Only"/>
   <result pre="compound concentrations and increase inhibition of viral replication [161]. Finally," exact="chloroquine" post="and hydroxychloroquine both inhibit SARS-CoV-2 in cell assays (EC50Â"/>
   <result pre="and increase inhibition of viral replication [161]. Finally, chloroquine and" exact="hydroxychloroquine" post="both inhibit SARS-CoV-2 in cell assays (EC50Â =Â 5.47Â"/>
   <result pre="inhibit SARS-CoV-2 Mpro [166], were employed in clinical trials, namely" exact="lopinavir" post="and ritonavir, which were administered in adults hospitalized with"/>
   <result pre="relatively more severe illness than older children, a trial of" exact="hydroxychloroquine" post="or lopinavir/ritonavir suggested their use in severe pneumonia and"/>
   <result pre="use in severe pneumonia and critically ill children [168]. The" exact="chloroquine" post="and hydroxychloroquine, originally employed for malaria treatment, deserve a"/>
   <result pre="receptor binding. Unfortunately, the clinical data and the effect of" exact="hydroxychloroquine" post="in combination with azithromycin are mostly controversial about their"/>
   <result pre="clinical data and the effect of hydroxychloroquine in combination with" exact="azithromycin" post="are mostly controversial about their efficacy in COVID-19 treatment."/>
   <result pre="azithromycin are mostly controversial about their efficacy in COVID-19 treatment." exact="Hydroxychloroquine" post="and chloroquine have certain limitations and toxicity, especially on"/>
   <result pre="mostly controversial about their efficacy in COVID-19 treatment. Hydroxychloroquine and" exact="chloroquine" post="have certain limitations and toxicity, especially on the heart"/>
   <result pre="heart and eyes. Considering their ocular, cardiac and neuro toxicities," exact="hydroxychloroquine" post="and chloroquine should not be recommended as preventive drugs"/>
   <result pre="eyes. Considering their ocular, cardiac and neuro toxicities, hydroxychloroquine and" exact="chloroquine" post="should not be recommended as preventive drugs for the"/>
   <result pre="35UlrichH.PillatM.M.CD147 as a target for COVID-19 treatment: suggested effects of" exact="Azithromycin" post="and stem cell engagementStem Cell Rev. Rep.16202043444010.1007/s12015-020-09976-732307653 36Mycroft-WestC.J.SuD.LiY.GuimondS.E.RuddT.R.ElliS.MillerG.NunesQ.M.ProcterP.BisioA.ForsythN.R.TurnbullJ.E.GuerriniM.FernigD.G.YatesE.A.LimaM.A.SkidmoreM.A.SARS-Cov-2 spike"/>
   <result pre="docking studies of TMPRSS2 with experimentally known inhibitors Camostat mesylate," exact="Nafamostat" post="and Bromhexine hydrochloride to control SARS-Coronavirus-2., ChemRxiv. (2020), doi:"/>
   <result pre="of TMPRSS2 with experimentally known inhibitors Camostat mesylate, Nafamostat and" exact="Bromhexine" post="hydrochloride to control SARS-Coronavirus-2., ChemRxiv. (2020), doi: 10.26434/chemrxiv.12162360.v1. 93GuttmanO.BaranovskiB.M.SchusterR.KanerZ.Freixo-LimaG.S.BaharN.KalayN.MizrahiM.I.BramiI.OchayonD.E.LewisE.C.Acute-pahse"/>
   <result pre="M. Yousfi, Hispidin and Lepidine E: two natural compounds and" exact="Folic acid" post="as potential inhibitors of 2019-novel coronavirus main protease (2019-nCoVMpro),"/>
   <result pre="Vitro Antiviral Activity and Projection of Optimized Dosing Design of" exact="Hydroxychloroquine" post="for the Treatment of Severe Acute Respiratory Syndrome Coronavirus"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7501538\results\search\drug\results.xml">
   <result pre="Substance Use and Addiction Effect of 2 Integrated Interventions on" exact="Alcohol" post="Abstinence and Viral Suppression Among Vietnamese Adults With Hazardous"/>
   <result pre="Alcohol Abstinence and Viral Suppression Among Vietnamese Adults With Hazardous" exact="Alcohol" post="Use and HIVA Randomized Clinical Trial Effect of 2"/>
   <result pre="and HIVA Randomized Clinical Trial Effect of 2 Interventions on" exact="Alcohol" post="Use and Viral Suppression Among People With HIV Effect"/>
   <result pre="Suppression Among People With HIV Effect of 2 Interventions on" exact="Alcohol" post="Use and Viral Suppression Among People With HIV GoVivian"/>
   <result pre="effect of 2 clinic-based behavioral interventions of varying intensity on" exact="alcohol" post="use and viral suppression among individuals with HIV and"/>
   <result pre="use and viral suppression among individuals with HIV and hazardous" exact="alcohol" post="use? Findings In this 3-group randomized clinical trial involving"/>
   <result pre="behavioral therapy, significantly increased the percentage of days abstinent from" exact="alcohol" post="at 12 months compared with the standard of care."/>
   <result pre="of the brief intervention in antiretroviral therapy clinics to reduce" exact="alcohol" post="use and increase viral suppression in this high-risk population."/>
   <result pre="compares the efficacy of 2 scalable antiretroviral clinicâ€&quot;based interventions on" exact="alcohol" post="use and viral suppression among adults with hazardous alcohol"/>
   <result pre="on alcohol use and viral suppression among adults with hazardous" exact="alcohol" post="use and HIV in Vietnam. Abstract Importance Hazardous and"/>
   <result pre="use and HIV in Vietnam. Abstract Importance Hazardous and heavy" exact="alcohol" post="use is common among people living with HIV and"/>
   <result pre="compare the efficacy of 2 scalable ART clinicâ€&quot;based interventions on" exact="alcohol" post="use and viral suppression. Design, Setting, and Participants This"/>
   <result pre="clinics in Thai Nguyen, Vietnam. Adults receiving ART with hazardous" exact="alcohol" post="use (Alcohol Use Disorders Identification Testâ€&quot;Consumption score â‰¥4 for"/>
   <result pre="were percentage of days abstinent from alcohol, confirmed using the" exact="alcohol" post="biomarker phosphatidylethanol, and viral suppression at 12 months after"/>
   <result pre="in a significant increase in percentage of days abstinent from" exact="alcohol" post="and a significant increase in viral suppression after 12"/>
   <result pre="intervention are needed. Trial Registration ClinicalTrials.gov Identifier: NCT02720237 Introduction Hazardous" exact="alcohol" post="use is highly prevalent among people living with HIV"/>
   <result pre="cohort of PWH in the United States, 27% reported hazardous" exact="alcohol" post="use and 34% reported binge drinking.2 In low-income and"/>
   <result pre="34% reported binge drinking.2 In low-income and middle-income countries, hazardous" exact="alcohol" post="use among PWH is common, with 20% to 46%"/>
   <result pre="is common, with 20% to 46% of PWH reporting hazardous" exact="alcohol" post="use.3,4,5,6,7,8,9 Alcohol use has been associated with decreased adherence"/>
   <result pre="with 20% to 46% of PWH reporting hazardous alcohol use.3,4,5,6,7,8,9" exact="Alcohol" post="use has been associated with decreased adherence to antiretroviral"/>
   <result pre="decreased adherence to antiretroviral therapy (ART)10,11,12 and decreased viral suppression.13" exact="Alcohol" post="use is also associated with elevated sexual and injection"/>
   <result pre="of HIV transmission.7,14,15,16 Despite the known adverse health consequences of" exact="alcohol" post="use, there is a lack of evidence-based interventions for"/>
   <result pre="lack of evidence-based interventions for PWH,17,18,19,20,21 and hazardous and heavy" exact="alcohol" post="consumption are frequently not addressed in HIV health care"/>
   <result pre="not addressed in HIV health care settings. Hazardous and heavy" exact="alcohol" post="use in specific subpopulations of PWH, including people who"/>
   <result pre="as well as transmission of HIV and other infections. Hazardous" exact="alcohol" post="use among PWID who are living with HIV is"/>
   <result pre="standard of care (SOC) on percentage of days abstinent from" exact="alcohol" post="(assessed with timeline follow-back interviews and confirmed using the"/>
   <result pre="alcohol (assessed with timeline follow-back interviews and confirmed using the" exact="alcohol" post="biomarker phosphatidylethanol)23 and viral suppression at 12 months after"/>
   <result pre="intervention and brief intervention have been highly effective in reducing" exact="alcohol" post="use among people living with HIV with hazardous or"/>
   <result pre="use among people living with HIV with hazardous or heavy" exact="alcohol" post="use in US settings24,25,26 and were selected for their"/>
   <result pre="at a study ART clinic and receiving ART; having hazardous" exact="alcohol" post="use, defined as having an Alcohol Use Disorders Identification"/>
   <result pre="receiving ART; having hazardous alcohol use, defined as having an" exact="Alcohol" post="Use Disorders Identification Testâ€&quot;Consumption score of at least 4"/>
   <result pre="of at least 10, out of concerns for risk of" exact="alcohol" post="withdrawal. Recruitment Procedures Recruitment began in March 2016 and"/>
   <result pre="Ministry of Health recommendation from their HIV clinician to decrease" exact="alcohol" post="use and a referral to harm reduction services and"/>
   <result pre="assigned to the brief intervention group. Because the concept of" exact="alcohol" post="reduction is novel in this setting, we selected a"/>
   <result pre="effectively refuse alcohol, to manage cravings and high-risk situations for" exact="alcohol" post="use, and to develop self-efficacy. Sessions also provided information"/>
   <result pre="included elements used in the combined intervention, including information about" exact="alcohol" post="and its effects as well as alcohol behavior change"/>
   <result pre="including information about alcohol and its effects as well as" exact="alcohol" post="behavior change strategies (eTable 2 in Supplement 2). Face-to-face"/>
   <result pre="Patient Health Questionnaireâ€&quot;9 and Generalized Anxiety Disorderâ€&quot;7 scores, respectively, and" exact="alcohol" post="dependence or alcohol abuse was defined using the Mini-International"/>
   <result pre="and Generalized Anxiety Disorderâ€&quot;7 scores, respectively, and alcohol dependence or" exact="alcohol" post="abuse was defined using the Mini-International Neuropsychiatric Interview version"/>
   <result pre="US Drug Testing Laboratories for phosphatidylethanol testing to detect any" exact="alcohol" post="use during the 3 weeks before the study visit."/>
   <result pre="before the study visit. Phosphatidylethanol is a direct metabolite of" exact="alcohol" post="consumption that serves as a biomarker for alcohol consumption"/>
   <result pre="metabolite of alcohol consumption that serves as a biomarker for" exact="alcohol" post="consumption during the preceding 3 weeks.23 Phosphatidylethanol levels of"/>
   <result pre="standard of care, on self-reported percentage of days abstinent from" exact="alcohol" post="measured by the timeline follow-back interview and viral suppression"/>
   <result pre="of less than 8 ng/mL, the established threshold for detecting" exact="alcohol" post="abstinence, and self-reported abstinence during the past 3 weeks"/>
   <result pre="12 (9-16) 12 (9-16) 12 (9-16) 11 (9-15) Currently has" exact="alcohol" post="dependence or alcohol abusea No 256 (58.2) 92 (62.6)"/>
   <result pre="(9-16) 12 (9-16) 11 (9-15) Currently has alcohol dependence or" exact="alcohol" post="abusea No 256 (58.2) 92 (62.6) 76 (51.7) 88"/>
   <result pre="(2.7) 5 (3.4) 4 (2.7) Abbreviations: ART, antiretroviral therapy; AUDIT," exact="Alcohol" post="Use Disorders Identification Test; GAD-7, Generalized Anxiety Disorderâ€&quot;7 score;"/>
   <result pre="reasons include currently participating in another HIV, drug use, or" exact="alcohol" post="program; planning to move from province in next 24"/>
   <result pre="months; and unwilling to adhere to program. bHigh risk of" exact="alcohol" post="withdrawal was defined as Clinical Institute Withdrawal Assessment of"/>
   <result pre="alcohol withdrawal was defined as Clinical Institute Withdrawal Assessment of" exact="Alcohol" post="Scale score of at least 10. Participants could rescreen"/>
   <result pre="comparable across groups (Table 1). Overall, 184 (41.2%) had current" exact="alcohol" post="dependence or alcohol abuse. Most had a history of"/>
   <result pre="(Table 1). Overall, 184 (41.2%) had current alcohol dependence or" exact="alcohol" post="abuse. Most had a history of injection drug use"/>
   <result pre="in Supplement 2). Table 2. Percentage of Days Abstinent From" exact="Alcohol" post="in the Last 30 Days, by Trial Group and"/>
   <result pre="attended the follow-up visit, baseline percentage of days abstinent from" exact="alcohol" post="use in the last 30 d, mean, % 3-mo"/>
   <result pre="2). Discussion In this randomized clinical trial, we observed that" exact="alcohol" post="reduction can be achieved through a brief intervention, leading"/>
   <result pre="intervention, leading to substantial improvement in viral suppression. Both integrated" exact="alcohol" post="reduction interventions, the combined intervention and brief intervention, led"/>
   <result pre="brief intervention, led to increased percentage of days abstinent from" exact="alcohol" post="compared with standard of care; this effect was sustained"/>
   <result pre="abstinent using the timeline follow-back interview was validated using the" exact="alcohol" post="biomarker phosphatidylethanol. In the 12-month visit, the proportion of"/>
   <result pre="not more, effective than the combined intervention on biologically validated" exact="alcohol" post="measures and viral suppression. Part of the explanation for"/>
   <result pre="for our findings may be that, given the lack of" exact="alcohol" post="reduction programs in Vietnam, even 2 in-person sessions and"/>
   <result pre="Vietnam, even 2 in-person sessions and 2 telephone sessions of" exact="alcohol" post="reduction counseling can increase awareness of the harms of"/>
   <result pre="alcohol reduction counseling can increase awareness of the harms of" exact="alcohol" post="and teach coping skills to manage high risk moods"/>
   <result pre="coping skills to manage high risk moods and/or situations for" exact="alcohol" post="use. Importantly, these results underscore that a brief intervention"/>
   <result pre="that a brief intervention provided by paraprofessional counselors effectively reduced" exact="alcohol" post="consumption and increased viral suppression among people with hazardous"/>
   <result pre="in a wide variety of low- to middle-income countries. Heavy" exact="alcohol" post="use among PWH is prevalent and is associated with"/>
   <result pre="and increased sexual and injecting risk behaviors.10,11,16 People who drink" exact="alcohol" post="excessively may be more likely to become HIV infected.21"/>
   <result pre="support.21,34 Training in alternative means of coping may both reduce" exact="alcohol" post="use and enhance well-being. But alcohol treatment has rarely"/>
   <result pre="coping may both reduce alcohol use and enhance well-being. But" exact="alcohol" post="treatment has rarely been incorporated into HIV care settings."/>
   <result pre="into HIV care settings. In the United States, a stepped" exact="alcohol" post="treatment intervention for patients with HIV and alcohol use"/>
   <result pre="a stepped alcohol treatment intervention for patients with HIV and" exact="alcohol" post="use disorder incorporating a physician-managed medication-based intervention, motivational enhancement"/>
   <result pre="are manualized and can be delivered by trained paraprofessionals. Notably," exact="alcohol" post="reduction and associated improvement in viral load were achieved"/>
   <result pre="drinking at hazardous or heavy levels but were not seeking" exact="alcohol" post="treatment. At 12 months, viral suppression was significantly higher"/>
   <result pre="the SOC group. This suggests that the brief intervention reduced" exact="alcohol" post="use, which in turn improved ART adherence, leading to"/>
   <result pre="often the most challenging to engage in HIV care. Self-reported" exact="alcohol" post="abstinence was a primary outcome, but other measures of"/>
   <result pre="alcohol abstinence was a primary outcome, but other measures of" exact="alcohol" post="reduction may also achieve viral suppression. Comparing the proportion"/>
   <result pre="achieve viral suppression. Comparing the proportion of patients who reduced" exact="alcohol" post="consumption between the SOC and combined intervention groups and"/>
   <result pre="brief interventions. Limitations and Strengths This study has limitations. Self-reported" exact="alcohol" post="abstinence is susceptible to social desirability bias. To assess"/>
   <result pre="than 8 ng/mL, the established cut-off for abstinence, to self-reported" exact="alcohol" post="abstinence. Only 1% to 6% reported no alcohol use"/>
   <result pre="to self-reported alcohol abstinence. Only 1% to 6% reported no" exact="alcohol" post="use in the past 21 days but had phosphatidylethanol"/>
   <result pre="with phosphatidylethanol levels of less than 8 ng/mL who reported" exact="alcohol" post="use in the past 21 days, suggesting possible imperfections"/>
   <result pre="between phosphatidylethanol levels of less than 8 ng/mL and self-reported" exact="alcohol" post="abstinence, it is still unclear how to best use"/>
   <result pre="that 65% of PWH are men36 and most individuals with" exact="alcohol" post="use disorder in Vietnam are men.36 Therefore, we anticipate"/>
   <result pre="account for a greater proportion of PWH and people with" exact="alcohol" post="use disorders This study also has several strengths. The"/>
   <result pre="lay counselors have effectively delivered psychological treatment for men with" exact="alcohol" post="dependence in primary care settings in India.38 Uptake of"/>
   <result pre="and group sessions, increased the percentage of days abstinent from" exact="alcohol" post="(confirmed using phosphatidylethanol), decreased the number drinks per drinking"/>
   <result pre="of ART clients. References References 1DukoB, AyalewM, AyanoGThe prevalence of" exact="alcohol" post="use disorders among people living with HIV/AIDS: a systematic"/>
   <result pre="2CraneHM, McCaulME, ChanderG, et al.Prevalence and factors associated with hazardous" exact="alcohol" post="use among persons living with HIV across the US"/>
   <result pre="2017;17(1):263. doi:10.1186/s12879-017-2374-028399823 4LunzeK, LioznovD, ChengDM, et al.HIV stigma and unhealthy" exact="alcohol" post="use among people living with HIV in Russia. AIDS"/>
   <result pre="2015;10(5):e0126236. doi:10.1371/journal.pone.012623625962171 6TranBX, NguyenN, OhinmaaA, et al.Prevalence and correlates of" exact="alcohol" post="use disorders during antiretroviral treatment in injection-driven HIV epidemics"/>
   <result pre="during antiretroviral treatment in injection-driven HIV epidemics in Vietnam. Drug" exact="Alcohol" post="Depend. 2013;127(1-3):39-44. doi:10.1016/j.drugalcdep.2012.06.00922749565 7LiL, LuoS, LanCW, et al.Alcohol use,"/>
   <result pre="et al.Longitudinal analysis of depressive symptoms, perceived social support, and" exact="alcohol" post="use among HIV-infected men who inject drugs in northern"/>
   <result pre="10AzarMM, SpringerSA, MeyerJP, AlticeFLA systematic review of the impact of" exact="alcohol" post="use disorders on HIV treatment outcomes, adherence to antiretroviral"/>
   <result pre="outcomes, adherence to antiretroviral therapy and health care utilization. Drug" exact="Alcohol" post="Depend. 2010;112(3):178-193. doi:10.1016/j.drugalcdep.2010.06.01420705402 11HendershotCS, StonerSA, PantaloneDW, SimoniJMAlcohol use and"/>
   <result pre="Defic Syndr. 2009;52(2):180-202. doi:10.1097/QAI.0b013e3181b18b6e19668086 12TranBX, NguyenLT, DoCD, NguyenQL, MaherRMAssociations between" exact="alcohol" post="use disorders and adherence to antiretroviral treatment and quality"/>
   <result pre="with HIV/AIDS. BMC Public Health. 2014;14:27. doi:10.1186/1471-2458-14-2724411007 13ChanderG, LauB, MooreRDHazardous" exact="alcohol" post="use: a risk factor for non-adherence and lack of"/>
   <result pre="use and sexual risk behavior among human immunodeficiency virus-positive persons." exact="Alcohol" post="Clin Exp Res. 2005;29(5):837-843. doi:10.1097/01.ALC.0000164363.40533.E015897729 15Le MarchandC, EvansJ, PageK,"/>
   <result pre="Exp Res. 2005;29(5):837-843. doi:10.1097/01.ALC.0000164363.40533.E015897729 15Le MarchandC, EvansJ, PageK, DavidsonPJ, HahnJAHazardous" exact="alcohol" post="consumption among young adult IDU and its association with"/>
   <result pre="adult IDU and its association with high risk behaviors. Drug" exact="Alcohol" post="Depend. 2013;127(1-3):143-149. doi:10.1016/j.drugalcdep.2012.06.02422819868 16LucasGM, GeboKA, ChaissonRE, MooreRDLongitudinal assessment of"/>
   <result pre="GeboKA, ChaissonRE, MooreRDLongitudinal assessment of the effects of drug and" exact="alcohol" post="abuse on HIV-1 treatment outcomes in an urban clinic."/>
   <result pre="al.HIV primary care providersâ€&quot;screening, knowledge, attitudes and behaviors related to" exact="alcohol" post="interventions. Drug Alcohol Depend. 2016;161:59-66. doi:10.1016/j.drugalcdep.2016.01.01526857898 18CarvalhoAF, HeiligM, PerezA,"/>
   <result pre="providersâ€&quot;screening, knowledge, attitudes and behaviors related to alcohol interventions. Drug" exact="Alcohol" post="Depend. 2016;161:59-66. doi:10.1016/j.drugalcdep.2016.01.01526857898 18CarvalhoAF, HeiligM, PerezA, ProbstC, RehmJAlcohol use"/>
   <result pre="RehmJAlcohol use disorders. Lancet. 2019;394(10200):781-792. doi:10.1016/S0140-6736(19)31775-131478502 19EdelmanEJ, WilliamsEC, MarshallBDLAddressing unhealthy" exact="alcohol" post="use among people living with HIV: recent advances and"/>
   <result pre="2018;31(1):1-7. doi:10.1097/QCO.000000000000042229176446 20MadhombiroM, MusekiwaA, JanuaryJ, ChingonoA, AbasM, SeedatSPsychological interventions for" exact="alcohol" post="use disorders in people living with HIV/AIDS: a systematic"/>
   <result pre="immunodeficiency virus (HIV) infection: current knowledge, implications, and future directions." exact="Alcohol" post="Clin Exp Res. 2016;40(10):2056-2072. doi:10.1111/acer.1320427696523 22BaumMK, RafieC, LaiS, SalesS,"/>
   <result pre="23HahnJA, DobkinLM, MayanjaB, et al.Phosphatidylethanol (PEth) as a biomarker of" exact="alcohol" post="consumption in HIV-positive patients in sub-Saharan Africa. Alcohol Clin"/>
   <result pre="biomarker of alcohol consumption in HIV-positive patients in sub-Saharan Africa." exact="Alcohol" post="Clin Exp Res. 2012;36(5):854-862. doi:10.1111/j.1530-0277.2011.01669.x22150449 24ChanderG, HuttonHE, LauB, XuX,"/>
   <result pre="26Scott-SheldonLAJ, CareyKB, JohnsonBT, CareyMP; collab: MASH Research TeamBehavioral interventions targeting" exact="alcohol" post="use among people living with HIV/AIDS: a systematic review"/>
   <result pre="doi:10.1007/s10461-017-1886-328831609 27HuttonHE, LancasterKE, ZuskovD, et al.Cultural adaptation of 2 evidence-based" exact="alcohol" post="interventions for antiretroviral treatment clinic patients in Vietnam. J"/>
   <result pre="adherence and competence in psychotherapy research in the addictions. Drug" exact="Alcohol" post="Depend. 2000;57(3):225-238. doi:10.1016/S0376-8716(99)00049-610661673 29Rivet AmicoKA situated-information motivation behavioral skills"/>
   <result pre="physician advice for problem drinkers: long-term efficacy and benefit-cost analysis." exact="Alcohol" post="Clin Exp Res. 2002;26(1):36-43. doi:10.1111/j.1530-0277.2002.tb02429.x11821652 31CareyMP, CareyKB, MaistoSA, GordonCM,"/>
   <result pre="Int J STD AIDS. 2001;12(6):365-375. doi:10.1258/095646201192330911368817 32collab: National Institute on" exact="Alcohol" post="Abuse and Alcoholism What are binge and heavy drinking?"/>
   <result pre="Stat Med. 2015;34(18):2602-2617. doi:10.1002/sim.650725872751 34WardellJD, ShuperPA, RourkeSB, HendershotCSStigma, coping, and" exact="alcohol" post="use severity among people living with HIV: a prospective"/>
   <result pre="Behav Med. 2018;52(9):762-772. doi:10.1093/abm/kax05030124756 35EdelmanEJ, MaistoSA, HansenNB, et al.Integrated stepped" exact="alcohol" post="treatment for patients with HIV and alcohol use disorder:"/>
   <result pre="et al.Integrated stepped alcohol treatment for patients with HIV and" exact="alcohol" post="use disorder: a randomised controlled trial. Lancet HIV. 2019;6(8):e509-e517."/>
   <result pre="doi:10.1016/S2352-3018(19)30076-131109915 36LincolnMAlcohol and drinking cultures in Vietnam: a review. Drug" exact="Alcohol" post="Depend. 2016;159:1-8. doi:10.1016/j.drugalcdep.2015.10.03026802499 37BlackburnNA, GoVF, BuiQ, et al.The cost"/>
   <result pre="doi:10.1016/j.drugalcdep.2015.10.03026802499 37BlackburnNA, GoVF, BuiQ, et al.The cost of delivering an" exact="alcohol" post="reduction program among persons with hazardous alcohol use who"/>
   <result pre="of delivering an alcohol reduction program among persons with hazardous" exact="alcohol" post="use who are living with HIV in Thai Nguyen,"/>
   <result pre="Health Action. In press. 38NadkarniA, WeobongB, WeissHA, et al.Counselling for" exact="alcohol" post="problems (CAP), a lay counsellor-delivered brief psychological treatment for"/>
   <result pre="Clinic, Thai Nguyen Province, Vietnam eTable 2. Descriptions of Each" exact="Alcohol" post="Reduction Intervention Evaluated eTable 3. Cohen d for Difference"/>
   <result pre="Difference Among Groups for Mean Percentage of Days Abstinent From" exact="Alcohol" post="in the Last 30 Days eTable 4. Difference Among"/>
   <result pre="Drinking Days in the last 30 Days eTable 10. Self-reported" exact="Alcohol" post="Abstinence in the Last 3 weeks and Phosphatidylethanol Levels"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7501552\results\search\drug\results.xml">
   <result pre="high-level resistance to all NRTIs, NNRTIs except for tenofovir and" exact="etravirine" post="to which low-level resistance was registered. Krasnoyarsk 16.2 HIV-1"/>
   <result pre="resistance to all NNRTIs and five NRTIs drugs except for" exact="emtricitabine" post="and lamivudine, to which intermediate level resistance was detected."/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7501848\results\search\drug\results.xml">
   <result pre="these selectable markers include antibiotic resistance genes against antibiotics like" exact="kanamycin" post="[29]. DoggyboneTM (covalently closed linear DNA construct) [30] and"/>
   <result pre="[122]. The polypeptide backbone is mainly made up of N-(2-aminoethyl)" exact="glycine" post="which is linked with nitrogenous bases of nucleic acids"/>
   <result pre="the large ribosomal subunit at 2.4 A resolutionScience2895481200090592010937989 103MuthG.W.Ortoleva-DonnellyL.StrobelS.A.AÂ single" exact="adenosine" post="with a neutral pKa in the ribosomal peptidyl transferase"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7502134\results\search\drug\results.xml">
   <result pre="recruited using respondent-driven sampling. PWID with urine testing positive for" exact="heroin" post="or methamphetamine and manifesting recent skin injection marks were"/>
   <result pre="five distinct profiles: profile 1: recent injection practices and high" exact="alcohol" post="consumption, profile 2: at-risk injection and sexual behaviors with"/>
   <result pre="aged 18 years and above with urine testing positive for" exact="heroin" post="or methamphetamine and manifesting recent skin injection marks (ascertained"/>
   <result pre="Frankfurt, Germany). The detection threshold was set at 300â€‰ng/mL for" exact="heroin" post="and 500â€‰ng/mL for methamphetamine. A fingerprint machine allowed unique"/>
   <result pre="and sexual behaviors were documented for the prior six months." exact="Alcohol" post="consumption was assessed by using the AUDIT-C score [21]."/>
   <result pre="consumption was assessed by using the AUDIT-C score [21]. At-risk" exact="alcohol" post="consumption was defined as a score of 4 and"/>
   <result pre="health (Table 1). Briefly, active variables included items related to" exact="heroin" post="and other drug use, injection and risky sexual behaviors,"/>
   <result pre="risky injection and sexual behavior, injection frequency and methadone use," exact="alcohol" post="consumption, drug use, duration of injection, and overdose. We"/>
   <result pre="(Table 2): 3.2.1. Profile 1: Recent Injection Practices and High" exact="Alcohol" post="Consumption (N = 176) This profile consists of PWID"/>
   <result pre="other profiles. They were predominantly males, and all presented hazardous" exact="alcohol" post="consumption, such as frequent binge drinking. 3.2.2. Profile 2:"/>
   <result pre="being more frequently single and without sexual activity. They injected" exact="heroin" post="safely and moderately every day, with less use of"/>
   <result pre="3.2.4. Profile 4: Frequent Injections with Safe Behaviors but High" exact="Methamphetamine" post="Consumption (N = 317) These PWID had the highest"/>
   <result pre="injection practices, unsafe sex, high stimulant (methamphetamine) consumption, or at-risk" exact="alcohol" post="consumption. These three profiles, representing 41% of PWID, are"/>
   <result pre="use of street methadone was a way to cope with" exact="heroin" post="shortage. Outreach interventions targeting awareness on transmission of blood-borne"/>
   <result pre="was not demonstrated by our data, possibly due to underreporting," exact="alcohol" post="use is known to be associated with disinhibited behaviors"/>
   <result pre="be associated with disinhibited behaviors and risk-taking practices [24, 25]." exact="Alcohol" post="use should be systematically assessed among PWID, and brief"/>
   <result pre="could then rather be related to inappropriate practices when injecting" exact="heroin" post="during methamphetamine rush, unsafe sex, and also HCV transmission"/>
   <result pre="risk of transmission of blood-borne viruses by obtaining evidence of" exact="heroin" post="injection (urine testing and recent skin injection marks) which"/>
   <result pre="an overviewJournal of Food and Drug Analysis2013214S42S4510.1016/j.jfda.2013.09.03225278736 2BeyrerC.RazakM. H.LisamK.ChenJ.LuiW.YuX. F.Overland" exact="heroin" post="trafficking routes and HIV-1 spread in south and south-east"/>
   <result pre="people who inject drugs in Tijuana, Baja California, MexicoDrug and" exact="Alcohol" post="Review201837112813610.1111/dar.1252428337798 16AharonovichE.SarvetA.StohlM.et al.Reducing non-injection drug use in HIV primary"/>
   <result pre="and depression: the PHQ-4Psychosomatics200950661362110.1176/appi.psy.50.6.61319996233 21BushK.KivlahanD. R.McDonellM. B.FihnS. D.BradleyK. A.The AUDIT" exact="alcohol" post="consumption questions (AUDIT-C): an effective brief screening test for"/>
   <result pre="test for problem drinking. Ambulatory Care Quality Improvement Project (ACQUIP)." exact="Alcohol" post="use disorders identification testArchives of Internal Medicine1998158161789179510.1001/archinte.158.16.17899738608 22BenzecriJ.-P.Analyse des"/>
   <result pre="donnÃ©es2010Technip 24NguyenT. V.Van KhuuN.NguyenP. D.et al.Sociodemographic factors, sexual behaviors, and" exact="alcohol" post="and recreational drug use associated with HIV among men"/>
   <result pre="in young social drinkersAlcoholism, Clinical and Experimental Research20143841143115010.1111/acer.12333 26BertholetN.DaeppenJ.-B.WietlisbachV.FlemingM.BurnandB.Reduction of" exact="alcohol" post="consumption by brief alcohol intervention in primary care: systematic"/>
   <result pre="Clinical and Experimental Research20143841143115010.1111/acer.12333 26BertholetN.DaeppenJ.-B.WietlisbachV.FlemingM.BurnandB.Reduction of alcohol consumption by brief" exact="alcohol" post="intervention in primary care: systematic review and meta-analysisArchives of"/>
   <result pre="drugs (PWID) in the city of Hai Phong, VietnamDrug and" exact="Alcohol" post="Dependence201818510611110.1016/j.drugalcdep.2017.11.03329432973 30BamvitaJ.-M.RoyE.ZangG.et al.Portraying persons who inject drugs recently infected"/>
   <result pre="95% CI Number of years since the first injection of" exact="heroin" post="â€ƒ&amp;lt;5 396 28.7 26.3-31.2 â€ƒ5 to &amp;lt;10 357 25.8"/>
   <result pre="21.4 19.3-23.7 â€ƒâ‰¥15 331 24.0 21.8-26.4 Number of days of" exact="heroin" post="injection, last month â€ƒâ‰¤15 111 8.0 6.7-9.6 â€ƒ&amp;gt;15 161"/>
   <result pre="â€ƒ&amp;gt;15 161 11.7 10.4-13.5 â€ƒEveryday 1108 80.2 78.9-83.5 Number of" exact="heroin" post="injections in a typical day, last month â€ƒ1 235"/>
   <result pre="â€ƒCannabis only 247 17.9 15.8-19.9 â€ƒOtherc 442 32.1 30.1-35.1 At-risk" exact="alcohol" post="consumptiona 421 30.4 28.0-33.1 Binge drinkinga 168 12.2 10.4-14.2"/>
   <result pre="2.4 1.7-3.4 aIn the past 6 months; bin addition to" exact="heroin" post="and methamphetamine; camong amphetamine, benzodiazepine, cocaine, methadone, and cannabis."/>
   <result pre="87 (25.5) Number of years since the first injection of" exact="heroin" post="â€ƒ&amp;lt;5 66 (37.5) 24 (30.4) 113 (24.2) 90 (28.4)"/>
   <result pre="116 (24.8) 71 (22.4) 90 (26.4) Number of days of" exact="heroin" post="injection, last month â€ƒâ‰¤15 24 (13.6) 4 (5.1) 32"/>
   <result pre="65 (82.3) 393 (84.2) 258 (81.4) 266 (78) Number of" exact="heroin" post="injections in a typical day, last month â€ƒ1 22"/>
   <result pre="(34.1) 35 (44) 24 (5.1) 297 (93.7) 27 (7.9) At-risk" exact="alcohol" post="consumptiona 176 (100) 55 (69.6) 393 (84.2) 252 (79.5)"/>
   <result pre="82 (24.3) aIn the past 6 months; bin addition to" exact="heroin" post="and methamphetamine; camong amphetamine, benzodiazepine, cocaine, methadone, and cannabis;"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7503980\results\search\drug\results.xml">
   <result pre="initial docking, the best candidates were found to be mezlocillin," exact="camazepam" post="and spirapril, targeting the catalytic site. Raltegravir, rolitetracycline, tolvaptan,"/>
   <result pre="spirapril, targeting the catalytic site. Raltegravir, rolitetracycline, tolvaptan, ciclesonide and" exact="rescinnamine" post="were found targeting the allosteric domain. All compounds have"/>
   <result pre="[20] and in cases of mild- to mid-stage COVID-19 [21]." exact="Ciclesonide" post="is a safe drug commonly used for inhalation in"/>
   <result pre="the best Mpro allosteric inhibitors. The efficacy and safety of" exact="tolvaptan" post="therapy was reported in patients with the COVID-19-associated syndrome"/>
   <result pre="was reported in patients with the COVID-19-associated syndrome of inappropriate" exact="antidiuretic hormone" post="secretion [25,26]. In our work, mezlocillin was the best"/>
   <result pre="reported antiviral activities of benzodiazepines [28]. According to our study," exact="spirapril" post="and ACE inhibitors could be a promising catalytic site"/>
   <result pre="In VS-based study, magnesium ascorbate, a buffered (non-acidic) form of" exact="vitamin C," post="was found to be the top lead compound among"/>
   <result pre="compound among 106 nutraceuticals against SARS-CoV-2 s Mpro [36], and" exact="tizanidine" post="was amongst the 11 approved drugs predicted to show"/>
   <result pre="potential SARS-CoV-2 Mpro inhibitors [38]. In another docking study, voriconazole," exact="tobramycin" post="and kanamycin showed potential activity against SARS-CoV-2 Mpro [33,37]."/>
   <result pre="Mpro inhibitors [38]. In another docking study, voriconazole, tobramycin and" exact="kanamycin" post="showed potential activity against SARS-CoV-2 Mpro [33,37]. Ospemifene was"/>
   <result pre="tobramycin and kanamycin showed potential activity against SARS-CoV-2 Mpro [33,37]." exact="Ospemifene" post="was among 51 hits selected in silico against Mpro"/>
   <result pre="among 51 hits selected in silico against Mpro [39], and" exact="propylthiouracil" post="was among the top 20 drugs showing the highest"/>
   <result pre="clinical trials are ongoing with oseltamivir with multiple combinations with" exact="chloroquine" post="and favipiravir [41,42]. The benefit of the ISM-SM approach"/>
   <result pre="the UniProt database (https://www.uniprot.org/) with the following accession numbers: Gaba" exact="alpha" post="subunit, P14867 d-alanyl- d-alanine carboxypeptidase Q75Y35, Angiotensin-converting enzyme P12821,"/>
   <result pre="Serbia. Supplementary Materials The following are available online: Figure S1:" exact="Camazepam" post="in the Mpro catalytic site; Figure S2: Mezlocillin in"/>
   <result pre="Figure S6: Tolvaptan in the Mpro allosteric site; Figure S7:" exact="Rescinnamine" post="in the Mpro allosteric site; Figure S8: CS of"/>
   <result pre="the Mpro allosteric site; Figure S8: CS of Mpro, Gaba" exact="alpha" post="subunit 1 and Camazepam; Figure S9: CS of Mpro,"/>
   <result pre="pneumonia: Report of three casesJ. Infect. Chemother.202010.1016/j.jiac.2020.04.007 22.A Trial of" exact="Ciclesonide" post="Alone or in Combination with Hydroxychloroquine for Adults with"/>
   <result pre="Chemother.202010.1016/j.jiac.2020.04.007 22.A Trial of Ciclesonide Alone or in Combination with" exact="Hydroxychloroquine" post="for Adults with Mild COVID-19ClinicalTrials. gov Identifier: NCT0433058Available online:"/>
   <result pre="Inhibit COVID-19 Virus Main ProteaseChemRxiv202010.26434/chemrxiv.12061302.v1 25.VerbalisJ.G.AdlerS.SchrierR.W.BerlT.ZhaoQ.CzerwiecF.S.Efficacy and safety of oral" exact="tolvaptan" post="therapy in patients with the syndrome of inappropriate antidiuretic"/>
   <result pre="oral tolvaptan therapy in patients with the syndrome of inappropriate" exact="antidiuretic hormone" post="secretionEur. J. Endocrinol.201116472573210.1530/EJE-10-107821317283 26.YousafZ.Al-ShokriS.D.Al-soubH.MohamedM.F.COVID-19-associated SIADH: A clue in the"/>
   <result pre="virtual screening-based study of nutraceuticals predicts the therapeutic potentials of" exact="folic acid" post="and its derivatives against COVID-19Res. Sq.202010.21203/rs.3.rs-31775/v1 37.TsujiM.Potential anti-SARS-CoV-2 drug"/>
   <result pre="Drugbank ID F Binding Energy (kcal/mol) Mezlocillin DB00948 0.1923 âˆ’8.6" exact="Camazepam" post="DB01489 0.1923 âˆ’7.5 Spirapril DB01348 0.1923 âˆ’7.1 Bacampicillin DB01602"/>
   <result pre="0.3183 âˆ’6.6 Carbinoxamine DB00748 0.3183 âˆ’6.6 Paromomycin DB01421 0.1923 âˆ’6.5" exact="Nifedipine" post="DB01115 0.1923 âˆ’6.3 Gemfibrozil DB01241 0.1923 âˆ’5.9 Trimethaphan DB01116"/>
   <result pre="0.3183 âˆ’6.6 Paromomycin DB01421 0.1923 âˆ’6.5 Nifedipine DB01115 0.1923 âˆ’6.3" exact="Gemfibrozil" post="DB01241 0.1923 âˆ’5.9 Trimethaphan DB01116 0.1923 âˆ’5.6 Phensuximide DB00832"/>
   <result pre="0.1923 âˆ’5.6 Phensuximide DB00832 0.3183 âˆ’5.6 Nitrendipine DB01054 0.1923 âˆ’5.4" exact="Paliperidone" post="DB01267 0.1923 âˆ’5.4 Levetiracetam DB01202 0.1923 âˆ’5.2 Chlorambucil DB00291"/>
   <result pre="0.1923 âˆ’5.4 Paliperidone DB01267 0.1923 âˆ’5.4 Levetiracetam DB01202 0.1923 âˆ’5.2" exact="Chlorambucil" post="DB00291 0.1923 âˆ’5.2 Vitamin C DB00126 0.1923 âˆ’5.1 Tizanidine"/>
   <result pre="âˆ’5.2 Chlorambucil DB00291 0.1923 âˆ’5.2 Vitamin C DB00126 0.1923 âˆ’5.1" exact="Tizanidine" post="DB00697 0.1923 âˆ’5.0 Ifosfamide DB01181 0.1923 âˆ’4.9 Aminophenazone DB01424"/>
   <result pre="âˆ’5.2 Vitamin C DB00126 0.1923 âˆ’5.1 Tizanidine DB00697 0.1923 âˆ’5.0" exact="Ifosfamide" post="DB01181 0.1923 âˆ’4.9 Aminophenazone DB01424 0.1923 âˆ’4.6 Mecamylamine DB00657"/>
   <result pre="0.1923 âˆ’5.1 Tizanidine DB00697 0.1923 âˆ’5.0 Ifosfamide DB01181 0.1923 âˆ’4.9" exact="Aminophenazone" post="DB01424 0.1923 âˆ’4.6 Mecamylamine DB00657 0.1923 âˆ’4.3 Tazarotene DB00799"/>
   <result pre="0.1923 âˆ’4.9 Aminophenazone DB01424 0.1923 âˆ’4.6 Mecamylamine DB00657 0.1923 âˆ’4.3" exact="Tazarotene" post="DB00799 0.1923 âˆ’4.1 molecules-25-03830-t002_Table 2Table 2 Docking scores of"/>
   <result pre="0.1054 âˆ’7.9 Rolitetracycline DB01301 0.4414 âˆ’7.6 Tolvaptan DB06212 0.1054 âˆ’7.3" exact="Ciclesonide" post="DB01410 0.1054 âˆ’7.2 Rescinnamine DB01180 0.4414 âˆ’7.2 Spectinomycin DB00919"/>
   <result pre="0.4414 âˆ’7.6 Tolvaptan DB06212 0.1054 âˆ’7.3 Ciclesonide DB01410 0.1054 âˆ’7.2" exact="Rescinnamine" post="DB01180 0.4414 âˆ’7.2 Spectinomycin DB00919 0.1054 âˆ’6.8 Cefotiam DB00229"/>
   <result pre="0.1054 âˆ’7.3 Ciclesonide DB01410 0.1054 âˆ’7.2 Rescinnamine DB01180 0.4414 âˆ’7.2" exact="Spectinomycin" post="DB00919 0.1054 âˆ’6.8 Cefotiam DB00229 0.1054 âˆ’6.6 Azatadine DB00719"/>
   <result pre="0.4414 âˆ’7.2 Spectinomycin DB00919 0.1054 âˆ’6.8 Cefotiam DB00229 0.1054 âˆ’6.6" exact="Azatadine" post="DB00719 0.1054 âˆ’6.5 Flecainide DB01195 0.1054 âˆ’6.2 Pivmecillinam DB01605"/>
   <result pre="0.1054 âˆ’6.8 Cefotiam DB00229 0.1054 âˆ’6.6 Azatadine DB00719 0.1054 âˆ’6.5" exact="Flecainide" post="DB01195 0.1054 âˆ’6.2 Pivmecillinam DB01605 0.1054 âˆ’6.2 Voriconazole DB00582"/>
   <result pre="0.1054 âˆ’6.6 Azatadine DB00719 0.1054 âˆ’6.5 Flecainide DB01195 0.1054 âˆ’6.2" exact="Pivmecillinam" post="DB01605 0.1054 âˆ’6.2 Voriconazole DB00582 0.1054 âˆ’6.1 Ambenonium DB01122"/>
   <result pre="0.1054 âˆ’6.5 Flecainide DB01195 0.1054 âˆ’6.2 Pivmecillinam DB01605 0.1054 âˆ’6.2" exact="Voriconazole" post="DB00582 0.1054 âˆ’6.1 Ambenonium DB01122 0.1054 âˆ’5.9 Amitriptyline DB00321"/>
   <result pre="0.1054 âˆ’5.8 Miconazole DB01110 0.1054 âˆ’5.8 Clofedanol DB04837 0.1054 âˆ’5.7" exact="Flutamide" post="DB00499 0.1054 âˆ’5.7 Leflunomide DB01097 0.1054 âˆ’5.7 Tobramycin DB00684"/>
   <result pre="0.1054 âˆ’5.8 Clofedanol DB04837 0.1054 âˆ’5.7 Flutamide DB00499 0.1054 âˆ’5.7" exact="Leflunomide" post="DB01097 0.1054 âˆ’5.7 Tobramycin DB00684 0.1054 âˆ’5.7 Clevidipine DB04920"/>
   <result pre="0.1054 âˆ’5.7 Flutamide DB00499 0.1054 âˆ’5.7 Leflunomide DB01097 0.1054 âˆ’5.7" exact="Tobramycin" post="DB00684 0.1054 âˆ’5.7 Clevidipine DB04920 0.1054 âˆ’5.6 Imipramine DB00458"/>
   <result pre="0.1054 âˆ’5.6 Ciclopirox DB01188 0.1054 âˆ’5.5 Oseltamivir DB00198 0.1054 âˆ’5.5" exact="Ospemifene" post="DB04938 0.1054 âˆ’5.5 Trimipramine DB00726 0.1054 âˆ’5.5 Ebselen DB12610"/>
   <result pre="0.1054 âˆ’5.5 Ebselen DB12610 0.1054 âˆ’5.3 Bepridil DB01244 0.1054 âˆ’5.1" exact="Ethinamate" post="DB01031 0.1054 âˆ’4.9 Propylthiouracil DB00550 0.1054 âˆ’4.5 lâˆ’Arginine DB00125"/>
   <result pre="0.1054 âˆ’5.3 Bepridil DB01244 0.1054 âˆ’5.1 Ethinamate DB01031 0.1054 âˆ’4.9" exact="Propylthiouracil" post="DB00550 0.1054 âˆ’4.5 lâˆ’Arginine DB00125 0.1054 âˆ’4.4 Isoflurophate DB00677"/>
   <result pre="0.1054 âˆ’4.9 Propylthiouracil DB00550 0.1054 âˆ’4.5 lâˆ’Arginine DB00125 0.1054 âˆ’4.4" exact="Isoflurophate" post="DB00677 0.1054 âˆ’4.2 Ethanolamine Oleate DB06689 0.1054 âˆ’4.1 lâˆ’Carnitine"/>
   <result pre="0.1054 âˆ’4.5 lâˆ’Arginine DB00125 0.1054 âˆ’4.4 Isoflurophate DB00677 0.1054 âˆ’4.2" exact="Ethanolamine Oleate" post="DB06689 0.1054 âˆ’4.1 lâˆ’Carnitine DB00583 0.1054 âˆ’4.1 lâˆ’Lysine DB00123"/>
   <result pre="0.1054 âˆ’4.1 lâˆ’Carnitine DB00583 0.1054 âˆ’4.1 lâˆ’Lysine DB00123 0.1054 âˆ’4.0" exact="Methoxyflurane" post="DB01028 0.1054 âˆ’3.6 molecules-25-03830-t003_Table 3Table 3 Proteinâ€&quot;ligand interactions in"/>
   <result pre="3Table 3 Proteinâ€&quot;ligand interactions in the catalytic site. Residue Mezlocillin" exact="Camazepam" post="Spirapril THR27 X HIS41 X X X GLY143 X"/>
   <result pre="4 Proteinâ€&quot;ligand interactions in the allosteric domain. Raltegravir Rolitetracycline Tolvaptan" exact="Ciclesonide" post="Rescinnamine ARG4 X X LYS5 X X X X"/>
   <result pre="Proteinâ€&quot;ligand interactions in the allosteric domain. Raltegravir Rolitetracycline Tolvaptan Ciclesonide" exact="Rescinnamine" post="ARG4 X X LYS5 X X X X X"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7505219\results\search\drug\results.xml">
   <result pre="viral particles from affected cells and mitigate cell-to-cell infection, while" exact="amantadine" post="and rimantadine block the transport of Hâ€‰+â€‰ions through the"/>
   <result pre="from affected cells and mitigate cell-to-cell infection, while amantadine and" exact="rimantadine" post="block the transport of Hâ€‰+â€‰ions through the viral M2"/>
   <result pre="effective in managing and preventing seasonal influenza A. Among these," exact="amantadine" post="is recommended for adults only [78]. Oseltamivir (Tamiflu) is"/>
   <result pre="oseltamivir-treated children as compared to placebo [81]. U.S. FDA approved" exact="zanamivir" post="for use as a dry powder in children aged"/>
   <result pre="release of virions after budding from the host cell Approved" exact="Zanamivir" post="RelenzaÂ® Inhalation IAV and IBV Peramivir RapivabÂ® Intravenous IAV"/>
   <result pre="the host cell Approved Zanamivir RelenzaÂ® Inhalation IAV and IBV" exact="Peramivir" post="RapivabÂ® Intravenous IAV and IBV Amantadine Symmetrel Oral IAV"/>
   <result pre="Inhalation IAV and IBV Peramivir RapivabÂ® Intravenous IAV and IBV" exact="Amantadine" post="Symmetrel Oral IAV Inhibits viral replication by blocking M2"/>
   <result pre="not in use due to high resistance to IAV Remantadine" exact="Flumadine" post="Baloxavir marboxil XofluzaÂ® Oral IAV and IBV Inhibit the"/>
   <result pre="in use due to high resistance to IAV Remantadine Flumadine" exact="Baloxavir marboxil" post="XofluzaÂ® Oral IAV and IBV Inhibit the cap-dependent endonuclease"/>
   <result pre="of vaccinationPLoS ONE201498e10617710.1371/journal.pone.010617725162536 78.Alves GalvaoMGRocha Crispino SantosMAAlves da CunhaAJAmantadine and" exact="rimantadine" post="for influenza A in children and the elderlyCochrane Database"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7505229\results\search\drug\results.xml">
   <result pre="cord-19BioRxiv20203993 CortegianiAIngogliaGIppolitoMGiarratanoAEinavSA systematic review on the efficacy and safety of" exact="chloroquine" post="for the treatment of covid-19Journal of Critical Care202010.1016/j.jcrc.2020.03.005 DandekarAGhaiRMigration"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7505701\results\search\drug\results.xml">
   <result pre="Medicine1179-7282Dove pmcid: 7505701269936 doi: 10.2147/RRTM.S269936 : Review Off-Label Use of" exact="Chloroquine" post="and Hydroxychloroquine for COVID-19 Treatment in Africa Against WHO"/>
   <result pre="7505701269936 doi: 10.2147/RRTM.S269936 : Review Off-Label Use of Chloroquine and" exact="Hydroxychloroquine" post="for COVID-19 Treatment in Africa Against WHO Recommendation Belayneh"/>
   <result pre="their benefit, there is worldwide controversy to use anti-malarial drugs," exact="hydroxychloroquine" post="and chloroquine, for the treatment of COVID-19. FDA issued"/>
   <result pre="opposing WHO warnings. In addition to this, falsified and substandard" exact="chloroquine" post="products started to emerge in some African countries. The"/>
   <result pre="of falsified and substandard products in the continent. Keywords COVID-19" exact="chloroquine" post="hydroxychloroquine off-label Africa fig-count: table-count: ref-count: page-count: Introduction Chloroquine"/>
   <result pre="falsified and substandard products in the continent. Keywords COVID-19 chloroquine" exact="hydroxychloroquine" post="off-label Africa fig-count: table-count: ref-count: page-count: Introduction Chloroquine and"/>
   <result pre="COVID-19 chloroquine hydroxychloroquine off-label Africa fig-count: table-count: ref-count: page-count: Introduction" exact="Chloroquine" post="and Hydroxychloroquine Chloroquine and its derivative hydroxychloroquine are old"/>
   <result pre="hydroxychloroquine off-label Africa fig-count: table-count: ref-count: page-count: Introduction Chloroquine and" exact="Hydroxychloroquine" post="Chloroquine and its derivative hydroxychloroquine are old drugs used"/>
   <result pre="off-label Africa fig-count: table-count: ref-count: page-count: Introduction Chloroquine and Hydroxychloroquine" exact="Chloroquine" post="and its derivative hydroxychloroquine are old drugs used for"/>
   <result pre="ref-count: page-count: Introduction Chloroquine and Hydroxychloroquine Chloroquine and its derivative" exact="hydroxychloroquine" post="are old drugs used for the treatment of malaria"/>
   <result pre="inflammatory diseases, and even have potential chemosensitization and radiosensitization activities." exact="Chloroquine" post="was discovered in 1934 by a German scientist called"/>
   <result pre="may also interfere with the biosynthesis of parasitic nucleic acids." exact="Hydroxychloroquine" post="was first synthesized in 1945 by introducing a hydroxyl"/>
   <result pre="introducing a hydroxyl group into chloroquine. Animal studies showed that" exact="hydroxychloroquine" post="is much less (around 40%) toxic than chloroquine.2 Hydroxychloroquine"/>
   <result pre="that hydroxychloroquine is much less (around 40%) toxic than chloroquine.2" exact="Hydroxychloroquine" post="was approved for use in 1955 for the treatment"/>
   <result pre="and other several diseases including arthritis and systemic lupus erythematosus.3" exact="Chloroquine" post="is a white or slightly yellow, odorless, and crystalline"/>
   <result pre="N4-(7-chloro-4-quinolinyl)-N1-N1-diethyl-1,4-pentanediamine as shown in Figure 1. The chemical structure of" exact="hydroxychloroquine" post="is drawn by introducing a hydroxyl group into chloroquine"/>
   <result pre="of hydroxychloroquine is drawn by introducing a hydroxyl group into" exact="chloroquine" post="as shown in Figure 2. Figure 1 The chemical"/>
   <result pre="structure of chloroquine. Figure 2 The chemical structure of hydroxychloroquine." exact="Chloroquine" post="and hydroxychloroquine have serious adverse events. They potentially cause"/>
   <result pre="chloroquine. Figure 2 The chemical structure of hydroxychloroquine. Chloroquine and" exact="hydroxychloroquine" post="have serious adverse events. They potentially cause heart rhythm"/>
   <result pre="of the problems related to these drugs. The overdose of" exact="chloroquine" post="and hydroxychloroquine are highly toxic and can cause seizures,"/>
   <result pre="problems related to these drugs. The overdose of chloroquine and" exact="hydroxychloroquine" post="are highly toxic and can cause seizures, coma, and"/>
   <result pre="highly toxic and can cause seizures, coma, and cardiac arrest.4" exact="Chloroquine" post="and hydroxychloroquine, alone or in combination with azithromycin, have"/>
   <result pre="azithromycin, have been highly advertised as possible therapies for COVID-19.5" exact="Chloroquine" post="phosphate stood out among possible personalized pharmacological therapies for"/>
   <result pre="COVIDâ€�19 patients with promising clinical outcomes after being treated with" exact="chloroquine" post="have recommended its possible use as an appropriate pharmacological"/>
   <result pre="evidence of their benefit, the globe continues the utilization of" exact="hydroxychloroquine" post="or chloroquine, often together with a second-generation macrolide for"/>
   <result pre="studies and a preliminary clinical report suggested the efficacy of" exact="chloroquine" post="for COVID-19-associated pneumonia, there is increasing interest in this"/>
   <result pre="with COVID-19 found that the employment of a regimen containing" exact="hydroxychloroquine" post="or chloroquine (with or without a macrolide) was related"/>
   <result pre="found that the employment of a regimen containing hydroxychloroquine or" exact="chloroquine" post="(with or without a macrolide) was related to no"/>
   <result pre="clinical trials is required before conclusively determining the role of" exact="chloroquine" post="and hydroxychloroquine in the treatment of COVID-19.13 The United"/>
   <result pre="is required before conclusively determining the role of chloroquine and" exact="hydroxychloroquine" post="in the treatment of COVID-19.13 The United States Food"/>
   <result pre="academic centers that are investigating the utilization of the drug" exact="chloroquine" post="to see whether it is accustomed to treating patients"/>
   <result pre="researches are continuing to work out the efficacy of using" exact="chloroquine" post="to treat COVID-19.14 Although large-scale clinical and basic researches"/>
   <result pre="plan, the FDA issued an emergency use authorization to use" exact="chloroquine" post="or hydroxychloroquine for the treatment of COVID-19. According to"/>
   <result pre="FDA issued an emergency use authorization to use chloroquine or" exact="hydroxychloroquine" post="for the treatment of COVID-19. According to the FDA,"/>
   <result pre="practice to use these drugs to COVID-19. FDA also allowed" exact="hydroxychloroquine" post="sulfate and chloroquine phosphate products to be distributed and"/>
   <result pre="these drugs to COVID-19. FDA also allowed hydroxychloroquine sulfate and" exact="chloroquine" post="phosphate products to be distributed and used for hospitalized"/>
   <result pre="France.12,17 President Donald Trump has been also tweeting consistently that" exact="hydroxychloroquine" post="and the antibiotic azithromycin could be one of the"/>
   <result pre="has been also tweeting consistently that hydroxychloroquine and the antibiotic" exact="azithromycin" post="could be one of the biggest game-changers in the"/>
   <result pre="of medicine. The president has said he has been taking" exact="hydroxychloroquine" post="to protect against the virus.18 The European Medicines Agency"/>
   <result pre="Medicines Agency (EMA) has warned against the widespread use of" exact="hydroxychloroquine" post="or chloroquine to treat COVID-19. The EMA noted that"/>
   <result pre="(EMA) has warned against the widespread use of hydroxychloroquine or" exact="chloroquine" post="to treat COVID-19. The EMA noted that there are"/>
   <result pre="The agency stressed that patients and healthcare professionals only use" exact="chloroquine" post="and hydroxychloroquine for their authorized use or as part"/>
   <result pre="stressed that patients and healthcare professionals only use chloroquine and" exact="hydroxychloroquine" post="for their authorized use or as part of clinical"/>
   <result pre="and hypoglycemia.19 The first randomized controlled clinical trial that tested" exact="chloroquine" post="and hydroxychloroquine in Brazil, Spain, and Mozambique also concluded"/>
   <result pre="The first randomized controlled clinical trial that tested chloroquine and" exact="hydroxychloroquine" post="in Brazil, Spain, and Mozambique also concluded that these"/>
   <result pre="clinical trial was prematurely halted as the higher dosage of" exact="chloroquine" post="diphosphate for 10 days was associated with more toxic"/>
   <result pre="toxic effects and lethality. The study recommended that the higher" exact="chloroquine" post="dosage should not be suggested for critically ill patients"/>
   <result pre="of its potential safety hazards, especially when taken concomitantly with" exact="azithromycin" post="and oseltamivir.21 After all, the World Health Organization (WHO)"/>
   <result pre="Health Organization (WHO) temporarily stopped any clinical trials that use" exact="chloroquine" post="and hydroxychloroquine to treat COVID-19 patients after the shocking"/>
   <result pre="(WHO) temporarily stopped any clinical trials that use chloroquine and" exact="hydroxychloroquine" post="to treat COVID-19 patients after the shocking result of"/>
   <result pre="drugs have much more harm than good as patients getting" exact="hydroxychloroquine" post="were dying at higher rates than other coronavirus infected"/>
   <result pre="the clinical trials, as well as the clinical use of" exact="hydroxychloroquine" post="or chloroquine with or without macrolide, are halted internationally"/>
   <result pre="trials, as well as the clinical use of hydroxychloroquine or" exact="chloroquine" post="with or without macrolide, are halted internationally as they"/>
   <result pre="international organizations recommend to do not use these drugs, both" exact="hydroxychloroquine" post="and chloroquine with or without macrolide are frequently used"/>
   <result pre="recommend to do not use these drugs, both hydroxychloroquine and" exact="chloroquine" post="with or without macrolide are frequently used in several"/>
   <result pre="African States (ECOWAS) has officially approved for the use of" exact="chloroquine" post="to treat coronavirus infected patients.22 This improper use of"/>
   <result pre="the study was to review the off-label use practice of" exact="chloroquine" post="and hydroxychloroquine for the treatment and prevention of COVID-19"/>
   <result pre="was to review the off-label use practice of chloroquine and" exact="hydroxychloroquine" post="for the treatment and prevention of COVID-19 in African"/>
   <result pre="without limitations, which focused on the off-label use practice of" exact="chloroquine" post="and hydroxychloroquine for the treatment of COVID-19 in African"/>
   <result pre="which focused on the off-label use practice of chloroquine and" exact="hydroxychloroquine" post="for the treatment of COVID-19 in African countries against"/>
   <result pre="reports that do not contain information about the use of" exact="chloroquine" post="and hydroxychloroquine to treat or prevent COVID-19 were excluded."/>
   <result pre="do not contain information about the use of chloroquine and" exact="hydroxychloroquine" post="to treat or prevent COVID-19 were excluded. Studies that"/>
   <result pre="COVID-19 were excluded. Studies that evaluated the prophylactic effects of" exact="chloroquine" post="or hydroxychloroquine were also excluded. Also, studies that are"/>
   <result pre="excluded. Studies that evaluated the prophylactic effects of chloroquine or" exact="hydroxychloroquine" post="were also excluded. Also, studies that are published in"/>
   <result pre="from the study. Search Strategy Data on the use of" exact="chloroquine" post="and hydroxychloroquine for the treatment and prevention of COVID-19"/>
   <result pre="study. Search Strategy Data on the use of chloroquine and" exact="hydroxychloroquine" post="for the treatment and prevention of COVID-19 disease in"/>
   <result pre="for COVID-19. The commonly used old antimalarial drugs, chloroquine, and" exact="hydroxychloroquine" post="have become the attention of global scientific media and"/>
   <result pre="officials, mainly by Trump, lead to the widespread use of" exact="chloroquine" post="and hydroxychloroquine for COVID-19, mainly for African peoples. It"/>
   <result pre="by Trump, lead to the widespread use of chloroquine and" exact="hydroxychloroquine" post="for COVID-19, mainly for African peoples. It leads to"/>
   <result pre="these drugs on the continent. For instance, Nigeria records several" exact="chloroquine" post="poisonings cases after using it for COVID-19 treatment. As"/>
   <result pre="hospital due to these drugs.29 The worldwide controversial reports that" exact="chloroquine" post="and hydroxychloroquine may be effective against COVID-19 have received"/>
   <result pre="to these drugs.29 The worldwide controversial reports that chloroquine and" exact="hydroxychloroquine" post="may be effective against COVID-19 have received great attention,"/>
   <result pre="poor health system. For instance, five different types of falsified" exact="chloroquine" post="tablets were discovered between March 31, 2020, and April"/>
   <result pre="Broadcasting Corporation (SABC) reported that Kenya approved the use of" exact="chloroquine" post="to treat critical cases of patients with coronavirus. However,"/>
   <result pre="Kenyan Health Director-General. He, however, said that the sale of" exact="hydroxychloroquine" post="and chloroquine over the counter at pharmacies is not"/>
   <result pre="Director-General. He, however, said that the sale of hydroxychloroquine and" exact="chloroquine" post="over the counter at pharmacies is not allowed. The"/>
   <result pre="Board has also banned over the counter sale of both" exact="hydroxychloroquine" post="and chloroquine in pharmacies. On the contrary to this,"/>
   <result pre="also banned over the counter sale of both hydroxychloroquine and" exact="chloroquine" post="in pharmacies. On the contrary to this, Kenyan medical"/>
   <result pre="rate. The government approved to treat all COVID-19 patients with" exact="chloroquine" post="by ignoring WHO caution. Ahmed Zouiten, the WHO representative"/>
   <result pre="of the patients did not experience any breathing problems after" exact="chloroquine" post="treatment. He noted that chloroquine acts positively on COVID-19"/>
   <result pre="experience any breathing problems after chloroquine treatment. He noted that" exact="chloroquine" post="acts positively on COVID-19 treatment.33 The Global Times report"/>
   <result pre="recommendations.34 Uganda recorded good results by treating COVID-19 patients with" exact="hydroxychloroquine" post="or chloroquine. The Uganda Ministry of Health told The"/>
   <result pre="told The Independent that they got good results by using" exact="hydroxychloroquine" post="and chloroquine in managing COVID-19 patients even though the"/>
   <result pre="Independent that they got good results by using hydroxychloroquine and" exact="chloroquine" post="in managing COVID-19 patients even though the drugs did"/>
   <result pre="has used either of the two drugs in combination with" exact="azithromycin" post="to manage COVID-19 patients at Entebbe General Hospital. Until"/>
   <result pre="treated by these drugs are fully recovered. In addition to" exact="chloroquine" post="and hydroxychloroquine, the patients have been given Vitamin C."/>
   <result pre="as well as deaths. Like many African countries, Egypt uses" exact="chloroquine" post="in treating COVID-19 patients. As Egypt Today report by"/>
   <result pre="countries, Egypt uses chloroquine in treating COVID-19 patients. As Egypt" exact="Today" post="report by mentioning the Egyptian Minister of Health, Hala"/>
   <result pre="Zayed, the Health Ministry spokesman, Khaled Megahed, told to Egypt" exact="Today" post="that the country denies producing chloroquine to treat COVID-19"/>
   <result pre="Megahed, told to Egypt Today that the country denies producing" exact="chloroquine" post="to treat COVID-19 patients. He denied the news that"/>
   <result pre="a pharmaceutical company in the Egyptian capital, Cairo, started producing" exact="chloroquine" post="phosphate medication primarily used to treat malaria patients. He"/>
   <result pre="US President Donald Trump, many clinical trials declared that both" exact="chloroquine" post="and hydroxychloroquine are not yet confirmed to be effective"/>
   <result pre="Donald Trump, many clinical trials declared that both chloroquine and" exact="hydroxychloroquine" post="are not yet confirmed to be effective for the"/>
   <result pre="Medical Appliances (ACDIMA) aims to produce around 200,000 doses of" exact="chloroquine" post="by last May.37 According to the AFP report, Algeria"/>
   <result pre="said that they have treated thousands of cases with this" exact="hydroxychloroquine" post="very successfully in Algeria. He also said that they"/>
   <result pre="Benbouzid, also said that Algeria had great success in using" exact="hydroxychloroquine" post="in combination with azithromycin. He also noted that there"/>
   <result pre="treatment is very effective.24 Morocco also continues the use of" exact="chloroquine" post="for COVID-19 treatment despite the controversy and warnings raised"/>
   <result pre="raised by the WHO. They were treating Covid-19 patients with" exact="chloroquine" post="since April 8 and appear to have no intention"/>
   <result pre="its use. He was explaining and defending the effectiveness of" exact="chloroquine" post="by involving viral inactivation. According to his statement, the"/>
   <result pre="involving viral inactivation. According to his statement, the use of" exact="chloroquine" post="provides good results and everyone can see it from"/>
   <result pre="recorded in Morocco have recovered from the virus after following" exact="chloroquine" post="treatment. According to Ait Tayeb, this treatment can reduce"/>
   <result pre="Moroccan Health authorities also started safeguarding a satisfactory stock of" exact="chloroquine" post="by purchasing from an international pharmaceutical company just two"/>
   <result pre="the country. In addition to this, the Health Ministry initiated" exact="chloroquine" post="therapy along with complementary medicine to enhance efficacy.38 Another"/>
   <result pre="manufacturing its hydroxychloroquine. However, Tunisia declared that the treatment with" exact="hydroxychloroquine" post="has been stopped in all the countryâ€™s hospitals following"/>
   <result pre="of West African States (ECOWAS) has approved the use of" exact="chloroquine" post="to treat coronavirus patients. ECOWAS supports the supplementary anti-viral"/>
   <result pre="patients. ECOWAS supports the supplementary anti-viral treatment of coronavirus with" exact="hydroxychloroquine" post="should be for mild forms of the virus. Meanwhile,"/>
   <result pre="treating COVID-19 patients. He told journalists in Accra that the" exact="chloroquine" post="tests at Ridge Hospital are still positive and the"/>
   <result pre="also reported that the government of Ghana decided to use" exact="hydroxychloroquine" post="for COVID-19 case management. However, Ghanaâ€™s COVID-19 case management"/>
   <result pre="in the country after WHO halting the clinical trials of" exact="hydroxychloroquine" post="as a possible treatment for coronavirus. The Director-General of"/>
   <result pre="case management team of Ghana has decided to stop using" exact="hydroxychloroquine" post="for the treatment of COVID-19.40 The Ghana News Agency"/>
   <result pre="of COVID-19.40 The Ghana News Agency reported that Ghana denies" exact="chloroquine" post="phosphate to cure coronavirus. The Director-General said that there"/>
   <result pre="The Director-General said that there is no strong evidence that" exact="chloroquine" post="phosphate 250 mg is an effective treatment of COVID-19."/>
   <result pre="use and abuse of drugs such as chloroquine, hydroxychloroquine, and" exact="azithromycin" post="in the treatment of Covid-19. According to GMA, these"/>
   <result pre="Drug Administration and Control (NAFDAC) said that they believe in" exact="hydroxychloroquine" post="and they will continue clinical trials of this drug"/>
   <result pre="they are confused by the data of WHO reports to" exact="chloroquine" post="whether it has from the Caucasian population or the"/>
   <result pre="However, the NAFDAC has warned Nigerians against taking self-medication of" exact="chloroquine" post="for treatment for coronavirus (COVID-19). Nobody should buy chloroquine"/>
   <result pre="of chloroquine for treatment for coronavirus (COVID-19). Nobody should buy" exact="chloroquine" post="and use it. Taking of chloroquine requires guidance and"/>
   <result pre="(COVID-19). Nobody should buy chloroquine and use it. Taking of" exact="chloroquine" post="requires guidance and supervision to protect patients from damage"/>
   <result pre="Centre for Disease Control (NCDC) warning to do not use" exact="chloroquine" post="and hydroxychloroquine for the treatment as well as for"/>
   <result pre="Disease Control (NCDC) warning to do not use chloroquine and" exact="hydroxychloroquine" post="for the treatment as well as for the prevention"/>
   <result pre="of coronavirus disease. The director noted that the use of" exact="chloroquine" post="and hydroxychloroquine for the management of COVID-19 disease has"/>
   <result pre="disease. The director noted that the use of chloroquine and" exact="hydroxychloroquine" post="for the management of COVID-19 disease has not been"/>
   <result pre="a pharmacy near his home in Lagos, the price of" exact="chloroquine" post="rises by more than 400% in a matter of"/>
   <result pre="that the Senegal government also continues treating COVID-19 patients with" exact="hydroxychloroquine" post="despite the ineffective and potentially harmful results of the"/>
   <result pre="Emergency Operations, Abdoulaye Bousso, told the AFP that the countryâ€™s" exact="hydroxychloroquine" post="treatment program would nonetheless continue, without offering further details"/>
   <result pre="of WHO. Seydi, the Senegalese infectious-diseases doctor, also believed that" exact="hydroxychloroquine" post="can be taken only after offered consent to patients"/>
   <result pre="told the Jakarta Post that Senegal is continuing to administer" exact="hydroxychloroquine" post="to COVID-19 patients. The official said that the results"/>
   <result pre="patients, said there is hopeful evidence that people treated with" exact="hydroxychloroquine" post="recovered faster. He told AFP that about 50% of"/>
   <result pre="and that he and his team are trying by combining" exact="hydroxychloroquine" post="with azithromycin to achieve better results.47 Off-Label Use of"/>
   <result pre="he and his team are trying by combining hydroxychloroquine with" exact="azithromycin" post="to achieve better results.47 Off-Label Use of Chloroquine/Hydroxychloroquine in"/>
   <result pre="results.47 Off-Label Use of Chloroquine/Hydroxychloroquine in Central Africa In Cameroon," exact="chloroquine" post="therapy for COVID-19 patients becomes the state protocol after"/>
   <result pre="the French expert, Professor Didier Raoultâ€™s recommendation. A mixture of" exact="chloroquine" post="(an antimalarial) combined with azithromycin (an antibiotic) to avoid"/>
   <result pre="Raoultâ€™s recommendation. A mixture of chloroquine (an antimalarial) combined with" exact="azithromycin" post="(an antibiotic) to avoid the risks of secondary infections"/>
   <result pre="and Cameroonâ€™s Ministry of Health proposed the widespread use of" exact="chloroquine" post="treatment. Although scientists lack conclusive data for their clinical"/>
   <result pre="wished to combine the treatment, as recommended by Raoult, with" exact="azithromycin" post="to avoid the risks of secondary infections. As the"/>
   <result pre="choice of dual therapy represents a logistical challenge in Cameroon." exact="Chloroquine" post="was massively used in the country at one time"/>
   <result pre="Tchuente, said that the government has ordered the production of" exact="chloroquine" post="to treat COVID-19 patients and they are started producing"/>
   <result pre="ordered them to produce at least eight million tablets of" exact="chloroquine" post="each day as the situation is getting worse. The"/>
   <result pre="in Cameroon is rising with the Covid-19 crisis. Several fake" exact="chloroquine" post="products are circulated within the Cameroon health network.49 Off-Label"/>
   <result pre="(SAHPRA) has warned health professionals to stop prescribing the medication" exact="chloroquine" post="to prevent infection or to treat the disease, COVID-19"/>
   <result pre="of the country released a new guideline that allows using" exact="chloroquine" post="only in hospitalized patients with severe COVID-19 and for"/>
   <result pre="for consented clinical trials. This new guideline also noted that" exact="chloroquine" post="should be distributed to all hospitals at affordable prices.50"/>
   <result pre="prices.50 The Katharine Child report to CNN also showed that" exact="chloroquine" post="is made available and affordable for every corner of"/>
   <result pre="still does not know enough to back the antimalarial drug" exact="chloroquine" post="into widespread use against the new coronavirus. A local"/>
   <result pre="medical regulator of the country to import half a million" exact="chloroquine" post="phosphate tablets for use in severely ill Covid-19 patients."/>
   <result pre="minister of Mozambique is also considering the possibility of using" exact="chloroquine" post="to treat severe cases of coronavirus disease. The National"/>
   <result pre="African press agency (APA) that the country allowed to use" exact="chloroquine" post="for severely affected patients and the experiment of the"/>
   <result pre="consented clinical trial. She told that the worldwide trends of" exact="chloroquine" post="use showed excellent results.52 Covid-19 complicates the tracing and"/>
   <result pre="the country. Like other African countries, anti-malarial drugs, chloroquine, and" exact="hydroxychloroquine" post="are being used to treat Covid-19 in Zimbabwe. However,"/>
   <result pre="However, Zimbabweâ€™s doctors advised their population to do not use" exact="chloroquine" post="as there is insufficient data on their use for"/>
   <result pre="the drugs can be life-threatening.53,54 Generally, many African countries use" exact="chloroquine" post="in an off-label manner for the treatment as well"/>
   <result pre="shown in Table 1. Table 1 African Countries Who Use" exact="Chloroquine" post="or Hydroxychloroquine in an Off-Label Manner for the Treatment"/>
   <result pre="Table 1. Table 1 African Countries Who Use Chloroquine or" exact="Hydroxychloroquine" post="in an Off-Label Manner for the Treatment and Prevention"/>
   <result pre="and Recommendations According to this review, many African countries use" exact="chloroquine" post="and hydroxychloroquine as both a preventive measure and for"/>
   <result pre="According to this review, many African countries use chloroquine and" exact="hydroxychloroquine" post="as both a preventive measure and for treating patients"/>
   <result pre="and toxicity findings of several clinical trials. Falsified and substandard" exact="chloroquine" post="and hydroxychloroquine drugs are started to emerge in some"/>
   <result pre="findings of several clinical trials. Falsified and substandard chloroquine and" exact="hydroxychloroquine" post="drugs are started to emerge in some African countries"/>
   <result pre="professionals are recommended to closely monitor patients with COVID-19 receiving" exact="chloroquine" post="or hydroxychloroquine and to consider patients with pre-existing heart"/>
   <result pre="recommended to closely monitor patients with COVID-19 receiving chloroquine or" exact="hydroxychloroquine" post="and to consider patients with pre-existing heart problems that"/>
   <result pre="Atlas, Statistical Atlas, et al. Animal toxicity and pharmacokinetics of" exact="hydroxychloroquine" post="sulfate. J Am Vet Med Assoc. 2020;256(12):1317â€&quot;1320.32459591 3.TanenbaumL, TuffanelliDL."/>
   <result pre="Dermatol. 1980;116(5):587â€&quot;591. doi:10.1001/archderm.1980.016402900970266990871 4.JuurlinkDN. Safety considerations with chloroquine, hydroxychloroquine, and" exact="azithromycin" post="in the management of SARS-CoV-2 infection. CMAJ. 2020;192(17):450â€&quot;453. doi:10.1503/cmaj.200528"/>
   <result pre="et al. Potential negative effects of the free use of" exact="chloroquine" post="to manage COVIDâ€�19 in Colombia. J Med Virol. 2020."/>
   <result pre="MisraDP, NegiVS. A systematic review of the prophylactic role of" exact="chloroquine" post="and hydroxychloroquine in coronavirus diseaseâ€�19 (COVIDâ€�19). Int J Rheum"/>
   <result pre="A systematic review of the prophylactic role of chloroquine and" exact="hydroxychloroquine" post="in coronavirus diseaseâ€�19 (COVIDâ€�19). Int J Rheum Dis. 2020;23(5):613â€&quot;619."/>
   <result pre="Infect Dis. 2020;7(4):105. doi:10.1093/ofid/ofaa105 10.SmitC, PeetersMY, van den AnkerJN, KnibbeCA." exact="Chloroquine" post="for SARS-CoV-2: implications of its unique pharmacokinetic and safety"/>
   <result pre="and safety properties. Clin Pharmacokinet. 2020;18:1. 11.MehraMR, DesaiSS, RuschitzkaF, PatelAN." exact="Hydroxychloroquine" post="or chloroquine with or without a macrolide for treatment"/>
   <result pre="properties. Clin Pharmacokinet. 2020;18:1. 11.MehraMR, DesaiSS, RuschitzkaF, PatelAN. Hydroxychloroquine or" exact="chloroquine" post="with or without a macrolide for treatment of COVID-19:"/>
   <result pre="SenS. An updated systematic review of the therapeutic role of" exact="hydroxychloroquine" post="in Coronavirus Disease-19 (COVID-19). Clin Drug Investig. 2020;28:1. 14.collab:"/>
   <result pre="Development of Treatments.2020. 15.collab: American Medical Association. FDA warns against" exact="chloroquine" post="for COVID-19 outside hospitals.2020Available fromhttps://www.ama-assn.org/delivering-care/public-health/fda-warns-against-chloroquine-covid-19-outside-hospitals. Accessed 819, 2020. 16.MahaseE."/>
   <result pre="outside hospitals.2020Available fromhttps://www.ama-assn.org/delivering-care/public-health/fda-warns-against-chloroquine-covid-19-outside-hospitals. Accessed 819, 2020. 16.MahaseE. Covid-19: WHO halts" exact="hydroxychloroquine" post="trial to review links with increased mortality risk. BMJ."/>
   <result pre="2020. 17.collab: The European Medicines Agency. COVID19: no Approval for" exact="Chloroquine" post="from EMA. 2020Available from:https://healthmanagement.org/c/hospital/news/covid-19-no-approval-for-chloroquine-from-ema. Accessed 819, 2020. 18.EricS. Unlike"/>
   <result pre="819, 2020. 18.EricS. Unlike FDA, European regulators refuse to clear" exact="chloroquine" post="for COVID-19 without data. 2020Available fromhttps://www.fiercepharma.com/pharma/europe-locks-down-chloroquine-scripts-as-researchers-china-report-positive-controlled-covid. Accessed 819, 2020."/>
   <result pre="Accessed 819, 2020. 19.HannahB. EMA warns about side effects of" exact="chloroquine" post="and hydroxychloroquine for COVID-19 treatment.2020Available fromhttps://www.europeanpharmaceuticalreview.com/news/117760/ema-warns-about-side-effects-of-chloroquine-and-hydroxychloroquine-for-covid-19-treatment/. Accessed 819, 2020."/>
   <result pre="2020. 19.HannahB. EMA warns about side effects of chloroquine and" exact="hydroxychloroquine" post="for COVID-19 treatment.2020Available fromhttps://www.europeanpharmaceuticalreview.com/news/117760/ema-warns-about-side-effects-of-chloroquine-and-hydroxychloroquine-for-covid-19-treatment/. Accessed 819, 2020. 20.EktorpE. Death"/>
   <result pre="Accessed 819, 2020. 20.EktorpE. Death threats after a trial on" exact="chloroquine" post="for COVID-19. Lancet Infect Dis. 2020;20(6):661. doi:10.1016/S1473-3099(20)30383-232473139 21.collab: Africa"/>
   <result pre="Accessed 819, 2020. 22.IsaacK. Ghana, Kenya approve the use of" exact="Chloroquine" post="to treat COVID-19 patients. Taylor and Francis group. 2020Available"/>
   <result pre="2020Available from:https://africafeeds.com/2020/04/01/ghana-kenya-approve-use-of-chloroquine-to-treat-covid-19-patients/. Accessed 819, 2020. 23.AbenaPM, DecloedtEH, BottieauE, et al." exact="Hydroxychloroquine" post="for the prevention or treatment of COVID-19 in Africa:"/>
   <result pre="Africanews. 2020Available fromhttps://www.africanews.com/2020/05/01/fiveafricancountries-with-ongoing-coronavirus-trials//. Accessed 819, 2020. 29.StephanieB, BukolaA. Nigeria records" exact="chloroquine" post="poisoning after Trump endorses it for coronavirus treatment. CNN."/>
   <result pre="819, 2020. 30.GnegelG, HaukC, NeciR, et al. Identification of falsified" exact="chloroquine" post="tablets in Africa at the Time of the COVID-19"/>
   <result pre="J Trop Med Hyg. 2020;103(1):73â€&quot;76. doi:10.4269/ajtmh.20-036332400349 31.ChinyanjaN, ZochitikaMKenya to use" exact="chloroquine" post="on critical cases of coronavirus. BBC. 2020Available fromhttp://www.channelafrica.co.za/sabc/home/channelafrica/news/details?id=fa515c2f-d19a-4779-8675 ff9af2771001&amp;amp;title=Kenya%20to%20use%20chloroquine%20on%20critical%20cases%20of%20coronavirus.."/>
   <result pre="VOA. 2020Available fromhttps://www.voanews.com/covid-19-pandemic/djibouti-treating-all-covid-patients-chloroquine-scientists-urge-caution. Accessed 819, 2020. 33.NiiNDjibouti, others warned about" exact="chloroquine" post="despite big COVID-19 recoveries. VOA. 2020Available fromhttps://face2faceafrica.com/article/djibouti-others-warned-about-chloroquine-despite-big-covid-19-recoveries. Accessed 819,"/>
   <result pre="chloroquine. The Independent. 2020Available fromhttps://www.independent.co.ug/uganda-records-good-results-treating-COVID-with-hydroxychloroquine-chloroquine/. Accessed 819, 2020. 36.MohhamadDEgypt uses" exact="chloroquine" post="in treating COVID-19 patients: minister. Egypt Today. 2020Available fromhttps://www.egypttoday.com/Article/1/83104/Egypt-uses-chloroquine-in-treating-COVID-19-patients-Minister."/>
   <result pre="Egypt Today. 2020Available fromhttps://www.egypttoday.com/Article/1/83104/Egypt-uses-chloroquine-in-treating-COVID-19-patients-Minister. Accessed 819, 2020. 37.AlexB. Egypt uses" exact="chloroquine" post="in treating COVID-19 patients: minister. Egypt Today. 2020Available fromhttps://www.egypttoday.com/Article/1/84462/Health-Ministry-denies-producing-chloroquine-to-treat-COVID-19-patients."/>
   <result pre="fromhttps://www.egypttoday.com/Article/1/84462/Health-Ministry-denies-producing-chloroquine-to-treat-COVID-19-patients. Accessed 819, 2020. 38.MussaK. Morocco continues the use of" exact="Chloroquine" post="despite controversy. The North Africa Post. 2020Available fromhttps://northafricapost.com/41247-morocco-continues-use-of-chloroquine-despite-controversy.html. Accessed"/>
   <result pre="Accessed 819, 2020. 39.BrianW. Covid-19: algeria and Morocco continue using" exact="chloroquine" post="despite concerns. al-bab.com. 2020Available fromhttps://al-bab.com/blog/2020/05/covid-19-algeria-and-morocco-continue-using-chloroquine-despite-concerns. Accessed 819, 2020. 40.JonathanD."/>
   <result pre="Accessed 819, 2020. 40.JonathanD. Ghana: govt to decide on hydroxy" exact="chloroquine" post="for COVID-19 case management. all African news. 2020Available fromhttps://allafrica.com/stories/202005270578.html."/>
   <result pre="African news. 2020Available fromhttps://allafrica.com/stories/202005270578.html. Accessed 819, 2020. 41.AlfonsonL. Ghana denies" exact="Chloroquine" post="Phosphate can cure coronavirus. African Press Agency. 2020Available fromhttp://apanews.net/en/news/ghana-denies-chloroquine-phosphate-can-cure-coronavirus."/>
   <result pre="2020Available fromhttps://www.myjoyonline.com/news/health/ghana-medical-association-cautions-against-use-of-chloroquine-others-in-the-treatment-of-COVIDâ€&quot;19/. Accessed 819, 2020. 43.FelixT. Nigeria goes on with" exact="hydroxychloroquine" post="clinical trials. Anadolu Agency. 2020Available fromhttps://www.aa.com.tr/en/africa/nigeria-goes-on-withhydroxychloroquine-clinical-trials/1854814. Accessed 819, 2020."/>
   <result pre="819, 2020. 45.ChikeO. NCDC warns Nigerians against the use of" exact="chloroquine" post="for COVID-19. Nairametrics. 2020Available fromhttps://nairametrics.com/2020/03/26/ncdc-warns-nigerians-against-use-of-chloroquine-for-covidâ€&quot;19. Accessed 819, 2020. 46.DangonT.Senegal"/>
   <result pre="with hydroxychloroquine. Africanews. 2020Available fromhttps://www.africanews.com/2020/05/28/senegal-to-continue-treating-COVID-19-patients-with-hydroxychloroquine//. Accessed 819, 2020. 47.ZohraB.Senegal says" exact="hydroxychloroquine" post="virus treatment is promising. AFP. 2020Available fromhttps://www.thejakartapost.com/life/2020/04/02/senegal-sayshydroxychloroquine-virus-treatment-is-promising-.html. Accessed 819,"/>
   <result pre="promising. AFP. 2020Available fromhttps://www.thejakartapost.com/life/2020/04/02/senegal-sayshydroxychloroquine-virus-treatment-is-promising-.html. Accessed 819, 2020. 48.DavidR.Covid-19: in Cameroon," exact="chloroquine" post="therapy hailed by French experts becomes state protocol. AFP."/>
   <result pre="protocol. AFP. 2020Available fromhttps://www.france24.com/en/20200503-covid-19-in-cameroon-a-chloroquine-therapy-hailed-by-french-expert-becomes-state-protocol. Accessed 819, 2020. 49.MokiEK.Cameroon begins large-scale" exact="chloroquine" post="production. VOA. 2020Available fromhttps://www.voanews.com/science-health/coronavirus-outbreak/cameroon-begins-large-scale-chloroquine-production. Accessed 819, 2020. 50.AishaAK.Doctors warned"/>
   <result pre="2020Available fromhttps://bhekisisa.org/health-news-south-africa/2020-04-01-doctors-warned-against-prescribing-unproven-medication-for-covidâ€&quot;19/. Accessed 819, 2020. 51.KatharineC.EXCLUSIVE: SA to roll out" exact="chloroquine" post="to tackle coronavirus. South African Broadcasting Corporation.2020Available fromhttps://www.businesslive.co.za/fm/features/2020-03-27-sa-to-roll-out-chloroquine-to-tackle-coronavirus/. Accessed"/>
   <result pre="South African Broadcasting Corporation.2020Available fromhttps://www.businesslive.co.za/fm/features/2020-03-27-sa-to-roll-out-chloroquine-to-tackle-coronavirus/. Accessed 819, 2020. 52.WakandoG.Mozambique: considering" exact="chloroquine" post="to tackle COVID-19. APA. Available fromhttp://apanews.net/en/news/covid-19-mozambique-to-experiment-chloroquine-against-severe-cases. Accessed 819, 2020."/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7505804\results\search\drug\results.xml">
   <result pre="-2.26 60536 6.94 60536 6.94 60536 6.94 12 46720 53292" exact="14.07" post="56175 20.24 56175 20.24 56175 20.24 13 36717 43582"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7505852\results\search\drug\results.xml">
   <result pre="employed as antibacterial or antifungal agents, e.g. spectinomycin, rifamycin, kanamycin," exact="daptomycin" post="and tetracycline from Streptomyces species (ProcÃ³pio et al., 2012),"/>
   <result pre="antibacterial or antifungal agents, e.g. spectinomycin, rifamycin, kanamycin, daptomycin and" exact="tetracycline" post="from Streptomyces species (ProcÃ³pio et al., 2012), polymyxins from"/>
   <result pre="use include Ï‰-conotoxin (from the marine snail Conus magus) and" exact="ecteinascidin 743" post="(from the tunicate Ecteinascidia turbinata). The former is used"/>
   <result pre="free radicals (Li et al., 2016), decreases the role of" exact="nitric oxide" post="(Tsai et al., 1999), inhibits STAT3, (Baek et al.,"/>
   <result pre="it could be related to the upregulation of the inducible" exact="nitrous oxide" post="synthase and, as a consequence, to the increased production"/>
   <result pre="synthase and, as a consequence, to the increased production of" exact="nitrous oxide" post="that is proposed to be an inhibitor of SARS-CoV"/>
   <result pre="cytopathogenic effects in infected Vero E6 cell (EC50 values for" exact="reserpine" post="and aescin were 6Â Î¼M and 3.4Â Î¼M, respectively)."/>
   <result pre="addition to the conventional standard therapy (including antipyretics or lopinavir/ritonavir," exact="azithromycin" post="and hydroxychloroquine). As for the tannin extracts, another ongoing"/>
   <result pre="8, 2020 exploiting a medical spray containing curcumin (20Â mg/ml)," exact="artemisinin" post="(6Â mg/ml), frankincense (15Â mg/ml) -and vitamin C (60Â"/>
   <result pre="curcumin (20Â mg/ml), artemisinin (6Â mg/ml), frankincense (15Â mg/ml) -and" exact="vitamin C" post="(60Â mg/ml) in micellar formulation against SARS-CoV2 infections (Table"/>
   <result pre="resulted to be all from plants, with the exception of" exact="framycetin" post="and sinefungin from Streptomyces. All compounds were classified to"/>
   <result pre="reviewEvidence-based Complementary and Alternative Medicine: ECAM20162016758495210.1155/2016/758495227200104 NorooziM.AngersonW.J.LeanM.E.Effects of flavonoids and" exact="vitamin C" post="on oxidative DNA damage to human lymphocytesAmerican Journal of"/>
   <result pre="guanine-N7-methyltransferaseAntiviral Research104201415616410.1016/j.antiviral.2014.02.00224530452 TorresM.C.M.Braz-FilhoR.SilveiraE.R.DinizJ.C.VianaF.A.PessoaO.D.L.Terpenoids from Croton regelianusHelvetica Chimica Acta932201037538110.1002/hlca.200900201 TsaiS.H.Lin-ShiauS.Y.LinJ.K.Suppression of" exact="nitric oxide" post="synthase and the down-regulation of the activation of NFkappaB"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7506176\results\search\drug\results.xml">
   <result pre="compared to cold alone. Indeed, under these conditions, viral particles" exact="dried" post="in the air, survive for a long time in"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7506363\results\search\drug\results.xml">
   <result pre="Hum Behav4202066666932576981 12GlasziouP.P.SandersS.HoffmannT.Waste in COVID-19 researchBMJ3692020m184732398241 13MehraM.R.RuschitzkaF.Patel AN&amp;gt; Retractionâ€&quot;hydroxychloroquine or" exact="chloroquine" post="with or without a macrolide for treatment of COVID-19:"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7508045\results\search\drug\results.xml">
   <result pre="protected from SARS-CoV-2 during treatment. Another study reported that some" exact="artemisinin" post="derivatives used alone (dihydroartemisinin and artesunate) showed inÂ vitro"/>
   <result pre="amodiaquine, a quinoleine antimalarial and one of the partners of" exact="artemisinin" post="derivative, was found to be active inÂ vitro at"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7508070\results\search\drug\results.xml">
   <result pre="preventive measure for the individual as well as the community." exact="Chloroquine" post="and hydroxychloroquine are the only drugs currently recommended for"/>
   <result pre="for the individual as well as the community. Chloroquine and" exact="hydroxychloroquine" post="are the only drugs currently recommended for the prophylaxis"/>
   <result pre="In a small study on patients with COVID-19 infection, oral" exact="chloroquine" post="was found effective in reducing the systemic viral load."/>
   <result pre="was found effective in reducing the systemic viral load. 0.03%" exact="chloroquine" post="eye drops have been used for the treatment of"/>
   <result pre="intracellular hypochlorous acid levelsSci Rep201881363030206371 7TitiyalJSKaurMFaleraRBharghavaASahRSenSEfficacy and safety of topical" exact="chloroquine" post="in mild to moderate dry eye diseaseCurr Eye Res2019441130612"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7509820\results\search\drug\results.xml">
   <result pre="with high risk factors for severe illness patients. Lopinavir/ritonavir and" exact="ribavirin" post="alone are not recommended for COVID-19 patients. Lopinavir and"/>
   <result pre="ribavirin alone are not recommended for COVID-19 patients. Lopinavir and" exact="ritonavir" post="Lopinavir and ritonavir is widely used as a boosted"/>
   <result pre="not recommended for COVID-19 patients. Lopinavir and ritonavir Lopinavir and" exact="ritonavir" post="is widely used as a boosted protease inhibitor in"/>
   <result pre="inhibitor in the treatment of HIV infection [50]. Lopinavir and" exact="ritonavir" post="can block the enzymes that required for virus replication."/>
   <result pre="that required for virus replication. Lopinavir is often combined with" exact="ritonavir" post="to extend the half-life of lopinavir by the inhibition"/>
   <result pre="is often combined with ritonavir to extend the half-life of" exact="lopinavir" post="by the inhibition of cytochrome P450 [51]. A study"/>
   <result pre="P450 [51]. A study had found that the Lopinavir and" exact="ritonavir" post="combined with ribavirin in the treatment of SARS was"/>
   <result pre="study had found that the Lopinavir and ritonavir combined with" exact="ribavirin" post="in the treatment of SARS was associated with better"/>
   <result pre="better effect [52]. And animal studies show that Lopinavir and" exact="Ritonavir" post="can reduce levels of coronavirus that cause SARS and"/>
   <result pre="signal, the test has limitations and still needs follow-up discussion." exact="Chloroquine" post="and Hydroxychloroquine Chloroquine, a widely used antimalarial and autoimmune"/>
   <result pre="test has limitations and still needs follow-up discussion. Chloroquine and" exact="Hydroxychloroquine" post="Chloroquine, a widely used antimalarial and autoimmune disease drug,"/>
   <result pre="reported may be a potential broad-spectrum antiviral drug [57, 58]." exact="Chloroquine" post="blocks viral infection by increasing endosomal pH required for"/>
   <result pre="SARS-CoV cellular receptor [59]. A study showed that remdesivir and" exact="chloroquine" post="are highly effective in the control of COVID-19 infection"/>
   <result pre="of COVID-19 infection in vitro [60]. Therefore, the efficacy of" exact="Chloroquine" post="needs to be clarified and applied to patients as"/>
   <result pre="be clarified and applied to patients as soon as possible." exact="Hydroxychloroquine" post="is a derivative of chloroquine. The two structures are"/>
   <result pre="and cough remission time of patients were significantly shortened in" exact="hydroxychloroquine" post="group. The proportion of patients with improved pneumonia was"/>
   <result pre="was higher than that of the control group (54.8%) [61]." exact="Hydroxychloroquine" post="can significantly shorten the clinical recovery time of patients"/>
   <result pre="with new coronavirus and promote the improvement of pneumonia. However," exact="hydroxychloroquine" post="or combined azithromycin is not recommended for COVID-19 patients"/>
   <result pre="and promote the improvement of pneumonia. However, hydroxychloroquine or combined" exact="azithromycin" post="is not recommended for COVID-19 patients base on Chinaâ€™s"/>
   <result pre="the antiviral effects of chloroquineLancet Infect Dis200662676910.1016/S1473-3099(06)70361-916439323 58.YanYet al.Anti-malaria drug" exact="chloroquine" post="is highly effective in treating avian influenza a H5N1"/>
   <result pre="of SARS coronavirus infection and spreadVirol J200526910.1186/1743-422X-2-6916115318 60.WangMet al.Remdesivir and" exact="chloroquine" post="effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in"/>
   <result pre="emerged novel coronavirus (2019-nCoV) in vitroCell Res202030326932020029 61.ChenZet al.Efficacy of" exact="hydroxychloroquine" post="in patients with COVID-19: results of a randomized clinical"/>
   <result pre="after lung cancer surgeryJAMA Oncol20173561061910.1001/jamaoncol.2016.582928056112 80.ZhongW-Zet al.Gefitinib versus vinorelbine plus" exact="cisplatin" post="as adjuvant treatment for stage II-IIIA (N1-N2) EGFR-mutant NSCLC"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7510719\results\search\drug\results.xml">
   <result pre="of NNRTI resistance mutations, reducing susceptibility to the first-generation drugs" exact="nevirapine" post="and efavirenz (13). Transmission network analyses revealed that K103N"/>
   <result pre="resistance mutations, reducing susceptibility to the first-generation drugs nevirapine and" exact="efavirenz" post="(13). Transmission network analyses revealed that K103N was the"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7511040\results\search\drug\results.xml">
   <result pre="other QT-prolonging drugs or those with prolonged QT at baseline.11" exact="Azithromycin" post="(a weak CYP3A4-inhibiting drug) is a macrolide antibiotic that"/>
   <result pre="needs special attention with proper ECG surveillance.12 The effect of" exact="azithromycin" post="on cardiac repolarization is especially enhanced when used in"/>
   <result pre="with virus-receptor binding and shows potential effectiveness as anti-viral therapy." exact="Chloroquine" post="is well known for its modest effect on prolonging"/>
   <result pre="by the human Ether-Ã -go-go-Related Gene) potassium channel blocking capabilities." exact="Chloroquine" post="may also increase the concentration of beta-blockers that are"/>
   <result pre="reason, heart rate and blood pressure should be monitored carefully.13,14" exact="Hydroxychloroquine" post="sulfate, a derivative of chloroquine, is known to be"/>
   <result pre="used experimentally in the treatment of COVID-19 in combination with" exact="azithromycin" post="and antiviral agents.15 Chloroquine and hydroxychloroquine are metabolised by"/>
   <result pre="treatment of COVID-19 in combination with azithromycin and antiviral agents.15" exact="Chloroquine" post="and hydroxychloroquine are metabolised by CYP3A4, and beside the"/>
   <result pre="COVID-19 in combination with azithromycin and antiviral agents.15 Chloroquine and" exact="hydroxychloroquine" post="are metabolised by CYP3A4, and beside the arrhythmic risks,"/>
   <result pre="meta-analysis showed that although there was no significant benefit of" exact="hydroxychloroquine" post="on viral clearance, a significant increase in mortality was"/>
   <result pre="arrest occurred more likely in patients receiving a combination of" exact="hydroxychloroquine" post="and azithromycin (adjusted OR, 2.13 [95% CI, 1.12-4.05]), while"/>
   <result pre="more likely in patients receiving a combination of hydroxychloroquine and" exact="azithromycin" post="(adjusted OR, 2.13 [95% CI, 1.12-4.05]), while the risk"/>
   <result pre="2.13 [95% CI, 1.12-4.05]), while the risk was lower when" exact="hydroxychloroquine" post="or azithromycin were used alone.21 How to accurately measure"/>
   <result pre="CI, 1.12-4.05]), while the risk was lower when hydroxychloroquine or" exact="azithromycin" post="were used alone.21 How to accurately measure the QT"/>
   <result pre="al.Vitro Antiviral Activity and Projection of Optimized Dosing Design of" exact="Hydroxychloroquine" post="for the Treatment of Severe Acute Respiratory Syndrome Coronavirus"/>
   <result pre="2020424. doi: 10.1111/bjh.16749. 11KALETRA(R) oral film coated tablets, oral solution," exact="lopinavir" post="ritonavir oral film coated tablets, oral solution.Product Insert. AbbVie"/>
   <result pre="doi: 10.1111/bjh.16749. 11KALETRA(R) oral film coated tablets, oral solution, lopinavir" exact="ritonavir" post="oral film coated tablets, oral solution.Product Insert. AbbVie Inc."/>
   <result pre="toxicity: an analysis of electrocardiograms in 85 patients treated with" exact="hydroxychloroquine" post="for connective tissue diseases.Rheumatology (Oxford)2007;46:808-810.17202178 16PageRL2nd, O'BryantCL, ChengD, DowTJ,"/>
   <result pre="of Patients With Coronavirus Disease 2019 (COVID-19) Infection Treated With" exact="Hydroxychloroquine" post="Alone or in Combination With Azithromycin in an Intensive"/>
   <result pre="(COVID-19) Infection Treated With Hydroxychloroquine Alone or in Combination With" exact="Azithromycin" post="in an Intensive Care Unit.JAMA Cardiol . Published online501,"/>
   <result pre="et al.Risk of QT Interval Prolongation Associated With Use of" exact="Hydroxychloroquine" post="With or Without Concomitant Azithromycin Among Hospitalized Patients Testing"/>
   <result pre="Prolongation Associated With Use of Hydroxychloroquine With or Without Concomitant" exact="Azithromycin" post="Among Hospitalized Patients Testing Positive for Coronavirus Disease 2019"/>
   <result pre="DufortEM, UdoT, WilberschiedLA, KumarJ, TesorieroJ, et al.Association of Treatment With" exact="Hydroxychloroquine" post="or Azithromycin With In-Hospital Mortality in Patients With COVID-19"/>
   <result pre="WilberschiedLA, KumarJ, TesorieroJ, et al.Association of Treatment With Hydroxychloroquine or" exact="Azithromycin" post="With In-Hospital Mortality in Patients With COVID-19 in New"/>
   <result pre="electrocardiograms.Heart1920;7:353-70. 29GautretP, LagierJC, ParolaP, HoangVT, MeddebL, MailheM, et al.Hydroxychloroquine and" exact="azithromycin" post="as a treatment of COVID-19: results of an open-label"/>
   <result pre="prolongation in coronavirus disease 2019 (COVID-19) patients treated with either" exact="chloroquine" post="or hydroxychloroquine in conjunction with azithromycin: Possible benefits of"/>
   <result pre="coronavirus disease 2019 (COVID-19) patients treated with either chloroquine or" exact="hydroxychloroquine" post="in conjunction with azithromycin: Possible benefits of intravenous lidocaine.HeartRhythm"/>
   <result pre="2020, ISSN 2214-0271, 10.1016/j.hrcr.2020.03.016. 42KimY, KimSY, LeeJS, KongHJ, HanDW.Effect of" exact="dexmedetomidine" post="on the corrected QT and Tp-e intervals during spinal"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7512176\results\search\drug\results.xml">
   <result pre="was extracted with magnetized silica from HIV-infected plasma lysed with" exact="guanidine" post="thiocyanate and with ethanol washes and elution steps performed"/>
   <result pre="silica from HIV-infected plasma lysed with guanidine thiocyanate and with" exact="ethanol" post="washes and elution steps performed using the NUCLISENS easyMAG"/>
   <result pre="Bio) with the following protocol specifications. Total RNA was first" exact="denatured" post="at 72Â°C with the addition of tagged random hexamers"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7513902\results\search\drug\results.xml">
   <result pre="mRNA expression [23]. Compounds such as iridoid glycosides and phenylethyl" exact="alcohol" post="glycosides are the basis for inhibiting the expression of"/>
   <result pre="resist oxidative stress, and regulate immunity [46]. Xingnaojing combined with" exact="azithromycin" post="can reduce the levels of serum inflammation indexes of"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7517057\results\search\drug\results.xml">
   <result pre="US, and in 1997, the susceptibility of Staphylococcus aureus to" exact="vancomycin" post="decreased in both the US and Japan [99]. In"/>
   <result pre="immunity is due to low levels of vitamin D and" exact="melatonin" post="and to staying indoors frequently during winter, increasing opportunities"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7517806\results\search\drug\results.xml">
   <result pre="the worldâ€™s largest opium-producing areas and an entry route for" exact="heroin" post="and methamphetamine [7]. This mountainous region is home to"/>
   <result pre="â€œhill tribesâ€�, ethnic minorities living in isolated villages. Use of" exact="heroin" post="and opium is more prevalent than in other Thai"/>
   <result pre="practices Table 3 shows that the main drugs used were" exact="heroin" post="(79%), methamphetamine (45%)â€‰and sedatives, such as midazolam and other"/>
   <result pre="drugs used were heroin (79%), methamphetamine (45%)â€‰and sedatives, such as" exact="midazolam" post="and other sleeping pills (31%). Methadone was used by"/>
   <result pre="evidence from respondent-driven sampling surveys in Bangkok and Chiang MaiDrug" exact="Alcohol" post="Depend2015148412613510.1016/j.drugalcdep.2014.12.03425640153 9.HaganHPougetERDes JarlaisDCLelutiu-WeinbergerCMeta-regression of hepatitis c virus infection in"/>
   <result pre="of illicit substances in Thailand: results from national household surveysDrug" exact="Alcohol" post="Rev20183721610.1111/dar.12689 25.JittiwutikarnJet al.Hepatitis C infection among drug users in"/>
   <result pre="and syringe borrowing among injection drug users in Bangkok, ThailandDrug" exact="Alcohol" post="Rev201029215716110.1111/j.1465-3362.2009.00093.x20447223 39.VoonPet al.High prevalence of syringe lending among HIV-positive"/>
   <result pre="male injection drug users in rural areas of southern ThailandDrug" exact="Alcohol" post="Rev201534664565310.1111/dar.1226825867927 45.VanichseniSTapperoJWPitisuttithumPKitayapornDMastroTDVimutisunthornERecruitment, screening and characteristics of injection drug users"/>
   <result pre="estimate the number of injection drug users in Bangkok, ThailandDrug" exact="Alcohol" post="Depend2007902â€&quot;322823310.1016/j.drugalcdep.2007.03.01317507180 49.SydorAConducting research into hidden or hard-to-reach populationsNurs Res2013203333710.7748/nr2013.01.20.3.33.c9495"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7518803\results\search\drug\results.xml">
   <result pre="myocardium and improve cardiac function: Co-enzyme Q, Vitamin C, sodium" exact="creatine" post="phosphate COVID-19 patient with arrhythmia Electrocardiogram abnormal, clinic symptoms"/>
   <result pre="granulocyte colony-stimulating factor (GCSF), IP10, MCP1, macrophage inflammatory protein 1" exact="alpha" post="(MIP1Î±), and TNF-Î± were significantly elevated in ICU patients,"/>
   <result pre="Coronavirus Disease 2019 (Tentative seventh version) recommends the use of" exact="lopinavir" post="and/or ritonavir, both of which are protease inhibitors and"/>
   <result pre="with statins or for patients with coronary heart disease [41]." exact="Chloroquine" post="can cause cardiac arrhythmias and even cardiac arrest, the"/>
   <result pre="arrest, the most serious adverse reaction [42]. For COVID-19 patients," exact="azithromycin" post="and hydroxychloroquine can increase the risk of different arrhythmias,"/>
   <result pre="most serious adverse reaction [42]. For COVID-19 patients, azithromycin and" exact="hydroxychloroquine" post="can increase the risk of different arrhythmias, such as"/>
   <result pre="failure rate when used in combination with drugs such as" exact="azithromycin" post="and quinolones [44]. Interferons may affect the cardiac conduction"/>
   <result pre="version) recommends the use of antiviral drugs, including Î±-IFN, lopinavir/ritonavir," exact="ribavirin" post="(combined with one of the above medications), chloroquine and"/>
   <result pre="Î±-IFN, lopinavir/ritonavir, ribavirin (combined with one of the above medications)," exact="chloroquine" post="and Arbidol [46]. Beyond that, many medications have been"/>
   <result pre="antiviral therapy combination of interferon beta-1b (IFN Î²-1b), lopinavir/ritonavir, and" exact="ribavirin" post="may help patients with mild to moderate COVID-19 recover"/>
   <result pre="binding site or changing its configuration may be potential approaches." exact="Chloroquine" post="inhibits viral infection by increasing the pH of the"/>
   <result pre="fusion and interfering with glycosylation at the ACE2 terminal [54]." exact="Chloroquine" post="phosphate has been proven to effectively inhibit SARS-CoV-2 in"/>
   <result pre="quickly reduced Ang II levels [58], while the administration of" exact="captopril" post="reduced IFN-Î³, prostaglandin E2 (PGE2), and TGF-Î²1 levels and"/>
   <result pre="II levels [58], while the administration of captopril reduced IFN-Î³," exact="prostaglandin E2" post="(PGE2), and TGF-Î²1 levels and increased interleukin 4 (IL-4)"/>
   <result pre="respiratory syndromeChinese J Cardiol312003727730 41WangpatharawanitP.SungkanuparphS.Switching lopinavir/ritonavir to atazanavir/ritonavir vs adding" exact="atorvastatin" post="in HIV-infected patients receiving second-line antiretroviral therapy with hypercholesterolemia:"/>
   <result pre="Dermatol.11619805875916990871 43ChorinE.DaiM.ShulmanE.WadhwaniL.Bar-CohenR.BarbhaiyaC.The QT interval in patients with COVID-19 treated with" exact="hydroxychloroquine" post="and azithromycinNat. Med.222020808809 44ZJ.The treatment and explanation of novel"/>
   <result pre="Chan, et al, Triple combination of interferon beta-1b, lopinavirâ€&quot;ritonavir, and" exact="ribavirin" post="in the treatment of patients admitted to hospital with"/>
   <result pre="the recognition of the 2019-nCoV by human ACE2bioRxiv5812020221224 54WangM.CaoR.ZhangL.YangX.LiuJ.XuM.Remdesivir and" exact="chloroquine" post="effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in"/>
   <result pre="the recently emerged novel coronavirus (2019-nCoV) in vitroCell Res.30202026927132020029 55GaoJ.TianZ.YangX.Breakthrough:" exact="chloroquine" post="phosphate has shown apparent efficacy in treatment of COVID-19"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7520644\results\search\drug\results.xml">
   <result pre="lungs. Macrophages secrete interleukin (IL)-1, IL-6, and tumor necrosis factor" exact="alpha" post="(TNFÎ±), which cause vasodilatation and high temperature and enhance"/>
   <result pre="patients with a severe course of the disease, significantly high" exact="alanine" post="aminotransferase and aspartate aminotransferase were observed, as well as"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7524442\results\search\drug\results.xml">
   <result pre="nivolumab [12], obinutuzumab [13], brentuximab [14]. Anticancer non-protein-based treatment with" exact="oxaliplatin" post="[15] and IMiDs (lenalidomide) [16] can activate cytokine storm"/>
   <result pre="Placebo-controlled Multi-center Study to Assess the Efficacy and Safety of" exact="Ruxolitinib" post="in Patients With COVID-19 Associated Cytokine Storm (RUXCOVID) (RUXCOVID)"/>
   <result pre="(RUXCOVID) (RUXCOVID) R NCT04362137 Multicentric (62 centers) worldwide Phase 3" exact="Ruxolitinib" post="for the Treatment of Acute Respiratory Distress Syndrome in"/>
   <result pre="NCT04361903 Pisa, Italy Treatment of SARS Caused by COVID-19 With" exact="Ruxolitinib" post="R NCT04334044 Huixquilucan, Mexico Phase 1/2 Baricitinib in Symptomatic"/>
   <result pre="Signals C NCT01752348 Aarhus C, Denmark Prevention and Treatment With" exact="Calcifediol" post="of COVID-19 Induced Acute Respiratory Syndrome (COVIDIOL) IP NCT04366908"/>
   <result pre="function of existing TH17 cells. Treatment with the JAK1/2 inhibitor" exact="ruxolitinib" post="signiï¬�cantly reduced the symptoms of disease and prolonged survival"/>
   <result pre="of disease and prolonged survival time in experimental murine model." exact="Ruxolitinib" post="diminished pro-inflammatory cytokine production, mitigating the cytokine-driven hyperinflammation that"/>
   <result pre="experimental work supports the integration of JAK inhibitors such as" exact="ruxolitinib" post="into clinical trials as a novel strategy to counteract"/>
   <result pre="August 2020) focusing on treatment COVID-19 associated cytokine storm with" exact="ruxolitinib" post="as monotherapy (NCT04362137, NCT04361903, NCT04334044 - see Table 1)."/>
   <result pre="us to use them in the treatment of cytokine storm." exact="N-acetylcysteine" post="(NAC) serves as a prodrug to L-cysteine and L-cysteine"/>
   <result pre="was published by Han et al. [48]. Sodium cromoglycate or" exact="ketotifen" post="generally used to treat allergic diseases, significantly inhibit degranulation"/>
   <result pre="Other experimental study evaluated mast cell degranulation after cromoglycate and" exact="ketotifen" post="in rat liver resulting in decreased levels IL-6 and"/>
   <result pre="highly pathogenic H5N1 influenza A virusBiochem Pharmacol.793201041342010.1016/j.bcp.2009.08.025(2010)19732754 45JangY.Y.SongJ.H.ShinY.K.HanE.S.LeeC.S.Depressant effects of" exact="ambroxol" post="and erdosteine on cytokine synthesis, granule enzyme release, and"/>
   <result pre="macrophages activated by lipopolysaccharidePharmacol Toxicol.924200317317910.1034/j.16000773.2003.920407.x12753420 46DemiralayR.GÃ¼rsanN.ErdemH.The effects of erdosteine and" exact="N-acetylcysteine" post="on apoptotic and antiapoptotic markers in pulmonary epithelial cells"/>
   <result pre="of mast cell degranulation, oxidative stress, proinflammatory cytokine, and inducible" exact="nitric oxide" post="synthaseDrug Des Devel Ther.16920155237524610.2147/DDDT.S88337 50GelerisJ.SunY.PlattJ.ZuckerJ.BaldwinM.Observational Study of Hydroxychloroquine in"/>
   <result pre="inducible nitric oxide synthaseDrug Des Devel Ther.16920155237524610.2147/DDDT.S88337 50GelerisJ.SunY.PlattJ.ZuckerJ.BaldwinM.Observational Study of" exact="Hydroxychloroquine" post="in Hospitalized Patients with Covid-19N Engl J Med.7202010.1056/NEJMoa2012410NEJMoa2012410 51HeG.LiQ.LiW.RuanY.XiongX.Effect"/>
   <result pre="Pharmacol.685201247950310.1007/s00228-011-1161-x22105373 53CecrdlovaE.PetrickovaK.KolesarL.PetricekM.SekerkovaA.Manumycin A downregulates release of proinflammatory cytokines from TNF" exact="alpha" post="stimulated human monocytesImmunol Lett.169201681410.1016/j.imlet.2015.11.01026602157 54DarwishI.MubarekaS.LilesW.C.Immunomodulatory therapy for severe influenzaExpert"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7525249\results\search\drug\results.xml">
   <result pre="the efficacy and safety of various treatments for COVID-19 [36]." exact="Chloroquine" post="phosphate Chloroquine phosphate is an old drug used to"/>
   <result pre="and safety of various treatments for COVID-19 [36]. Chloroquine phosphate" exact="Chloroquine" post="phosphate is an old drug used to treat malaria,"/>
   <result pre="and adequate safety in the treatment of COVID-19-related pneumonia [37]." exact="Chloroquine" post="phosphate was also used against the SARS-CoV and Zika"/>
   <result pre="virus epidemics as an important controlling agent. The role of" exact="chloroquine" post="is to increase the pH of intracellular vacuoles and"/>
   <result pre="thus having an anti-rheumatic response [38]. Other studies reported that" exact="chloroquine" post="has potential activity against various viruses by deceleration of"/>
   <result pre="interfering with cellular SARS-CoV receptor glycosylation [39]. The activity of" exact="chloroquine" post="against viruses and as an anti-inflammatory agent might be"/>
   <result pre="treat individuals with COVID-19 pneumonia. Over the last 70 years," exact="chloroquine" post="has been found to be a cost-effective and safe"/>
   <result pre="be a cost-effective and safe drug [37] and in China," exact="chloroquine" post="phosphate at a dose of 500 mg/day in numerous"/>
   <result pre="shown potential activity against COVID-19. Hence, it is postulated that" exact="chloroquine" post="could be used as a possible treatment for individuals"/>
   <result pre="as a possible treatment for individuals with COVID-19-related pneumonia [40]." exact="Hydroxychloroquine" post="Hydroxychloroquine, an aminoquinoline, is less toxic; with the N-diethyl"/>
   <result pre="an aminoquinoline, is less toxic; with the N-diethyl chain of" exact="chloroquine" post="substituted by an N-hydroxyethyl side chain. This alteration in"/>
   <result pre="side chain. This alteration in the side chain makes the" exact="hydroxychloroquine" post="more soluble than chloroquine. The antiviral activity of hydroxychloroquine"/>
   <result pre="the hydroxychloroquine more soluble than chloroquine. The antiviral activity of" exact="hydroxychloroquine" post="is similar to that of chloroquine; by increasing the"/>
   <result pre="similar to that of chloroquine; by increasing the pH the" exact="hydroxychloroquine" post="affects the activated immune cells and Toll-like receptor-mediated signal"/>
   <result pre="and reducing the production of interleukin-6 (IL-6) [41]. Even though" exact="hydroxychloroquine" post="and chloroquine have the same antimalarial action, hydroxychloroquine is"/>
   <result pre="the production of interleukin-6 (IL-6) [41]. Even though hydroxychloroquine and" exact="chloroquine" post="have the same antimalarial action, hydroxychloroquine is preferred over"/>
   <result pre="Even though hydroxychloroquine and chloroquine have the same antimalarial action," exact="hydroxychloroquine" post="is preferred over chloroquine for its low ocular toxicity"/>
   <result pre="chloroquine have the same antimalarial action, hydroxychloroquine is preferred over" exact="chloroquine" post="for its low ocular toxicity [42]. Prolonged treatment (at"/>
   <result pre="ocular toxicity [42]. Prolonged treatment (at least 5 years) with" exact="hydroxychloroquine" post="may cause retinopathy, which is a dose-limiting adverse effect"/>
   <result pre="body weight [40]. Although in their activity against coronaviruses both" exact="chloroquine" post="and hydroxychloroquine have the same theoretical application, the anti-coronaviral"/>
   <result pre="[40]. Although in their activity against coronaviruses both chloroquine and" exact="hydroxychloroquine" post="have the same theoretical application, the anti-coronaviral activity of"/>
   <result pre="hydroxychloroquine have the same theoretical application, the anti-coronaviral activity of" exact="chloroquine" post="is supported by more clinical data [43]. Availability of"/>
   <result pre="chloroquine is supported by more clinical data [43]. Availability of" exact="hydroxychloroquine" post="and chloroquine is low in some countries, and chloroquine"/>
   <result pre="supported by more clinical data [43]. Availability of hydroxychloroquine and" exact="chloroquine" post="is low in some countries, and chloroquine has a"/>
   <result pre="of hydroxychloroquine and chloroquine is low in some countries, and" exact="chloroquine" post="has a more adverse effect than hydroxychloroquine. For instance,"/>
   <result pre="adverse effect than hydroxychloroquine. For instance, in individuals with COVID-19," exact="chloroquine" post="leads to prolongation of the QT interval when interacting"/>
   <result pre="crucial when unable to treat COVID-19 patients, to consider using" exact="hydroxychloroquine" post="instead of chloroquine. In Iran, it was necessary to"/>
   <result pre="instead of chloroquine. In Iran, it was necessary to use" exact="hydroxychloroquine" post="instead of chloroquine due to scarcity. Hydroxychloroquine hindrance by"/>
   <result pre="In Iran, it was necessary to use hydroxychloroquine instead of" exact="chloroquine" post="due to scarcity. Hydroxychloroquine hindrance by other antiviral agents,"/>
   <result pre="necessary to use hydroxychloroquine instead of chloroquine due to scarcity." exact="Hydroxychloroquine" post="hindrance by other antiviral agents, such as oseltamivir, lopinavir/ritonavir,"/>
   <result pre="etÂ al. conducted a comprehensive meta-analysis on the use of" exact="chloroquine" post="derivatives in COVID-19 patients. It was observed that the"/>
   <result pre="COVID-19 patients. It was observed that the combined therapy of" exact="hydroxychloroquine" post="with azithromycin was more effective than hydroxychloroquine alone and"/>
   <result pre="It was observed that the combined therapy of hydroxychloroquine with" exact="azithromycin" post="was more effective than hydroxychloroquine alone and the combined"/>
   <result pre="combined therapy of hydroxychloroquine with azithromycin was more effective than" exact="hydroxychloroquine" post="alone and the combined therapy was considered more important"/>
   <result pre="therapy [45]. Despite controversy as the virus spreads across borders," exact="chloroquine" post="derivatives are used by physicians on a large scale"/>
   <result pre="The novel pro-drug remdesivir, a nucleotide analogue intracellularly activated to" exact="adenosine" post="triphosphate analogue, which hinders the viral RNA polymerase, was"/>
   <result pre="to treat COVID-19, and further research is needed. Lopinavir and" exact="ritonavir" post="Lopinavir are protease inhibitors that are usually used to"/>
   <result pre="virus infection with and a booster drug ritonavir. Lopinavir and/or" exact="ritonavir" post="have inÂ vitro anti-coronaviral activity; they inhibit the proteases,"/>
   <result pre="polyprotein processing in coronaviruses. InÂ vitro studies have reported that" exact="lopinavir" post="can inhibit SARS-CoV, and the EC50 of lopinavir is"/>
   <result pre="reported that lopinavir can inhibit SARS-CoV, and the EC50 of" exact="lopinavir" post="is acceptable. Against SARS-CoV-2, lopinavir showed efficacy in Vero"/>
   <result pre="SARS-CoV, and the EC50 of lopinavir is acceptable. Against SARS-CoV-2," exact="lopinavir" post="showed efficacy in Vero E6 cells, with an estimated"/>
   <result pre="[56]. In Singapore, five individuals with COVID-19 were treated with" exact="lopinavir" post="and ritonavir within 1â€&quot;3 days of duration, but evidence"/>
   <result pre="Singapore, five individuals with COVID-19 were treated with lopinavir and" exact="ritonavir" post="within 1â€&quot;3 days of duration, but evidence of clinical"/>
   <result pre="integrase protein) and human immunodeficiency virus 1. This confirms that" exact="ivermectin" post="is responsible for inhibiting the nuclear import of integrase"/>
   <result pre="protein and human immunodeficiency virus type-1 replication. Other effects of" exact="ivermectin" post="have been reported, other than the inhibition of the"/>
   <result pre="pseudorabies virus-infected mice [66]. An inÂ vitro study reported that" exact="ivermectin" post="was found to be an inhibitor of SARS-CoV-2. A"/>
   <result pre="and available in most countries [74]. According to new studies," exact="dexamethasone" post="was the first agent to be proven to cause"/>
   <result pre="on various drugs that may help against COVID-19 found that" exact="dexamethasone" post="improves the survival of patients with COVID-19 who are"/>
   <result pre="history, and must consult the official recommendations of WHO for" exact="dexamethasone" post="clinical use, because from time to time drugs are"/>
   <result pre="are approved. It was also explained in the study that" exact="dexamethasone" post="does not help those who are mildly infected with"/>
   <result pre="synthesis Remdesivir PubChem CID:121304016 Image 1 Intravenous COVID-19 A prodrug," exact="adenosine" post="nucleotide analogue, which acts as an RdRp inhibitor 1.76"/>
   <result pre="HIV Inhibition of protease 26.62 Î¼M Yes Viral entry inhibitors" exact="Hydroxychloroquine" post="PubChem CID:3652 Image 4 Orally Antimalarial Increase the endosomal"/>
   <result pre="interference Glycosylation of SARS-CoV (ACE-2) cell receptor 4.51 Î¼M yes" exact="Chloroquine" post="PubChem CID:2719 Image 5 Orally Antimalarial 2.71 Î¼M Immunomodulatory"/>
   <result pre="such as chloroquine, hydroxychloroquine, lopinavir/ritonavir, favipiravir, remdesivir, tociluzimab, nitazoxanide and" exact="ivermectin" post="[92]. We also discuss diagnostic procedure such as molecular"/>
   <result pre="review of early and emerging optionsOpen Forum Infect Dis742020ofaa10532284951 37GaoJ.TianZ.YangX.Breakthrough:" exact="chloroquine" post="phosphate has shown apparent efficacy in treatment of COVID-19"/>
   <result pre="acid receptorsNat Struct Mol Biol26201948148931160783 39PlantoneD.KoudriavtsevaT.Current and future use of" exact="chloroquine" post="and hydroxychloroquine in infectious, immune, neoplastic, and neurological diseases:"/>
   <result pre="Struct Mol Biol26201948148931160783 39PlantoneD.KoudriavtsevaT.Current and future use of chloroquine and" exact="hydroxychloroquine" post="in infectious, immune, neoplastic, and neurological diseases: a mini-reviewClin"/>
   <result pre="neoplastic, and neurological diseases: a mini-reviewClin Drug Invest382018653671 40SavarinoA.BoelaertJ.R.CassoneA.MajoriG.CaudaR.Effects of" exact="chloroquine" post="on viral infections: an old drug against today's diseases?Lancet"/>
   <result pre="dosing per recent ophthalmology guidelinesArthritis Res Ther20201813329976231 42TanY.W.YamW.K.SunJ.ChuJ.J.H.An evaluation of" exact="chloroquine" post="as a broad-acting antiviral against hand, foot and mouth"/>
   <result pre="and mouth diseaseAntivir Res149201814314929175128 43SahraeiZ.ShabaniM.ShokouhiS.SaffaeiA.Aminoquinolines against coronavirus disease 2019 (COVID-19):" exact="chloroquine" post="or hydroxychloroquineInt J Antimicrob Agents55202010594532194152 44MillionM.GautretP.ColsonP.RousselY.DubourgG.ChabriereE.Clinical efficacy of chloroquine"/>
   <result pre="(COVID-19): chloroquine or hydroxychloroquineInt J Antimicrob Agents55202010594532194152 44MillionM.GautretP.ColsonP.RousselY.DubourgG.ChabriereE.Clinical efficacy of" exact="chloroquine" post="derivatives in COVID-19 infection: comparative meta-analysis between the big"/>
   <result pre="and the real world2020100709 45AndreaniJ.Le BideauM.DuflotI.JardotP.RollandC.BoxbergerM.InÂ vitro testing of combined" exact="hydroxychloroquine" post="and azithromycin on SARS-CoV-2 shows synergistic effectMicrob Pathog145202010422832344177 46ColsonP.RolainJ.-M.RaoultD.J.Chloroquine"/>
   <result pre="real world2020100709 45AndreaniJ.Le BideauM.DuflotI.JardotP.RollandC.BoxbergerM.InÂ vitro testing of combined hydroxychloroquine and" exact="azithromycin" post="on SARS-CoV-2 shows synergistic effectMicrob Pathog145202010422832344177 46ColsonP.RolainJ.-M.RaoultD.J.Chloroquine for the"/>
   <result pre="the 2019 novel coronavirus SARS-CoV-2Int J Microb Agents5532020105923 47WangM.CaoR.ZhangL.YangX.LiuJ.XuM.Remdesivir and" exact="chloroquine" post="effectively inhibit the recently emerged novel coronavirus (2019-nCoV) inÂ"/>
   <result pre="in SingaporeJAMA32320201488149432125362 58GautretP.LagierJ.C.ParolaP.HoangV.T.MeddebL.SevestreJ.Clinical and microbiological effect of a combination of" exact="hydroxychloroquine" post="and azithromycin in 80 COVID-19 patients with at least"/>
   <result pre="58GautretP.LagierJ.C.ParolaP.HoangV.T.MeddebL.SevestreJ.Clinical and microbiological effect of a combination of hydroxychloroquine and" exact="azithromycin" post="in 80 COVID-19 patients with at least a six-day"/>
   <result pre="treatment of Coronavirus disease 2019Eur Rev Med Pharmacol Sci2420203390339632271456 60ChenC.Y.WangF.L.LinC.C.Chronic" exact="hydroxychloroquine" post="use associated with QT prolongation and refractory ventricular arrhythmiaClin"/>
   <result pre="host antiviral responses and inhibits Ebola virusiScience1920191279129031402258 66CalyL.DruceJ.D.CattonM.G.JansD.A.WagstaffK.M.The FDA-approved drug" exact="ivermectin" post="inhibits the replication of SARS-CoV-2 inÂ vitroAntivir Res178202010478732251768 67KetkarH.YangL.WormserG.P.WangP.Lack"/>
   <result pre="replication of SARS-CoV-2 inÂ vitroAntivir Res178202010478732251768 67KetkarH.YangL.WormserG.P.WangP.Lack of efficacy of" exact="ivermectin" post="for prevention of a lethal Zika virus infection in"/>
   <result pre="Wuhan, ChinaJAMA32320201061106932031570 74WHOWHO, Adapted from WHO welcomes preliminary results about" exact="dexamethasone" post="use in treating critically ill COVID-19 parents16 June 2020WHOGeneva"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7527651\results\search\drug\results.xml">
   <result pre="associated with resistance, rapidly detecting multidrug-resistant TB strains resistant to" exact="rifampin" post="and isoniazid, allowing appropriate therapies and curbing transmission of"/>
   <result pre="the viral entry to the cell [180, 228, 229]. Chloroquine," exact="hydroxychloroquine" post="and baricitinib mechanisms of action are not fully understood;"/>
   <result pre="inhibit the proteolysis. Lopinavir/ritonavir inhibits specifically the proteinase 3CLpro [231]." exact="Ribavirin" post="and favipiravir both have wide antiviral activity and have"/>
   <result pre="TB/HIV co-infected patients, lopinavir/ritonavir is not recommended in combination with" exact="rifampicin" post="due to cytochrome P450 (CYP) induction. Superboosting of lopinavir/ritonavir"/>
   <result pre="to cytochrome P450 (CYP) induction. Superboosting of lopinavir/ritonavir by additional" exact="ritonavir" post="in children on rifampicin-based TB treatment could be attempted"/>
   <result pre="attempted as comparable drug exposure was achieved in situations without" exact="rifampicin" post="[166]. Alternatively, rifabutin at a dose of 150â€…mg once"/>
   <result pre="drug exposure was achieved in situations without rifampicin [166]. Alternatively," exact="rifabutin" post="at a dose of 150â€…mg once daily has been"/>
   <result pre="once daily has been used in combination with lopinavir/ritonavir [167]." exact="Chloroquine" post="phosphate and hydroxychloroquine Chloroquine and hydroxychloroquine are being evaluated"/>
   <result pre="been used in combination with lopinavir/ritonavir [167]. Chloroquine phosphate and" exact="hydroxychloroquine" post="Chloroquine and hydroxychloroquine are being evaluated in several clinical"/>
   <result pre="used in combination with lopinavir/ritonavir [167]. Chloroquine phosphate and hydroxychloroquine" exact="Chloroquine" post="and hydroxychloroquine are being evaluated in several clinical trials"/>
   <result pre="combination with lopinavir/ritonavir [167]. Chloroquine phosphate and hydroxychloroquine Chloroquine and" exact="hydroxychloroquine" post="are being evaluated in several clinical trials for therapy"/>
   <result pre="unknown [169, 170]. Both drugs have immunomodulatory properties [171, 172]." exact="Chloroquine" post="has been shown to reduce tumour necrosis factor-Î± production"/>
   <result pre="combining these drugs with TB drugs such as moxifloxacin, bedaquiline," exact="delamanid" post="and clofazimine due to the risk of increased QTc"/>
   <result pre="drugs with TB drugs such as moxifloxacin, bedaquiline, delamanid and" exact="clofazimine" post="due to the risk of increased QTc prolongation. An"/>
   <result pre="issued a warning on these two drugs [175]. In addition," exact="rifampicin" post="increases chloroquine CYP3A4- and CYP2D6-mediated metabolism to desethylchloroquine and"/>
   <result pre="warning on these two drugs [175]. In addition, rifampicin increases" exact="chloroquine" post="CYP3A4- and CYP2D6-mediated metabolism to desethylchloroquine and bisdesethylchloroquine [176]."/>
   <result pre="meropenem; AMI: amikacin; STR: streptomycin; ETO: ethionamide; PTO: prothionamide; PAS:" exact="p-aminosalicylic acid;" post="CYP: cytochrome P450; UGT: UDP glucuronosyltransferase. #: recommended based"/>
   <result pre="in the metabolism of baloxavir (minor extent) and umifenovir, and" exact="clofazimine" post="is a CYP3A4 inhibitor; Æ’: both drugs primarily undergo"/>
   <result pre="Janus kinase JAK1/JAK2 inhibitor baricitinib are being studied [177, 178]." exact="Azithromycin" post="may be of potential interest for its immunomodulatory effect"/>
   <result pre="drugs Antiviral candidates such as azvudine, baloxavir marboxil, favipiravir, remdesivir," exact="ribavirin" post="and umifenovir are being tested for COVID-19 (figure 2)"/>
   <result pre="virus: ice-cold acetone (90â€…s), ice-cold acetone/methanol mixture (40/60, 10â€…min), 70%" exact="ethanol" post="(10â€…min), 100% ethanol (5â€…min), paraformaldehyde (2â€…min) and glutaraldehyde (2â€…min)."/>
   <result pre="(90â€…s), ice-cold acetone/methanol mixture (40/60, 10â€…min), 70% ethanol (10â€…min), 100%" exact="ethanol" post="(5â€…min), paraformaldehyde (2â€…min) and glutaraldehyde (2â€…min). Commonly used brands"/>
   <result pre="that can be damaged by sodium hypochlorite, products based on" exact="ethanol" post="of at least 70% can be used [203]. The"/>
   <result pre="to 48â€…h on plastic surfaces [205], and 6â€…days in the" exact="dried" post="state [202]. The virus does not survive well after"/>
   <result pre="5 (13.5) 8 (21.6) 15 (40.5) 8 (21.6) 3.7Â±1.1 12." exact="Chloroquine" post="and hydroxychloroquine have potential to improve the treatment success"/>
   <result pre="8 (21.6) 15 (40.5) 8 (21.6) 3.7Â±1.1 12. Chloroquine and" exact="hydroxychloroquine" post="have potential to improve the treatment success rate of"/>
   <result pre="E32â€&quot;E42. doi:10.1016/S2352-3018(18)30293-5 167LanNT, ThuNT, Barrail-TranA, et al.Randomised pharmacokinetic trial of" exact="rifabutin" post="with lopinavir/ritonavir-antiretroviral therapy in patients with HIV-associated tuberculosis in"/>
   <result pre="in Vietnam. PLoS One2014; 9: e84866. doi:10.1371/journal.pone.008486624465443 168PrincipiN, EspositoSChloroquine or" exact="hydroxychloroquine" post="for prophylaxis of COVID-19. Lancet Infect Dis2020; in press"/>
   <result pre="in press [10.1016/S1473-3099(20)30296-6]. doi:10.1016/S1473-3099(20)30296-6 169ChenZ, HuJ, ZhangZ, et al.Efficacy of" exact="hydroxychloroquine" post="in patients with COVID-19: results of a randomized clinical"/>
   <result pre="2020; preprint [10.1101/2020.03.22.20040758]. doi:10.1101/2020.03.22.20040758 170GautretP, LagierJC, ParolaP, et al.Hydroxychloroquine and" exact="azithromycin" post="as a treatment of COVID-19: results of an open-label"/>
   <result pre="Immunol2012; 42: 145â€&quot;153. doi:10.1007/s12016-010-8243-x21221847 173SavarinoA, BoelaertJR, CassoneA, et al.Effects of" exact="chloroquine" post="on viral infections: an old drug against today's diseases?Lancet"/>
   <result pre="ValFFA, SampaioVS, et al.Effect of high vs low doses of" exact="chloroquine" post="diphosphate as adjunctive therapy for patients hospitalized with severe"/>
   <result pre="doi:10.1001/jamanetworkopen.2020.885732330277 175collab: Food and Drug AdministrationFDA cautions against use of" exact="hydroxychloroquine" post="or chloroquine for COVID-19 outside of the hospital setting"/>
   <result pre="Food and Drug AdministrationFDA cautions against use of hydroxychloroquine or" exact="chloroquine" post="for COVID-19 outside of the hospital setting or a"/>
   <result pre="Discov2020; 19: 149â€&quot;150. doi:10.1038/d41573-020-00016-032127666 182WangM, CaoR, ZhangL, et al.Remdesivir and" exact="chloroquine" post="effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in"/>
   <result pre="drug combination features and better inhibition on drug-resistant strains than" exact="lamivudine" post="in vitro. PLoS One2014; 9: e105617. doi:10.1371/journal.pone.010561725144636 236AbrahamGM, MortonJB,"/>
   <result pre="April 1, 2020. 243PandieM, WiesnerL, McIlleronH, et al.Drugâ€&quot;drug interactions between" exact="bedaquiline" post="and the antiretrovirals lopinavir/ritonavir and nevirapine in HIV-infected patients"/>
   <result pre="et al.Drugâ€&quot;drug interactions between bedaquiline and the antiretrovirals lopinavir/ritonavir and" exact="nevirapine" post="in HIV-infected patients with drug-resistant TB. J Antimicrob Chemother2016;"/>
   <result pre="doi:10.1111/jphp.1201423488780 246LuZK, YuanJ, LiM, et al.Cardiac risks associated with antibiotics:" exact="azithromycin" post="and levofloxacin. Expert Opin Drug Saf2015; 14: 295â€&quot;303. doi:10.1517/14740338.2015.98921025494485"/>
   <result pre="295â€&quot;303. doi:10.1517/14740338.2015.98921025494485 247ChatreC, RoubilleF, VernhetH, et al.Cardiac complications attributed to" exact="chloroquine" post="and hydroxychloroquine: a systematic review of the literature. Drug"/>
   <result pre="doi:10.1007/s40264-018-0689-429858838 248KrzeminskiP, LesiakA, NarbuttJSeizures as a rare adverse effect of" exact="chloroquine" post="therapy in systemic lupus erythematosus patients: a case report"/>
   <result pre="Heart J2016; 37: 2768â€&quot;2801. doi:10.1093/eurheartj/ehw21127567406 252ShakilAO, Di BisceglieAM, HoofnagleJHSeizures during" exact="alpha" post="interferon therapy. J Hepatol1996; 24: 48â€&quot;51. doi:10.1016/S0168-8278(96)80185-18834024 253SharifianMR, KamandiS,"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7533207\results\search\drug\results.xml">
   <result pre="that showed efficacy in a randomized controlled trial [5], and" exact="dexamethasone" post="is another medication that showed efficacy in severe COVID-19"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7533477\results\search\drug\results.xml">
   <result pre="by SARS-CoV. There was evidence of muscle weakness and raised" exact="creatine" post="kinase levels in patients who had previously suffered from"/>
   <result pre="infection has been observed to range from asymptomatic rises in" exact="creatine" post="kinase and lactate dehydrogenase to rhabdomyolysis.111,112 Myalgia, weakness and"/>
   <result pre="patients had significantly raised levels of myoglobin, lactate dehydrogenase and" exact="creatine" post="kinase.111,112 Mechanisms of injury could be multifarious111,112: (1) direct"/>
   <result pre="rate of infections was higher in those taking interferon-beta and" exact="glatiramer acetate," post="and still higher in those taking fingolimod, natalizumab or"/>
   <result pre="infection was diagnosed in an MS patient under treatment with" exact="fingolimod" post="in May 2020 from Iran.128 Severity of the underlying"/>
   <result pre="Dravet syndrome, where fever control is crucial to allay seizures," exact="acetaminophen" post="can be used.145,146 Patients with tuberous sclerosis or autoimmune"/>
   <result pre="them more susceptible to infections.145â€&quot;147 Nevertheless, some studies have shown" exact="everolimus" post="to prevent viral infections.147,148 A major drawback in the"/>
   <result pre="need for regular sleep, healthy eating habits and avoidance of" exact="alcohol" post="and other recreational drugs must be reinforced on the"/>
   <result pre="disorders should continue treatment to prevent relapses, including corticosteroids, azathioprine," exact="mycophenolate mofetil," post="tocilizumab, rituximab or eculizumab. If at all drugs need"/>
   <result pre="addiction and substance abuse. Canada has reported an increase in" exact="alcohol" post="intake in about 20% of adults in the age"/>
   <result pre="breeding ground for an increase in chronic stress, anxiety, depression," exact="alcohol" post="dependence168 and self-harm. Conclusion Neurological manifestations in SARS-CoV-2 are"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7534958\results\search\drug\results.xml">
   <result pre="infect birds (gamma and deltacoronaviruses) and several mammalian species (mainly" exact="alpha" post="and betacoronaviruses), including humans.10,11 Coronaviruses have been isolated from"/>
   <result pre="seven coronaviruses that can infect humans (HCoVs) are classified in" exact="alpha" post="coronavirus (229E, NL63) or beta coronavirus [OC43, HKU1, Middle"/>
   <result pre="include FDA-approved antivirals, such as inhibitors of HIV-1 [e. g.," exact="lopinavir" post="(1) /ritonavir (2)] and HCV [e.g., boceprevir (3)] proteases,"/>
   <result pre="HIV-1 [e. g., lopinavir (1) /ritonavir (2)] and HCV [e.g.," exact="boceprevir" post="(3)] proteases, as well as antineoplastic [e.g. carmofur (4)]"/>
   <result pre="as well as antineoplastic [e.g. carmofur (4)] and antibacterial [e.g.," exact="doxycycline" post="(5)] drugs.73,78,79,80,81,82 Chemical structures for compounds 1-14 are shown"/>
   <result pre="Putative inhibitors of SARS-CoV-2 PLpro include FDA-approved drugs such as" exact="fostamatinib" post="disodium (6) (a tyrosine kinase inhibitor used in the"/>
   <result pre="from SARS-CoV-2, as demonstrated for remdesivir (8) (Fig. 6B), an" exact="adenosine" post="triphosphate analog.92,93,96 Other potential inhibitors include clinically available drugs,"/>
   <result pre="nucleic acid analog used in the treatment of influenza, and" exact="ribavirin" post="(10), a synthetic guanosine nucleoside indicated for the treatment"/>
   <result pre="immunodeficiency syndrome (AIDS), such as vapreotide (11) (somatostatin analog) and" exact="atazanavir" post="(12) (HIV protease inhibitor), as well anti-HCV protease inhibitors"/>
   <result pre="(12) (HIV protease inhibitor), as well anti-HCV protease inhibitors [e.g.," exact="daclatasvir" post="(13)] and bismuth salts [e.g., bismuth potassium citrate (14),"/>
   <result pre="regarded as potential inhibitors of SARS-CoV-2 methyl transferases, such as" exact="adenine" post="dinucleoside S-adenosylmethionine analogs [e.g., dinucleoside 13 (15)], predicted for"/>
   <result pre="potential inhibitors of SARS-CoV-2 methyl transferases, such as adenine dinucleoside" exact="S-adenosylmethionine" post="analogs [e.g., dinucleoside 13 (15)], predicted for SARS-CoV N7-MTase"/>
   <result pre="including COVID-19.67,122,123,125 This can be exemplified by the FDA-approved drugs" exact="gliclazide" post="(17), a sulfonylurea administered to non-insulin-dependent diabetes mellitus patients,"/>
   <result pre="(17), a sulfonylurea administered to non-insulin-dependent diabetes mellitus patients, and" exact="memantine" post="(18), an N-methyl-D-aspartate receptor antagonist used in the management"/>
   <result pre="an anti-SARS-CoVs activity by disturbing ACE2 glycosylation, as proposed for" exact="chloroquine" post="(20).131 Renin-angiotensin-aldosterone system (RAAS) inhibitors, such as ACE inhibitors"/>
   <result pre="Renin-angiotensin-aldosterone system (RAAS) inhibitors, such as ACE inhibitors [ACE-i, e.g.," exact="captopril" post="(21)] and angiotensin receptor blockers [ARB, e.g., losartan (22)],"/>
   <result pre="stages.65,138 Potential TMPRSS2 blockers include some serine protease inhibitors [e.g.," exact="camostat" post="mesylate (23)], commercially available compounds [e. g., ZINC64606047 (24),"/>
   <result pre="agents that increase endosomal pH (avoiding cathepsin L activation) [e.g.," exact="chloroquine" post="(20) and hydroxychloroquine (26)] and cathepsin L inhibitors [e.g.,"/>
   <result pre="endosomal pH (avoiding cathepsin L activation) [e.g., chloroquine (20) and" exact="hydroxychloroquine" post="(26)] and cathepsin L inhibitors [e.g., teicoplanin (27), a"/>
   <result pre="role in COVID-19 management.66 Dipeptidyl peptidase-4 (DDP4), also known as" exact="adenosine" post="deaminase complexing protein 2 or T-cell activation antigen CD26,"/>
   <result pre="a discussion about the use of DDP4 inhibitors, such as" exact="sitagliptin" post="(29) (anti-diabetic drug), in the treatment of COVID-19.152,153,155,156 In"/>
   <result pre="drug Previous use Predicted targets Discovery origin Experimental evidence Reference" exact="Pemirolast" post="(30), nitrofurantoin (31), isoniazid pyruvate (32), eriodictyol (33), cepharanthine"/>
   <result pre="use Predicted targets Discovery origin Experimental evidence Reference Pemirolast (30)," exact="nitrofurantoin" post="(31), isoniazid pyruvate (32), eriodictyol (33), cepharanthine (34), ergoloid"/>
   <result pre="targets Discovery origin Experimental evidence Reference Pemirolast (30), nitrofurantoin (31)," exact="isoniazid" post="pyruvate (32), eriodictyol (33), cepharanthine (34), ergoloid (35) and"/>
   <result pre="Discovery origin Experimental evidence Reference Pemirolast (30), nitrofurantoin (31), isoniazid" exact="pyruvate" post="(32), eriodictyol (33), cepharanthine (34), ergoloid (35) and hypericin"/>
   <result pre="assays Mefuparib (37) achieved an EC50 of 5.12 Î¼M. 164" exact="Atazanavir" post="(12) and efavirenz (38) HIV SARS-CoV-2 3C-like protease (Mpro)"/>
   <result pre="achieved an EC50 of 5.12 Î¼M. 164 Atazanavir (12) and" exact="efavirenz" post="(38) HIV SARS-CoV-2 3C-like protease (Mpro) Molecule transformer drug-target"/>
   <result pre="HIV SARS-CoV-2 3C-like protease (Mpro) Molecule transformer drug-target interaction (MT-DTI)" exact="Atazanavir" post="(12) can been found in lungs after administration and"/>
   <result pre="cough and dyspnea) in a small group of patients.c 161" exact="Toremifene" post="(40), sirolimus (41), mercaptopurine (42), irbesartan (43) Multiple Multiple"/>
   <result pre="dyspnea) in a small group of patients.c 161 Toremifene (40)," exact="sirolimus" post="(41), mercaptopurine (42), irbesartan (43) Multiple Multiple targets in"/>
   <result pre="a small group of patients.c 161 Toremifene (40), sirolimus (41)," exact="mercaptopurine" post="(42), irbesartan (43) Multiple Multiple targets in humans and"/>
   <result pre="group of patients.c 161 Toremifene (40), sirolimus (41), mercaptopurine (42)," exact="irbesartan" post="(43) Multiple Multiple targets in humans and coronaviruses Systems"/>
   <result pre="network Antiviral activities against coronaviruses has been described for selective" exact="estrogen" post="modulators toremifene (40), immunosuppressants sirolimus (41) and mercaptopurine (42)"/>
   <result pre="activities against coronaviruses has been described for selective estrogen modulators" exact="toremifene" post="(40), immunosuppressants sirolimus (41) and mercaptopurine (42) and angiotensin"/>
   <result pre="has been described for selective estrogen modulators toremifene (40), immunosuppressants" exact="sirolimus" post="(41) and mercaptopurine (42) and angiotensin receptor blockers irbesartan"/>
   <result pre="for selective estrogen modulators toremifene (40), immunosuppressants sirolimus (41) and" exact="mercaptopurine" post="(42) and angiotensin receptor blockers irbesartan (43).d 52 a:"/>
   <result pre="immunosuppressants sirolimus (41) and mercaptopurine (42) and angiotensin receptor blockers" exact="irbesartan" post="(43).d 52 a: Cepharanthin (34) has been shown to"/>
   <result pre="and other flavonoids on SARS-CoV-2.166,167b: a recent study showed that" exact="Atazanavir" post="(12) inhibited Mproin vitro with greater potency than lopinavir"/>
   <result pre="that Atazanavir (12) inhibited Mproin vitro with greater potency than" exact="lopinavir" post="(1).168c: despite the small size (12 patients) and open"/>
   <result pre="baricitinib (39) showed potential safety when used in combination with" exact="lopinavir" post="(1) / ritonavir (2).169 As of August 3rd 13th,"/>
   <result pre="potential safety when used in combination with lopinavir (1) /" exact="ritonavir" post="(2).169 As of August 3rd 13th, 2020, there are"/>
   <result pre="the isolated proteins. From this analysis, four compounds [pemirolast (30)," exact="nitrofurantoin" post="(31), isoniazid pyruvate (32) and eriodictyol (33)] displayed potential"/>
   <result pre="proteins. From this analysis, four compounds [pemirolast (30), nitrofurantoin (31)," exact="isoniazid" post="pyruvate (32) and eriodictyol (33)] displayed potential to disrupt"/>
   <result pre="From this analysis, four compounds [pemirolast (30), nitrofurantoin (31), isoniazid" exact="pyruvate" post="(32) and eriodictyol (33)] displayed potential to disrupt the"/>
   <result pre="of small compounds and protein targets. The authors found that" exact="atazanavir" post="(12), remdesivir (8) and efavirenz (38) are potential inhibitors"/>
   <result pre="targets. The authors found that atazanavir (12), remdesivir (8) and" exact="efavirenz" post="(38) are potential inhibitors of Mpro, while atazanavir (12)"/>
   <result pre="(8) and efavirenz (38) are potential inhibitors of Mpro, while" exact="atazanavir" post="(12) also yielded nanomolar predicted binding affinity for RdRP,"/>
   <result pre="selected by the authors are from a diverse set, including" exact="toremifene" post="(40) (selective estrogen receptor modulator), sirolimus (41) (immunosuppressant), mercaptopurine"/>
   <result pre="authors are from a diverse set, including toremifene (40) (selective" exact="estrogen" post="receptor modulator), sirolimus (41) (immunosuppressant), mercaptopurine (42) (antineoplastic) and"/>
   <result pre="a diverse set, including toremifene (40) (selective estrogen receptor modulator)," exact="sirolimus" post="(41) (immunosuppressant), mercaptopurine (42) (antineoplastic) and irbesartan (43) (antihypertensive)."/>
   <result pre="including toremifene (40) (selective estrogen receptor modulator), sirolimus (41) (immunosuppressant)," exact="mercaptopurine" post="(42) (antineoplastic) and irbesartan (43) (antihypertensive). An interesting finding"/>
   <result pre="estrogen receptor modulator), sirolimus (41) (immunosuppressant), mercaptopurine (42) (antineoplastic) and" exact="irbesartan" post="(43) (antihypertensive). An interesting finding was that the selected"/>
   <result pre="of Coronavirus-related disease, such as emodin (44) in SARS-CoV, and" exact="mercaptopurine" post="(42) and toremifene (40) in SARS-CoV and MERS-CoV.52 In"/>
   <result pre="such as emodin (44) in SARS-CoV, and mercaptopurine (42) and" exact="toremifene" post="(40) in SARS-CoV and MERS-CoV.52 In addition to identifying"/>
   <result pre="between them were also suggested by the network, such as" exact="sirolimus" post="(41) and dactinomycin (45), and mercaptopurine (42) and melatonin"/>
   <result pre="also suggested by the network, such as sirolimus (41) and" exact="dactinomycin" post="(45), and mercaptopurine (42) and melatonin (46).52 In vitro"/>
   <result pre="the network, such as sirolimus (41) and dactinomycin (45), and" exact="mercaptopurine" post="(42) and melatonin (46).52 In vitro and in vivo"/>
   <result pre="as sirolimus (41) and dactinomycin (45), and mercaptopurine (42) and" exact="melatonin" post="(46).52 In vitro and in vivo studies - Genome"/>
   <result pre="Reference Remdesivir (8) Ebola RNA polymerase 0.77 Î¼M 129.9 194" exact="Chloroquine" post="(20) / Hydroxychloroquine (26) Malaria / Lupus and rheumatoid"/>
   <result pre="Ebola RNA polymerase 0.77 Î¼M 129.9 194 Chloroquine (20) /" exact="Hydroxychloroquine" post="(26) Malaria / Lupus and rheumatoid arthritis Acidification in"/>
   <result pre="/ 14.4 to 61.5 depending on multiplicities of infection 194,195,196" exact="Ritonavir" post="(2) + lopinavir (1) HIV 3-chymotrypsin-like protease (3CLpro) and"/>
   <result pre="61.5 depending on multiplicities of infection 194,195,196 Ritonavir (2) +" exact="lopinavir" post="(1) HIV 3-chymotrypsin-like protease (3CLpro) and papain-like protease (PLpro)"/>
   <result pre="inhibited virus infection efficiently in human liver cancer Huh-7 cells." exact="Chloroquine" post="(CQ; 20) and its less toxic derivative, hydroxychloroquine (HCQ;"/>
   <result pre="Huh-7 cells. Chloroquine (CQ; 20) and its less toxic derivative," exact="hydroxychloroquine" post="(HCQ; 26), are used to treat malaria and lupus/rheumatoid"/>
   <result pre="(20) itself.207 It is also good to point out that" exact="chloroquine" post="(20) has shown in vitro activity against many different"/>
   <result pre="but no significant beneficial effect on animal models.208 The association" exact="ritonavir" post="(2)/lopinavir (1) is used together with other antiretrovirals for"/>
   <result pre="of human immunodeficiency virus since the beginning of the century.209" exact="Ritonavir" post="(2) is a potent CYP3A inhibitor therefore inhibiting the"/>
   <result pre="is a potent CYP3A inhibitor therefore inhibiting the metabolism of" exact="lopinavir" post="(1), increasing its plasma levels. Both are reported as"/>
   <result pre="Wilde et al. that demonstrated antiviral in vitro effect of" exact="lopinavir" post="(1), but not ritonavir (2), against SARS-CoV, MERS-CoV, and"/>
   <result pre="demonstrated antiviral in vitro effect of lopinavir (1), but not" exact="ritonavir" post="(2), against SARS-CoV, MERS-CoV, and hCoV-229E, with mean EC50"/>
   <result pre="most promising therapies: remdesivir (8); CQ (20) or HCQ (26);" exact="ritonavir" post="(2)/lopinavir (1); ritonavir (2) /lopinavir (1) plus interferon-beta, an"/>
   <result pre="remdesivir (8); CQ (20) or HCQ (26); ritonavir (2)/lopinavir (1);" exact="ritonavir" post="(2) /lopinavir (1) plus interferon-beta, an immune response modulator.44"/>
   <result pre="compared to placebo group (11 vs 15 days) 216; NCT04280705" exact="Chloroquine" post="(20) Multicentre &amp;gt; 100 patients 500 mg per day,"/>
   <result pre="day, once daily for more 4 days Higher dosage of" exact="chloroquine" post="(20) has toxic effects and increased lethality, with any"/>
   <result pre="toxic effects and increased lethality, with any clinical benefit 218" exact="Hydroxychloroquine" post="(26) non-randomised, non-double-blind, non-placebo-controlled 36 patients 600 mg of"/>
   <result pre="Hydroxychloroquine (26) non-randomised, non-double-blind, non-placebo-controlled 36 patients 600 mg of" exact="hydroxychloroquine" post="(26) daily for 10 days Hydroxychloroquine (26) significantly reduces"/>
   <result pre="patients 600 mg of hydroxychloroquine (26) daily for 10 days" exact="Hydroxychloroquine" post="(26) significantly reduces viral load despite small sample size"/>
   <result pre="(26) significantly reduces viral load despite small sample size 219" exact="Ritonavir" post="(2)/lopinavir (1) Randomised, controlled, open-label 199 patients 400 mg/100"/>
   <result pre="a day for 14 days No benefit was observed with" exact="lopinavir" post="(1)-ritonavir (2) treatment compared to standard care in severe"/>
   <result pre="treatment compared to standard care in severe Covid-19 patients 220" exact="Ritonavir" post="(2)/lopinavir (1) plus interferon Phase II, randomised, controlled, open-label"/>
   <result pre="measure the effectiveness of CQ (20) at 500 mg of" exact="chloroquine" post="diphosphate (corresponding to 300 mg of chloroquine (20) base)"/>
   <result pre="500 mg of chloroquine diphosphate (corresponding to 300 mg of" exact="chloroquine" post="(20) base) per day, for ten consecutive days on"/>
   <result pre="load in COVID-19 patients and its effect is reinforced by" exact="azithromycin" post="(AZ; 49) combination.219 Until this moment there is clinical"/>
   <result pre="patients is still expected for concluding on the efficacy of" exact="hydroxychloroquine" post="(26). Ritonavir (2) and lopinavir (1) were developed to"/>
   <result pre="still expected for concluding on the efficacy of hydroxychloroquine (26)." exact="Ritonavir" post="(2) and lopinavir (1) were developed to target HIV-1"/>
   <result pre="concluding on the efficacy of hydroxychloroquine (26). Ritonavir (2) and" exact="lopinavir" post="(1) were developed to target HIV-1 protease and postulated"/>
   <result pre="whether these drugs are useful for COVID-19 treatment or not." exact="Ritonavir" post="(2)/lopinavir (1) plus interferon-beta, a cytokine involved in inflammatory"/>
   <result pre="Infection in a Nonhuman Primate Model.233 The study (NCT04276688) administered" exact="ritonavir" post="(2)/lopinavir (1) 400 mg + 100 mg/ml twice daily"/>
   <result pre="tested in COVID-19 clinical trials include CQ (20), HCQ (26)," exact="Ritonavir" post="(2) and Lopinavir (1).239,240 A recent research article published"/>
   <result pre="optimised synthetic pathways found in patents and articles for some" exact="Ritonavir" post="(2) and Lopinavir (1) are discussed below, as CQ"/>
   <result pre="each of the drugs we had the synthesis reviewed here." exact="Ritonavir" post="(2) - The first disclosure of ritonavir (2) is"/>
   <result pre="synthesis reviewed here. Ritonavir (2) - The first disclosure of" exact="ritonavir" post="(2) is presented in a patent from 1994, assigned"/>
   <result pre="above deficiencies, a recent Chinese patent concerning the synthesis of" exact="ritonavir" post="(2) has been released. The synthetic pathway described in"/>
   <result pre="addition-elimination reaction with reagent (76), thus obtaining the final product" exact="ritonavir" post="(2) (Fig. 16).252 When comparing both patents, it is"/>
   <result pre="is ease to scale-up the production. Fig. 16: synthesis of" exact="Ritonavir" post="(2) via a cost-effective and easy synthetic pathway. Lopinavir"/>
   <result pre="- The first synthetic methods related to the synthesis of" exact="lopinavir" post="(1) are present in a patent from 1996 owned"/>
   <result pre="are similar, involving the synthesis of a key intermediate amino" exact="alcohol" post="unit, that is then connected to the appropriated side"/>
   <result pre="production. The most recent patent related to the synthesis of" exact="lopinavir" post="(1) is dated 2018 and it is from the"/>
   <result pre="1996, by Abbott Laboratories. The patent describes the synthesis of" exact="lopinavir" post="(1) by a one-pot procedure starting with the formation"/>
   <result pre="nucleophilic addition-elimination reaction to occur, affording (1) after treatment with" exact="NaHCO3" post="(Fig. 17). Therefore, it is possible to synthesise lopinavir"/>
   <result pre="with NaHCO3 (Fig. 17). Therefore, it is possible to synthesise" exact="lopinavir" post="(1) in high yield (90%) in an optimised method,"/>
   <result pre="materials, number of steps and overall yield. Regarding chiral centres," exact="ritonavir" post="(2) and lopinavir (1) have four chiral centres each,"/>
   <result pre="steps and overall yield. Regarding chiral centres, ritonavir (2) and" exact="lopinavir" post="(1) have four chiral centres each, and they are"/>
   <result pre="number of steps and lower overall yield when compared to" exact="ritonavir" post="(2) and lopinavir (1). However, one of the steps"/>
   <result pre="and lower overall yield when compared to ritonavir (2) and" exact="lopinavir" post="(1). However, one of the steps in the synthesis"/>
   <result pre="(alone or in association with other drugs) and the association" exact="lopinavir" post="(1)/ritonavir (2) have been the focus of most clinical"/>
   <result pre="inhibitors of coronavirus RNA cap guanine-N7-methyltransferaseAntiviral Res201410415616424530452 112Ahmed-BelkacemRSutto-OrtizPGuiraudMCanardBVasseur J-JDecrolyESynthesis of" exact="adenine" post="dinucleosides SAM analogs as specific inhibitors of SARS-CoV nsp14"/>
   <result pre="molecular modelling studies reveal a new mechanism of action of" exact="chloroquine" post="and hydroxychloroquine against SARS-CoV-2 infectionInt J Antimicrob Agents202055510596010596032251731 119StopsackKHMucciLAAntonarakisESNelsonPSKantoffPWTMPRSS2"/>
   <result pre="studies reveal a new mechanism of action of chloroquine and" exact="hydroxychloroquine" post="against SARS-CoV-2 infectionInt J Antimicrob Agents202055510596010596032251731 119StopsackKHMucciLAAntonarakisESNelsonPSKantoffPWTMPRSS2 and COVID-19"/>
   <result pre="is a potential ion channel that can be inhibited by" exact="Gliclazide" post="and MemantineBiochem Biophys Res Commun20205301101432828269 127McKinneyCAFattahCLoughreyCMMilliganGNicklinSAAngiotensin-(1-7) and angiotensin-(1-9) function"/>
   <result pre="preclinical studies 131DevauxCARolain J-MColsonPRaoultDNew insights on the antiviral effects of" exact="chloroquine" post="against coronavirus what to expect for COVID-19?Int J Antimicrob"/>
   <result pre="models for SARS and MERS coronavirusesCurr Opin Virol20151312312926184451 194WangMCaoRZhangLYangXLiuJXuMRemdesivir and" exact="chloroquine" post="effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in"/>
   <result pre="vitro antiviral activity and projection of optimized dosing design of" exact="hydroxychloroquine" post="for the treatment of severe acute respiratory syndrome coronavirus"/>
   <result pre="homoharringtonine inhibit SARS-CoV-2 replication in vitroAntiviral Res202017810478610478632251767 198CalyLDruceJDCattonMGJansDAWagstaffKMThe FDA-approved drug" exact="ivermectin" post="inhibits the replication of SARS-CoV-2 in vitroAntiviral Res202017810478710478732251768 199ZhangJMaXYuFLiuJZouFPanTet"/>
   <result pre="against SARS coronavirus infectionsExpert Rev Anti Infect Ther20064229130216597209 204FernerREAronsonJKChloroquine and" exact="hydroxychloroquine" post="in covid-19BMJ2020369m1432m143232269046 205Al-BariMAATargeting endosomal acidification by chloroquine analogs as"/>
   <result pre="Ther20064229130216597209 204FernerREAronsonJKChloroquine and hydroxychloroquine in covid-19BMJ2020369m1432m143232269046 205Al-BariMAATargeting endosomal acidification by" exact="chloroquine" post="analogs as a promising strategy for the treatment of"/>
   <result pre="SARS-CoV-2 infection in vitroCell Discov202061161632194981 207McChesneyEWAnimal toxicity and pharmacokinetics of" exact="hydroxychloroquine" post="sulfateAm J Med198375111186408923 208TouretFde LamballerieXOf chloroquine and COVID-19Antiviral Res202017710476210476232147496"/>
   <result pre="toxicity and pharmacokinetics of hydroxychloroquine sulfateAm J Med198375111186408923 208TouretFde LamballerieXOf" exact="chloroquine" post="and COVID-19Antiviral Res202017710476210476232147496 209LvZChuYWangYHIV protease inhibitors a review of"/>
   <result pre="studies of drug repurposing and synergism of lopinavir, oseltamivir and" exact="ritonavir" post="binding with SARS-CoV-2 protease against COVID-19J Biomol Struct Dyn202010.1080/07391102.2020.1752802"/>
   <result pre="treatment of Covid-19 - Preliminary reportN Engl J Med202010.1056/NEJMoa2007764 217GaoJTianZYangXBreakthrough" exact="chloroquine" post="phosphate has shown apparent efficacy in treatment of COVID-19"/>
   <result pre="clinical studiesBiosci Trends2020141727332074550 218BorbaMGSValFFASampaioVSAlexandreMAAMeloGCBritoMEffect of high vs low doses of" exact="chloroquine" post="diphosphate as adjunctive therapy for patients hospitalized with severe"/>
   <result pre="syndrome coronavirus 2 (SARS-CoV-2) infectionJAMA Netw Open202034e20885732330277 219GautretPLagier J-CParolaPHoangVTMeddebLMailheMHydroxychloroquine and" exact="azithromycin" post="as a treatment of COVID-19 results of an open-label"/>
   <result pre="Antimicrob Agents202055410593310593332147516 225collab: FDARemdesivir EUA letter of authorization2020https://www.fda.gov/media/137564/download 226SavarinoABoelaertJRCassoneAMajoriGCaudaREffects of" exact="chloroquine" post="on viral infections an old drug against today's diseasesLancet"/>
   <result pre="against today's diseasesLancet Infect Dis200331172272714592603 227ChatreCRoubilleFVernhetHJorgensenCPers Y-MCardiac complications attributed to" exact="chloroquine" post="and hydroxychloroquine a systematic review of the literatureDrug Saf2018411091993129858838"/>
   <result pre="diseasesLancet Infect Dis200331172272714592603 227ChatreCRoubilleFVernhetHJorgensenCPers Y-MCardiac complications attributed to chloroquine and" exact="hydroxychloroquine" post="a systematic review of the literatureDrug Saf2018411091993129858838 228DamleBVourvahisMWangELeaneyJCorriganBClinical pharmacology"/>
   <result pre="literatureDrug Saf2018411091993129858838 228DamleBVourvahisMWangELeaneyJCorriganBClinical pharmacology perspectives on the antiviral activity of" exact="azithromycin" post="and use in COVID-19Clin Pharmacol Ther2020108220121132302411 229MehraMRDesaiSSKuySHenryTDPatelANRetraction cardiovascular disease,"/>
   <result pre="drug therapy, and mortality in Covid-19N Engl J Med20203822625822582 230MehraMRDesaiSSRuschitzkaFPatelAN.RETRACTED:" exact="hydroxychloroquine" post="or chloroquine with or without a macrolide for treatment"/>
   <result pre="and mortality in Covid-19N Engl J Med20203822625822582 230MehraMRDesaiSSRuschitzkaFPatelAN.RETRACTED: hydroxychloroquine or" exact="chloroquine" post="with or without a macrolide for treatment of COVID-19:"/>
   <result pre="COVID-19: a multinational registry analysisLancet202010.1016/S0140-6736(20)31180-6 231BoulwareDRPullenMFBangdiwalaASPastickKALofgrenSMOkaforECet al.A randomized trial of" exact="hydroxychloroquine" post="as postexposure prophylaxis for Covid-19N Engl J Med202010.1056/NEJMoa2016638 232ZumlaAChanJFWAzharEIHuiDSCYuen"/>
   <result pre="marmosetJ Infect Dis2015212121904191326198719 234NukoolkarnVLeeVSMalaisreeMAruksakulwongOHannongbuaSMolecular dynamic simulations analysis of ritronavir and" exact="lopinavir" post="as SARS-CoV 3CLpro inhibitorsJ Theor Biol2008254486186718706430 235ChuCMRole of lopinavir/ritonavir"/>
   <result pre="Chem19984146026179484509 252NingZRanGRenXUZhangYIZhouZ2019Preparation method of ritonavirChinese patent 253ShoujunWDequanWUYuyouXChaoZ2018Method used for preparing" exact="lopinavir" post="using one-pot methodChinese patent"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7536086\results\search\drug\results.xml">
   <result pre="fight against the COVID-19 outbreak. COVID-19 SARS-CoV-2 plasma therapy viraemia" exact="chloroquine" post="1. Introduction The first case of SARS-CoV-2 was reported"/>
   <result pre="patients basically emphasizes the use of medicines like hydroxychloroquinone, chloroquinone," exact="azithromycin" post="and ivermectin, along with vitamin B and vitamin C"/>
   <result pre="hydroxychloroquinone, chloroquinone, azithromycin and ivermectin, along with vitamin B and" exact="vitamin C" post="supplements; supportive care includes oxygenation, management of fluid and"/>
   <result pre="pathogens with UV light exposure or with the aid of" exact="riboflavin" post="are some other suggested procedures to improve safety in"/>
   <result pre="all five patients were provided with mechanical ventilation along with" exact="methylprednisolone" post="and other antiviral agents. The normalization of body temperatures"/>
   <result pre="70Bello-LÃ³pezJ, Delgado-BalbuenaL, Rojas-HuidobroD, Rojo-MedinaJ2018Treatment of platelet concentrates and plasma with" exact="riboflavin" post="and UV light: impact in bacterial reduction. Transf. Clin."/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7536932\results\search\drug\results.xml">
   <result pre="and Sons Inc.Hoboken pmcid: 7536932 doi: 10.1002/rmv.2163RMV2163 : Review: Reviews" exact="Azithromycin" post="in viral infections Oliver and Hinks OliverMadeleine E.1HinksTimothy S."/>
   <result pre="medium, provided the original work is properly cited.file:RMV-9999-e2163.pdf Abstract Summary" exact="Azithromycin" post="(AZM) is a synthetic macrolide antibiotic effective against a"/>
   <result pre="inhibits T cells by inhibiting calcineurin signalling, mammalian target of" exact="rapamycin" post="activity and NFÎºB activation. AZM particularly targets granulocytes where"/>
   <result pre="urgent mandate to perform wellâ€�designed and conducted randomised clinical trials." exact="azithromycin" post="coronavirus COVIDâ€�19 macrolide mechanism review SARSâ€�CoVâ€�2 virus Funding University"/>
   <result pre="Biomedical Research Centre (BRC) fig-count: table-count: page-count: word-count: OliverME, HinksTSC." exact="Azithromycin" post="in viral infections. Rev Med Virol. 2020;e216310.1002/rmv.216332969125 Funding information"/>
   <result pre="Health Research (NIHR) Oxford Biomedical Research Centre (BRC) Abbreviations AZM" exact="azithromycin" post="CAP community acquired pneumonia CCL Câ€�C motif ligand CD"/>
   <result pre="ERK extracellular signalâ€�regulated kinase GMâ€�CSF granulocyteâ€�macrophage colonyâ€�stimulating factor (CSF2) HCQ" exact="hydroxychloroquine" post="hPSC human pluripotent stem cell ICU intensive care unit"/>
   <result pre="interferon IRF3 Interferon Regulatory Factor 3 ISG interferonâ€�stimulated gene IVM" exact="ivermectin" post="LMWH low molecular weight heparin MAPK mitogenâ€�activated protein kinase"/>
   <result pre="NCT National Clinical Trial PBEC primary bronchial epithelial cell PGE2" exact="prostaglandin E2" post="PRR pattern recognition receptor RIGâ€�1 retinoic acidâ€�inducible gene 1"/>
   <result pre="TGFâ€�beta transforming growth factor beta TLR Tollâ€�like receptor 1 INTRODUCTION" exact="Azithromycin" post="(AZM) is a secondâ€�generation, broadâ€�spectrum, synthetic macrolide antibiotic used"/>
   <result pre="effects.23, 24, 25, 26 TABLE 1 Viral infections in which" exact="azithromycin" post="has demonstrated antiâ€�viral effects Pathogen Findings Method Study Human"/>
   <result pre="but secretion of ILâ€�1Î², ILâ€�6 and ILâ€�8 were reduced by" exact="clarithromycin" post="(another macrolide) in a separate study of RV,36 alongside"/>
   <result pre="In a second, larger, openâ€�label, randomised controlled trial 2â€‰days of" exact="clarithromycin" post="500â€‰mg and naproxen 200â€‰mg twice daily reduced 30â€‰day mortality,"/>
   <result pre="larger, openâ€�label, randomised controlled trial 2â€‰days of clarithromycin 500â€‰mg and" exact="naproxen" post="200â€‰mg twice daily reduced 30â€‰day mortality, high dependency unit"/>
   <result pre="of influenza deaths, particularly in the elderly. Nonetheless in vitro" exact="clarithromycin" post="reduced viral replication in the A549 human lung cell"/>
   <result pre="viral replication in the A549 human lung cell line.41 Likewise" exact="clarithromycin" post="reduced viral titres and supernatant cytokines on cultured human"/>
   <result pre="particle internalisation.43 Some murine studies have investigated macrolides in vivo." exact="Erythromycin" post="improved survival during severe H2N2 infection,44 associated with reduced"/>
   <result pre="free radicals. Other macrolides leucomycin A3, spiramycin and a nonâ€�antibacterial" exact="erythromycin" post="derivative (EM900) each reduced weight loss, improved survival and"/>
   <result pre="for autophagosomeâ€�lysosome fusion.52 A focussed study on two candidate molecules," exact="hydroxychloroquine" post="and AZM, suggested a synergistic inhibition of SARSâ€�CoVâ€�2 replication"/>
   <result pre="This synergy has been proposed to allow effective use of" exact="hydroxychloroquine" post="at less toxic concentrations, and is an approach tried"/>
   <result pre="of viral diseases. TABLE 2 Immunomodulatory and antiâ€�inflammatory properties of" exact="azithromycin" post="Property Effect Specific Findings Study General antiâ€�inflammatory properties Destabilisation"/>
   <result pre="endothelin 1 expression in epithelial cells Human bronchial epithelial cells." exact="Erythromycin" post="and clarithromycin reduced enfothelinâ€�1 expression Takizawa et al72 Inhibition"/>
   <result pre="expression in epithelial cells Human bronchial epithelial cells. Erythromycin and" exact="clarithromycin" post="reduced enfothelinâ€�1 expression Takizawa et al72 Inhibition of endocytosis/induction"/>
   <result pre="al84 Inhibition of neutrophil elastase and MMP9 Human in vivo." exact="Clarithromycin" post="reduced airway neutrophil elastase and MMP9 Simpson et al86"/>
   <result pre="CXCL8 release Shinkai et al106 Reduced CXCL8 (ILâ€�8) Human trial." exact="Roxithromycin" post="reduced CXCL8 in nasal lavage in chronic rhinosinusitis, with"/>
   <result pre="antiâ€�inflammatory effects of macrolides. Schematic showing major proposed mechanisms of" exact="azithromycin" post="antiâ€�viral (green) and antiâ€�inflammatory or immunomodulatory (purple) activities. AZM,"/>
   <result pre="including eosinophils and basophils.68 Macrolides also inhibit mammalian target of" exact="rapamycin" post="(mTOR) activity, also important in T cell activation and"/>
   <result pre="of the RECOVERY trial showing a significant mortality benefit with" exact="dexamethasone" post="in patients with severe COVIDâ€�19 disease and respiratory failure.132"/>
   <result pre="regime, duration of therapy, whether being used in combination with" exact="hydroxychloroquine" post="and, critically, according to the population being studied. Those"/>
   <result pre="The first trial to publish results compared standard care with" exact="hydroxychloroquine" post="(HCQ) 400â€‰mg twice daily or with HQC 400â€‰mg twice"/>
   <result pre="and from Pfizer to support conduct of a trial of" exact="azithromycin" post="in COVIDâ€�19. AUTHOR CONTRIBUTIONS Madeleine E. Oliver and Timothy"/>
   <result pre="final manuscript. Supporting information Table S1 Current clinical trials of" exact="azithromycin" post="in SARSâ€�CoVâ€�2 LINK Click here for additional data file."/>
   <result pre="and from Pfizer to support conduct of a trial of" exact="azithromycin" post="in COVIDâ€�19. DATA AVAILABILITY STATEMENT Data sharing not applicable"/>
   <result pre="clinical research in resourceâ€�limited settings. Lancet. 2020;395(10233):1322â€�1325.32247324 7GielenV, JohnstonSL, EdwardsMR." exact="Azithromycin" post="induces antiâ€�viral responses in bronchial epithelial cells. Eur Respir"/>
   <result pre="2010;36(3):646â€�654.20150207 8SchoglerA, KopfBS, EdwardsMR, et al. Novel antiviral properties of" exact="azithromycin" post="in cystic fibrosis airway epithelial cells. Eur Respir J."/>
   <result pre="HinterwirthA, ArzikaAM, et al. Reduction of coronavirus burden with mass" exact="azithromycin" post="distribution. Clin Infect Dis. 2020;ciaa606. doi:10.1093/cid/ciaa606. Online ahead of"/>
   <result pre="Sci U S A. 2016;113(50):14408â€�14413.27911847 12LiC, ZuS, DengYQ, et al." exact="Azithromycin" post="protects against Zika virus infection by upregulating virusâ€�induced type"/>
   <result pre="2015;1(7):317â€�326.27622822 15KawamuraK, IchikadoK, TakakiM, EguchiY, AnanK, SugaM. Adjunctive therapy with" exact="azithromycin" post="for moderate and severe acute respiratory distress syndrome: a"/>
   <result pre="trial. Antiviral Res. 2017;144:48â€�56.28535933 17ShinaharaW, TakahashiE, SawabuchiT, et al. Immunomodulator" exact="clarithromycin" post="enhances mucosal and systemic immune responses and reduces reâ€�infection"/>
   <result pre="Chest. 2017;151(5):1069â€�1080.27884765 19HigashiF, KuboH, YasudaH, NukiwaT, YamayaM. Additional treatment with" exact="clarithromycin" post="reduces fever duration in patients with influenza. Respir Investig."/>
   <result pre="patients with acute lung injury. Chest. 2012;141(5):1153â€�1159.22116799 21TahanF, OzcanA, KocN." exact="Clarithromycin" post="in the treatment of RSV bronchiolitis: a doubleâ€�blind, randomised,"/>
   <result pre="2002;69(1):53â€�57.11847511 23McCallumGB, MorrisPS, ChatfieldMD, et al. A single dose of" exact="azithromycin" post="does not improve clinical outcomes of children hospitalised with"/>
   <result pre="pneumonia. Intensive Care Med. 2013;39(4):693â€�702.23344833 25PintoLA, PitrezPM, LuisiF, et al." exact="Azithromycin" post="therapy in hospitalized infants with acute bronchiolitis is not"/>
   <result pre="26KneyberMC, van WoenselJB, UijtendaalE, UiterwaalCS, KimpenJL. Dutch antibiotics in RSVTRG." exact="Azithromycin" post="does not improve disease course in hospitalized infants with"/>
   <result pre="Cochrane Database Syst Rev. 2015;9:CD002997. 28BrusselleGG, VandersticheleC, JordensP, et al." exact="Azithromycin" post="for prevention of exacerbations in severe asthma (AZISAST): a"/>
   <result pre="trial. Thorax. 2013;68(4):322â€�329.23291349 29GibsonPG, YangIA, UphamJW, et al. Effect of" exact="azithromycin" post="on asthma exacerbations and quality of life in adults"/>
   <result pre="2017;390(10095):659â€�668.28687413 30JohnstonSL, BlasiF, BlackPN, MartinRJ, FarrellDJ, NiemanRB. The effect of" exact="telithromycin" post="in acute exacerbations of asthma. N Engl J Med."/>
   <result pre="Immunol. 2008;122(4):671â€�682. quiz 83â€�4.19014757 33TaylorSL, LeongLEX, MobegiFM, et al. Longâ€�term" exact="azithromycin" post="reduces Haemophilus influenzae and increases antibiotic resistance in severe"/>
   <result pre="ASR . Airway abundance of Haemophilus influenzae predicts response to" exact="azithromycin" post="in adults with persistent uncontrolled asthma. Eur Respir J."/>
   <result pre="TLR3 expression. FASEB J. 2006;20(12):2121â€�2123.16914605 36JangYJ, KwonHJ, LeeBJ. Effect of" exact="clarithromycin" post="on rhinovirusâ€�16 infection in A549 cells. Eur Respir J."/>
   <result pre="I interferon pretreatment. bioRxiv. 2020. 39SuzukiT, YamayaM, SekizawaK, et al." exact="Erythromycin" post="inhibits rhinovirus infection in cultured human tracheal epithelial cells."/>
   <result pre="Lung Cell Mol Physiol. 2001;280(6):L1115â€�L1127.11350790 41MiyamotoD, HasegawaS, SriwilaijaroenN, et al." exact="Clarithromycin" post="inhibits progeny virus production from human influenza virusâ€�infected host"/>
   <result pre="cells. Biol Pharm Bull. 2008;31(2):217â€�222.18239276 42YamayaM, ShinyaK, HatachiY, et al." exact="Clarithromycin" post="inhibits type a seasonal influenza virus infection in human"/>
   <result pre="(Tokyo). 2019;72(10):759â€�768.31300721 44SatoK, SugaM, AkaikeT, et al. Therapeutic effect of" exact="erythromycin" post="on influenza virusâ€�induced lung injury in mice. Am J"/>
   <result pre="Care Med. 1998;157(3 Pt 1):853â€�857.9517602 45SugamataR, SugawaraA, NagaoT, et al." exact="Leucomycin A3," post="a 16â€�membered macrolide antibiotic, inhibits influenza A virus infection"/>
   <result pre="46FageC, PizzornoA, RheaumeC, AbedY, BoivinG. The combination of oseltamivir with" exact="azithromycin" post="does not show additional benefits over oseltamivir monotherapy in"/>
   <result pre="J Med Virol. 2017;89(12):2239â€�2243.28792077 47BeigelmanA, MikolsCL, GunstenSP, CannonCL, BrodySL, WalterMJ." exact="Azithromycin" post="attenuates airway inflammation in a mouse model of viral"/>
   <result pre="drugs against COVIDâ€�19. Preprints. 2020doi:10.20944/preprints202003.0302.v1. 52RennaM, SchaffnerC, BrownK, et al." exact="Azithromycin" post="blocks autophagy and may predispose cystic fibrosis patients to"/>
   <result pre="Le BideauM, DuflotI, et al. In vitro testing of combined" exact="hydroxychloroquine" post="and azithromycin on SARSâ€�CoVâ€�2 shows synergistic effect. Microb Pathog."/>
   <result pre="DuflotI, et al. In vitro testing of combined hydroxychloroquine and" exact="azithromycin" post="on SARSâ€�CoVâ€�2 shows synergistic effect. Microb Pathog. 2020;145:104228.32344177 54GautretP,"/>
   <result pre="synergistic effect. Microb Pathog. 2020;145:104228.32344177 54GautretP, LagierJ, ParolaP, et al." exact="Hydroxychloroquine" post="and azithromycin as a treatment of COVIDâ€�19: results of"/>
   <result pre="Microb Pathog. 2020;145:104228.32344177 54GautretP, LagierJ, ParolaP, et al. Hydroxychloroquine and" exact="azithromycin" post="as a treatment of COVIDâ€�19: results of an openâ€�label"/>
   <result pre="al. Risk of QT interval prolongation associated with use of" exact="hydroxychloroquine" post="with or without concomitant azithromycin among hospitalized patients testing"/>
   <result pre="prolongation associated with use of hydroxychloroquine with or without concomitant" exact="azithromycin" post="among hospitalized patients testing positive for coronavirus disease 2019"/>
   <result pre="(COVIDâ€�19). JAMA Cardiol. 2020;e201834. doi:10.1001/jamacardio.2020.1834. 56MaisonnasseP, GuedjJ, ContrerasV, et al." exact="Hydroxychloroquine" post="use against SARSâ€�CoVâ€�2 infection in nonâ€�human primates. Nature. 2020doi:10.1038/s41586-020-2558-4."/>
   <result pre="Rev Med Virol. 2020;e2134doi:10.1002/rmv.2134. 32618072 58AlbertRK, ConnettJ, BaileyWC, et al." exact="Azithromycin" post="for prevention of exacerbations of COPD. N Engl J"/>
   <result pre="59VosR, VanaudenaerdeBM, VerledenSE, et al. A randomised controlled trial of" exact="azithromycin" post="to prevent chronic rejection after lung transplantation. Eur Respir"/>
   <result pre="biological mechanisms. Respiration. 2011;81(1):67â€�74.20733281 61HuiD, YanF, ChenRH. The effects of" exact="azithromycin" post="on patients with diffuse panbronchiolitis: a retrospective study of"/>
   <result pre="63NagaiH, ShishidoH, YonedaR, YamaguchiE, TamuraA, KurashimaA. Longâ€�term lowâ€�dose administration of" exact="erythromycin" post="to patients with diffuse panbronchiolitis. Respiration. 1991;58(3â€&quot;4):145â€�149.1745845 64WengD, WuQ,"/>
   <result pre="with diffuse panbronchiolitis. Respiration. 1991;58(3â€&quot;4):145â€�149.1745845 64WengD, WuQ, ChenXQ, et al." exact="Azithromycin" post="treats diffuse panbronchiolitis by targeting T cells via inhibition"/>
   <result pre="proliferation. J Surg Res. 2000;90(1):76â€�81.10781378 67SrivastavaP, VardhanH, BhengrajAR, et al." exact="Azithromycin" post="treatment modulates the extracellular signalâ€�regulated kinase mediated pathway and"/>
   <result pre="DNA Cell Biol. 2011;30(8):545â€�554.21438755 68RolfeFG, ValentineJE, SewellWA. Cyclosporin A and" exact="FK506" post="reduce interleukinâ€�5 mRNA abundance by inhibiting gene transcription. Am"/>
   <result pre="Biol. 1997;17(2):243â€�250.9271313 69MiyazakiM, ZaitsuM, HonjoK, IshiiE, HamasakiY. Macrolide antibiotics inhibit" exact="prostaglandin E2" post="synthesis and mRNA expression of prostaglandin synthetic enzymes in"/>
   <result pre="pathways. Eur J Pharmacol. 2012;690(1â€&quot;3):207â€�213.22766066 72TakizawaH, DesakiM, OhtoshiT, et al." exact="Erythromycin" post="and clarithromycin attenuate cytokineâ€�induced endothelinâ€�1 expression in human bronchial"/>
   <result pre="J Pharmacol. 2012;690(1â€&quot;3):207â€�213.22766066 72TakizawaH, DesakiM, OhtoshiT, et al. Erythromycin and" exact="clarithromycin" post="attenuate cytokineâ€�induced endothelinâ€�1 expression in human bronchial epithelial cells."/>
   <result pre="J. 1998;12(1):57â€�63.9701415 73TytecaD, SchanckA, DufreneYF, et al. The macrolide antibiotic" exact="azithromycin" post="interacts with lipids and affects membrane organization and fluidity:"/>
   <result pre="Biochem Biophys Res Commun. 2008;377(1):268â€�274.18840403 77WilmsEB, TouwDJ, HeijermanHG. Pharmacokinetics of" exact="azithromycin" post="in plasma, blood, polymorphonuclear neutrophils and sputum during longâ€�term"/>
   <result pre="Drug Monit. 2006;28(2):219â€�225.16628134 78WildfeuerA, LaufenH, ZimmermannT. Distribution of orally administered" exact="azithromycin" post="in various blood compartments. Int J Clin Pharmacol Ther."/>
   <result pre="Ther. 1994;32(7):356â€�360.7952797 79IshimotoH, MukaeH, SakamotoN, et al. Different effects of" exact="telithromycin" post="on MUC5AC production induced by human neutrophil peptideâ€�1 or"/>
   <result pre="human neutrophil peptideâ€�1 or lipopolysaccharide in NCIâ€�H292 cells compared with" exact="azithromycin" post="and clarithromycin. J Antimicrob Chemother. 2009;63(1):109â€�114.18931390 80BosnarM, KelnericZ, MunicV,"/>
   <result pre="ShoreE, et al. Steadyâ€�state intrapulmonary concentrations of moxifloxacin, levofloxacin, and" exact="azithromycin" post="in older adults. Chest. 2004;125(3):965â€�973.15006955 82TsaiWC, RodriguezML, YoungKS, et"/>
   <result pre="in older adults. Chest. 2004;125(3):965â€�973.15006955 82TsaiWC, RodriguezML, YoungKS, et al." exact="Azithromycin" post="blocks neutrophil recruitment in Pseudomonas endobronchial infection. Am J"/>
   <result pre="Respir Crit Care Med. 2004;170(12):1331â€�1339.15361366 83CulicO, ErakovicV, CepelakI, et al." exact="Azithromycin" post="modulates neutrophil function and circulating inflammatory mediators in healthy"/>
   <result pre="generation by neutrophils. Inflammation. 2016;39(3):1039â€�1048.26983705 86SimpsonJL, PowellH, BoyleMJ, ScottRJ, GibsonPG." exact="Clarithromycin" post="targets neutrophilic airway inflammation in refractory asthma. Am J"/>
   <result pre="87YamaryoT, OishiK, YoshimineH, TsuchihashiY, MatsushimaK, NagatakeT. Fourteenâ€�member macrolides promote the" exact="phosphatidylserine" post="receptorâ€�dependent phagocytosis of apoptotic neutrophils by alveolar macrophages. Antimicrob"/>
   <result pre="Antimicrob Agents Chemother. 2003;47(1):48â€�53.12499168 88PolancecDS, Munic KosV, BanjanacM, et al." exact="Azithromycin" post="drives in vitro GMâ€�CSF/ILâ€�4â€�induced differentiation of human blood monocytes"/>
   <result pre="J Leukoc Biol. 2012;91(2):229â€�243.22131344 89MurphyBS, SundareshanV, CoryTJ, HayesDJr, AnsteadMI, FeolaDJ." exact="Azithromycin" post="alters macrophage phenotype. J Antimicrob Chemother. 2008;61(3):554â€�560.18230686 90LegssyerR, HuauxF,"/>
   <result pre="phenotype. J Antimicrob Chemother. 2008;61(3):554â€�560.18230686 90LegssyerR, HuauxF, LebacqJ, et al." exact="Azithromycin" post="reduces spontaneous and induced inflammation in DeltaF508 cystic fibrosis"/>
   <result pre="fibrosis mice. Respir Res. 2006;7:134.17064416 91BosnarM, BosnjakB, CuzicS, et al." exact="Azithromycin" post="and clarithromycin inhibit lipopolysaccharideâ€�induced murine pulmonary neutrophilia mainly through"/>
   <result pre="Respir Res. 2006;7:134.17064416 91BosnarM, BosnjakB, CuzicS, et al. Azithromycin and" exact="clarithromycin" post="inhibit lipopolysaccharideâ€�induced murine pulmonary neutrophilia mainly through effects on"/>
   <result pre="Pharmacol Exp Ther. 2009;331(1):104â€�113.19633061 92LendermonEA, CoonTA, BednashJS, WeathingtonNM, McDyerJF, MallampalliRK." exact="Azithromycin" post="decreases NALP3 mRNA stability in monocytes to limit inflammasomeâ€�dependent"/>
   <result pre="SegeM, WennerstromU, Damâ€�LarsenS, PerssonJ. Leaky lysosomes in lung transplant macrophages:" exact="azithromycin" post="prevents oxidative damage. Respir Res. 2012;13:83.23006592 94KurdowskaA, NobleJM, GriffithDE."/>
   <result pre="damage. Respir Res. 2012;13:83.23006592 94KurdowskaA, NobleJM, GriffithDE. The effect of" exact="azithromycin" post="and clarithromycin on ex vivo interleukinâ€�8 (ILâ€�8) release from"/>
   <result pre="Res. 2012;13:83.23006592 94KurdowskaA, NobleJM, GriffithDE. The effect of azithromycin and" exact="clarithromycin" post="on ex vivo interleukinâ€�8 (ILâ€�8) release from whole blood"/>
   <result pre="Chemother. 2001;47(6):867â€�870.11389120 95SugiyamaK, ShiraiR, MukaeH, et al. Differing effects of" exact="clarithromycin" post="and azithromycin on cytokine production by murine dendritic cells."/>
   <result pre="95SugiyamaK, ShiraiR, MukaeH, et al. Differing effects of clarithromycin and" exact="azithromycin" post="on cytokine production by murine dendritic cells. Clin Exp"/>
   <result pre="Exp Immunol. 2007;147(3):540â€�546.17302905 96IwamotoS, AzumaE, KumamotoT, et al. Efficacy of" exact="azithromycin" post="in preventing lethal graftâ€�versusâ€�host disease. Clin Exp Immunol. 2013;171(3):338â€�345.23379441"/>
   <result pre="Immunol. 2013;171(3):338â€�345.23379441 97IwamotoS, KumamotoT, AzumaE, et al. The effect of" exact="azithromycin" post="on the maturation and function of murine bone marrowâ€�derived"/>
   <result pre="Immunol. 2011;166(3):385â€�392.22059997 98LinSJ, YanDC, LeeWI, KuoML, HsiaoHS, LeePY. Effect of" exact="azithromycin" post="on natural killer cell function. Int Immunopharmacol. 2012;13(1):8â€�14.22410149 99YamasawaH,"/>
   <result pre="Cell Mol Biol. 2004;30(4):569â€�575.14551160 100StamatiouR, ParaskevaE, BoukasK, GourgoulianisKI, MolyvdasPA, HatziefthimiouAA." exact="Azithromycin" post="has an antiproliferative and autophagic effect on airway smooth"/>
   <result pre="muscle cells. Eur Respir J. 2009;34(3):721â€�730.19386688 101DaenasC, HatziefthimiouAA, GourgoulianisKI, MolyvdasPA." exact="Azithromycin" post="has a direct relaxant effect on precontracted airway smooth"/>
   <result pre="J Pharmacol. 2006;553(1â€&quot;3):280â€�287.17070799 102AsgrimssonV, GudjonssonT, GudmundssonGH, BaldurssonO. Novel effects of" exact="azithromycin" post="on tight junction proteins in human airway epithelia. Antimicrob"/>
   <result pre="in Wuhan, China. Lancet. 2020;395(10223):497â€�506.31986264 104ImamuraY, YanagiharaK, MizutaY, et al." exact="Azithromycin" post="inhibits MUC5AC production induced by the Pseudomonas aeruginosa autoinducer"/>
   <result pre="cells. Antimicrob Agents Chemother. 2004;48(9):3457â€�3461.15328111 105RibeiroCM, HurdH, WuY, et al." exact="Azithromycin" post="treatment alters gene expression in inflammatory, lipid metabolism, and"/>
   <result pre="Pharmacol Ther. 2014;143(2):225â€�245.24631273 112LucchiM, DamleB, FangA, et al. Pharmacokinetics of" exact="azithromycin" post="in serum, bronchial washings, alveolar macrophages and lung tissue"/>
   <result pre="LeaneyJ, CorriganB. Clinical pharmacology perspectives on the antiviral activity of" exact="azithromycin" post="and use in COVIDâ€�19. Clin Pharmacol Ther. 2020;108(2):201â€�211.32302411 114CiganaC,"/>
   <result pre="use in COVIDâ€�19. Clin Pharmacol Ther. 2020;108(2):201â€�211.32302411 114CiganaC, AssaelBM, MelottiP." exact="Azithromycin" post="selectively reduces tumor necrosis factor alpha levels in cystic"/>
   <result pre="2020;108(2):201â€�211.32302411 114CiganaC, AssaelBM, MelottiP. Azithromycin selectively reduces tumor necrosis factor" exact="alpha" post="levels in cystic fibrosis airway epithelial cells. Antimicrob Agents"/>
   <result pre="inflammation in mice. Respirology. 2015;20(7):1055â€�1065.26053964 116RatzingerF, HaslacherH, PoepplW, et al." exact="Azithromycin" post="suppresses CD4(+) Tâ€�cell activation by direct modulation of mTOR"/>
   <result pre="activity. Sci Rep. 2014;4:7438.25500904 117MorinagaY, YanagiharaK, MiyashitaN, et al. Azithromycin," exact="clarithromycin" post="and telithromycin inhibit MUC5AC induction by Chlamydophila pneumoniae in"/>
   <result pre="Rep. 2014;4:7438.25500904 117MorinagaY, YanagiharaK, MiyashitaN, et al. Azithromycin, clarithromycin and" exact="telithromycin" post="inhibit MUC5AC induction by Chlamydophila pneumoniae in airway epithelial"/>
   <result pre="Ther. 2009;22(6):580â€�586.19716898 118CiganaC, NicolisE, PasettoM, AssaelBM, MelottiP. Antiâ€�inflammatory effects of" exact="azithromycin" post="in cystic fibrosis airway epithelial cells. Biochem Biophys Res"/>
   <result pre="Biochem Biophys Res Commun. 2006;350(4):977â€�982.17045242 119YamauchiK, ShibataY, KimuraT, et al." exact="Azithromycin" post="suppresses interleukinâ€�12p40 expression in lipopolysaccharide and interferonâ€�gamma stimulated macrophages."/>
   <result pre="Int J Biol Sci. 2009;5(7):667â€�678.19893639 120HodgeS, HodgeG, JersmannH, et al." exact="Azithromycin" post="improves macrophage phagocytic function and expression of mannose receptor"/>
   <result pre="Crit Care Med. 2008;178(2):139â€�148.18420960 121HodgeS, HodgeG, BrozynaS, JersmannH, HolmesM, ReynoldsPN." exact="Azithromycin" post="increases phagocytosis of apoptotic bronchial epithelial cells by alveolar"/>
   <result pre="macrophages. Eur Respir J. 2006;28(3):486â€�495.16737992 122ArakiN, YanagiharaK, MorinagaY, et al." exact="Azithromycin" post="inhibits nontypeable Haemophilus influenzaeâ€�induced MUC5AC expression and secretion via"/>
   <result pre="Am J Pathol. 2005;167(3):651â€�661.16127146 126HalldorssonS, GudjonssonT, GottfredssonM, SinghPK, GudmundssonGH, BaldurssonO." exact="Azithromycin" post="maintains airway epithelial integrity during Pseudomonas aeruginosa infection. Am"/>
   <result pre="Engl J Med. 2020;NEJMoa2021436. doi:10.1056/NEJMoa2021436. 133CavalcantiAB, ZampieriFG, RosaRG, et al." exact="Hydroxychloroquine" post="with or without azithromycin in mildâ€�toâ€�moderate Covidâ€�19. N Engl"/>
   <result pre="doi:10.1056/NEJMoa2021436. 133CavalcantiAB, ZampieriFG, RosaRG, et al. Hydroxychloroquine with or without" exact="azithromycin" post="in mildâ€�toâ€�moderate Covidâ€�19. N Engl J Med. 2020;NEJMoa2019014. doi:10.1056/NEJMoa2019014."/>
   <result pre="al. A multiâ€�centre openâ€�label twoâ€�arm randomised superiority clinical trial of" exact="azithromycin" post="versus usual care in ambulatory COVIDâ€�19: study protocol for"/>
   <result pre="Syst Rev. 2019;1:CD011825.30656650 136YanagiharaK, IzumikawaK, HigaF, et al. Efficacy of" exact="azithromycin" post="in the treatment of communityâ€�acquired pneumonia, including patients with"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7536958\results\search\drug\results.xml">
   <result pre="therapies. There were 423 studies (61%) that evaluated drugs, including" exact="hydroxychloroquine" post="(122, 17%), lopinavir/ritonavir (36, 5%) and chloroquine (31, 4%)."/>
   <result pre="evaluated drugs, including hydroxychloroquine (122, 17%), lopinavir/ritonavir (36, 5%) and" exact="chloroquine" post="(31, 4%). Other interventions included traditional Chinese medicines (84,"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7537045\results\search\drug\results.xml">
   <result pre="spike protein and cleaved spike (S2 subunit), respectively. TMPRSS2 inhibitors," exact="camostat" post="and nafamostat, blocked entry of SARSâ€�CoV-2 but not VSV."/>
   <result pre="Caluâ€�3 cells were treated with 10Â Î¼M camostat, 10Â Î¼M" exact="nafamostat" post="or DMSO for 1Â h. Then, the cells were"/>
   <result pre="human lung epithelial cell line Caluâ€�3 treated with TMPRSS2 inhibitors" exact="camostat" post="and nafamostat (FigÂ EV1D). SARSâ€�CoVâ€�2 pseudovirus infection was abolished"/>
   <result pre="epithelial cell line Caluâ€�3 treated with TMPRSS2 inhibitors camostat and" exact="nafamostat" post="(FigÂ EV1D). SARSâ€�CoVâ€�2 pseudovirus infection was abolished in cells"/>
   <result pre="numbers of EGFPâ€�positive cells, pretreated with 25HC as compared with" exact="ethanol" post="(EtOH) vehicle, and challenged with EGFPâ€�expressing pseudovirus (FigÂ 2B)."/>
   <result pre="Â±Â SD of nÂ =Â 3. *PÂ 0.05. FTMPRSS2 inhibitors" exact="camostat" post="blocked entry of SARSâ€�CoV and MERSâ€�CoV pseudoviruses. Caluâ€�3 cells"/>
   <result pre="and MERSâ€�CoV pseudoviruses. Caluâ€�3 cells were treated with 10Â Î¼M" exact="camostat" post="or DMSO for 1Â h. Then the cells were"/>
   <result pre="Cathepsin B/L and compared with DMSO control. We found that" exact="camostat" post="mesylate, a TMPRSS2 inhibitor, dramatically reduced viral entry in"/>
   <result pre="plasma membrane of 25HCâ€�treated cells. Caluâ€�3 cells were pretreated with" exact="ethanol" post="or 5Â Î¼M 25HC for 1Â h. Cells were"/>
   <result pre="MERSâ€�CoV pseudovirus into 25HCâ€�treated Caluâ€�3 cells. Cells were pretreated with" exact="ethanol" post="or 5Â Î¼M 25HC for 16Â h, washed, and"/>
   <result pre="lung epithelial cells. Caluâ€�3 cells were treated with 10Â Î¼M" exact="camostat" post="or 25Â Î¼M Eâ€�64D for 1Â h. Then, the"/>
   <result pre="25HC and TMPRSS2 inhibitor to block SARSâ€�CoV-2 entry. Addition of" exact="Nafamostat" post="in 25HCâ€�treated cells were infected with SARSâ€�CoV-2 pseudovirus and"/>
   <result pre="SARSâ€�CoVâ€�2. To address this question, Caluâ€�3 cells were pretreated with" exact="ethanol" post="or 25HC and challenged with SARSâ€�CoV or MERSâ€�CoV pseudoviruses"/>
   <result pre="in medium containing 2% LPDS prior to the treatment of" exact="ethanol" post="or 5Â Î¼M 25HC for 16Â h. Subsequently, cells"/>
   <result pre="40Â Î¼M SZ58â€�035 for 16Â h, prior to treatment with" exact="ethanol" post="or 2.5Â Î¼M 25HC for 1Â h. Cells were"/>
   <result pre="rescues viral entry viral entry. Caluâ€�3 cells were pretreated with" exact="ethanol" post="or 5Â Î¼M 25HC for 16Â h in the"/>
   <result pre="ACAT1 and ACAT2. 48Â h postâ€�transduction, cells were treated with" exact="ethanol" post="or 5Â Î¼M 25HC for 16Â h. Then, the"/>
   <result pre="USAâ€�WA1/2020 strain infection in Caluâ€�3 cells. Cells were pretreated with" exact="ethanol" post="or 25HC followed by infection. At 48Â h postâ€�infection,"/>
   <result pre="waterâ€�soluble cholesterol, and Sandoz 58â€�035 were obtained from Sigma. Camostat," exact="nafamostat" post="and Eâ€�64d were purchased from Selleck Chemicals. VSV pseudovirus"/>
   <result pre="inoculum. 2Â days postâ€�inoculation, cells were washed and stained with" exact="crystal violet." post="Plaque numbers were counted and used to calculate virus"/>
   <result pre="and Sandoz 58â€�035 rescue assays Caluâ€�3 cells were pretreated with" exact="Ethanol" post="or 5Â Î¼M 25HC for 16Â h. For cholesterol"/>
   <result pre="LiH, LuoJ (2020) An experimental trial of recombinant human interferon" exact="alpha" post="nasal drops to prevent coronavirus disease 2019 in medical"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7540197\results\search\drug\results.xml">
   <result pre="to select virtually 1,697 FDA-approved clinical drugs, finding that Losartan," exact="Montelukast" post="Sodium, Quercitrin, Zanamivir, NAD1, Candesartan, Chlorhexidine chlorhydrate and Fostamatinib"/>
   <result pre="drugs, finding that Losartan, Montelukast Sodium, Quercitrin, Zanamivir, NAD1, Candesartan," exact="Chlorhexidine" post="chlorhydrate and Fostamatinib disodium exhibited binding energy superiors to"/>
   <result pre="Losartan, Montelukast Sodium, Quercitrin, Zanamivir, NAD1, Candesartan, Chlorhexidine chlorhydrate and" exact="Fostamatinib" post="disodium exhibited binding energy superiors to âˆ’7.5Â kcal/mol [2],"/>
   <result pre="molecular modelling studies reveal a new mechanism of action of" exact="chloroquine" post="and hydroxychloroquine against SARS-CoV-2 infectionInt. J. Antimicrob. Agents J.2020"/>
   <result pre="studies reveal a new mechanism of action of chloroquine and" exact="hydroxychloroquine" post="against SARS-CoV-2 infectionInt. J. Antimicrob. Agents J.2020 9GurwitzD.Angiotensin receptor"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7544206\results\search\drug\results.xml">
   <result pre="be essential for IAV replication, such as the Double-stranded RNA-specific" exact="adenosine" post="deaminase ADAR and the U6 snRNA phosphodiesterase USB1 (52,53),"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7544963\results\search\drug\results.xml">
   <result pre="vaccine,19 antimicrobials, didanosine20 and hydroxychloroquine,21,22 antiparasitics, ivermectin23 or combination of" exact="hydroxychloroquine" post="and ivermectin,24 antibiotics, azithromycin25 or antiviral drugs ART26 like"/>
   <result pre="21.ZhangTY, ZhongBMeeting the Potential Emergency Global Drug Supply Challenge of" exact="Hydroxychloroquine" post="for COVID-19. Med Drug Discov. 2020;5:100036. doi:10.1016/j.medidd.2020.100036.32292908 22.PicotS, MartyA,"/>
   <result pre="for prospective clinical trials to test the post-exposure potential of" exact="hydroxychloroquine" post="against COVID-19. One Health. 2020;9:100131[published online ahead of print,"/>
   <result pre="Apr 4]. doi:10.1016/j.onehlt.2020.100131.32292817 23.CalyL, DruceJD, CattonMG, JansDA, WagstaffKMThe FDA-approved drug" exact="ivermectin" post="inhibits the replication of SARS-CoV-2 in vitro. Antiviral Res."/>
   <result pre="WangE, LeaneyJ, CorriganBClinical Pharmacology Perspectives on the Antiviral Activity of" exact="Azithromycin" post="and Use in COVID-19. Clin Pharmacol Ther. 2020;108(2):201â€&quot;11. [published"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7545115\results\search\drug\results.xml">
   <result pre="care in Houston and nationwide. The first antiretroviral (ARV) drug," exact="zidovudine" post="(AZT), was approved by the Federal Food and Drug"/>
   <result pre="31 52 176 27 93 â€ƒNo. of Licensed Providers for" exact="Buprenorphine" post="(2020) 768 328 213 553 1240 1865 408 1613"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7545798\results\search\drug\results.xml">
   <result pre="HIV on ART -Case report HIV Latent TB SARS-CoV N/A" exact="Abacavir" post="300â€‰mg Efavirenz 600â€‰mg Kaletra Tenofovir 300â€‰mg Ribavirin 1200â€‰mg prednisolone"/>
   <result pre="ART -Case report HIV Latent TB SARS-CoV N/A Abacavir 300â€‰mg" exact="Efavirenz" post="600â€‰mg Kaletra Tenofovir 300â€‰mg Ribavirin 1200â€‰mg prednisolone 25â€‰mg Diagnosed"/>
   <result pre="report HIV Latent TB SARS-CoV N/A Abacavir 300â€‰mg Efavirenz 600â€‰mg" exact="Kaletra" post="Tenofovir 300â€‰mg Ribavirin 1200â€‰mg prednisolone 25â€‰mg Diagnosed with PTB"/>
   <result pre="TB SARS-CoV N/A Abacavir 300â€‰mg Efavirenz 600â€‰mg Kaletra Tenofovir 300â€‰mg" exact="Ribavirin" post="1200â€‰mg prednisolone 25â€‰mg Diagnosed with PTB during hospitalization Mild"/>
   <result pre="N/A Abacavir 300â€‰mg Efavirenz 600â€‰mg Kaletra Tenofovir 300â€‰mg Ribavirin 1200â€‰mg" exact="prednisolone" post="25â€‰mg Diagnosed with PTB during hospitalization Mild course SARS"/>
   <result pre="old female with confirmed COVID-19 Case study PTB COVID-19 N/A" exact="hydroxychloroquine" post="400â€‰mg twice daily in addition to antibiotics. Anti TB"/>
   <result pre="76â€‰years -Case series Previous TB PTB COVID-19 N/A Lopinavir +" exact="Ritonavir" post="Arbidol Methyl prednisolone Antibiotics Traditional Chinese medicine Intravenous immunoglobulin"/>
   <result pre="Previous TB PTB COVID-19 N/A Lopinavir + Ritonavir Arbidol Methyl" exact="prednisolone" post="Antibiotics Traditional Chinese medicine Intravenous immunoglobulin Ventilatory support Antituberculosis"/>
   <result pre="and history of Parkinsonâ€™s disease. Case study PTB COVID-19 N/A" exact="Hydroxychloroquine" post="Oxygen supplementation Anti-TB drugs TB diagnosed in hospitalization Critical"/>
   <result pre="Case study Disseminated TB COVID-19 N/A COVID-19 convalescent plasma Favipiravir" exact="meropenem" post="Ventilatory support Anti-TB drugs TB diagnosed in hospitalization Critical"/>
   <result pre="diabetic, with confirmed COVID-19 Case study PTB COVID-19 N/A Lopinavir/ritonavir" exact="Ribavirin" post="Dexamethasone Prophylactic anticoagulation Supportive ICU care Anti-TB drugs Previous"/>
   <result pre="confirmed COVID-19/TB co-infection Case series PTB COVID-19 N/A Arbidol Moxifloxacin" exact="Linezolid" post="immunomodulatory therapy with thymopentin Ventilatory support Anti-TB drugs The"/>
   <result pre="HIV 20 confirmed COVID-19/TB cases Retrospective cohort study (Cohort B)" exact="Hydroxychloroquine" post="Lopinavir/ ritonavir Azythromycin Empiric antibiotic Enoxaparine 4000â€‰IU Dexamethasone Oxygen"/>
   <result pre="confirmed COVID-19/TB cases Retrospective cohort study (Cohort B) Hydroxychloroquine Lopinavir/" exact="ritonavir" post="Azythromycin Empiric antibiotic Enoxaparine 4000â€‰IU Dexamethasone Oxygen through non-rebreather,"/>
   <result pre="A case of SARS-CoV/HIV/TB co-infection [31] was managed with abacavir/efavirenz/kaletra/tenofovir/ribavirin," exact="prednisolone" post="and anti TB drugs and another case with SARS-CoV/TB"/>
   <result pre="the Xpert MTB / RIF assay detects M. tuberculosis and" exact="rifampicin" post="resistance within less than two hours [55]. Xpert MTB/RIF"/>
   <result pre="positive and the culture is negative, start TB preventive treatment." exact="Isoniazid" post="monotherapy for six (6) months is recommended for the"/>
   <result pre="in high burden HIV/TB countries [57]. Rifampicin or rifapentine plus" exact="isoniazid" post="daily for three (3) months should be offered as"/>
   <result pre="as an alternative to six (6) months of isoniazid. However," exact="rifampicin" post="and rifapentine should be prescribed with caution in HIV/COVID-19"/>
   <result pre="a wide variety of pathogens [58], including SARS-CoV. Lopinavir /" exact="ritonavir" post="(LPV/r) has a moderate anti-SARS-CoV-2 antiviral activity which works"/>
   <result pre="studies were low of power. Drug-drug interactions between PIs and" exact="rifampicin" post="are known in HIV/TB co-infection. Studies have demonstrated that"/>
   <result pre="HIV/TB co-infection. Studies have demonstrated that co-administration of PIs with" exact="rifampicin" post="reduces PIs systemic concentration to less than 75% (cytochrome"/>
   <result pre="may compromise COVID-19 treatment. Remdesivir should also not associate to" exact="rifampicin" post="in COVID-19/TB co-infection because of strong induction [64]. A"/>
   <result pre="of strong induction [64]. A recent review has reported that" exact="chloroquine" post="phosphate and hydroxychloroquine showed favorable outcomes in the recovery"/>
   <result pre="[64]. A recent review has reported that chloroquine phosphate and" exact="hydroxychloroquine" post="showed favorable outcomes in the recovery of COVID-19 patients"/>
   <result pre="outcomes in the recovery of COVID-19 patients [26, 65â€&quot;68]. Both" exact="chloroquine" post="and hydroxychloroquine are metabolized by hepatic cytochrome P450 enzyme"/>
   <result pre="the recovery of COVID-19 patients [26, 65â€&quot;68]. Both chloroquine and" exact="hydroxychloroquine" post="are metabolized by hepatic cytochrome P450 enzyme 2D6 (CYP2D6)"/>
   <result pre="CYP3A4 and CYP2D6 [70]. The reduction in the efficacy of" exact="chloroquine" post="when administered in conjunction with rifampicin may be due"/>
   <result pre="in the efficacy of chloroquine when administered in conjunction with" exact="rifampicin" post="may be due to the inducing effect of rifampicin"/>
   <result pre="with rifampicin may be due to the inducing effect of" exact="rifampicin" post="on multidrug resistance associated protein (MRP) and development of"/>
   <result pre="associated protein (MRP) and development of CYP450 [70]. Additionally, high-dose" exact="chloroquine" post="is more toxic than lower dose [64]. This is"/>
   <result pre="than lower dose [64]. This is why; studies should clarify" exact="chloroquine" post="and hydroxychloroquine dose adjustment in COVID-19/TB co-infection. Based on"/>
   <result pre="dose [64]. This is why; studies should clarify chloroquine and" exact="hydroxychloroquine" post="dose adjustment in COVID-19/TB co-infection. Based on the above,"/>
   <result pre="adjustments should be taken into consideration in case PIs, chloroquine," exact="hydroxychloroquine" post="and remdesivir are administered with rifampicin. Another option is"/>
   <result pre="remdesivir are administered with rifampicin. Another option is to shift" exact="rifampicin" post="to rifabutin or adapted TB regimens without rifampicin. In"/>
   <result pre="administered with rifampicin. Another option is to shift rifampicin to" exact="rifabutin" post="or adapted TB regimens without rifampicin. In contrast, clofazimine"/>
   <result pre="to rifabutin or adapted TB regimens without rifampicin. In contrast," exact="clofazimine" post="used in MDR-TB is a strong inhibitor of PIs,"/>
   <result pre="national guidelines and continue ART. Preferred COVID-19 antivirals are oseltamivir," exact="chloroquine" post="or hydroxychloroquine associated to LV/r or darunavir/cobicistat and Azithromycin"/>
   <result pre="and continue ART. Preferred COVID-19 antivirals are oseltamivir, chloroquine or" exact="hydroxychloroquine" post="associated to LV/r or darunavir/cobicistat and Azithromycin may be"/>
   <result pre="oseltamivir, chloroquine or hydroxychloroquine associated to LV/r or darunavir/cobicistat and" exact="Azithromycin" post="may be indicated [68]. Chloroquine: 1â€‰g PO once on"/>
   <result pre="1, then 400â€‰mg PO once daily for 4â€&quot;7â€‰days [64] or" exact="lopinavir" post="400â€‰mg/ritonavir 100â€‰mg PO twice [65]. All of them should"/>
   <result pre="PO twice [65]. All of them should be associated with" exact="Azithromycin" post="[64]. Drugs interactions should be reviewed as described above."/>
   <result pre="recommended in severe/critical COVID-19 however this cannot be administered with" exact="rifampicin" post="[64]. Short period low-dose corticosteroid therapy is preferred over"/>
   <result pre="severe COVID-19. Short period low-dose corticosteroid therapy, anticoagulant therapy and" exact="norepinephrine" post="as the first-choice vasopressor are recommended [64]. Anticoagulant therapy"/>
   <result pre="in meta-analyses http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp. Accessed 29 July 2020. 26.WangMCaoRZhangLYangXLiuJXuMet al.Remdesivir and" exact="chloroquine" post="effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in"/>
   <result pre="J Epidemiol202041E057 46.Zhang H, Yuan Y. Efficacy and Safety of" exact="Nintedanib" post="in the Treatment of Pulmonary Fibrosis in Patients with"/>
   <result pre="amplification test for rapid and simultaneous detection of TB and" exact="rifampicin" post="resistance2016 56.Cattamanchi A, Ssewenyana I, Nabatanzi R, Miller CR,"/>
   <result pre="Int AIDS Soc. 2020. 10.1002/:jia2.25489. 62.AcostaEPKendallMAGerberJGAlston-SmithBKoletarSLZolopaARet al.Effect of concomitantly administered" exact="rifampin" post="on the pharmacokinetics and safety of atazanavir administered twice"/>
   <result pre="of concomitantly administered rifampin on the pharmacokinetics and safety of" exact="atazanavir" post="administered twice dailyAntimicrob Agents Chemother20075193104311010.1128/AAC.00341-0717576825 63.KaranjaJKKiboiNGNebereSNHO A.Highly active antiretroviral"/>
   <result pre="vitro antiviral activity and projection of optimized dosing design of" exact="hydroxychloroquine" post="for the treatment of severe acute respiratory syndrome coronavirus"/>
   <result pre="review. Inf Prev Pract 2020; https://doi.org/10.1016/j.infpip.2020.100061. 69.JuurlinkDNSafety considerations with chloroquine," exact="hydroxychloroquine" post="and azithromycin in the management of SARS-CoV-2 infectionCan Med"/>
   <result pre="Prev Pract 2020; https://doi.org/10.1016/j.infpip.2020.100061. 69.JuurlinkDNSafety considerations with chloroquine, hydroxychloroquine and" exact="azithromycin" post="in the management of SARS-CoV-2 infectionCan Med Assoc J202019217E450E45310.1503/cmaj.20052832269021"/>
   <result pre="Assoc J202019217E450E45310.1503/cmaj.20052832269021 70.SousaMPozniakABoffitoMPharmacokinetics and pharmacodynamics of drug interactions involving rifampicin," exact="rifabutin" post="and antimalarial drugsJ Antimicrob Chemother200862587287810.1093/jac/dkn33018713760 71.MarquezBVan BambekeFABC multidrug transporters:"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7546461\results\search\drug\results.xml">
   <result pre="of (Re-)emerging and foodborne outbreaks in Europe https://www.compare-europe.eu/ COPCOV Chloroquine/" exact="hydroxychloroquine" post="prevention of Coronavirus Disease (COVID-19) in the healthcare setting;"/>
   <result pre="Analyses of (Re-)emerging and foodborne outbreaks in Europe; COPCOV, Chloroquine/" exact="hydroxychloroquine" post="prevention of Coronavirus Disease (COVID-19) in the healthcare setting;"/>
   <result pre="synthetic genomics platform. Nature. 2020;582:561â€&quot;565. 10.1038/s41586-020-2294-932365353 48JakharD, KaurI. Potential of" exact="chloroquine" post="and hydroxychloroquine to treat COVID-19 causes fears of shortages"/>
   <result pre="platform. Nature. 2020;582:561â€&quot;565. 10.1038/s41586-020-2294-932365353 48JakharD, KaurI. Potential of chloroquine and" exact="hydroxychloroquine" post="to treat COVID-19 causes fears of shortages among people"/>
   <result pre="Med. 2020;26:632. 49U.S. Food &amp;amp; Drug Administration. FDA statements on" exact="hydroxychloroquine" post="and chloroquine. Available from: https://www.fda.gov/drugs/drug-safety-and-availability/fda-cautions-against-use-hydroxychloroquine-or-chloroquine-covid-19-outside-hospital-setting-or. 50LiG, De ClercqE. Therapeutic"/>
   <result pre="Available from: https://opencovidpledge.org/about. 76Financial Times. AbbVie drops patent rights for" exact="Kaletra" post="antiviral treatment. Available from: https://www.ft.com/content/5a7a9658-6d1f-11ea-89df-41bea055720b. 77Netherlands Authority for Consumers"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7548526\results\search\drug\results.xml">
   <result pre="and systems biologyFront Life Sci201912142610.1080/21553769.2019.1682064 28.The ASCO Post. FDA approves" exact="larotrectinib" post="for solid tumors with NTRK gene fusion. Dec 27,"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7549853\results\search\drug\results.xml">
   <result pre="sars-cov-2 infection sars-cov-2 pathogenesis sars-cov-2 induced ards sars-cov-2 treatment remdesivir" exact="dexamethasone" post="The content published in Cureus is the result of"/>
   <result pre="intubationÂ [24]. Corticosteroids (Dexamethasone) Current guidelines recommend the use of" exact="dexamethasone" post="(6 mg/day for 10 days) in patients with SARS-CoV-2"/>
   <result pre="randomized control trials have shown that the early introduction of" exact="dexamethasone" post="or methylprednisolone to patients with moderate-to-severe ARDS can reduce"/>
   <result pre="trials have shown that the early introduction of dexamethasone or" exact="methylprednisolone" post="to patients with moderate-to-severe ARDS can reduce both mechanical"/>
   <result pre="study on 213 patients demonstrated that the early use of" exact="methylprednisolone" post="(0.5-1 mg/kg/day for three days) resulted in a reduction"/>
   <result pre="of critically-ill patients from China revealed that patients treated with" exact="methylprednisolone" post="(median dosage of 40 mg/day for eight days) were"/>
   <result pre="treated with standard of care (SOC) plus 6 mg/day of" exact="dexamethasone" post="for 10 days to SOC alone. Preliminary analysis of"/>
   <result pre="SOC alone. Preliminary analysis of 6,425 patients (2,104 from the" exact="dexamethasone" post="arm and 4,321 from the control arm) revealed statistically"/>
   <result pre="as the basis for the NIHâ€™s recommendation for the use" exact="dexamethasone" post="in SARS-CoV-2 patients who require ventilator or supplementary oxygen"/>
   <result pre="the treatment arm, is warrantedÂ [37]. In the event that" exact="dexamethasone" post="is unavailable, it is reasonable to use alternative glucocorticoids,"/>
   <result pre="hydrocortisone. The total daily dose equivalencies to 6 mg/day of" exact="dexamethasone" post="for these medications are 40 mg, 32 mg, and"/>
   <result pre="trial by Gilead Sciences. June 1, 2020). Chloroquine, Hydroxychloroquine, and" exact="Azithromycin" post="Current guidelines recommend against the use of high-dose chloroquine"/>
   <result pre="and Azithromycin Current guidelines recommend against the use of high-dose" exact="chloroquine" post="(600 mg BID for 10 days) or hydroxychloroquine plus"/>
   <result pre="of high-dose chloroquine (600 mg BID for 10 days) or" exact="hydroxychloroquine" post="plus azithromycin for the treatment of SARS-CoV-2Â [24]. Chloroquine"/>
   <result pre="chloroquine (600 mg BID for 10 days) or hydroxychloroquine plus" exact="azithromycin" post="for the treatment of SARS-CoV-2Â [24]. Chloroquine and its"/>
   <result pre="or hydroxychloroquine plus azithromycin for the treatment of SARS-CoV-2Â [24]." exact="Chloroquine" post="and its analog hydroxychloroquine have historically been used to"/>
   <result pre="for the treatment of SARS-CoV-2Â [24]. Chloroquine and its analog" exact="hydroxychloroquine" post="have historically been used to treat malaria and certain"/>
   <result pre="reach sufficient antiviral concentrations along with their concurrent use with" exact="azithromycin" post="(another QTc prolonging agent) has further exacerbated these concerns."/>
   <result pre="exacerbated these concerns. Thus far, the safety and efficacy of" exact="chloroquine" post="and hydroxychloroquine in SARS-CoV-2 have been evaluated through a"/>
   <result pre="concerns. Thus far, the safety and efficacy of chloroquine and" exact="hydroxychloroquine" post="in SARS-CoV-2 have been evaluated through a number of"/>
   <result pre="small clinical trials, case series, and observational studies. Studies on" exact="chloroquine" post="have shown minimal efficacy in the treatment of SARS-CoV-2"/>
   <result pre="(600 mg BID for 10 days)Â [42-43]. Studies looking at" exact="hydroxychloroquine" post="have been inconclusive, with results varying from worse to"/>
   <result pre="varying from worse to better outcomes. One study found that" exact="hydroxychloroquine" post="was more likely to be given to patients who"/>
   <result pre="older, underlying comorbidities) and therefore could not be determined whether" exact="hydroxychloroquine" post="administration resulted in an increased or reduced risk of"/>
   <result pre="While others have shown no treatment benefits among patients receiving" exact="hydroxychloroquine" post="Â± azithromycin compared with patients not receiving hydroxychloroquine or"/>
   <result pre="have shown no treatment benefits among patients receiving hydroxychloroquine Â±" exact="azithromycin" post="compared with patients not receiving hydroxychloroquine or SOC aloneÂ"/>
   <result pre="patients receiving hydroxychloroquine Â± azithromycin compared with patients not receiving" exact="hydroxychloroquine" post="or SOC aloneÂ [45]. Conversely, a potential increased risk"/>
   <result pre="and Drug Administration (FDA) does not approve the use of" exact="hydroxychloroquine" post="and chloroquine for the treatment of SARS-CoV-2Â [24]. Immune-Based"/>
   <result pre="Administration (FDA) does not approve the use of hydroxychloroquine and" exact="chloroquine" post="for the treatment of SARS-CoV-2Â [24]. Immune-Based Therapies On"/>
   <result pre="by health care providers with extensive airway management experience. Both" exact="dexamethasone" post="and remdesivir have demonstrated positive early results in clinical"/>
   <result pre="ahead of print]N Engl J MedHorbyPShen LimWEmbersonJet al.2020 38Remdesivir and" exact="chloroquine" post="effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in"/>
   <result pre="J MedGoldmanJDLyeDCBHuiDSet al.2020 42Effect of high vs low doses of" exact="chloroquine" post="diphosphate as adjunctive therapy for patients hospitalized with severe"/>
   <result pre="with chloroquineJ Mol Cell BiolHuangMTangTPangPet al.32232512202032236562 44Association of treatment with" exact="hydroxychloroquine" post="or azithromycin with in-hospital mortality in patients with COVID-19"/>
   <result pre="Mol Cell BiolHuangMTangTPangPet al.32232512202032236562 44Association of treatment with hydroxychloroquine or" exact="azithromycin" post="with in-hospital mortality in patients with COVID-19 in New"/>
   <result pre="patients with COVID-19 in New York StateJAMARosenbergESDufortEMUdoTet al.24932502323202032392282 45Outcomes of" exact="hydroxychloroquine" post="usage in United States veterans hospitalized with COVID-19 [Online"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7550555\results\search\drug\results.xml">
   <result pre="National Heart, Lung, and Blood Institute 10.13039/100000050 National Institute on" exact="Alcohol" post="Abuse and Alcoholism 10.13039/100000027 National Institute of Diabetes and"/>
   <result pre="National Heart, Lung, and Blood Institute, the National Institute on" exact="Alcohol" post="Abuse and Alcoholism, the National Institute of Diabetes and"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7551028\results\search\drug\results.xml">
   <result pre="initially forfeited especially for long-term safety reasons. For instance, the" exact="Thalidomide" post="tragedy which became widespread across Europe, Australia and Japan"/>
   <result pre="safer and more careful approach, the company Celgene successfully repositioned" exact="Thalidomide" post="into an effective cancer drug therapy for multiple myeloma."/>
   <result pre="humans. An early example in research was the use of" exact="Hydroxychloroquine" post="(HCQ) in combination with azithromycin, which generated deep interest"/>
   <result pre="with azithromycin, which generated deep interest in the potential of" exact="Chloroquine" post="(CQ) and its derivates for consideration as a potential"/>
   <result pre="primarily on cancers [31]. For instance, it was found that" exact="Leflunomide" post="(LEF), a drug for active rheumatoid arthritis, might increase"/>
   <result pre="back to as early as the 1970s, where the drug" exact="Minoxidil" post="was approved to treat hair loss aside from its"/>
   <result pre="hypertension then became a treatment for hair loss prevention [49,50]." exact="Minoxidil" post="was first introduced in the 1970s/1980s to counteract hypertension."/>
   <result pre="the 1970s/1980s to counteract hypertension. However, patients who had consumed" exact="Minoxidil" post="came across a widespread side effect known as hypertrichosis,"/>
   <result pre="loss in exclusive rights on the drug in 2017. 4.3." exact="Duloxetine" post="Repositioned for Stress Urinary Incontinence Duloxetine was a norepinephrine"/>
   <result pre="drug in 2017. 4.3. Duloxetine Repositioned for Stress Urinary Incontinence" exact="Duloxetine" post="was a norepinephrine and serotonin reuptake inhibitor developed by"/>
   <result pre="4.3. Duloxetine Repositioned for Stress Urinary Incontinence Duloxetine was a" exact="norepinephrine" post="and serotonin reuptake inhibitor developed by Eli Lilly &amp;amp;"/>
   <result pre="was to treat major depressive disorder [56]. However, serotonin and" exact="norepinephrine" post="are also known to exhibit excitatory effects on urethral"/>
   <result pre="musculoskeletal pain treatment, respectively [57,58]. As of the year 2011," exact="Duloxetine" post="has generated more than $9 billion in revenue. 4.4."/>
   <result pre="where it was intended for abortion with the active ingredient," exact="mifepristone" post="which, is now considered a remedy for Cushingâ€™s syndrome."/>
   <result pre="patients who suffered from the adverse effects upon administration of" exact="Carbamazepine" post="ER as compared to the traditional IR (immediate-release) at"/>
   <result pre="initial unpropitious outcome of drug development. For example, the once-controversial" exact="Thalidomide" post="that was initially intended for sedative purposes is now"/>
   <result pre="and highly resistant and orphan diseases. 5.1. Novel Uses of" exact="Zidovudine" post="for Viral Diseases The development of a drug for"/>
   <result pre="other drug classes like the non-nucleoside reverse transcriptase inhibitor (NNRTI)," exact="Efavirenz" post="(EFV), has reported promising results on multidrug-resistant HIV-1 patients"/>
   <result pre="example, it was discovered that two current drugs, iodixanol, and" exact="sirolimus" post="work synergistically at specific concentrations for HIV treatment via"/>
   <result pre="molecular docking simulations [78]. 5.2. New Life to almost Extinct" exact="Auranofin" post="Drug repositioning is also important to eradicate multitudinous highly"/>
   <result pre="Also, the significant adverse effects over the long-term usage of" exact="Auranofin" post="such as diarrhoea, vomiting, abdominal cramps and symptoms of"/>
   <result pre="away from that particular drug. However, in a recent study," exact="Auranofin" post="exhibited antigiardial activity, especially on a metronidazole-resistant strain by"/>
   <result pre="counter oxidative damage in Giardia Lamblia [68]. Apart from that," exact="Auranofin" post="has also shown a positive outcome in fighting HIV."/>
   <result pre="to assemble and release [79]. According to Lewis et al.," exact="Auranofin" post="notably reduces the cell-associated viral DNA reservoir and induces"/>
   <result pre="a side note, a recent study evaluated the effects of" exact="Auranofin" post="on melanogenesis [80]. This study assessed and discovered that"/>
   <result pre="Auranofin on melanogenesis [80]. This study assessed and discovered that" exact="Auranofin" post="successfully inhibited key factors in melanogenesis by inhibiting tyrosinase"/>
   <result pre="of melanosomes in immature stages. With this promising outcome, repositioning" exact="Auranofin" post="can undoubtedly benefit patients by providing a cheaper and"/>
   <result pre="to be used for COVID-19. Two HIV protease inhibitors, namely," exact="Ritonavir" post="and ASC09, are currently underway in clinical trials to"/>
   <result pre="This study describes the potential of the approved anticancer drug" exact="Carfilzomib" post="for COVID-19 and other drugs such as antibiotics through"/>
   <result pre="elaborately explained in their research article. Repurposing the Antimalarial Drug" exact="Chloroquine" post="for SARS-CoV-2/COVID-19 Treatment Recently, there have been discussions on"/>
   <result pre="Treatment Recently, there have been discussions on repurposing the antimalarialdrug" exact="Chloroquine" post="(CQ) or its alternatives CQ phosphate or Hydroxychloroquine (HCQ)"/>
   <result pre="the antimalarialdrug Chloroquine (CQ) or its alternatives CQ phosphate or" exact="Hydroxychloroquine" post="(HCQ) for the treatment of SARS-CoV-2 patients. Initially, CQ"/>
   <result pre="C infection, HCQ used in combination with pegylated interferon and" exact="ribavirin" post="resulted in a positive effect on reducing the viral"/>
   <result pre="already available drugs against 2019-nCoV infection, namely ribavirin, penciclovir, nitazoxanide," exact="nafamostat" post="and CQ [91]. The highlight of their results has"/>
   <result pre="Aventis Paris developed Prednisporin, which combines two old drugs, glucocorticoid" exact="Prednisolone" post="acetate and the immunosuppressant Cyclosporine A for the treatment"/>
   <result pre="drug-disease relationships for computational drug repositioningBrief. Bioinform.20111230331110.1093/bib/bbr01321690101 14.GautretP.LagierJ.ParolaP.HoangV.MeddebL.MailheM.DoudierB.CourjonJ.GiordanengoV.VieiraV.et al.Hydroxychloroquine and" exact="azithromycin" post="as a treatment of COVID-19: Results of an open-label"/>
   <result pre="Method for Quantitative Structureâ€&quot;Activity RelationshipsJ. Chem. Inf. Model.20155526327410.1021/ci500747n25635324 37.SpauldingA.RutherfordG.SiegfriedN.Stavudine or" exact="Zidovudine" post="in three-drug combination therapy for initial treatment of HIV"/>
   <result pre="Transl. Med.20161411510.1186/s12967-016-1031-526727970 51.Camacho-MartÃ­nezF.Hair Loss in WomenSemin. Cutan. Med. Surg.200928193210.1016/j.sder.2009.01.00119341939 52.EpsteinE.Topical" exact="minoxidil" post="therapy for androgenetic alopeciaArch. Derm.198812432232310.1001/archderm.124.3.3223345081 53.MessengerA.RundegrenJ.Minoxidil: Mechanisms of action"/>
   <result pre="Am. Acad. Dermatol.20085954756610.1016/j.jaad.2008.07.00118793935 55.RenaudR.XuerebH.Erectile-dysfunction therapiesNat. Rev. Drug Discov.2002166366410.1038/nrd89812216576 56.GoldsteinD.LuY.DetkeM.HudsonJ.IyengarS.DemitrackM.Effects of" exact="Duloxetine" post="on Painful Physical Symptoms Associated With DepressionPsychosomatics200445172810.1176/appi.psy.45.1.1714709757 57.DoanT.PollastriM.WaltersM.GeorgG.The Future"/>
   <result pre="computational drug repositioning approachAsian J. Sci. Technol.20191099789984 79.LewisM.DaFonsecaS.ChomontN.PalamaraA.TardugnoM.MaiA.CollinsM.WagnerW.Yalley-OgunroJ.GreenhouseJ.et al.Gold drug" exact="auranofin" post="restricts the viral reservoir in the monkey AIDS model"/>
   <result pre="induces containment of viral load following ART suspensionAIDS2011251347135610.1097/QAD.0b013e328347bd7721505294 80.GoenkaS.SimonS.Organogold drug" exact="Auranofin" post="exhibits anti-melanogenic activity in B16F10 and MNT-1 melanoma cellsArch."/>
   <result pre="Arbidol for COVID-19: A Randomised Clinical TrialmedRxiv202010.1101/2020.03.17.20037432 90.CalyL.DruceJ.CattonM.JansD.WagstaffK.The FDA-approved drug" exact="ivermectin" post="inhibits the replication of SARS-CoV-2 In VitroAntivir. Res.202017810478710.1016/j.antiviral.2020.10478732251768 91.WangJ.Fast"/>
   <result pre="J.200526910.1186/1743-422X-2-6916115318 99.HelalG.GadM.Abd-EllahM.EidM.Hydroxychloroquine augments early virological response to pegylated interferon plus" exact="ribavirin" post="in genotype-4 chronic hepatitis C patientsJ. Med. Virol.2016882170217810.1002/jmv.2457527183377 100.YaoX.YeF.ZhangM.CuiC.HuangB.NiuP.LiuX.ZhaoL.DongE.SongC.et"/>
   <result pre="Vitro Antiviral Activity and Projection of Optimized Dosing Design of" exact="Hydroxychloroquine" post="for the Treatment of Severe Acute Respiratory Syndrome Coronavirus"/>
   <result pre="Treating COVID-19Available online: https://www.cebm.net/covid-19/chloroquine-and-hydroxychloroquine-current-evidence-for-their-effectiveness-in-treating-covid-19/(accessed on 6 March 2020) 102.SavarinoA.BoelaertJ.CassoneA.MajoriG.CaudaR.Effects of" exact="Chloroquine" post="on viral infections: An old drug against todayâ€™s diseasesLancet"/>
   <result pre="a reality?Nat. Rev. Clin. Oncol.2010740141410.1038/nrclinonc.2010.6420551945 111.DrilonA.CamidgeD.OuS.ClarkJ.SocinskiM.WeissJ.RielyG.WinterM.WangS.MontiK.et al.Efficacy and safety of" exact="crizotinib" post="in patients (pts) with advanced MET exon 14-altered non-small"/>
   <result pre="and the prior art patents of competitorsDrug Discov. Today2014191841184710.1016/j.drudis.2014.09.01625269415 114.StewartA.How" exact="Thalidomide" post="Works Against CancerScience201434325625710.1126/science.124954324436409 115.KimH.OhS.Novel Systemic Therapies for Advanced Gastric"/>
   <result pre="and their new roles. Drug Original Medication Repositioned Medication References" exact="Auranofin" post="Rheumatoid arthritis Metronidazole resistant Giardiasis [68] Crizotinib Anaplastic large-cell"/>
   <result pre="roles. Drug Original Medication Repositioned Medication References Auranofin Rheumatoid arthritis" exact="Metronidazole" post="resistant Giardiasis [68] Crizotinib Anaplastic large-cell lymphoma Non-small-cell lung"/>
   <result pre="[68] Crizotinib Anaplastic large-cell lymphoma Non-small-cell lung cancer (NSCLC) [81]" exact="Duloxetine" post="Major depressive disorder Stress Urinary Incontinence (SUI) [5] Everolimus"/>
   <result pre="Tuberous sclerosis complex [22] [72] Korlym Abortion Cushingâ€™s Syndrome [66]" exact="Minoxidil" post="Hypertension Androgenic alopecia (Hair loss) [51] Sildenafil Angina, chest"/>
   <result pre="(Hair loss) [51] Sildenafil Angina, chest pain/discomfort Erectile Dysfunction [55]" exact="Thalidomide" post="Morning sickness pregnant women Multiple myelomas [13] Zidovudine Anticancer"/>
   <result pre="Dysfunction [55] Thalidomide Morning sickness pregnant women Multiple myelomas [13]" exact="Zidovudine" post="Anticancer agent Antiretroviral agent-HIV [75] viruses-12-01058-t002_Table 2Table 2 Summary"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7551260\results\search\drug\results.xml">
   <result pre="factor (G-CSF), granulocyte-macrophage colony-stimulating factor (GM-CSF), IP-10, macrophage inflammatory protein-1" exact="alpha" post="(MIP-1Î±), and TNF-Î± [12,74]. However, these proinflammatory cytokines were"/>
   <result pre="patients treated with a triple combination of IFNÎ²-1b, lopinavir-ritonavir, and" exact="ribavirin" post="showed faster viral clearance and more rapid clinical improvement"/>
   <result pre="Host Microbe20202786386910.1016/j.chom.2020.05.00932464098 127.HungI.F.LungK.C.TsoE.Y.LiuR.ChungT.W.ChuM.Y.NgY.Y.LoJ.ChanJ.TamA.R.et al.Triple combination of interferon beta-1b, lopinavir-ritonavir, and" exact="ribavirin" post="in the treatment of patients admitted to hospital with"/>
   <result pre="SARS-CoV-2: New treatment option for COVID-19Antimicrob. Agents Chemother.202064e00754-2010.1128/AAC.00754-2032312781 132.WangM.CaoR.ZhangL.YangX.LiuJ.XuM.ShiZ.HuZ.ZhongW.XiaoG.Remdesivir and" exact="chloroquine" post="effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in"/>
   <result pre="effective in inhibiting SARS-CoV-2 infection in vitroCell Discov.2020610.1038/s41421-020-0156-0 134.SchoergenhoferC.JilmaB.StimpflT.KarolyiM.ZoufalyA.Pharmacokinetics of" exact="lopinavir" post="and ritonavir in patients hospitalized with coronavirus disease 2019"/>
   <result pre="inhibiting SARS-CoV-2 infection in vitroCell Discov.2020610.1038/s41421-020-0156-0 134.SchoergenhoferC.JilmaB.StimpflT.KarolyiM.ZoufalyA.Pharmacokinetics of lopinavir and" exact="ritonavir" post="in patients hospitalized with coronavirus disease 2019 (COVID-19)Ann. Intern."/>
   <result pre="with COVID-19Clin. Exp. Rheumatol.20203852953232359035 138.McInnesI.B.ByersN.L.HiggsR.E.LeeJ.MaciasW.L.NaS.OrtmannR.A.RochaG.RooneyT.P.WehrmanT.et al.Comparison of baricitinib, upadacitinib, and" exact="tofacitinib" post="mediated regulation of cytokine signaling in human leukocyte subpopulationsArthritis"/>
   <result pre="Inhibits TMPRSS2 Blocks the spread and pathogenesis of SARS-CoV [131]" exact="Chloroquine" post="Hydroxychloroquine Inhibit viral entry and endocytosis Immunomodulatory effects [132,133]"/>
   <result pre="TMPRSS2 Blocks the spread and pathogenesis of SARS-CoV [131] Chloroquine" exact="Hydroxychloroquine" post="Inhibit viral entry and endocytosis Immunomodulatory effects [132,133] Lopinavir/Ritonavir"/>
   <result pre="Immunomodulatory effects [132,133] Lopinavir/Ritonavir Inhibits coronavirus 3CLpro activity [134] Remdesivir" exact="Ribavirin" post="Favipiravir Binds viral RdRp, which inhibits viral replication via"/>
   <result pre="replication via premature termination of RNA transcription [124,132] Corticosteroids Dexamethasone" exact="Methylprednisolone" post="Potential prevention or mitigation of the systemic inflammatory responses"/>
   <result pre="entry and infection Inhibition of IL-6 induced STAT3 phosphorylation [138]" exact="Ruxolitinib" post="JAK inhibitor selective for JAK1and JAK2 Theoretical antiviral activities"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7551931\results\search\drug\results.xml">
   <result pre="prepared in distilled water supplemented with penicillin (100 U/mL) and" exact="streptomycin" post="(100 Âµg/mL) and stored at 4 Â°C. 2.2. Cells"/>
   <result pre="(FBS; Life Technologies, Eugene, OR, USA), penicillin (100 U/mL), and" exact="streptomycin" post="(100 Î¼g/mL) at 37 Â°C in an atmosphere containing"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7553131\results\search\drug\results.xml">
   <result pre="wide range of clinical application. â€¢Administration of high dose of" exact="vitamin C" post="as therapeutic agent can favorably impact patient with viral"/>
   <result pre="and develop an optimal therapeutic protocol for high dose of" exact="vitamin C" post="treatment for pneumonia and ARDS in patients with viral"/>
   <result pre="and tissue damage. To combat this, administration of high dose" exact="vitamin C" post="(ascorbic acid or ascorbate), in addition to the standard"/>
   <result pre="cytoprotection, and immunoregulation. The implementation of a high dose of" exact="vitamin C" post="therapy could dramatically reduce the need for high doses"/>
   <result pre="of oxidative stress injuries [24]. 5 A possible role of" exact="vitamin C" post="in anti-viral infection and related complications Vitamin C has"/>
   <result pre="free radicals and oxidants. Specialized cells can take up reduced" exact="vitamin C" post="(AscA) through Na+-dependent ascorbate cotransporters (SVCT1 and SVCT2). Most"/>
   <result pre="ascorbate cotransporters (SVCT1 and SVCT2). Most other cells take up" exact="vitamin C" post="in its oxidized form (DHA) via facilitative glucose transporters"/>
   <result pre="mammals, except for humans, primates, and guinea pigs, can synthesize" exact="vitamin C" post="in their livers with increased production during stress. Vitamin"/>
   <result pre="facilitates the production of catecholamines, vasopressin, Lâ€�carnitine, collagen, neurotransmitters, and" exact="cortisol" post="[26], these molecules are central to cellular function and"/>
   <result pre="anti-viral activity and immune enhancement. It has been shown that" exact="vitamin C" post="is an essential factor in the production of type"/>
   <result pre="both RNA and DNA viruses, lessening viral infectivity. In addition," exact="vitamin C" post="can detoxify viral products that produce pain and inflammation."/>
   <result pre="pathways associated with sepsis [34], [35]. Mice that were given" exact="vitamin C" post="did not experience multiple organ dysfunction syndromes, while mice"/>
   <result pre="multiple organ dysfunction syndromes, while mice that were deficient in" exact="vitamin C" post="were much more susceptible to sepsis-induced organ damage. A"/>
   <result pre="proposed mechanism is that ascorbate enhances the synthesis of vasopressors" exact="norepinephrine" post="and vasopressin by acting as a cofactor. Therefore, the"/>
   <result pre="is that ascorbate enhances the synthesis of vasopressors norepinephrine and" exact="vasopressin" post="by acting as a cofactor. Therefore, the administration of"/>
   <result pre="blood pressure and fluid loss. [36]. A high dose of" exact="vitamin C" post="may be a proven therapeutic agent that not only"/>
   <result pre="and sepsis In a study looking at the impact of" exact="vitamin C" post="on oxidative stress and inflammation in common infectious disease,"/>
   <result pre="stress and proinflammatory markers, suggesting a possible therapeutic benefit for" exact="vitamin C" post="in patients with severe CAP and other types of"/>
   <result pre="a high percentage of critically ill patients are deficient in" exact="vitamin C" post="despite receiving standard nutrition. In an observational study, Carr"/>
   <result pre="that 75% of critically ill patients had plasma levels of" exact="vitamin C" post="that were abnormally low, resulting from increased metabolism from"/>
   <result pre="from an overactive inflammatory response. A common way to supplement" exact="vitamin C" post="in a clinic is through an intravenous (IV) vitamin"/>
   <result pre="vitamin C in a clinic is through an intravenous (IV)" exact="vitamin C" post="administration. A phase I trial in patients with severe"/>
   <result pre="injury and reduced inflammatory biomarker levels [41]. High dose IV" exact="vitamin C" post="is commonly used by complementary and alternative medicine practitioners"/>
   <result pre="out to practitioners showed that over 20,000 patients received IV" exact="vitamin C" post="over periods of 2 years, with a mean number"/>
   <result pre="adverse effects [42]. Clinical trials have reported positive results in" exact="vitamin C" post="therapy for respiratory infections. Nathens et al. infused ascorbic"/>
   <result pre="hours following ECMO (extracorporeal membrane oxygenation) initiation, high dose IV" exact="vitamin C" post="began with the dose being 200â€‰mg/kg every 24â€‰hours divided"/>
   <result pre="evidence of post-ARDS fibroproliferative sequelae [21]. Dietary antioxidants rich in" exact="vitamin C" post="significantly attenuate hyperoxia-induced acute inflammatory lung injury by enhancing"/>
   <result pre="reduction in 28-d mortality in patients who supplemented with antioxidant" exact="vitamin C" post="and E.[46] Vitamin C has also been shown to"/>
   <result pre="conditions. Marik et al. [47] reported their use of IV" exact="vitamin C" post="in 47 sepsis ICU cases, finding a significant reduction"/>
   <result pre="rate in groups treated with a high dose of IV" exact="vitamin C." post="Several other trials have also shown that administration of"/>
   <result pre="C. Several other trials have also shown that administration of" exact="vitamin C" post="to patients with sepsis is associated with better patient"/>
   <result pre="organ failure scores or biomarker levels with 167 patients comparing" exact="vitamin C" post="infusion with placebo [49]. This lack of difference might"/>
   <result pre="body weight daily and short time frame of only 96â€‰hours" exact="vitamin C" post="infusion in these patients with sepsis and ARDS. Vitamin"/>
   <result pre="Hemila et al. determined that many of the studies shown" exact="vitamin C" post="reduces the duration and severity of colds [50], but"/>
   <result pre="that the combination of the supplemental and therapeutic dose of" exact="vitamin C" post="has effects on reducing symptoms and length of the"/>
   <result pre="the disease, but only administration of a therapeutic dose of" exact="vitamin C" post="(3.0â€‰g/day to 4.0â€‰g/day) during the disease to better recover"/>
   <result pre="health. [51] Meta-analyses of randomized controlled studies have shown that" exact="vitamin C" post="may protect against contrast-induced acute kidney injury and shorten"/>
   <result pre="about preventing atrial fibrillation in high-risk patients and found that" exact="vitamin C" post="affects decreasing incidence while lowering the length of hospital"/>
   <result pre="Other studies have shown that a high dose of IV" exact="vitamin C" post="is effective against viral infections such as the common"/>
   <result pre="treatment of pneumonia and ARDS The dose and pharmacokinetics of" exact="vitamin C" post="have varied greatly, especially with high dose vitamin C"/>
   <result pre="of vitamin C have varied greatly, especially with high dose" exact="vitamin C" post="treatment.[56]. Pharmacokinetic trials concluded that IV 2 to 3â€‰g/d"/>
   <result pre="treatment.[56]. Pharmacokinetic trials concluded that IV 2 to 3â€‰g/d of" exact="vitamin C" post="was required only to normalized plasma levels, while a"/>
   <result pre="ameliorate respiratory and systemic infections [40]. The antioxidant capacity of" exact="vitamin C" post="is dose-dependent, and direct radical scavenging capacity is maximal"/>
   <result pre="and direct radical scavenging capacity is maximal at a plasma" exact="vitamin C" post="level &amp;gt; 175â€‰mg/l (1000â€‰Î¼mol/l), more than ten times normal"/>
   <result pre="normal physiological level. Ascorbate prevents the interaction of superoxide and" exact="nitric oxide" post="only at very high concentrations [57]. Results from pharmacokinetic"/>
   <result pre="oral doses of 1.25â€‰g/day ascorbic acid produce mean peak plasma" exact="vitamin C" post="concentrations of 135â€‰Î¼mol/L, which are about two times higher"/>
   <result pre="Different from oral administration, which is regulated via the sodium-dependent" exact="vitamin C" post="transporter-1(SVCT1), intravenous administration bypasses this pathway and resulting in"/>
   <result pre="differences between the pharmacokinetics of oral and intravenous administration of" exact="vitamin C" post="[59], [60]. They noted IV vitamin C was much"/>
   <result pre="intravenous administration of vitamin C [59], [60]. They noted IV" exact="vitamin C" post="was much more bioavailable inside the body, and there"/>
   <result pre="administration can produce plasma concentrations as high as 26,000â€‰Î¼mol/L [61]," exact="vitamin C" post="serum levels reached 70-fold compared to those that may"/>
   <result pre="levels in critically ill patients, a minimum of 2â€&quot;3â€‰g intravenous" exact="vitamin C" post="is necessary [63]. For therapeutic purposes, the intravenous dose"/>
   <result pre="is necessary [63]. For therapeutic purposes, the intravenous dose of" exact="vitamin C" post="can be range between 10-16â€‰grams per day to obtain"/>
   <result pre="following the intravenous administration. That suggests the optimal frequency of" exact="vitamin C" post="treatment should be 4 times daily [64]. The data"/>
   <result pre="daily [64]. The data from the above-mentioned pharmacological studies of" exact="vitamin C" post="indicate that intravenous administration is currently the only way"/>
   <result pre="ARDS, and sepsis. The treatment with a high dose of" exact="vitamin C" post="should start with 10â€‰grams and above per day. Also,"/>
   <result pre="10â€‰grams and above per day. Also, the daily dose of" exact="vitamin C" post="as a preventive agent should be started at 2000â€‰mg"/>
   <result pre="with few significant adverse side effects reported. Only 10â€‰mg/d of" exact="vitamin C" post="is necessary to prevent scurvy, but the â€˜tolerable upper"/>
   <result pre="stated to be 2â€‰g/day for adults [65]. High dose intravenous" exact="vitamin C" post="administration has been clinically used for several decades, and"/>
   <result pre="and a phase I-II study studying the effects of IV" exact="vitamin C" post="with cytotoxic chemotherapy in patients states that a high"/>
   <result pre="been speculations about the potential harm of larger doses of" exact="vitamin C," post="research has shown that there is no concern for"/>
   <result pre="patients have been observed taking as much as 100â€‰g/day of" exact="vitamin C" post="without developing diarrhea and reported adverse side effects. A"/>
   <result pre="A possible mechanism has been attributed to the changes in" exact="vitamin C" post="metabolism caused by a severe infection [68]. Other possible"/>
   <result pre="effects that have been reported with extremely high doses IV" exact="vitamin C" post="include dizziness, nausea, dry mouth, perspiration, and weakness [69]."/>
   <result pre="The caution has been advised for the use of IV" exact="vitamin C" post="in patients with end-stage renal failure predisposed to oxaluria."/>
   <result pre="renal failure predisposed to oxaluria. It has been reported that" exact="vitamin C" post="intake as a possible cause of renal failure and"/>
   <result pre="Case reports have described oxalate nephropathy in burn patients after" exact="vitamin C" post="administration (101â€‰g and 224â€‰g in less than 24â€‰hours), but"/>
   <result pre="individuals following 80â€‰g intravenous administration.[75] However, the lower of intravenous" exact="vitamin C" post="doses typically used for prevention and therapy with less"/>
   <result pre="of hydrogen peroxide generation at these doses. High concentrations of" exact="vitamin C" post="can also affect blood glucose measurements for some point-of-care"/>
   <result pre="Therefore, glucose measurements after the administration of pharmacological doses of" exact="vitamin C" post="should be performed at the central laboratory.[77] 9 Ongoing"/>
   <result pre="with COVID-19 pneumonia. The patients will be administered 10â€‰grams of" exact="vitamin C" post="with 250â€‰mL of saline intravenously on top of conventional"/>
   <result pre="Hydroxychloroquine, Vitamin D, and Zinc to test if the drug" exact="Hydroxychloroquine" post="has more effect than normal nutritional supplements. This study"/>
   <result pre="study in Turkey (Identifier: NCT04326725) is testing the effects of" exact="vitamin C" post="and Zinc alongside hydroxychloroquine to see if the supplements"/>
   <result pre="is testing the effects of vitamin C and Zinc alongside" exact="hydroxychloroquine" post="to see if the supplements can boost the effects"/>
   <result pre="wide range of clinical applications. Administration of high dose of" exact="vitamin C" post="as a therapeutic agent can favorably impact patients with"/>
   <result pre="outcome of the disease. Application of a high dose of" exact="vitamin C" post="can dramatically reduce the need for treatment with high"/>
   <result pre="infections by boosting the innate immune defense. In infected patients," exact="vitamin C" post="therapy may shorten the course and prevent the complication"/>
   <result pre="prevent the complication of the disease [47][78]. In addition to" exact="vitamin C," post="other nutraceutical antioxidants that widely available as OTC drugs"/>
   <result pre="L-carnitine, Coenzyme-Q10, zinc, and selenium compounds. Given the fact that" exact="vitamin C" post="is inexpensive and has a history of efficacy and"/>
   <result pre="post-infection complications among patients who were or were not self-administering" exact="vitamin C" post="during the course of their diseases. This may provide"/>
   <result pre="timely data on the possible preventive and therapeutic values of" exact="vitamin C" post="for the medical and public interest in the current"/>
   <result pre="Signaling.43200251753112215220 20NakamuraH.NakamuraK.YodoiJ.Redox regulation of cellular activationAnnual review of immunology1511997351369 21FowlerIIIAAKimC.LeplerL.Intravenous" exact="vitamin C" post="as adjunctive therapy for enterovirus/rhinovirus induced acute respiratory distress"/>
   <result pre="acidJournal of Biological Chemistry.27040199523706237127559541 26CarrA.C.MagginiS.Vitamin C and immune functionNutrients.91120171211 27BhararaA.GrossmanC.GrinnanD.Intravenous" exact="vitamin C" post="administered as adjunctive therapy for recurrent acute respiratory distress"/>
   <result pre="Activity Of Ascorbic Acid At Influenza InfectionInfektsiya Immunitet.742017319326 32WilsonJXEvaluation of" exact="vitamin C" post="for adjuvant sepsis therapyAntioxidants &amp;amp; redox signaling.191720132129214023682970 33MagginiS.MaldonadoP.CardimP.Fernandez NewballC.Sota"/>
   <result pre="Cellular and Molecular Physiology.30312012L20L3222523283 36CarrA.C.ShawG.M.NatarajanR.Ascorbate-dependent vasopressor synthesis: a rationale for" exact="vitamin C" post="administration in severe sepsis and septic shock?Critical Care.191201541826612352 37ChenY.LuoG.YuanJ.Vitamin"/>
   <result pre="infiltration, and oxidative stressJournal of surgical research.16722011e307e31319959187 40CarrA.C.RosengraveP.C.BayerS.ChambersS.MehrtensJ.ShawG.M.Hypovitaminosis C and" exact="vitamin C" post="deficiency in critically ill patients despite recommended enteral and"/>
   <result pre="patients: a prospective, randomized, double-blind, placebo-controlled trialAnesthesia &amp;amp; Analgesia.993200485786315333422 47MarikP.E.KhangooraV.RiveraR.HooperM.H.CatravasJ.Hydrocortisone," exact="vitamin C," post="and thiamine for the treatment of severe sepsis and"/>
   <result pre="randomized, double-blind, placebo-controlled trialAnesthesia &amp;amp; Analgesia.993200485786315333422 47MarikP.E.KhangooraV.RiveraR.HooperM.H.CatravasJ.Hydrocortisone, vitamin C, and" exact="thiamine" post="for the treatment of severe sepsis and septic shock:"/>
   <result pre="in septic shockJournal of research in pharmacy practice5220169427162802 49TruwitJ.D.HiteR.D.MorrisP.E.Effect of" exact="vitamin C" post="infusion on organ failure and biomarkers of inflammation and"/>
   <result pre="the common coldCochrane Database of Systematic Reviews.12013 51RanL.ZhaoW.WangJ.Extra dose of" exact="vitamin C" post="based on a daily supplementation shortens the common cold:"/>
   <result pre="and infectionsNutrients.942017339 57JacksonT.S.XuA.VitaJ.A.Keaney JrJ.F.Ascorbate prevents the interaction of superoxide and" exact="nitric oxide" post="only at very high physiological concentrationsCirculation research83919989169229797340 58PadayattyS.J.SunH.WangY.Vitamin C"/>
   <result pre="of the National Academy of Sciences938199637043709 60LevineM.RumseyS.C.DaruwalaR.ParkJ.B.WangY.Criteria and recommendations for" exact="vitamin C" post="intakeJama.2811519991415142310217058 61PadayattyS.J.RiordanH.D.HewittS.M.KatzA.HofferL.J.LevineM.Intravenously administered vitamin C as cancer therapy: three"/>
   <result pre="Sciences938199637043709 60LevineM.RumseyS.C.DaruwalaR.ParkJ.B.WangY.Criteria and recommendations for vitamin C intakeJama.2811519991415142310217058 61PadayattyS.J.RiordanH.D.HewittS.M.KatzA.HofferL.J.LevineM.Intravenously administered" exact="vitamin C" post="as cancer therapy: three casesCmaj.1747200693794216567755 62ChenQ.EspeyM.G.SunA.Y.Ascorbate in pharmacologic concentrations"/>
   <result pre="Calcium and Vitamin D2011National Academy PressWashington, DC, USA 66HofferL.J.RobitailleL.ZakarianR.High-dose intravenous" exact="vitamin C" post="combined with cytotoxic chemotherapy in patients with advanced cancer:"/>
   <result pre="Journal of urology15561996184718518618271 74BuehnerM.PamplinJ.StuderL.Oxalate nephropathy after continuous infusion of high-dose" exact="vitamin C" post="as an adjunct to burn resuscitationJournal of Burn Care"/>
   <result pre="burn resuscitationJournal of Burn Care &amp;amp; Research.3742016e374e37925812044 75QuinnJ.GerberB.FoucheR.KenyonK.BlomZ.MuthukanagarajP.Effect of high-dose" exact="vitamin C" post="infusion in a glucose-6-phosphate dehydrogenase-deficient patientCase reports in medicine20172017"/>
   <result pre="in a glucose-6-phosphate dehydrogenase-deficient patientCase reports in medicine20172017 76ChoJ.AhnS.YimJ.Influence of" exact="vitamin C" post="and maltose on the accuracy of three models of"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7557800\results\search\drug\results.xml">
   <result pre="without genuine medical research. It was widely emphasized to take" exact="vitamin C" post="to boost immunity and strengthen the body as a"/>
   <result pre="cold. A meta-analysis showed the role of prophylactic intake of" exact="vitamin C" post="in reducing the duration of disease but no effect"/>
   <result pre="being conducted at Cleveland Clinic to study the role of" exact="vitamin C" post="as a supplementary medication for shortening the duration of"/>
   <result pre="new likely outbreak centers are also being done. Publicity of" exact="Chloroquine" post="Media is the primary source of information and plays"/>
   <result pre="it be harmful but it can have unintended consequences. TheÂ" exact="hydroxychloroquine" post="(HCQ) example fits the scenario. HCQ, a lyso-somatotrophic agent,"/>
   <result pre="fuse with lysosomal membranes, thus entering the cells and replicating." exact="Chloroquine" post="being a weak base, enters into lysosomes and raises"/>
   <result pre="can no longer enter the cells. The productive role of" exact="chloroquine" post="against SARS-CoV- 2 has been demonstrated in vitroÂ [20]."/>
   <result pre="is yet to be determined. Several deaths were reported from" exact="chloroquine" post="misuse, following Trump's endorsement of this drug as a"/>
   <result pre="limited trials, ICMR (Indian Council of Medical Research) recommended using" exact="chloroquine" post="in healthcare workers and asymptomatic contacts without significant data."/>
   <result pre="data. However, the CDC's clinical guidance on the use of" exact="chloroquine" post="for prophylaxis was lacking because of the absence of"/>
   <result pre="not have a promising drug for COVID-19 treatment. Thus, when" exact="chloroquine" post="appeared as a hope, it sparked the interest of"/>
   <result pre="as a potential cure. Some politicians created hype and promoted" exact="chloroquine" post="by declaring it effective against the novel coronavirus and"/>
   <result pre="2 A Graphical representation of the social media mentions of" exact="hydroxychloroquine" post="and chloroquine. We used the tool Awario.com to generate"/>
   <result pre="the tool Awario.com to generate the drug mentions using keywords," exact="Hydroxychloroquine" post="and Chloroquine, and created a bar graph showing the"/>
   <result pre="cases. Moreover, many deaths were reported because of it's overuse." exact="Chloroquine" post="can have many adverse effects, the vast majority of"/>
   <result pre="as self-medication, while his wife got critically ill [23, 24]." exact="Chloroquine" post="gained all this attention after a small non-randomized clinical"/>
   <result pre="[25]. However, a subsequent randomized clinical trial using high dose" exact="chloroquine" post="was halted in phase 2b due to the lethal"/>
   <result pre="[26]. The FDA also had to issue a warning against" exact="chloroquine" post="for COVID-19 after the results of the study were"/>
   <result pre="the study were shared [27]. In just a small period," exact="chloroquine" post="was portrayed over social media as a wonder drug"/>
   <result pre="vitro antiviral activity and projection of optimized dosing design of" exact="hydroxychloroquine" post="for the treatment of severe acute respiratory syndrome Coronavirus"/>
   <result pre="as coronavirus â€˜game changerâ€™ increasingly linked to deaths520202020https://www.washingtonpost.com/politics/drug-promoted-by-trump-as-coronavirus-game-changer-increasingly-linked-to-deaths/2020/05/15/85d024fe-96bd-11ea-9f5e-56d8239bf9ad_story.html 22Nigeria has" exact="chloroquine" post="poisonings after Trump praised drugNigeria Has Chloroquine Poisonings After"/>
   <result pre="deaths520202020https://www.washingtonpost.com/politics/drug-promoted-by-trump-as-coronavirus-game-changer-increasingly-linked-to-deaths/2020/05/15/85d024fe-96bd-11ea-9f5e-56d8239bf9ad_story.html 22Nigeria has chloroquine poisonings after Trump praised drugNigeria Has" exact="Chloroquine" post="Poisonings After Trump Praised Drug. Bloomberg32020SotoSotoA.(2020March212020https://www.bloomberg.com/news/articles/2020-03-21/nigeria-reports-chloroquine-poisonings-after-trump-praised-drug 23Man fatally poisons"/>
   <result pre="himself while self-medicating for coronavirus, doctor says 42020VigdorVigdorN.(2020April242020https://www.nytimes.com/2020/03/24/us/chloroquine-poisoning-coronavirus.html 24Hydroxychloroquine and" exact="azithromycin" post="as a treatment of COVID- 19: results of an"/>
   <result pre="Antimicrob AgentsGautretPLagierJCParolaPet al.10594956202032205204 25Effect of high vs low doses of" exact="chloroquine" post="diphosphate as adjunctive therapy for patients hospitalized with severe"/>
   <result pre="clinical trialJAMA Netw OpenBorbaMGSValFFASampaioVSet al.20885720202032020 26FDA cautions against use of" exact="hydroxychloroquine" post="or chloroquine for COVID-19 outside of the hospital setting"/>
   <result pre="Netw OpenBorbaMGSValFFASampaioVSet al.20885720202032020 26FDA cautions against use of hydroxychloroquine or" exact="chloroquine" post="for COVID-19 outside of the hospital setting or a"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7558548\results\search\drug\results.xml">
   <result pre="Of several approved drugs, in two separate in vitro studies," exact="chloroquine" post="(CQ) and hydroxychloroquine (HCQ) showed potent antiviralÂ activity against"/>
   <result pre="drugs, in two separate in vitro studies, chloroquine (CQ) and" exact="hydroxychloroquine" post="(HCQ) showed potent antiviralÂ activity against SARS-CoV-2 [4]. Furthermore,"/>
   <result pre="to block viral entry of SARS-CoV-2 and influenza viruses [12]." exact="Serine" post="proteases involved withÂ the pathogenesis of respiratory viruses are"/>
   <result pre="often access molecular andÂ biologicalÂ redundancies in their host. Although" exact="camostat" post="inhibited SARS-CoV-2 entry and replication, it did not completely"/>
   <result pre="which is a competitive IMPDH inhibitor. In addition to dGTP-depletion," exact="ribavirin" post="also enhances viral mutagenesis byÂ the incorrect substitution of"/>
   <result pre="[19]. However, despite a well-documented history of broad-spectrum antiviral activity," exact="ribavirin" post="displayed strikingly weak antiviral activity against SARS-CoV, MERS-CoV, andÂ"/>
   <result pre="is effective in inhibiting SARS-CoV-2 infection in vitroCell Discov202061610.1038/s41421-020-0156-032194981 5.GaoJYangXBreakthrough:" exact="chloroquine" post="phosphate has shown apparent efficacy in treatment of COVID-19"/>
   <result pre="associated pneumonia in clinical studiesBiosci Trends202014727310.5582/bst.2020.0104732074550 6.GelerisJet al.Observational study of" exact="hydroxychloroquine" post="in hospitalized patients with Covid-19N Engl J Med202010.1056/NEJMoa201241032379955 7.RosenbergESet"/>
   <result pre="with Covid-19N Engl J Med202010.1056/NEJMoa201241032379955 7.RosenbergESet al.Association of treatment with" exact="hydroxychloroquine" post="or azithromycin with in-hospital mortality in patients with COVID-19"/>
   <result pre="Engl J Med202010.1056/NEJMoa201241032379955 7.RosenbergESet al.Association of treatment with hydroxychloroquine or" exact="azithromycin" post="with in-hospital mortality in patients with COVID-19 in New"/>
   <result pre="8.MercuroNJet al.Risk of QT interval prolongation associated with use of" exact="hydroxychloroquine" post="with or without concomitant azithromycin among hospitalized patients testing"/>
   <result pre="prolongation associated with use of hydroxychloroquine with or without concomitant" exact="azithromycin" post="among hospitalized patients testing positive for coronavirus disease 2019"/>
   <result pre="coronavirus disease 2019 (COVID-19)JAMA Cardiol201910.1001/jamacardio.2020.1834 9.SalehMet al.The effect of chloroquine," exact="hydroxychloroquine" post="and azithromycin on the corrected QT interval in patients"/>
   <result pre="2019 (COVID-19)JAMA Cardiol201910.1001/jamacardio.2020.1834 9.SalehMet al.The effect of chloroquine, hydroxychloroquine and" exact="azithromycin" post="on the corrected QT interval in patients with SARS-CoV-2"/>
   <result pre="activity of the IMP dehydrogenase inhibitor VX-497: a comparison with" exact="ribavirin" post="and demonstration of antiviral additivity with alpha interferonAntimicrob Agents"/>
   <result pre="a comparison with ribavirin and demonstration of antiviral additivity with" exact="alpha" post="interferonAntimicrob Agents Chemother20004485986610.1128/aac.44.4.859-866.200010722482 19.CrottySet al.The broad-spectrum antiviral ribonucleoside ribavirin"/>
   <result pre="with alpha interferonAntimicrob Agents Chemother20004485986610.1128/aac.44.4.859-866.200010722482 19.CrottySet al.The broad-spectrum antiviral ribonucleoside" exact="ribavirin" post="is an RNA virus mutagenNat Med200061375137910.1038/8219111100123 20.ChoyKTet al.Remdesivir, lopinavir,"/>
   <result pre="Res202017810478610.1016/j.antiviral.2020.10478632251767 21.FerronFet al.Structural and molecular basis of mismatch correction and" exact="ribavirin" post="excision from coronavirus RNAProc Natl Acad Sci U S"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7561179\results\search\drug\results.xml">
   <result pre="the ROS required for antimicrobial properties. Recently, a polymer containing" exact="crystal violet" post="dye and gold nanoclusters was shown to produce ROS"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7567346\results\search\drug\results.xml">
   <result pre="Violence : Biology and Life Sciences : Nutrition : Diet:" exact="Alcohol" post="Consumption : Medicine and Health Sciences : Nutrition :"/>
   <result pre="Consumption : Medicine and Health Sciences : Nutrition : Diet:" exact="Alcohol" post="Consumption : Medicine and Health Sciences : Mental Health"/>
   <result pre="Physical Sciences : Chemistry : Chemical Compounds : Organic Compounds:" exact="Alcohols" post=": Physical Sciences : Chemistry : Organic Chemistry :"/>
   <result pre="Physical Sciences : Chemistry : Organic Chemistry : Organic Compounds:" exact="Alcohols" post=": Medicine and health sciences : Clinical medicine :"/>
   <result pre="Abuse : Medicine and Health Sciences : Pediatrics: Child Abuse" exact="Alcohol" post="use, depressive symptoms, and intimate partner violence perpetration: A"/>
   <result pre="A longitudinal analysis among men with HIV in northern Vietnam" exact="Alcohol" post="use, depressive symptoms, and intimate partner violence perpetration among"/>
   <result pre="and source are credited.pone.0240674.pdf Abstract Background While the link between" exact="alcohol" post="use and male-perpetrated intimate partner violence (IPV) has been"/>
   <result pre="research is needed to test whether psychosocial factors interact with" exact="alcohol" post="use to exacerbate IPV perpetration. We tested whether depressive"/>
   <result pre="Nguyen, Vietnam. Participants were clinic patients with HIV and hazardous" exact="alcohol" post="use. Questionnaires were administered at baseline, three, six, and"/>
   <result pre="Questionnaires were administered at baseline, three, six, and 12 months." exact="Alcohol" post="use was assessed as proportion of days alcohol abstinent."/>
   <result pre="12 months. Alcohol use was assessed as proportion of days" exact="alcohol" post="abstinent. Analyses were restricted to males who reported being"/>
   <result pre="test whether time-varying depressive symptoms modified the time-varying effect of" exact="alcohol" post="use on IPV perpetration. Results Time-varying depressive symptoms modified"/>
   <result pre="Time-varying depressive symptoms modified the effect of proportion of days" exact="alcohol" post="abstinent on IPV perpetration. However, the pattern of effect"/>
   <result pre="for depressive symptoms, those who reported higher proportion of days" exact="alcohol" post="abstinent than usual had significantly lower odds of IPV"/>
   <result pre="positive for depressive symptoms, there was no observed effect of" exact="alcohol" post="use on IPV perpetration (OR = 4.28, 95% CI"/>
   <result pre="and IPV. Men who concurrently report depressive symptoms and heightened" exact="alcohol" post="use may be socially isolated from an intimate partner"/>
   <result pre="less alcohol-related IPV perpetration. Mental health interventions addressing depression and" exact="alcohol" post="misuse integrated into HIV services may reduce IPV perpetration."/>
   <result pre="found at the following doi: 10.1001/jamanetworkopen.2020.17115. Introduction The link between" exact="alcohol" post="use and male-perpetrated intimate partner violence (IPV) has been"/>
   <result pre="established [1â€&quot;8]. The alcohol-IPV relationship is often explained by immediate" exact="alcohol" post="intoxication effects, such as distorted perceptions of cues or"/>
   <result pre="relationship conflict [4, 5, 7, 9â€&quot;11]. However, meta-analytic reviews on" exact="alcohol" post="use and IPV perpetration have observed large heterogeneity in"/>
   <result pre="and reduce IPV perpetration among men. As both IPV and" exact="alcohol" post="use lead to numerous health consequences, including HIV/STI infection,"/>
   <result pre="including HIV/STI infection, depression, physical injury, and death, IPV and" exact="alcohol" post="interventions are urgently needed to improve the health and"/>
   <result pre="and well-being of men and women at-risk for IPV [13â€&quot;17]." exact="Alcohol" post="use and IPV perpetration are highly prevalent in Vietnam"/>
   <result pre="men reported ever perpetrating IPV against their wife [22]. Men's" exact="alcohol" post="use is also closely tied to their masculinity [23]"/>
   <result pre="Organization found that the annual per capita consumption of pure" exact="alcohol" post="in Vietnam was 5.1 liters [14], which is greater"/>
   <result pre="[14], which is greater than the global consumption of pure" exact="alcohol" post="per capita (4.3 to 4.7 liters) [27]. Traditional gender"/>
   <result pre="Traditional gender norms characterize men as having volatile tempers and" exact="alcohol" post="is perceived as a driver of men's aggressive or"/>
   <result pre="behavior [20]. Menâ€™s use of violence under the influence of" exact="alcohol" post="is often viewed as uncontrollable and an innate demonstration"/>
   <result pre="men with HIV, a group at high risk for hazardous" exact="alcohol" post="use, IPV perpetration, and forward HIV transmission [16, 17,"/>
   <result pre="Vietnam and other global settings examining how depressive symptoms and" exact="alcohol" post="use interact to influence IPV perpetration. Alcohol use may"/>
   <result pre="depressive symptoms and alcohol use interact to influence IPV perpetration." exact="Alcohol" post="use may be associated with IPV perpetration for some"/>
   <result pre="that of their inhibitions [37â€&quot;39]. Depressive symptoms may interact with" exact="alcohol" post="use to drive individuals past their aggressive thresholds. In"/>
   <result pre="experience depressive symptoms more susceptible to the disinhibiting effects of" exact="alcohol" post="intoxication on IPV perpetration [32â€&quot;34]. Empirical evidence also suggests"/>
   <result pre="perpetration [32â€&quot;34]. Empirical evidence also suggests that the co-occurrence of" exact="alcohol" post="use and mental health exacerbates violence outcomes. A nationally"/>
   <result pre="substance abuse did [40]. Another United States study found that" exact="alcohol" post="use strengthened the relationship between mental illness symptoms and"/>
   <result pre="research in India has suggested that depressive symptoms interact with" exact="alcohol" post="use to drive IPV perpetration [41]. In this study,"/>
   <result pre="of the alcohol-IPV relationship among men with HIV and hazardous" exact="alcohol" post="use in Vietnam. We investigated whether the concurrent effect"/>
   <result pre="use in Vietnam. We investigated whether the concurrent effect of" exact="alcohol" post="use on IPV perpetration differed at times when an"/>
   <result pre="symptoms. Our specific hypothesis was that the time-varying association between" exact="alcohol" post="use and IPV perpetration would be stronger at times"/>
   <result pre="of two evidence-based, manually guided, individually delivered interventions to reduce" exact="alcohol" post="use and determine the impact on viral load [42,"/>
   <result pre="data were collected from clinic patients with HIV and hazardous" exact="alcohol" post="use (N = 440) in Thai Nguyen, a semi-urban"/>
   <result pre="screening survey. The survey included the World Health Organization (WHO)" exact="Alcohol" post="Use Disorders Identification Test (AUDIT-C) survey items to determine"/>
   <result pre="and (4) currently participating in other HIV, drug use, or" exact="alcohol" post="program, study, or intervention. Eligible participants were asked to"/>
   <result pre="the baseline questionnaire and Timeline Followback (TLFB) to measure daily" exact="alcohol" post="use over the past 30 days [46]. Eligible participants"/>
   <result pre="follow-up visit. The behavioral assessment collected quantitative data on sociodemographics," exact="alcohol" post="and drug use, mental health, and violence. At the"/>
   <result pre="as reporting recent psychological, physical, and/or sexual IPV perpetration [50]." exact="Alcohol" post="use The TLFB was used to measure alcohol use;"/>
   <result pre="perpetration [50]. Alcohol use The TLFB was used to measure" exact="alcohol" post="use; the tool has been shown to be valid"/>
   <result pre="a daily behavior calendar to help promote memory recall for" exact="alcohol" post="use. Using the TLFB data, we assessed alcohol use"/>
   <result pre="recall for alcohol use. Using the TLFB data, we assessed" exact="alcohol" post="use as proportion of days alcohol abstinent in past"/>
   <result pre="TLFB data, we assessed alcohol use as proportion of days" exact="alcohol" post="abstinent in past 30 days (0 to 1). Depressive"/>
   <result pre="measured using the nine-item Patient Health Questionnaire-9 (PHQ-9) scale (Cronbach's" exact="alpha" post="at baseline = 0.83) [53], a tool that has"/>
   <result pre="select variables with the potential to confound the relationship between" exact="alcohol" post="use and IPV perpetration [1, 6, 56â€&quot;60]. Exposure to"/>
   <result pre="status [64, 65]. Second, a commonly used theoretical model in" exact="alcohol" post="and IPV research posits that relationship conflict may explain"/>
   <result pre="represents the log odds of IPV perpetration at baseline. The" exact="alcohol" post="use variable used to estimate time-varying (or within-person) effects"/>
   <result pre="the adjusted conditional growth model tested the time-varying effects of" exact="alcohol" post="use and depressive symptoms and the two-way interactions among"/>
   <result pre="depressive symptoms and the two-way interactions among depressive symptoms and" exact="alcohol" post="use on IPV perpetration adjusting for covariates. Any non-significant"/>
   <result pre="model. If an interaction term was significant, the effect of" exact="alcohol" post="use on the predicted probability of IPV perpetration was"/>
   <result pre="deviation [SD] = 5.6; Table 1). The median percent days" exact="alcohol" post="abstinent increased over time (Baseline: 36.7, Interquartile range [IQR]"/>
   <result pre="Virally suppresseda,b 268 (85.6) 247 (86.4) 257 (88.0) 237 (84.9)" exact="Alcohol" post="Use Median percent days abstinent in past 30 days"/>
   <result pre="Depressive symptoms significantly modified the effect of proportion of days" exact="alcohol" post="abstinent on IPV perpetration (Table 3). However, the pattern"/>
   <result pre="found to weaken the inverse relationship between proportion of days" exact="alcohol" post="abstinent and IPV perpetration (Fig 2). At times when"/>
   <result pre="for depressive symptoms, those who reported higher proportion of days" exact="alcohol" post="abstinent than usual were less likely to report IPV"/>
   <result pre="symptoms, there was no significant association between proportion of days" exact="alcohol" post="abstinent and IPV perpetration (Slope: OR = 4.28, 95%"/>
   <result pre="as a function of depressive symptoms and proportion of days" exact="alcohol" post="abstinent at times when participants screened positive and negative"/>
   <result pre="the zero value is each participant's average proportion of days" exact="alcohol" post="abstinent reported across the study period. Values greater than"/>
   <result pre="greater than zero represent participants reporting higher proportion of days" exact="alcohol" post="abstinent than average and values less than zero represent"/>
   <result pre="less than zero represent participants reporting lower proportion of days" exact="alcohol" post="abstinent than average. 10.1371/journal.pone.0240674.t003Table 3 Final adjusted conditional growth"/>
   <result pre="modela (N = 313). aOR (95% CI) p-value Fixed Effects" exact="Intercept" post="0.30 (0.13, 0.71) 0.006 Time 0.55 (0.41, 0.73) &amp;lt;0.0001"/>
   <result pre="Intercept 0.30 (0.13, 0.71) 0.006 Time 0.55 (0.41, 0.73) &amp;lt;0.0001" exact="Alcohol" post="use 0.17 (0.06, 0.45) 0.0004 Depressive symptoms 3.96 (2.18,"/>
   <result pre="0.17 (0.06, 0.45) 0.0004 Depressive symptoms 3.96 (2.18, 7.20) &amp;lt;0.0001" exact="Alcohol" post="use*Depressive symptoms 25.02 (3.54, 176.78) 0.001 Random Effects Variance"/>
   <result pre="arm. 10.1371/journal.pone.0240674.t004Table 4 Simple intercepts and slopes, proportion of days" exact="alcohol" post="abstinent by depressive symptoms. Â Intercept Slope OR (95%"/>
   <result pre="slopes, proportion of days alcohol abstinent by depressive symptoms. Â" exact="Intercept" post="Slope OR (95% CI) p-value OR (95% CI) p-value"/>
   <result pre="Odds Ratio; CI = Confidence Interval. Discussion In this study," exact="alcohol" post="use and depressive symptoms did not act synergistically to"/>
   <result pre="times when participants reported having depressive symptoms, the effect of" exact="alcohol" post="use on IPV perpetration became non-significant. However, at times"/>
   <result pre="at times when participants reported having no depressive symptoms, more" exact="alcohol" post="use was associated with significantly higher odds of IPV"/>
   <result pre="This finding diverges from empirical and theoretical evidence suggesting that" exact="alcohol" post="use and depression interact to exacerbate violence outcomes [32,"/>
   <result pre="research among Vietnamese men with HIV identified depressive symptoms and" exact="alcohol" post="use as independent correlates of IPV perpetration [31]. Our"/>
   <result pre="these findings to suggest that while both depressive symptoms and" exact="alcohol" post="use may be independently associated with IPV perpetration [31],"/>
   <result pre="threshold and disinhibition theories, which suggest that people who use" exact="alcohol" post="and experience depressive symptoms may have higher odds of"/>
   <result pre="of IPV perpetration as compared to those who only use" exact="alcohol" post="[37â€&quot;39]. However, an inherent assumption in these theories is"/>
   <result pre="[37â€&quot;39]. However, an inherent assumption in these theories is that" exact="alcohol" post="use and depressive symptoms are aggression-provoking factors both independently"/>
   <result pre="suggests that Vietnamese men with HIV who are concurrently using" exact="alcohol" post="and experiencing depressive symptoms may not express aggression-provoking symptoms,"/>
   <result pre="such as hostility or anger [33, 69]. The combination of" exact="alcohol" post="use, depressive symptoms, and HIV infection may lead to"/>
   <result pre="energy and fatigue [70, 71], resulting in no relationship between" exact="alcohol" post="use and IPV perpetration. Additionally, the co-occurrence of alcohol"/>
   <result pre="between alcohol use and IPV perpetration. Additionally, the co-occurrence of" exact="alcohol" post="and depressive symptoms may result in other forms of"/>
   <result pre="potential explanation may be the unique intersection between depressive symptoms," exact="alcohol" post="use, and social isolation in Vietnam. Men may respond"/>
   <result pre="of depression with social isolation [72, 73], leading to reduced" exact="alcohol" post="use as drinking alone is uncommon [23, 24]. Instead,"/>
   <result pre="Vietnam [23, 24, 74]. Those experiencing the co-occurrence of heightened" exact="alcohol" post="use and depressive symptoms may represent a particularly isolated"/>
   <result pre="under which men with HIV may or may not use" exact="alcohol" post="as a coping strategy when experiencing depressive symptoms. Due"/>
   <result pre="with HIV globally and in Vietnam [71, 74], intervening on" exact="alcohol" post="use and depression may be promising IPV prevention strategies."/>
   <result pre="hazardous drinking [31]. Incorporating mental health services addressing depression and" exact="alcohol" post="misuse into HIV care and treatment may reduce depression,"/>
   <result pre="alcohol misuse into HIV care and treatment may reduce depression," exact="alcohol" post="use, and IPV perpetration among men with HIV. Systematic"/>
   <result pre="that mental health treatments for common mental disorders and for" exact="alcohol" post="misuse could effectively reduce IPV [75, 76]. However, there"/>
   <result pre="risk of mortality than non-PWID with HIV [78] and hazardous" exact="alcohol" post="use and depressive symptoms are highly prevalent among PWID"/>
   <result pre="79]. As the co-occurrence and dynamics of depressive symptoms and" exact="alcohol" post="use may differ between HIV-infected men with and without"/>
   <result pre="administration, reducing the likelihood of social desirability bias. Estimates of" exact="alcohol" post="use may also be subject to recall bias as"/>
   <result pre="self-report. However, sub-analyses of the study data validated the self-report" exact="alcohol" post="measures using phosphatidylethanol (PEth) [42], a biomarker that is"/>
   <result pre="(PEth) [42], a biomarker that is a direct metabolite of" exact="alcohol" post="consumption [83]. Participants who dropped out of the study"/>
   <result pre="longitudinal study contributes important findings on the intersection between hazardous" exact="alcohol" post="use, depressive symptoms, and IPV perpetration in a high-risk,"/>
   <result pre="alcohol-IPV relationship. These results suggest that men who reported higher" exact="alcohol" post="use and depressive symptoms than usual may be experiencing"/>
   <result pre="IPV perpetration. Alternatively, men with HIV who are concurrently using" exact="alcohol" post="and experiencing depressive symptoms may have fatigue or reduced"/>
   <result pre="to reduce IPV perpetration have either targeted participants who misuse" exact="alcohol" post="or those who screen positive for depressive symptoms [75]."/>
   <result pre="Stud Alcohol. 2002;63(2):205â€&quot;14. 10.15288/jsa.2002.63.20512033697 6TschannJM, FloresE, PaschLA, MarinBV. Emotional distress," exact="alcohol" post="use, and peer violence among Mexican-American and European-American adolescents."/>
   <result pre="and European-American adolescents. J Adolesc Health. 2005;37(1):11â€&quot;8. 10.1016/j.jadohealth.2004.07.00915963902 7ForanHM, O'LearyKD." exact="Alcohol" post="and intimate partner violence: a meta-analytic review. Clin Psychol"/>
   <result pre="9CraneCA, GodleskiSA, PrzybylaSM, SchlauchRC, TestaM. The Proximal Effects of Acute" exact="Alcohol" post="Consumption on Male-to-Female Aggression: A Meta-Analytic Review of the"/>
   <result pre="2016;17(5):520â€&quot;31. 10.1177/152483801558437426009568 10ReyesHL, FosheeVA, BauerDJ, EnnettST. Developmental Associations Between Adolescent" exact="Alcohol" post="Use and Dating Aggression. J Res Adolesc. 2012;22(3):526â€&quot;41. 10.1111/j.1532-7795.2012.00799.x23589667"/>
   <result pre="and Dating Aggression. J Res Adolesc. 2012;22(3):526â€&quot;41. 10.1111/j.1532-7795.2012.00799.x23589667 11QuigleyBM, LeonardKE." exact="Alcohol" post="and the continuation of early marital aggression. Alcohol Clin"/>
   <result pre="11QuigleyBM, LeonardKE. Alcohol and the continuation of early marital aggression." exact="Alcohol" post="Clin Exp Res. 2000;24(7):1003â€&quot;10. 10924003 12FerrerVB, E.; GarciaE.; ManasseroM."/>
   <result pre="batterers and non-batterers: The case of psychopathology and consumption of" exact="alcohol" post="and drugs. Psykhe. 2004;13(1):141â€&quot;56. 13Global and regional estimates of"/>
   <result pre="Geneva, Switzerland: World Health Organization; 2013. 14Global status report on" exact="alcohol" post="and health. Geneva: World Health Organization; 2014. 15LiY, MarshallCM,"/>
   <result pre="McBrideRS, RebomboD, KhumaloM, ChristofidesNJ. Gendered syndemic of intimate partner violence," exact="alcohol" post="misuse, and HIV risk among peri-urban, heterosexual men in"/>
   <result pre="and the Challenges of Masculinity. Men and Masculinities. 2015;19(1):64â€&quot;84. 23LincolnM." exact="Alcohol" post="and drinking cultures in Vietnam: A review. Drug Alcohol"/>
   <result pre="23LincolnM. Alcohol and drinking cultures in Vietnam: A review. Drug" exact="Alcohol" post="Depend. 2016;159:1â€&quot;8. 10.1016/j.drugalcdep.2015.10.03026802499 24HershowRB, ZuskovDS, Vu Tuyet MaiN, ChanderG,"/>
   <result pre="That You Can't Break&quot;: Perceived Barriers and Facilitators to Reduce" exact="Alcohol" post="Use and Improve Antiretroviral Treatment Adherence among People Living"/>
   <result pre="Improve Antiretroviral Treatment Adherence among People Living with HIV and" exact="Alcohol" post="Use Disorder in Vietnam. Subst Use Misuse. 2018;53(7):1084â€&quot;92. 10.1080/10826084.2017.139298629537932"/>
   <result pre="Vietnam. Subst Use Misuse. 2018;53(7):1084â€&quot;92. 10.1080/10826084.2017.139298629537932 25LuuBN, NguyenTT, NewmanIM. Traditional" exact="alcohol" post="production and use in three provinces in Vietnam: an"/>
   <result pre="OhinmaaA, DuongAT, NguyenLT, Van HoangM, et al.Prevalence and correlates of" exact="alcohol" post="use disorders during antiretroviral treatment in injection-driven HIV epidemics"/>
   <result pre="during antiretroviral treatment in injection-driven HIV epidemics in Vietnam. Drug" exact="Alcohol" post="Depend. 2013;127(1â€&quot;3):39â€&quot;44. 10.1016/j.drugalcdep.2012.06.00922749565 27Recorded alcohol per capita (15 years)"/>
   <result pre="HIV epidemics in Vietnam. Drug Alcohol Depend. 2013;127(1â€&quot;3):39â€&quot;44. 10.1016/j.drugalcdep.2012.06.00922749565 27Recorded" exact="alcohol" post="per capita (15 years) consumption in litres of pure"/>
   <result pre="Vietnam. AIDS Behav. 2020;24(9):2555â€&quot;2571. 10.1007/s10461-020-02813-532078077 32QuigleyBM, HoustonRJ, AntoniusD, TestaM, LeonardKE." exact="Alcohol" post="use moderates the relationship between symptoms of mental illness"/>
   <result pre="Clin Psychol. 2005;73(2):239â€&quot;48. 10.1037/0022-006X.73.2.23915796631 38McNaughton ReyesHL, FosheeVA, BauerDJ, EnnettST. Heavy" exact="alcohol" post="use and dating violence perpetration during adolescence: family, peer"/>
   <result pre="neighborhood violence as moderators. Prev Sci. 2012;13(4):340â€&quot;9. 10.1007/s11121-011-0215-821494801 39ParkerRN, RebhunL." exact="Alcohol" post="and Homicide: A Deadly Combination of Two American Traditions."/>
   <result pre="and mental disorder: results from the National Epidemiologic Survey on" exact="Alcohol" post="and Related Conditions. Arch Gen Psychiatry. 2009;66(2):152â€&quot;61. 10.1001/archgenpsychiatry.2008.53719188537 41SatyanarayanaVA,"/>
   <result pre="ChanderG, LatkinCA, MaiNVT, et al.Effect of 2 integrated interventions on" exact="alcohol" post="abstinence and viral suppression among Vietnamese adults with hazardous"/>
   <result pre="alcohol abstinence and viral suppression among Vietnamese adults with hazardous" exact="alcohol" post="use and HIV: A randomized clinical trial. JAMA Netw"/>
   <result pre="ZuskovD, MaiNVT, QuynhBX, ChanderG, et al.Cultural adaptation of 2 evidence-based" exact="alcohol" post="interventions for antiretroviral treatment clinic paitents in Vietnam. J"/>
   <result pre="Prostitution Prevention and Control; 2014. 45BaborTF, Higgins-BiddleJC, SaundersJB, MonteiroMG. The" exact="Alcohol" post="Use Disorders Identification Test Guidelines for Use in Primary"/>
   <result pre="Care. 2001. 46SobellLC, BrownJ, LeoGI, SobellMB. The reliability of the" exact="Alcohol" post="Timeline Followback when administered by telephone and by computer."/>
   <result pre="Timeline Followback when administered by telephone and by computer. Drug" exact="Alcohol" post="Depend. 1996;42(1):49â€&quot;54. 10.1016/0376-8716(96)01263-x8889403 47StrausMA, DouglasEM. A short form of"/>
   <result pre="BMC Womens Health. 2018;18(1):13610.1186/s12905-018-0628-730092785 51FiellinDA, McGinnisKA, MaistoSA, JusticeAC, BryantK. Measuring" exact="alcohol" post="consumption using Timeline Followback in non-treatment-seeking medical clinic patients"/>
   <result pre="without HIV infection: 7-, 14-, or 30-day recall. J Stud" exact="Alcohol" post="Drugs. 2013;74(3):500â€&quot;4. 10.15288/jsad.2013.74.50023490581 52VakiliS, SobellLC, SobellMB, SimcoER, AgrawalS. Using"/>
   <result pre="the Timeline Followback to determine time windows representative of annual" exact="alcohol" post="consumption with problem drinkers. Addict Behav. 2008;33(9):1123â€&quot;30. 10.1016/j.addbeh.2008.03.00918562125 53PenceBW,"/>
   <result pre="56DasguptaA, SilvermanJ., SaggurtiN., GhuleM., DontaB., BattalaM., et al.Understanding Menâ€™s Elevated" exact="Alcohol" post="Use, Gender Equity Ideologies, and Intimate Partner Violence Among"/>
   <result pre="HaTV, LatkinCA, SripaipanT, et al.Decreased injecting is associated with increased" exact="alcohol" post="consumption among injecting drug users in northern Vietnam. Int"/>
   <result pre="use treatment in Brazil and England: A cross-cultural comparison. Drug" exact="Alcohol" post="Rev. 2017;36(1):34â€&quot;51. 10.1111/dar.1243627709693 59MachisaMT, ChristofidesN, JewkesR. Structural Pathways between"/>
   <result pre="Intimate Partner Violence (IPV). PLoS One. 2016;11(3):e015098610.1371/journal.pone.015098626986056 60CunradiCB, MairC, ToddM." exact="Alcohol" post="outlet density, drinking contexts and intimate partner violence: a"/>
   <result pre="A systematic review. BMC Womens Health. 2019;19(1):3410.1186/s12905-019-0728-z30764813 76WilsonIM, GrahamK, TaftA." exact="Alcohol" post="interventions, alcohol policy and intimate partner violence: a systematic"/>
   <result pre="review. BMC Womens Health. 2019;19(1):3410.1186/s12905-019-0728-z30764813 76WilsonIM, GrahamK, TaftA. Alcohol interventions," exact="alcohol" post="policy and intimate partner violence: a systematic review. BMC"/>
   <result pre="et al.Longitudinal Analysis of Depressive Symptoms, Perceived Social Support, and" exact="Alcohol" post="Use among HIV-Infected Men Who Inject Drugs in Northern"/>
   <result pre="EmenyonuNI, KigoziIM, ShiboskiS, et al.Phosphatidylethanol (PEth) as a biomarker of" exact="alcohol" post="consumption in HIV-positive patients in sub-Saharan Africa. Alcohol Clin"/>
   <result pre="biomarker of alcohol consumption in HIV-positive patients in sub-Saharan Africa." exact="Alcohol" post="Clin Exp Res. 2012;36(5):854â€&quot;62. 10.1111/j.1530-0277.2011.01669.x22150449"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7568023\results\search\drug\results.xml">
   <result pre="in COVID-19 include lymphocytopenia, thrombocytopenia, elevated CRP, elevated ALT, AST," exact="creatine" post="kinase, D-dimer, and markers of cell damage, e.g., troponin,"/>
   <result pre="via oral route) empirically (Control and Prevention 2014). Corticosteroids (methyl" exact="prednisolone" post="40â€&quot;120Â mg/day) were given as a combined regimen if"/>
   <result pre="not indicated in the management of COVID-19. Investigational therapies include" exact="hydroxychloroquine" post="alone or in combination with azithromycin, remdesivir, and lopinavir/ritonavir."/>
   <result pre="infections in pigsVet Res2019509010.1186/s13567-019-0712-531694705 El-BatalAIMosallamFMEl-SayyadGSSynthesis of metallic silver nanoparticles by" exact="fluconazole" post="drug and gamma rays to inhibit the growth of"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7570423\results\search\drug\results.xml">
   <result pre="fluid retention113. Additional mechanisms, such as a reduction of endothelial" exact="nitric oxide" post="synthase activity and nitric oxide levels, as well as"/>
   <result pre="as a reduction of endothelial nitric oxide synthase activity and" exact="nitric oxide" post="levels, as well as the release of vascular endothelial"/>
   <result pre="antiviral agents. Of the repurposed antivirals investigated to date, the" exact="adenosine" post="analogue remdesivir was initially identified as a promising therapy"/>
   <result pre="patient groups such as kidney transplant recipients. The anti-malaria drug" exact="hydroxychloroquine" post="has also been investigated for its ability to inhibit"/>
   <result pre="However, available evidence does not support a beneficial effect of" exact="hydroxychloroquine" post="over standard therapy in treating mild-to-moderate disease201, nor as"/>
   <result pre="post-exposure prophylaxis strategy202. Moreover, two clinical trials have shown that" exact="hydroxychloroquine" post="treatment poses serious safety concerns, increasing the risk of"/>
   <result pre="shedding207. However, early reports from China indicated that treatment with" exact="methylprednisolone" post="decreased the risk of death of patients with COVID-19"/>
   <result pre="A preliminary study found that an early, short course of" exact="methylprednisolone" post="therapy improved outcomes of adult patients with COVID-19 with"/>
   <result pre="with SARS-CoV-2 infection122. A large randomized controlled trial showed that" exact="dexamethasone" post="reduced 28-day mortality in severely ill patients who were"/>
   <result pre="those receiving no respiratory support216. These findings are encouraging since" exact="dexamethasone" post="treatment is also highly beneficial in patients with pre-existing"/>
   <result pre="COVID-19 patients with a synthetic biological immune response modifier, thymosin" exact="alpha" post="1 (ref.232), effectively restored CD8+ and CD4+ T cell"/>
   <result pre="CD8+ T cells233. Compared with untreated patients, supplementation of thymosin" exact="alpha" post="1 in COVID-19 patients with severe lymphocytopenia was associated"/>
   <result pre="promising approach than LMWH may be the serine protease inhibitor" exact="nafamostat" post="mesylate, which is under investigation in four different clinical"/>
   <result pre="showed that prophylactic anti-coagulation therapy supplemented by the anti-platelet drug" exact="dipyridamole" post="prevented the progression of COVID-19 to severe stages of"/>
   <result pre="levels243. Notably, through virtual screening of an approved drug library," exact="dipyridamole" post="was also found to suppress SARS-CoV-2 replication in vitro243."/>
   <result pre="coronavirus infection and spreadVirol. J.200526910.1186/1743-422X-2-6916115318 201.CavalcantiABet al.Hydroxychloroquine with or without" exact="azithromycin" post="in mild-to-moderate Covid-19N. Engl. J. Med.202010.1056/NEJMoa201901432706953 202.BoulwareDRet al.A randomized"/>
   <result pre="mild-to-moderate Covid-19N. Engl. J. Med.202010.1056/NEJMoa201901432706953 202.BoulwareDRet al.A randomized trial of" exact="hydroxychloroquine" post="as postexposure prophylaxis for Covid-19N. Engl. J. Med.202038351752510.1056/NEJMoa201663832492293 203.MagagnoliJet"/>
   <result pre="postexposure prophylaxis for Covid-19N. Engl. J. Med.202038351752510.1056/NEJMoa201663832492293 203.MagagnoliJet al.Outcomes of" exact="hydroxychloroquine" post="usage in United States veterans hospitalized with Covid-19Med202010.1016/j.medj.2020.06.00132838355 204.BorbaMGSet"/>
   <result pre="with Covid-19Med202010.1016/j.medj.2020.06.00132838355 204.BorbaMGSet al.Effect of high vs low doses of" exact="chloroquine" post="diphosphate as adjunctive therapy for patients hospitalized with severe"/>
   <result pre="210.ShangLZhaoJHuYDuRCaoBOn the use of corticosteroids for 2019-nCoV pneumoniaLancet202039568368410.1016/S0140-6736(20)30361-532122468 211.BlumCAet al.Adjunct" exact="prednisone" post="therapy for patients with community-acquired pneumonia: a multicentre, double-blind,"/>
   <result pre="covid-19 â€&quot; preliminary reportN. Engl. J. Med.202010.1056/NEJMoa2021436 217.JacobKAet al.Intraoperative high-dose" exact="dexamethasone" post="and severe AKI after cardiac surgeryJ. Am. Soc. Nephrol.2015262947295110.1681/ASN.201408084025952257"/>
   <result pre="pitfalls and pearlsClin. J. Am. Soc. Nephrol.20181381582210.2215/CJN.1299111729475991 219.DusheikoGSide effects of" exact="alpha" post="interferon in chronic hepatitis CHepatology199726112S121S10.1002/hep.5102607209305675 220.AlattarRet al.Tocilizumab for the"/>
   <result pre="clinical applications of thymosin Î±1Expert Opin. Biol. Ther.2009959360810.1517/1471259090291141219392576 233.LiuYet al.Thymosin" exact="alpha" post="1 (TÎ±1) reduces the mortality of severe COVID-19 by"/>
   <result pre="240.US National Library of Medicine. ClinicalTrials.govhttps://clinicaltrials.gov/ct2/show/NCT04418128 (2020). 241.YamamotoMet al.Identification of" exact="nafamostat" post="as a potent inhibitor of Middle East respiratory syndrome"/>
   <result pre="the split-protein-based cell-cell fusion assayAntimicrob. Agents Chemother.2016606532653910.1128/AAC.01043-1627550352 242.AnsarinKet al.Effect of" exact="bromhexine" post="on clinical outcomes and mortality in COVID-19 patients: a"/>
   <result pre="patients: a randomized clinical trialBioimpacts20201020921510.34172/bi.2020.2732983936 243.LiuXet al.Potential therapeutic effects of" exact="dipyridamole" post="in the severely ill patients with COVID-19Acta Pharm. Sin."/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drug\PMC7574529\results\search\drug\results.xml">
   <result pre="to deprioritising self-care and harm reduction. One women who uses" exact="heroin" post="and crack daily said: Today I had money, and"/>
   <result pre="reduction. One women who uses heroin and crack daily said:" exact="Today" post="I had money, and I wanted to spend it"/>
   <result pre="out by the NSPs: The kit they give you as" exact="alcohol" post="wipes and a syringe, but where are you supposed"/>
   <result pre="inject drugs: an international systematic review of high seroprevalence areasDrug" exact="Alcohol" post="Depend20121249510710.1016/j.drugalcdep.2011.12.02022257753 4.Medina-PeruchaLScottJChapmanSBarnettJDackCFamilyHA qualitative study on intersectional stigma and sexual"/>
   <result pre="2S969710.1097/QAI.000000000000062125978489 20.WechsbergWMDerenSMyersBKirtadzeIZuleWAHowardBet al.Gender-specific HIV prevention interventions for women who use" exact="alcohol" post="and other drugs: the evolution of the science and"/>
   <result pre="substance abuse treatment programming for women: a reviewAm J Drug" exact="Alcohol" post="Abuse200329195310.1081/ADA-12001883812731680 22.TerplanMHandDJHutchinsonMSalisbury-AfsharEHeilSHContraceptive use and method choice among women with"/>
   <result pre="use disorders and its consequences for healthcare delivery: systematic reviewDrug" exact="Alcohol" post="Depend2013131233510.1016/j.drugalcdep.2013.02.01823490450 27.MaltaMRalil da CostaMBastosFIThe paradigm of universal access to"/>
   <result pre="of their risks, experiences and needs. Sydney: National Drug and" exact="Alcohol" post="Research Centre, UNSW Australia; 2010. 101.TaplinSMattickRPThe nature and extent"/>
   <result pre="rates of reports, removals at birth and children in careDrug" exact="Alcohol" post="Rev201534313710.1111/dar.1216524890662 102.GrellaCEFrom generic to gender-responsive treatment: changes in social"/>
   <result pre="in substance abuse treatmentJ Psychoact Drugs20084032734310.1080/02791072.2008.10400661 103.SordoLChahuaMBravoMJBarrioGBrugalMTDomingo-SalvanyAet al.Depression among regular" exact="heroin" post="users: the influence of genderAddict Behav20123714815210.1016/j.addbeh.2011.09.00921968230 104.Rowan-CzalGAChathamLRJoeGWSimpsonDDServices provided during"/>
  </snippets>
 </snippetsTree>
</projectSnippetsTree>
